<SEC-DOCUMENT>0000950170-23-002830.txt : 20230215
<SEC-HEADER>0000950170-23-002830.hdr.sgml : 20230215
<ACCEPTANCE-DATETIME>20230215083146
ACCESSION NUMBER:		0000950170-23-002830
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230215
DATE AS OF CHANGE:		20230215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allovir, Inc.
		CENTRAL INDEX KEY:			0001754068
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				831971007
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39409
		FILM NUMBER:		23633739

	BUSINESS ADDRESS:	
		STREET 1:		1100 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(617) 433-2605

	MAIL ADDRESS:	
		STREET 1:		1100 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ViraCyte, Inc.
		DATE OF NAME CHANGE:	20180924
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alvr-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-14T16:04:25.4726+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:alvr="http://www.allovir.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_871cf843-6bae-437f-95c7-ea585ae4dff2" name="dei:EntityCentralIndexKey" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033">0001754068</ix:nonNumeric><ix:nonNumeric id="F_c1ab136d-680d-45ec-99a6-7401e7e06c0a" name="dei:DocumentFiscalPeriodFocus" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033">FY</ix:nonNumeric><ix:nonNumeric id="F_fb8a9d38-01ce-4a93-beea-aee65bc7b04d" name="alvr:OperatingLossCarryforwardsCarrybackPeriod" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033">P5Y</ix:nonNumeric><ix:nonFraction id="F_794d01a1-aca2-4aae-acbc-307b1688cae1" name="us-gaap:PreferredStockValue" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e33bdda4-f497-4a6e-b92c-1b3e161d699e" name="dei:AmendmentFlag" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_6fd272f4-1070-42c6-9b05-cfa962784023" name="us-gaap:PreferredStockValue" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alvr-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_51750031-7f9c-4c75-a085-4599ec0a8c7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-02</xbrli:startDate><xbrli:endDate>2020-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a663255-07b3-4b0c-81df-49da0711cfc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aab4b39-a49a-4d2d-a277-8f923ab3d97d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2440698-340f-405b-82b8-2ee426f49c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b229f14-0e9d-4a8c-9c99-2fac3bf93e45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e1405d7-d3f6-4118-b825-18c83ba250f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SecondSOWAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb50bcd6-a9a6-4061-9ef2-e7d4b30b505a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alvr:CancerResearchAndPreventionInstituteOfTexasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4638e48c-caee-470f-8e9f-fd72016b2756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b872f5d-6e7d-409f-b489-675ef849e5c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:RedumptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca1c64ca-7e9c-446e-8772-b18830c91079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1809599-290d-4a09-84c6-6e1cc69305a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_617f4174-88a5-4f52-8e3f-dafed24ab46e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05a46537-0f3d-403a-bd4b-9b51a77c50b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_871ad9af-02db-4352-9621-2c92ad7156c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26adca99-ca18-49de-923e-a278ee315f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edef2090-5f5c-44a5-91fc-85d5605d9a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a0554a-094f-4ada-b6e2-8ae4cc043eaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dba3ee0-797d-4488-a999-52e2d13730df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48c024c0-d687-47ba-9b05-7f832db9c0ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd837554-2d0e-44a4-89f5-21197c0c9b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_160a6c1c-126c-4390-a8b9-a1f7c5589625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:OptionToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef1fea4e-8882-400a-ae32-d746b5237239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50437763-ff2d-4d51-98a3-8c880a8fe158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2765896-7ab5-4950-93b3-5422a0d04d3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_929b39a9-292b-4663-ab90-74229b474881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_530cd7cd-8adc-465e-b494-4eb7a45191a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cb1ed55-c237-4a84-8a95-212c9e28b1d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34bd2dd2-4644-4d61-9dd2-0ea6e25b44ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09a37f2c-e1fe-4c12-9a21-29a9a69ff02e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a13a2d7-5fd2-4d62-8f2a-c04d53be3758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f54245dd-ad04-435d-9405-f93c21c6df54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0de4aa3b-f8d3-4a15-88ec-81d1af1626ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">alvr:AccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe20c7f0-e4e5-4327-8d78-110f415bf544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1ac0558-7793-4cbc-abac-375855874e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75215896-db5d-4536-a304-39f269881d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6d7b88b-a721-4583-9af3-cdcbc9a426d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3854674-c6cb-450f-a8f1-f217cae5fd90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05b6c22e-9c40-4013-83f9-51bb3313e591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56bf8742-8a30-46a1-808e-e166b1e6b639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16d12274-58f7-4d85-a851-cdb95fe02f19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddd9b411-5433-4b78-876b-16099390a62c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d26fd97-1281-48e9-9f0c-80658a0a41dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2c0042d-4a48-4498-a1f0-1bd575db97dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14bd8057-2b3c-443a-8b90-b6382cbf114b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de179e1a-a46a-42ff-ade3-641aee56fdf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0369a67b-84df-4183-8524-460dca6b72af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_232cbeff-83b0-4296-a32f-459b4b6c2711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1176b604-ee17-4ddb-be7e-456b15cb96ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SubleaseWithAmagPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca8bd669-1d5c-4b9a-921e-86a2b0097299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevatebioBasecampIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa412a85-c19c-4db1-b1d6-89d57a67aedd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a42b0c01-30a3-4913-9e9a-d46c91274d8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b58947d-f992-4988-85a8-62bc792aa149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db4ec574-667d-4e70-a4cf-db9a6e572237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed61a91e-38ee-40bf-89a6-4063803306fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dd688fa-9bfb-450c-823f-914d71bdb20b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:ResearchCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35bb2d87-2273-4b9b-abe3-66c79a568333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5df06e65-2e31-4282-a0c9-44687c839727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62c6f492-44c1-46c2-b513-632f27ed7e91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_235f6d4f-ef0b-4fbc-b567-efa82b6fd888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34017843-7cb8-4d00-86bb-8889a840a88a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_978fec4b-4bb3-4327-9bc3-a12cff64e534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SecondSOWAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf392d2-9387-428a-99dd-65df376878d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_477148ad-c1c9-490f-97aa-87c51b482f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bd4967c-de1f-4ce5-9073-2145721fd38c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cd782a5-8539-46d4-88c3-5b91917b87e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba9cbb52-e4cc-4b69-b43d-08477c237f07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_caad09b2-8a5c-427a-bf14-b4c5d6dc2fac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alvr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddb75e86-804f-400d-952a-974d942d169c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b6e5424-0ab6-4de8-961e-ab8143059eb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75223583-180e-4986-994f-4bfea6c4561f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ac4b804-48e5-4500-bafb-20607b67d00c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e73a754-0c34-4892-ba85-21910762594e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51c4f488-3970-4c54-84de-f12cde7d10db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">alvr:AccruedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebbb3c52-5b08-40b2-b326-8098da241ddd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0711afd-ddae-4cbb-95eb-8a59378fefed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_227c3050-c341-4701-9bbc-1a6d93036b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alvr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1c6fa03-2ee5-482c-8fcc-3134560afe02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1a7c8cb-c126-4a75-84cc-77ae967326ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2ebfc16-1156-46e3-a10c-6844f6815d58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f6f1e4d-56e5-462f-b160-b281f07868df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b98a7795-ec31-4702-95a8-60d00f9f4656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_befdac74-700b-4c42-b7e1-ec0012c1f70b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62600b73-3cde-4af9-85cb-8d2dcf5152ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89b61897-7cb1-4529-aa9a-3dcca0317455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alvr:CancerResearchAndPreventionInstituteOfTexasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c070771-4f77-4eda-b36a-c12f31943e25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e238b96f-4a9e-4feb-94c6-0c19c3005824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:NewLeaseAgreementWithBpBayColonyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2423b8cb-2946-470e-a22d-8cdaaa80af94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_364b0156-c9eb-4a54-8db9-564a84677c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a071b5e-8a39-4f87-993b-1f4dca7d0685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec9f3cbd-6e49-4297-9fce-29d9733f0dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_868e0009-9125-478f-bcb4-16998a2eebfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7155aa6-ec63-47bc-af6f-62110067cad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_260a042b-801a-42d1-b1f2-f77d80a4d46a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8351b805-5c1a-4d38-8217-30f5d6839ca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b40c6bb-4bfb-4418-9f73-133bb83a5cc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc2f8cf1-b175-4168-8c12-2ca0ee568e4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_028feb25-e5dc-4693-838f-892bc643344f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de1adbb2-e1ee-4eaa-9635-a371d6880799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d003b5a4-37dd-4bf1-a824-7458b10262ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2d19e85-a506-472f-9db8-0cfeb581c0c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_276e92a2-b36d-49d9-b698-ebe3737df111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64a704c4-3d7f-4e2b-9ec5-bfbaf9960234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6f0fa23-53ee-473a-93c3-d9f513ff687e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3d1dc62-3ca8-4a65-8d93-bffe388766da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c5c0b15-4d90-49b6-b481-28b693927667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c580b793-4a8d-44b5-9ac5-f169ca597d82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:OriginalSOWAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3f9b887-cf21-4bb9-8973-a2512cec26c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2690d392-2fbc-4b1f-8ea4-61ecf654db96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8f5f95d-8c74-42da-8e94-481be7b2c583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6a30e50-19aa-46ea-ad75-47a4021abf20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e51cc0b-f9e3-4e56-9d47-caa41e9a1eab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dc312bf-dbc1-46c6-bfff-794105b41f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_183322ca-7ab4-457e-8a32-87ac4df2d1d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:OptionToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8964311a-67d6-48e8-930b-0c03d707e7e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79512046-91c6-49b4-ae01-0e273533c65f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd2342e2-4156-4233-ac5f-e78b1c441b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20d83d46-ff82-406b-8ed4-fbca2c534f99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d14225a-1f51-4be3-8682-e3fe75c16bf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad4867e-83a6-4c90-8517-df9e8041faad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45693ffc-b960-4db0-a592-606079f137e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d21593fe-88fc-485a-877e-34bb4604b4f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e64c980b-ef3a-4f68-b295-dd082f470d79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b319269-2fae-4e66-8b64-b20a04c36873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca66d82-2e78-437b-aec1-7a4f3bee0629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95a486e9-ee67-47cd-9f0c-c1d735435df0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c3fe01a-8496-428e-84e7-1771deb6fcdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a68d724b-186e-40cb-914f-9f396ee8efa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76cdb962-34b7-4488-9b22-155ce39bf6f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afd1f979-2cf1-48e4-85ce-a45e00e28ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be903c41-fc2c-4418-82d1-61c35c6f02d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a765caa-d973-4579-b4bc-2ffa5b45e639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a87737f-16d9-4518-9638-fffb2170c6fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001754068</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Security"><xbrli:measure>alvr:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>alvr:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>alvr:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6cde47ad-fcdd-464e-9335-ba901086ed11" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_21d51f43-038b-4eae-85e7-07333f45136e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f2f4b61-d25c-44cc-b16e-5139691b40d9" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a81cc9df-3ee5-4cc7-960c-ec4c2a93aae8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b1556e8d-2cb5-41db-95b4-90975378ba22" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1138fef4-741c-4a92-a1c1-afe60d9d737d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ff45a5f7-dcf1-4b7d-b262-0c31b1b1a5c1" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39409</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a469a160-7f39-485b-b5a1-ee2498b0a8c7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db18e5a0-3206-4ee6-97a3-5d43b0d8af1c" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_265f8078-69c1-4673-96fc-bbd1af857c00" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83-1971007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6cfbdd36-6c19-4504-9cda-7487f8b7e168" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1100 Winter Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a79e3fac-1aae-4c49-b076-5ec270b5ddb0" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_960184f8-2475-408d-ba36-d29aabab76e8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_671f395b-2ef9-4fe6-b6d1-629d89adbc77" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02451</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_93950211-ea59-4d61-a926-b65bb4e4cdb5" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ffca941a-8a89-44ec-a285-e81c35a19912" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">433-2605</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_939aa3d1-ead6-4779-aa4b-0053f70406c4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c715749b-1e22-404f-9883-3b456bd61f0b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5c8a673-1fdf-4a51-b4f8-7d5be0060577" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c87c27b-8a21-42f1-a243-87c0c4c15db4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88522d10-f496-4301-915a-d24ce886b274" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_526d85c6-ba28-439c-93c3-4d9df3877e7f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de284ab6-5912-4020-bd79-a2b2560b1b59" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the @Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.657%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.898%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed3fb1fd-e761-4916-ab53-7165987d1b10" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_33fe247f-6204-43ce-8add-e0990042026f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3779a8f-3a2b-4ae2-8654-17fa4f15737f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_91d11fbf-d184-4987-9680-7d31188415b1" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52d5dcb1-62c3-4991-8f7a-6f5d50666012" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_566792c6-4d6e-48c2-a6db-0e341f5e7ba4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_613e7569-4bd2-43dd-880d-7aaddbb01936" contextRef="C_afd1f979-2cf1-48e4-85ce-a45e00e28ade" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">143.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2022, the last business day of the registrant's most recently completed second quarter. In determining the market value of non-affiliate common stock, shares of the Registrant&#x2019;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock, par value $0.0001 per share, outstanding as of February 9, 2023 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f8cee16-e078-4f0c-89fe-e71d55699e6f" contextRef="C_4b229f14-0e9d-4a8c-9c99-2fac3bf93e45" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">93,463,200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52ac1a76-eaf8-495e-8b89-5b779f1861fd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Proxy Statement for the registrant&#x2019;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Annual Meeting of Stockholders, or the Proxy Statement, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#x2019;s fiscal year end of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.0%;"></td>
    <td style="width:83.0%;"></td>
    <td style="width:6.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#special_note_regarding_forwardlooking_st"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selected Financial Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_fj"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#n16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Material Risks Associated with Our Business</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled &#x201c;Risk Factors.&#x201d; These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where our contracted third parties, including contract research organizations, or CROs, and contract development and manufacturing organizations, or CMOs or CDMOs, have significant research, development or manufacturing facilities, concentrations of clinical trial sites or other business operations, causing disruption in supplies and services.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a late clinical-stage cell therapy company and we have incurred net losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is highly dependent on our lead product candidate, posoleucel (previously referred to as Viralym-M or ALVR105), and we must complete clinical testing before we can seek regulatory approval and begin commercialization of any of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend substantially on intellectual property licensed from third parties, including Baylor College of Medicine, or BCM, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and manufacturing process, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are early in our development efforts and have only a small number of product candidates in clinical development. All of our other product candidates are still in preclinical development. If we or our collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidates in clinical trials, and any other product candidate we advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our third-party partners are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to develop an efficient and highly productive manufacturing supply chain for our allogeneic, off-the-shelf single- and multi-VST cell therapies. Delays in process performance qualification to validate the drug product manufacturing process could delay regulatory approvals, our development plans and thereby limit our ability to generate revenues.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock may be volatile.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors below, in the section entitled &#x201c;Risk Factors&#x201d; and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="special_note_regarding_forwardlooking_st"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including but not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success, cost, timing and potential indications of our product development activities and clinical trials, including the ongoing and future clinical trials of posoleucel and ALVR106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of our planned Investigational New Drug, or IND, submissions to the FDA for our product candidates, including ALVR107;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of the initiation, enrollment and completion of planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to research, develop and commercialize our product candidates, including posoleucel, ALVR106, and ALVR107;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of the initiation, completion and outcomes of our preclinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of development of any of our product candidates or clinical development programs and our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully manufacture and distribute posoleucel, ALVR106 or any other future product or product candidate;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential benefits of and our ability to maintain our collaboration with our existing collaborators, including BCM, and establish or maintain future collaborations or strategic relationships or obtain additional funding;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to maintain our existing license agreements, including Baylor College of Medicine, or BCM, and to license additional intellectual property relating to any future product candidates and to comply with our existing license agreements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks associated with the COVID-19 pandemic, including the emergence of new variants, which may adversely impact our business and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the markets for our VST product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether the results of our clinical trials will be sufficient to support domestic or foreign regulatory approvals for any of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully commercialize our product candidates, including posoleucel and ALVR106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate and degree of market acceptance of our product candidates, including posoleucel and ALVR106;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of any approved product we develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments in the United States and foreign countries with respect to our product candidates or our competitors&#x2019; products and product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reliance on third-party contract manufacturers and the performance of our third-party suppliers and manufacturers to manufacture and supply our product candidates for us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competing therapies that are or become available;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to attract and retain key scientific or management personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectation about the period of time over which our existing capital resources will be sufficient to fund our operating expenses and capital expenditures;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of laws and regulations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments and projections relating to our competitors or our industry;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, you can identify forward-looking statements by the words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;objective,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;should,&#x201d; &#x201c;will,&#x201d; or &#x201c;would,&#x201d; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read the section titled &#x201c;Risk Factors&#x201d; set forth in Part I, Item 1A of this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read this Annual Report on Form 10-K, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. We are developing three innovative, allogeneic, off-the-shelf VST therapy candidates targeting 11 different devastating viruses. The most advanced is posoleucel, a multi-VST therapy that targets six viruses: adenovirus, or AdV, BK virus, or BKV, cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, human herpesvirus 6, or HHV-6, and JC virus, or JCV. Posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel is being studied in three ongoing Phase 3 registrational trials for 3 distinct indications - the prevention of clinically significant infections from multiple viruses, the treatment of virus-associated hemorrhagic cystitis, or HC, and the treatment of AdV infections &#x2013; all in allogeneic hematopoietic cell transplant, or HCT, patients who are at high risk for life-threatening viral infections from the six viruses targeted by posoleucel. We have successfully accelerated the multi-prevention study in recognition of the fact that prevention best addresses patients&#x2019; unmet medical needs. The three Phase 3 studies are expected to complete enrollment by the end of 2023, enabling potential data readouts from all three trials in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three registrational trials were informed by the positive results of proof-of-concept studies with posoleucel for both treatment and prevention. In the CHARMS Phase 2 treatment trial, 95% of allogeneic HCT patients with one or more treatment-refractory infections achieved a clinical response with posoleucel. In the Phase 2 multi-virus prevention trial, posoleucel demonstrated a substantial reduction in the expected rate of clinically significant viral infections or diseases, with 88% of patients remaining free of clinically significant infections caused by any of the six viruses that posoleucel targets through the Week 14 primary endpoint.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the ongoing Phase 3 registrational studies, posoleucel has been studied in a Phase 2 proof-of-concept study for the treatment of BK viremia in kidney transplant patients. Positive topline results of this study were reported in February 2023, showing balanced safety across posoleucel and placebo groups and clinically meaningful greater viral load declines with posoleucel versus placebo. This is the first study of posoleucel in SOT patients, and the results of this trial will inform next steps for this potential indication as well as the company&#x2019;s broader SOT strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the strength of the posoleucel Phase 2 data for both treatment and prevention, the FDA has granted posoleucel Regenerative Medicine Advanced Therapy (RMAT) designation for each of the three indications being evaluated in Phase 3 clinical trials &#x2013; for the treatment of HC caused by BKV, for the treatment of AdV infection in adults and children following allo-HCT, and for the prevention of clinically significant infections and disease caused by posoleucel&#x2019;s six target viruses. Similarly, based on data generated from the Phase 2 POC treatment trial and the critical medical need, the European Medicines Agency (EMA) has granted posoleucel PRIority MEdicines (PRIME) designation for the treatment of serious infections with AdV, BKV, CMV, EBV and HHV-6. Posoleucel was one of the first seven investigational therapies to receive both PRIME and RMAT designations and, to our knowledge, is the only investigational therapy to receive three RMAT designations. While these designations may not lead to a faster development process and do not increase the likelihood that a product candidate will receive approval from the FDA or EMA, we expect that PRIME and RMAT designations will result in increased EMA and FDA interactions to support our development efforts and may enable an expedited regulatory review process. In addition, the FDA also granted posoleucel Orphan Drug Designation for the treatment of virus-associated HC, and the EMA granted Orphan Medicinal Product designation to posoleucel for its targeted viruses in HCT patients, including for the potential prevention of infections or disease by these viruses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In clinical trials conducted to date, we have treated more than 300 transplant patients with either single or multi-virus targeted allogeneic VSTs, and our product candidates have been generally well-tolerated and have been associated with clinical benefit. We believe that our allogeneic, off-the-shelf VSTs can benefit patients with other conditions characterized by T-cell deficiencies who are at high risk for life-threatening viral diseases, including immunocompromised cancer patients, the elderly and young children with immature immune systems. We are advancing a pipeline of VST therapies for delivery to individuals with compromised immune systems and those who are at high risk, or suffering from, the life-threatening consequences of viral diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use. Our VST production process selectively expands polyclonal (CD4+ helper and CD8+ cytotoxic) virus-targeted T-cell populations. The critical components of our off-the-shelf VST platform, for which patents are issued and/or pending, include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Methods of identifying immunodominant viral antigens in target viruses; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, our selection algorithm to identify healthy donors from whom to generate VSTs that provide coverage to over 95% of patients in our targeted populations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Methods of rapidly and selectively expanding polyclonal VSTs </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, our algorithm to choose the appropriate partially HLA-matched off-the-shelf VST therapy to deliver to each patient. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have applied this expertise in the development of additional product candidates that may benefit high-risk individuals:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106 is our second off-the-shelf, multi-VST product candidate that we developed to target devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV, and respiratory syncytial virus, or RSV. Our POC clinical trial is enrolling patients in the United States, or U.S.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also developing ALVR107 designed to target hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infections. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study. The company expects to initiate clinical development of ALVR107 after completion of the posoleucel Phase 3 registrational studies.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR109 is an allogeneic, off-the-shelf single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. ALVR109 is designed to arrest the progression of COVID-19 by eradicating SARS-CoV-2 virus-infected cells.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If approved, we believe posoleucel has a large global market opportunity to treat and prevent devastating viral diseases. Based on the established epidemiology of our target Phase 3 indications, we estimate the addressable patient population for posoleucel will be approximately 41,000 HCT patients annually in 2025. The addressable patient population could expand beyond HCT patients into SOT patients as well as beyond the transplant setting to additional immunocompromised patients suffering from these devastating viral infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to leverage ElevateBio&#x2019;s cell therapy expertise to develop and manufacture VST therapies for clinical trials and commercialization. ElevateBio has established ElevateBio BaseCamp, Inc., or BaseCamp, a centralized cell and gene therapy development and manufacturing facility dedicated to the production of products for its affiliated companies. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management team has significant experience in successfully advancing products from early-stage discovery through commercialization. Our Chief Executive Officer, Diana Brainard, has more than 20 years of experience in the biopharmaceutical industry and academic medicine. During her 10-year tenure at Gilead Sciences, Diana served as the head of the virology therapeutic area, leading the development and launch of some of the most successful drugs of the last decade, including Sovaldi, Harvoni, Epclusa and Biktarvy. In 2020, she led the company-wide initiative to rapidly advance Veklury (remdesivir) to become the first and only antiviral to receive regulatory approval for the treatment of SARS-CoV-2, which earned her global recognition as one of the most influential people in the fight against SARS-CoV-2. Her industry career began at Merck, where she held positions in clinical pharmacology and experimental medicine. Diana also serves as an Independent Director of Nektar Therapeutics and Affinia Therapeutics.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vikas Sinha, our President and Chief Financial Officer, brings more than 25 years of experience in executive finance roles within the biopharmaceutical industry. He served as the Chief Financial Officer of Alexion Pharmaceuticals for more than 11 years, where he oversaw the global expansion of the company across 50 countries and revenue growth to more than $3 billion. Prior to joining Alexion, Vikas held various positions with Bayer AG across the world, including CFO, Bayer Pharma, North America and CFO, Bayer Yakuhin, Japan. He also serves as Chief Financial Officer of ElevateBio and an Independent Director and Audit Committee Chair at Verona Pharma. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have raised $156.9 million in aggregate gross proceeds through private financings, $317.7 million in aggregate gross proceeds through our IPO, which closed in August 2020, and $126.6 million in aggregate gross proceeds through a registered direct offering in July 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are advancing a pipeline of three allogeneic off-the-shelf VST therapy candidates targeting 11 different viruses to treat and prevent life-threatening viral diseases. For each of these pipeline therapies, we have global development and commercialization rights. The chart below summarizes key information about our programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_0.jpg" alt="img101536035_0.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An allogeneic, off-the-shelf VST therapy candidate targeting six common viruses: AdV, BKV, CMV, EBV, HHV-6 and JCV, which can lead to devastating viral disease in the allogeneic HCT population. Given that posoleucel is multi-VST product candidate, the therapy has multiple potential applications. To this end, three Phase 3 registrational trials are ongoing&#x2013; one for the treatment of virus-associated HC, one for the treatment of adenovirus infection and one for multi-virus prevention, all in HCT patients. All three Phase 3 trials are expected to complete enrollment in 2023, potentially enabling data readouts in 2024.</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Promising efficacy and safety results from the completed Phase 2 treatment and prevention trials in allogeneic HCT patients enabled the rapid progression of posoleucel into Phase 3 development. In the CHARMS Phase 2 POC treatment trial, 95% of allogeneic HCT patients with infections from one or more of the target viruses and who previously failed or were intolerant to conventional antiviral treatments, achieved a clinical response when treated with posoleucel therapy. In the Phase 2 multi-virus prevention trial, posoleucel demonstrated a substantial reduction in the expected rate of clinically significant viral infections or diseases, with 88% of patients remained free of clinically significant infections caused by any of the six viruses that posoleucel targets through the Week 14 primary endpoint.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Phase 2 POC trial of posoleucel to treat BK viremia in kidney transplant patients completed in 2022. Positive topline data from the BKV study were reported in February 2023, showing balanced safety across posoleucel and placebo groups and clinically meaningful greater viral load declines with posoleucel versus placebo.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. An allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses: hMPV, influenza, PIV and RSV. Our POC clinical trial is enrolling patients in the U.S.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR107</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. An allogeneic, off-the-shelf VST therapy candidate designed to target HBV-infected cells with the aim of curing chronic HBV infections. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study. The company expects to initiate clinical development of ALVR107 after completion of the posoleucel Phase 3 registrational studies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to extend our leadership position in the development of allogeneic, off-the-shelf VST-cell therapies to serve patients at risk of the life-threatening consequences of severe viral diseases. To achieve this, we are pursuing the following strategies:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerate the completion of posoleucel registrational trials for three indications with no FDA-or EMA-approved or effective treatment options. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By targeting six devastating viral pathogens, we believe that posoleucel has the potential to fundamentally transform the care of HCT and SOT patients, as well as other individuals at high risk for opportunistic viral infections, by substantially reducing or preventing disease morbidity and dramatically improving patient outcomes. We have three ongoing Phase 3 trials of posoleucel &#x2013; one for the treatment of virus-associated HC, one for the treatment of AdV infections, and one for multi-virus prevention &#x2013; all in allogeneic HCT patients. These trials offer the fastest path to deliver posoleucel to patients in need, with the prevention indication offering the most transformative potential for the management of allogeneic HCT patients. We have successfully accelerated the multi-prevention study in recognition of this fact. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opportunistically expand the posoleucel patient population to SOT. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A POC trial evaluating posoleucel for the treatment of BKV in kidney transplant patients was completed last year, and positive topline data from this study were reported in February 2023. The results of this study will inform next steps for this potential indication and our broader SOT strategy.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Position the company for portfolio expansion through development of earlier stage assets either internally or with potential partners. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our highly efficient and versatile off-the-shelf VST therapy platform allows us to profile viruses and rapidly develop novel therapies for existing and emergent life-threatening viral infections and serve the large number of patients with devastating viral diseases. We intend to leverage the versatility of our platform to potentially address a broad spectrum of patients who could benefit from &#x201c;off-the-shelf&#x201d; VST therapies, including other individuals with compromised immune systems and those who are at high risk for the life-threatening consequences of viral diseases.</span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106 is already in the clinic, with a POC trial currently enrolling transplant patients in the U.S. We believe that ALVR106 has the potential to transform the treatment of respiratory viruses and substantially reduce the severity of respiratory infections while improving patient outcomes. While ALVR106 is currently being studied in transplant patients suffering from respiratory viral infections, our goal is to expand to other high-risk patient populations, such as immunocompromised cancer patients, the very young and the elderly. In addition, we have completed preclinical and IND-enabling studies of ALVR107 as a potential cure for chronic HBV infections, and plan to move ALVR107 into clinical development after completing the posoleucel Phase 3 studies. And we have demonstrated our ability to rapidly initiate the development of and progression into the clinic of a VST therapy in response to emerging pathogens, with the SARS-CoV-2 specific VST therapy candidate ALVR109.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leverage our differentiated, proprietary and versatile process to rapidly and efficiently manufacture our VST therapy candidates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed an efficient, reliable and scalable manufacturing process for our allogeneic, off-the-shelf VST therapy candidates. We also plan to leverage the substantial cell therapy manufacturing expertise and state-of-the-art facility of ElevateBio to expand internal capabilities for our growing global manufacturing network. We will leverage Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, our proprietary algorithms for donor selection and VST therapy HLA matching, to efficiently build our global supply chain to serve a growing number of patients that could benefit from our highly innovative off-the-shelf ready-to-use VST therapy candidates. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Build a fully integrated, global VST therapy company.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We intend to continue building unparalleled bench-to-bedside capabilities to discover, develop, manufacture and commercialize our highly innovative off-the-shelf VST therapy candidates, if approved, to serve a large number of patients suffering from the life-threatening consequences of viral diseases. Initially, to launch our late clinical stage therapies for the treatment of transplant patients, we will establish a focused commercial infrastructure targeting high-volume transplant centers globally. As we eventually progress to serve non-transplant patients at high-risk for the life-threatening consequences of viral diseases, we will expand our global commercial capabilities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Immune System and the Role of T Cells</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In healthy individuals, the adaptive immune response forms a critical component of the body&#x2019;s natural defense system and provides protection against numerous disease-causing viruses, as depicted in the figure below. Certain types of T cells have an essential role in driving the immune response to viruses. The major role of CD8+ &#x201c;cytotoxic&#x201d; T cells is to kill virus-infected or otherwise diseased cells, while the major role of CD4+ &#x201c;helper&#x201d; T cells is to produce soluble proteins, known as cytokines, which produce direct antiviral effects and support CD8+ T-cell survival. CD4+ T cells can also signal other immune cell types, including antibody-producing B cells, thereby influencing the broader antiviral immune response. CD8+ and CD4+ T cells are vital components in maintaining adaptive immunity against many devastating viruses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_1.jpg" alt="img101536035_1.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 1. T cells play a central role in response to viral infection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T cells recognize viruses via their T-cell receptors, or TCRs, which selectively recognize &#x201c;foreign&#x201d; viral peptides displayed by a compatible &#x201c;self&#x201d; human leukocyte antigen, or HLA, proteins present on the surface of virus-infected cells or antigen presenting cells. Once T cells bind to the peptide-HLA complex, they become activated and start to multiply as the body mounts an immune response to control or eliminate the virus. In contrast, if the peptide displayed by the HLA allele is not &#x201c;foreign&#x201d; but instead from a &#x201c;self&#x201d; antigen, then T cells do not bind to the cell and no immune response is generated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To be clinically effective, at least a portion of the infused, allogeneic, off-the-shelf VSTs must be compatible, or partially HLA matched, with the patient so that some of the infused T cells can bind to viral peptide-HLA complexes, resulting in selective antiviral effects against virus-infected cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While HLA alleles provide a defining feature of an individual&#x2019;s biology, there are only a limited number of unique HLA types among humans. This important characteristic has allowed us to develop allogeneic VSTs from donors who are carefully chosen to provide HLA coverage to the broad patient population at risk of devastating viral infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VST therapies are specifically designed to enhance and restore T-cell function. In patients with T-cell deficiencies, uncontrolled viral infection, replication and expansion can result in severe and devastating consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transplantation and Immunosuppression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are two major types of transplant procedures: HCTs and SOTs. In each procedure, the immune system of the patient is suppressed or eliminated to prevent rejection of the transplanted cells or organs. In the case of HCT, this immunocompromised state is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">typically temporary and resolves once the transplanted donor stem cells begin to replenish the cells of the immune system. In SOT, most patients require a high dose of immunosuppressive drugs for the first six months post-transplant and some degree of immunosuppressive treatment for the rest of their lives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCTs are clinical procedures used in the treatment of severe and life-threatening diseases primarily of the blood and immune systems, including some forms of leukemia and lymphoma, genetic diseases and other blood-based diseases. In HCTs, physicians remove diseased or, in the case of some genetic diseases, missing blood cells, along with the stem cells that lead to their formation. The physician then replaces the diseased or missing blood cells with healthy red and white blood cell-forming stem cells from donors. The process of destroying the defective cells, known as conditioning, also leads to the depletion of the patient&#x2019;s immune cells, leaving patients highly vulnerable to disease-causing viruses, which can become life-threatening due to their weakened immune systems. Patients can remain vulnerable for an extended period until the donor stem cells take up residence and begin to reconstitute a functional immune system. A key challenge in HCT is the identification of transplant material that is immunologically compatible with the patient. The selection of donors for HCT procedures requires that the donor&#x2019;s HLA antigens comprise a close match to those of the patient, as an exact match is not often available. Procedures using more stringent conditioning enable these patients to receive partially matched stem cells from allogeneic donors. This more stringent conditioning, known as myeloablative conditioning, leaves the patient extremely immunosuppressed and highly prone to potentially deadly viral diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In up to 90% of allogeneic HCT patients, the suppressed immune system allows viruses that were previously in a latent, quiescent state to reactivate and more than 60% of allogeneic HCT patients experience a reactivation of more than one virus, including BKV, CMV, AdV, EBV and HHV-6, as depicted in the figure below. In healthy, immunocompetent individuals, these viruses typically lead to mild, self-limiting infections. However, in immunocompromised patients, once reactivated, each of these viruses has the potential to cause significant morbidity and even mortality. It is estimated that more than 20% of all deaths associated with HCTs are due to infections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_2.jpg" alt="img101536035_2.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 2. Approximately 90% of patients undergoing allogeneic HCT have at least one viral infection and 62% have more than one. Multiple viruses contribute to significant mortality</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SOT has been established as a definitive treatment option for patients with organ failure. Over the past few decades, SOT procedures have rapidly progressed and now include a variety of solid organs, including the kidney, lung, liver, heart, intestine and pancreas. The increase in organ transplants has been matched by improved short- and long-term graft survival. This is due, in large part, to the use of immunosuppressive drugs that prevent the immune system from rejecting the transplanted organ. However, typically SOT patients require some degree of immunosuppressive therapy life-long, which leaves them vulnerable to viral infections and disease for a longer duration than HCT patients. In addition, high-risk SOT patients, including recipients of organs mismatched at a high number of HLA antigens, highly sensitized recipients, or ABO blood type incompatible recipients, tend to receive more rigorous immunosuppressive induction treatment, further increasing the risk of these patients contracting potentially deadly viral diseases. Further, SOT patients with the viral infections and diseases our product candidates aim to treat or prevent, suffer from worse outcomes, including graft failure, despite current standard of care treatment, as depicted in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_3.jpg" alt="img101536035_3.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 3. BKV in kidney transplant recipients leads to decreased graft survival despite standard of care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe transplant patients represent one segment of the large number of immunocompromised patients suffering from devastating viral infections who could potentially benefit from allogeneic, off-the-shelf VST therapies. Other individuals with weakened immune systems, including those with primary immunodeficiencies, the elderly and very young and patients who have compromised immune systems due to cancer or the treatment of their cancer are all at high risk of the life-threatening consequences of viral diseases and infections. Each of these target patient populations represents a large potential market that is currently untapped or underserved by existing therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Limitations of Current Therapies for Immunocompromised Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are no FDA- or EMA-approved antiviral drugs to treat the majority of the diseases and patients we are planning to target using our allogeneic off-the-shelf VSTs. When used clinically, available antivirals are often ineffective, toxic, can lead to emergence of virus escape mutants that are treatment-refractory and despite their use patients often succumb to their infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, there are limitations to prophylactic approaches, such as vaccines, in immunosuppressed patients, the elderly, and the very young who may be unable to mount an effective immune response that protects against the target viruses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In contrast, the adoptive transfer of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expanded VSTs to HCT patients has generated promising preliminary disease outcome measures and safety data in treating a range of viral diseases in clinical trials. We designed an approach whereby VSTs could be prospectively generated from healthy, third-party donors expressing common HLA polymorphisms who were seropositive for all of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">targeted viruses. These VSTs were prepared by stimulating peripheral blood mononuclear cells, or PBMCs, with viral antigens followed by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expansion and cryopreservation to enable utilization when needed by patients. We then clinically assessed whether such allogeneic VSTs, when administered as a partially HLA-matched off-the-shelf therapy could still provide clinical benefit in a safe manner. We have treated more than 300 allogeneic HCT patients with either single or multi-virus targeted allogeneic VSTs.  These off-the-shelf VSTs have been generally well-tolerated and were associated with clinical benefit as indicated by the high response rate demonstrated in immunocompromised patients with drug-refractory infections and diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach to Allogeneic Off-the-Shelf T-Cell Immunotherapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an urgent medical need for therapies to treat a large number of patients suffering from devastating viral diseases who currently have limited or no treatment options. Our approach involves the restoration of viral immunity through the adoptive transfer of VSTs, which have been prospectively generated from healthy, eligible donors. These cells are immediately available for &#x201c;off-the-shelf&#x201d; administration to patients at risk from the devastating consequences of viral diseases due to T-cell deficiencies, as depicted in the figure below. The partial HLA match between the allogeneic VST therapy and infected patient allows the infused T cells to recognize and selectively kill virus-infected cells while leaving non-virus-infected host cells intact, thereby minimizing the risk of therapy-associated graft-versus-host disease, or GVHD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_4.jpg" alt="img101536035_4.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 4. Adoptive transfer of off-the-shelf VSTs kill virus-infected cells and restore virus-specific T-cell immunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VSTs are generated from a panel of healthy, third-party blood donors that collectively express a diverse array of HLA allele subtypes. Collectively, these VSTs, which therefore recognize viral peptides displayed by an array of different HLA alleles, form a mini-bank of product candidates that provide coverage to more than 95% of patients in our targeted populations. These VSTs can be stored in a cryopreserved state and thus supplied rapidly and globally as an off-the-shelf therapy for patients suffering from, or at risk for contracting, one or more viral diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Using our versatile and robust off-the-shelf VST platform, we are able to rapidly generate VST therapies for the treatment of a spectrum of viral diseases. This is demonstrated by our pipeline of four innovative, allogeneic off-the-shelf VST therapy candidates targeting both multi-virus (posoleucel and ALVR106) and single-virus indications (ALVR109 and ALVR107). Our portfolio not only showcases our potential to target multiple devastating viral diseases, but also highlights our ability to rapidly respond to emerging viruses, as evidenced by our COVID-19 program, and extend allogeneic off-the-shelf VST therapies beyond transplant patients in order to treat others at high risk of developing viral diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_5.jpg" alt="img101536035_5.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 5. AlloVir&#x2019;s versatile off-the-shelf VST manufacturing platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Proprietary Allogeneic VST Therapy Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are uniquely positioned to rapidly develop and implement T-cell therapies to treat and/or prevent a range of viral diseases, given our team&#x2019;s extensive experience in the fields of virology, immunology and cell therapy. We have leveraged this expertise to design the robust and reproducible allogeneic VST therapy production process depicted in the figure below. This process is comprised of three steps that enable the reliable generation of allogeneic, off-the-shelf, single or multi-virus-specific T cells: (1) our virus-specific T-cell profiling and targeted donor selection process, Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; (2) rapid and scalable off-the-shelf VST manufacturing; and (3) our proprietary, customized VST-cell line selection process, Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which allows for rapid patient access to our allogeneic VST therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_6.jpg" alt="img101536035_6.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 6. Key advantages of AlloVir&#x2019;s patented, highly efficient and industrialized VST platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 1: Profiling T-Cell Responses to Viruses and Donor Selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Identifying immunodominant viral antigens and selecting targeted donors, using Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, from whom to generate VSTs specific for these immunodominant viral antigens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To define a hierarchy of immunodominance, we first analyze the T-cell immune response present in healthy individuals who have naturally controlled a viral infection. To delineate which viral antigens induce the strongest T-cell immune responses we evaluate two parameters: (1) the number of donors whose T cells recognize each of the expressed viral antigens and (2) the strength of the T-cell response induced by each antigen, as measured using functional assays such as production of cytokines. Using these parameters, we can establish a hierarchy of immunodominance and determine which antigens to select for incorporation into our VST manufacturing process. We identify and advance at least two viral antigens in each target virus. This allows us to generate polyclonal VSTs that recognize multiple parts of each of the target viruses, thereby minimizing the risk of virus immune escape with our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Donor Selection&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We next apply our Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> algorithm, as depicted in the figure below, to select the optimal combination of donors from whom to generate VSTs. Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> compares the HLA types of our targeted patient population with a pool of diverse healthy, eligible seropositive donors and identifies a subset of donors, or a mini-bank, that collectively provide greater than 95% of all patients with an appropriate partially HLA-matched VST line. To ensure redundancy and that each patient has multiple VST line options, we build one or more additional mini-banks using the same strategy. In this way, we can assure both breadth and depth of patient coverage with our VST bank.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_7.jpg" alt="img101536035_7.jpg" style="width:605px;height:277px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 7. Implementing the Cytokin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> algorithm to efficiently select donors from whom to generate mini-banks of VSTs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 2: Rapid and Scalable Off-the-Shelf VST Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Applying our patented manufacturing platform to selectively, efficiently and rapidly expand polyclonal VSTs that are cryopreserved and available as an off-the-shelf therapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To selectively activate and expand VSTs, we stimulate donor peripheral blood mononuclear cells, or PBMCs, with overlapping peptide libraries spanning immunodominant viral target antigens, in cell culture medium supplemented with growth factors for a period of approximately two weeks. During this timeframe, polyclonal VSTs are stimulated and expand while T cells that could potentially react with non-virus-infected patient cells and cause toxicities such as GVHD are deselected. In addition, for each virus we target at least two viral antigens in order to minimize the risk of virus immune escape. Once generated, these VSTs are stably maintained in a cryopreserved state allowing for immediate patient access. Each manufacturing run from an individual donor yields hundreds of product candidate doses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to generate allogeneic, off-the-shelf VSTs in a single expansion step allows us to minimize antigen competition and preserve polyclonality. As a result, our polyclonal VSTs are comprised of both helper (CD4+) and cytotoxic (CD8+) virus-specific T cells that recognize multiple parts of each of our target viral antigens, or viral peptides, presented by different HLA alleles. As a result, we can deliver our product candidate to patients based on partial HLA match. The partial HLA match between the allogeneic VST-cell line and infected patient allows the infused T cells to recognize and selectively kill virus-infected cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To facilitate investigational product supply for our clinical trials, we currently manufacture posoleucel and ALVR106 at external cGMP CMOs and leverage a network of cGLP contract testing laboratories.  We are also able to leverage ElevateBio&#x2019;s cell therapy expertise to develop and manufacture VST therapies for clinical trials and commercialization. ElevateBio has established ElevateBio BaseCamp, Inc., or BaseCamp, a centralized cell and gene therapy development and manufacturing facility dedicated to the production of products for its affiliated companies. Therefore, we have also added ElevateBio BaseCamp to our manufacturing network.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 3: Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and Immediate Patient Access to Our Allogeneic VST Therapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rapidly identifying the appropriate VST line for each patient using the Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> algorithm, ensuring immediate accessibility to therapy for high-risk patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The final component of our process relates to the clinical use of our allogeneic off-the-shelf VST therapy. The Cytomatch</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> algorithm guides the selection of the VST cell line for patient treatment. A specific drug product lot is selected for infusion based on the level of HLA matching between patient and associated VST-cell line, with two HLA allele matches set as a minimum threshold. The &#x201c;best&#x201d; VST-cell line is rapidly identified and can be immediately packed and shipped to the treatment center, where it can be thawed and infused to patients without the need for additional manipulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Highly Innovative Allogeneic VST Therapy Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline of allogeneic, off-the-shelf VST therapy candidates is designed to restore virus-specific T-cell immunity in patients suffering from, or at risk for, life-threatening viral diseases. Our proprietary VST therapy platform can be used to generate allogeneic cell therapies targeting single or multiple viruses at commercial scale. We own worldwide development and commercialization rights to all our cell therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_8.jpg" alt="img101536035_8.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 8. AlloVir&#x2019;s pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead product candidate, posoleucel, is a multi-VST therapy targeting six viral pathogens: AdV, BKV, CMV, EBV, HHV-6 and JCV, which has the potential to fundamentally transform the treatment landscape for immunocompromised individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are initially focusing the development of posoleucel in immunocompromised HCT and SOT patients who are at high risk for life-threatening viral infections and are focused on the use of posoleucel as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of virus-associated HC (BKV and/or AdV)</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of AdV infections </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prevention of multi-virus infections (AdV, BKV, CMV, EBV, HHV-6 and JCV) in HCT patients</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment of BKV infections in kidney transplant patients </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel is designed to restore virus-specific T-cell immunity and eradicate active viral infections and associated morbidities. We believe that posoleucel has the potential to fundamentally transform the management of viral infections in HCT and SOT patients, as well as in other individuals at high risk for opportunistic infections. We believe that posoleucel will substantially reduce or prevent virus-associated morbidity and mortality and dramatically improve outcomes for patients with otherwise devastating viral diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the strength of the posoleucel Phase 2 data for both treatment and prevention, the FDA has granted posoleucel Regenerative Medicine Advanced Therapy (RMAT) designation for each of the three indications being evaluated in Phase 3 clinical trials &#x2013; for the treatment of HC caused by BKV, for the treatment of AdV infection in adults and children following allo-HCT, and for the prevention of clinically significant infections and disease caused by posoleucel&#x2019;s six target viruses. Similarly, based on data generated from the Phase 2 POC treatment trial and the critical medical need, the European Medicines Agency (EMA) has granted posoleucel PRIority Medicines (PRIME) designation for the treatment of serious infections with AdV, BKV, CMV, EBV and HHV-6. Posoleucel was one of the first seven investigational therapies to receive both PRIME and RMAT designations and, to our knowledge, is the only investigational therapy to receive three RMAT designations. While these designations may not lead to a faster development process and do not increase the likelihood that a product candidate will receive approval from the FDA or EMA, we expect that PRIME and RMAT designations will result in increased EMA and FDA interactions to support our development efforts and may enable an expedited regulatory review process. In addition, the FDA also granted posoleucel Orphan Drug Designation for the treatment of virus-associated HC, and the EMA granted Orphan Medicinal Product designation to posoleucel for its targeted viruses in HCT patients, including for the potential prevention of infections or disease by these viruses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel for Allogeneic HCT Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCT conditioning regimens often require the complete elimination of a patient&#x2019;s own stem cells, a procedure referred to as myeloablation. These patients are left without a functioning immune system and are consequently in a severely immunocompromised state until their donor stem cells take hold, or engraft, and repopulate the bone marrow. During this period, these patients are highly susceptible to infection. We believe that, as depicted in the figure below, our VST therapy candidates can play the key role of providing bridging immunity between myeloablation, where patients have little-to-no immune function of their own, and reconstitution of their immune systems after the donor stem cells engraft and expand to physiologic levels. We believe that by restoring immunity during this time of severe immune compromise, our VST therapy candidates may substantially reduce or prevent virus-associated morbidity and mortality, thereby dramatically improving patient outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_9.jpg" alt="img101536035_9.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 9. Posoleucel is designed to treat and prevent viral diseases until the patient&#x2019;s own immune system recovers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In approximately 90% of allogeneic HCT patients, the suppressed immune system allows viruses that were previously in a latent, quiescent state to reactivate. Furthermore, more than 60% of allogeneic HCT patients experience a reactivation of more than one virus targeted by posoleucel. These viral infections can cause multi-organ disease and multi-organ failure that may be life-threatening and that typically require hospitalization. It is estimated that more than 20% of all deaths associated with HCTs are due to infections. There are currently no FDA- or EMA-approved therapies for treating most viral infections in the post-transplant setting, and current antiviral therapies are associated with significant toxicity, including renal insufficiency and bone marrow suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Phase 2 POC CHARMS Clinical Results in Allogeneic HCT Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluated posoleucel in a Phase 2 open-label POC trial where VSTs were administered to 58 allogeneic HCT patients with treatment-refractory infections. We refer to this trial as CHARMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary objective of CHARMS, which was not statistically powered for superiority or significance, was to determine the feasibility and safety of administering partially HLA-matched multi-VST therapies targeting six viruses in HCT patients with persistent viral reactivations or infections. Patients were eligible following any type of allogeneic transplant if they had AdV, BKV, CMV, EBV, HHV-6 and/or JCV infections that were relapsed, reactivated or persistent despite standard antiviral therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_10.jpg" alt="img101536035_10.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 10. CHARMS&#x2014;Phase 2, proof-of-concept, open-label trial design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The treatment schedule encompassed an initial single infusion of 2 x 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> partially HLA-matched multi-VSTs/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the patients had a partial response, or a PR, within 28 days of the first infusion, as defined by a 50% or greater fall in viral load, they were eligible to receive up to four additional doses from day 28 after the initial infusion and at two weekly intervals from day 28.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficacy endpoints for CHARMS were resolution of the target infections, as measured by viral load, and resolution of clinical signs and symptoms, as determined by the primary investigator. Clinical and virologic responses were assessed by week 6 per protocol and at additional timepoints where feasible. A complete response, or CR, was defined as return of viral load to normal range and resolution of clinical signs and symptoms. A PR was defined as a decrease in viral load of at least 50% from baseline or 50% improvement in clinical signs and symptoms. No response, or NR, was defined as either stable or progressive disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The demographics and clinical characteristics for the 58 unique patients enrolled and treated in the CHARMS trial are presented in Table 1. These patients were infused with posoleucel therapy matched at one to seven HLA alleles. In this clinical trial, we observed the delivery of partially HLA matched VSTs were generally well-tolerated. These final trial results were published in Clinical Cancer Research in January 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.984%;"></td>
    <td style="width:51.016%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.75pt solid rgba(50,64,107,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Characteristic</span></p></td>
    <td style="border-top:0.75pt solid rgba(50,64,107,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number (%)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sex (N = 58)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;position:relative;min-width:fit-content;">a</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Male</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 (52)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Female</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28 (48)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Age (N = 58)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;position:relative;min-width:fit-content;">a</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xf0a3;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 years of age)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 (31)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adult</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40 (69)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Race (N = 58)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;position:relative;min-width:fit-content;">a</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Black or African American</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (5)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">White</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51 (88)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asian</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 (5)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluable infections treated (N = 70)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BKV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27 (39)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24 (34)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AdV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 (16)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HHV-6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (6)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EBV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 (3)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JCV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (1)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.5pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid rgba(50,64,107,1);vertical-align:middle;border-bottom:0.5pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Number of infections per patient at study entry (N = 58)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;position:relative;min-width:fit-content;">a</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46 (79)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11 (19)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 (2)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Number of infusions per patient (N = 58)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;position:relative;min-width:fit-content;">a</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44 (74.6)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11 (18.6)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 (6.8)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  The CHARMS trial treated 58 unique patients. One patient was enrolled twice, treated first for AdV and then for JCV. This patient was counted twice for some efficacy and once for safety. One patient with HHV-6 was not evaluable for response rate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Table 1. CHARMS clinical trial patient demographic and clinical characteristics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical and Virologic Response</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the 58 unique patients evaluated for efficacy by six weeks post infusion, 55 had a CR or PR, representing a 95% response rate, as depicted in the figure below. Twelve patients were co-infected with at least two different viruses and of these, ten patients (83%) responded to posoleucel by six weeks post-infusion. This demonstrates the potential for treating patients with multiple viral infections with off-the-shelf posoleucel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><img src="img101536035_11.jpg" alt="img101536035_11.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 11. Posoleucel Phase 2 proof-of-concept trial (CHARMS): 95% overall response rate in patients with viral disease by 6 weeks in 58 unique patients</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In Vivo VST Persistence</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to provide bridging immunity to HCT patients, allogeneic off-the-shelf VSTs must persist and provide continued antiviral protection until the transplanted stem cells engraft and the patient&#x2019;s own immune function is restored. To examine how long our posoleucel cells persisted in patients, we examined the peptide epitope specificity of circulating T cells to discriminate between infused and endogenous virus-specific T cells. Of 16 patients that we tested, we were able to confirm the persistence of allogeneic VSTs in 11 patients for up to 12 weeks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Safety Profile</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The overall analysis of preliminary safety results gathered in the CHARMS trial showed that treatment with posoleucel was generally well-tolerated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety monitoring in the CHARMS trial consisted of several assessments, including assessments of both GVHD and serious adverse events, or SAEs, as reflected in the table below. Overall, 23 deaths occurred during the study; none of these deaths was deemed related to study treatment. Of the 23 deaths, 6 were associated with treatment-emergent AEs (TEAEs), and 5 deaths occurred during the protocol-specified AE reporting period. Treatment-related TEAEs &#x2265; Grade 3 occurred in 8 (13.8%) participants, however there were no TEAEs leading to interruption or discontinuation of study intervention, there were no dose-limiting toxicities, and no deaths were attributed to treatment-related TEAEs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, safety findings were consistent with those expected in an allogeneic HCT patient population with persistent and/or refractory viral infections, including the known risks of GVHD. To date, no overt safety signal has been detected above and beyond the safety findings expected to be found in patients who have already undergone allogeneic HCT.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.843%;"></td>
    <td style="width:75.157%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:18.0pt;">
    <td style="border-top:0.75pt solid rgba(50,64,107,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13 patients with acute GVHD (within 42 days of last infusion of posoleucel)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9 patients with prior history of acute GVHD</span></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;   5 grade I and 1 grade II skin GVHD: resolved or improved with topical treatment</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;   1 grade I skin GVHD: resolved after systemic corticosteroids</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;   1 grade II skin GVHD flare: resolved after resumption of systemic corticosteroids</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 grade III GI GVHD flare: occurred coincident with rapid corticosteroid taper, resolved after resumption of systemic corticosteroids</span></p><p style="text-indent:0.0pt;font-size:18.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4 patients with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">de novo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;GVHD</span></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  2 grade I skin GVHD: resolved with topical treatment</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 grade I skin GVHD: resolved with tacrolimus and prednisone</span></p><p style="margin-left:7.2pt;text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 grade I skin GVHD: resolved with topical treatments plus low-dose systemic corticosteroids</span></p><p style="text-indent:-23.75pt;padding-left:23.75pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6 grade 5 SAEs (deaths)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  3 multi-organ failure</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 respiratory failure</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  2 deaths not otherwise specified</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(50,64,107,1);vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8 grade 4 SAEs (reported from 7 patients, 5 of whom also had Grade 5 SAEs reported and are included above)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(50,64,107,1);text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(50,64,107,1);text-align:left;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  2 respiratory failure</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  2 aspartate aminotransferase increased</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 hypoxia</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 dyspnea</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 sepsis</span></p><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;  1 vomiting</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Table 2. Serious adverse events and GVHD in the CHARMS trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment of Virus-Associated Hemorrhagic Cystitis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HC is the primary clinical manifestation associated with BKV following HCT, occurring in 8-25% and 7-54% of pediatric and adult patients, respectively. HC can also be caused by other viruses, including AdV and CMV. However, up to 90% of cases of HC are caused by BKV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between 65-90% of individuals are infected with BKV by the age of ten. Most infections are asymptomatic, but the virus remains latent in the body, primarily in kidney cells throughout life. BKV can reactivate during periods of immune compromise with the virus being detected in the urine of over half of HCT patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than half of patients with HC present with clot formation and/or severe bladder hemorrhage with renal impairment. Bleeding may be life-threatening requiring urologic interventions including the removal of the urinary bladder, or cystectomy. Clinical manifestations of HC include kidney dysfunction or failure, bright red-colored urine due to the presence of blood in the urine, as well as abdominal pain so severe and debilitating that patients often require continuous narcotic infusions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A recent, prospective, multi-center trial of the natural history of BKV after allogeneic HCT in 193 patients found that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22% of patients developed grade 2 or higher HC, and 18% had a high level of BK viremia (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">&#xf0b3;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10,000 copies/mL) in the first three months post-HCT; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients with a high level of BK viremia in the first three months after transplant had a significantly lower estimated glomerular filtration rate, or eGFR, at 12 and 24 months (on average 20mL/min/m</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lower by two years after transplant) and a 6-fold higher risk of receiving dialysis (p=0.004); </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients with high levels of BK viremia have been found to have significant reduction in kidney function (17-26% below baseline) as compared to patients with low levels of BK viremia (4-5% below baseline). Additionally, 18% of patients with high levels of BK viremia required dialysis, compared with 3% of patients with low levels of BK viremia; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A high level of BK viremia was associated with a significantly higher risk of death; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Virus-associated HC has been associated with increased mortality, with patients with high levels of BK viremia experiencing mortality rates of 44%, compared with 19% in patients with low levels of BK viremia; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asymptomatic viremia was common and associated with decreased kidney function, and; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients with detectable BKV-specific T cells were 5-fold more likely to clear viremia, but patients who received off-label cidofovir were not. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently no FDA- or EMA-approved therapies for virus-associated HC. The current standard of care relies on supportive care to address the symptoms and manifestations of HC; urinary bladder irrigation to avoid its obstruction by blood clots; narcotics to alleviate suffering; hyperbaric oxygen therapy; cystectomy in uncontrollable bleeding cases; and dialysis for acute renal failure. The antiviral cidofovir is sometimes used off-label to treat virus-associated HC. However, cidofovir has been associated with kidney toxicity, which may compound the kidney damage caused by virus-associated HC itself.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Clinical Data&#x2014;BKV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Phase 2 proof-of-concept trial for posoleucel, we treated 27 evaluable patients with BKV disease and 100% achieved an overall response by six weeks post-infusion. Overall response rates were defined as achieving either a PR or CR by six weeks post-infusion, as described in the protocol criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 23 patients infused with posoleucel, HC severity was retrospectively graded using the National Cancer Institute cystitis grading scale. This was performed by three physicians independently based on chart review of clinical and laboratory documentation.  These patients treated with posoleucel therapy showed a rapid improvement in disease severity; complete resolution of macroscopic hematuria was observed in 43%, 61% and 74% of patients  weeks 2, 4 and 6 post-infusion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_12.jpg" alt="img101536035_12.jpg" style="width:380px;height:355px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 12. Time to resolution of BKV-HC following treatment with posoleucel</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a retrospective study conducted at BCM, out of 33 pediatric allogeneic HCT patients with an average of Grade 3 BK-HC receiving current standard of care, only 36% had resolved their disease by week 6. Furthermore, less than 10% of the patients had resolved their disease by week 2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our data provide preliminary evidence demonstrating that posoleucel has the potential to meet unmet medical needs in allogeneic HCT patients with virus-associated HC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have initiated our Phase 3 virus-associated-HC registrational trial. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial is designed to assess the safety and efficacy of posoleucel therapy compared to placebo for the treatment of patients with virus-associated HC following allogeneic HCT. The primary endpoint is the time to resolution of macroscopic hematuria. As these HCT patients often experience multiple viral infections, secondary endpoints include the reduction in viral load for AdV, CMV, EBV, HHV-6 and JCV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><img src="img101536035_13.jpg" alt="img101536035_13.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 13. Phase 3, multicenter, randomized, double-blind, placebo-controlled virus-associated HC trial design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the PRIME and orphan drug designations granted by the EMA, posoleucel has received an RMAT designation from the FDA for the treatment of HC caused by BKV in adults and children following an allogeneic HCT. We expect that RMAT designation will result in increased FDA interactions to support our development efforts and may enable an expedited regulatory review process for product approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment of Adenovirus Infections</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AdV viremia occurs in 32% of pediatric allogeneic HCT patients and 6% of adult allogeneic HCT patients. In the HCT setting, patients can present with AdV disease due either to reactivation or de novo exposure. Infection usually occurs between two and three months post-transplant and is a significant cause of morbidity and mortality. The spectrum of AdV-associated disease in HCT patients ranges from mild gastroenteric or respiratory symptoms to severe hemorrhagic enteritis, hemorrhagic cystitis, nephritis, hepatitis, pneumonia, encephalitis, myocarditis, and potentially lethal multiple organ involvement, frequently associated with hepatic failure. Off-label use of cidofovir has been established as the current standard of care treatment to control the replication of virus and prevent disseminated viremia. However, it has limited efficacy irrespective of dose and its use is limited due to toxicity to the kidneys and poor bioavailability. To date, no adequately powered, randomized well-controlled trials demonstrating significant efficacy of cidofovir use for adenoviral disease versus control have been performed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Clinical Data&#x2014;AdV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">          In our CHARMS trial, 83% of patients with AdV infection achieved a response by six weeks post-infusion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated our Phase 3 AdV trial at the end of 2021. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of posoleucel therapy for the treatment of pediatric and adult allogeneic HCT patients with AdV infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_14.jpg" alt="img101536035_14.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 14. Phase 3, randomized, double-blind, placebo-controlled adenovirus treatment trial design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prevention of Multi-Virus Infection and Associated Disease in HCT Patients</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximately 90% of all allogeneic HCT patients experience at least one infection associated with BKV, CMV, AdV, EBV or HHV-6 and more than 60% of patients experience infections caused by two or more of these five viruses within 100 days post-allogeneic HCT. Because of the increased morbidity and mortality associated with viral infections in transplant patients, prevention of viral disease is important for the overall health and survival of patients. Prophylactic therapy, which is a treatment administered to patients at risk for developing viral disease, and preemptive therapy, a treatment of patients with evidence of virus replication in blood, are the two major strategies used for disease prevention. Clinical guidelines recommend that allogeneic HCT patients infected with CMV or AdV should be monitored weekly for virus replication with a sensitive diagnostic technique for at least the first three months after HCT. There are currently no FDA- or EMA-approved antiviral therapies for prevention of multiple viral diseases or infections in transplant patients with one single therapy. For CMV alone, letermovir is approved for CMV in seropositive patients. However, drug resistant CMV has emerged with the use of letermovir, which may limit or restrict its utility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Clinical Data&#x2014;Multi-Virus Prevention in HCT Patients</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Out of 26 high-risk allo-HCT patients who received posoleucel in this open-label study, 22 (85%) patients experienced reactivation of at least one of posoleucel&#x2019;s target viruses. Despite these expected high rates of viral reactivation, only three clinically significant infections were observed through Week 14. These results represent a substantial reduction in the expected rate of clinically significant viral infections or diseases in this high-risk patient population. Biomarker analyses demonstrated that viral control was associated with expansion of functional VSTs, and the presence of posoleucel was confirmed both during the infusion period and up to 14 weeks after</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the last infusion.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment with up to seven doses of posoleucel over 12 weeks was generally well tolerated with no unanticipated safety signals. Rates of GVHD were similar in frequency and severity to those expected in this high-risk allo-HCT population. Three (12%) treatment-related serious adverse events were reported. No episodes of cytokine release syndrome were reported.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on preliminary data from the open-label, Phase 2 POC study for multi-virus prevention, we initiated a global, registrational Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial of posoleucel for multi-virus prevention. The study is enrolling patients in North America, Europe, Asia and Australia.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_15.jpg" alt="img101536035_15.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 15. Phase 3, randomized, double-blind, placebo-controlled multi-virus prevention trial design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment of BKV Infections in Kidney Transplant Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BK virus reactivation in KT patients is due to T-cell immune deficiencies caused by intensive immunosuppressive induction therapy followed by maintenance immunosuppressive treatment. BKV reactivation causes interstitial nephritis and progressive allograft injury. Routine screening for BKV reactivation after transplantation has been widely recommended and is performed at most transplant centers. The goal of diagnosing and managing BK viremia early in the course of active infection is to prevent allograft failure that is associated with BKV-associated nephropathy. BK viremia is detected in up to 20% of KT patients and up to 50% of patients with BK viremia progresses to BK nephropathy, resulting in decreased graft function and graft survival. Nearly half of all patients who develop BK nephropathy experience allograft failure. Because KT patients remain on immunosuppression for life, BK viremia and BK nephropathy onset is not restricted to the first year post-transplant. There are currently no FDA- or EMA-approved therapies for the treatment of BK viremia or BK nephropathy in KT patients. Treatment primarily involves reduction of immunosuppression. However, this results in patients being at increased risk of immune mediated acute allograft rejection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Clinical Data&#x2014; BKV Treatment in Kidney Transplant Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the end of last year, we completed a proof-of-concept, multi-center, randomized, double-blind, placebo-controlled, Phase 2 trial evaluating posoleucel for the treatment of BKV in KT patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_16.jpg" alt="img101536035_16.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 16. Phase 2, randomized, double-blind, placebo-controlled BK virus treatment in kidney transplant trial design</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary endpoint of the posoleucel Phase 2 BKV treatment study in kidney transplant patients with BK viremia was the safety and tolerability of posoleucel versus placebo. Posoleucel was generally well tolerated in the study, with balanced safety across posoleucel dosing groups and placebo, and adverse events rates and severity consistent with the underlying patient population and background immunosuppression. Low rates of infusion reactions were observed in patients receiving posoleucel (2%) and those receiving placebo (5%). There were no deaths or reports of graft versus host disease or cytokine release syndrome. Emergence of donor-specific antibodies was uncommon and occurred with similar frequency in patients receiving posoleucel (7%) or placebo (5%). Three patients who received posoleucel were reported to have acute rejection per biopsy report by a central reader; none of these cases were assessed by the investigator as related to study drug.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key secondary endpoint of the study was the change in BK viral load in patients receiving posoleucel versus those receiving placebo. The efficacy analysis excluded six patients in whom significant reductions in immunosuppression were made immediately prior to study entry. Posoleucel achieved greater viral load reductions versus placebo across all BK viral load measures. Antiviral responses among posoleucel patients increased over time, with maximal responses observed at Week 24. This clinically meaningful treatment effect was strongest among patients receiving posoleucel every two weeks and among those with high viral loads at study screening.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The topline data described above will inform next steps for this potential indication as well as our broader strategy in solid organ transplant patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prevention of Multi-Virus Infection and Associated Disease in SOT Patients</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to HCT patients, the prevention of viral disease in SOT patients is important for both graft survival and the overall health and survival of patients. Published clinical guidelines recommend that all high and intermediate risk SOT patients, which account for nearly 90% of all SOT patients, should receive prophylactic therapy for CMV, which is only one of six viruses that posoleucel targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently no FDA- or EMA-approved antiviral therapies for prevention of multiple viral diseases or infections in SOT patients with one single therapy. Data from our ongoing multi-virus prevention study in allogeneic HCT patients and our Phase 2 study of kidney transplant patients with BK viremia will inform the potential for a POC study of posoleucel for multi-virus prevention in SOT patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Viruses Targeted by Posoleucel</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Epstein-Barr Virus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Epstein-Barr virus is a latent herpesvirus that infects more than 90% of humans worldwide and establishes life-long latency after primary infection. During a primary infection, an immunocompetent host will mount vigorous CD4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and CD8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cellular immune responses and these T cells control both the primary infection and any periodic EBV reactivations. However, EBV reactivation can cause significant morbidity and mortality in immunocompromised patients and uncontrolled EBV reactivation can lead to fulminant viremia and progress to life-threatening post-transplantation lymphoproliferative disorder, or PTLD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PTLD can occur at any age and after all types of transplants, though allogeneic HCT patients are at particular risk. The median time to development of EBV-associated PTLD, or EBV-PTLD, after HCT is two to four months. Fever and lymphadenopathy are the most common symptoms and signs of EBV-PTLD and, if not treated, PTLD generally progresses rapidly to multi-organ failure and death. Off-label rituximab has been used to treat EBV-PTLD. However, response to rituximab is not universal and mortality remains high in rituximab-refractory patients. In December 2022, tabelecleucel received marketing authorization in Europe to treat patients with relapsed or refractory EBV-PTLD who have received at least one prior therapy; the cell therapy has not been approved in other regions at this time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our CHARMS trial, two evaluable patients with EBV infections were treated with posoleucel;  the overall response rate to EBV by six weeks post-infusion was 100%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Human Herpesvirus Type 6</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are two variants of HHV-6: HHV-6A and HHV-6B, both infect and establish latency in different cell types including CD4+ T lymphocytes, monocytes, and other epithelial, fibroblastic and neuronal cells. No disease has been causally linked to HHV-6A, and its natural history is unknown. In contrast, HHV-6B primary infection is ubiquitous in the first two years of life, sometimes causing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">exanthema subitum</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (also known as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">roseola infantum</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and sixth disease). Subsequent viral latency gives the potential for reactivation and disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HHV-6 reactivation is the most frequent cause of encephalitis after HCT. Disease onset is typically two to six weeks post-transplant. Initial signs and symptoms include confusion, delirium, short-term memory loss, syndrome of inappropriate antidiuretic hormone secretion and seizures. Long-term outcomes can result in brain damage, memory defects and death. HHV-6 is also associated with delayed engraftment, allograft failure, acute GVHD and CMV reactivation. There are currently no FDA-approved treatments for HHV-6. The use of off-label antivirals is limited by several factors. Ganciclovir is associated with dose-limiting bone marrow toxicity which may delay HCT engraftment, cidofovir is associated with kidney toxicity and foscarnet is also associated with kidney toxicity, as well as the risks of infection and deep vein clots stemming from its required route of administration.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our CHARMS trial, three evaluable patients with HHV-6 infections were treated with posoleucel; the overall response rate by six weeks post-infusion was 100% (3/3). One additional patient was found to have chromosomal integration of HHV-6 and was excluded from the efficacy analyses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Posoleucel Commercial Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. We are focused on the global development and commercialization of posoleucel as we see a large opportunity to serve patients suffering from devastating viral diseases and infections worldwide. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our initial launch indications for the treatment and prevention of viral diseases in HCT patients, we believe approximately 30% of our annual addressable patient population is in the United States, 35% in the European Union, 5% in Japan, and 30% in 11 other target markets in the rest of the world. We project the addressable transplant patient population for posoleucel for the treatment and prevention of our target viral diseases will be approximately 41,000 HCT patients annually in 2025. There is significant unmet demand for HCT procedures as a result of the lack of access to matched or unmatched stem cell donors. By treating and preventing viral diseases, we believe that posoleucel can address this unmet medical need by enabling more patients to benefit from a curative haploidentical HCT procedure, which represents the fastest growing subset of the existing allogeneic HCTs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1&#x2014;Posoleucel Treatment and Multi-Virus Prevention in Allogeneic HCT Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, approximately 38,000 allogeneic HCTs were performed in our target markets. We project this to grow by 3% annually to approximately 45,000 procedures per year by 2025 and estimate that approximately 41,000  allogeneic HCT patients will be eligible for posoleucel therapy for virus-associated HC, AdV and multi-virus prevention.  <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The observed incidence of virus-associated HC is 8-25% and 7-54% in pediatric and adult patients, respectively, and is higher after allogeneic HCT than after autologous HCT, particularly after haploidentical HCT with post-transplant exposure to cyclophosphamide as prophylaxis for GVHD. By 2025, we estimate there will be approximately 6,700 allogeneic HCT patients annually who develop virus-associated HC.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The incidence of AdV viremia is 32% among pediatric allogeneic HCT patients and 6% among adult allogeneic HCT patients. By 2025, we estimate there will be approximately 4,500 allogeneic HCT patients annually who develop AdV viremia.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximately 90% of all allogeneic HCT patients reactivate at least one of our six target viruses. By 2025, we estimate the addressable patient population for multi-virus prevention will be approximately 41,000 patients, inclusive of the addressable patient populations for virus-associated HC and AdV. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An analysis from the National Marrow Donor Program calculated that the demand for HCT procedures exceeded the number performed in the U.S. by approximately 290%. Lack of access to HLA matched or unmatched stem cell donors is a contributing factor to the unmet demand for allogeneic HCT. To broaden the pool of donors, researchers developed haploidentical transplants, in which a healthy first degree relative can often serve as a donor. Instead of a near-total HLA match, donors for a haploidentical transplant need to be only a 50% match to the patient. In addition to making it easier to find a suitable donor, haploidentical transplants can often be performed more promptly than traditional unrelated donor transplants. Importantly, this enables more patients to receive this curative treatment option for their underlying diseases faster. The successful outcome of haploidentical HCT is dependent on the use of T cell-replete conditioning strategies, which in turn leaves patients highly vulnerable to viral diseases and infections. By treating and preventing viral diseases and infections, we believe that posoleucel can accelerate the paradigm shift toward haploidentical HCT and enable more patients to benefit from this curative HCT procedure.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2&#x2014;Posoleucel Treatment and Multi-Virus Prevention for Solid Organ Transplant Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing posoleucel for the treatment of BK viremia in KT patients and for multi-virus prevention in SOT patients. Approximately 114,000 SOTs were performed in 2020 in our target markets, of which 72,000 were KTs. We project this to grow by 2% annually to 126,000 SOTs by 2025, of which almost 80,000 are for KT, and we estimate that approximately 110,000 KT and SOT patients will be eligible for posoleucel therapy for BK viremia and multi-virus prevention. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BK viremia is detected in up to 20% of KT patients and up to 50% of patients with BK viremia will progress to BK nephropathy, resulting in decreased graft function and graft survival. We estimate that there will be more than 14,000 KT patients annually who will develop BK viremia and can benefit from posoleucel therapy. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Published clinical guidelines recommend that all high-risk (seropositive donor/seronegative recipient, or D+/R-) SOT patients and intermediate risk (D+/R+ and D-/R+) SOT patients should receive prophylaxis for CMV, which is just one of the six viruses posoleucel targets. High-risk patients represent approximately 18% of SOT patients and intermediate risk patients approximately 69%. By 2025, we estimate the addressable patient population for multi-virus prevention in all SOT will be approximately 110,000 patients, inclusive of the addressable patient populations for BK viremia.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3&#x2014;Posoleucel for Other Viruses Associated with Transplant and Immunocompromised Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe posoleucel can also address high unmet medical need in transplant patients with viral diseases associated with EBV, HHV-6, and JC viruses. EBV-PTLD is a severe complication after allogeneic HCT. PTLD was diagnosed in 4% of HCT patients. There are currently no FDA-approved therapies for patients with EBV-PTLD. Over 90% of individuals are infected with HHV-6 before the age of two. In over half of allogeneic HCT patients, HHV-6 is reactivated resulting in clinical manifestations such as encephalitis, delayed engraftment and an increased rate of GVHD leading to increased mortality. Up to 80% of the general population is seropositive for JCV. Rates of PML, the primary disease caused by JC virus, are elevated in HCT patients. The median survival time for HCT patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with PML is less than two years.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe transplant patients represent only one segment of the large number of patients suffering from devastating viral infections who could potentially benefit from posoleucel. Other individuals with weakened immune systems, including those with primary immunodeficiencies, the elderly and very young and patients who have compromised immune systems due to cancer or the treatment of their cancer are all at high risk of the life-threatening consequences of viral diseases and infections. Each of these target patient populations represents a large potential market that is currently untapped or underserved by existing therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Commercialization Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If approved, we intend to commercialize our highly innovative off-the-shelf VST therapies globally to serve a large number of patients suffering from the life-threatening consequences of viral diseases. Initially, to launch our late clinical stage therapies for the treatment of transplant patients, we will establish a focused commercial infrastructure targeting high-volume transplant centers globally. Based on the relatively small number of transplant centers that perform the majority of these transplant procedures, we believe that the entire target market for our VST therapies could be served by a small global team. In the US, there are approximately 185 stem cell transplant centers, of which the top 70 centers perform 80% of the allogeneic HCT, and in the five major European countries (Germany, France, UK, Italy, Spain) there are approximately 410 stem cell transplant centers, of which the top 129 centers perform 80% of allogeneic HCT. Furthermore, in the U.S. there are approximately 240 centers performing kidney transplants, of which the top 100 centers perform 80% of the transplants. We believe that many of these same transplant centers will also have participated in our pivotal and proof-of-concept trials for posoleucel and ALVR106 and will have significant experience with our investigational VSTs, which will support commercial launch and adoption of our therapies. As we eventually progress to serve non-transplant patients at high-risk for the life-threatening consequences of viral diseases, we will expand our global commercial capabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our team has extensive experience launching and commercializing specialty pharmaceuticals globally with a strong track record of achieving broad patient access resulting in industry leading product launches. By targeting severe viral diseases that result in prolonged hospitalization, multi-organ disease and failure and increased risk of death, and currently have limited or no treatment options, we believe that our therapies have the potential to transform the lives and care of patients globally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Transplant-Related Viral Diseases Cause Significant Burden to the Healthcare System</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Along with increased morbidity and mortality, viral diseases and infections in allogeneic HCT patients have a significant impact on healthcare costs. We conducted a real-world claims analysis to assess the economic burden, health resource utilization, and clinical outcomes between allogeneic HCT patients with virus-associated hemorrhagic cystitis and those without virus-associated HC. The study population included 13,363 patients with a first (index) allogeneic HCT procedure between January 1, 2012 and December 31, 2017 from the Decision Resources Group Real World Evidence Data Repository. As shown in the figure below, HCT patients with virus-associated HC incur significantly greater healthcare reimbursement costs (p&lt;0.0001) in the 1-year post allogeneic HCT. After adjusting for baseline characteristics, follow-up duration and number of comorbidities, mean reimbursement costs were approximately $200,000 higher for allogeneic HCT patients with virus-associated HC versus allogeneic HCT patients without virus-associated HC, regardless of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether patients had GHVD. Patients with virus-associated HC had higher length of stay (LOS) for the index hospitalization (p&lt;0.0001), higher readmission rate (p&lt;0.0001) and higher number of days in the hospital after the index hospitalization (p&lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_17.jpg" alt="img101536035_17.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 17. Real-world claims analysis confirms high economic burden of virus-associated HC and multiple viral infections</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, this claims analysis also showed that allogeneic HCT patients with an increasing number of double-stranded DNA viral infections (BKV, CMV, AdV, EBV and HHV-6) have a significantly higher burden of reimbursements and healthcare resource utilization and poorer patient outcomes within one year of undergoing allogeneic HCT. Adjusted mean reimbursement costs were $198,000 for patients with no viral infection, $314,000 for patients with one viral infection, $426,000 for two viral infections, and $571,000 for three or more viral infections in patients without GVHD. In patients with GVHD, the reimbursement costs were higher and similarly increased substantially with each additional infection, with patients with 3 or more infections incurring $843,000 in reimbursed costs. Our results are consistent with those previously published on the high economic burden of transplant-related viral infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106 and ALVR109 VST Therapy for Respiratory Viruses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acute respiratory tract infections due to respiratory viruses including RSV, influenza, PIV, hMPV and coronaviruses such as SARS-CoV-2, the virus that causes COVID-19, are a major public health problem. For example, RSV-induced bronchiolitis is the most common reason for hospital admission in children less than one year of age. The lack of approved antiviral agents to treat many respiratory viruses underscores the need for alternative treatment and prevention strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have two VST therapy candidates to target devastating respiratory viruses: ALVR106, an allogeneic off-the-shelf multi-virus-specific T-cell therapy for RSV, influenza, PIV, and hMPV, and ALVR109, an allogeneic, off-the-shelf VST therapy for SARS-CoV-2. We also amended our then-existing sponsored research agreement with BCM, which we refer to as the BCM SRA, to support their work on the initial discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106: VST Therapy for the Treatment of Patients with Respiratory Viruses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing ALVR106 as an allogeneic, off-the-shelf VST therapy designed to treat or prevent four common respiratory viruses, RSV, influenza, PIV, and hMPV. A Phase 1/2 POC clinical trial of ALVR106 to target severe respiratory diseases in high-risk populations is ongoing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_18.jpg" alt="img101536035_18.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 18. Consequences to high-risk patients with respiratory virus infections</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pre-Clinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As illustrated below, our preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data demonstrates that ALVR106 can be reproducibly generated from healthy seropositive donors and reactive cells have potent antiviral activity against each of the target viruses. Additionally, these cells do not target non-virus-infected autologous or allogeneic cells. We believe this data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_19.jpg" alt="img101536035_19.jpg" style="width:720px;height:317px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 19. ALVR106 has selective antiviral activity against target viruses, leaving non-virus infected targets intact</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Respiratory Virus Infections in HCT Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Respiratory tract infections due to RSV, influenza, PIV and hMPV, are detected in up to 40% of allogeneic HCT patients. In approximately half of these patients, these viral infections progress from less serious upper respiratory tract infections, with symptoms similar to those of a common cold, to far more serious lower respiratory tract infections, with severe symptoms including pneumonia and bronchiolitis. These more serious infections are associated with mortality rates between 20-45%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RSV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSV is a common infectious complication of transplantation, with an incidence of up to 12% in HCT patients. In immunocompetent adults, infections from RSV typically result in upper respiratory tract infections characterized by cough, fever and runny nose. However, in approximately two-thirds of infected HCT patients, an RSV infection develops into a lower respiratory tract infection characterized by severe symptoms including pneumonia and bronchiolitis. These infections are associated with morbidity and mortality rates of up to 28%. Therapy for RSV infections in HCT patients consists primarily of supportive care. Aerosolized ribavirin, or RBV, is FDA-approved for the treatment of RSV but is logistically difficult to administer, as it requires a specialized nebulization device that connects to an aerosol tent surrounding the patient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Influenza</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Influenza infections have been found in up to 46% of allogeneic HCT patients. Approximately 20% of HCT patients with influenza infections progress to develop pneumonia which has been associated with a 30-day mortality rate of 28%. Influenza infections are a major cause of morbidity and mortality in individuals who have weakened immune systems, the elderly and patients with chronic diseases. While there are preventative vaccines for influenza, they are only partially effective in HCT patients. Available antiviral drugs are associated with the development of drug resistance at high rates in HCT patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PIV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PIV primarily affects young children and can cause upper respiratory tract infections and lower respiratory tract infections including conditions such as the common cold, croup, bronchitis, bronchiolitis and pneumonia. In immunocompetent individuals the course of these infections is limited due to antiviral responses from both the innate and adaptive immune systems. Up to 18% of immunocompromised HCT patients develop PIV infections, which can lead to decreased lung function, multiorgan failure and graft loss. Mortality rates of HCT patients with PIV infections can be as high as 60%. There are currently no FDA- or EMA-approved vaccines or treatments for PIV infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">hMPV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between 5-9% of HCT patients develop hMPV infections. hMPV is a ubiquitous virus to which nearly the entire population globally has been exposed by age five. In the majority of cases, hMPV results in upper respiratory infections with symptoms similar to that of the common cold. In 21-40% of hMPV infections in HCT patients, however, the viral infection progresses from a mild upper respiratory disease to a serious lower respiratory disease that is associated with fatality rates of up to 80%. There are currently no FDA- or EMA-approved therapies or vaccines for hMPV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A Phase 1/2 clinical trial of posoleucel in autologous and allogeneic HCT patients with respiratory viral diseases is enrolling patients in the U.S. This POC trial is a Phase 1/2, double-blind, placebo-controlled, dose escalation and expansion trial of ALVR106 in addition to standard of care to assess safety and efficacy of ALVR106.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_20.jpg" alt="img101536035_20.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 20. AVLR106 Phase 1/2 POC trial design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Respiratory Virus Infections in High-risk Populations: Elderly, Young, Cancer Patients</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In developed countries, there are well-defined high-risk populations in whom RSV infection is more likely to progress into a severe lower respiratory tract infection, including infants less than three months of age or born prematurely, the elderly and immunosuppressed patients. In children, bronchiolitis and pneumonia are the most common clinical manifestations. RSV is responsible for between approximately 66,000 and 199,000 deaths each year. In adults, RSV infections develop annually in 3-7% of elderly individuals and in 4-10% of high-risk adults, where they can cause pneumonia and bronchitis and may lead to death. Importantly, previous infection does not confer immunity. To date, there is no FDA- or EMA-approved vaccine and no clear evidence that treatment with antiviral agents or anti-inflammatory agents reduces the length of infection or the duration of hospital stay in any population. A neutralizing monoclonal antibody, palivizumab, has been developed as immunoprophylaxis to prevent RSV infection; however, its use is limited to high-risk infants because evidence of its effectiveness is limited in broader patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Influenza</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Influenza virus infection causes substantial morbidity and mortality. The World Health Organization, or WHO, estimates that annual epidemics cause 3-5 million cases of severe illness worldwide, and influenza-associated respiratory deaths are estimated to be between approximately 290,000 and 650,000 persons annually. Of these, the highest mortality rates are observed in people aged 75 years and older (51.3 to 99.4 individuals per 100,000). The overall rate of respiratory-associated deaths is also relatively high in patients less than five years of age (2.1 to 23.8 per 100,000). These events occur despite the availability of vaccines and antiviral therapies for influenza. A recent study in the United States demonstrated that vaccination was only 38% effective for influenza A or B viral infections. In the event of infection, patients may be treated with neuraminidase inhibitors, such as oseltamivir and zanamivir. However, not only must these antivirals be administered early in the disease course, they may induce resistance to the influenza virus.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PIV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PIV is among the most common respiratory tract infection worldwide and is associated with both upper and lower respiratory tract infections in both children and adults. Progression from upper to lower respiratory tract infection is most common in children less than five years old and in immunocompromised adults, including the elderly and those with hematologic malignancies. In children, seasonal epidemics account for 40% of hospitalizations for lower respiratory tract illness and 75% of croup cases. Overall, 7% of pediatric hospitalizations for febrile respiratory illness in children less than 5 years old are due to PIV. The estimated annual cost of pediatric hospitalization and emergency room visits due to PIV is greater than $200 million, according to a 2016 study. PIV accounts for 15% of respiratory illness in adults and most commonly manifests as upper respiratory tract infections or pneumonia. Approximately 2.0-11.5% of adult hospitalizations for respiratory illnesses are due to PIV. Currently there are no FDA- or EMA-approved vaccines or antiviral therapies for PIV, and treatment of infection consists of supportive care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">hMPV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to other respiratory pathogens, hMPV causes both upper and lower respiratory tract infections with the most severe disease observed in infants, young children, the elderly, and immunocompromised patients. The most common diagnoses associated with hMPV are bronchiolitis and pneumonia. Studies in children either in the hospital or seen in the outpatient setting show that hMPV is associated with between 6% and 40% of acute respiratory illness. Similar to other respiratory viruses, exposure does not confer immunity, and despite almost all people having been infected with hMPV by age five, re-infection occurs throughout adulthood and is associated with morbidity and mortality in the elderly population. In one study, 46% of hMPV cases were seen in patients greater than 65 years of age and 60% of these patients were hospitalized. In a separate study in an elderly care center, 50% of infected patients developed bronchitis or pneumonia, which led to 50% mortality. Currently there are no FDA- or EMA-approved vaccines or antiviral therapies for hMPV, and treatment of infection consists of supportive care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also plan to test ALVR106 in high-risk patient populations outside of the transplant setting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commercial Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106 is an allogeneic, off-the-shelf VST therapy candidate designed to target four common respiratory viruses that represent important causes of morbidity and mortality in HCT and SOT patients, as well as other high-risk patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ALVR106 for Transplant Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In HCT patients, respiratory viral infections occur in both allogeneic HCT and autologous HCT patients. Respiratory viruses infect patients both within the first year post-transplant and beyond. Our target population for ALVR106 includes patients who have undergone allogeneic and autologous HCTs and who have lower respiratory tract infections and upper respiratory tract infections at medium or high risk of progressing to lower respiratory tract infections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We project the number of allogeneic and autologous HCT procedures to grow 3% annually to approximately 42,000 and 51,000 procedures annually, respectively, by 2025 in our target markets in North America, Europe, Asia Pacific and Latin America. By 2025, we estimate there will be nearly 16,000 HCT patients annually infected with one of the four respiratory viruses targeted by ALVR106. We believe that ALVR106 will be effective for treating infections in HCT patients with one or more of the targeted respiratory viruses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Respiratory viruses can infect patients of all types of SOTs, although the majority of the literature describes devastating consequences in lung transplant patients. Our initial target population will include lung transplant patients hospitalized for respiratory viruses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We project the number of new lung transplants to grow 2% annually to approximately 7,000 new lung transplants annually by 2025 in our target markets. We estimate the size of the prevalent lung transplant population to be nearly 56,000 patients in our target markets. By 2025, we estimate that there are annually over 12,000 lung transplant patients that are infected with one of the four respiratory viruses targeted by ALVR106.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ALVR106 for High-risk Populations: Elderly, Young, Cancer Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe transplant patients represent only a small fraction of the large number of patients suffering from devastating respiratory infections who could potentially benefit from ALVR106. Other individuals with weakened immune systems, including those with primary immunodeficiencies, the elderly and very young and patients who have compromised immune systems due to cancer or the treatment of their cancer are all at high risk of the severe consequences of respiratory infections. Each of these target patient populations represents a large potential market that is currently untapped or underserved by existing therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR109: VST Therapy for the Treatment of Patients with COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SARS-CoV-2 infection causes the severe and life-threatening viral disease, COVID-19. COVID-19 has become synonymous with profound depletion of endogenous T cells, or lymphopenia, resulting in a state of acute immune deficiency, rendering infected individuals susceptible to developing overwhelming and sometimes fatal pneumonia. Beyond the lungs, COVID-19 is a multi-organ disease that affects the heart, kidneys, brain, liver and gastrointestinal tract, as well as causing blood clots.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Studies to date estimate that the risk of mortality is up to 500% higher in patients 65 years of age or greater than in those aged 30 to 59 years. In addition, other risk factors for severe COVID-19 include chronic lung or heart disease, hypertension, diabetes and underlying immune compromise. Accordingly, there is an urgent need to rapidly develop an effective therapy for COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T cells are known to play a critical role in controlling viral infections, including respiratory infections caused by SARS-CoV, the coronavirus with the highest known homology to SARS-CoV-2. Greater than 80% of hospitalized patients with COVID-19 are lymphopenic, with reduced CD8+ and CD4+ T-cell counts. These reductions in T-cell counts correlate negatively with survival. Reduced T-cell counts have been observed to be prevalent in older COVID-19 patients and those with severe illness, regardless of age. As further data on the immunogenicity of SARS-CoV-2 continue to emerge, the important protective role of SARS-CoV-2-specific T cells is increasingly being recognized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ALVR109</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR109 is a SARS-CoV-2-specific T-cell product candidate comprised of polyclonal (CD4+ and CD8+) VSTs that is generated from healthy, eligible seropositive donors and targets immunogenic viral antigens. As illustrated below, preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data developed pursuant to the BCM SRA indicated that ALVR109 demonstrated selective cytolytic activity against target cells presenting SARS-CoV-2 antigens while leaving non-virus infected targets intact. Preclinical data presented at IDWeek 2021 demonstrate that ALVR109 provides antiviral activity and coverage against multiple SARS-CoV-2 variant strains.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img101536035_21.jpg" alt="img101536035_21.jpg" style="width:720px;height:335px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 21. ALVR109 has demonstrated selective cytolytic activity against SARS-CoV-2 while leaving non-virus infected targets intact</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In recent publication, ALVR109 was well-tolerated and was associated with clinical improvement in four transplant and non-transplant patients, with cells that expanded and persisted post-infusion. Positive reports of ALVR109 compassionate use in immune-compromised patients also have been published and presented, including presentations at the 2022 American Transplant Congress, providing important insight into the potential utility of a virus-specific T cell approach to treating respiratory viruses in immunocompromised patients.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of ALVR109 demonstrates our ability to rapidly and efficiently develop new VST therapy candidates in response to emerging viral pathogens. Our approach of delivering high-risk patients with banks of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ex vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-expanded, VST therapies generated from healthy immune donors is designed to address the underlying immune deficiency. Furthermore, VST therapies are prospectively prepared and thus immediately available as an off-the-shelf therapy. These VST therapies are polyclonal and target multiple virus-expressed antigens, which we believe makes them less susceptible to viral point mutations that typically confer drug resistance. We believe these features distinguish our approach from others currently in development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are monitoring the evolution of the SARS-CoV-2 virus and the COVID-19 pandemic to guide the next steps for this program in the context of our broader R&amp;D portfolio and priorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR107: VST Therapy for the Treatment of Hepatitis B Virus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hepatitis B Virus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global prevalence of HBV has been estimated to be between 292 and 360 million people with approximately 260 million people living with chronic HBV infection. HBV is most common in the Western Pacific and African regions, where approximately 6% of the adult population is infected. In contrast, only approximately 1.6% and 0.7% of the European and Americas regions, respectively, are infected. About 30% of patients with chronic HBV develop liver cirrhosis, and nearly 23% of these die within five years of developing cirrhosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current treatment options for chronic HBV consist of life-long antiviral therapy to suppress virus replication. This can slow the progression of liver cirrhosis and reduce the incidence of liver cancer. However, there are no curative therapies available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chronic HBV infection is associated not only with significant morbidity and mortality as noted above, but also with weak or absent endogenous HBV-specific T-cell reactivity. In contrast, clinical recovery and effective antiviral therapy are associated with sustained viral control by HBV-specific T cells. Therefore, an off-the-shelf VST therapy that could cure HBV would meet a critical unmet medical need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POC for the potential of adoptive T cell therapy to achieve functional HBV cure has already been established. A Taiwanese study published in Blood in 2005 demonstrated that 65% of chronic hepatitis B patients who underwent allogeneic HCT transplantation and received cells from a donor with natural HBV immunity, achieved functional HBV cure post-transplant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ALVR107</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR107 is an allogeneic, off-the-shelf VST therapy designed to cure patients with HBV. ALVR107 is comprised of a bank of VSTs manufactured from eligible third-party healthy donors who are pre-screened for infectious agents and disease risk factors. These donors are chosen to reflect and accommodate the HLA diversity of the patient population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study. The company expects to initiate clinical development of ALVR107 after completion of the posoleucel Phase 3 registrational studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our innovative and proprietary technology, the expertise of our executive and scientific team, and our access to cell therapy process development and manufacturing expertise at ElevateBio and BaseCamp provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions and public and private research institutions. VST therapies that we successfully develop and intend to commercialize may compete with existing therapies and new therapies that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, may have a more established presence in the market and significantly greater financial, technical and human resources than we have. The competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel. Smaller or early-stage companies may also prove to be significant competitors through collaborative arrangements with large and established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, or are less expensive than any products that we may develop. Our competitors may also obtain FDA or other regulatory approval for their products faster than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If approved, our VST therapies would compete with cell therapies and antivirals used to treat and prevent the viral diseases our VST therapies target.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cell Therapies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently no FDA-approved cell therapies for treating or preventing the viral diseases and infections we are targeting. Atara Biotherapeutics, Inc.&#x2019;s Ebvallo&#153; (tabelecleucel), an off-the-shelf, allogeneic T-cell immunotherapy, for HCT and SOT patients with EBV+PTLD (EBV-associated post-transplant lymphoproliferative disease), received European marketing authorization in December 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antivirals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently no FDA or EMA-approved antiviral therapies for treating most viral diseases and infections in the post-transplant setting, and current antiviral therapies are associated with significant toxicity, including renal insufficiency and bone marrow suppression. Despite the availability of antivirals for some of the viral diseases we are targeting, patients continue to experience high levels of morbidity and mortality. Additionally, the effectiveness of these antivirals is limited due to the emergence of drug resistance. Similarly, there are limitations to prophylactic approaches, such as vaccines, which may not work well in immunosuppressed patients, the elderly, and the very young who are unable to mount an effective immune response. The antiviral therapies currently available for the indications we are targeting with our allogeneic, off-the-shelf VST therapy candidates are listed below. Unless otherwise noted, there are no antiviral therapies approved by the FDA for the treatment or prevention of the viral diseases we are targeting:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> With the exception of valganciclovir, ganciclovir and letermovir for the prevention of CMV disease, and maribavir for the treatment of refractory CMV infection/disease, there are no products FDA-approved for the treatment of AdV, EBV, BKV, HHV-6, or CMV infections or their consequent diseases in allogeneic HCT or SOT patients. Furthermore, there are currently no FDA- or EMA-approved antiviral therapies for the prevention of multiple-viral diseases or infections in transplant patients. Cidofovir is sometimes used off-label for the treatment of BKV-associated HC and AdV infections in HCT patients. Additionally, Vera Therapeutics has completed a Phase 2 clinical trial for MAU868 for the treatment of BKV in KT patients and is exploring the development of MAU868 for the treatment of BKV cystitis in HCT recipients. Memo Therapeutics&#x2019; MTX-005, a therapeutic antibody candidate, is in Phase 1 development for the treatment of BKV infection in renal transplant patients. Helocyte, Inc. is conducting Phase 2 clinical trials of its Triplex vaccine to control CMV infections in HCT patients. Rituximab, an approved antiviral treatment for rheumatoid arthritis and B-cell non-Hodgkin&#x2019;s lymphoma, is used off-label for the treatment of EBV infections in HCT and SOT patients. Brincidofovir, a lipid conjugate of cidofovir, is in early development by SymBio Pharmaceuticals for the treatment of adenoviral disease after allogeneic HCT. AiCuris has in early development AIC468 to prevent BK viral infection in transplanted kidneys. Finally, intravenous immunoglobulin (IVIG) has been explored for the prevention and treatment of BKV associated nephropathy in renal transplant patients, but not in HCT patients. Even in renal transplant patients, there is limited efficacy data for IVIG to support routine use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The FDA has approved ribavirin (aerosol) to treat RSV infections in children and pavilizumab to treat RSV infections in children younger than two years old. Ribavirin is also used off-label for the treatment or prevention of RSV infections in HCT and SOT patients and PIV infections and hMPV infections in HCT patients. AstraZeneca is conducting a Phase 2 clinical study of nirsevimab to treat RSV infections in immunocompromised children. Certain approved antiviral medications, including oseltamivir, zanamivir, baloxavir and peramivir, are used to treat influenza infections in HCT and SOT patients. Ansun BioPharma, or Ansun, is conducting Phase 2 clinical trials of DAS181 to treat influenza infections. Several vaccines are FDA-approved and in clinical development for the prevention of influenza infections. Ansun is also conducting Phase 3 clinical studies of DAS181 to treat PIV infections in immunocompromised patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR107:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> There are numerous antiviral therapies approved by the FDA and in clinical development for the treatment of chronic HBV infections. However, these current treatment options for chronic HBV consist of life-long antiviral therapy to suppress virus replication. This can slow the progression of liver cirrhosis and reduce the incidence of liver cancer, but there are no curative therapies available.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our intellectual property is critical to our business and we strive to protect it, including by obtaining, maintaining, defending, and enforcing patent protection in the United States and internationally for our proprietary technology, improvements, platforms, product candidates and components thereof, novel biological discoveries, new therapeutic approaches and potential indications, and other inventions that are important to our business. For our product candidates, generally we initially pursue patent protection covering compositions of matter, methods of production, and methods of use. Throughout the development of our product candidates, we will seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional pharmaceutical formulations, methods of use and production.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of January 18, 2023, our patent portfolio includes ten patent families exclusively in-licensed from Baylor College of Medicine, or BCM, in our field (one of which is co-owned by AlloVir). These families include issued and pending patents related generally to our allogeneic, off-the-shelf, single and multi-VST cell therapies, our clinical product candidates posoleucel, ALVR106 and ALVR109, various pre-clinical product candidates including ALVR107 and ALVR108, and our current clinical and backup processes for generating VST-cell products and banks. Specifically, we exclusively in-license at least four issued U.S. patents, 54 patents issued in foreign jurisdictions, and 80 patent applications pending worldwide. Our issued patents are expected to expire between 2030 and 2033, and any patents that may issue from our pending patent applications are expected to expire between 2030 and 2042, absent any patent term adjustments or extensions. As to the patent term extension to restore patent term lost during product development and the FDA regulatory review process, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio related to our posoleucel product candidate includes two patent families directed to multi-VST compositions and methods of making and using such compositions therapeutically. The first family includes two issued U.S. patents with claims directed to our clinical and backup methods of making multi-VST cell lines and related patent applications are pending in the U.S. and Europe. Patents in this family are expected to expire in 2030, absent any patent term adjustments or extensions. The second family includes one issued U.S. patent with claims directed to methods of making posoleucel, one issued European patent with claims directed to methods of making multi-VST compositions including posoleucel and ALVR106, and a second issued European patent with claims directed to compositions of multi-VST compositions including posoleucel and ALVR106, made via such methods. The first European patent is validated in 19 European states, and the second in 21 European States, each including Denmark, France, Germany, Spain and the UK. Related patent applications are pending in the U.S. and in Europe. Patents in this family are expected to expire in 2033, absent any patent term adjustments or extensions as noted above.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio related to our ALVR106 product candidate includes the two patent families discussed above with respect to posoleucel as well as a patent family directed to the ALVR106 product and methods of making and using the same therapeutically. This patent family includes one U.S. pending patent application and 14 pending patent applications in foreign jurisdictions including Australia, Canada, China, Europe, and Japan. Any patents that may issue from this patent application are expected to expire in 2040, absent any patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio licensed from BCM also includes a patent family related to our ALVR109 product candidate and methods of treating COVID-19 and other coronavirus infections using the same. This patent family includes one U.S. pending patent application, and 4 pending patent applications in foreign jurisdictions including Canada, Europe, Japan, and Taiwan. Any patents that may issue from the patent applications in this family are expected to expire in 2041, absent any patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio licensed from BCM also includes two pending U.S. provisional patent applications, one pending PCT application, and one pending application in Taiwan related to VST compositions, including our ALVR107 and ALVR108 product candidates, and methods of making and using the same therapeutically. Any patents that may issue from the patent applications in this family are expected to expire in 2042, absent any patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our portfolio further includes other patent families related to our VST technologies. For example, our portfolio includes one patent family  with one U.S. pending patent application and 15 pending patent applications in foreign jurisdictions including Australia, Canada, China, Europe, and Japan, and relates to our process of selecting donors for VST generation and our methods of matching patients with suitable VST-cell lines; one patent family with  one pending U.S. application and 13 pending applications in foreign jurisdictions including Australia, Canada, China, Europe, and Japan, and relates to methods for the prophylactic treatment of viral infections; one patent family with one issued U.S. patent, three issued foreign patents, and pending patent applications in the U.S. and foreign jurisdictions including Australia, Canada, China, Europe, and Japan, and is directed to methods of identifying peptides that are likely to be immunogenic; one patent family including one pending PCT application and pending applications in foreign jurisdictions directed to universal antigen-specific T cells compositions and methods of making and using the same; and one patent family including 11 issued patents (including a European patent validated in 7 European states) and 3 pending patent applications with claims directed to methods of rapidly expanding T-cells. Patents in the T-cell expansion family are expected to expire in 2032, and any patents that may issue from the immunogenicity family, the  donor selection family, the methods for prophylactic treatment family, or the universal antigen-specific T cell family are expected to expire in 2036, 2040,  2040, and 2041, respectively, absent any patent term adjustments or extensions. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as noted, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely on trade secrets relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. It is our policy to require our employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees and consultants also provide that all inventions conceived by the employee or consultant in the course of employment or consulting relationships with us or from the employee&#x2019;s or consultant&#x2019;s use of our confidential information are our exclusive property and require such employees and consultants to assign their title, right and interest in such inventions to us. Although we take steps to protect our proprietary information and trade secrets, including through such contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, including through breaches of such agreements with our employees and consultants. Thus, we may not be able to meaningfully protect our trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sponsored Research, Collaboration, License and Other Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, we signed a License Agreement, or the License Agreement, with BCM, whereby we acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights in the field of viral infection.  In May 2020, we entered into an amended and restated exclusive license agreement, or the A&amp;R License Agreement, with BCM, pursuant to which we obtained (a) an exclusive worldwide license, with the right to sublicense, under certain patent rights and other intellectual property rights of BCM, to make, have made, use, market, sell, offer to sell, lease, import and export products in a particular field, except that such license is non-exclusive within a particular subfield, and in addition with respect to certain patent rights such license is limited to two particular subfields, and (b) an exclusive, worldwide sublicense, with the right to further sublicense, under all patent rights and other intellectual property rights that are exclusively licensed to BCM by a certain third party licensor, to make, have made, use, market, sell, offer to sell, lease, import and export products in the same field. Our rights are subject to the rights of the U.S. government and certain rights retained by BCM.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the A&amp;R License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country. We may terminate the A&amp;R License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the A&amp;R License Agreement in its entirety for our uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BCM maintains control of all filing, prosecution and maintenance of its patent rights licensed by us, and we are responsible for all related costs and expenses during the term of the agreement. We also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by us. If BCM licenses the patent rights licensed by us to third parties for additional fields of use, our responsibility for patent-related costs and expenses will be reduced on a pro-rata basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the A&amp;R License Agreement, we must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the original agreement executed in June 2017, we paid BCM a non-refundable license fee of $250,000. During the term of the A&amp;R License Agreement, we are obligated to pay BCM a non-refundable annual license maintenance fee of $20,000 on the first through fourth anniversaries of the original agreement date and $40,000 beginning on the fifth anniversary of the original agreement date, but beginning with the fifth anniversary of the original agreement date, license maintenance fees are fully creditable against royalty revenue due in the applicable year. We are required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that we are able to successfully develop, launch and commercialize a product under the A&amp;R License Agreement, total milestone payments could exceed $40.0 million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than 1% to the low single-digits, on net sales of any products that are commercialized by us or our sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by us. To the extent we sublicense our license rights under the A&amp;R License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we entered into the First Amendment, or the License Amendment, to the A&amp;R License Agreement. Under the License Amendment, we assumed responsibility from BCM for the filing, prosecution and maintenance of the patent rights licensed by us from BCM under the A&amp;R License Agreement that are in common with the License Agreement. Further, BCM also transferred to us the right of enforcement against third parties for any suspected infringement of any claims in such patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we signed a second License Agreement, or the Second License Agreement, with BCM, whereby we acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights outside the field of viral infection (all fields other than those covered by the License Agreement Amendment noted above).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the Second License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country, provided that the Second License Agreement shall not expire later than March 25, 2040. We may terminate the Second License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the Second License Agreement in its entirety for our uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, BCM transferred to us control of all filing, prosecution and maintenance of the patent rights licensed by us, and we are responsible for all related costs and expenses during the term of the Second License Agreement. BCM also transferred to us the right of enforcement against third parties for any suspected infringement of any claims in the patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. We also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the Second License Agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by us, to the extent not already paid by us under the A&amp;R License Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, we must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the Second License Agreement, we paid BCM a non-refundable license fee of $125,000. During the term of the Second License Agreement, we are obligated to pay BCM a non-refundable annual license maintenance fee of (a) $20,000 for the first through fourth anniversary of the effective date of the Second License Agreement, and (b) $40,000 for the fifth anniversary of the effective date and continuing thereafter, but beginning with the fifth year, license maintenance fees are fully creditable against royalty revenue due in the applicable year. We are required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that we are able to successfully develop, launch and commercialize multiple products under the Second License Agreement, total milestone payments could exceed $30.0 million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than 1% to the low single-digits, on net sales of any products that are commercialized by us or our sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by us. To the extent we sublicense our license rights under the Second License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sponsored Research Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2019, we entered into a sponsored research agreement, or SRA-2, with BCM, under which we agreed to pay BCM for performing certain research activities related to virus specific T-cell manufacturing for a one-year period, renewable for an additional one-year term upon written consent of both parties. SRA-2 requires us to make payments to BCM totaling $1.0 million, payable in four equal installments. SRA-2 was amended in March 2020 to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. In June 2020, a second amendment was entered into resulting in a no-cost extension through November 30, 2020, upon which the agreement terminated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we entered into a Research Collaboration Agreement, or the Research Agreement, with BCM, under which we agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021, and continuing for a three-year period thereafter. The Research Agreement requires us to make payments to BCM totaling approximately $2.0 million per year, for a total of $6.0 million over the term of the Research Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Redeemable Preferred Stock Redemption Agreement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, we entered into a redeemable preferred stock redemption agreement, or Redemption Agreement, to redeem shares of our Series A1 convertible preferred stock held by certain investors, including executive officer Ann Leen, director and former executive officer Juan Vera and entities affiliated with director, Malcolm Brenner and former director, John Wilson (or their affiliates). Pursuant to the Redemption Agreement, for a period of 20 years from the date of the first commercial sale of Viralym-M by us, we are obligated to make earnout payments to such investors on at least an annual basis. The earnout payments will be 10% of our net sales of Viralym-M, which number will be reduced to a high single-digit percentage if certain events occur. Specifically, royalties due to third parties for the sale of Viralym-M are subtracted from the earnout payments due to the investors. Further, if the investors receive at least $50,000,000 in earnout payments from us during the three-year period after the first commercial sale of Viralym-M, the earnout payment percentage will be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our versatile VST manufacturing platform supports the rapid, robust and scalable generation of single- and multi-virus specific cell therapeutic candidates for clinical use. We leverage Cytokin&#153;, our proprietary algorithm to select donors from whom to generate VSTs such that there is broad patient HLA coverage through an efficient set of donors. Virus-specific T-cells from individual healthy seropositive donors are expanded in a fully good manufacturing practices, or cGMP, compliant process, which is scaled to produce hundreds of patient doses from each manufacturing run. Our VST cell therapies are maintained in a cryopreserved state ready for &#x201c;off-the-shelf&#x201d; use. Cytomatch&#153;, our proprietary algorithm for HLA matching, identifies the best VST cell line for each patient. In combination, these elements allow us to efficiently build our global supply chain to serve a growing number of patients who could benefit from our highly innovative off-the-shelf VST therapy candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To facilitate investigational product supply for our posoleucel and ALVR106 clinical trials, we manufacture posoleucel and ALVR106 at external cGMP CMOs and leverage a network of cGLP contract testing laboratories. We believe this approach for our clinical product candidates is most cost-effective at our current clinical phase and production scale and has allowed us to rapidly prepare for clinical trials in accordance with our development plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, biological products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing, quality control, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, advertising, post-approval monitoring, and post-approval reporting involving biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources, and we may not be able to obtain the required regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Biological Products Development Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	submission to the FDA of an application for an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	approval of the protocol and related documentation by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each study may be initiated;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	performance of adequate and well-controlled human clinical trials according to the FDA&#x2019;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	preparation of and submission to the FDA of a biologics license application, or BLA, for marketing approval that includes sufficient evidence of establishing the efficacy, safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials;</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with current good manufacturing practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s identity, strength, quality and purity and, if applicable, the FDA&#x2019;s current good tissue practices, or CGTPs, for human cellular and tissue products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	review of the product candidate by an FDA advisory committee, where appropriate and if applicable;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	payment of user fees for FDA review of the BLA (unless a fee waiver applies); and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	FDA review and approval of the BLA, resulting in the licensure of the biological product for commercial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before testing any biological product candidate, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, may include laboratory evaluations of product biological characteristics, chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs, if applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the United States, an IND must be submitted to the FDA and the FDA must allow the IND to proceed. An IND is an exemption from the FD&amp;C Act that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA allowance that such investigational</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Submission of an IND therefore may or may not result in FDA allowance to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators who generally are physicians not employed by, or under, the control of, the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on data from the ongoing study that are available to the DSMB members.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information about certain clinical trials must also be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The investigational product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The investigational product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The investigational product is administered to an expanded patient population to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for approval and product labeling.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, FDA may require, or firms may voluntarily pursue, post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor&#x2019;s data safety monitoring board, may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies may complete additional animal studies and also must develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP and as applicable CGTP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. In most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA targets ten months from the date FDA files the application (i.e., the filing date) in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application granted priority review by FDA. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency. The FDA may refer applications for novel biological products or biological products that present difficult or novel questions of safety, efficacy, or quality to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Where applicable, the FDA also will not approve the product if the manufacturer is not in compliance with the CGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human patient. The primary intent of the CGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through appropriate screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To ensure cGMP, CGTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings precautions or interactions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase IV post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan drug designation may also entitle a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions. To be eligible for fast track designation, new drugs and biological product candidates must be intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as a fast track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the FDA&#x2019;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. The FDA may take other actions appropriate to expedite the development and review of the product candidate, including holding meetings with the sponsor and providing timely advice to, and interactive communication with, the sponsor regarding the development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product candidate is eligible for priority review if it treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#x2019;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a product candidate may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials with due diligence and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. In addition, for products being considered for accelerated approval, unless otherwise informed by the FDA, the FDA generally requires, that all advertising and promotional materials intended for dissemination or publication within 120 days following marketing approval be submitted to the agency for review during the pre-approval review period, and that after 120 days following marketing approval, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RMAT Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the 21st Century Cures Act, enacted in December 2016, Congress created the Regenerative Medicine Advanced Therapy, or RMAT, designation to facilitate an efficient development program for, and expedite review of, a product candidate that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND. The FDA has 60 calendar days to determine whether the drug meets the criteria. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may, as appropriate, fulfill such requirements through the submission of clinical evidence from clinical trials, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Like some of FDA&#x2019;s other expedited development programs, RMAT designation does not change the standards for approval but may help expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements, as well as requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. We currently rely, and may continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers also must comply with the FDA&#x2019;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detentions or refusal to permit the import or export of the product, restrictions on the marketing or manufacturing of the product, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products, and those supplying products, ingredients, and components of them</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are required to register their establishments with the FDA and certain state agencies, and they are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Additionally, discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Affordable Care Act, or ACA, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to exclusivity under the BPCIA, a biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, including some regulatory exclusivity periods tied to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Foreign Corrupt Practices Act, U.K. Bribery Act and Other Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act of 1977, or FCPA, prohibits United States corporations and individuals from engaging in certain activities to obtain or retain business or secure any improper advantage, or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any employee or official of a foreign government or public international organization, or political party, political party official, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA also includes employees and officials of state- owned or controlled enterprises, which may include healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations are also subject to non-United States anti-corruption laws such as the U.K. Bribery Act 2010, or the Bribery Act. As with the FCPA, these laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as trade control laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the Bribery Act, the FCPA and other anti-corruption laws and trade control laws could subject us to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Regulation Outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements and processes governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trials Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted for each clinical trial to each country&#x2019;s National Competent Authority, or NCA, and at least one independent Ethics Committee, or EC, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#x2019;s requirements, the corresponding clinical trial may proceed. Under the current regime (the EU Clinical Trials Directive 2001/20/EC and corresponding national laws) all suspected unexpected serious adverse reactions to the investigational drug that occur during the clinical trial have to be reported to the NCA and ECs of the European Union Member State where they occurred.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new Clinical Trials Regulation, which will be directly applicable in all Member States (meaning that no national implementing legislation in each European Union Member State is required), aims at simplifying and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the assessment of clinical trial applications. It is expected that the new Clinical Trials Regulation will come into effect following confirmation of full functionality of the Clinical Trials Information System, the centralized European Union portal and database for clinical trials foreseen by the new Clinical Trials regulation, through an independent audit, which is currently expected to occur in January 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Drug Review and Approval</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Economic Area (comprised of the European Union Member States plus Norway, Iceland and Liechtenstein), or EEA, medicinal products, including advanced therapy medicinal products, or ATMPs, are subject to extensive pre- and post-market regulation by regulatory authorities at both the EEA and national levels. Under Article 2(1) of Regulation (EC) No 1394/2007, or the ATMP Regulation, ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products. Somatic cell therapy products comprise cells that have undergone substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, where such cells are to be administered to human beings in order to cure, diagnose or prevent disease. We anticipate that our current development products are somatic cell therapy medical products which would be regulated as ATMPs in the EEA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain regulatory approval of ATMP in the EEA, we must submit a marketing authorization application, or MAA, under the centralized procedure administered by the European Medicines Agency, or EMA. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across all of the EEA. As provided for in the ATMP Regulation, the scientific evaluation of MAAs for ATMPs is primarily performed by a specialized scientific committee called the Committee for Advanced Therapies, or CAT. The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use, or CHMP. The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EEA Member States. The maximum timeframe for the evaluation of an MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days.  Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#x2019;s recommendation.  Accelerated assessment may be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The application used to submit the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, certain specific requirements set out in the ATMP Regulation, for example certain particulars to be contained in the summary of product characteristics. A MAA holder for an ATMP in Europe must also put in place a system to ensure that each individual product, and its starting and raw materials, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January, 1 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Data and Marketing Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EEA also provides opportunities for market exclusivity. Upon receiving a marketing authorization in the EEA, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#x2019;s pre-clinical or clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization during a period of eight years from the date on which the reference product was first authorized in the EEA. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#x2019;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Products with an orphan designation in the EEA can receive ten years of market exclusivity, during which time &#x201c;no similar medicinal product&#x201d; for the same indication may be placed on the market. A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two years of market exclusivity in the European Union where an agreed Pediatric Investigation Plan for pediatric studies has been complied with. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either the prevalence of such condition must not be more than five in 10,000 persons in the European Union when the application is made, or without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EEA to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EEA, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ten year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Otherwise, orphan medicine marketing exclusivity may be revoked only in very select cases, such as if:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	it is established that a similar medicinal product is safer, more effective or otherwise clinically superior;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	the marketing authorization holder consents to a second orphan medicinal product application; or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;	the marketing authorization holder cannot supply enough orphan medicinal product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From January 1, 2021, a separate process for orphan drug designation will apply in Great Britain. There will be no pre-marketing authorization orphan designation (as there is in the EEA) and the application for orphan designation will be reviewed by the MHRA at the time of the marketing authorization application. The criteria are the same as in the EEA, save that they apply to Great Britain only (e.g. there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the EEA, companies developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA&#x2019;s Pediatric Committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The marketing authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted by the PDCO of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization with the results of pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PRIME Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2016, the European Medicines Agency, or EMA, launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority Medicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EEA or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#x2019;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from one country to another. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as &#x201c;Brexit&#x201d;). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January 31, 2020. A transition period began on February 1, 2020, during which European Union pharmaceutical law remained applicable to the United Kingdom, and ended on December 31, 2020. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the United Kingdom legislation now has the potential to diverge from European Union legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long term. The MHRA has recently published detailed guidance for industry and organizations to follow now the transition period is over, which will be updated as the United Kingdom&#x2019;s regulatory position on medicinal products and medical devices evolves over time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the U.S., no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. The coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as cell or gene therapy products. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. Factors a payor considers in determining reimbursement are based on whether the product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many third-party payors are increasingly limiting both coverage and the level of reimbursement of new drugs. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, CMS, other divisions of the United States Department of Health and Human Service, or HHS, (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. Our clinical research, sales, marketing and scientific/educational grant programs may be subject to the following laws, each as amended, as applicable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by, Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. A claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the False Claims Act. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The False Claims Act also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, there  may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which require applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers or patients; state laws that require pharmaceutical companies to comply with the industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require the licensure of pharmaceutical sales representatives; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and foreign laws that govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government enforcement agencies have shown increased interest in pharmaceutical companies' product and patient assistance programs, including reimbursement support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. In addition, at least one insurer has directed its network pharmacies to no longer accept co-pay coupons for certain specialty drugs the insurer identified. In addition, in November 2013, the CMS issued guidance to the issuers of qualified health plans sold through the ACA's marketplaces encouraging such plans to reject patient cost-sharing support from third parties and indicating that the CMS intends to monitor the provision of such support and may take regulatory action to limit it in the future. The CMS subsequently issued a rule requiring individual market qualified health plans to accept third-party premium and cost-sharing payments from certain government-related entities. In September 2014, the OIG of the HHS issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the federal Anti-Kickback Statute and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using co-pay coupons. Accordingly, companies exclude these Part D beneficiaries from using co-pay coupons. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on our sales, business, and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third party patient assistance programs that receive financial support from companies have become the subject of enhanced government and regulatory scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria and do not link aid to use of a donor's product. However, donations to patient assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives. Specifically, in recent years, there have been multiple settlements resulting out of government claims challenging the legality of their patient assistance programs under a variety of federal and state laws. It is possible that we may make grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or evolving government guidance in the operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, business partners, or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could impact our business practices, harm our reputation, divert the attention of management, increase our expenses, and reduce the availability of foundation support for our patients who need assistance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 2, 2020, the United States Department of Heath and Human Service, or HHS, published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers (PBMs), unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between PBMs and manufacturers. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and PBM service fees are currently under review by the current U.S. presidential administration and may be amended or repealed. Further, on December 31, 2020, CMS published a new rule, effective January 1, 2023, requiring manufacturers to ensure the full value of co-pay assistance is passed on to the patient or these dollars will count toward the Average Manufacturer Price and Best Price calculation of the drug. On May 21, 2021, PhRMA sued the HHS in the U.S. District Court for the District of Columbia, to stop the implementation of the rule claiming that the rule contradicts federal law surrounding Medicaid rebates. It is unclear how the outcome of this litigation will affect the rule. On May 17, 2022, the U.S. District Court for the District of Columbia granted PhRMA&#x2019;smotion for summary judgement invalidating the Accumulator Rule. We cannot predict how the implementation of and any further changes to this rule will affect our business. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the current U.S. presidential administration may reverse or otherwise change these measures, both the current U.S. presidential administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers, are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, criminal and/or civil penalties, damages, fines, disgorgement, reputational harm, imprisonment, the exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the United States government, and/or the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to similar penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk of our being found in violation of these laws is increased by the fact that many of these laws have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust system to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may violate one or more of the requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial cost.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data Privacy and Security Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to data privacy and security laws in the United States and various jurisdictions around the world in which we operate or from which we collect or otherwise process personally identifiable information (&#x201c;personal information&#x201d;). In the United States, HIPAA, imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#x201c;covered entities&#x201d; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of personal information to HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, certain states govern the privacy and security of health information and/or other personally identifiable information, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted the CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The CCPA went into effect on January 1, 2020, and the California Attorney General commenced enforcement actions against violators beginning July 1, 2020. While there is currently an exception for protected health information that is subject to HIPAA and/or that is collected, used, or disclosed in clinical trial research, as currently written, the CCPA may still impact our business activities. The uncertainty and enforcement surrounding the implementation of CCPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a California ballot initiative, the California Privacy Rights Act, or &#x201c;CPRA,&#x201d; was passed in November 2020 and became effective starting on January 1, 2023. The CPRA imposes additional obligations on companies covered by the legislation and significantly modifies the CCPA, including by expanding consumers&#x2019; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA, as modified by the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain other states, including Colorado, Connecticut, Utah and Virginia have passed laws comprehensive consumer privacy laws that impose similar privacy obligations and we also expect anticipate that more states to may enact legislation similar to the CCPA. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collection, use, storage, disclosure, transfer, or other processing of personal information regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the EU GDPR, which became effective on May 25,  2018. Following the United Kingdom's (&#34;UK&#34;) withdrawal from the EU (&#34;Brexit&#34;), the EU GDPR has been incorporated into UK laws (&#34;UK GDPR&#34; and together with the EU GDPR, &#34;GDPR&#34;). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union and the UK, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million (&#163;17.5 million) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.  Despite Brexit, the EU and UK GDPR remain largelyaligned.Currently, the most impactful point of divergence relates to transfer mechanisms (i.e., the ability for EU/UK companies to transferpersonal information to third countries, including the United States), because it requires us to implement a variety of different contractual clauses approved by EU or UK regulators. This complexity and the additional contractual burden increases our overall risk exposure. There may be further divergence in the future, including with regard to administrative burdens. The UK has announced plans to reform the country&#x2019;s data protection legal framework in its Data Reform Bill, which will introduce significant divergence from the EU GDPR. Compliance with the EU GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European or UK activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines and penalties if we are unable to comply. The regulatory framework governing the collection, processing, storage, use and sharing of certain information is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform capabilities. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our posted privacy policies, evolving laws, rules and regulations, industry standards, or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the ACA, was enacted which includes changes to the coverage and payment for products under government health care programs. Among other things, the ACA:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increases the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extends the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishes annual fees and taxes on manufacturers of certain branded prescription drugs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D.; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expands the entities eligible for discounts under the PHS Act&#x2019;s pharmaceutical pricing program, also known as the 340B Drug Pricing Program. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021, through August 15, 2021, for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the Biden administration, on October 13, 2017, former President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the ACA. The former Trump administration concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the ACA have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those appropriations are made. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. On August 14, 2020, the U.S. Court of Appeals for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the years preceding and including 2017. For CSR claims made by health insurance companies for years 2018 and later, further litigation will be required to determine the amounts due, if any. Further, on June 14, 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor payments to third-party payors who argued the payments were owed to them. On April 27, 2020, the United States Supreme Court reversed the U.S. Court of Appeals for the Federal Circuit's decision and remanded the case to the U.S. Court of Federal Claims, concluding the government has an obligation to pay these risk corridor payments under the relevant formula. It is unclear what impact these rulings will have on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013, and, due to legislation amendments to the statute, including the Bipartisan Budget Act of 2018, or BBA, will stay in effect through 2030, unless additional Congressional action is taken. However, the Medicare sequester reductions under the Budget Control Act have been suspended from May 1, 2020, through March 31, 2022, due to the COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction began April 1, 2022 and remained through June 30, 2022. The 2% payment reduction resumed on July 1, 2022. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In December 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of the federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. In addition, CMS published a final rule that would give states greater flexibility, as of 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to request access to certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of these changes on the regulatory approvals of our product candidates, if any, may be. In the U.S., the European Union and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices for certain products in certain markets. For example, in the U.S., there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At a federal level, President Biden signed an Executive Order on July 9, 2021, affirming the administration&#x2019;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#x2019;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#x201c;best price&#x201d; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, on August 6, 2021, CMS announced a proposed rule to rescind the Most Favored Nations rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">rule until January 1, 2026. This deadline was pushed back to January 1, 2027 by the Bipartisan Safer Communities Act. The Inflation Reduction Act of 2022, or the IRA, further delayed implementation of this rule to January 1, 2032. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In August 2022, the IRA was signed into law. The IRA includes several provisions that will impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business and the healthcare industry in general is not yet known. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 106 full-time employees, including 20 with Ph.D. or M.D. degrees, and 80 who are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Internet address is www. allovir.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">http://www.sec.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is subject to numerous risks. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, as well as our other public filings with the Securities and Exchange Commission, or the SEC. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects and could cause the trading price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Current Novel Coronavirus (COVID-19) Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, in regions where third parties for which we rely, including CROs or CMOs, have significant research, development or manufacturing facilities, concentrations of clinical trial sites or other business operations, causing disruption in supplies and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by health epidemics in regions where third parties for which we rely, as in contract research organizations, or CROs, or contract manufacturing organizations, or CMOs, have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. On January 30, 2020, the World Health Organization, or WHO, announced a global health emergency because of SARS-CoV-2, a new strain of novel coronavirus originating in Wuhan, China, and the risks to the international community as the virus spread globally beyond its point of origin. In March 2020, the WHO declared the COVID-19 outbreak a pandemic, which continues to spread throughout the world. The spread of this pandemic has caused significant volatility and uncertainty in U.S. and international markets. This could result in an economic downturn and may disrupt our business and delay our clinical programs and timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and manufacturing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our clinical trials may be affected by the COVID-19 pandemic, including the emergence of new variants. Clinical site initiation and patient enrollment may be delayed due to prioritization of healthcare system resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, the ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the beginning of the COVID-19 pandemic, several vaccines for COVID-19 have received Emergency Use Authorization by the U.S. Food and Drug Administration, or the FDA, and a number of those later received marketing approval. Additional vaccines may be authorized or approved in the future.  The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global pandemic of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Clinical Development, Regulatory Review and Approval of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Clinical Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are early in our development efforts and have only a small number of product candidates in clinical development. All of our other product candidates are still in preclinical development. If we or our collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are early in our development efforts, and only a small number of our product candidates are in or are entering into clinical development. The majority of our product candidates are currently in preclinical development. We have invested substantial resources in identifying and developing potential product candidates, conducting preclinical studies and clinical trials and developing an efficient and scalable manufacturing process for our product candidates. Our ability to generate revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates and our ability to generate revenues and achieve profitability will depend on many factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical studies and clinical trials with positive results; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of regulatory approvals from applicable authorities and successful completion of any post-marketing requirements or commitments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protecting our rights in our intellectual property portfolio, including by obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing and maintaining adequate supply of our product candidates, including third-party donor starting material for global clinical trials, raw materials used in the manufacturing process, manufacturing capacity and release testing capacity; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing and qualifying redundant supplies for critical starting materials including third-party donor material, cell culture media, peptides, cytokines, human AB serum and drug product final formulation buffer; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing or making arrangements with third-party manufacturers or completing our own manufacturing facility for clinical and commercial manufacturing purposes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing manufacturing and distribution processes for our multi-VST cell therapy product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing our product candidates at an acceptable cost; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attracting, hiring and retaining qualified personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching commercial sales of our products, if approved by applicable regulatory authorities, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our products, if approved by applicable regulatory authorities, by patients and the medical community; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved by applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectively competing with other therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protecting our rights in our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining a continued acceptable benefit/risk profile of the products following approval; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining and growing an organization of scientists and functional experts who can develop and commercialize our products and technology. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which could materially harm our business. Our revenues for any of our product candidates for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price, and whether we own the commercial rights for such territory. If the addressable patient population in such territory is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenues from sales of our products, even if approved. In addition, we anticipate incurring significant costs associated with commercializing any approved product candidate. As a result, even if we generate revenues, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations as planned and may be forced to reduce or discontinue our operations. In addition, regulators may determine that our financial relationships with our principal investigators, some of whom receive compensation as consultants, in a perceived or actual conflict of interest, may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success is dependent on the regulatory approval of our product candidates. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not obtained regulatory approval for any of our product candidates, including our clinical-stage product candidates, posoleucel and, ALVR106. Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to successfully commercialize our product candidates in a timely manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the study designs and substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any future product candidates will ever obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disagreement with the design or conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to demonstrate to the satisfaction of regulatory agencies that our product candidates are safe and effective, or have a positive benefit/risk profile for its proposed indication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of clinical trials to meet the level of statistical significance required for approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disagreement with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a Biologics License Application, or BLA, or other submission or to obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to obtain and retain accurate data in our clinical trials.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. The FDA or a comparable foreign regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">indications than we request (including failing to approve the most commercially promising indications), may grant approval contingent on the performance of costly post-marketing clinical studies, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the clinical trial requirements of the FDA, the European Medicines Agency, or the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates, such as our novel multi-VST-cell therapy, can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. There are currently no FDA approved cell-based therapies for the treatment of viral diseases, including those that our product candidates are designed to target. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Industry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for biological products, or biologics, or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory landscape that applies to gene and cell therapy product candidates is rigorous, complex, uncertain and subject to change. Our single- and multi-VST cell therapy product candidates represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our ability to achieve regulatory approval, if at all, and commercialization or payor coverage and reimbursement of our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success is dependent on our single- and multi-VST cell therapy approach. Because these programs, particularly our pipeline of allogeneic T cell product candidates that are bioengineered from donors, represent a unique approach to immunotherapy for the treatment of virus-infected cells in order to restore T cell immunity, developing and commercializing our product candidates subjects us to a number of challenges, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approval from the FDA and other regulatory authorities, which have limited experience with regulating the development and commercialization of T cell immunotherapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing and deploying consistent and reliable processes for procuring blood from consenting third-party donors, isolating T cells from the blood of such donors, activating the isolated T cells against specific antigens, characterizing and storing the resulting activated T cells for future therapeutic use, selecting and delivering a sufficient supply and breadth of appropriate partially HLA-matched cell line from among the available T cell lines, and finally infusing these activated T cells into patients to enable the VSTs to recognize and eliminate virus-infected cells in the patient and induce antiviral benefit; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relying on healthcare provider site availability and accessibility to patients for receipt of T cell infusions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">utilizing these product candidates in combination with other therapies, including immunomodulatory therapies currently used to treat patients in our target population, which may increase the risk of adverse side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of each of our product candidates, particularly those that may be unique to our multi-VST cell therapy product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">understanding and addressing variability in the quality of a VST donor&#x2019;s T cells, which could ultimately affect our ability to manufacture product in a reliable and consistent manner; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing processes for the safe administration of these products, including long-term follow-up and registries, for all patients who receive these product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing our product candidates to our specifications and in a timely manner to support our clinical trials and, if approved, commercialization; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sourcing clinical and, if approved by applicable regulatory authorities, commercial supplies for the materials used to manufacture and process these product candidates that are free from viruses and other pathogens that may increase the risk of adverse side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing a manufacturing process and distribution network that can provide a stable supply with a cost of goods that allows for an attractive return on investment; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales and marketing capabilities ahead of and after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing therapies for types of diseases beyond those initially addressed by our current product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory requirements governing the development of gene therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Therapeutic Products, or OTP, within the CBER, to consolidate the review of gene therapy and related products, and to advise the CBER on its review. In addition, under guidelines issued by the National Institutes of Health, or NIH, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical trial can begin at any institution, that institution&#x2019;s institutional review board, or IRB, and its IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Moreover, serious adverse events or developments in clinical trials of gene therapy product candidates conducted by others may cause the FDA or other regulatory bodies to initiate a clinical hold on our clinical trials or otherwise change the requirements for approval of any of our product candidates. Although the FDA decides whether individual cell and gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA, and other regulatory bodies to amend the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Further, as we are developing novel potential treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. The prospectively designed natural history studies with the same endpoints as our corresponding clinical trials may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be sure that the manufacturing processes used in connection with our T cell immunotherapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, comparable to those T cells produced by our partners historically, scalable or profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, actual or perceived safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved by applicable regulatory authorities, of physicians to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subscribe to the novel treatment mechanics. The FDA or other applicable regulatory authorities may ask for specific post-market requirements, such as establishment of a Risk Evaluation and Mitigation Strategy, or REMS, and additional information informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Physicians, hospitals and third-party payors are often slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience delays in our ongoing or future clinical trials and we do not know whether clinical trials will begin or enroll subjects on time, will need to be redesigned or will be completed on schedule, if at all, such as on account of the COVID-19 pandemic and its impact at clinical trials sites or on the third-party service providers on whom we rely. In July 2020, the Investigational New Drug, or IND that Baylor College of Medicine, or BCM, submitted for ALVR109 was placed on clinical hold for safety concerns related to the quality of ancillary reagents unique to ALVR109. The FDA subsequently lifted this clinical hold and cleared the IND for ALVR109 but there can be no assurance that the FDA or comparable foreign regulatory authorities will not put clinical trials of any of our product candidates on clinical hold in the future. Any inability to commence or complete our planned clinical trials of our product candidates as a result of a clinical hold or otherwise, will delay or terminate our clinical development plans for our product candidates, may require us to incur additional clinical development costs and could impair our ability to ultimately obtain FDA approval for our product candidates. Clinical trials may be delayed, suspended or prematurely terminated for a variety of other reasons, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on the design and implementation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in obtaining authorization to commence a trial, including the delay or ability to generate sufficient preclinical data to support initiation of clinical trials, or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability of CROs to perform under these agreements, including due to impacts from the COVID-19 pandemic on their workforce; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in obtaining IRB approval or the approval of other reviewing entities, including comparable foreign regulatory authorities, to conduct a clinical trial at each site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial sites from our clinical trials or the ineligibility of a site to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in recruiting and enrolling suitable subjects to participate in a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in subjects completing a study or returning for post-treatment follow-up; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites and investigators deviating from study protocol, failing to conduct the study in accordance with regulatory requirements, or dropping out of a study; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to identify and maintain a sufficient number of trial sites, including because potential trial sites may already be engaged in competing clinical trial programs for the same indication that we are treating; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our third-party clinical trial managers to satisfy their contractual duties, meet expected deadlines or return trustworthy data; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or failure in adding new trial sites, including due to changes in policies of the clinical research sites or local IRBs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interim results or data that are ambiguous or negative or are inconsistent with earlier results or data; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">feedback from the FDA, the IRB, data safety monitoring boards or comparable foreign authorities, or results from earlier stage or concurrent preclinical studies and clinical trials, that might require modification to the protocol for a study; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decision by the FDA, the IRB, comparable foreign authorities, or us, or a recommendation by a data safety monitoring board or comparable foreign authority, to suspend or terminate clinical trials at any time for safety issues or for any other reason; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unacceptable benefit/risk profile, unforeseen safety issues or adverse side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to demonstrate a benefit from using a product candidate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in finding subjects from whom to obtain cell lines, including on account of the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in locating cell lines for which it is difficult to find a match; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in manufacturing or obtaining from third parties sufficient quantities and breadth of appropriate partially HLA matched cell lines from among the available T cell lines to start or to use in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of adequate funding to continue a study, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional studies or increased expenses associated with the services of our CROs and other third parties; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in governmental regulations or administrative actions, failure by us or third parties to comply with regulatory requirements, or lack of adequate funding to continue a clinical trial. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including: </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possibility that the viral diseases that many of our product candidates address are under-diagnosed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changing medical practice patterns or guidelines related to the indications we are investigating; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the severity of the disease under investigation, our ability to open clinical trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of subjects to clinical sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">travel restrictions and other potential limitations by federal, state, or local governments affecting the workforce or affecting clinical research site policies implemented in response to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in or temporary suspension of the enrollment of patients in our ongoing and planned clinical trials due to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design and eligibility criteria of the clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ability to obtain and maintain patient consents; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risk that enrolled subjects will drop out or die before completion; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competition for patients from other clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to manufacture the requisite materials for a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risk that we do not have appropriately matched HLA cell lines; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new product candidates that may be approved for the indications we are investigating. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely on CROs, other vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Additionally, we or our collaborators may experience unforeseen events during or resulting from clinical trials that could delay or prevent receipt of marketing approval for or commercialization of product candidates. If we or our collaborators are required to conduct additional clinical trials or other testing of product candidates beyond those that we or our collaborators currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of such product candidates, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur unplanned costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining or fail to obtain marketing approval for product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval in some countries and not in others; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to changes in the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be sued; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays or quality issues in the conduct, completion or termination of any clinical trial of our product candidates, the approval and commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any delays in completing our clinical trials for our product candidates may also decrease the period of commercial exclusivity. In addition, many of the factors that could cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results. Our existing product candidates in clinical trials, and any other product candidate we advance into clinical trials, may not have favorable results in later clinical trials or receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials, including our Phase 3 pivotal and Phase 2 proof-of-concept clinical trials of posoleucel, will generate adequate data to demonstrate the efficacy and safety of any of our product candidates. Likewise, a number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience than us, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier preclinical studies or clinical trials. Despite the results reported in earlier preclinical studies or clinical trials for our product candidates, to date, results may not be replicated in subsequent trials, and we do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market posoleucel, ALVR106, ALVR109 or any future product candidates we develop from our allogeneic T cell immunotherapy platform. Additionally, certain of our clinical trial endpoints also may not be adequately powered in a particular subpopulation of our trial population. Additionally, all of our clinical trials to date have been open-label trials. An &#x201c;open-label&#x201d; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#x201c;patient bias&#x201d; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#x201c;investigator bias&#x201d; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficacy data from prospectively designed trial may differ significantly from those obtained from retrospective subgroup analyses. In addition, clinical data obtained from a clinical trial with an allogeneic product candidate such as posoleucel may not yield the same or better results as compared to an autologous product candidate. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in such studies nonetheless failed to obtain FDA, EMA or other necessary regulatory agency approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates will be adversely impacted. Even if we believe that we have adequate data to support an application for regulatory approval to market any of our product candidates, no cell-based therapies for the treatment of viral diseases have been approved to date, and the FDA or other regulatory authorities may not agree and may require that we conduct additional clinical trials to support the regulatory approval of our product candidates. If we fail to obtain results in our planned and future preclinical and clinical activities and studies sufficient to meet the requirements of the relevant regulatory agencies, the development timeline and regulatory approval and commercialization prospects for any potential product candidate, and, correspondingly, our business and financial prospects, would be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, &#x201c;topline&#x201d; or preliminary data from our clinical trials that we may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may announce or share with regulatory authorities interim &#x201c;topline&#x201d; or preliminary data from our clinical trials,  such as the June 2022 announcement of preliminary results for our Phase 2 posoleucel study for the treatment of BK virus, or BKV, in adult kidney transplant recipients, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.  We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Preliminary or &#x201c;topline&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. As a result, interim, &#x201c;topline,&#x201d; and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary, &#x201c;topline,&#x201d; or interim data and final data could impact the regulatory approval of, and significantly harm the prospects for any product candidate that is impacted by the applicable data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, &#x201c;topline,&#x201d; or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates, the methods used to deliver them or their dosage levels may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Undesirable side effects caused by our product candidates, their delivery methods or dosage levels could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. As a result of safety or toxicity issues that we may experience in our clinical trials, we may not receive approval to market any product candidates, which could prevent us from ever generating revenues or achieving profitability. Results of our trials could reveal an unacceptably high severity and incidence of side effects, or side effects outweighing the benefits of our product candidates. In such an event, our studies could be delayed, suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, while we note the summary of safety findings we have gathered, to date, certain populations of patients receiving our product candidates may experience side effects in greater frequency or severity than others who may receive our product candidates and additional clinical research is planned to more fully understand the safety profile of our product candidates in our patient populations and indications of focus.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences include that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be forced to suspend marketing of that product, or decide to remove the product form the marketplace; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw or change their approvals of that product; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to change the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or to sued and held liable for harm caused to subjects or patients; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product may become less competitive, and our reputation may suffer. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designation to our product candidates, or to obtain and maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. The FDA has granted orphan drug designation to posoleucel for the treatment of virus-associated hemorrhagic cystitis. In the European Union, the prevalence of the condition must not be more than 5 in 10,000. The EMA has granted posoleucel orphan drug designation to treatment in HCT. This designation covers the treatment of all viruses targeted by posoleucel in all HCT patients: BK virus, or BKV, cytomegalovirus, or CMV, adenovirus, or AdV, Epstein-Barr virus, or EBV, and human herpesvirus 6, or HHV-6. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication, for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the product was designated. Even if we or our collaborators obtain orphan designation to a product candidate, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. The scope of exclusivity is limited to the scope of any approved indication, even if the scope of the orphan designation is broader than the approved indication. Additionally, exclusive marketing rights may be limited if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a product with the same active moiety for the same condition if the FDA concludes that the later product is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are unable to manufacture sufficient supply of the product. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similarly, in Europe, a medicinal product may receive orphan designation under Article 3 of Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (2) the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment. Moreover, in order to obtain orphan designation in the EU it is necessary to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product will be of significant benefit to those affected by the condition. In the EU, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and applicants can benefit from specific regulatory assistance and scientific advice. Products receiving orphan designation in the EU can receive 10 years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. However, the 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation&#x2014;for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the first applicant consents to a second orphan medicinal product application; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the first applicant cannot supply enough orphan medicinal product. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our collaborators do not receive or maintain orphan drug designation to product candidates for which we seek such designation, it could limit our ability to realize revenues from such product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Sales, Marketing and Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face competition from numerous pharmaceutical and biotechnology enterprises, as well as from academic institutions, government agencies and private and public research institutions. Our commercial opportunities will be significantly impacted if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are less expensive or obtain more significant acceptance in the market than any product candidates that we develop. Additionally, our commercial opportunities will be significantly impacted if novel upstream products or changes in treatment protocols reduce the overall incidence or prevalence of diseases in our current or future target population. Competition could result in reduced sales and pricing pressure on our product candidates, if approved by applicable regulatory authorities. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair any ability to commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While there are currently no FDA- or EMA-approved drugs for our indications (other than for COVID-19), many of the approved or commonly used drugs and therapies for our current or future target diseases, including letermovir, cidofovir, ganciclovir, valganciclovir, foscarnet, oseltamivir, zanamivir, baloxavir, ribavirin, tenofovir, and entecavir, are well established and are widely accepted by physicians, patients and third-party payors. Some of these drugs are branded and subject to patent protection, and other drugs and nutritional supplements are available on a generic basis. Insurers and other third-party payors may encourage the use of generic products or specific branded products. We expect that, if any of our product candidates are approved, they will be priced at a significant premium over competitive generic products. Absent differentiated and compelling clinical evidence, pricing premiums may impede the adoption of our products over currently approved or commonly used therapies, which may adversely impact our business. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will become as our products continue in clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors or potential competitors have significantly greater market presence, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do, and as a result may have a competitive advantage over us. Smaller or early-stage companies may also prove to be significant competitors, including through collaborative arrangements or mergers with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, commercial and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these factors, these competitors may obtain regulatory approval of their products before we are able to, which will limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and cheaper than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or noncompetitive before we can recover the expenses of development and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are at any early stage of establishing an organization that will be responsible for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without a sufficiently scaled, appropriately timed and trained internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The incidence and prevalence of the target patient population for posoleucel are based on estimates and third-party sources. If the market opportunity for posoleucel or our other product candidates is smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodically, we make estimates regarding the incidence and prevalence of target patient populations based on various third-party sources and internally generated analysis. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity for posoleucel will depend on, among other things, acceptance of posoleucel by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with posoleucel, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have received Regenerative Medicine Advanced Therapy, or RMAT, designation for the treatment of HC caused by BKV in adults and children following allogeneic HCT , adenovirus (AdV) infection following allogenic hematopoietic stem cell transplant (allo-HCT) and for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediatric patients following allo-HCT &#x2013; adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus-6 (HHV-6) and JC virus (JCV), and received eligibility for the PRIME scheme from the EMA for the treatment of serious infections with BKV, CMV, AdV, EBV and HHV-6 in HCT patients, for posoleucel. These designations may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have received RMAT designation from the FDA for posoleucel for the treatment of HC caused by BKV in adults and children following allo-HCT, for the treatment of AdV infection following allo-HCT, and for the prevention of clinically significant infections and end-organ diseases from AdV, BKV, CMV, EBV, HHV-6 and JCV in children and adults following allo-HCT. We have also received PRIME designation from the EMA for the treatment of serious infections with BKV, CMV, AdV, EBV and/or HHV-6 in HCT patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company may request RMAT designation of its product candidate, which designation may be granted if the product meets the following criteria: (1) it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites post-approval, if appropriate. RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#x2019;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. There can be no assurance that the FDA would allow any of the product candidates we may develop to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#x2019;s accelerated approval will eventually be converted to a traditional approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PRIME is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. To qualify for PRIME, product candidates require early clinical evidence that the therapy has the potential to offer a therapeutic advantage over existing treatments or benefits patients without treatment options. Among the benefits of PRIME are the appointment of a rapporteur to provide continuous support and help build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RMAT designation and PRIME eligibility do not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation or PRIME eligibility. Additionally, RMAT designation and access to PRIME can each be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if our product candidates receive regulatory approval, we will still face extensive ongoing regulatory requirements and continued regulatory review, which may result in significant additional expense, and our products may still face future development and regulatory difficulties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, materials and facilities, qualification testing, quality control, further development, labeling, packaging, storage, distribution, post-approval clinical data, adverse event reporting, safety surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-marketing information. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and product listing, as well as continued compliance by us and/or our contract manufacturing organizations, or CMOs, and CROs for any post-approval clinical trials that we conduct. The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may require labeling changes or establishment of a REMS, impose significant restrictions on a product&#x2019;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, manufacturers of drug products and their facilities are subject to initial and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, Good Clinical Practices, or GCP, current good tissue practices, or cGTP, and other regulations. For certain commercial prescription biological products, manufacturers, and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issue warning letters or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners, or require other restrictions on the labeling or marketing of such products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend, withdraw or modify regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or modify any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to approve pending applications or supplements to applications filed by us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the U.S. Federal Trade Commission, the Department of Justice, or the DOJ, the Office of Inspector General of the HHS, state attorneys general, members of the U.S. Congress and the public. Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by comparable foreign entities and stakeholders. Violations, including actual or alleged promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or comparable foreign bodies. Any actual or alleged failure to comply with labeling and promotion requirements may result in fines, warning letters, mandates to corrective information to healthcare practitioners, injunctions, or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any current or future product candidate. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or to the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained. Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes to regulations, recommendations or other guidelines advocating alternative therapies for the indications we treat could result in decreased use of our products, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Business Development and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not successfully identify, acquire, develop or commercialize new potential product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety of the product candidates as demonstrated in clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications and patient populations for which the product candidate is approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians and patients of the drug as a safe and effective treatment; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the administrative and logistical burden of treating patients, including the availability and accessibility of healthcare provider sites for administering infusions to patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the adoption of novel cellular therapies by physicians, hospitals and third-party payors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages of product candidates over alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety of product candidates seen in a broader patient group, including its use outside the approved indications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any restrictions on use together with other medications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of our products as well as competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of manufacturing and distribution processes for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement from, and our ability to negotiate pricing with, third-party payors, providers and government authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts and those of our collaborators. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.  For more information regarding the risks related to insurance coverage and reimbursement please see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2013; Government Regulation &#x2013; Coverage and Reimbursement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities.  Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval, and ultimately our ability to successfully commercialize any product candidate for which we obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Third-party payors in the U.S. often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on our lead product candidate, posoleucel, and we must complete clinical testing before we can seek regulatory approval and begin commercialization of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no guarantee that any of our product candidates will proceed in preclinical or clinical development or achieve regulatory approval. The process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as planned or, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no guarantee that the results obtained in current clinical studies or planned Phase 3 clinical trials of posoleucel will be sufficient to obtain regulatory approval or marketing authorization for HC, AdV, prevention or any other indication. Negative results in the development of our lead product candidates may also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes because, although other product candidates may target different indications, the underlying technology platform, manufacturing process and development process is the same for all of our product candidates. Accordingly, a failure in any one program may affect the ability to obtain regulatory approval to continue or conduct clinical programs for other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because we have limited financial and personnel resources and are placing significant focus on the development of our lead product candidates, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to those future product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the Affordable Care Act, or ACA, and the passage of additional laws and regulations may result in the expansion of new programs, such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business &#x2013; Government Regulation &#x2013; Healthcare Reform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the U.S.have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect the product candidates we develop will be regulated biologics and therefore they may be subject to competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when processes intended to implement BPCIA may be fully adopted by the FDA, any of these processes could have a material adverse effect on the future commercial prospects for our biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the approval of a biologic product biosimilar to one of our products could have a material adverse impact on our business as it may be significantly less costly to bring to market and may be priced significantly lower than our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers, third-party payors, physicians and healthcare providers will be subject to applicable anti-kickback, fraud and abuse, and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights are and will be applicable to our business.  For more information regarding the risks related to these laws and regulations please see &#x201c;Business &#x2013; Government Regulation &#x2013; Other Healthcare Laws and Compliance Requirements.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Even if precautions are taken, it is possible that governmental authorities will conclude that our business practices could, despite efforts to comply, be subject to challenge under current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our current and future business arrangements with third parties, and our business generally, continue to comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with any such laws and regulations. If our operations, including our arrangements with physicians and other healthcare providers, are found to be in violation of any such laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, reputational harm, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, additional reporting requirements, and/or the curtailment or restructuring of our operations, as well as additional reporting obligations oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in and failures to comply with U.S. federal and state and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, HIPAA, as amended by HITECH, imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#x201c;covered entities&#x201d; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">breaches of individually identifiable health information to HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#x2019; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C. &#167; 45(a). The FTC expects a company&#x2019;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#x2019;s guidance for appropriately securing consumers&#x2019; personal information is similar to what is required by the HIPAA security regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, certain states govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA will require covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The CCPA went into effect on January 1, 2020, and the California Attorney General commenced enforcement actions against violators beginning July 1, 2020. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our business activities. Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020 to amend and expand the CCPA. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). We will continue to monitor developments related to the CCPA, as amended and anticipate additional costs and expenses associated with compliance. The uncertainty surrounding the implementation of CCPA exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to additional privacy restrictions in various foreign jurisdictions around the world in which we operate or process personal information. The collection, use, storage, disclosure, transfer, or other processing of personal information regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the General Data Protection Regulation 2016/679, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#x20ac;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#x2019;s decision to leave the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In addition, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines and penalties if we are unable to comply.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including David Hallal, our Chairman and former Chief Executive Officer, Diana Brainard, our Chief Executive Officer, Vikas Sinha, our President and Chief Financial Officer, and Ann Leen, our Chief Scientific Officer. While we expect to engage in an orderly transition process as we integrate newly appointed officers and managers, such as Diana Brainard who was appointed Chief Executive Officer effective May 17, 2021, we face a variety of risks and uncertainties relating to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. In addition, the loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business. For example, Dr. Leen is a Professor at Baylor College of Medicine and is also a co-founder of Marker Therapeutics. There could be a diversion of attention with an increased focus on her other service obligations and such a loss of her services to us could result in delays of our product development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and impact our operations. Additionally, some of our executive officers, directors and other personnel split their time between AlloVir and ElevateBio. For instance, David Hallal serves as Chief Executive Officer of ElevateBio and Chairman of both AlloVir and ElevateBio, and Vikas Sinha serves as Chief Financial Officer of both AlloVir and ElevateBio. As a result, these individuals may not be able to devote their full attention to us, which could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conduct our operations at our facilities in Waltham, Massachusetts, Houston, Texas and Dublin, Ireland. Each of those regions serve as headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock options that vest over time and offer an employee stock purchase plan. The value to employees of restricted stock and stock options that vest over time, as well as shares purchased through an employee stock purchase plan, may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with ElevateBio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Hallal, our Executive Chairman and former Chief Executive Officer, also serves as the Chairman and Chief Executive Officer of ElevateBio, and Vikas Sinha, our President and Chief Financial Officer, also serves as the Chief Financial Officer of ElevateBio. Ansbert Gadicke and Morana Jovan-Embiricos, two members of our board of directors, also serve as directors of the board of directors of ElevateBio. In addition, certain of these individuals own equity interests in ElevateBio, which may represent a significant portion of these individuals&#x2019; net worth. Although, we have adopted a written related party transactions policy that such transactions must be approved by our audit committee, their positions at ElevateBio and the ownership of any ElevateBio equity or equity awards creates, or may create the appearance of, conflicts of interest when we ask these individuals to make decisions that could have different implications for ElevateBio than the decisions have for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 106 employees. As our development and commercialization plans and strategies develop, and as we begin operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. In particular, we may need to add substantial additional personnel and other resources to support our development and potential commercialization of our product candidates. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our preclinical studies and clinical trials effectively; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, maintaining, motivating and integrating additional employees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our managerial, development, operational, information technology, and finance systems; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanding our facilities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical and clinical studies effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and third party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our platform and product discovery efforts, we may collect and use a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#x2019; personal data could result in significant liability under state law, such as state breach notification laws, federal law, such as HIPAA, as amended by HITECH, and international law, such as the GDPR and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the computer systems of various third parties on which we rely, including our CROs and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, and telecommunication and electrical failures. We exercise little or no control over these third parties, which increases our vulnerability to problems with their systems. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of data from completed or future preclinical studies and clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed and our business could be otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions, the severity and frequency of which may be amplified by global climate change, could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. or foreign tax law or changes in our effective tax rates could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation and foreign income taxation are constantly under review by persons involved in the legislative process, by the Internal Revenue Service, the U.S. Treasury Department and foreign tax authorities. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), and, subject to certain changes in tax law made by the CARES Act as discussed below, the limitation of the deduction for net operating losses from taxable years beginning after December 31, 2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), and the modification or repeal of many business deductions and credits. In addition, on March 27, 2020, President Trump signed into law the &#x201c;Coronavirus Aid, Relief, and Economic Security Act&#x201d; or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#x2019; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to tax in both U.S. and foreign jurisdictions and determining our worldwide tax liabilities is complex and requires significant judgment. We could incur additional tax liability if relevant tax authorities disagree with our reported tax positions. Our effective tax rate could be adversely affected by changes in the mix of earnings in countries with different statutory tax rates, challenges to our transfer pricing practices, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, and changes in our tax filings due to tax audits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to use our U.S. federal, U.S. state and foreign net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unused U.S. federal tax losses for tax years beginning before January 1, 2018 and prior tax years will carry forward to offset future taxable income, if any, until such unused losses expire. Unused U.S. federal tax losses generated for tax year beginning after December 31, 2017 will not expire and may be carried forward indefinitely, and generally may not be carried back to prior taxable years, except that, under the CARES Act, net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five tax years preceding the tax years of such losses. Additionally, for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, both our current and our future unused U.S. federal and state tax losses and unused U.S. federal and state research and development tax credits may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if we undergo an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. As of December 31, 2022, we reported U.S. federal and state net operating loss carryforwards of approximately $0 million and $3.6 million, respectively, federal and state research and development tax credit carryforwards of $6.6 million and $1.3 million, respectively, and federal orphan drug credit carryforwards of $4.8 million. Our ability to utilize those net operating loss carryforwards could be limited by an &#x201c;ownership change&#x201d; as described above, which could result in increased tax liability to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we reported foreign net operating loss carryforwards of $72.9 million. Our ability to utilize those net operating loss carryforwards are dependent upon our generation of future taxable income</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unstable market, economic or geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global credit and financial markets have experienced and are likely to continue to experience extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Further, geopolitical instability outside the U.S. may also impact our operations or affect global markets, such as the recent invasion of Ukraine by Russia. While we do not currently conduct clinical trials in the Ukraine or Russia, we cannot be certain what the overall impact of these events will be on our business or on the business of any of our third party partners, including our CROs, contract manufacturers or other partners or on the health care systems in the European Union and in other impacted countries. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Litigation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be at an increased risk of securities class action litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical studies and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical studies, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for any product candidates or products that we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination of clinical trial sites or entire trial programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to study subjects or patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of management and scientific resources from our business operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any products that we may develop; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decline in our share price. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Intellectual Property Litigation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, on us and our partners, including BCM, not infringing the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation and other adversarial proceedings, both within and outside the United States, involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interference or derivation proceedings, oppositions, reexaminations, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and post-grant review proceedings before the USPTO and non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of third parties&#x2019; patent rights, as it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may assert infringement claims against us based on existing or future intellectual property rights, alleging that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">materials, formulations, methods of manufacture or methods for treatment related to the use or manufacturing of our product candidates that we failed to identify. For example, patent applications covering our product candidates could have been filed by others without our knowledge, since these applications generally remain confidential for some period of time after their filing date. Even pending patent applications that have been published, including some of which we are aware, could be later amended in a manner that could cover our product candidates or their use or manufacture. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. In addition, we may have analyzed patents or patent applications of third parties that we believe are relevant to our activities and believe that we are free to operate in relation to any of our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated, which may block our efforts or potentially result in any of our product candidates or our activities infringing their claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our partners, including BCM, are sued for patent infringement, we would need to demonstrate that our product candidates, products and methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving that a patent is invalid or unenforceable is difficult and even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. If any issued third-party patents were held by a court of competent jurisdiction to be valid and enforceable and cover aspects of our materials, formulations, methods of manufacture or methods for treatment, we could be forced, including by court order, to cease developing, manufacturing or commercializing the relevant product candidate until the relevant patent expires. Alternatively, we may desire or be required to obtain a license from such third party in order to use the infringing technology and to continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonably terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property licensed to us. Additionally, in the event of a successful intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent, or to redesign our infringing product candidates, which may be impossible or technically infeasible, or require substantial time and monetary expenditure. In addition to paying monetary damages, we may lose valuable intellectual property rights or personnel and the parties making claims against us may obtain injunctive or other equitable relief, which could impose limitations on the conduct of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may face claims that we misappropriated the confidential information or trade secrets of a third party. If we are found to have misappropriated a third party&#x2019;s trade secrets, we may be prevented from further using these trade secrets, which could limit our ability to develop our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defending against intellectual property claims could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle before a final judgment, any litigation could burden us with substantial unanticipated costs. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions, and other interim proceedings in the litigation and these announcements may have negative impact on the perceived value of our product candidates, programs or intellectual property. Any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. As a result of all of the foregoing, any actual or threatened intellectual property claim could prevent us from developing or commercializing a product candidate or force us to cease some aspect of our business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may infringe our patents or misappropriate or otherwise violate our intellectual property rights. Our patent applications cannot be enforced against third parties practicing the technology claimed in these applications unless and until a patent issues from the applications, and then only to the extent the issued claims cover the technology. In the future, we or our partners may elect to initiate legal proceedings to enforce or defend our or our partners&#x2019; intellectual property rights, to protect our or our partners&#x2019; trade secrets or to determine the validity, ownership, enforceability or scope of our intellectual property rights. Any claims that we or our partners assert against perceived infringers could also provoke these parties to assert counterclaims against us or our partners alleging that we or our partners infringe their intellectual property rights or that our intellectual property rights are invalid or unenforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties, brought by us or our partners, or declared by the USPTO may be necessary to determine the priority of inventions or matters of inventorship with respect to our patents or patent applications. We or our partners may also become involved in other proceedings, such as reexamination or opposition proceedings, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, post-grant review or other pre-issuance or post-grant proceedings before the USPTO or in non-U.S. jurisdictions relating to our intellectual property or the intellectual property of others. An unfavorable outcome in any of these proceedings could result in us losing our valuable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">intellectual property rights, require us or our partners to cease using the related technology and commercializing our product candidates, or require us to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our partners a license on commercially reasonable terms if any license is offered at all. Even if we or our licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our partners. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any intellectual property proceedings can be expensive and time-consuming. Our or our partners&#x2019; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our partners can. Accordingly, despite our or our partners&#x2019; efforts, we or our partners may not be able to prevent third parties from infringing upon or misappropriating our intellectual property rights, particularly in countries where the laws may not protect our rights as fully as in the U.S. Even if we are successful in the relevant proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted from other activities. In addition, in an infringement proceeding, a court may decide that one or more of our patents is invalid or unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#x2019;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Condition, Capital Needs and Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Financial Condition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a late clinical-stage cell therapy company and we have incurred net losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#x2019; equity and working capital. Our net losses were $168.7 million and $172.0 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $465.8 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to conduct clinical trials for our lead product candidate, posoleucel, for our initial and potential additional indications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and continue research, preclinical and clinical development efforts for our additional product candidates, including ALVR106 and ALVR107 and any future product candidates we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek to identify additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals for posoleucel or any other product candidates that successfully complete clinical development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to help us comply with our obligations as a public company; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative personnel, to support our product candidate development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize any product candidates for which we may obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add equipment and physical infrastructure to support our research and development; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license other product candidates and technologies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, or other regulatory authorities to perform clinical trials in addition to those that we currently expect, if there are any delays in establishing appropriate manufacturing arrangements for our product candidates, or if we experience delays in the completion of our clinical trials or the development of any of our product candidates for any reason, including as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our company was formed in August 2013. Since inception, we have devoted substantially all of our resources on raising capital, organizing and staffing our company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing posoleucel, ALVR106, and other product candidates and preparing for clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. We have financed our operations primarily through private placements of our preferred stock, our initial public offering, or IPO, in August 2020 and our registered direct offering in July 2022. We have not yet demonstrated our ability to successfully complete any Phase 3 clinical trials, obtain regulatory approval, consistently manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for the successful commercialization of any of our product candidates. In addition, the allogeneic, off-the-shelf, multi-virus specific T approach of our cell therapies is new and largely unproven. Any predictions about our future success, performance or viability, particularly in view of the rapidly evolving immunotherapy field, may not be accurate given our limited operating history and lack of approved products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, given our limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities and may not be successful in such a transition. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, our financial results for any quarterly or annual periods may not be indicative of future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Capital Needs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect to continue to spend substantial amounts of capital to continue the preclinical and clinical development of our current and future programs. If we are able to gain marketing approval for any product candidate we develop, including for any indication for which we are developing or may develop posoleucel, we will require substantial additional funding in order to launch and commercialize such product candidates, to the extent that such launch and commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are not the responsibility of a collaborator that we may contract with in the future. In addition, other unanticipated costs may arise in the course of our development efforts. Under the terms of our license agreements with each of our partners, including BCM, we are obligated to make payments upon the achievement of certain development, regulatory and commercial milestones. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. Additionally, any COVID-19-related program setbacks or delays due to changes in federal, state, or local laws and regulations or clinical site policies could impact the timing and cost of the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of researching and developing posoleucel for our initial and potential additional indications, as well as ALVR106, ALVR109 and other product candidates we may develop, including any COVID-19-related delays or other effects on our development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, developing manufacturing and distribution processes and obtaining marketing approvals for posoleucel for our initial and potential additional indications, and ALVR106, ALVR109 and other product candidates we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if approved, the costs of commercialization activities for posoleucel for any approved indications, or ALVR106, ALVR109 or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of a collaborator that we may contract with in the future, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of posoleucel for any approved indications or ALVR106, ALVR109 or any other product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we in-license or acquire rights to other products, product candidates or technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development, increase our office space, and establish a commercial infrastructure; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ongoing costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had cash, cash equivalents and short-term investments of $233.8 million as of December 31, 2022. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Any of our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing cash, cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months following the issuance of these financial statements. This estimate may prove to be wrong, and we could use our available capital resources earlier than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds earlier than planned.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to develop an efficient and highly productive manufacturing supply chain for our allogeneic, off-the-shelf single- and multi-VST cell therapies. Delays in process performance qualification to validate the drug product manufacturing process could delay regulatory approvals, our development plans and thereby limit our ability to generate revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approvals for our CMOs are delayed, we may not be able to manufacture sufficient quantities of our drug candidates, which would limit our development activities and our opportunities for growth and revenues. In addition to the risks described in &#x201c;Risks Related to Our Dependence on Third Parties,&#x201d; our existing CMOs, contract testing laboratory or existing raw material suppliers will be subject to ongoing, periodic inspection by the FDA, EMA or other comparable regulatory agencies to ensure compliance with cGMP and cGTP. Our or their failure to follow and document our adherence to these regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or, in the future, commercial use, may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of commercial marketing applications for our product candidates. We also may encounter problems with the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieving adequate or clinical-grade materials that meet regulatory agency standards or specifications with consistent and acceptable production yield and costs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shortages of qualified personnel, raw materials including cell culture media, peptides, cytokines or drug product formulation buffer or key contractors, including on account of the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with applicable regulations could also result in sanctions being imposed on us or our partners, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates, operating restrictions and criminal prosecutions, any of which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing advanced manufacturing techniques and process controls is required to fully utilize our or our partner&#x2019;s facility. Without further investment, advances in manufacturing techniques may render our or our partner&#x2019;s facility and equipment inadequate or obsolete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A number of our product candidates, if approved by applicable regulatory authorities, may require significant commercial supply to meet market demand. To meet such demand, we will need to increase, or &#x201c;scale up,&#x201d; the production process by a significant factor over the initial level of production. If we are unable to do so, are delayed in doing so, or if the cost of this scale up is not economically feasible for us or we cannot find a third-party supplier, we may not be able to produce our product candidates in a sufficient quantity to meet future demand or at commercially feasible costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Third Party Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We and our third-party partners are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the license of our existing product candidates, we acquired manufacturing process know-how and, in some cases, inventory of process intermediates and clinical materials from our partners. Transferring manufacturing processes, testing and associated know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Each stage is retroactively and concurrently verified to be compliant with appropriate regulations and to confirm that no changes have occurred that require the conduct of any bridging studies to maintain the validity of manufacturing data in support of our clinical product candidates or any future approved products. As a result, there is a risk that all relevant know-how was not adequately transferred to us from our partners or that previous execution was not compliant with applicable regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we need to conduct significant development and scale-up work to transfer these processes and manufacture each of our product candidates for various studies, clinical trials and commercial launch readiness. To the extent we elect to transfer manufacturing within our network, we are required to demonstrate that the product manufactured in the new or &#x201c;receiving&#x201d; facility is comparable to the product manufactured in the original or &#x201c;sending&#x201d; facility. The inability to demonstrate to each of the applicable regulatory authorities that comparable drug product was manufactured could delay the development of our product candidates. Additionally, the manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, and numerous other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The processes by which our product candidates are manufactured were initially developed by our partners for clinical purposes. We are advancing the existing processes to support advanced clinical studies and commercialization. Developing commercially viable cell therapy manufacturing processes is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical studies or commercialization, including cost overruns, potential problems with process scale-up, process reproducibility, process comparability, stability issues, consistency and timely availability of reagents or raw materials. The manufacturing facilities in which our product candidates will be made could be adversely affected by earthquakes and other natural disasters, equipment failures, labor shortages, power failures, and numerous other factors. In the case of highly innovative advanced therapy medicinal products (ATMP), reagents and raw materials of optimal pharmaceutical grade are not always available and, in those cases, health agencies must grant exemptions as part of the registration process.  If such exemptions are not granted, regulatory approvals may be delayed until such time as these requirements are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process of manufacturing cellular therapies is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing and distribution processes for any of our product candidates could result in reduced production yields, impact to key product quality attributes, and other supply disruptions. Product defects can also occur unexpectedly. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, these manufacturing facilities may need to be closed for an extended period of time to allow us to investigate and remedy the contamination. Because our multi-VST cell therapy product candidates are manufactured from the blood of third-party donors, the process of manufacturing is susceptible to the availability of the third-party donor material. The process of developing products that can be commercialized may be particularly challenging, even if they otherwise prove to be safe and effective. The manufacture of these product candidates involves complex processes. Some of these processes require specialized equipment and highly skilled and trained personnel. The process of manufacturing these product candidates will be susceptible to additional risks, given the need to maintain aseptic conditions throughout the manufacturing process. Contamination with viruses or other pathogens in either the donor material or materials utilized in the manufacturing process or ingress of microbiological material at any point in the process may result in contaminated or unusable product. This type of contaminations could result in delays in the manufacture of products which could result in delays in the development of our product candidates. These contaminations could also increase the risk of adverse side effects. Furthermore, our allogeneic products ultimately consist of many individual cell lines, each with a different HLA profile. As a result, the selection and distribution of the appropriate cell line for therapeutic use in a patient requires close coordination between clinical operations, supply chain and quality assurance personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any adverse developments affecting manufacturing operations for our product candidates may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of our drug product which could delay the development of our product candidates. We may also have to write off inventory, incur other charges and expenses for supply of drug product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. Inability to meet the demand for our product candidates could damage our reputation and the reputation of our products among physicians, healthcare payors, patients or the medical community that supports our product development efforts, including hospitals and outpatient clinics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maintaining clinical and commercial timelines is dependent on our end-to-end supply chain network to support manufacturing; if we experience problems with our third party suppliers, the development and potential commercialization of our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely in part on our CMOs or our partners for the production of our product candidates and the acquisition of materials incorporated in or used in the manufacturing or testing of our product candidates. Our CMOs or partners are not our employees, and except for remedies available to us under our agreements with our CMOs or partners, we cannot directly control whether or not they devote sufficient time and resources, including experienced staff, to the manufacturing of supply for our ongoing preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To meet our projected supply needs for clinical and commercial materials to support our activities through regulatory approval and commercial manufacturing of posoleucel and ALVR106 or any future product candidates resulting from our allogeneic T cell immunotherapy platform, we will need to transition the manufacturing of these materials to a CMO or our own facility. Regardless of where production occurs, we will need to develop relationships with suppliers of critical starting materials or reagents, increase the scale of production and demonstrate comparability of the material produced at these facilities to the material that was previously produced. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. We would expect additional comparability work will also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies and the related evaluations intended to demonstrate the comparability of material previously produced with that generated by our CMO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to successfully transfer and produce comparable product candidates, our ability to further develop and manufacture our product candidates may be negatively impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While access to the ElevateBio manufacturing facility provides us with flexibility within our manufacturing network, we still may need to identify additional CMOs for continued production of supply for some of our product candidates. Given the nature of our manufacturing processes, the number of CMOs who possess the requisite skill and capability to manufacture our T cell immunotherapy product candidates is limited. We have identified a limited number of alternate suppliers in the event ElevateBio and the current CMOs that we utilize are unable to scale production, or if we otherwise experience any problems with them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing cellular therapies is complicated and tightly regulated by the FDA and comparable regulatory authorities around the world, and although alternative third-party suppliers with the necessary manufacturing and regulatory expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers, transfer manufacturing procedures to these alternative suppliers, and demonstrate comparability of material produced by such new suppliers. New manufacturers of any product candidate or intermediate would be required to qualify under applicable regulatory requirements. These manufacturers may not be able to manufacture our product candidates at costs, or in sufficient quantities, or in a timely manner necessary to complete development of our product candidates or make commercially successful products. If we are unable to arrange for alternative third-party manufacturing sources, or to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them. In addition, should the FDA or comparable regulatory authorities not agree with our product candidate specifications and comparability assessments for these materials, further clinical development of our product candidate could be substantially delayed and we would incur substantial additional expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility that the third-party manufacturer does not maintain the financial resources to meet its obligations under the manufacturing agreement, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control, including a failure to manufacture our product candidates or any products we may eventually commercialize in accordance with our specifications, misappropriation of our proprietary information, including our trade secrets and know-how, and the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP, cGTP and similar regulatory jurisdictional standards. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory agencies may also implement new standards at any time or change their interpretations and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#x2019; compliance with these regulations and standards and although we monitor our manufacturers, we depend on them to provide honest and accurate information. Any failure by our third-party manufacturers to comply with cGMP or cGTP or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, including on account of the outbreak of infectious disease, such as the COVID-19 pandemic, could lead</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to a delay in, or failure to obtain, regulatory approval of any of our product candidates. In addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure of outside supplies of the product candidate, total or partial suspension of production, suspension of ongoing clinical studies, refusal to approve pending applications or supplemental applications, detention or product, refusal to permit the import or export of products, injunction or imposing civil and criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are dependent on a limited number of suppliers and, in some instances, a sole supplier, for some of our components and materials used in our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently depend on a limited number of suppliers and, in some instances, a sole supplier, for some of the components and equipment necessary for the production of consumables, raw materials and starting materials used in the drug product manufacturing process. Specifically, we utilize single sourced suppliers for cell culture media, peptides, cytokines and drug product formulation buffers for the manufacturing of drug product. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that decides not to continue producing these materials for us. Our use of a sole or a limited number of suppliers of raw materials, components and finished goods exposes us to several risks, including disruptions in supply, price increases, late deliveries and an inability to meet customer demand. There are, in general, relatively few alternative sources of supply for these components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. For example, the FDA or EMA could require additional supplemental data, manufacturing data and comparability data up to and including clinical trial data if we rely upon a new supplier. Any disruption in supply from any supplier or manufacturing location, including on account of the COVID-19 pandemic, could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, adversely affecting our business. Establishing additional or replacement suppliers may not be accomplished quickly. While we seek to maintain adequate inventory of the components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to conduct our clinical trials and, if our product candidates are approved, to meet the demand of our customers and cause them to cancel orders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as part of the FDA&#x2019;s approval of our product candidates, the FDA must review and approve the individual components of our production process, which includes raw materials, the manufacturing processes and facilities of our suppliers. Some of our current suppliers have not undergone this process nor have they had any components included in any product approved by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on these suppliers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the interruption of supply resulting from modifications to or discontinuation of a supplier&#x2019;s operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#x2019;s variation in a component; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a lack of long-term supply arrangements for key components with our suppliers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a delay in delivery due to our suppliers prioritizing other customer orders over ours; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">damage to our reputation caused by defective components produced by our suppliers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these risks materialize, costs could significantly increase and our ability to conduct our clinical trials and, if our product candidates are approved, to meet demand for our products could be impacted. Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure, or total or partial suspension of production of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we and our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our or our third-party manufacturers&#x2019; use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials with a policy limit that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions, which could adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our sole raw material suppliers, clinical or commercial drug product manufacturing facility is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently manufacturing our posoleucel and ALVR106 VSTs at an external cGMP CMO and ALVR109 has been manufactured at an academic cGMP facility, and we primarily rely on a single contract testing laboratory for each drug product release test. We are also utilizing single sourced suppliers for cell culture media, peptides, cytokines and drug product formulation buffers for the manufacturing of drug product. We plan to qualify back up and redundant raw material suppliers and additional CMOs to increase manufacturing capacity. If any manufacturing facility, raw material or drug product in our manufacturing network, or the equipment in these facilities, is either damaged or destroyed, we may not be able to quickly or inexpensively replace our manufacturing capacity or replace it at all. Additionally, changes to the manufacturing process that occur in the transfer or setup of new manufacturing facilities could require that we conduct bridging studies before being able to proceed with either clinical or commercial manufacturing activities. In the event of a temporary or protracted loss of a facility or its equipment, we may not be able to transfer manufacturing to a third party in the time required to maintain supply. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements or may require regulatory approval before selling any products manufactured at that facility. Such an event could delay our clinical studies or reduce our commercial product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our product candidates if there were a catastrophic event or failure of our current manufacturing facility or processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are, and expect to remain, dependent on third parties to conduct our ongoing clinical trials and any future clinical trials of our product candidates. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators, and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our current product candidates and any future product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. Further, the performance of our CROs may also be interrupted by the ongoing COVID-19 pandemic, including due to travel or quarantine policies, heightened exposure of CRO staff who are healthcare providers to COVID-19 or prioritization of resources toward the pandemic. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our current product candidates and any future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend substantially on intellectual property licensed from third parties, including BCM, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We depend substantially on the exclusive license agreement with BCM for data and know-how, which we refer to as the BCM License, for our intellectual property, data and know-how. The BCM License imposes, and we expect that future license agreements will impose, various development, diligence, commercialization, and other obligations on us. This license may be terminated upon certain conditions. Any termination of this license could result in the loss of significant rights and could harm our ability to commercialize our product candidates. To the extent BCM fails to meet its obligations under the license, which we are not in control of, we may lose the benefits of the BCM License. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. In addition, the resolution of any such disputes could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may rely on third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us. It is possible that the licensors&#x2019; infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect such licensed intellectual property, our ability to commercialize products could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not realize the benefits of strategic alliances that we may form in the future or of potential future product acquisitions or licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may desire to form strategic alliances, create joint ventures or collaborations, enter into licensing arrangements with third parties or acquire products or businesses, in each case that we believe will complement or augment our existing business. For instance, we have entered into the BCM License. These relationships or transactions, or those like them, may require us to incur nonrecurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, reduce the potential profitability of the products that are the subject of the relationship or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic alliances and transactions and the negotiation process is time-consuming and complex and there can be no assurance that we can enter into any of these transactions even if we desire to do so. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate a positive risk profile. Any delays in entering into new strategic alliances agreements related to our product candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we license products or acquire businesses, we may not be able to realize the benefit of these transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following an acquisition or license, we will achieve the financial or strategic results that would justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates and manufacturing process, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trademarks, trade secrets and confidentiality agreements&#x2014;both that we own or possess or that are owned or possessed by our partners that are in-licensed to us under licenses including the BCM License&#x2014;to protect the intellectual property related to our technology and product candidates. When we refer to &#x201c;our&#x201d; technologies, inventions, patents, patent applications or other intellectual property rights, we are referring to both the rights that we own or possess as well as those that we in-license, many of which are critical to our intellectual property protection and our business. For example, our product candidates and platform technology are protected primarily by patents or patent applications of our partners that we have licensed and as confidential know-how and trade secrets. Additionally, our earlier stage product candidates are not yet protected by any patents or patent applications. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies and erode or negate any competitive advantage we may have.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is highly uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no assurance that all potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where searching was done. Further, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Thus, we may be unaware of prior art that could be used to invalidate an issued patent or prevent a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pending patent application from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of such claim. For example, we received an NIH grant related to our posoleucel technology prior to the filing of our patent applications covering our posoleucel technology. If the United States or another jurisdiction decides that the NIH grant is relevant prior art to our patent applications, that could affect our ability to obtain valid and enforceable patent claims protecting our posoleucel program. As a consequence of these and other factors, our patent applications may fail to result in issued patents with claims that cover our product candidates in the United States or in other countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if patents have issued or do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the validity, ownership, enforceability or scope thereof, which may result in these patents being narrowed, invalidated, circumvented, or held to be unenforceable. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if unchallenged, our patents and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products on an independent basis which have the same or similar effect as our product candidates and which do not infringe our patents or other intellectual property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened, it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also desire to seek a license from a third party who owns intellectual property that may be necessary or useful for providing exclusivity for our product candidates, or for providing the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to obtain a license from such a third party on commercially reasonable terms, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain patents licensed from third parties. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us. It is possible that the licensors&#x2019; infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. For example, under the BCM License, we have comment rights on all prosecution; however, BCM is not obligated to proceed in accordance with our comments. In addition, BCM has the first right to institute an action or proceeding against third party infringing activities, although we have step-in right if BCM fails to bring such an action or proceeding. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our partners have filed a number of patent applications covering our product candidates or methods of using or making those product candidates. We cannot offer any assurances about which, if any, patents will be issued with respect to these pending patent applications, the breadth of any such patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our partners were the first to file any patent application related to a product candidate. We or our partners may also become involved in proceedings regarding our patents, including patent infringement lawsuits, interference or derivation proceedings, oppositions, reexaminations, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and post-grant review proceedings before the USPTO the European Patent Office and other non-U.S. patent offices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if granted, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent generally occurs 20 years after the earliest U.S. non-provisional application is filed. Although various extensions may be available if certain conditions are met, the life of a patent and the protection it affords is limited. If we encounter delays in our clinical trials or in obtaining regulatory approvals, the period of time during which we could exclusively market any of our product candidates under patent protection, if approved, could be reduced. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be vulnerable to competition from biosimilar products, as we may be unable to prevent competitors from entering the market with a product that is similar or identical to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. In the European Union, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#x201c;nonexclusive, nontransferable, irrevocable, paid-up license&#x201d; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#x201c;march-in rights&#x201d;. March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#x201c;nonexclusive, partially exclusive, or exclusive license&#x201d; to a &#x201c;responsible applicant or applicants.&#x201d; If the patent owner refuses to do so, the government may grant the license itself. Some of our licensed patents are subject to the provisions of the Bayh-Dole Act. If our partners fail to comply with the regulations of the Bayh-Dole Act, they could lose title to any patents subject to such regulations, which could affect our license rights under the patents and our ability to stop others from using or commercializing similar or identical technology and products, or limit patent protection for our technology and products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting, enforcing and defending patents on all of our product candidates in all countries throughout the world would be prohibitively expensive. Our intellectual property rights in certain countries outside the United States may be less extensive than those in the United States. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we and our partners may not be able to prevent third parties from practicing our inventions in countries outside the United States, or from selling or importing infringing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection or where we do not have exclusive rights under the relevant patents to develop their own products and, further, may export otherwise-infringing products to territories where we and our partners have patent protection but where enforcement is not as strong as that in the United States. These infringing products may compete with our product candidates in jurisdictions where we or our partners have no issued patents or where we do not have exclusive rights under the relevant patents, or our patent claims and other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us and our partners to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our partners. We or our partners may not prevail in any lawsuits that we or our partners initiate, and even if we or our partners are successful, the damages or other remedies awarded, if any, may not be commercially meaningful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some jurisdictions including European Union countries, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our partners are forced to grant a license to third parties under patents relevant to our business, or if we or our partners are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, expected by the end of 2023, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC).  This will be a significant change in European patent practice.  As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. It is our initial belief that the UPC, while offering a cheaper streamlined process, has potential disadvantages to patent holders, such as making a single European patent vulnerable in all jurisdictions when challenged in a single jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the U.S. and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have in-licensed a significant portion of our intellectual property from our partners, including BCM. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hold rights under license agreements with our partners, including the BCM License, that are important to our business. Our discovery and development platform is built, in part, around patent rights in-licensed from our partners. Under our existing license agreements, including the BCM License, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales. If there is any conflict, dispute, disagreement or issue of nonperformance between us and our counterparties regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations, we may be liable for damages and our counterparties may have a right to terminate the affected license. The termination of any license agreement with one of our partners, including BCM, could materially adversely affect our ability to utilize the intellectual property that is subject to that license agreement in our drug discovery and development efforts, our ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected product candidates and our ability to commercialize the affected product candidates. The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Furthermore, a disagreement under any of these license agreements may harm our relationship with the partner, which could have negative impacts on other aspects of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and other elements of our technology, discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with our product candidates, thus eroding our competitive position in the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements and invention assignment agreements with our employees, consultants, and outside scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, collaborators, or outside scientific advisors might intentionally or inadvertently disclose our trade secrets or confidential, proprietary information to our competitors. In addition, our competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, the laws of certain foreign countries do not protect proprietary rights such as trade secrets to the same extent or in the same manner as the laws of the United States. Misappropriation or unauthorized disclosure of our trade secrets to third parties could impair our competitive advantage in the market and could materially adversely affect our business, results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Patents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. or foreign patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the U.S. or non-U.S. jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#x2019;s patents or patent applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The America Invents Act also included a number of significant changes that affect the way patent applications are prosecuted and also affects patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review and, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be difficult for our stockholders to sell shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our IPO closed on August 3, 2020. Prior to our IPO, there was no public market for shares of our common stock. Although we have completed our IPO and shares of our common stock are listed and trading on The Nasdaq Global Select Market, an active trading market for our shares may never develop or be sustained. Our stockholders may not be able to sell shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The trading price of our common stock may be volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this quarterly report, these factors include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our ongoing, planned or any future preclinical studies, clinical trials or clinical development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment, or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse results or delays in preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in our regulatory filings or any adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in laws or regulations applicable to our products, including, but not limited to, clinical trial requirements for approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse developments concerning our manufacturers or our manufacturing plans; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to establish collaborations if needed; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns or adverse events related to the use of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and growth of our initial virus target markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully treat additional viral diseases; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in quarterly operating results; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our cash position; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publication of research reports about us or our industry, or viral immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">overall performance of the equity markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us or our stockholders in the future; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting practices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments relating to intellectual property or proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including intellectual property or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general political and economic conditions, including impacts from the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, financial condition, results of operation and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers, directors, and 5% stockholders beneficially owned approximately 74% of our common stock as of December 31, 2022. These stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on terms that are unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, including incurring additional debt, making capital expenditures, entering into licensing arrangements or declaring dividends. If we raise additional funds from third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for our product candidates, grant to others the rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or take other actions that are adverse to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2020 Stock Option and Incentive Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, expanded research and development activities, and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities, or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our 2020 Stock Option and Incentive Plan, or 2020 Plan, our management is authorized to grant stock options to our employees, directors, and consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of our common stock reserved for issuance under the 2020 Plan increased on January 1, 2021 and shall be cumulatively increased each January 1 thereafter by 5% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following 2020, the year in which we completed our IPO, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to not &#x201c;opt out&#x201d; of this exemption from complying with new or revised accounting standards and, therefore, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualify as an emerging growth company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#x201c;say on pay&#x201d; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could depress the market price of our common shares, could make it more difficult for you to sell your common stock at a time and price that you deem appropriate and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing or cause us to take other corporate actions they desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, as our principle office is located in Waltham, Massachusetts. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#x2019; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">purporting to require claims under the Securities Act be brought in federal court were &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with our IPO, we began the process of documenting, reviewing, and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. We have begun recruiting additional finance and accounting personnel with certain skill sets that we will need as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#x2019; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock may depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conduct our primary operations out of leased space in Waltham, MA, which is intended for general office, research and development, laboratory use, and light manufacturing. Our Waltham, Massachusetts property is comprised of a lease with BP Bay Colony, LLC and a sublease of office space with AMAG Pharmaceuticals, Inc. We have rights to the leased space in Waltham through July 30, 2030. We also lease an office space containing a one room suite with workplace capacity for six individuals, which is located in Houston, Texas. This lease will terminate effective March 31, 2023. We additionally lease an office space containing a one room suite with workplace capacity for four individuals located in Dublin, Ireland. This lease expires on December 31, 2023. We believe that our current facilities are sufficient to meet our current and near-term needs and that, should it be needed, suitable additional space will be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become subject to arbitration, litigation or claims arising in the ordinary course of business. We are not currently a party to any material arbitration or legal proceedings. The results of any future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock began trading on The Nasdaq Global Select Market on July 30, 2020, under the symbol &#x201c;ALVR.&#x201d; Prior to that time, there was no public market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Record</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 9, 2023, we had approximately 59 holders of record of our common stock. Certain shares are held in &#x201c;street&#x201d; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of then-existing debt instruments and other factors the board of directors deems relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We deemed the equity grants and exercises of stock options issued under our equity compensation plans prior to the completion of our initial public offering in August 2020 to be exempt from registration in reliance on Rule 701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, we closed our initial public offering, in which we issued and sold an aggregate of 18,687,500 shares of common stock, including the additional shares granted to the underwriters, at a public offering price of $17.00 per share. This included the full exercise of the underwriters&#x2019; over-allotment option to purchase an additional 2,437,500 shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All of the shares of common stock sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (Reg. No. 333-239698 and Reg. No. 333-240181), which was declared effective on July 29, 2020. Following the sale of the shares in connection with the closing of our initial public offering, the offering terminated. Morgan Stanley &amp; Co. LLC, J.P Morgan Securities LLC and SVB Leerink LLC acted as joint book-running managers and Piper Sandler &amp; Co. acted as co-manager of the IPO.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate net proceeds to use from the public offering were $292.0 million, inclusive of proceeds from the over-allotment exercise, after deducting underwriting discounts and commissions and offering expenses payable by us. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information related to use of proceeds from registered securities is incorporated herein by reference to the &#x201c;Use of Proceeds&#x201d; section of our final prospectus related to the IPO. There has been no material change in our planned use of the net proceeds from the offering as described in our prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on July 30, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On On July 26, 2022, the Company entered into the Securities Purchase Agreement with certain investors for aggregate net proceeds of $126.4 million after deducting issuance costs of $0.2 million. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors in a registered direct offering an aggregate of 27,458,095 shares of the Company's common stock, at a purchase price of $4.61 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. Selected Financial Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K.  This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. We are developing three innovative, allogeneic, off-the-shelf VST therapy candidates targeting 11 different devastating viruses. Our lead product, posoleucel (previously referred to as Viralym-M or ALVR105), is a multi-VST therapy that targets six viruses: adenovirus, or AdV, BK virus, or BKV, cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, human herpesvirus 6, or HHV-6, and JC virus, or JCV. We believe posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel is being studied in three ongoing Phase 3 registrational trials for 3 distinct indications - the prevention of clinically significant infections from multiple viruses, the treatment of virus-associated hemorrhagic cystitis, or HC, and the treatment of AdV infections &#x2013; all in allogeneic hematopoietic cell transplant, or HCT, patients who are at high risk for life-threatening viral infections from the six viruses targeted by posoleucel. We have successfully accelerated  the multi-prevention study in recognition of the fact that prevention best addresses patients&#x2019; unmet medical needs. The three Phase 3 studies are expected to complete enrollment by the end of 2023, enabling potential data readouts from all three trials in 2024. In addition to the ongoing Phase 3 registrational studies, posoleucel has been studied in a Phase 2 proof-of-concept study for the treatment of BK viremia in kidney transplant patients. Positive topline results of this study were reported in February 2023. This is the first study of posoleucel in SOT patients, and the results of this trial will inform next steps for this potential indication as well as the company&#x2019;s broader SOT strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline includes additional investigational VST therapies that may benefit high-risk individuals. ALVR106 is our second off-the-shelf, multi-VST product candidate targeting devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV and respiratory syncytial virus, or RSV. A Phase 1b/2 POC clinical study of ALVR106 is enrolling patients in the U.S. In the preclinical space, we are developing ALVR107 designed to target hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infection. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study after completion of the posoleucel Phase 3 studies. ALVR109 is an allogeneic, off-the-shelf, single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. Data from the POC clinical trial of ALVR109 were reported in 2021, and positive reports of ALVR109 compassionate use in immune-compromised patients also have been published and presented, including poster presentations at the 2022 American Transplant Congress.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, we have devoted substantially all of our resources on raising capital, organizing and staffing our company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing posoleucel, ALVR106, ALVR107,and other product candidates and preparing for clinical trials and establishing arrangements with third parties for the manufacture of our product candidates and component materials. We do not have any product candidates approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, we completed an initial public offering, or IPO, of our common stock and issued and sold 18,687,500 shares of our common stock at a public offering price of $17.00 per share, resulting in net proceeds of $292.0 million after deducting underwriting discounts and commissions and offering costs. Prior to our IPO, we funded our operations through equity financings and received proceeds of $156.3 million, net of issuance costs of $0.6 million, from the sale of our preferred stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2022, we entered into a Securities Purchase Agreement, or the Securities Purchase Agreement, with certain investors for the issuance and sale of 27,458,095 shares of our common stock for aggregate net proceeds of $126.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we filed an automatically effective registration statement on Form S-3, or Registration Statement, with the SEC which registered the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warrants and/or units of any combination thereof. We simultaneously entered into a sales agreement with SVB Leerink LLC, as sales agent, to provide for the issuance and sale by the Company of up to $100.0 million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Registration Statement and related prospectus filed with the Registration Statement, or the ATM Program. On February 10, 2022 we filed a Post-Effective Amendment No. 2 to the Registration Statement and on February 18, 2022 we filed Post-Effective Amendment No. 3 to the Registration Statement. As of December 31, 2022, no sales had been made pursuant to the ATM Program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant operating losses since inception, including net losses of $168.7 million and $172.0 million for the years ended December 31, 2022 and 2021, respectively. At December 31, 2022, we had an accumulated deficit of $465.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, particularly if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and conduct additional preclinical studies and clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional clinical and scientific personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expand our manufacturing capabilities with third parties and establish manufacturing capabilities in-house; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals and pursue commercialization for any product candidates that successfully complete clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we had cash, cash equivalents and short-term investments of $233.8 million. We believe that our existing cash, cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months following the issuance of these financial statements. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#x201c;&#x2014;Liquidity and Capital Resources.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of our product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the ongoing COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted our operations, including the interruption of our preclinical and clinical trial activities and potential interruption to our supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, our planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay our ability to obtain regulatory approval and commercialize our product candidates. Furthermore, COVID-19 could affect our employees or the employees of research sites and service providers on whom we rely, including contract research organizations, or CROs, as well as those of companies with which we do business, including our suppliers and contract manufacturing organizations, or CMOs, thereby disrupting our business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which we and the companies with which we do business operate could materially impact the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. For the health and safety of our employees, the Company has implemented work-at-home policies and we have generally restricted on site staff to only those employees who are fully vaccinated or essential to the development and research of product candidates; accordingly, we may experience limitations in employee resources. The outbreak and any other preventative or protective actions that we, our suppliers or other third parties with which we have business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay, or otherwise adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are still assessing our business plans and the impact the COVID-19 pandemic may have on our ability to advance the testing, development and manufacturing of our drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom we rely, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in our sector in particular. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties on whom we rely or with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Relationship with ElevateBio</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 17, 2018, we entered into a Series A2 Preferred Stock Purchase Agreement, or the Series A2 Agreement, with ElevateBio, and ElevateBio was a purchaser in our registered direct offering in July 2022. ElevateBio, through its diverse platform of technologies to support cell and gene therapy products and expertise, provides drug development and manufacturing services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of ElevateBio&#x2019;s purchase of our Series A2 Preferred Stock, which converted to common stock upon completion of our IPO, and as a result of ElevateBio&#x2019;s participation in the July 2022 registered direct offering, ElevateBio acquired an ownership interest to our consolidated financial statements appearing elsewhere in this Form 10-K. The Chief Financial Officer of ElevateBio currently serves in a similar management role with us. In May 2021, Diana M. Brainard M.D., succeeded David Hallal, ElevateBio&#x2019;s Chief Executive Officer, as the Company&#x2019;s Chief Executive Officer. Mr. Hallal currently serves as Executive Chairman of the Company's board of directors. In addition to Mr. Hallal and Mr. Sinha, two other members of the Company's board of directors, Morana Jovan-Embiricos and Ansbert Gadicke, also serve as directors of the board of directors of ElevateBio.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of costs incurred in connection with our research and development activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">external research and development expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our clinical trials and other scientific development services; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to manufacturing material for our clinical trials, including fees paid to CMOs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing scale-up expenses and the cost of acquiring and manufacturing clinical trial materials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related costs for those employees involved in research and development efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of acquiring and developing clinical trial materials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses to acquire technologies, such as intellectual property, to be used in research and development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upfront and maintenance fees incurred under license, acquisition and other third-party agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent, maintenance of facilities and equipment and software. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our discovery studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. Once a product candidate has been identified, research and development costs incurred are allocated as product candidate costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We track these external research and development costs on a program-by-program basis once we have identified a mature product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not allocate employee costs, costs associated with our discovery efforts, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and third-party consultants primarily to conduct our research and discovery activities as well as for managing our process development, manufacturing and clinical development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our clinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly with our ongoing clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other research and development activities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing an appropriate safety profile; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether our product candidates show safety and efficacy in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continued acceptable safety profile of the products following any regulatory approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. For example, if the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or another regulatory authority</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of employee-related costs, including salaries, bonuses, benefits, stock-based compensation and other related costs, as well as expenses for outside professional services, including legal, accounting and audit services and other consulting fees, rent expense and other general administrative expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Total Other Income (Loss), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists of interest income on cash, cash equivalents and short-term investments held in financial institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other income (loss), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Other income (loss), net&#x201d; consists primarily of investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income tax (benefit) expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax (benefit) expense consists of current income tax (benefit) expense which is expected to be (refundable) payable for the current year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.333%;"></td>
    <td style="width:1.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.698%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.892000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.892000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,870</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,735</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,865</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,332</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,083</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,249</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171,202</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169,818</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,384</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(171,202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(169,818</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,384</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (loss), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,876</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,315</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (loss), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">351</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,452</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,803</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(168,975</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(170,955</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,980</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax (benefit) expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(265</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,272</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(168,710</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(171,962</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,252</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development costs for each of the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.45%;"></td>
    <td style="width:1.397%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.520999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.397%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.918%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.397%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.918%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct research and development expenses by program:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">posoleucel</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,629</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,696</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,933</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALVR106</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,313</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,224</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,911</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel expenses (including stock-based compensation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,541</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,387</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,796</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,409</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,870</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,735</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,865</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $118.9 million for the year ended December 31, 2022, compared to $120.7 million for the year ended December 31, 2021. The decrease of $1.9 million was primarily due to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $8.9 million increase in costs related to the development of posoleucel, our most advanced product candidate, primarily due to an increase in costs related to the development of clinical trials of $14.6 million, offset by a decrease in costs related to the outsourcing of manufacturing of $5.7 million;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $4.9 million decrease in costs related to the development of ALVR106, primarily due to a decrease in costs related to the outsourcing of manufacturing of $5.9 million, offset by an increase in costs related to the development of clinical trials of $1.0 million;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $4.5 million decrease in personnel expenses, primarily due to a decrease in stock-based compensation expense of $6.6 million, offset by an increase of $1.2 million in external consulting; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a $1.4 million decrease in other research and development expenses, primarily due to a $3.8 million decrease in costs related to the development of clinical trials and outsourcing of manufacturing for discovery drug programs, offset by an increase of $2.0 million in occupancy charges related to the corporate office.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $52.3 million for the year ended December 31, 2022, compared to $49.1 million for the year ended December 31, 2021. The increase of $3.2 million primarily consisted of an increase of $4.0 million in stock-based compensation expense and an increase of $0.9 million in occupancy charges related to the corporate office, offset by a decrease of $1.4 million in external consulting and professional services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Total Other Income (Loss), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total &#x201c;other income (loss), net&#x201d; was $2.2 million for the year ended December 31, 2022, compared to $(1.1) million for the year ended December 31, 2021. The increase of $3.4 million is primarily attributable to an increase of $2.3 million resulting from a change in amortization and accretion of discounts and premiums on short-term investments and an increase of $0.6 million in interest income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Tax Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense was $(0.3) million for the year ended December 31, 2022, compared to $1.0 million for the year ended December 31, 2021. The decrease of 1.3 million in income tax expense was due to a transfer of intellectual property rights between tax jurisdictions in 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we have funded our operations primarily through equity financings and have received net cash proceeds of approximately $156.3 million from the sale of our preferred stock, $292.0 million of net proceeds from the sale of common stock in our IPO and $126.4 million of net proceeds from the Securities Purchase Agreement entered into on July 26, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 6, 2021, we filed the Registration Statement with the SEC and simultaneously entered into a sales agreement with SVB Leerink LLC, as sales agent, for the ATM Program. As of December 31, 2022, no sales had been made pursuant to the ATM Program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than our manufacturing, licensing and lease obligations described further below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, our cash, cash equivalents and short-term investments were $233.8 million. We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months following the issuance of these financial statements. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical development, seek regulatory approval and pursue commercialization of any approved product candidates. We expect that our research and development and general and administrative costs will increase in connection with our planned research  and development activities. If we receive regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the amount of our working capital requirements. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of researching and developing posoleucel for our initial and potential additional indications, as well as ALVR106 and other product candidates we may develop, including any COVID-19-related delays or other effects on our development programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of, and the costs involved in, obtaining marketing approvals for posoleucel for our initial and potential additional indications, and ALVR106 and other product candidates we may develop;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if approved, the costs of commercialization activities for posoleucel for any approved indications, or ALVR106 or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of a collaborator that we may contract with in the future, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of posoleucel for any approved indications or ALVR106 or any other product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we in-license or acquire rights to other products, product candidates or technologies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our headcount growth and associated costs as we expand our research and development, increase our office space, and establish a commercial infrastructure; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ongoing costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for each of the periods presented (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.024%;"></td>
    <td style="width:1.758%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.134%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.758%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.328%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(142,052</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(106,319</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(80,478</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185,983</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,961</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(95,569</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,852</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $142.1 million for the year ended December 31, 2022, reflecting a net loss of $168.7 million, partially offset by non-cash charges of $42.8 million. The non-cash charges primarily consist of stock-based compensation expense of $41.3 million. The change in our net operating assets and liabilities of $(16.1) million was primarily due to a decrease of $12.6 million in accounts payable, accrued expenses and amount due to related party, and an increase of $3.0 million in prepaid expenses and other current assets and prepaid expenses to related party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $106.3 million for the year ended December 31, 2021, reflecting a net loss of $172.0 million, partially offset by non-cash charges of $46.3 million. The non-cash charges primarily consist of non-cash lease expense, amortization of discounts on short-term investments and stock compensation expense. The change in our net operating assets and liabilities of $19.4 million was primarily due to an increase of $20.3 million in accounts payable, accrued expenses and amount due to related party and an increase of $1.0 million in income tax payable partially offset by an increase of $1.2 million in prepaid expenses and other current assets and an increase of $1.1 million in other assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $80.5 million for the year ended December 31, 2022, which was primarily due to purchases of investments of $228.8 million, partially offset by investment maturities of $148.3 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by investing activities was $186.0 million for the year ended December 31, 2021, which was primarily due to investment maturities of $262.6 million, partially offset by purchases of investments of $76.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $127.0 million for the year ended December 31, 2022, which was primarily due to net proceeds from the issuance of common stock in registered direct offering, net of issuance costs of $126.4 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities was $0.2 million for the year ended December 31, 2021 due to proceeds from the exercise of stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease payments represent our commitments for future minimum lease costs under non-cancelable leases for our corporate headquarters in Waltham, MA and for dedicated manufacturing suites for the manufacture of AlloVir products at a third party contract manufacturing organization, or CMO.  The total payments for our operating lease obligations at December 31, 2022 is $41.2 million, of which $9.1 million is due in the next twelve months and the remaining payments are due over the term of the respective leases. For additional details regarding our leases, see Note 5 to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sponsored Research and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, we entered into a Research Collaboration Agreement (the &#x201c;Research Agreement&#x201d;) with BCM, effective on the same date, under which we agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021 and continuing for a three-year period thereafter. The Research Agreement requires the Company to make payments to BCM totaling approximately $2.0 million per year, for a total of approximately $6.0 million over the term of the Research Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and testing and manufacturing services, which can contain purchase commitments or other noncancelable obligations. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of services provided up to one year after the date of cancellation. The amount and timing of such payments are not known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or we may be required to make royalty payments under license and grant agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time. See &#x201c;Business&#x2014;Sponsored Research, Collaboration and License Agreements&#x201d; as well as Note 8 to our consolidated financial statements for a description of our license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We grant restricted stock and stock options to employees, consultants, and directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We measure stock-based compensation for employees and non-employees based on the grant date fair value of the stock-based awards, and recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved using a graded-vesting basis over the requisite service period. For awards with only a service condition, we expense stock-based compensation on a straight-line basis over the requisite employee service period, which is generally the vesting period of the respective award.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense is classified in our consolidated statements of operations and comprehensive loss based on the function to which the related services are provided or in the same manner in which the grantee&#x2019;s payroll costs are classified or in which the grantee&#x2019;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to our IPO, we estimated the fair value of each stock option grant and restricted common stock award. We consider the fair value of our common stock prior to the IPO, an input to the option pricing models, a critical accounting estimate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of our common stock and assumptions we make for the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option and our expected dividend yield.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term of our options granted to employees and non-employees has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options, and we calculate the expected term of these awards using the midpoint between the vesting date and the contractual term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, dividends on our common stock; therefore, the expected dividend yield is assumed to be zero.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to our IPO, the fair value of each restricted common stock award was estimated on the date of grant based on the fair value of our common stock on that same date. In estimating its stock price, the Company utilized a hybrid method consisting of an option-pricing method and a zero-value scenario. We determine the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. We expect to continue to do so until we have adequate historical data regarding the volatility of the trading price of our common stock on Nasdaq.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As there had been no public market for our common stock prior to the initial public offering of our common stock, the historical estimated fair value of our common stock has been approved by our board of directors, considering our most recently available independent third-party valuations of common stock. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a third-party valuation firm prepared valuations of our common stock using either an option pricing method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to considering the results of the third-party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, which may be a date later than the most recent third-party valuation date, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prices at which we sold preferred stock and the superior rights and preferences of the preferred stock relative to our common stock at the time of each grant;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the progress of our research and development efforts, including the status of clinical studies for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the lack of liquidity of our equity as a private company;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our stage of development and business strategy and the material risks related to our business and industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the achievement of enterprise milestones, including entering into collaboration and license agreements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the likelihood of achieving a liquidity event for the holders of our preferred stock and holders of our common stock, such as an IPO, or a sale of our company, given prevailing market conditions; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are significant judgments and estimates inherent in these valuations. The assumptions underlying these valuations represent management&#x2019;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the closing of our initial public offering, the fair value of our common stock is determined based on the quoted market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 5, 2012, the Jumpstart Our Business Startups Act, or the JOBS Act, was enacted. The JOBS Act provides that, among other things, an &#x201c;emerging growth company&#x201d; can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. As an emerging growth company, we have irrevocably elected to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth public companies on a case-by-case basis. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to rely on certain of the other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging growth company, we are not required to, among other things, (i) provide an auditor&#x2019;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b), and (ii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements (auditor discussion and analysis).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will remain an emerging growth company until the earlier to occur of (1) the last day of our fiscal year (a) following the fifth anniversary of the closing of our IPO, (b) in which we have total annual gross revenues of at least $1.0 billion or (c) in which we are deemed to be a &#x201c;large accelerated filer&#x201d; under the rules of the SEC, which means the market value of our common shares that is held by non-affiliates exceeds $700 million as of the last day of our second quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A description of recent issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a smaller reporting company, we are not required to disclose this item.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements, together with the independent registered public accounting firm report thereon, are presented beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and our Chief Financial Officers concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and our principal financial officer, and effected by our board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (U.S. GAAP), and includes those policies and procedures that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of assets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in (2013 Framework). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for &#x201c;emerging growth companies&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(e) and Rule 15d-(e) under the Exchange Act that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9c_disclosure_regarding_fj"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of the Stockholders and is included herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of the Stockholders and is included herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of the Stockholders and is included herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of the Stockholders and is included herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our independent public accounting firm is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_056f5b64-e63f-44da-937c-e4bbaa989d80" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bce8e2f1-4653-4724-8c76-edc490dea756" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, MA, USA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, PCAOB Auditor Firm ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_89cad007-6ab0-4c87-9574-108c8aa42c9d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of the Stockholders and is included herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) Consolidated Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are included this Annual Report on Form 10-K:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3) Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibit_index"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:89.88%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,1);text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000119312520208027/d63073d8k.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant&#x2019;s Current Report on Form 8-K (File No.001-39409) filed on August 3, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000119312520208027/d63073d8k.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant&#x2019;s Current Report on Form 8-K (File No.001-39409) filed on August 3, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement among the Registrant and certain of its stockholders, effective as of May 8, 2019 (incorporated by reference to Exhibit 4.2 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000156459021005652/alvr-ex42_626.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of the Registrant&#x2019;s securities registered pursuant to Section 12 of the Securities and Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.2 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.1#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 Equity Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.2#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Stock Option and Grant Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.3#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.4*#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000095017022001075/alvr-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Executive Cash Bonus Plan</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.5#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.4 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.6#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.5 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement between the Registrant and Regus Management Group, LLC, dated as of January 3, 2019, as amended by the Renewal Agreement, entered into on December 10, 2019 (incorporated by reference to Exhibit 10.6 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:89.88%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.8&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Exclusive License Agreement, by and between Baylor College of Medicine and the Registrant, dated as of May 11, 2020 (incorporated by reference to Exhibit 10.7 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.9&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sponsored Research Agreement, by and between Baylor College of Medicine and the Registrant, dated as of June 18, 2019, as amended by the Amendment to Sponsored Research Agreement, entered into on April 7, 2020 (incorporated by reference to Exhibit 10.8 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset Rental Agreement, by and between ElevateBio Management, Inc. and the Registrant, dated as of May 1, 2019 (incorporated by reference to Exhibit 10.9 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.11</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease Agreement, by and between ElevateBio Management, Inc. and the Registrant, dated as of May 1, 2019 (incorporated by reference to Exhibit 10.10 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.12#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, by and between Juan Vera and the Registrant, dated as of October 1, 2018 (incorporated by reference to Exhibit 10.11 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.13#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520187665/d932810dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement, by and between Ann Leen and the Registrant, dated as of October 1, 2018 (incorporated by reference to Exhibit 10.12 of the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-23969) filed on July 6, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.14&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Preferred Stock Redemption Agreement among the Registrant and certain of its stockholders, effective as of September 17, 2018 (incorporated by reference to Exhibit 10.13 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.15#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312521089593/d242363dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement by and between the Registrant and Diana Brainard, effective as of March 17, 2021 (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-39409) filed on March 22, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.16#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000095017021000980/alvr-20210630ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transition Agreement by and between the Registrant and David Hallal, dated May 18, 2021 (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Quarterly Report on Form 10-Q (File No. 001-39409) filed on August 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.17#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000095017021000980/alvr-20210630ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consulting Agreement by and between AlloVir, Inc. and David Hallal, effective as of July 22, 2021 (incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Quarterly Report on Form 10-Q (File No. 001-39409) filed on August 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.18#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Executive Employment Agreement, by and between the Registrant and Vikas Sinha, dated as of October 2, 2019 (incorporated by reference to Exhibit 10.15 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.19#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000119312520197425/d932810dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement, by and between the Registrant and Agustin Melian, dated as of March 21, 2019 (incorporated by reference to Exhibit 10.16 of the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-239698) filed on July 23, 2020).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.20#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000156459021005652/alvr-ex1017_627.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement, by and between the Registrant and Ercem Atillasoy, dated as of July 14, 2020 (incorporated by reference to Exhibit 10.17 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.21&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000156459021005652/alvr-ex1018_1063.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement, by and between Baylor College of Medicine and the Registrant, dated as of November 30, 2020 (incorporated by reference to Exhibit 10.18 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.22&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000156459021005652/alvr-ex1019_1062.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research Collaboration Agreement, by and between Baylor College of Medicine and the Registrant, dated as of November 30, 2020 (incorporated by reference to Exhibit 10.19 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.23&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000156459021005652/alvr-ex1020_1061.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Amended and Restated Exclusive License Agreement by and between Baylor College of Medicine and the Registrant, dated as of November 30, 2020 (incorporated by reference to Exhibit 10.20 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:89.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.24+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000119312521271445/d216131dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease by and between AlloVir, Inc. and AMAG Pharmaceuticals, Inc., dated September 8, 2021 (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-39409) filed on September 13, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.25+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001754068/000119312521271445/d216131dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease by and between AlloVir, Inc. and BP Bay Colony LLC, dated September 8, 2021 (incorporated by reference to Exhibit 10.2 of the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-39409) filed on September 13, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;10.26</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001754068/000119312522202719/d286495d8k.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement, dated as of July 26, 2022, by and between AlloVir, Inc. and the investors identified therein (incorporated by reference to Exhibit 10.1 of the Registrant&#x2019;s Current Report on Form 8-K filed on July 26, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1754068/000095017022001075/alvr-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries of Registrant (incorporated by reference to Exhibit 21.1 of the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-39409) filed on February 10, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="alvr-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;24.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on signature page).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="alvr-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="alvr-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;32.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="alvr-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;32.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="alvr-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Schedules to the Sublease and Lease have been omitted pursuant to Item 601(b)(2) of Regulation S-K because they contain information that is both (i) not material and (ii) of the type that the registrant treats as private and confidential. The registrant will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="n16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Form 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 15, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Diana Brainard</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diana Brainard</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each person whose individual signature appears below hereby authorizes and appoints Diana Brainard with full power of substitution and resubstitution and full power to act as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agent or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.009%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:43.296%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:21.62%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Diana Brainard, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diana Brainard</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vikas Sinha</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Financial Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vikas Sinha</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Hallal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Hallal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jeffrey Bornstein</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jeffrey Bornstein</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Malcolm Brenner, MD, PhD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Malcolm Brenner, MD, PhD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ansbert Gadicke, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ansbert Gadicke, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Morana Jovan-Embiricos, PhD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Morana Jovan-Embiricos, PhD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Juan F. Vera, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Juan F. Vera, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Shawn Tomasello</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shawn Tomasello</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:95.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Financial Statements for the Years Ended December 31, 2022 and 2021:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(PCAOB ID No. 34)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_members_interest"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Changes in Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGIST</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the stockholders and the Board of Directors of AlloVir, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of AlloVir, Inc. and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#x2019; equity, and cash flows, for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED BA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LANCE SHEETS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.702%;"></td>
    <td style="width:1.683%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.373%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.674%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.567%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6091b339-d4de-4085-bf46-7eb5564079db" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30fa7c52-4242-42fb-a6a2-d7e10b1359bc" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,661</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9440b6a6-2110-4c09-abfe-19b46eb1826f" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,703</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d2ce892-2fb0-429c-906b-bdd4961e5ceb" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_186d8d03-8832-4eab-8d91-d2370667c64b" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad19c65e-8a7d-4f6d-8461-8ba1d246f0a1" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28291d5f-2b06-477f-8628-be1b8552c817" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_446a1cfc-2a4a-4dce-bf61-2ecd5608600e" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses to related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00f6b081-0f79-4858-82da-7edf27c3fb01" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:PrepaidExpensesToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f82edbf0-d324-43e0-a561-2b30a7111e6d" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">243,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ccbc708-5137-4452-996f-a0ab6c5b2bad" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b3d6efa-47bb-4ab5-a000-72069ed7a93b" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39fdf307-bcfc-46b1-bd5b-7d770cd6948c" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9905dae8-2164-4b84-8c1f-2963f78901d7" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1e00437-0fff-4546-8476-ebfa91151f76" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8665e047-2a37-4f82-91fb-c3674434252b" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">930</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72f7512b-7508-4c08-876b-3af49821e1f5" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fceba8f7-f64b-43f7-810e-f3fd92e07c71" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5f1c53a-20d7-4dc4-a131-eaaf0bda5a1a" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_512b5a71-bb14-43fc-8470-828545fbee89" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_846a0da6-9956-4269-b138-71ed5bc308b6" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d413d2ad-5215-4297-aa4c-977dd550addf" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2405008-fac4-4249-b2df-b1c91514e7ab" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61d02d58-a153-42ba-aae8-36250499be16" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e9acd1a-65d8-43fe-8d29-7d9f59e2d366" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69925b54-d1e9-4e5e-b6c8-fdf82b95197e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9563bb1d-7558-4b06-880d-ebb54aaac307" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d2d0667-d997-4e7e-9bce-b1ca7b28f449" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,165</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaa5a1ec-02da-4b96-bd57-cd7b479c5d0e" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount due to related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86900308-431b-433f-bdb6-1b42128d23b3" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_659a1cc2-be6b-4783-b948-338adc8102f5" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,742</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44e7e260-c0ec-40a9-a470-2a21139de866" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1efe003-078e-4c6b-a4e3-4aa143a0ac5f" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,853</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liability, long-term</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40f4affe-4142-497d-93d3-53c6504836d6" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_402435ac-71c6-4008-bdf1-64cec6650ec3" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbc2500c-c936-42e7-aa3f-a84cac86ccbd" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,560</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd6c080b-db9a-4765-88cc-ad39d64fd3ba" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc1611e7-3d25-4bae-b862-5d813eb895a3" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_e5061c65-56f3-4a34-9ebc-07eec720e511" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd5da05a-0832-4961-a6cb-3bb7537d7277" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_551045f9-1df9-4b41-a2e5-a7a29fa43892" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at December 31, 2022 and December 31, 2021, respectively; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fca22031-4860-47ff-9de7-7f297dddb72f" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f6ca3a43-4197-46c0-ab0e-140d59f4d2e8" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e5177103-1748-4224-923f-307a7d72d742" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2b867970-5102-478e-8b4a-58b8304270ca" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6fd272f4-1070-42c6-9b05-cfa962784023;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_794d01a1-aca2-4aae-acbc-307b1688cae1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b744cb67-0b12-4b51-9523-64649d17f6c2" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_dd832dcf-1a62-4375-9fdd-6a3a5f096f55" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08ebdb70-9f3b-47e0-89a8-4d98e01beba5" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_49054fae-d6ca-4fd6-afe8-43832a2cc29a" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at December 31, 2022 and December 31, 2021, respectively; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3e0c9a9-7d0e-4704-8c37-7bb8966597e7" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">93,268,069</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b91d30da-fa0e-4b54-a429-5feea5bae738" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">65,170,332</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued at December 31, 2022 and December 31, 2021, respectively; and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_679a9860-90f1-43a3-95c8-112ea29fa227" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">93,093,243</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29458ea4-57cb-48f1-9538-327285f734be" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">63,565,886</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares outstanding at December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d35c8f99-0dca-47c7-ab9d-522d88d48671" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e310a5af-1e8a-4af8-8308-58248a6aac2c" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94a2fe2a-06d9-4826-bf89-f1d2bb84d112" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">690,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7897ba96-124d-47dd-89db-27e648ce5358" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">522,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d19de77a-7931-4f38-a49d-e78e23574c8b" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a20607b3-3ee8-4220-82a8-87a7e900205d" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cff2a947-28be-4130-b344-261bb20057d1" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">465,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e05cac42-6890-40a9-b996-cc79c8d83768" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">297,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08ecc282-6ebc-4bc7-ac96-99c8f42e3d62" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0f67e11-fd1a-470d-8dab-36982300504c" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dc23fb4-c1c3-443a-9138-7f15050effd4" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42f028e6-212e-4fa4-bd49-a06a5ab3d954" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPER</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATIONS AND COMPREHENSIVE LOSS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.067%;"></td>
    <td style="width:1.915%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.453999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.915%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.648%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d751fc35-02fe-4bcf-8a61-f58111721f6c" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">118,870</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9882de40-563f-4924-a0fc-043805309816" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f0e2a54-08f5-4ef7-ab83-a782f20d904f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d494156b-662f-45fe-a1c8-826eedaa584e" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a985c5aa-a4d5-4661-b919-277809227ed4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee28448b-a321-448a-9ae4-66ce6ba18318" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc37b3f3-84fe-4d0e-b375-def4ba70ff3f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d99ef5b1-7695-43aa-be54-392b1e621523" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">169,818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (loss), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecfa5f46-ada1-4f9e-b633-67d3681195c4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,876</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a3a7ebb-44cd-483a-a966-a230b716b2a9" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (loss), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9fa5954-7caf-47e8-bcc8-69e756625e19" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bc9724d-c05c-4a3e-af1d-292bbb7ac2bd" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fdd139d-5ee0-4e37-aca8-113241cd47f6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11986138-0a0a-486a-98e7-17758ee0b1c1" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">170,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax (benefit) expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_379675af-bfb4-49c8-9e3c-df249fc26ae0" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88db3043-1aa5-4098-9a81-17ca92170734" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee5c9cc8-2ab1-445a-9ce7-8b8d148d53cb" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3445bf02-84af-4f59-a082-fcbb521262ad" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#x2014; basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c14df31-559b-4625-b0fb-1727c82b0474" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_f724a988-07f7-46f0-98de-6a2dcaf08bdd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.20</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_732baf6d-6a2c-45c1-a7fb-c7e23e72f7f7" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_82cb6689-0c19-4b4e-a6ae-09fb974b4993" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.74</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding &#x2014; basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a4614d6-8692-43b5-9b44-ab4bcdfb96b8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_e7c6ce53-f7ca-4aa9-b600-e7622343bd4a" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">76,654,856</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef147c7c-0d44-4774-b903-421470b754fd" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_89a56ba0-4463-492d-a988-dfc1264c94ff" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">62,782,126</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b919d42-0bb7-4947-8b36-67194df3454a" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dff536b3-09e9-45e8-a2a3-d4b3a8692597" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income (loss), net of tax:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized (loss) gain on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a2493df-7a9f-4ea4-a4c7-9f63199f35b7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f5678f6-10f5-4c25-b18c-8c629836d724" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6934f83e-b26f-4f7f-89ff-3f5e1242dc94" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f74f192-9b85-4154-b10e-369cf0bf67d6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f54b4ab-7823-41a3-9027-b06bd3918c3a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cf1e897-50b6-4fde-af31-07267fa72720" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">169,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe24c4bc-64cb-49f7-8898-a34cf7b05723" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">172,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_members_interest"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CHANGES IN STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.736%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.993%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.626%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.023%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.626%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Loss) Income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_543f441e-4d8c-4037-adef-8364e49e43de" contextRef="C_0b319269-2fae-4e66-8b64-b20a04c36873" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,931,255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2188dc5-6497-426a-b84c-489313ed8358" contextRef="C_0b319269-2fae-4e66-8b64-b20a04c36873" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e6e3fc0-6d49-4ebd-b3db-b325791105f1" contextRef="C_5a13a2d7-5fd2-4d62-8f2a-c04d53be3758" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">478,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa818210-1122-4d44-b17d-9c1c29ad5844" contextRef="C_f3f9b887-cf21-4bb9-8973-a2512cec26c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f04a5c5-7609-4fc7-ba04-f7d1840ff36a" contextRef="C_16d12274-58f7-4d85-a851-cdb95fe02f19" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e7905a3-bba7-4ce1-b7df-0ed9f830134c" contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c585287d-86a6-44a4-82be-af9807c794f9" contextRef="C_9cd782a5-8539-46d4-88c3-5b91917b87e4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93f7e5be-7bec-463c-953d-7467b7aca813" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, upon vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66019cd1-e91e-48f3-847c-1a0be303056a" contextRef="C_c3854674-c6cb-450f-a8f1-f217cae5fd90" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,609,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, upon exercise of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5524d3a2-be3a-40fe-b5b6-a5bb6e520daf" contextRef="C_c3854674-c6cb-450f-a8f1-f217cae5fd90" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e1e33ba-3406-431e-83da-ae18975893dc" contextRef="C_9cd782a5-8539-46d4-88c3-5b91917b87e4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdf0380b-d973-4d23-a186-59214d361754" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ddd2b33-3f34-48d5-9928-92ca98c76e89" contextRef="C_e6a30e50-19aa-46ea-ad75-47a4021abf20" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b7c8c47-2092-4835-8caf-452bd6647750" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1447c880-0a83-4427-ba55-9c1affd9cc5e" contextRef="C_e6a30e50-19aa-46ea-ad75-47a4021abf20" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cfac677-d31d-4894-8794-9a89abb8c16f" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66e7ae0d-c65e-48e7-b97c-1f70cf094bad" contextRef="C_8e51cc0b-f9e3-4e56-9d47-caa41e9a1eab" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1ff48b5-5c67-4a01-bb4d-7119daa624ac" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a995a8a-6271-4031-ae12-0fd8a9cf59dc" contextRef="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">63,565,886</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed4cb229-0792-4545-8be5-df96a8ccaa44" contextRef="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c4b6dd4-85be-4e56-bf9d-f26a1484a7da" contextRef="C_b2d19e85-a506-472f-9db8-0cfeb581c0c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">522,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bda90048-0d51-4e59-93fe-be7bd8bfb87b" contextRef="C_7dba3ee0-797d-4488-a999-52e2d13730df" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec469ad3-0ac0-4187-9e49-5441c64ace3e" contextRef="C_5b6e5424-0ab6-4de8-961e-ab8143059eb0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">297,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fe1754a-bc35-4ecb-bc88-718ccd3d0c8f" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8079880e-71d0-4dde-9bf7-75fb2ae6835f" contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27d29c01-ad42-418b-b9ff-6dd1f0caffa2" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock, upon vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdfee90b-2d33-4274-bf46-a412c8fa2966" contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,912,210</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of common stock under the 2020 Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0eff21db-c255-44d6-88da-e2db21c0c8f3" contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">157,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1479d817-3011-4f8b-820b-fadf82bfab7d" contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bc47767-52aa-416a-a637-eebb0e646aad" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in registered direct offering, net of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7be66f4-78d2-41b7-98f1-e3a14da6b0c5" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;million issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0baf3948-6cef-4bf0-9710-cdc0bb3d197f" contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,458,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79e8000d-d4a2-425c-b0c0-fa75e6fc22d9" contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_635601f9-0b45-47bd-8f95-60da1561b04d" contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea208eef-8d80-4e9a-9e64-53f05596cfe9" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_078319b3-8e7a-4594-b9d2-2c1fce50cf9b" contextRef="C_befdac74-700b-4c42-b7e1-ec0012c1f70b" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5fd1198-357a-4fb7-a23b-0f4eaec19c89" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80129229-c8af-438a-89a5-cbac70d18d89" contextRef="C_7d26fd97-1281-48e9-9f0c-80658a0a41dd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f6836de-5af2-496b-9002-4284565666cb" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4280abc-e410-485b-b75a-067e45e26708" contextRef="C_bd837554-2d0e-44a4-89f5-21197c0c9b79" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">93,093,243</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f53be03f-b051-4642-b4ec-b84ef3d3169b" contextRef="C_bd837554-2d0e-44a4-89f5-21197c0c9b79" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a1bef56-30e2-4f69-b77f-94a33038b485" contextRef="C_dbf392d2-9387-428a-99dd-65df376878d8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">690,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39775a9f-53de-4aed-a903-b444c010a36f" contextRef="C_235f6d4f-ef0b-4fbc-b567-efa82b6fd888" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aacf8d2-7968-42ef-88ce-eee5343b2af0" contextRef="C_76cdb962-34b7-4488-9b22-155ce39bf6f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">465,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30c7d2d5-6369-47b5-9ea8-9e7b1abb120e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ENTS OF CASH FLOWS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.627%;"></td>
    <td style="width:1.359%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.474%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.359%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.182%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0231a1e5-f7f6-4719-a0fb-cba5d277fe32" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7073045c-376c-4ac6-8480-493a459ca30a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37bd9eec-a96e-4d59-8a6d-f2b0d8ff7dfd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50932c04-25aa-412d-97d6-87f04b36851d" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d63a6c6-729f-4fe2-b825-b1c3c80c51cc" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01bbb995-db1a-4799-bedd-b01f6a2ee519" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Accretion) amortization of short-term investment (premiums) discounts</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bad505ae-8ed8-4652-a2c9-9c2e161c6f94" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,076</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d744d1f2-47bc-4bb6-9c85-a414e96a9c8c" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,197</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90870c9d-0a8e-402b-9a3e-712f88e3e4f3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f55f491-cdc3-439b-8467-dd166b3f9306" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff82c071-2ad0-46e8-90e6-eb3c02f82be1" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c902bb8-be41-4508-aa8c-6f5435ee87c2" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets and prepaid expenses to related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f82b81d9-97ee-4913-aee4-37210ef4c4ed" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81c69b1b-6171-4413-94c6-440115388490" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa86c5f2-ddaa-4b5f-a077-b0707d87a559" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a40805d8-7441-49d4-843e-def7cbe12686" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5d103e1-4ce6-4bfd-a4f4-cdd30d126344" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncreaseDecreaseInIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85021ce3-2138-4a32-ae66-53ab2c09a1b1" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncreaseDecreaseInIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable, accrued expenses and amount due to related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d21cc48-797d-4f60-985a-0f93047dd805" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e24c55a0-b7d0-4a92-b199-e40c9ec3eee9" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82bef789-e268-4586-a569-461b2217b486" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">142,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cad954fa-0834-40b5-ae2f-009d7e8a07f7" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3393d2ee-b185-407a-9ee4-72a08e86fea1" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7815f897-c737-4336-8767-018bdc5a0a6f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f9768c2-8472-4be5-a6a9-5cd057361a13" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d63c5d93-d34c-4533-b9ae-f14a2dd8b420" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3199b48c-42db-41ae-bca3-698694af3b73" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">262,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b03fa3a-8fbd-43e8-be89-be48c40b7cda" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64ada76c-fcdc-431b-a60c-e748779c47de" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in registered direct offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42f461be-b220-4f4e-a80a-773b58941eaf" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efa1d099-bfa6-477d-94ba-bc74b8cd84b6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2e4b456-0a75-4149-a3b9-2543bbc84918" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c103372f-bf35-4caa-b8c8-348e73faa0d7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2838b9de-5f71-4dc5-9eb3-7850b8f8b334" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e24a8d5a-a520-4b68-845c-6ac8dc8bd76d" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_877901c9-67f6-4af2-9ef6-406dd951d722" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">95,569</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d41a394-546d-4669-b096-9439e31f4586" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a64062d5-8cc6-4803-9dfd-eb23dec191b7" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c1cf2f0-f8fd-4a25-baa6-11edc8357c14" contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,661</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_108ea805-c67c-4689-8a5b-5aa95f1cdf7f" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18269c55-b4ed-4b4f-9430-bc69d3143509" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash investing and financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized (loss) gain on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83a9a217-ddbc-44aa-9c92-425114d9439d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:UnrealizedGainLossOnAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f718d492-abdc-47e4-a116-e3651a8c9229" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:UnrealizedGainLossOnAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for operating lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b9cf0b9-797e-400b-839e-915c0536c9e7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0b3191f-8c89-4970-a1a7-b8be5996a276" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,386</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduction of right-of-use asset due to modification and remeasurement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b61932db-092e-46df-9b35-105a7c935e33" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:IncreaseDecreaseInRightOfUseAssetDueToModification" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47d3d7d7-fadf-49a5-a692-8f59f8ff433b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f974019-4879-4425-9df2-bd5abfc3dea0" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">899</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of cash flows</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income taxes paid, net of refunds</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f71caa11-2d4e-4ed9-841a-3cd19dc7926b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4d110b0-7e8c-46df-827a-9ce59f3962f0" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8111443a-3e3f-4f2a-8c11-7eb766d5dddd" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,661</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b60135e6-dd95-4c67-bba9-19966a08d03e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc0f3a0c-adb6-4121-a147-3c40509e6b36" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae405765-abc8-423a-bd2a-91263336ddd5" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09d2ad3e-4129-4a1a-ba2e-2f1bf506ba30" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb34d6aa-43b8-4348-9484-a7c710b6ae69" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of the Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AlloVir, Inc. (&#x201c;AlloVir&#x201d; or &#x201c;the Company&#x201d;, formerly known as ViraCyte, Inc.) is a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. The Company&#x2019;s innovative and proprietary virus-specific T cell, or VST, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. The Company is developing three innovative, allogeneic, off-the-shelf VST therapy candidates targeting 11 different devastating viruses. The Company's lead product, posoleucel (previously referred to as Viralym-M or ALVR105), is a multi-VST therapy that targets six viruses: adenovirus, or AdV, BK virus, or BKV, cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, human herpesvirus 6, or HHV-6 and JC virus, or JCV. The Company believes that posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel is being studied in three ongoing Phase 3 registrational trials for 3 distinct indications - the prevention of clinically significant infections from multiple viruses, the treatment of virus-associated hemorrhagic cystitis, or HC, and the treatment of AdV infections &#x2013; all in allogeneic hematopoietic cell transplant, or HCT, patients who are at high risk for life-threatening viral infections from the six viruses targeted by posoleucel. We have successfully accelerated the multi-prevention study in recognition of the fact that prevention best addresses patients&#x2019; unmet medical needs. The three Phase 3 studies are expected to complete enrollment by the end of 2023, enabling potential data readouts from all three trials in 2024. In addition to the ongoing Phase 3 registrational studies, posoleucel has been studied in a Phase 2 proof-of-concept study for the treatment of BK viremia in kidney transplant patients. Positive topline results of this study were released in February 2023. This is the first study of posoleucel in SOT patients, and the results of this trial will inform next steps for this potential indication as well as the company&#x2019;s broader SOT strategy.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s pipeline includes additional investigational VST therapies that may benefit high-risk individuals. ALVR106 is the Company&#x2019;s second off-the-shelf, multi-VST product candidate targeting devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV and respiratory syncytial virus, or RSV. A Phase 1b/2 POC clinical study of ALVR106 is enrolling patients in the U.S. In the preclinical space, the Company is developing ALVR107 to treat hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infection. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study after completion of the posoleucel Phase 3 registrational studies. ALVR109 is an allogeneic, off-the-shelf, single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. Data from the POC clinical trial of ALVR109 were reported in 2021, and positive reports of ALVR109 compassionate use in immune-compromised patients also have been published and presented, including poster presentations at the 2022 American Transplant Congress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was formed on August 16, 2013 as a Delaware limited liability company (&#x201c;LLC&#x201d;), under the name AdCyte LLC and on July 29, 2014 the Company changed its name to ViraCyte LLC. On September 17, 2018, the Company converted from a Delaware LLC to a Delaware corporation (&#x201c;LLC Conversion&#x201d;) and changed its name to ViraCyte, Inc. On May 22, 2019, the Company changed its name to AlloVir, Inc. The Company has principal offices in Waltham, Massachusetts, Houston, Texas and Dublin, Ireland.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 8, 2019, AlloVir formed AlloVir International Designated Activity Company (&#x201c;AlloVir International&#x201d;), a wholly-owned subsidiary established in Ireland.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 9, 2019, AlloVir Securities Corporation was incorporated as a Massachusetts Security Corporation, a wholly-owned subsidiary of AlloVir.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2019, AlloVir International formed AlloVir Italia S.R.L., a wholly-owned subsidiary in Italy.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2021, AlloVir Inc. formed AlloVir U.S., Inc., a wholly-owned subsidiary of AlloVir.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, the Company completed an initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_441d3c91-36d1-4892-8ba0-4b5f9b30393a" contextRef="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,687,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9b65d07-0cd3-4750-a96b-102fa0309124" contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">17.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fea47833-02a1-45cc-8363-e599c37f050c" contextRef="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d" name="alvr:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">317.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f055f4ad-9a94-40a2-b77a-cb64b73ae4d5" contextRef="C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">292.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d9c7587-d64c-4cb1-b660-685e4aa5d89d" contextRef="C_64a704c4-3d7f-4e2b-9ec5-bfbaf9960234" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">39,859,139</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40e87e71-4336-4007-beb7-ec2cd147f89e" contextRef="C_ef1fea4e-8882-400a-ae32-d746b5237239" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of convertible preferred stock outstanding.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2022, the Company entered into a Securities Purchase Agreement (the &#34;Securities Purchase Agreement&#34;) with certain investors for the issuance and sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ca1f934-6ff4-4f8a-a4c9-0fd12bcc1f2d" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,458,095</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb755bc4-0e8e-419d-b207-eff0ba55c5c6" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">126.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ElevateBio, LLC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 17, 2018, the Company executed a Series A2 Preferred Stock Purchase Agreement (&#34;Series A2 Agreement&#34;), with ElevateBio, LLC (&#34;ElevateBio&#34;) and ElevateBio was a purchaser in our registered direct offering in July 2022. ElevateBio, through its diverse platform of technologies to support cell and gene therapy products and expertise, provides drug development and manufacturing services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of ElevateBio&#x2019;s purchase of our Series A2 Preferred Stock, which converted to common stock upon completion of our IPO, and as a result of ElevateBio&#x2019;s participation in the July 2022 registered direct offering, ElevateBio acquired an ownership interest in the Company. The Chief Financial Officer of ElevateBio currently serves in a similar management role with AlloVir. In May 2021, Diana M. Brainard M.D. succeeded David Hallal, ElevateBio&#x2019;s Chief Executive Officer, as the Company&#x2019;s Chief Executive Officer. Mr. Hallal currently serves as Executive Chairman of the Company's board of directors. In addition to Mr. Hallal and Mr. Sinha, two other members of the Company's board of directors, Morana Jovan-Embiricos and Ansbert Gadicke, also serve as directors of the board of directors of ElevateBio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">           </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2022, the Company has funded its operations primarily with proceeds received from the sale of common stock, research grants, and from the sale of preferred stock. The Company has incurred recurring losses since its inception, including net losses attributable to common stockholders of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97c625f6-c0f0-4fbb-b511-5292da2adceb" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">168.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f959fad5-74a6-4fd9-afc1-dac5375deeb7" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">172.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. In addition, at December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaecedfc-2056-42c1-acf1-8c5a09c86d38" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">465.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that its $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71e65ed6-4739-4dde-a40b-02b252f56a84" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">233.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash, cash equivalents and short-term investments held at December 31, 2022, is sufficient to fund planned operations for at least twelve months from the date that these consolidated financial statements are available to be issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Considerations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the recent COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted the Company&#x2019;s operations, including the interruption of preclinical and clinical trial activities and potential interruption to the Company&#x2019;s supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay the Company&#x2019;s ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay the Company&#x2019;s ability to obtain regulatory approval and commercialize product candidates. Furthermore, COVID-19 could affect the Company&#x2019;s employees or the employees of research sites and service providers on whom the Company relies on as well as those of companies with which the Company does business, including suppliers and CMOs, thereby disrupting business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which the Company and the companies with which it does business operate could materially impact</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. For the health and safety of our employees, the Company has implemented work-at-home policies and we have generally restricted on site staff to only those employees who are fully vaccinated or essential to the development and research of product candidates; accordingly, the Company may experience limitations in employee resources. The outbreak and any other preventative or protective actions that the Company, its suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay or otherwise adversely impact the business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is still assessing business plans and the impact the COVID-19 pandemic may have on its ability to advance the testing, development and manufacturing of drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom the Company relies on, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or this sector in particular. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies on or with whom it conducts business, were to experience shutdowns or other business disruptions, the Company&#x2019;s ability to conduct business in the manner and on the timelines presently planned could be materially and adversely impacted.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d494699-ce55-4552-8bd0-2c9afc87a454" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_082b02d6-2ceb-4460-a915-c57b3db6e075" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:BasisOfPresentationAndConsolidationPolicyTextBlock" escape="true" continuedAt="F_082b02d6-2ceb-4460-a915-c57b3db6e075_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_082b02d6-2ceb-4460-a915-c57b3db6e075_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the Company&#x2019;s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_091f8fff-3a19-4768-b20b-f0f106f72e22" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_091f8fff-3a19-4768-b20b-f0f106f72e22_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_091f8fff-3a19-4768-b20b-f0f106f72e22_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d48e717-cbbb-4605-b8e1-a177543a8067" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#x2019;s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#x2019;s long-lived assets are held in the United States.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db4f5705-8f2c-4671-8709-bbfab7c51b4a" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99a5e1bf-5baf-4b7e-9b14-91c6fa005a27" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_99a5e1bf-5baf-4b7e-9b14-91c6fa005a27_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_99a5e1bf-5baf-4b7e-9b14-91c6fa005a27_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents are short-term, highly liquid investments with original maturities of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c812e48f-6080-4230-b817-51eabddb5c36" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:CashAndCashEquivalentsMaturityPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a0d9895-00c0-41c0-bfd9-8a8e37f96a8c" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:ShortTermInvestmentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0afdd83-844b-4042-8d9a-ebf81d272e82" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:ShortTermInvestmentsMaturityPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in &#34;other income (loss), net&#34;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0dfb81c-7e6d-4403-ac3f-8bb375a9a003" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:NumberOfIndividualSecuritiesWithImpairment" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4444ad3e-74f9-400a-ba00-3092fb77e373" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:NumberOfIndividualSecuritiesWithImpairment" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> individual securities with impairments at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_205497c2-556a-41f0-9eec-aaf6fc176d86" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#x2019;s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5e70e9d5-be25-41c2-9818-162aab7bb5aa" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_5e70e9d5-be25-41c2-9818-162aab7bb5aa_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b51f1ee9-e0ca-4dc8-a380-d889093c06cf" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records property and equipment at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cece726a-48b8-4b03-bdbd-631570568099" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PropertyPlantAndEquipmentBasisOfValuation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a415139e-be1b-4fa2-8558-0ef091e056d2" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.18%;"></td>
          <td style="width:4.918%;"></td>
          <td style="width:45.902%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5176b9ca-e7ce-4343-a8f0-0885047169ec" contextRef="C_d003b5a4-37dd-4bf1-a824-7458b10262ac" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99262ae8-392b-4d3d-83e7-5e5a54f4a7f0" contextRef="C_7a663255-07b3-4b0c-81df-49da0711cfc1" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_5e70e9d5-be25-41c2-9818-162aab7bb5aa_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f3aed44-2e48-439f-8e87-3cbf8f56b342" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for long-lived assets in accordance with ASC Topic 360, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;ASC 360&#x201d;). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_474636da-be52-447f-83b6-cfa7de8d7aa6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7a3ccbf4-5f65-421f-aec0-aa4fc3de2a47" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognized any impairment losses during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce5924bd-deaa-4735-91dd-8fffbbeb53f4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#x2013; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#x2013; Valuations based on inputs that are unobservable and significant to the overall fair value measurement. </span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company&#x2019;s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6ff6ad0b-b662-4189-a233-14a15982c0e8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:DeferredOfferingCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c91218c-ace9-49bc-9306-7c1d44d658ab" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e2976660-7d89-4b9b-ace5-8e29dcef3a3b" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> deferred offering costs.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a56f542-9d97-4a9a-b448-2eb995bc4c4d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:InternalUseSoftwarePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cloud Computing Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is  a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_be240c53-2c70-456e-a76f-1db50b023aa9" contextRef="C_2c5c0b15-4d90-49b6-b481-28b693927667" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94ede637-7e03-47f1-91bb-a80ccaed075e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CapitalizedComputerSoftwareAmortization1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06a12b87-f75b-4118-a46b-443844d9b5cf" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CapitalizedComputerSoftwareAmortization1" unitRef="U_USD" scale="0" decimals="1" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c1f624f-39ee-455a-b06f-e7a0518ca082" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:OtherIncomeNetPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Loss), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records interest expense, investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in &#x201c;other income (loss), net&#x201d; over the same period in which the qualifying costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e889389-5e8b-4806-82f5-23269c7a7e78" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_2e889389-5e8b-4806-82f5-23269c7a7e78_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_2e889389-5e8b-4806-82f5-23269c7a7e78_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_904bed05-19aa-44fb-b45c-9157b61afdf9" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7294426c-89c7-486d-8cfa-b4a467df1c53" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants restricted stock and stock options to employees, consultants and directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee&#x2019;s payroll costs are classified or in which the grantee&#x2019;s service payments are classified. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black&#x2011;Scholes option pricing model. As there was no public market for the Company&#x2019;s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#x2019;s board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Privately Held Company Equity Securities Issued as Compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Following the closing of the initial public offering, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#x2011;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method. The &#x201c;simplified&#x201d; method estimates the expected term of stock options as the mid&#x2011;point between the weighted average time to vesting and the contractual maturity. The risk&#x2011;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2e067db-4878-4133-ba96-647e7725a034" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19ff5c58-6bb6-4548-96d9-74f94196bc1e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is determined by dividing net loss by the weighted&#x2011;average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti&#x2011;dilutive. Therefore, the weighted&#x2011;average shares used to calculate both basic and diluted loss per share are the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ad5f8eec-bf07-41dd-a1f4-513734e2a411" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_ad5f8eec-bf07-41dd-a1f4-513734e2a411_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_ad5f8eec-bf07-41dd-a1f4-513734e2a411_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a85fbc5-e8fd-4368-aebb-b6183997dff0" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_1a85fbc5-e8fd-4368-aebb-b6183997dff0_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_1a85fbc5-e8fd-4368-aebb-b6183997dff0_1"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe4aa380-8bd5-4a86-b40c-ec5249781887" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no off-balance sheet risk.</span></ix:nonNumeric></span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1b4ffa75-4936-4820-a94d-c8c41b0db2ca" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Exchange</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of certain intercompany transactions in September 2021, the Company determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (&#x201c;USD&#x201d;) during the year ended December 31, 2021. Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in &#34;other income (loss), net&#34; within the consolidated statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of operations and comprehensive loss.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aee79334-9544-494b-b6cb-848663be8d40" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder&#x2019;s deficit that are excluded from net loss. The Company's comprehensive loss includes unrealized gains (losses) on available-for-sale securities during the year ended December 31, 2022 and 2021 and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia during the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_28d46eaf-cea4-4de3-9e96-2ab28b456619" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. Options to renew or options to cancel a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3901e81b-913b-4bba-8e66-97555360dbd8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 16 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fe2e821-1eb9-4cbc-abf2-cda7e9945919" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c384804d-c36d-4d4e-b962-b6a83adff9c6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d0afa87-3891-47ab-854a-61372ef51a0e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true" continuedAt="F_7d0afa87-3891-47ab-854a-61372ef51a0e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_7d0afa87-3891-47ab-854a-61372ef51a0e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments&#x2014;Credit Losses (Topic 326)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_859e6597-58e1-4f7e-bdee-0ded60bb2207" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5cdf6fe4-2902-4367-bfd7-4ffc965ca4aa" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the amortized cost and estimated fair value of the Company&#x2019;s U.S. government treasury securities and marketable securities, which are considered to be available-for-sale investments and are included in short-term investments on the consolidated balance sheets:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.595%;"></td>
        <td style="width:1.227%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.972000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.227%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.972000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.227%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.177000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.227%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.372%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00544887-557e-4a98-b735-7e52c4ff609e" contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c39c7259-8974-45e7-8127-912f0a9016c1" contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75c07062-15d7-4830-9c01-11a9e2f590fe" contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2644ad6-5f7d-481e-98f2-eb4cd2a5701a" contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e176d23-242d-4395-b7b7-106cd112dcbb" contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca830549-1328-4d5b-b7df-d33258384dee" contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d88ea18a-a25f-42b3-a07a-62c3b200bc62" contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99bb731e-51cd-425b-97f2-54bc7dc95dd2" contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_672b6e03-d88f-4263-8d22-3f442a23d520" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00812119-6d1a-4698-a489-62bd6991fd74" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a16ad06-6d98-4eda-a991-9517efddeada" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">337</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abcc81c2-cd9c-48b1-8697-2fde5e97611d" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63d4dd2e-801f-40e8-8763-d13b8a16cb5e" contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,092</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3424268d-740f-44c2-8fbe-ed7353a07130" contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b9602b6-6271-4fd1-967f-65d7e4af9e4e" contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a06caee1-6d07-4219-a40c-948c8a1cf31c" contextRef="C_0369a67b-84df-4183-8524-460dca6b72af" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,568</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d5aafb5-dc93-41ac-972a-c6b471bd5102" contextRef="C_0369a67b-84df-4183-8524-460dca6b72af" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4cdfc81-33e0-4f00-973f-6286acda210f" contextRef="C_0369a67b-84df-4183-8524-460dca6b72af" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56a5a16d-fa18-4e7a-be75-fdc1ad8355b4" contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,821</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59cb4dde-26e8-4db3-bb0f-bf3755de2b53" contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b7ee88e-0075-4dde-8cd6-955fb38b24c6" contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff90cf25-d0b0-42dc-ac2d-e1a9d01723a5" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9a0e57e-aa05-4b43-b29f-974a0b27b8d3" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1fe8868-19a1-4f4d-aa52-2e1f6734dfc1" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c0d58d9-ad61-45b7-97ca-c61ab967d4d8" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain short-term debt securities with original maturities of less than three months are included in cash and cash equivalents on the consolidated balance sheets and are not included in the tables above. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all investments had contractual maturities within one year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_28072613-cbb5-44e9-95ad-32ec13bbe302" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e644af8-faa3-444e-a66f-1170b63d99c5" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.396%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae240cf2-9be4-4546-853b-cc99205f3ec1" contextRef="C_f54245dd-ad04-435d-9405-f93c21c6df54" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c03c6cdc-200c-4fff-8ec2-eebb56b160e2" contextRef="C_a42b0c01-30a3-4913-9e9a-d46c91274d8f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc348110-92f5-421a-9e1c-58efcbc59d8a" contextRef="C_d21593fe-88fc-485a-877e-34bb4604b4f0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0523d6e4-a559-440c-8234-bd2885cea3d7" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_290fd80b-73d8-4024-9bdc-7a03e630fcbe" contextRef="C_b98a7795-ec31-4702-95a8-60d00f9f4656" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18bfc422-4767-419d-9cf2-0c6ad67f1043" contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88bf03a3-2c0a-4798-a5af-ff250c30fa3a" contextRef="C_477148ad-c1c9-490f-97aa-87c51b482f68" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e90e502d-23af-489d-8334-047609f5785a" contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2c18409-d91e-42fd-8d4a-3e89b54de012" contextRef="C_d21593fe-88fc-485a-877e-34bb4604b4f0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fba1ab7f-32ea-46be-8a23-73ff7fb7e82e" contextRef="C_ca1c64ca-7e9c-446e-8772-b18830c91079" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4365ae6-4f0d-48b4-bcf1-4d6363eb55a2" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.23%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.396%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca8d09c6-ca1a-4b21-8898-8b242795fc81" contextRef="C_62600b73-3cde-4af9-85cb-8d2dcf5152ba" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4362a2dd-a33e-48d4-9e49-fe707a6b7487" contextRef="C_0a071b5e-8a39-4f87-993b-1f4dca7d0685" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94f65673-2971-40de-b388-1d76f3a99d93" contextRef="C_a68d724b-186e-40cb-914f-9f396ee8efa8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5575af7f-d0ba-4a39-bbb8-79f20aad29bd" contextRef="C_0369a67b-84df-4183-8524-460dca6b72af" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13bcc465-6bad-4494-ae58-8da271b405a2" contextRef="C_e64c980b-ef3a-4f68-b295-dd082f470d79" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fe8ed21-92d9-4018-8439-236b20b36d97" contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9e3dbb3-cf00-4934-87a5-59bad2c67614" contextRef="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,378</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d07550a0-5d08-4212-b392-8aa7af5e607d" contextRef="C_eca66d82-2e78-437b-aec1-7a4f3bee0629" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,751</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1769aac-d33d-4243-b720-13b60f6c8c54" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150,129</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_327b78f1-cbca-438e-b7df-f281d82aee7f" contextRef="C_f2ebfc16-1156-46e3-a10c-6844f6815d58" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_243f4e0d-5c7f-46f0-96af-96305eb914b6" contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1aac99d-e8d7-48c9-b6d2-4a8a1dd763e3" contextRef="C_a68d724b-186e-40cb-914f-9f396ee8efa8" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76cad6c7-065d-4ca1-973b-ef89ec076bbc" contextRef="C_0369a67b-84df-4183-8524-460dca6b72af" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d75537e7-df90-4063-b968-e71bc6a27ec4" contextRef="C_e64c980b-ef3a-4f68-b295-dd082f470d79" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff0fa5ee-50da-4b47-9b37-86043284c1a8" contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e5986af-f623-4820-b703-263bac3b72e4" contextRef="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12f43f3e-55cb-46cf-b680-57a4b1701bc0" contextRef="C_eca66d82-2e78-437b-aec1-7a4f3bee0629" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63bd5d7b-3f57-4886-b08f-493a04cbe8a8" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, there were no transfers between levels. The Company classifies its money market fund and U.S. government treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its marketable securities (corporate and agency bonds and commercial paper) as Level 2 assets under the fair value hierarchy, as these assets have pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, prepaid expenses to related party, accounts payable, amount due to related party and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b0fc353-67af-45e0-ad2a-ca5f85246fca" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company uses an incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate represents the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company estimates this rate based on prevailing market conditions, comparable company and credit analysis, the impact of collateralization, and the term of each of the Company&#x2019;s lease agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DMS Agreement with Third-Party Supplier</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2019, the Company entered into an interim services agreement which ultimately led to a Development and Manufacturing Services Agreement (&#34;DMS Agreement&#34;) with a third-party supplier in July 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The DMS Agreement specifies a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility. The DMS Agreement initially expired upon the later of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_184a4750-093b-4aef-9b3d-cf5a98910deb" contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd" name="alvr:LeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and (2) the completion of services under all statements of work (&#x201c;SOWs&#x201d;). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b88c224b-308e-43e2-8065-e7acc398582b" contextRef="C_9e73a754-0c34-4892-ba85-21910762594e" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective June 2022, the Company entered into a First Amendment to the DMS Agreement to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1de91ede-01ee-45dc-bc42-d3aa9fa64623" contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the expiration date to June 2024 provided that the terms and conditions of the DMS Agreement will continue to apply to any active SOW's. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d250f3a7-e225-435c-89ef-4aadebb352d2" contextRef="C_9e73a754-0c34-4892-ba85-21910762594e" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DMS Agreement (or any individual SOW) may be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f4177193-6b5d-43d7-8fbd-21b8e41bda0f" contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminated</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> earlier by AlloVir at any time by providing 190 days&#x2019; notice.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In March 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85dfea28-a48f-43d8-b319-afaf5fc5b9d0" contextRef="C_276e92a2-b36d-49d9-b698-ebe3737df111" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_33e0776a-f69d-4165-ae6e-761621818b7e" contextRef="C_276e92a2-b36d-49d9-b698-ebe3737df111" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.9</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over a total estimated lease term of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dd7837ae-7927-4102-83c7-dba6c7b189af" contextRef="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274" name="alvr:LesseeOperatingEstimatedLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.25</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9bfdd5d4-7244-4118-aee4-ed49046bf653" contextRef="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274" name="alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In September 2019, the Company executed a SOW for another dedicated manufacturing suite under the DMS Agreement with substantially the same terms as the original SOW. In September 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7453421-51cf-4225-8c52-94c37fe9c3db" contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_bddd4dc1-7c0b-4d4d-b8ef-057f4519621a" contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over a total estimated lease term of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e758158c-dc4c-4c0a-941f-5bfdb224efec" contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99" name="alvr:LesseeOperatingEstimatedLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a7e6447-7cbf-42b9-9ae8-4fb84ba6cd2c" contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99" name="alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SOW calls for a fixed monthly payment through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e8a8778-5397-4d4e-82bb-f303b5200227" contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99" name="alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef381cd1-150f-4dcf-8b93-04df9649b6f8" contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options.  The use of these manufacturing suites qualifies as a lease under ASC 842, as it includes an identified asset for exclusive use by the Company at its direction.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company entered into amendments to both SOWs under the DMS Agreement. The original SOW under the DMS Agreement (beginning March 2019) was modified to add a new termination clause whereby the Company can terminate the lease upon entering into a contract for another suite at the facility. Management concluded that the SOW amendment constituted a lease modification under ASC 842 and recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae74877f-c549-446b-9f3b-4895ee7927e3" contextRef="C_c580b793-4a8d-44b5-9ac5-f169ca597d82" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_816333f2-6b73-49c0-9b7c-f063a621f046" contextRef="C_c580b793-4a8d-44b5-9ac5-f169ca597d82" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset and lease liability in February 2022. The original SOW under the DMS Agreement was terminated in October 2022 upon execution of the new 2022 SOW under the DMS Agreement. The second SOW under the DMS agreement (beginning September 2019) was terminated as of the effective date of the amendment in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20ed01b7-4110-421a-b887-57998c2a3aa7" contextRef="C_6e1405d7-d3f6-4118-b825-18c83ba250f6" name="alvr:LeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As a result of the amendment, which also represented a lease modification under ASC 842, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac87ade0-98fc-43e3-a602-6a156b144f2c" contextRef="C_978fec4b-4bb3-4327-9bc3-a12cff64e534" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_19d5c3fa-b4cb-402b-8931-c1f2ae552c3d" contextRef="C_978fec4b-4bb3-4327-9bc3-a12cff64e534" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">2.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset and lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, the Company entered into a new SOW under the DMS Agreement (&#34;2022 SOW under the DMS Agreement&#34;) with a third-party supplier. The 2022 SOW under the DMS Agreement contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, fixed batch payments and other related fixed costs, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61a9b5a3-b7b8-47ed-be0f-cdf5afcce4ed" contextRef="C_75223583-180e-4986-994f-4bfea6c4561f" name="alvr:UtilizationFeePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0875904-909a-4295-be4e-b87505c854c2" contextRef="C_0a765caa-d973-4579-b4bc-2ffa5b45e639" name="alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.25</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> year lease term ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c71c7e70-ece3-44fc-9fc4-5d6b8c356ec1" contextRef="C_0a765caa-d973-4579-b4bc-2ffa5b45e639" name="alvr:LeaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, testing, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and commenced in October 2022, the point at which the suite was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed44a703-1e25-48e1-b0e7-6bdda03fb3ab" contextRef="C_75223583-180e-4986-994f-4bfea6c4561f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_0d664e19-e186-48a6-970e-bc68ae9d8772" contextRef="C_75223583-180e-4986-994f-4bfea6c4561f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 DMS Agreement with BaseCamp</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into a new Development and Manufacturing Services Agreement (&#x201c;2020 DMS Agreement&#x201d;) with ElevateBio BaseCamp, Inc. (&#34;BaseCamp&#34;) and signed a SOW in November 2020. The 2020 DMS Agreement and related SOW contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, and other related fixed costs, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07fe028b-3f76-4034-bb7e-edfce7c8d53f" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="alvr:UtilizationFeePayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d8ff1362-a6da-4427-9275-2697d00f559a" contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7" name="alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease term (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84fb0668-2cbe-417d-9aac-87bcfc19b538" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease with a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db4e0767-fac1-4dad-9756-55419be4b479" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal option), that covers costs associated with reserving capacity for AlloVir, as well as cleaning services, utilities, handling and maintenance of the manufacturing suite. At inception of the lease, the Company estimated that the exercise of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02fc4f89-5978-4745-90bc-96ed461dc501" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal option was reasonably certain to occur, and the Company was reasonably certain that it would not exercise its early termination right, providing for a total estimated lease term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f4245d8a-379f-4e41-845f-b2ad223ae2c4" contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7" name="alvr:LesseeOperatingEstimatedLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c6b16ad-fa43-4462-925d-85a88ea06292" contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7" name="alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating lease and commenced in February 2021, the point at which the new facility area was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa7d7597-11bd-438e-ae67-762c7f992fe2" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5265585d-5f75-4231-8169-80751d949ce2" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company prepaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e1c3522-d50d-460b-bf01-e9ead91a3ab4" contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237" name="alvr:PrepaidUtilizationFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the suite utilization fee, which was reclassified from prepaid expense to the ROU asset upon lease commencement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company decided not to exercise the one-year renewal option and subsequently executed a Change Order to modify the terms of the SOW under the 2020 DMS Agreement. Management concluded that the amendments laid out in the change order collectively constituted a lease remeasurement under ASC 842 and recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fd08420-8bb4-49c6-9b37-5b116d115d3f" contextRef="C_2423b8cb-2946-470e-a22d-8cdaaa80af94" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related lease liability and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b62c81da-1c12-4df1-a4c8-378d8c73910e" contextRef="C_2423b8cb-2946-470e-a22d-8cdaaa80af94" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waltham Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company entered into a new lease agreement with BP Bay Colony LLC and a sublease with AMAG Pharmaceuticals Inc. for the lease of property in Waltham, Massachusetts (collectively, the &#34;Waltham leases&#34;). The space identified under the Waltham leases is intended for general office space, research and development, laboratory use, and light manufacturing. The Waltham leases have been classified as operating leases and commenced in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54cb1455-a94a-478f-b6e0-558e4cc40038" contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637" name="alvr:LeaseCommencementMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the inception date, the Company has recorded an ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b3f93e-9979-456e-895b-27764273c100" contextRef="C_e238b96f-4a9e-4feb-94c6-0c19c3005824" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_939e66c6-6303-4a65-adcc-f0f19f827141" contextRef="C_e238b96f-4a9e-4feb-94c6-0c19c3005824" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the lease and a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be5f1d4c-6a90-4955-ad92-7e23aadb119b" contextRef="C_1176b604-ee17-4ddb-be7e-456b15cb96ce" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_87bbcf18-a749-4364-b417-8108aab18f1a" contextRef="C_1176b604-ee17-4ddb-be7e-456b15cb96ce" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the sublease based on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d30c054-60ac-4c16-bcba-9cd471ca94f7" contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 30, 2030</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> end date for the Waltham leases. As part of the arrangement, there were also variable costs for common area maintenance fees that were not included in the measurement of the lease. The agreement also provides a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4c8c91c-c818-48c2-b5a7-90da360d63ce" contextRef="C_232cbeff-83b0-4296-a32f-459b4b6c2711" name="alvr:TenantImprovementAllowanceToBeReimbursed" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million tenant improvement allowance which is to be reimbursed by the landlord over the duration of the first </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d416c2a0-c023-4da2-bcf2-263606c25e94" contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637" name="alvr:TenantImprovementAllowanceReimbursementPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Waltham leases. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2aed9fa-b1fe-445c-be98-3c698f9fb406" contextRef="C_ddd9b411-5433-4b78-876b-16099390a62c" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the tenant improvement allowance has been used. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da3e93b1-2aa9-4d56-80be-ba22c7e016b3" contextRef="C_48c024c0-d687-47ba-9b05-7f832db9c0ca" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2c6d896-4d2c-41cc-b220-e193465fe34e" contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to renew the leased space</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional one time period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b305a6b9-1c15-4024-a50f-8b39d89a5630" contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637" name="alvr:AdditionalOneTimeLeasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with written notice from the Company. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has no reasonable certainty that this option to extend will be exercised.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6c4de93-e071-4eb7-9642-223325235641" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.231%;"></td>
        <td style="width:1.944%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.824%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6794dfe1-4ee4-40e6-81a9-c98645b64f5e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54c0dd69-daaa-4897-8bec-d40ceca6bfed" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a30005d1-e7f5-46f2-8e72-ad56e2d2b9f8" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,229</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17e65d7e-12db-4174-9932-00424d6c675a" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f59f3a2-f71c-4b66-9bd9-b459494fc513" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4412a40-eb10-4741-a7d2-8e51856145db" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0cc02bd-506a-4d55-8e6d-078ff5921af4" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02c1ec9c-f28a-478a-8c8b-f82f6cd6cf1e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_041d012d-f709-4993-82e1-9ab629f50d02" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#x2013; current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9caec006-6a55-4b38-853b-431de79296d0" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#x2013; long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4044d9e6-2726-4a30-b9a3-19721d6316ed" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,222</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb883dd4-7960-4331-873f-b2df4088496c" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e51e2a41-2e91-45eb-a10f-0d725d64b635" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Cash paid for operating leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fd7160b-9796-434c-942d-1c55c0b3d652" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70251c7a-6682-4a40-85f7-46ce5339f620" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The Company&#x2019;s total variable lease costs, such as materials, non-fixed batch payments, testing, storage, knowledge and tech transfer, and other common area</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintenance fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, related to the operating leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cd400ab-d8a2-43bb-83c3-6dc0d900c527" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18deab9c-73b6-4222-ac7c-f11c5195fbfc" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average remaining lease term is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9f8858ce-018f-45b1-9b3e-0d49d0eb59de" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.93</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The weighted average discount rate is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41f0ada1-7ea0-4183-9b9e-01fcf4175b5d" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">6.23</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_358e6510-9750-4752-ac2c-09dab5db66e3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46d71f9f-52e4-479b-ac78-6c772085f1b6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.383%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.513%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.397%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.707%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5064c8b-6234-4768-9fab-c173c1803550" contextRef="C_028feb25-e5dc-4693-838f-892bc643344f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83ad9c20-6c20-4a37-b56a-f6717789ed13" contextRef="C_e1ac0558-7793-4cbc-abac-375855874e63" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1b8ec8d-e88a-4ab4-849f-67ded89b4e00" contextRef="C_4638e48c-caee-470f-8e9f-fd72016b2756" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb719b69-2202-4ecd-9794-26b20b390409" contextRef="C_a6d7b88b-a721-4583-9af3-cdcbc9a426d2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">435</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a6538ea-c0e3-4e12-9c94-42cf33765ead" contextRef="C_4c070771-4f77-4eda-b36a-c12f31943e25" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_143ede05-80ac-4804-bafc-ac62c5f1f9a2" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b31d718-0228-4573-b24a-95b0925cf93c" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,830</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_babd15c4-2cc4-44f1-86c1-e9ee188dee77" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,004</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89f3ea25-f39e-4eb8-9142-ef105eedac5b" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_739816d0-1a6f-4372-adc7-56cfba3f538d" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">930</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_930d6e78-424d-4da7-b181-115e42038afc" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,549</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b047b0d-bd36-44e7-ab02-6ea258550f25" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9348b98-e878-4f6d-b27d-10ddf2841b67" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2484b84-a620-4946-b4a5-90a4d781e8b3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:AccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a08e4594-d71f-4cdd-970f-0960d4b94d09" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f50a029-a188-4d7c-ab5d-42c7a8b623f2" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,416</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_621f8e4d-cded-47b9-8980-402172f34083" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bfb3fb4-a93a-4b01-9b7d-123e5aff4e92" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05d8400b-8427-4bcf-8320-25829bf1a344" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2510725-ae1b-453e-abbc-11fa324027c9" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4e3a166-17c3-483d-a6fe-71b918de466a" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="alvr:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d4f730f-99de-482f-9ca1-f39f0e42ec91" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">504</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3a21971-f9a5-4aa5-96a7-a78fba544c2b" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,685</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b8f6ad9-af7b-42e1-9be8-e55b81b8e282" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">828</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7a11651-aa6d-4268-b291-fc21a37af03f" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c022d70e-5c32-42a3-b84a-968cb6947b34" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f05366c-6058-4d3a-8864-24ae5051f3b2" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e392c18-a92d-40b7-9c8b-7572aecb05dd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Sponsored Research, Collaboration and License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, the Company signed a License Agreement (the &#x201c;License Agreement&#x201d;) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights in the field of viral infection. In May 2020, the Company amended and restated the License Agreement (the &#x201c;A&amp;R License Agreement&#x201d;), pursuant to which the Company obtained (a) an exclusive worldwide license, with the right to sublicense, under certain patent rights and other intellectual property rights of BCM, to make, have made, use, market, sell, offer to sell, lease, import and export products in a particular field, except that such license is non-exclusive within a particular subfield, and in addition with respect to certain patent rights such license is limited to two particular subfields, and (b) an exclusive, worldwide sublicense, with the right to further sublicense, under all patent rights and other intellectual property rights that are exclusively licensed to BCM by a certain third party licensor, to make, have made, use, market, sell, offer to sell, lease, import and export products in the same field. The Company&#x2019;s rights are subject to the rights of the U.S. government and certain rights retained by BCM.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the A&amp;R License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country. The Company may terminate the A&amp;R License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the A&amp;R License Agreement in its entirety for the Company&#x2019;s uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BCM maintains control of all filing, prosecution and maintenance of its patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the agreement. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the agreement with respect to the filing,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prosecution and maintenance of the patent rights licensed by the Company. If BCM licenses the patent rights licensed by the Company to third parties for additional fields of use, the Company&#x2019;s responsibility for patent related costs and expenses will be reduced on a pro-rata basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the A&amp;R License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the original agreement executed in June 2017, the Company paid BCM a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb5810c-2b80-4bfd-bf1b-491461d924a2" contextRef="C_45693ffc-b960-4db0-a592-606079f137e6" name="alvr:NonRefundableLicenseFeePayments" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the term of the A&amp;R License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee, but beginning with the fifth year after the original agreement date, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize a product under the A&amp;R License Agreement, total milestone payments could exceed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dfa96b8-9c4a-4ebc-ae63-f1f595622355" contextRef="C_ba9cbb52-e4cc-4b69-b43d-08477c237f07" name="alvr:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2838d63-ba52-444d-8c1f-cb34193155c3" contextRef="C_871ad9af-02db-4352-9621-2c92ad7156c5" name="alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the A&amp;R License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company also entered into the First Amendment (the &#x201c;License Amendment&#x201d;) to the A&amp;R License Agreement. Under the License Amendment, the Company assumed responsibility from BCM for the filing, prosecution and maintenance of the patent rights licensed by the Company from BCM under the A&amp;R License Agreement that are in common with the License Agreement. Further, BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in such patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company signed a second License Agreement (the &#x201c;Second License Agreement) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights outside the field of viral infection (all fields other than those covered by the A&amp;R License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the Second License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country, provided that the Second License Agreement shall not expire later than March 25, 2040. The Company may terminate the Second License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the Second License Agreement in its entirety for the Company&#x2019;s uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, BCM transferred to the Company control of all filing, prosecution and maintenance of the patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the Second License Agreement. BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in the patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the Second License Agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by the Company, to the extent not already paid by the Company under the A&amp;R License Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the Second License Agreement, the Company paid BCM a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96abd253-0595-464a-9f27-5b6a04b5c1cf" contextRef="C_a1c6fa03-2ee5-482c-8fcc-3134560afe02" name="alvr:NonRefundableLicenseFeePayments" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the term of the Second License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee of (a) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67b656da-03f0-4544-b4ba-82a80f07ecaf" contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223" name="alvr:NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the first through fourth anniversary of the effective date of the Second License Agreement, and (b) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9d7e516-b0ca-42f9-a848-ea41213e7f9e" contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223" name="alvr:NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">40,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the fifth anniversary of the effective date and continuing thereafter, but beginning with the fifth year, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize multiple products under the Second License Agreement, total milestone payments could exceed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4563281-55b1-4aba-9621-8c22472b4ba9" contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223" name="alvr:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00e0acfe-e29f-4e62-a585-90a6896f8ead" contextRef="C_6ad4867e-83a6-4c90-8517-df9e8041faad" name="alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the Second License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into a Research Collaboration Agreement (the &#x201c;Research Agreement&#x201d;) with BCM, under which the Company agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021 and continuing for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_60dd305c-dac2-4437-b4d7-68e37d3bf782" contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b" name="alvr:AgreementForPerformingResearchActivitiesTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period thereafter. The Research Agreement requires the Company to make payments to BCM totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fad7005b-a136-4036-99d9-6de67d14bc14" contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b" name="alvr:ResearchActivitiesPerformingFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, for a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd7b9fcd-aea1-4669-97a4-62aa15a116e2" contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b" name="alvr:AggregateResearchActivitiesPerformingFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the term of the Research Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collectively under the agreements above and for services provided by BCM the Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65be6ff7-f9f2-4075-93ed-73c1bbc39d46" contextRef="C_a3d1dc62-3ca8-4a65-8d93-bffe388766da" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3b00940-63a7-47ee-804f-4222ffd1106d" contextRef="C_34017843-7cb8-4d00-86bb-8889a840a88a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, and the payments were classified in research and development expense in the consolidated statements of operations and comprehensive loss. As of December 31, 2022, and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6711571f-d31d-4249-8efd-0f50f2b34347" contextRef="C_51c4f488-3970-4c54-84de-f12cde7d10db" name="alvr:AccruedMilestoneExpenses" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc6adf9f-bc73-4403-ab29-6f19189c67a4" contextRef="C_0de4aa3b-f8d3-4a15-88ec-81d1af1626ad" name="alvr:AccruedMilestoneExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in accrued milestone expenses are recorded under accrued expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CPRIT Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2017, the Company was awarded a grant (the &#x201c;CPRIT Grant&#x201d;) from the Cancer Prevention and Research Institute of Texas (&#x201c;CPRIT&#x201d;). The CPRIT Grant required that the Company grant CPRIT a non-commercial license to technology developed under the grant and pay CPRIT a share of revenue on sales of commercial products developed using CPRIT funds equal to low single digits of revenue until such time as CPRIT has been paid an aggregate amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9179a0fc-e20a-4283-9219-30ce41301664" contextRef="C_89b61897-7cb1-4529-aa9a-3dcca0317455" name="alvr:MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the grant award proceeds.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91af4be6-cc4b-4fac-b635-b43df1a534ce" contextRef="C_89b61897-7cb1-4529-aa9a-3dcca0317455" name="us-gaap:PaymentsForRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0bd7ce08-a582-4551-b763-f2ad071b0c1d" contextRef="C_eb50bcd6-a9a6-4061-9ef2-e7d4b30b505a" name="us-gaap:PaymentsForRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalty payments were made under this license agreement during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Redeemable Preferred Stock Redemption Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company entered into a redeemable preferred stock redemption agreement, or Redemption Agreement, to redeem shares of our Series A1 convertible preferred stock held by certain investors, including executive officer Ann Leen, director and former executive officer Juan Vera and entities affiliated with director, Malcolm Brenner and former director, John Wilson (or their affiliates). Pursuant to the Redemption Agreement, for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3567350b-78b1-4797-9d4c-1db75f41f857" contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2" name="alvr:EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of the first commercial sale of Viralym-M, the Company is obligated to make earnout payments to such investors on at least an annual basis. The earnout payments will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14b1aedc-c6ad-408b-aaf6-1347117a6203" contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2" name="alvr:EarnoutPaymentAsPercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net sales of Viralym-M, which number will be reduced to a high single-digit percentage if certain events occur. Specifically, royalties due to third parties for the sale of Viralym-M are subtracted from the earnout payments due to the investors. Further, if the investors receive at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd457253-b535-4495-8b7d-a51e6a8403c8" contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2" name="alvr:MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in earnout payments from AlloVir during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b146896f-2db7-4dee-b126-438b8ff389aa" contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2" name="alvr:PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the first commercial sale of Viralym-M, the earnout payment percentage will be reduced.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span><span><ix:nonNumeric id="F_c668a608-3266-4c31-94b3-53f05095f3b7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_c668a608-3266-4c31-94b3-53f05095f3b7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Stockholder&#x2019;s Equity</span></ix:nonNumeric></span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_c668a608-3266-4c31-94b3-53f05095f3b7_1"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, in connection with the closing of the Company&#x2019;s IPO, the Company filed its amended and restated certificate of incorporation, which authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32e983fb-98d3-42d5-a45b-06fbfa1aabb4" contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a0e0760-1d82-4166-9e81-bc0e480490d4" contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value per share. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c08e5b47-5626-4b0a-9e44-88120b74cfba" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b7ca7bad-9364-4ef4-82b5-b423229eaf95" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2655ea68-83ba-42d9-aa96-3cba4fff5143" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3511338e-6b74-49ab-94d1-abdc9bbc8813" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock issued or outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03363e59-7ef1-4adb-bb12-091bc90136fd" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7e16c6ef-820b-4a70-940c-5785f0b4e391" contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_499b8119-c41c-4a21-885e-cad67c2497d3" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_cc72ce7e-234c-4ecc-b9ff-160eaa3408e7" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2022, the Company entered into the Securities Purchase Agreement with certain investors for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_271aa4d4-7e0c-445f-9f31-81af54b4a6ce" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">126.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb73ac62-0e83-420d-ad7e-fd06183f782e" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="alvr:SaleOfStockOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors in a registered direct offering an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b63fa698-2168-45a3-818f-4e2d75e4fa09" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,458,095</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a90b2f39-c1b6-4a53-a1e8-6a561271c1ee" contextRef="C_227c3050-c341-4701-9bbc-1a6d93036b5a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (the &#34;Shares&#34;) at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9270d2df-d643-4259-85e4-8cbe979fd1d2" contextRef="C_227c3050-c341-4701-9bbc-1a6d93036b5a" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.61</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per Share (the &#34;Offering&#34;). The Offering was made without an underwriter or a placement agent, and therefore, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51ef9db0-a1c2-4d95-af99-63859004f0ca" contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3" name="alvr:UnderwritingDiscountsCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> underwriting discounts or commissions in connection with the offering.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a summary of the rights and privileges of the holders of the Company&#x2019;s common stock at December 31, 2022 and 2021:</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Rights</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1bb3645c-07c3-4c64-bb40-61ecb7a30950" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4490edc-6014-44d4-a1da-4e91dbd578db" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:NumberOfVotesPerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.</span></ix:nonNumeric></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67e142a7-8c71-41a9-8502-4f1d976dac47" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:DividendsCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared or paid.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Preference</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the then-outstanding shares of preferred stock.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rights and Preferences</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_cc5f4db8-ba60-4ad7-9b5e-3cac4d6811bd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.772%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.741%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.144%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c6783d-fd01-4b71-b21a-d448ebfc781c" contextRef="C_f0711afd-ddae-4cbb-95eb-8a59378fefed" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,239,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e469503-dc10-4c98-9ea6-18b457c937ba" contextRef="C_530cd7cd-8adc-465e-b494-4eb7a45191a4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,866,909</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24d1ab0f-06a8-475f-9c48-88fc8c7e3151" contextRef="C_160a6c1c-126c-4390-a8b9-a1f7c5589625" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,922,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9df289dd-3542-45ef-8747-4d0e030b96c0" contextRef="C_183322ca-7ab4-457e-8a32-87ac4df2d1d3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,155,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for grant under the 2020 Stock Option and Grant Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b93f245-5892-445d-b058-f3c7fd5329b5" contextRef="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,253,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af715a11-33b3-4a60-85f4-e4eb6819584e" contextRef="C_79512046-91c6-49b4-ae01-0e273533c65f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,812,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for issuance under the 2020 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e131673-7ac3-474f-86c0-58986d242dfd" contextRef="C_75215896-db5d-4536-a304-39f269881d56" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">454,302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37b768e6-1a2f-40b9-8665-e2169daf835d" contextRef="C_51a0554a-094f-4ada-b6e2-8ae4cc043eaf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">611,354</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca5b3e5-a34c-4491-8260-1ce806b8b938" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,869,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf1fbca2-a890-483b-80cf-7a89b3e7a722" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,445,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_75131eb7-bd3c-4e7b-a4fc-d3054436762a" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17b47bd8-1eca-4961-95dc-a1d134aa8d32" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.645999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.622%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.043999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a755259f-4d00-4e90-ae1f-5223e4064536" contextRef="C_1b40c6bb-4bfb-4418-9f73-133bb83a5cc8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcc6aaa0-485f-4e9c-9d90-e538dd0723e5" contextRef="C_34bd2dd2-4644-4d61-9dd2-0ea6e25b44ad" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,632</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dbfd26d-cc47-48fa-b0ef-5d390d1df2db" contextRef="C_c8f5f95d-8c74-42da-8e94-481be7b2c583" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,301</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51956062-1bf5-4bf9-a589-6ab86e59b15f" contextRef="C_edef2090-5f5c-44a5-91fc-85d5605d9a25" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40decdd5-5fd4-4166-a526-789ae6afe630" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dc48e83-81d0-49c3-9ce6-b2832e25a09e" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s 2018 Plan provided for the Company to issue restricted stock, restricted stock units, incentive stock options, and non-statutory stock options and other stock-based awards to employees, officers, members of the Board, consultants and advisors of the Company. The 2018 Plan was most recently amended in July 2020. The awards granted under this plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_846a03c1-763f-4e98-bc11-0d0130fe2dfe" contextRef="C_a2440698-340f-405b-82b8-2ee426f49c94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5fb85dca-2195-408f-b0ff-b3162661b738" contextRef="C_a2440698-340f-405b-82b8-2ee426f49c94" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contractual term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51269357-9d16-481c-928b-f64ac62745a8" contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,715,415</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock under the 2018 Plan. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_812ca4a9-e529-499a-a660-aace17ef62ae" contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df" name="alvr:NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">64,042</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options under the 2018 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a725b4c-98fe-4323-9320-1a03e460f628" contextRef="C_2ac4b804-48e5-4500-bafb-20607b67d00c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,616,772</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock granted under the 2018 plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87745d56-a85d-4d5f-b088-ee12db52a3c5" contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remain available for future issuance under the 2018 Plan. Any options or awards outstanding under the 2018 Plan remain outstanding and effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Stock Option and Grant Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2, 2020, the Company&#x2019;s Board of Directors adopted and in July 2020 the stockholders approved the 2020 Stock Option and Grant Plan (the &#x201c;2020 Plan&#x201d;) which became effective on July 28, 2020, the date immediately prior to the date on which the registration statement related to the IPO was declared effective, and as a result no further awards were made under the 2018 Plan thereafter. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7637436f-e31d-4184-9180-2742534d079d" contextRef="C_14bd8057-2b3c-443a-8b90-b6382cbf114b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,008,734</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. The number of shares of our common stock reserved for issuance under the 2020 Plan shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37f8885c-717f-4013-886b-a36af40d1619" contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. Accordingly, on January 1, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd2a0826-78d5-41b7-b96d-85270826b164" contextRef="C_929b39a9-292b-4663-ab90-74229b474881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,528,817</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were added to the number of available shares under the 2020 Plan. The awards granted under this plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4aacfc48-b163-4f5e-ace7-6d2337dc104a" contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77051206-c617-4ad5-8904-b753d498f740" contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contractual term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5a7e735-272a-4377-848a-d7e7ff6005ee" contextRef="C_a2765896-7ab5-4950-93b3-5422a0d04d3d" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,858,755</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f9409c9-038b-4bc6-897f-207a41315173" contextRef="C_617f4174-88a5-4f52-8e3f-dafed24ab46e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,076,516</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock granted under the 2020 Plan. There is an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdd12195-84ed-4b29-bb25-598c7fe5ffbc" contextRef="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,253,680</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Common Stock</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1136fccb-6d94-4738-8e1b-ce0430fca691" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted common stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.112%;"></td>
        <td style="width:1.171%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.017999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.084999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Grant Date<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96025857-eef4-439c-ae84-04f2ee9ce458" contextRef="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,866,909</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c434b1fe-aeb0-40c1-b48b-fd0517dbe97e" contextRef="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">15.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1864293-d0bb-4283-bad4-26a470b64ac0" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,632,996</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e24ae45-2631-414c-bab7-aea63c7e7f9b" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ab8862-8f69-46e6-a3c0-7e5f503a3559" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">348,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5fc25b9-5287-4356-bd71-31e6ce483ccd" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e53af4ab-28b6-42b2-9b41-f85338372f2d" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,912,210</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_808ab6b5-0ec4-420c-ac06-fc8440422242" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5172353d-adb7-4d7d-adbd-f136d7dd0471" contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,239,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e22f281a-8132-44be-905b-2324e9c18f8e" contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e9745c4-ac42-4222-9534-cc838e7302ad" contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">27.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation cost related to the restricted stock, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2287d40a-ebc9-410f-b203-28af1d6623d6" contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.54</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c761905-63cc-46d7-8bf0-b3a39c96d663" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.350000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.305%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.35%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.372%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.316%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.535%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Contractual<br />Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3d25211-6e84-42b7-80f7-fd6e44c3728d" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,155,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c08026ce-c4aa-4441-989f-8e721ab57de7" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">23.42</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0946346e-3599-4213-b8ea-3de56c4eb5cc" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ce2d2e7-9e31-4e26-9621-cc45feeca4cb" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ebb54f6-5bec-4bd9-92af-e2f0c0cfcbb7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,051,906</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_596f08d8-d11b-49ef-a6e1-cf23549ad2b1" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a2cd143-e6f4-48c7-ac29-a49f51a2f44e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,284,164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa03927c-9d43-4bdf-8160-736fd7d81f8d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5868e17c-f4bc-4909-9f4f-576b35a9cbb5" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,922,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c93ab3-7216-4c83-9470-50b27ec69fa0" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">17.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_015bf2ee-70d9-40b4-995d-026a532e7847" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a1007a4-ab2c-4fa0-ae50-c6dd3d4d012e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5f08aa9-1708-45ff-b7c3-0c0851362a17" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,945,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66da9c29-783f-4944-bfa5-ce663ac115d7" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">22.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eefb63ce-e6c1-4874-b81c-aab713a61468" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bced49a9-55f6-4750-a783-953da6754128" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of options exercised were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca0d114a-363b-43b5-830d-91039f914faa" contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f274da9-1cc8-41a3-870f-603fa9aaa1bc" contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the year ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01edbc5d-5afb-43aa-acca-7b204e3fce58" contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.61</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c51b6b-ad20-48e3-8350-3de5b2482869" contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">24.76</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. The weighted average grant date fair value of options vested was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eca7835-6e63-405b-a793-5fd1c7493281" contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">19.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_849c99a4-edb8-4e2e-a672-f4200df59571" contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.61</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91746a7a-edd4-4753-a490-1807ab817332" contextRef="C_56bf8742-8a30-46a1-808e-e166b1e6b639" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to unvested stock options, which is being recognized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9d886b7-29ce-4b12-bba3-26bae4b74240" contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.20</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_795da760-b64a-4f92-b318-509e722f7ee4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.151%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.608%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.142%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3092cda8-97dd-41b1-ae92-f4fa498800a8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.07</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d9c684f1-a2f4-4f8b-b22b-14c91b40449c" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.06</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b7801ac-80d1-4f43-b6d9-e1d460186077" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba479bc5-958d-4e0a-9524-3280fe4c2cb3" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35a0ea2f-9f6c-47a5-b10e-6fbfc9aa4e74" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80476c06-79ad-4d1c-8ee3-7efe40c00267" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea5d4dca-2d02-4b13-b2d9-f0721b331455" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4938fda3-1c02-49ea-9534-b10cb7a2cd9f" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49a70158-7386-4d2e-9767-2c83b923558d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6291f40-6840-40b6-8091-fab0fd725848" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" unitRef="U_USDollarShare" scale="0" decimals="2">32.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was adopted by the Board of Directors and approved by the stockholders. The purpose of the 2020 ESPP is to provide eligible employees of the Company and other designated companies, with opportunities to purchase shares of the Company&#x2019;s common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1c5a194-d756-4283-bed5-b5e3faf7cc3e" contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initially, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67249b30-67dd-4789-ba57-469017fe6cdb" contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">611,354</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock in the aggregate were approved and reserved for this purpose. The number of shares of common stock reserved and available for issuance under the 2020 ESPP shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by the least of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79d3ae23-cf55-43e6-9be1-668b79f307ac" contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17" name="alvr:MaximumAnnualIncreaseOfCommonStockReservedForIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,222,707</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6d1bc6f-17fc-44c8-9287-aa86cb451a29" contextRef="C_fe20c7f0-e4e5-4327-8d78-110f415bf544" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such number of shares of common stock as determined by the Administrator. The Board of Directors elected not to increase the number of available shares as of January 1, 2021 and 2022. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_198d5a29-449a-472e-85cb-88884e6d1c90" contextRef="C_8964311a-67d6-48e8-930b-0c03d707e7e5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">454,302</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance under the ESPP.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP allows eligible employees to authorize payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef875d24-1227-46c4-80f5-5eb50723b003" contextRef="C_fe20c7f0-e4e5-4327-8d78-110f415bf544" name="alvr:PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their base salary or wages up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fc2b82b-cec4-49f9-b1a0-c7f1244f6e6e" contextRef="C_09a37f2c-e1fe-4c12-9a21-29a9a69ff02e" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb960f40-20bf-4ac5-ad1f-f8b0e7075196" contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17" name="alvr:PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Market </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82e29622-be6c-4d3e-92c4-88b5ca43a245" contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149" name="alvr:OfferingPeriodDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) on the first trading day of the offering period or (ii) the last day of any offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares and compensation expense is recognized over the offering period.  The first ESPP offering period was shortened in duration to three months and commenced on April 1, 2022 and ended on June 30, 2022. New six-month offering periods will commence each January 1 and July 1 thereafter during the term of the plan, with the administrator having the right to establish different offering periods.</span></ix:nonNumeric></span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#x2019;s shares at the discounted price. The Company makes no contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering period, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#x2019;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da4421f8-829f-4c09-95a8-6e470ef70aaa" contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">157,052</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at an average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff239178-8920-4a0a-aa12-5db34f278218" contextRef="C_8964311a-67d6-48e8-930b-0c03d707e7e5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Cash received from purchases under the ESPP for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d21f7e27-3276-42da-a813-afb13df41c60" contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527a8057-1f52-4c5b-8623-b9931b8ee2ca" contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of compensation expense for the ESPP during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_536baa45-bb41-4408-b7f9-8fc3d3d939ec" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_643b098d-b5aa-4c6f-9fb6-7c0b2949758b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.144%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.037%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.231%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4bb5238-dcd6-4ea3-b343-e5bd4851e843" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">113,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33088527-2862-4e14-925c-b2726a1aeec1" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,045</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f24be7d-7c6c-4db2-9400-3f9c716aada7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58dfd34b-9e32-4915-a213-06122f157720" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43a1b7ee-a8c0-4015-a90b-ca10ac931b0b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fde1240-6b60-42ce-a4db-cd9a22947d7a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">170,955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66b8f7bb-f64e-4d88-9ae2-28e7c88c66e3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provision for income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.185%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.516%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.709999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58ab5ace-2df7-45bc-b7e7-6fab0c59735b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da81ca19-7c1e-4752-ae26-302e3489cc2b" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98066ceb-bd83-4c28-bf72-b15e9c1d9320" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9f22678-cf4a-4f49-a6c1-b0280fba13f4" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90177bc5-f5a3-47f2-b55a-7c8e353c45e3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56a67925-7c1c-4220-b175-0c235ef07ce3" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1cfb668-43f4-4fef-bdfd-8f8b67902735" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcc2a7ae-168f-40cc-be9e-87c3bdadcd61" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_97570571-3fec-4dc1-8be4-d20db2c25440" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s income tax (benefit) expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.492%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.610999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.225%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.602%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit at the federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9be879c2-6ae2-404a-a6dc-dbe99b02a8e5" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,472</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77b08500-a2fb-411f-8bc5-396f02ec28ff" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b608704a-9fb2-4952-a1da-e200ef8e979e" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,901</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_818cf265-31d4-4d83-a08b-730712568a7f" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase (decrease) resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c47c283-b1a5-4f5d-ac37-6f30ffb8c6ab" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_888ec4e4-a7e4-4d99-b7ed-3da2632ceb5a" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73c00315-343d-46df-a01b-33b3a125c39b" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_750269b7-5894-4d3c-8721-b1484f7f0507" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">25.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c153c40b-c681-45ae-bf5d-bb698c540ad7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,603</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34690417-840f-48ea-b4d8-54124cbde482" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfdb8106-6ad4-4034-9a15-14b632bc8567" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20ef116c-e690-46bb-a51c-c128727cb2d5" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b794836-d4c9-4efd-8f3f-b8f14dea1e8e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09c17626-d245-4df0-b9af-ea383a616a63" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_289e89ff-a5ad-443d-a055-63caa6df08ea" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b83ce32-5310-42bb-86cd-ad14fd29ce30" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property transfer</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_719779b0-1da7-4523-a118-b0702e5f098d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c12ee38-dae3-4fde-b2b9-e85f61d82c73" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6657e95c-603e-4bb9-a161-004bf0a4c75a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">14.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5318c3b-51ad-4629-beed-d20138c30872" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ae1ac5a-c5e6-4e72-85c2-fbd93b515350" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71bac5c6-cd62-49b9-9877-ff42961bf9e7" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab3ca4e6-0fde-4a99-9244-775511ef64ff" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Officer's compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe9c89c9-02cb-4771-b920-63b411b013c2" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab290961-aa8c-4c2c-9c3f-5e1b54db725b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39842107-d902-4876-8987-83166b13251a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9288b7e4-b317-4448-a85c-547bf5843aab" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0eaeec96-9667-4407-b21b-7146c7bc913f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b87731d7-0851-4286-8e72-311a2ed4c68d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fc8e14-896b-45e6-8f73-1e498929fb5d" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b50462c1-586c-4e63-8470-223b62ee8a8c" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3850a573-c1b3-4971-85b6-e9520fbe303e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">182</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ec74d50-3dfc-49b8-b368-57c73e35509f" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88d620ff-1e4e-43aa-873f-701ed367f9af" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa326f5b-6094-486e-8a08-e5b9f6799a75" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f562fa13-2899-40d2-b2c8-41800aaf0d6a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">730</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bda89450-7ff1-4d13-8880-0e7a26a945ea" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90bdb08e-09e8-4510-9095-97f9b88be7c7" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00595212-d86c-4b96-b3bc-e778b7a5c20d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_407b86e5-8a4c-40f7-85c0-b799c0bfc751" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b1be561-f3ce-416b-bba8-1a75d705213f" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, the Company began applying the requirement to capitalize U.S. research and development expenses in the period incurred, as required by the Tax Cuts and Job Act of 2017. During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company transferred intellectual property rights between tax jurisdictions, resulting in a deferred tax benefit on the basis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difference </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in our intangible assets.  The additional deferred tax asset was offset by valuation allowance, resulting in no net impact to deferred tax expense (benefit).  The transfer of intellectual property rights generated U.S. current income tax expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4adb9049-0897-4d5a-9d06-08d74ae07b3f" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after utilization of net operating loss and tax credit carryforwards.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c11b225f-4830-469b-8bc1-523900cc20e5" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of deferred income taxes consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.619%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.012%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdb33b2f-5ede-4870-a98d-6005259907e7" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad0109e-b62d-4167-8dd9-2b93d90ad4cd" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77828cf3-9ea7-45f3-a177-e387acc23bf0" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81abb09b-93bd-4b81-9acf-32a8031bfde9" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,683</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_968368d3-e942-45f1-85dc-bd685d9c5684" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea81c4c3-1520-40de-8562-af0c3893945d" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50bf3b9a-902d-4483-8fca-bbc4095ab65e" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:DeferredTaxAssetsLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebac901d-6ff1-481c-a7b7-2fc458362b8c" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="alvr:DeferredTaxAssetsLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,865</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-qualified stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ef97fc6-1de3-44a3-b172-e96a0567ed3c" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6865561-95f3-4748-a366-7cdf9091dedf" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_927da998-4a3b-491e-8c2d-6e4de1fc9c43" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69aaf7b1-fb00-4eb9-9826-27be08fe02e1" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalization of R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32c76096-f152-4909-ba93-8ad7b55e3568" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47af1359-4615-4736-a40b-52a485555d37" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,661</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e31609c3-3980-4915-96d4-16fc3d5c4e87" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d0b2300-db5f-4af2-bcd9-c86642b894c9" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b4e6239-1122-4aea-bde0-ad5dbc3e5f71" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5eac029-0ee6-496e-adec-63906715f7cb" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15f185e3-effa-43e0-9fd8-446c3f98f797" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eec70a8b-0110-4029-8f28-b4c9a06b85aa" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_521c7b42-2e05-4c86-be22-54a1ca16e21e" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51548adb-4871-4604-aa79-9a704050eed6" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3754e58-ecd7-430d-b00f-ff08d8ad676a" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40b5d9fc-94ec-4eca-884a-71ce316109c8" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="alvr:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01a58330-3a11-4074-b43b-a3e32871b7d5" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="alvr:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00005017-133b-465f-a395-eac60ef0fa0b" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc645e90-d038-4e48-af62-b9bd6e61de94" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b17e36-e515-431f-a2a3-0e11c3824f7a" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb3ad673-923a-4fa9-9e36-8e1179a0c7f7" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#x2019;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At December 31, 2022 and 2021, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying consolidated balance sheets. For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c045369-7462-41b8-90cc-1cbb9ac774da" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was principally due to net operating losses, tax credits, tax basis generated from the intellectual property transfer, and U.S. research and development expense capitalization.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8c7f8b2-cfd9-4012-82f7-f6b8976921c7" contextRef="C_fc2f8cf1-b175-4168-8c12-2ca0ee568e4e" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80430bc7-0c5d-42c3-b172-75852b31e2dd" contextRef="C_caad09b2-8a5c-427a-bf14-b4c5d6dc2fac" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards have no expiration. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_fb8a9d38-01ce-4a93-beea-aee65bc7b04d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior tax years.  In addition, net operating losses generated in these years could fully offset prior year taxable income without the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81f607c7-8deb-461b-af8d-f94213946da0" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the taxable income limitation under the TCJA which was enacted on December 22, 2017.  Given that the Company utilized a substantial portion of its net operating losses in 2021, is expected to utilize all remaining net operating losses in 2022, the net operating loss carryback provisions under the CARES Act are not applicable to the Company.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused state net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b08b9216-cbb7-4767-b3d9-18bfc1ba2f3f" contextRef="C_ed61a91e-38ee-40bf-89a6-4063803306fc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af3cafac-d143-4771-b473-d58a8d39396a" contextRef="C_0c3fe01a-8496-428e-84e7-1771deb6fcdf" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The state net operating loss carryforwards expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f09e632b-d3dd-4244-ab06-a65e54676af9" contextRef="C_5df06e65-2e31-4282-a0c9-44687c839727" name="alvr:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused foreign net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91c403d0-4388-42ef-993c-0da9f762f950" contextRef="C_ec9f3cbd-6e49-4297-9fce-29d9733f0dee" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">72.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa7b5e1b-6aa5-4f37-b4f3-d0af1a9c54a4" contextRef="C_de179e1a-a46a-42ff-ade3-641aee56fdf6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The foreign net operating loss carryforwards have no expiration.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de7d308a-bb88-41a3-a69a-18118aa33672" contextRef="C_364b0156-c9eb-4a54-8db9-564a84677c30" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8cb3a77-1694-46b1-8935-d4d234389f89" contextRef="C_c1a7c8cb-c126-4a75-84cc-77ae967326ea" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development tax credit carryforwards that may be available to offset future federal income taxes through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11763bc2-b347-499d-a584-9103765323f6" contextRef="C_05b6c22e-9c40-4013-83f9-51bb3313e591" name="alvr:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had a federal orphan drug credit (ODC) carryforward related to qualifying research of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a39a58b3-6cfc-4182-b4dd-089c18c00f08" contextRef="C_6cb1ed55-c237-4a84-8a95-212c9e28b1d9" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that will begin to expire</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4229e006-0cef-4112-a999-6e435b81784c" contextRef="C_de1adbb2-e1ee-4eaa-9635-a371d6880799" name="alvr:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company also had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd923663-2bc8-46b6-883a-ed778d8593f0" contextRef="C_260a042b-801a-42d1-b1f2-f77d80a4d46a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaf08ef4-6279-466a-abd8-e044cb128ce0" contextRef="C_fa412a85-c19c-4db1-b1d6-89d57a67aedd" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development tax credit carryforwards that may be available to offset future state income taxes in the state of Massachusetts through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1bb08baa-1aaa-4e98-b75b-8414a7c10333" contextRef="C_0aab4b39-a49a-4d2d-a277-8f923ab3d97d" name="alvr:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of net operating loss and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax expense, respectively. The Company has completed several financings since its inception which may result in a change of control as defined in Section 382 of the Internal Revenue Code or could result in a change in control in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d18372a5-405a-4273-9923-c3a05a1c8559" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3be07a36-b856-4e1a-9651-e0f151036c51" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> uncertain tax positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb3d8b49-eb0e-4871-9ed5-af4426fc40aa" contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5ca97a21-b7b0-4f79-9290-26e9c3b2b20a" contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accruals for interest and penalties at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for the tax years December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e5fd9b05-6e8a-4198-a863-2bc160850a60" contextRef="C_05a46537-0f3d-403a-bd4b-9b51a77c50b9" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0e2b1836-10a0-4fca-aae3-195349ee4670" contextRef="C_f6f0fa23-53ee-473a-93c3-d9f513ff687e" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as the Company was incorporated in September 2018. There are currently no federal, state or foreign income tax audits in progress. The resolution of tax matters is not expected to have a material effect on the Company's consolidated financial statements.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe138e6f-8234-42e9-a8d6-93d06f71c049" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Net Loss per Share</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fec107eb-1e75-401e-a2e9-76ecedeb9917" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.745%;"></td>
        <td style="width:1.683%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.351000000000003%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.674%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.545%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss &#x2013; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17ee79dc-582f-4189-94f6-16c2f70d55e6" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,710</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c1865f7-4df4-48a2-b567-ed367381351a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171,962</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding &#x2013; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bb870cd-6d45-43c6-8dc6-5317065a6de3" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_e5a669a8-80c0-4b0e-beb8-fe693ae15c2d" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">76,654,856</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efe0ffb9-981d-4c22-b072-09be61fbc585" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_7ae82f4c-ff67-4597-bc67-32305bc47cf7" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">62,782,126</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#x2013; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4275c259-8233-4027-99b5-1e9df231fb30" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_11d9bbb5-4865-485c-829c-a7ad61aa7741" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.20</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9f8099e-1e64-4f5a-88f0-c4c4963eac0a" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_f2809a87-237c-49fc-8635-5f2800909d3d" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.74</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d183e72a-c912-4a90-b730-ed206105f51b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the amounts outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.485%;"></td>
        <td style="width:1.237%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.319%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.237%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.721999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ce8c97-8303-46f4-ae74-d07666d1262d" contextRef="C_9d14225a-1f51-4be3-8682-e3fe75c16bf8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,922,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cf9e730-f67a-4a72-aab9-15da0bcfef5d" contextRef="C_62c6f492-44c1-46c2-b513-632f27ed7e91" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,155,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2986f71-81b0-4b2d-86f2-6d339a3b57f2" contextRef="C_26adca99-ca18-49de-923e-a278ee315f05" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,239,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e419922-b2f9-4c19-b895-1d5aadcb816f" contextRef="C_c2c0042d-4a48-4498-a1f0-1bd575db97dc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,866,909</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_837da6f3-bc42-488c-8279-49f3cc9e6c98" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company entered into a lease agreement and a sublease agreement for the lease of property in Waltham, Massachusetts (see Note 5). The Company also leases an office space in Houston, Texas under an operating lease which will be terminated effective </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d71444c4-0abf-4a22-8542-8868da423047" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="alvr:LeaseTerminationEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and an office space in Dublin, Ireland under an operating lease that expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d8a60e1-6a28-4e00-afa8-b9d9528f376e" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALLOVIR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#x2014;(Continued)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. At December 31, 2022, there were no matters which would have a material impact on the Company&#x2019;s financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and testing and manufacturing services, which can contain purchase commitments or other noncancelable obligations. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of services provided up to one year after the date of cancellation. The amount and timing of such payments are not known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or we may be required to make royalty payments under license and grant agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time (see Note 8).</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_74108bdd-3ee8-4d7f-aa6a-7ab07c299f20" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company entered into a Management and Administrative Services Agreement with ElevateBio Technologies, Inc. that provides for ongoing services to the Company in areas such as information technology, human resources and administration management, and facilities. The Company is billed monthly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into the 2020 DMS Agreement with BaseCamp pursuant to which BaseCamp provides products and services that are used in the Company's laboratory operations, including consulting services, project management services, quality control services and cGMP drug product manufacturing (see Note 5).</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbc86dbf-b026-401c-8a3f-ab72e0abe693" contextRef="C_ca8bd669-1d5c-4b9a-921e-86a2b0097299" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prepayment to BaseCamp for future services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01896b34-c673-4bc1-a1cc-5dcc0f49c93a" contextRef="C_8351b805-5c1a-4d38-8217-30f5d6839ca6" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00d78958-cd96-49c6-9ae4-a2a16a1d5440" contextRef="C_2690d392-2fbc-4b1f-8ea4-61ecf654db96" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively, related to services provided to the Company by ElevateBio and affiliates. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company owed ElevateBio and affiliates $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f71d7858-a95e-49c9-8099-344e25950dad" contextRef="C_ddb75e86-804f-400d-952a-974d942d169c" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91119f35-17e5-49d3-acac-0cb461e5bb68" contextRef="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively and had prepaid expenses with ElevateBio and affiliates of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc343fe7-078f-44ec-83ca-2b4471a1780e" contextRef="C_ddb75e86-804f-400d-952a-974d942d169c" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0ff1a03-ecfd-4885-b8ca-dfa6517453d5" contextRef="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Members of the Company&#x2019;s management and board of directors received consulting fees totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb9a1b4d-14ca-45a3-80a0-a31bac66889b" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:ManagementFeeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55d16a93-afe2-43dd-96b1-07a9dbe5bfff" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:ManagementFeeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e0b48ec-81a3-4458-b9c3-e07a641dd4e8" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true" continuedAt="F_7e0b48ec-81a3-4458-b9c3-e07a641dd4e8_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Employee Benefit Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_7e0b48ec-81a3-4458-b9c3-e07a641dd4e8_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company made matching contributions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f64e19bb-1186-4bba-ab67-c33a141cc8e4" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c15c3476-df82-45a1-b2d7-4f2297874380" contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_970e28b8-2f15-4e3d-9a95-8427f9ee11cd" contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the financial statements at December 31, 2022 and for the year then ended, the Company has evaluated all subsequent events through February 15, 2023, the date the consolidated financial statements were available to be issued, noting there were no events or matters identified that require additional disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>alvr-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement No. 333-258539 on Form S-3 and Registration Statement Nos. 333-262632, 333-253028 and 333-240259 on Form S-8 of our report dated February 15, 2023 relating to the financial statements of AlloVir, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, Massachusetts<br><br>February 15, 2023<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>alvr-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Diana Brainard, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of AlloVir, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:43.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 15, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Diana Brainard</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diana Brainard</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>alvr-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Vikas Sinha, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of AlloVir, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:43.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 15, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vikas Sinha</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vikas Sinha</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Financial Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>alvr-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of AlloVir, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:43.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 15, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Diana Brainard</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diana Brainard</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>alvr-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of AlloVir, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:43.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 15, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vikas Sinha</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vikas Sinha</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Financial Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img101536035_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"^X5<C/Y5NU"<(7E:Q.J;*7P2M))O&DURH/EV]H^YNV6( '\_P JP-"N-?\
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M^N-Y_P"@&NA^)_AW4O$WA>&QTN%9;A;M)2K.%^4*P/)^HJMX4\+ZKI?POO\
M1+N!4OYHKA402*02ZD+R#BLU)>Q2OU';WCS[X*:79W_B:\N;J!97M8 T(<9"
ML6QNQZX_G7I/Q:!/PVU/CHT/_HU:POA5X*USPMJ>H3ZM;)%'-"J(5E5\D-GL
M:[WQ-HJ>(O#=]I+OY?VF/:K_ -U@05)]L@459KVRE?30$O=//O@21_PC^J#/
M/VH?^@"N)T#_ )+C_P!Q6X_]">K6D^ /B+I%]+9Z>9+*&?"RSQ7:B,KTW<'/
MKVS6UX?^%^N>'_B#97BJMQIMM*&-R9%!;Y.3MSG[Q-;-P3D^9:H6NAJ_$_X>
M:EKVHQZYHI$ERD822W+;6.TDAE)XSST]A6-H/Q4UK2=8ATKQ?99VN$:=XO+F
MBSQN(Z$8/8#CUKHO&NA^/G\2+K'AO40T*QB-+9'";!WW*YVOD\Y/Y<5S%O\
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ML^T33(RHO<JJGDGZ#MDUK))2C)NUD+HT:=KYO_#.%QY@^7)\O_=^TC^N:?\
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MRT+2;%MR/!%Y??#3$'/_ 'SL-;'QKA-AX:T#3[9=MG$[(!Z;$ 0?D6IOP_\
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M .$HU#6/ME[*R/<(R$_?( PY/.,CL/TI_P ;O^1XM_\ KPC_ /0WKT#XF?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\
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M -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(5F&W=\IX/Y4E1AU_K5%/$5'LMO\GI^!T5GJEI?R/' \@D10QCEB>)MIZ'#
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MEL8;8.3TP<#//UH6TN9M12^%K*D,^JK*JLA#!%A*[V'5<D=\'I2]E"[^?_#
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M6;:\BNPQC6==O7S8'C_+<!G\* (KK5+&QD$=U=Q0N1N"NV#CUJ'_ (2'1_\
MH(V__?=:5%4G'JOZ^XAJ=]&ON_X)F_\ "0Z/_P!!&W_[[H_X2'1_^@C;_P#?
M=:5%.\.S^_\ X K5.Z^[_@F;_P )#H__ $$;?_ONC_A(='_Z"-O_ -]UI447
MAV?W_P# "U3NON_X)F_\)#H__01M_P#ONC_A(='_ .@C;_\ ?=:5%%X=G]__
M   M4[K[O^"9O_"0Z/\ ]!&W_P"^Z/\ A(='_P"@C;_]]UI447AV?W_\ +5.
MZ^[_ ()F_P#"0Z/_ -!&W_[[H_X2'1_^@C;_ /?=:5%%X=G]_P#P M4[K[O^
M"9O_  D.C_\ 01M_^^Z/^$AT?_H(V_\ WW6E11>'9_?_ , +5.Z^[_@F;_PD
M.C_]!&W_ .^Z/^$AT?\ Z"-O_P!]UI447AV?W_\  "U3NON_X)F_\)#H_P#T
M$;?_ +[H_P"$AT?_ *"-O_WW6E11>'9_?_P M4[K[O\ @F;_ ,)#H_\ T$;?
M_ONH+K5M!O;9[>XOK9XFQD>9@\<@@CD$'G(K9HH3BM4G]_\ P!.,VK-K[O\
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MJ[4::Z>4H.X7>QV]NGI70T4U.*5E?[_^ 2Z<F[NU_3_@F;_PD.C_ /01M_\
MONC_ (2'1_\ H(V__?=:5%*\.S^__@%6J=U]W_!,W_A(='_Z"-O_ -]T?\)#
MH_\ T$;?_ONM*BB\.S^__@!:IW7W?\$S?^$AT?\ Z"-O_P!]T?\ "0Z/_P!!
M&W_[[K2HHO#L_O\ ^ %JG=?=_P $S?\ A(='_P"@C;_]]T?\)#H__01M_P#O
MNM*BB\.S^_\ X 6J=U]W_!,W_A(='_Z"-O\ ]]T?\)#H_P#T$;?_ +[K2HHO
M#L_O_P" %JG=?=_P3-_X2'1_^@C;_P#?='_"0Z/_ -!&W_[[K2HHO#L_O_X
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M^_\ X 6J=U]W_!,W_A(='_Z"-O\ ]]T?\)#H_P#T$;?_ +[K2HHO#L_O_P"
M%JG=?=_P3-_X2'1_^@C;_P#?=(?$6CCKJ-O_ -]UIU!=?<C_ .NJ?S%%X=G]
M_P#P M4[K[O^"5/^$AT?_H(V_P#WW1_PD.C_ /01M_\ ONM*BB\.S^__ ( 6
MJ=U]W_!,W_A(='_Z"-O_ -]T?\)#H_\ T$;?_ONM*BB\.S^__@!:IW7W?\$S
M?^$AT?\ Z"-O_P!]T?\ "0Z/_P!!&W_[[K2HHO#L_O\ ^ %JG=?=_P $S?\
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M?]^W_P#BJY"FFE]7I?RC^M5OYCL?^%DZS_S[6'_?M_\ XJD_X65K/_/M8?\
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MUY^::>E'L*?8?/+N>@_\+C\0_P#/GI?_ 'ZD_P#BZ3_A<GB'_GSTO_OU)_\
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M\B_<_5/_ $-: )M&_P"0?']*T*S]&_Y!\?TK0H **** "BBB@ HHHH ****
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M.:-!I=F\KP0ERK3$%CN8L<X '5CVK2J+[3!_SVC_ .^A1]I@_P">T?\ WT*
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MO^@9_P"1X_\ XJO;**/KM3LA_4:?=GB)\ >)_P#H&?\ D>/_ .*I#X \3_\
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M_5H'@A^'/BO_ *!7_DQ%_P#%4T_#CQ9_T"O_ "8B_P#BJ]]HH^N5.R']7B>
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M^J?^AK0!-HW_ "#X_I6A6?HW_(/C^E:% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <'?6_P!EO9H>RMQ].WZ5I^&[D1WCP,>)5R/J/_K9JWK^
MFR7$D4]O&7<_(P'Z&J,5M;:6ZRW4OF7*G*PQ'[I_VC2KXFE1I\]65D>92PM;
MZQ:FK_Y'645!:727ELDR=&'(]#W%3TH3C4BIQ=TSU&FG9A7B7B+X5:OJ?Q<6
M[@A/_"+WMQ#>WQ$J >9&&X*$[CDYY _Y:&O;:*H1Q7Q%T'Q/JMC97GA+5Y;+
M4K&7S/($Q2.Y7CY6'W3C QN&.2.*\_U7PQ\3OB-<Z?8^*=)TC2;"UG65[F%E
M,A X(7#N<X)X^49QFO=:* ,7Q;87.I>#-9T^RC\VYN+*6&)-P&YBA &3@#GU
MK-^&FC:AX?\ A[I.EZI;_9[V!'$D>]7VY=B.5)!X(Z&NLHH **** ,[7=431
M="O-1D(_<1%E!_B;HH_$X%?,SNTDC.Y+,Q))/<U[CXRU31=1E;0=2$_D AWG
MMWYBD[<?Q<'GKUZ9%>?7'PZU,WML-.FBU#3[B4(MW#_RS![NO5<?YYXKLP=:
MDKJ^IZ5&E*C#FFK7.[^$NE&S\-2W[KA[V7(_W$R!^NZN_JM864.FZ?;V5NNV
M&",1H/8#^=6:YJD^>;D<%27-)R"BBBH("BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHK-U_4)=*T2XO8%1I(]N X)'+
M =B/6G&+DTEU)G)0BY/9&E17FW_"PM6_Y][+_OA__BJ3_A86K?\ /O9?]\/_
M /%5U?4JIQ?VE0\_N/2J*\T/Q#U;_GWLO^^'_P#BJ3_A8FK_ //O8_\ ?#__
M !5'U*J']HT/,],HKS+_ (6+J_\ S[6/_?#_ /Q5)_PL75_^?:Q_[X?_ .*H
M^I51_P!HT/,].HKS#_A8VL?\^UC_ -\/_P#%4G_"Q]8_Y]K'_OA__BJ/J54/
M[0HGJ%%>7?\ "R-8_P"?:Q_[X?\ ^*I/^%DZQ_S[6'_?M_\ XJCZG5']?HGJ
M5%>6_P#"R=9_Y]K#_OV__P 52?\ "RM9_P"?:P_[]O\ _%4OJ=4?U^B>IT5Y
M6?B7K/\ S[6'_?M__BJ3_A9FL_\ /M8?]^W_ /BZ/J=4/KU$]5HKRG_A9NM?
M\^MA_P!^W_\ BZ0_$W6O^?6P_P"_;_\ Q='U.J/Z[2/5Z@NON1_]=4_F*\O_
M .%G:U_SZZ?_ -^W_P#BZBE^)FLN%!MK#A@>(W['_?H^IU0^NTCURBO)C\4-
M;_Y]=/\ ^_;_ /Q=)_PM'6_^?73_ /OV_P#\71]3JC^N4CUJBO)#\4M;_P"?
M73_^_;__ !=(?BEKG_/KI_\ W[?_ .+H^IU0^MTCURBO(O\ A:>N?\^NG?\
M?M__ (ND_P"%J:Y_SZ:=_P!^W_\ BZ/JE4?UNF>O45Y ?BKKG_/IIW_?M_\
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M4R2:LRD?4VBZU8Z_ID5_82^9"_!!^\C=U8=B*T*^=_AUJ.N6?B>*#1HS.LQ
MN(&.$*#JS'^'&>#^'.<'Z(KRZU/V<K&\7=!1116104444 %%%% !63XE_P"1
M?N?JG_H:UK5D^)?^1?N?JG_H:T 3:-_R#X_I6A6?HW_(/C^E:% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %>[LH+V+9,N<=&'4?2N8O
MM'N+,EE!EB_OJ.GU%=?17EYAE-#&J\M)=U^O<Z*.)G2T6QY^"0<@X(K0@UF^
M@  EWJ.T@S^O6NBN=(L[HEFCV.?XDX/^%94WAJ0$F&X5AV#C%?,SR;,<'+FP
M[O\ X7;[U_PYZ"Q5"JK3_$$\32 ?O+96_P!UL?XU7UWQF=&N((18>:9K=9@W
MG;=N21C&WGI3&T+4%Z1*WT<?UK.\4^&M6U._LWM;4.D=HD;L9%&&!;(Y/N*]
M7*JV8R<UB4]+6NO^!J52I8.55<UK:]?^"4+KXAZI*"((;> >N"Q_7C]*YV^U
M6_U-]UY=2S<Y 8_*/H.@KH+;X?:O-S,]O /=RQ_08_6M_3_AYI\!#7MQ)=-_
M=7Y%_3G]:]?DJSW/0^LY?AM86OY:O[_^">>6=C=:A.(;2!YI#V09Q]?2O0O#
M_@6&S*76I[9YQRL(Y1#[_P!X_I]:ZJTL;6P@$-I!'#&.R#&?KZU8K:GAU'5Z
MGF8O-ZE9<M/W5^)GZ[_R+NI_]>DO_H!K0K/U[_D7M3_Z])?_ $ UH5T'D!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50TC1K#0=
M/%CIL!AMP[R;2[.2S,68EF))))/4U?HH Q+[PCH6I7&H3W=CODU"*.*Z(E=?
M-5#E,@,!D'N.>U6O[!TO[3J-PUFCOJ2+'=B0EUF55*@%2<8P2.!SWK1HH Y7
M1/AOX0\.ZH=2TK0X(+SDK*7>0IGKM#$A>I'&..*Z>:))X9(9%W1R*589QD$8
M-/HH JV&FVFF:7!IMG%Y5I;Q"&*/<6VH!@#)))X]352W\-:-:^'ET!+")M*5
M"@M9<R+M)S@[B2>3GFM6B@#DM%^&7@WP]J8U'3-"ABNUY21Y'EV'U4.Q"GW&
M*Z'5=*LM;TV;3M0A\ZUFP)(]Q7."".00>H%7**  # Q1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]6TJQUS2[C3-2@$]G
M<+LEB+$;A]001^%7** ,VYT#3+O3+73IK4&TM'B>"(.RA#&04Z'/! Z_C4FK
MZ/8:[ISZ?J4'GVKLK,F]ER58,.5(/4"KU% &1X@\+Z)XJLUM-;TZ&\B4Y3?D
M,A[[6!!7\#4'AOP7X=\(I*NA:7#:&7[[@L[L/0LQ+8]LXK>HH SM;T+3/$>E
M2Z9J]HMU9RX+QLQ7D'(((((.?0TFF>'],T::::PMC%)-%%%(QD9MRQ+M0?,3
MT''OWS6E10!R-[\+_!6HZTVKW7A^VDO&?>[;G".W<L@.QB>^1S5OQ%X"\+^*
MYK>;6M(BNI;==D;AWC(7^[E",CV/')KHZ* .:'P_\*KH5YHBZ/$NFWDHFFMU
M=PI<  ,,'*_='W<5I:;X?TO2+B6XL;8Q2RP0V[L9';,<0(0<D] 3SU/?-:=%
M &/_ ,(KHO\ PCA\/_8O^)6V<P>:_=]_WL[OO<]:J>(_ 7A?Q;+%+KFD174L
M2[4E#O&^WT+(02.3P>*Z.B@#'C\*Z'#IMCIT.G116=A.MQ;11$H$D4DAN#R<
MDGG.>^:M2:/82ZL=4DMPUX;8VID+$@Q%MQ7;G'7VS5ZB@#*\/^&])\+:>UAH
MMI]EM6E:4QB1G&XXR1N)QT''2M6BB@ HHHH *PO&7_(J7O\ VS_]#6MVLGQ+
M97&H>'[JUM8_,F?9M7(&<.">3QT%:4FE4BWW1EB$W2DEV?Y'D!IM;_\ PANO
M_P#/A_Y&C_\ BJ3_ (0S7_\ GP_\C1__ !5>W[:G_,OO/FOJ];^1_<S --/>
MN@/@SQ!_SX?^1H__ (JD_P"$+\0?] __ ,C1_P#Q5'MJ?\R^\?U>M_(_N9SY
MI#6__P (5XA_Z!__ )&C_P#BJ/\ A"O$/_0/_P#(T?\ \52]M3_F7WE?5ZW\
MK^YG/4TUT/\ PA/B'_H'_P#D:/\ ^*I/^$)\1?\ 0/\ _(T?_P 51[:G_,OO
M']7J_P K^YG/4TUT7_"$>(O^@=_Y&C_^*I/^$'\1?] [_P CQ_\ Q5'MJ?\
M,OO*]A5_E?W,YXTVNB_X0?Q'_P! [_R/'_\ %4G_  @WB/\ Z!W_ )'C_P#B
MJ7MJ?\R^\?L*O\K^XYT]:;71GP-XC_Z!W_D>/_XJD_X07Q)_T#O_ "/'_P#%
M4>VI_P R^\KV%7^5_<<V:0]*Z3_A!/$G_0-_\CQ__%4A\">)?^@;_P"1X_\
MXJCVU/\ F7WC5&I_*_N.;IC?UKIO^$#\2_\ 0-_\CQ__ !51R>!?$B %M.QE
M@!^_CZD_[U+VM/\ F7WE>QJ?RO[CG33373'P%XF_Z!O_ )'C_P#BJ3_A ?$W
M_0,_\CQ__%4>VI_S+[RO8U/Y7]QS)IIZ5TQ\ >)_^@9_Y'C_ /BJ0^ /$_\
MT#/_ "/%_P#%4O:T_P"9?>/V53^5_<<S3373_P#"O_$__0,_\CQ?_%4A^'_B
MC_H&?^3$7_Q5'M:?\R^\:I5/Y7]QS!Z4VNH/P^\4?] O_P F(O\ XJD_X5[X
MI_Z!?_DQ%_\ %4>UI_S+[RO93[,Y<TAKIS\/?%/_ $"__)B+_P"*H_X5YXI_
MZ!?_ ),1?_%4O:T_YE]Y7LY]F<M3374_\*[\5?\ 0+_\F(O_ (JD/P[\5?\
M0*_\F(O_ (JCVM/^9?>5[.?9G+&FUU7_  KKQ7_T"O\ R8B_^*I/^%<^*_\
MH%?^3$7_ ,51[6G_ #+[Q^SGV.4/6D-=6?ASXK_Z!7_DQ%_\533\./%G_0*_
M\F(O_BJ7M:?\R^\KDEV.4IK?UKK/^%;^+/\ H$_^3$7_ ,54<GPY\5H 6TK&
M6 '^D1=3_P "H]K#^9%*$NQRQZ4AKK#\-O%O_0)_\F8O_BJ3_A6OB[_H$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9^O?\B]J?\ UZ2_^@&M"L_7O^1>U/\ Z])?_0#6A0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !YD?]]?SH$B$X#J3]:/+C_N+^5 C0'(10?I0 ZBBB@ HHHH **** "BBB@
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M%% !1110!GZ]_P B]J?_ %Z2_P#H!K0K/U[_ )%[4_\ KTE_] -:% !1110
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MKH["[@\;?$.UU"W/F:5H=DLL38X>YN$##V.V/'T+UV>E:18Z)I,&EZ=!Y-E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC<O]X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^= "T4FY?[P_.C<O\
M>'YT +12;E_O#\Z-R_WA^= "T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_>'YT
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MHHH **** "BBB@ HHHH S]>_Y%[4_P#KTE_] -:%9^O?\B]J?_7I+_Z :T*
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M\D_[Y%/HH 9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\
MOD4^B@!GDQ?\\D_[Y%'DQ?\ /)/^^13Z* &>3%_SR3_OD4>3%_SR3_OD4^B@
M!GDQ?\\D_P"^10(HU.1&@([A13ZQ?%D\MMX9O)8)7BD79AT8J1\ZCJ*J$>:2
MCW(J3Y(.78VJ*\8.MZM_T%+W_P "'_QI#KFK8_Y"E[_X$/\ XUW?4)=SS?[5
MA_*SVBBO%?[<U?\ Z"E[_P"!#_XTTZ[J_P#T%;[_ ,"'_P :7U"7<?\ :D/Y
M6>V45XD==U?_ *"M]_X$/_C33KNL?]!6^_\  A_\:/J$NX_[3A_*>WT5X>=>
MUC_H+7W_ ($/_C33KVL?]!:^_P# E_\ &CZA+N/^TH?RGN5%>&'7M9_Z"U__
M .!+_P"--_M_6?\ H+7_ /X$O_C1]1EW'_:,?Y3W6BO"/[?UG_H+W_\ X$O_
M (TA\0:U_P!!>_\ _ E_\:7U&7<?]H1_E/>**\%/B#6O^@O?_P#@2_\ C2'Q
M#K7_ $&-0_\  E_\:/J,NX_K\>Q[W17@1\0ZWC_D,:A_X$O_ (TA\0ZW_P!!
MC4/_  )?_&CZC+N/Z]'L>_5!=?<C_P"NJ?S%>#?\)%K?_09U#_P*?_&HW\0Z
MV<9UC4#@@\W+_P"-'U*7<?UV/8^A**^?#XCUS_H,ZC_X%/\ XTT^(]<Q_P A
MK4?_  *?_&E]2EW']<CV/H6BOGC_ (237<?\AK4?_ I_\:3_ (237?\ H-:C
M_P"!3_XT?4I=Q_6X]CZ(HKYU/B77O^@WJ7_@4_\ C33XEU[_ *#>I?\ @4_^
M-'U*7<?UI=CZ,HKYQ/B77O\ H-ZE_P"!<G^-(?$VOX_Y#>I?^!<G^-'U*7<?
MUE=CZ/HKYN/B;7_^@YJ7_@7)_C3?^$GU_P#Z#FI_^!<G^-+ZG+N/ZPNQ])T5
M\U?\)/X@_P"@[J?_ (%R?XTA\4>(,_\ (=U/_P "Y/\ &CZG+N/VZ['TM17S
M.?%'B#_H.ZG_ .!<G^--/BGQ#C_D/:I_X&2?XT?4Y=Q^V78^FJ*^9#XI\0_]
M![5/_ R3_&KFD^._$.E:E%=MJ=W=HI^>"YG9T=>XP2<'WI/"2MN4JJ/H^H+K
M[D?_ %U3^8JCX>\0V/B72TOK&3(/$D9^]&W=2/\ .:O77W(_^NJ?S%<MFG9F
MA/1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ+_R+]S]4_P#0
MUK6K)\2_\B_<_5/_ $-: )M&_P"0?']*T*S]&_Y!\?TK0H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#/U[_D7M3_Z])?_ $ UH5GZ]_R+VI_]>DO_ * :T* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,TW7;74[_5;.%)4DTR=8)V
MD "EBBOE<$\88=<5IUXEJ^D^)];UOQS:Z1Y)TV*_AFNK;>RRW^(8\VX8?<4J
M#D]R0.F: /1K7QO9ZA8ZC?Z;INJ7]E92>6MQ:P*ZW39 ;R1NRX4GEL <'!.*
MZ<<BO/=?U^SN?@W/JGAF5[*W6&-(!!F%[?$BJ4POW2.01_2HI['4_&GC36[0
M^)=4TFST8PQ00Z9,(FD=XPY>0D'<.<;>G'UR =EH6OVOB"&]EM(YD6TO);.3
MS5 )>,X)&">/3^5:M>&6']LVW@UK2TUN2#4)O&;6TM_;C;ORV&;;T(/7:>.U
M;XN-5\!:_KUJ-;U+6;--"DU2)=3G\UTF1BI ; PIXX% 'JE%?/NGZ]XDMEL]
M8MXOB3>ZLYCDGBNM/SITRDC>JQK]P8SAAS[<UWVN>([KP=KWB.6YGGEM[O35
MOM.CED+*LR?NVB4$\99HC@?WC0!Z!/-';6\D\SA(HU+NQ[ #)-1V%];ZGIUM
M?VDGF6US$LL3X(W*PR#@\C@US%YHMTGPIFTN^U*^-XFFGS[M)SYS2!=S?.<G
M!.1].*X33-)U!=!^'NC6?B36;:'5;>66XE6Z_>(AMT;9&<84#&%R#MR<4 >U
M45XSXGCU2ZUZ?1M)U3QGJ(TR"&%4TNX2V6.39D^?<N3YKL,,> !FDT_4O$/B
MG1OA[$VOWMA/J'VQ+RXMG >1(U(]-I; X;'!.1S0![/17E-M%XKT^P\;>&]'
MUB]U.]L1;OIT][,&G"RKN==Y&"V V"> <=*J^ -7DL_%L.G7VI>,;66YC=?L
M/B2/SDGD SF&88Q@!N,88&@#V"LPZY;#Q,-!V3?:C9F\WX&S9OV8SG.<^WXU
MY;HNBZ_KG@JX\1/XXUBVN[22[:TC2?\ <H(Y7XF#9,G3N0 N!CCG0M/$#77B
M"U\0W4Z6+R>#?M4DS1EUA8N&+;<@L ><=^E 'JM%>":=J'B;3?$'AS4OM'B]
MK;4+^&VN9=:N(U@E$F<A+89*9QD<\8Q6Q-I>O:Q:>--67QAK5F=*U"Z-C;6\
M^V-3&H;#Y!+*>!MS@<^IH ]7;5+)-8CTEIA]ND@:X6+:>8U8*3GIU85<KR33
MM/EUOXH>&]8GU;4XYKCP^E])%#<;8RP:,%-N/]6Q.2O<XKUN@ HHHH ****
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MXTT]*1:&FFTXTVD4AM-/6G4T]:"T---/2G&FGI2+0TTTTXTTTBD:_AOQ)?\
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M )%[4_\ KTE_] -:%9^O?\B]J?\ UZ2_^@&M"@ HHHH **** "BBB@ HHHH
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M\A0@ J1USD\BJ&A_#O3]'U6'4Y]6UO6+JW!^S-JMZ9Q;Y&"4&  2..<UV%%
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MZ!^"#C/7&:;<?#C0I_#<&BQO?6X@N/M<=[#<D7*SG.9?,.<L<GK_ $&.NHH
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M*!D623;@N2!PP/8'TK2DTJD6^Z,J\7*E)+>S/&S2'I76GX>ZM_S\67_?;_\
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M  J[6_\ GZT__OX__P 11]8I?S#^KU?Y3AC3&[?6NZ_X5;K?_/UI_P#W\?\
M^(J.7X8:V@4FZT_E@O$C]S_N4?6*7\Q2P]3L<2::>E=T?A7KA_Y>M._[^/\
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MY%^Y^J?^AK6M63XE_P"1?N?JG_H:T 3:-_R#X_I6A6?HW_(/C^E:% !1110
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M%]F@_P">,?\ WR*/LT'_ #QC_P"^10!+147V:#_GC'_WR*/LT'_/&/\ [Y%
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MB@ HHHH **** "BBB@ J"Z^Y'_UU3^8J>H+K[D?_ %U3^8H0$]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5D^)?^1?N?JG_H:UK5D^)?\ D7[G
MZI_Z&M $VC?\@^/Z5H5GZ-_R#X_I6A0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KW_(O:G_ ->D
MO_H!K0K/U[_D7M3_ .O27_T UH4 %%%% !1110 4444 %%%% !1110 4444
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MK2*%;;QP,#C.?QK)U+X<:9?P:<(-3UC3;FQM4LTO-.N_)FDB4<*Y P1WZ=:
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MBL+/SOD89WY!P .,YQUXS0!VE%<#XGUK6==\)Z9J?@HM<Q7C"7:L;HY5#O\
MOAEV?<*%2#NW8R.M=CI+WDFDVLE^Z-=/&'D*0-" 3SC8Q)7'3!)Z4 7:***
M"BBB@ HHHH *PO&7_(J7O_;/_P!#6MVL+QE_R*E[_P!L_P#T-:TH_P 2/JC'
M$?P9^C_(\E/>HS4A[U&:]\^60QJC-2-49I&J&-WJ,U(W>HS2-$1FF&GFF&D:
M(C-1M4AJ-J1JAAZU$:E/6HC2-4,-1-WJ4U$W>D:Q&&HFJ4U$U2:Q&-7KWPX\
M9WNJHFB7\<L[P%&BN@,X4,/E<_R/?I7FV@>'K[Q+JJ6-C'DGF20_=C7NQ/\
MG->_Z+X;L/#&D0V5DF294,LS#YI6R.3_ $':N7$SC;E>YT4T]S?HHHKSC8**
M** "BBB@ HHHH **** "BBB@ HHHH **** "H+K[D?\ UU3^8J>H+K[D?_75
M/YBA 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_Y%^Y^J
M?^AK6M63XE_Y%^Y^J?\ H:T 3:-_R#X_I6A6?HW_ "#X_I6A0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH *@NON1_\ 75/YBIZ@NON1_P#75/YBA 3T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_Y%^Y^J?\ H:UK5D^)
M?^1?N?JG_H:T 3:-_P @^/Z5H5GZ-_R#X_I6A0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KW_(O
M:G_UZ2_^@&M"L_7O^1>U/_KTE_\ 0#6A0 4444 %%%% %.ZTNPOI1)=6D4S@
M;0SKDX]*A_X1[1_^@=;_ /?%:5%4IR6B9#IP;NTC-_X1[1_^@=;_ /?%'_"/
M:/\ ] ZW_P"^*TJ*?M)]V+V5/^5?<9O_  CVC_\ 0.M_^^*/^$>T?_H'6_\
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M[1_^@=;_ /?%'_"/:/\ ] ZW_P"^*TJ*/:3[L/94_P"5?<9O_"/:/_T#K?\
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M!UO_ -\4?\(]H_\ T#K?_OBM*BCVD^[#V5/^5?<9O_"/:/\ ] ZW_P"^*/\
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M'_H(?^08_P#XFCZI7_F_%C^NX;^3\$>F?\(]H_\ T#K?_OBC_A'M'_Z!UO\
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MOA_Y?P1Z]_PCVC_] ZW_ .^*/^$>T?\ Z!UO_P!\5X^?B#XH_P"@I_Y+Q?\
MQ--/Q"\4_P#04_\ )>+_ .)H^K5OYOQ8_;4/Y?P1[%_PCVC_ /0.M_\ OBH+
MG0-)5(\:?;C,BC[GO7D1^(?BK_H*?^2\7_Q-12?$+Q2X ;5,X8$?Z/%U!_W:
M/J];^;\6/VE#^7\$>T_\(]H__0.M_P#OBC_A'M'_ .@=;_\ ?%>+GXC>*_\
MH*_^2\7_ ,333\1_%G_05_\ )>+_ .)H^KUOYOQ8^>C_ "_@CVK_ (1[1_\
MH'6__?%'_"/:/_T#K?\ [XKQ,_$CQ9_T%O\ R7B_^)II^)/BW_H+?^2T7_Q-
M+ZO6_F_%E<U'^7\$>W?\(]H__0.M_P#OBC_A'M'_ .@=;_\ ?%>'GXE>+O\
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M(]H__0.M_P#OBM*BCVD^[#V5/^5?<9O_  CVC_\ 0.M_^^*/^$>T?_H'6_\
MWQ6E11[2?=A[*G_*ON,W_A'M'_Z!UO\ ]\5FZ]HNFVNC3S064,<JE-K*N"/G
M%=)63XE_Y%^Y^J?^AK1[2?</94U]E?<2Z+_R#X_I6C6?HW_(/C^E:%0:!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%) R2)M+*>02NTG/?-7-;UB\T+5/B!?6$BQ7?EZ;%%*X!6)I!LWG/'&[/X4
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MYM3T1'T^:,\EKB/Y$'ONRA_X%72>"= ;PWX2LK"8[KLJ9KI^[S.=SG\R1^%
M'0T444 %87C+_D5+W_MG_P"AK6[63XELKC4/#]U:VL?F3/LVKD#.'!/)XZ"M
M*32J1;[HRKINE)+L_P CQ\TPUT!\&:__ ,^'_D:/_P"*I#X+\0?] _\ \C1_
M_%5[?MJ?\R^\^:6'K?R/[F<\:::Z$^"O$'_0/_\ (T?_ ,533X)\0_\ 0/\
M_(T?_P 52]M3_F7WEK#U?Y7]S.=---=$?!'B+_H'_P#D:/\ ^*II\#^(O^@=
M_P"1X_\ XJCVU/\ F7WE*A5_E?W,YP]::>M=(? WB/\ Z!W_ )'C_P#BJ:?
MOB3_ *!W_D>/_P"*I>VI_P R^\M4*O\ *_N.;-,/6NE/@3Q)_P! W_R/'_\
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M^R?6KYXNG;K;;05FI?,HZYKOB^3QGX=>[5M*TN?4_(AM8I6#SJK %I.F00>
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M<?2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%U]R/_KJG\Q4]077W(_^NJ?S%" GHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LGQ+_ ,B_<_5/_0UK6K)\2_\ (OW/U3_T-: )M&_Y!\?TK0K/
MT;_D'Q_2M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQ+_ ,B_<_5/_0UK6K)\2_\ (OW/U3_T-: )M&_Y!\?TK0K/T;_D'Q_2M"@
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MAFBN(4FAD62)QN5U.01ZBGUY1[J=S/\ [.NO^@S??]\0?_&Z/[.NO^@S??\
M?$'_ ,;K0HH S_[.NO\ H,WW_?$'_P ;JS;6\L 827D]SGH90@V_3:H_6IZ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D?_ %U3^8KB<G)W9O:RL3T445(PHHHH **** "BBB@ HHHH **** "BBB@
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M;_8-A_=N/_ J7_XJC^P;#^[<?^!4O_Q5:5%/VD^[%[*G_*ON,W^P;#^[<?\
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M[MQ_X%2__%4?V#8?W;C_ ,"I?_BJTJ*/:3[L/94_Y5]QF_V#8?W;C_P*E_\
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M/=2,$5XW\+/AEK?AWQC=7^NQG[+IT3VVE,94<,C.Q+ *25X).#C[] &;\3M
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MBN)_L76_^@I??^!#?XT?V+K?_04OO_ AO\:+1[AS3[?C_P  [:BN)_L76_\
MH*7W_@0W^-']BZW_ -!2^_\  AO\:+1[AS3[?C_P#MJ*XG^Q=;_Z"E]_X$-_
MC1_8NM_]!2^_\"&_QHM'N'-/M^/_  #MJ*XG^Q=;_P"@I??^!#?XT?V+K?\
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M]BZW_P!!2^_\"&_QHNOYF.TOY5_7R.B_X1G0/^@)IO\ X"1_X4G_  C&@?\
M0#TS_P !(_\ "N>_L76_^@I??^!#?XT?V+K?_04OO_ AO\:+K^9A[W\J^_\
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MM'N'-/M^/_ .VHKB?[%UO_H*7W_@0W^-']BZW_T%+[_P(;_&BT>X<T^WX_\
M .VHKB?[%UO_ *"E]_X$-_C1_8NM_P#04OO_  (;_&BT>X<T^WX_\ [:BN)_
ML76_^@I??^!#?XT?V+K?_04OO_ AO\:+1[AS3[?C_P  [:LGQ+_R+]S]4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]UC./SZ5U.E_#+5KHA[^6*RC[KG>_P"0X_6O7:*PJ9E4E\*L=-+):,=9MO\
M#^OO,+0_".DZ#A[:#S+@#F>7YG_#L/PK=HHK@G.4W>3NSU:=.%./+!604445
M)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP?:'6/R=A+*2QVGT) //;@BKUG.T\3^8 )(Y&C?:, D'K^(P?QI!I]HKVSK
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MLR2Y+(J@/@*6_B( Z=_YT]]'LY(PC";/ WBXD#\9Q\^[=W/?FIVLK=HXXS$
MD2E44$@*"-N./:C0-3+;Q3IPNIH 79HE+?*R$M@9("[MW3U ''6I4UU&,@>Q
MNHBBN3YAC W+R5SOQG!!S]WWJ1M.T]9Y%Q-N=0'B6:0K@\ E <#IUQV/-/\
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MU@XEL8+A99"1!"A948I@-^[B'(QP=O?EAP:U'T.X?8[06DS9RHF=@83A?G7
MSN&WL1VY%='11SL+&/>:6T^J+<M;6LR84&64MYD0&<JH Y# \\CKR#TJ@NE3
M:AI$@,1<\0VZW)\L^4K9!8.C<G R&7G Z5T]%',PL<_#H4R20L\=H2(84=@
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img101536035_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;(&
M,;!" Y!VD]C45BKII]LL@=7$2A@[;F!P,Y/<^] $]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M935T)NQ[]17'> /'L'C6QFW0"VO[;'G1!LJ0>C*?3@\=J[&HE%Q=F,****D
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MHH **** "BBB@ HHHH YCXB?\D^UO_KV/\Q7'_ C_D7=4_Z^Q_Z *[#XB?\
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M_P"O2_%G2?["\#>'-+^T-<"UD:,2LNTL O'%6G!SBUOZ6%K8I_$/_DE?@O\
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M9^@JJ+2IRYMM >XSP2MWXR^+3>(8;/[-:QRM<3;>53Y2%7..6)_/DU8\>?\
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M]-TZVU.ZALI);4/ DA",&8 Y'O6;XN\6>)[#XIWVG:3?SMO=(+>V+DQAI(E
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MB-H/_7A#_P"@"K7B3_D5M7_Z\IO_ $ U5\%?\B-H/_7A#_Z *M>)/^16U?\
MZ\IO_0#7&_C^970\K^ 7_,P_]NW_ +5KGKWQAXOB^(>J:=I6I7,TCW\]K;02
M/N1<R%5P#P,#UX%=#\ O^9A_[=O_ &K69X/C#_'S420#LO;UAGZN/ZUV.WM)
MMKH3T11U]OB'X$O;74-0UJXE\\_*PN6EB)'.UE;COZ>N*W_BA=:EX@\"Z)KT
M$HBTZ6)6NK<.<&1L8X[X(;FMCXZ_\BA8?]?Z_P#HMZR/$7_)OFD_]L?_ $(T
MHRYE"=M;AW19^#>G:_#:1ZG<7X.@/!*L5N9C\CB3EMN,#HW.>]9UYXI\6_$7
MQ+/IOA2Y>QTZ G]\CF+*YP'=Q\W/8#\N,UUWPW@DNO@_#;PL5EEBN40CL2[@
M5Y)X$\+VOB/4[K3+O69=*O$QY<6SF4@D,O)'S#CCW/I0K.4Y/H'8ZG4H_B%\
M-O)U*?5CJ>GAPKJ\SRH,]F#<KGL1_7%>G/XWTU? @\5X8VQBW"+/S%\[=GUW
M<9_&O.M2^%.D:<\-OJ?C<V[3G;&DZJN\_0O_ )XJ_P",?!TN@?!^33;6[DO8
M[6Z%R7V;?D).> 3P"V:B7)/EUUOVL/5'.6EW\1/B3//=6%Y)9V*,5 BG,$2G
M^[QRQ^N?PK9T*W^*7AOQ#;V<R3:I:2<OYT_F1;0>?WC<H?0?H:Z#X.ZWIUSX
M+M]+CFC6^M7D$L)8!FW.6# =Q@@?A782>)M$BUF+2'U2V%_*,I#OY/MGH#Z
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MO2**/:S[AR(\W_X51_U&O_)7_P"SH_X51_U&O_)7_P"SKTBBCVL^X<B/-_\
MA5'_ %&O_)7_ .SH_P"%4?\ 4:_\E?\ [.O2**/:S[AR(\W_ .%4?]1K_P E
M?_LZ/^%4?]1K_P E?_LZ](HH]K/N'(CS?_A5'_4:_P#)7_[.C_A5'_4:_P#)
M7_[.O2**/:S[AR(\W_X51_U&O_)7_P"SH_X51_U&O_)7_P"SKTBBCVL^X<B/
M-_\ A5'_ %&O_)7_ .SH_P"%4?\ 4:_\E?\ [.O2**/:S[AR(\W_ .%4?]1K
M_P E?_LZ/^%4?]1K_P E?_LZ](HH]K/N'(CS?_A5'_4:_P#)7_[.C_A5'_4:
M_P#)7_[.O2**/:S[AR(\W_X51_U&O_)7_P"SH_X51_U&O_)7_P"SKTBBCVL^
MX<J/./\ A5/_ %&O_)7_ .SH_P"%4_\ 4:_\E?\ [.O1Z*/:R[CY4><?\*I_
MZC7_ )*__9T?\*I_ZC7_ )*__9UZ/12]I+N%D><?\*I_ZC7_ )*__9T?\*I_
MZC7_ )*__9UZ/11[20SSC_A5/_4:_P#)7_[.E_X55_U&O_)7_P"SKT:BCGD!
MYS_PJK_J-?\ DK_]G1_PJK_J,_\ DK_]G7HU%+GD.[/.?^%5?]1G_P E?_LZ
M/^%5?]1G_P E?_LZ]&HHYF',SSG_ (57_P!1G_R5_P#LZ7_A5?\ U&?_ "5_
M^SKT6BCF8^9GG7_"J_\ J,_^2O\ ]G1_PJO_ *C/_DK_ /9UZ+12YF'/(\Z_
MX59_U&?_ "5_^SH_X59_U&?_ "5_^SKT6BB['[21YW_PJS_J,_\ DK_]G1_P
MJS_J,_\ DK_]G7HE%%P]I+N>=_\ "K/^HS_Y*_\ V='_  JW_J,_^2O_ -G7
MHE%(?M9]SSO_ (5;_P!1G_R5_P#LZ7_A5O\ U&?_ "5_^SKT.B@/:S[GGG_"
MK?\ J,_^2O\ ]G1_PJW_ *C/_DK_ /9UZ'10/VT^YYY_PJ[_ *C/_DK_ /9T
M?\*N_P"HQ_Y*_P#V=>AT4K(/;U.YYY_PJ[_J,?\ DK_]G1_PJ[_J,?\ DK_]
MG7H=%%D/V]3N>>_\*O\ ^HQ_Y+?_ &='_"K_ /J,?^2W_P!G7H5%'*@^L5.Y
MY[_PJ_\ ZC'_ )+?_9T?\*O_ .HQ_P"2W_V=>A44N5#^LU>YY[_PJ_\ ZC'_
M )+?_9T?\*O_ .HQ_P"2W_V=>A44<B#ZS5[_ )'GW_"L/^HQ_P"2W_V='_"L
M/^HQ_P"2W_V=>@T4<D1_6JO?\CS[_A6'_48_\EO_ +.C_A6'_48_\EO_ +.O
M0:*7)$/K=;O^1Y]_PK#_ *C'_DM_]G2_\*Q_ZB__ )+?_9UZ!11[./8?UNMW
M_(\__P"%8_\ 47_\EO\ [.C_ (5C_P!1?_R6_P#LZ] HH]G'L'URM_-^"//_
M /A6/_47_P#);_[.C_A67_47_P#);_[.O0**7LH=A_7:_P#-^"//_P#A67_4
M7_\ );_[.E_X5E_U%_\ R6_^SKOZ*/90[!]=K_S?@C@/^%9?]1?_ ,EO_LZ/
M^%9?]1?_ ,EO_LZ[^BCV,.P_KU?^;\$<!_PK/_J+_P#DM_\ 9T?\*S_ZB_\
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M/&W_ $&__)6'_P"(H_X6QXV_Z#?_ )*P_P#Q%'U2?=!S(^G**^8_^%L>-O\
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M /)6'_XBCZI/N@YD?3E%?,?_  MCQM_T&_\ R5A_^(H_X6QXV_Z#?_DK#_\
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M2L/_ ,11]4GW0<R/IRBOF/\ X6QXV_Z#?_DK#_\ $4?\+8\;?]!O_P E8?\
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M^$DFOZMH=I?RVUPY&^)=\AW *I;!.,GW'M7F'B#5+?6=:N+ZUTV#3H),;+6
M *@  [ =>O0=:TC/F;5MA6+UEX-U&^\(7GB:*:U%E:N4=&9O,)^7H-N/XAWK
MGJ]9\._\D!U__KX;^<=:4W_"+^&_AOX<UR^\,V>H74D:HJ[%3S&922SG:=W
M/4'D_C6?M6FU:^MAV/%**]U\4+X)\*OIFO-X8@N7U1%"6V L,:8!9]F"N[#+
MQCMVY)I:]X5T:P^,/A^*WL+<65^A>6U,8,18!A]T\ =./44U73Z?T@L>+T5[
M_;)X,F\?WW@]?"EGN9&=[ID7[^T,508R@P>"".1T[U!X>L?!>IZYJW@J'PY$
M191N#?38::1@P5B&QE<$\8/X"E]8\@Y3P>BO4/ >B6$WAKQLMU8VUU/9PLL,
MDL*NR$))RI(R#D#I3/A5I>GZCH_BE[ZPM;IX+96B:>%7,9VR<KD<=!T]*MU4
MK^06/,J*]=\#V'AU?A5J.KZUI$-X+:Z9BPC'FL!LPH?J!D^O<U-J4'AOQC\+
M-1UVQ\/VVD7=@Y %NJCD;3@E0NX%6[C@TO;:VMUL%CQRBO>M"\&6V@^$=-N+
M;PC;^(]1O$66X-Q+$HC##/'F9'&0, <\Y/2N,^+/A.Q\/WNGW^G6IM(K]&,E
MMD%8I%QD#!(_BZ#CCBE&O&4N4+'*^%/"E]XPU233]/EMHI8X3,3<,RK@$#L#
MS\PKKV^!OB=5)%[I+$=A-)D_G'2_ W_D=KO_ *\'_P#0TKIM%^&VFV/B!O$T
M/BI;R&SN&FD2S@W$$$DJ2KL?J,9Q45*KC)J]OD-(\8U72KS1=3GT[4(3#=0M
MAT)S[@@]P1S5.O7K"#2_BC\5[J[>-CI5K;@[3E3.%PHSW ).?7 %=9-X,L?$
M=KJ%A>>";?0PBG['>P20EG/8D1\CL<'(Z\U3KJ-E):]16/G6BO9_ WA:VN/
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MU.UL(619;F9(4+DA06( SCMS7I?Q9\-V&F:7HNIP:7#IM[<@I=6]N (PVT'
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M8+?[,AC&QT7>%QC)Y.?>J7@+0-#BTS7_ !3K=FMW;:?*Z16Q4%<CD_*>">5
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MAB<;2>!T/>N'\.W<%AXFTJ\N7V007<4DCX)VJK@DX')X%9E%.,%&/*@N=?\
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M_P"SII'B0#8)A"VYE'0+D9Q5:]3P-XGO3K%QKMSHMS<-YEW9&S:8%S]XQLO
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MW0X/3IZFMJ\\"V&GVLD%YXIL8-<C@\]].>,A1QG9YQ.W?CMZ_G6;XHU:TO\
M^P6LIO,:TTR&"7Y2-LBDY'(YZCD<5NZW/X*U^[N?$5UK%]%=7$89]*BMCO\
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M2-1-[;WCM<%C"T9C9F)*8;KCU]ZWI;SPCXBM=-U#5]5NK&\LK6.VGLH[8O\
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M?6WV#E/EG^Q=5_Z!E[_WX;_"C^Q=5_Z!E[_WX;_"OJ;_ (1JS_NBC_A&K/\
MNBG]<EV#E/EG^Q=5_P"@9>_]^&_PH_L75?\ H&7O_?AO\*^IO^$:L_[HH_X1
MJS_NBCZY+L'*?+/]BZK_ - R]_[\-_A1_8NJ_P#0,O?^_#?X5]3?\(U9_P!T
M4?\ "-6?]T4?7)=@Y3Y<DTK690@DL+]PB[5W0N=J^@XX')IG]BZK_P! R]_[
M\-_A7U-_PC5G_=%'_"-6?]T4?6Y=@Y3Y9_L75?\ H&7O_?AO\*/[%U7_ *!E
M[_WX;_"OJ;_A&K/^Z*/^$:L_[HH^N2[!RGRS_8NJ_P#0,O?^_#?X4?V+JO\
MT#+W_OPW^%?4W_"-6?\ =%'_  C5G_=%'UR78.4^6?[%U7_H&7O_ 'X;_"C^
MQ=5_Z!E[_P!^&_PKZF_X1JS_ +HH_P"$:L_[HH^N2[!RGRS_ &+JO_0,O?\
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M4']BZK_T#+W_ +\-_A7U-_PC5G_=%'_"-6?]T4OK;[!RGRS_ &+JO_0,O?\
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MJS_NBC_A&K/^Z*/KDNP<I\L_V+JO_0,O?^_#?X4?V+JO_0,O?^_#?X5]3?\
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M\*/[%U7_ *!E[_WX;_"OJ;_A&K/^Z*/^$:L_[HI_7)=@Y3Y9_L75?^@9>_\
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M%?4W_"-6?]T4?\(U9_W11]<EV#E/EG^Q=5_Z!E[_ -^&_P */[%U7_H&7O\
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MHNK:]O\ .QZ#17S[173]4\SQO[>_Z=_C_P  ^@J*^?:*/JGF']O?]._Q_P"
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MOGVBCZIYA_;W_3O\?^ ?05%?/M%'U3S#^WO^G?X_\ ^@J*^?:*/JGF']O?\
M3O\ '_@'T%17S[11]4\P_M[_ *=_C_P#Z"HKY]HH^J>8?V]_T[_'_@'T%17S
M[6KHFI#2YXYU0&7[0@#8Y *2 C/H<C\A4SPW+%RN;8?./;58T^2U_/\ X![;
M1533KDW5FDIZD5;KE/;"BBN>\;DCPA?8/_//_P!&+3BN9I&=:I[.G*?9-_<=
M#17S[177]4\SPO[>_P"G?X_\ ^@J*^?:*/JGF']O?]._Q_X!]!45\^T4?5/,
M/[>_Z=_C_P  ^@J*^?:*/JGF']O?]._Q_P" ?05%?/M%'U3S#^WO^G?X_P#
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M44 %%%% !1110 4444 %%%% !1110 5QOQ)_Y%^W_P"OI?\ T!Z[*N-^)/\
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MK0_^1GB_W%_F:]UM_P#4)]*\RO\ Q&?:97_ND/G^;)****R.\**** "BBB@
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MM@U=(+CR/LWDRQD#<#S]WG![>E5;?6]%CMKW2I8+U]*G<2QME?.C? S[=O\
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M!?+/(ZYYZ 5=/B;0Y-336Y+"[_M15'[M77R2X& V>OZ5QP!8@ $D\ "M'4=
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MU8W-F;:QT2VL@S[WDW>8_P! Q&5'L*GDES)FSQ%#V4HZ-N_2U^S6GZH[X?\
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M?76WZFLQT_PWHND2OIEM>27J^;.\Z;R%XX7/ .#^E/T"PTK4KS5M4CM8(K>
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MND7E@!?E!.../J*S-'FM=:MM:GETNPA,%D?+6*  *?F.[GOTY]JH_P#"7?\
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M/^^11_P@\/\ <3_OD4?6EV#^PJG\Z/-**]+_ .$'A_N)_P!\BC_A!X?[B?\
M?(H^M+L']A5/YT>:45Z7_P (/#_<3_OD4?\ "#P_W$_[Y%'UI=@_L*I_.CS2
MBO2_^$'A_N)_WR*/^$'A_N)_WR*/K2[!_853^='FE/7K!_U\I_Z"]>D?\(/#
M_<3_ +Y%9/B#PPFG6]G*@49NE!P,?P/43Q"G%Q2-\/E4\/5C5<D[/_@'=:%_
MR"XO]VM.L[1!MTV(>U:-<A[X5SWCC_D4+W_MG_Z,6NAK+\01+/I:Q.H9'N;=
M65AD$&9,@U4':29CB8\U&<>Z?Y'B-%>HW/@NVDF+)#$JGLJ 5#_P@\/]Q/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB#[Y[<]O>JB['-B*4II<IP6GZ7>:I-Y=I"7Q]YNBK]379Z;X(M(,/?2&X?\
MN+\J#^I_2NEMK:&T@6"WB6.->BJ*COY6@LI73[P& ?2B[8H8:$%>6H^VL[:S
M39;01Q+Z(H&:FJ"RC\JTC7<6R,Y)SUYJ>I.F.PUT61"CJ&4\$,,@UD0W::?J
M[:?@+;O@Q =$)'3Z9K9KC==EWZO+M/W,*"/I515SFQ53V<5);W.RHJ&TE,]G
M#*>KH&/UQ4U2=*=U<*S]>_Y%W4_^O27_ - -:%9^O?\ (NZG_P!>DO\ Z :J
M/Q(BM_#EZ,Y72(S+IEP@ZE#CZXXK5\+7.^ H3TJCX<_U!I-#;[)K%Q;'@+(0
M![=OTI,T.TK.F_Y&.S_Z])__ $.&M$<BLZ;_ )&.S_Z])_\ T.&B.YG5^'YK
M\T:-%%%(T"BBB@"AJ^IKI=EYH3S)G81PQY^^QZ#Z=ZYIK26\;S=1N)+B0\E
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M/_K\7_T!ZJ.YG5^'YK\T8: VEY:7(X61<'ZC_P"MBO0+602VZL.XKB;B'S=
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M&]=?#_J5^E5+<SI?#\W^;'T445)H%%%% !1110 4444 %%%% !1110 4444
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M8]&==.K7;7-"R?GJO7_@&S1156_N3:V^\$9R.OIGFH.HM451CO&!^;D5*U]
MF/,?9GN1Q^?2@":;_5-]*PK-F,4@RP(D8 UN&1'B+*ZLOJ#D5E*@0$#NQ- %
MZQN7E4QR_P"L3^+LP]:MUE1R&-@0:THY!(N1U[B@!]94MP9II0/N*=H/KZUH
MS-LB8^U92H(QM'U/U[T &2L\#@XP^#^(K8'(%8Y&9(O]_P#I6P.@H 6BBB@
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MYFMF@ HHHH *\Z\8Z/?>&-;/COPW 9)%4+K&GITO(!_&!_ST4<Y]/Q!]%HH
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MIL4@WR!<Y/K_ ("LX1E4E=G76K0PM+ECOT1T?@:RFEM[W5)<[[F3Y<]^I/\
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M!_.MVMJ[M)07V=/\_P 3FPB;@ZKWD[_+I^%OF%%%%8'4%%%% !1110 4444
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MCK5S]JU:XD!R-Q ^@X_I26FC6'B:PO=!U.,O;74>05X:-UY5U/9AS_\ JIV
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M_CW7_>_H:MU4U#_CW7_>_H::W S:***LD**** "BBB@ HHHH **** "BBB@
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MVW_HF6G'<SJ_#\U^:-&BBBD:!5#6F*Z-<E<YV8X]S5^H;J 75I+ W212OTH
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M_(Y0?]>L?_H;UU\/^I7Z54MS.E\/S?YL?1114F@4444 %%%% !1110 4444
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M5C(M[(TRQ06<WDR32L%3< "<$GMG'UIUC:V%JDUW:%2MR?-DG,IDW\<'<2>
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M^]4O#NIF)C:3Y5U."#V-;%N<V\9_V16%XBM?(:/4H?E<,%DQW]#7I09QM'9
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MUZQ_^AO77P_ZE?I52W,Z7P_-_FQ]%%%2:!1110 4444 %%%% !1110 4444
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M6M!EFBBBLP"@ DX'6BM*TM?+ D<?.>@]*3=@'6ML(5W-]\_I5FBBH*"BBB@
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M,XR=H'UR*TP,  5S6LW!U*\CL+?YHXVS(PZ%O3\*]:*.-LU/"@(L^:@\>?\
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MWK\=I"T0;*P\D#^)^PKQ6:9[B=YI#EW.XFM7Q%J[:K?MM<F&,G:?[Q[M6/3
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MKYIU?Q7'!JQ6<M/([%KB3.2"?YFG&$8[(4ZLY_$[G=>$(P;NYD(Y5 !^)_\
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MC3C%R=D-)O8Z[09FGT*S9W+R+&(W8G.67Y3S]0:T:Y*R\8Z;:P)$VE7]E O
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MGID=JU*@M(1!;J@["IZW,PKE?'G_ ""+/_K\7_T!ZZJN5\>?\@BS_P"OQ?\
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MI;F=+X?F_P V/HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH *SM1_X_\
M2/\ K[;_ -$RUHUG:C_Q_P"D?]?;?^B9:<=S.K\/S7YHT:***1H%(2 "3T%+
M2,H92IZ$8- '@WC[6'U'6FBW'8IW$?R'X"N2KUG6/AA+>ZA)<1SGYSR0PY_
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M>?,(K8@9QW<_P@9_^M7(X34K1.>5-WT1-H^OZ5IVE06EQ<^5+$S1E#&V<AB
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MCK**JV.HV>IVXGLKF.>(_P 2-G'U]*M5BU;<SV"BBB@ HHHH **** "BBB@
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M//\ D$6?_7XO_H#UU5<KX\_Y!%G_ -?B_P#H#U4=S.K\/S7YHAMIQ;:.9C_
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MVZTB3R+E6E@'"MW45JP:A9W";X[F/'<%L$?7-:UU80W:X=0:Q9?"L#2;EX%
M$MBZW>IF6+YHT7:&]?6N@JI8V,=E$$05;H **** "BBB@#C=>_Y'*#_KUC_]
M#>NOA_U*_2N0U[_D<H/^O6/_ -#>NOA_U*_2JEN9TOA^;_-CZ***DT"BBB@
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M<YX<_P!0:VGK%\.?Z@UM/31;,G69?*TR7'5_D'X__6S3O#]OY6IV1QUM)_\
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M$?E7FQZ5WMY,8_![20=[=0".P.,TI4E';J*5-1T74EE\::;:SF-$EF"G!=
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M[*YCGB/\2-G'U]*Y:W-V,*ER&#0M)MF5HM.M59>C>4"P_$\UH445SF04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '"?%:%F\-6\X'$-RI/X@U1@
M(DACD'1E!'Y5VGB32AK7AZ\L<?/)&2G^\.1^M><>%[LSZ=]DEXN+4F-U/7 Z
M5V4G>G;L;Q=X>APNLHT>M7JMU\UC5*NN\:Z2\<R:E$I*.-LN.Q[&N1KOIRYH
MIG;!WBF%%%26]O+=W$=O A>61MJJ!5E'KWA%FF\+V#-R?+V_D2*Z*.+) />J
MNCZ<--TJULQSY,84GW[UIG;!"\SG"HI8GV S7DSE>3L>;)W;L<E\,U(BURV!
M^6.[X_4?TKO(X"K;F[=!7$_"R-GTO4;YAQ<W1(/J!_\ KKO:FN_WC%62=1LI
MQZI92V$E\DW^CQ;M[E2"NWKD$9_2EM-2M+Z22.WE+O&J.P*,N PRO4=Q7,7T
M$B:M<:&BGRM2G2X!'0)R9!^:C_OJFZS>W4)\2B*YFC$"VWE!9"/+SC.WTS[5
MQ.JUO_6YV+"1EI%[V:]&TOU?W':45R<S-HNI:+Y^J73P3/*TSW,WRYV# /0
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M^+G+$>W &?K7K%16UM#9VT=M;1+%#$H5$08"@=JEJ:D^>5R*D^>3D%9^O?\
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MZ]X8M$2[U73[E[&=%:258P&CD(&>5/0GU%5[;0O$C6T;?:]-5F4')1^/P_\
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MONV_]')6C6=K7_'C%_U]VW_HY*J/Q(SK?PY>C-&BBBI- HHHH **** ,W4]
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MW;=VU0<;B1TQ0DWL*Q?HJ&UG^U6D-QY4L/FH'\N9=KID9PP[$=Q4U( HHHH
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M &?S2X\O?OQM8KUP/3TK5K.47%M,S:L[,*S]>_Y%W4_^O27_ - -:%9^O?\
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MI7(:]_R.4'_7K'_Z&]=?#_J5^E5+<SI?#\W^;'T445)H%%%% !1110 4444
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M!8[=P!^]3C.P9Q@\=*V+OX?>%[Z\FN[G3-\\SF21OM$HRQ.2<!L5>C\+:+$
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M2!=;+-(V5+&P%TDQ90WSN2"JGH"!TYKL]2\)Z%J^H)?7^FQ37*8 <DC..FX
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M "BBB@ HHHH **** "BBB@ HHHH *YGQM_R#K'_K\7_T6]=-7,^-O^0=8_\
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M$?\ "#P_W$_[Y%'_  @\/]Q/^^17;T4<S[A[&G_*ON.(_P"$'A_N)_WR*/\
MA!X?[B?]\BNWHHYGW#V-/^5?<<1_P@\/]Q/^^11_P@\/]Q/^^17;T4<S[A[&
MG_*ON.(_X0>'^XG_ 'R*/^$'A_N)_P!\BNWHHYGW#V-/^5?<<1_P@\/]Q/\
MOD4?\(/#_<3_ +Y%=O11S/N'L:?\J^XXC_A!X?[B?]\BC_A!X?[B?]\BNWHH
MYGW#V-/^5?<<1_P@\/\ <3_OD4?\(/#_ '$_[Y%=O11S/N'L:?\ *ON.(_X0
M>'^XG_?(H_X0>'^XG_?(KMZ*.9]P]C3_ )5]QQ'_  @\/]Q/^^11_P (/#_<
M3_OD5V]%',^X>QI_RK[CB/\ A!X?[B?]\BC_ (0>'^XG_?(KMZ*.9]P]C3_E
M7W'$?\(/#_<3_OD4?\(/#_<3_OD5V]%',^X>QI_RK[CB/^$'A_N)_P!\BC_A
M!X?[B?\ ?(KMZ*.9]P]C3_E7W'$?\(/#_<3_ +Y%'_"#P_W$_P"^17;T4<S[
MA[&G_*ON.(_X0>'^XG_?(H_X0>'^XG_?(KMZ*.9]P]C3_E7W'$?\(/#_ '$_
M[Y%+_P (1#G[B?\ ?(KMJ*7,^X>QI_RK[C,TG3?[/AV9K3HHI&@50U/3+;4H
M0L]O%*5SM,B!MN>N,]*OT47L)I-69Q3>"(2Q(CC _P!T4W_A!X?[B?\ ?(KM
MZ*KF?<CV-/\ E7W'$?\ "#P_W$_[Y%'_  @\/]Q/^^17;T4<S[A[&G_*ON.(
M_P"$'A_N)_WR*/\ A!X?[B?]\BNWHHYGW#V-/^5?<<1_P@\/]Q/^^11_P@\/
M]Q/^^17;T4<S[A[&G_*ON.(_X0>'^XG_ 'R*/^$'A_N)_P!\BNWHHYGW#V-/
M^5?<<1_P@\/]Q/\ OD4?\(/#_<3_ +Y%=O11S/N'L:?\J^XXC_A!X?[B?]\B
MC_A!X?[B?]\BNWHHYGW#V-/^5?<<1_P@\/\ <3_OD4?\(/#_ '$_[Y%=O11S
M/N'L:?\ *ON.(_X0>'^XG_?(H_X0>'^XG_?(KMZ*.9]P]C3_ )5]QQ'_  @\
M/]Q/^^11_P (/#_<3_OD5V]%',^X>QI_RK[CB/\ A!X?[B?]\BC_ (0>'^XG
M_?(KMZ*.9]P]C3_E7W'$?\(/#_<3_OD4?\(/#_<3_OD5V]%',^X>QI_RK[CB
M/^$'A_N)_P!\BC_A!X?[B?\ ?(KMZ*.9]P]C3_E7W'$?\(/#_<3_ +Y%'_"#
MP_W$_P"^17;T4<S[A[&G_*ON.(_X0>'^XG_?(H_X0>'^XG_?(KMZ*.9]P]C3
M_E7W'$?\(/#_ '$_[Y%'_"#P_P!Q/^^17;T4<S[A[&G_ "K[CB/^$'A_N)_W
MR*/^$'A_N)_WR*[>BCF?</8T_P"5?<<1_P (/#_<3_OD4?\ "#P_W$_[Y%=O
M11S/N'L:?\J^XXC_ (0>'^XG_?(H_P"$'A_N)_WR*[>BCF?</8T_Y5]QQ'_"
M#P_W$_[Y%'_"#P_W$_[Y%=O11S/N'L:?\J^XXC_A!X?[B?\ ?(H_X0>'^XG_
M 'R*[>BCF?</8T_Y5]QQ'_"#P_W$_P"^11_P@\/]Q/\ OD5V]%',^X>QI_RK
M[CB/^$'A_N)_WR*/^$'A_N)_WR*[>BCF?</8T_Y5]QQ'_"#P_P!Q/^^11_P@
M\/\ <3_OD5V]%',^X>QI_P J^XXC_A!X?[B?]\BC_A!X?[B?]\BNWHHYGW#V
M-/\ E7W'$?\ "#P_W$_[Y%'_  @\/]Q/^^17;T4<S[A[&G_*ON.(_P"$'A_N
M)_WR*/\ A!X?[B?]\BNWHHYGW#V-/^5?<<1_P@\/]Q/^^11_P@\/]Q/^^17;
MT4<S[A[&G_*ON.(_X0>'^XG_ 'R*/^$'A_N)_P!\BNWHHYGW#V-/^5?<<1_P
M@\/]Q/\ OD4?\(/#_<3_ +Y%=O11S/N'L:?\J^XXC_A!X?[B?]\BC_A!X?[B
M?]\BNWHHYGW#V-/^5?<<1_P@\/\ <3_OD4?\(/#_ '$_[Y%=O11S/N'L:?\
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M)I?^$:L_[HH_X1JS_NBC0+5.Z^[_ ((G_"7Z'_S]R?\ @-+_ /$T?\)?H?\
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M_P!T4?\ "-6?]T4:!:IW7W?\$3_A+]#_ .?N3_P&E_\ B:/^$OT/_G[D_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5MBMH2ELR*DP,>/+5.!DG?DGJ  /K19=PN=#+J%K%9M=-(3"K;,HA8EMVW
M&2<\<4EIJ-O>NZ1>:KH 626%XFP>APX!(X/-946CYT?3;$6IMXPZO<K&PC*D
M*3G*'J6 Y!JK>Z'.(I(HXKF>(SY=A*DDLT>T[5/G$@A6)X/UZT6079U-1M/&
MMQ' 6_>R*S*N.H&,G]1^=85KHT\,]M"RL;7R4\YGD!.49F5,  8RPZ#&%Q5C
M4["XO;J0",F%HXX<[@/E+YD[Y^Z *+(+FS17+/H4\0\VTLTBGW7#H5*C9D;$
M7KP"#O('&1SS4@\/+%<@P6:(J7,1C8,,JB+DO]6;Y2>I&,\467<+G2T5RR:9
M?W-O!#/:-$JQB.0M(N7+R!IF^4GLO'.?F[4DFCS)+(3I27%N\DICM=Z!(V.T
M*Y!..0I.1D@L>,FCE7<+G137UM 9Q+*%\B,229!^53G'U^Z>.M5_[;L!;M,9
M)0%<1E#;R"3<1G&S;NZ<].G-5K2WOM/M;R4PFZN@J)$N\ RA4 ')/&6+'FJZ
M0WH\F];3[E[J.??,CM$ID!1E^0!R %R.">F>IZED%S7_ +1L]UHOVA";O_4
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M]*+*P&Y1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img101536035_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC5RCI(NUT;K@CZ$=*F5&I%7DM!J<6[)FS117S=X[N[[Q3XW\1364\@M])@.
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M2>/2=1BNGMS^\5,@CWY R/<<5RO@'QWIGB71XM'D-W/>VNG!KQ[A<B3 "O\
M-DEB2>_6J/PK?P6VI:D/#$.H+<&-3*UYCY4SPJX/K_(4W1Y5+F3NA<]VK'J%
M%<?XH^)?AWPG=_8[R6:XNP 7@M4#LF>F[) 'TSFKOA7QOHGC"*0Z9.XFBYDM
MYEVR*/7&2"/<$UFZ4U'GMH5S*]KG1T5R%Y\2_#FG>([G1+V>:WGM@3)+(@$?
M"[N#G)..@QR>*S]*^,7A;5M7BTZ/[; \SB..6>("-F)P.0Q(R?4"FJ%1J_*'
M/'N=_17C_P 8O'36*)H.E7E[::E#,DLTL#F,;"A^7<#D_>4X]JZ/X<^/=/\
M$6GVNDB2[DU&TL4>YEN!PQ7:K'=DDG)ZFJ>'FJ:J"]HN;E.]HKSN^^-7A.RO
MWM5-[=*K;3/!"IC_  )8$CW KL]$URP\1:7%J6F3&6VDR Q4J01U!!]*B5*<
M%>2L-2B]$S1HK+U_Q%I?AG3_ +=JUR((2VU?E+%FQG  [\5Q=O\ &[PG/>+
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MQ.$/F W,BQF-E7J<#)#^F#CK5_5XQBG.5F^A/M&WHKGLU%9FN:_IGAO36O\
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MQ'-<)<7MTZM,\8(0!0=JC/)QD\^_2HKSA*G=M.7E^HX)J6BT,7XZ?\B);_\
M80C_ /0)*@T7_DW67_L'W/\ Z&]=)\2/"E]XQ\-1:;I\MM%,ETLQ:X9E7:%8
M=@3GYAVJ/3_"&H6GPI?PM)-;&^:UFA$BLWE;G9B.=N<?,.U1&I%48QOKS%.+
MYV_(X'X*^&]&UG3-6N-3TVVO)%E6)3.@<*I7)P#P#[]:H_!B"-?B!K-F5#6_
MV&9"C#(8"6,8.>O!->B_#'P7J7@O3K^WU&>UE>XF5T-N[,  ,<[E%9O@#X=:
MOX5\8:AJ]]<V,EO<021HL#N7!:16&05 Z*>]:SK1;J:[VL0H-<NAP5MI>GM\
M>VTXV%J;'[8Z_9C"OE8\LG&W&,9]JN_&UFC\2Z+I,, 2QAM%,-O'A$R7*D #
M@<*H]JZV#X<:Q'\6#XJ-S8_83<-+Y8=_-P4*]-N,Y/K6Y\0O $'C:QA:.9;;
M4;;/DS,N58'JK8YQGOV_&G[>"JP;>EOQ#D?*UYGE_B?2?%'B+3+2RB^'\>F_
M9GRDEJ@!VXP5/MT/X5H_%ZZU*'P5X1LKSS$DE@WW:LW/FK&@P?4Y9JU;#PE\
M5 T%E/XGA@LX&7$HD+L0,?[(9NG1B,UW/C3P=;>,]!^P7,HBN(V\R"X5,['Q
M@\9Z'N,^GI2=:,9PO:R[7#D;3*/@WPAX<C\(Z-*NE64TC00W)G>)6=I" V[<
M1GK^72N*^/5C:Q6NE7D=K"ES-*ZRSK& [@*,!FZG'O46G_#SXDV$<>E6_B*&
MVTY&#!H[E\*,YX&W/X< UWGCWP7+XR\,0V0NHTU"W821S,I5';&&! S@'\<<
M=:A25.LIN=T-IR@U:PG@S2-,M/ >G7UKIUI#=S:6GFSQ0JLDF4!.Y@,G)YYK
MSCX!_P#(<UC_ *]D_P#0JZ[P!X8\:Z$9K'6;VWDTE;5X8(1+NV.2,$?+G'7J
M>_2CX8_#S5O!>I7]QJ-Q92I<0JB"W=V((.>=RBFY1C&HN:][6!)MQ=CA/A19
M6WB3XA:E=:U!'=3"&2X\NX4./,+J"2#UQD_G3M<MH?#GQWL8]%C6!6NK?,,/
MRJOF;0Z@#H"">/>NH\0_"S6;3Q-+K_@S48[2:5F=H&8H5+?>"G!!!/8XQ5KP
M7\+[ZP\1'Q'XHOH[W40Q>-$8N ^/OLQ R1V &!QS6KK0NZG-HU:Q*A+X;==S
MCOB]"EQ\4K""4;HY(($89QD%V!J]\:O#FCZ+I^BR:7IUM9L7DC8P1A=X 4C=
MCJ?<\\UTOC?X<:QXE\<6>MV=S8QVT*1*RS.X<[6). %([^M:?Q.\$ZEXULM/
MATV>TB:VD=W-R[*"" .-JGTJ85XIT]=%N-P;YM#$\3^$-1\8?"WPPVFLKW=K
M90R>2S!?-#1+G!/&>!U]ZP?#GC:#1]6TS1_%_A:VM;FS*I!>"W"21<;0S*1R
M/<'WP:[;7?!WB:Y\*>'['1M=2QO-*@C1U1F5)75 N=X&<#!P"O.>:YF/X9>+
M?$VNVEYXSU6WEM[;"[8R"[J#G: % &>Y/-*G.#@U-JVOJ$D[W2U/9J^=?B3X
MDMY_BO#).C3V6DR11M$A^_M.]Q^9*_A7T2V[:=H!;' )P,UYIX!^'>K^'O%E
M_KVMW5E<3W".%^SN['>[!F8[E'I^IK##3A3YIR[&E1.5DCRS6/'%M>_$FT\5
MV%I+;"-XFFC=@2VWY6Z>J "NK^/<B2W.@21L&1X965AT()3!KNOB;X'NO&NF
M6,=A+;17=K,6#7#,%V,/F&0"<Y"]JYKQ-\,/$OB#0/#MFUYI@NM,MW@F=Y9-
MK#(";3LR?E49R!S75"M2<H3VM=&3A*TD=KX/\(:'HFC:;/::;;_;! KFZ9 9
M69E^8[NHSD\=*\)\(7NJW/BS4-3@\/1Z]?MND>.?YO++-R^#W[9[9KZ8T^W>
MUTVUMY"I>*%$8KT)  XKRO7OA;K5CXEEU[P7J4=G+*6=H'8IM)Y(4X(*D\X.
M *QH5E>2F]^Y<X.RMT,WP7HGB6/XK)K=QX=DTFQN1()TC $: QG^;@'ZFO1_
MB)#+/\/=<2$D,+8MQZ*03^@-9W@K1/&MEJ5Q?>*-<BNDEBV+:IR%.<[N JJ>
MHX!SGVKMW19$9'4,K#!4C((K*M5_>*6FEMBH1]UKN>2_ 2[MV\/:I9!E^TI=
M"5E[[&0 '\U:O6MPW;<C=C..]>,ZM\']8TO67U+P9JPM0V2(GE:-TS_"K*/F
M7ZX_&M?P1X \36'B4>(/$>NR27"QF,1),93(I_A<L,!1UP._<8K2O&G-NHI;
M].I,'**46CB["WB\0_'ZY@UB,31+>3J(9?F5A&K; 0>HPH./:D^,%A9^'?&F
MF7>C11V=PT*S%+=0@#JYVL .A./TKMO&WPPO=3\0+XC\-7T=EJ60TBN2@+#^
M-6 .#C&1C!JAH/PKUO4/$L6N^--1CNWB*LL"N7+D= QP %![#.:WC6A=5.;1
M*UB'"6L;==S)^/A9KK0&9=K&&4E?0Y3BG_$OPQHND_#/1KNPTVWM[GS85:9$
MP[AHV)W-U;D \UU7Q/\  &J^-;G39--N+*(6J2*_VEV7.XKC&U3Z5?\ '/@W
M4?$W@FPT6RFM8[FWDB=VF9@A"HRG!"D]3Z5G3K14::OM>Y4H-N6AQ%KX6T0_
M :34SIL!U!H&F-R5S(&$A PW4# Q@<5'X#=C\#O%BDDA6GP/3]RE=[#X.U"/
MX3GPJ9K7[<;=HO,#-Y62Y;KMSC!]*S/#/P^U;1OAUKGAZXN+)KN_,AB>-W,8
MW1JHW$J#U!Z T>VBXR3?VOP#D=UIT.5^"WAK1=:TK5YM3TVWNY%D6)3,F[:I
M7)QGH?<<UB_!W0M,UCQ;>QZE9Q7<=O;%XTF7<N[>!DKT/!/6O4OACX+U+P7I
MU_;ZC/:RO<3*Z&W=F  &.=RBLWX;_#K5_!^OWU_J%S8RQ3P&-1;N[,#N!YRH
M]*J==?O+2WM82@_=T.*\/VD&E?M!_9+*,0VZ74ZK&O 53$QP!Z4VPMXO$/Q^
MN8-8C$T2WDZB&7YE81JVP$'J,*#CVKM[7X=:O!\6F\5M<V)L#/))Y8=_-PT9
M4<;<=3ZTWQM\,+W4_$"^(_#5]'9:ED-(KDH"P_C5@#@XQD8P:?MX.6^\;7\Q
M<CMMU.)^,%A9^'?&FF7>C11V=PT*S%+=0@#JYVL .A./TK1^/A9KK0&9=K&&
M4E?0Y3BM;0?A7K>H>)8M=\::C'=O$598%<N7(Z!C@ *#V&<UK_$_P!JOC6YT
MV33;BRB%JDBO]I=ESN*XQM4^E$:L(U()RO:]V#BW&3MN<W\1?"VAZ7\+=-NK
M'3+>WN5>#,R)AVW(<[FZM^-=O\)6+?#'1RQR<3#\IG%'C3PAJ'B/P+;:'9S6
MR7,1A+/,S!/D7!P0I/Z5I^!M!NO#/@ZPT>]DADN+?S-[0DE#ND9A@D ]&':N
M>I54J%F];FD8VG?R.)^/7_(JZ;_U^_\ LC52US_DW*R_ZYP?^C177?$SP=J'
MC/1;2RTZ:UBDAN/-8W#,H(VD<;5//-5M1\#ZG>?">W\*QSV@OHTC4R,[>5\K
M[CSMST]JNG4@J<$WLQ2B^:7H<GX \+:'J'PGU*^N],MYKQTN/W\B;G3:OR[2
M?NX]L4O[/S$KXA7/R@VQ _[^_P"%=MX0\(:AH'P_N= NIK9[J43!7B9BGSC
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M_P!FWHP<)6:MU.1^-^A:3I4.CW6GV=O9SNTD;+;QB,.H"D$@>F>OO]*ZV_\
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MB\7Z?H'^EZ>+RRM3'=O-(X#R$+DKA#G)!/;K7IFGV[VNFVMO(5+Q0HC%>A(
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MGI5M65U#*P96&00<@BO ?CE"]QXXTR&(;I'L555]3YCX'XUWGP_\7PR?"O\
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MDBME\MV4$KEN<'M2>'XD@_:+DCB4(GVNZ^51@<Q2'^=>A> ?AM_P@]]>7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5>^L;74[&:RO8$GMIEV21N.&%6**$[ ><O\$_"#3F0+?*I
M.?+%Q\H]N1G]:['0?#FD^&K(VFDV:6\;'+D9+.?5F/)K5HK25:I-6D[DJ$5L
M@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,7Q%X5TCQ5;0V^KP/-'"^]%65DP<8[$9JUHVAZ9X?L!9
M:59QVMN#NVIDECZDGDGW)K0HJN>5N6^@K*]PHHHJ1A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5SJ2O_PE=W'N.T;,#_@ KHJYI/\ D;[S_@'_ * M '2T4=J* "BBB@ HHHH
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MAN^MK5)+G[997=PP*J5C'S-R<9 R>*BB^'OE_#23P?\ VIG><_:_L_3]YO\
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MWKM%=:C"9+53&V)%$4C$YQ@<'O\ 2LG30#I_PK!&1]KG_P#1JULZ4'TTT_\
M26R.9]_ZN=\GQ5T9S=0#3-;%_;'Y[#["?/*XR7VYP% ZY(K7C\<Z"_A$>)C=
M,FGGCYE^??G&S:/XL_X].:YC20/^%V>*SCD:?%S_ ,!CKB;;3+O4/@G:36J7
M$BV>KM<3);G]YL&02ON,Y]NO:H]C3=NFWXHKGDOQ/6M!\;Z?KNHMIOV/4=.O
MQ'YJ6^HV_DO(G]Y>3D5G^$)=9'C+Q+::QJ7VQXDM754!6*+<')"*2<#H,]3C
MFN;\)6_AS5_&5C>:9J_BO69[*-G%S>R!H(,J048NH;//1>OX&O3H-+L[;4[O
M488=MW=A%GDW$[P@(7@G QD]*SJ*-.\4MU^I4;RLRY1117,:!1110 5S2?\
M(WWG_ /_ $!:Z6N:3_D;[S_@'_H"T =+VHH[44 %%%% !1110 4444 !HH-%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%%  :*#10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_D;[S_@'_H"T =+VHH[44 %%%% !1110 4444 !HH-% !1110 4444 %%%%
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M?!.T#N< G'H#4U !1110 4444 %%%% !14,EW;1211R7$2/*_EQJS@%WP3M
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MN/,:L6 QG'5CSC/-9H\'Z"MK=V\>GB*.ZNS?2>5*Z,)^/WB,I!1N!RI'?U-
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MMQMQ[C<<UU'V:#_GC'_WR*/LT'_/&/\ [Y%/DONR5B^5WA!+^O4SM.\/V-C
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MF.X%\ABQSN/ QSUM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !116!XHOY;6RB^RW/ERF8*VUAG&#UI2=E<TI4W5FH+J;DDJ1*6=@H S
MR:YN[\5F5VM],MI)W9#MD7.5/^[M.<4V7PQ?7D\37^H":-#R,'..^*V]/TFT
MTV,+!'D@DAW +<^^*CWGY'2EAZ2NWSO\#!TO0)K^9[[68Q)YR_<.Y'# XY
MQP*ZB&"*WB$<,:H@   %24548I&%:O.J]=NW0****HQ"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#F]3_P"1KM_^O=?_ $)JZ-?NBN<U/_D:[?\
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M@ HHHH **** "BBB@ HHHH ***9+-'"C-(X4*-QSZ4 E?8<[K&A=V"J.22<
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MZ;9WUQ$@02W$"N??J/6O,/@G%%;^)/',,,:1Q1ZAM1$& H#/@#VH ]DHHHH
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M#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "&EHHH ****
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M;K\#A(OA'X62%%EAN)) H#/YS#<>YQVK6LO 7ANPMA!'I=M(H).Z>".5N?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFD_Y&^\_P"
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ME*Y(P =Q10.E% '+:A;:CI7BZ37+#2YM3BN[);6:&WDB22-XV9D;]XR@J0[
M\Y&!P<\3>&M/O/#VA6UC-:O<7,KSW-P\#)Y<<CNTA7+%21EMH(';G%='BDQ[
MF@#@?#Z:RVL+K'B'PMJDNKR$QI();1K>PB)^[&//W=,;FQN;'3&!5_78_$&K
MZ3JWAZ?2=WVU98(=1B>,6Z1.,*75I/,W@'D*I!(&, \=ABB@"M]@MGCB6:&.
M8QJ%5I5#'CW->3?!<!?%'CL*H4#4L  8 ^9Z]BKQ[X,?\C5X\_["1_\ 0Y*
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M^><?_?P_X4;I_P#GG'_W\/\ A0!+146Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (4
M2T5%NG_YYQ_]_#_A1NG_ .><?_?P_P"% $M%1;I_^><?_?P_X4;I_P#GG'_W
M\/\ A0!+146Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (4 2T4U"YSO51Z;6S_04Z@
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MRIP#@_C2;MJ5&+E)174R_%.HVBZ;<6)E_P!)8(0FT]-P/7&.@K6TK_D#V/\
MU[Q_^@BN?TC2[O4+N+5-1:WN(I(\;64$^W&,5U2(L:*B*%51@*!@ >E3&[?,
MSJQ')3@J,7=K5^NPM%%%6<84444 %>0_%#7I]9U:+P?80/YJSIYS,!M9F"E,
M'J -YSFO7J\YT;_DN_B'_L'I_P"@P5C6NTH]V>KE,HTZLZS5W"+DO6Z7ZEW0
M?A9H&D7"W4J2WLABVO#>".6,$XR0-G7C@UW"(L:*B*%11A5 P /2EHK2,(Q5
MHHX<1BJV(ES59-L****HP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH YO4_^1KM_P#KW7_T)JZ-?NBN<U/_ )&NW_Z]U_\ 0FKHU^Z* %H[
MBBCN* "BBB@"KJ.HVNDZ?-?7LOE6\(R[;2Q]   "22<  #))K$M/&ME<!?M-
ME?6.;_\ L]OM*I^[F*AE#%'8 -N !]>#C(S:\7PP3^%[U+FUO[F/"-LT^,/.
M"'4JR*>"5(#8YZ=#TKA-#.E:CKDMIJ'C*SDD.J+>OI;V#Z?<27(5-@*3.7*C
M:K *HR>^!B@#U:BBDP: ,S5O#VFZW)#+>Q3>="K*DMO<R02!6QN7=&RDJ<#(
M)QP/2IUTFRC@MH(8F@@MHS%%#!*T<:J1MQM4@' Z9''48J[28/K0!SVG^"-%
MTI(([$ZI!#;D&*%=7N_+7!SC9YNTCVQBK$_A31;C53J,MHYG:19G03R"*210
M KM$&V,PP,,5)&!SP*V<44 +7CWP8_Y&KQY_V$C_ .AR5[#7CWP8_P"1J\>?
M]A(_^AR4 >PT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444E "T5YQ\6=;U/1K+2GTR^FM6EFD5S&<;@%&,UQ%G>?
M$N]MHKNTEU>:"0;XY%VE6'K6BIW5[G1##N<5*Z1[]17):3_PD*_#LB],YUS[
M-+C)7S-_S;/;.,5YF6^*;8)&LC@#@**2A?J3"CS-KF6A[S17@W_%T_\ J-?^
M.UZAX#.N#PTO_"0F?[<9W/[_ !NV9XZ42A97N%2CR*_,F=317AU__P +.&HW
M0A_M?R1,_E[-N-NXXQ[8Q5<'XIC_ *#7_CM5[/S+6&_O(]YHKB_AW_PD?]D7
MG_"1_:_M'VC]W]IQG9M'3';.:X_Q*OQ'7Q+J/]GG5#8F8FW\@J4V=L5*A=VN
M1&C>3C=:';>,_'=MX.EM(YK&>Y:X5F'EN%"A<>OUKI+*ZCO]/M[J-2J7$2R
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M110 4444 %%%%  :*#10 4444 %<EXZ>W6TMUO-?T33K1MXEM-9MHYH+S !
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M/&&0$KO0L '3((W+D>] &O14%G>0:A90WELQ>"9 \;%2NY3T." :GH ****
M"BBB@#G?%O\ J;'_ *^!715S?BR1"ED@=2XG&5SR.*Z2H7Q,ZJO\"G\PHHHJ
MSE"BB@D $G@"@#SKXQNZ^&; ([(6OE!*G!^X]26?PETRTU&TO?[5U&5[:994
M61E()4@XZ>U<[XABLO'/Q/L]/MM5\RQ:U#;[=PZAU#GITST_.O8ZYHQC4G*3
M1[N(KUL%A:5&G*S:;>G1[?J%%%%=)X04444 %%%% !1110 4444 %%%% !11
M10 445GW>NZ18,JWFJV-LS<J)KA$)^F30-)O8T**\\UOXERVWB%-*T#3H=;W
MPB0/:W&_GG(^4'H!FHO^$\\8_P#0AW?_ 'T__P 34<\3=8:I:_ZH](HKS?\
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M.* 'T444 %<TG_(WWG_ /_0%KI:YI/\ D;[S_@'_ * M '2]J*.U% !1110
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M #!SP!75XP*1!@4ZM(Q45:)Q5Z]2O-U*KNV)12T51D)2T44 %%)FB@!:***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<WJ?_(UV_P#U[K_Z$U=&OW17.:G_ ,C7;_\ 7NO_ *$U=&OW10 M'<44=Q0
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M>'M"$K75T[VZWU.QQQ2]*XW^VO$W_0//_@.U']M>)O\ H'G_ ,!VK7VB//\
MJ$_YE]YUXFBW?ZQ/^^A2^='_ ,]$_P"^A7GVF>&KG4;B9;E);7:-VYXN&)/2
MM3_A!1_S_P#_ )!_^O24I-:(J6%P\'RRJZ^AUHFB_P">B?\ ?0I?.B_YZ)_W
MT*Y'_A!1_P __P#Y!_\ KT?\(*/^?_\ \@__ %Z?-+L3[##?\_?_ "5G7>=%
M_P ]$_[Z%'G1?\]$_P"^A7(_\((/^?\ '_?G_P"O1_P@@_Y_Q_WZ_P#KT<T^
MP>QPW_/W_P E9UWG1?\ /1/^^A1YT7_/1/\ OH5R/_""#_G_ !_WZ_\ KT?\
M((/^?\?]^O\ Z]'-/L'L<-_S]_\ )66?%NIW%G':FSNC'EFW["#G@8S5!(O%
M[HKJ\A5@"/G3I4I\"?*0+_&?^F7_ ->NNBB\J&./.=BA<^N!2492=WH:RKT:
M-.,:5I/6[:..\CQA_>D_[^1T>1XP_O2?]_(Z[3%&*KD\V9?77_)'[CB_(\8?
MWI/^_D='D>,/[TG_ '\CKM,48I<GFP^NO^2/W'%^1XP_O2?]_(Z/(\8?WY/^
M_D==IBC%')YL/KK_ )(_<<&?#^MW]_%)J$3,I(623S$R%K:'@O3/[]S_ -_!
M_A718I::IQ%/'5I6Y7RI=M#G?^$+TS^_<_\ ?P?X4A\%Z9_?N?\ OL?X5T=%
M'LX]B/KF(_G9SG_"%Z;_ ,]+K_OX/\*V;"QBTZS2UA+&-,X+G)Y.:M452BEL
MC.I7JU%:<FQ #WHQ2T46,A*7%%%, Q1110 4444 %<TG_(WWG_ /_0%KI:YI
M/^1OO/\ @'_H"T =+VHH[44 %%%% !1110 4444 !HH-% !1110 5S*Z5K&A
MW][+H<=A=V=],UR]K=SO;F&5L;F5U1]P;&=I48.3DYP.FHH Y_2]&OGUU]?U
MA[<7IM_LL%O:EFCMXRVYOG8 NS$+D[5 P !U)Z"BB@ HHHH **** "BBB@ K
MF_%RATL$895I\$>U=)7%:+I']K>9<374H,,^ O4<8/>HGV1V8-1C)U9.RC^I
MUMG8VVGPF&UC\N,MN(W$\_C]*L4459R.3D[O<*J:GJ-OI&F7&H71800+O<J,
MG'TK(\8^*T\(Z9!>O9M="6<0A%?:1E2<]#Z5Y_ /B+XSTB]@D>"WM)&,3Q74
M/E.1P>/DSCWK*=51?*M6>CA,NE5BJU22C"^[=K][;E%%;XI_$".>6SE72;=&
MMY)83@A!YC1L<]"3CBO8-#T:U\/Z/!I=F9#;P;MAD;+?,Q8Y/U)JIX3T9M"\
M-V5E-'"MS'$%F:(<,1GOCGK6W2I4^7WGNQYCC?;25&EI3CHEZ7U^=PHHHK8\
MP*J7VJ:?I:HVH7]K:*YPAN)EC#'VR1FO-?'WC^=-4AT30;N>TOXKKRIW:-=I
MS@#!.>Y]*2_^'?B[79[0:[KUG>VT$H<QD%3C(W $*.H%9N?2*.J.'22E4=D_
MO+_C7XC6EM#+I.BR->W=S;DQ7-A,KB-LD8^7)R,9_&G?#/PW?VAD\2:C?//<
M:E!AXY4(=2&[DGGIZ5T&F> /#&C:C#J%AIGDW4))23SY6QD$'@L1T)KI:%%M
MWD$ZT%#DI+?=L****T.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBH+R:6WLIIH+=KB5$++"K!2Y'8$\4
M 3T5A:5XNTK5+G[&7DL]0[V5XGE2@^P/WO7@FH;[Q?;6GC&P\.1P^=<7(+2N
M'P(1@D<8Y)P>.,<4^5E\DKVL='14,UW;6\L,4]Q%%),VV)7<*9#Z*#U/TK.U
MK7HM+LKJ2W-K<W=L$+VTEXD)4,0 69N%Z\9ZT)7)46]$:]%4GUC3(;C[/-J-
MG'<;E4Q-.H8,W*C&<Y/;UH_M?3/L!OO[1M/L8.TW'GKY><XQNSC.>*+!RLNT
M53N=7TVSN([>ZU"T@GDQLCEF56;/ P"<FGWNHV.FQK)?7MO:HQPK3RJ@)] 2
M:5@LRS15:ZU&QLK9;F[O;>W@;&V66544YZ8).*E@GAN8$GMY4EA<922-@RL/
M4$=: LR2BBB@04444 <WJ?\ R-=O_P!>Z_\ H35T:_=%<YJ?_(UV_P#U[K_Z
M$U=&OW10 M'<44=Q0 4444 %%%% " 4M Z4F: ,+5-!O9M975]'U""QO3;_9
MIC/:F=)8\[E^4.A#*2<'./F.0>,6-(T3^Q-.LM.LYT:TA#^?YT6Z2=F)8MN!
M 4EB2?E.<X&*UJ3- ')6G@N:#[#8S:G'+H>GW(N;2S%KMD!4EHU>3<0RH3D
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M0+;S]2O(X 59D5F^:3:,D*.YZ<>]>>^*?BKH]YX;O+?1KN\AU!PODN(RA'S
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M,U3\F_\ B*]%HHYH]@YZ?\OXL\Z_X6;J/_0F:I^3?_$4?\+-U'_H3-4_)O\
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M7Q5<6MSJ<M\);:(1*8+DQ@C.><=_>O ]2\%^*O#/B1/#MO;P/;:Q>2/9))<
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MBC0AUUK3?_ I/\:\3UOP/\0-7NUF7P]8Q(B[5#7R%L>YSZUE_P#"L/B" ?\
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M;(U9@HXRV,#(YY%/GEW%]8J]SC8_@[H29W27SY_O7*\?E&*?_P *AT#TN_\
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MS9-D$DBPHS'#RLBD1KG/S.0.#SP:V58,H92"",@CO4MW,W)RW9'NG_YYQ_\
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MHHH **** "BBB@ HHHH YO4_^1KM_P#KW7_T)JZ-?NBN<U/_ )&NW_Z]U_\
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M:99W!MKG4XX5,$3CALC=YA53P65" <\\4 =7M!HP*4'(R.E% "8&*-HQ2T4
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M::;:*5MK6%88@QR=JC R>YXJW4-M;P6=O';6T$<%O$H2..)0JHHZ  < 5-0
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M_P#D:[?_ *]U_P#0FKHU^Z* %H[BBCN* "BBB@ HHHH **** "BBB@ HHHH
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M8O!JL;7CQW-E=:BC!Y6$2[)<D84^8F[9@%1@;5X ]2JM?V$&I64EI<^;Y,F
MPBF>)B,]-R$''J,\C@T >?65I'?>$K37M4M-6AO=0OO[2%QI:&6>R++MC.T
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M - 6@#I>U%':B@ HHHH **** "BBB@ -%(>G%8E[?ZO%,5MX+=D]65C_ %H
MW**YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X
M;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X
M;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]
MK7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]
MK7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^
MU-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^
MU-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#
MI:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X
M;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X
M;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]
MK7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]
MK7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^
MU-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^
MU-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#
MI:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X
M;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X
M;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]
MK7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]
MK7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^
MU-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^
MU-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#
MI:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X;_XJ@#I:*YK^U-?_ .?:U_[X
M;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]K7_OAO\ XJC^U-?_ .?:U_[X
M;_XJ@#I:*YK^U-?_ .?:U_[X;_XJC^U-?_Y]K7_OAO\ XJ@#I:*YK^U-?_Y]
MK7_OAO\ XJC^U-?_ .?:U_[X;_XJ@!=3_P"1KM_^O=?_ $)JZ-?NBN8@BU"]
MU:.[NXXT94" 1@@8!)[D^M=.O"B@!:.XHIKDA25ZCI0 ZBN?N=1UJ.8K%;VQ
M3L61O_BJB_M37_\ GVM?^^&_^*H Z6BN:_M37_\ GVM?^^&_^*H_M37_ /GV
MM?\ OAO_ (J@#I:*YK^U-?\ ^?:U_P"^&_\ BJ/[4U__ )]K7_OAO_BJ .EH
MKFO[4U__ )]K7_OAO_BJ/[4U_P#Y]K7_ +X;_P"*H Z6BN:_M37_ /GVM?\
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M_P"*H_M37_\ GVM?^^&_^*H Z6BN:_M37_\ GVM?^^&_^*H_M37_ /GVM?\
MOAO_ (J@#I:*YK^U-?\ ^?:U_P"^&_\ BJ/[4U__ )]K7_OAO_BJ .EHKFO[
M4U__ )]K7_OAO_BJ/[4U_P#Y]K7_ +X;_P"*H Z6BN:_M37_ /GVM?\ OAO_
M (JC^U-?_P"?:U_[X;_XJ@#I:*YK^U-?_P"?:U_[X;_XJC^U-?\ ^?:U_P"^
M&_\ BJ .EHKFO[4U_P#Y]K7_ +X;_P"*H_M37_\ GVM?^^&_^*H Z6BN:_M3
M7_\ GVM?^^&_^*H_M37_ /GVM?\ OAO_ (J@#I:*YK^U-?\ ^?:U_P"^&_\
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M^U-?_P"?:U_[X;_XJ@#I:*YK^U-?_P"?:U_[X;_XJC^U-?\ ^?:U_P"^&_\
MBJ .EHKFO[4U_P#Y]K7_ +X;_P"*H_M37_\ GVM?^^&_^*H Z6BN:_M37_\
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M5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M%
M";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;
M5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M%
M";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;
M5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M%
M";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;
M5]!2T4 )M7T%&U?04M% ";5]!1M7T%+10 FU?04;5]!2T4 )M7T%&U?04M%
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M^$@2Z2>$\-OC8\D9W CTZ&N]T_X;:)8^';_P_+-?WVDW;!A:WEQO6WP<@1$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0<D9Z\'/X5V^&QF\':UI%SK<USJ>LNLEYJ<L RS*5QB,$ * N ,\9/TKO**
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M6T<"Q&>%XGVR.54[2"1D XZ>E4;G2M1NB;AQ;K,\P9XDN'0*@0J,2!=V<G/
M7.<9QU22#4VA=VQC=Q<1%$4,S!QA01D$^Q%1ZAJ$&F64EU<;MB G:B[F; S@
M#\#^63P*PK;2)8Y],LY,GRK9%O&",8W$9!C 8C!.[/'7!.>U:USIT\NF7]M]
MMEG>XB=$,X0!"01_ HXY[YHL@N+<ZM#;7:0-%,V0A>1 -L6\[5W<YY/H#CO@
M4MMJT-S>M;+%,N-^R1@-DFP[6V\YX)QR!GMFJU[IEU->$Q-#]GG6)9B[$,OE
ML6^48P<@XZC'7GI2V6FW4%^K2F'[- 9C"58EV\QMWS#&!CD=3GKQ1I8-2_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img101536035_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI^JQ&73[ZVNXQP6@E5P/K@\5X#X$\"W7CC2)3<ZQ);:?9RE(857?B0@$G!(
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M]IPS=.H&.>*]!KDFDG9%H\@^)7Q'U/1-=MK3P_J-N8OLX>4HJ2C<688SS@X
MX]Z]5M-3T_4&9;*^MKED&6$,JN1]<&OF'QQX:A\)^)'TN"XDG18D?>X /(]J
M]M\.^#++X<6>KZK'>S72BV+NLBA<! 6XQ735IP4(VW_,F+=SL+_5-/TN(2ZA
M?6UHAZ-/*J _3)I]GJ%EJ,/G6-W;W473?!('7\P:^>/#6CWOQ3\7WD^JW\B(
MB&61EY*@G"H@/0<G\O>DU*&_^$_CR-;*[DF@V)-@_*)XB2"K <=0PS^-+ZLK
M\M_>#FZGTA13(I$FB26,Y1U#*?4&GUR%A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7@WQT_Y&C3O^O+_ -G:O>:R-6\+Z)KMPD^J:;!=2HNQ6D!R
M%SG'ZUK1J*G/F8I*Z.!M/B_X;T[PS:6HBN[FYAM$B,0B 4L$ ())Z9^OTKF/
M@IIEW<>*[G55C9+."!T9P,*78C"?ES[8'K7JZ_#[PDC!AH%GD>J9'Y&N@M[:
M"S@2"V@C@A086.) JK] .*T=6"BU!;BY7?4^;M0L(-4^,L]C=*6@GU<QR*#C
M*E^1FNS^,G@Y$M+?Q#IT"QB!5@N4C& $'"-CVX7Z;?2O2?\ A$?#_P#:W]J_
MV5;_ &_S?.\_!W;\YW?6M6YMH;RUEMKF)98)4*21L,AE(P0:;Q'O1:Z"Y=#D
M/AGXN'BGPTBW$F=1L\17&3R_]U_Q _,&NTK(TKPMHFAW#W&EZ=#:RNNQFCR,
MC.<'GVK7K";BY-QV*6VIX)\4[>3PY\2;+7;=<";R[D8XS)&0"/R"_G5OX-V4
MFK^+]6\0W*Y:,,<G_GI*Q)(_ -_WU7KVK^'])UY8AJMA#=B$DQ^8/NYQG'Y#
M\J=I.AZ9H4#P:7916L4C;V6,=3C&:V==>SY;:[$\NMSSSXZ?\BOIW_7[_P"R
M-4/AK_DWZ^_Z]KK_ -":O2=6T33-=MT@U2SBNHD;>JR#@-C&?UI(-"TNVT=]
M(ALHDT]U96MP/E(;J/QS4JJE!1[.X[:W/)/@-_Q^ZW_USA_FU=O\5[22[^'>
MH^4I9HC'*0/[H<9/X#)_"NATCPWH^@O*VEZ?#:M* )#&#\P'3^9K2=$EC:.1
M5=&!5E89!!Z@BE.JG5YT"6ECP+X;_$;3/"&@7MA?V]U([SF>+R54AB55=IR1
MC[H_SUS_ (=2R7'Q?LIY86ADEEN)&C;JNZ*0X_6O:+?X=^$K745OX=$@6=6W
M+EF*@^H0G;^E:,?AG18M:.LIIT*ZB6+?: /FR1@G\B16SKT_>LMQ<K.,\8^,
M?!4^MR>'?$5FUQ' H+7(0D1.>J@K\PXQR/IVKR@+96?Q"LQX,NKFXB^T1_9W
M=2&))Y'0$KUZCIUKZ(UGPIH7B!@VJZ9!<R ;1(05<#TW#!_6HM%\&^'O#TQF
MTO2X8)B,>:27<#V9B2*F%:$(V5_T!Q;9NU\\_&O_ )'N/_KRC_\ 0FKZ&K&U
M3PGH.MW8NM2TN"YG"A-\@.=HZ#]36=&HJ<N9CDKH\_\ C1_R)6C?]?*_^BVK
M<^$__),K7_>F_P#0VKK-4T+2]:M8K;4K**Y@B;<B2#A3C&?RJ;3M+L=)L5L;
M"V2WMESB).@R<FAU$Z?)YA;6YX#\%_\ D?A_UZ2?TKZ)K%TOPEH&BWGVO3=+
MM[:XVE?,C!S@]16U17J*I+F015D?.'Q6C$OQ.N8VSAU@4X]T6N^^)W@*UE\'
MV]QI%L(Y='BP$4<M!U8>Y!^;/^]W-=O?^$?#^J:@;^^TJWGNCC,K@YXX'\JV
M2 P((!!X(-6Z^D>7H'+N>9_![Q=_:VC'0[N3-Y8*/*+'EX>@_P"^>!]"*X#P
MK_R6Y?\ L(W/_L]>X:?X.\/:3?)>V&E6]M<IG;)&"",C![TZW\(^'[75?[3@
MTJWCOM[2>< =VXYR?QR:/;03DTMQ<KT/%?B[I]QI/Q 75UC_ '=TL<T;]BZ
M*1]?E!_&M7QY\3M&\2^#3IMC#="ZN&1G5U 6+:0QYSSTQQ7L6J:3I^M61L]2
MM(KFW)SLD&<'U'H?<5E6'@/POIL,\5KHUNJSH4DW[G+*>HRQ) ^E.->%H\RU
M0<KZ'$?!?_D2M9_Z^6_]%K7)?!3_ )'N3_KRD_\ 0EKW72]"TO1;66VTVRBM
MH)6W.D8X8XQG\JKZ7X3T'1+LW6FZ7!;3E2F^,'.T]1^@I.NO?TW#EV/%?C=_
MR/%O_P!>$?\ Z&]=-\7-#N+_ ,(:-JMO'O6PCQ-CJ$=5^;Z J/SKT35?"F@Z
MW=BZU/3(+J=4"!Y <A020/U-:ZQHD0B50(PNT+VQZ4>WLHVZ#Y=SY]\,WGPP
MET2%=?TV6'48UVRL))V64C^(;6P,^G%>H?#J+PE+IMSJ'A:S>V263RIUDD9G
MRF=N0S-CAL\>OM5JX^&W@^YN?M$FAP"3)/R,Z+D_[*D#]*WK2RT_1=/,5G;0
MVEK$I8K$@4 #J3C^=*K5C):7!)H\8^)UI-X3^(FG>)[./Y)V64CH#(F RGTR
MN/S-:?P0TEY!JOB&X!:25_L\;GJ?XG/XDK^1KF/&?C>Z^(TUAH^EZ3(@67<J
M[M[R.1@=!\H )_GQBO;O"FA)X;\,V.E)@M#'^]8?Q2'EC],DX]L5K5DX4E&6
M[_(E:RN;-%%%<1H?.WCK_DMLG_7W:?\ H$=?1-8MWX2T"^U0ZG=:7;RWI96,
MS [LJ %/X8'Y5M5M5J*:BET)2L?.?BK_ )+<W_81MO\ V2OHRL6X\(^'[K5?
M[3GTJWDOMZR><0=VX8P?PP*VJ*M1344N@)6/F'3[[3;OQ]<W?C?[0\7F2><H
MW'#@X"D#G:.F!Z#M5/Q%>Z3J'C#S]#M/LNG;XUBCV!,XP"<>Y!-?1&J>!/#&
MLZ@;Z_TB&6Y/WG#,F[W8*0#^-37/@WPY=FW,VC6C?9D$<.$QL4$D 8]R3^-=
M"Q,+WLR>1G$?'3_D5]._Z_?_ &1JUOA/_P DRM?]Z;_T-JZW5M$TS7;=(-4L
MXKJ)&WJL@X#8QG]:ET[2['2;%;&PMDM[9<XB3H,G)KG=1>R4/,JVMSP'X+_\
MC\/^O23^E=CXC\7_  ^\0ZM=Z9KUM(/LK&*._5"<D=<%/FP#GJ"#UKOM+\):
M!HMY]KTW2[>VN-I7S(P<X/45%K'@GPWKT[3ZEI,$TS?>E7*,WU*D$UI*M"4^
M9W$HM*QX9X&_T?XJVL?AV>XFLC.RAW7!>#'.X?3Z<XZ4WQS=K8?%V\O'4LEO
M>0RLJ]2%5#@?E7OVB^&-%\.JXTG3H;8OPSJ"6(]"QR<>V:\(\5@-\;7# ,#J
M-N"",@_<K:G452HVNPFK(V/B3\2M*\2^'8M+TE+@F259)GE3:% SA>O)SC\J
MZ'PMX=N[#X)ZK#)$5N;ZWGN5CQ\V#& H^I"@_C770_#WPG;Z@+Z+0[99PVX?
M>*@]>$)VC\JZ;K7/*M%148+S*47>[/!/@CJ]I9>(;S3YV*S7\:B#C@E-S$'T
MX_E61XLNXKKXL70\3M<?V?#=&-D3.5A'W0!V!&"<>I/6O;[;P'X8L]935K72
M8X;U'+J\<CJ%)]%!V]_2IM:\&^'O$5PEQJNF17$R# DW,C$>A*D$CZUI[>'M
M'*VZ%RNUCYY\=7_AR^U: >&+/[/8PPA&;R]OF/DG//)X('/->K^.O^2(V_\
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M.SNO_?))'Z5NWVDZ?J>G'3[RTBFLSC]R1A>.1P/3%3*K'F35].X[,\Y^!?\
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MS_SXZO\ ]^8__CE9GQ8M&\3^#M'\3:?#(;>)3(ZL!O6.0+@D#/0@9Y[UW/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<;B6W@'D'<3CUQ7D?B?PUX/T?29/[.\4_;]4C8#RECRDG.&P5! [GENU=_\
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M!^8,!CJ ,9/7VKL/CK=WPU+2[,LXL#"90!]UI-Q!SZD#;_WU[US?B6_\$_\
M"(V=AX>LY#J)9'GN98SN  .X%CZDCA>.**"DHQ=]_P"M0E:YZS\.-8N=9^&Z
M27<AEF@$EN7;JP4<9]3@@9KS/X*?\CW)_P!>4G_H2UWGP:C,OP]N(P<%[J5<
M_55KS?X6:G;Z%X^C34-T1F5K0?+G;(S* #Z<C%0E_$2'V/I*BBBN$T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *R-6\+Z)KMPD^J:;!=2HNQ6
MD!R%SG'ZUKT4TVM4!S]MX%\*VLGF1:!8;NH+PA\?3=FM]5"J%4 *!@ =!2T4
M.3>[ I:IH^G:U:?9=2LX;J'.0LBYP?4'L?I6+8_#SPEIMR+BVT2W\T-N!D+2
M 'V#$@5T]%-3DE9,5D(55E*D J1@@C@BN6G^&W@^XN?M#Z' 'R3A'=%_[Y!
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M/PQ>ZN-5GTF,WOF"7S4D=,N.=Q"D G(]*Z.BA2DG=,+!1114@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!0\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_O
MM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U
M-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='
MF/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1
M_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\
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M -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\
M=_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]O
MSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T
M 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY
M$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,
M?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\
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MS'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T -MR6C)))Y[U-3514&%&!3J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^7GGGCBA)L#3HIK2(L9D9U" ;BQ/ 'KFJ-GKVCZC<&WLM6L;F< DQP7".P_
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MP<#(&,UT&J>#/[2\=:7XE^W^5]AC\O[-Y.=_WN=V[C[WH>E;>U@FGY/T%9G
M>!VD^'?CRY\-ZQY174%0P7@7 9N<<GG!.1]1[UT/QETE[GPO!JT (N--G#AA
MU",0#^NT_A6YXX\"V_C.WM?]+-E=VKEH[A8]YVGJN,CN <YXQ[UL?V2]UX:;
M2=5N1>/);F":?R]GF9&-VW)P>_7K6;JKFC4Z]1VTL>5ZQJB_$;Q+X1TF)MUO
MY*WEX!R >K*?P4C_ (%7M&,# K@_ OPTB\&:C<WS:C]NEEB\I#]G\O8,Y/\
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MG&3C\ZOUSRFW=="D@HHHK,84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!5M-,T^PEGEL[&VMY)VW3/#$J&0\G+$#D\GKZU
M:HHHO< HHHH **** (YX(;J"2"XBCFAD4J\<BAE8'J"#P13+2SM;"V2VL[:&
MV@3.V*% BKDY. ..M3T47 **** "BBB@ JG#I&FV]])?0:=:17<F=\Z0JLCY
MZY8#)JY11< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF1RI*,HP-/H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ [BBCN** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#G?"TKRVF78FNBKFO"7_'G72T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 44C,%4LQ 4#))Z"O/[3XFV^L_$33O#^BQK<:9+'.9M0*-LD=
M%SMB;.& [GGJ,>I /0:*Y'QEXIU#2+W3-$T"R@O-=U1G\A;ABL,2(,M(^.<#
MC@=>?H:WASQ3KZ^*6\,>+;&Q@U"2W-U:7.GLY@N$!PP ?D,..OZ<9 .WHHKG
MO&?BA?"6@_;EM6N[J:9+:TME;;YTSG"KGL.I_"@#H:*\VG\6^-_"][I\WB[3
M-%?2;ZY2U,VER2;[5W/REP_##UQ_@#I^)O%.N+XG@\+^$[*QN-4-O]KN9]09
MA!;Q;MHR$^8L3V'3CKS@ [:BN+\,^,K^>?6=*\3V,-EJ^D1B>8VI9H9X2"1)
M'GG'!&#_ (@9>F^/]8=?#>J:E:V2:3XAN3;P0Q*_GVQ.3$68L5?=CG"KC/>@
M#TBBN>CUZXO?'$FBV*0M9V%OYFH3,I)61_\ 51J<@ X!8Y!XQTS70T %%!(
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M=G^[DXQNQU[50T?P0?#_ (TU'6=+U'R--U$;KG2_(RGG?\]$;<-I]1@YR?;
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M';%>AUF:IH=MJU[I=U/),KZ;<_:81&0 S;&3#9!R,,>F* .>;'_"Z4\W'_(
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M_&I:* (ML_\ STC_ ._9_P :-L__ #TC_P"_9_QJ6B@"+;/_ ,](_P#OV?\
M&C;/_P ](_\ OV?\:EHH BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&I:* (M
ML_\ STC_ ._9_P :-L__ #TC_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ]
M(_\ OV?\:EHH BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&I:* (ML_\ STC_
M ._9_P :-L__ #TC_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\
M:EHH BVS_P#/2/\ []G_ !HVS_\ /2/_ +]G_&I:* (ML_\ STC_ ._9_P :
M-L__ #TC_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\:EHH BVS
M_P#/2/\ []G_ !HVS_\ /2/_ +]G_&I:* (ML_\ STC_ ._9_P :-L__ #TC
M_P"_9_QJ6B@"+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\:EHH BVS_P#/2/\
M[]G_ !HVS_\ /2/_ +]G_&I:* (ML_\ STC_ ._9_P :-L__ #TC_P"_9_QJ
M6B@"+;/_ ,](_P#OV?\ &GH'&=[*?3:N/ZFG44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UX2_X\ZZ6N:\)?\
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MLD+.-T^".".FWJ<4 >N45PVK_$"]7Q!=:'X7\-7'B"\L@#>LMREO% 2,A=[
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MV&E8Y#G.)YA]6&P'T4^M ':445QGC'X@)X0UW2-,;2I[YM227R_L[?/O7 5
MN.=Q8#.1CK0!V=%</I/CZ_/B&UT3Q/X8N-!NK[=]BD-TEQ%,0,E=Z@!6]O\
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MNW7^ON/3J*XQOBAX<A(^V->6BG^.6W++^:;JT;3QYX5O<>3K]B">@EE$9/\
MWUBM5%M72T/-G&4)<LU9G145!;7EK>)OM;F&=?6)PP_2IZ1(4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '->$O^/.NEKFO"7_'G72T %%%% !1110 4444
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MR_\ /'_QX4;Y?^>/_CPH EHJ+?+_ ,\?_'A1OE_YX_\ CPH EHJ+?+_SQ_\
M'A1OE_YX_P#CPH EHJ+?+_SQ_P#'A1OE_P">/_CPH CN=/LKT8N[.WG'_36,
M-_,5DOX*\-MDII%M 3U^SKY0_)<"MK?+_P \?_'A1OE_YX_^/"AZJQ49.+YH
MNS//]8^'<R*SZ;*)T/\ RQFP&_ ]#^.*\TU;P=$EPT<D,MC.#R-G'_?)_I7T
M7OE_YX_^/"J][9PZC#Y-Y8QS)Z.1Q]#V_"LU"5-\U)V9Z4<Q]I'DQ45-?B?/
M-E\-[R_8'2]:L#..D4[/#(?IP0?P-:7_  C7Q3T'YK:74'C':"\$J_\ ?!;^
ME>@:I\/W),NEN5[^3*P/Y-_C^=5=$\3ZAH6HG3M8,C0J=A$ART1]<]Q_D5LL
M=5B[54A3RZC6BYX25[='N<4/B9\0-!8+JMKNQQB^LC'^J[:VK#X\'A=1T+ZO
M;S_^RD?UKU\2M+&"(E='&00X((-8]_X2T'4\F[\/6,C'JXC56_[Z&#6_M:4O
MBA]QY7*UU.>L/C)X2N\">6[LR?\ GO 2!^*;JZ:P\7^'=3P+36[&1CT3SE5O
M^^3@_I7)W_P=\,7>3!:W=D>WDW.1_P"/AJYF^^!4_+6&K@^B7$6/_'@?Z4<M
M"6S:%>1[6"& (((/((I:^?!\-_B%H)W:7,Y"\YLKW9^A*TO_  E?Q/\ #V!>
M17S1+_S]6>]3_P #QG]:/JZ?PR3#F[H^@J*\,L/CMJ<>!J&CVL^.I@D:(_KN
MKI++XX:!/A;NQO;5CU. ZC\0<_I4RP]1=!\R/3Z*PM'\7:-KP']F7UM.Y&?+
M$H63_O@X;]*V-\O_ #Q_\>%8M-:,HEHJ+?+_ ,\?_'A1OE_YX_\ CPI 2T5%
MOE_YX_\ CPHWR_\ /'_QX4 2T5%OE_YX_P#CPHWR_P#/'_QX4 2T5%OE_P">
M/_CPHWR_\\?_ !X4 2T5%OE_YX_^/"C?+_SQ_P#'A0!+146^7_GC_P"/"C?+
M_P \?_'A0!+146^7_GC_ ./"C?+_ ,\?_'A0!+146^7_ )X_^/"C?+_SQ_\
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M20Q+8[?@0#UBBO&/!'C6PA\?66@:+XNU#Q'I6HQ2$_VDLAGM947<")&1=RL
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M=I;>99Z=)<M=2;U'EAXP%X)R<D=@:YWXQZ?=NVB7&ER*E]?R/HK#N\5PO/\
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M_'G72US7A+_CSKI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV0JEXKDD# 4@MR!R0.<=JKV47NOZN%V>GZQXZT71=+TW4YGFGLM0<)#+;IN
M!&<D$@X^@)]JCTOQ[INJ:E<:<+'4[6]AA,Z6]U;>6\R#N@SSGMG&:X?7=-M=
M,\.>![6TAOHK;^UD=(M0"^<H9LX8+P.O3\^:WM2 'QUT8XY.EOG_ ,B5G[.%
MOO\ P'=B>%_B8-2M=8O-8LKJTM;21W6?R#Y4:#:!&6SDRDMG&.]:^E?$+2]3
MU2UT^2QU33Y;L$VK7UMY:3C&?D.3GC^8KAO#<^F+X>\5^&]6L[VZN1?2SRV=
MK$3+Y>4&]<X&01G&<X&<$5#X;U*XMO%&E67A3Q+J6L6,D@6ZL;R!L6L(ZY9N
M!CG[H'(QSG%7*E%WLA)L]5O_ !%9Z=X@TW1KB.<3ZB'\F0*#'E1D@G.0?P[U
M1T_QSI&HZKK&GQ"=9-)5FG=U 5@I(8K@Y.".X%97Q2AFM]!L]>M5!N='O([E
M1CJN<$?3D?E7EU_I]_HWAW2-5MD)NO$5O/;W+?WC)(&7IW(/Z5-.E&<;_P!?
MU8;;3/2[7QTNK>(M'DM)M2AL[NTFF6P:RB8S;-XSOWE@<KP #G ]:S+'XCZI
MJ_AKQ+=)8W5I<6BRR6TXMP88@H4!&8YS)DDD$5*VGII/Q3\(:?']RVTIH@?7
M"N,US^E7UO:>"?'&@3LT>I)-<SF%D8?)\JYSC'7MU[U:A%[+M^8KLZW0?B98
MO8:+%JD>H>;>(D;:@]ILMWF(Y4-QW]!C\*Z#7_&.G>'[R"Q>"]O;^=2\=I8P
M^;*5'\6,CC@_D:\_\4?)\(?"!7@B>U(QZ[&K7U.\B\(?%2YUW6%E32[^Q$,=
MVL;.L3C;E3M&1G;[]1[XATXMW2[Z!=G20^.M'N/#-[KD/VAH;'(N8#'MFC8?
MPE20,\^N*EO_ !CIVGZ#I>L2PW36^HO$D*HJEU,BY7<-V![X)K@(-.O==TGQ
M[K5I9W"6FJ(HLXVC(>?9DE@O7GM]367J_B>QU7P5X3TNT\]Y[.ZMDNLPL%B9
M%*[2Q&,GD@ ] ::HQ;T[_H',=P_CVZ7XE-X>&DWK6D<80F*WW.79E E;GB(
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M\7R>'+#P_+J-UY EB,=PJ!B1GYMPPHQGG)YP,<T_93O:P71VM%>?7GC.36O
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M%8H6C<, PX(R.XJ:O&_A5K.I>'OAOJFKZT;#^Q;1YY(A;[_/:02-O4Y^7!.
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M,44 >5R2++\0OAG(C!D;2[@J1W'DK5/XIZ!I?_";:3XA\2:1<:CX<%FUI=-
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M?[RJ%)[@]>Y%O5/$UC\3?$'AJP\+K/>6EAJ4>H7UZ8'CC@$>2$RP&6.>@_\
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M=JMT+^SOU@>2-RRX:,E02&!'3^7&6^$]8.O?$7QCJ*V<]K!+IEO]G%PFQWC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>URT>D:YJNHZ1/KJV$2Z5(9T>SG>1KF0QLF2&1?+&&)V@MG@9P.>IH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [BBCN** "L[7[NXL/#FIWE
MHNZY@M)98@>[*A(_45HTC*&4JP!4C!!Z&@#RBR\%_P!O_! VVF2))JVN6\%U
M=7EW(Q,TNY78NV">.0*T=!LK70/C'J&E:1!#;6%QHL5S<6]NBI&DRR;%(4#
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M +[/^- $M%1?9X_1O^^S_C1]GC]&_P"^S_C0!+147V>/T;_OL_XT?9X_1O\
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M?8XO.\K^YY_7&..F,<8K;\2> ;?6+'1TTJ_ET:]T7 T^Z@0/Y2[0NTJ3\RD
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MMCI<KJ7:]TQ%%O< 'H>CJW/W6!'7#&@#K:*** "BBB@ HHHH **** "BBB@
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M=4?>I'0\, 1^%2Z9&D7Q<UF.-%1%T:T"JHP /,EX H [2BBB@ HHHH ****
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M?_GXD_)?\*/*?_GXD_)?\*EHH B\I_\ GXD_)?\ "CRG_P"?B3\E_P *EHH
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MM#L)=,T6ULYF1I(E(8H21U)XS6A134$MB*F(G434NKO^%@HHJ*>YAM@AFE5
M[!%W'[S$X %48I-NR):*JC4;0ZD=.$O^E"/S#'M/W?7.,5:HO<'%K=!1110(
M**** .:\)?\ 'G72US7A+_CSKI: "BBB@ HHHH **** "BBB@ HHHH ****
M"L[7M&@\0Z%=Z5<NZ0W*;"R=5[@C\0*T:*:;3N@>IQ_@+P#;^!K:\5+U[R>Z
M92\ACV !<X 7)_O'G-=A113G.4Y<TMQ))*R"N!?_ )+]'_V+1_\ 2BN^JO\
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MT/3;Q[RPT;3[6Z?(::"U1';/7+ 9-6GL+.2_COWM(&O(D,<=PT8,B*>JAL9
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MQB6,2##;3TR*RO'VG?VIX'U:'[;>6FRV>7?:2^6S;5)VDX/RG&".XKR\)?\
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MB8]R!_=]Z +=%5]]Y_SP@_[_ !_^)HWWG_/"#_O\?_B: +%%5]]Y_P \(/\
MO\?_ (FC?>?\\(/^_P ?_B: +%%5]]Y_SP@_[_'_ .)HWWG_ #P@_P"_Q_\
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MB@ HHJAK5E=:CHUW965^UA<3QE$ND3<T6>I R.<9P<\'F@"XL:I([C.7()_
M8I]>,:=I6D>%OBEI%CHECJNC!I)(KR^U!Y?)U0[#A$))5G+?-GY>G .17L]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(Q$S;G9PIY8%SC YYS67J-_\1-(U2_@L-%M=?LKB4O97+W<=L;12!\DB8!<
M]".2.IS7>44 87@[09/#7A6RTN:5))XPSS/&,*9'8NVWVRQQ[5NT44 %%%%
M!1110 5S-GI-[%\2-4U9X<6,^FV\$<N]?F=7D+#&<C 8<XQS7344 %%%% !1
M110 4444 %>5^,;;QCJGC [_  <^M>';38UK;#58;:*:3@F253DO@\!3@#&<
M'->J44 8WAK4-9U'3GEUO0!HEPDA1+<7:7&Y,##;D  Y)&/:MFBB@ HHHH *
M*** "L[7;?4[K1+N'1KU++4F3-O.Z!U5P<@,"#P<8/&0#D<UHT4 >;-:^-?&
M&HZ3;:[H%KHFGZ=>1WLUPEZEPUR\>2HC4#Y%)Y.[G'>O2:** "BBB@ HHHH
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M\E].#+@;8TQ&IQD;<<*#Z5Z=:^&]-UWXK^(;S5$>;^SOL,]M&9&5$E\LGS"
M0&(P,9R.OK0!Z717SJ-(F\-3#Q)JFDR:E#'<^>_BS1=:S(Z[^\3,5;/"D  8
MZ&OHA'62-74Y5@"#[4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YKPE_QYUTM<UX2_X\ZZ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** #N**.XHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$KO_ +_-_C0!TU%<S_8NI_\ 02N_^_S?XT?V+J?_ $$KO_O\W^- '345S/\
M8NI_]!*[_P"_S?XT?V+J?_02N_\ O\W^- '345S/]BZG_P!!*[_[_-_C1_8N
MI_\ 02N_^_S?XT =-17,_P!BZG_T$KO_ +_-_C1_8NI_]!*[_P"_S?XT =-1
M7,_V+J?_ $$KO_O\W^-']BZG_P!!*[_[_-_C0!TU%<S_ &+J?_02N_\ O\W^
M-']BZG_T$KO_ +_-_C0!TU%<S_8NI_\ 02N_^_S?XT?V+J?_ $$KO_O\W^-
M'345S/\ 8NI_]!*[_P"_S?XT?V+J?_02N_\ O\W^- '345S/]BZG_P!!*[_[
M_-_C1_8NI_\ 02N_^_S?XT =-17,_P!BZG_T$KO_ +_-_C1_8NI_]!*[_P"_
MS?XT =-17,_V+J?_ $$KO_O\W^-']BZG_P!!*[_[_-_C0!TU%<S_ &+J?_02
MN_\ O\W^-']BZG_T$KO_ +_-_C0!TU%<S_8NI_\ 02N_^_S?XT?V+J?_ $$K
MO_O\W^- '345S/\ 8NI_]!*[_P"_S?XT?V+J?_02N_\ O\W^- '345S/]BZG
M_P!!*[_[_-_C1_8NI_\ 02N_^_S?XT =-17,_P!BZG_T$KO_ +_-_C1_8NI_
M]!*[_P"_S?XT =-17,_V+J?_ $$KO_O\W^-']BZG_P!!*[_[_-_C0!TU%<S_
M &+J?_02N_\ O\W^-']BZG_T$KO_ +_-_C0!TU%<S_8NI_\ 02N_^_S?XT?V
M+J?_ $$KO_O\W^- '345S/\ 8NI_]!*[_P"_S?XT?V+J?_02N_\ O\W^- '3
M45S/]BZG_P!!*[_[_-_C1_8NI_\ 02N_^_S?XT =-17,_P!BZG_T$KO_ +_-
M_C1_8NI_]!*[_P"_S?XT =-17,_V+J?_ $$KO_O\W^-']BZG_P!!*[_[_-_C
M0!TU%<S_ &+J?_02N_\ O\W^-']BZG_T$KO_ +_-_C0!TU%<S_8NI_\ 02N_
M^_S?XT?V+J?_ $$KO_O\W^- '345S/\ 8NI_]!*[_P"_S?XT?V+J?_02N_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5>Y%U;:J;N*SDNXWA6("-T4QD,22=Q'!R.G/R]*JW5C?7DDAFB3+Q11?(PP
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M5IB_SG:JQQM(S'&>%4$G@>E2Q2QSPI-$X>-U#*PZ$'H:H2R%M)@^S6$SP2(
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MQ8\"/&#SS]\C' '%=#2:[ @HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img101536035_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_''CNR\%V49DB-
MQ>S@^1;JV.G\3'L/Y_GBHQ<G9 W8ZRBO$S\7O%MO$E_=>&HETU\;)/)E0,#Z
M2$E3^5>I>%O%%AXLT==1L-R@-LDB?[T;CJ#^?6KG1G!78E),VJ***R&%%%%
M!117C&L?&C4;+7KVWM-.M)K"WN#")6W;F )&<@XYP2*TITY5-(B;2/9Z*CMY
MX[JVBN(6#12H'1AW!&0:DK,84444 %%%% !1110 4444 %%%% !117D?B[Q;
MKNG?%?3])M-0>*PEEME>$*I!#, W)&>:NG!S=D)NQZY1114#"BO/_B1X^O\
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MC8] ,G^5 $U%>#Z)KGC_ .(&L7<NEZLME#;LK,@.Q(U8D!1P2QP#U]*]W P
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M">]3*-DG<$QU%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC1FR(R#M('IG(_*MCX&?\BA?_P#7^W_HM*Y?X*OY7BG6)-K-MLV;:@R3AUX
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M:U=1V@O$"D[6(,@SG& ?[I-:.B^+="\0SR0:3J"7,D2[W5488&<9Y J$^&=
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M-034&MAI<]O,T0CW>=DL<$[AC[GH>M>U>--'_MWP=JFGA=TCPEXA_MK\R_J
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M,6^F3&_E6*"5U.X.$(QM YR2HX[<]:ZV'PY/X9^!NIVMVNRZFB:XF3^X6V@
M^X &?>IG>RY][Z>@UY'&>#O#.O>/M%-B^JFTT>RE/+*7\R1N?NY&<#'4\9XZ
MFN@^)6O7F@P:-X,TV]-K&MK$MQ<AMN5^X 2.0/E)/U%:_P #/^10O_\ K_;_
M -%I67\8_#5X=4L_$MK:_:;:*-8[F,*6"[6)!8#^$@X/ICWHYDZW++9!;W;G
M(7QMO!-S8ZGX8\6#4;@N?M$:J5![\C/*GIS_ /J^B[&Z6^T^VNU&U9XEE ]
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M10 4444 %%%% !1110 4444 %%%% !1110!$MK;I.TZP1+*W60( Q_&I:**
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MQ.UO$9ATD*#=^=3444 ! (((R#U!J&&UM[;=Y$$46XY;RT"Y^N*FHH ****
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MI:* "BBB@ HHHH CF@AN(_+GB25/[KJ&'Y&G(B1H$C554=%48 IU% !1110
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MY$?]W]31Y$?]W]30!4\Q_P"^WYT>8_\ ?;\ZM^1'_=_4T>1'_=_4T 5/,?\
MOM^='F/_ 'V_.K?D1_W?U-'D1_W?U- %3S'_ +[?G1YC_P!]OSJWY$?]W]31
MY$?]W]30!4\Q_P"^WYT>8_\ ?;\ZM^1'_=_4T>1'_=_4T 5/,?\ OM^='F/_
M 'V_.K?D1_W?U-'D1_W?U- %3S'_ +[?G1YC_P!]OSJWY$?]W]31Y$?]W]30
M!4\Q_P"^WYT>8_\ ?;\ZM^1'_=_4T>1'_=_4T 5/,?\ OM^='F/_ 'V_.K?D
M1_W?U-'D1_W?U- %3S'_ +[?G1YC_P!]OSJWY$?]W]31Y$?]W]30!4\Q_P"^
MWYT>8_\ ?;\ZM^1'_=_4T>1'_=_4T 5/,?\ OM^='F/_ 'V_.K?D1_W?U-'D
M1_W?U- %3S'_ +[?G1YC_P!]OSJWY$?]W]31Y$?]W]30!4\Q_P"^WYT>8_\
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M@;K/_?J+_P".4?\ "]?#?_0-UG_OU%_\<K;ZK6_E9'MJ?<]0HKR__A>OAO\
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MM9_[\Q?_ !R@_'SPN/\ F'ZS_P!^8O\ XY1]7J]@]I#N>IT5Y7_POWPM_P!
M_6?^_,7_ ,<H_P"%^^%O^@?K/_?F+_XY1]7J]A>UAW/5**\K_P"%^^%O^@?K
M/_?F+_XY2?\ "_O"O_0/UG_OS%_\<H]A4[![6'<]5HKRK_A?WA7_ *!^L_\
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M6_M2WE7,*3('&& 8 C(]>:F5.4=T-23V+U%%%04%%%% !1110 4444 %%%%
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M-;I7;WGQ#O/$&C7MAXGACU)VCS97(BCCDMY,CD%0/E/<=Z+3P-I::987&O\
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M\ZX*DHE2BW=:/R!3>SU/2?!?C2TTO1;O1DUJYT$?:FN+>\-HMT&0@#8Z[>O
MY&*LS^-[&7QMH5Q=^(+G4K6P67SKV:S6%=SH1\B(F['3[V?PKRVIGM+F.WAG
M>WE6&<D12,A"R8.#M/0X/I6;P\.9OOZ?\.4JLK6-S6=4L[OP?X?L()M]S:/<
MF=-I&S>X*\D8.1Z5;;6M/.F>"X1<?O--FE:[&QOW8,X8=N>.>,UR_P!DN?L?
MVO[/+]FW^7YVP[-^,[=W3..<5#6GLXVMZ_C?_,GF9V\'B#3$\6^+KYKG%MJ%
MM>1VK^6W[QG;*#&,C/OBJVC:WIUIX5L[*>XV7$>NQ7;IL8XB" %L@8Z]NOM7
M(TE3[*-A\[.WA\0:6GBWQ??-=8MM0MKR.U?RV_>,[908QD9]\55TGQ!9:;X0
MM;=GWWEOKD=[Y 4_-&J8SG&.O&,YKE[JUN+*=K>[MY8)EQNCE0JPR,C(//0U
M#2]E%H?.SU";5?!=GJ'B/4[/6KFXN-7LKA8H6M'18'DY*,W\1)Z$   ')Z5@
MWVNZ;-KWA"YCN<PZ?:6D=TVQOW;(Y+#&.<#TS7-V&BZKJRNVG:9>WBQD!S;P
M-(%)Z9V@XIM_I&IZ44&HZ==V9?[OVB!H]WTW 5$:44[7U*<VUL=G>^*-*^R7
M1BN#*Y\3'4418V!>#!^8$C ^AYJU9SZ;>?%F0:5>R:EINN"6.Z"PM&467=N4
MANNWAMW3BO-:U-*\1ZOH=M>V^F7KVT=Z@2?8HRP&<8)&1U/(QUH='1\H*>NI
M9\9:K'K'BN^N8,?94<06X'01(-JX]L#/XU+=ZI9R_#W3M+2;-[#?S321[3PC
M*H!SC'4'O7.4AJ^162[$\SNWW.A\$:II^C>+;.^U,$6\>X>8J!S"Q4A9 IZ[
M20?PKMM=\4Z1/X.UK39/&5YKE_=>4\336;PQ+M<$JJXX.,DDX!P*\HH((QD=
M>E9SI*4N9E1FTK'HNO\ BC1;W_A,/(NS(-02R%L!&Z^9Y>W?U7C&#UQ[9K?T
MWQOH5AIRB?Q=>ZCI?DX;1+[31+*>,;#-@*>?PKQJI8+.ZNC(+>VFE,49ED$:
M%MB#JQQT ]:AT(VM<I5'>YL^#]7M-&\;Z=JET&CM(IRS[06**01]3C/Z5T,5
MQX2N=*OO"]YK\T5I%>_;+'5$LG96W( RM'][Z?Y%>?4AJY4TW>XE*VAUGBO5
M-'&CZ3X?T*YFO+2P,DLMW+$8_.D<C)53R  ._P#]>D\+ZSHYTB\\.^(C/'IM
MS*L\-U NY[:8#&['=2.#^GJ.4I\$$UU.D%O%)-,YPD<:EF8^@ ZTN1<MA\SO
M<[67_A"O#>EWK6&HGQ'J=S$T,)EL#%#; XRY#Y)<=B*GGG\'>*[#2KK6->N=
M(OK*UCM+B$6;3"=4X#(R\*2/7OV]>,U'1=5TD(=2TR\LA)G9]I@:/=]-P&:S
MVZ5"@GJG\QN5EL>@ZOXQTO5;3Q>(V>!;U+.&PAD0EF2%@.2,@' SR>]&@^*]
M(TQ/ S3W#$Z9<7+7BK&V8ED;Y3TYXYXSTKSRDI^RC:W];6(YW>_]=SM-9OM$
MM?!MYH>FZK]O;^V!<Q2?9WBWQ>3@G##C#'&,YXS5^6X\&^++'2;K6-?N=(O[
M*TCM+B 633"=8^ R,O"DCU[]O7SRDI>S\PY_(]#U?QCI>K6GC 1L\"WL=G#I
M\,B$LR0L!R1D X&>3WKC/#^L3>'_ !!8ZK!]^UF5]O\ >7^)?Q&1^-9]-IJ"
M2L#DV[G;^/-;T6>VLM%\,S-+I4,DMW(YC:/=-(Q.""!G8N%!K37Q7HH\O-[T
M\)'33^Z?_CX_N=/UZ>]>:TE1[-6L5SN]STKP/XETJP\(SZ8?$D_AK4#=F66Z
MBLC.;F/: $R.5(.?0<]\\:.M>,O#UUK-Q<V^K7%Q$_AF33A)<Q/YKSY. _&,
MGKGI7DE%)TDW<:F[6-3PS>0:?XJTB]NI/+M[>]AEE?!.U5<$G Y/ [5T+Z_I
MAT[QW$+GY]4N8Y+,>6W[U1.SD]./E(/.*XF@TW%-W$I6.V@U_3$TKP-"USB3
M2[V66\'EM^Z4S*P/3G@$\9K<\-^/;'2_$GBI$U:;3;?5KIIK;4XK83>7AV(W
M1L"2I#>F1_+RRBI=--:C4VCU7Q-\0E$VB^7XGN_$<EE?I>2.UA':0X7HJC9O
MW<G)SCV],+Q%;>!)4U+5[+7M0N[R\9I;?3Q:&(P.QR?,D;*LHR>%YZ<]ZX>F
MGK25-+8;FWN>JZ3XE\,QWO@S6)]7:&YTRU-C=VC6TAV*%EQ(& (.2P&!SS[&
MLFTO/"WB7PIINF:YK<VBWNE-*L4XLVN(YHG;=C"\A@?T]>W 44>S7<.<].D\
M8: NH7EI9SS)IEKX<FTNSEFC.^>4\Y( .W))ZX QVKG].UK2H? <.F74\XG7
M7$NWCM\K((1'M+*Y&T-GI7(T4*"0<S/:=2\=:(OAK4+.[\6S^)H)[=H[;3[G
M2O+EB<CY6:8@9*^HY]*\IU728=/L-)NH;S[1]OMC,RF(IY1#LA7D_-RIYX%9
M=/DFEF""21W$:[$W,3M7T'H.31&'+L-RON,KZ4^$'_(%M?\ K@G_ *"*^:Z^
ME/A!_P @6U_ZX)_Z"*PQ6R-*.[/5:***XCH"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Q^.?_(EV7_80
M3_T7)7IU>8_'/_D2[+_L()_Z+DKHPG\:)E6_AL\ HHHKZ,\L****0!1110 4
M&B@T )79_"\.WC(+',L+FTN LK-M"'RVPQ/;'7-<96YX3UFWT+67O+I)7C:V
MFA B )RZ%1U(XR:SK)RIM(N#M)-GI6A6>OZ+,NOZOX^M+S0[9L7 AOY+M9/^
MF>TC&3T]17)^&_"%CK.GWNNWMOJ\EC]I,,%II-N)9F/7)X(50".O7^>'X3\1
M#P_J3_:8FN-,NT,%];#_ ):1GN!TW#J/YC-;OA_QCI>E6-YHLTVN0Z8UR9[6
MZTZ80W*Y&-KC=M8$ =^/Y<TH5(WY?+;M_F:J47:Y)/\ #V ^*]$LHIKVUT[5
M@S)]NA\NXB*9W(RG W=,'H=U0>+_  IH^BZ=YUI%KUE<K*(_)U6W7;,#U*21
MC;QZ$\U%J_BK2-0UO36>VU;4-+M P?\ M'4)'GE+?Q AMJ$8& O!QS6AK7CG
M2F\+WFC:7+K]]]KV@MK,Z.( K _(%R<\8Y-"]M>._P#3_P @]RS*7_"':?\
M\+.3PUYUU]B8 E]R^9S#OZ[<=?;I74>#ELL> ENQ,2)+[R/+QCS-XQNS_#C/
M3G.*S8/'7A0>(;/Q'/I>IG5_)$5P%=/)4B/9O09!8D8&"0!G/)%8^E^,[/31
MX48V\[MI$\[W P &61OX>>2!GKCFIE&I.-FGM^-G_P  :<8NZ_K5$ZZ)I>HZ
M9&]A>:LNFSZ_%:+;SRJ/E9!N<J!MWY) /ICBI[[P?X4?^WM/TK4]4DU728I9
MR9T00R*A^91CG(Z9X!/(&*I+XGT&QMHK/3HM1-M%K<6HIYZIO\M4 93AL;LY
MQVQCFJEKXGLH/$/B74&BN#%JEO=10@*NY3*<KNYX'KC/XU5JFZN*\31@\,^$
MM,@TZU\1ZEJ<>J7\238LT0Q6RO\ <WY&2<<G'_USSGBW1[?0?%>H:7:O*\%O
M($1I2"Q& >2 !W]*]#L]-@URVT&]UOPGKES?I;Q)#-IY1K:YC'W#*V?D..#T
M/\AP_P 0IXKCX@:S)"ZNGVC;E3QD  C\P:*4VYV;_JX3BE$Z:]\):,=8\2S:
MUJVJM!I<=JXF+K+-)O494Y')Z = .,Y KFO%FA:3I]CI.JZ%<W<NGZBDA5+L
M*)8V1L,#MX[_ /ZZTM:\9Z=J(\4>3#=+_:J6BP;U4;?*QNW8;CIQC/X5A:GK
M5M>^%-#TJ-)1/8&<RLP&T[V!&TYSVYR!13516;_K3_,)..MOZU-GP_J%[IOP
MUUZXL+N>UG%];+YD$A1L$/D9!S5CPWKNI^(]'\0:+K-Y-?VPTZ6\B>Z<R-#+
M'@J0Q.1W&/\ Z^<[PSK7AVW\.:EHWB!-4,5U/%,C:>(]PV!NI<^_I4MWXB\.
M:5HE]IWA6RU$2Z@@BN+S473>L><E%5.,'N?\A2C=M6UOO]PT]$[FQ8?#W3(=
M)T^75K;Q+=7=]"LP;2;+S(;=6^[O;!W'')"\UBW_ (,BT^S\20233/J>C2Q.
MH7 26W<XW;2,@C*D\\9K9L?B!I=QI-C%JMWXGL[JSA6 #2+T1PSJO"EE)&TX
MP#CZUA6/BZV3QQ<ZM>6]R^F7:/;W%NT[3R&%EVXWR'+$8!Y/;M4Q]K=W&^32
MQ;M?!VE?VCHNGWEQJ NKFP-[<Q6T)F=BW,<4:JORMMY)8X'M6AXD^'%C8VFD
M7=DVIZ?'>WR6;QZL(MZ;NDG[LX '/!YJCIWCJU7QCK>J:A#>+::I$\ >S<)<
M6Z9&S8<XR H&,_X&36?%OAB;PY!I%A8ZK<)%J"7DC:C,"UR-I5@S*V5., ;?
M3/6D_:\R&N2S+/BSP)H>A:=>&-/$5K<VWW)[VV5[:Y.<85XP=I/4;B/2I_%&
MG>&M3?P=8P3ZG;-/91*LCP"7]QE\#9&"S2EN.!CD4U_'^@Z?HU];:2?$4[75
MN]NMEJ5RCVL 88.WDL<=O6JFF^.=#LV\.7TME?MJ.FVYL9PC*$,)#C?&V=PD
M&X'L.H]ZA*I:[OI_D.\;Z%S7?AWHVG^')-;C@\16=O:S1"=-06$/-&S!6,87
ME2,Y^:KWBG3M*O?&&LKI]UJUK<0:&TUQMD5$<+%'L3@9*E?O ]^E8FI>+?"_
M_"+:QI.FIK\UQJ C;[7J4J2,2C@A2 V N,\C)YHO?&V@7%_=ZG#;:DE[?:.]
MC<HP0QB78BJ4.<[?E.<\].*253=WZ_H-N/0DM_!_@R)M M=2U+5TO]9M8I$6
M!8S'"[\ L2,[2>  ,C!R>:SK7PCHFE6FH:AXIOKU;2WOGL+>*P1?-GD3[S?-
MD!0,?GU]:5YXGLKC6O"]XD5P(]*MK:&<%1EC&Y+;>>1Z9Q74:;+%XKTO6?MW
MA_6+_17U62YMI]+"-=6\C\E3'D_*5QS@C/KVI\\5=L2Y7L<QXT\/:)H]IHU[
MH5Y=W-KJ,+R[KG (PV,8 &".0>O(JWH%_-X:^'=_K>FXCU.[OQ8"Y R\$03>
M=OH6/&?;VJY\4$M+2S\,V%K9S6(@LY#]DN&S+&K/\I?T9L$X[9Q6!X7\266F
MVMYI.M6+WVC7I5I(XWVR12+TD0^N.,=Z%>5-=?\ AP=E((_'6M2:/J.E:G<R
MZK:WD84"]E:0PN""'4DY!'ITK47PYX.T;3M-'B?4-7_M#4(%N0E@D>RWC?[I
M?=R>.>.?;IE)?$GA;0M+O8?"=CJC7U[$UO)>ZFZ;H8VQN"*G&3ZGD4J^(_!V
MLZ=II\3Z?JYU#3X%M@]@\>RXC3[H?=R....??I@=^B:0=-62P> ='L+KQ*-=
MU*Z6TTE8)89[15)GCE.5^4]R, <X!)SD"@^ ]#U/7/#(T;4KQ=*UOS>;Q4\Z
M)H_O+QA23T'OZU2U+QS!JMMXI$UK)"^JBV2UBCPR0I"W"L<@_= Z#KZ55A\2
MZ.=(\,V%]I\]W%IKW!NH]YC#"1@5*,K9R.O..12M4W?]:?YDWA_7K_D:'C'P
M=HVC:>);&'Q#8W8F$0@U>V7;/GO')&-G'H3SFMP?"O2H)8=(NHO%#ZI(JAK^
MWT_=8Q2,,X)QN8 \%@<?3FL_6OB!I/\ PBUYH^D3>(;XW90;];G21;<*P8>6
M%R<\8Y-7G^)NBW[)J-_<>+H;\*/-L;'4C'9R,!C^]N0'T7I4/VMB_<N<YIGA
M+1].TN^U3Q?=7L5O!>M81V^G!3+),O+'+\!0/7K_ #TT\ ^'KG5_"T5EJ-[<
M6.M+<NTN55E$>=H V\,.C9SR#C%96F>*M%O=/O\ 2O%5IJ$ME/>-?0364VZ>
M&5AAAF0G>",<MD]3R3QTVL^(=.T&/X?:UI>GO'IUNMULMG?+LF_:Q)Z;B"3Z
M9-.3G>W_  VPERV.%TC0+?4?#7B#4'>87&G>0(%5@%8R2;3NR/3I@BNZ'PJT
MF"6'2+J+Q2^J2*H:_M]/W6$4C#."<;F4'@L#CZ<UA7GBCPC9>'=<TOP[I^JQ
M/J+0R+/>,C$%)-VS"GY5 S@_,23STK:?XG:+?LFHW]QXNAOPH\VQL=2,=G(P
M&/[VY ?1>E*3J/5?UL.*BMS"TWPCX?L_#E_JGBF[U*&2RU1K!X;$(QD(7.%W
M# .<G).,#&,FIYOA_I \4!8]5N%\._V6NKM</&#,L!XVX'!?/'3OTXYPKWQ-
M!>^#[O3)([C[;<:N=0+,Q=0I0K@NS%BV3U.<^N:V(/'>FQWVG+-97$^G?V&F
MD7\60CL,DEHR">AP1G'?IUIM3W$N4A@\+>&?$VO:38>%-3U ?:G<7,.H0@RP
M*HW%P4&UL@'"@YR!Z\:6L_#S2SHNHW.C6GBBUN-/B,[MK%CY4-PB_>\M@HVG
M'(#<FLZW\5>%_#&M:9>^%=+U%S;NS7-QJ,X665&4J8U$9VKP20V,YQ^-_6O'
M>B2:/?0Z;>^,;JYNXS&(]3U1O(@!ZD!&R_&1ALCUJ7SW5KV&N6VI;L?AKH8\
M-:9?7X\1S27ULLYO=.MTFMK;=V=1F0[>^!7ELZ)'/)''()45B%< C< >#@\C
M/O7H_ACQMX8T.QM)5'B>PO8%!EM=/O%-I<N/XG#DD;NX X[5P>N:F=:UV_U,
MP) ;N=YO*3D)N.<9[_6JAS7=Q2M96*%-/6G4T]:T("BBB@84444@$HHHH&%?
M2GP@_P"0+:_]<$_]!%?-=?2GP@_Y MK_ -<$_P#017+BMD;4=V>JT445Q'0%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4?VE_=_'_@!]5\SYEMM=UBSLS9VNJWT%J<YABN'5#GK\H.*SJ^JO^$2@I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4D1NC*V0?QJ6O#++4KW39?,L[F2$YR0IX/U'0UV^@>.Y[NYCM+ZV!9N/-CX
M^H/^?:D!WE%,CD65 RG(-/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **HZAK&GZ6O^EW21L>B=7/T4<US%
M]XWGDRFG6@C7_GK<=?P4?U/X4 =F\B1(7D=411DLQP!7.W_C33;7*6N^]D'_
M #RX3_OH\?EFN)O+JZU!]]]<R7!!R%8X4?11P*HWEW;V%I)=74JQ01+N=VZ
M4 ;FH>*=7O\ *B<6L1_@M^#^+=?RQ6'M 8MU8\DGDGZFN?/C.U41S3:;JD-E
M(P5;N2WQ'ST)YR >,'%7M4UD6,\%I;6SWE].I:.!&"_*.K,QX44 :)JGJ%_;
M:9927=W((X8Q\S8S[  =S6%+J^H:KIVK6,4+:?K5DJN(TD$FX?>&#CD'&/QK
M);3!)X!L[[1D:2Z62*_DR2[2RK]_(/4YSQ[4 =%:>(K:ZO8[.6UO+.:4%H1=
M1;/- Z[3D\^QP:U37"+=6=Y/936E]+K>L-*K()@RQVXS\S%%P%P/7/XUWAH
M8:::>::: (S333S330 PUL>'K1IKL..YP*R I9@HZDXKT'PAIH&UR.%% '96
M47E6R*>N*L4 8&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BFB1"<!U)] :=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !67?Z=<?;5U'3YEBN@GER)(,I,H.0&]",G!]S6C--';PO-,X2-%+,QZ "
MN8EUG4=1RUH5M+5ON,Z;I''K@\"J4;F56M&GH]7V);3[?XHL(I;HPVVGR$[X
M8F+/, <8)XPIQVY-=(    , = *XZQ34M+M8[>SOE:&,85)X@>^>HP:UK/Q"
M/.2WU*#[+*YPD@.8G/H#V/L:.7L9QQ,&[237J;E%%%2=(4444 %%%% !1110
M 4444 %%%% !1110 4444 %>>_#+_D7=._Z](O\ T 5Z%7GOPR_Y%W3O^O2+
M_P! %4OA?]=Q=3T*BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4452O]7L-, ^UW21
ML>B=6/T4<F@"[37=(T+NP55&2S' %<C>>,+B7*Z?:")?^>MSU_!!_4_A7/W4
MMQ?OOOKF6Y.<A7.$'T4<4 =??>,=.M\I:![V0?\ /+A ?=SQ^6:YN^\1:M?Y
M4SBTB/\ !;\-^+GG\L50Q@8 J.1TB0O(ZHB\EF. * (Q&JDL!\S<ECR3]345
MW<1VEI-<R[O+A1I&VC)P!DX'>JNKZW;:1I#ZFZO/;(5#-!AL D#=UZ#-<U>Z
MQKB6=O>ZG#:P:/?%8I%@=A/;+)PKE^G<9P* .JL[R#4+.&ZMWW131K(OK@C(
MS7.>.F$=CI<TPS9QZE"UR#TV9/7VSBF>#+6#1KS6-#$:K-;SB1'Q\TL+#*$G
MOCD5TU[9P:A936ES&)(9E*.I[@T ..&&>".M<5K>M)=61OK&*:W$5\;"ZO4B
M#2Q1#[Y3&< G'/Z9J_#X>UVVMQ8P>)&6R4;4)ME,RI_=WY].^*VM,TRVTC3X
MK*T4B*/NQRS$\DD]R30!Q^E:<6\06NIZ!;%-/C3R;B6YW(]T&))<;AEL'')Z
MGCH*Z72=)31X;B&*5GAEG>9$(P(PW.T>V?YUJ&FF@"/:JDD #/)P.M--2&F&
M@!AIIIYIIH C---/--/ H M:9;&XO%X^Z?UKUK1;06MD@QSBN(\):;YDJL5]
MS]:](10B #M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBJLET2^V/&T<%
M^OY4 6J*IK<R*W)WKZ8P:M(ZR+N4Y%).X#J1W6-"S$!0,DFEJE?.'3R58<GY
MS_='O3 <;TD96%L>K$"J<U]$S'S94QV0<@?7UK.O+MKB0I&2(P>OK5=8JY9U
MWLC>-+JS82>WEX5HS[8JY;2[9/)8D@C<F3^8KCI=6T^"Z%O)<*K\[O\ 9(]:
MU4N)45>=ZCD9[?0TH8CN.5!HZBBLBWNO.4%9)%9>HW9_G6A;3&52K_?4X/O[
MUTQDI;&#36Y/1115""BBB@ HHHH **** "BBB@ HHHH **** .?\3R&7[%I^
M?DGD+R#U5.<?B<5EZGJ5OI5L)9LDL<(B]6-:FN?)K.G.P^5TDC!]&X/]#7%^
M-XY5NK1R#Y7ED ]MV>?TQ6].*DTF>/C*LJ:J5%NK+\%_F2P^-(_- FLBL>>J
MODC\,5U$/V35; ,NV:WE'^?H:\HKT7P%;S#1I7<'RWF)C!^G/ZUK6I1C'FB<
M>7XJI6J>SJ:IF_H%Q*OVG3;AS)):$;'8\M&WW<^_!'X5M5RAU:VTJYU;59B6
MA4QVL2(,M+(H/"^O)_0UDR:QXAU$ES>QZ>AY6&",.5^K'J?I6/LW)WV/H,+%
MNGY:_F>@T5P]OJ/B2VPR7EM?J.L4\?EL?HR]_J*Z#1_$-OJLCVTD4EI?QC+V
MTWWL>JGHP]Q4RIM:[FS@UJ;%%96H:A=1ZC;Z?:1Q+).C.)IB=HQU  Y8XYQQ
M]:NV<$UO"5N+I[F1FW%F4*![ #H/KGZUF26**** "BBB@ HHHH **** "BBB
M@ KSWX9?\B[IW_7I%_Z *]"KSWX9?\B[IW_7I%_Z *I?"_Z[BZGH5%%%2,**
M** "BBB@ HHHH **** "BBB@ KS+_A>7AG_GQU?_ +]1_P#QRO3#T-?&==^"
MP\*W-S]+'-B*LH6Y3Z _X7GX9_Y\=7_[]1__ !RC_A>?AG_GQU?_ +]1_P#Q
MROG^BN[^SZ)S_6:A] ?\+S\,_P#/CJ__ 'ZC_P#CE'_"\_#/_/CJ_P#WZC_^
M.5\_T4?4*(?6:A] ?\+S\,_\^.K_ /?J/_XY1_PO/PS_ ,^&K_\ ?J/_ ..5
M\_TAH^H40^LU#Z!_X7GX9_Y\-7_[]1__ !RC_A>?AG_GPU?_ +]1_P#QROGZ
MBE]0HA]9J'T#_P +S\,_\^&K_P#?J/\ ^.4G_"\_#/\ SX:O_P!^H_\ XY7S
M_11]0HC^LU#Z _X7IX9_Y\-7_P"_4?\ \<H_X7IX9_Y\-7_[]1__ !ROGZBC
MZA1#ZS,^@?\ A>GAG_GPU?\ []1__'*/^%Z>&?\ GPU?_OU'_P#'*^?:*7U"
MB'UF9]!?\+T\,?\ /AJ__?J/_P".4G_"]?#'_/AJ_P#WZC_^.5\_&DH^HT0^
ML3/H+_A>OAC_ )\-7_[\Q?\ QRC_ (7MX8_Y\-7_ ._,7_QROGRDI?4:(_K$
MSZ$_X7MX8_Y\-7_[\Q?_ !RD_P"%[>&/^?#5_P#OS%_\<KY\H-+ZC2']8F?0
M?_"]O#'_ #X:O_WYB_\ CE'_  O?PQ_SX:O_ -^8O_CE?/=)2^I4@]O,^A?^
M%[^&/^?#5_\ OS%_\<H_X7QX7_Y\-8_[\Q?_ !ROGJDI?4Z0_;S/H7_A?'A?
M_GPUC_OS%_\ '*/^%\^%_P#GPUC_ +\Q?_'*^>:2E]3I#]O,^AO^%\^%_P#G
MPUC_ +\Q?_'*/^%]>%_^?#6/^_,7_P <KYXI*7U2D'MIGT1_POKPO_SX:Q_W
MYB_^.4A^/GA8?\P_6/\ OS%_\<KYW-,;K1]4I ZT['T5_P +]\+?] _6?^_,
M7_QRC_A?OA;_ *!^L_\ ?F+_ ..5\Z&DH^J4R?;S/HO_ (7]X5_Z!^L_]^8O
M_CE'_"_O"O\ T#]9_P"_,7_QROG.D-+ZI3'[>9]&_P#"_P#PK_T#]9_[\Q?_
M !RD_P"%_P#A7_H'ZS_WYB_^.5\Y4AI?5:8_;S/H[_A?_A7_ *!^L_\ ?F+_
M ..4?\+_ /"O_0/UG_OS%_\ '*^<:*7U6F'MIGT=_P - >%?^@?K/_?F+_XY
M1_PT!X4_Z!^L_P#?F+_XY7SA24OJU,?MI'TA_P - >%/^@?K/_?F+_XY2?\
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M*** "BBB@ HHHH **** "O/?AE_R+NG?]>D7_H KT*O/?AE_R+NG?]>D7_H
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M)#PI(XY! )P>^*:Q4'=+].]N_P"8>RDMSSRVMI[RYCM[:&2:>0[4CC4LS'V
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M\6RQ2:1=W=L$DFCLK64(!@\!Y'8;4&<%LD].I-+VBLWV'R.YR5(:]A\1>"-
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MPM(=?\+P:K=6<8AANOM3PML'W0X48?'3GM6>WBG=9:_;C3K>$:L8B%MP(XX
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M<0LH,K\'A6"H,>IYKE?"OB5/#EU=_:=.CU&QO;<VUS:O(8]ZD@\,.5(('/\
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M-C,&&5&X\<<@5BWFMW-]H^G:9*D0@L#*8F4'<?,8,=W..HXP!0J+O9[?\/\
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M3_\ I)<5NUA:]_R&?#'_ &$G_P#22XJH[_>)[&[1114C"BBB@ HHHH ****
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MT5ZY_P *@M_^>MY_WVO_ ,31_P *@M_^>MY_WVO_ ,32^OT0^K5#R.BO7/\
MA4%O_P ];S_OM?\ XFD_X5!;_P#/6\_[[7_XFCZ_1']6J'D=%>N?\*?M_P#G
MK>_]]K_\31_PI^W_ .>M[_WVO_Q-'U^B'U:9Y%17KO\ PI^W_P">M[_WVO\
M\31_PI^W_P">M[_WVO\ \32^OT0^K3/(C25Z]_PI^W_YZWO_ 'VO_P 32?\
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M #WO_P#OM/\ XFE]:IC]A,\6HKVG_A2EG_SWO_\ OM/_ (FC_A2EG_SWO_\
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M\4/PJ\0^,;Y+WQ;XA)*\+#;1Y"CT4G 'Y&NQTGX/>#=*VLVG/?2#^.\D+_\
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M^$XXP#*/PKH;?3;>W "H* .+L?"LTS^;.69FZLY))_$UTUEX>MK8 E036R%
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M)8:G<ACD2WK%%^H+D#'TKZ<TOPYHNB*!IFE6=H1_%%$ Q^K=3^-:E4\5&/\
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M,T2NIAECP&"M@_O >G:JCN)[&W17$2>,O$$;E3X;LB1Z:F__ ,8IG_":Z_\
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ML_\ P9O_ /&*/^$UU_\ Z%JS_P#!F_\ \8HY7_3"YW5%<+_PFNO_ /0M6?\
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M291<*'FG7I)*?N_0=J74-;>XF.F:)B>];AYEY2 >I/K3CX6:X.-0U>^NH_\
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MR+NG?]>D7_H KT*JG\3%'9!1114C"BBB@ HHHH **** "BBB@ HHHH ****
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MOL-O_P \U_*C[#;_ //-?RJS10!6^PV__/-?RH^PV_\ SS7\JLT4 5OL-O\
M\\U_*C[#;_\ /-?RJS10!6^PV_\ SS7\J/L-O_SS7\JLT4 5OL-O_P \U_*C
M[#;_ //-?RJS10!6^PV__/-?RH^PV_\ SS7\JLT4 5OL-O\ \\U_*C[#;_\
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M]H\EO'?P>2UQ ES$-ZMNC;[IX)QG'0\U0H5&F^@^>7<]5_X7]XK_ .?#1O\
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M\<O^1,LO^P@G_HN2NC"?QHF5;^&SP TE*:2OHCS!#10:*0"&B@T4#$-%!HI
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M1W,\&Y;\7K_N9/*W@*AR"/=L\D\8Q7,VEEX6\-^%=+U#7='GUB\U8R,JI=-
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M_P"BY*]-KS+XY?\ (F67_803_P!%R5T83^-$RK?PV> &DI325]$>8(:*#12
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M"F:XM([B[;79RMPY<9^08.P8. >?IZ\;?>"]/O?$>JP:5XDT"VL8)%,+7>H
M!U9=V$8 [@O3/M51KQ;8.FT96@>#-0U^PEU 75AI^GQ/Y1N]0N!%&7Z[0<$D
M_A3M2\$:IIM_IUNTUE<0:C*(K:]M9O,@=B0,;@,\9]/SK3M[A--\,6^G^)-+
M:^T22ZF:RO;*["NCJ=LA7J&!P" P'K5VUTNSSH.J:!J>HRZ+_;4,,EE?8#0S
MY!#84[6RO< '^DNI)._0:BK'":E8RZ9J=U83,C2VTK0N4)*DJ2#C/;BJM>MZ
MA>:/KNI>,=&/A^QA^QP75U#>A#]I,R/DEGSR"2>.@''-7K/1-,T;1=)@B3P2
MS7%I'<7;:[.5N'+C/R#!V#!P#S]/5?6++5:A[.[T9Y/9:+<WVCZEJ<3Q"#3Q
M&958G<V]MHV\8Z]<D5I2^"[NWTG3;^ZU+2[;^T&C\FWEN#YP1R0)&4*<)QG/
M]>*Z>>ST_2=,\>P:5/!=6$;63PM'()4*F3=MW#J!G'X57^)>M_;['P[!_9FF
MVWF:=#<^9;0;'7.X>6ISQ&.H7UH]I*4DEM_P$PY4EK_6IQ6MZ/=Z!K-UI=Z%
M%Q;OM8H<JW<$'T((/XUJ1^"-8F;18H5AEN=8C:6WMU<[UC'\;Y& ",D<G@5T
MM_I,OCP^%-3A;,][_P 2Z_<8^22(9+GW,?S?A4+>(-0U'XB7VIZ'91W5G8VT
MD2VI<(K62+L8#D'D'/&2">AQ1[236F_4?*KF?>?#?4H+.XGL]5T75)+9"\UM
MI]Z)9D4=25P.GM3-"^'MQXAM;:2T\0^'DGN 2MI+>D3C&>"@4G.!GZ5HZ)9^
M&_$&HK;^&Y]9T+794?[.K3"2#(4DH'7#C(R,G-9GPS!7XBZ6IZAI0?\ OV])
MRGRO75>0)1NC/\0>%_[ AAD_MS1-1\UBNS3KOSF3'=A@8%8!KN_AV^@+>:FN
MJMI:7[(HL6U:(R6P.3OW#( .,8)/'--^)&DM9W%A>KIFE6T5Q&RFXTB;=;7#
M*>JKCY" 1D<Y]>M-5+2Y&)QTYD9>A>"-2US3FU(W.GZ;IP?RUN]1N!#&[_W5
M."2?PQ5;Q'X4U'PT;=[E[:YM+D$V]Y9RB6&7'7:WM[@5K^.3*=(\)>42=._L
ME/)Q]WS<GS?^!9QG\*J:#I.KZS::9:3R2)X>EU6. DR*%$SX!V@G).WT&*%*
M7Q-Z#:6R.6HKUBTU'1=:\92^#6\(:9;:>\LEI%<0PD7<14$!S(3SR,D$?7..
M:*:CIGA;P3X>N3X<TC4[RXFNDEFNX-X9$DQT[GI@G. />E[5[6U#D\S@+72[
MR]LKV\@AWV]DBO.^X#8&8*/KR>U4Z]IGN+/PPOC^TL-'TV2UA6VGCCN8/,&)
M"GR'GE022!V-8]\FFLGA/PW#HVF1-K%G9M=7Y@'GC<^#L;^$G!R>2<U*K7Z?
MU:XW \NK1O-$N;+1--U:1XC!J!E$2J3N7RV"G<,8ZGC!->CV>HZ+K7C.7P:W
MA#2[;3WEDM(KB&$B[B*@@.9">>1D@CZYQS4MAH]OI'@-=?*OID=Q?"8X+*</
M\I(')7=C/M0ZK[?U9@H>9YC6K<>'KNW\,V>O^9!)97,SP8C8EXG7LXQQD<C!
M/'I7H?C?28KKPK/?V6G^%KJ*VD5A>Z"_DM"A.,2Q<[LDCOD?G7.>"W_MC0==
M\*.07N8?MMD#_P ]XADJ/=ER/PH]I>/,@Y;.QS^D>'[O6;/4[N&2&*WTZW\^
M>29B!UP%& <L3T[<=:J:II_]EZA):?:[2[V!3YUI)YD;9 /#8&<9P?<&NKU4
M_P#"/?#G3=(&!=ZU)_:%UZB$<0J?8\M767\&CZ)J?C6]_L'3;D6$5BUM;S6Z
M^4C, #P,<$G) QGO2=1I_P!>2&HZ'CE:-CHES?Z-J>J1/$(-.$9F5B=S;VVC
M;Q@\]<D5Z=X<;3(=#@U;5=-\):=_:$TLQ;48&N&D3=@>3 N/+0<J.3G&:A\0
MZ79Z-#\1[+3XA#:I]A9(UZ+N8,0/;)/%+VNMK?U<?)I<\WT'1+GQ%K$.EVCQ
M)/,'*M,2%&U2QS@$]%/:LRNQ^%W_ "4+3_\ KG/_ .B7J_X>O-.T7X:3ZO-H
M.FZE?#5A!"U[#O5 8LG(&"PZ_+G&3GM3E-IV]!*-T<=HNCW>OZS:Z58JIN;E
M]B;VPH[DD^@ )_"EUS2?[$U-[$ZA8WQ0 F:QF\V(Y'0-@<CO7K6C36%A\4M!
MN=/T;3X(]:TI+B2+RLBW<HY)BY^7.W''8GUJIX9L]/U#1;_Q3+9>$;:_NK[[
M/%#JW[FRA14&=D?.6.<^W6H=5WO;0KD/'Z#7KEUX8\/:EXVT B319?M,4TFH
M6>B76^ M$I8;1U0.,#'L<'O7(ZOXST_5(82OA'1K.YM[E987M8]B-&/^6<J?
M\M >,G(_6J52^R$XVW,A_#5Y;7]W8W\UI87%M:_:BMS,%WC:&"*1G+D,,"L:
MO;/$L]MK/C37[:YTG31]B\/231R);#>SF*)@S$YR5Z*>,"N>OM5TOP/8Z)I\
M/A;2-3>ZL(KR[NK^#S7D,G.(SGY0!QGGZ>LQJ-]-1N*/-**]?ETK0_#$_C2Z
M&BVM]#;165Q:6UXN[R&E.=I/7 +<C/( !JG._A>]N_!?B+5M)LM.L[TW"7\-
MI$5@+1G"-L';)&1Z=<T>U\OZM<.0\KHKUOQUI$5WX4GO['3O"EU%;2(PO?#[
M^2T*$XQ+%SNR2/XLC\Z\DJH2YE<4E8*2EI*H0&DI324@"BBBD,2OI+X0?\@6
MU_ZX)_Z"*^;:^DOA!_R!;7_K@G_H(KEQ6R-:6YZK1117&;A1110 4444 %%%
M% !1110 4444 !Z5A^"_^1$\/?\ 8,MO_12UN'I6'X+_ .1$\/?]@RV_]%+5
M+X7_ %W%U-RBBBI&%%%% !1102 "2< 4 5=0U&TTJS>[OITAA3JS']!ZFN/D
M^(-S=,?[(T*>>+M-.XC#?05A7MZ?%FN27LQW:;:N8[2(]'(ZN?6M2/M77&E&
M*]Y79NH*.^Y93QQK$)S=^&I&3N;><,0/IBMG2/&NC:O*(%G:VNO^>%RNQOP[
M'\*R8NU+>:/8:O%Y=Y;JY_AD'#K]#2E&#Z6$U%]#KK^*XFL)X[280W#(1'(1
MG:?6O$;RVN;6ZDAO%<7$;8F#')+'^+/<'L?P[5VL&MZAX+D6VU9Y;[2'!$%U
MC,D9QPC>M2WOAK4O$\4FKW3+:W>S%I;?PA.N)#W)_3^7/4IVTZ,E7IR4EJ>?
M\8KM_AS-=_:KFV\U/LFSS#$Q^;)X##TZ?CCVKG=)\/WFIZD]I'"\<D3;91*I
MQ#ZY/?V Z]\=*]7TC1K71K006ZY8\R2-]YSZFL*5+V=]3LQ^.^M./NVM_7W%
MB>UBE0@H.:PM/'V6]N+(\ GS$'\_Z5TM<_KEE-O2ZMB5EC.016C5SSR.ZT\D
MF2#OU7_"J!W(2&!!]#21^)7B;;>6;#U:,_TK6M;VRU%,Q2(Y'56X8?@:YIT;
MZHVC5MN96_BGHLDGW$9OH*T[@V5E&99_*C7W')^@KF]4\1W<=M-=P#[-9P*7
M9MN6('^>E*.';8W6-A+&>0_, @]ZLS&+3;)Y%^^1A2>K,>E8,&LZS+ DD9AF
MCD4,D@0$$'H1BKMAIM]?W27%](S[>@/ 'T%:QHJ+,Y5'(W=$M?(LES]XC)-:
ME,C01H%':GUL0%<UX\9AX6E5<[6FB5\?W=XS72U3U;3X]5TJYL9>%F0KGT/8
M_@<54':2;*B[23//[R]^PV%Q<@9\I"P'TZ5Y?>7D]_<-/<R%W;UZ#Z5Z(L;R
MPW&F7Z%+F(&*92,9]&'L1S7"7FB7]E.8S;R2+GY71<@C\*]2C97.VC97ON7O
M".L3Z3KUL$=O(F<1R)G@@G&<5ZJ\4%SXVTSS88Y<VDP(=0W0@CK7F_AGPU<G
M4(KZ^3R+> ^8%?AF(Z?05Z5X6ADU'5;G6W5A;B/[-:[AC<N<LX]B?Y5CB7&]
MUV,ZS5[HT;*PU>P26UMGL8[;S7:)W#.P4G.-HV@=^]%]=O8/;F\D\T@%7D5-
MHY/7'-;M9^K6D=Q:.7&<#->><ABWR[;S/!# $$=ZYOQ!>W5O=(JW$UO"(_,1
MXDW$R X /'0Y%=1=VY6TMW&3LC56_*JZ%6 # $>]>=45I';1FE9DMA<$Z;!-
M=,(V* N7^7!]\T/KNEQ-L:]BS['/\JXK7[FXEU6:.5VV(<(O;%9?%>;4Q34F
MDBK7/45FBN$6:)TD4CY77G]:YK6M&NKJ^DN(#"XEC$1$J\Q\]14_A821Z0Q<
M$*TA*9[BM21^:ZZ4G**D.,G%Z%6RMVB2VMV<R.N 6)R2?6M^!F.J[1T6(?J3
M66)8--3[3=DAV_U<8^\:O:+)+=RR74J;=W"KZ#L*]"A!I79R59<S-RBBBN@R
M"BBB@ HHHH **** /%_ ]G!<:-8LZ8D%O'MD0E6'RCH1S7<PWVK6./+N%O(A
M_P L[CY7Q[./ZBN,\ _\@2R_Z]X__017:&JG\3%'9&E;>*+-V6.\62RE/&)Q
MA2?9AQ^M;2.LBAD8,#R"#UKD'574JP!4\$$=:QM4U"'PS;+=PRW-N&D"!+?#
M*203RC''8].:(Q<WRQW%.<81<I/0]*HKS&Q^+MLIV7UE.X'22%5!/_ 2W'YU
M?_X6[H'_ #YZE_W[C_\ BZZ/J6(_D9S?7L/_ #H[^BN _P"%NZ!_SYZG_P!^
MH_\ XNC_ (6[H'_/GJ?_ 'ZC_P#BZ/J6(_D8?7L/_.COZ*X#_A;N@?\ /GJ?
M_?J/_P"+H_X6[H'_ #YZG_WZC_\ BZ/J6(_D8?7L/_.COZ*X#_A;N@?\^>I_
M]^H__BZ/^%NZ!_SYZG_WZC_^+H^I8C^1A]>P_P#.COZ*X#_A;N@?\^>I_P#?
MJ/\ ^+H_X6[H'_/GJ?\ WZC_ /BZ/J6(_D8?7L/_ #H[^BN _P"%NZ!_SYZG
M_P!^H_\ XNC_ (6[H'_/GJ?_ 'ZC_P#BZ/J6(_D8?7L/_.COZ*X#_A;N@?\
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M&RNW! 'IT/%4]7UJYUE; 7"1+]BM4M(_+!&47."<D\\^WTKHO^%9Z[_?M/\
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M9$&UM;*/RHH3ZJOKQW-:G_"L=>_YZ6G_ 'V__P 32?\ "L->_P">EG_WV_\
M\32]K0OS75PY*EK#Y_BEK<T4K)8Z/!J$T9CEU.&S"W+@C!R^<<CT%<U=ZW<W
MNBZ;I4B1"#3S*8F4'<WF,&.XYQU'& *Z+_A6&O?\]+/_ +[?_P")H_X5AKW_
M #TL_P#OM_\ XFDJE!;-#<:CW*\?Q"U1-:U+4I++3;C^TH4AN;6>$O"P4 *=
MI;.1CU[UCZEX@O=3ETV5Q'#)IUM';0-""#M0DJ3DGYN>O%=!_P *PU[_ )Z6
M?_?;_P#Q-)_PJ_7O^>EG_P!]O_\ $T*K16S#DJ/H/G^*>MS13,ECH\&H31F.
M74X;,+=.",'+YQR/05CV?C+5=/AT:.T,,1TEI3 X0DN)#EP^3@CMT'!K5_X5
M?KW_ #TL_P#OM_\ XFC_ (5?KW_/2S_[[?\ ^)J>>@NJ'RU"KK'C[4-5TN;3
MH-,TC2[>X(-P--M!"9\'(#'))&>:Y_2=4N=%U:UU*S8+<6T@D3/0D=C['H?8
MUU7_  J_7O\ GI9_]]O_ /$TG_"KM?\ ^>EG_P!]O_\ $TU5HI63$X3>MCG=
M?UZ[\1ZQ+J5XL*2.JJL<*[8XU4 !5&3@ "M#4?&VI:G_ &SYT%HO]KK L^Q&
M&T18V[<MQTYSG\*TO^%7:_\ \]+/_OM__B:3_A5VO_\ /2S_ .^W_P#B:/:T
M>X^2?8ATCXBZII&DVNG_ -GZ3>"S+&TGO;3S);?)S\C9XYYZ&JVJ^.M3U<ZR
MUQ!9JVKK MR8T8?ZK&TK\W!..>OMBK__  J[7_\ GI9_]]O_ /$T?\*MU_\
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M](?[1;2$D=5/(8>A%:-MKEA.H%PRV\P^\L@X_ UYT\'!N]C95GU(T!8!(D)
MX 4=*O6UD5;?*,MV7TK.O=7:Y_T72B2S?>F P!]*JIH.I2 ;[F8CT+FM84$M
M63*JWHC5>QAU#6-Q(81(%..<'K700PI @5!@"L_2--^P0X/7O6I72C(****
M"BBB@ HHHH **** /'? /_($LO\ KWC_ /0179FN+\ _\@2R_P"O>/\ ]!%=
MH:J?Q,4=D--<9\06/]F0+V\\'_QUJ[,UQ?Q!_P"0=!_UV'_H+5T8+_>(>IRX
M[_=Y^AWWAWP[HD_AG2I9=&T^21[.%G=[5"6)0$DG')K2_P"$8T#_ * >F?\
M@)'_ (4>&/\ D4]&_P"O&#_T 5JUG4J3YWJ]S2E2AR+1;&5_PC&@?] /3/\
MP$C_ ,*/^$8T#_H!Z9_X"1_X5JT5'M9]V7[*'\J,K_A&- _Z >F?^ D?^%'_
M  C&@?\ 0#TS_P !(_\ "M6J]]]L^Q2_V?Y'VO;^Z^T9\O/^UCG'TIJI-NW-
M^(.G!*_*ON*7_",:!_T ],_\!(_\*/\ A&- _P"@'IG_ ("1_P"%<M!XC\6M
MJNI6EP-!C33%22ZD"S8V$;B5P220 >U=##XS\/3VEQ=QZG&8+<*97*, -W(
MR.3P>!S6TZ=>.S;]+O?8PA4H2W27K9;;EC_A&- _Z >F?^ D?^%'_",:!_T
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M/L-O_P \U_*K-% %;[#;_P#/-?RH^PV__/-?RJS10!6^PV__ #S7\J/L-O\
M\\U_*K-% %;[#;_\\U_*C[#;_P#/-?RJS10!6^PV_P#SS7\J/L-O_P \U_*K
M-% %;[#;_P#/-?RH^PV__/-?RJS10!6^PV__ #S7\J/L-O\ \\U_*K-075Y:
MV,/G7ES#;Q9QOFD"+GTR::3>B$VEJQOV&W_YYK^5'V&W_P">:_E4-MKFD7LZ
MP6NJV,\S9Q'%<(S'\ <U?H<7'1H%)2U3*WV&W_YYK^5'V&W_ .>:_E5FBD,K
M?8;?_GFOY4?8;?\ YYK^56:9--%;PO--(D<2#<SNP55'J2>E $/V&W_YYK^5
M'V&W_P">:_E5@$$ @@@]"*6@"M]AM_\ GFOY4?8;?_GFOY5+#/#<(7AE250Q
M4LC!AD'!''<'BH+S5-/T[9]NOK:UWYV>?,J;L=<9/--1;=D)R25VQWV&W_YY
MK^5'V&W_ .>:_E3KB]M+.V^TW-U#!!Q^]ED"KSTY/%-@U"RNIW@M[RWFFC +
MQQRJS*#T) /%'*[7L',KVN'V&W_YYK^5'V&W_P">:_E4DES!"&,L\:!2 Q9P
M,$G S]3TJ6E8=RM]AM_^>:_E1]AM_P#GFOY59J*YN8+.!I[J>."%/O22N%4=
MN2>*$K@W;5D?V&W_ .>:_E1]AM_^>:_E20:G875K)=6]];36\>=\L<JLB8&3
MD@X''-658,H92"I&01T--IK<2:>Q7^PV_P#SS7\J/L-O_P \U_*K-5/[4T_?
M;I]NM=UR,P+YRYE'^SS\WX4)-[ VEN.^PV__ #S7\J/L-O\ \\U_*IW=(HVD
MD=41069F.  .Y-)%+'/"DL4BR1.H970Y# ]"#W%*P[D/V&W_ .>:_E1]AM_^
M>:_E39=5TZ"T2[FO[6.V<[5F>90C'G@,3@G@_E36UC3$LDO7U&S6T=MJ3F=0
MC'G@-G!/!_*JY)=B>>/<D^PV_P#SS7\J/L-O_P \U_*H+;7='O)U@M=5L9YG
M^['%<(S'OP <UH4G%QW0U)2U3*WV&W_YYK^5'V&W_P">:_E5FBD,K?8;?_GF
MOY4?8;?_ )YK^56:* *WV&W_ .>:_E7"_#!%7P]IY ZVL7_H KT.O/?AE_R+
MNG?]>D7_ * *I?"Q=3T*BBBI&%%%% !1110 4444 %%%% !1110 'I6'X+_Y
M$3P]_P!@RV_]%+6X>E8?@O\ Y$3P]_V#+;_T4M4OA?\ 7<74W****D84444
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M(+(?*HS6C@#M2T4 %%%% !1110 4444 %%%% !1110!XWX!_Y ME_P!>\?\
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MGA7_ *&;1O\ P/B_^*H_X33PK_T,VC?^!\7_ ,51R2[!S+N;E%8?_":>%?\
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M=)6A1_G/[Q%"-D-][D]^IZU+_P )IX5_Z&;1O_ ^+_XJC_A-/"O_ $,VC?\
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M>2,'-=!X<O#>K?2%+-R+C;]LLTVQW0VCYAR<D?=/)Y'6C_A-/"O_ $,VC?\
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M%?\ H9M&_P# ^+_XJCDEV#F7<W**P_\ A-/"O_0S:-_X'Q?_ !5'_":>%?\
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MRT]-DD0C SO+#!KIM%U4ZC$2PPP]*RQ%&2;GT.B+6QJT445RE!1110 4444
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M$2@KIJ* .9_X1*"C_A$H*Z:B@#F?^$2@H_X1*"NFHH YG_A$H*/^$2@KIJ*
M.9_X1*"C_A$H*Z:B@#F?^$2@H_X1*"NFHH YG_A$H*/^$2@KIJ* .9_X1*"C
M_A$H*Z:B@#,TW28]/SLK3HHH *\X^+O_ "!+3_KZ7_T!J]'KSCXN_P#($M/^
MOI?_ $!JZL%_O$/4Y,=_N\_0[+PQ_P BGHW_ %XP?^@"O,OB_P#\AVP_Z]O_
M &8UZ;X8_P"13T;_ *\8/_0!7F7Q?_Y#MA_U[?\ LQKIP/\ O?WG-C_]S^X[
M33]6.A_#.QU%;?SS%;1_NPV-V2!UP?6O)?%WB%O$NK)?-:&U(B";"V[."><X
M%=;HOQ1M=*T2ST]],ED:WB$982  X]L5R?C#Q%%XFUA+Z&V:W58A'L8@]">?
MUKMPE"=.M*4H;WUO^APXS$0J48QA/9+2WZGNOA[_ )%O2^G_ !Z1=/\ =%:5
M9OA__D6]+_Z](NW^R*TJ\*I\;/?I_ O0*R-;U."TM71RI8CH>U7KZY%K:/*>
MPXKP_P =:Y<W=VFEV[,TLY&\#J<GA:NG%*+J2V1%>JJ4.9BZQXTLD=X+6'[4
M3D$GA?P]:RK/Q-J]E9QQC3BT,:X#-&W3ZUVWASPK9:%:H\D:37S#,DK#.T^B
M^@K<EF8(QYX%3+%592O>QRJG6E[TI6\D>9/X\EG41RPO$1_<;(_(U'INE7?B
MF\:ZOI66W7_.T4_Q(D=S>P((D#R2G+;><"M_4+G_ (1WPF'A"B4J%3_?;O6F
M,K3=J3V1FTVW[1W430B?1/#D0CWV]J<?Q'YC_6K]AKNG:@^VTOHIG_NJW/Y5
MXE)(\TK2RN7D8Y9F.231'(\,BR1.R2*<JRG!%<-S%8YIV4=#W'5M)L]<LFMK
MN,$D?))CYD/J#7F.FW,GAG6;JQN]@ RI=QV['Z&N[\+ZTVL:-'-(?WZ'9)[G
MUKE/B+:HFJVEV%!\Z/:_'4J?_KUM0J>SJ1GV.BNURJO'I^1H6.HZ/<SK)'-I
MRREL\E0V:]%T#5+2U3:W\7\0/%>6:3H6DWR%9["%P1D<8-:(\&W%E^^\.ZG+
M:N.?LT[;XF]O:OJ,3AJ4O=O8Z8N2UL>W0SQSJ&C<,/:B:>.!=TCA1[UY-X<\
M975IJG]F:M;M9:BH_P!4Q^24>J'O6IKFMSS2QE5W>8^Q06PH/O7C3P,H3LWH
M:JHFM#N8M9LY91&LHW&M '(S7G&C6%U-=!YIP>1PHPJ_3N:]$BQY:@-G ZUA
MB*4:;7*4G<?1117.4%97B?\ Y%/6?^O&?_T UJUE>)_^13UG_KQG_P#0#5TO
MC7J15^"7H<;\(O\ D"7?_7TW_H"UZ/7E'PMUFPL;"XM;JX6&1YRZ[^%(VJ.O
M3M7JJ.LBAD8,#R"#UK?&_P"\3]3# _[O#T'4A(5220 .232US_C+4OL'A^5$
M;$MR?)7Z'[Q_+/YBN4ZBEH'BP:C?7L,IP/-+P?\ 7/H!^F?QJ_KAW:QX7(_Z
M"3_^DEQ7EUI<M97<5PIQL//T[UZ'<7:W5[X5<$'_ (F+_P#I)<54=_O$]CK*
M***D84444 %%%% !1110 4444 0W3^7 Q[G@ =S7.7;.6C@8_P"K4!L>N*V+
MB?-TZ@\QQY ^O4_Y]:P4^9BQZDYKFQ$M+&U):W.;UC4+JWU&2-+EX!%&'CCV
MAO-/-=1:AI;6*1U(9D!(/TJIJ.HV]@T D@>>=R3&D:AFX')_*K^G7D.I6BW,
M 8(25PV,C!QR*XVSLEK%:&;JR6$:?Z7*B%N@/4U!X76V74+B""59898]P /\
M0_\ K5@^(H9XM:G\\DACF,GIM]JQ)'N;:9;FTD:.5#D%3BN:&,<:EI+0QE"Z
M/59[9X3E 63]14'F]C6-I7C%XX$75(G?*Y66,<GZBDO_ !3/*@%C9*F[D-(N
M6_+H*]%THR7-%Z&:FUHT6I-*L'NA<_9U\T,&!' !'M5Y8IICA$/U/ K+TOQ<
M(AY6M(D/I<*N%'U%7Y_&6BA&6UNA=R]DA'\S25*.]RI59/H:>G0".&4YR[/M
M)^@_^O63?V2WMI+;-PW\)]#61I^OZA87D]Q=Q&2UN&#%%ZI]/PKHVEANX5OK
M5]\,G4]P?>BK&,X61,&T]3@)--O8IO):VD+YP,+D'\:[K0+>:ST>&&<;9 2=
MOIDU,DG'6DN+M+:VDG?)6-2QQUXK@IX=4W=,VWT.:UO5-1AU695GEBV[5MH1
M%E9SN[_CQVZ5TJNS01M)]\J"V!CGOP:R[#7/MUV()[,P2M$)$R =P^O:M&1Z
MZ+%S>RL-DGGBMG6VXDE<(&_NCO6[I%HUK:*K=>]9D*K#:1RRC[TRD?K700RQ
MRH#&ZL,=C7H45:".&H[R)****U("BBB@ HHHH **** "N>U[Q FG(P5U4*,L
M[' 45>UJ_P#L5H=I^=N!7F5O9-XOUFYDNRSZ38.$\O.!<3=>?51Z5W83#J7[
MR>R(G*VB$E\:W]Z6.FV-U>QYYDW"-#]">M4G\5:C#_Q_Z-<I'W:*42X'N.*P
M/&GCFXMM3DTO1]D,5L=CR!1U]%'8"N:M/&FIQ3 W;BXB)^8%0&'T(KZ"EA8.
M-^6QS.JD[-GIMI>Q:Q.+BPEVQQK\S8P6)Z @]A70Z1:QK-Y]TXZY8_R KS![
MK[&T>M:<VT,H\U1P)$[Y'J*W-/UG4M79H-+6/9_%=3YV+]!W-8U<%**;3-.>
MSLSTW5O%D%G;;;<$GH#7$7_B--662(H\DKJ4 *X'IR:EB\'"] .HZ]J$SGJ(
M2L2CZ "L_6_"=SH<*W.F:A+> <M;7 &XC_98=ZYZ-##Q]Q/5^0Y.3UL7(+R[
MOI8]-TZ$_;2H,AE!V1+_ 'FQ^GK3-3TO0-(YUO4FN+AN<2$G\E%:/@IA%X=F
MU-U'GW;,Y)ZA%X5?T_6O']0O)M0U">[N&+2RN6)/;GI7AXFO*<FKZ'%7K<D5
M)J[>QW,5EX;U:3;I5YY-SU4#*G^E6]'UO4-$UA--U)R2W^IG/\7L:\T21X76
M2-BKH<JP."*](\56[7OA2UU0#$\(27('/.,_K65*K*G*ZV,Z55R3E%6:[=4>
MP:3J(O[8,?OCK7-W?P]M]8\57>L:M,9(9&7RK:,D A5 ^8]>W0?G3/ VI+=0
MQL&7]Y&&(SWQ7<5USE*A4?LW:Z/2E3A6BN=76Y%;6L%E;I;VL*0PH,+'&H '
MX5+117*W?5FR5M$%%%% !1110 4444 %%%% !7GOPR_Y%W3O^O2+_P! %>A5
MY[\,O^1=T[_KTB_] %4OA?\ 7<74]"HHHJ1A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5YQ\7?^0):?]?2_^@-7H]><?%W_ ) EI_U]+_Z
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M4-CT%<S87&IS:O"TANO,8L9XWXB5>BD5E.A"IJQQ@];]#H+/0;:6%%D4-%
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M'I7CSPT%3;B="D[G;T4=117G%A1110 4444 %%%% !7GOPR_Y%W3O^O2+_T
M5Z%7GOPR_P"1=T[_ *](O_0!5+X7_7<74]"HHHJ1A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^07'7EXWWZ4*KW?_#&U/1N)IT445YAJ%97B?_D4]9_Z\9__ $ UJUE>)_\
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M_P"0):?]?2_^@-7H]><?%W_D"6G_ %]+_P"@-75@O]XAZG)CO]WGZ'9>&/\
MD4]&_P"O&#_T 5JUE>&/^13T;_KQ@_\ 0!6K6%3XWZF]+X(^B/,?B]G_ (DW
M7_62=/\ @->EP_ZB/_='\J\T^+P_Y W'\<G?_=KTN'_41_[H_E756_W:E\_S
M.6A_O-7_ +=_(?1117$=Q5U& 7%E)'CM7@?BRV;2/%,6H."+:[7R96[*XZ9_
M#'ZU[[>WD5G 7D(^GK7G>OP6>NQS03P@PRC!'H?4>]>OE=65.5[:&517VW/-
M=;T9M2LP]N!]HBY4?WAW%<-)YD,C1RHR.IP588(KOU74- #!XIK_ $U&*I<1
MKEE4>H[U<CU+PWJP7[3):NWI.NTC\37T<:ZDN:.J.><%)WO9GG=I*WGH%4LQ
M., 9)KU;PKJD5WIYTVZQD H W<'JIJ W/A#3(F>.6QAD(X,(W,?RK!)NM1U
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M*ZMYG6>(723Q5I@ 7>+:0-GKC(Q5^/PQ)<R1W*1X9L'<K$9^N.M<IH=XVO\
MB:2\'*N?)C]@#R:]GMHA!;I'_=%>FI2H48W6KU/8I+FO+N5=*L/L%J(R<L>3
M5^BBN.4G)W9T!1114@%%%% !1110 5Y[\,O^1=T[_KTB_P#0!7H5>>_#+_D7
M=._Z](O_ $ 52^%_UW%U/0J***D84444 %%%% !1110 4444 %%%% !1110
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MJS_NBC_A&K/^Z*/KO_3N/W!]1_Z>3^\\N_X2GQ__ ,_A_P"_4'^%'_"4^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!%/K+\/Z'#X<T:'2[>YN;B"'/EM<LK,H)SMR .!VK4KSG:^AJ%%%%( HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M![7_ .,T?9O&'_0QW_\ X#VO_P 9KT#:OH*-J^@HYG_2"QY_]F\8?]#'?_\
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M'_0QW_\ X#VO_P 9H^S>,/\ H8[_ /\  >U_^,UZ!M7T%&U?04<S_I!8\_\
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ML>?_ &;QA_T,=_\ ^ ]K_P#&:/LWC#_H8[__ ,![7_XS7H&U?04;5]!1S/\
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MK@# S^5=3M7T%  '04G)L+"T444AA1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y7QE(SR:;:G_5,[S,/4H
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MS)48HR=&T<:>A9\%S^E:]%%8SFYOFD;)6"BBBI **** "BBB@ HHHH ****
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MF*0RQV[*L2D,PCWR-R,^H&,8([CBHH];NEMO+>[#7#V^;?<J[I6DD*QM@#L
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MFU(D.R*/Y002#R3@\\8)X[UT]%'-Y!8YJ/6+H'[-/<HMX'@C9 HR!M#R/C'
M(W 9X^7BH6U/48DBDDO=JRP)+,7B7;;!Y %/3LNX')(X!]:ZNBCF78+'-VEX
M;F\M3-=>=;0/-/'<R!5WHJA QP ,9D;!  (%/\22Z3OBM[W[)]JE1A"UU(%2
M(<9?D]1QC'S'V&2.AHHOJ%CEHO(_M],2"34/M*[7)R[6_D]<_P!S.?;=[U8B
M6ZM4UE+))KB<W:C)=2_,4>6^8@<9) X'0<"NAHHY@L8_AR4?V-;1.KQR?/M2
M5U+L W)X)SU&36/?2WW_  G.FRW%M.L"O+' H9"A79R_WLY^HZ 8R:["BA2U
MN%C,NQ8:SHAG,45U;M$9(C+'D=#@@,.#61.]GI6E:?#:WT.DRW"!OD$,:M\H
MR[;U.<>V"2<>XZJBA.P6.5DUJX7Q'%;1WJO 9/):(LFXCRBP?:%)P3CYMP!Z
M;>]+#?:C]FC#7\C/<16LF\QIF,R/M8* N,8Z9SCWKJ:*.9=@L<I<ZI=PP".3
M4FA*?: DQC3,\B/A$(VXR1V4 G'&*MKK,O\ ::6<DRK.UVJF' W",P[NG7&[
M//KQ7044778+%6XU"VMK5+J25?L[%?WP8; #T8GICWK >:VED$^H.BZ9=S2N
MSRG;&^T*L88GC:0&(SP>*Z>.-(HECC&U% 51Z"G4D[!8YJ4:9'';#8MOHKN[
M/N^6%FP N1T"'YCV!('7/,L!TV&QU*90D6B;!CR\JC<'>5 ['*CCJ<UT%%/F
M"QQJ'2'MXY6:Q32Y+K=-;QNC0P_NV"[]IV@D@$]LXZGDWX8G,7AR:5YMX?:$
M=B !Y,G)'=L8Z]/;)ST=%#D%C!M]/L%U;4+Z."WL_LZF'SXT1""5#NY.,=QU
MST/K5+Q<8A<V<L[V+)##*Z0WD3.LSX7"CH-W7')// /;J9(UEC:-QE'!5AZ@
MTZA2UN%BE:7-MJ%O);^7AD54G@92-A90=IXYX/:LFU+SW$.FR@N-,)>4XSNQ
MQ#]25^;ZK71T4KA8XFUUZ^GM[PC4H2/+AE25G3$89B&!*QD(< #G>%/5C3SJ
M,U[;Z=(Q,C[N6=4)8B>+&&3@CG&5P#C.!T'9T57,NPK'&V>JZA<VS/-<6\[>
M9 3$I#F%S( 5(\M=I]B2PQU[U-;:U<"V,[:@)XP+=[ARB@6[,^)$) X '9N1
MW-=912YEV'8QH;L:AH-]*]PXC+3HLT2DD(&(!4+R>/3DU!X=:S6YN(K-;!T"
M*6GT\[8F.3P4!(5OQ)(ZXX%=!11<+'%76HZA=IJL,MY$BK#/N@1P7B53P=OE
M_*".[,<@Y'MLZS?O:Z99FWOE0S,%%RSHJM\I/+%2HSCLIST &<C<HHYEV"QS
MV@7YNYDN+B1!-<65N>H&YOWA.!^!./:K%TMW/KQ-I/!";:V^8S0F0'>W;#+C
M_5C\ZV:*+ZW"QQ7]JW5M;VJ0W:1W$VVX*D*GG&63/"D,Q !Z#&/[WI836M1-
MW>2F>W*0K*6M5DW.F,A,KY8*L3CJY!R<"NMHI\R[!8YG[1J<,^UM1DF,=S%$
M5\E!YAV[Y!P.FWICG.>3TJA_:UQJ,5U$^I 6\RQ NCQYBWR;=N=N%^7.02Q]
MQW[6BES>06.5_MFXC\UQ>F>6-9O.M0BCR54,%)(&0Q(7J<')P,4[5X](M+.Q
MT^\-H;D6_E0O=.%2(  %^3UZ8Q\Q]ADCJ**.8+'+1>1_;Z8D$FH?:5VN3EVM
M_)ZY_N9S[;O>BXMXX[75TEF5HUOHGD-VYV2?)$2'(!VJ?I@>F.*ZFBCF"QC^
M'90; *3"BO)(UO'$V5\L$#Y,@94$\' &".@(JIXL4LNGK(T"69F;SVN1NB'R
M-MWC(R,^XYQ71T47UN%M+&/H%_#<:;:VQB,,XMDD:!BS;4.0#ENN<=SFJD>C
MVL6H:FVGV=I;W<:(;>18$&QBI]N,]ZZ.F2QK-$\;%@K#!*.5/X$8(_"BX6.;
MEU>>>&WNWOCI]G<3^6&9$!15C8G)8$ [QCGT'K5=M9U-KBQ4W,$(>.-E$AV&
MY)8@X7RV+< '"E<;N>*Z=;*W1+9%CPMM_JAD_+P5_'@GK5BGS+L%F<SXD2T?
M5;(7<^F1)Y$N#J,(D0G*= 67G\:?<Q//X0L8I RR.;=3O))SO7G)Y]_6NCHI
M<VP6./-]<HNHZE !'+.D&6<X$2!V0DG#8 P3D@@9R13+C6=32QM3_:%JBOYI
M%UYH"R%2 J[C"0QZ\*HSC@UV=%/F78+'&7-Y<6DE](MT&N1<,^QD4^4?LQ((
M!7(&1CGL/KF_/>W-KYEO/J;QQ+=JCWCK&&C0Q;@#\NT?-QDCOCKS725!=6L=
MY$(Y6F50<YBF>(_FI!_"ES(+&//<27?@>>XG=6>2T<LQ7 /![=JS+-_LYN!I
MEU8>6[6R>=IT(2-2TA##;N92^".?3''3/7PQ1P0I#$H6- %51V%/HY@L<=J&
MI7]C=3P17D4""1LW,Q2,R,(X\ D1L&)R3@ $XX/&*FOHW&L27LCAI5CM%56B
M1E3=(<[<KN'3U[^PQU=%',%CE8]1OXK O+?NWF6UO,TK1H/(#L0Y&%Q@#GYL
MXQSD5L:'=/=V4DC7/VE5F=$FP!O4' /'!X[C@]JO3P)<PM$YD"MU,<C(WX,I
M!'YTEM;16D AA4A 2?F8L23R22<DGW-#::"Q+1114C"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJED=0L
MQ &*CS8W8ARAPK G!'(.!VJ[10!S>K>')9X#!I^T(\4JNTMS(K[VQABX!9QQ
M@J3CIUP,6UTZ]CN9 ([.2&:1)7DE)+HRJ%P%Q@_=X;(QGH<<[-%5S,5CF(]
MU"WT^WM(WAD2)U<YG>-SE"&'F!2PP<$8QD?+P!S5ET^\LXK2P$2SRO;V\,C"
M.1E3RW)R&V[?7[Q4C&>>E=C11S,+&!8Z-<V6H23[8I IE:)FNI26+G.-ARJ#
MG!(!SUP*WZ**3=QV"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img101536035_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;)&XP\3?W6%;=9M-.S+W"BBBD 445Y9KGB_QI9_%NTT2STTOH[R1+Q 2)8V
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ML_\ _(S:]_UP7_T.J?QJN;FS^*NE75FNZZAM8)(5V[LN)7*C'?D#BKG[/_\
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M#[3XB..=EOS^,E.5HN;MV$M;%7PQKGBWP1\4+;PQKFIRW\%U*D+K),TJG?\
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MQ45H1O=MF)9>(-:?]GK4=3;5[\Z@EZ%6Z-R_FJ/,C& ^<XP3W[U;^&EAXO\
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M:*W$EPT$;%<8R5ZENHS^'OZEX!MO%.C^'KK_ (3&_CG,3LT3EO,=8QG+,_\
M$#U'<#KZ#C/';?#?Q?KM[9WFK#3=9M%V&_5?W<A'53V;;T['L"<8JE\'K_5-
M<T#Q+X9ENGN+*.V,=M,Q/[LN&7 )Y /4#M@U,E>&UAK211_X23Q3\4-=O%T[
M7X_#^BVQVINN#"64YQG!R[$#)&<#^:CQ-XH^&&OV<>I:_'X@T6X(#L)S,54'
MG&3E6 .0,X/\N6\%Z)X0EO[_ $KQM<7>F7\$NV-O,")D<,K':<$$=3P:ZE?#
M/P?DUN#28M:U&::8A4DBDW1EB<!=P3J?R]ZT:BG:VGH2KO4V_C-XPU>QO-'T
MG2M0?3[.^C$TE[&Q3(+8'S#D #DXY.:T_AQHOC73-89[[Q%;ZMX>>'<DPN#<
M"4G. A/*X[]OKU%GQY/X#M[+2_"GB>>3(B"P3KS);*%VAV8#C.,="#CD8%>>
M^ ;Q_#'Q9AT'P_K)U71KMBLA3[C#86SCIN7'WAUP?7%9I7IV2*>DCZ,KB?B[
M_P DMUO_ '8O_1J5VU<3\7?^26ZW_NQ?^C4K&G\:-);,S?@;_P DVA_Z^I?Y
MBO(M._X2*7XM:]9>&)A!?WEU=0-.1Q%'YI9FS@[?NCGKZ<XKUWX&_P#)-H?^
MOJ7^8KC/AB ?CKXFR.GVS'_?]:W3M*;,VKJ)E7FI>-_A=XSL4U;6YM0M[@K(
MZM</+',A;###\JPQU ].O2O1/B]X^N_"=A:Z=I!VZG?9(EV[O*C'&0/[Q)P.
MO0^U<I^T%_R%_#G^[+_Z$E2?':RNK'Q!H/B1(3);0XB;^Z'5]Z@_4$_E324G
M%OS$[JZ1'9^#?BUIUF-=B\0227@7S6L)KMY&8?W2K H3[9^AS4'PFUGQ%XFO
M_$MG<ZU?//+I[B S7,C+!(QP&7).W!/;D5Z$WQ@\&C0_[2&I@R;-WV3:?.W?
MW<8]>_3WKSOX"W!NO&6NW!4*9;?>5'09D!Q2O)PDY(-+JS.2TKPUXCNOB;=Z
M+:ZZ\.M1O*)+\3R L5'S'>/F.:^JT!6-0QR0 "?6O!O"_P#R<EJG_76Y_P#0
M:][J*[;:]"J:W/'OVA?^19TC_K\/_H!KS_5?B3<^)? FG^"[303YL<4$ E64
MRO(8P -J! 03M]3P2*] _:%_Y%G2/^OP_P#H!KB?$NC7/@^U\&^.-'38);&U
M,V!\HF$2]<=G7.?HWK6M*W(KDSO=GKWA&W;X?_"B!M9!5[*"2XGC7DJ68ML'
MOR!]:\RT^[\8_$V:YU*7Q7#H.GK)LC@6Z,0XYP%!!;&>68]>G3CU+Q&P\>?"
MB\ET?,AOK02PHI^8LI#%/KE2OUKQ'P)HWP]U?3I(?$VHW6G:I$Y!W3".-U[$
M$J<$="":B&SD]QRZ+H=;X>\9^(?!7C:V\.^(]7CUC3;QE6.[67SBN[A6#GGK
M@,ISCJ/=/BGXGURX^(,'A>VUHZ)IX1,W!E:)6+#.YV7G;_#CID<U'HWA7X4:
MGXE32M-U?5)+T,&A97^21ASA6V=L>U=/\1;KX>Z[K2:!X@O3:ZG#%E+V,8\@
MGD(S<CGK@C ]033]WG3M^'XBUMN:7PUTKQGI1O8_$6KQ:AIW'V23S3,TG0[U
M<\[<<8/?ICOR/PUUW6+_ .+^O65YJM]<6D2W7EP37#O&F)E PI.!@<53^#.J
M7EAXYU'PU::B=1T58Y'20 A 58 .H/W<YP1WR.N*S]!U:U\$?'76WUIS;6\\
MMPGFLIPJR.)$8X[$ ?G0XZR7D.^QT'QJUS5]*\4:##IVJWUG%+&3(EO</&'^
M<#D*1FL_XX_\CYX<_P"N2_\ HVL_XCZY8>.OB+H-CH,OVQ8RD)D0':S,^3CV
M ZGZ^E:'QQ_Y'SPY_P!<E_\ 1M5!6<5ZBD[W*?QXTG5;?6HM3N-1:73+IPMM
M:&1B(65%#':?E&3SQ7J?PPT?6-&\)(FL:FU^]PRSP,TKOY41C7:GS=,8/ XY
MKBOVB/\ D$:'_P!=Y?\ T$5ZOX>_Y%G2O^O.'_T 5E.3]DBDO?9I4445@:!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 8GB+PCH7BR.W36['[4M
MN6,0\UTVDXS]UAGH.M:]O;Q6EM%;0+LBB01HN2<*!@#)]JX;QM\4].\$ZY::
M9<V-Q</-&)I'C( C0L0",_>/RGCCZUWBL'0,IR",BJ:DDK["5KZ"]:X?5?A%
MX,U>\>[DTLP32-N?[-*T:L?]T<#\ *[BBDI..P-)[F5H/AK1_#%D;31[&.UB
M)RVW)9SZLQY/XUB:_P###PGXDOWO[[3BMVYS)+!(T9?Z@'!/OC/O785YGKOQ
MP\,Z-JLEA%#>7YA8I+-;JNP$=0I)&[G\/0FJCSMWCN)\J6IV^@>'-)\,:?\
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MN*ZUK3?M4\4?EHWGR)A<DXPK =2:S+?X2>!;:998] C+#H))Y9%_)F(-/O\
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MN4^*VL>+;^#2[;Q)ID-M%&BRQS10.FZ1XU+*26()7.#CN#6_\,85E^.OB9V
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M>8VP<XZ<]Z(PCK%:L&WHQ?CQJ6M3ZU%875@L6DV[AK2Y\M@96:-2X+9P<'T
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MOAO1_#J3)I&GPV:S$&01 C<1G&?S-:E%%<[=]S4**** "BBB@ HHHH ****
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M4$C@_AU\-_\ A )-1;^UOM_VP1C'V?RMFS=_M-G.[VZ4FN_#7^VOB'I_BO\
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MA79^ ?ACIG@??<B9KW4I%V-<NFT*O<(O./KDFNYHJG5FU9L2@D[G!^%OAO\
M\(UXYU;Q+_:WVG^T!,/L_P!GV>7YDJR?>W'.-N.@ZU8^(G@#_A/;2Q@_M/[#
M]ED9]WD>;NR ,?>7'2NTHI<\K\W4?*K6,T:+:R^'$T2]5;FV^S+;2!A@. H7
M/MTS[5Y+/\!KNVOY3HOBB6ULY3RC1MO5?0E6 ?\ 2O;**(U)1V$XI[GD^C?
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M(M[_ .PM=*(VG\KS,+D;AC(ZC(Z]ZS_ 7@J#P-H+Z='<_:Y99C++<&/9N/
MQDX  ]?7UKJ:*?,[<O0+*]S&\5^'8/%?AJ\T:XD\I;A1MEV[O+8$%6QD9P1T
MR*YC2_AK/I_PZU'PA+KOGQ73$Q7'V7;Y()!(V[SD9!/4=37H%%"FTK(&D]3@
MM-^&O]G_  VOO"']K>9]J9F^U_9L;<E3]S=S]WU[UK>!_!Z^#?#)T9[P7RF5
MY#(8?+!#8XVY/IZUT]%#G)JS!12/'-9^!*_VE+>>&M<DTU)/^7=E8A<GD!P0
M<>Q!^M;?@7X16'A34!JU]>-J6IC)1V3:D1/4@9)+<]3^5>D453JS:M<7(KW/
M)_BSJ'@RZN[?1?$\6HVUTJ>9;7\$(945N">OS#(Y&,\<5YU?>$_ VCZ9/>3>
M-QJ^R)S:V-K%L9G(^4,=S8&<$\#H:^A/$7A71O%5D+76+)+A5Y1_NO&?]EAR
M/Y&N0M?@=X,MIQ(\%Y<@$'9-<';_ ..@&M(5(J-KLF46V97[/^G3V_A74+Z1
M"L=U= 1$_P 008)'MDD?@:L>)O@M!?ZU)K'A[5Y='NY&9W15)3<>I4J04SSD
M<]>,5ZA;6L%E;1VUK#'#!$NU(XU"JH] !TJ6LW5?,Y(I15K,\E\,_!9K'7HM
M9\0:Y-J5Q X>-$W#+#H6<G)'MQ]>U;WQ%^&__"?R:<W]K?8/L8D&/L_F[]^W
M_:7&-OOUKO**7M)7YKARJUC)\0:+_;OAB]T;[1Y'VJ P^=LW;<CKC(S^=97@
M3P4G@OPY/H\EZNH)-.\S.T'EC#*J[2NYL_=_6NKHI<SM8=E>YX]JGP.:'4Y;
MWPMX@GTH2?\ +$[OER>0'4@X]B#]:U/ _P (HO#.LC6]3U674=17.S:"J*3P
M2222Y^N![=*]-HJG5FU:XN17N<%JGPU_M+XDVOB_^UO+\AHV^R?9L[M@Q]_=
MQGZ5I>-_ .E>.;!(KPO!=P@_9[J,99,]01_$O X_(BNKHJ>>6COL/E1X:?@-
MK$NRTF\7%M/7HGE.<?1"^!^=>K^%/"]CX0T*+2;!YGB5B[/*^2S'J?0?0?\
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M_P#U$_\ R7_^RI/^%??]13_R7_\ LJ[:BCVT^X>RCV.(_P"%>_\ 44_\E_\
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MTG_"IO\ J-_^2O\ ]G7I5%'UFKW#V,.QYI_PJ7_J-_\ DI_]G1_PJ3_J-_\
MDI_]G7I=%'UFKW_(/8P['F?_  J/_J.?^2G_ -G2?\*B_P"HY_Y*?_9UZ;13
M^M5>_P"0>QAV/,?^%0_]1S_R4_\ LZ3_ (5!_P!1W_R4_P#LZ]/HH^M5>_Y!
M[&'8\P_X4_\ ]1W_ ,E/_LZ3_A3W_4=_\E/_ +.O4**/K57O^0>QAV/+O^%.
M_P#4>_\ )/\ ^SI/^%.?]1[_ ,D__LZ]2HH^M5N_Y![&'8\L_P"%-_\ 4>_\
MD_\ [.D_X4U_U'O_ "3_ /LZ]4HH^MUN_P"0>PI]CRO_ (4S_P!1_P#\D_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_X69XF_Z)QJ_P"<G_QFCZK5[?BO\P]M#^DSTRBO,_\ A9GB;_HG&K_G)_\
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MR\,_\^.K_P#?F/\ ^.4?5*W\H>VI]STRBO,_^%Y>&?\ GQU?_OS'_P#'*/\
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M** "BBF-*@[Y^E #Z*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH:
M):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH:
M):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH:
M):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH:
M):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH: ):*B\]?0T>>OH:
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MM)C_ &AGCL?7@4$XIAS.YZG17CJ>(-;LO#_CW0+G5+FYN-$BW6NH;MLVQAD
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M8GN%YW'!Y(Z<G)Y(SQQZ)64U:5BXNZ"BBBI&%%%% !1110!QGQ7_ .2::O\
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MZ.3_ %;?2O,:2>A]K3E*4$Y*S[%2BBBD6%%%% !1110 4444 %%%% !1110
M5SOCW_D0->_Z\9?_ $$UT5<[X]_Y$#7O^O&7_P!!-5'XD)['E'@SX4:#XB\#
M6VMWNH7UM<2K(699$$2;790<%<XP.>:WO@YXBG30=<AU2_,NGZ4X:.YD;(5,
M-G!ZX^7('O6-X#^$N@>)_"%CK%]=:DEQ.7WI#(@3Y791@%">@]:[O7?!5MIO
MPQU70O#MJR.\1<*#N>9@03D]R0N/T%=$Y)MQ;Z_<9Q3W,)OC2TIEN[+PEJ=S
MHT+8DO@2 H[D@*5'XL*ZG4?B)HMCX*B\41F2XM9B$BB4 .TAS\A[ C!S].,\
M9X/PW\3/#.E_#4:3>"2/4+>V> V9A8^<QSW P <\Y([U4TS2K+2O@D!XKL-3
M:SN;WST^R*OFVX( 5R&(P#@]<_>'K2=./56U^\%)]SM8?B/>6>LZ=8>)/#4V
MCQZD=MK.+M)U9B0 &V@;>H^F>G>KWC/XAV7A*XM[".SFU'5;@9BM(#@XS@9.
M"1DYQ@$\5Y,&O?!FH:0?"7C5=8ANYE1=/C;<0"1PT>6 STS\K#/'MTWB:^3P
M?\:K?Q#J\,ITRZMA''.J;A$VW:<>XQR.N&H]G&X<SL=1X8^)D.M:V-$U;1[O
M1-4==T4%SG#CKC)"D'&3T[=:QM*_Y.)UK_KP7_T"*LO4M8M/'_Q6\./X<$D\
M&FD2W-V(F0!0V['S ''&.1R6K1L$,G[0>O(IP6TT 'T^2*ERI7Z:#O?[RWJ7
MQ?$>I7<&B^&[[5[.R;;<WD)(1,9R>%;C@\DC./3FMN\^(E@OP^D\6Z=;M=PH
M54V[OY;*Q8*5)P<$9SWS^->.>&'TC08M6TOQ)XA\1Z+>V\S?Z/I\S(D_&.@4
M_-QU) ((YKJ[G2M/A^ ^JOH,.KFRN)5N%74 ADP'0,P"<;<+G\">E.5.*:5A
M*3/0M3\8_P!G?#Q/%?V#S-UM#/\ 9?.QCS"HQOV]MW7':JM]\1+#2_ MAXEO
MK=T-ZBF&TC<,Q8C.W.!P,<G%>:ZUX_T6]^#EKX?MII9M3^S0PRQ>2P$0C*DL
M6QC'R]B>HI_BBWGB^'/@'6?*>6ST_8UPJC. =I!_\=(^I'K25)=5U!S['9:'
M\6!>Z]:Z3K?AZ]T26\P+9YR2)">!U52 3P",C-3>(?BB--UZ;1M$T"\UR[MA
MFY%N2!%^2L3C//  ]:B'Q4\-ZGXFTBRTJQEU2XN"4\Y(=KVY..!O R."20<
M+WKSV*.PT#XA>([7Q)KNN:&)YFFAGTZ5D$REF(W;58GAN#T&&H4$WJOD#D^Y
MZ</&%AXR^&^OW=FDD,L-E/'/;R_>B;RV_,'L:;\'?^2::=_OS?\ HQJYSPM:
M:'_P@?C'4]#?7)(;FUF6275#&?-=4<EEV\G[W)/^-='\'?\ DFFG?[\W_HQJ
M4TE%I=QIW:.\HHHK T"BBB@ HHHH **** "BBB@ HHHH Q_"9_T.NEKFO"7_
M !YUTM !1110 4444 %%%% !1110 4444 %%%% $<W^I;Z5YE\*O^1K\<_\
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M-FDA,OB&Y555F7;M6,J2V<]01C'?I79:'/I.E:@WA+2K:9?L-N)Y'^\B[V.
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[XJ_\
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M%+^%4^7YF4_CC_70]1HHHKG-0HHHH **** "BBB@ HHHH **Y_7_ !MX?\-
MC4M0C68#B"/YY#_P$=/QQ7FFL_'>0EH]%TE0.TMVV3_WRO\ C0![717SF/%W
MQ+\3-FQ-_P"6>GV.WV+_ -] ?UI5\"_$O5!NN#>X;_GXOA_+=0!]%T5\[?\
M"H/&Q&3);Y]#=<TT_#GXC:>,VQG./^?>_ _]F% 'T717SD=8^*/AO#3G51&O
M_/>+SDQ]2#_.MC2?CKJ4#*FL:7!<+T+P$QL/P.0?TH ]UHKD?#_Q*\,^(BL<
M%\+:Y;_EA=?NV)] >A_ UUU !1110 4444 %%%% !1110!C>+_\ D2M>_P"P
M=<?^BVKG/A%_R3^P^LO_ *,:NC\7_P#(E:]_V#KC_P!%M7.?"+_DG]A]9?\
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M'IU.*GT*ZFO="LKFX;?++$&=L 9/X5+BTKFL:T93Y%VO_7WFA1114FH4444
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MQ-8\(>']>5AJ.E6TKG_EH%VN/^!#!JAJGQ"\/V&DO>P7L=VX^5((VP['W!Y
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M3J;)_JV^E9C*E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\^E=<"& (.0>17-^,BH\*76[NR ?7<*WK(,+"W#?>$2Y^N*0R>BBB@ HHHH
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M1*T;_KRA_P#0!70_]W7J_P D9?\ +WY'14445SFI'-_J6^E>9?"K_D:_'/\
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ME4[/S37YI';S5$KN.GEJ=116=8:FMU\C</6C3G!P=I%QDI*Z"BBBI*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?PE_QYUTM<UX2_P"/
M.NEH **** "BBB@ HHHH **** "BBB@ HHHH CF_U+?2O,OA5_R-?CG_ *_E
M_P#0YJ]-F_U+?2O,OA5_R-?CG_K^7_T.:NBE_"J?+\S*?QQ_KH>HTV21(HVD
MD=4C0%F9C@*!U)-<;9>,-3N?B1<^')-,"6<2$B7!WC R')Z;3T''<<]JN>.5
M$VF:?92L5M;O48(+G#8S&220?8D ?C4>R:DHOJ:7)(/'_A6YU 6,6LP&<MM&
M58(3[.1M/YUK3ZQI]MJEOID]TD=Y<*6BB;(+@>AZ=NE-U'2=-O-%ETZ[@B6P
M\O:4P%5% ZC^[CU[5PWBF*.77;2ZT^03?8='-Y;2*^_<(YHVX;OE01GOFJA"
M$W9707:.\U+5K#2(8Y;^Y2!))!&F[)+,>@ ')I;'5++49;J*UFWR6DIAG4J5
M*..W(&?J.#7 ^,;I-;E^T0L'M+".U96[&2:5#^811_WW6_(HT7XA1S=+?6X/
M*;T$\0RI_%,CZBCV2Y?/^OT"YT$VIV=OJ5MI\DV+NY#-%&%))"C))(& /<XJ
MW7&Z;!<:_K&N:U:W7V9@/[/T^X,8DV*AR[A3PP+Y_*NQ4$( S;F Y.,9K.<5
M'0$9_P#;NF_8+V^^T_Z-8N\=P^QOD9/O#&,G'MFL'_A:'@W_ *#'_DM-_P#$
M5EG_ )$/QK_U^7U7K/Q!XO6S@5/ ^]!&H#?VM$,C'7&*V5*.O^:7YBN=>EW;
MO9+>B51;-&)1(WRC9C.3GIQZTVRO;?4;*&\M)/,MYE#QO@C<#WP>:SM=T2UU
MJT0W_G-%"C.;828C=L C>!][!'':H/ __(CZ-_UZI_*L>5<G,A]3H**Q/%]_
M=:7X3U&^LI/+N88MT;[0<'([$$5B37/BG0[JQU'4M2M;NRN[F.">SCMPGV?>
M< H_5L$C.?R]'&FY*]PN=M5/4]5L=&L7O-1N8[>W7@N_<^@'4GV%<E"_BS6]
M0UF.PUNWL;>ROGBB+6JR,^%4[#G&%&>O)Y/I67/JNJ:_?^&9$TZVN+U4NBT4
MKE8(YXV"&0]20.2 .>15QHZZO^K7"YW6B^(=)\16[SZ5>I<I&=KX!5E/NK $
M?E64/B+X4:_%D-5S<&7R@GV>7[V<8SMQU[U2T>>_B\37T.KZ791Z[)8^9%<6
M#MY=Q&K8VD,>&#$<GU]!6=I]UXL\'>'+674-.TTZ7;*!<1QS,URNYOF<G[AY
M).!GZU2I1N_PU0KGHU% ((!'0T5S%!1110 4444 %%%% !1110 4444 %%%%
M 'EWQ5_Y&OP-_P!?S?\ H<->FP_ZE?I7F7Q5_P"1K\#?]?S?^APUZ;#_ *E?
MI715_A4_G^9E#XY?UT)****YS4.U>5:A_P G Z%_UY/_ .@3UZKVKRK4/^3@
M="_Z\G_] GKHP^\O1_D95=EZH]5HHHKG-0HHHH ***.E #7=8T+NP55&2Q.
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M!)PP_P :UJ "BBB@#C/BO_R335_^V/\ Z.2M'P+_ ,B5HW_7E#_Z *SOBO\
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M:NA?[N_5?DS+_E[\CO****YS4*;)_JV^E.ILG^K;Z4 5**** "BBB@ HHHH
M**** "BJ-WJ<-MD9W-Z"LV3Q#C@*H^IK:-"<E>QFZL4['045C0:\CL ZX'J*
MU8IXYUW(P(J9TIPW0XU(RV9)129'K2UF6%1RI&Z'>H('K4E,E_U3?2FMQ/8Y
M::!+_4A#&@ 9MM6+[PO$LD9A08C.X.#@C\:=HP']KDGMG'Y&MG5I&73)RIP=
MN/PS45\7*E5J3W4-$ODG^-_R,J=&,X+N_P#.QF1:Q%90B&*,RD=6)P*LV^JV
M]^?(GBV%N@)R#^-<Y0"5(8'!'(KY.6;8B=1RG9I]+'J+#0C&R+]];-IMV)(C
M\AZ5OV4_VBV5^_>J.H@3Z4LA^]@-^=1Z!-NC=,C KZO"3=2E*#^S:WH^GRL_
MD>;-<E1-=?S1M4R25(ER[ "H;V[2S@,C$>U<!K?BF:6Y:ULE$UP!EB3\D?U]
M3[5TTZ/,N:6B(JUE#1:L[:36K=&P,GZ4^#5K>8XW;3[UY3(;R3,EUJLX]1$1
M&H_S[TL5UJ-L?,M-0^T*.L<^&!_X$.16EJ#TU,N>NM6CV-6##(.12UQ/AWQ0
M+H&-@4E0XEB8\K[^X]Z[2-Q(@93P:RJ4G#T-Z555%H.HJ-YXH_O.!^-1_;;?
M_GHOYU"BWT-.9=RQ2,P49)P*BFN4A@,N<@>E<CJWB(F3R8PSRM]V*/J?KZ"M
M*5%S]#.I54/4[".>.4D(X)'H:DKD] 6^:17G"JQ.2$)P!Z9KK :5:FJ<K)CI
M3<U=A11161H%%%% !1110 4444 8_A+_ (\ZZ6N:\)?\>==+0 4444 %%%%
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M4N/MGX_UH NUQ_Q-MOM'@JY;&3#(D@]N<?UKL*YSQ[C_ (0C4\_W%_\ 0UH
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M,RG\<?ZZ'J-%%%<YJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBGP<FE?Y)?L3-@]=\O3]6'Y5QWP&TTM>:MJ;+\J(D"'W)W'^0_.@#V^BBB@
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MZYP>#R".*T$O[.2Y-LEW TZ]8ED!8?AUK(;2;RSLM0O)+Z6]U%[=DCDV!-H
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M31B6)D/<8I]%"=@>ISRZ)'!</<2[<8Y;') [5EZIJTTUS'86$)FN'!\N)3@
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M,'5=2FG+<****YSJ"BBB@#'\)?\ 'G72US7A+_CSKI: "BBB@ HHHH ****
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MPJ/5_P#A*=)\=W6KZ1X7_M>VNK"& G[?%;[&1G)^]DG[P[5=]?\ @D6T_P"
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M7Z5O5_A4_G^9G#XY?UT)****YS4.U>5:A_R<#H7_ %Y/_P"@3UZKVKRK4/\
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M1G2V]M!:1"*WA2*,=%1<"I:** "BBB@ HHHH XSXK_\ )--7_P"V/_HY*T?
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MT]!7HMBB06ZQAAGO7;6;I453ZLA6G5YNQ:HHSFBO..H**** "BBB@#'\)?\
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M2M>_[!UQ_P"BVKG/A%_R3^P^LO\ Z,:NC\7_ /(E:]_V#KC_ -%M7._"0;?
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MB:U*K!2M[K5G_DT<-+#U(S<6]5M_FCH++QJJQ!;W:&'4YI\WC6WF4K98=_\
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M-7Z^BKM.HVCCI*T$%%%%9&AC^$O^/.NEKFO"7_'G72T %%%% !1110 4444
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M/BO_ ,DTU?\ [8_^CDK1\"_\B5HW_7E#_P"@"L[XK_\ )--7_P"V/_HY*T?
MO_(E:-_UY0_^@"NA_P"[KU?Y(R_Y>_(Z*BBBN<U(YO\ 4M]*\R^%7_(U^.?^
MOY?_ $.:O39O]2WTKS+X5?\ (U^.?^OY?_0YJZ*7\*I\OS,I_''^NAZC117'
M>/?%M[X972[;3H[$7>I7!A2?4)"EO#@ DN1SW]?\*P2;=D:-V.QHKSFY^(6K
M:'X/U6_\0Z0EOJ5E.+>'RUD%O>%ONM&Q!.W /Y#D9XNZ;\0K+4-16==1L#I
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MF3G^'(.1BCDE:]@YD=517.Z5XZ\,ZWI][?:=JL<\%E&9;@B-U:- "22A ;&
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ML%%%% !1110 4444 8_A+_CSKI:YKPE_QYUTM !1110 4444 %%%% !1110
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M1U!!P0?8BFYRM=K0%%=&>?7\&J6?C/P[J0\.75O;SZ2U@T.GQB9+&1VX#$
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M10 4444 %%%% !1110 4444 %-D.$)QR!3J* .#UK[3?.;=4^64[9'[*O?\
M$]*U5L&&FF3;S_2MTZ?;F7S"@S4[1JT93'RD8KM>*2MRHY%AWKS&+HUP#$8"
M?F4Y%0:M:NEP9U4F-^I'8TR[M)K"X\R/.,Y!%6[?68V4+.I![D5\_F& T<?L
M-W36MO)^GY'9AZ]GK\75&*.3@<GVKH-$M&MTDN9ALW# ![#UI#J=C'\RJ"WL
M@JC=ZG/>_NHE*H>P[UPX'+FJBE#WGTTLEZLWK8A<MI:?F-NY3J.J$KRN<#Z5
MTD*".)4'85FZ3I_DIYLB_.>E:M?2<JIP5).]MWW;U9QPO)N;ZA1114&A5OX6
MFM'1.M<[IVB2?;Y9GW N1DGL!T _7\ZZRC %;0KRA'E1E.DI2NQ%7:H7THP/
M2EHK$U"BBB@ K&UK39+T';RK*5(SVK9HJZ<W"5T1."FK,YV#2&M=-*A>54*H
M] *S=+T^5-4EE8$F1E[= !T_G7:4T(JG(4 UNL4[.Z,GAU=68HX I:**Y3H"
MBBB@ HHHH **** "BBB@#'\)?\>==+7->$O^/.NEH **** "BBB@ HHHH **
M** "BBB@ HHHH CF_P!2WTKS+X5?\C7XY_Z_E_\ 0YJ]-F_U+?2O,OA5_P C
M7XY_Z_E_]#FKHI?PJGR_,RG\<?ZZ'J->9?$S^TO^$U\$?V1]D_M#S[GR?M>[
MRL[5^]MYQC/2O3:S[[0].U+4M/U"[M_,NM/9FM9-[#RRP / .#P!US6,)<KN
M:-71P%SX;\1VSZ_XPUZ^T^+4H]&FM[=-)#HJX4L'+-\VX$<?_6K%:XUK1_A]
MH5[_ ,)-J377B&>TM[B[N9MZV<;!LF,'[IQC+'DX)SGFO8KRT@U"QGL[I/,M
M[B-HI4R1N5A@C(Y'![52D\.:1-X>309K&.72TC6);>0E@%7IR3G(P.<YJU4[
MDN/8\VN[K5/"NMZYX>M]?U+4[5] GOEENY_,GM95! (<8(!XP/4C\<RRNM7T
MK0/"'B6'Q=J6HW6HW<-K/9SS^9"ZMD,H7KN7&"3DY]Z]$7P#HND^&M8TWP]I
M\%G-J%K)"9'=VR64@;F8LV 3_P#6JKX2^&VB:!!IEY<:9:-KEK L<ES$6*EP
M,%@#@9_VMH-5SQL+E9R$":M>6_CS69/$>L(-*NKV.TM8[MEC7Y#@D=>,C: <
M BLW4=:\5:Q/X?T>PEU255T&"]D^R:FEE-*Y'S2-*X.\#N/7)KV"/PQH\-GJ
MEI'9X@U6226\7S7_ 'K.,,<YRN1Z8JEJ?@'POK-A8V5_I,<T%C&(K;]XZLB
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M?8ZG>ZG:V^R^O$19Y3(QWA!A>"<# ]!7.^$?">I:=XAUCQ'KSZ>VJZCLCVV
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M5EZ'X=TGPU:S6VCV:VL$TQG=%9B-Y !(R3@8 X'%:E9S?-*Z*BK*QY=\5?\
MD:_ W_7\W_H<->FP_P"I7Z5YE\5?^1K\#?\ 7\W_ *'#7IL/^I7Z5M5_A4_G
M^9G#XY?UT)****YS4.U>5:A_R<#H7_7D_P#Z!/7JO:O*M0_Y.!T+_KR?_P!
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MXG.64_-R3ZGGISQ3]I'J+E9P,<&M:)X&T+QH_B'6KZ17MKB^@FNG:+[.WRL
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M&<D*&9"H)P,XR?2H?"FDSZ%X4TS2KIXWGM;=8G:(DJ2/0D X_"IA-1B-IMF
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MR5H^!?\ D2M&_P"O*'_T 5T/_=UZO\D9?\O?D=%1117.:D<W^I;Z5YE\*O\
MD:_'/_7\O_H<U>FS?ZEOI7F7PJ_Y&OQS_P!?R_\ H<U=%+^%4^7YF4_CC_70
M]1HHHKG-3F_&OBZ/P;HT5\]H;J2:X6WBC\U8EWL"<L[<*.#S7*>(O'6NS?#C
M5M0MM%N=+U"W=8V?SE>-48_ZV*7&V0=OEZ$^U=AXPT?4M;T,VNEW%G',)%=H
M;ZW6:"X4=4<$$@'U7D8KB].^%^I)X9\365S<Z=:7&L*@CM;!9!:P%.00&Y^;
MOQQ[UK#DM=D2O?0FO?BC<Z+9Z9976B1C69K7[1-;W.JPPI''DJK><_#,V,[1
MSS[5:N?BI&UCX=N=(T6?46UHRHD*S!'CDCP"IR"#R>N1@#-9E_\ #SQ)>7-E
MK$B^&+O5EM/L=S;WMN\MJ54G9(F02'QC/ '7Z52\1:'J.BZM\/=,L+RTCU-)
M;IO/2S2*%G*J2#'&% 4_=XYQSUJTH,5Y'=^%/%\GB"\U'3-0TJ72M6T\KY]J
M\HE&UAE65P #_P#7[UH^*YI;?PAK4\$CQ31V,[I(C%65@A(((Z$5QRZ5XE\,
MV'B+Q7=W&EW/B.]$2K"B2FV5$(544<,6;.![XYZUVNM6-QJWAC4+!"B7-W9R
M0C>2%5V0CG&>,GWK-I*5UL4KV/*D^*FB#X5&Q;Q#<?\ "0_V<8]VR;S/.V_\
M]-O7/?/XUK^'O$PMM4TV34;K4G$7A..^N'>[+Q-@C<QB*Y,G7Y]WMCO71)X5
MOE^%1\+F6W^W?V<;3S-S>7O*XSG&<?A6&O@&]MSYUZT<]K'X6_LF6*U):9Y!
MR2@8 $<<9(YQQ5W@[DVD.A^*=^_]C2W'A&YMK/6+R.WM+F2[0JR.<;R ,@]P
MIZC/-8^F>.==T:[\83?V3?ZU9V.JS-)+)>!$M80?NINR3C&=JC %<KHNL:EX
MAF\(Z M]%='3-2A9;2.SE2:.&,G+SL?E!  &%)'/)S7ID'@?4XM#\;633VGF
MZ[<SS6Q#MA XP-_R\'UQFJDHQT:$FV=A;:F-0T"+5=/B,HN+87$$4C;-VY=R
MJ3@X[#H<>]<O#\1([KP[H.HVNFM+>:O=BT6S\[!B8$AR6V\A=N>@ZCI4^G^
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M?P3_ -!K_P E9O\ XBCV%7^5_<P]I#NCLZ*XS_A:_@G_ *#7_DK-_P#$4?\
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M/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P# V/\ ^*H]G/L'-'N;-%8W_"7^&?\
MH8M(_P# V/\ ^*H_X2_PS_T,6D?^!L?_ ,51[.?8.:/<V:*QO^$O\,_]#%I'
M_@;'_P#%4?\ "7^&?^ABTC_P-C_^*H]G/L'-'N;-%8W_  E_AG_H8M(_\#8_
M_BJ/^$O\,_\ 0Q:1_P"!L?\ \51[.?8.:/<V:*QO^$O\,_\ 0Q:1_P"!L?\
M\51_PE_AG_H8M(_\#8__ (JCV<^P<T>YLT5C?\)?X9_Z&+2/_ V/_P"*H_X2
M_P ,_P#0Q:1_X&Q__%4>SGV#FCW&^,O^1(U[_L'7'_HMJ\^\/RY\.Z5'$-\G
MV.+@=OD'6NK\5>*/#USX0UJ"#7M+EEDL)T2-+R-F9C&P  !Y)-8WPCTV)O!=
ME<,H+$R?^C&K+$X*->E%U-D]N^@Z=;EF^7JC<TGP^TC">ZY/H:ZJ&!(4"HH
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M]EB&<_CTK)AM[S7;]9[E=D2_<C'11_C0!L^&8#%8@D=:WJBMX%@A5%' %2T
M%%%% !1110 4444 %%%% !1110 4444 -D7=&1ZBN U'P%9W=[+/_9]H6D8L
MS&!<L3R2>.M>@T4U)K9B:3W/,_\ A75G_P! ZT_[\+_A1_PKJS_Z!UI_WX7_
M  KTRBJ]I/N+ECV/,_\ A75G_P! ZT_[\+_A1_PKJS_Z!UI_WX7_  KTRBCV
MD^X<L>QYG_PKJS_Z!UI_WX7_  H_X5U9_P#0.M/^_"_X5Z911[2?<.6/8\S_
M .%=6?\ T#K3_OPO^%'_  KJS_Z!UI_WX7_"O3**/:3[ARQ['F?_  KJS_Z!
MUI_WX7_"C_A75G_T#K3_ +\+_A7IE%'M)]PY8]CS/_A75G_T#K3_ +\+_A1_
MPKJS_P"@=:?]^%_PKTRBCVD^X<L>QYG_ ,*ZL_\ H'6G_?A?\*/^%=6?_0.M
M/^_"_P"%>F44>TGW#ECV/,_^%=6?_0.M/^_"_P"%'_"NK/\ Z!UI_P!^%_PK
MTRBCVD^X<L>QYG_PKJS_ .@=:?\ ?A?\*/\ A75G_P! ZT_[\+_A7IE%'M)]
MPY8]CS/_ (5U9_\ 0.M/^_"_X4?\*ZL_^@=:?]^%_P *],HH]I/N'+'L>9_\
M*ZL_^@=:?]^%_P */^%=6?\ T#K3_OPO^%>F44>TGW#ECV/,_P#A75G_ - Z
MT_[\+_A1_P *ZL_^@=:?]^%_PKTRBCVD^X<L>QYG_P *ZL_^@=:?]^%_PH_X
M5U9_] ZT_P"_"_X5Z911[2?<.6/8\S_X5U9_] ZT_P"_"_X4?\*ZL_\ H'6G
M_?A?\*],HH]I/N'+'L>9_P#"NK/_ *!UI_WX7_"C_A75G_T#K3_OPO\ A7IE
M%'M)]PY8]CS/_A75G_T#K3_OPO\ A1_PKJS_ .@=:?\ ?A?\*],HH]I/N'+'
ML>?:=X"L[2]BG_L^T#1L&5A N5(Y!''6N_C7;&!Z"G45+DWNQI);!1112&%>
M?>,/!-GK^IK>3VGFRJ@C#>8P^4$G& <=2:]!I" >HJHRE%WB[":3T9XW_P *
MOL/^@>?^_K_XT?\ "K[#_H'G_OZ_^->R;5]!1M7T%7[>K_,_O9/LX=D>-_\
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MU[)M7T%&U?04>WJ_S/[V'LX=D>-_\*OL/^@>?^_K_P"-'_"K[#_H'G_OZ_\
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M[,82KOV1;HI N2,%P2N"0/O(^1ZFNBMU(#EH!'(2"[+C$C;1R.Y].>>/I4M
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MGV I;:YANX!- VY"2.05((.""#R"#V-4[ZV>%;*6SMA(MI)D6\95,J5*_+G
MXSTR.E9.LZ??:JMO+)8RJ@$@^SQ20LRL2-KMO!4' .2N2,\$\TDDPN= E];2
M7;VJ29F3.Y=IXQM)YZ?Q+^=6*Y.]T2\FGN"\$DL39R5DC+/Q#V<;6^XW#  X
M[9%;.@6]Q:Z1'#<PI$ZLV$4!<#/&0&8#Z X';'2AI6N%S3HHHJ1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img101536035_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF23118\R5$STW
M,!F@!]%(K*RAE(*GD$'K2T %%%% !1110 4444 %%1O<0Q-MDFC1NN&8"I.M
M !1110 444R::*WA:6:1(HD&6=V"@#W)H ?14%I>VM_;BXL[F&YA/22&0.I_
M$<5/0 444R2:*+'F2HF>FY@,T /HI%964,I!4\@@]:6@ HJ,7$#/L$T9?.-H
M89J2@ HHHH **** "BBB@ HJHNJ:>]S]F6^MC/\ \\A,I;\LYJ>:>*WC,DTJ
M1(.K.P4#\318"2BJL>IV$ML]S'?6SP)R\JRJ57ZG.!3[2]M;^W%Q9W,-S">D
MD,@=3^(XIV8$]%%%( HJJFIV$E\UBE];-=J,M LJF0#W7.:M46 **** "BBB
M@ HHHH **** "BBCI0 45&EQ#*VV.:-VZX5@:DH **** "BBB@ HJI)JFGPW
M MY;ZV28\"-IE#'\,YJW18 HHHH **** "BBB@ HHHH **** "BBB@ HHI&9
M54LQ 4<DD]* %HID<T4N?+E1\==K XJ"34["*]2RDOK9+M_N0-*H=OHN<FBP
M%JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJMUJ=A8RQ
MQ7=];6\DIQ&DLJH7/L">:M4 %%'2HTN(96VQS1NW7"L#0!)1110 4444 %%%
M% !1110 444C,JJ68@*.22>E "T4R.:*7/ERH^.NU@<4^@ HHIKND:[G957U
M8X% #J*9'+'*"8W5P.,J<T^@ HJ-[B&)MLDT:-UPS 5)UH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_B+X^7P=9PP6
ML:3:G<@F-7^[&HXWD=^> /KZ5W%?./Q>E>?XCW$4C82**&-2>@4J&_FQK?#P
M4YV9,G9%FS7XI^(+/^V+2ZU-X&RR%+A80X_V4R,C\/I72_#KXFZA=ZO'X?\
M$1W32,8X;EQL<./X''KV!ZYXYS7K=O;Q6EK%;0($AA01HHZ*H& /RKYR^*"+
MIOQ.NY[0!),Q3C;V?:#GZDC/XUM"4:S<&K=B6N74^B+O4]/T]E6]OK:V9QE1
M-*J$_3)J0W=LMI]K:XB%ML#^<7&S;USNZ8]Z\5^/'_(4T;_KC)_Z$*[._P#^
M2&)_V XO_12UC[)<L97W*OJT=G9ZE8ZAO^Q7MM<[,;_)E5]N>F<'CH?RI(-4
MT^YN6MH+^UEN$SNBCF5F&.#D YXKR3X"?\S!_P!NW_M6N#6/5+KXA:EI^D2F
M*ZOKR>VW XPC.=V3V&!S[5:PZ<Y1OL+FTN?2=KK>E7U[)9VFI6=Q=1 EX8IE
M9U .#D YZD?G5^N%\"_#>+P7>SWIU$W<\T/E']SL"C()QR?0?E7=5A-13M%W
M12OU/F[3O$_CO7=?;2],UFZ>X9GV(9%487)/)]A6I=>+OB/X(O8#KA:6&3.U
M+@(Z2 =<.G(//K^%<UX0\06GACQR-5O8YI((FE5EA4%OF! P"0._K6Y\0_'\
M'CE+'3=)L+E4CEW_ +U1YCN1@*%4GU/?GBO1E'WTN56,KZ;GNVAZO!KVB6>J
M6RLL5S&'"MU4]P?H<BH[CQ+H5G/Y%SK6G0S9V^7)=(K ^X)XKGM*\(W4?PKA
M\.2W#VEXUNV9(Y"/+D9B^"1U&3@CN,UY5K7@[P?HNDW*2>+UGUB.,E8H8]T;
M.!G8=H.,],DC'>N.%*$I-7-&VCZ(CDCFB66)U>-QN5E.01Z@UY%\2OB/J>B:
M[;6GA_4;<Q?9P\I14E&XLPQGG!P!Q[U!\#-9N7?4M&DE+VZ(+B)3SL.<-CV.
M1Q_C7GOCCPU#X3\2/I<%Q).BQ(^]P >1[5K2HQ55QEK8ERTNCZ>M-3T_4&9;
M*^MKED&6$,JN1]<&DO\ 5=.TN,2:A?6UHAZ&>54!^F3S7'^'?!EE\.+/5M5C
MO9KI1;%W610N @+<8KR+2GL/&WB2\U#QAKYLHL94!OF.2<(F00JCZ>GKFLH4
M8R;:>B*<K'TA9WUIJ$'GV5U!<Q=/,AD#K^8ID^J:?:W*VUQ?VL4[XVQ23*K'
M/ P"<UX!X<OX/"/Q/MK71-5-[I-U-'"S[N'5\#YATRI/7V]ZG^,\CP_$"&6-
MBLB6D3*PZ@AFP:I8;WU&^C0N;2Y[G>Z]H^FW"V]]JME;3-TCFN%1C^!-6WN;
M>*V^TR3Q)!@-YK. N#T.>E>!^+?AI<Z1X3?Q)>:RUW?$H]PK(2&WD#AB<D@G
MJ1S[5T/PZLV\9?"W4?#UY=21Q)<A$D49*("D@ S[@_G2=&/+S)Z=1\SO8-+^
M).HW7Q3?3)]2M5T(7$\89E15VJK[3O\ <@<YYS7K5M=VU[")K6XBGB)P'B<,
MI_$5\N^&_#4.N>.8O#\EQ)%$\LR>:H!;Y%8CCWVUZ]X@W?"_X8M9Z;=/+/),
M889G #*SY8G [@ X]\5=>E'F48[BBWU.YN]?T:PN!;WFK6-O.3@1S7"(WY$U
M?CD26-9(W5T895E.01Z@U\W>&_#_ (5U?29;[Q%XI:UU"9V*QA@2O/WGR"6)
M//4?6NI^">N7*ZI?^'Y9_-MEB,\/S$A2K ';['=G\*B>'2BVGL"D>P7VI6.F
M0^=?WEO:Q'@//*$!_$FO%_C?=6U])H-S:7$-Q \<P66%PZG!3."*Y]C??%'X
MC^1+=&*!W?R^=PAA7^Z/4@#ZDYJ/XB^"8O!=U8PV]]+<P7*NZK*H!0C /3@Y
MR.PZ5M2I1A-7>HI.Z/=O W_(B:'_ ->4?_H(KH*Y_P #?\B)H?\ UY1_^@BM
MF]MA>6-Q:F22(31M'YD3%67(QD$="*XI_$RUL5;WQ!HVFR^5?:M8VTG V37"
M(WY$U<MKFWO(%GM9XIX6^[)$X93]"*\&O? 7A/1HYH]=\:*-2Y)6"/?M;MN
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M:^&M&N8K?6(-3::8/(]N040@8P,$\^_TXKIM0UO2M**KJ.IV=HS?=$\ZH3]
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MWP=S^R@CCZUI.E*<U%OH)-)'L=IK^C7]P;>SU:QN)P<&.&X1V_(&KES=6]G
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M2274=,GL!52H1C)1OJ)2;5STQ]8TR.Q^W/J-HMGG'V@SJ(\^F[.*=8:G8:I
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M1FM;2M$TS0[<V^F6,%K&>2(EP6/N>I_&BI6C).U]?/0%%H^=]#O6^'7Q)?\
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M.6AW'V^QUV./=;&(6TK#^%@25S]<D9]OI7L]K9VMA;K;V=M#;PK]V.% BCZ
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M :N4-6 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0\@_\!K3^$'@VWCLK+Q6+N4SRK+&8-HV@;BN<]>U6/CF0WA;32#D&\!!_P"
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M2DG=,+%#2M$TS0[<V^F6,%K&>2(EP6/N>I_&LW6? WAKQ!>?;-3TJ.:XP 9
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ME%=0@[@'ZJ?4$<C\*T**5W>XSGK3P-X8L;">RM]&ME@N %E#98N 00"Q)/4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"AYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[
M^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\
MB/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_
M]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\ N_J:
M/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_
M[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZ
MF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(
M_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_W
MV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\
MB/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_O
MM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J:
M *GF/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_
M +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;
M\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(
M_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^W
MYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH
MJ>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\
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MS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\
MN_J: *GF/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6
M_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF
M/_?;\Z/,?^^WYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZ
MFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: &VY+1DDD\]Z
MFIJHJ#"C IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113(Y4E
M&48&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !113'E6,J&(!;I0 ^B@'-% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=Q'&SL<*
MH)--AF29-R'(H DHHHH **** "BBB@ HHHH *.]%'>@ HHHH **** "BBB@
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M]-O0_C7I_A7Q3!XCLN=L5[&/WL(/_CR^W\J\0JQ97MQIUY'=VDK131G*L/\
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M\:1IM\R,W/,OS=0<_P#ZZN.!4DGS]OQ-EB=;<O?\#V;SA_=?_O@T></[K_\
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M9I$1EN[16WR(0,'(.,]MN/S.*KZQ%X[N='DAOX9#:1C,NPQ[F ]=IR?PKJ?
M&BK8:&M_*I-W>_O&9N2$_A'X]?QKK:[I8E4FJ<4FH]_Q,U"^KZGSA17HOCCP
M7L\S5M+B^3[UQ @Z?[2CT]1^-<+INFW6K7T=G9Q&25S^ '<D]A7JTJ\*D.=,
MQ<6G8L:!%J4NM6XTG<+P-E6'11W)]O6O>H]XB3S2IDVC<5'&>^*\OO\ 4K+P
M5I\FD:2PEU608NKO'W#Z#W]NWUKJ? >IZEJ>A&34 6"/LBG;K(.^?7'3/?\
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MV_>'Y@&HO"3I<3ZYXAF;*S3LJ,1TB0<?I@?A4?A6=HO".KZ@/OO/<3Y]\?\
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M\SNJ+&7.PC)Y [_6NC'A'1#D26UR_NTO^!KJ>(IT7:1CA,)4JOVG0M6LOD^
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M*YC#Q,"._J*B:ZHF2ZHEHHHJ""GJW_('OO\ KWD_]!-4O#G_ "#D^E7=6_Y
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MQF/.[/OBLN >,FT[4&&J1?)C.;N-B.><-G"?B13=1L_#[^-K@7&LW$3-(QD
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M<7X#..5A[#Z^OTK5TK1+;2H\H/,G(^:5AS^'H*TZ<JE]$)1[A1116984444
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M_B-)Y.FR1>89?(!DSY'!SD8[C(]LUZ[:_P#'M'_NBJT.E6T%U)=0Q11W$O\
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M/^0GJ7_7)/YFMR.^ C"9^Z,5RUJ$57E&*T5OR/7>(:I1D^IK7%VPSBXV_P#
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M=117FG2%%%% !4-V0+.?/_/-OY5-5'5I/+TZ3'5B%IK<:W.?MHO.N8H\9W,
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MK+LD7&5Y SU'(XKQ[PY\3W3Q+I=M+XYM?$4>HW"V\MH-(>T-L6^ZT;E0& ;
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M'GH:\>U.?QSXE^'NK>)UUFQCTR[LIV313:# M\,,^=G=YFT$XZ9].WJ'A?\
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MQI(LU DA(&Y_-X(D(.[  4'CG'(!Z]4,MU;P300S3QQRSL5A1F ,A )(4=^
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M(?G/H3TS6;:_#O4["Y2TL?&6HVWAQ)O.72XHE61?FW;!< [PF>WIQGO7?44
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M3DRVF7S'B0'[X&.?<@]ZV/#_ ( L-"U-=2EU36=7O8T:.&;5;PSF%6QN"#
MSCKC- 'F\,'B.'X<Q^-?^$QUE[VUN&:.T:<&W:+[04*NI&7.,\L3C@=J]HU/
M[:VCWG]FE!?F!_LQ?[HDVG;GVSBL;_A"=-_X0IO"OGW?V%LYDWKYO,GF==N.
MOMTK>N[.WO[&:RNHEEMYXS%)&W1E(P0?PH \4\+:KJ6C>)M-C\0:CXTT^\FF
M6&Z75E%SI]P[#&R)QCRR6(((R!C%0:EXAU;6_$.L3S-\046TO9;:R3PY:AK5
M!&=N7/\ RT)(R0?7%>@Z?\+M)LK^VN)]6U[4+>UD66VL;Z_:6WA93\I5,#[O
M;)-2ZK\-=,U+5KC4;;5M<TE[IM]U%IE\8([AL8RZX/) P<8S]: ,&UU34=2U
M+X=W^KVD]MJ!2^$\4\)A?<L1&2A^[G&<>_%<1;^)?$.KVC:^G_"Q3JTA>6U2
MPL0^F 9.Q-F?WBXX+=?RKVF#P?I-I+H36B2P1Z*LBVL2,-I#KM;=D$D]\YZ]
M<UAW'PGT6:ZF,6IZ[::=.[/-I5KJ#1VDA8Y;* 9 .>0"!0!1OGU;QKXDT_1I
M-4U/P_;+H\>I7$=BQ@N'E=BNPL1E57!R,=3S[4O'GAB]7PMX;L;_ ,2:G<S1
M:S!"+J%Q"[K))A6;&<N@QAO7G'-=?K_@32]=^QR)<W^E75G'Y,%WI=QY$JQ<
M?N\X.5X'&/IWJ*7X>:+)X1'AU)+V*'SA<_:XYS]I\\-N\WS"#\Y/?'Y<4 <K
MK&N:KX>;QK'::C<2/9PZ=;VLMW(9!"T@V&4@\9YW$XY(YJ:^T?5? EUH^K1>
M+=9U07.H06=Y::C.)(Y1*=I,2X&P@G< ">!^?61^"=+\O58[M[J^35+:&VNQ
M=2!BZQIL!R #N.<DYZ\C%9VD?#'2=+U2UOYM3UO4S9-NLX-1OC-%;'& 47 Q
M@<#.>U '(S:7KVL6GC35E\8:U9G2M0NC8VUO/MC4QJ&P^02RG@;<X'/J:]1\
M/7LNI>&M+OIR#-<VD4LA QEF0$_J:K6_A>QMM/UJR26X,>KS333DLN5:10K;
M>.!@<9S^-:.F6$6E:5::? SM#:PI"C.06*J !G&.>* +5<UX2_X\ZZ6N:\)?
M\>= '2T'I10>E !1110 4444 %87C)-;D\(ZDGAPXU8QX@PP4]1NVD\!MN<$
M]\5NU0UG1[+7])GTS4(C);3@!@&*D$'(((Y!! (/M0!Y9X$UF33_ !1'8WVH
M^,;:6XBD'V'Q)'YR3R*-V89AC;@!N,88&N9M_$OB'5[1M?3_ (6*=6D+RVJ6
M%B'TP#)V)LS^\7'!;K^5>L:)\.M.T?58=2N-6UO6+JW!^S-JMZ9Q;Y&"4&
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MF?\ A$H*/^$2@H Z:BN9_P"$2@H_X1*"@#IJ*YG_ (1*"C_A$H* .FHKF?\
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M$H* .FHKF?\ A$H*/^$2@H Z:BN9_P"$2@H_X1*"@#IJ*YG_ (1*"C_A$H*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ=%7RF?M"Y15
M.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*'M"Y1
M5.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*'M"Y
M15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*'M"
MY15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*'M
M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*'
MM"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'*
M'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%'
M*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=%
M'*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ=
M%'*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RBJ
M=%'*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%RB
MJ=%'*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%R
MBJ=%'*'M"Y15.BCE#VA<HJG11RA[0N453HHY0]H7**IT4<H>T+E%4Z*.4/:%
MRBJ=%'*'M"Y15.BCE#V@44451F%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 > Z'\5
M&\+Z;XKDU._GU'4?[2>+3[6>=GV@9]3\J#CICT%>@_#O1-:L]/D\0>)M>NKR
M]OT\_P @W3&VMHV^;"KG;G'<< <#N3Y_\.? NA^*[SQI-JEN99OMDMK$YY\D
M,6.]1_>!Q@^U7O!6HZBV@>)?A?J3[=8M+:>&P+MCSD*G"@GMR"/]EO05*+?D
M=>/C!X=\T2&TU<:69?)&KFR/V,MG'W\YZ^U;\/C+39O&C^%MEPE\+87,4KA?
M*F0@'Y"&R3U[#[IKY^LX-._X1*'P]=W?C&?Q 9?(D\.171BA/SYW &)E"]#S
MDY]N:]#^(NG3^$M-\)>++.*22XT$QVUPI<,6A*[2&8 9YRN<#[_2BX.*._T7
MQ?8:]X@UC1[."Z\W2G$=Q,ZKY18YX4AB2>#U Z5;\3:U%X=\,ZCJ\Q 6U@9P
M"?O-C"C\3@?C7+_"'2I+'P-%?W(_TS5YGOYB>IWGY?\ QT _B:POC7=7.K+H
MG@K32/MNK7(=MQPH1>F[&3C)ST_@-.^@K:V,/X9Z]XDTGQ;IEKXFU.[N[7Q'
M8_:+0W,SR"-\DJ!DG&5'0?WEKU+Q9XWTGP<EJ+];F>YNWV6UI:1>9+*<@<#(
M'<=^_&:\8\9^%?B1H^D6.O:OJ^F7D.@NCVRVB8>$94 \1+E1A<Y/:NA\5ZM#
M%XR\%?$62":306M=DSHF_P"SE@V"P'H7_P#'3CG%*]AM798T_P 97.N?'*P@
MM)M6M[$:<WGZ9=!X2DH5SAHR=N[&TYY'3FN_\->-=+\3Z3>ZC;K<6L=C,\-R
MEVJH\109).&(QCW[&O-=.U^R\2?M#Z=J&G1S"T.FLL<TL+1^>-KG>H8 E><
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<;XT\$7WC.:&VF\13VFA_(;C3XK929F4DY\W.1VXP1Q
MFNRHH!.Q';P16MM%;PH$BB0(BCHJ@8 _*I*** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ "BF^8@D$>]?,(+!<\D#OC\15,:SI9U3^RQJ5F=0QG[)YZ^;C&<[,YZ<]*
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M)/04 /HJI'J>GS26T<5];.]U&9;=5F4F9!@ED&?F'(Y''(JRLB.6".K%#M8
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MS!$Q,13;D1,QR%.>0>N!6)=>$-=E\ >)-.CLT^W7.LR7MM$TR@2Q^:CCY@2
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M%[(8-DCK)< _.&5N#$>PZ^M=-X3T>_;7H[VY\ >'_#5O C8:,137+N1@;'C
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MYT*\\V/*\E'4DLIQR#T.*M>.O!\NJV>C7&E:?87DVC2$QZ?>H##/$5VM'SD
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M<5UE>5?#S26D\9:J1*LVE>'I9K+3"O*@ROYCC/<J"$^E>JTT)A1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH BNK:&]M)K6X3?#,C1R+DC*D8(R.>AJ/3["UTK3K>PLHO*M;>,11)N+;5
MP!DDD_C5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%.HHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHK*N]:^S^)-.T:.W\V2[BFGD??CR43:,XQSEF [=Z -6BBB@ HHHH
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M;#-M()VX./J:Q8O,M_ 5O827,LT.G^+TM(&F;)6))AM&?;->LVN@VMIXAO\
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MZ'!Z+I-KXRO_  [X?UMI9=(L_#5M=I9I*T:S2MA=S;2"< #'/&?<U+IGA[4
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M@\'(((Y!! .:YO3/AQIUAJ=O?7>KZ[J[6K^9;1:G?&:.%\$!E7 Y /!.<4-
MGH<;XA_Y WQ7_P"NT'_HJ.K%WX1L?"&K^#M6TN>\&HWFH16M]<RW#N;M70[M
MX8D=NP_I7;WG@C3+ZV\002SW83765KDJZY0JH4;/EXX4=<U?U/P]::M_97GR
M3K_9ETEU#Y; ;G4$ -D'(Y[8HL%SS[2/#%CXQ?7_ !'J]W=C5;?4+FWM)X[E
MD^P)$<*$4''3D[@0<^YSG^$_^/3X5<YYON?7]V]1>)M,6;Q)JR/X4\8P374I
M#1Z-<9L-1&,*\S8&S/\ $.WUS7<>%O ZZ?H7A,:B\B:AHD<C!(G!3?(I#!N.
M<;N,$=.] [GE]EIVM>,([C7+OP1>:S=RW$HAU!?$*VK6^UBH6./HFW'<')Y[
MU[1X.&M+X3TY/$,;1ZJD>R<,ZN202 2RD@D@ _C6+??##2KK4;F[L]5US2EN
MW,ES;:=?&&&9CU++@\GOC%=9IFFV>CZ;;Z=I\"P6EN@2*->B@>YY)]SR:$A-
MW.*\<VRZ]XO\->%[V:5-)O5N)[J*.0I]H,:@JA(YQR21G^E8-OIT'@KQQXCC
MT9Y&BL_#33VUO)(9/((=B$!.3C(S@YZUZ%XE\+:?XIM(8;UKB&6WD\VWNK64
MQS0/C&Y&'0_F*HZ#X!TKP_JDVHQ7-_=W5Q;?9KB2]F$IG&[.YR1DMT'I@ 8H
ML">APZ> =(D^'H\5MJ.H?\)$=/\ M_\ ;'VU_,#[-^.NW;VQC..]+-IL?CKQ
M=X3_ +:,XBN?#IN+J&*1HA-DKE6*D';DYQ["NB/PB\/%S#]LUD:27WG2!?-]
MDSG/W.O7GK74'P]9?\)%:ZVID2>VM&LXXD($8C+ ],9R,#'./:BP7/+6EN/!
MGA_XA:;HMU/#:Z?-;BR#.6-J)@NXJ3SQNR.>V?4U;\4>!]*\$^%G\4:%=7T.
MM69BE:\:[=VO"74%9 3M8-GH *]!7PGIAN=<FG22X36M@NX92"F%38 N "./
M<\],5A67PIT*UO+:2:^UB^M+1Q):Z?>7IDMH&'W=J8[>Y-%@N9-WX:T[Q9\5
M-6MM9CEFLXM.M)C:B5D1I,N S;2"=H+8&<?,:O3@:C)XYU8#,%O9/I=L?01Q
MLTF/^!OC_@%=;!H5K;^)+S74DF-U=P1V[H2-@5"2"!C.?F/>J%SH4>E>!]5T
MVQ$]P\EO<OE_FDEDDW,<X R26[#THL%SR[_A%[#3OA+8^-K>]N4\0VMG!-%?
M&X;  *@0[0=NW'R8QD]^]='/X<T[Q=\4-4@UJ&66T33;2<V@E9%:3+X+;2"2
MN6 &<?,:?X1^&&F/H&A7.IMJP$<$4\FD3W#"V6<#)=HB,ALY)&<=>*[J#0K6
MW\27FNI),;J[@CMW0D; J$D$#&<_,>]"0-G :9X3TOQ]K/B*]\2&YN_L6I26
M-I:BX>..UCC  954CDYSDUC&\U";08?"DNJWDEB?$YT=KUI?WLEL!NV%QWS\
MN?PZ<5WFL_#G2M6U:?5(-0U?2;NY %T^EW9A%P ,#>,$'CTQ5MO ?AX^$AX9
M6R*::I#J$D(</G._?UW9[_ATXHL%SD(O"FE>$_BMX7M=',L-I+;WC_9&F:18
MVV#++N)(W<9YQ\M,T=T7X$:\2R@!-1!)/?S)*Z?1_AUIFD:W::R=2U>^U&V6
M1!<7]UYSNKC&UB5Z+S@#'4YS52[^$^@W<^H9O-6CL[YGDDL([LBV$K=9!&1C
M=GD9R <<<"BP7,(Z;!XLUOPUX:U:25M'A\/17QM4E:,7$N53YBI!(4<\'O5C
M6?"VF6'PX\5Z)_:@U&SLD>YMK-I"9-/PF]$)#$D C(W8X]:ZC5_ >EZQ8:9
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M3CJP/H,].E '?:=K&EZQ&\FEZE9WR(=KM:SK*%/H2I.*=JER]EI-Y=QA3)!
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M0O"FJZ]XYFUJUL+JZBU242"[VMY,.!AAG[F3N^88/'7BL_0Y))/#'P\W2/)
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MZ4^EK;:II=RMW?+;3.+U,0)U9S@]N!SC&X5M1:I(VO7$;7VE'3DLTN%59O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '(:A\+?!6J:BU_=Z! UPS;F,<CQJQZY*JP
M4^_'-=*NF6":9_9BV=NMAY9B^S","/8>"NWICVJU10%SE-.^&WA#298I;'18
MH98KA;E'$LA82+G!R6S@9/R]/:MZQTFQTZZO;FT@\N:^E\ZX;>QWO@+G!/'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img101536035_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_7.jpg
M_]C_X13617AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    /    L8=I  0    !    P    .P #J0R   G$  .I#(
M "<0061O8F4@4&AO=&]S:&]P(#(T+C$@*%=I;F1O=W,I #(P,C,Z,#$Z,C8@
M,#4Z,#8Z,S4 061A;2!,:6YD:&]R<W0   .@ 0 #     ?__  "@ @ $
M 0   EV@ P $     0   14         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M^TC/R'6EL;6[VMCPED.VASMC?WD!V9A5#(%5-8<ZW<(K$/)_G+7[3^D?]/\
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M&S]W]+^C_P"+1R,?[0*R\[G8Q:#[=NP'Z7]?_H)5_9_U,ASM=WIS'<;G>HF
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MK--652:ZZ0VF;F$RT>RN=WNV_0_ZU6BTW=(9=C/.73[&@O/K,]KOI;?I?O\
M_GQ;R2!0;O5J?MCI/_<['_[=9_Y)+]L=)_[G8_\ VZS_ ,DKB2"&G^V.D_\
M<['_ .W6?^253,R>CY5M=AZE0STPYL"RLSO']9:Z26FGF/MZ)%Z_W97_ '.'
MU_\ ->=MHZ+::S^UJAZ8( ]2ON9_>1\O)Z2_I+>GLSZ7>VJK>+&%VUKF-?9M
MW?F,;ZBVTD1TKN:_QO5_ST#Y8U\M>G^Z_P#_V?_M'/A0:&]T;W-H;W @,RXP
M #A"24T$!       (AP!6@ #&R5'' (   (  !P"4  .061A;2!,:6YD:&]R
M<W0X0DE-!"4      !"/)T\X2Q'FP.;/B4J[O#Z(.$))300Z      #O
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!7_0M         "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 %_T+0 !  ( 7_0M  $  CA"24T$)@      #@
M   _@   .$))30/R       *  #_______\  #A"24T$#0      !    %HX
M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$1       $     (   )
M   "0      X0DE-!!X       0     .$))300:      -1    !@
M       !%0   ET    . $0 ;P!N &\ <@!3 &4 ; !E &, = !I &\ ;@
M  $                          0             "70   14
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   14     4F=H
M=&QO;F<   )=    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $5     %)G:'1L;VYG   "70    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 20"? P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M&$\NK=+=V;<X3X.8]SF/;_(>DIF[+Q6D?Y'R""QKY%-?YS0_9_.?3KW>F_\
MX17,;'P[ZO4.&*3)&RUC0[0Q/MWM]W]99IZ+C@//[/VRX/<\9=C2"UKF5^]I
M#F>E78]E6W^:_P &I6=(KML-EO3_ %2YS7N:_+L<PED>GOI?-3]NS\]B2G5^
MPX7^@K_S0G^P87^@K_S0LP]/'VK[8.GM^T[O5:\9+A[@(]H'MV^[Z'\W[_\
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MPXGRG\UZ-Z =E6W'8K/6>-S031MVQP9_G?\ .468U#CC26/8YAANW1XV\_\
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M9]^%B8>7?<]YKKM!L#=I=+HTK#BW_2?]!.E1D>$:$Z!&,2X8@ZRV7MZG:'9
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ML87;6N8U]FW=^8QOJ+;21'2NYK_&]7_/0/EC7RUZ?[K_ /_9.$))300A
M  !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
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MC\^Q/>RV\&A1;(W;YTK04 X@D^GKTD&IOQ=&&_V3[Y,_][#^Z_\ 8]?];?\
M7CV4M<(W"W4?ZO\ 2]>I_2ZZ_P!D^^3/_>P_NK_T .M__J;W[ZA/]\+_ *OR
MZ0^ ?7_5^WKW^R??)G_O8?W5_P"@!UO_ /4WOWU"?[X7_5^77O /K_J_;U[_
M &3[Y,_][#^ZO_0 ZW_^IO?OJ$_WPO\ J_+KW@'U_P!7[>O?[)]\F?\ O8?W
M5_Z '6__ -3>_?4)_OA?]7Y=>\ ^O^K]O7O]D^^3/_>P_NK_ - #K?\ ^IO?
MOJ$_WPO^K\NO> ?7_5^WKW^R??)G_O8?W5_Z '6__P!3>_?4)_OA?]7Y=>\
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M7[>O?[)]\F?^]A_=7_H =;__ %-[]]0G^^%_U?EU[P#Z_P"K]O7O]D^^3/\
MWL/[J_\ 0 ZW_P#J;W[ZA/\ ?"_ZORZ]X!]?]7[>O?[)]\F?^]A_=7_H =;_
M /U-[]]0G^^%_P!7Y=>\ ^O^K]O7O]D^^3/_ 'L/[J_] #K?_P"IO?OJ$_WP
MO^K\NO> ?7_5^WKW^R??)G_O8?W5_P"@!UO_ /4WOWU"?[X7_5^77O /K_J_
M;U[_ &3[Y,_][#^ZO_0 ZW_^IO?OJ$_WPO\ J_+KW@'U_P!7[>O?[)]\F?\
MO8?W5_Z '6__ -3>_?4)_OA?]7Y=>\ ^O^K]O7O]D^^3/_>P_NK_ - #K?\
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M/[J_] #K?_ZF]^^H3_?"_P"K\NO> ?7_ %?MZ]_LGWR9_P"]A_=7_H =;_\
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M)V?Y2R;NZ;V]O2+9G>'9(W='L'IBGDCB;<NZ=TQ2A0<^Y9@@]U[IQ[2^,/\
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M_O&2A_\ 1P]Z_P#VQ/?OWO<?[^_XR.O47TZ]_P ,I_RT_P#O&2A_]'#WK_\
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M[C^55)@>S*S8_P#=5:S%8[+?W:R>37(@9=)]-BR17%X]9O8MJ_QOS[=^B/\
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M\/?O 7UZ]3KU_P##W[P%]>O4ZQ@W]N1S"3 '2$BG5'>#'_8RKL\?^!=]$_\
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MV^/WR%\F1P76V5VI@\'2U?\ N-Q%?MMV$3N =(D4 C@G@VN/?NO=)SY"=_\
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MZB6)MTC>T3-NFIF:<AIT)8 *2"$ ]VW/EU[>(D<1FGKPQ\5>M^UGN3!-,D+
M"I/=FN1+Q_3H0*8%.KK>]_D-239#-=?TNT\#FL319%<5EZ[<+L85<#U>-#P
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MNQ?XQDP02F.:,\_T>-E=3_B"/?NO='8S?R*Q&-ZCP_9E)AS6UV?R*8K%[?\
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MJ=G;4_NC'*FT:;8*=1;/+)N6^Y]VG>*G;X)52/=>ZO4V5/N6HVEMF??!Q_\
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M>_=>Z#+:6!_O1N"BV]_RFY#_ &/OW7NE12TM7NC;^Y]PY:U=_<_:^WL5B_\
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M;[M+#_$I(1_L??NO=('>V!_NON"MV]_SK\7MW_WE??NO=*?)?Q;8>/H_M/\
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MI8?)_ 8+;_3.87 XRBPPKMR8#4V/QB LQ86)1%'X'U^GOW7N@IZXQE)1]_\
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M6%S*)9#0 URBGA]@)^S/#KMOMONGR[+]YA]VEO[9=O>Q@42F50G;:WJGNT
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M[3M)-ROM':,4G7_]PO(U_3I:XX8?7V1=(^OH'>_=>ZA'ZK_L?:"\_P!RH/\
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M$W5MO)*QQV?V]DX<QBI['ZB>G94N./I]/R1?W"?A^'=S@@U[?\'YCH$3J8I
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MDW%6=NX!L30[C.6Q=5)C=R_QW,L5N87?U( 2;$\C_7'MOI9U9_\ Q/%_P_\
MC'W])_"=/WWWVL>+1>^O5]--OS]?Q;W[KW58.^L9U_GNVZK<5-V]@8\-7Y%<
MIE:Q<9N4YW"$#]",+*0+6!XN/Z>_=>ZLVQF=Q6<Q]/EL1E:*OQ# D5]$^I#8
M6L+:M*DGD>_=>ZKC[YQ77V\>Q$RE+VO@\>:U1B,H&&X\XV(T@"]H28EN!^+
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MH[/_ /%NNB/_ (!;Y&>Y /\ R2X_^:#?X5Z;_'^?7__5VQOY:/\ QZ'RH_\
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M*]PXX^ALE!_U=WY^O4V1M]=>L1_J[?R].AGVYO"IV)USVSLNLJEHJ_/?W?\
MX2Q'*W%FL;<7]HNO= QDL768O(5N(JO^!N/]^Z]T9KX];P_T=Y#?])E2115W
M60W;B[?FU^#?\&_OW7NBRU/W9_RNK^N0_P!RO^V]^Z]T,_2NYJGK+<]%NNM&
MJAW!MG/-;G]2,'0C\DAU!'OW7N@9R5+5TOV66J_^8@_W*_[[C^GOW7NAFZ,R
M=9MCL;8&X%-L-N'<QVH#_0_0&_\ K[M]^Z]TR]UY.KWCO_L#=?\ RY<=N<;4
MY_P _P#L2]^Z]T'^-I:N];EJ3_F'_P#<K_Q3^OOW7NEIVSO =B;WS.ZAQ0*
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M>6\=H;IW=;O;K3K_ /YD;_"/^/D_O1M7W[KW1G*GXT_+O*=H?WWRV6^0]?\
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M>24:CZ]L*@X%S8%N?\.??NO===T=4CJGK;;.WQDWS5;G]]Y[+93),NF^M _
M/-U#<_X\>_=>ZX]0]54F[JGN/K*KRA-712;>CQN4%SXQM#<TC*Q !)!= O\
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M6I*O['^Y_P#N5Y_\.H'_ 'KW[KW1@,+T .SNO^LMQ8O<(P58-B+BLH?X8/\
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M?S_P]1NI_P#LJ'N/_M73?^[[:_O76^AP^1'_ #)K?W_:HD_ZY>_=>Z)EMO\
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M3W[KW4/XX?\ ,X.]?^UI_P#+7O+W[KW4SYG?\>SL/_P[%_ZUQ^_=>ZX]5_\
M94O;O_:OC_ZVQ^_=>Z%GY&?\R<WW_P!J[;__ +TE+[]U[HJ&U/\ F8_Q8_\
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M[_WGX/?NO=5ZYO\ X^CY3_\ :M_^6C9WOW7NCM=!?\R?V%_VI8O^AYO?NO=
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M9)D1\&+C2(P25'']??NO=/.P]B[=Z[P*X';E-64>'5S7#[^O,KI(X!:[!AH
M !/T''/OW7NH60ZOVIF=ZT?8-935?]Y<?C3C(VCKG$:1$Z@K*K$7%SR"+_7W
M[KW7>P.NMN=98FLQ6UJ6KI*&MR+9&1<A7F0B1PNKU>HJM@18CG\^_=>Z]OWK
MC:W9V/HL;NNEJZVBH,@,ICS05YB9I5'I8L."OXM_MC[]U[KV'ZOVIA-YYK?]
M#2UB[FW JC)LU>SQE;6L([J+#\<GW[KW47L?K#;O:^-H,3N(UIHJ#)IDE_AV
M2*%G -@?Z*WXXX_Q]^Z]TT;?Z7V9MK>TV_<6,M_')\8V*?R9*22(PBY/I]%V
M8$<$V]W91)J)S3I#=56]5_//_'1TJ][[6Q>]]JYS:&<2HDQ6=Q[XW("D8QMX
M9F4R!)-+%&-A^"./=A<_3NM,'U_+[#TGYILDOMO,;5TD_G\24KGY=%EB^*74
MU,>L<7'B\J%ZAR3Y+9K-FZIC2S-N ;LCNOE"R**X6(/U3BX//L6S<Y3WD-Q*
M\RGQ&! "@5("J<Z/1!Z>E3U#.\^UVW6VT^V5LJGQ+-MQTT8Y$L@;-9#4Z>%#
M@\?3HV#4E+D\-5X^I&JER%))12"]KI)Y8C;CZA3_ +Q[!6X4N9= ./\ +@]3
MO?R&VW'<7/$^'^W2/M]>@L_V7?K48?";?^PR!HL!FO[SXO\ W*,"N=N?W"-)
M) M>UO\ 8^[].]#][]U[H!/] '6APV:V_P#95OV&X,K_ !;)_P"Y5B6SEAZA
M8 A_\+'W[KW0QXW%4N*Q]%C**R4=#0)CZ,%@2$5 OU'YTQC_ &WOW7N@JJ.B
MNO:RNWK75-)7-5]@"^Y[9-KN--Q;\J/]O[]U[H2-K[:Q6T<%0X#$H(\7CE"T
M*,P)122P&H6!Y/'OW7NDQF.K]JYC>E#V!64U6=S8W&-C<>ZUQB18R6:P4%AJ
M_J;_ ./OW7NN6P>N=K=8XZLQ6UZ:KHZ*OR!R,J5V0,G[I U%23?3Q^DCF_/O
MW7NFC</3>RMS[NH-ZYBEK7SF-%L<RY(HMP/JJ7;_ &US[]U[J3U[U7M+K.#*
MT^U:2N S4HER0R.1\IN%91:P)7TL?H+_ ./OW7NG7?W76W.S,32X3=5-55-#
M29"/((M%7&$^5 ^C6YTLRV:UM/'X/OW7NF[']7;5Q6]JWL*DIJS^\U=C!BY"
MV1)!C'+ #78&P^O-OZ>_=>Z%3W[KW5=N2_XN%;_VM#_T-[]U[J#[]U[JF#Y]
M]H?(3K#Y8;+W#T-O?:6U:W9_P/\ F-W3E-M]D8O=&^MAYC_0_NGIK>/_ !Z6
MR]]]:?[_ (_[.'W[KW0+;<_FO=\[H^2'7VT_[D=:8/K'(?[*UBMT;;R7]U\%
MOS,?[,AT".XMW]J;1W;O3O;^_P#_ ,8X_P">>_T8[H_O7_!LK_N?]^Z]T5?=
MO\RSOGOC;^]-D5>[-I?W8_BGPZ[IV'O;J7%_Z*,\-O;P^:6S=G?W4_YGMV7_
M +\<[&_YZ3^Z^ZO^K![]U[I4[$[E^8._>\NB=OX_Y+[&S/9F/^=O\R7K\KEM
MM[FW#@]GX+I[:*C:VV-V=3KWE$-YI),&;:"VNJD*2Q&H^Z]T8#:7\T'Y2[HQ
M'QPQ-7LCJ6A[!^<'5_3>5^.?\-VONC^ X?L'_2I_<[Y>?WO_ -_V.>N-C?[^
M'W[KW6P/[]U[KWOW7NO>_=>Z--T)4@[?S%&?^4'*,G^P*,?^(]^Z]T/7OW7N
MB1_-S:?:&_>@-ZX'IG)=ETN_FKMNY3%CK#/)B<OF9-N;I@EAP%:K[]ZUJX=F
MUC1/'N([>W3MW<?@C58I%\@C/NO=5[9;!?S7-SY7(G-X[ 8)>O-\]?[GZTVI
MC\EMS^X_^_6ZNWDJQMV?_?G_ $B;XV;4[\7$#<Z[D0O)>R WY]U[KV3HOYLV
M[^F\MM_<F4[%P>[,ET]D\CM'<6S,5\7]C[P7L:+=N[Y,]M;M2-M^=F4T3C9G
M\%_N<^V0MY!DAN Z@H'NO=(SO/%?SBM^]=_(_:&)IMPQ8?=66[(V'L0;+QW1
M^VM[X3K[=/5W>$/5&\-I;F??L<05]^3]?G=LA3^].VA_$WV\6"H1[KW0A]N[
M<_F:4OR7R^]MF8K=HZQVEMJ38NU3LW)=%ZHNOMV[G^-<KS;4VGO;?6O=?=L2
M;4W;9]S:-IKJ50064'W7NLS93^;W!AXZW<<-#7[@K:'"/N;&=:T71PSFU#1Q
M;/@G_P!%*;QD$512[[WY49C4-SAH8]O8<&PFL??NO=#-U'4?S):+L/H?*=OO
M/N/:V<WAV!C>[MM[;H^E<;L?:6UZ':FTAL[>5-N<O4]B5$TF]ZG,*V$C1Y:A
M'4,V'7#J,W[KW0!;BV%_-(ZSWQW#4]25N>W13;][F[BW[L^NWEF>CLSA4PC[
MED?:&T]S)NXQR[+V<.OH<7_=+^[0#C<NO^\-E+@^Z]U<=U+1;\QW6>R:?LG+
M5N;W\-K;>;>>3KZ/;N),FX?MX#N62.#:H2BA(J"]M!9#I4Z@2P'NO="6?JO^
MQ]H+S_<J#_;?X!TG'!NJ/<'_ -O*.S__ !;KHC_X!;Y&>Y /_)+C_P":#?X5
MZ;_'^?7_T=L;^6C_ ,>A\J/_ !=[Y!__ "G^S?>/[5OL'^7HFM^/1V^V<GNW
M![#SF3V#1)7;D55,2\'Z7#-8W_3P!_2_LGLP"PK_ *N/1S%2B]!A\;=T=J[H
MP^7'8E-7"DI&$>*K\IBFPN:DU7#*\6K2WI'U-K?U_!WU[H;=[U&X<?M+<59M
M''4F:W/1;>S,FW,76L%&3SBPNT4+GG]N25;$#]6JWT]^Z]U1[_+G^07\P[M+
MY&[GV]\@MN[MJ>LSC\_)NL[QV"NQ&Z^SZ.)-K0;64 B:.H165E(/!N.0"/=>
MZOBR<]5!B:NKQ-.*RL2A+4"<?N,5O&+G\<@_X^_=>Z)IT3OWOK.=A9'%[TQ%
M>=N*CFO_ (EB1A6P\FDE="G]3$_C\^_=>Z/)[]U[JO2?NCNH=Z#;:T?^X,[H
M_AG]WCC+NV M;RF3]1D/^J^OOW7NK"_?NO=$8[8[![^P7:E%C=J8C(?P9H@,
M=1T.*_C.(S"Z;%I) (Y(W Y/Z2I_I;W[KW1X8/\ -K[]U[HHWR3WAW!M:HVP
M.O:.K_A-:"N3R.,PZYIX\T9'\"%.&5"J< VO;W[KW1@NN\EN'*;.VW5[SHUQ
MVYZ[&!\G0?ZF3DMJ7Z?HM_KW]^Z]T!GR@["[ V)@<*^RA]A2Y#(^/+;C- \J
MXA+DBZL=-V^M[7/]??NO="5T?N3>.YNO,/EM[TBQ9JKC)#C2HR"6;]Q5/"KZ
M3_MO\/?NO=/?;.6W9A-@[CRFRZ1:[<M'3ZL;"P!!8E"U^.;7]^Z]T&7QRW+V
M7N;:U=5=D4M:C)7F/$U^4QAP>7R<8OI+0!T32 E@18_B]O?NO="AVCF=P8'8
M.YLOM.D6NW'08MFQJ6!NY*D,38\<'_8\^_=>Z+[\8>Q^R]\S[GI][?=5N(H6
M5<5DI,<(@YO^@N 23IO86/T]^Z]T<*>_@F\/Z[-:U_U6%[?XV]^Z]T2'J+??
MR S?:E?C=VX?(MMJ.-_XB:_%?P;$XBR$Z8=6IGD(' YN??NO='F]^Z]T0_']
MA_('_3:VWZO#UXVP-T-COX<,0#@Q@;?YQ=UE&O(/K]"?]Z]^Z]T?#W[KW6L#
M_-!^5_\ -=ZD^8.S-E?%S:.\3U//C-NS;)CVAU@^_,%V'N1U5]W0[MW/)LJH
M6FCB!%HE;0IN1R23[KW6R%M&JW-D=H;=K-V8^CQ&YZS;V";<6+HF3*1XS<$L
M2MN:ECE1-,L2ROI!-S?ZW/U]U[HMWR(WUW9MC<>$I>OJ+(?P5\6UJZAPRYEL
MIG&Y2 QV]*HEA;^O^O[]U[HTNUZG,5& PU9GJ5,?F:O'1-E,?8#1EM*^4 @#
M@F,_["WOW7N@.^1NY>R]M;=P]3UQ25LFO(>++9#&8LYS+8N(CDK SR+I8/8W
MO?Z?3W[KW0@=+9G>N?V#ALEV!0I0[CD5O.B@#4#P&X_)_P!Y]^Z]TE_D%N#L
M#;&R5JM@05QR#9%?XED*#$_QB3%X..YFD\#6-R+<CZ6/X]^Z]U)Z(W#V%N;8
MJUF_Z-Z3,?Q&1:!JW%G$-D,':,P.:<:R"4U>H+_2_!]^Z]TNNQ<EN?%[(W+6
M[/HER&Y:/&M+BZ#CU2\ $?EO2#_K6]^Z]T7[XV;P[?W0=R_Z0J2K_A5"H7&9
M')XE<*\F9#IYD"GU/'I?GZ@$CW[KW1I,U4Y&FQ%=58FE%9E4H6>@H&8 /-Q9
M?Q^6%_\ 6 ]^Z]T4+H/?/>NY=[YBF[ H:U=M1XD+D37XA<$V&SRV)BC'^I95
M(L/]?\>_=>Z.Q[]U[HB$'8WR _TZ_P  .'KSM;^\IQ1Q8P['!_W;M?\ O1_>
MG3K/ _3:_P"+>_=>Z/?[]U[HBW9V]N_,7VV,9M3$US[82OP46,I7Q^K#Y9"?
MWP:B^M277U686(_P][S7I6 H )].CNQ)>-2?]]]/\?=@W33RK4FN.M:'^<%\
MI/YG73/R!ZSV[\3ML[YINJLAMK!Y&CW#UWU8>UQNSL5]RK ^TMTP/LZN%)#/
M3:3XUDL5?41=C[$=C;!E(9<Y_G4>N,>G44;YOZ!QI?Y^=/P_T<Y_GU?STCF]
M^[@Z>ZTR_;V!H-L=K9O8VV,IV1MS%S>;$XG?53MVEFW-@XI6+DPT=7Y%4&XT
MQ_4VY)-SB568)E?+^7[?3H9<KWWC1*2:.?Y&K?+!P#T@/DIO/M;;%/ML=>4M
M>:.N<C*Y#&XH9LQCZA=-N%TV(_J.?:3H_P"AIZUR6Z,IL?;.2WK1I0;FK<8I
MRJ*  C_J!*CZ$@W_ -Y]^Z]TDN\,[OK:NPJS*;!I!79M:]!Y!B_XP,?A2&%0
MWA!Y "J1>]KD?CW[KW2:^-N\^PMX;7S%7V!22AZ/)F/%Y2MQ9PIRB$$F7QFZ
MD*P )L2+CW[KW0I=HY+=&*V-N;*;*HTK=S4>-9L6AL=;<.; _4BWOW7N@6^-
M>\^UMST^Y!V'2UXHZ%P,5D,EBAA#(/J5TVY73<G^@Y]^Z]T9VJ%3!0U1I;-5
MV++_ ,&-OH#_ (>_=>Z)ATMO[OC.]EU^+WIB:_\ @HCOD?O\5_!?X19;IH46
MUG^@_/OW7NCQ>_=>ZK@W)54F+J,UELO5T%#1X_\ O#E<IDLE;_</[]U[H(Z;
MOCI&JV?6=A4G<?4M=U]C\I_"O[[?Z4-K_P!P_P"\)_[.W_8>_=>Z[R6\ND:K
M=%%M[+;LZEKMZ9_:_P#"L7C<ENC:XSV8V]O#_>/[C_[]+W[KW28QN\OBUE*>
MB[-Q.[/CO74>W_\ ?@8KLC&[HZO_ -P_]-J_WM_^5[W[KW4'^*?$3:^S\+O?
M[OXTX/9>\,I;%[U_BG5^"V'O#</]ZCO$?[^W_P /GW[KW2H_BGQ\P/8%%M[[
MOI;!]M[P_P!_7B]M_P 4VO@M^;P_[.J__,P/?NO=5P_Z>/@;E.X-E_(6KRV_
M/]+?3_QS[C[4ZO\ C?\ Q3:^"P/6_7O]Z_[G;OW5M':7_,O_ ._/8_\ =+_G
MI_\ CU??NO=6B83MKKW/8?"Y:DWOM'[+<&4_NKB_]_1M?_F87_/*_P!?[\6_
MYA[W[KW4W:6_.O=^?QG^Y&]]I;Y_N_E/X5NC^[>Z-KYW^#[A_P">5W</Z>_=
M>Z6GOW7NA]Z&J-5?N2EO^F@B;_;.!_A>U_?NO=&C]^Z]U[W[KW3:HCC34B:!
M_74S?FWT-_Z^[SW"Q$"1_P"7^8=-"ZN[U:Q)3\U_R@>G5)N_=Z_S0J3Y [NV
MOL[;;UG2>4^2'7&Z=K[W?;&UD?%=#;2W+T[M#MGJD),WE,W8D.[6W!#GV]<<
M>&W6JV7^"#W1/]V&(CC_ %>M/3HIO-ZW+83_ (Q;U3C^'T&2 K<-?'R_P+39
MW<7\PK,8/8N'W/T;D<<U17=#8S<VYFI-OOON-JO=/PV'<%3NATJ(MDP"/9/;
M'8ND0;>AT?W-)4JQ#!'O.W-!N"&)PT9S4$$'M XAB#FOKPST))MJVK=)/J(Y
MJ)Q-0X\J>;+7AFH].@E[![S_ )H/7W;_ ,E<AL[IC>';?7F+K=R4/46 W+M?
M:E'LEX9-R=.-MD[:DV93TO9&Z5_N6=V3.4&X766-2=(!4FV\6XEV]1$5\2AJ
M,5^)>(J/YCIV:TVF>%;<2]X&<.1Z^=!_@_R="'V5\@?YD<M%MO.[6^+:JM+V
M"V8R6RZ*ID9\KL3[?N/:+;9W))-*S[LG\4.TMSDQG:K%]6%/K9V*06#2YJ*?
M:/2OKZ?RZ1",S_#P_P!7V>G1I,=OCO"K^:Z;6"]F47Q_P_33Y/(KN#8VW9]D
M;VW]NO\ NBNU/[E9ZBV#_?\ VI4]=T]%FSNB+/[A8:\OC B?4>]^']/FO^K^
M?6O#\'CU8'[]U[KWOW7NH1^J_P"Q]H+S_<J#_;?X!TG'!NJ/<'_V\H[/_P#%
MNNB/_@%OD9[D _\ )+C_ .:#?X5Z;_'^?7__TML;^6C_ ,>A\J/_ !=[Y!__
M "G^S?>/[5OL'^7HFM^/3+\BNU]V9'?>Y=O8K/UV/VW@1_#91B[<RL 7)(X)
M+?GV4V7$_P"KUZ.8C@= WLKL_>VSLQ1Y7%[@SQH:#C*XPY.^ (_QN"""/>NO
M= =_.$^7_:>P-Q]:]0]-;WSNRJ3<&QY=^[XR>W",+G<BC,B[4A@W;8>%&DA!
M91]6'/T%O=>ZH9V;W]WKLC.4NY]F]J]DX?<<B-D9*Z@W-N=T='!5D=&!5D<$
M@@\$>_=>ZVK,Q\H=S]F]-]&;GVGE?M,GV#UC@]U;FDV]I=XL]-X3)#"Y&J.%
MC3Y0E0;$J+_06]U[H$<;OS>^+R'\6Q.[,]0UOT_XNG]?]:WOW7NCR[W[PS=/
MT!LK<.+R4='O/=YCQHR#(I"O P;=+J""$:(BXM:Q M:WOW7NB&_WHW9_$?XO
M_>'/?QK_ )V7\5_Q]^Z]T<G:O?>;@Z WIE<QDXZ_>>!S46W<?D#&I,LVZ#&8
M96-@?)&\63(8W(\8 ]^Z]T43);RWOE,A]WEMV9ZMK/\ M:?[Z_OW7NCM?&_N
M3/U.V>P*7>V4K:X[2QG]Z<;E,D "=NA6(N;7-K<>_=>Z)?N#LS?^[:U<EG-T
MYR.-!9$3)A$5;\*JK8*/];W[KW1C/C7V]NFAW?0[2W)GZZOVS6X_-R*<E8'#
M/!()8QJL2 ''^V)]^Z]T"&_^VM[[\S%;5Y7<->,*,G_N+QF-R=L#^+?CW[KW
M2]Z%[7W7A-_;8V]5[@K:W;>>R;8O(4&4R*R&-RI D4'ZD:OZB_T]^Z]TI?D7
MVONO);]S6U,1G:W&[;P9&/E&+ YE=1Y&8KPQOQ?^@]^Z]T%'7/;&]=BY_#U-
M/N#/'!MDR,MB\GE < 01R#?^OOW7NAD^2?<.ZZC>U=M7;V=K<9MS"8L23+C"
M&_C$C 7!<?JTGC_8<>_=>Z+GM7L+>FT:ULG@\]G*5&!5T?)!D93]0RM=2/\
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M6XW;F""F08RQ_C#6N;L!Z]-[ ^_=>Z O:O9O8&T*YLG@L_G'2A%CBVR0;;[
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M#5IU' H3I%:9[:^O44?>3@V+EG<MUAV9E:V14-$9F".6C$J"FLC2U25KV,6
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M*DV%B-QX_::;BF1G>+=FZ8"\J(K$M&BU62)(X'D6_P"H7]U[H;NM]KU?]_\
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M^47\T_YQ56XJSJK;OR+['VKL[KW*G8(W-MO(K@MP;NW%M 6W@=V[NM<$CCW
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MB,A.G3R/\Y?_ !'OW7NF;:G46?P/<-7O^IRF%?#-MG^$+CUBD;-*3<ZVD"A
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M0&Y+O3K/#;M79%;EWBS1MCBHQ[?P9'/)0R*Y&D7L0"1;W[KW0Y>_=>Z!O?\
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MO_?Z_P# !=]#$8K\\*+#_8_[]'V4V7'_ %?/HXB_"?MZ0..Q=7E,?FJNDO\
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M (K^3_S%/M=T3=#CV_N1>UL_1Y2AJK4.T.LL%F,K^?5+(TDA_P!B[D^_=>Z
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MXO3F(#2IY_7<_P!/?NO=5TU.U\35;(WINN]?_&L?OS^%<?[[^OOW7NC_ +=
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MU[\#W[KW1&\'MG$4V!ZEW52&O^^S^^UQF5'^&T#L\#_;E3_MO?K(_2,&]/\
M9^WUZ]>CZM2O^KR^STZ.!O\ ^$'3?8O9.U>TL^NYCG-H;J&^\70T68,>&_O
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MIMUMC\O]7S^?3'NC^<[U/-U9N7=_6/5G;9R^-V)O_+XO(;WVQMX8'$[EV?\
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M .UO@?\ K8??NO= KL3_ +*+ZV_\15@?_>4/OW7NCQ;M_P"/6W+_ .&]G_\
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M^_=>Z"C+]%=+Y[?M%VOGNJ=A9SL_'8DXG'[ZR&U=NS;XCQ-QJA3<C()S!<W
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M%I!\;DZKJ6!_)8 _7CVSTLZ>,)@</MZ@3&83&46'HD!*T= BQQK<6N+!>?\
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M4NS:]:'<\NWLTFWJXA7\&;,4GVSD'CTU6D7_  3_ (>PIN>WWJ\N712?_&5
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M!\N/EQQU3;_);V'\L-J[^[8KNX<_D#ULN+DQ*8#<>^UWSGLIV!_>5Y'W2\K
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MBR']X=_Y3_WCMH?^\E[S7]@(/ZH6R@_ZLW'S?^/KBQ]^.XD]R/OX;-[&L?\
M%QXN,?\ 3/6&X>D1XQ?\I'_0!4_4V!JL[35U+2D"LW?N?;VP<620  .22;\#
M_BT>S7[[7,DD7M1LD<9R?&_[3+'^CU@#]T_:=NO]A>Z=*L*?Q^<EXOD1Z>G4
MKOK+XGJG*=Y9JD'V%%L).P'VN/K;<+*&V@+V'TWR<1[YP^U')9YK]VMF,IKF
M8?LLYAY.G\'^KSSV]HFVN\YAGLI$JJFG%_\ ?<Y\J>GKU2Y\@NGZ7JG:7Q>!
MQ*T.9[+^/([0R17ZYD;P[-W9)M'4;GU#9+XD?ZP]]D-BWT#:KI0,*P _WJOI
MZD]= ]LYR!VF]0 45P!3[037LXU)'ET8C)=7TE5T_P#(+L+^$_?474&4Z=Z7
MVMD?^=/N'_F,+?\ H)^\?+\_7;O(3\O^.#[/3K$G>]U^NWF4D^G_ %;7Y#TZ
M17Q>ZQH^X\QVWM0TOWE;0?'3N'?NUR2 #N/:)_O>HN?RS&P_J>/9#T'^MO3^
M7)V6G:?PWZ)W"U4*ZLQNU(]C5[#ZK+L>279SDCZ<C;0_WGW[KW1WC]5_V/M!
M>?[E0?[;_ .DXX-U1[@_^WE'9_\ XMUT1_\  +?(SW(!_P"27'_S0;_"O3?X
M_P ^O__5VQOY:/\ QZ'RH_\ %WOD'_\ *?[-]X_M6^P?Y>B:WX](#Y![QS&\
M-^;EHVJZS^[FW\F-K8_'(NE6D(N[ ?4!FN?919?%_J^?1S%^'TZ";:F<S^VJ
MYL]@*FNHZO @Y1EQX#*RD$$,I!!!'U'OW7NC4_*#L3)[GJ=M;?V[E*T89MKC
M=66.- !:WTN?J;#^OOW7NB?83^+?Q&B_A-7D*&M^O^XT7^O^O[]U[HU'=?<>
M5WCL_K+$XG*U_P#N1VQ_%MT_PW_E\D_7_P!Y++^_=>Z*OC?O/XA1?PK_ ('?
M\NO^&_T]^Z]T<W-]V;AJ?CEMEJ/+Y#^^FXLF-JG(  9RX+7;@?J:X!/] /?N
MO=$DJ?O/N:W[O_@;_L/\/^(]^Z]T<SK#N#/;8ZA[.QF7R58=T[0\?]V6R:@L
MPW4[R0B]B3XY'++_ $)-N??NO=% R57EJK(?=Y:KKZZM^G^Y+_?'W[KW1P/C
M#V'E-M9?-;<W'DZQ\(=L#=.+#J""I/JX-_[/OW7NBL;KW-G]WY89_/U5=6+G
ME&3Q*Y$!54+]% '  ''OW7NA.Z"WCE=G;_VQ_E=?0[8S^4_NKD\;:^!!_!%[
M\@^_=>Z3';.\,IOG=V8SU34UU9@UR6X,3B%4 !5 L H%@ H' 'X]^Z]U!ZQW
M?GMC[EQ&=QE374F"HLE@$RZD KFD92&5A]""#S[]U[K/\Z^Q=PY_L2MV!M_*
MUW]V=H[:P>6W+C<=D-##.&0Z 0?5RNZ\.3?Z^\*??OF8;E?1FW'Z2UX'%2MO
MZJ/,'J,-_O6!T5X4KG%>WY>7#HCFU,ENK"5S9[:V4K<+E\"#DVK\> RLK AE
M8$$,"#R#[ABYNGWO;D@B/>/RSK!]%_A]>B"POW5PRDA@:BG'S\Z=6:=S]P9?
ML/#[ H\!EJTT60V-@MU[EQV,'(SKOK"$V_LDVM]+ >^BG(G,ZW5@33NH!_QJ
M2OX1QH.I51@S YX#]M*=%UQO\6I<A]WB:NOH:W_JV^SS:#]3N#G_ %?"W^;H
MXBX+CHY?8W=&<R7077K4>2JZ#=&[O)C,ED\:HU*VUG+S$-;CRO8FWU/U]K>M
M]$H_Z:^?K]?]X_V_OW7NC?[3[JW#C.B^P<95Y:O&YMOY';V(VSD./XZQW>RM
M&3_0QD&W^O[]U[HIF3^\_B%;_%OO_O>/XI_$O]?CZ^_=>Z.9\<NR\KL_$[]P
M.ZZNMK*7;FV/[U8N@R2J7\9Y:,$@V5R!?_6_K[]U[HH&Y,IN'/9#^+;AJZ^N
MK<A_N5_W)<?[S]/?NO=#C\:][Y/:._L)15V2K:79>=?/8] UOX")(V#QL+CA
ME918^_=>Z"??N[\]OG/5>Z<E45M7CZW);@3$+7J%7"H!90J@ *H L !]/?NO
M=*?I7>&4V+O;;64IJJNH]K9+<YQ&6! *LI%B&!X(/OW7NE+\B]SY?<_8FY=6
M4KJS;> R0VOC\8+?P'R,!K+%?26O]2/K[]U[H)MF;FSVT<M2;IP-374L>"R1
M7+I0*&5E8:65E((92."/H1[]U[HQWR@[$RNYMW_W>V]E:X;8V_B]O93*'&V)
M(W=<*6/%SI_VWOW7NBL82JRV+R'W>WJNNH:W'_[E?XEC?]]?W[KW5>G_  I/
M^>':'6_PJ^,?2G0V\=T[*[=^5W81H=QY/9>17!Y_)["V?3?9;NVU#P#$W8N\
M-W8E+BQTD@W!-_=>Z^=14Y3+?QC[O[NO_C7\3_XN/^\>_=>Z^@Q_PG]^>7=&
M^_A%\@_C3W'OW=.;[L^.'=.WMD;8RNX\B,YO[$[$WA!]K_=MF !:7K?>&T<O
M'J/.@6^@]^Z]U:94_=_Q"M^[O][_ +Q]/?NO='*Z6[7S&V.NNUL9GLM65M;L
M[''*;<;)CU&'Q2V13;_CL5-N.+^_=>Z*#FZK+93(?=[AJZ^MK<A_N5_B62]^
MZ]T8SXT=AY39^Z%Q>7J:T[:SNV-Q99,>4!*': *L5)_2Q5B#;\'W[KW1?MUY
MS/[EKESV?J:ZLJ\\!E%7( *JJ   J@   ?0>_=>Z'3XP;ORVVM_83$5E9D!M
MG>#9_&#'BW\"_O$K!A:XMS:W^M[]U[H,^V=XY7?F[\UN"JJZ^MVN,GN'$[6
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M1G<9E-Q?PH?QP:FE!8&VK4P O<VX%OS[RIYHVH\U<S<U)JP([4@?[0 GBG\
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M'_J_(='C^//4/6G5/\TW9>QMA;3Q^U=LU_Q0&9R6-CU:<QN#=>W/)NF]['4
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M9^Y_]RG_ *%7X/)]^Z]T.=3T#O7?F V9NO9&6P5#1Y_K#;V)RG\24DFR!_2
M"2+'\?GCZ^_=>Z#SLOK2KBW]MG8&)6A2MV]UIA8K-]3X)Y-U[P<?C3)X[C_
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ME=R?W\_O_M=MX[QVA+M':DFR(XVCCWI_"9&LQ;0ITAF*J?=>Z^>]_LN>]_\
M9</]FP^[P'^C'_3Q_H!_AO\ %?\ <]_I"_NK_?+W[KW7T2/AM_)O[TZ _F8_
M(/Y7XS=G6P^*WR/Q6WMVG;V.R6ZDWLF>4;.WF[OMJ0)3J(]ZKF68%P=.8-@?
M?NO='FS>U\M4_P"D'=E)]A]G@-T?PK*?U_W^'OW7NC*9[X][RW=3T&X=EY;#
M4&&WGL;8,>2QF2KIG+-''M.5@ B-P8X&(/YX Y(O[KW05]H]<U0[/W/M/;W\
M/_WY^Q-O90$G_F'MH;5L ?\ $D^_=>Z66V^E,_VAU3U]D]IU=#0U^.'8&+RG
M\2'UU;J>W/T)_;/OW7NDQV?U/E,?N[K'K2B;'MF/[BNO'^J3=N\]W-_L0P(]
M^Z]T]=<]/9_L/KC!Y7:M90T&Z-I;]W"JY') FYT;0>PL/J50G_8?U]^Z]TS=
MG]3Y38NWNI-E5)QS[FW#E=Q>I2"+@[.4BX^MF%O?NO=3>K^ILKO''=S]?DX_
M^\V RNW #<_P'^\6T=U[Q"_[R??NO=4@?,GX6]H?'+HKY1]R=T9;;&<W3W)\
M@-ATVV/X#4U64*[;BJ=W;H 85,4120R'%70C6!A02 ""9VY0WU/J4AC-:HS'
MCBA('E\S^SK)/E+FT37,<"^:,Q_(D#\(]3Y>7[2\_#CXO9^3Y8;:Z.WM5X!J
MKNSXQ]@9/'Y/'-_&AA=M]O=$;QBVPY+6'[*ZC_C;V?\ ,G,;+'JC-0&_P,H;
M\/EG[>CKFC=P+=K@916 /R&I%;R\LGYTZO@^'WPO[H^,G0>Y,+W5N':^<R&T
M=B]C#;"[?K9\LV&&ZT1W>T\<9*#S907Y!+<?0V@7>-T^J4@</^B?D/3K'O?^
M9OJ4H.'_ $3_ $1Z=*78&U\MB]T=+[AJ_L/LMX;H_P!Q?_DG[J]DEEMGU!+?
MZO/Y] F FY8M_J_R=#)E_C+NG;E;O+<E35X([8P.+[#RN+7A7!3;&C:@93:S
M1-PW]"/?NEO16_X75TN/PNX;_P"19#*#%?[[_'W[KW1O<I\4M_5&>S%-B\MA
M*#962W5_$QC/OYB?X!_J="H6!/OW7N@/['V;5Y7?_<]7B?L11;/R@RN4O]1_
MOZ0?]?@^_=>Z-)U1U7G9\STOVIBJW'46*H=@G%[EANHDDX:P4&W!T_7Z#\\>
M_=>Z/)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[JI'^9K;^\?Q0M]/]-]+;_DO:_N.N>;D-!'&/(G_K&?
M3K)_[M$9&V>[Y/F=J_X]<=)+JW_LLOY_7^@V;2_^\@X_XGV_R':>(UTWJ"/V
MLX]>B3W0E5?N\<@@C(:X_P"TKH"J4?\ .*_QF/\ X$UFQ_MY)S[S6O[I=BYK
MYM8^4-H/V@_)NN'FUV1_X'_V8'SW?_NXGY]"Y7@'KOYXD_CLW;A_V)[1(_XG
MWR-W"S/-.S<UZ3YV_P#U<'S3^#_5YY][;9$;3S&/G!_U<8^ORZ+PUO\ ATS^
M7Y_C\0!_M_[D]M#_ (CWGC[83%ONY6OSGE_[3AUD!R[*6Y'VBOFT_P#U=Z(9
MM&I_[%/_ "%;^GSJC'^WVQM(G_H7V+><(0]SM I^!_\ #T)_=:(/SYL-?2;_
M *L1]6K==?\ ;W;J_P#\4GVS_P"\RGN.^H<ZO8]^Z]U"/U7_ &/M!>?[E0?[
M;_ .DXX-U1[@_P#MY1V?_P"+==$?_ +?(SW(!_Y)<?\ S0;_  KTW^/\^O_7
MVQOY:/&T/E.?_ W?D%_\I_LWWFXU3%R."C_#]GSZ)K?C3[>AD^9!OLK9O_A[
M4_\ O(D]E-E>48D<?^+^71S$/A^T_P"7ILZQY^4W88_KM4__ "G>]&\)%"/]
M7[.E9G4@CH</D*MNF]^G_JS2#_DZ+WH78' ?ZOV=564*:GTZ)KML?[_#XL?X
MXS_Y:=XC_>A[W]9QQQ_U>G5O'7NS_JX='@[H4#J7L,_]FMF_]XAD'O0NP,CC
M_J^751(-0/E_L=5\XWZ_%;^G]Z/_ )JGNWUI]/\ 5^SISZA>%?\ 5^SJUGQ_
M[[_?'W3ZE?\ 5_Q73&OJGZW_ !A?L$_]_0V\/_>R]V^M\Z?ZOV=/_4+Z_P"K
M]G5JNRU!VIMD_P#9N8'_ 'FD0?\ $>]&[!X_ZOY=-M*"<'_53JO_ #]O](?R
MA_\ #4SMO_0EV=;WX7A 4>G_ !7ITF\4?Q=&^^/=O]#&P[_\J,O_ +O:O_B/
M>C=:C6F?]0].O>*#C5T$7:%O]FGZDM_SRY_WO>8/O8N](H!C_5\NM&45'=UF
M^&Y V?O2_P#SVT__ $*GO379>E?]5?RZWX@/XNH_R=&G?O1(_P"SG'_O4;+]
M[%YIX</]7RZ5I, #4]=_'(7[7^0?_AT?_+3O/_BOO9O*BA'^K]G7FG5A2O4K
MYL_]D\[T'X2MV^J_ZS;FH?\ BGN'O=?:K2?D+P]78C8^+SGB)\^@_O?^XX/F
M3T5SHFR_+#8?X'^R^;-_WGKG:QM_M_<:<G1V=G[I[" V=,G\7_*$WV^O1);Y
MF7_2I_QT='J^1B_\88WT?^K?@3_M]QT7O*P7=,TS_J^70Z$P#5KC/15=I_\
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MR='CHER^4TK>SS*HD;CZWO\ X^_?4-Y#_5^SK8FQDFO^K\^E)]M2_P#*NO\
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MPV:6GP+7_3'I=]0?7ITZR_F.?"GJO U. QF].R<Q25N0DR8>LZEW:&4RV#
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M8O\ Z+'=/_7CW[]SS_PK_O77OJ/F>O?\.W?#O_G>=B_^BQW3_P!>/?OW//\
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0]L/U7T^'R\_7_#W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img101536035_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"^X5<C/Y5NU"<(7E:Q.J;*7P2M))O&DURH/EV]H^YNV6( '\_P JP-"N-?\
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M^N-Y_P"@&NA^)_AW4O$WA>&QTN%9;A;M)2K.%^4*P/)^HJMX4\+ZKI?POO\
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MBSQN(Z$8/8#CUKHO&NA^/G\2+K'AO40T*QB-+9'";!WW*YVOD\Y/Y<5S%O\
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ML^T33(RHO<JJGDGZ#MDUK))2C)NUD+HT:=KYO_#.%QY@^7)\O_=^TC^N:?\
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MRT+2;%MR/!%Y??#3$'/_ 'SL-;'QKA-AX:T#3[9=MG$[(!Z;$ 0?D6IOP_\
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M .$HU#6/ME[*R/<(R$_?( PY/.,CL/TI_P ;O^1XM_\ KPC_ /0WKT#XF?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\
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M -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(5F&W=\IX/Y4E1AU_K5%/$5'LMO\GI^!T5GJEI?R/' \@D10QCEB>)MIZ'#
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MEL8;8.3TP<#//UH6TN9M12^%K*D,^JK*JLA#!%A*[V'5<D=\'I2]E"[^?_#
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M6;:\BNPQC6==O7S8'C_+<!G\* (KK5+&QD$=U=Q0N1N"NV#CUJ'_ (2'1_\
MH(V__?=:5%4G'JOZ^XAJ=]&ON_X)F_\ "0Z/_P!!&W_[[H_X2'1_^@C;_P#?
M=:5%.\.S^_\ X K5.Z^[_@F;_P )#H__ $$;?_ONC_A(='_Z"-O_ -]UI447
MAV?W_P# "U3NON_X)F_\)#H__01M_P#ONC_A(='_ .@C;_\ ?=:5%%X=G]__
M   M4[K[O^"9O_"0Z/\ ]!&W_P"^Z/\ A(='_P"@C;_]]UI447AV?W_\ +5.
MZ^[_ ()F_P#"0Z/_ -!&W_[[H_X2'1_^@C;_ /?=:5%%X=G]_P#P M4[K[O^
M"9O_  D.C_\ 01M_^^Z/^$AT?_H(V_\ WW6E11>'9_?_ , +5.Z^[_@F;_PD
M.C_]!&W_ .^Z/^$AT?\ Z"-O_P!]UI447AV?W_\  "U3NON_X)F_\)#H_P#T
M$;?_ +[H_P"$AT?_ *"-O_WW6E11>'9_?_P M4[K[O\ @F;_ ,)#H_\ T$;?
M_ONH+K5M!O;9[>XOK9XFQD>9@\<@@CD$'G(K9HH3BM4G]_\ P!.,VK-K[O\
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MJ[4::Z>4H.X7>QV]NGI70T4U.*5E?[_^ 2Z<F[NU_3_@F;_PD.C_ /01M_\
MONC_ (2'1_\ H(V__?=:5%*\.S^__@%6J=U]W_!,W_A(='_Z"-O_ -]T?\)#
MH_\ T$;?_ONM*BB\.S^__@!:IW7W?\$S?^$AT?\ Z"-O_P!]T?\ "0Z/_P!!
M&W_[[K2HHO#L_O\ ^ %JG=?=_P $S?\ A(='_P"@C;_]]T?\)#H__01M_P#O
MNM*BB\.S^_\ X 6J=U]W_!,W_A(='_Z"-O\ ]]T?\)#H_P#T$;?_ +[K2HHO
M#L_O_P" %JG=?=_P3-_X2'1_^@C;_P#?='_"0Z/_ -!&W_[[K2HHO#L_O_X
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M^_\ X 6J=U]W_!,W_A(='_Z"-O\ ]]T?\)#H_P#T$;?_ +[K2HHO#L_O_P"
M%JG=?=_P3-_X2'1_^@C;_P#?=(?$6CCKJ-O_ -]UIU!=?<C_ .NJ?S%%X=G]
M_P#P M4[K[O^"5/^$AT?_H(V_P#WW1_PD.C_ /01M_\ ONM*BB\.S^__ ( 6
MJ=U]W_!,W_A(='_Z"-O_ -]T?\)#H_\ T$;?_ONM*BB\.S^__@!:IW7W?\$S
M?^$AT?\ Z"-O_P!]T?\ "0Z/_P!!&W_[[K2HHO#L_O\ ^ %JG=?=_P $S?\
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M?]^W_P#BJY"FFE]7I?RC^M5OYCL?^%DZS_S[6'_?M_\ XJD_X65K/_/M8?\
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MUY^::>E'L*?8?/+N>@_\+C\0_P#/GI?_ 'ZD_P#BZ3_A<GB'_GSTO_OU)_\
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M\B_<_5/_ $-: )M&_P"0?']*T*S]&_Y!\?TK0H **** "BBB@ HHHH ****
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M.:-!I=F\KP0ERK3$%CN8L<X '5CVK2J+[3!_SVC_ .^A1]I@_P">T?\ WT*
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MO^@9_P"1X_\ XJO;**/KM3LA_4:?=GB)\ >)_P#H&?\ D>/_ .*I#X \3_\
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M_5H'@A^'/BO_ *!7_DQ%_P#%4T_#CQ9_T"O_ "8B_P#BJ]]HH^N5.R']7B>
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M^J?^AK0!-HW_ "#X_I6A6?HW_(/C^E:% !1110 4444 %%%% !1110 4444
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M73_^_;__ !=(?BEKG_/KI_\ W[?_ .+H^IU0^MTCURBO(O\ A:>N?\^NG?\
M?M__ (ND_P"%J:Y_SZ:=_P!^W_\ BZ/JE4?UNF>O45Y ?BKKG_/IIW_?M_\
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M4R2:LRD?4VBZU8Z_ID5_82^9"_!!^\C=U8=B*T*^=_AUJ.N6?B>*#1HS.LQ
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M']7J_P K^YG/4TUT7_"$>(O^@=_Y&C_^*I/^$'\1?] [_P CQ_\ Q5'MJ?\
M,OO*]A5_E?W,YXTVNB_X0?Q'_P! [_R/'_\ %4G_  @WB/\ Z!W_ )'C_P#B
MJ7MJ?\R^\?L*O\K^XYT]:;71GP-XC_Z!W_D>/_XJD_X07Q)_T#O_ "/'_P#%
M4>VI_P R^\KV%7^5_<<V:0]*Z3_A!/$G_0-_\CQ__%4A\">)?^@;_P"1X_\
MXJCVU/\ F7WC5&I_*_N.;IC?UKIO^$#\2_\ 0-_\CQ__ !51R>!?$B %M.QE
M@!^_CZD_[U+VM/\ F7WE>QJ?RO[CG33373'P%XF_Z!O_ )'C_P#BJ3_A ?$W
M_0,_\CQ__%4>VI_S+[RO8U/Y7]QS)IIZ5TQ\ >)_^@9_Y'C_ /BJ0^ /$_\
MT#/_ "/%_P#%4O:T_P"9?>/V53^5_<<S3373_P#"O_$__0,_\CQ?_%4A^'_B
MC_H&?^3$7_Q5'M:?\R^\:I5/Y7]QS!Z4VNH/P^\4?] O_P F(O\ XJD_X5[X
MI_Z!?_DQ%_\ %4>UI_S+[RO93[,Y<TAKIS\/?%/_ $"__)B+_P"*H_X5YXI_
MZ!?_ ),1?_%4O:T_YE]Y7LY]F<M3374_\*[\5?\ 0+_\F(O_ (JD/P[\5?\
M0*_\F(O_ (JCVM/^9?>5[.?9G+&FUU7_  KKQ7_T"O\ R8B_^*I/^%<^*_\
MH%?^3$7_ ,51[6G_ #+[Q^SGV.4/6D-=6?ASXK_Z!7_DQ%_\533\./%G_0*_
M\F(O_BJ7M:?\R^\KDEV.4IK?UKK/^%;^+/\ H$_^3$7_ ,54<GPY\5H 6TK&
M6 '^D1=3_P "H]K#^9%*$NQRQZ4AKK#\-O%O_0)_\F8O_BJ3_A6OB[_H$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9^O?\B]J?\ UZ2_^@&M"L_7O^1>U/\ Z])?_0#6A0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !YD?]]?SH$B$X#J3]:/+C_N+^5 C0'(10?I0 ZBBB@ HHHH **** "BBB@
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M%% !1110!GZ]_P B]J?_ %Z2_P#H!K0K/U[_ )%[4_\ KTE_] -:% !1110
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MKH["[@\;?$.UU"W/F:5H=DLL38X>YN$##V.V/'T+UV>E:18Z)I,&EZ=!Y-E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC<O]X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^= "T4FY?[P_.C<O\
M>'YT +12;E_O#\Z-R_WA^= "T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_>'YT
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MHHH **** "BBB@ HHHH S]>_Y%[4_P#KTE_] -:%9^O?\B]J?_7I+_Z :T*
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M\D_[Y%/HH 9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\
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MM/EUOXH>&]8GU;4XYKCP^E])%#<;8RP:,%-N/]6Q.2O<XKUN@ HHHH ****
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MXTT]*1:&FFTXTVD4AM-/6G4T]:"T---/2G&FGI2+0TTTTXTTTBD:_AOQ)?\
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M )%[4_\ KTE_] -:%9^O?\B]J?\ UZ2_^@&M"@ HHHH **** "BBB@ HHHH
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M\A0@ J1USD\BJ&A_#O3]'U6'4Y]6UO6+JW!^S-JMZ9Q;Y&"4&  2..<UV%%
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MZ!^"#C/7&:;<?#C0I_#<&BQO?6X@N/M<=[#<D7*SG.9?,.<L<GK_ $&.NHH
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M*!D623;@N2!PP/8'TK2DTJD6^Z,J\7*E)+>S/&S2'I76GX>ZM_S\67_?;_\
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M  J[6_\ GZT__OX__P 11]8I?S#^KU?Y3AC3&[?6NZ_X5;K?_/UI_P#W\?\
M^(J.7X8:V@4FZT_E@O$C]S_N4?6*7\Q2P]3L<2::>E=T?A7KA_Y>M._[^/\
M_$4A^%6N8_X^]._[^/\ _$4OK%+N4J%3L<)VIM=Y_P *IUW'_'WIW_?Q_P#X
MBD_X51KO_/WIW_?Q_P#XBCV]/N5[&IV."---=Z?A/KW_ #]Z;_W\?_XBD/PF
MUX_\O>F_]_'_ /B*7MZ?<I49]C@333TKOS\)=>_Y^]-_[^2?_$4A^$FO_P#/
MWIO_ '\D_P#B*/;T^Y2I3['GYIM>@'X1:_\ \_FF_P#?R3_XBD_X5#K_ /S^
M:9_W]D_^(I>WI]RE2GV//J:>M>A?\*@\0?\ /YIG_?V3_P"(I/\ A3_B#_G\
MTS_O[)_\12]O3[E*G+L>>&FGI7H9^#WB#_G\TS_O[)_\12'X.^(?^?S2_P#O
M[)_\11[>GW*4)=CSLTTUZ*?@YXA_Y_-+_P"_LG_Q%6M,^#>H_P!HQ'5+VS^Q
M@YD%N[EV'H,J ,^M)UZ?<M0D8'@;P+<>*KS[1<!X=+B;]Y*.#(?[J_U/:O=A
M:6]A8VUI:0I#!$Z*D:#  S5BTM+>PM(K6UA2&")=J1H, "DNON1_]=4_F*X*
MM5U)>1M&-D3T445B4%%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_
MY%^Y^J?^AK6M63XE_P"1?N?JG_H:T 3:-_R#X_I6A6?HW_(/C^E:% !1110
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M%]F@_P">,?\ WR*/LT'_ #QC_P"^10!+147V:#_GC'_WR*/LT'_/&/\ [Y%
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MB@ HHHH **** "BBB@ J"Z^Y'_UU3^8J>H+K[D?_ %U3^8H0$]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5D^)?^1?N?JG_H:UK5D^)?\ D7[G
MZI_Z&M $VC?\@^/Z5H5GZ-_R#X_I6A0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KW_(O:G_ ->D
MO_H!K0K/U[_D7M3_ .O27_T UH4 %%%% !1110 4444 %%%% !1110 4444
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MK2*%;;QP,#C.?QK)U+X<:9?P:<(-3UC3;FQM4LTO-.N_)FDB4<*Y P1WZ=:
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MBL+/SOD89WY!P .,YQUXS0!VE%<#XGUK6==\)Z9J?@HM<Q7C"7:L;HY5#O\
MOAEV?<*%2#NW8R.M=CI+WDFDVLE^Z-=/&'D*0-" 3SC8Q)7'3!)Z4 7:***
M"BBB@ HHHH *PO&7_(J7O_;/_P!#6MVL+QE_R*E[_P!L_P#T-:TH_P 2/JC'
M$?P9^C_(\E/>HS4A[U&:]\^60QJC-2-49I&J&-WJ,U(W>HS2-$1FF&GFF&D:
M(C-1M4AJ-J1JAAZU$:E/6HC2-4,-1-WJ4U$W>D:Q&&HFJ4U$U2:Q&-7KWPX\
M9WNJHFB7\<L[P%&BN@,X4,/E<_R/?I7FV@>'K[Q+JJ6-C'DGF20_=C7NQ/\
MG->_Z+X;L/#&D0V5DF294,LS#YI6R.3_ $':N7$SC;E>YT4T]S?HHHKSC8**
M** "BBB@ HHHH **** "BBB@ HHHH **** "H+K[D?\ UU3^8J>H+K[D?_75
M/YBA 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_Y%^Y^J
M?^AK6M63XE_Y%^Y^J?\ H:T 3:-_R#X_I6A6?HW_ "#X_I6A0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH *@NON1_\ 75/YBIZ@NON1_P#75/YBA 3T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63XE_Y%^Y^J?\ H:UK5D^)
M?^1?N?JG_H:T 3:-_P @^/Z5H5GZ-_R#X_I6A0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KW_(O
M:G_UZ2_^@&M"L_7O^1>U/_KTE_\ 0#6A0 4444 %%%% %.ZTNPOI1)=6D4S@
M;0SKDX]*A_X1[1_^@=;_ /?%:5%4IR6B9#IP;NTC-_X1[1_^@=;_ /?%'_"/
M:/\ ] ZW_P"^*TJ*?M)]V+V5/^5?<9O_  CVC_\ 0.M_^^*/^$>T?_H'6_\
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M[1_^@=;_ /?%'_"/:/\ ] ZW_P"^*TJ*/:3[L/94_P"5?<9O_"/:/_T#K?\
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M!UO_ -\4?\(]H_\ T#K?_OBM*BCVD^[#V5/^5?<9O_"/:/\ ] ZW_P"^*/\
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M'_H(?^08_P#XFCZI7_F_%C^NX;^3\$>F?\(]H_\ T#K?_OBC_A'M'_Z!UO\
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MOA_Y?P1Z]_PCVC_] ZW_ .^*/^$>T?\ Z!UO_P!\5X^?B#XH_P"@I_Y+Q?\
MQ--/Q"\4_P#04_\ )>+_ .)H^K5OYOQ8_;4/Y?P1[%_PCVC_ /0.M_\ OBH+
MG0-)5(\:?;C,BC[GO7D1^(?BK_H*?^2\7_Q-12?$+Q2X ;5,X8$?Z/%U!_W:
M/J];^;\6/VE#^7\$>T_\(]H__0.M_P#OBC_A'M'_ .@=;_\ ?%>+GXC>*_\
MH*_^2\7_ ,333\1_%G_05_\ )>+_ .)H^KUOYOQ8^>C_ "_@CVK_ (1[1_\
MH'6__?%'_"/:/_T#K?\ [XKQ,_$CQ9_T%O\ R7B_^)II^)/BW_H+?^2T7_Q-
M+ZO6_F_%E<U'^7\$>W?\(]H__0.M_P#OBC_A'M'_ .@=;_\ ?%>'GXE>+O\
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M(]H__0.M_P#OBM*BCVD^[#V5/^5?<9O_  CVC_\ 0.M_^^*/^$>T?_H'6_\
MWQ6E11[2?=A[*G_*ON,W_A'M'_Z!UO\ ]\5FZ]HNFVNC3S064,<JE-K*N"/G
M%=)63XE_Y%^Y^J?^AK1[2?</94U]E?<2Z+_R#X_I6C6?HW_(/C^E:%0:!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%) R2)M+*>02NTG/?-7-;UB\T+5/B!?6$BQ7?EZ;%%*X!6)I!LWG/'&[/X4
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MYM3T1'T^:,\EKB/Y$'ONRA_X%72>"= ;PWX2LK"8[KLJ9KI^[S.=SG\R1^%
M'0T444 %87C+_D5+W_MG_P"AK6[63XELKC4/#]U:VL?F3/LVKD#.'!/)XZ"M
M*32J1;[HRKINE)+L_P CQ\TPUT!\&:__ ,^'_D:/_P"*I#X+\0?] _\ \C1_
M_%5[?MJ?\R^\^:6'K?R/[F<\:::Z$^"O$'_0/_\ (T?_ ,533X)\0_\ 0/\
M_(T?_P 52]M3_F7WEK#U?Y7]S.=---=$?!'B+_H'_P#D:/\ ^*II\#^(O^@=
M_P"1X_\ XJCVU/\ F7WE*A5_E?W,YP]::>M=(? WB/\ Z!W_ )'C_P#BJ:?
MOB3_ *!W_D>/_P"*I>VI_P R^\M4*O\ *_N.;-,/6NE/@3Q)_P! W_R/'_\
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M^R?6KYXNG;K;;05FI?,HZYKOB^3QGX=>[5M*TN?4_(AM8I6#SJK %I.F00>
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M<?2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%U]R/_KJG\Q4]077W(_^NJ?S%" GHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LGQ+_ ,B_<_5/_0UK6K)\2_\ (OW/U3_T-: )M&_Y!\?TK0K/
MT;_D'Q_2M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQ+_ ,B_<_5/_0UK6K)\2_\ (OW/U3_T-: )M&_Y!\?TK0K/T;_D'Q_2M"@
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MAFBN(4FAD62)QN5U.01ZBGUY1[J=S/\ [.NO^@S??]\0?_&Z/[.NO^@S??\
M?$'_ ,;K0HH S_[.NO\ H,WW_?$'_P ;JS;6\L 827D]SGH90@V_3:H_6IZ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D?_ %U3^8KB<G)W9O:RL3T445(PHHHH **** "BBB@ HHHH **** "BBB@
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M;_8-A_=N/_ J7_XJC^P;#^[<?^!4O_Q5:5%/VD^[%[*G_*ON,W^P;#^[<?\
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M[MQ_X%2__%4?V#8?W;C_ ,"I?_BJTJ*/:3[L/94_Y5]QF_V#8?W;C_P*E_\
MBJ/[!L/[MQ_X%2__ !5:5%'M)]V'LJ?\J^XS?[!L/[MQ_P"!4O\ \51_8-A_
M=N/_  *E_P#BJTJ*/:3[L/94_P"5?<9O]@V']VX_\"I?_BJ/[!L/[MQ_X%2_
M_%5I44>TGW8>RI_RK[C-_L&P_NW'_@5+_P#%4?V#8?W;C_P*E_\ BJTJ*/:3
M[L/94_Y5]QF_V#8?W;C_ ,"I?_BJ/[!L/[MQ_P"!4O\ \56E11[2?=A[*G_*
MON,W^P;#^[<?^!4O_P 51_8-A_=N/_ J7_XJM*BCVD^[#V5/^5?<9O\ 8-A_
M=N/_  *E_P#BJ/[!L/[MQ_X%2_\ Q5:5%'M)]V'LJ?\ *ON,W^P;#^[<?^!4
MO_Q5']@V']VX_P# J7_XJM*BCVD^[#V5/^5?<9O]@V']VX_\"I?_ (JC^P;#
M^[<?^!4O_P 56E11[2?=A[*G_*ON,W^P;#^[<?\ @5+_ /%4?V#8?W;C_P "
MI?\ XJM*BCVD^[#V5/\ E7W&;_8-A_=N/_ J7_XJC^P;#^[<?^!4O_Q5:5%'
MM)]V'LJ?\J^XS?[!L/[MQ_X%2_\ Q5']@V']VX_\"I?_ (JM*BCVD^[#V5/^
M5?<9O]@V']VX_P# J7_XJC^P;#^[<?\ @5+_ /%5I44>TGW8>RI_RK[C-_L&
MP_NW'_@5+_\ %4?V#8?W;C_P*E_^*K2HH]I/NP]E3_E7W&;_ &#8?W;C_P "
MI?\ XJC^P;#^[<?^!4O_ ,56E11[2?=A[*G_ "K[C-_L&P_NW'_@5+_\51_8
M-A_=N/\ P*E_^*K2HH]I/NP]E3_E7W&;_8-A_=N/_ J7_P"*H_L&P_NW'_@5
M+_\ %5I44>TGW8>RI_RK[C-_L&P_NW'_ (%2_P#Q5']@V']VX_\  J7_ .*K
M2JIJ>H1:5I\M[.KM''C(0 GD@=R/6FIS;LFQ2ITHIMI6]"#^P;#^[<?^!4O_
M ,51_8-A_=N/_ J7_P"*K$/Q"TD?\N][_P!\)_\ %4A^(ND#_EVOO^^$_P#B
MJU]EB/,Y_;83NC<_L&P_NW'_ (%2_P#Q5']@V']VX_\  J7_ .*K"/Q'T<?\
MNU]_WPG_ ,533\2-''_+M??]^T_^*H]GB/,?M<+Y&_\ V#8?W;C_ ,"I?_BJ
M/[!L/[MQ_P"!4O\ \57/_P#"RM&_Y]K_ /[]I_\ %4G_  LS1?\ GUO_ /OV
MG_Q='L\1YC]IAO(Z'^P;#^[<?^!4O_Q5']@V']VX_P# J7_XJN</Q.T4?\NN
MH?\ ?M/_ (ND_P"%HZ(/^774/^_:?_%T>SK^8^?#>1TG]@V']VX_\"I?_BJ/
M[!L/[MQ_X%2__%5S/_"T]#_Y]=0_[]I_\72'XJZ&/^734?\ OVG_ ,71[.OY
MCYL/Y'3_ -@V']VX_P# J7_XJC^P;#^[<?\ @5+_ /%5RY^*^A#_ )=-1_[]
MI_\ %TT_%G01_P NFI?]^T_^+I<E?S'^X[+[CJO[!L/[MQ_X%2__ !5']@V'
M]VX_\"I?_BJY0_%O0!_RZ:E_W[C_ /BZ:?B]H _Y<]3_ ._4?_Q=')7\PM0[
M+[CK?[!L/[MQ_P"!4O\ \51_8-A_=N/_  *E_P#BJY$_&#P^/^7/4_\ OU'_
M /%UN>&_'&C^*)98;(S13QC/DW"A68>HP3D4FJT5=W*4*+V2^XTO[!L/[MQ_
MX%2__%5!<Z%8*D>%N.9%'_'U+Z_[U;-077W(_P#KJG\Q6:J3[LKV5/\ E7W%
M3^P;#^[<?^!4O_Q5']@V']VX_P# J7_XJM*BCVD^[#V5/^5?<9O]@V']VX_\
M"I?_ (JC^P;#^[<?^!4O_P 56E11[2?=A[*G_*ON,W^P;#^[<?\ @5+_ /%4
M?V#8?W;C_P "I?\ XJM*BCVD^[#V5/\ E7W&;_8-A_=N/_ J7_XJC^P;#^[<
M?^!4O_Q5:5%'M)]V'LJ?\J^XS?[!L/[MQ_X%2_\ Q5']@V']VX_\"I?_ (JM
M*BCVD^[#V5/^5?<9O]@V']VX_P# J7_XJC^P;#^[<?\ @5+_ /%5I44>TGW8
M>RI_RK[C-_L&P_NW'_@5+_\ %4?V#8?W;C_P*E_^*K2HH]I/NP]E3_E7W&;_
M &#8?W;C_P "I?\ XJC^P;#^[<?^!4O_ ,56E11[2?=A[*G_ "K[C-_L&P_N
MW'_@5+_\54%SH5@J1X6XYD4?\?4OK_O5LU!=?<C_ .NJ?S%"J3[L/94_Y5]Q
M4_L&P_NW'_@5+_\ %4?V#8?W;C_P*E_^*K2HH]I/NP]E3_E7W&;_ &#8?W;C
M_P "I?\ XJC^P;#^[<?^!4O_ ,56E11[2?=A[*G_ "K[C-_L&P_NW'_@5+_\
M51_8-A_=N/\ P*E_^*K2HH]I/NP]E3_E7W&;_8-A_=N/_ J7_P"*H_L&P_NW
M'_@5+_\ %5I44>TGW8>RI_RK[C-_L&P_NW'_ (%2_P#Q5']@V']VX_\  J7_
M .*K2HH]I/NP]E3_ )5]QF_V#8?W;C_P*E_^*H_L&P_NW'_@5+_\56E11[2?
M=A[*G_*ON,W^P;#^[<?^!4O_ ,51_8-A_=N/_ J7_P"*K2HH]I/NP]E3_E7W
M&;_8-A_=N/\ P*E_^*H_L&P_NW'_ (%2_P#Q5:5%'M)]V'LJ?\J^XS?[!L/[
MMQ_X%2__ !59NO:19VVC3S1";>I3&ZXD8??'8MBNDK)\2_\ (OW/U3_T-:/:
M3[@J5-?97W$NB_\ (/C^E:-9^C?\@^/Z5H5!H%%%% !1110 4444 %%%% !1
M110 4444 %%%% !535+^/2]+NKZ3E8(R^/4]A^)P*MUPWQ0O_L^@06:G#74V
M2/55Y/ZE:UH4_:5%#N88JK[&C*IV1Y3=7,MY=S7,[;I97+N?4DY-=+X#\/KK
M>M^;<)NM+3#R CAV_A7^OT%<K7N'@72QIGA6URH$MR//<_[W3_QW%>YC:OLJ
M7N[O0^8RW#^WQ%Y;+5G2445X%\7FBN/B38V/B^_U.R\(O:@Q26:Y4R\Y)X()
MSUX) QQSFOGCZX]]HKQ_X4:9%INNWW_"->+K?5_"CP K9S3L;F"3C#&,J H^
M\,\9XXXJGX7\?:-X:^%FJ^(-$\*?8[>'5/)>R_M%Y/,=@@+[V4D<$<8[>] '
MME%>8R?%NZLK[16U3PC>V.D:NR);7\ERC'+8P3&!D#G/)!QSCM6MXG^(4VD^
M*;?PSH>@S:YK,D7GO"EPL"1)SR78$9XZ''4<\T =Q17E,WQ%;Q7IOCC0WT6?
M3WTW2IBYGE!<MY9#*5 P,'/(8@]>]9W@3QG;^$/@UX:'V26^U&_GF@LK*)@K
M3/YS]ST R,GGJ* /9Z@O;.#4+*:TN4#PRJ593_GK7(^'?'MQJ'B5_#>OZ#-H
M6LF'[1#"UPLZ31]RKJ ,\'CV/I7:TTVG=":35F?/6M:7+HVKW-A-R8FPK8^\
MO4'\1BDT?4I='U>VOX?O0ODC^\O0C\1D5W_Q4TL&"SU5%&Y6\B0^H.2O\C^=
M>95])0J*O13?7<^,Q5)X;$.,>FJ/I&&:.X@CGB8-'(H=6'<$9!I]<=X&O;O4
M/"-LEM<0QR6KM"YFA,F0.5QAEQP0*Z'R=8_Y_K'_ , G_P#CM?.U8<DW'L?7
MT:BJTXS75&A16?Y.L?\ /]8_^ 3_ /QVK-LETBM]JFAE;/RF*(Q@#WRS9J#4
MGHHK.U[5HM"T&^U2;E+:%I,?WCV'XG II-NR R=/\>:/J7C&Z\,0"X^VVV[,
MC*OEN5QN53NR2,GL.AJ[J'B>RTWQ)IFA317#76HAS"Z*"B[1D[B3D?@#7SSI
M_BW3-/CT._A2[_MRUU"2ZO9V10DJ2'YE!#9/  Y'<UZOXDFCN?BQX(GA</%)
M#,Z,.A!0D&NVIAE"5NEG]Z,8U&T=EXF\16WA;19-5O+>YGMXV57%LJLRY. 3
MDCC.!^-27^O6.G>')-=E=FLD@$^4 )92,@#GJ<COWJ36]+CUK0[[3)?N74+1
M9]"1P?P.#7AMKK-YK_A31OA])YBZA_:)M;H?Q)!&0WZ9/_?NLJ-)5%?L]?0J
M<G%GH>J?%O0](M=.GN[#50-0M_M,2B*/<$)(&?G[XSWX(J[X5^)F@>+M0:PL
MA=0704NL=S&JEP.NTJQ''I7)>.#JVF_$[PZOAFQ@N;Z'3V2"WF(";1N!_B7H
MOO1X+EU;Q;\1GUC7C965_H\+6[6$,;)(=V1N.XG*_,>03VZ9YU=&G[/FMTOO
M^A//+FL=UJOCC1=)U^PT229YK^\E$0C@ ;RB3@%^1@?F?:IO$?BW3_#1MHKB
M*[N[RZ8B"SLHO-FDQU(7(X'UK@?%7AG2O#OBKP@VGVX66ZU<RSS-R\A+*>3Z
M#/ Z5LWY(^.^E>8<(=)?R\^N7SCWK/V4-&MK-_</FEJC=MO'&GW_ (<FUBPL
MM2O/(D$,UE!;[KF-\@%2F>V<GFLM?BE8#5K+3;GP_P"(K.YO)%CA%U9K'N)(
M&>7R0,\X!JMX"W_\)YXZQ_J?MD>,=-WSY_I47@B,>*/&>M^,+C]Y%#*;#3LC
MA47JP^H(_P"^FING"/-=:+]>@<TG8](HHHKD-0HHHH *Y;Q#X]TOP_J TP6F
MI:IJ902M9:7:F>5$/\3#@ ?4YKJ:XCP$(1K/C'S0HU,ZPYGS]_RMJ^3[[=O3
MMUH OZ3X\TC6-+U*[BBO;>?3(S)>6%U!Y5S" I890G'(''./>M[3+^+5=*M-
M0@5UANH4F17 #!6 (SC//-<UXIGT)#K<"K%_;\NAS.Q6,E_LX#8RV, ;CP"<
MG\*XK3;#6] TWP1KW_"2ZA.;Z:TL[C3V<"T$,B8 2/'#  ?,>3R>* /9**\I
ML6U-)/%_BFXUO5)ET2\O1:::MP1;L%CS^\7JP!/ S@8]ZJWNE:[H/@N/QPOC
M;5KO4HH([R:VGG4V,RM@F-8@/ER#@$'Z8SP >P53N=0^S:C96?V.[E^U%QYT
M46Z*':N?WC9^7/0>IKSN;2=5\6^._$MI_P )1K6E6%M!:/%!8S^61(\9.<D$
M@<<J,9)YZ5%X>U_5[Y/A]+>WTTDLXODN]C$"X,:L%+*, _=SSWH ]5K/UW6+
M?P_H=YJ]VDKV]I$99%B +$#T!(&?QK@/">BZ[XEL-/\ &+^,=4@O+J7SS9*0
MUDL(<CRO*XYVC&[.<\]:Z/XF_P#),_$/_7D] &[J6KV^E:#=:Q.DK6]M;M<.
MJ %RH7<0 2!G'O7/:S\1++1UTC9HVMZC+JEL;J"'3[59G5 %)W+N&/OCID5R
M/B7_ (6A_P ('J?V[_A#_P"S_P"SY/.\C[3YOE[#G;GC=CUXS2WO_"0?VWX#
M_P"$:_LS^T/[!D_Y"7F>5LVPY^YSGI0!UVC_ !#L-7>[M_[)UJQU"VMFNA87
M]GY,\T:]XP3AN>.HY-;V@ZW9^(]"L]7L"YMKJ,.@<89>Q5@,\@@@_2N"TT^(
MK?XFZ3-XU&F&XN+.>WTPZ47\I6^5Y-XD^;<548/3@^M+I^L0_#T>+]+G7_1K
M#.J:>AXWQS$_NU^DN5_X$* .VTKQ%::SJNK6-I%.?[,F6":=E C>0KN*J<Y)
M7(SD#D]ZUZYSP+H<N@>$K2VNR6U";-U>N>2T\AW/GZ$X_"NCH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K,U+7+;2]2TJQG29I=2F:"$H 55
ME0N=V2,#"GIFM.O/OB3_ &M_;/A#^P_L7]I?VA)Y/V[?Y.?(?.[9\W3/3OB@
M#K-9U^UT.;3(KF.9VU&\2SA\I00KL"06R1@<'IGZ5SFI?$VVL-;O]*@\,>)]
M2EL9!'-+IU@)HPQ4,!D/Z,.H%<QX@_X3O^WO"'_"4?\ ".?8_P"VX=G]F>?Y
MF_:V,^9QMQGWZ58LO^$W_P"$W\8_\(M_PCWV;[?'YO\ :GG;]_D1_=\OC&,=
M: .G'Q(T0^'UUKR;];=;U+*Z1X-DEG(Q S*K$;0,C)&>HZUU=Q<16MK+<SN$
MAB0R.YZ*H&2?RKS3PWHSZW8^-O#OB,1#7;N4/?26YS#AXP(6BZ$!0G1N<@YZ
MU5N-=N_$?P_T;PPS-'K.IW)TJ] /S1K <7#_ (HO3_IH* /2/#^M0^(M"M-7
MM[>X@@ND\R-+A5#[<\$@$CD<CGH16E4,4,5G9I#!'MBAC"(B]E P /P%>;>$
M]%UWQ+8:?XQ?QCJD%Y=2^>;)2&LEA#D>5Y7'.T8W9SGGK0!Z?17):'>W$WQ"
M\6VDEU*\-NEF8H6D)6/=&Q)5>@R1SCKBN%L+C6/$&D^![%?$.I6O]HRZ@MU=
M07)\UT4L1ACGG P"<X[4 >ST5X=XBU347\5WN@O/X^ET[1XH((G\.KYDLKF,
M,SSRGDL<CCIQFO1/AUJFK:IX98ZS;:C%<6]P\*/J-J;>::(8*.R],X."1P2#
M0!UM%%% !1110 4444 %%%% !6%XR_Y%2]_[9_\ H:UNUA>,O^14O?\ MG_Z
M&M:4?XD?5&.(_@S]'^1Y*>]1FI#WJ,U[Y\LAC5&:D:HS2-4,/2HS4AZ5&:1H
MB,TPT\TPTC5$9J-JD-1M2-$1M4;5(U1M2-41FHS4AJ,TC5$;4ZUN[BPNXKJU
MF:&>)MR.AP0::U1FI9K$^@/ WCFW\4VGV>X*0ZI$O[R/H)!_>7^H[5U-U]R/
M_KJG\Q7RS:W=Q87<5W:3/#/$VY)$."#7N_@[QM%XLTY8IE$6I6[Q^<@'RL-P
M&Y?;V[5YU>AR/FCL=4)7T9VU%%%<IH%%%% !1110 4444 %%%% !1110 444
M4 %%%% !4%U]R/\ ZZI_,5/4%U]R/_KJG\Q0@)Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K)\2_\ (OW/U3_T-:UJR?$O_(OW/U3_ -#6@";1
MO^0?']*T*S]&_P"0?']*T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KRGXJSEM9L;?M';E_\ OIB/_9:]6KR#XH9_X2F+/3[*F/\ OIJ[LN5ZZ/,S
M=VPS]4<?;0FYNH8%^](ZH/Q.*^C8XUBB2-!A$ 51Z 5\^:'C_A(--W=/M46?
M^^Q7T+6^:/6*]3DR.*Y9OT"O+/'.H^.="\3/<6^B?\)1X6NH@K::L"LT3XY^
MZA;J,Y(8<D<<5ZG17E'O'AG@/P_K.J?$Z/Q3'X0_X1+2H+9XGM0IC\]B",;"
M%]0>% ^4=ZYZS\,>(%^ VN:<VAZF+Z36EE2V-I)YK)B/Y@N,D<'GVKZ'OM8T
MS2Y;>+4-1L[22Y;9 EQ.L9E;CA02-QY'3U%2WU_9Z9:/=W]W!:6R8WS7$@C1
M<G RQ.!S0!Y3\3=&U2_\-^"(K/3;RYDMKN!ITA@9S$ @R6 'R@>]/URUUCPC
M\97\6P:'J.L:7J5D+:46$?FR0,-O1?3Y%/.!\QYXKTNYU[1[*PAO[O5K&"RF
M ,5Q+<(L<@(R"K$X.1Z5RVK^"?#7CK4;?Q'8ZQ=P7L2>4FHZ+?!691GY=PW#
MN>G/- 'G>C-J&J^,_BD9M.D@O;G26"V:_/(,QX1?ESEL;<@9Y) S6?+X!UF]
M^&'@RYET&YNVTFXN#?:3(&AFDB>8G@<-G [<_,"*],\,-\/?!C7HMO%FGS7U
MU)F[NK[5HI)Y6!/WCD=,GL/>NPTSQ!HNM/(FE:O87[1@%UM;E)2@/3.TG% '
ME?P_\*VA\=_VOI7@>?0-(M(2(YM3:X6[DE8$$!&E*[<$\E3TZY/'LM%% '/^
M-[47?@_4%QDH@E'MM(/\@:\+KZ!\28_X1C5L]/L<O_H!KY^KV\L?[N2\SYK.
MXKVL7Y'IOPGN"8=3MST5HW'X[@?Y"O1Z\O\ A1G[;J?IY:?S->H5P8]6Q$OE
M^1ZN5N^%C\_S"BBBN,] *Q_$WARU\5:*^E7L]S#;R.K.;=E5FP<@<@\9Q^5;
M%%--Q=T)J^AFZEH=EJGA^;1)D*V<L/D83 *J!@8SW&!CZ5R^K?"G1=:T_2[.
M\O\ 4RFFPF"%EDC#%,\;ODP<8 &,<5W5%5&K./PL3BGN<1X8^%NB>$]975+"
MZU"2=49 L\B%<'KT0']:T;+P+I%AXRNO%$)G^W7"L"C,OEJ2 "RC&<G'KW-=
M-13=:<FVWN"A%=#%NO#-E=^*[+Q%)+<"\LX6AC16'ED-G.1C.?F/>HKKPC8W
M/BVU\2I/=6]_!'Y3"%U"3)SPX*G/7U';T%;]%+GEW\A\J,76_#-EKVH:5>W4
MMPDFF3^?"(F #-QPV0<CCMBH_$?A+3_$IMI;B6ZM;NU8F"[LY?+FCSU ;!X-
M;U%"G)6L]@Y4S&T#PSI_AO2Y+&P$I$K&2:>5]\LKGJS-W/X8I?#/ARS\*Z,F
MEV,D\D*NS[IRI8ECDY( 'Z5L44G.3O=[A9(****D84444 %<KXB\ Z7XAU%=
M3%WJ6EZFJ",WNEW1@E=/[K'!!'X9KJJ* .6TCP!H^C:9J5I%)>7%QJ<;1WE_
M=3>;<R@@CER,< \<8]JN3>%+&?2=&TUI;D0Z3+!- P9=S&(87=Q@@]\ ?A6[
M10!E:9X>LM+CU..,R31ZE=274ZS$$;G #*, ?+@=#GZUR]M\)-!M[B$-J&MW
M&FP2"2'29[]GM(V!R,)C. ><$FN]HH S+/0[:RUS4]6B>8W&HB(3*Q&U?+4J
MNT8R.#SDFLW3O!&F:9_8ODSW;?V0T[6^]U.XS9W;\+SC)QC'XUTM% '#GX5Z
M%_:?V@7>K+8&?[0='%X19&3.[/E8_O<XSCVQQ74:[H]OX@T.\TB[>5+>[B,4
MC1$!@#Z$@C/X5H44 4-2TBWU70;K1YWE6WN;=K=V0@.%*[202",X]JY[6?AW
M9:PND;-9UO3I=+MC:P3:?=+"[(0H.YMIS]P=,"NPHH Y/P_\/]/T+51JLNIZ
MQJ]^D;1PW&JWAG:%6^\$X &<>F:M:_X+TKQ'J^F:G?&X$VGON58G"K, RN%D
M&/F4,JL!QR*Z*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K,U+0[;5-2TJ^G>99=-F:>$(0%9F0H=V0<C#'IBM.B@#*UG0+77)M,EN
M9)D;3KQ+R'RF #.H( ;(.1R>F/K7.:E\,K:_UN_U6#Q/XGTV6^D$DT6G7XAC
M+!0H. GHHZDUW%% &'X9\*:?X5MKB.SDNKB>YD$ES=WDQEFG8# +,>N!]!4-
MEX+TJP\87GB:$W'VVZ0J8F<>5&2%#,JXX9MBY.><5T5% !7#GX5Z%_:?V@7>
MK+8&?[0='%X19&3.[/E8_O<XSCVQQ7<44 <IK?P_TG7=?&L2W6IVL[1""YCL
M[MH8[N,=$E Y8<D<$5+I?@72](30TMI;K;HQG-L&9<'S<[@V%&<9XQC\:Z:B
M@#D_$'@#3]>U0ZI%J6KZ1?L@CEN-)NS TRCH'X(.,]<9K9T#0+#PWI:Z?IZR
M>7O:1WED+R2NQRSNQY+'UK3HH **** "BBB@ HHHH **** "L+QE_P BI>_]
ML_\ T-:W:PO&7_(J7O\ VS_]#6M*/\2/JC'$?P9^C_(\E/>HS4A[U&:]\^60
MQJC-2-49I&J&'I49J0]*C-(T1&:8:>:8:1JB,U&U2&HVI&B(VJ-JD:HVI&J(
MS49J0U&:1JB-JC-2-6CH'A^^\2:HEC8QY)YDD/W8U_O$_P"<U#:2NS:)'H'A
MZ^\2ZHEC8QY)YDD/W8U[L3_G-?0&B^&[#PQI$-E9)DF5#+,P^:5LCD_T':I_
M#?ANQ\,:6ME9)DGF69A\TK>I_H.U:-U]R/\ ZZI_,5YM:LZCLMCJC&R)Z***
MYRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NON1_]=4_F*GJ"Z^Y'
M_P!=4_F*$!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9/B7_D
M7[GZI_Z&M:U9/B7_ )%^Y^J?^AK0!-HW_(/C^E:%9^C?\@^/Z5H4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E7Q5MRNKV%SVD@,?_?+$_P#LU>JU
MQ'Q/L#<^'H;M5RUK,"3Z*W!_7;77@I\M>)P9G3Y\+*W37[CR>UG-M=PSKUBD
M5Q^!S7T:CK)&LB'*L 01W!KYMKW+P/J@U/PK:$MF6W'D2#W7@?I@UW9G"\8S
M['EY)52G*F^NOW'14445XQ]&>:_'#P^^L_#Z6\ME)N]*E6[0KP=HX?\ 0[O^
M US'CK73X_T#P+H-G)AO$$J3W00\HJ##_D2Q_P" 5[9<V\5W:S6TZAXID:-U
M/=2,$5XW\+/AEK?AWQC=7^NQG[+IT3VVE,94<,C.Q+ *25X).#C[] &;\3M
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MBN)_L76_^@I??^!#?XT?V+K?_04OO_ AO\:+1[AS3[?C_P  [:BN)_L76_\
MH*7W_@0W^-']BZW_ -!2^_\  AO\:+1[AS3[?C_P#MJ*XG^Q=;_Z"E]_X$-_
MC1_8NM_]!2^_\"&_QHM'N'-/M^/_  #MJ*XG^Q=;_P"@I??^!#?XT?V+K?\
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M]BZW_P!!2^_\"&_QHNOYF.TOY5_7R.B_X1G0/^@)IO\ X"1_X4G_  C&@?\
M0#TS_P !(_\ "N>_L76_^@I??^!#?XT?V+K?_04OO_ AO\:+K^9A[W\J^_\
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MM'N'-/M^/_ .VHKB?[%UO_H*7W_@0W^-']BZW_T%+[_P(;_&BT>X<T^WX_\
M .VHKB?[%UO_ *"E]_X$-_C1_8NM_P#04OO_  (;_&BT>X<T^WX_\ [:BN)_
ML76_^@I??^!#?XT?V+K?_04OO_ AO\:+1[AS3[?C_P  [:LGQ+_R+]S]4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]UC./SZ5U.E_#+5KHA[^6*RC[KG>_P"0X_6O7:*PJ9E4E\*L=-+):,=9MO\
M#^OO,+0_".DZ#A[:#S+@#F>7YG_#L/PK=HHK@G.4W>3NSU:=.%./+!604445
M)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP?:'6/R=A+*2QVGT) //;@BKUG.T\3^8 )(Y&C?:, D'K^(P?QI!I]HKVSK
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MLR2Y+(J@/@*6_B( Z=_YT]]'LY(PC";/ WBXD#\9Q\^[=W/?FIVLK=HXXS$
MD2E44$@*"-N./:C0-3+;Q3IPNIH 79HE+?*R$M@9("[MW3U ''6I4UU&,@>Q
MNHBBN3YAC W+R5SOQG!!S]WWJ1M.T]9Y%Q-N=0'B6:0K@\ E <#IUQV/-/\
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MU@XEL8+A99"1!"A948I@-^[B'(QP=O?EAP:U'T.X?8[06DS9RHF=@83A?G7
MSN&WL1VY%='11SL+&/>:6T^J+<M;6LR84&64MYD0&<JH Y# \\CKR#TJ@NE3
M:AI$@,1<\0VZW)\L^4K9!8.C<G R&7G Z5T]%',PL<_#H4R20L\=H2(84=@
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img101536035_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ-[B&)MLDT:-UPS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(Y]_KQ6AX%T2V\/^%H+&UU%-0C#NYN(R-A)/(7!/ ^OK7(?'3_D5]._Z_?\
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M-CJ$?;\WT!4?G7'>&;SX82Z)"NOZ;+#J,:[96$D[+*1_$-K8&?3BOH,@,""
M0>"#WKEKCX;>#[FY^T2:' ),D_(SHN3_ +*D#]*NG62AR2O\A..MT9/A'_A&
MU\*:QJW@JQ>"=HY$,<CL[F1%8H"&9L9SD8]:\A\&7OAG^VKN]\8^?<Y7?'D,
MX>0GDMCDGZ\=<U]*6&G66E6BVMA:PVT"](XD"CZ\=_>L.X^'OA.ZU%K^;1+=
MKAFW,<L%)]2@.W]*(5HKFO?7[P<6>$:!<VEY\5K"YL+?[/9RZFK0P[0NQ"W
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MHHHKF+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8L..O /'>I?'?@YO FK6*VVH23B9/-CDV[&1E/L?H0:O>%?^2W+_ -A&Y_\
M9ZW/CQ_R%-&_ZXR?^A"M.=JK&/2PK:7*&K_#Z_O/!,GC+4=:>YOYH$NVC9,@
MHP! W9Z@$=L<8]ZZCX&:C/<:'J=A(Y:*UF1XP?X0X.0/;*Y_$UKZI_R0F/\
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M$JYP !PK = .U=-17+.JV[QT*43R_P 7Z#JFB>.+/QAHND?VI&D0CGM5&7!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEAM;D#R8V4&5R>BA03D\>M,T/QOIVMZFVF&UO]/O_+\U+?4(/*>1/[R\G/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1110 4444 %59O]::M55F_UIIHB>PRBBBJ,PHHHH ****
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M,^E:M/HD[$QL3);L>_M^7Z@U;]^/FOR.>+]A5_NR_!_\'\SJZ***Q.\****
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MVPN4[;5[ZTD3Q!Y=U"_F^1Y>V0'?C&<>N*GN+BS:ZO;U+^U9+C3FC5!*-P8
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MS[8KEA3A2Y Y3JM5FM6TVX+W%LTTC I]ED(\P^KKT_/-4--P^A:I&/O (_X
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M?O71ULDH_"9.39!965OIUG%:6L8C@B&U$!)P/QJ>BBD(**** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !56;_ %IJU56;_6FFB)[#****HS"BBB@
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M+#8.0I[''3(Z^V:WZ**ILR"BBBD 4444 %%%% !1110 4444 %%%% !1110
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MY77J5=9NYT5<)1PSM25K^OZA1112,@HHHH **** "BBB@"W_ &IJ'_/]<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN^];=S]VL2[[UO2(J&-<UD3]36O<UD3]37I4CCF5#UI12'K2BN@Q'4HI*44
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M/D]FV[WW\K>2[CQ3A313A78>..%.%-%.% AU.%-IPH <*=313J0APIU-%.H
M<*QK[Q+:V6M6FE)%+<W,[A72'DQ@]S_/'IS]7SZ_8PZY:Z.6E>YN#M/DKN,6
M1P3_ )X')XJ[X<\)6GA^2>X\U[J]F8EKB4?-M)Z?XGN:N,5O(SG.VB)-#\*:
M?H5W=7</F37-PY)EF.YE4G.T'^O4UNT44VV]S$****0PHHHH **** "BBB@
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M=]ZV[G[M8EWWK>D14,:YK(GZFM>YK(GZFO2I'',J'K2BD/6E%=!B.I124HH
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M[:.J\WYZ'AU==HG@NUOM(MM1U?7[;2(KR1H[,2QE_-*_>).0$4'C)_PR\?\
M"ML#/_"69[X^SUZ%X:U"XO="T*'PM)"VFVES+%J4=YY?FK;%R07SZKDG;U/L
M#6=*FF]=3LQN-J1IITTXZZMZ='W36^FWD>=:+X)AOK6\OM3UJWT_3[>Y%HER
ML9G6:7/\.TCY>^?>L/7]%N/#NN76E73*TL# ;DZ,",@CZ@BO1_[/M_%?AG5M
M#\-F!GM]=:YCB#*@,!RH9<D949_(#VKE?B;J%OJ/CJ]DM9$DBB5(?,0Y#%5
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MQZV-"_Y>/^ _UJ*OPL:W-BBBBN0L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK-_K35JJLW^M--$3
MV&44451F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:(?+\7:
MK%_>0/\ R_\ BJVZPH#Y'CP]O/M_SP/_ +&KAM)>1SUM)4W_ 'OSNCJJ0]*6
MD/2L3O1&:8U/-,:D:(C:F&GM3#2+1&:C-2&HS4FB&&F&GFF&D6AAJ,]*D-1G
MI2-$,-1FI#49I%H8:Q/%/_(NW?\ P#_T-:VS6)XI_P"1=N_^ ?\ H:UG4^!^
MATX;^+'U1YQ1117E'TX4444 %%%% !1110!R%[_Q_7'_ %U;^=05/>_\?UQ_
MUU;^=059WK8****8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH .U-IW:
MFUK3V//QOQ(****T.(**** "BBB@ HHHH **** '=J*.U%<SW/;A\*"BBB@H
M**** "BBB@ KMJXFNL-_ UU]E20&8@XP,@&A0E/X5L<F*J0AR\SM?1$LUS#;
ME!+(J%SA<]ZSWTZ>\O6>\<&!#^[C4]13K72V,YN;YQ--G@=A6G6[J1P[M1=W
M;5_Y?YGF*E+%*]>-HWT7_P E_D(JA%"J % P .U+117(=VP4444 >P4445]<
M?FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !6QH7_+Q_P'^M8];&A?\O'_  '^
MM15^%C6YL4445R%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %59O\ 6FK559O]:::(GL,HHHJC,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K U4_9O$VCW73<WE$_CC
M_P!F-;]8'BR-O[,BN$X>"4,#Z?Y.*NG\5CFQ7\)R72S^YG64AZ4R"9;BWBF7
M[LB!Q]",T\]*Q9Z"=]41FF-3S3&I&B(VIAI[4PTBT1FHS4AJI<7MI;.$GNH8
MF(R%>0*<>O-2W8UBF]$2&F&JYU33O^?^U_[_ "_XTPZII_\ S_6W_?Y?\:GF
M7<U5.?8L&HSTJ ZG8?\ /];?]_5_QIAU*PQ_Q^VW_?U?\:7,NY:A+L3FHS4)
MU&Q_Y_;?_OZO^-,.HV7_ #^6_P#W]7_&IYEW+4)=B8UB>*?^1=N_^ ?^AK6D
M=0LO^?NW_P"_@_QK'\2W=M+X?NDCN(G8[,*K@D_.*BHUR,Z</&7M8Z=4>?44
M45Y9]*%%%% !1110 4444 <A>_\ ']<?]=6_G4%3WO\ Q_7'_75OYU!5G>M@
MHHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [4VG=J;6M/8\_&_$@
MHHHK0X@HHHH **** "BBB@ HHHH =VHH[45S/<]N'PH****"@HHHH *"0.M-
M+<X R:7&<9ZUT*AR)2K:)_?]QPO&>U<J>&UDNKORW[7[^2$SN!QD5UUE806*
M8C7+G[SGJ:Y.NVJ*M9V<*>D7T,Y8:SC4J^]-*U_\ET_,****YB@HHHH ****
M /8**K_;[/\ Y^X/^_@_QH^WV?\ S]P?]_!_C7UG/'N?G/LJG\K^XL457^WV
M?_/W!_W\'^-'V^S_ .?N#_OX/\:.>/</95/Y7]Q8HJO]OL_^?N#_ +^#_&C[
M?9_\_<'_ '\'^-'/'N'LJG\K^XL457^WV?\ S]P?]_!_C1]OL_\ G[@_[^#_
M !HYX]P]E4_E?W%BBJ_V^S_Y^X/^_@_QH^WV?_/W!_W\'^-'/'N'LJG\K^XL
M457^WV?_ #]P?]_!_C1]OL_^?N#_ +^#_&CGCW#V53^5_<6**K_;[/\ Y^X/
M^_@_QH^WV?\ S]P?]_!_C1SQ[A[*I_*_N+%%0+>VCL%6ZA9B< "0$DU/34D]
MB91E'=6"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *V-"_Y>/^ _UK'K8T+_ )>/^ _UJ*OPL:W-BBBBN0L**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK
M-_K35JJLW^M--$3V&44451F%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&PVH+W_CT?\/YU/4%[_QZ/^'\ZP>QW1^)&111161V!1110 4444 %%%%
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M_P#CE4Z<N92M'3R(6;T5!Q?M'>WVM=.WZGSA@X.328/K7TA_PI_P-_T")O\
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MH_X5GX6_Y]M0_P#!M=__ !VCZI+N']L0_E9YW17HG_"L_"W_ #[:A_X-KO\
M^.UCZSX \/6FJ^'H8(M02.[U!X9Q_:ET=Z"UGD YDX^9%/'IZ9H^J2[A_;$/
MY6<W8?\ (1M?^NR?S%=U3U^&OAA&#+;ZBK Y!&KW8(/_ ']J?_A M"_O:O\
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M([:W7S[Z8'RHV.!QU=R.BC(R?< <D"G7/@O0-'MXK> :O>:G<_<7^V;I&G<
M R2%9  H&-S8XX !)4&Y8?#?1K>(/<SZI/>.,2SC5KM-W)(4 2_=&2 "2<=2
M3DE>V0^49 DD<$:32^;*% >3;MW'N<=JDJU_P@6A?WM7_P#!U>?_ !VC_A M
M"_O:O_X.KS_X[3]LNP<I5HJU_P (%H7][5__  =7G_QVC_A M"_O:O\ ^#J\
M_P#CM'MEV%RE6BK7_"!:%_>U?_P=7G_QVC_A M"_O:O_ .#J\_\ CM'MEV#E
M*M%6O^$"T+^]J_\ X.KS_P".T?\ "!:%_>U?_P '5Y_\=H]LNP<I5HJU_P (
M%H7][5__  =7G_QVC_A M"_O:O\ ^#J\_P#CM'MEV#E,C5=6L=$L3>ZC.(+9
M656D8$@%C@9Q[FN@\,W,%Y;RW%K-'-"X4I)&P96'/0BN3\<?"RWUOPO-8:-+
M=I>R21[7O-4NI8E4,"Q*N[ \9[5=^'?PPM/ $,CIJ=Y>74RXERY2'/M&#C/N
M<GZ5$ZO,K#2L=Y1116104444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%9/B/7(M T>6\?#2?=A0_QN>G
MX=S]*:5W8#D/B1XDV(-#M7^9L-<D'H.H7^I_"O.+:XEM+F.X@<I+$P9&'8BB
MXN);NYDN)W+RR,7=CU)-15V1BHJQ@W=W/>_#FMQ:_H\5Y'@2?=F0?P..H^G<
M>QK6KQ'P9XB.@:PIE8_8Y\),/3T;\/Y9KVU6#*&4@@C(([URU(<K-8NZ%HHH
MJ"@HHHH **** "BBB@ HHHH **** "BH;R6:"RGEMK<W,Z1LT< <)YC <+N/
M R>,FN&\*7WB6;XAZQ;>(;B$$:=;S165JS&&W#/(,9/WFXY;'/0< 4 =CHNF
M)HNA:?I4<C2)96T=LKL,%@BA03]<5>KSKXG^(M2CT;5-*\/7#07MK8M>7UVA
M(-M$ =J@CI(Y! [@!CZ5W>FNTFEVCNQ9FA0EB<DG:* +5%%% !1110 4444
M%%%% !1110 4444 %%%<KXE\.:SXCU6"%-?N])T6.$L_]F3>5=2SYXR^T@(%
M].I//:@#<O\ 3$O[S3+EI&4V%RURH ^^3#)%@_A*3^%7J\PTG5-?TWPWXUL[
M'4;C6WT8M'IU[.HDE=_+W,C$?ZQD8X]2>/:LOP[J!LO$_AW^Q/'-_P")GU(L
M-3LY[@3+"FPGS HY@VM@;3UR!VH ]CHHHH **** "BBB@ HHHH **** *]M9
M6]H\[PQ[7GD,DKDDL[=.2?0  #H  !Q1'96\5[->+'_I$RJKR$DG:O11GH.I
MP.,DGJ:L44 %%%% !1110 4444 %%%% !1110 452U:XO[73)I=,L5O;T8$4
M#RB)6)(&2QZ  DGOQQS7*?#^[UR;4O%,.OWR75W;WZ+B'(AB!A1ML:GHHS]3
MU/)H ZJ73$EUVTU4R,'MK:>V"8X(E:)B?P\D?F:O5Y#;V/B/Q'X8N_'4'BO4
M[2]_?7%C80R 6:Q1LP5'C(^<D+R3Z^U:EWJ&H>.]3T/2;35KS1[*XT=-6NY;
M!_+G;>0J(KD':,[B?7% 'I5%<9X)GU&QU?7?#&HZC-J7]F-#);7=P<S/#*I(
M5S_$0589[UV= !1110 4444 %5[NRM[Y(TN8_,1)%D"$G:6'(R.^#S@\9 /4
M"K%% $%Y:07]I):W*%X9!ATW$;AZ''8]".XR#Q4RJJ*%4 *!@ #@"EHH ***
M* "BBB@ HHHH ***I:M<7]KIDTNF6*WMZ,"*!Y1$K$D#)8]  23WXXYH NU1
MO],2_O-,N6D9387+7*@#[Y,,D6#^$I/X5ROP_N]<GU/Q1!K]\EU=V]^B8AR(
M8@84;;&IZ*,_4]3R:X'5=7O#%K6LW'CG4+#Q/9WDL=GH*2A8V"OB./[/C,N]
M<?,/[V><4 >[45Y_KS:MXH\3Z;X9CU.\T6 :;_:-^]A)LG+%@BQJ^#M .XGU
MQ5WP3/J-CJ^N^&-1U&;4O[,:&2VN[@YF>&520KG^(@JPSWH [.BF3316\$D\
MTBQQ1J7=V. J@9))]*\B\8_%.TU+PO-'I,6NZ>TT\(L]1>V>"&Z'FKN$4@.>
M5#<'&1F@#V"BN1U[XAZ?H>K2:7#I6M:O>0(KW$>E69G^SAAE=YR ,CD5;LO&
MNDZC-H:VOGO%K4<KVLVP! 8QED;)R&Z\8/W30!T=%<KJ/C_2--34VD@OIC8W
M<=B%@A$C7-PZAO+B .68 \YQ4_AGQG8^)I[FU2QU/3;ZW59)+/4[4P2[&) <
M#)!4D$=>U '1U7MK*WM'G>&/:\\ADE<DEG;IR3Z   =   .*Y_Q'X\TSPSJL
M.F75KJ%S>W%NT]O#9P>:TV&"[%4');J>F, \T:7X_P!#U+0M1U9VN;"/3<B^
M@O83'-;D#.&3GDCIC.>G6@#H([*WBO9KQ8_](F55>0DD[5Z*,]!U.!QDD]35
MBN*TCXFZ5JNJVMA+IFM:8;T[;.?4;(PQ7)QD!&R<DCD9QG(IFI?%+2--U*[M
MCI>N7-K92&*[U&UL#):V[+]X,X.?E[X!H [BBN NO'%S'\5-/T*&QU*?3;BP
MW[X;4-&SNR;9M^<^6H)!/8GH:V?B'=7%C\/==NK2>6WN(K1VCEB<HR'U!'(-
M '345P/B7QWX?_X0/4_L/BO3/[0_L^3R?(U&/S?,V'&W#9W9].<U5FU#6]=_
MX1OPSINIRV+3Z3'?ZEJ"X:?R\*H5"<X9F)^;J,9H ](HKAM/\(Z_X:UJQGTO
MQ-JFK:=)(4O[;6;D3$)@X>-]N00<?+WS7/\ C7P?<Z==:?=6WC/Q='_:6KQ6
M\D2ZH1'&DK'(0!>,=!UQ[T >LT5B>&O#G_"-VDUO_;.L:IYK[_,U2Z\]TXQA
M3@8'M6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9FJ^'],UMHVU&V,_E A!Y
MKJ!GKP"*=KNJ?V)H=WJ7D^=]G3?Y>[;NY]<''Y547Q%N\&_\)#]E_P"74W'D
M>9[9QNQ^N*:ONA:%?_A ?#/_ $#/_(\G_P 51_P@/AG_ *!G_D>3_P"*IH\:
M6,/@^W\0WT;01SCY8$;>Q;)&T'C/3/:L1?B?)!+%)JGAN_L;&5@$NGR00>AP
M5 /'/!/XU?O]Q>Z;O_" ^&?^@9_Y'D_^*K>M+6&RM8K:W4K#$NU%+%L#TR23
M7.^(?%5_I$EL=-T"YU:">+S/.MRVU1VZ(W;FL32OB3J6KS1?9O"5V\#RB-YX
MY6=4Y&22(\<9SUI6DT&B/0Z***@H**** "BBB@ HHHH **** "BBB@ KD[&S
MN4^*FKWC6\RVLFE6T:3%"$9A)*2H;H2 1Q[BNLHH \>\2_#WQ;9>'O$TMAXO
MDN8;X3W$NGQZ/&TER6!_=^9N+GC"C'0#@5Z3X6LM2T_PW96VK:@;^\2,;IC;
MK"<=EV#@8&![XK8HH **** "BBB@ HHHH **** "BBB@ HHHH *\V^(WB'6H
M-5M=$LM+\1G3)(O-O;[1;$S2L"2!$C<!#QDMDD<8%>DT4 >8I+)KOPYU?0?"
MOAC6M >VA000ZA;?9//!;+JC;B26"L"Q/5P2>:R;&UCU37M C\-_#[4/#-U8
MW:27M_/9K;H(0,/&&!S-NZ<^QKV2B@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N3\*V=S;^)O&$L]M-%%<:A&\+NA42+
MY$8)4GJ,@C([BNLHH \AM[[Q'X<\,7?@6#PIJ=W>_OK>QOX8P;-HI&8J[R$_
M(0&Y!]/>M2[T_4/ FIZ'JUII-YK%E;Z0FDW<5@GF3KL(9'5"?F&=P/IFO2J*
M .,\$P:C?:OKOB?4=.FTW^TVACMK2X&)DAB4@,X_A)+,<=J[.BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .3\*V=U;^)O&$LUO-%'<:A&\+
MNA42*((QE2>HR",CTKS2337M=&O]"U/X<ZEJGBB9Y=FLQVZR1S.S$I+]I)S'
MC@X[8 XS7N]% 'F]]%KOA/5]%\13:=>:Z1I"Z;J8L$\R<2 AA(J<;@6W _7-
M:O@F#4;[5]=\3ZCITVF_VFT,=M:7 Q,D,2D!G'\))9CCM79T4 9?B33)-:\,
M:II<3K')=VLD"LPX!92 3^=>5^(-7\0:QX#C\,IX'UB&\M?LJ7,DD&Z%1&Z<
MPLN?,/'8<#)SQ7M%% 'COC"#4+GQCJD&M:'XLU>RD6-=+@TJ8I9E=@R)2I&U
MM^<L<\=L 4[3M,O-)^"&F7EQ936FI^'9FOEAN 8V'EROO7GLT989Z'(->P5A
M>(_"EGXH:R6_NK]+>VDWO:P7!2*YY!VRK_$ 0/3O0!Q$WA\_\*GLQJ?A^ZUF
MXN[C^TKZ*TE\NYBDE)<R1C^)UW!=N1D4OPTAUZ+7K@1_\)2OAP6Y!3Q,%$XG
MW#'ECKMVYST'XUZG10!YMXIU6XT7XKZ??0:1=ZHJ:)-YL-FH:94\Y/F121N.
M<# .<$^E9MWH.N>+M,\6:VFCRZ?)J*V@L=/O $EG%NV_,JYPI8_* 3QCGCFO
M2'T.V?Q/%KYDF^UQ6C6:H"-FQG#DXQG.5'?\*TZ /+[[6=6\=W.CZ5#X1UG2
MQ;:A!=WEWJ, BCA$3;B(FS\Y)& 0.AS7/>)]+GM_$^I3:7H'C72]7FF:2.?0
MY1)97;'[LDI. N?XE[<YS7N-% 'FVW7;#QEX7OM7TZ]NIKK1CIUY<6$6];>X
M9T8LY'"KP>>GI2:]X&N-(\"^)([36_$NN7%U8M%';W]T;GGK\BA0<FO2J* .
M!\2^!/#_ /P@>I_8?"FF?VA_9\GD^1IT?F^9L.-N%SNSZ<YJK/8:UH*>'/$^
MF:5-?R6^DQV&HZ>N%F,>U6#(#U96!RO4YQ7I%% ' 6_BGQ)XKU6QMM'\/ZOH
M=C%.LE_>ZM;+$S1CDQ1H=V2W W=JU/'5I<W<?A\6UO--Y6MVLLGE(6V("<L<
M= .YKJZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[QW_P B1JW_ %Q_
MJ*\]6P\:?\(!YXU>R_L;[$6^S[!O\K'W<^7UQ_M?C7JVK:9#K.E7&G7#2+#.
MNUFC(# >V0:KC0+5?#/]@B2;[+]G^S[]PW[<8SG&,_A5QE9":N>87#K!X:\!
MW%T!]@CN&,Q(^4?.",_@&_(UZEJVI:/::>EQJD]L+21EV-+AE8D\$#G/KGMU
MJ"+POIB^&X]!FB:YLHUV@3'YNI.<C&#SU&*P+7X4^&[:Z6=_MEPJG(BFE&S]
M%!/YT-I[BLT=EYL<UGYL3J\;Q[E93D$$<$5Q/PF_Y%.?_K\?_P!!6NZV+Y?E
M@!5QM '&!67X=\/6GAK3WLK*2>2-I#*3,P)R0!V XXI)Z-#ZFM1114C"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD-
M "T5&:8: )Z*K&F&G8"Y15 TTT6 T:*RR::318#6HK')II-/E%<VJ*P\T9HY
M0N;E%8F:<#1RA<V:*R :<#2L%S5HK,!IXHL,T**I"G"BP%NBJXIXI 2T4T4Z
M@ HI*2@!U%1FDH EHJ&D- $]%5J2G8"U150TVBP%VBJ-(:+ 7Z*SC246 TJ*
MS*::+ :M%9-)185S7HK'---.P7-JBL2DHY0N;E%85%'*%S=HK"HHY0N;M%85
M%'*%S=HK"HHY0N;M%85+1RA<W**Q12T<H7-FBL>EI6"YKT5E"EHL!J45F4HH
ML,TJ*SQ2T6 OT51%.%%@+E%5*6BP%JBJXI:0$]%0TX4 244REH =12"EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0T +149IIH
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MAH;R"+9.B9C4H&R&/8\\5T-)2TF,44X4@I:0Q:44E.% "BEI*6D HIPIHIU
M"THI*44 .%+2"EI **<*:*<* %I124HH <*6D%+2&**6D%+0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4TTZFF@!IIIIQIIIB&&FFGF
MF&@!IKAM)\$Z1?Q75SJNF.;I[R<Y=Y$)7>=IP".,=Z[DTTU2=@L<UKNE&UTJ
MP_LFQ1UTZY2=;6/ WJ,@X]^<_6JD=U=^(=>TZX32;VRMK$O(\E['Y;,Q4J%4
M9)QSDGVKK3331<5CS*2SO;:[9-&TW7M.O_,R(D</99SR=QX(_P XKHC!<?\
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M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7 ]*0#13J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJ"ZM NFVMY.'3[0JE8T1I&)(S@!1D\9[=J0ZWI_F0H)RQE",K+&S+ASA26
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M<LK1R"155,*!M?)!QD$\ ]:74"6-M-EMI+90EQ#(!,Z>7YBL)&)!P!@@G/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img101536035_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\Z?&"XDNOB)+;NV$@ABB3/0 C=_-C7T77A_QL\-
M7":E!XA@C9[:2,0W!49\MQ]TGV(X^H]Q73A6E4U)GL>TV5I#86,%G;($@@C6
M.-1V4# J>O*O#WQHT?\ L2%-:2ZCOX8PKF./>)B!C<#G@GK@XKH_!'Q"M?&E
MQ?016<MM);G<@;Y@T9X!)' ;/;\L\UG*C.-VT-21XEXBU"?2OBGJ.H6L:23V
M^I/)&C@D%@V0" 0:W-3^+/BK4M)O+&XTNP2"Y@>&1EMY055E()!+XS@U6_YK
MM_W&O_9Z]S\7_P#(E:]_V#KC_P!%M774G&+BG&Y"3U/)?@1_R&]6_P"O9/\
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M'+Z +CQS\7$U6UM7CMUNTNY.?]6B$8R?4[1^)IGQ>FDN?B-/#(V%BBAC0GH
M5#?S8U]!:=I=AI%J+;3K.&UA'.R) H)]3CJ:\<^-OAF9+ZW\10(6@D007&!]
MQA]UC[$<?@/6JI5E*JNBM9 XV1[1:6L-E9P6EN@2&&-8XU'90, 5\Y_$Q%TG
MXGW5Q9@(X>*Y 7M)M!)^I//XUWNA_&C1ET&$:LETNH11A9%CCW"5@,;@<\9Z
M\XQ7":/;7GQ+^)37LL12!I1-/W$<2X 7/J0 OZTJ$)4Y.4]@DTU9&[\=KJ1M
M<TJS)/E1VS2@=MS-@_\ H(KU3P190Z?X(T6&!5"FTCD;;W9U#,?Q)-<1\:_#
M5QJ&G6FMVD;2&R#)<*HR1&>0WT!SGZY[5G^!?BUIFF^';?2]<6=);1/+BFC3
M>'0?=!'4$# _"DXN=&/+T'>TM3V:BN$\*?$^P\5^))]*M[*>%-F^WE?DR8^]
MN ^[VQR?SP*[NN64)0=I%)W/#_BGX+UB'Q*_B;2899X9-DDAA&7@D4 9P.<<
M Y['/2CP]\;[R I!X@LEN4'!N+<;)![E>A_#%=-K7Q?L=$\73Z5+I\\EG;_N
MY9TX<2=\*<97\1ZCC&>$^)?B?PEXCMK:71K-AJ1EW37'D^7E,'*M_>.<<^W6
MNV"<THU(Z=R'IJF>H^,=*L?'W@>*>TU#;:H?ML<J)NW[4<;<'&.ISZ8KQ#P%
MX2C\9ZY/ITEXUJ([9I]ZQ[\X95QC(_O?I7LGPTTF[A^&"VURK(]VLKQJW!5'
MX7\^OXUY5\,?$%AX3\7SSZP[V\+VSV[-Y;,4;<IY !/\)'2BDY1C.,7ML#U:
M;.M^+&E+H?@'P]I:RF9;6;RQ(5P6PAYQ75?#K_DC]G_UQN?_ $9)6'\89H=:
M\!Z7J]@YFM#<JP<*1\K*P!(/(Y 'XUC^$_B7I&B?#G^QYXKA]0B66..-$^63
M>S,#N[?>Y_K4\LIT4EO<+I2*'P-_Y'6\_P"P<_\ Z,CJ/Q_JNH^,OB&/#MM,
M5MH;D6D,9;Y-^<,[>^<_@*E^!P*^-[T$$$:=("#_ -=(ZSO$!D\&_%^6_N(6
M,2WWVQ0O\<;MN./S8?45JU^^;ZVT%]D?X\^'C^"M(M9X]6>ZAN)@CQ&/8-X4
MD-U(/&1[9]Z[#P[H/_"1_ @V*+NN 9IH/7S%=B /KROXUB?%3QWHGBC2;&RT
MF669HYO.=VC*!?E(QSR3S].*[_X0_P#).;'_ *Z2_P#H9K.I*:I*4M[C27-H
M<M\#-;!MM3T65\>61=1 GL<*_P" ^7\S6)X+A/C+XOW.L2+OMH)7N^?0';$/
MJ/E/_ :H^*XY_ /Q#U*2T4K!>V\QA X&V5&''^Z__H(KO_@IHGV'PK/JDBXE
MU"7Y3_TS3('_ (]N_2G4M&,JB^T"UT/3*^<_BE_R5.?_ +8?^@K7T97SC\5G
M$?Q/N9&^ZH@)^@1:RPGQOT'/8]Z\26-OJ7AK4K2Y16BDMWSGL0,@_@0#^%>+
M? VYD3Q;?6X)\J2R+L/=77!_\>/YUL^,OC#I][H=SIVA17#37*&)YY5"*BD8
M.!R2<9';'6I_@MX6N+6UO-=O86C6[C\BW5A@M'G+-]"0,?2JC%PHRY^H-WDK
M'&:AJZ_$3QO(NK:S'IND1EC"97&U$' "@D LW&3]>PQ4=Q<6WP^\86=WX;UQ
M=1LV4-+Y;@Y7.&C?:<'CD'W]JH6>FZ9X=\:S:9XMM)7LXF:-S&S KW608P2,
M8_ UW=OIWPBO-3L["T,\TUVXC0K),JJ3TW%L=3QWY-;R:CI9M6[:$K4;\<]1
MOUGTNQ1W73I8C*=I^61P<<^N!C_OJJ?AOX>^'M=^P76A^+)/M491[F$@),O]
M[9T*GL#R/>N[\<>)O!]I<V_A[Q'!Y\4J;VVH6^SCHI./F!//W><?6O%O$\.A
M:3KUO-X/U6XN$P) V&#0OG@!B 3^7YU%'F<%%:?D.6]SM_CNH6[T)1D@12CD
MY/5.];>KZQ>Z+\#-,GL'>.:6V@A\U.L:L.2#V],^]<Y\:7GDC\-272[;AK5S
M*OHYV9'YUU=_=P67P&MY;BS2[0Z?"@C?H&;: QQTP2#]0*C_ )=P]0ZLX'0/
MA]9ZW\/-1\23ZA*MY$)9(U##8-@R0^1G)^O<5<^#/AN'4]8EUEYI8Y-,D78@
M VR;U8<GVQ^M8OAW1-#OM!4WGCC^S#,Q^T6!A8@X/!^\ >,'I_*O:O =IX8T
MS26L?#FH07G/F3NLJM(Q]6 Z#L.*NM4<8R5]_((J[/&O&CWL?Q@O?[.F,%ZU
MS''#(#C:S(J@Y[=:7QW\.KKPCIUKJ<^JB]>YF\N;,94AR"V<DG<.#R<5)XJ_
MY+<W_81MO_9*[SXY_P#(H6'_ %_K_P"BWJE-IP2ZH5MSHOAGJEQJ_@+3I[J0
MR3H&A9V.2VUB 2>YQBNNK@O@]_R3RU_Z[2_^A5WM<-56FS1;!11168PHHHH
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MMC%;MY:07]E<6=RGF6]Q&T4J9(W*PP1D<C@]JFHI.3>['8Y_1_!'A[0?M/\
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M#I-A#:JWWBHRS?5CDG\36G10YR:LV%D-=%D1D895@01[5QW_  JCP3_T!?\
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M)1E7 _WEP?PK+T_X8^$--N4N(M(625#E3/(\@'_ 2<'\177452J22LF*R #
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS'_OM^=6_(C_ +OZFCR(_P"[^IH J>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\
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MYU;\B/\ N_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH
MJ>8_]]OSH\Q_[[?G5OR(_P"[^IH\B/\ N_J: *GF/_?;\Z/,?^^WYU;\B/\
MN_J:/(C_ +OZF@"IYC_WV_.CS'_OM^=6_(C_ +OZFCR(_P"[^IH ;;DM&223
MSWJ:FJBH,*,"G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_@;'_\ %5LU\<5]CUSUZ*IVL]S.I#E"BBBN<S"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXX;]X8[:-MP@MU*H6]3DDG\ZBE3;LTNNY,(MV:-K1_A:]SH<.K:YKEIHL%P
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M'--/)]V*-4&6/Z?G63KW_)+/"'_7:Z_]&&NGUE=:/QBNWT"XM4OX[)76&Y)
MN%$8S&!CDGKR1TSD8I7:U7][\Q?\$XW4/!MA_85WJV@^(8M7BLBOVJ/[,\#Q
MAC@, Q.17) %B !DG@ 5ZS>6%OK_ (=U>[UWP</#]W8VS2I?1(8$EESPNP@;
MLGC^+KU%>7:?(D6I6LDO^K29&;/H",UK3DVG?^ON+B[G6>*8QH$>D^%8L!H
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M "BBB@ HHHH **** "BBB@ K['KXXK['KAQGV?F85N@4445PF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&_%
M7_DFNK?]L?\ T<E?-5?2OQ5_Y)KJW_;'_P!')7S57HX/X'ZG31^$MW>J:A?Q
M0Q7E]<W,< VQ)-,SB,<<*">.@Z>E5***ZK6-2[8ZQJ>EAQI^HWEH'^\+>=H]
MWUP1FJT\\UU.\]Q+)+*YRTDC%F8^Y/6HZ*++<#2C\0ZU#:"TBUC4$M@NT0K<
MN$QZ;<XQ6<K,C!E8JP.00<$&DHHLD!H7FNZQJ%N+>]U6^N81@B.:X=U_(G%0
MVFIW]A'-'9WUS;QSC;*L,K()!SPP!Y')Z^M5:*++8+%JQU*_TR5I;"]N;21A
M@M!*T9(],@TR[O+J_N&N+RYFN)V^]),Y=C]2>:@HHLMP+ZZYJR6/V%=4O19X
MV_9Q</Y>/3;G%17NIW^I,C7]]<W31KM0SRLY4>@R>!56BBR"QHGQ!K1LOL1U
M>_-KMV>1]I?9M]-N<8JK:7MU87 N+.YFMIEZ20R%&'XCFH**+(+%J^U*^U.4
M2W][<W<BC:'GE:0@>F2:+G4[^\MX+>ZOKF>" ;88Y9698QC&%!.!P!TJK119
M 6K'4[_2Y&DT^^N;21QM9K>5HR1Z$@CBKQ\6^)&4JWB#52#P0;V3G]:QZ*3B
MGN@L@HHHJ@"BBB@"9+RZBM);6.YF2VF(,D*N0CD="1T.*+6[N;*X6XM+B6WF
M3[LD3E&'T(YJ&BE8"S>ZC?:G,)K^]N+J4# >>5G('IDFJU%% !5ZVUK5;*U:
MUM-3O8+=L[HHIV5#GKD XJC10U?<!\4LD$JRQ2-'(ARKH<$'U!JU?:SJFJ*B
MZAJ5Y=JARHN)VD"_3).*I4460$\E[=RVL-K)=3/;0DF*%I"4C)Y.T=!GVI\V
MI7US>B]GO;B6Z&,3O*S.,=/F)SQ56BBR O7VMZKJ<:QZAJ=[=HARJW%PT@!]
M0"35&BBA*VP'2:YJ]KK>AZ7=23%=9LU^R2J0V9HEY20'&,C[IR<G@U@W=Y=7
M]RUQ>7,UQ.V-TLSEV.!@9)YZ5#1244A)6+)U"]-@+ WEP;,-O%OYK>6&]=N<
M9]ZK444QA5^;6]6N+$6,VJ7LEH  ('N',8 Z?*3CBJ%%%@)[2]N]/N!<65S-
M;3 8$D,A1A^(YI;R^N]0G,][=3W,Q&#)-(7;'U-5Z*+=0"NC_M:TT_P0=*LI
M1)>ZC,)+YPI'EQH?DCR1SD_,2..@KG**35P:N%%%%4 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?8]?'%?8]<.,^S\S"MT"BBBN$P"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XW
MXJ_\DUU;_MC_ .CDKYJKZ[U72K+6]-FT[48?.M)L;X]S+G!##E2#U KF?^%5
M>"O^@+_Y-3?_ !==="O&G&S-J=115F?-5%?2O_"JO!7_ $!?_)J;_P"+H_X5
M5X*_Z O_ )-3?_%UM]<AV9?MHGS517TK_P *J\%?] 7_ ,FIO_BZ/^%5>"O^
M@+_Y-3?_ !='UR'9A[:)\U45]*_\*J\%?] 7_P FIO\ XNC_ (55X*_Z O\
MY-3?_%T?7(=F'MHGS517TK_PJKP5_P! 7_R:F_\ BZ/^%5>"O^@+_P"34W_Q
M='UR'9A[:)\U45]*_P#"JO!7_0%_\FIO_BZ/^%5>"O\ H"_^34W_ ,71]<AV
M8>VB?-5%?2O_  JKP5_T!?\ R:F_^+H_X55X*_Z O_DU-_\ %T?7(=F'MHGS
M517TK_PJKP5_T!?_ ":F_P#BZ/\ A57@K_H"_P#DU-_\71]<AV8>VB?-5%?2
MO_"JO!7_ $!?_)J;_P"+H_X55X*_Z O_ )-3?_%T?7(=F'MHGS517TK_ ,*J
M\%?] 7_R:F_^+H_X55X*_P"@+_Y-3?\ Q='UR'9A[:)\U45]*_\ "JO!7_0%
M_P#)J;_XNC_A57@K_H"_^34W_P 71]<AV8>VB?-5%?2O_"JO!7_0%_\ )J;_
M .+H_P"%5>"O^@+_ .34W_Q='UR'9A[:)\U45]*_\*J\%?\ 0%_\FIO_ (NC
M_A57@K_H"_\ DU-_\71]<AV8>VB?-5%?2O\ PJKP5_T!?_)J;_XNC_A57@K_
M * O_DU-_P#%T?7(=F'MHGS517TK_P *J\%?] 7_ ,FIO_BZ/^%5>"O^@+_Y
M-3?_ !='UR'9A[:)\U45]*_\*J\%?] 7_P FIO\ XNC_ (55X*_Z O\ Y-3?
M_%T?7(=F'MHGS517TK_PJKP5_P! 7_R:F_\ BZ/^%5>"O^@+_P"34W_Q='UR
M'9A[:)\U45]*_P#"JO!7_0%_\FIO_BZ/^%5>"O\ H"_^34W_ ,71]<AV8>VB
M?-5%?2O_  JKP5_T!?\ R:F_^+H_X55X*_Z O_DU-_\ %T?7(=F'MHGS517T
MK_PJKP5_T!?_ ":F_P#BZ/\ A57@K_H"_P#DU-_\71]<AV8>VB?-5%?2O_"J
MO!7_ $!?_)J;_P"+H_X55X*_Z O_ )-3?_%T?7(=F'MHGS517TK_ ,*J\%?]
M 7_R:F_^+H_X55X*_P"@+_Y-3?\ Q='UR'9A[:)\U45]*_\ "JO!7_0%_P#)
MJ;_XNC_A57@K_H"_^34W_P 71]<AV8>VB?-5%?2O_"JO!7_0%_\ )J;_ .+H
M_P"%5>"O^@+_ .34W_Q='UR'9A[:)\U45]*_\*J\%?\ 0%_\FIO_ (NC_A57
M@K_H"_\ DU-_\71]<AV8>VB?-5%?2O\ PJKP5_T!?_)J;_XNC_A57@K_ * O
M_DU-_P#%T?7(=F'MHGS517TK_P *J\%?] 7_ ,FIO_BZ/^%5>"O^@+_Y-3?_
M !='UR'9A[:)\U45]*_\*J\%?] 7_P FIO\ XNC_ (55X*_Z O\ Y-3?_%T?
M7(=F'MHGS517TK_PJKP5_P! 7_R:F_\ BZ/^%5>"O^@+_P"34W_Q='UR'9A[
M:)\U45]*_P#"JO!7_0%_\FIO_BZ/^%5>"O\ H"_^34W_ ,71]<AV8>VB?-5%
M?2O_  JKP5_T!?\ R:F_^+H_X55X*_Z O_DU-_\ %T?7(=F'MHGS517TK_PJ
MKP5_T!?_ ":F_P#BZ/\ A57@K_H"_P#DU-_\71]<AV8>VB?-5%?2O_"JO!7_
M $!?_)J;_P"+H_X55X*_Z O_ )-3?_%T?7(=F'MHGS517TK_ ,*J\%?] 7_R
M:F_^+H_X55X*_P"@+_Y-3?\ Q='UR'9A[:)\U45]*_\ "JO!7_0%_P#)J;_X
MNC_A57@K_H"_^34W_P 71]<AV8>VB?-5%?2O_"JO!7_0%_\ )J;_ .+H_P"%
M5>"O^@+_ .34W_Q='UR'9A[:)\U45]*_\*J\%?\ 0%_\FIO_ (NC_A57@K_H
M"_\ DU-_\71]<AV8>VB?-5%?2O\ PJKP5_T!?_)J;_XNC_A57@K_ * O_DU-
M_P#%T?7(=F'MHGS517TK_P *J\%?] 7_ ,FIO_BZ/^%5>"O^@+_Y-3?_ !='
MUR'9A[:)\U45]*_\*J\%?] 7_P FIO\ XNC_ (55X*_Z O\ Y-3?_%T?7(=F
M'MHGS517TK_PJKP5_P! 7_R:F_\ BZ/^%5>"O^@+_P"34W_Q='UR'9A[:)\U
M45]*_P#"JO!7_0%_\FIO_BZ/^%5>"O\ H"_^34W_ ,71]<AV8>VB?-5%?2O_
M  JKP5_T!?\ R:F_^+H_X55X*_Z O_DU-_\ %T?7(=F'MHGS57V/7&_\*J\%
M?] 7_P FIO\ XNNRKGQ%:-2UNAE4FI6L%%%%<QF%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JNI6:ZAIEU9OTFB9,^F1UJU10!Q
ML]T^I^$=)T]F(GOI$M9?4!#^\_1#^=-:>5/!,VE*_P#I*3G3%R?5MH_\<(-7
M--T.[@\5W%Q-&!80F22T;</OR[2_'48P>OK3WT6Z;QBMSL']G9%TS;A_K@AC
M QUZ8.?:M;K]2-26YUBXL[G^RM&TA[][6-!+B98DC!'RC)ZG Z5*_B6!='6]
M%M.9VE^SBTP/,\W.-G]<^G-86O>%WEURXO\ ^PX]7CN IV_:S \1 P>^"#@>
M]/E\(22^%X[5;&UBE2Z^T_8Q-(488QM+DYSCN,#-*T=!ZFWIVMW<]Z++4]*?
M3IY%+PYF659 .HW+T/MZ5E^&=5*:;I^G6EO]HG)=YSOVK!'O;EC@\GLO?VJ'
MP]X=-OJ\=X?#L.E+$K<F]>=V)&.,-M Y.<@TNE>'[[1UT^^M;7%UO>.^@#K^
M\C9R0V<X)7@_3BFU'86IU6H73V6G7%S%;R7+Q(66*/[SGT%>!ZQJ]WK>HR7E
MX^Z1N H^Z@[*!Z5]"UYSXZ\$^=YNKZ7%^\^]<0*/O>K*/7U'?^?7E]:G"=I+
M5]3R\VP]6K34H/1;K]3FIM0N]'\'Z.NGW$ELUV\TTSQ,59BK;0"1SC%0>+F-
MQ<:;?.!Y]W81RS$#&Y^03^@HT[5M(FT>+3-<M[MDMY&>WEM"N\!OO*0W&,\U
M)]GN/&WB&.#3[?[/:PQ+$F[D0Q+T+'N>M>DER2YI*UKW9X\G[2')%WORI+S6
M_P#7F=)\.O$UW)G2;I'EMXES'/U\H?W3[>G^'3T/[9;_ //3]#571=%M-!TY
M+.T3"CEW/WG;N36C7B8BI"I4<H*R/IL'2J4J*A4=W_6A!]LM_P#GI^AH^V6_
M_/3]#4]%8'20?;+?_GI^AH^V6_\ ST_0U/10!Q?Q"\7W7AOPXUQI=NTT\C>7
MY^W*6^?XF'?V[9Z^A^;U:2_U%6N)7DDGE'F2,<L23R2?6OL"XMX;JWDM[B))
M89%*NCC(8'J"*^=?B)\/9_"5Y]OT\/)I,K_(W4P-V5CZ>A_#KU[L)4BO=ZF<
MT]SM;^2:T\8)867C>UT^:V*066C>2[6Y0  )*P(4%OQ(SQVKQJ_-W8ZY<EXQ
M9WD-PQ*0_*(7#'A>>,'ISVKLE\5>$+O4(O$&IZ1J3:XFV1X8)4%K-*O1R3\R
MY(!(&1]>\O@WP7>?$'7[K6]34PZ:]PTLS(-OG.3DHGMZGM]:UA^[3<A/78]1
M^'7C"[\2>'1/JENT4\+>7]HVX2X_V@/7U[9Z>@Z_[9;_ //3]#3K:V@L[:.V
MMHDB@B4(D:# 4#H *EKSI-.3:5C1$'VRW_YZ?H:/MEO_ ,]/T-3T5(R#[9;_
M //3]#1]LM_^>GZ&IZ* (/MEO_ST_0T?;+?_ )Z?H:GHH @^V6__ #T_0T?;
M+?\ YZ?H:GHH @^V6_\ ST_0T?;+?_GI^AJ>B@"#[9;_ //3]#1]LM_^>GZ&
MIZ* (/MEO_ST_0T?;+?_ )Z?H:GHH @^V6__ #T_0T?;+?\ YZ?H:GHH @^V
M0^K_ /?MO\*/MD/J_P#W[;_"IZ* (/MD/J__ '[;_"C[9#ZO_P!^V_PJ>B@"
M#[9#ZO\ ]^V_PH^V0^K_ /?MO\*GHH @^V0^K_\ ?MO\*/MD/J__ '[;_"IZ
M* (/MD/J_P#W[;_"C[9#ZO\ ]^V_PJ>B@"#[9#ZO_P!^V_PH^V0^K_\ ?MO\
M*GHH @^V0^K_ /?MO\*S_$Y#>%-38=#:N1Q[5KU1UFSDU'1;VSA95DGA:-2Y
MP 2.^*:W$]CF-.GT6X:U@/@R[0OM4S2:6@0?[1;T]ZU+S4]8N-5N+#1+>RQ:
MJOG37C-MW,,A5"\],&MV!#%;Q1MC*H%./85AWNF:S;:M<7^B3V6+H+YT-XK;
M=RC 92O.<8&*JZ;%8S[O4Y=2L]/^TP""[M]7BAGC!R PYR#Z$$&EMM3ETRVU
M0V\ GNI]7>&",M@%B!U/H ":M1^'+M+2W\RYCFNSJ"WMS(05!QV4<]  !1+X
M<NI+6["7,<-T=0-[;2 %@IX ##CMD'ZU5XBU%AU37;6_BLM5@L=]TCBVFM2Y
M02*,[6#<],]*B;Q5-]ET6188]UV0;I<']TNX(V.>/G8#FK%GI>M76JVU]K=Q
M9;;3<88;-6VEF&-S%N>!GBH!X7GWZR#.ACNHV2T&3^ZW$N<\?WSGC/2E[O4>
MI?@UV#[3J#7=S:V]G!<"WB>1PF]PH+\DX/)QQZ&I(M6^T:_'9P/#+:/9FX65
M#NR=^W@@XQ3=/T.!-&@M-2@MKN56,LID0.ID8DLPW#U)JMJ&C7T.I6E[H364
M!BA-N\,R$1["<\!>X-+2X]2O=>([Z&SN9HK:*62/4Q9I& 1O7([D_>YZ]/:I
M[35-9MM7M[/6;:S6.[W>1+:LQ"L!G:V[OC/(]*R=1TB]T_1UAFO%:XN=8CE6
M=5Z%F&"5Z9R.G3WK7M-+UBYU:"]UJYM&6TW>1%:*P#,1C<V[OC/ ]:;M86IN
M23)%C?NYZ84G^5,^V0^K_P#?MO\ "IZ*S*(/MD/J_P#W[;_"C[9#ZO\ ]^V_
MPJ>B@"#[9#ZO_P!^V_PH^V0^K_\ ?MO\*GHH @^V0^K_ /?MO\*/MD/J_P#W
M[;_"IZ* (/MD/J__ '[;_"C[9#ZO_P!^V_PJ>B@"#[9#ZO\ ]^V_PH^V0^K_
M /?MO\*GHH @^V0^K_\ ?MO\*/MD/J__ '[;_"IZ* (/MD/J_P#W[;_"C[9#
MZO\ ]^V_PJ>B@"#[9#ZO_P!^V_PH^V0^K_\ ?MO\*GHH @^V0^K_ /?MO\*/
MMD/J_P#W[;_"IZ* (/MD/J__ '[;_"C[9#ZO_P!^V_PJ>B@"#[9#ZO\ ]^V_
MPH^V0^K_ /?MO\*GHH @^V0^K_\ ?MO\*/MD/J__ '[;_"IZ* (/MD/J_P#W
M[;_"C[9#ZO\ ]^V_PJ>B@"#[9#ZO_P!^V_PH^V0^K_\ ?MO\*GHH @^V0^K_
M /?MO\*Y^^N;C4KP6ZJ44'Y4;C\373U5N[5I<30,([E1A7P#D>AJDTA,Q)9(
MSI4T,/\ JHI% ;NQYR:G@69K6R\NZ6V ZH[;=_/4>M5Y-5NUMYH)V83$X^X.
M!W%-CFM+L0I/#.9D 0"(C#@=,YJK")H;V6WUB6..)BDDG,7?ZBNBJM;VJQS/
M<.H\Y\9[[1Z"K-0W<:"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D>*?^14U7_KV?\
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MD8CD$CH16]64]9,:V"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MR>PT2VAESY[+YDQ/4R,=S?J32E;5@K[&E1114%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 51O]9TO2F1=1U*SLS("4
M%Q.L>['7&XC-7J\]\<365OXST-[_ $2XUF'[)<#[+!:"X;.8_FV'CCU]ZN$>
M9V$W8["S\1:)J-RMO9:QI]S.P)$4%TCL0.O .:TJXOPS=:)=:MBR\#WNCSI&
MS"ZN-)2W7T*AQSDYZ?6LF+QKXM_L.+Q#+I>E_P!DI,8YU5Y!,Z^9LWJ.0H'H
M<G@GH:ITVW9!<]*J&WNK>[5VMKB*81N8W,;AMKCJIQT(]*Y?4-=\17NO7>F^
M&K/3VCL GVJ:_=P'9AN"(%[XQR>.?SYS1=?U+1O"EY>PZ>K7L_B)X7M)&R07
M< H&R!G/ /3O0J3:"YZC17(6&O>(['7[33_$MGIR0WX?[-/8NY",HW;'W=3@
M'D<<?E07Q/XPU"PEUW2]*TMM&7>\<$TD@N9XU)^92/E&<9 /ZTO9L+G<_:8/
MM7V7SX_M&SS/*WC?MSC=CKC/&:EKC)?$R2ZF;RRM;5E;0&OXIY(OWOWLA"0?
MN^H]>]4['Q9XI4Z'?ZIINFQZ7JKQPA8)',T;.,JS9XVG&<<D9 )H]FPN=_G]
M**\OTG6M?T&R\9:K>06%Q%;WKDI 9-WG8C&>?^684@^O!K<\(^)]7UF_,-W+
MH-[;M&7\[2;DDPGC DC<[N>>0.,<TY4FDV%SM****R&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#D DBI+C6=+LYYH+G4K.":&+SY8Y9U5DCSC>P)X7/&3Q0!>HJIIVJZ=J]O\
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M\RQH<]/F)Q0!<HJO97UIJ5JEU8W4%U;O]R:"0.C?0C@U.S*BEF(50,DDX %
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MZ1DV\4DH3SY,9"KZY]NV:H_#_7=:\0Z3+?ZM=^'[A6*^5_8TKR>62N624L2
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M\+PR2FV76[>!Y<[78OOWMD="2Q/'3->QUSWBOPO_ ,).=&/VS[-_9NI17_\
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M.WD&<AB@'WAZ@BN+^&OA30_%7ABZ\0>(-.M]3U/5+J<W$EVGF-&%<J$7/W,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB+0!4$I' ;CGMP?2I-?\2:3KWQ;\#1:3>Q7R6LMUYL]NPDB!:+A=X^4MA22
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M@X5@>_IGH#C0\.Z=X7/Q'TP:=XL\2^)=0M(99A+)?I=VMLK+M(=\<%L\!3U
MS7J<NG6=QIXL+FUBN+38$,,R!U('0$'K3=-TC3-'A:'2].M+&)CN9+6!8E)]
M2% H X?X4 8\8' R?$=US_WS7('3;O5O 7Q3L[&-Y+AM<G=4C&68*R,0!W.
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M4HNUD=R",CJ,XZ^XSL^";'PZ/&6K7&CZ_P"(=?N;>P\B:_O;I+BV 9@PC60
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M^F/ID.D6$=A(27M4MD$3$]24 P>@[4_3=%TK1HWCTK3+.Q1SN=;6!8@Q]2%
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MC./_ *^+GPC &F^)2  3XAO,^_*UW&G:5IVD6_V?3+"ULH"=WEVT*QKGUPH
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M[*H[L?3^E3Z/J1U?2K>_-C=V/GKN$%XJK*H[;@I.,]<9SZXH O4444 %%%%
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M.%(0IVA5W,[9(PH'7&3R.* -:BBL?Q1XDL_"7A^XUJ_CGDMH"H98%!<[F"C
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MU)8G;(,G> 3D;#T..M %34_%VN77PHN6N+^6+6=,UI--N;JU<Q&4K*H+#;C
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MKU];:=-X@O'O-U[,L0"MQ$@+$=(U4X^M5_B%X,U76];TW4-#98WN(GTO5&R
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MXIA#;"\6YDFDD7:6RG 4#UY^N>  ^'D:7WC#QQK%R@:_&JM9*[<LD,:C:H]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.NXKGQ3XQDBOM8O8IM"+076K*5DN$&X%T&!A,\#CUK9U:-%_9ST@!% $%@<
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M+6YBB0(KH!\DJJ  %8>@_  BNVH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *P=.\-?8/&.L^(/M?F?VE%!'Y'EX\ORP1G=GG.?08K>HH RO$.GZ
MIJ>DO;:/K)TB[9@1="W6<A>XVM@<^O44SPQX=M/"N@6^DVCO(L>YGFDY>5V.
M6=CZDFMBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKGM>_P"$Q^VQ
M_P#"._V%]E\L;_[0\[?OR>FSC&,?K5&S_P"%C?;8/MO_  BOV3S%\[R?M&_9
MGYMN>,XSC-:*G=7NB>;R.OKG?$6OW6D:WX;LK>.%H]3O6MYC("2JB-FRN",'
M('7-=%7"?$.>*PUGP;J5U(L5G;ZOMEE<X5-\3J"3V&>]9E&QXWU^Z\->'?[0
MLXX9)OM4$.V925VO(J'H1S@G%:5[X@T73FF6^U>PM6AV^:)[E$,>[.W=D\9P
M<9ZXKE/BK<P/X;L-.69#=WVI6B6T0;YI,3*Q('H .M9\/AO1M>^,_B*;5M.M
M[[[-86HB2YC$B+N#9.T\9^4<_6@#T5+VTDLA>I=0M:%-XG60%"OKNZ8]ZIZ?
MXCT/5KE[?3=9TZ]G09:*VNDD91ZD*217DMC)I&D_#G4]+O-*?4[4^)IK*QTX
MW1A1W\S*(SY 5 03SD>H-5+NRN-.^)G@WS_#_AK09GO#MM]+?-P4*D$R;552
MO;./7'>@#T70_'5O/=Z['KM[INGQV6JR6-JTDHB\U552,[VY;GMCZ5?UKQ!<
MZ=XK\,Z7;I ]OJLDZS.P)8!(BZ[2#CKZ@\5PWA30?"6K:_X[FUNUL+JZBU68
M2"[VMY,&T88;ON9.[YA@\=>*S?",DLA^&>Z1Y8$NM2CM7?[S0*CB//X ?AB@
M#UZ[U_1M/O8[*]U>PMKN7'EP37*([YZ84G)K1KYZ\.>'_$/B72]5O3IW@6^D
MDN[@7LVL+.]W"P8@AF'W  !MVXP,5[#X @NK7P-I5O>:C9ZC+%$4^U6<YFBD
M4,0NUR!G P/PH 3QQXM@\&^'7U*0V[3&1(X8IIA'O+, 2.YP"6('8=NM:[ZU
MI4>EKJCZG9+I[ %;MIU$1![A\X_6N/\ C%9VMS\/IWN+:&5XKFW,;2(&*9E0
M'&>F02/H:S]8T?0KKXKZ)HNJ6=H-(@TEY-.L755@:?S,, GW6(3'&/?% 'HM
MCJ%EJEJMUI]Y;W=NQPLMO*LB'\02*P_''BV#P;X=?4I#;M,9$CABFF$>\LP!
M([G )8@=AVZUS6@V.F:-\9=0T_P]%!!9R:2)=0MK8XCCG$@"?*.%8J3P,<<]
M^;GQBL[6Y^'T[W%M#*\5S;F-I$#%,RH#C/3()'T- '8/K6E1Z6NJ/J=DNGL
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M'.T@@YZ<BHK;Q/X?O;\6-KKFF3WAR!;Q7<;2<=?E!S7F^@V/AGP_\#8M9O\
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M-T?3ED49X6[N%!(]RL?'L6H Z[2=89K&:?5=1T<G[:]O%)9S_N_O[4C8L?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS2(K5IK4VDOE.XWQ$Y(//)_VOO>]=)10!D3>%]&G\.0^'Y;/=I<*QK'!YKC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\M\[2R9!4^C*<%3[$"L2]^*/@G3]8.DW7B"V2\5]C *[(K9QAG *C'?)X[T
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M&2.,9(!W, "#@X()S0!TE%<AI/Q2\%:YJB:;I^O0R7<C;41XY(P[>BEU )]
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MD4\8#;)%0D95AP1P<$?A5OP9J%UJW@K1=0OI?-NKFSBEEDVA=S%02<  #\*
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MD$UX<A8RCIO([*64!C]": .KHKG/$GCSPQX1FBAUS5HK6:4;EB"/(^/4J@)
MX/)XXK5TC6=-U_3H]0TJ\BN[23[LD9R,CJ#W!]CS0!>HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_=&20!CGKFN5T_PA9>*/B;XYDEO-0L+RVN;;R;S3KDPS(K1?,N[D8.!G([4
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M#5[_ ,'IXGU:37[CQ)X/U22X9);?3YY1%J:#A9/EC(.[\.O4Y)H 6TM+&P\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM0427@\M_,MK8) %X61V9<\N 1G/'&>!D8HLQW1?_P"$<3<3]H.TW/FXV?\
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MU 6%6B(%JRQ@9^90VW:>>H![>U07L,\\=M;P:=)&B;'B82($A(/1T#8.,#&
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M'.WCTS67=Z-J!ET[;:L[VL=L%E0QX4JPW@ESN' XV 9[D\"BWF!U0M+87#7
MMXA,Q!,FP;B0, YZ]"1]*9_9]D99I?L=OYDZ[)7\I<R+Z,<<CZU@2:%.(IVA
MM8UN)XKM)'RH+[GS&&/?CIZ>U-O+"_ODG:73I!%-<JQB)A=PHB SAF*'YAWS
MQR!GD%O,+F_'I>GPHJ1V-JBJXD4+"H 8<!AQU'K2KIM@B3HME;*EP<S*(E D
M/^UQS^-8%KHJ_82^L11Q&/3XHO/D92864.&(;L1D<U>TR"[N]'FN7F$-[>H,
M2A=P0 84@<<=6[?>I->8%^S33I+22WLXH/LR.T3QQQ@)D?>&,8J);[35U,PJ
M +DL4,@@8 M@$KYF-N< <9SP*K:/;7&E1M;W*QL);DB+R(]H VYR06)Q\OUI
M9OMEWJOESV%P+2)OW+HT>PG'^L;Y]W&3@8]^3C!;4".*?P[]EN3%;6_E,R^:
MBVA_>DGY2%VY?)S@@'.#BKIU'37@BNI'0+(_V9#)&58LQQLVD9!R.1CMGM67
M;1ZM9V_F1Z:3/%;16J)YB'>5)W./F&5 P0"03TXZU9-B\VE1!;25+D7$;N;@
MQ^8?WJ,[$J2.0N< ]@,<"FTA&AY%AIMIO6W@@M[?,@$<0 3@Y( '7!/2I'>W
MM]D;;4$S$*H7AC@L?Y$U!JD4MYI5_;1Q-O>)D3+ ;R5['/'7'..E8\N@HMVH
M73(7M5N]ZH%3"JT.TM@G^]@GOQG!I))[C-F"STV<P7T-I;%O+7RIO) 8+CC!
MQD#':K*P1)+)*D2+))C>X4 MCID]\5QUOIDGF16RZ5LN8K6V"ONC'V9@[[GX
M/?!/RY)[U=L=+N;;6+N5M/+V\J2^;Y@B)DR<[58$%P?21>/[V.K:\Q7->=-)
MCOVFEM[?[6-A:3R07^8[5^;&?45::RM7B,36T+1L@C*&,$%!T7'I[5F?8;N6
M^\UX@JM<-*<D<*B;8QQSR26]JP[70KX6]XDMA,D<\<)>-6@!:16); Y##D?Z
MPDD=31;S'<ZG[-IR(NF?9;<1NI<6XB&P@$9.,8ZD58%M N-L,8QNQA1QN.6_
M,]?6N630KFXTZ.*ZL8B8K6X2),*NUV92AV[F"G@GY3@=L=*U]3MYKNW@62R:
MZCBE!FMR4_?C8>@)P<,0<-C[OTRFO,"_!86=JBI;VD$*(Q=5CC"@,1@D8'7'
M%2>1 L*Q^5&(DP57:,+CD8';%<T^DSM/"4TOR\+$+=_.5OL85R6&2<C*D#"Y
M';H :LVNBF*Y\U[.,&9;E;AB%)D#/E WJ,?ETXHMY@:-I%IMY')=V]K$1<C$
MCM;[#*/?(!8?I5F>TMKH(+BWBF$;!T\Q VUAW&>AKE!X>N8Y-. M9 L4,*J(
M#"H@D!RY)92PSG.4Y..>QK0L+"ZM-4-T]D?L\A80P*RYM,MR?O8^;J=O3&.<
MTVEW%<V9+&SFNH[J6U@>XC&$E:,%U^AZCK4GD1>?Y_E)YVW9YFT;MN<XSUQ[
M5SDFE7#&]5-.Q>R";&H><%WJV=JY!W'C:,$ #&0>!DCT0SE%;2T@LC<F3[(^
MPA!Y17)525Y;' SZGO2MYCN;\WV6VMF65$6&1MK+LR&+G'0=<D_K1#86=M (
M(+2"*(-O$:1A5W=<X Z\#FL"PT:ZMKJU46RQ0B"*29MP^:958<X.2<L#N_V1
MS5"UT*^%O>)+83)'/'"7C5H 6D5B6P.0PY'^L))'4T[+N*YU,]MIT\L=I<6M
MO(QW3HCQ!AD$9;D8SEOKS5?5KG3F465XTC$LC^5'"TC-@D@;0IR/E.?:L9-"
MN;C3HXKJQB)BM;A(DPJ[79E*';N8*>"?E.!VQTK0D&JV\4TD-I))/<S89HVC
M+11JH (#, 2<$C)XW<@XP2R[@/=_#TBV5N]O:/&R@VZ_9MR('.!_#A-QXYQD
M\5)%>:*US*RI$DBJS-*UN4#!!M)#D -@$C@G JF^GW(816]C(D$Z0*3)(F8-
MCEFW?,<D@Y!&<GKCK2SPZAJGVQ;FPGA<Q21VQ9X_*4'N2'+$MQSC@<>I)9 7
M;*;1TLUDM((H88Y@H06YC*2-@#Y< @D,.W0^E7X[2VBE66.WB214\L,J $+G
M.W/I[5B'3KK4II#=VC6]O/(7>-G5F $809P2,DDG@G[HJ&#2M3DEC>Y4*UPP
M-T=X(!C_ -7CGN<'^=%EW&;MREE&K27$41$K(C%H\[SG"@\<\GCTJ26SM9W#
MRVT,C@A@SH"01G!_#)Q]37(0:!>QV$R-9SO(S0&57DA"SE9 7(V 9R ?F<[C
MGD4^;3F\R&!M(\P/%<M#:;D_< LFT]=HP>?E)QGBCE7<5SKDMX8\;(8UP@0;
M5 ^4=!]/:FFTMB@0V\10(8PI08"''R_3@<>U<Y-H3^>;FYTY+]A< R*=A:5/
M)"_Q$#&\9P2.F>N*I7T'V62RM;I(I[QH($@'GJ7A(<[L G<01@94'.TYP*.7
MS"YV@C02-($4.P + <D#H,_B?SIL,$5O$(H(DBC&<(BA0._05S5UH;FP"+IX
M=YKN1[C8(V=EW.4/SG:0,C@@X!X&>D<&@7$MM:F\LU>:.&TC)=E)7:Q\P Y_
MNGGU'%*R[CN;E[-I=A=I=W,2"[9<+(EN7D*Y P"H)ZL!CWJ6"2RU)&F2-7(!
MA?S82K@=U(8 @'@X/7BL*/1;W[/+&(S;[)T2W\LI\D8F+EESD#@C@C^$<5'K
MN@7,L!BMXY[UW65S,WE;O.(4*3NPJC QE5W#'49.79=Q79TD^G6-TL:W%G;S
M"($1B2)6V \<9'%*-/LA=+="TMQ<J-JS>6-X&,8SC.,5SL-G-<:S/)'9[;A+
MI2UYN7Y%\E<IUW<YZ 8YS4%CX?N5MWBFMIB7>#S_ #'AVS%9 78! "PQGESN
M.<8HMYA<Z8R6(U!;4^3]K8&X";1NXPN_]<9_PJK)_8D$5Y";>VV+(IN(D@W;
MG;!7*@?,QX]3TIYT_P K5+:2UACAA2WEC)10 K'RPO Z\+^E4-/T_4M+:]9Q
M'>!PF/)7RGD/.YLES\W)/.,GN*2L,M75]HK"UO;E8W8%C"[VY9XMI^8_=RF#
MU)QCO4SW>F->36K(K2RC9+^X)63"YV%L88[<_+G..U9+:??Q6^8;)G$L4\*Q
M/*NZ(2$$%R3\W(.2"QY[U?D@N7U"T46L@%LPQ<&4&-DVX/RYSOY(SMX]>2*=
MD NGMHT\DEK:62Q-&H=HWLFAP""H.&4=1D?3-/\ LNB#37?[':"SB9G9?LXV
MJR9!.W'48(J6QBF@CGFFB9IYYV9E!7(7=M7OC 4 _GWXK#G\/R-;7&RRC,LT
M5TLA.W+EGW1@DGGIQZ>U'7<#H!IFG[X7%C;;H<>4WE+E,=-O''X4U;;3KF?<
M+6W>6UD(#&(9C<X8X)'!.0<BL7_A'TGNQ-)IL81I\E'"'$7D!0I )&-P''3(
MS[U?T"UNK*W:*Y@96?:V[<I Q'&N#SG.0?R^F4_4#5:*-VW-&C-M*Y*@G!ZC
MZ<"HX+&TMHXXX+6")(R618XPH4GJ0!T/)_.IZ*D8SRH][/L7<X"LV.2!G /Y
MG\ZK?V3IOV3[)_9]I]FW;O)\E=F?7;C&:N447 HC2+'[8MT;:)G1$2(,BD1!
M<XV\<=>WH*F%A9B2:06D ><8F;RQF0?[1QS^-6**=V!7GL+.ZC=+BT@F1V#,
MLD88,0, G/4TC:?9.\#M:6[-;\0DQ@F/_=XXZ#I5FBE<"-[>&3S-\,;>8NQ]
MR@[UYX/J.3Q[U!'I>GPHJ1V-JBJXD4+"H 8<!AQU'K5NBBX%:/3[*'S/*L[=
M/,<2/MB4;F!R&/')SSFK-%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img101536035_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU?73ZGXI6UU($&$7.7>8GT)8=,=!DTH4+IN3M8'(^F:"0.IQ7$:%:W_P_P#
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MYX)DD&_"*H)*GZ[A^5>5^#O#ESXIUW^SK2[6UE\II/,;.,#'''UJZ=FY3O\
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M"74;3O=&GH7C7P;J.IQZ=HMW";NXSMCCM)(]^T%CDE . #U->6?'+_D=;/\
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MTKC8/@QX4ANQ.WVZ9 <^3).-GTX4']:R]I3G!*=]!V:>AT7C30U\3>#[ZQC
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MRI<1+L6>!PK[>N#D$$9.>15"T^%?A>TT:?31;S2+.5,EQ)(/-.#D , ,#(Z
M#--5J=HM[H.5ZF-X'1I/@==(HRS6MX /?YZY#X(ZC:VGB6]MIYECENH L*G^
M-@<D#WQS^%>U:'H5CX>TB/2[!7%JA8@2-N/S')Y_&N:LOA5X=T[Q##K-DU[!
M+#+YJ0K*/*!],%<X]LU*JQ:FGU"ST/-OC?;R1^,[:8@^7+9)M..,AF!'\OSK
MV'P_XLT36-+CDM-1@9H;999TWX:%0.=WIBI?$OA32?%=FEMJD!?RR3%(C;7C
M)ZX/OCH>*R?#GPST'PU/<RVYNKG[3"T$J7;JZ,A()!4* >@ZU,JD)4TGNAV:
M9P&MZ7\.O%<-WJFFZW%I%[\S/'+\BNWKL///^R>_3-2_ [6-1EU"_P!*DEDD
MT^.W\U%8Y$3[@,#T!!/'M757OP9\*7=R9HUO;4$Y,<$PV_3Y@2!^-=5X>\,Z
M3X7LC:Z5;")7(,CD[GD/JQ/7^57.M#V;BKOUZ"47>YKT445R%A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBF/*L94,0"W2@!]% .:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%5\LC"G@YSGYAVII-[ ;U%%%( HHHH **** "BJVH7L>FZ;=7TRNT5M$TSA
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M'8F-2TB#TRI/8]6!..*E\'^ M2;P/XATR]CDLH]2;-G!<,"T>WE6?'0D[0>
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M7-S&) RK&AC?<[$#);..1VJ[X":^\'^"?$7B6[LC!%,5DM;:3Y<XR <=0"7
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MR[?BQ6=BK\,?%MW?:UJ/A^YU8ZO;PQ&6UO71E=U! (.[G^(=>>#R16;\//\
MDE?B[_MX_P#1(KO/",/B]_M5YXIN8%,O^HL($3$/KE@,GV^8USG@WPGK>E>
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M<[N'&=V[C[_IVKJJ*:DX[!8****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XC_P"0CI?UD_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'RH8*6).#NH ]5HHHH **** "N=\1_\ (1TOZR?^RUT5<[XC_P"0CI?UD_\
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M%T]D%^SFXW#:%VC;TST_VO>O7O*?_GXD_)?\* ):*B\I_P#GXD_)?\*/*?\
MY^)/R7_"@"6BHO*?_GXD_)?\*/*?_GXD_)?\* ):*B\I_P#GXD_)?\*/*?\
MY^)/R7_"@"6BHO*?_GXD_)?\*/*?_GXD_)?\* ):*B\I_P#GXD_)?\*/*?\
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M<3\*HM1_X5CH7]H2S)-]G^56 R(]Q\OJ,_<VUV/E/_S\2?DO^% $M%1>4_\
MS\2?DO\ A1Y3_P#/Q)^2_P"% $M%1>4__/Q)^2_X4>4__/Q)^2_X4 2T5%Y3
M_P#/Q)^2_P"%'E/_ ,_$GY+_ (4 2T5%Y3_\_$GY+_A1Y3_\_$GY+_A0!+14
M7E/_ ,_$GY+_ (4>4_\ S\2?DO\ A0!+147E/_S\2?DO^%'E/_S\2?DO^% $
MM!Z5YI_PE>M?\_O_ )"3_"C_ (2O6O\ G]_\A)_A71]6F.P[X>^"]1L/ .N:
M#KML;5]0NKG $B/^[D4*&^4D>O'6N:3P5XWU/PYI7@/4]+LX='L+I7EU=;I6
M\^%6)"K%]X-@]3Z=JZ/_ (2O6O\ G]_\A)_A1_PE>M?\_O\ Y"3_  H^K3"P
M:SH7B?PY\0;WQ3X8TF#6(M3M%@N+1KE8&CD0 *X+<$8 X'/7ZUN?#;PI=>$O
M"QM=0>)]0NKB2[NO*^ZKOCY0>^ !6'_PE>M?\_O_ )"3_"C_ (2O6O\ G]_\
MA)_A1]6F%CTNBN7\*ZG?ZM]K^UW3-Y6S;M1!UW9[>PKH_*?_ )^)/R7_  K&
M<7%V8B6BHO*?_GXD_)?\*X+4/$NKV^I74$=X0D<SHH,:= 2!VJH4W/1#2N>A
M5P/@;PWJND>+O&M[J-IY5KJ=ZLMJ_F(WF)\^3@$D=1UQ5+_A*]:_Y_?_ "$G
M^%'_  E>M?\ /[_Y"3_"M/JTPL<XW@KQOIGAO5? 6G:99W&CWUTSPZN]TJ^1
M"S E6B^\6XZCU[UT.N>#M9T'7_#GB'PM91:G)I5@--FL9)E@::(#"LKMP",G
M/X=:=_PE>M?\_O\ Y"3_  H_X2O6O^?W_P A)_A1]6F%C2^'?AG5-*FUS7-=
MBA@U36[H3R6T+AQ @SM0L."?F.<<5W->:?\ "5ZU_P _O_D)/\*TM!U_5;_6
MK>VN+PF)]VX"-!T4GT]J3P\DKA8[FBHO*?\ Y^)/R7_"CRG_ .?B3\E_PK 1
M+17'>)]9U+2]2C@M;ME1H0Y!1#SEAZ>U8O\ PE>M?\_O_D)/\*WC0E)70[%[
M3/#FK6_QIUKQ!+:[=+N=.C@BG\Q3N<;,C;G<.AZBL"\\-^,O#6K^*8?#FD6N
MIZ?XB8RK,]TL)LY'!#%E;EQ\Q.!Z#Z5H_P#"5ZU_S^_^0D_PH_X2O6O^?W_R
M$G^%/ZM,+%*_^&VJZ1X6\(-H7D7>K^&Y3,878(MSO.Z10QZ<]">WO6OX-\/Z
M[/XUU;QGXCL(=-NKN!+2WL8YUF,4:X)+.O!)*CI57_A*]:_Y_?\ R$G^%'_"
M5ZU_S^_^0D_PH^K3"QZ717FG_"5ZU_S^_P#D)/\ "O1O*?\ Y^)/R7_"LZE-
MPW!JQ+1354J,%RWN<?TIU9B"N=\1_P#(1TOZR?\ LM=%7.^(_P#D(Z7]9/\
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MDP2F/.=A."",^U,M_A[H]OX8U/0Q-?2#5%(O;Z:?S+F8D8W,[ C('3C'MR:
M.*\4:.O@WP#'<>'XKIM6UZYM8+^[^UE9K@ODD^8Y*QEB2,@ #=[53\/>&O$F
MB^*-+N]&\ W.@0&X5=1?_A($NDGA/#;XV/)&=P(].AKUG5/#VFZUX??1-1@^
MT6+QK&RL<'Y<8.1T(P#D5S^C_#33-+U2VO[G5M<U=[1MUI%JE\9H[=L8W(N
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  Z44#I10 4444
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M]/8UT%%%$FF]%8$FMPKPJRTWQ'?_  \U;Q6_C77([JPDNY+.".X_=!8W;Y9
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MKT7_ )_?_(3_ .%'_"5Z+_S^_P#D)_\ "O-**U^K0'8]+_X2O1?^?W_R$_\
MA1_PE>B_\_O_ )"?_"O-**/JT L>E_\ "5Z+_P _O_D)_P#"M"QU"UU*!IK2
M7S(U;:3M(YP#W'N*\DKO/!3LNC3 1.W^D-R"/[J^IK.K1C"-T#1U%%1>:_\
MS[R?FO\ C1YK_P#/O)^:_P"-<Q)Y!1117JF@4444 %%%% '9> _^8A_VS_\
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M3Z9#_JE^E/H **** "BBB@ HHHH **** "BBB@ K,N?$>AV5^MA=ZUIT%XV
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M&\AU&PMKVW):"XB66,D=589'Z&@">BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ '2B@=** "L*X\':%<W\EY+9N7EE6>6(7$JP2R#
M&'>$-Y;-P.2I/ ]*W:* ,;4_"NCZQ>?:KVU=Y6012;+B2-9D!R$D56"R+R>'
M!')]36A=6%M>P1P7$6Z*.1)%0,5&4(*Y Z@$ X/'%6:* ,FY\,Z1=ZS'JT]J
M7O(RC ^:X1F3.QFC!V,R[CAB"1V/ K6HHH **** /CBBBBO<.X**** "BBB@
M#V3X#_\ ,P?]N_\ [5KV.O'/@/\ \S!_V[_^U:]CKRL3_%9RU?B85X=\0?\
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M:]N'2BB@#S<6GC/P;K6L?V%H-KKNF:I=O>Q_Z:MM);2.!O#;AAER.,<U5N_
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ML'TSGMFO2** /)-3\':EHOB?5[RU\":+XLL=3N#=(;AX8I[9R!O4M(IRI(R
M/4UI77@W69/"6G3V6F:%IFNV&HC4H;&PC\JW)'R^6Y'WF*'!88&1CIS7I-%
M'F]E:>,M;^(&@Z]K.@PZ58V<-S$8%O$G>,LH 9F&,[C@  '&#GK6;?>"_$<W
MP_O]-BLU>9]=FO9+%KH1B]MFD+>7O4_+N!!Y(Z<UZU10!XE9>#-?;Q3X=U*U
M\ Z7X?L;"]5IXX+N.:X<$$%RXQE /X<YR>A[=;#H.L+XW\4V]QI2R:%X@A4&
M_2Y3,.V'R]IC/S$GGD<=/P] HH \6T_PCX@TJQBT,_#/PIJ,\*B&/7)S"(G
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M4_Y&6T_X'_Z U34^!B9Z71117F$' ^./^0U#_P!>Z_\ H35S-=-XX_Y#4/\
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M';3LQPFU\Y^;MD#\*P[75+#QSXVO=?TS3[N_T&ST2:RFE2%D-\[MDPH'V[L
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M2]6TK2Y4FDN]3D>.%(@#M"KN9VR1A0.XSU'%9NM: GB3X=OI PCS62>2V/\
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MEO+J.XH(U#;68=0KXVL?8$UY?X6NKG6/%OCS[)K=OK.H2Z+Y:7=I;"!'D (
M4 G=@X&[O],5M:5X@\ 2?#SPUIMPL5W<PO;+%IEJP6Z2[! +;0RLI#9))(!&
M>N>0#U"#6+"YUB[TF*?=?6B))/%L8;%?.TYQ@YP>AKC?''Q+T[0_"EQJ&F7L
M;72WOV!?,@D($JL/-&,#E5R0>AQWZ5737M*\/?%_Q&=9U"VL$N=.M)(7N9!&
ML@7>&P3U.3TZ]:X^2]AN_@WXHOHR5@E\1M*ID&TA3<1G)!Z<4 >KW7CKPS8^
M'+;Q!=:M%#IET,P3.C R?[J8W$\=,5:\/>*-$\5V37FAZC%>0HVU]H*LA_VE
M8 C\17F?CVZ:?XA>'-5M/%=IHVG36$J6>K-;1W4'F[P6&YCL7*X^;/\ #CO6
MIX!M(W\<ZGJ'_"=6OB6\-DD=S]DTY(8P-V49I(R49N&&/O8]A0!V/C#Q&/"_
MAZ74$MS=73.D%K;!L&:9SM5<]N3D^P-<XNA?$Z>-;Z3QEIMM<D;CIJ:6KVX/
M]TRD[\>]7_B38WD^@66HV-N]S-H^H0ZB;>,9:5(R=P4=SM8G'M67KWBGP5XK
MT."<>/YM(BB)E/\ 9^HBVN&X^ZR$%C],=: %UKQ1XFT_P=I'B.[M?[.DM+U4
MUFS*!E>$N8V9202!G:PP>AY)KH?'.NSZ%X/N[S3V!OYMEO98 ;,TC!4(!X."
M<_A7.?#JU?Q#\/-5L]1O-2O[&]NKF&WN=0=VEEMF "-EQGISTQG-9'AB\NO$
M&I>&_#%\Q>X\-O-)J63G+PGRH"?7(;?[XH Z[0M3U7_A/=1T.^OC<P6>EVL@
M)C12TK%@[_*!UVCCH.P%3:GK%_;_ !(T#28I]MC=V=U+-%L4[F39M.<9&,GH
M:Y74?!N@>,/B_K,6O6'VM+?3+5HAYTD>TEG!^XPST'6DL_!GA_P?\7/#T>@V
M'V1;FQNS*/.DDW%=F/OL<=3TH -"@\>^*EU*^MO'O]G01:C<VT=O_8\$VU8Y
M"H^8X)XKHO"FNZVOB&_\*^)O(FU&U@2ZM[VW38EU QV[BO\ "P88/_ULG%^'
MWBGP]I.F:O:ZEKNF6=P-:O6,5S=QQN 93@X8@U;\/:A!XL^*%_K^EMYVDZ?I
MPTY;H?<GF:02-L/<* !GU/H10!Z%1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 #I10.E% !1110 4444 %%%% !1110!\<4445[AW!1110 4444 >
MR? ?_F8/^W?_ -JU['7CGP'_ .9@_P"W?_VK7L=>5B?XK.6K\3"O#OB#_P C
MQJ/_ &R_]%K7N->'?$'_ )'C4?\ ME_Z+6M<#_$?H3'<YFBBBO5+"BBB@ KI
MOA]_R/&G?]M?_1;5S-=-\/O^1XT[_MK_ .BVK.M_#EZ,'L>XT445X1D<#XX_
MY#4/_7NO_H35S-=-XX_Y#4/_ %[K_P"A-7,UZ-+X$6M@HHHK084444 %>R5X
MW7LE<N*Z$R"N:\<?\@6'_KX7_P!!:NEKFO''_(%A_P"OA?\ T%JPI?&A+<X"
MBBBO1+"BBB@ HHHH ]8TC_D"V'_7O'_Z"*N53TC_ ) MA_U[Q_\ H(JY7ERW
M9F8WBO\ Y%J[_P" ?^AK7FE>E^*_^1:N_P#@'_H:UYI79AO@*B%%%%=!0444
M4 %=_P"!_P#D"S?]?#?^@K7 5W_@?_D"S?\ 7PW_ *"M8XCX"7L=+1117 2>
M-T445ZIH%%%% !1110!V7@/_ )B'_;/_ -FKLJXWP'_S$/\ MG_[-795Y]?^
M(R'N%>4:O_R&K_\ Z^)/_0C7J]>4:O\ \AJ__P"OB3_T(UIAMV.)2HHHKL*"
MBBB@ K9\*?\ (RVG_ __ $!JQJV?"G_(RVG_  /_ - :IJ? Q,]+HHHKS"#@
M?''_ "&H?^O=?_0FKF:Z;QQ_R&H?^O=?_0FKF:]&E\"+6P4445H,**** "O9
M*\;KV2N7%="9!1117(2%<[XC_P"0CI?UD_\ 9:Z*N=\1_P#(1TOZR?\ LM &
M_#_JE^E/ID/^J7Z4^@ HHHH **** "H+JRM;T1"[MH9Q%(LL8EC#;'7[K#/0
MCL>HJ>B@"*ZM;>]MI+:[@BG@D&UXI4#*P]"#P:KZ;H^F:-"T.EZ=:6,3'<R6
ML"Q*3ZD*!5VB@ K/L=!T?2[F6YT_2;&TN)O]9+;VR1L_.>2 ">:T** ,R[\.
M:'?WZWUYHNG7%XN,7$UJCR#'3YB,U.FDZ;';7%LFGVBV]R[//$L*A96;[Q88
MPQ/<GK5RB@"AINAZ1HJNNE:796(D.7%K;I%N^NT#-1WWAW0]3NTN]0T;3KNY
M3 6:XM4D=<=,,02*TZ* *][I]EJ5JUK?VEO=6S?>AGC#H?J",4S3M*T[2+?[
M/IEA:V4!.[R[:%8USZX4 5;HH KWUA9ZG:M:W]I!=V[_ 'HIXQ(A^H(Q26.G
M66F6JVNGV=O:6Z\B*WB6-!^  %6:* (+.RM=/M4M;*VAMK=,[(H8PB+DY. .
M!R34&I:+I6LQI'JFF6=\D9RBW4"RA3Z@,#BKU% %*UT?3+&=9[33K.WE2+R5
MDB@5&$><[ 0/NYYQTS3(M!T>'5&U2+2;"/4'SNNUMD$ISUR^,_K6A10!2O\
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M*;P5X4N)I)IO#&BR2R,7=WL(BS,3DDDKR36S;V\-K D%O#'##&,)'&H55'H
M.!4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT,SW6H;S=J5R5:(NQXZYSC\<8Z'1O"]AXVD\1>(]:N;K^U;74KFVLYDN73[
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  .E% Z44
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M@K6.(^ E['0;I_\ GG'_ -_#_A1NG_YYQ_\ ?P_X5+17 2>-T445ZIH%%%%
M!1110!V'@4R#[?L56_U>=S8_O>QKK]T__/./_OX?\*Y+P'_S$/\ MG_[-795
MY]?^(R'N1;I_^><?_?P_X5Y9JV?[9OL@ _:),X_WC7K%>4:O_P AJ_\ ^OB3
M_P!"-:8;=CB4J***["@HHHH *V/"VX>([3: 3\_!./X&K'K9\*?\C+:?\#_]
M :IJ? Q,]&W3_P#/./\ [^'_  HW3_\ /./_ +^'_"I:*\P@\_\ &I<ZS#O5
M0?LZ]#G^)O:N;KIO''_(:A_Z]U_]":N9KT:7P(M;!1116@PHHHH *]?W3_\
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M/@/_ ,S!_P!N_P#[5KV.O*Q/\5G+5^)A7AWQ!_Y'C4?^V7_HM:]QKP[X@_\
M(\:C_P!LO_1:UK@?XC]"8[G,T445ZI84444 %=-\/O\ D>-._P"VO_HMJYFN
MF^'W_(\:=_VU_P#1;5G6_AR]&#V/<:***\(R.!\<?\AJ'_KW7_T)JYFNF\<?
M\AJ'_KW7_P!":N9KT:7P(M;!1116@PHHHH *]DKQNO9*Y<5T)D%<UXX_Y L/
M_7PO_H+5TM<UXX_Y L/_ %\+_P"@M6%+XT);G 4445Z)84444 %%%% 'K&D?
M\@6P_P"O>/\ ]!%7*IZ1_P @6P_Z]X__ $$5<KRY;LS,;Q7_ ,BU=_\  /\
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M([/_ (2*\T3RY_M-I9K>.^T;"C$@ '.<_*>WXUYWI?\ PF__  F?C+_A%O\
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M[1=R>9+)[LV!DU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9ND65AYGF?9H$AW[<;MJ@9QVZ5;JO9:A9:G:K<V%W!=V[?=E@D$B'Z$'%6*
M,'Q5X:_X2:UT^#[7]F^QW\-[N\O?O\LYV]1C/KV]*WJ** .*UWP-J%WXF?7_
M  _XFN-#O+B%8;P+;)<).J_=.UC@,!QGG^>8M%^&-AIVB>(=+O\ 4+G4DUN4
MO/--Q*!@ 9;)RP.6W<#)Z5V<-[:W%S/;PW,,D]N0)HDD!:(D9 8#D9'(S4]
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MN4-E=_$C4GTPC:8X;***X*^GGCYL^^*[B^U&QTNV-SJ%Y;VD ZRW$JQJ/Q)
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MI&M:UXUN=2O-,N1+&AL4BA*<[EV*>&/'SY[=#VO2?#O?Y_\ Q-,>;XA37/\
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MZ$R):YKQQ_R!8?\ KX7_ -!:N@^S0?\ /&/_ +Y%<YXUACCT:$I&BG[0HR%
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MM=%7.^(_^0CI?UD_]EH WX?]4OTI],A_U2_2GT %%%% !1110 4444 %%%%
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M19(/-08*.A;YL[> #WKT:@#S30]"T_QOXM\0:YX@MDOX["_?3;&TN!OAA6,
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M.GV-O96R[8+>-8HUSG"J, ?D* ,#QUXCN_"WA^/4;*U2ZF-W!!Y+_P 8=PI
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M 9&W&>AY/Z5V>L:/?W7Q#\,ZK#!NLK*&[6XEWJ-A=5"\$Y.2#T!H ZJBBB@
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MXX_Y L/_ %\+_P"@M72US7CC_D"P_P#7PO\ Z"U84OC0EN<!1117HEA1110
M4444 >L:1_R!;#_KWC_]!%7*IZ1_R!;#_KWC_P#015RO+ENS,QO%?_(M7?\
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MZPU@+)8U"VH\I9"^3.6SGR\87=Z@C% 'HM%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  .E% Z44 %%%%
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M_P!_C_\ $USUYQG;E);+%%,C,A7]ZJJV>BMN'\A3ZYQ!7.^(_P#D(Z7]9/\
MV6NBKG?$?_(1TOZR?^RT ;\/^J7Z4^F0_P"J7Z4^@ HHJM)J-E#>QV4MY;I=
MRC=' TJB1QZA<Y(X-"5P+-%%% !117F/PZ\=ZIJ>N7^C^(7#/-<7#Z7<;542
MQQR%'BPH'S+@'U()]* /3J*Y/P]KMU<^(_%\&H7:?8M,NHUAWA46&,PJ[9;
MXR2<DT:;\3?!FKZP-*L=?MI;PML5"K*KMTPK, K$]L$Y[4 =9117,Z[\0O"?
MAK4X]-U?6H;:\< ^5M=RH/3<5!"_\"QQS0!TU%9T^O:9;:AIUC+=*)]2#&T
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M8=7B_LNVE,4MS(CQJ'XX&X L>1TSFI/#GC;PYXN$W]A:K%=M",NFUD=1Z[6
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M/% '645Y/JM]XHO]8\4*OVBPO]*LK.\@MK>]>2"4H\CMM.%W*ZC:05'(P0<
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M@ KG?$?_ "$=+^LG_LM=%7.^(_\ D(Z7]9/_ &6@#?A_U2_2GTR'_5+]*?0
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M[MWM[F&.:&0;7CD4,K#T(/!H \UO-5T;Q!\7?#4GAVZM;VZM8+E]0N;0B11
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M;4[*:PC#%[J.=6B4+URX.!COS2Z;K.EZS$\NEZE9WT:-M=[6=90IZX)4G!H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ '2B@=**
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M5#L63);]RYWOEE^]@.>'' SSV5% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<[XC_P"0CI?UD_\ 9:Z*N=\1_P#(1TOZR?\ LM &_#_JE^E/ID/^J7Z4
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"*6X@MUS--'&/5V _G4']K:;_T$+7_ +_+_C3KRQBO%VR#
M(K._X1JS_NB@"_\ VMIO_00M?^_R_P"-']K:;_T$+7_O\O\ C5#_ (1JS_NB
MC_A&K/\ NB@"_P#VMIO_ $$+7_O\O^-']K:;_P!!"U_[_+_C5#_A&K/^Z*/^
M$:L_[HH O_VMIO\ T$+7_O\ +_C1_:VF_P#00M?^_P O^-4/^$:L_P"Z*/\
MA&K/^Z* +_\ :VF_]!"U_P"_R_XT?VMIO_00M?\ O\O^-4/^$:L_[HH_X1JS
M_NB@"_\ VMIO_00M?^_R_P"-']K:;_T$+7_O\O\ C5#_ (1JS_NBC_A&K/\
MNB@"_P#VMIO_ $$+7_O\O^-']K:;_P!!"U_[_+_C5#_A&K/^Z*/^$:L_[HH
MO_VMIO\ T$+7_O\ +_C1_:VF_P#00M?^_P O^-4/^$:L_P"Z*/\ A&K/^Z*
M+_\ :VF_]!"U_P"_R_XT?VMIO_00M?\ O\O^-4/^$:L_[HH_X1JS_NB@"_\
MVMIO_00M?^_R_P"-']K:;_T$+7_O\O\ C5#_ (1JS_NBC_A&K/\ NB@"_P#V
MMIO_ $$+7_O\O^-']K:;_P!!"U_[_+_C5#_A&K/^Z*/^$:L_[HH O_VMIO\
MT$+7_O\ +_C1_:VF_P#00M?^_P O^-4/^$:L_P"Z*/\ A&K/^Z* +_\ :VF_
M]!"U_P"_R_XT?VMIO_00M?\ O\O^-4/^$:L_[HH_X1JS_NB@"_\ VMIO_00M
M?^_R_P"-']K:;_T$+7_O\O\ C5#_ (1JS_NBC_A&K/\ NB@"_P#VMIO_ $$+
M7_O\O^-']K:;_P!!"U_[_+_C5#_A&K/^Z*/^$:L_[HH O_VMIO\ T$+7_O\
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M_P O^-4/^$:L_P"Z*/\ A&K/^Z* +_\ :VF_]!"U_P"_R_XT?VMIO_00M?\
MO\O^-4/^$:L_[HH_X1JS_NB@"_\ VMIO_00M?^_R_P"-']K:;_T$+7_O\O\
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MIO\ T$+7_O\ +_C1_:VF_P#00M?^_P O^-4/^$:L_P"Z*/\ A&K/^Z* +_\
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MZJT>2=K(#M<9)(W XSQ4&@ZV=8CNXI[;[)?V,YM[JW$GF!&P&!5L#<I5E(.
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M?-&I) QG'5CSC/-8^H^([U/$;Z%I.GVEU>Q6@NY!>7IM@R,Q4>7B-R_*G)P
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MQ^%9T7A/389TF2YUDLC!@'UJ\=<@YY4RD$>Q&*W** ,?Q'HTFN6$=LC6.U9
M[QWUJ]Q#(,'AHUD0-R01NR 0#C(!%<:=XE73)X!K&F1S*J?93:Z:T*IM.=K!
MI9 5(&W@ @'(KH** .2NO#-YXDN9;C7XK6U'V">PCAL[AIQMFV[G+M&A!^4
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M;R%_E.&RH7(P>#D"BS"YHT5D6_B"VFMHYY%=/,BC<1K'(\F6W<;0N3]T\C/
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MHNO::T+RB=MB;>L+@L&.%*C&6!/ (R#19C-*BJ5QJMI:PQ2S-*!*NY46!V?
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MFE1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME]X38/FSC&!G&WKWQQ6Q12YF%CGK?PU+;1S".\BCW/&Z)% 5B#(P.XIOQDX
M.W:/:K5[H$=U 8X[B9,EB3+(\W5&7C<W'WL\>E:]%',PLC-FTGSC<9FP)IXI
MON]-FWCKWV_K5%/#DWV=XIKR"8>3' BR6H9-J$D;E+'<3GG&WIQBN@HHYF%C
M C\-R1V]NHOR9;<'RV9&95.]64 ,Q.T;,8W=^HJ<:&QCDWW6Z26&9'81X!:0
M@D@9X QTR?K6Q11S,+(CA1XU*LZLHP%PN"!@=>>><^G]:DHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img101536035_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +^ S0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %#DXR!]*L0?#7Q9X9O+@^$?$<$%I.<F.Z'(],C8P)'K@5U'A7PMK]A#=?\
M"1>(IM2%PC(;<$E%#=3N89^@& *UJ54[M-:^MR4CC+#Q?IB:U>GP+X(>\N6&
MV6Y&57&3SM (4$Y[KG%87P_>Z_X7,YN[:.TN7>X\ZWB^[&VUB5')X!KH]/\
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M6Z4;>744MH7FM+G&"X&>,_+WZ''KFI['X8ZMJNO1:MXTUB/46AQM@A!V'!R
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M<U#PQ!I]_P"5:Z;;%#%*CK'Y?0##$8&<@>^:\\^+-M;Z+X+T'2=)D8Z9YTC
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M5V@YD=Q15+5=5LM$TV;4-0G6"VB&6<_H .Y/I7E]Y\>+..X*V>A33P@X#RW
MC)'K@*W\Z4*4Y_"@;2W/7:*Y3P?X_P!)\8J\=L)+>]C7<]M+C./52.HKG?B/
M\1KG13<Z3H22C4+?8US=&(,D"M@@#(().X#D8Y]>@J4W+DMJ%U:YZ;15#1+B
M6\T#3KF=]\TUK%)(V ,L5!)P..M7ZAJV@PHHHI %%%% !1110 4444 %%%%
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MMY+E8H?)0;0DF%^8+DX'J:[#P"H3P#H@48'V1#^)YKS3P+_R7+7_ /KK>?\
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MW_Q[_P"9?_[>?_:5>O6'_(.M?^N2?R%>0_'O_F7_ /MY_P#:5>O6'_(.M?\
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M36Y*NC95E+]B*TTE.*:TL+9,[KPVWC>*9M9\4:G91Z3]G:=K2.,;X^,C)V\
M#)^\:YFR\8>.?'FIW*^%OLVFV$!QYTZ!OIN)#<GT XKTSQ-I\NJ^%]4L+?\
MUUQ:R1Q\]6*G _$UY5\'_%&EZ'9ZAHVKW$5A<?:#*KW!\L'Y0I4L> 1MZ'U-
M80M*,II*Y3WL:FC>/?$&A>+(O#?C..%GG*K'=Q@+][A2<8!4GC.!COTK'\5_
M\E\TG_KK:_SJKXRNX/'GQ.TNST)S<)"J1O<1_=&'+,P/H >OK5KQ7_R7S2?^
MNMK_ #K6,4G>UFTQ7-WQQXYUVV\86_A?0&MK6>0)NN;@#[S#( W< 8QV))XJ
M)KSXJ^']5M5O(X-=MI3\PMHE  &,@L%7:>>">/K4_C^Z\":AKT>E>($NH-0
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M$48"@= !V%.K!N[N4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M1?NCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PK#P;X
M?TO6Y=9LM.2*_E+EI1(YY8Y;"D[1GV%;M%--K8"&ZM;>^M9+:Z@CG@D&UXY%
M#*P]P:Y8_"[P89O-_L1-V<X\^7;^6[%=?134Y1V8K(KV5C:Z;:1VEE;Q6]O&
M,+'&H4"K%%%2,P]!\(:%X8DGDT>Q^S-. LA\YWW =/O,?6KFLZ'IWB'3S8:I
M;_:+8L'*;V3D=.5(-:%%5S-N]]0L8[>%M&?PW_PCS6>=*P!Y'FOT#;Q\V=WW
MN>M3:9H.EZ/I']E65HJ6/S9A=C(#NZYW$YS6E12YGM<+'(R_"_P9--YK:'&&
MSG"32*O_ 'R& _2NBTW2K#1[-;33K2*V@4YV1K@9]3ZGWJY13<Y/1L5D<Q??
M#OPGJ.H/?W6C1/<2,6=A(ZAB>I*A@"?PK7U;0]+UZV%OJEC#=1*<J)%Y4^H/
M4?A6A11SR[A9'-:9\/\ PKH]VMU9:-"DZ'<KR,\A4^HWDX-:6N>'M+\2626>
MKVOVFW202JGF,F& (!RI!Z,:TZ*'.3=[ZA9%>PL;;3+""QLX_*MH$"1IN+;5
M'09/)K+L/"&A:9KEQK5G8^7J%P7:6;SG.XN<M\I; R?05N44N9]QV,K6O#6C
M>(HECU;3XKH)G:S9#+]&&"/SJKHW@CPWX?N?M.F:5%#/C D9FD8?0L21^%;]
M%/GE:U]!61AZYX/\/^(Y4EU;3(KB51M$FYD;'IN4@D53F^'7A*>PBLGT6$01
M,74([HV2,$E@06_$FNHHH4Y+1,+(PM8\&Z#K]O9P:I8FXCLE*0 SR*5! !Y#
M G[HZYZ5MQHL4:QH,*H"@>@%.HI.3:LQA7-ZIX \+:S=-<WVC0O,QRSQLT18
M^IV$9/UKI**%)QV86,O1O#FC^'H6BTG3X;4/]XH,LWU8Y)_.K=_I]GJEH]I?
MVT5S;O\ >CE4,#5FBB[;N!REO\-/!UK="XCT.$R Y D=W7_OEF(_2N@U#3;/
M5--FTZ\A$EI,FQXPQ7*^F001^%6Z*;G)ZMBLC-T30=,\.V!LM*MOL]N7,A3S
M&?YC@$Y8D]A52R\':!IVO3:W:V'EZC,SO)-YTAR7.6^4MCDGTK=HHYI:Z[CL
M8&M^"?#GB*Z6ZU72XYYU&WS [HQ';)4C/XU%>> O#-_'91W.EADLD\NW432*
M$7.<<,,\^M=)10IR745D%<_K'@CPUK]P;C4M)AEG/WI%+1LWU*D$_C7044E)
MK5#,K1?#6C>'8V32=/AM=_#,H)9OJQR3^=0W?A#0K[7XM<N+'?J4)5DF\YQ@
MK]WY0VW]*VZ*?-*][A8RM:\-:-XA1%U;3X;K9]UF!#+[!A@C\ZS-.^'7A+2[
MI+FTT6$3(=RM([R[3Z@.2*ZBBA3DE9,5D%9NMZ#IGB*P%EJMM]HMPXD">8R?
M,,@'*D'N:TJ*2;3NAE73M.M=)T^"PL8O*MH%VQIN+;1]22:RM<\$^'?$EVEU
MJVFK<3HFP2"5T.WK@[2,_C6_10I-.Z86,Z^T'2]3TQ-.OK*.YM8U"HDV6*X&
M 0QYS[YS6+:?#7P?8W*W$.APF13D>;(\@S_NLQ'Z5U=%-3DM$Q61!=V5K?VC
MVEW;QSV\@VM'(H*D?2N9A^&7@V"Y%PFAQ%P<X>61E_[Y+$?I76T4*4ELPL1M
M!"]N;=XHV@*[#&5!4KTQCICVKE9/AAX,EG,S:'$&)SA9I%7_ +Y#8_2NNHH4
MI1V86,U_#^E2:&^B_88DTYTV-!%E 1_P'!_&C1-!TSP[8&RTJV^SVY<R%/,9
M_F. 3EB3V%:5%+F=K7&86N>#M \274-SJVG+<S0KL1C(ZX&<X.TC(SZUN !0
M   !P *6BAMM68&)H_A#0M!U"XO],L?(N;@%97\YVW G)X9B!SZ4EAX0T+3-
M<N-:L['R]0N"[2S><YW%SEOE+8&3Z"MRBGSR[BLC"U[P=H'B:>*?5[#[3)"I
M1#YTB8&<_P +"L7XDZCJ.GZ7$8M!M]8TN3<MY"ZL63IM88Z#KSC@@5V]%.,V
MFKZV!H^=[KQ%X._L.[L_#_A2ZM]9NXC"2[&7RL\-M)8GID< 5ZG\+- O/#W@
MQ(;^(PW-S,UPT3?>3(  /H<*#CW]:[6BM)UN:/*E^-Q*-@KGM7\"^&==N6N=
M1TB&6=OO2*S1LWU*D9_&NAHK%2:U3*,#1_!/AO09Q/INDP13#[LK%I&7Z%B2
M/PK>90RE6 ((P0>]+10Y-ZL#E;WX:^#[^=II]#A#L<GRG>(?DC 5KZ1X>TC0
M(FCTK3X+4-]XHOS-]6/)_$UIT4W.35FQ60C*&4JP!!&"#WKE;OX:^#[VY-Q-
MH<(D)R?*D>-<_P"ZK ?I75T4*4H[,=BGIFDZ?HUF+33;2*U@!SLC7&3ZGU/N
M:N445+=]P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $7[
MH^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1?NCZ4M(OW1]*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!%^Z/I2TB_='TI: "BBB@ HHHH *
M*** "BJ.KZSIV@Z=+J&J7D5K:Q#+22-C\!ZGV'-9?@KQ;#XUT ZQ;6SV\!N)
M(HU=LLRJ<!CQP2.<<X]30!T5%<%<_$+4I[S4?^$>\*7.LZ=ILK0W5XETD677
M[ZQ(03)CVQGMGBM>7QWHL?@1/%PDD?3Y(@\:JN9'8G:(P/[V[Y<>N: .FHKA
MK/Q[J<.KZ=9>)?"T^BQ:G)Y-G<F[2=6D(RJ/M V,>PYY^AKN: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?FO\ C1YK_P#/O)^:_P"-2T4
M1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (U+
M10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_ ,^\GYK_ (T>:_\ S[R?FO\
MC4M% $7FO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?FO\ C1YK_P#/O)^:
M_P"-2T4 1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/O)^:_P"-'FO_ ,^\
MGYK_ (U+10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_ ,^\GYK_ (T>:_\
MS[R?FO\ C4M% $7FO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?FO\ C1YK
M_P#/O)^:_P"-2T4 1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/O)^:_P"-
M'FO_ ,^\GYK_ (U+10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_ ,^\GYK_
M (T>:_\ S[R?FO\ C4M% $7FO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?
MFO\ C1YK_P#/O)^:_P"-2T4 1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/
MO)^:_P"-'FO_ ,^\GYK_ (U+10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_
M ,^\GYK_ (T>:_\ S[R?FO\ C4M% $7FO_S[R?FO^-'FO_S[R?FO^-2T4 1>
M:_\ S[R?FO\ C1YK_P#/O)^:_P"-2T4 1>:__/O)^:_XT>:__/O)^:_XU+10
M!%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (U+10!%YK_\^\GYK_C2K(S, 874>I(_
MQJ2B@ HHHH **** "BBB@ HHHH 1?NCZ4M(OW1]*6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K,E\0Z5!,\4EUM=&*L/+8X(X/:M.O
M,=5_Y"][_P!=Y/\ T(T >@6>L6&H3&*UG\QPNXC8PXZ=Q[UP_CWXCW7@KQ;H
MMHUG%-I%Q&TM]*$9I(4#!=X(.,#()R#GI5[P;_R%Y?\ K@?_ $):I^([.WU'
MXP:)97<2RVT^C7<<L;#(920"* .D\7:_+HG@?4=>T[R)W@MO/A+Y:-^F#P1D
M8/8UHV^I1#1+?4;Z:&W1X$ED=V"(N0">2>!S7C&K7MQX5\'>*OA[JLK.L%B]
MQHUS(>9[;/W/]Y.1] >,"NK\5/X>.F^#X]:M=0U2Y51+9Z19QB473"( ET/!
M50<\D=^HR* .\TW7-(UD.=+U6QO@GWS:W"2[?KM)Q7-Z#\0]+UGQ/KVEM?:;
M'#IQ06\BW2DSKL+2..<87&#CI@Y-<1;2M'\:O"<L/A)O#:W<%W'("T0-T@B+
M#<D?W=I ZGGCTJWI^F6$.L?%5XK&V1X(@(66)08PULVX+QQGOCK0!ZK_ &E8
M?V;_ &E]MMOL'E^;]J\U?*V8SNWYQC'?.*CDUK2HHK:634[-([J,RV[M.H$R
M!=Y9#GY@%^;([<]*\^_YMM_[E[_VE6+>Z;:ZO9?!VQO8EEMI+9?,C;D.!:HV
MTCN#C!'<4 >MQ:UI4^FG4H=3LI+ 9S=).IB'_ P<?K2:;KFD:R'.EZK8WP3[
MYM;A)=OUVDXKBO'%IX2TZ70+.\TJYNF6YEFL]#TRV1DNI-OS,\> "%SNR2.I
MSGD5S-M*T?QJ\)RP^$F\-K=P7<<@+1 W2"(L-R1_=VD#J>>/2@#T/PEXCO->
MO_$<%U' BZ9JDEG"8E(+(H!!;).3SVQ]*B\7^)[W0-8\,6=K%;O'JNHBUG,J
ML2J$=5P1@_7-9OPW_P"0OXX_[&";_P!!6LWXNP7=UJG@J"QO?L5W)JX6*Y\H
M2>4VWAMIX;'H: /0M;O9--T'4;Z%4:6VM99D#@E2RJ2,X[<5S&F^*-4U/P+X
M>UL3Z+9W6H2PB<7CM'$58D,L7.?,./E!)K#\0>%O'L/AO5);CXD?:($LY6DA
M_L.!/,4(<KN!R,CC/:L.;_DC'P^_["EA_P"AM0!Z]J.NZ1HYC&J:K8V)D^X+
MJX2+=]-Q&:H>*/%%IX<\)7FNF:VD2.$O;AY@JSO@E55NY..,9KA_$'A_5]*\
M<:OKS^$K3Q7INHQQ*%=T\^T55VE55P05)YPOXU40>';OX'^)[?2+:\2"S%T6
MLM3C'F64V"Q0#'R@9XQSSUSF@#T?0O$EAJ_A>VUHW]EY1@1[F2.93'"^T%E)
MSQ@GH3D5<TW6=+UF-I-+U*SOHT.&:UG64*?<J37E,FE6.IZQ\.O#=Q;1)H\N
MGMJ$]JB!8[J98EQO &&QU.>N3FM;Q-I=CX6^(?@[4=#LXK*:_NGL;N*U01I/
M$5_B4<':><_3T% '=R>(]#AE$4NLZ<DAF-OL:Z0'S1C,>,_>&1QUY%6[*_L]
M2M_/L;N"ZAW%/,@D#KN!P1D'&0:\V\!>'M)U#Q7XVU"^L+:ZN$UR2.-IX@_E
M@;6RN>AR0<C^Z/2H;;5X_AWK?CVRDPMN(?[=L8R?O&0;74>WF!0/K0!Z?:7]
MG?K*UG=P7 AE:&4PR!]DB_>5L=&'<'D58KF?A]H;^'_!&FV<^3>/']HNF;EF
MFD.]\GN<G'X5TU '/7&OW$GC>U\/:?'$XCMS=ZC*X)\J,Y6-%P1\[-SSG"J>
M.15ZY\2:%9Q22W6M:=!'%,8)'END4)* "4))X8 CCKR*Y3X?G[5XJ\=ZA+S.
MVKBUW?\ 3.*,!!^IK)\#>&M'U;Q1XXO=2T^WO9%UF:!!<QB147 )VAL@$Y&3
MU.!0!ZA#/%<PI-!*DL3C*NC!E8>H(ZU)7COAFTTQ/AYXTTC4-(O]6T>Q\17%
MM%IUBK/,8UDC*J@5E/#'<<$< U@_V+\//^B1>.?_  $N/_CU 'J/B;Q-J]OX
MAL?#7ANQMI]5N8&NI)KTL(+>%3MW-MY8D\  ^GK2>%?%.J7GB#4O#7B&TM(-
M7L8DG\RR=C#/$W\2AOF4@X!!]:T+"2TE\.VNCZ/<G2+O^S8VMK:<*US9Q[0J
MEXF).5X!W9&1@DUQ?A."\\)_%+4-'UJ\75;S5K,7J:JX*2;(R5\IER54#DC;
MC^6 "U'XR\9ZU87NOZ!I.DC0K5Y!%'?/(MQ=K&2&9"/E3)! # \BMV3Q=<7W
MP[A\6:):+,#"MT]K*"6,:G]ZBD$?. &P>1D=.:B\7Z-J7C;00OASQ6EG:2QN
MC?9T65+GG&#(#E1PRG:>YSG&*7X9:I;ZW\/; I816:0*UF]M&2R*8SM.">2#
MC/))YZGK0!U&GW]MJFG6U_9R"2VN8EEB<=U89%6:X+X/LZ^ 4LV8LEE>7-M&
M3UV+*V/YUWM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 B_='TI:1?NCZ4M !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !69+X>TJ>9Y9+7<[L68^8PR3R>]:=%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &I:* (ML_P#STC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &I:* (ML_P#STC_[]G_&E42AAN="/0(1_6I*
M* "BBB@ HHHH **** "BBB@!%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $7[H^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/'/CQ_S+_P#V\?\ M*O&Z]D^/'_,O_\ ;Q_[2KQNO5PW\)'72^%!1116Y844
M44 %%%% !1110 5]7>$?^1+T+_L'6_\ Z+6OE&OJ[PC_ ,B7H7_8.M__ $6M
M<6,^%&-;9&S1117 <X4444 %%%% !1110 4444 (OW1]*6D7[H^E+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >.?'C_F7_P#MX_\ :5>-U[)\>/\ F7_^
MWC_VE7C=>KAOX2.NE\*"BBBMRPHHHH **** "BBB@ KZN\(_\B7H7_8.M_\
MT6M?*-?5WA'_ )$O0O\ L'6__HM:XL9\*,:VR-FBBBN YPHHHH **** "BBB
M@ HHHH 1?NCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \<^/
M'_,O_P#;Q_[2KQNO9/CQ_P R_P#]O'_M*O&Z]7#?PD==+X4%%%%;EA1110 4
M444 %%%% !7U=X1_Y$O0O^P=;_\ HM:^4:^KO"/_ ")>A?\ 8.M__1:UQ8SX
M48UMD;-%%%<!SA1110 4444 %%%% !1110 B_='TI:1?NCZ4M !7"Z_\4+/P
M]JEW8S^&O$MR+7[]S:V(>$C:#D,7' SS]#7=5S'Q!TB_USP3?V.F!7NSLD2%
MFPLP1U8QD^C $?C0!SL?QDL9;#[?'X/\8/9[=_VA=,4Q[?7=OQCWKK/"/BJT
M\9:"FL6-I>VUM([(@NXPC/C^(8)!7.1G/4&N87XL6T<0MY/"7B>/40-OV)=/
M).[T#9P5]_3M6O\ #O1]0T?PU+_:<"6MS>WL]Z;2-LK;"1MPC!]O;UH ZVBB
MB@ HHHH **\#L-4\"^)K.3Q!X[U5Y;W4)Y6L[<23$6$"N43"QY"'*YW-C/YY
MZG7KG4="^%^C:58^(WU.XU:^@TVVU9  YCE8D$$$Y(0;=V??K0!ZG17DWB3P
MQI?PU_L?Q'X=\ZS,=_#;W\;7#LMW#(=K%PQ(W G(/_UJ]9H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,\0:Y;>&]#N-6O$F>WM]NY
M80"QW,%& 2!U8=Z:3;L@W-.BO-/^%W^&O^?'5O\ OU'_ /'*/^%W^&O^?'5O
M^_4?_P <K3V%3L7[.78]+HKS3_A=_AK_ )\=6_[]1_\ QRC_ (7?X:_Y\=6_
M[]1__'*/85.P>SEV/2Z*\T_X7?X:_P"?'5O^_4?_ ,<H_P"%W^&O^?'5O^_4
M?_QRCV%3L'LY=CTNBO-/^%W^&O\ GQU;_OU'_P#'*/\ A=_AK_GQU;_OU'_\
M<H]A4[![.78]+HKS3_A=_AK_ )\=6_[]1_\ QRC_ (7?X:_Y\=6_[]1__'*/
M85.P>SEV/2Z*P_"OBJQ\7Z7+J&GQ7$44<QA(N%56W!5;L3QAA6Y6;33LR6K!
M1112$%%%% !1110 4444 %%%% !1110 4444 >.?'C_F7_\ MX_]I5XW7LGQ
MX_YE_P#[>/\ VE7C=>KAOX2.NE\*"BBBMRPHHHH **** "BBB@ KZN\(_P#(
MEZ%_V#K?_P!%K7RC7U=X1_Y$O0O^P=;_ /HM:XL9\*,:VR-FBBBN YPHHHH
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MB@ HHHH **** "BBB@ HHHH **** /'/CQ_S+_\ V\?^TJ\;KV3X\?\ ,O\
M_;Q_[2KQNO5PW\)'72^%!1116Y84444 %%%% !1110 5]7>$?^1+T+_L'6__
M *+6OE&OJ[PC_P B7H7_ &#K?_T6M<6,^%&-;9&S1117 <X4444 %%%% !11
M10 4444 (OW1]*6D7[H^E+0 5@^,O#\GB?PO=:9!<"WN69);>9AD)(CAU)'<
M97!]C6]7(?$^_O--^'VI7%E/);.3%')<1CYH8VD57<8YR%)^G7M0!C:'I&OQ
M:]KOB?6;K1)O$0T\6MI9VTK>5 BY;YRW(#-@GTS^ Z3P1X>N_#F@R0ZC/'/J
M-W=2WMX\0(3S9&W$+GG X'X5PVB^%O#&F_$*^TNPAB_L6\\+*\[^>6$P>=@S
ME\]U Y!KI/A-.\O@V2);F2ZL;:_N;?3[B1MQEMED(0Y[]Q^% '<T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7&_%7_DFNK?]L?\ T<E72^./J5'XD?-5%%%>R=@4444 %%%% !1110 4444
M>^?!#_D2[S_L(O\ ^BXZ]+KS3X(?\B7>?]A%_P#T7'7I=>17_B,Y*GQ,****
MR("BBB@ HHHH **** "BBB@ HHHH **** /'/CQ_S+__ &\?^TJ\;KV3X\?\
MR_\ ]O'_ +2KQNO5PW\)'72^%!1116Y84444 %%%% !1110 5]7>$?\ D2]"
M_P"P=;_^BUKY1KZN\(_\B7H7_8.M_P#T6M<6,^%&-;9&S1117 <X4444 %%%
M% !1110 4444 (OW1]*6D7[H^E+0 5P^M_"3P=XAUBYU74M/EEO+@AI'%S(H
M)  ' .!P!7<4@96SM(.#@X/0T ><_P#"BO '_0*G_P# N7_XJNO\->%]*\(Z
M4=-T:!H;4R&7:TC.=Q !Y)SV%8^H^+]7;6KW3?#GAA]7-@RI=S27J6R([*&"
M+N!+':03P ,UL>&]?3Q%ICW0M9K2>&9[:YMIB"T,J'#+D<'L01U!% &Q1110
M 4444 4-9UK3O#^E3:GJMTEK9P@&25@3C)P  ,DG/8<U,^H6D>FG49+A([,1
M><9I#M4)C.XYZ#'K7CWQ#E;QSH/B'4E9O^$>T*&1+3' N[L?*TF>Z("5'8DD
M]JV_B!FX\"^$-*)/V?5=4T^RN!G[T;#<0?Q44 =3H?Q"\*^(]0^P:5K$4]T0
M66)HWC+@9R5W@;AP>F>E=-7G7Q;2'3O#^CZQ#&([K2]4MGMW0 %%+;64?[)'
M!'3@5Z+0 444UY$C +NJ@^IQ0 ZBHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3
M!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\ /:/_ +Z%'VF#_GM'_P!]"@"6BHOM
M,'_/:/\ [Z%'VF#_ )[1_P#?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^
MTP?\]H_^^A1]I@_Y[1_]]"@"6OE'_A+O$O\ T,.K?^!LG_Q5?5/VF#_GM'_W
MT*^/:[<&D^:YO16YL_\ "7>)?^AAU;_P-D_^*H_X2[Q+_P!##JW_ (&R?_%5
MC45V\L>QM9&S_P )=XE_Z&'5O_ V3_XJC_A+O$O_ $,.K?\ @;)_\56-11RQ
M[!9&S_PEWB7_ *&'5O\ P-D_^*H_X2[Q+_T,.K?^!LG_ ,56-11RQ[!9&S_P
MEWB7_H8=6_\  V3_ .*H_P"$N\2_]##JW_@;)_\ %5C44<L>P61L_P#"7>)?
M^AAU;_P-D_\ BJ]!^#VNZOJ?BZ[AU#5;Z[B6P=PEQ</(H;S(QG!)YP3^=>2U
MZ3\$W2/QG>%V"C^SW&2<?\M(ZRK12IO0F:7*SWZBHOM,'_/:/_OH4?:8/^>T
M?_?0KRCD):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?
M_?0H EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\
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M %%%% !1110 4444 %%%% !1110 5\<5]CU\<5W8/[7R-Z/4****[C<****
M"BBB@ HHHH *]+^"'_(Z7G_8.?\ ]&1UYI7I?P0_Y'2\_P"P<_\ Z,CK&O\
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M^1TO/^P<_P#Z,CK&O_#9-3X6>^4445Y)QA1110 4444 %%%% !1110 4444
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MOJ[PC_R)>A?]@ZW_ /1:UQ8SX48UMD;-%%%<!SA1110 4444 %%%% !1110
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M/-?_ )X2?FO^- $M?'%?87FO_P \)/S7_&OCVN[!_:^1O1ZA1117<;A1110
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M_P#GC=?]\K_\50!T5%<[_P )EI__ #QNO^^5_P#BJ/\ A,M/_P">-U_WRO\
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MDGFV=NUHD*B0#"O(03O8#H>.>>YKNJ** "BBB@ HHHH **** "BBB@ HHHH
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M)O\ D7KK_@'_ *&*UJR?$W_(O77_  #_ -#% 'GE%%% !1110 4444 %%%%
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M_P"8;_VU_P#9*XBNW^(7_,-_[:_^R5Q%>KAOX2.NE\*"BBBMRPHHHH ****
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M[_+_ (T 6Z*J?VKIW_/_ &O_ '^7_&C^U=._Y_[7_O\ +_C0!;HJI_:NG?\
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M7%C/A1C6V1LT445P'.%%%% !1110 4444 %%%% "+]T?2EI%^Z/I2T %%%%
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M?*?_ ,"7_P :/KD.S#VT3YRHKZ-_X5%X/_Y\I_\ P)?_ !H_X5%X/_Y\I_\
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MMN<#=Y>S?TSC./>@#4HJAH>K0Z]H=EJUO%-%!>0K-&DX <*PR,@$CISUJ_0
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MK3,F_A949E&W#8R!QSTKL-?\)^([W1?#FH1ZA;WGBG0Y1.9)%$<5R6&)(_E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6XM[]DTJ[AG>QDA1[O4#*S,P^XHWL-N0.21VX].@T^)X--M89%VO'"BL/0@
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img101536035_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVMWJ-Q:)?RNZF*-@O1B!A2<]!7)^+/AT-9\=OJG_  D=K;+*\;/%(V)8]H4
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MMK@K]X0RJ^/K@T68%JBBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^0WJW_7LG_H5>YUX9\"/^0WJW_7LG_H5>YUABOXK*AL>3?'?_D"Z1_U\/\
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M.&Y\'_%=M5: M&UTM]%SQ(I.6&?KN%;-)UO.V@OLG9Z5\$XM/U/3[R76I9!
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M &M\!=,G1<S6$*W"X'.T$AOPP2?^ UJ_![78V\!W4-Q)@:7(Y;VC(WY_/?\
ME71>!+>*[^&NE6\RAXI;0QNI[J<@BO"X=0N/!LGBS079@UQ$;0<?>(D S]"A
M?\Q1%>T4H>8;69TGPIM)/$?Q$OM?N5R(/,N"3R!)(2 /R+?E5'6+[4OB9\15
MTA+IH;(3O' F<I&B Y?'=B 3^(%>C_!W1O[,\$K>2+B;4)3,<]=@^51^A/\
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MYO*?45,,SY( C!W,21T''/KT[U]4U\[?"#_DHZ_]<9J>'=H382W1WND^ /\
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MV<UI<QB2">-HY$)QN4C!'Y&L+2O ?AG19)WL-*1/M$1BE625Y5=,@X*NQ!Y
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MJ5Y)J&W]Q&N\@G_:W*,#\0?K78_!S1;IO"&IKJ44G]GZ@VV*)R5WH5*NPQR
M<@9]J[*S\ ^%+&59(-"L]ZG(,B^9@_\  LUT8    P!T JYU[QY5?YB4=;F%
MH/@[0?#,\TVD6'V:290CGSI'R <_Q,:BU/P)X;UC5SJM_IOG7I*GS?/D7[N
M. P'8=JZ*BL.>5[WU*L@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0\Q_[[?G1
MYC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T
M5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-
M'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OS
MJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM
M^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]
M30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=
M_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_W
MV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?
M^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_
MW?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$
M?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F
M/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4
M\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>
M1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K
M?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WY
MT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U-
M %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]
M31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;
M\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[
M[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=
M_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_
MW?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_
M]]OSJWY$?]W]31Y$?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S
M'_OM^='F/_?;\ZM^1'_=_4T>1'_=_4T 5/,?^^WYT>8_]]OSJWY$?]W]31Y$
M?]W]30!4\Q_[[?G1YC_WV_.K?D1_W?U-'D1_W?U- %3S'_OM^='F/_?;\ZM^
M1'_=_4T>1'_=_4T -MR6C)))Y[U-3514&%&!3J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHK USQKX>\-WJ6>K:A]GN'C$JIY,CY4D@'*J1U4TU%MV0TF]C?HKC?^%J^
M"O\ H-?^2LW_ ,11_P +5\%?]!K_ ,E9O_B*KV4_Y6/EEV.RHKC?^%J^"O\
MH-?^2LW_ ,11_P +5\%?]!K_ ,E9O_B*/93_ )6'++L=E17&_P#"U?!7_0:_
M\E9O_B*/^%J^"O\ H-?^2LW_ ,11[*?\K#EEV.RHKC?^%J^"O^@U_P"2LW_Q
M%'_"U?!7_0:_\E9O_B*/93_E8<LNQV5%<;_PM7P5_P!!K_R5F_\ B*/^%J^"
MO^@U_P"2LW_Q%'LI_P K#EEV.RHKC?\ A:O@K_H-?^2LW_Q%'_"U?!7_ $&O
M_)6;_P"(H]E/^5ARR['945QO_"U?!7_0:_\ )6;_ .(H_P"%J^"O^@U_Y*S?
M_$4>RG_*PY9=CLJ*XW_A:O@K_H-?^2LW_P 11_PM7P5_T&O_ "5F_P#B*/93
M_E8<LNQV5%<;_P +5\%?]!K_ ,E9O_B*/^%J^"O^@U_Y*S?_ !%'LI_RL.67
M8[*BN-_X6KX*_P"@U_Y*S?\ Q%'_  M7P5_T&O\ R5F_^(H]E/\ E8<LNQV5
M%<;_ ,+5\%?]!K_R5F_^(H_X6KX*_P"@U_Y*S?\ Q%'LI_RL.678[*BN-_X6
MKX*_Z#7_ )*S?_$4?\+5\%?]!K_R5F_^(H]E/^5ARR['945QO_"U?!7_ $&O
M_)6;_P"(H_X6KX*_Z#7_ )*S?_$4>RG_ "L.678[*BN-_P"%J^"O^@U_Y*S?
M_$4?\+5\%?\ 0:_\E9O_ (BCV4_Y6'++L=E17&_\+5\%?]!K_P E9O\ XBC_
M (6KX*_Z#7_DK-_\11[*?\K#EEV.RHKC?^%J^"O^@U_Y*S?_ !%'_"U?!7_0
M:_\ )6;_ .(H]E/^5ARR['945QO_  M7P5_T&O\ R5F_^(H_X6KX*_Z#7_DK
M-_\ $4>RG_*PY9=CLJ*XW_A:O@K_ *#7_DK-_P#$4?\ "U?!7_0:_P#)6;_X
MBCV4_P"5ARR['945QO\ PM7P5_T&O_)6;_XBC_A:O@K_ *#7_DK-_P#$4>RG
M_*PY9=CLJ*XW_A:O@K_H-?\ DK-_\11_PM7P5_T&O_)6;_XBCV4_Y6'++L=E
M17&_\+5\%?\ 0:_\E9O_ (BC_A:O@K_H-?\ DK-_\11[*?\ *PY9=CLJ*XW_
M (6KX*_Z#7_DK-_\11_PM7P5_P!!K_R5F_\ B*/93_E8<LNQV5%<;_PM7P5_
MT&O_ "5F_P#B*/\ A:O@K_H-?^2LW_Q%'LI_RL.678[*BN-_X6KX*_Z#7_DK
M-_\ $4?\+5\%?]!K_P E9O\ XBCV4_Y6'++L=E17&_\ "U?!7_0:_P#)6;_X
MBC_A:O@K_H-?^2LW_P 11[*?\K#EEV.RHKC?^%J^"O\ H-?^2LW_ ,11_P +
M5\%?]!K_ ,E9O_B*/93_ )6'++L=E17&_P#"U?!7_0:_\E9O_B*/^%J^"O\
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5[Y\$/^1+O/\ L(O_ .BXZ\#KWSX(?\B7>?\ 81?_ -%Q
MUS8K^&9U?A/2Z***\PY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNFFFH),TBK)(****L84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>^?!#_D2[S_L(O\ ^BXZ\#KWSX(?
M\B7>?]A%_P#T7'7-BOX9G5^$]+HHHKS#E"BBB@ HHHH **** "BBB@ HHHH
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M0_\ Q-9/_"T=$_Y]=0_[]I_\71_PM'1/^?74/^_:?_%T>SEV#F1K?\()X/\
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MZNY1N$:]  !U)/057,N7FZ!=6N85%=)KGA,:?#87FE:@FK:??N8H)XXC&WF
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M445YARA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:WD=Y'%!.//C^ZYWC)7U&<@'OBJ'CUE@?0M+/^OL-+ACG']UV&XK^ (K-O\
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M+N.[,;_A$?#7_0O:3_X!1_\ Q-'_  B/AK_H7M)_\ H__B:V:*.:7<+LQO\
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M+VD_^ 4?_P 31_PB/AK_ *%[2?\ P"C_ /B:V:*.:7<+LQO^$1\-?]"]I/\
MX!1__$T?\(CX:_Z%[2?_  "C_P#B:V:*.:7<+LQO^$1\-?\ 0O:3_P" 4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/M2ZGJL%[I=C:QI('MU <L!@\ <<T :_BNYV2V\'D0MYB@^8R9=>>Q[53\8
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M@ HHHH **** "BBB@ KN/!O_ "")?^NY_P#05KAZ[CP;_P @B7_KN?\ T%:
M.AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?QE_P A
M>+_K@/\ T)J[BN'\9?\ (7B_ZX#_ -":@#GJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN/!O_ "")?^NY_P#0
M5KAZ[CP;_P @B7_KN?\ T%: .AHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y7Q+H]_J&HQRVL'F((0I.]1SDGN?>NJHH \\_P"$9UC_
M )]/_(B?XT?\(SK'_/I_Y$3_ !KT.B@#SS_A&=8_Y]/_ "(G^-'_  C.L?\
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M  C.L?\ /I_Y$3_&O0Z* ///^$9UC_GT_P#(B?XT?\(SK'_/I_Y$3_&O0Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJK?7T=C#O;ES]U?4U@6^KW$5V9I&
M+JY^9.V/:J46Q7.IHID,T<\2R1L&5NAI]2,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,W_/T_\ WRO^%'DS?\_3_P#?*_X4 3T5!Y,W_/T__?*_X4>3-_S]/_WRO^%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9:K\3P,5EE15+X=V3W7;_@&'X(\$&_:/5=5C/V;[T,+#_6_[3?[/\_IU]5
M  & *    !@"BN"O7E6ES2/6PN%AAH<L?F^X4445@=(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2.BNA1P&4C!![TM% '.ZE!>6+;XKB?[.>!B0_+[5DO
M(\CEY'9F/4L<FNV=%D0HZAE88(/>LRWT.*&[,K-OC!RB'M]:M2[DM$.E:8S!
M+BZR0H_=1L>GO6W114MW*"BBBD 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFSX.B$LKPZUK5NLDC2&.&Z"
M("QR< +[UTE%--K85C'A\.Q1VL,$M_?W7E7*W*O<3!VW+T7./N^U7'TR"34S
M?/N:0VYMRAQM*DYZ8ZU<HHNPL<RW@?370Q&ZU P*08H6N-R0D'/R @X].<\$
MUT%W:07UI+:W,8DAE4JZGN*FHH<FPLC!LO"=G:7D-P]W?W9@.8([JX+I$?\
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M<    5<T;XE>#O$&J_V9IFN037AR%C*.F\CLI90&/T)H ZNBBO/=4\=+X?\
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MJ6T>J&-!$>$0E ZC'8 L,>@KOO%FD^'X?@K>V\4%LNFPZ89;5@JX#[,HP/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 457BOK
M.>\N+2&Z@DN;?;Y\*2 O%N&5W*.5R.1GK4=[JVFZ;+;Q7VH6EK)<OL@2>94,
MK<<*"?F/(X'K0!<HHHH **** "BBHYYXK:"2>XE2*&)2\DDC!510,DDG@ #O
M0!)15(ZQI@BLY3J-GY=Z0MJWGKB<D9 0Y^8D>F:NT %%-=UC1G=@J*,LS'
M]35)=<TE[>TN%U2R,%XXCMI!<)MG<YPJ'.&/!X'I0!?HHJNM_9/?O8+=P&\C
MC$KVXD'F*AX#%<Y ]Z +%%9XU_1CIJZD-6L/L#/L6Z^TIY1;.,!\XSGC&>M6
MFNK=+J.U>>);B12R1%QN8#J0.I H FHHHH **** "BH;JZM[&UDNKN>*WMXE
MW22RN$1!ZDG@"FF_LPMLQNX-MT0(#Y@Q+D9&W^]QSQ0!8HHHH **:[K&C.[!
M4499F. !ZFHK.\M=0M([NRN8;FVD&4FAD#HPZ<,.#0!/1110 4444 %%%% !
M14,UU;V[Q)-/%&\S;(E=P"[=< =S35O[-[][!;N!KU$$CVXD!D5"<!BN<@>]
M %BBBB@ HHJ%KJW2ZCM7GB6XD4LD1<;F ZD#J0* )J*** "BBB@ HJO)?V<5
M]#8R7<"7<REHH&D DD ZE5SD@=\4Z.[MII)HXKB)W@.V55<$QG&<-Z''K0!-
M15>RO[/4K1+NPNX+JV?.R:"0.C8.#AAP>015B@ HHI"0 23@#J30 M%5[*_L
M]2M$N["[@NK9\[)H) Z-@X.&'!Y!%!O[(:@-/-W +TQ^:+;S!YA3.-VW.=N>
M,]* +%%5-0U33])M_M&I7UM9P9QYES,L:Y],L0*-/U33M7M_M&FW]K>P9V^9
M;3+(N?3*DB@"W116?J&NZ/I$L46I:K8V4DW^K2YN$C+_ $#$9_"@#0HHJO>W
MUIIMH]W?74%K;1XWS3R!$7)P,L>!R0* +%%5I=1L8+FVMYKRWCGNL_9XGE4-
M-@9.P$Y; YXJS0 4444 %%-=UC1G=@J*,LS'  ]345G>6NH6D=W97,-S;2#*
M30R!T8=.&'!H GHHHH **** "BBJYO[(:@-/-W +TQ^:+;S!YA3.-VW.=N>,
M]* +%%5[6_LKYIUM+N"X-O(8IA#('\MQU5L'AAZ'FK% !1110 4444 %%%%
M!115>WO[.[N+BWMKN"::V8+/''(&:(D9 8 Y4X]: +%%%% !15>TO[*_\[['
M=P7/D2&&7R9 _EN.JM@\,/0\T3W]E;75O:SW<$5Q<EA!%)(%>4@9.T$Y; ZX
MH L45!=WEK86SW-Y<PVUN@R\LSA%7ZD\"J^FZYI.LJ[:5JEE?"/AS:W"2[?K
MM)Q0!?HK$N?&/A>RN9+:Z\2:/!<1,5DBEOHE9".H(+9!HMO&/A>]N8[:U\2:
M//<2L%CBBOHF9R>@ #9)H VZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KDY/B+X?B\6KX;:6;[69!%YHC_ '0D
M/1,YSG/'3'O765R<GPZ\/R^+5\2-%-]K$@E\H2?NC(.CXQG.>>N/:KAR:\PG
M?H=91114#/&K_P ;Z;X'^(?CZ]O,S7,B6(M;1/OS,(6)^BCJ6[#W(!Z'P!H
MUC[/X[UV\AU36+V+?;&/_4V,1Z1QCLPY!)YSD>I,?AS3K.Y^-7C>\GMHY+B"
M&RCBD=<E%>$[@/KM%9UI*?A-XT73)FV^#]<F)M')^6PN3U0GLK?_ %^S&@#<
MOO%'BK6?$.HZ5X,L=*,6F.(KJ^U5Y/+:4C)C18^<@$9)_P ,Q+XYUN;PEXAD
M&EV]OXFT''VJT<F2%QC=N0@@X9 Q'.0>N:X'4] \%:#XW\0GXAZ1<""^O&N]
M/U(&<Q.C\F,^4>&!SU'],]Y\,-,T!+;5[K0?"\VE:5=.L<4US/([7R*#\_ER
M9*+\QQZY_"@#3\4>-FTSP':Z[I$<5Q=ZB8(["*7)6224C ."#P,GKVKKH?,\
MF/SBIEVC>4&!NQSCVKQ?PQIUS=^/+'PA<J_V#PC<7%VI/1U<@VW/J%=O^^:]
MKH X*^\4>*M9\0ZCI7@RQTHQ:8XBNK[57D\MI2,F-%CYR 1DG_#,$OBBYU[P
M%XQL-5L5L=:TNRGAO($??&<Q,5=#_=8<X/(K@]3T#P5H/C?Q"?B'I%P(+Z\:
M[T_4@9S$Z/R8SY1X8'/4?TST.AZ?H<'P^\:WWA[PS/H^FW%C*D%Q<7$C->JL
M3_.$<DHN6..><^V* +%CJW]F^$OA?#_9]A=?;);>'?=0[V@_=_?C.?E;WK9U
M+Q7XHU;Q1?Z'X,L=+==,"K>7VJ/)Y7F,,^6H3DD#J?Y<9Y63_D6OA!_U]VW_
M *+K2M?$5E\-?&7B6#Q()K;3M5NA?V=^L#R1N67#1DJ"0P(Z?RXR :/AWQOK
M>L:UXET?6=(M;.72;)&>(9</(0V3G.&1@ 0, X.#FN.US79;CX>_#G6H=)MD
MF.KQR1Z?I\?E1E@9 $09.W) _.MGPYK!U[QYXVU%;.>U@ETF'[.+A-CO&%?#
ME>H!Y(![8KG#>S:=\*_AA>6]M)=2PZJCB",9>3!DRJCN2.GO0!V]QXN\;>%[
MBTO/%NE:-_8ES,D,DVFRR&2S+G"F3?PPR<$K_@#K6FK>9\6M4TK[!8+Y6DQS
M?;%AQ</E\;&?/*CJ!BN2\8>+]-^).CKX1\+I>7E[>SQ"Z8VSQK8QJX9FD+ 8
M(QC SS[X!W-.7;\=]97TT*$?^1* .0T'5O[&^ %A=_V?87W_ !,BGDWT/FQ_
M-<$9VY'(Z@]C6IK'_"6?\+\L/LO]BX_L]O)\WS?^/7S!OW8_Y:9SC'R],US4
M7_)N%A_V%5_]*37:^*M6L_#?QET/5=6=[;3YM,DM$N#$S(93)D+E0<&@#J?#
M?B*[U+7?$.CZE'!'=:9=*(O*4J'MW7=&QR3SU!QQQTIG@?Q+>>*[34]1EB@3
M3UOI8-/:-3NDB0XWL22#DYZ =*Y+XJ7%YX7U:#7],B8RZI92Z/)L'/G,-T#?
M4'<*] \+Z'%X:\,:=H\/*VD"QEO[S=6/XDD_C0!SOB#Q3XAF\5GPQX1LM.EO
M8+=;F\NM1=Q#"K'"IA/F+'K2)XOUZ'P!KVJZGHHL-9TE)@8Y$<P3E%R'0\%D
M/L>W6L;4-7MOA_\ %+6-8UU9H='UNU@\N^2%I$CEB&THVT$@D<CC_P"M9UKQ
M/+XK^%OB^^32Y[/3EM9DLYYR0UTFPYD"$ JOIUS[4 5)_%'BZ]\":GXCU/2-
M _L233#<6UI,LDLDAPN/-7.THPR< Y' ]ZQO%T_BBZ\1?#RXTN+0X5EC#V,<
MBRJJ2F$%PX7I&!C:%Y]:Z;7?^3>Y/^P%'_Z+6L;Q/?0:+:_#+7+_ ,R/3+)5
M-S<+&SB+= H7.T$\F@#J-:\4>(I?$ \->%['3I]4@MEN+ZZO7<6UON^ZN%^8
MDX)'MCWQ)X>\6:O+J.I:!XCL+6UURRMOM2O:.S6]S$<@.F?F&#P0>:\^\7:1
MX5C^(ESXA\8Z7/>>'-7M()+348C-L@=4 PXC(8;@ 1D'^>-OP%I_A)M2U?4/
M!_AF>UTU+)HEU>:XFQ<D\E$CD)R!M'S<<C&* +7A+Q?XT\6Z)#KDNFZ'#H;6
M\HG#^89I756R47)4)N&W#'. 34^B^*]6_P"%9^'KO0_#5O-J&I$Q1VUG"T5I
M:C<V7?&=B#'KR33OAC_R0ZQ_Z\[C_P!">N*AU6]T[X2>!4-]J6FZ%,T@U34-
M-4^= H9M@R 2H))R0.W?H0#MK;Q9XQT/Q9I&C^+K#19(-7=HK>YTIY!Y;J,X
M99.3VZ8Z_A7:0_VW_P )!<>=_9_]B^2OD;-_VCS?XMV?EV]<8YKPM8_#S>/O
M!VI^'_[8O;0Z@(I=8U%Y2L[LIVHGF8)Q@Y( '2O=(=>TR?Q!<:%'<[M2MX5G
ME@\MAM0\ [L;3UZ YH TJ\JT?QOX\\57.L6F@Z7HB-IM_-;O=WQE6)E5L*BJ
MI)+X&2>!R..:]5KQ'P-\0-(\(MXEMO$'VBSMI-<NGM[P6[R1RMNPT>5!PPP#
MSV- '<:%XZNK[0-:EO\ 19TUS16,=UIMKF5I&QE#'CDANWX]1S6%JOB[XD>'
M]$/B75-$T :2@62:QCFE%W$C$#!8_)D9&<#\*H0/XB&A>//&^DZ==VUWJOE#
M3[:6+]^(HAL,NP]R"S <]._?B?$9\+:UX*O7TO4?$_B76(H1++)?23>798P7
M9\@(, $ #=ST]: .V^(5QXDO/'/@FYT?^R?)F=Y-/^U^;GS#'EO-V_P[<8V\
MYZUU-MKH@^)NJV5[9:;"+718[J:^CA(F/S?,I?/*#D@8KG/%VHVVE+\-O$%V
MSKI5H=T]RL;.L8>%0I.T$\U++;IXA^)_B:WM)04U'PLB12= 1(2%/ZB@"W;^
M*_B'K.F_\)%HV@Z,-%8&6"SNYI!>7$0Z,"/D4L.0#^O&9_$/Q,EM?!_AWQ%H
M=BMVFJWD<!MI00_S!LH"" &W+C)R/8UYEI.G_"_3-&CT[Q7X:OX?%5NOE2V0
M-T7NI!P#'L;9ANW0?AS77Z]81Z;X1^'EM%HQT9?^$AM7_L\W#3F#<SM@NW)/
M.3Z9QVH V+CQ?XX\-ZMI+>*-+T4Z5J=VEHITZ60RVSO]W>6X;OG:.Q]JR]8_
MX2S_ (7Y8?9?[%Q_9[>3YOF_\>OF#?NQ_P M,YQCY>F:W/BW_P >'A?_ +&*
MS_\ 9JI^*M6L_#?QET/5=6=[;3YM,DM$N#$S(93)D+E0<&@">3QAXOU[Q%K%
MAX2M=!$&D3&"8:G+)YT[ <E%3[JYR 6X/KUKL?#&KW>N>'[:_O\ 2[C3+M\K
M-:3J0T; D'&0,@XR#Z&O)?&,O@"[\2ZBOC33;WPYK$,W^C:C:&5C=Q@#;(K(
MA7=ZY4XP!GJ!W7PKDUN7PD[ZS+>S)]KE^P27ZXN'MN-ADSSD\]>V.V* +NC^
M*+F;Q+XHTG5%MXAI+1S0O&I7?;NFX,V2<D$$$C K \&?$RYUSPGX@UC6+6"V
METL&=8X@1N@,?F1D@L>2,]_RK*^+OVS1]9M=0TZ/=+KMD^A.5."'=@4;\B]9
M'C71IM.\;6OA6PC<6?B6SL[64IQA;=\.<_\ 7,8_&@#J+#Q)JM[XC\&I?Z9H
M_P#:6IZ5<71G^SMO@;;N548L2JD$;ASGFLSX7_\ "3_\)#XQ_M#^R/LWV^7[
M;]G\W?\ :-H_U>>/+QZ\UN:VBQ_&SP>B*%1=/NPH'0#:*H>"M6L].\<>-- O
M'>#4[S49;NW@>)AYL6P?,&QC''K0!@_#;4?'C?#>R3PSI>C_ &6T:8&34I9-
M]R?,9B(U3 &,XRQY->I>"_$R>+_"=EK2P&!IU(DB)SL=258 ]QD&N>^"_P#R
M2?2?]ZX_]'/3?@G_ ,DOL/\ KO<?^C6H V]<\17FC>,/#UB\<']E:HTMN\I4
M[XYPNZ,9SC#8(QCJ*AO/$E[-\0!X;LH8&LX-.:[OYF5BR%B5C12#@$X).0>*
M/B3ILM]X,N;FU3=>Z8Z:C:\9^>$[^/JH8?C61\,XYM2TC6O%UVA6?7[EYHU;
M[R6Z I$I^@!_,4 <K\,?BCX-\.?#_3M*U;6/L][ TWF1?99GVYE9ARJ$=".]
M:6A^*]%\6_'.&^T.]^UVT6@O$[^4\>&$V<8< ]"*W?@K_P DITC_ 'I__1SU
M'/\ \G!6O_8NM_Z/- &=X$T+3O':WOC/Q':Q:G/>7,L5G!=()(K:W1BJJJ'C
M)P23C^N>BA^'MAI?B^SU[P\\>CJJM'>V=O#B&[0CY1M! 4@\Y _"N9T/7H?A
M2U]H'B6WN;;1A=23:;J:0M+"T;G=Y;[ 2K@D]N?R)T[3QO>^-?$^F0>#_M T
M.WD,NI:E+:E8IE P(8]XSDGJ1@B@#T6O$%TKQ#K7QQU(:C8>%[T6T,!=;N&2
M01VI?*F,$'$V,Y)XSTXKV^O/=(&?CEXE'_4+MOYT 5HO&'C;Q3/>W7@[2=(&
MCVDSP)-JDD@>[93AO+"$!1GCYOSZ@9WC7Q1'XM^!.MW_ -E>TN8I$MKJV<Y,
M,R3(&7/<>_O4'A'QIIOPUTJ?PGXICNK.]L[B4VI6W:1;V-W+*8RHP3SCG';W
M S=4T[4+3X$>+=0U*T>SGU?43J MI!AHD>:/:&'8X&<>] '5^*?^2B?#7ZW7
M_HE:L7WBWQ5K7B34=(\%Z=IABTMQ%=WVJLXC:7&?+14YR/7I].":_BG_ )*)
M\-?K=?\ HE:SM/\ $UE\,O%/B6R\3K/:66IW[ZC8WPA:2.7>!N3*@D,".F/Z
M9 +L_P 2M6A\)ZK>3:9!;:SH-W#%JMJVZ1#$S %XR".H.1G.,<YZU>\>_$*X
M\*:IH-O8P6]Q!>.)+UY,GRK?>B;U(88.7ZG(JAX1TJ;Q7-XVUJ\L9;33_$02
MVM8[A-KO$D93S"O49SD?Y-<EX=T^]\9^%O%7V^$BXTS2$T2$'YLRPY=B!ZEP
MGY"@#TS6/$UXGC/^P+2&UEMHM*FO[TS(6.,[8U&& Y.<Y!X]*Y5?B!?Z-\+_
M  EK&GZ+I_F:C=K;-86L1BC 8O\ +$-WRDE1R<CD\4OPVFGU_P .^)/&%XC"
M?4HA;QEC_P LX8=O'H"^\US]O_R2SX7?]AVV_P#1DE '77'B_P <>&]6TEO%
M&EZ*=*U.[2T4Z=+(9;9W^[O+<-WSM'8^U:OB3Q7KG_"41^%_"5C97.IBW^U7
M5Q?NP@MD)PH(7DL?0>W7G%+XM_\ 'AX7_P"QBL__ &:JFL:I%X!^)]]KVL13
M+H>L6449O8X6D6WFBXVN%!(!!X]_H< %K0O&?B>3XA0>$]?TNPMIELGN99[8
MLR388!6C).0O4$,,Y'6NL\3ZQ=Z'H4UY8:5<ZI>;E2&UMU)+LQP"2 =JCJ3V
MQ7GVE^)H/%/QJTR^L+>X&FKI$Z6]S-&8_M'SKN95;!VC@9(&3GTKH_BGJ.K:
M9X/$VE/=PJUU$EY<V:;IK>W).]T'J, 9[9[=: ,>_P#%WCSPI<:==^*--T"7
M2KRZ2V;^S9)1- 7/!._AL>WIVJW/_P G!VO_ &+K?^CS7EGB<>%KS3]/U'P_
M=Z_KK6U_ UUJ^HRS-' F\#;EPH+$D< >M>IS_P#)P5I_V+K?^CS0!F^#M;M?
M#>G?$36+W<;>TUZZD8(,LWW< >Y.!^-/E\9?$/3]('BC4O#VD#00HFELH9G^
MVPPG^(D_(2!SC&?I6+::'=>(_!OQ/TNQ7?=2Z[.T29QO961PO/KMQ^-7-7^)
M^G^(/!5UX=T^QOY/%%Y;&S;2C:.'AD8;&+$C:%&2<Y],X[ '5^(_&UU"VBZ?
MX7LX=0U76HS/;?:&*110A=QEDQSCD<<$\]^#D+XS\9Z3XPT#P[XATO25?4IG
M!O+$R-$\84DA0Q#*X.,YR"#Q5'4K2?X?ZOX0UZ\@EN--L=)_LG4)8(S(;? !
M$F ,[<@@G_$ P:IXTT_Q=\0/!+:+'<3Z;#?2YOGA:.-Y#$?D0, 20,DG'&1Z
MT =)?>*/%6L^(=1TKP98Z48M,<175]JKR>6TI&3&BQ\Y (R3_AE;7QWJ$GA3
MQ++>:?%9^(- B<W%L6+PLP0NCJ002C 9QG(_6O.]3T#P5H/C?Q"?B'I%P(+Z
M\:[T_4@9S$Z/R8SY1X8'/4?TSN:7I^AP?#CQO?>'O#,^CZ;<64B07%Q<2,UZ
MJQM\X1R2BY8XYYS[8H NKXU^(MSX3C\66VAZ$FDI;"XDMYI9/M,J 99TP=J@
MC) ))QZUT6J^/6B\,Z%?:1IQN]3U[RQ8V;OM ++N8NW]U1U/_P"NJT'_ "0%
M?^Q:_P#;>N'U[0(]1^''P]U>\TJ?5=*TVW7[?:VY82&)XU!<;2"=I4'@_IG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWO74T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPZ^) LVLH=MZ@8:2S&WC1MHD\HGG&W=^7'&* />+#7=(U2XFM]/U6QNYH?\
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M]#7O^B,SZ!IS,Q9FM8B23DD[10!2\2ZW-I45E:V*12:GJ-P+>T27)4'!9G8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"6:>5F4@@C:Q;*\CL1Z5V]% &+J'A+0M4UZQUR\L%DU.QQ]GN!(ZLN#D [2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<PW,UOYEPFR4JC8&\?WL<'^O6@#N:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P 3?%C^%+7Q?'H>FPZ%"R1WT<TKFX=MXC=H@/E50V0-V2<=*];4AE!'0C-
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5C'PAX9)R?#NDD_]>4?_P 36S133:V
MI6&CZ9I7F?V=IUI9^9C?]G@6/=CIG:!GJ?SJ[112;ON!YD&\:>&_&/B6YTSP
M7_:]EJ5S'-%/_:D-O@+$JD;6R>H/7%:FAZ1XBUKQ9!XG\46EOIPLH'AT_3(9
M_.,3/]^1W  )(   XQZ=^YHH \E\3Z.;_P"+MKHUK*ALM5BAO]7@7D@6S'83
MV <E%_X#71>.['6+V6%8?".D>)],\L@VMQ*L,\4A_C5WRNW''&&SWK<T+P?H
M'AFXO+C1]-CMI[QR\\@9G9SG/5B2!GL,#VK<H \ET3X=:J/ _BK3#:0:*NL
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M'X)\2V?@_P =Z==:/96USJJ%K.&PD18"6C(V*,C;@X&6QD\Y/6O8J* .)LM
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M_6O5(P5C4'J !3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNEPV0?W4@/7&2.G% 'K]%<=JWQ T?PHFC6NL-<B2^M3*DJ('!**N0>=Q9B0
M #DFET'XC:5KFLKH\MAJVD:E(A>&VU6T,#3*.24Y(/?WX- '845Q_B#XCZ3H
M6L'2(K+5-7U)$\R:UTJU\]X5/0OR .W?/(]:9>>,=#U[X=:KK-K>ZA%9PPNM
MP;,B*[MV'51N^ZX_*@#LZ*XN_P#B!H7A>PT"/4)-09-1M/,MYG02.VU%(#X.
M2[;@. <D]J=H/Q)TK6]=319M.UC2-1E0R00:K:>09E')*<G. #UQTH [*BO*
M] \<WU]\8-8TR;3=?%F8XH88I+;$=J1G=(XS\JOCAN<\5Z%IVK_VC?ZC:_V=
MJ%K]BE$?FW,&R.?(^]$<_,OOQ0!I45YM\7?%=]X>L=)@L;?50\]]"TD]G%E"
M@;F(MG[[=E[X-:O]NV=[XR\->8?$%C=WME--%828BAP!SY\><[QVQG% ':45
MY[)\8=#\FZ:UTK7;Z2TFDCN8K.S$K0*A(,CD-M53@XR<\'BGW?Q?\.0V4=[9
M6NKZI9;!)<7-A9F2*T! .)6) 4X/(Y(H [^BL'4_&.AZ5X:@\07%YG3[A4-N
MT:%FF+C*JJ]23Z?GC%9VA?$72]9UA-)GT[5]'OYE+V\.K6A@-P!UV<D''IUH
M Z^BF32>3#))L=]BEMJ#+-@= .YKS#X:^-KW7O$WB2UO;'6U0WCO"]W;[8[2
M-0 (7.?D?OM_'- 'J5%>?7'QB\/13S&"QUF\TVWD\N?5;6R+VD9[Y?.<#V!]
MLUW=I=V]_9PW=I,DUO,@DCD0Y5E(R"#0!-17'^(/B-I7A[7'T66QU2\U'R4F
MCM[&W$KS!BPP@!R2-I)S@8[YXIVK?$32])AT]9+#5KC4;^ 7$.EVMH9+H)ZL
M@/RX]SV/H: .NHKG?#OC72/$EK>20&XLY['_ (_+2^B\F:WXSEU/08YSDBL!
M/C#H#/'-)IVNPZ5(X2/5Y;!ELVR< A\YQGCI0!Z#17/^*/&6D^$K:"2_::6>
MY;9;6EK'YDUPWHB]^HY.!R/6J_AGQYI?B:^GTY+;4-.U.!?,>PU*W\B;9_>"
MY.1^- '445YQX/\ $4UG9^/=2U2YN[JWTS6+HJA<NR1( =B!C@#T&0*[!/$=
MF_A >)A'/]B-C]NV;1YGE[-^,9QNQ[XSWH UZ*\G^(?Q!GB\+^'+[1[764BU
M.XM[CS8(1_JB<F%F#<.W&%'7!YKI/[=L[WQEX:\P^(+&[O;*::*PDQ%#@#GS
MX\YWCMC.* .THKAM5^*FBZ=JEU86NGZQJ[V1Q>2Z99^=';'N';(QCGIGH>]:
M=]X\T.T\%_\ "61S27>E'9A[< M\S!.C$8()Y!QC!H Z:BO/V^,'A^*XB::P
MUJ'3)I!'%J\MBRV;D]"')SCWQ7H .1D=* "BN/\ $'Q'TG0M8.D166J:OJ2)
MYDUKI5KY[PJ>A?D =N^>1ZTDWQ!TZZ\#7GB/1X+V_P#(!1[:"#=/#)T(=#TV
MYR?;GF@#L:*\I^#-Q>:M93:MJ%[XKGNY(5\PZHV+*0LQ.ZV'?&W!],]*[7Q3
MXSTGP<MA)JYE2&\G\A944%8S@G+9(.,#L"?:@#H:*X*#XN>'S>RVFHV>L:3,
M(_,@74;)HS=#.!Y2@DL2>@P"?SK1\-?$#3?$FKSZ0+#5=,U*&+SOLFIVODR/
M'G&Y1D\9(ZXH ZRBN%U+XJ:197]W:V>DZ[JZV3F.ZN-,L3-# XZJSD@9'?&:
MV8?''A^?P<?%2WX&D!"S2LI!!!QMV]=V>,4 =#17&Z!\2=)U[6(=*;3]7TR[
MN$,EJNI6GDBY4#),9R<\<]JBU+XH:3I^MWNC1Z9K-_J%G*$E@L+03-M*AO,P
M&X0;@,G!ST!H [>BN.U[XD:3H>J_V3'8ZKJNIK&))K32[7SY(%(R"_( [=^X
M]:O:=XYT#4_"]QXABO/+L+4-]I\U"KP,O577J&]N_;- '1T5PVF_%31[_4K.
MSN-+US3$OG$=G=:A8F*&X8_="-D]>V<=:T?$WCO3/#-];Z<]KJ.I:E.AD2QT
MVW\^;8.-Y&1@?C0!U%%8.A^,-&U_P_-K5M<&&UMRZW(N5\MK=D&65P>A KFX
M?C'X=EFC=[+6H-+ED\N/5YK$K9L<X'SYSC/'(^N* /0J*Y;Q-X_T3PEJ%A::
MH9Q]NCDDBDB0.OR ?+UR2<@  ')/:H-!^(VE:YK*Z/+8:MI&I2(7AMM5M# T
MRCDE.2#W]^#0!V%%<AHFM:6FN>+W.H:IBPF0W?V^53;P#83^Y Y5<#)SWJGI
MGQ8T'4]3L[7[%K%I!?2>597]W9F.WN6/0(^><]L@4 =W117E$/CK^POB9XQL
M[UM6U(@VOV'3;.-[A\>63(43.%'()/':@#U>BN>\*^,M,\7VUR]BEU;SVDGE
M7-I>1>5-"W8,N3_/M6#<?%W08IIGAT_6[S38'*3:K:V#26D9'#$OG.!Z@'VS
M0!W]%<QKWC[0?#MCI5_>3L]CJ<@2&YA :-05W;F.1\N/3)]JR8/BYX?-[+::
MC9ZQI,PC\R!=1LFC-T,X'E*"2Q)Z# )_.@#O:*Y/PU\0--\2:O/I L-5TS4H
M8O.^R:G:^3(\><;E&3QDCKBJ.I?%32+*_N[6STG7=76R<QW5QIEB9H8''56<
MD#([XS0!W5%>9>//B#%)\*9=<\-O?RB]7RXKNUA/^BD-\QD)Y3H5SZD8]:VK
M3Q[:6_AS0;V^TW5[9M2NXM/CCN8 DHD;@.P+?<.,YY.#TH [.BL;Q%XELO#,
M5A)>Q3R"^O8[*/R5!P[YP3DCY>.>I]JR/$'Q&TKP]KCZ++8ZI>:CY*31V]C;
MB5Y@Q880 Y)&TDYP,=\\4 =A17&:/KMCJ'CJX EUR"Z;28KE[.\95MH8V;@[
M,Y67USVK/G^,6A1++<P:3X@O-+B8J^JVVGEK48."=Y(X![XH ]#HJMI]_:ZK
MIUO?V4RS6MQ&)8I%Z,I&0:\TU;QS?6GQGLM*73=?DL8[5HF@AMLI*[,/WX&?
MFC4'!;MSQ0!ZI17E$/CK^POB9XQL[UM6U(@VOV'3;.-[A\>63(43.%'()/':
MNT\->-M+\4V-Y<6<=W!-8L4NK2[B\N:%L9PRY[X/?M0!T=%<3X>^)^E>*+VT
M@TO2]9DAG7+7AM!]G@;:6*22!L!L#H,]0,YJI<?&+P]%/,8+'6;S3;>3RY]5
MM;(O:1GOE\YP/8'VS0!Z#16!JOC#2]*M-&NB9+JWU>ZBM;62V"LI:3[K$DCY
M?<9/M4WB+Q+9>&8K"2]BGD%]>QV4?DJ#AWS@G)'R\<]3[4 ;-%<UXG\<:7X6
MN+6SG@OK[4;H%H+'3X#-.ZCJVWCCZGL?0U4T'XDZ+XAUV+1+:WU"#46A>66"
MZ@$3V^TC*R G(8Y!& 1CO0!V%%>/^%_B*-*G\3VE[%KNN7L>MW/EVME ]U)!
M -H7J<(F00!GUP*](\,^)M-\6Z,FIZ6[F$L8W25-KQN.JL.Q% &Q17":5?7N
MG_&'6]'N[RXEM+^QBOK*.61F6+:=DBH"<#).<"N/\7^(]9C\?7^N66J7<.B>
M&[FRMKNVCE;RIQ(Q\TLH."5W <^U 'M=%<7\0+V[9= T73KJ>WN-6U*.-I+>
M0I(L" R2$$$$<*!]#4^O_$+3-"U9M)BL-6U?48T$DUMI5H9WA4]"_( S]<\C
MUH ZVBL/1/%VC:_H4NL6EULM;?<+D3CRWMV4999 ?ND5SD7Q>T!Y8I)-/UNW
MTJ5PD>L3V#)9L2< [\YP3QDB@#OZ*X3Q!J-W'\6?!UI!>3K9W-O>-+"DI$<N
M$!4LH.&QVS6_I7BFRUK7-0TW3X;F=+ [)[U57[.)>\0;.6<=\ @=R#@4 ;E%
M97B6;6+?PY?2:!:K=:KY>+:)G51O)QDEB!QG."><8KS7Q+X?\1>#/"<OBN/Q
MOK-QJUHJ2W%O=S![.4E@&18L87K@8/Y9R #U^BL;5/$EGHGA5M>U$-#"D"RM
M'CYRS 80#NQ)  ]:XWX8ZKXAU+Q+XL'B*219UDMI$L_,+):JZ%@B@\ @%0<=
M2#UH ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0VUTP(\TN\C*#UVER=OX8K5L=#T[3M3U#4K2V\N[U%D:ZDWL?,*C"\$X&!Z
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MP/F1V)SQSR>3G/>O7[70M-LM:O\ 5[>VV7]^(UN9=['S @PO!.!@>@%8%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img101536035_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/
M$>JKH?AS4-38C-O SJ#W;&%'XG II7=D!IT5\T:?\0?%EG=V%_>:K=RV1G&Y
M'(VRJI!=?R/ZU]*QR)+&LD;!D<!E8="#WK2K1=.UR5*XZHY)X8FVR2QH<9PS
M 57OM6T[2U5M0U"UM WW3<3+'GZ9(KPCXUS177BW3[FWECF@DTY-DD;!E;$D
MG0BBE2]I*PV[(^@P01D'(-%4M'_Y EA_U[1_^@BHY_$&BVUU]EGU>PBN <>5
M)<HKY^A.:SL[V0S1HI 0P!!!!Y!'>JMKJNG7KNEI?VL[(,L(IE8J/4X/%*P%
MNBL^UU[1[ZZ-M::M8W%P,YBBN$=^.O .:T*;36X!16=/X@T6UN?LUQJ]A#/G
M'E27**V?H3FM!65U#*0RD9!!R"*+- +15*WUC3+NX^SVVHV<TW/[N.=6;CKP
M#FI[J\M;&'SKNYAMXLXWRN$&?3)HLP"ZO+:QMVN+RXAMX%^]),X11]2>*6VN
MK>]MTN+6>*>!QE)(G#*P]B.#7'>/M)T[QCX7BC37;.UBCN0\=PTJF)F (VDY
MZX)/X5:\ Z+:^%_"1MTU6"]C$KS2W$;CRU.!D Y.  /YFKY5R7OJ*^IUE%4X
M=5TZX@EG@U"UEABYDD2965/J0>*CAUW1[FTDNX-5L9;:)@LDR7",B$] 6!P#
MR*BS&:%%5[2_L[]&>SNX+E%.&:&0. ?0XJ)-8TN2[^R)J5FUSN*>2LZE]PZC
M&<YHLP+M%17%S!9P-/<SQP0K]Z25PJCZDU6LM:TK4V*V&IV5VPZB"=9#^AHL
M]P+U%%<7\4M5OM&\%R7>G7,EM<">-1(AYP3R*<8\TE%";L=I17SYH-[\3_$6
MGOJ.D:C<W,,4IB;,T:G< ">&QGAA6[X.^)>O6_BB+P]XI3>\DHM][1!)8Y"<
M*#C (/ Z=\Y-;2PTE>S3L+F/6[W5=.TUHUOK^UM6E.(Q/,J%S[9/-6^M>7_$
MGP19^(M>MKV7Q%9:=((!&T-TP&5#$AEY'J?RKNX+S2]#TZRL9]4MD$5NB1M/
M.JM(J@ -R><XZUG*"Y4T]1WU-6BFHZ21K)&RLC %64Y!![BJMOJ^F7=Q]GMM
M1M)IN?W<<ZLW'7@'-9V&7**K7NHV.FQB2^O;>UC/1IY50'\2:++4;'4HC+8W
MEO=1CJ\$JN!^(-.SM<"S17/^,_$"^'?#-]>1W$*7B19@21AEF)P,+WKF_ASX
M]?7=(NIM?U&QAN4N-D:EEB)7:#T)YY)JU3DX\R%=7L>B44R::*WB:6>5(HU^
M\[L% ^I-4;;Q!HM[<_9[75]/GG)QY45RC-GZ YJ+,9H$A022 !R2>U,CGBE)
M$<J.1UVL#6;XI_Y%#6O^O"?_ -%M7D7P(_Y#>K?]>R?^A5I&GS0<[[";UL>Y
MT45XAK-K\5[:YU"[CFNTL(GDE5A=0X6,$D'&[/3MUI4Z?/UL#=CV^BOF[0O$
M'Q$\2W4EMI&J7=S-&GF.OG(F%R!G+$=R*]>\ Q>)['2+Y_%\KK*LN^-YID8+
M&%Y.5) &<]:NI0Y%JT)2N=G3)IHK>%YII$CB0;F=V 51ZDGI5:'5=.N()9X-
M0M988N9)$F5E3ZD'BL'Q,FD>,?!VH6=OKMFEN=H:ZCG1TC8,& 8@XYX[]ZR4
M;O4=SH;+4++4H//L+RWNH<[?,@D#KGTR#BK-<)\,O"UOX9L+\0ZS;:D]Q(I<
MVS@I'M!P.IY.3^E=?>ZMINF8^WZA:6F1D>?,L>?S-.<4I6CJ">FI<IDDT46/
M,D1,]-S 9J&RU"RU*(RV-Y;W48."\$JN,_4&O)?CU_J-!_WI_P"4=.G3YYJ(
M-V5SV)65U#*P93T(.0:6N9^'G_)/]%_Z]Q_,U/XWO;G3O!>K7=I,T-Q% 621
M>JG(YJ>7WN4+Z7-^BOG/0-<^)/B+[1)HVH7=U]EV^:/,C&W=G'#8S]T],]*W
MO#GQ7US2]<72O%T8,>\1RRR1>5+ 3W8  $?AG'.?7>6&DKV:8N='MU%("& (
M((/(([UGS^(-%MKK[+/J]A%< X\J2Y17S]"<USI-[%&C12 A@"""#R".]4K[
M6]*TR18[_4[*T=AD+/<+&3^!-"3>P%ZJ=MJVG7EU+:VNH6L]Q#_K(8IE9T^H
M!R/QJ:*>WOK;?;SI+$X($D3AA^!%>6>!? -AH?C$:A#XGL[XQ+((H('&]L@C
M+ ,>@/YXJXQ33;>PFSUFBH+N\M;"W,]Y<PV\(ZR32!%'XGBJ*>)_#\J[H]=T
MQUZ96[C/]:A)O89JT5475-/>R:\6^M6M5.&G$RE ?=LX[BD_M;338M>_VA:?
M9$.&G\Y?+'U;.*+,"Y152QU33]41GT^_M;M5X9K>99 /K@FK=*U@"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOF*.@Z=,UZ!\>87:PT2<*?+265"<< D*1_Z"?RJI?QH,2^%G<_#S_DG^B_\
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MCK7-? C_ ) NK_\ 7PG_ *#6,)R5&4NMQM+FL<1X+%UX7^+,.F)/O"W;V<I
MP)%Y&<?7!KZ0KYVB_P"2\'_L+M_Z$:^B:G%:N+\AP"BBBN4L**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L"V\%>
M';36!JT&F1K?B1I?.+N3N;.3R<9Y-;]%--K8 KG]-\$>&]'U)-0T_2X[>Z3.
MV1'?C((/&<=#7044*36P&%K7@SP[XAN!<:II<4\X 'F!F1B!T!*D$_C45QX#
M\+W5I;6LNC6Y@MMWE(N5QNQD\$9)P.3FNBHI\\EU%9#(HHX8$AC4+&BA%7T
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M=C-97D0EMIEVR1DD!A^%6**')MW8'*)\-/!R.&&A0$C^\[D?D370:?I6GZ3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Q_[[?G5OR(_[OZFCR(_[OZF@"IYC_WV_.CS'_OM^=6_(C_N_J:/(C_N_J:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:,!"5C7(!8JO)"CG ["L/4KZ^NM%F:WU/3+B,30KYUJK=W4%2H<XZCG=R,C
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M?KS7H=?'$=M<2PRSQ02O%#@RR*A*QY.!N/;)XYKW#X7_ !)_M)8M!UJ;_35
M6VN'/^N'96/][T/?Z]=Z^&45S0)C+N>KT445QEA1110 4444 %%%% !1110
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M&XX!]O>NGCD26-71@RL,@BI:L"=QU%%%(84444 %%%% !1110 4444 %%%%
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MR7%XFHH4M6VW]_\ D=+\.)=;_LIQ/%YFG#_CW+MAL]P/]G^O2NV\VX_Y]O\
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M[:Z-PBV]_ (XVNF=T#&,[2X.3]X]2<'H3@&NJ;1=/-HEJ("L<;^8I21E</\
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MXS6)HGARVTVSLQ,@>Y@7J)7:,/C!95)P#[@ \GUK<HDTV"(/,N?^?=/^_O\
M]:CS+G_GW3_O[_\ 6J>BI&0>9<_\^Z?]_?\ ZU'F7/\ S[I_W]_^M4]% $'F
M7/\ S[I_W]_^M1YES_S[I_W]_P#K5/10!!YES_S[I_W]_P#K4>9<_P#/NG_?
MW_ZU3T4 0>9<_P#/NG_?W_ZU'F7/_/NG_?W_ .M4]% $'F7/_/NG_?W_ .M1
MYES_ ,^Z?]_?_K5/10!!YES_ ,^Z?]_?_K4>9<_\^Z?]_?\ ZU3T4 0>9<_\
M^Z?]_?\ ZU'F7/\ S[I_W]_^M4]% $'F7/\ S[I_W]_^M1YES_S[I_W]_P#K
M5/10!!YES_S[I_W]_P#K5#=27WV9_)A17QP0^3^ QUJ[13N!Q,<LL4^]"1+D
MC.,G)_K5UHW%M'9$[KB20-MS]SCO[G-:U]8E)OMMK&K3+G*$<-[C'>N=EE60
M$""-&SRP+9_4FM$[D;&E=Q.NEF-89%2*4<E"">.6/XU+H!N<L!_Q[=\^OM57
M3;26]C,)&VW#[V?OG'05TT<:0QK'&H5%& !4R=M!H=1114%!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '#WOPVL+GQ EY')Y5BQ+S6R\9;T4]
ME/?T[=>.UBBC@B2*)%2- %55&  .PI]%:5*TZB2D[V,:6'I4FW!6N%%%%9FP
M4A 8$$ @\$&EHH X@_#;3SXC^V[@-/\ OFTQ_'Z9_N]_TKME4*H50 H& !VI
M:*TJ5IU+<[O8QI8>G1O[-6N%%%%9FP5%=6T%[:RVMS$DL$JE)(W&0P/4&I:*
M /-M!^$&FZ1XJFU.:47-G&P>SMG&=C=?G/?';UZFO2:**N<Y3=Y,2204445
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MZ&'5O_ V3_XJL:BCECV"R-G_ (2[Q+_T,.K?^!LG_P 51_PEWB7_ *&'5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[P)()//&!SS]*.=V5EJPYM$>9T5Z]<SCPQ<^-;O2X8K>>-+*58]@9;>5SEL
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MKSQWJ/QU<W*^/M%NC#]GNQ;6DAB52OEOG. .V#VI\[;LO/\  ?,V>?,I5BK
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M[^Q__&Z/^%(>&O\ G^U;_O['_P#&Z7UBC>_Z![2!XW!XIUNUOK.]@OWCN+.
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M?[5O^_L?_P ;H^M4P]K$\#HKWS_A2'AK_G^U;_O['_\ &Z/^%(>&O^?[5O\
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MIW]JZ=_S_P!K_P!_E_QI\5_9SR".*[@D<]%20$G\,UY=6MX9_P"1AM?^!_\
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MO_ __0#636MX9_Y&&U_X'_Z : /0Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_%
MMM=W6A*ME:R7<\5[9W'D1LBLZQ7,4C %RJYVH>I%;E% '/\ _"0ZI_T)FN?]
M_K+_ .2*/^$AU3_H3-<_[_67_P D5T%% '/_ /"0ZI_T)FN?]_K+_P"2*/\
MA(=4_P"A,US_ +_67_R17044 <__ ,)#JG_0F:Y_W^LO_DBC_A(=4_Z$S7/^
M_P!9?_)%=!10!S__  D.J?\ 0F:Y_P!_K+_Y(H_X2'5/^A,US_O]9?\ R170
M44 <'XCU&ZO_ +-]IT:^TW9NV_:W@;S,XSCRI'Z8[XZC&><9%K_Q^0_]=%_G
M73^-O^7'_MI_[+7*Q/Y4R28SM8-CUQ0!V6M1:*=4$M]=SQ7"JIVH#C';HI_G
M1INI1ZGXFDEA5A&EJ44MU/S#G]:YG5]2_M2]^T^5Y7RA=N[=T]\"ET?5/[)N
MWG\GS=R%-N[;W!]#Z4 :NEVZ1::;F:VL45I#B>\.[</14Q_6IM2TFSFUO3HH
MD6..X4L_EC:"!SP.U9D&MQ#3DLKNQ2YCC8M&2Y7'UP.>M%]K\MW/9W"0K#-;
M]U;*GIV["@"U=7^F)=W5C/IL26Z9C22%!Y@8'&<Y_P ^]3Z;86\&AQW>+%IY
MF/S7Q^0 $\ >O%53XDC622Y@TZ.*]D7:TWF$CZA<55M=:"6)LKVU6[@W;U!<
MJ5/U'^>: -;R+*/Q%ILMF]N3)GS4@D#*K =O0?X5+Y]G=^))].FT^!DD+ RD
M?/NQG.?3CM6-)KTDFJV]XT*B.W&(X5;  QZU9_X26(74MXFF1K=L,"7S"<#W
M&.3[\4 /LK"ULK74KV>%;DVLIBC1_NYSC)]>HILT5OJGA^:_6UBMKBW?#>2N
MU6'';\:H6&LRV9G66);B&X.98W.,GUSV-.O-8$UB+*TM5M;;.YE#%BQ]R: *
MFG*KZG:HZAE:9 01D$9%=7!96?\ PD&IQO:0F*.%2J;!@<#IZ5R%K/\ 9KN&
M?;N\MP^W.,X.:V$\1[=1O+O[)G[1&$V^9]W QG..: +$0M=3\/7LIL;>"2WY
M1HEP?Q/4U8OKW'A&UD^RVW[PE-OE\)]X94=C[UAV>J_9-,N[/R=_VC^/=C;Q
MZ8YHGU7S]%M].\G;Y+;O,W9SU[8]Z -'6[:"*[TL1P1HKHNX*@ 8Y'7UJW<V
M^EP^*A'<QPQ0>2"JX"IN]^WK6<?$,<D-L+C3XYI[< )*9".GM^%1W&NK<:K]
MM>QA="@1HI<.#[@XX- &CJ]G*NGR,VEV;(/F2XLSMV#W'?\ E2SZ9;7*Z%"(
MTC\Y,R,B@%L*#R?S_.LYM<ABLY[>PT];;SQB1C*7R/;/2F7&N22QZ>(HO*DL
MA@-NSNX Z8]OUH U(YK"?6GTDZ9;K!EHPZK^\!&>=WX4EA96MI8ZOY]O%<&V
M<A2Z\\#UZBJG_"1Q+,UW'ID27S#!FWDC/KMJI;:PT-A>VSQ&1[HY,A?&#],<
MT :%ZEO>^%UOQ:003I)M_<KM!&<5SE:(U7&A'3/)ZOO\S=[YZ8_K6=0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
MMX9_Y&&U_P"!_P#H!K)K6\,_\C#:_P# _P#T T >AT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% ')^-O^7'_ +:?^RUR5=;XV_Y<
M?^VG_LM<E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %:WAG_D8;7_@?_H!K)K6\,_\C#:_\#_] - 'H=%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#/:V]SM^T012[?N^
M8@;'TS47]E:=_P ^%K_WY7_"K=% %3^RM._Y\+7_ +\K_A1_96G?\^%K_P!^
M5_PJW10!4_LK3O\ GPM?^_*_X4?V5IW_ #X6O_?E?\*MT4 5/[*T[_GPM?\
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M%K_WY7_"K=% %3^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PJW10!4_LK3O\
MGPM?^_*_X4?V5IW_ #X6O_?E?\*MT4 5/[*T[_GPM?\ ORO^%']E:=_SX6O_
M 'Y7_"K=% %3^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PJW10!4_LK3O^?"U
M_P"_*_X4?V5IW_/A:_\ ?E?\*MT4 5/[*T[_ )\+7_ORO^%']E:=_P ^%K_W
MY7_"K=% %3^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PJW10!4_LK3O\ GPM?
M^_*_X4?V5IW_ #X6O_?E?\*MT4 5/[*T[_GPM?\ ORO^%']E:=_SX6O_ 'Y7
M_"K=% %3^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PJW10!4_LK3O^?"U_P"_
M*_X4^*PLX)!)%:01N.C)& 1^.*L44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4456O-1L=.6-KZ]M[59&V(9Y53<WH,GDT 6:*** "BO.?B'#>:EXT\':+#K
M.JZ9;7S78G?3;HPNVR-67D<'D=P>IJCXC\&ZEX3\/7^OZ5X[\3/=V$+3K'J=
M\+B"0+R59"H'/2@#U2BO)M?\;R6>N_#S6+V[N+*POK2>>[MHF<K(S0J54H/O
MG<P &#R:ZG0?B-I>N:[_ &+)IVKZ5J#QF2&'5+3R#,HZE.3G\<4 =A17'ZY\
M1M,T?6)=)MM-UC6;^!0UQ#I-F9S ",C><@#-6=)\?^']7\,WFOQ73PV=B6%V
MMQ&4D@91DJR^O(Z9STH Z>BN&TWXJ:/?ZE9V=QI>N:8E\XCL[K4+$Q0W#'[H
M1LGKVSCK6IXE\<:9X9N[>QEM[_4-2N$,D5AIUN9YV0=6V\8'7J>Q]* .EHK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=J@UFST^P^!^O-#KPUZVEUI9IKF.S-NI8RQ[U5<X(R"<KQSQTKU/7?AMX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JUYJ-CIRQM?7MO:K(VQ#/*J;F]!D\FK->>?$?X>7WC*]L;JQOH86@
M0QO'/NV[2<[EP#S[?3FK@HN5I.R$_(]#HJII5C_9FD6=AYK3?9H$A\QNK[5
MS^E6ZAC.(\4W]W;?$GP/:PW<\5M<->^?$DA5)0L(*[@#@X/(STK+O=;U7XBZ
MK-HWA6\FT_0;24+?ZY V'F8<F*W/\W_IC=7^*.AQ^)/''@?2)KF>WAN7O%E>
M!MKE!&I9<_[0!4^Q-5W@7X/>*XYK=67P5K$@29,EAI]Q@ /DY.UL<_\ U@"
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M)UW5ULG,=U<:98F:&!QU5G) R.^,U3UR6*\^-WA>/3W62YLK2Z;4/+Y,<3*
M@?'3YCD ^OO61HNM^(]=T.]U70+GPQX8\-+/+B3R-\ZX;YG=<A 3UP>>>_!(
M!H>//B#%)\*9=<\-O?RB]7RXKNUA/^BD-\QD)Y3H5SZD8]:M-XFM+^Q\'7-Z
MOB73)KJ^6"*# A,SA<?OU)^:(]>.3Q7 Z2V_]F37F\SS<W$I\S&-W[U><=LU
MVGC,@W7PV(.0=4A_]%T =!K_ ,0M,T/5FTF+3]6U?48T$DUMI5H9WA4]"_(
MS]<\CUJS9^.=&U#PG>^(K1YI+6R21KF'9MFB9!ED921AAZ$X]Z\V\/:=XCOO
M'GC.STWQHFAWHU)I7M7TV*X>6(C]VX9R#M"D# X'XU8M=.CL_#?Q*F;Q6GB"
M^EM"MZ\=@+=(I5B<=5)1C@C.WICGDT = _QF\/BV2]CTO7I]-(4RZA#8%K>
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M&O,/B"QN[VRFFBL),10X Y\^/.=X[8SBN!NR!\#_  &2< :E9?\ H;5V&O\
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M[MXT6--.G0"&2+.&0#('W<X[5TE% '@$_AO3]8M+G2_"OPSU;1]4U "&YO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS3]9U:75+?5M;T>\G"BXDTF],'G[1A=XP02!WJUIW@71]+73%M?M 73[B2Z
M>3>9YW4J9)21EFPQP<CK["NEHH RFT"U;Q5'XB,DWVQ+-K()N'E["X?.,9SD
M>N/:JD/A#3X=-U^Q6:Y,6N3337)++N0RH$;9\O P.,Y_&N@HH XO4_AKIVHV
M6AV\>L:U8-HMN;:VGL;E8I2A55.YMO7"CICO5GP_X'_X1_4OMO\ PE/B;4OW
M93R-2U#SHN<<[=HY&.#75T4 87A#3K_2O#D-KJ5S=7%R))7+W=QYTH5G8HK/
MW(4J#CCCCBKVLZ+IWB#2YM-U6TCNK288>-_T((Y!'J.:OT4 >?Q_"+16DC2_
MUCQ#J=A$P9-.OM1,ELN/NC9@' ]"?SKJ=3\.66JSZ1+(9(O[*N1<VZ0[57<%
M*@$8/RX;H,5KT4 9?B+0+#Q1H-UH^I(S6MRN&*'#*0<AE/8@@$5<L+0V.GV]
MH;F>Y,,8C\ZX(,CX&,L0 "??%6** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS'(K6\+_ /(HZ+_UX0?^BUKS/6=0UO7?B+K$VD^%1XAT[3K1M((^WQVZI)(
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MSNEN606&QW8;0I Z_,203S]*V-/UR^FU_3-=D0O?GP0]T1C[\@=6SCW//XT
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ML;-9WC1W(;#-L()*X..>YK?^%(E@\-:AISW$L\6G:K=6=N96W,L2-\JY]LT
M=U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&^,5O<,?O%TP>O?!%;K>$-*$N@M;I);1:&S&TAA("<H4PV02>#Z@YZDUO44
M8ESX5TV\UV[U6Y$DSW=A_9TT#$>4T6XL>,9R<D=:YZ#X3Z/'/$MQJ_B"]TZ)
ME:/2[O4&DM%VD%1LQD@$# )/XUWE% '+>)/ >F>)-0AU(W>I:9J<4?E"]TRY
M,$ICSG83@@C/M4ND^!]%TK1;[3#'/?)J&?MT]]*99KHD8R[GVZ8QCMS7244
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M;YI+:W8?=VICMZ$G\:R;CP0WB#XH>);NYDUC3%%O:"TU&PE:W9OE(=5?&&'
MR.>@Z5ZE10!S</@/P[#X0?PO]AWZ9)DR*[DN[DY+ENN[/.?88XXK/T?X::9I
M>J6U_<ZMKFKO:-NM(M4OC-';MC&Y%P!D#@9SCZ\UVE% &3I7AZTTB;5I;>2=
MFU.Y:ZF\Q@0K%0I"X P, =<UFVG@/2[/3- L(Y[PQ:'<?:+8LZ[G;YN'^7D?
M.>F.U=110!PVH_"O2+_5+V]BU;7;"*_D,MW96-\8H)V/WBRXR<]^:W?"GA33
MO!VE2:9I;7'V1IWG5)G#^7NQ\JG&=HQWR?<UN44 -=%D1D=0R,"&4C((]*X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%5KS4;'3EC:^O;>U61MB&>54W-Z#)Y- %FBBB@ HKSGXAPW
MFI>-/!VBPZSJNF6U\UV)WTVZ,+MLC5EY'!Y'<'J:H^(_!NI>$_#U_K^E>._$
MSW=A"TZQZG?"X@D"\E60J!STH ]4HKAKGXFZ;I6EZ#/JEI>?:M7L!=10VL7F
M%GVH?+49R6)< #\R*2V\2V6K>+_#K/'XDTZ[N[:Y:*PN L,1"<,9X\D[ACY:
M .ZHKSV3XPZ'Y-TUKI6NWTEI-)'<Q6=F)6@5"09'(;:JG!QDYX/%/N_B_P"'
M(;*.]LK75]4LM@DN+FPLS)%: @'$K$@*<'D<D4 =_17/ZKXUT/2/#MKKD]RT
MEI>;/L@AC+R7#.,JJ+U)([<>]9>C?$S2M5UV#1;K3-:T:_N5+6\6JV9@\[')
MV\GT/7% ':45Q&I?%#2=/UN]T:/3-9O]0LY0DL%A:"9MI4-YF W"#<!DX.>@
M-;^A>([37Y=2A@AN()].NC:SQ7"J&#  @C!/RD'@T ;%%8V@^);/Q%+J:V,<
MX33[MK.2610$DD7[VS!.0,]3BI/$7B/3/"VE-J.JS&.'>(T5%+/(YZ(JCDDT
M :M%<AH7Q%TO6=8329].U?1[^92]O#JUH8#< ==G)!QZ=:@U3XH:-IFN7^B"
MPU:]U2S9!]ELK7SI)@RABR 'H 1DMCKQF@#MJ*YWPIXTTKQ?#=&Q6ZM[FS<)
M=6EY%Y4T).<;EYZX/?M6)+\7/#ZW<RP6>L7>G6\ACN-6M;(R6<)'7=(#T'J
M1Z9H [VBO+_"7CB+1_A;+XCUJYO+^!=0FC\P/YKE6F*I@NP^49'?@5I?\+=\
M/+=1^=9ZQ!IDLGEQ:O-9%;.0YP,29SC.><8X]* .^HKG_%'C+2?"5M!)?M-+
M/<MLMK2UC\R:X;T1>_4<G Y'K5?PSX\TOQ-?3Z<EMJ&G:G OF/8:E;^1-L_O
M!<G(_&@#J**\_P!*\9:-HG@O5]=:XUR\LK74Y(93?.DDJN752$^8 1@D8!/
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M2T(_YYG=P<\X]J .\HKE_$_C[1?"&HV-EJWVA&O8Y'BDCC#+\F/EQG)8D@
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M."TA."G0KGUK4C^(5A8>#]-U34-/UB&>Z(M[>PDM";NXD _A3/.<9!)[CUH
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M>6*:X@M86G=+<!G90,DKD@'CGK0!H45AZAXKTS3?!S>*)FD;3A;+<C8 796
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MWA/5]9GU/5&L+74)TFEU6022*X8#9'MS\F2 HZ\T =S17!VGQ8T>74K2SO\
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M;+_T8*L7UIK5S\<-<MM/\5IH%U<65NUJ9+".X-Q$%^94WD8PP)P.OX5W5O\
M#7PC::9=:;;Z0([.ZG2XEA6XEP9$.5(^;C'H,"M#Q'X0T#Q;!'#KFF17BQG,
M;,2KIZX92& ]LT <7X9TB2S^(NJS:EXU37=:CTOR;BWCTQ;?RTW J69"5R.?
ME/S8/I5SX*Q1I\)]-*H 9'N&?C[Q\UQS^ %=7H'A70_"]@]CHNG16<$ARX0D
MLY_VF)+'\35C1=$T[P]I,6EZ5;_9[*'=LBWL^-S%CRQ)ZD]Z /%K'C]EF_\
M^VO_ *4UV7B_3]*U2V\)0R^()=#US[VE7B1EP6\L;E/\/(QP2,]!GI776?A3
M0['PX_A^#3T_LEPX:VD9I 0Q);EB3U.>O':J,?P[\)Q^&SX>_L>-]*\TS""2
M1WVN>K*S,64_0COZT <GHNH^)-%^)&EZ)XJ&C:Q=WMO,+;5+6$)=0HHW$2#
MPAQT'&>YKN/%^B)XC\(:KI+#)N;=E3V<#*'\& -0>&_ GACPC)++H>D0VLLH
MVO+N:1R..-SDD#@< XXKHJ /GZZN)?B+H6J:HK.UQH?A^%01]Y;S<)9,>_[D
M#IWKJ_"5\OB[4?%7C 8,'V"/3K7'8+%YDOU^=L?A7?:7X6T718-0@T^Q6&+4
M)7FNE+LPD=AAC\Q. ?08%.T?PUH^@:)_8VEV8M]/._,0=FSN^]\S$GOZT >.
MD@? KP*2< :K;?\ HYZ[/QC&DOQ=^'ZR*& -ZP!]1$"#^8KIY/!?AZ7PJGAF
M33$?1XQA+=W<[>2<AB=P.2><YI;3P;H%B^CO;V!1M'61+ F:1O)#C##EOFR/
M[V<=J .8\:@?\+3^'IP,^;>#/_;):] G!-O( ,DJ>/PJE>Z%INHZKIVIW=MY
MEYIQ=K63>P\LN,-P#@Y [@UHT >:_"'4[&R^$%K-=7<,,=DUP+EG<#R3YKG#
M>G!!_&N%4A_V5YB.0;@G_P FJ]8?X9^#)->.MOH%L;\R>:7RVTOG.XIG83GG
M..M77\%>'G\,OX<;3\Z3(YD:W\Z3EB^_.[=N^]SUH YSXOQ1Q_!W58T151(X
M J@<*!*@&*K:I-%8_%SPC<ZBXCM)=+FM[61SA!<'!(SV)7@>O KN]8T33M?T
M>;2=3M_/L9@HDBWLN<$$<J0>H'>F:SX=TCQ!I7]F:M817=GQB.3/RD< J1R#
MCN#F@#A_'%WITGQ3\!VJR1MJ45S,S(IRR1F/OZ9(XSZ&N=\/:=XCOO'GC.ST
MWQHFAWHU)I7M7TV*X>6(C]VX9R#M"D# X'XUZ)I7PX\):(]H^G:-';R6DQGA
M<2R%@Y!7))8EN"<!L@9XJ;Q'X"\+^+9HYM;TB*ZFC&U90[1OCT+(02/8T <1
MH6G1V>G?$*9O%:>(+Z6W*WKQV MTBE6)QU4E&.",[>F.>36)XA$Q_9^\(217
M'V>"*>S:XG\H2K&G(W,AX8!BIP>#C%>R:7H&DZ+I(TK3M/@M[$ @P*ORMG@[
ML_>)[DYS5#1O!'AOP_97UEINE116M^<W,#NTB2<$8VN2 ,'H,"@#SGQ;X?U>
M?PW"WB/XKPRZ5=2Q>3LT.)C*^X%-GEMN)S@_+V]JZ#0Y4M_CCXEAO9 +BXT^
MU:RW\%XE&'"Y_P!KD@?TK9TCX8^#-"U5=3T[08(KQ3N21G>0(?559B%/N ,5
MH>)/!GAWQ='$FNZ7%>>3_JW+,CKZ@,I!Q[9Q0!EWNH>'[WP[XPCT/[,9X(9U
MOWMX-@:8QG.YL .V.I!..]<I'KEOHGP/\*RR:=8ZA/<"VMK6.^ \A)FSM=R>
M@7!.?U%>E:5X?TG1-)&E:;I\%O8X(,*KD-D8.[/WB1U)SFLBT^'/A&QTJ_TN
M#18A8WSB2X@>1W5F'0C<QVD9_AQ0!YA\2G\516NB1^)M?T8O+J<#1Z9I]NPW
M8;[^]SNP.G3'-=6UWIUM^T0RWCQI<3:&B6K2$#+^8<J,_P 1&?P!K=M?A7X)
ML]/FL;?084AF96<^;(9"58,/WA;<!D X!QQ5_6/ OAKQ!>SWFJZ5'=W$T"VS
MO([_ ' VX  '"D'^(8/O0!S.N30WGQP\+0V$B/=6=I=-J'EG)CB90$#_ / C
MD ^OO7'W4=S+\._BLMIN\S^VYV.WKL#H7_\ '0:]<\.>$- \)6\D.A:9#9K*
M<R,I+._IEV)8@=AG S5G3-!TS1VOS8VHB-_<-<W.79A)(WWC\Q.,^@P/:@#R
MF[TC6+OX>->WWQ7M1X;FM CXT.#:(R,;!M;.1TP.<CUKU'0;*%?"&FV+3F]M
MQ8QP^:\1C\Y-@&2AY7(['IFL6+X5>!H-6&IQ^';47(?>/F<Q@^T>=GZ5V- '
MA6GF;4)-#^&$NZ7^S-6F:_W<[K2!O,BW?[+;T'X5U:?\EK\0_P#8O1_^AUV\
M'A[2K;Q#=:]#9JFJ742PS7 9LNBXP,9P.@Y ["E&@:8-;N-9%M_I]S;BUEE\
MQOFB!R%QG ^H&: //_A]!,?V?$CL%(NI+"[\O9U,A,F,>^<5@^"M-\0WOPXM
M+NQ^)EM8Z3#;%9K8Z-;NMK@?,CL3GCGD\G.>]>PZ-HVG^'])@TO2[?[/90 B
M./>S[<DD\L23R3U-<]?_  L\$ZGJS:I=^'[9[MGWLP=U5FZY9%8*<]\CGO0!
MY^VG6-KX=^%]G:ZC_:MB-9!BN7MF@\Q2S,/D;D =/?&:Z_QE%'+\5?A]O16Q
M)>L,CN(@1^O-==?>'M*U%]->YLU8Z9*)K,*S((G P" I ( ['BGWFB:??ZKI
M^IW-OOO-/,AM9-[#R]Z[6X!P<CU!H XW5>/CMX?(X+:1< X[C=7'Z1K<&A_#
MG4I)--LK^>X\4S6]K'? >2DS/\KN3T"X)S^HKV*;0].GUVWUN2WW:C;0M!%-
MO8;4;DC;G!_$51'@KPZ-$N]&;2XGT^[G:XFAD9G#2,<E@220<^A&.V* /)?B
M4_BJ*UT2/Q-K^C%Y=3@:/3-/MV&[#??WN=V!TZ8YKWBN/M?A7X)L]/FL;?08
M4AF96<^;(9"58,/WA;<!D X!QQ784 >?^+-:OU\>:9H?AZPT4Z[)9/<?;]44
M_NH=V"B;?F))!. <<?4CE](DU0_'RPAUC7++5+V+3)1(MG (TMN2?+ZDD]^>
M>:]*\2>"_#OBZ.%==TN*[\G/EN69'7/4!E(./;.*9IW@;PUI%U87.G:3#:S6
M"NMNT3,N X ;=S\Y( Y;)H Y[X;$?V_X[&>?[<?_ -!%=!X^_P"2>^(O^P=/
M_P"@&I8O!OA^#Q2_B6'34CU=U*O<)(Z[@1@Y4':2?7&:U;^QMM4T^XL+R/S;
M:YC:*5-Q7<K#!&1@CCTH Q? C*GP[\.LQ"J-,MR23@ >6M<;I^J66I>/_&'B
MR-!=:+IFE"Q>50&2=ES)(J]F ''XCUK57X*?#Q6##P\,@YYO)R/RWUV=CI6G
MZ9IRZ?8V5O;62@@011A4P>O XY[^M 'D%SJ7BJ^^&<VK?VEX8\.>'9K)S;VU
MG 9'V,IQ%R0@8]/E'![9XJ[::9+??L_:+>6@/V_2H(]1M2.N^)BQ'XKN'XUU
M]C\+?!.G:DVH6OAZU2Y;)RS.RJ3W522JGTP!CM2ZK<P> ?"]KIVA^&M3U&'#
MPVUK9(TPC)R1YC,250D]><4 8?A"Z3QG\1-2\61'=I]C9Q6%D<YRSJ)9#]1N
M"UZ0[K&C.[!44$LQ. !ZUR_PZ\,-X1\$6&ES*JW6#-<[>GF.<D>^.%_X#70Z
MA8V^J:=<V%XADMKF-HI4#E=RL,$9!!''H: //YI;[XJ2/:VIDLO!:2%)KD$K
M+J94_=C_ +L61RW5N@[XT?'ND^'9M)T:QOM0DT6:.ZCCTB[MT(\B8#"J,# !
M Q@D#CK5?_A27P\_Z%[_ ,G;C_XY72?\(?X?/AB/PV^F12:1&NU+:0LX7DG(
M8DMG)/.<T >8^(-"OF\:^#M,U;Q3<:]K:ZDET$6!($M[>/+,QC3N2 -S'G&!
MWKVJN?\ #?@?PUX1,C:'I,-I)*,/)N9W(]-SDG' XSBN@H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**.M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD;G4<_-QG&>*Z36/'MAIOA[2M4M+6YU"75RBZ?:0@"29G7< <\* .I[5EVX
M^ *@  ?\(WV_Z]ZYJ;Q/J&A_#WP!I]EJ=OHR:G;I'-JUQ")$ME6,$#!^7+$]
M^.#TZ@ Z?3OB#JD?B2PT3Q/X3N-#EU$LMI,+Q+F-V R5+*!M/Y]14/A?_DL_
MCK_KC8_^BJX2ZFMI/B;X.\OQG=^)IDO<3S I]EA++\H78-H8X/&2>*[OPO\
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MN4[CG 7('"C  P/>O1OAQ_;'_""Z7_;'V'?]GC^S_8]^/)V+LW[OX^N<<>E
M'5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[2"*XN2#/+'&%>4@8!8@9; XYJQ10!0U/0](UH1C5=*L;\1Y*"ZMTEVYZXW
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MHS2-I>DV-B9/OFUMDBW?7:!FM"B@"O!86=M=7%U;VD$5Q<D&>6.,*\I P"Q
MRV!QS3;33;&PDN)+.RMK>2YD,L[0Q*AE<_Q,0/F/N:M44 %9UMH&C65_)?VF
MD6$%[)G?<16R+(V>N6 R:T:* *XL+-=0;4!:0"]:/RC<B,>84SG;NQG&><=*
M9J.E:=J]N+?4["UO8 VX1W,*R+GUPP(S5NB@""SLK33K5+6RM8;:W082*",(
MB_0#@52'AG01J7]I#1--%^&W_:A:1^;N]=^,Y_&M2B@"KJ&F:?JUM]FU*QMK
MR#.?*N8ED7/KA@118:;8:5:BUTZRMK.W!)$5O$L: GJ<* *M44 %9LWAW0[C
M4QJ4VC:?)?@@BZ>U0R@CI\Y&?UK2HH ;)&DT3Q2HKQN"K*PR&!Z@CN*CM+2V
ML+6.UL[>*WMXAMCBA0(B#T ' J:B@#,N?#FAWFH+J%UHVG3WJD%;B6U1I 1T
MPQ&:MW5A9WS0-=VD%PUO()83+&',;CHRY'!]QS5BB@ KC?'>AZCK-]X5DL+;
MSDL=8BNKD[U79$ <MR1GKT&37944 9]AH.CZ5<37&G:58V<TW^MDM[=(V?G/
MS%0">?6IM0TS3]6MOLVI6-M>09SY5S$LBY]<,"*M44 5K/3K'3K,6=C96]M:
MC.(8(E1!GK\H&*+73[*RL5L;2SM[>S4%5MXHE2, ]0% Q@Y/YU9HH JPZ986
M^G#3H;&VCL0I06R1*(MIZC:!C')XJ+3=#TC15==*TNRL1(<N+6W2+=]=H&:O
MT4 4=2T72M9C2/5-,L[Y(SE%NH%E"GU 8'%26^F6%I<-<6UC;0S/&L321Q*K
M%%^ZI(&<#L.U6J* $95=2K ,I&"",@BLNW\,:!:0W,-MH>F0Q72E+A([2-5F
M4]0X ^8?6M6B@"FVE:<XLPVGVK?8L&US"I\C P-G'R\<<8I-0T?3-7$0U+3;
M.]$+;H_M,"R;&]1N!P?I5VB@"CJ6B:3K*(FJ:997RH<HMU;K*%/MN!Q4ITZQ
M.G'3C96YL2GEFV\I?+*?W=N,8]JLT4 ,AABMH(X((DBAC4(D:*%55'   Z"G
MT44 5-/TO3])MVM]-L+6RA9BYCMH5C4L>IPH SP.:<-.L1J)U$6=N+XQ^2;G
MRE\TIG.W=C.W/.,XJS10!#=V=K?VSVUY;0W-NXP\4R!U8>X/!J'3=(TS1X6A
MTO3K2QB8[F2U@6)2?4A0*N44 9NH^'M%U>9)M3T?3[V6,81[FV21E^A8'%6;
MO3K&_L_L=Y96]S:\?N9HE=..1\I&.,#%6:* *M[IMAJ<4<5_96UW'&XD19XE
MD"N.C $<$9/-6J** ([BWAN[>2WN88YH)5*21R*&5U/4$'@BEAABMH(X((DB
MAC4(D:*%55'   Z"GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<#DYZ4]M:L5AAE#S.)MVQ8[>1V^4X;*JI(P>#D#%59K*Z%I=%(=\@O5N$CW
M>8H93@<XR<'&<<^E5'TZ<QI,^GW1N'>9E-O=^6T&]L@-AP". 3@GD=#3L@NS
M=:]MDNQ:&4?:#$91$ 2VP$#.![G\:J+K^GMYH+7"-$%++):RHWS'"X!4$DG@
M 9IRV<HU:TN"B';;R+-(N!ER8\>YX4_E5:6QN&T^XD>*5KN2Y\X"*1%=0K83
M:6^7(4#@\'G/6DD@U+4NMZ?#!%-),RI)G'[I\KC[Q88RH'<G&.]2G4K;[8UH
M/.:51EMD#LHXSRP&T'';-8 TS4H;=I!;R7$US'/&ZR2)NC+E=K,1A>B\[<X[
M BKT5A+!JH:"VN(SO5I+C[3F*10H!RF[[W&/N]AS3L@NR_9ZK:WT\D$/GB6-
M0S++;R1$ YP?F4>A_*KM4+&*:".>::)FGGG9F4%<A=VU>^,!0#^??BK]2QA1
M112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img101536035_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1TJ9O*L+N-F0MP NWS8S_P!\DCZFN/U$RZY9>(/%5TIQ/>)#%N[,Q+X'^ZJ
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MTT5F9GCA .5BB0$E@/[Q"Y^I]*]-^#^C?V9X(CNG7$U_(TYSUV_=4?D,_P#
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M .^Y(.<G/''3K74?!O69[7Q)J'AW[5]IL2CR0,"=NY6QE1V# Y_ 5S/@JZ\
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M)EPA8J5'J!@G'TZ<Y?\ R]CZ!T9B?$OP)I/A"QTN;3KJ9WG+(ZRL&+X .\8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$+;XW#N=I]>3BNEHHIN3ENPL8.E>"_#NB:A]NT[3([>ZP5\Q78G!Z]3BB_\
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M@3PQI]E<6EMH\"0W*;)<EF9EZXW$DX_&M'1M"TSP_9O::5:+;0/(9&16)RQ
M&>2>P'Y5HT4.4GNPL<WJ/@'POJNIG4;S28WNRP9I$D>/<1W(5@":Z2BBDY-[
ML85@:;X*\.Z1J0U&PTR."[7=B4.Q/(P>IQWK?HH3:V *P=*\%^'=$U#[=IVF
M1V]U@KYBNQ.#UZG%;U%";6B BN;>*\M9K:X0/#,C1R(?XE(P1^1K+T7PIH?A
MV:672=/2UDE4*Y5F.0.>Y-;-%%VE8#GM6\"^&=<OOMNHZ3%+<G&9 S(6Q_>V
MD9_&B]\#>&-0BMHKG1[=H[9-D*KE BYSCY2.]=#13YY=Q61!>6=MJ%I+:7<*
M36\J[7C<9#"LG0_!N@>&[J6YTC3Q;32IL=A*[9&<XPS$#FMVBDI-*R8QDL23
MPO%(NZ-U*L/4'@URP^&?@Y2"-#AR.>9'/_LU=9134I1V86,_3-"TG1E8:9IU
MK:;AAC#$%+?4CD_C6A112;;W YO5/ 'A;6;IKF^T:%YW.YGC9HRQ]3L(S^-:
M>D:#I6@P&'2[""U1OO>6O+?4]3^-:-%-SDU9L5D<WJG@'PMK5RUS?:- \S'+
M/&S1ECZG81G\:TM'T#2= @:'2K"&U1CEM@Y;ZD\G\36E10YR:LV%D8*>"_#L
M>M'6$TR,:@93-Y^]L[SR3C..]>4_%34C+\0K&QUR*4:%;;'41+AI%8#>0>O4
M8Z]O6O=*IZAI6GZM"(=1L;>[C!R%GC#@'VSTK2G5Y97EJ)JZ/!/$J?# :%,^
MAR7AU(K^Z1?,P&_VMXQCZ&NT^#N@W4?A+4CJ<+BRU)L1PR9&]-I#-Z@-G'X5
MW%IX.\-6,HEM]"T]) <J_P!G4E3[$CBMNKG7O'E5_F"CK<QM%\*:'X=FEETG
M3TM9)5"N59CD#GN346H^"_#NK:H=2OM,CFO#M/FEV!^7IP#CL*WJ*PYY7O<=
MD%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Q_[[?G5OR(_[OZFCR(_[OZF@"IYC_WV_.CS'_OM^=6_(C_N_J:/(C_N_J:
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MKX*_Z#7_ )*S?_$4>RG_ "L.678[*BN-_P"%J^"O^@U_Y*S?_$4?\+5\%?\
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M_A:O@K_H-?\ DK-_\11_PM7P5_T&O_)6;_XBCV4_Y6'++L=E17&_\+5\%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6SX1_Y'30O^PC;_ /HQ:QJV?"/_
M ".FA?\ 81M__1BU,OA8GL?5U%%%>*<04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%9^IZ[H^B>5_:VJV-AYV?+
M^UW"1;\8SC<1G&1T]16?_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\
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M.SS?,SAB<YVCUIPA)23?F.,7='-4445TF@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6SX1_Y'30O^PC;_ /HQ:QJV?"/_ ".FA?\ 81M__1BU,OA8GL?5U%%%
M>*<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI/<2O++)9R,[NQ+,?-;DD]:T/$GVC_A<D'D[\_:K7R,?W=J8Q[5GS2:^_P#
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MO!IVEV\5PC*;C2IMUM.P/55Q\A (R.<TX5;M)@I7T.+HHHK8L**** "BBB@
MHHHH *V?"/\ R.FA?]A&W_\ 1BUC5L^$?^1TT+_L(V__ *,6IE\+$]CZNHHH
MKQ3B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVT8P^J0XO++U6(9^;'8]_I7/'7["7Q[K/BI)5$5OODM$<X::0C9'A>N/XCZ
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M_L(V_P#Z,6L:MGPC_P CIH7_ &$;?_T8M3+X6)['U=1117BG$%%%% !1110
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MC)!XR3^=5O\ A$?#7_0O:3_X!1__ !-;-%/F?<=V8W_"(^&O^A>TG_P"C_\
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M\ H__B:V:*.:7<+LQO\ A$?#7_0O:3_X!1__ !-'_"(^&O\ H7M)_P# */\
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MY#H][?->6L32YN$7RYE7KMQR/QJA=0:=JMU;:?X<LKCS'9F+74BAW.,[1S@
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MX_X3+3O^>-U_WRO_ ,51_P )EIW_ #QNO^^5_P#BJX>B@#N/^$RT[_GC=?\
M?*__ !526_BNPN;F*!(KD-(X0$JN,DX]:X.K>E?\A>R_Z[Q_^A"@#TZBBB@
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M1G)?#_PE+%*NLZA$4('^C1MUY_C(^G3\_2O1Z**PE)R=V:)604445(PHHHH
MX?QE_P A>+_K@/\ T)JYZNA\9?\ (7B_ZX#_ -":N>H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K>
ME?\ (7LO^N\?_H0JI5O2O^0O9?\ 7>/_ -"% 'IU%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RNNZC:Z3XV
MT:\O9&BM_P"SKZ+S-C, YDM2!P#U"M^1JU_PF_AW_H(?^09/_B:Z"B@#G_\
MA-_#O_00_P#(,G_Q-'_";^'?^@A_Y!D_^)KH** .?_X3?P[_ -!#_P @R?\
MQ-'_  F_AW_H(?\ D&3_ .)KH** .?\ ^$W\._\ 00_\@R?_ !-'_";^'?\
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M54JWI7_(7LO^N\?_ *$* /3J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#A_&7_(7B_ZX#_T)JYZNA\9?\A>+_K@/_0FKGJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JW
MI7_(7LO^N\?_ *$*J5;TK_D+V7_7>/\ ]"% 'IU%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!P_C+_D+Q?\ 7 ?^A-7/5ZS10!Y-17K-% 'DU%>L
MT4 >345ZS10!Y-17K-% 'DU%>LT4 >345ZS10!Y-17K-% 'DU%>LT4 >345Z
MS10!Y-17K-% 'DU%>LT4 >345ZS10!Y-17K-% 'DU%>LT4 >345ZS10!Y-17
MK-% 'DU%>LT4 >345ZS10!Y-17K-% 'DU%>LT4 >345ZS10!Y-17K-% 'DU%
M>LT4 >345ZS10!Y-17K-% 'DU6]*_P"0O9?]=X__ $(5Z=10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%41K-@=+?4A/FT0L&<(V05;:1MQG.1CI0!>HJH^IV:0VDS3C
MR[MU2!@I.\L,CH/09YJW0 4457AO;>XNKFVBDW36Q595VD;2PW#GOP>U %BD
M9E1"[L%51DDG  I2<#)KR?QSXT_M%WTK39/]#4XFE4_ZT^@_V?Y_3KOAZ$JT
M^6)RXO%0PT.:6_1=SIK7XB:;<^(FT\C9:'Y(KHGAG]QV!['_ !X[*OGI=%U!
MK$W@@'E"/S<>8N_9G&[9G=MSWQBN]\">-=WE:/JDOS<+;SL>OHA_H?PKMQ."
MBH\U+6VYYV"S*<I\F(TOL_T_R/2*J:GJ5KI%A+>WD@2&,?B3V '<FGWU[;Z=
M9RW=W*(H(AEF/^>M>(^*?$]QXDO]YS':1DB&'/0>I]S7+A<*Z\O)'9CL;'#0
M[R>R/3O"WC2U\1R2V[QBVNE)*1EL[T]0?4=Q^/TZBOF^WN);6XCG@D:.6-@R
M.IP017M/@_Q;%XBM/*F*QZA$O[Q.SC^\O]1VK?&8/V?OPV_(YLNS'VW[NK\7
MY_\ !.GK!\4^*+;PW8AV ENY/]3#GK[GT J7Q)XCM?#FG&>;#SOD0P@\N?\
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M=Z6N(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *HZCJ4=BH&-\IZ+GMZFC4=12QBP,-,P^5?ZFN<N(+HEYYQEN"_S D9Z
M9'4548WW$V=5:W45Y )8CQW'<'TJ>N3M6NM/?SU7Y!C>NX'@^HZC\:Z:VN8[
MN$2Q'(/4=P?0T25@3)J***D84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&&P2>"1\IYHLPN;5%5-,O3J.F6]Z8C$)TWJA.2%/3L.V#5ND,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV4C/!)X />CFD_F&ALT56T^^@U/3X+RVECEBE0,&C<.ON,CK@\59K,84444
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M18@I^8J5V2D#K@(S'/;BNHHI<P6&QQK%&L: *B@*H'8"G444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAM=/BMH0G_%/WT:K&O81QX&!7HE%'M=;V"Q1T:Z@O-%LI[::.:%H5VO&P8'
MP>1[\5>HHK)C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !16'<>,_"UI<26]SXET>&>)BDD4E]$K(PX((+9!'
MI6AIVKZ;K$#3Z9J%I?1*<&2VF650?3*DT 7**KVE_97_ )WV.[@N?(D,,ODR
M!_+<=5;!X8>AYJQ0 4444 %%%% !115>]O[/3;5KJ_NX+6W3[TL\@1%^I/%
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M/LKJ"YAW%/,AD#KN!P1D=P>*L4 %%%5TOK26]ELH[J![N%0\D"R NBGH2O4
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MX8>AYH L4444 %%5Y[ZTM9[>"XNH(9KABD$<D@5I6 R0H/WCCGBK% !1110
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MZ>M9=QXK\<>&#;ZEXMTO13HDTJ13-ILLAFL]Y #/OX< D [?K6?XVAU3Q_\
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MR(& )(&<G'&1ZU[#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9UAI0L]2
MU*_>8RS7LBDY7 C1%VJ@^GS'/JQK1HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L[4]*&ISZ>TDQ2&TN!<F,+_K&4':">P!.[Z@5HT4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!4U2SDU#2KJRBN#;O/$T?G*NXID
M8) /?%2VMM%96<%K NV*&-8T'HH&!^@J:B@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "L[1]*&E07"F8SS7-Q)<RR%=NYF/0#L  %'L*T:* .
M6A\-7D?Q0N?$QE@^Q2Z6MD(PQ\S>)-V<8QC'OGVKJ:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"Q^W7<:%HK7S1%YK=EWGA?J:P[GQ9-9^*/#NA7&F;)]7MY99&\\'[.T:!BO
MP_)QG(Z5Y?9V5QIWP^^*=E=7DEY-!=2(;B4Y>0"-<%CW;&,^]7M:T9]?\1?#
M33A>3VD4FDR^=) ^US&(H]R@]MPXSZ$T >TU@7FNZCI]CXAO;S1?*MM,B::U
M?[4K?;%5"Q. ,Q\C'.?6N$U3PW8?#+Q+X;U'PR;BTL]1U%-.O; SO)%*) 0'
M^8DA@1Z_US%!]_XQ?[A_])FH [S3_$>HZKHGA_5+'1/.BU,1O<C[6J_8XV7.
M[D#S,=,  U+8^)X[[QGJGAU+9E?3X(IGF+<.9,D #V'>O-9/^1:^$'_7W;?^
MBZL^&O!GA^'XX>(GCT_#6,4%U;_OI#LDE#;V^]SG)X.0.U 'K]%>5Z-K8\!^
M&/&6E3D Z!+)-9*Q^]#-EH1_WV2M=7\.M#?P_P"!-+LYL_:GC^T7);J99#N;
M/ODX_"@#J:*\DL/#6G_$SQ1XIO?$9N;BWTZ_;3K&V6X>-+?8!EP%(RQ)SS3O
MB%I6H>'?@FVG3:O)J%U;7, BO)4VN1YZE-W)R5&!GOB@#TG6KS4;'3_.TO2_
M[3N?,5?L_P!H6'Y2?F;<W' YQWJC<>)XX/'%GX8%LS2W%F]V9]V H5MN,=R:
M\X\?>"M&\)_#Z>73HIC=7=]9FZN)IWD>9Q)G<=Q(!)))QBIM8\&Z!>?'RP,]
MAO-QI[7\O[Z0;ITD 5^&XP .!Q[4 >OT5X%JFI:=XI\9^(3XE\->*M?L["\:
MRL[;2X'>V@"<,Q*.IWL>>>Q'MB]I]UJ8^&OCW39[#7;72+:T9M,_MJW:.98V
M1MT>3]X*1QR< B@#V35+B\M=,N9["Q^W7<:%HK7S1%YK=EWGA?J:FM9)I;2&
M2X@\B=XU:2'>&\MB.5R.#@\9KQNX\&Z7IGP<U'Q$5FFUN^T,&YNY9W8L&56P
M%)V@#  P!@#%7O$H\/-X:\(CQ7XBEM-'-A'NTF!9-U\_EK@L8SNVCCC'4]:
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MD4GG;G! )/)-4/!?@72?%UYXODUTW-U9QZ]<I%9BX>.)7R"9"$(RQ! YZ 4
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MEE2&-@K.7=R H 4$G)- %^BBN0E^*/@F#6SI$GB&V6\#^61M?8&]#)C8/SH
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M)",O'L:-P/7:X!(Y'(&*K:O\2?!^A:O_ &5J6NV\%Z" T>UV"$]F900OXD4
M=5165J_B31=!TI=3U/4K>WLGQLF9LA\C(VXR6R.>,\50\-^/_"WBVXEM]#U>
M.ZGC7<T1C>-]OJ X!(]QZT =)17(2_%'P3!K9TB3Q#;+>!_+(VOL#>ADQL'Y
MULZ_XFT;PM8"^UK4(K.W+;59\DL?15 ))^@H UJ*R/#WBC1/%=DUYH>HQ7D*
M-M?:"K(?]I6 (_$5KT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 0W<<TUG/%;3_9YWC98YM@?RV(X;:>#@\XKDO^$;\;
M?]#_ /\ E&A_QKLZ*J,FMA6,S0['5+"S>+5M8_M6<R%EF^S+!M7 ^7:O!YR<
M^]:$TT=O!)-*P2.-2[L>@ &2:?4<\$5S!)!<1)+#*I22.10RNI&""#P01VI-
MW=QGC.B>$O$WC?3-8\00^*/[)LO$DDA>SDTR.=FMQE(\NS CY.F/7-:6D6EU
MXL^$5]X>E<_VYH4K6B.3@B> [HF'?D!1GZUZI;V\-I;QV]O#'#!$H2..-0JH
MH&  !P /2HK?3[*TN;BYMK.WAGN2&GECB56E(X!8@98CWI >=^"M6_X3_P 7
MIXE:(K;Z3IZ6J(RXVW<H#38S_= "?B:YJXACN/AG>PS(KQ2>+V1T89# W8!!
MKVFRT^RTZ.2.QL[>U220RNL$2H&<]6( Y)]:B_L72OLQMO[,L_(,WV@Q>0NT
MRYW;\8QNSSGKGF@#SOXOQ3QW'A2Y74TTFPM[YQ)>M:+<);2%,1LR-\N,Y&3T
MSGM57PY;+>?$;3;V?XDV7B._@MIL0V6F1KF(C!#RPL0H#%2 _?IUKUBXMX;N
MW>WN88YH9!M>.10RL/0@\&JFFZ)I.BI(FE:796*2$%UM;=(@Q'KM S0!XP-/
MM%_9JU6001[YIY9I&VC+.+K:"3Z@*!^%=AXAMH+/XE_#F.VACA14O8U6-0H"
M" 87CM[5W']C:7_9C:9_9MG_ &>V=UKY"^4<G<<IC'7GIUYJ:6PLY[JWNIK2
M"2XMMWD2O&"\6X8;:3RN1P<=: /$YQ&O@!KF[C,FEVWC*2;4%V[AY G;)8=Q
MDKFN_L]<\':QX]LFTHQ:CK"V,@^V6,H>."#(^60JV.21@8)!]*ZR'3K&WMY;
M>"SMXH)F9Y8TB55=F^\2 ,$GOGK46FZ+I6C+(NEZ996*R'+BU@6(,?4[0,T
M0^)(;JX\+:M#8[OM<EG,L.WKO*$+C\<5Y;%XG\!K\$/[,>YT\2#3_);3B!Y_
MVK;C_5_>W>9SNQ[Y[U[-6<?#^BG5/[4.D6!U#.?M?V9/-S_OXS^M 'GNEV,R
M>./ 46J1![VV\/2%_,7E)0(U)Y[\D?G7J=0-96KWL=Z]M"UU&AC2<Q@NJGJH
M;J <#CVJ>@#Q36#<Z/>:W\.;8-'_ &_?1RZ<R@X2WF)-Q^"['X_VZZ_4+:&S
M^*WA"UMXQ'##IEY'&BCA5 C 'Y5V<NGV4U]#?2V=O)>0 K#<-$IDC!ZA6QD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M66G%W- VV0Q1EF*!NV<_YZ'N=,\)>(M(\2^(FM[G2Y=#UEY;AO,\Q;F.5DP
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M+FSTUV#K-L4AW52"P QCD8P>?7>L?AQK5KX0\8Z1/J=O>7FMRO)%<REEW%E
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MB@#.70].3Q ^NK;8U)[<6K3[VYB#;@NW.WKWQFM&BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Q?$7A+0O%D-M%KE@MY';2>9$K2.NUNG\)&1['BM>**."%(88UCB
MC4*B(,!0.  .PI]% !1110 R6*.>%X9HTDBD4JZ.,JP/!!!ZBN.A^$O@2WU+
M^T(_#EMY^[< SNT8/_7,ML_2NTHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$,/0@U7.E:<UNEN;"U,,;;DC,*[5/J!C -":0-&)=W%V-7>Y:8>4L=L$@#.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img101536035_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG[P'7.,5<J3FXQTV%>USV>BOGGQGI'C71[2U\3:KKDOGW$H!AMYF7[.Q!(
M.,<8X_6O9O ^L3Z]X,TS4;HYN)8L2,!C<RDJ3^.,UG.ERQ4D[C4KNQ!XZ\6/
MX-T*/4DLQ=EYUA\LR;,9!.<X/I3-%\;6U_X%_P"$HU");*!0Y= ^_&UB  <#
M)/\ 6N?^-_\ R)$'_7['_)J\8N_$EQ=^&=,\/;FBL;1FDDV\F1V8G<1WP#P*
MVI4%4II^8G*S/=? WC[4?&M[<;-#6UL(/OW+7!8[CT4#:,GN>>*S=-'Q$_X6
M=*;LR?V%YKYR5\GRL';M[[NGOUS7:^%-.TS2_#-A;Z.0UD8@Z2#K)N&2Q]S7
MEFB^(=:F^.%QILNJWCV O+A!;-,3&% ; V],"HBDW+E6E@[7/;*\[^*OC'5_
M",&F/I+P*;AY!)YL6_@ 8QS[U@_$OQWK(\2Q^%_#LKPS HDLD7^L>1\80'L,
M$<^]<3X\L/&&EVFGVGBB[^UQ%FDMY3)YA#8 92Q /IQ^551H:IRZ] E+L?07
MA?4+C5?"VF:A=%3<7%NDDA48&XCG K6KR/Q%J5]I7P/T*YT^\GM)]MNOF0N5
M;!4Y&17.16'CCQEX+.L2ZTT5C8PMY4?F,'N=F=S$@]>",GTJ/8W]Z]E<?,>_
MT5Y7\&?$U[J6CZE::E=23K8E7CEE;+*C Y!)ZXVUSDWBKQ?\0O$%U;^'=0&F
MZ?;\JWG>5\N< LW4DXZ"E["7,TWL'-H>[T5Y%X \7:];>+YO"'B2X%U)M;RI
M]X9@P&[&X?>!7GU&*I^']>UOP]\7I= U?5;RZLYI&AB%Q*6&&^:-AGOT'XT.
M@[M7V5PYCVF@\"O&_&VN:UJ?Q4L/#FC:I=VD2^7',+:4J"3\S$X]%KV,#:H'
M/'')J)TW%)OJ-.YXW/\ '&\@FE0^&?EC<KN-PP'!QG[E1CX[7;*2GAG<!W6Y
M8_\ LE=U\4/^2<:S_P!<E_\ 0UK ^!O_ ")UY_U_-_Z"M="]E[/GY?Q)UO:Y
MZ#I%\VJ:-97[1>4US DICSG;N .*NUY3\:=:U71X]&.F:C=69D:7?Y$A3=@+
MC..M5_#V@>+?%^JZ9XLU353;6(E26*Q#N-T2].!QSC//7-9>R]WG;LA\VMCU
MZBO*_%]K\1;_ ,0W<5AJ<&FZ-%@Q7'G"%2".A;EB0<^U8'@;QMX@T[QQ'X>U
MG4AJ5O/)Y'F&42[7QE65QU!Z?C0J#<>9-!S:GN=%>*_%/Q/KFA^/K!-,U"YC
MC%M%)]F60B.1M[##+WS@"L+QII/C3P['9^(=4UZ5KFZEVE8)67R'QN"X^[C
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MY0,'((ZFA48^S<F]1<VI[[1117,6%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %177_'G-_P!<V_E4M(RAT*L,J1@B@#YK^&/AC3/%?B*\LM5CE>&.W,JB
M.0H=V\#J/8U[GX?\#>'?#,IFTS3T2X(QY\C%WQZ GI^%3Z-X/\/^'[N2ZTK3
M(K6>1-C.A;)7.<<GUK;K>M6<WH]"8QL>$_';_D8])_Z]6_\ 0ZZKXN?\DQMO
M^N\'\C79:UX2T'Q%<13ZMIL5W+$NQ&<D;1G..#5G5-"TS6M.73]1LTN+12K"
M)B< CIT--5DE#R#EW/+=)U:^T3X &]TYBER'9!(O6,-+@L/< UQ&ECP>_@[4
M=0UN[FN?$<F]8(I&<E3_  M[^I)-?1%IH&DV.C-H]O8Q)IS!E-N1E2&Z]:P]
M-^&/A+2[TW<&E*\G.T3.TBIGT!.*N->"OOJ[B<6<%\$+J"RTWQ'=7<BQV\(B
M>1VZ!0K9)KG==MOA_JMC<ZOHNK3:5?C=(MA+&<.WHN/NY]C@>U>ZZ1X4T+0H
M;B'3-,AMX[G F098/C.,@D^IK"N?A/X.NKLW!TLQDG)2*9T0_P# 0<4*O#G<
MM4'*[6//]%GUSQ=\'-=M)WFNGLI5-N[Y9W5<,RY[X_\ K5ROA/3?!&IVD@\1
MZK>:?>*QVE<>6Z=L?*<'KQ7TKIVFV6DV,=EI]M';6T8PL<8P!7,ZI\,/"6K7
MC74^F>7,YW.8)&C#'U(!Q3CB(ZK9/L#B97PPT7PM:'4-1\-:C=W@8BWE^T8&
M,<@@;0<'/6NUUO6['P]I,VI:C+Y=O$.2!DL3T '<FFZ+X?TKP]:&VTJRBM8F
M.6V#ECZDGDU)JVCZ?KM@;'4[5+FV9@QC<G&1T/%<\I*4[O8I*R/G36?%2>.O
M%,4VOWKZ?HT))2*-2Y5/0 #EV[GM7N'@_P 5^&M:B_LOP\[^790KB,PL@5.@
MZCFH_P#A6/@O_H 6W_?3_P"-:FB^$]"\.S2S:1IL5I)*H5V0D[@.<<FM:M2G
M*-E?0E)HMZSJ]IH6D7.IWTFRWMTW,<9)] /<GBO.IO&_PZ\9:7G7XH[><+RE
MQ&?,7_==1S^?X5ZA+%'/$T4L:R1N,,CC((]"*XV[^$_@Z\N#,=+,))R5@F=%
M/X XK.FX+XKW\AN_0\N^$L#-\37?3?-;3XHYMS-P?*/";O?.W\J=XPNDT7XX
M+J%X&6WCN+>=F S\FT D>O0_E7N6BZ!I7AZT-KI5E%;1$Y;8.6/J2>3^-4_$
M7@S0O%7EMJMD)98AA)48HX'ID=JV^L1=3F:TM87+H<S\0-6L/$GPKU2\T>Y6
M[MXW0,Z X&UU)Z^F:Y#P%XYT7P_\.M0L;V<B^$DIBMPI+2[U &.W7K7K.B^%
M-&T#2)M+L;7%G.298Y'+[R1@YS["LK3OACX2TO4UO[?3,S(VZ,22,Z(>Q"DX
MJ8U*:BX.]KW&T[W/-?@2G_$^U9#Q_H:C_P >K*\":K;^"?B->1ZT3!&/-MI)
M"I.P[@03CL<=?>O=M*\+:)H=[<7FF:=%;7%P")70G+<Y[GUJEX@\!>'/$UTM
MUJ5@&N0 #-$YC9@.Q(Z_C5.O%RE=:,7*['A_CW7M/\1?$6&\TR7SK9#!$),8
M#$-R1GMS7L_Q*T#_ (2#P3>PQINN;<?:8?7<O)'XC(_&IQ\._"0BM4_L.VQ:
M_P"J/.0<YR3GDY]:S/B#\0X_!9M[5+'[5=7<3LF7VJF, 9&.>3^E)SYY15-;
M!:U[GCV@-/XTUSPIH4JDP6"E']XPQ<G_ +Y 6OIL# P.E>1?!CPK<V@N_$6H
M0-"]POEVR.NT["<LV.P)P!]*]=I8F2<[+9#@M#QKX]_ZG0O]Z;^2TB_%K2-)
M\!6>G:>)I]4CLT@YC*I&^W!))ZX]NM>H:WX9T;Q&(1J]A'=B DQ[R1MSC/0^
MPK.M?AWX1LYUFAT"S#KR"ZEQ^3$BB-6GR*,EL)IWNC@O@GX9NHH[[7KJ-HX[
MB+R+<L,%QG+,/;( _.O.[/1])LO%UWI/BV6[M((G=/-@QE6SP3D'*D=Q[5]3
MJJHH50%4#  & !6#X@\%Z!XG97U33TEF4;5F4E' ]-PYQ3CB?>;EU!QT/-_"
M7AGX>MXOLET77KZ[OK<_:8U)7RV*]L[!D\YP*D\;2?#SQ'XCO+34-0DT[4[;
M$;WL:YCD('*GJ"5Z=OK7H&@>!/#GAJ;[1ING(MQ@@3R,7< ^A/3\*BUSX>>&
M/$%R;F^TU1<-]Z6%C&S?7;UH]K'GO=ARNQY?\)=6O[7QQ+H5K?R7VD%)3N(.
MT!?NR*#]W/ Q[U!\//\ DM5Y_OW?_H5>S:!X4T3PQ$Z:38I 9/OR9+._U8\T
MRP\'^'],U=]6LM,AAOW+%IE+9.[[W?'-$J\6Y66Z#E>AY!XO:*/XR[]#OX=*
MOXU#S75XX6'S=GTZ%< YZFMWPUX<CO\ QO'XB\0^+-'U#4$(:*WLIU(+ 87T
MX'8 5R7BR[TW4/BAJ2^+H[FRM(\Q1&SC =@/N,V0=P(SSSV':L'6M-\.75Y:
M6G@QM5O[F0D,LT8Z]MN #G\*Z%%N*6VF_P#P2;ZG<_'O_D(:-_UQE_F*Z7XD
M_P#)'H/]RV_I72'P;IFLZ-I<?B6RBO[VUMEC:21C][ W=#SR*UM0T+3-5TI=
M+OK-)[)0H$+$X&WIT/:N7VL4HKL7;<X3X6ZE;Z/\*)=1NR1;VTD\K[1DX![5
MN>"?B%8>-9+N&WM9[6>V 8QRD'<A. 01_*MRS\.Z1I^C2:1:V$4>GR!@\ R5
M;=UZ^M5O#G@_1/"BSC2+3RFG(,CLY=B!T&3V'I4RE"7,[:O8$FC3U/\ Y!5Y
M_P!<'_\ 037SG\,/$&A^'=6O9]=QY$MNJ1Y@,OS;L] #CBOI22-)8GCD7<C@
MJP/<&N4_X5CX+_Z %M_WT_\ C3I5(QBXRZ@TV[H\6\8:IIOBKQM8MX4L'B<E
M(P4B\LRR;LA@HZ8'?VKJ/CON6;0MQRPBER?4_+7J^D>%M"T%B^EZ5;6KD8+H
MGS8]-QYI-;\+:)XC:%M7TZ*[,((C+DC;GKT/L*T5>*E%I:(7*['E?B#X<6A^
M%>G7^EPEK^V@%U,V/FG5U!<'Z=1["NI^$GB[_A(/#O\ 9UU+NO\ 3U"$D\R1
M?PM_0_0>M=]!;0VUI':PQJL$:"-$Z@*!@#\JQM*\%^'=$U W^F:7%:W1!4R1
MLPX/48SC%9NJI0<9?(?+9Z&\1D8/2OF/599O!/BGQ1I<*D1W4,ELGLCD,I_
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M+M&7^N#S]:T=!\*Z+X9B9-)L([<N,/)RSO\ 5CR:UJ5U.+LW^@E&QXS\/O\
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M1W+9 SG'!]:U5>*E%]E87*['&?&O_D1+/_K\C_\ 06K=^%?_ "3?2/\ =?\
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MXWY4 7MP]11N'J*H^4_]QORH\I_[C?E0!>W#U%&X>HJCY3_W&_*CRG_N-^5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !152^U6PTP1F^NX;<2
M$A/,;&['7%1V.M:9J4K165]!<2*NYEC<$@>M.SW"Y?HHJ*>YAMD5YY5C5F"
ML<98G %("6BB@D 9)P!0 456L]0M-0C:2SN8YT1MK-&V0#Z59H **9'-',&,
M4BN%8JVTYP1U'UI] !1437$*7$=NTJB:0%D0GE@.I'YU+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *",C!Z444 85WH1:Z5K<A8G/S _P?2M>VMHK2$1
M1+@#J>Y/J:FHIMMBL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/!'<PM%*NY3^E8L&
M@,+L^<P,"\C'5O;VK>HIIM"L(JA5"J  . !2T44AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5+4=.COHNRRK]U_Z'VJ[10G8#)TO2/LQ\ZX ,W\*]0O_P!>M:BBFW< HHHI
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBHKF=+6UFN),[(D+M@<X R: ):*QH=<NIX
M(YH] U(QR*&4[X!D$9'_ "UJ3^U[W_H7]2_[[M__ ([0!JT5E?VO>_\ 0OZE
M_P!]V_\ \=H_M>]_Z%_4O^^[?_X[0!JT5E?VO>_]"_J7_?=O_P#':/[7O?\
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MC.$W'K@XX_&I]NDW?Y?<+G/&Z*]FA\%Z)9?%JTM$LX)M-O+*2?[+)B18W'!
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MG<BE.3BKH)-I7/-:*M^6EMK/EZE;LD<=SMN85;:5&[YE![8YKO;3X>V$NO\
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M/YYKBZ*?LXWN'*CMM5\3^#]1DOKW_A$9O[1N\L6>\(C20]6 'OS5+_A+(?\
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M $ ;C_OM/_BJ/^%<>,?^@#<?]]I_\57T_11]<GV0>V9\P?\ "N/&/_0!N/\
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M^^T_^*H_X5QXQ_Z -Q_WVG_Q5?3]%'UR?9![9GS!_P *X\8_] &X_P"^T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+=^+=
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M:;_X$I_C7RK11]3CW#V*[GU5_P )KX7_ .A@TW_P)3_&C_A-?"__ $,&F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U:^73-(N[UND$3.!
MZG' _.KE<I\19S#X/G4''FR(A_//]*<5=I">B/&Y)7FE>65BTDC%F)[D\FFT
M45W&!V>G0"?X>*IU*+3\:B3YLA8 _+T^7FC5%_L+PG+87-^VHR:DR2V[H&:*
M-5/)#'N?05A'5HCX371_*?S1=FX\SC;C;C'KFGVNLP_\(Y<Z/?122IN\VTD3
M&87[]?X3_C6?*RKF7;/#'<QO<0^="K9>+=MWCTSVKH_%5T;[1?#UR8HH=\$N
M(XEPJ .  !]!7+UIZCJ<=[I.DV:1NKV44B.S8PQ9LC%6UJF(CEETM-0@DM[2
MXDM54&6&>0 NW?D=!TK8\5W37VE^'[DQ11%[63$<2X50'P !]*PKYK%ID.GQ
M3QQ; &$S!B7[D8[58U+4H[W3-*M4C=7LH7C=FQAB6SD4K:I@-DFTJ/4H9;>T
MGDM%4&2&>0 NW?D=!TK6\6737MCH%RT<<9DLV.R)=JJ-^  /2L._:Q:=3I\4
M\<.P9$[!FW=SQVJQJ6I1WUAI5ND;JUE 8G+8PQ+9R*+:I@9M&2"""01R".U%
M%4(]\\-:D=7\.V5ZYS(\>)/]X<']16K7$_#"8R>&YHCTBN6 _$ _UKMJXIJT
MFC=.Z"BBBI&<+\7_ /DG=Y_UVA_]#%?.5?1OQ?\ ^2=7G_7:'_T8*^=[90]Y
M;JP!5I4!![@L*]+"?P_F=-'X2*BO9_%UQX3\+>(X-)'@6VO?-B63?" &Y)&
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MK4L/#>N:I:-=V&DWES;J2#+%$2N1UQZ_A5[3-#M;KPGJ6I3B475M?VULH#8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB/\ A3?A#_GWO/\ P*:C_A3?A#_GWO/_  *:CZW3\P]M$^=Z*^B/^%-^$/\
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M4WX0_P"?>\_\"FH_X4WX0_Y][S_P*:CZW3\P]M$^=Z*^B/\ A3?A#_GWO/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"^3_C1_P )CJ/_ #QMO^^3_C0!W%%</_PF.H_\\;;_ +Y/^-'_  F.H_\
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M.H_\\;;_ +Y/^-'_  F.H_\ /&V_[Y/^- '<45P__"8ZC_SQMO\ OD_XT?\
M"8ZC_P \;;_OD_XT =Q17#_\)CJ/_/&V_P"^3_C1_P )CJ/_ #QMO^^3_C0!
MW%%</_PF.H_\\;;_ +Y/^-'_  F.H_\ /&V_[Y/^- '<45P__"8ZC_SQMO\
MOD_XTA\9:B 3Y-M_WRW^- '<T5';R&6VBD;&70,<>XJ2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J.L_P#("U#_ *]I/_035ZJ.L_\ ("U#_KVD_P#030 [2?\ D#6/
M_7O'_P"@BKE4])_Y UC_ ->\?_H(JY0 4444 %%%% !1110 4444 8OBO_D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6(@J%N1*)!GD8]:LZY9102W&HW$?G;]B1QAL!3M'S-CGZ"L::]L_L[PV>GK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]_%_QH/A?5R#_HJ_]_%_QH [RS_X\;?_ *YK_*IJBMD:.UA1AAE101[XJ6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-S$&$<T:R*'4J<$9&0>AYZ5YA>:EKOAVX\8Z.==N[Y;70SJ-K<W"IYL,AWC
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MUCS%O'M[>8Z:ZRW$0 99'C ^4\X..,B@#N)=:LH=?M]$=G^VW$#W$:[3@HI
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ML1@;0#L..X!XH ]>HKS[2=+\4K9Z1KTWB\RRW)BEO+2ZC1;4QO@E(\#<K#.
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M.\C&/E.#WXKA[&Y\71_"^W\<2>*KB6[M[7[3]B>)/(EB4G*OQN+D?Q C![4
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M<:_\0A%IUXW]CZ=IZ33A,;9II^8P?8(-W_ A0!V-%%% !1110 4444 %%%%
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M(Y%B3^+;O!P2>IZ]NE=K10!QU[H'B2W\)7EG;^);^]U225&@NFCBC:,97*\
M#;P2>^"<5V&,K@GMBEHH XY_A]:O\/8?"!OY_(B=7%QM7><2^9TZ=>*V+[P[
M#?>*-,UQYW62PAFA6( ;7$@4'/TVULT4 >=S_"B*;1I]#'B355T0L7M[$;-L
M)W;A\V-S*#R%)Q6]-X+L[G5-<O)[B5EUBQ2RFB  "(JL,@^OS&NFHH Y+3/
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MTSQ'JFF:5?2-+<V%OL*[G/S[&*EHP?0&NXHH XZ_^'\4NJ66HZ7K%[I5Q8V
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M2=1T:\2\FD;2],_LU%90 ZY4[C[_ "U7OOA_8ZA!XHAGNY]GB!HWEV@ PE%
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MWN)8T&/]8?F;=UZ"NA\=:W'XI7P5=:?<:>VB7\TK/_:0;[,9@@\N.8*>H.[
M/&X4 >J)JVFR6)ODU"U:T!P9UF4QCG'WLXZFIYKF"V"&>:.(.X1"[!=S'H!G
MJ3Z5Y)H_AA=0\3:[HUS>^'XX[W2C%>:=HT,JQJQ;]W,V<HKCGC(.,'%2>%;^
MZ\8ZWX=TV_0E_#$+RZD&Y!O%)ABS[X5Y/Q% 'K9( ))P!U)JM9ZG8:AO^Q7M
MM<^6</Y,JOM/H<'BN,^+\MW'X$(MI%C@DO(([R1]P18"^&W[>=O0''8FN;TS
M2I;#QWX<D2]\)V,S!PL&B02AKN#9R'QE=HX(9NXZT =9X:\7:IX@TC2;_P C
M3H1<WT]O<(\Q4[$9U'E@_>;Y1D?6NJEU33H+K[+-?VL=QM+^4\RA]H&2<$YQ
MCO7C'A?']E^ <_\ 0P7W_M:EM++PM=_"?7]0U\6AU_==F]GG(^TQW(9PB@GY
MAQL 4<$4 >HZEKEW:W%U+;?V?-81:4]Y&?/S*\@)Q\HZQD?Q>M2>&O$=MKFC
M:7/+<6J:A>645T]HDH++O0,<+G..:\WL1BZM#@;O^%?_ -16?/8^&+;X0Z!?
M:$+4>(<VALYX2#<O<ED#J2/F/\0*G@ 4 =]XH\7:IX=TS6[Y8-.F2SN+:*V1
M9BSE9"H;S0/NGYN/45<UKQ:_AR'Q!?ZBMDUAI\<;6Z0W \^1F7)5U/"DG[OJ
M*\V\8 >5\1^F?[2TO/Y1U;\8VT5Q)\5_,A20I:64B[E!VL(3AA[CUH ]9TW6
M+'5((7MKNWD>6$3>7',KD*>,\=L\9]15M+B"2>6&.:-Y8L>8BL"R9&1D=LBO
M-=9CL?"W_")>+K..""PM4%C?F!0%%O, =QQQA9 #_P "-;OPYM)6T*XUZ[C*
M7NNW+W\@;JL;<1)] @7\S0!U%YJ-CIR*]]>6]JC':K3RJ@)]!DTEQJ5C:(KW
M-[;PJR&13)*J@J,989/09'/N*\_2TT74OBMXEC\31VD[P6UM_9T5\%*" H3(
MR!N/OYR>V!6+:Z=X9U?Q+X'L]/MI+K0XCJGD1W?SH^TI]W/WHP<[>W ]* .[
MU7Q:-%@UK4KM["72[*UCGM_(N09I2P)P0>!G V^O-:UAKVGWN@V^L&[MHK66
M-7:1IEV(2.5+=,@\5Y9XIL+47?Q*M8[6$0P:%:&*((-L>U)2NT=L8X]*K:M:
MM+JW@G3[6/0TTQM*,L$6HH3:2W7R[LJF 9,'(SZGO0![,NH6367VU;RW-IC/
MGB5?+QZ[LXK.N]9+7EC%IESIDZ-=^1=A[D;D&TG" =7R!\I[9KQ_4+-['PK\
M0H5U#1FC^R1&:PTB*18+>7/WAN^4,PZA3V&0*Z_7-&TW1KWP'#IMC!:H^JH7
M\I I<B!^6/<^YH [^XU;3;.Y2VN=0M()W^Y%+,JLWT!.34[W5O'<Q6[SQ+/*
M"8XF<!G ZX'4XKPB_6RU70_%&L0VOARVLY+BY66XU@FYOF=<C"CCR^1A5[<5
MZ7X.CTJ[\->#[R]-M+JZZ7']FDF8&;F)?,VYY/OB@#L20 23@#O5.TU;3K^5
MXK/4+6YDC^^D,RN5^H!XKG?B;?6ECX#OVO89IH)C' 4BG\G)=P!ND_A7U/IF
MN BM3I7Q(\&QL/#%I.\LJBWT2,J_EF%L>8Y/S#.,9')YH ]0\2^)+;0]'U.:
M*XM'U"UM)+F.TDE 9]JDCY<YQQ5S2=5BU"PL9))(4N[FTCN6@5QN 8 D@=<9
M.,UXS#8>%KOX.ZY?:ZMH?$&;DWD\VW[2EV&;:H)^8?P@ <$5TFB30V?Q(T"6
MZEBA$WA*-(VD8*&8.I(!/?'.* .L\7>*CH&E1W-B+>ZE^WP6<J%\^7YC '..
MA .<&IM.\8:=J?B[5?#L3QBXTY8B6,RGS68,6"KG/RXY]":\HU&[M[[3_$MU
M:3)- _C"TV2(<JV/+&0>XR#S6\^GZ3'XX^)+731V&=/MV%W#$#+"KQ2>9(@
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MFIV$D<\B7ULR6YVS,LJD1GT8YX_&O%;ZQL;3PA\5O)M;:*=;Z1%V(H81%8R
M,<A<\XZ9KH?%VF:%I.D>&]&M-%LM^H72&-)I/(MG=(R0UP0,R=>%/4T >D6N
MJ:?>V[W%I?6MQ#'G?)%,KJOU(.!1'JNG372VL5_:O<.@D6)9E+LI&0P&<XQW
MKQK3D%GXZ\1VIDT-96\-3-/!HL1CA5@W 89Y?!Z\<$4ZZT'2M+^$'A/6;.P@
MBU-9=.G^UJN)2SLF[+]<$$C&<8H ]DN-3T^SN([>YOK:">7_ %<<LJJS_0$Y
M-+<ZA969875Y;P%4\QO-E5<)G&XY/3) S7C_ (ATRWEU_P 57-NOA[6X6?\
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M;);'7G;R><GW-86H+9ZKH_BG5XK7PY;6CW%RLUQK#&YO6=<C"CCR^1A5[<4
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MUXOBBL[>0:'96]S"6+?O#)G(;V&.U=<NLV,=DD]Y>VMN?*22023*H3<.,Y/
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MH[,*%,?E?(S!>/7![\^E 'J5%%% !1110 4444 %%%% !1110 4444 %%%%
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MXJS10!CWGA3P]J&IKJ5YHEA/>K@B>2W5GXZ<D<U+JWAS1=>\K^UM*L[WRO\
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MM(O+4XC1L_.23C*\8H UKOXF:/;2W3)8ZM=6%I(8[G4;:T+VT3#[V6SD@=R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=+L;BX8E3N5@6..O&!VJ"\^'FJZAH&M?;-2M9=<UBYMIIY0C)!&D+J5C0<G
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M/-++90VDJ:E"[>3Y8^]$5YP<\KQGUJI'\.]9&CWME<:I:7,UQKT6K>>8RFX
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MWR.4?*MA@5.01@\=\U>'PYO+33K*[L=6C'B2VOIM0:\EA_=32RC$BL@.0A&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img101536035_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI)JFGQ2-')?VJ.IPR
MM,H(/N,U;KR/QM\++)H==\2?VE<>=LEN_)V+MR 6QGTK2G&,G:3L)MK8]/\
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MQI;>&I+"9YYY(8Q,KC:#(0!QUXS4WC7Q[:^"GLEN+*:Y^U!ROEL!MV[>N?\
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MIQI3DKI!='I5%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU>^46TD<9& 6)W 8)_@![]Z]&KA?B)X'U#QHUC';ZA!;6]L&8K(I)9FQSQZ
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MXY^'5EXS\JY$YM-0B78LP3<'7KAAQ^!SW[UQD7P9UNZGAAU7Q&)+",\*C.[
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M)Z3HFL S?8(HU$D3%"65-IQ['T^E9GC_ .'TWBZ#28;&Z@LX[!9$"NI((8(
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MEO[KP[;I/J,T;M.I52 I<$GYB/XL5Z[XU\?W'A/2M.MDMDGUV\A5C$WW8S@
MD@=?FR  >Q].?._A-J-EHGCC4!JEW#9AK:2(/.X1=XD4XR>!T/Y59^,D$B^,
M],U$SNEG/;1B*YB&[9M<DE<$9(#!NO>M)Q4ZRBUH2G:)K'Q[XY\*WEG-XMTZ
M+^S[ML?*JAU'?&TG!&<X;K_+I/B;XQU'PUH^F7FCRP_Z5(06>/<"NW(Q7$W'
M@G2]3M[;[3\4(KI)G40I*N\[CP/E,N0>?3CO6I\9K3[!X2\/6?F>9]G;RMY&
M-VV,#./PJ.6#G'3\!W=F4]6^)'CJ32HM:L]*6RTD;1Y[P[]YZ9)/\)/3 ]LU
MT5UXSUW6OA;'K6C6<37F]XKY<96.-4;>ZY(_V3WQGO2:]_R;]%_V#K3_ -"C
MJE\.8VF^#6MQH,NXNE4>I,0I/EY>:VSL/6YQ/PVN_%MM-=KX:M4G@>2+[665
M3M'S8ZD=MW2N]\5>-]8TKXGZ?HEL;?[)+);J=\0+@.P#8;MQ6#\$M9TW36UB
MWOKZWM9)S"8A-($WXW@@$]3R./>HO'?_ "6_2O\ KM9_^ABM))2K--=!+2)Z
M1XWUKQ/I2V</AO1UO9;EF5I2"PB(]1P!D9Y)QQ7 GXC^-/"NOV]OXMLXOL\I
M#.@1=P0G!*,AP<>AS6C\6?&.K:9K-EH6FWC:?%-$LLURO#89BO#=0!MSD<UY
MUX[TW3]-O+..S\1MKD[1%IYS*)%4YX ()QWXR:FC33BE)+4)/L>C?'4AM#T@
M@Y!N'(/_  &N]\%_\B/H7_7A#_Z *\Z^,JL?!_AY\<!P"?<QC_"N_P# 5W;W
M?@71C;S)*(K2.)]C9VNJ@%3Z$5E-?N8^HU\1Y7\:;[6VU6.QN[=$T=9 ]E*!
M\TC"-=^>>Q8CH*[#X<ZEXH33=_B*".WT6WT]'MIMJC**!@G!)^[SS6-\>8V-
MGH<@'R+),I/N0F/Y&NDL[VT\0_"EM-TJ^AGOO[&$;01R R*PBVE2O49(Q5MW
MHQT#[3.3/Q&\9^*]3N4\(::@M;;YCE%9BO8L6( )QPHYZ]:Z;X=_$67Q1<3Z
M3JMNEOJD"EOD!42 '#?*>C#C(_EBN2^#7B+2-&MM7M-3O8+*5G216G<(' !!
M )[CT]ZJ^ "=;^,U]JUBK?8EEN;@MC */N"Y]"2P./:JG3C:4;6MU$F]#WFO
MG?P_#I5Q\8=3CUE;5K(W5WN%T5"9W-C.>*^B*^;]+\.VGBGXL:II=])/' ]W
M=,6@8!LAF(Z@C]*SPVTK]ARZ!\18/#5IX@L1X0>+S N9?LDA=1)N^7:<GGZ>
MU>R>,_&B^#O#T%W-"LU_<82*#. 6QEB?8?U'UKR/0K6U\ _%A;+6(8YK=9/+
MBN)5^X&^Y*.V>@)[<^E=)\>+.X:/1KU0S6R&6)CCA&.TC\P#_P!\UK**E.$'
MJN_<2=DV0R>._B)HUI;Z[JVF6YTF=U 0HJ\$9&,'<N1T+9KT/6/&]AIG@A/$
MJ*98IHU-O$3M+NW13Z8YS]#7E*>&-,U708[FZ^* -JZJS6]PI)0_W2AESD?3
MZ5M_$;P_)HWPETBQ@N3>0V5TI>94VAE8/AL9.!E@.O>IE"G*45Y^:!-HRF\9
M?$#7/#FIZ@^F13Z'-!+#*4B"A%*D,RG.XXSR>1Q6A\&[B2T\*>)KF+ DA D7
M(R,A&(JSI'B[08_@K/82:A!%>K8SVWV8M^\,C!@,+U(.0<].:I_""-IO!_BF
M)!EW7:H]28VJI?!)6MJ"W1TGPJ\9:OXM_M;^U7A;[+Y/E^7'M^]OSG_OD54\
M+>.M;U;XF7VA74D!L89+A4"Q -A&(7FN5^#?B/2=!EUI-4O8K43I$T;2' ;9
MOR![_,.*;\-[N*_^,-[>0$F&X:ZEC)&"59B1Q]#2G22E/32P)['4^,?B;J5O
MXC_X1SPM:)<7JOY;RLN\E^ZJOMW)]_3-;G@>^\<W%[=0>*;*&*"- 4EVJ'9C
MV&TE2,9SZ<5YIH]Y#X4^--Y+K1,49N9P9G'W1)DJ_P!"".?0U[7:>(M'UN>Y
ML-+U:VN+F.+<WD.'V@\ @C@X/ITX]16=6*A%*,>FXUJSSO4OB'XF\0^(KC2/
M!%E')';DAKA@I+@'&[+$*JYZ9R3^E;/@/QYJ.L:S=^'O$-K';ZM;9(,8P'VG
M# CD9'7(."/U\B\)Z66UR\TN]\2R^&[A/D+$$!V4X*L=ZX([9]Z]+\$>"["R
M\9-JEOXQBUF[MD/G1I'ECO!4$OO:M*L*<8M?Y_F)-L[CQI_R(^N_]>$W_H!K
MPOX?W_@JSM+T>*K=)96=3 6A9\+@Y^[^%>Z>-/\ D1]=_P"O";_T UXE\.(O
M!4EG?GQ4;82B1?(\YV7Y<'.-I^E30_A2W^0Y;GLO@M?#$VF2WWA>VCAMIGV2
M,L;)N9?4'TW?K7":S\3M>UCQ')HO@NS278643%0[28ZL,_*J^Y]O7%=UX8N/
M#$NFW.F^%;F 11@LRPLS;"W&>?I^E>1?"G5;+PMXPO[36W6RD>(P>9,=H1U8
M95B>F<=?:E"*;E)J[7<&]D>I^#M3\4'2[^X\86\%HMJ3MD PQ4#+,<$C [$>
M]<.?B-XS\5ZG<IX0TU!:VWS'**S%>Q8L0 3CA1SUZUZ!JNI6/BSPGK]GH5]%
M>3K;20D0'=\Q0D#/<'ID<=?2O./@UXBTC1K;5[34[V"RE9TD5IW"!P 00">X
M]/>B"5I3Y=>P/HCK?AW\19?%%Q/I.JVZ6^J0*6^0%1( <-\IZ,.,C^6*Y_5/
MB=X@TWQ[J&D06<=_$DC0VULD>'+X&W)')K(\ $ZW\9K[5K%6^Q++<W!;& 4?
M<%SZ$E@<>U/L/^3B7_Z^Y?\ T2U7[."G+3I<5W8M6WQ+\7Z-XNMK'Q/:1103
MN@>#R@I1&.-RD$YQ[D]".*[/XB_$ >#;>"VM(4GU*Y4LBR$[8UZ;B!UYX XZ
M&N"^,_\ R/ND_P#7I'_Z->CXR02V?CG3-3F1GM&@C"\<91R67\B#^-"IPFXN
MVX7:N6I/B%X]\,36EWXDTM&L;KE4,:H<>@*GY3[,,UV_C7Q?-IW@*+Q!H<L9
M\YHC&\B;AM;U'K7(_%[Q7H>K^%+&TTZ_M[R:2Y6<")]QC4*P^;^Z?F P>>M1
M^(;*XT_X :9;W0990\;E6&" SLP'X BER1ERR:L[A?<K2_$KQQ?^'DU'3M+6
M.UMEQ=7OD[@[ \D \ =,X!QZBK%K\3O%_B'1E@T+1!)J$()N[F./<@';:IX!
M/H<].!Z:OAG_ )-^N_\ KRO/_0GJ'X$?\@75_P#KX3_T&G+D49/E6C#6ZU-'
MX7>/[[Q6UY8:JL9N[=!*DL:[=Z9P<CID''3U]JJ> O&^L:]X[U'2[TV_V:*.
M5E\N(*Q*NJC)[\$USGP7X\>:M_UZ2?\ HU*/A1_R5/5_^N-Q_P"C4HG3BG.R
MZ F]#HO&/Q-U*W\1_P#".>%K1+B]5_+>5EWDOW55]NY/OZ9K<\#WWCFXO;J#
MQ390Q01H"DNU0[,>PVDJ1C.?3BO--'O(?"GQIO)=:)BC-S.#,X^Z),E7^A!'
M/H:]OT[Q)HNKWLMGIVIVUW/$@D=87#@*3C.1P?PZ9'J*SJQ4(I1CTW&M6:,W
M^HD_W3_*OFGX=7OA>QU.\?Q2D#VY@ A$T#2C?N'0 ''%?2TW^HD_W3_*OF[X
M91^&I-6O1XF-F+<0#ROM3[1NW#I[XIX?X)?+8);HT_"EI:ZO\8%O/"]L\&DV
M\GFDD$!$V8;KTW-G ]_;CL/$7CK6]-^*=CX?MY(1833VT;AH@6PY4-S^-<)K
M,NDVGQ.TUO [X7?$I\AF*&4L0P7/\)7&>W6M'XA3IIGQGL+^Y.V"*2TG9L?P
M*PR?_'36KBI25^Q-[([/XJ>--8\)2Z4NE/"HN1*9/,C#?=VXQ^9IWQ!\9:OX
M<\-:+?:>\*SW>/-+Q[@?D!X';FN'^,GB/2==O=*CTN]CNOLZ2&1X^5&XK@9[
MGY36Q\7_ /D2O#/X?^BQ40IJT+K>XV]R]H_C3QGXJUW3YM,TUK?0O.C2><P@
M[U!&\[C]#]WI2>,?B3K*^*3X;\*6Z272/Y;R%-[-)C)50> !SDGT/3%=WX(1
M4\#:$$4*/L,1P!CDJ"?UKQO1+ZW\.?&Z^EUB00QF[N5,TO 7?N*L?0$$<^]*
M"C*3]W8;ND97BZ^U^]\8:7_PDMBMIJ$*11_*,"1/,8AN"1U)'!QQ7K_Q"\>G
MPC#;VEE;K<ZI=@F-&R51<XW$#DY/ 'L?Q\S^)NL:?K/Q%TZ73;N*ZBAAAA>2
M)MR[A(S8!Z'AATJY\9[2>'QOIU[+++%;2VZ*DZ+DQE7.['(R1D-U'6M.53<%
M)=&*]KV-0^/?'/A6\LYO%NG1?V?=MCY54.H[XVDX(SG#=?Y=)\3?&.H^&M'T
MR\T>6'_2I""SQ[@5VY&*XFX\$Z7J=O;?:?BA%=),ZB%)5WG<>!\IER#SZ<=Z
MU/C-:?8/"7AZS\SS/L[>5O(QNVQ@9Q^%1RP<XZ?@%W9E/5OB1XZDTJ+6K/2E
MLM)&T>>\._>>F23_  D],#VS7IG@CQ*?%?A:VU.2-8YR6CF1?NAU/./8C!_&
MN4U[_DWZ+_L'6G_H4=3_  4_Y$23_K]D_P#05J*BBZ;:5K.PU>YN^._&</@S
M1EN3$)[N=BEO"3@$CJQ]AQ^8KS=OB#\1-.L;?7[_ $Z!M(G8;08@JD'IT.Y<
M]B>.G6KWQXLKAHM&OE#-;QF6)CCA6;:1^8!_*I_%OC'0+WX11V=M>V\EU<6\
M$2VJL"\;*5)W+U&-IYZ'BJIPBH1=KW>H-ZLW=?\ %&H:W\-1K'AFW61IU9;F
M-\$PQ[&\SN.00.?QQ7FGPFF\0PZZXT:V26R>:!=0<JI,<>YNF3D<;NGI7;_#
MZRN+3X-:H\X8"YCNIH@PQ\GE[1^!*D_C69\!/^9@_P"W;_VK35H4YI+86[1[
M'-_J)/\ =/\ *OGOX0Z#I>OZSJ,&JV4=U$EL&57S\IW 9&*^A)O]1)_NG^5?
M/OP@UO3-"UG4KC5+V*UB:V"JTA^\=PX'K44+^SG;R'+=#?%NG#X9_$*SO-%9
MUMV19TC8DX4DJ\9)Z@X_7VS7:_%'QQJWAG4-,CTMK?RYX3*?-B#\YX(]*XKQ
M;J:_$GXB6-IH\;R6RA;='((W+N+.Y'4  G\!6I\=@!K6D # %LV /]ZME'FE
M!3WL3T=CN?B-XZN/!^DV7V.&.2^O=VQI!E4"@;C@=3\PQ61X?UGXF_VKIPU+
M3+:XT^](8R@*!&A&<ED)V\>H.>G6MGQ]8^%]4TK3['Q#J"V$LK'[)/G!5MO.
M<\;>F<X'3FO,[+5-5^'WB^RTS3]?AU?3IF3,4,F^,JS8QMR0C]^#Z?2LJ<5*
M%DM?,IO4] \=_$&\T;5X/#WA^T6ZU>;;DL"PC+?=4+W)'// &.O;(TSQ]XJT
M#Q+9:3XTLXDCO,;)D"ADW' /R$@C/!'4=?KR7CVSDMOBY,UYJ$VFPW+QNE\B
MDF-"@7< "#@$$'![&M@> -.U'5+!)OB3#J%R[YMXRHE8XYP/WIQG%6H4U!7Z
MKS%=W/0O&^M>)]*6SA\-Z.M[+<LRM*06$1'J. ,C/)..*X$_$?QIX5U^WM_%
MMG%]GE(9T"+N"$X)1D.#CT.:T?BSXQU;3-9LM"TV\;3XIHEEFN5X;#,5X;J
M-N<CFO.O'>FZ?IMY9QV?B-M<G:(M/.91(JG/ !!.._&311IIQ2DEJ$GV/9_B
M3XYF\'Z9:?88HY;R]+"-I.415 RV!U/S#%8_A_6?B;_:NG#4M,MKC3[TAC*
MH$:$9R60G;QZ@YZ=:T_&=EX8U3P[H]CXBU!;&:51]DG)P5;8,YSQMZ9S@=.:
M\YLM4U7X?>+[+3-/U^'5].F9,Q0R;XRK-C&W)"/WX/I]*FG!.%DM?,;>IZ!X
M[^(-YHVKP>'O#]HMUJ\VW)8%A&6^ZH7N2.>> ,=>V1IGC[Q5H'B6RTGQI9Q)
M'>8V3(%#)N. ?D)!&>".HZ_7DO'MG);?%R9KS4)M-AN7C=+Y%),:% NX $'
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MVM_ FH:_H<\5YY)\I'4$JKEPF3]-V??CL:\?+CQ!X0U'7->\92O?#<L.F^<
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MKN+PI:VRV]N-XC<)N9,X!8N>I]!C'ZUT/PW\):?HNIZCJ=CXGAUD,I@F,<8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4455%[&;Q[;/SIC/XC-
M%JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS2?\C?>?\ _] 6NEKFD_Y&^\_P" ?^@+0!TG:EI.U+0 4444 %%%% !1110
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MK3[WXGW_ (5'B.+Q%IWV,1/-Y<L4:N53.1_JL=C_ !?C72>$/^2)K_UXW/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH YI/^1OO/^ ?^@+72]JYI/^1OO/\ @'_H"UTO:@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *.]%'>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N7\5>$I_%-U8K+JSV^FV\BRR6B0 F5P3@
M[\Y'!QC!KJ**<9.+N@W"BBBD 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5S2?\C?>?\  /\ T!:Z6N:3_D;[S_@'_H"T =)VI:3M2T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!S2?\C?>?\  /\ T!:Z7M7-)_R-]Y_P#_T!:Z7M0 4444 %%%%
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M%H?_ (.9O_D6@#H**Y_[9XP_Z 6A_P#@YF_^1:/MGC#_ * 6A_\ @YF_^1:
M.@HJAH>IC6O#^FZJL1A%[:Q7(C+;MF] V,]\9J_0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <TG_(WWG_ /_0%KI>U<TG_ "-]Y_P#_P! 6NE[
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1WHH[T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?FO\ C1YK_P#/O)^:_P"-2T4
M1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (U+
M10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_ ,^\GYK_ (T>:_\ S[R?FO\
MC4M% $7FO_S[R?FO^-'FO_S[R?FO^-2T4 1>:_\ S[R?FO\ C1YK_P#/O)^:
M_P"-2T4 1>:__/O)^:_XT>:__/O)^:_XU+10!%YK_P#/O)^:_P"-'FO_ ,^\
MGYK_ (U+10!%YK_\^\GYK_C1YK_\^\GYK_C4M% $7FO_ ,^\GYK_ (T>:_\
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M/%<^GWUW81>([E/L!M78I'+@"[B'\6#M!(!X''L >X>:_P#S[R?FO^-'FO\
M\^\GYK_C4M% $7FO_P ^\GYK_C1YK_\ /O)^:_XU+10!%YK_ //O)^:_XT>:
M_P#S[R?FO^-2T4 1>:__ #[R?FO^-'FO_P ^\GYK_C4M% $7FO\ \^\GYK_C
M1YK_ //O)^:_XU+10!%YK_\ /O)^:_XT>:__ #[R?FO^-2T4 1>:_P#S[R?F
MO^-'FO\ \^\GYK_C4M% $7FO_P ^\GYK_C1YK_\ /O)^:_XU+10!%YK_ //O
M)^:_XT>:_P#S[R?FO^-2T4 1>:__ #[R?FO^-'FO_P ^\GYK_C4M% $7FO\
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MVSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_ $ M#_\
M!S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_
M]L\8?] +0_\ P<S?_(M'VSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!
MS-_\BT?;/&'_ $ M#_\ !S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\
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M#_H!:'_X.9O_ )%H Z"BN?\ MGC#_H!:'_X.9O\ Y%H^V>,/^@%H?_@YF_\
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M2'5/^A,US_O]9?\ R10 ?\(;I?\ S]:Y_P"#V]_^/4?\(;I?_/UKG_@]O?\
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M0!WE%(S!5W,0H'4D\5']I@_Y[1_]]"@"6BHOM,'_ #VC_P"^A1]I@_Y[1_\
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M_0F:Y_W^LO\ Y(H Z"BN?_X2'5/^A,US_O\ 67_R11_PD.J?]"9KG_?ZR_\
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MYUQM8^I&T8/; ]*L44 %%%% !1110 4444 %,F,BPR&%$>4*2BNQ52W8$@'
M]\'Z&GT4 <YHFM:YJ6JWUK>:1IUM#8S_ &>>6'47E8N8DE&U3"H(Q(HY(YSP
M>_1US_A[_D.>+/\ L*Q_^D5K704 %%%% !1110 4444 %%%% !1110 4444
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M6BNEI/<YTVMA , #T]:6BBF(^C/AA_R3K2O^VW_HUZZZN1^&'_).M*_[;?\
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M444 %<TG_(WWG_ /_0%KI:YI/^1OO/\ @'_H"T =)VI:3M2T %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH P_#?_,7_P"PG-_2MRL/PW_S%_\
ML)S?TK<H **** "BBB@ HHHH **** "BBB@ HHHH **** .:3_D;[S_@'_H"
MUTO:N:3_ )&^\_X!_P"@+72]J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ H[T4=Z "BBB@ HHHH **** "BBB@ HHHH **** /G/XG_P#)1=5_[8_^
MBDKD:Z[XG_\ )1=5_P"V/_HI*Y&O7I? O0\FI\;]0I" RE6 ((P0>]+16A!#
M':6T+AX[>%&'1E0 U-11222V&VWN%%%%,1Z[\#_^8]_V[_\ M2O7:\B^!_\
MS'O^W?\ ]J5Z[7EXG^*ST\/_  T%%%%8&P4444 %%%% !1110 4444 %%%%
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M>YTS3H+6UDE)7>R%]X< '"NK8R,D'G''(!VM%(5#KAU!!Z@\BH_LT'_/&/\
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M/LT'_/&/_OD4 <M\3_\ DG6J_P#;'_T:E?.=?1'Q-@B3X>:HRQ(I'E<A0/\
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M%'V:#_GC'_WR* ):*B^S0?\ /&/_ +Y%'V:#_GC'_P!\B@"6BHOLT'_/&/\
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M $']5_\  R3_ !KZCKY%KZZKEQ:2M8ZL(V[W"BBBN([ HHHH **** "BBB@
MHHHH **** .:3_D;[S_@'_H"UTO:N:3_ )&^\_X!_P"@+72]J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ H[T4=Z "BBB@ K&\4)<RZ%)%:77V>:26
M)<B?R6D4NNZ-'_A=ERJD8.2.1U&S5:_L+;4[*2SO(O,@DQD;BI!!R"",$$$
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M?FO^-'FO_P ^\GYK_C4M% $7FO\ \^\GYK_C1YK_ //O)^:_XU+10!%YK_\
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MK_\ /O)^:_XT>:__ #[R?FO^-2T4 1>:_P#S[R?FO^-'FO\ \^\GYK_C4M%
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M"BBB@ HHHH **** "BBB@ HHHH **** "N:3_D;[S_@'_H"UTM<TG_(WWG_
M/_0%H Z3M2TG:EH **** "BBB@ HHJ*YN8+.UENKF5(8(4+R2.<*J@9))]*
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M_P! 6NE[5S2?\C?>?\ _] 6NE[4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1WHH[T %%%% !1110 4444 %%%% !1110 4444 ?.?Q/\ ^2BZK_VQ
M_P#125R-==\3_P#DHNJ_]L?_ $4E<C7KTO@7H>34^-^H4445H0%%%% !1110
M!Z[\#_\ F/?]N_\ [4KUVO(O@?\ \Q[_ +=__:E>NUY>)_BL]/#_ ,-%#6O^
M03/_ ,!_]"%<E76ZU_R"9_\ @/\ Z$*Y*L#8**** "BBB@ HHHH *[6Q_P"0
M?;?]<E_D*XJNUL?^0?;?]<E_D* )Z*** "BBB@ KD?B?_P DZU7_ +8_^C4K
MKJY'XG_\DZU7_MC_ .C4JZ7QKU(J? _0^<Z***]@\D**** "BBB@ HHHH ^H
M_"G_ ")VB?\ 8/@_]%K6O61X4_Y$[1/^P?!_Z+6M>O&E\3/7C\*"BBBI*"BH
M_M$(N1;&:/SRAD$6X;BH."V.N,D#/O4E !1110 4444 %%%% !1110 4444
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M4_\ S\2?DO\ A4M% $7E/_S\2?DO^%'E/_S\2?DO^%2T4 1>4_\ S\2?DO\
MA1Y3_P#/Q)^2_P"%2T4 -52HP7+>YQ_2G444 %%%% '-)_R-]Y_P#_T!:Z7M
M7-)_R-]Y_P  _P#0%KI>U !1110 4444 %%%% !1110 4444 %%%% !1110
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MA(S.Z*0'4^6HVL"O7 YK>L=;U&;QE>Z9&1&CRQRE[D,R!!#&6BB (PY+$\\
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M*Y&O7I? O0\FI\;]0HHHK0@**** "BBB@#UWX'_\Q[_MW_\ :E>NUY%\#_\
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M+"BBB@"Q8?\ (1MO^NJ?S%=Q7#V'_(1MO^NJ?S%=Q0 4444 %%%% '*^)?\
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M* "BBB@#7\._\A"3_KD?YBNEKFO#O_(0D_ZY'^8KI: "BBB@ HHHH *YI/\
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MQI__ "$K7_KLG\Q2ELRH[HZCQ'_R*^K?]>4W_H!KYZKZ%\1_\BOJW_7E-_Z
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MUVO+Q/\ %9Z>'_AHH:U_R"9_^ _^A"N2KK=:_P"03/\ \!_]"%<E6!L%%%%
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M5_!D;X;^+$['XG_\DZU7_MC_ .C4KYSKZ,^)_P#R3K5?^V/_ *-2OG.N#"?
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M!I/^_L?_ ,57TA11];GV0?58=V?-_P#PK?Q=_P! :3_O['_\51_PK?Q=_P!
M:3_O['_\57TA11];GV0?58=V>:_"OP_JWAO^UO[6LI+?[1Y/E='W;=^?NYQ]
MX=:]%\]/[LG_ '[;_"I:*PG-SES,WA!0CRHS]3)N-.EBB21G;&!Y;#N/:N=_
MLV]_Y]I/RKLJ*@HXW^S;W_GVD_*C^S;W_GVD_*NRHH XW^S;W_GVD_*C^S;W
M_GVD_*NRHH XW^S;W_GVD_*C^S;W_GVD_*NRHH XW^S;W_GVD_*NHM9!'9P1
MNL@98U!'EMP0/I5JB@"+ST_NR?\ ?MO\*//3^[)_W[;_  J6B@"+ST_NR?\
M?MO\*//3^[)_W[;_  J6B@"+ST_NR?\ ?MO\*YSQY9W.L^"]0T_3X))KJ7R]
MD>TKG$BL>3@= :ZBBG%\K30I*Z:/F_\ X5OXN_Z TG_?V/\ ^*H_X5OXN_Z
MTG_?V/\ ^*KZ0HKI^MS[(Y_JL.[/F_\ X5OXN_Z TG_?V/\ ^*H_X5OXN_Z
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MR1HNPC+%2 ,D>M>-_P#"#>)?^@5)_P!]I_C7N]%.CB9T4U%"K8>-5IR/"/\
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MN+2]>2>"1%,94':3SD>E='10!%YZ?W9/^_;?X4>>G]V3_OVW^%2T4 -5PXR
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MP#_T!: .D[4M)VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7?_?YO\: .FHKF?[%U/\
MZ"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=3_Z"5W_W^;_&C^Q=3_Z"
M5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\ Z"5W_P!_F_QH Z:BN9_L
M74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74_P#H)7?_ '^;_&C^Q=3_
M .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7?_?YO\: .FHKF?[%
MU/\ Z"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=3_Z"5W_W^;_&C^Q=
M3_Z"5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\ Z"5W_P!_F_QH Z:B
MN9_L74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74_P#H)7?_ '^;_&C^
MQ=3_ .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7?_?YO\: .FHK
MF?[%U/\ Z"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=3_Z"5W_W^;_&
MC^Q=3_Z"5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\ Z"5W_P!_F_QH
M Z:BN9_L74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74_P#H)7?_ '^;
M_&C^Q=3_ .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7?_?YO\:
M.FHKF?[%U/\ Z"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=3_Z"5W_W
M^;_&C^Q=3_Z"5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\ Z"5W_P!_
MF_QH Z:BN9_L74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74_P#H)7?_
M '^;_&C^Q=3_ .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7?_?Y
MO\: .FHKF?[%U/\ Z"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=3_Z"
M5W_W^;_&C^Q=3_Z"5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\ Z"5W
M_P!_F_QH Z:BN9_L74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74_P#H
M)7?_ '^;_&C^Q=3_ .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/_H)7
M?_?YO\: .FHKF?[%U/\ Z"5W_P!_F_QH_L74_P#H)7?_ '^;_&@#IJ*YG^Q=
M3_Z"5W_W^;_&C^Q=3_Z"5W_W^;_&@#IJ*YG^Q=3_ .@E=_\ ?YO\:/[%U/\
MZ"5W_P!_F_QH Z:BN9_L74_^@E=_]_F_QH_L74_^@E=_]_F_QH Z:BN9_L74
M_P#H)7?_ '^;_&C^Q=3_ .@E=_\ ?YO\: .FHKF?[%U/_H)7?_?YO\:/[%U/
M_H)7?_?YO\: %3_D;[S_ (!_Z M=+VK#TW1Y;:Y:>:5Y9&ZL[$D_B:W* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2N[_ %>W=^G09Z5,=;T\2Q1^<Q,H0J5B<@!CA=Q PN3QSCFBS"Z-"BJ/]LV
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M8FII];M8[&]NHA+,+4-N B< L"00#CGD<XSCO1RL5T:5%9EMKEM/>O:L)(Y
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MK)(^\.(]J1.[%BN[ "@D\<\4687+M%1P3Q7,$<\+AXY%#*P[BJHU)#JILMG
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M,5S:HJI%J5K/=M;1NQD7/6-@K8X.UB-K8[X)Q4$^N65K++'<2%3&Q&(XW<@
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M0)+/=%PFS!0L2>.?O=?RJPFA".$QK.H!2%?DA"@>6Y;@# &<].WO6?!KM[)
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M:6&XNQ+FW%M&5BV;$&<$\G+<]>!QT%5Y]7U&$26R_9IKL2J$:*(D,I0OC:7
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MHI&P:,QMMR3NYR,] ,'UI68:$@\*C[&(7FMG*3^='$]L7MTX(*B-G.!R3PP
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MJ2BANXPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(N%C2?+1C?E\R'Y22?EX!8D\]JO66C^5JZ32:?&L*R3/'@(1$24"D<Y&0I/
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M3C(Z]>20@*HO-!L;5KF.T$<+DO(T5@_#(>KX3Y2#_>P:LRMI6FP(WV18UN)
MP2&T9F=\;LE54G/&<D=J@CM)I;2TA-O/&C7'F77GLA=\ MD[21RP7@=N, 5+
MJ%C+=75N;<26I2X+R3QB/<P\HC=\P.>H7D9X].:- #[?I-RB6HB,T=S\QC6T
M=U.6(.\!<+\P.=V.0<U'OT"0-:&VM2EF'<(UM\B ??*97!P3SMZ'K5>326M;
MI!:6]VTQ"_Z8+G"D[BQ\Q-R@\L3PI')X%,_LVZD,EO-8[X(DN0"9@HN/,;(
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M@ D=2"<<XZY%E3=S:G&DVF7$=E 1Y.UHMF<?>;Y\\<@*![\\8=A#Y6T.RU%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img101536035_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM;^UG9!N<13*Q4>IP>*\Q^"&OW5[87^CW,K2):;)("S9*JV05^@(&/J:\O\
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M-Y';WDMR+IE8F10-NW/I]:ZJN622?N[%(****D84444 %%%% !1110 4444
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M/&Q&"0?:J.N>%-#\2B/^U]/CN6C&$<LRL!Z;E(./:KVFZ;::/IT.GV$/DVL
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVCP7_P!AEU6RCN\$^0TZA^!GIG/3FI;35=.OY&CL[^UN74;BL,RN0/7 -.S
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M3T(R>GO4\]W;6UL;FXN(HH!@F61PJ\].3Q19@3457M+^SOT9[.[@N44X9H9
MX!]#BJ]_KND:7(L>H:I96CMR%GG5"1]":+.]@-"BHK>Y@NX1-;3QS1'H\;AE
M/XBHK[4[#2XA+?WMO:QGHT\JH#],FBSV M457L]0LM1A\ZQN[>ZBZ;X) Z_F
M#3KFZM[*!I[JXB@A7[TDKA5'U)XI6Z 3450L-<TG5&*Z?J=G=L,Y6"=7(_ &
MK]-IK< HHK,_X2/0_M7V7^V=/^T9QY7VE-V?IG-"3>P&G3)98X(S)+(D:#JS
ML !^-.)"@DD #DDU\]?%G79=:\9C2X+U'L;81H@63]WO8 EB>F?FQGMCZUI2
MI>TE84G9'OUK?6E\A>TNH+A1U,4@<#\JEEBCGC,<L:R(>JN,@_A7%_#OP9IW
MA>*]N+#5H]3^T[$,L87"[<Y PQZ[OY5)\2/&<G@_0XI+2-'OKIS'#O&50#EF
M([XR./4TN2\^6&H7TNSLZ*^?+-?BIKEBNM6EUJ,EN^60I<K&'&>2(\C(X]/I
M7J'PXU3Q-JNB32^)+?RW23RX9'3RY),<-N7&!@\9XSSQW-3H\BO=,2E<ZD:G
M8-?&Q%];&\ R;<2KY@'^[G-6J\GMOA]IL?Q(_M8>*;5G%Z;D689?.\S<6V'Y
MO7VSVQ7JDT\5M"TT\J11(,L[L%51[DU,XQ5N5W&F245D1>*_#LV[RM>TQ]O7
M;=QG^M7(-4T^ZAEFM[ZUFBB&9'CF5E0=>2#Q4.+709;HJI!JNG7,,LUO?VLL
M47,CQS*RI]2#Q4=AKFDZK(\>GZG9W;IRRP3JY ]< T68$]Y?V6G1"6]NX+:,
MG >>0("?3)-3(Z2QK)&RNC#*LIR"/45P7Q-\)VGB:/3VN-<MM,D@+A!<D!9
M=N<9(Y&!^=:MB;+P7\/$6+4H;F.SM9'BG=P!,PW-@<\\\  FKY%RIIZBOJ=#
M<ZC8V;*MU>6\#-PHEE52?IDTVXU73K/ROM-_:P>=_JO-F5=_^[D\_A7S5X7T
M9/&^O7;ZUKJ6;%/-:>=@6E<D *-Q'^1BO1?%_P -M,NYM)B;Q+::<;2RCM3'
M<[061<_. 6'))/'ZUK*A",E%R_ E2;/6^M%5=-MH[+2K.TBE,L<$"1I(3DN%
M4 '/OBJ]WXAT6PN!;WFKV%O,3CRY;A%;/T)KGM=Z%FE138I8YHEEB=9(W&5=
M3D$>H-9UUXCT.QF\F[UG3X)<XV2W**P/T)H2;V TZ*9#-%<0I-!(DL3C*NC!
ME8>H(ZU7?5-/CO19O?6JW1( @,RAR3T^7.:5@+=%9MSX@T6RO!:76K6,%R?^
M64MPBM^1.:NW%U;VD)FN9XH8AU>1PJ_F:=F!+17D'@OXDZAJWC6\M=6U*UCT
ML)*T7F!(P,,-HW<9X->MP7$-U L]O-'-$_*R1L&4_0BJJ4Y0=F).Y)102 ,D
MX KPWQ3\3M=UW7#HOA(.D7F&-)(!NEN".X/\*]^.W)-.G3E4>@-V/<J*\(MS
M\6/#M_:RRK>W2SR*@CFE6XC))Z-@G8/?(^M>Z0F4P1F=468J-ZH<J&QR >,C
M-%2GR=;@G<?16;<>(=$M+K[-<ZQ80W&<>5)<HK9^A.:T5974,I#*1D$'((J&
MFABT54?5-/CO19O?6JW1( @,RAR3T^7.:@N?$&BV5X+2ZU:Q@N3_ ,LI;A%;
M\B<T68&E11UJG?ZMIVEH'U"_M;12,@SRJF?ID\TDK[ 7**KV=_9ZC#YUC=P7
M46<;X) ZY^H--OM3L-+B$M_>V]K&>C3RJ@/TR:=G>P%JBJ]GJ%EJ,/G6-W;W
M473?!('7\P:9<ZII]E,L-U?6L$KC*I+,JLPZ< FBSV MT50N];TJPNHK6\U*
MSM[B4@)%+.JLV>F 3FI'U33X[T6;WUJMT2 (#,H<D]/ESFBS MT5FW/B#1;*
M\%I=:M8P7)_Y92W"*WY$YK2ZT6: *@NKZTL4#W=U!;J>AED"#]:?/<06L1EN
M)HX8QU>1@H'XFOF2WSX^\=2-JVK):0SL[F>9AMC09*HH8@>@ S[\UK2I<]VW
M9(ENQ].12QSQB2&1)$/1D8$'\13ZQ?">A6_AOPU::9:W N8XPSB< #S-S%L\
M$^OZ5/\ \)'H?VK[+_;.G_:,X\K[2F[/TSFLVM78HTZ**J1ZII\UXUI%?6KW
M*DAH5F4N".N5SGBIL!;HJA!K>E75^]A;ZE9S7B EH(YU9UQURH.>*S_&][<Z
M=X+U:[M)FAN(H"R2+U4Y'-4HMM(+F_17EGP;\0ZOKW]M?VK?S7?D^1Y?F'.W
M/F9Q]<#\JL?&'7M5T+3]+DTN^EM6EE<.8S]X #%:>Q?M/9]2>;2YZ717-> ;
M^YU+P+I=[?3M-<21L9)7/)P[#G\!7F7BGXG:[KNN'1?"0=(O,,:20#=+<$=P
M?X5[\=N2:4:,I2<5T&Y)(]RIDL4<T312HLD;##*XR"/0BO"[<_%CP[?VLLJW
MMTL\BH(YI5N(R2>C8)V#WR/K7:^/;7QY=2::WAKS(\0G[4L%PBJ'XX!<@D=>
M<53HV:7,A<QW-II]E8!A9V=O;ANHAC"9_(59KYIU7Q1X_P!%U5M,U#5KN&\7
M;F/S4;[PR.1D=_6NZ\+:?\4(O$UC)K3W)TU9/WX:YA8;<'L&R><=*J6':5W)
M I>1ZY117AOQ2\7>(-&\:26FG:K<6UN((V$:$8R1R:RI4W4ERH;=CW*BO!]0
MF^+/ANU?4+NYN&MHL-(^^*95'N.2!ZG%>B?#CQNWC+29S=1)'?VC*LPC&$8-
MG:P].AR/;WJIT7&/,FFA*5]#I=2T/2M8"C4M.M;O;]TS1!BOT)Z57T_PMH&E
M2K+8Z/8P2K]V5(%WC_@6,U:O]8TS2QG4-0M+3(R//F5,C\33['4K'4X3+87M
MO=Q@X+P2JX!^H-9WE;R'H6J*XOXD^+)/#7AMY-.O((]2:5%1&VLP4\D[3VP/
MUH^'_BY=<\,VDNJZG:-J<LCJ8]Z(YPQ ^0>V.U5[.7)S] OK8ZJ74[""\CM)
MKZVCN9/N0O*H=OHI.35JO)_%?P^TW5_'3ZC-XIM;1I7C:6U=E\U2%4 +\PZ@
M#''&>]>L4IQBDFF"845F+XBT-[O[(NL:>USG'E"Y3=GTQG-:,DB11M)(ZI&@
M+,S' 4#J2:EIH8ZBJD&JZ=<PRS6]_:RQ1<R/',K*GU(/%1V&N:3JLCQZ?J=G
M=NG++!.KD#UP#19@7Z*XOXD^+)/#7AMY-.O((]2:5%1&VLP4\D[3VP/UH^'_
M (N77/#-I+JNIVC:G+(ZF/>B.?F(4!![8[5?LY<G/T%?6QVE%5KW4++38?.O
MKRWM8LXWSRJBY^I-,L-6T[5$+Z??VMVH&28)5?'UP:BSM<8Z^U/3],C$E_?6
MUHAX#3S+&#^)-3Q2QSPI+#(LD3J&1T.0P/0@CJ*\@^,WA2QBM'\3++<_;998
MX6C++Y>W:1P,9SP.]>C:%=VUCX*TJYO+B*W@2RAW2S.$5<JH&2>!S6DH)04D
M]Q7UL;E9\&O:/<WAL[?5;&6Z&08([A&?C_9!S5:6?1/%FF7NFP:E;7D,L>R;
M[)<JS(&Z'*DX_'TKPCQ-9^%UU:VT#PW:3V6IVUV8)[^]NMB$J<;LEB!R,Y 7
MIP.:=*DINS$W8^D**BMDDCM84ED\R14 =_[QQR:EK$H**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O#/CO\ \AO2?^O9_P#T*O<Z\,^._P#R&])_Z]G_ /0JZ,+_ !43
M/8ET_P"-%OI?A>RTZWTB5[NUM(X%>20!"RH%R0.<<9Q4?P6\/7TNN3^()XGC
MM%B:.-V&/-=B,X]0 #^.*T]>\#66I_";2]0TVPMX=2M["&Y=X855IQY8+AB!
MECWYR<CWJ7X+^+/M5C)X<NY/WUN#):DG[T>?F7\"<_0^U;2<?9R=->I*W5SF
M?B-KTGB/Q[_84^H+9:3:3"%G8G8"/ONP[D<@?3W-9'B;3?#_ (<-CJ/A+Q+)
M<W228<;AO0XR&! ''&,>]6?B!I"^'_B3+=ZE8FYTR[G^T[ Q42H3\ZA@1A@<
M]_3UK<DO/@VEO'(NF74CL0#$KW 9,]R2^./8FM8M1C'E3MY"W;-;XD:[J.I?
M"O1[^WW1Q7QC-YY?094G:?\ 9W?R%<=X7\*>$/$FCQ0MXBFL=>8D&*<*(R<\
M!00-V1C^+/M7J_B7Q%X:\$^'-/L);,7.GW(\J*U3$@,74M\QY'(ZGG->-^-U
M\#R1P7/A2:X6>1SYULR.$1<=06&0<]@2/IBLZ+;CRI-:[_YCEN>B_%K3X]*^
M&6FV$4DLB6]W%&'E<LS81^237*^"?AI_PF/AS^T;S5YHE4M#;1*NX)@YYR>F
M2>!CZUH^+I+Z;X%>'WU$N;DW*9+_ 'BN)=A/_ =M1_#WXE:+X8\)/IU_'=&Y
MCD>1!&@(DSR #GC\:(\ZI>YO<-+ZF;\+-4O?#_Q ;0I9#Y%P\EO-'N^42(#A
MA[Y7'T-1?$/_ )+')_UVM?\ T!*D^%]A<^(?B0VM/%^YMWDNIF[!WW;1GURV
M?^ FH_B'_P ECD_Z[6O_ * E::>V?>POLG3?'K_4:#_O3_RCK,\-_#2_\;:;
M;:YK.KM"DD:QP1B/<WE)\H[C:..GX]ZT_CU_J-!_WI_Y1UWOP\_Y)_HO_7N/
MYFL.=PH1<1VO)F-\1?!EMXA%C=76MKI=C:@K-YK?N]O8J"0 W49]/I7C/BO2
M_#>D26I\.:])J$G/G H5,9&,,K8 ]?<8KI_C1=W4GC.VM+II1810(T2+T.2=
MS#MGC'X"LCQMJ'@R72[&R\*V+(\;;YKAXR&88Q@EN3SSZ5K04DHZ[BE;4]3M
M+ _$;X4Z:NH74D<C#<\J#+,T;,F3GUQDUXYX#\+0>+_$+:;/<R6Z"!I=\:@G
M((&.?K7N/PJ7?\,=*7U$X_\ (SUXWX#UJ#P3XXDDU=)(TC22VFVKDHV1V^JU
M--R7/&/38;Z-GHOCF\F^'OPZL-#TNZD\Z9FA6XSM=4R68C'0\@?C7*^%/A/_
M ,)+X2_MB;49(;JXWFW3:"O!(!<]>2#T[>M=+\4K=/%W@2P\0Z0&GM[9VD)V
MD-Y9^5CCV*C/MGTK,\%_%72]!\$QZ=?13M>V8=851<K*"25Y[=<'Z4H\_LKP
MWOJ#M?4C^#/B:]AUF7PU=R,]NZ,\"NV?*=>JK[$9./4>YK"^)%S=6?Q<N;FQ
M)%W&T#0D#)W>6F/UK2^#6C76H>+)]>DC_P!'ME<>8>\K\8'X$Y^H]:H?$/\
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M/5;+5VU&TE4R+(CC8L:C/0'!;KS_ "YKR2QN;/QUXKNK_P 6ZW]@M<%E ;D
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M2\"9<(6*E1Z@8)Q].G.;_P"7L?071F%\2O NE>$;/2Y]-NII&N-R2+,X8M@
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M^I_&O;**(U7%W:NQM%32K233](LK.64S26\"1-(?XRJ@$_I5NBBLGJ,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LG5O#.BZ[+'+JFG0W3QJ51I ?E'I6M133:U0$5M
M;0VEK#:V\:QP0H(XT'15 P!^58]EX,\.:=?I?6>D6\%U&2R21@@@GKW]S6[1
M0I-;,"GJ6E6&L6AM-1M(;J G.R5<@'U'H?>L.S^'/A&PN1<0:';^8#D>:S2
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M_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\
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M -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\
M=_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]O
MSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T
M 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY
M$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,
M?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\
M=_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^W
MYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T
M>1'_ '?U- #;<EHR22>>]34U45!A1@4Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HS2&B@ S1D4E)2&/HJ.C<1WIA8
MDHI@?UIP8'H:!6%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M2BBB@!*2EI*0Q*2EI*!@:2E--- QP<CWJ0,&Z5#2=Z+A8L45&LG9OSJ2F2U8
M****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !110: $HHI#0,*0T&D-( -)110,0TE+
M24#"DI:2D,2G(Y4^U-I* +(((R*6JZN4/M4X((R*HAJPM%%% @HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **CDFCBQO;D]%')/T%,W7$GW$6)?5^3^0_P : )Z*@^SL
MW^LN)6]@0H_3FC['#W#M_O2,?YF@">BH/L<'9"/HQ']:/LJC[DDR_20G^>:
M)Z*@\NX7[MP&]I$_J,4>=,G^M@)']Z,[A^7!H GHJ..:.7.QP2.H[CZBI* "
MBBB@ HHHH **** "BBB@ HHHH *2EI* "DI:2@8E)2TE(8E%%!H 2DI324#"
MD-!I#2&%)2FDH&(:<DFP^U-I* M<N45!#)_"?PJ>J,VK!1110(**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBHY)TC;:26<]$49- $E%09N9.@2$>_S-_@/UH^S%O\
M63S-]&V_^@XH GHJ#['!W5C]7)_K1]C@[(1]&(_K0!/14'V4#[DTR_\  RW\
M\T;+E/NS(X]'3!_,?X4 3T5!Y\B?ZV!@/[R?./\ ']*DCECE7,;JP]C0 ^BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI&8!54<DD]A0,?13(9HKB".>"1)8I%#I(C!E93R"".HI] "4E+24#"DI::2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J"SYMED[R9<_CS_*IZ@LN+.)>Z#8?J./Z4 3T444 %%%<
M_J6I7=OXNTJQBFVVTZ,9$V@[B >^,CI2E*QI2I.HVEV;^[4Z"BN?UG4KNT\1
MZ-:02[8+AF$J[0=V,=R,C\*R9KSQ)J'B74;'3-1AACMB"%E1<8..^TFH=1+2
MQO3P<II2YDE:^OK;L=M17)Z/JFLV_B,Z-J\L%RS1>8LD0 V]^< ?R]*SM=NO
M%FC(+B75+<PR3>6BI&I(SDC.4]!2=5)7L7' 2E4]GS*[U6^M^VAWM%<)JUWX
MJT/2S<7>IP.SRHB&*-3CAB<Y0>@KNE.5!]JJ,^9VL8UL.Z45+F33OMY6_P Q
M:***LYPIDT?FP21_WE(I]% $<$GFV\<G]Y0:QM&\3Q:SJ=Y9);21&#)#L<[@
M#@Y'8^U:UGQ!M_NNR_DQIT=M!#)))%!&DDIS(RH 7/N>]*2=]#2$H*,E)7;V
M\B6O(?%.K^"M)^+%^WC.*R>&32K86_VJR-R P>3=@!&QQCTKUZN?MM#N8?'F
MHZZTD)M;FP@MD0$[PR.Y)(QC'S#OZTS,X'P]?Z.?$&O^)?!&GK;Z+;Z,PD=;
M5H+>XN5)9=J87.U00V /O>_-Y_B!XCTOPA!K^LV>C1?VHUO'I< F>,*9%)9K
MB1SM50!NP.W!.:]!UJRDU'0M0L8619;FVDA0N<*"RD#..W-<MK/@636/ >CZ
M,\UJM_I:P/&TT(G@>2--I#(P^9""1TSR#VH H^$_'U_>^(H=$UJ]\-7TUU&\
MEO/H%X954H,E)%8E@2,D'IQBL?1/B?XAUO5XS GAHVSW1A.DM=O#J*+NVDXD
MPC$#YL#KTZUL^$_!&K6.NQ:GJ]CX1L/LZ.L46A::%9V88W-(Z[EP,\+C.>?2
ML?6_AQXH\17,EKJDOA:>W=@/[8^P,NH[ <C[N$![=<4#-'Q1\0M1MO%%UH>B
MWGAFQ:Q1#<7&OWAB5V89"1JI!.!@ENG.*)_B3J%QX.L-4TFPLKG49-533)K9
M9]\3.20?+D4XP?E(;D 'D'%-\2?#S49?$5QK&BVOAK46O$C$\'B&S,VQD7;N
M1U!89 &5Z=ZN0>!+VWT'2;-9-+6YM]8BU*Y^RVBVL.U3RJ*B\D# !;DXY-("
MA<^(O&?E^(/#^JVFBQZHNEM>VEQ:O*8&CSM96S\VX<X(QSCBKWA&XU2V^#4-
MSJD6GS-%I6^WCC5F1X1""@D#=6(^\!QZ5L:AX:N+_P 6SZF9HDM)M'DT\C),
M@=GSG&,8Q[U6T+0-=MOAU+X=U673FNTM'LK:2U+[#'Y>Q"^X9W>N!B@9B#Q5
MXHGNM#T?PYI>C![O0X[XFXWQPVQR!@!<DKS@*.>>N!72^"O$%_X@TBY;5;2&
MVU*RNY+.Y2!B8RZ8RRYYP<CUJKH7A6^TS7=*OII;=HK30DTV0(S$F164DC('
MR\=>OM5_PSHESHKZT;EXF^W:G+>1^62<(P7 .0.>#TS]: !M;N1X^70MD7V4
MZ8;S?@[]_F!,9SC&/;\:YK4?'FKVFE7]U;V%M<SV_B$:5%  5,D9*CJ6P'.<
M9Z>U:7B7P_XAD\46/B'PS=Z='=1VS6=Q#J"N8WB+!@1LYW CV^M<EKOAG5M$
M\+):W6J1R7U_XJ@N8[R-,E2[J Q0@ $$9V\CH,T#.ETSQ'XKL/$UCI7BO3]+
M2'4PXL[C3I'81NJ[O+DW]25!Y&!Q^5;XKMK2Z=H?]D&Q&=7M@WVHOS)O'E_=
M_AW?>[XZ5;TWP[XHO_$EGJWBR_TMX],WFRMM-C=5=V&WS)"YSD*2 HXYZ^NE
MXUT*_P!>T.*+2YK>*_M;N&\MS<@^47C8, VWG'TH QKSQ#XRO]9GT;P[9Z+]
MHTZ&(ZA=WSR^3YSKNV1JOS=.<GU_/;\(^(+C7].N1J%FMGJ=C<O:7D"MN4.N
M#E3W4J01]:P[OP_XSL-9FUGP]>:(+G488AJ-I?+*81,B[=\3+\W3C!]*V_"/
MA^YT#3[HZA>+>:E?7+7=W.B;5+L ,*.R@  ?2D-'&?$6>3Q7H/B&&!W71-'M
MI&FD0D?:KM02$![I'P3ZM@?PFM'Q#:0:SJ_@?0[Y/.T^=9;F:!ONRM%$I0,.
MXRV<>U1>(O@UX4U+3M2DT_28XM7N$D:&XENI]JRMDAB-Q&,GT/TJ[=^ FL=
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MWHRGN"*CM6WVD+'J4&?RH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#&DBPLWFER[2S3SONDGD8Y9W/<FM:BD.QCZ#H7]AMJA^T^=]OOY+S[FW9O
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK^%/L'E_V=;QS_:O.SYFX*<;-O&-W7)Z5L-X@T9-3&F-J]@M^3@6IN4$N?\
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M4XIQ;C\,E^)WU% .0".AHKH/'"F2R"*,N<GT ZD^E/JM<<W-NIZ?,WY#']:
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MXCU*+4=6T>"YNXP )"S+N Z!@" P_P![-7= \-:1X8M)K31K-;2":8S.BNS
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M24M)2&)24M)0,7<13@X[\4RDH"Q-14()'0T\2#OQ3N*P^BBB@04444 %%%%
M!1110 4444 %17&W[/(63>%4M@=>/2I:* *DMN9;5,MOD5?O?WJS0"3@#FM9
M?]'D2,?ZISA1_=.,X^G%5%!MKW++\I/!^M4F(C6TG;^ CZ\5*NGR'[SJ/UK1
MHI7"Q2&G+WD)^@H.G)CAV!]ZNT478[&3+:RP_-U [CM5@,+RV*G_ %J?K5ZL
MF7=;73>6<8/'TI[B'6+;;D#^\"*U*QX&_P!)1CW:MBDP04444AD<LGEJ HR[
M'"KZFEBC\M3D[G;EF]34?WK_ )_@CR/Q/_UJGH **** "BBB@ HHHH ****
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M2.?5E!J2B@!BQ1I]R-5^@Q3Z** (+3Y8VC_YYN5'TZC]"*GJ"VY:=NS2G'X
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MEI8W+'_CRB_W:L56L#FS3VR/UJS5(YY;L****!$<L0E4#)##E6'4&JS.\/\
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M?RK0IDD4<R[9$##W'2BQ2DRK12M:R1\Q/O7^XYY_ _XU&) 6V,"C_P!UNO\
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MAAU4C!'X5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 444UW6-2SL%4=S0 ZHY)HXL!
MC\QZ*!DG\*9F:?[N8H_[Q'S'Z#M^/Y5)'"D6=B\GJQY)^IH C_TB7_IBOX%O
M\!^M/C@CB)8#+GJS')/XU)10 4444 %%%% !6;=W7F$QH?D'4^M27MSC,2'G
M^(_TJA5)"848)IZH6QZ$TY ,@'CG(S3 CP>?:A6*L&'4'-2, J[2><YP*B((
MZT"-P'(!'0UG2+^\;ZFKUN<V\?\ NBJLH_>M]:DI,?9\%Q]*MU5MOOGZ598X
M4GT%(#'N'WSNWOQ3,'&>U !)XIZ[64J"<GUJR1A!&>.E)4SCDJ.2>H%,:/&2
M/NXS0,GM+KRB$<_(?TK3K"J_97.?W3G_ '3_ $I- B]1114C"BBB@ IDD22K
MMD4,/>GT4 4GMI8N8R9$_NL?F'T/?\:C5U?('4=01@C\*T:BFMXYN6&&'1EX
M(HL6IM%6DI&5X6"28.?NL.A_P-+FI-$[[!29HI,TBA:2BB@ HIZPN_1>/4U.
MEJ!RYS["BPG)(K*K.<*":LQVP'+\GTJ<*%&  !2U21E*;>P=****9 4444 %
M%%% !63/X?M;GQ1::_++.UQ:6[V\$)*^4F\@LX&,[B !G.,=JUJ* ,G7_#UK
MXA@M([F6>%[2ZCNX);=@KI(AXY(/!R0>.AK@]/\ AZFMZQXGNKVZUW27FU>3
M#65R]N+N#RTP&!&'3);D>IYKU*B@#SOQ1X,L[B_\%Z+9V%Q%I%G+.I:T+J;8
M"%MC[QRIWX(8GD^N:V-)^'VE:3::DAO-2O[O48#;W&H7]SYUP8R" H8C  SZ
M>F<X%=924 8-[X0TK4?"D'AR\266R@BCCC??MD4Q@;7##&&&.H_E6=H?P\T_
M1=1;4GU76=3U$1-##=ZG=^>]NK=?+R-H_$'^==?24#.4B^'VCP:5IME!+=QR
MZ?=_;8KT2*;AYB279V*D-NR0V1R/3 J5_!&F/%+&9[O$FKKJYPZ_ZY2"%^[]
MSY1QU]ZZ:DI 9AT2V/B8:]OE^U"T-GLR-FS?OSC&<Y]_PK$O_AYI&H6-W;/<
M7\3SZBVII<P3B.6WG(QF-@.!CUSU^E=;69:ZW;7>OZAH\:R?:+&.*25B!M(D
MW;0.?]DY^M S T7X;:3HNJS:D+[5;Z[N+5[2YDO[KSC.C$?>)&<C&!C'%1I\
M,M(7P[;Z.VH:NXM)3+979N\7%H2-NV-P!A0!T((KM:R_$>L?V!X;U'5_(\_[
M%;O/Y6_;OVC.,X./R- &/I7@#3-+M=11[[5-0NK^W-K-?7]UYT_E$'Y58C
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M: &R2",#@LS<*HZDTU(26$DIW/V]%^G^--@!<F=Q@O\ =!_A7M_C_P#JJ>@
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M'8D9]ZD.EV1U@:MY/^G"#[-YNX_ZO=NVXSCKSG&:!G,^(/\ DIO@W_KE?_\
MHM*[&J=QI5E=:G9ZE-#NN[(2"WDW,-@< -P#@Y '4&K9I#04E!H- Q*:22P1
M!N<]!V'N:'8(A8]!Z59MH3''E_\ 6/RWM[?A0D*3L$-NL1W$[Y#U8_T]!4U%
M%49!1110 4444 %%%,DD$49=N@H @O+CRDV*?G;]!693I':1R[=3498B0+V(
MS5K06X.0%/S 'M4)82,F>O0T\,BDDCG=CGFFSJ !(O44F:15G8?*0L1_2@2@
M#E6'ID5'&3-+N/W5Z"IV 92#WHW):2T8V-2,D]^WI6\GW%^@KGXE!&26R.",
MUT(& !28/<YF;B>0>C'^=:.C-\\P]A6;=<7<P_Z:-_.KVBG_ $B0?[/]:DVD
MO=-2[_X]9/I6(XVMOZ@=16W=<VLGTK":-2ZJ![GGM5+8Q6X2/E#A3CUJ08:,
M9Z8IU568Q%T['I3>@XKFT0Y' 4*#@D\FK ((X.:BC58XP3U(R:5=AD!4=1GB
MA!*SV)58HP93@CI6Q!*)H@PZ]QZ&L1&W;O8D59M9_)EY/RMP:'J1L:U%%%2,
M**** "BBB@ IDL?FIC.&'*L.QI]% $<,GF(<C#J=K#T-25 _[JY23^&3Y&^O
M8_S'XBIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "H)_P!XZ0=F^9_]T=OQ./UJ>H+?YY)9O[S;%^B\?SS0
M!/1110 4444 %%%% !1144\HAB+=^@^M %2_GR?*4\#[U4U(!Y&1]:"2223D
MFE1=Y('7&0/6K))HE5E<*>2.AIOS+!\N00>:C0LK KUJZF6&63!/6@930EI5
MR3UJ6Z!^4]J>;<!PR'&#G%2.@="IH H44YT*-AAS30,G IB-J(8B0>BBH)3F
M0D4YY"1M7H*CQ4#'1D+(">E66Y4^XJK@BGQR%#@]* ,JBE888@]J5$9VPHJA
M$UJ#\Q[5%(2LK8)'-7$0(H45&+<%RSG.3T% R+YF@.XDY( I9$540,V,#H*L
M/\J@A-Q'0"J3LS,2W6@!&VY^4$#WJ[83_P#+%C[K5-E*XSU(S2*Q5@P.".10
MQ&Y13(9!+$KCOUI]04%%%% !1110 4CJ'1D895A@BEHH AM6+6Z[CEERK?4<
M'^535!#\MQ<)[AQ^(Q_,&IZ& 4444 %%%% !1110 444&@!,T9HHH **** "
MBC-)0,6DHI*0"TE%)0 M)124#"BBB@ I**2@84444#$I*6DI %)110,*2BDH
M&%)110 D:^;= ?PQ_,?KV_Q_*KU5K)<6XD/64[S^/3],59JC)N["BBB@0444
M4 %%%% !69>S^9)L4_*OZFK=W-Y,/!^9N!655)"8U@Q^ZP'U%0,[+<(7&!C&
M<\5.S[74$<-QGWJ.ZB2>W>.1R@92-RG!&>X/K0_(N#L]3@=8\1.UR+BY>[T^
M*-WAFLW3#S(PP'0]"1UZ\>OK0TSQ$XL]/BL;B[E2QA_?6@3<]Q(S'(&,_*/4
M]..,FLW5-)O+BPA4+=(89FBABO9\R39QG8N  !C/]>*K:)87MG*]R89RS6^Z
M.*WG\N61&_B7 .<8Y'TKS'4GSGVD,+A_8=+KIIY_YO6]UWT/8]-E,]FDC1M$
MSJ&,;=5R.A]ZMUSOAZ'^S=-ACWW#!AO87#9==W.#]*Z%6#*"IR#7HTW>*N?'
MXFFH5';8<HRX'J:VR0H))  ZDUB(ZHZLYPH()-5;[47NVVKE8AT7U^M.3L9T
MX.1'=.KW<S*<J7)!]>:LZ3/'#=GS&VAEP">F<UG*&=@J@ECT [T'()!X([5G
M<ZW!-6.MN.;:3_=-8]166I-%&UO,<QE2%/\ =_\ K5+6D7<Y)P<7J%4[IAYH
M'<"K$LRQ+D]>PK/9RSEF/4\T2?0THP=^8T@ RC(!XJ)619I",!5'/UJ"2[9A
MM0;1^M,B <[6D"KGIZTG+L"I-)N19@9V4[5'))R:G7('S')H "K@8 %(C;T#
M 8!JT92=]4C4L9]Z>6Q^9>GN*MUBQ2&*0..HK91@Z!EZ$9J6B4+1112&%%%%
M !1110!'<1F6!T'#$?*?0]OUI8I!+"D@Z,H-/J"U^5)(_P"Y(P_ \C]#0!/1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% #)I/*ADD_NJ6_*D@C\JWC0]54 _6F7G-OM_O.J_FP!J>@ HHHH ***
M* "BBB@ K+O9O,FV@_*O'XU>N9?)@+#J>!615)"85/'&'(8(R^X:H!UJR7:.
M+<WWVZ>PIB'O(D)X&7[U";IST %-C02$@D@]<]J<+<G[LB'\:!@+IQU -3Q3
M"0XQ@U$+1CU<?A4JI' ,D\^IH >\:N,,,TR.W$;%LY]/:GQRK*#MSQZT^D
M$G%3I&%&3UI(TP-QZU)28QCH''OZU 00<&K51R)D9'44("I) LC GCUQWIZH
M$&%&!3JCEE$6,@G/I3$,EG$9V@9/\JA-S(?0?A5@K%.N0>?4=:A-H1T<?C3
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M.*.5)!!!'!!KGI_%TC^7-I]Q#]@AD,5VSK\\>>%8 ]LUW6NZ>6C:Y@^5L8?
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M\6XYIXF21@JQ[_<T#*RAV&Q02#Z5/':@<R'\*=+<!/E0<C]*AC8L_F2,=JT
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M6-Q^JU/4$O\ Q^0?1A_*A 3T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!!<_>@_P"NH_D:GJ!_WEVB=HQO/U/
M_K^E3T %%%% !1110 4R9MD+MZ T^JM^VVWQ_>.*$!F4Y I<;SA>]-J18BZ9
M3DCJ*LD<9MZN#P"!M [5)&1%Y:C[SG)/MVI'MY' <)ANXS^M"6CL<N=H_,T#
M*YR22>M*7)4+V'IWJ[]DBQ_%]<TL=LD;;N2>V:+@1QVY9!YI) Z+Z5850H
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M<>6V@@9]JY;S?&7AWQ5XBFTSP;_:UGJ%TD\4_P#:D,' B1"-K9/53UQ7H]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2,0JEB< #)-+4%U\ZI#_ST;!_W>I_P_&@
M!;4'RC(PPTAWGV]!^6*FHHH **** "BBB@ JAJ+<QK]35BW8L]P221YN![8
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M1!)&R$D C!(.#3!;PB-8PH"H0P /0^M0XWT1O3K..K;N1>796N3B-2/4Y-4
MDNJ3F0Y2%> ?\]ZEU/YF$20 -(X4R$=?I6BB)!"%& BBE;F=NAIS^SBI[R9#
M'8VT1!6($CNW-9%_=_:9SM/[M>%]_>I[W5@ZM% .#P7/]*HVENUU.(UX'5CZ
M"LYR3]V)TX>E*-ZM7\2QI]H;F7<P_=*>??VJW;6T5W+<R.N4+X4C_/TJ>2/#
M164)V(5+.1UV_P#UZB0FQN9$CYM\KE3U7=QG]*I12W,I595+N+L^GI?\V3V>
MZ&26U)W"/!4^QKI(#FWC/^R*Q<#.<#/K6S:\VT?TK2UE8XI2YI7):***0BCJ
M)_U8^M84,"7;M/.-WS$(I/  K:U$_O4'M6;<2M%&-@&]F"KGIDT[*VI<)-.T
M=V4(K59'O+8X!#!E]NM8UW/%8"4W+K&(AE\GH/6M28>3I=Q?F=([B/>PED.%
M!' !]J\UU_5!(([BZBC?4[B I*\,@:&2,_=88.0P(Z>V:Y:TE&)[F H2KU&K
MZ;?.WY?U8]/TJ\@O[41%DD^4,O?<AZ&I;C2XG3,(V/\ 7@UY5I>L3&^;4;-;
M>WNXE6/,T@$21  8 SDDG/T^M>L:?J=OJ,*O"P.1D8.01Z@]ZNC4C45F<^/P
M=7!SYX/1_@R"SG7FTNT4,O0L!S3KO3[=;:26,;2!D<\4NJQ +'<!0Q1@"#W'
M^?YU8CBBEMMHB:)=V2F,<@UI;>+.-SM:K%VONBO:6]I<0 F$!QPX).0:M0VW
MD-\DC^7C[C<@?2E-LOV@3J2K]&QT8>]35:C8PJ57+9Z,*UK-MUJGMD5DUI:>
M<PL/1J;,D2.Q-[$@)"A&8CUZ ?S-3U7/_(07WB/\Q5BI&%%%% !1110!!<?)
M)#+Z-L/T;C^>*GJ.>/S8)$'5E('UI89/-@CD_O*#0 ^BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J!/WEY(W:-0@^IY/_LM3
MU!:<VXD[R$O^!/'Z8H GHHHH **** "BBFNVQ&8]@30!7L#NMV?^_([?^/&J
M5V<W3_6K>E@C38<]<$G\S5*X.;B3_>-4MQ$=*J[F"C')QS3HT\R0+G&<TB[0
MWSAL>@IB)[8#>T4B\]0#ZBH1(P=F_B.0<U*;F1B/+4#' XR?SJW%N9=\T:+[
M]Z0RO:09/FN.!TS_ #JS%+YKOC[B\ ^M5;FZWY2/[O<^M6;2/RX!GJW-# KW
MTF6$8Z#DU5((4''!Z4Z5BTK$]<U,D)EMTR0JJ3DGTI["(-YV!1P <TVI657)
M$*G"C)8GK45 &I8?\>WXFK-0VJ;+9!WQFIJAE!5'4>D?XU>JIJ"Y@#?W336X
M,S>E.+DJJGHO2D R0/7UJ9%3)AE&UL\-5$D.TA0V.#Q5ZRDW1E#U7^507$;1
M11H>V>119L1< #H1S0QELR@3^4X&&''^%4[B(P2AE^[G(J>^0X60=N#3K>X6
M5=DF-WOWI 58FWW.2H^<\CZT3+OF\N,9"C'Y59F8VYS' H_VA4 G5E960+NZ
MLE,"O13E3=*$4]3@&D(P2/2@1:T\_OV'JM6+P[7M6])@/S!']:JV)_TD?0U/
MJN?L89?O(ZL/J#2ZCZ%VBD!# $=#S2U(PHHHH **** ((?EN+A/4AQ^(Q_,&
MIZ@?Y;V-NSH5/U'(_K4] !1110 4444 %%%% !1110!%(N#D=*CJR1D8JNZE
M3[4F7%B5#+:6T\\$\UO#)-;DM#(Z M&2,$J3R,CCCM4M%(H7-)110!"EI;17
M4UU';Q)<3!5EE5 'D"YVACU.,G&>F:FHS24 +29HI,T +29HI,T#%I*** "B
MBDI#"BBDH&%%%)0 444R1PD;.>B@F@"Q8KGS9?[S;1]!_P#7S5NHK:,Q6T:'
MJ%&?KWJ6K.=NX4444 %%%% #7;8C-Z FH; 8L+?U,8/YBB_;983D==A _&GV
MHVVD(](U_E3Z 94IS,Y]6-,I2<DFH9YO)\KC(=PA/IG-5L))MV0Z:58(S(^=
MHQD@=*S[Y2+J)@^(9\))@\'G-79UED0+$T8!^\6&>/854.G6<4.R:5B!SEI,
M ?0=*B=WH=%!QCJWJ77A1WC8_P#+,Y [=*R=2O&N)1:VYW#.#C^(^E<7KFMR
MP7^(Y[N"VM9@") =MRF0#M/3/7C\>U4M!U:&*:$VM]=(8)9;B:)DW/<#(VQH
M!G.0#G.,9)[9KFEB$WRH]BCE4X0]LW?LK/UU_KJ=I>VXM72+.7VY<^_I6OI$
M'E6@D(^:3G\.U<[%?-JSI=2P/;&4C,;]4&<5V*J%4*HP , 5I22<FT<>.<X4
MXTY;O<1'1RQ4@E3M/L::L*!Y&(W%R"<^W2L[[:8;FX@A3S)7DRH[#@9)JY'(
M82D5Q-OFD)( '\O:ME),X94I0VZ_?W+-:]K_ ,>T?TK(K;C79$J^@ IR,4.H
MHHJ1F;J'^N7_ '?ZU4(!ZCI5[45^X_X5G32K!$TCYVKR<#-4MA)-NR*UY91S
M:==6XACF$JL?*E^ZS=@?;.*\IUO2O/(BG:VM=2M;=I)K>&/9#%$O(&1G+DGW
MZ]:]3GFFMC]I1O.MFY9>Z^X]JKQ65AJUK=BX@25+ARKY&&*Y! R.1T!K"K35
M30]? XN>$O4>J\N^W7R_36QY?%H\VFWDE@@M+RZD1)"KKF-XB <JQP01G_"N
M_2S%C8VT]H-D2C&%_@(XJYJUC:VUI;&&)$,0$*8'(0#@9ZX&*ET:5)K62V<
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MCO1)7-*-3D;?]?>9*:;)#')--/\ 9HL9*1L3QZ9J"STPWSM(2Z6Y/!)^9O\
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M94_]"%4K'_CY'T-7;GK /64?U-)[@$ORW4#_ -[<A_$9_I4]07G%N7[QD/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT5AT89%+4-HKI:QHZE2HQ@D< =.GMBIJ0!1110 4444 %%%% !1110 4444
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M3_XJBP$]%0?:)/\ GSF_-/\ XJC[1)_SYS?FG_Q5%@)Z*@^T2?\ /G-^:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8.J7FH65RDJRPGR[":5XBC;7<;>?O<#)]^,^M1WVL:C874$3""95:(7#)"5
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M)"@8%5;H2>>2.M7ZD84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2\-JSRB17$9/D/L#$ @;\;<G(XSWJ'3(YX7G=K2>*.>7<$ED5W4[>68[CD<
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MZ GBJ^H6%SY,$5HF1;VTBQG( $A4(O4]@6-)(#3NKJ*S@,T[,$! ^5"Q))P
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img101536035_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +:!GP# 2(  A$! Q$!_\0
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MVC2K]T?2EH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
M:-&S_:-.HH ;L_VC1L_VC3J* &[/]HT;/]HTZB@!NS_:-&S_ &C3J* &[/\
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M44 -V?[1HV?[1IU% #=G^T:-G^T:=10 W9_M&C9_M&G44 -V?[1HV?[1IU%
M#=G^T:-G^T:=10 W9_M&C9_M&G44 -V?[1HV?[1IU% #=G^T:-G^T:=10 B_
M='TI:1?NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !114-U=06-I+=74J0P0J7DD<X"@=2: )J*\;U'XT:C?:BUGX5T(W>#\KRH\
MC2>X1,$#\?RIEC\:-6T_4EM?%.@BV4_>\J-XG09Z[')S^8KJ^IU;7L8^WAW/
M9Z*@L[RWU"SAO+259K>9 \<B]&4]#4]<NQL%%%<-K_Q(M=+\86/ABUMFFO9K
MJ"&X=_E2)9"O3^\=K?0>_2KA3E-VBB9245=G<T445!0445Y9XR^)6L^'O',6
MAVEM8/;-Y67EC<O\_7D,!^E:4Z4JCM$F<U%79ZG11169044V218HVD<X506)
M] *XGPG\1;?QAXHO-/L+5DLK>W,@FEX>1MP'3L.?K]*N-.4DVEHB7))I/J=Q
M17 ^._%/B[0M5MH/#V@_VA;/!ODD^QRS;7W$8RA ' '%=U;N\EM$\B[9&0%E
MQC!QR*)4W&*D^H*2;:)****@H***P_&'B >%_"U[JNU&EB3$*/T:0G"@XY(R
M<GV!IQBY-)";LKLW**\.T+XU:U=:]I]MJEGIT5C<2JDDD44BL%)V[@2Y& ?;
ML:]QK2K1G2:4B85(SV"BBBLBPHK%\4>)K+PGHKZG?+(T881HD:Y9W(.![=#S
M4'@KQ')XK\-QZM);K;^;+(JQJV<!6(&3W-7[.7+SVT)YE?EZG0T5Y[X7\5^,
MM4\72:?JWA_[)I@\S;<_8YH\X^[\S$KS7H5%2FX.S",E)70445SWC35M9T7P
M\UWH6G_;KT2JHA\EY?E/4[4(-*,7)I(;=E<Z&BN8\*Z_JE[X3EU;Q)8G3[B$
MR-)$('CQ&HSG:Q)Z9JCX,^($?C36=2@M+0PV=HB&-Y#\\A)(R1T XZ<U3I2U
M?87.M/,[6BBBLR@HHHH **** "BN>\:>*$\(>&YM4:#SY RQQ1[MH9STR?3
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M444 %%%% !1110 4444 %%%% !1110!E>(_^0#<_5/\ T-:IZ'_JEJYXC_Y
M-S]4_P#0UJGH?^J6@#H#]VA?NCZ4'[M"_='TH 6BBB@ HHHH **** "BBB@
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MT_JM7EYK"]M"]KGJU%%%<YJ%%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_H:U3T/_5+0!T!^[0OW1]*#]VA?NCZ4 +1110 4444 %%%% !1110 4444
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MXC!/\+!^1GU'YU4\&74'AKXPW4>K,L ,T\'F2<!68G:<^A]?>O2?BYK-A:^
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M(BTMT0VW2:?<]TL/^0=:_P#7%/Y"I9IH[>"2>5@D4:EW8]@!DFHK#_D'6O\
MUQ3^0KBOB]KO]C^!YK>-]MQJ#"W0#KMZN?R&/^!5Y4(.<U%=3LE+EC<\_P#
M,#>-_BK?:[=Q[[>(O<%7Y'/R1K^ _P#0:J>%9&\!?&!],F8K;/,UHQ8XRCX,
M;?GL/YU'X-T?XDZ?I7VWPQ;>5:7V'WDV^9 N0#B0Y'>LGQMI7C*VNXM9\4P%
M)YB(DG5HN2HR!^[/!QW]O:O7LI3<.96:M:^IPW:BI6=]SZ+\4:]#X9\.7FK3
M+O$"?)'G&]R<*/S(_"O%]('Q(^(2W6IV6M26ENCE5"W+VZ%@,[$"#G (Y/YU
MU/C/49/%7P1AU6$;W_=27 7G#*VU_P FY^E6_@MJME)X)-D)HUN;6:0RH6 .
MT\AOIVS[5QTU[*BYI7E>WH;R?/-1OI8R_ASXJ\4W6JWGAS6X[J9@LD:73H<P
M2J#E6<#IP>3SG'K7FFJ:+KMK\0H](N]3\[6S<P1K>>>[8=@FQMY&[C*\XR,<
M5[9I'Q3L=9\8MX?MM/FDS*\<=U$X9&"@DL1Q@<>]>=^+@(?C_;2R,JH;^Q<D
MG   B'/Y5O1E)5)7C:ZN9U$G!:WU.B\61>)O"7PJACOM<N)-3_M 9NK>[D+%
M"&PN\X;''3I3+.77-7^!IU&#5]1&I6LLD_GK<R>8Z*Q#*6!R1MR<>PK9^-CH
M_@--K*VV^C!P<X.U^*N?"%$E^&MK'(H9&DF5E/0@N>*QY[4%4:UYC3E_><OD
M1_"#Q+/K_A:6WO;F6XO;*8J\DKEW9&^922>3_$/^ UR6D:YK'C'XQ2I::K?Q
MZ1;S&1H8KAUC,4> /E!QAF S_O5S,=_=?#3Q=XBTZ/>$EMY8(C_O#=$_X C\
MS7H'P/T'['X?NM:E3$E[)Y<1(_Y9IW'U;/\ WR*TJ0C34ZJZ[?,F,G-QAVW,
M#QOK^LVGQ@BL;;5K^&T,]J#!'<NL>"%R-H..<G-4_C7IFK6WB!=0NK[S=-NF
MQ:6WFNWDE8T#_*1M7)YXZ]ZB\?\ _);8?^OBT_DE=+\>T)T[1).,+-*I_$+_
M (5=-\LZ5NJ)EK&?J8VD^&/&4'@"YU:/Q#=+;?85N+*"VO9@R $$C;P!\F[@
M$\XKK_@UXFN=<T"\L]0NYKF\LYL^9-(7=HW'&2>3@AOTKI/ 3PR^ =$B+1ON
MLE!3(.1C!X_2O&;#4'^%_P 1-:MV#>3Y,T<0QD,"N^$_GM'XFLKNNIPMJM47
M_#<9=#=GUS6/%7QG_LW3]6OH-,@N-CQV]RZ(4B^^< @?,01GW%>WUX]\#=%8
MP:EXAN 3)._V>)FZD#YG/XG;^1KV&N?%M*:A'IH:4;N/,^IQ/Q*\;OX-T:+[
M(J/J-V2L(<95 /O.1WQD8'J?:O/+'0OBGKNEKKD>MW48E7S(H&O&B:1>Q"#Y
M0#[XJU\>K287VCWFTF Q21;NP8$''Y']#7J'AWQ!I5]X3L]0AO+=+:.W02%G
M $)"X*MGIC%:I^RHQE!7;W(:YZC3>QPWPV^(&I:]+=>'-9?_ (F:1/\ 9[@C
M8S$<%6Q_$.N?8]^OEFOZ-KEAXW33-2U+[3JQDA477GN^&;&P[V&[C([<8KJO
M KC7/C?/JEC&3:">ZN2V.B,KJ"?3)<?G4?C_ /Y+;#_U\6G\DKJ@E"LU%6NK
M_,RE>5--]SV'P1H^MZ)H+6FOZC]OO#.SB;SWE^0@8&7 /8\>]=&2%!)( '))
MI:X_XG:]_8/@:^D1]MQ=#[-#ZY?J?P7<?RKRDG5G;JSLTA'T/,?#I/CWXTR:
MFPWV=M*;A<]!''A8_P SM./K5.$_\*]^,Y4_)9&XV\]/(EZ?]\Y'XK5;P3H_
MQ"M;%]4\*VVRWO/E,I-O\X4D<"3D#.>G7\*K>.='\<$1:SXMMNF+=9P8?=@"
M(_QY(KU[+VCAS+EM:U]3AN^7FL[WN?07C#_D2-?_ .P=<?\ HMJ\W^ ?_'EK
MG_72'^3UT5AKG_"0_!.^O&?=.NE7$,_/.](V!)^O!_&N=^ ?_'EKG_72'^3U
MQ1BXX>I%]&CH;O4BT>Q5\[>/K:3P9\5H]6MD*Q2RI?1@?Q9/[P?B0WX-7T37
MF/QMT/[?X5AU6-,RZ?+\Q Y\M\ _^/;?UK/!S4:MGL]"J\;PNNA?^*7B2.R^
M';R6LHW:HJPPL#U1QN8_3;D?C5#X)Z#_ &?X6FU65,3:A)\I(Y\M,@?F=Q_*
MO(9M5U#Q;#X;\.J"6M%^S1'^\7?@_0*%'X&OJ+3K"'2],M;"W7$-M$L2#V48
MK6O'V%'V?5LBF_:3Y^Q\Z>"=;T[P]\2[F_U2X^SVJM.I?8S\DG'"@FO4M9^+
M7@[^R+I+>^>\E>)D6%;:1=Q(Q@EE Q7EO@G1-.\0_$NYL-4M_M%JS3L4WLG(
M)QRI!K5^)'PY3PFT6MZ(A?3@X$L,H\P0MV)W9RIZ<]_K715A1G549MWM\C*$
MIQ@W'8M_ G2[LZWJ.K&-A9K;&WWD<,[,K8'K@+S]178:W\+QXF\;7.L:QJ4C
M:=\@@LXR<X"*""3]T%@3A?7J#6E\-O%MGXG\.JD4$%I=6F$FM85"HOHR@=%/
M/T.:[.N.M7J*M*6SV-Z=.+@EN> _!-53X@ZDBC"K8R@#V\V.MSX^7+K9:%:@
MGRY))I&&>ZA /_0S6+\%O^2AZI_UY2_^C8ZW?CW9R2:9HMZ 3'#-+$Q[ N%(
M_P#0#75*WUR-_P"M#)?P&==8Z7 /A##I[(OEOH^6&.-S1;B?^^B37G'P<U.>
MRTCQ7L/$%J+E!Z,JO_/C\J[NR\2V'_"FTU W,7[K3/(8%AGSA'LVX]2PZ>]<
M5\&='EOM%\4..$N8!:(?5BKY_+<OYUE'2E4YNZ_,MZSC;L<EX \6V/A#4+[5
M;RUDO+MXA' @(').6)8YQT'8GFN\\/\ BSP5XV\61RZMH'V369F00S/.TB.R
M\*,C #=,<?CTKF_@T-.M_&UQ%J:QI=K"5MA, -L@89 ST;&?UIOQ92V'Q)@&
MC^4+HQ1>;Y..+C>V,X_BQLKIJ1C.LXV:=M[F,6XP3Z7V/HFBBBO&.\**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z/I2TB_='TI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D=%D1D=0RL,%2,@CTI:
M* /+=<^"&C:A=O<:9?3:;O.3%Y8EC!_V1D$#VS4>C_ S2;.Z2;4]2FU!$.?*
M6/R5;V/)./H17JU%='UJM;EYC+V,+WL4[B[T[1;%&N;BVL;2/$:M*ZQHO' R
M< =*^=O'2Z?XI^*'DZ!()Q>/%$TD?*-)PI(]1C&3[$U[_P")/#MEXIT:32[]
MID@=E8M"0&!!R,$@C]*Q?#'PT\/>%+W[;9I<3W8!"37+AB@/7   'UQFKP]6
M%).;OS"JPE.T>AU%A9PZ=I]O96Z[8;>-8D'H%&!7#^-OA79^+]4&IQZ@]C=%
M DA\H2*X'0XR,'''7M7H%%<\*LX2YHO4TE!25F<IX;\"V6A^$9_#MW-_:-M.
M[-*9(]@.X#@#)QC&>O6N,OO@+8RW)>QUR>WA)SY<MN)2/;(9?Y5Z]16D<35B
MVT]R72@U9HY+P=\/=(\&AY;8R7%[(NU[F7&<>B@=!^OO65XH^%__  DGBZ/7
MO[8^S[/+_<?9M^=G^UO'7Z5Z%14JO44N>^HW3BURVT,C6]>T+28)8=8U&T@#
MQ%C#+( SH<@X7JW<<5X/\)]#BU?X@"YC1S8Z?NN%WCG.<1@^^3G_ (#7L?BW
MX>Z/XRN[>YU&:\BD@0QJ;=U7(SGG*FM+PWX5TGPI8-::5 45SNDD=MSR'U)_
MH.*VIUH4Z34;\S(E"4IIO9&U7D>H? BQN-1DGL]:DM;9V+" VX<KGL&W#C\*
M]<HK"G6G2^!V+E",_B1YWXP^%@\5W&GRC63:BSM%ML&V\PO@GYL[QCK77:MX
M=T_7=!_LC4H_.@V*-PX96 P&4]C6M10ZTVDK[;#4(J^FYXX_P#MC<;H_$,JP
M9^XUJ"V/][<!^E>D^&/"^F^$]*%AIL;;2=TDKG+RMZL?Z=*VJ*JIB*E16D]!
M1IPB[I&=KVG3:OH5[IUO=_9)+F(Q>?LW[ >#QD=LCKWKG? 7P^A\#I>M]N^V
MSW14&3R?+VJN>,;CW/\ *NSHJ%4DHN">C&XIOFZA7F^G?"C^R?&X\16.M^4@
MN6F%K]ESA&SN3=O]"1G%>D440J2A=1>X2@I6N<-XR^%^D^+KK[=YTEC?D /-
M&H82 =-R\9/OD5AZ)\#M+L+Y+C4]2DU%(V#"$0B)&]F^9B1[<5ZK16D<35C'
ME4M"72@W=HR/$?ARR\3:#-I%WN2&0 JT> 8V'0C_ #TKB_"/PB3PMXEM]8_M
MM[DP;]L0MO+!W*R\G<?[V>G:O2Z*F-:<8N">C&Z<6^9K4\]\+_"__A&_%TFO
M?VQ]HW^9^X^S;,;_ /:WGI]*ZKQ3X?A\4>';K29I/*$P&R7;N\M@<AL9&>GK
M6Q12E6G*2FWJ@4(I66QQ?@+X>P^!_MLGV[[;/<[5\PP^7L49X W'J3^@K3\:
M>%_^$O\ #S:5]L^R9E63S?*\SIVQD?SKH:*'5FY^T;U&H14>7H<WX0\))X6\
M,G19+H7L;.[,YB\L$-U&,G^=<)/\!K-K]I+?7IH;8ME8FMPSJ/3?N'\J]?HJ
MHXBK%N2>K)=*#236QPOQ(U_PX/"&KZ9>ZC;O=-$46UCD5I1+P4RO4<X.3VKC
MO@3H6Z74=>E3A0+6 D=SAG(_\='XFNRU[X4^'_$6O3ZQ>37R3S[3)'#(BH<*
M%Z;2>@'>NLTK2;'1--AT_3H%@M81A$'/U))Y)/K6OMH0H^SA>[W)Y)2J<TNA
M=HHHKD-CS'Q%\%='U>^DN].O9-->5MSQK&)(\]\+D$?3.*L>%O@]H_A^_CO[
MRZDU*YB(:(/&$C5AWVY.3]37HU%;_6:O+R\VAG[*%[V.;\;^$_\ A,M!73/M
MOV/;.LWF>5YG0$8QD>OK4W@[PU_PB?AR'2/M?VKRW=O-\O9G<<],G^=;U%9^
MTER<E]"N5<W-U*.L64VI:->6-O=?99;B)HA/LW[,C!.,CG'O7+^ OAW#X(DO
M9C?_ &Z>Y"J'\GR]BC)(QN.<G'Y"NVHH522BX)Z,'%-\S"O-H?A/]B\<CQ)8
M:W]G NC<"V^RY #'YDW;QP02.G&:])HHA4E"_*]PE!2W/-/&'PD_X2OQ)<:O
M_;?V7S51?*^R;\;5 Z[QZ>E87_"@?^IF_P#)#_[97M%%;1Q=:*44]%Z$.C!N
M[1QW@'P)_P (/#?1_P!I?;?M3(V?(\O;M!_VCGK6)XN^$$/B?Q'/J\6KBR,X
M7?$+7?E@,;L[QUP.U>F45"Q%13<T]64Z<7'EMH5=.L(=+TRUL+=<0VT2Q(/9
M1BN1\??#O_A.+FRF_M7[%]E1UQ]G\S=N(/\ >&.E=Q140J2A+GB]1RBI*SV*
MNF6?]G:59V/F>9]F@2'?C&[:H&<=NE<-XU^%-IXMUA=3@U#^S[@IMFQ!Y@E(
MZ-]X8../RKT.BG"K.$N:+U"4(R5F4-%LKO3M'MK.]OOMT\*!#<>7L+@="1D\
MXQSGFN0\=_#3_A-M5MK[^U_L7DP>3L^S>9GYB<YW#UKOJ*(590ESQ>H2@I+E
M85YMXJ^#NE>(-2EU"SO9-.N)FW2JL0DC9NYVY&"?K7I-%*G5G3=X.P2A&2LS
MAO!7PPTSP?=&^-P]]?[2JS.@18P>NU<G!/KDUO>*/"NF>+=+^PZE&WRG=%*A
MP\3>H/\ 0\'\JVZ*<JLY2YV]04(I<J6AX_;_  $LTNPUQKT\EMGF-+8(Q'^\
M6(_2O5-+TNST73(-.L(1#:P+M1!^I)[DGG-7**=2O4J?&[BC3C#X4%%%%9%A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5XC_ .0#<_5/
M_0UJGH?^J6KGB/\ Y -S]4_]#6J>A_ZI: .@/W:%^Z/I0?NT+]T?2@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?!7PT_X0_P 176K?VO\
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M:?ZR,G[I;?UZ<XZC..U>E444ZE651WDPC!15D<#X*^&G_"'^(KK5O[7^U^?
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M).?NJ,]*J>%G&+G=-(2K1;4;'JM%>+:GXZ\>Z_XEN-,\+Z?):I%DHLENHD9
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MXRK-G.T_W>F.]=/7F/QU_P"1(LO^PBG_ *+DJ*$5.HHRV*J-J#:.T\)>(/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\V2*4(?X3M!S^?-3"K&?M%.6]M1R@X\K2V/;JJ:GI\.JZ5=Z?<#,-S$T3\=
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MEZ>QK24E'W@HHHK T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#K/1YGB:XAM! S(24+;<<$@''X5QGPU^'6K^#=:N[W4;FQECFM_*46[NQ!W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH)I %" ]=JCH3ZY-=O16T\55G'EE+0S5&$7=(****P- HHHH **** "BBB@
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M[H^E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &5XC_Y -S]4_P#0UJGH?^J6KGB/
M_D W/U3_ -#6J>A_ZI: .@/W:%^Z/I0?NT+]T?2@!:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\
MSTC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2
M/_OV?\:-L_\ STC_ ._9_P :EHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :
MEHH BVS_ //2/_OV?\:-L_\ STC_ ._9_P :EHH :@D&=[*WIM7']33J** "
MBBB@ HHHH **** "BBB@!%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH RO$?_ " ;GZI_Z&M4]#_U2U<\1_\ (!N?JG_H:U3T/_5+0!T!^[0OW1]*
M#]VA?NCZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "+]T?2EI%^Z/I2T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!E>(_P#D W/U3_T-:IZ'_JEJYXC_ .0#<_5/
M_0UJGH?^J6@#H#]VA?NCZ4'[M"_='TH 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH RO$?_(!N?JG_H:U3T/_ %2U<\1_\@&Y^J?^
MAK5/0_\ 5+0!T!^[0OW1]*#]VA?NCZ4 +1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !17GFI?%'^S]4N[+^QO,^SS/%O\ M6-VUB,XV<=*J_\ "W?^
MH'_Y-_\ V%5RLYGBZ*=K_F>FT5YE_P +=_Z@?_DW_P#84?\ "W?^H'_Y-_\
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M17":%X\NEL_$T?BFUM[6_P##@5[LV99HY49"Z,@;GD X!]O6LYO%OC^'0/\
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M)VA=Q!! ' Y]:[C3M9\;VFN:=;ZWIFEWNG7Y9?M>C^:1;$#(\S?G*GIN&/\
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M\MCIFJ?A/Q9IOPZTJ]\->)OM%I>VEW.]J!;NXO8W<LK1E002<XQD8_/'K=%
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M//3^[)_W[;_"I:* (O/3^[)_W[;_  H\]/[LG_?MO\*EHH B\]/[LG_?MO\
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MV_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\
M?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_
M '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)
M_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_N
MR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/
M[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//
M3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* &I('S@,,?WE(_G
M3J** "BBB@#*\1_\@&Y^J?\ H:U3T/\ U2U<\1_\@&Y^J?\ H:U3T/\ U2T
M= ?NT+]T?2@_=H7[H^E "T444 %>8>*/$6BZ_P"-%\-:EK&G66BZ6R7&HK=W
M21&[FZQP@,1E%X9NV<"O3ZS+CP[H=W.\]SHVG33.<O)):HS,?<D9- 'F?@76
M+";P1XUMK+4+66]^UZE<QPQ3*TAC(^60*#DKDC!Z<BNK\!1PCX0:.B!3&=,!
M8=B2I+?J33O _@B/PQ::JEU;:>9KN^N)4DMTY%NY!6,DJ",8^Z.*PXO!7C72
MM&N?"VC:SI:>'Y-\<-S<)(;NVB<G**!\K8R0"2#]., &I\&WE?X3:"9OO>7(
M!_NB5POZ8KNJH:+I-MH.B66E68(M[2%8DSU( ZGW/7\:OT (Q"@DYX]!FH_/
M3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"C
MST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_P
MH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO
M\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[
M;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]
M^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG
M_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[
M)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_
MNR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]
M/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O
M/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"
M+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH
M B\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:
M* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]/[LG_?MO\*//3^[)_P!^V_PJ
M6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\
M*EJKJ6I6>CZ9<ZC?S""TMHS)+(03M4=>!R?H.: )?/3^[)_W[;_"CST_NR?]
M^V_PJMHVLZ?X@TF#5-+N1<V4X)CE"E<X)!X(!'(/45>H B\]/[LG_?MO\*//
M3^[)_P!^V_PHN;F&SM9KJYE2&"%#))(YPJ*!DDGL !3;*\M]0L;>]M)!+;7$
M2RQ2 $!D89!Y]010 [ST_NR?]^V_PH\]/[LG_?MO\*EK/LM;T_4=1U#3[2X\
MRZT]T2ZCV,/+9AN49(P<CTS0!;\]/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_
MNR?]^V_PH\]/[LG_ '[;_"I:* (O/3^[)_W[;_"CST_NR?\ ?MO\*EHH B\]
M/[LG_?MO\*//3^[)_P!^V_PJ6B@"+ST_NR?]^V_PH\]/[LG_ '[;_"H;[5+'
M36MEO+F.%KJ9;>!6/,DC=% [FK= $7GI_=D_[]M_A1YZ?W9/^_;?X5+10!%Y
MZ?W9/^_;?X4>>G]V3_OVW^%2T4 1>>G]V3_OVW^%'GI_=D_[]M_A4M5+/5+'
M4)[N&SN8YI+.7R;@(<^6^ =I/K@CZ4 3>>G]V3_OVW^%'GI_=D_[]M_A4M%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8/@?_D0/#G_8+MO_ $4M;U8/@?\ Y$#PY_V"[;_T4M;U
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5XC_Y -S]4_P#0UJGH
M?^J6KGB/_D W/U3_ -#6J>A_ZI: .@/W:%^Z/I0?NT+]T?2@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH XZ]\5W]M?W$"16Q6.5D!*MG ./6H/\
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MA<?B#C/%2>*M4U?QAJOA"2R\*:Y:V5EKMK-<RWMJ8W7YNH09.P -N<X X]:
M+FH^*-7U3QWK&A1^+[+PO]@:-+6":UCD>[+)NWDR'&.>B\X_7NO"TVN3Z!"?
M$=O!#J:LRR&!@4D /RN,$XR,'%<9XGNDFUF^L?%G@&XUJQ# Z=>Z;8?:&*$<
MJYSN1@>,C /\]7X5Z+J.A^%)[>_MYK2*6^FFLK*:7>]K;-C9&QYY&"?Q]: ,
M7XL6&IW.N^#FL]9>S1]5CBC06Z/Y<N&(ERW4@<;3Q6_K$'C.XU&"QLM6@TK3
M(+16GU=X(Y9;B;."HC)VH.^2.^!57XFV]]CPUJ=GIMW?QZ;J\5S<16<?F2B,
M!@2J]3U'2N9\16IN_'S:KXE\*:UKFA7%E"VF0V]L\HM7VY<2PY&UR2>3TX'T
M -?PSXKUDZEXIT*_UBSU>32[1;BUU&VC12V5.0ZJ2H8$#C_&H/"VO>*!X)C\
M<^(==22PCL'F;3(K.-?,V@A6,G!#,1G &.0,5G>%=&O[;Q=XLN%\*S:)8WVD
M+]BMHX!MP 5VDI\HD/WBN<\]^M='H'AJYU3X(6OAV[CEL[J?33 5F0JT;G.-
MRGD8..* ,BZN_B/;>")O%[:[9^8;,WC:0+%0D,13=Q)RQ=1SSD9&*EU#QSJO
M]A^#--MM2LK+5=;T^.ZN]3O0HC@01JS,%X4LS$X'3Z=L[6?%>OI\+M1T&\\)
MZM#JD&ER6]U<R1 6@18R'D$N<'*Y(4<YX]ZCNO#4TFA^ /$RZ!'KUM9:/#;7
MVG-"LCM&T2D.BMP64YXZ_J0 ;6C^*M2TSQE8>'K[Q/8>(;;5HY?LU[;QQI+;
M2HN[:ZQDJ5(Z' YK&\$C7=!_X6!JQU634S87ET7L_LJ)]JG5%82$J,KG&-J\
M5N>'(H+_ ,7VL^C?#NUT32[:-VGO[_2TMK@R$8585&".IRQ[9Z=V>'&US1M>
M\;:?!HUT+Z[O9M0L+F>!OL<H*KM4R X!)'3_  H H:#KWBW5[&PUC1_%^EZ]
M/(T;WFAK!%#Y2,1O"MD."H/\77'X'URO"O$.G)XJL(X=/^'6J:5XP9XS]O2V
M^S002!@6D\Y3AAUQU/XBO<XE98D5VW.% 9O4^M #J*** "BBB@ HHHH ****
M "BBB@!%^Z/I2TB_='TI: "N/@^(WAK4?"^K:VKS/INGR&"ZWP'.> 1M[CYA
M7851U"?3](TF[O;M8H;."-IISL&-JC).._2@#QC1/'/P9\.:L^J:3IT]M>L"
M/-%O(VW/7:&8A?3Y0..*W?!_C3X;WOCB:30X+C^W=8D;?/) WS<;B 2<*/ES
MQU/6K9^)>EK\/K_Q=/X;FMK>.?R;*&=%5KL$#:X., $ELXS@*>O2G^#?'=UJ
M/B.#1/$?A8:'J%U ;FQ88*S*!DCIPP'./KG'< ]*HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8U;Q
M?_9>IS6?V'S?+V_/YVW.5!Z;3ZUT]>8^+/\ D9KS_@'_ * M7!)O4X,QKU*-
M)2INSO\ YFU_PG__ %#/_(__ -C1_P )_P#]0S_R/_\ 8UQ=%:\D3Q?[1Q/\
MWX+_ ".T_P"$_P#^H9_Y'_\ L:/^$_\ ^H9_Y'_^QKBZ*.2(?VCB?YOP7^1T
M^C^+4T?1+#2X[!I$L[:.W5VGP6"*%!/R^U7?^$__ .H9_P"1_P#[&N+HHY(A
M_:.)_F_!?Y':?\)__P!0S_R/_P#8T?\ "?\ _4,_\C__ &-<711R1#^T<3_-
M^"_R/2-"\3_VU?/;?8_)VQF3=YN[."!C&!ZUT%>?>!?^0W-_U[-_Z$M>@UE-
M)/0]S 59U:/--W84445!VA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5XC_Y -S]4_P#0
MUJGH?^J6KGB/_D W/U3_ -#6J>A_ZI: .@/W:%^Z/I0?NT+]T?2@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N9\3>%+C6=1L=5TO69](U6S5XTG2)94=&QE7C;AAQQR,9KIJ*
M .4\.^#9M,UVXU_6=9FUG698!;+.\*PI#%G=M2-<@9/).3_//5T44 %%%% !
M1110 4444 %5[^R@U/3KJPNE+6]U"\,J@XRK @C/T-6** /.F^&VM7.EIH5]
MXWO9_#RJL9M!9QI,\0QA&F!R1@8/'(KT&""*UMXK>! D42!$0=%4# 'Y5)10
M 4444 %%%% !1110 4444 %%%% !1110 4444 (OW1]*6D7[H^E+0 5R_P 1
MM+N]9^'>N6%BK/<RVQ,:+U<J0VT>YQC\:ZBLWQ!'J\NA72Z#-;PZIM!MWN!F
M/(()#<'@C(Z=Z /#+[Q!;?%";P3X0TFTN!%:/'-JL;Q%5@$:A2OY;QZ?,HZG
M [#4M2C\5_'+0;+3(I63PVMR^H3F,JJM(@4)D]>0/8Y)&<41?$O7/"SE/'/@
M^XLE)^?4]-7S8&]VP3C_ +Z)]J[CPYXF\->(HGGT'4+.X,AWRK%A9,XZNIPP
M/U% &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>8^+/\ D9KS_@'_ * M>G5YCXL_Y&:\_P" ?^@+
M6E/<\O-_X"]?T9BT445N?.A1110 4444 %%%% '3^!?^0W-_U[-_Z$M>@UY]
MX%_Y#<W_ %[-_P"A+7H-<]3XCZ7*_P#=UZL****@]$**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO$?\ R ;GZI_Z&M4]#_U2U<\1_P#(!N?JG_H:U3T/_5+0!T!^[0OW
M1]*#]VA?NCZ4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "+]T?2EI%^Z/I2T
M %9VO:W9^'-$NM7U!G6TM5W2%%W-C( P/J16C3)8HYHS'+&LB'&5<9!QSTH
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M4?9X/^>,?_?(H DHJ/[/!_SQC_[Y%'V>#_GC'_WR* )*\Q\6?\C->?\  /\
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M?V>#_GC'_P!\BC[/!_SQC_[Y% $E%1_9X/\ GC'_ -\BC[/!_P \8_\ OD4
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M!)14?V>#_GC'_P!\BC[/!_SQC_[Y% $E%1_9X/\ GC'_ -\BC[/!_P \8_\
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M^^10!)134C2/.Q%7/7 Q3J "BBB@ HHHH **** "BBB@!%^Z/I2TB_='TI:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 97B/_ ) -S]4_]#6J>A_ZI:N>(_\ D W/U3_T-:IZ'_JEH Z
M_=H7[H^E!^[0OW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD&TXP!(2><#H>M 'HE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>(_^0#<_5/\ T-:IZ'_JEH Z _=H7[H^E!^[0OW1]* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **\E^'/Q$U74/$EYHOB63<+NXG_ +)N3&B!Q&Q5XOE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'C7A[PJ?%7PRO8K:3R-5L]8N[G3KD'!BG60E>?0]#^?:E\->*_\ A+/B;X;G
MN(_L^J6NFW=MJ%L1@PSJRAACL#U'Y=C7IOASP[:>&-.DL;*2>2*2XDN"9F!;
M<[;B. .,]*H1^!-&@\=OXP@$\6HR0F*1$91$^1C<1C.[ '.>W2@#C]1LM2;4
M[LI\$=%O5,SD73WMF&F&X_.04R">O//-+?:M>^%OAOXEU-_A]IOAV1(XT2WB
MEAF2YWMY>YQ&H&%W=#UYKU6J]]8VVI6,]C>PI/;3H8Y8W'#*1@B@#QW7OATG
MA;P)'K<&OWEY<:0JWRVUVXDL)&!R0L.,*#GY<=.*]@TR\.HZ39WIC,9N($F*
M'JNY0<?AFN-C^$^B@16USJ>N7NEPL&BTNZOB]JN/NC;C) QP"2*[L    8 Z
M 4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 (OW1]*6D7[H^E+
M0 51UG2K;7=%O-*O%)MKN%H9-IP0",9'N.HJ]6+XMUX>&/">IZT8Q(UI 71#
MT9^B@^V2* /.K+3/B[X.MDTG2#HVN:; -EK)=921(Q]U3\R]![M]:V?"G@[Q
M)<>*E\6^-KZVFU*")H;&SM!^ZME8$,?]X@D=^#R3P!P&N>'M?M;;PGXKU[Q%
M>W6HZEK5HK6:OM@@1\OM"^HV@<8')Z]:[@7&L>$_C':V4^IRWNB^)O.>*&7_
M )=9HU#$+[8P.,9W<\C) /3:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"_9_QH EHJ+;/_ ,](_P#OV?\ &C;/_P ](_\ OV?\: ):*BVS_P#/2/\
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MT;9_^>D?_?L_XT 2T5%MG_YZ1_\ ?L_XT;9_^>D?_?L_XT 2T5%MG_YZ1_\
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M]J]MIUW+YMQI=O>%+65B<G* 9&3U (KNJ* (X(8K:WC@@C6.*)0B(HP%4#
M]L5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z/I2TB_='TI: "FO''*
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M;?X4>>G]V3_OVW^% $M%1>>G]V3_ +]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/\
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M//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\* ):*B\]/[LG_?MO\
M"CST_NR?]^V_PH EHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_
M  H\]/[LG_?MO\* ):*B\]/[LG_?MO\ "CST_NR?]^V_PH EHJ+ST_NR?]^V
M_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\* ):*B\]/[LG_?
MMO\ "CST_NR?]^V_PH EHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_
MW[;_  H\]/[LG_?MO\* ):*B\]/[LG_?MO\ "CST_NR?]^V_PH EHJ+ST_NR
M?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\* ):*B\]/[
MLG_?MO\ "CST_NR?]^V_PH EHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6BHO/3
M^[)_W[;_  H\]/[LG_?MO\* ):*B\]/[LG_?MO\ "CST_NR?]^V_PH EHJ+S
MT_NR?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\* ):*B
M\]/[LG_?MO\ "CST_NR?]^V_PH EHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6B
MHO/3^[)_W[;_  H\]/[LG_?MO\* ):*B\]/[LG_?MO\ "CST_NR?]^V_PH E
MHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\*
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M4_\ 0UJGH?\ JEJYXC_Y -S]4_\ 0UJGH?\ JEH Z _=H7[H^E!^[0OW1]*
M%HHHH *AND:2SGC099HV 'J2*FHH Y+X?Z#=Z5\-M,T36+;RKA('BGAWJV-S
M-QE20>#V-<O9:=X_\/>&IO!VG:/:WD"*\%EK3WB(L<3$X+Q_>+*#V&.G7'/J
MM% &5X9T.'PUX9T[1H&WI9PK'O(QN;^)OQ))_&M6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $7[H^E
M+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S+XN_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-/I][;7<2ML,EO*LBAL XR"><$?G3L]P+5%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 1?NCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /,OB[_ ,P;_MO_ .TZ\RKTWXN_\P;_ +;_ /M.O,JUCL>)C/XT
MOZZ!1115',%%%% !1110 5I^&_\ D:-(_P"OV'_T,5F5I^&_^1HTC_K]A_\
M0Q0RH?$CZ'HHHK ^B"BBB@ HHHH *\Q\6?\ (S7G_ /_ $!:].KS'Q9_R,UY
M_P  _P#0%K2GN>7F_P# 7K^C,6BBBMSYT**** "BBB@ HHHH Z?P+_R&YO\
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M[=17B/\ PLCQ+_S]Q?\ ?A?\*/\ A8_B7_G\B_[\)_A1R,/K]+LSVZBO$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M05S_ (G_ .77_@?]* .?HHHH **** $"*I8JH!8Y8@=3C&3^ %+110 4444
M:&B?\AB#_@7_ *":["N/T3_D,0?\"_\ 03784 %%%% !1110 4444 97B/\
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MC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
M0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H
M?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .
M?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z
M'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\
M'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_
M (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH
M** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/
M!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_
M ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/
M^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"
MIH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_
M^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y_
M_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0
MJ:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?
M_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?
M_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
M@NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@H
MH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'
M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\
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M4 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\
MZ%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\
M$T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">
M#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%3
M0_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T
M/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3704
M4 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\
MZ%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\
M$T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">
M#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%3
M0_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T
M/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3704
M4 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\
MZ%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\
M$T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">
M#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%3
M0_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T
M/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3704
M4 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\
MZ%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\
M\%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\
M$T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">
M#_\ H5-#_P#!=#_\37044 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%3
M0_\ P70__$UT%% '/_\ "">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T
M/_Q-=!10!S__  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\3704
M4 <__P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%30_\ P70__$UT%% '/_\
M"">#_P#H5-#_ /!=#_\ $T?\()X/_P"A4T/_ ,%T/_Q-=!10!S__  @G@_\
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M7=1Z59)-<>6(_-<( S[1PN3DX'3-;7PNU[4O$?A!K[5;G[1<B\GBW[%3Y5;
M&% '2@#M**\^\/>,;I9/'=WK5T9;+1+Z1856-04B52=HP!D\=\FL[23\2?%N
MCQ^(K7Q#8:-%=+YUGIGV%9E:,_=\R0_,"1@Y []!T !ZE17EES\0]3O_ (/Z
MYK< 33]?TJ0VMRJ*'6.974,5# @@AN^>XR<9J&2?XF77@\>+8M?L+3;9_;%T
MC["KK)&%W?/*>0Y7G  &>.* /6:*XFVNM=\=>"=%U;0M>70+BXC$LY6R2Z#'
M&"H#G@!@>>M<3J=S\0K?QK8^%=*\?G4K^4>;>$:-;QI9P_WF/S9)[+QVYY%
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MH/ES[$UZ!96D&GV-O96R!(+>)8HT'\*J, ?D* )Z*** "BBB@ HHHH ****
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MF@#R;48?"_\ PH?Q-=^$M*O-/TZ=A_Q\ESYQ61!O7<[':?PZ=.*[_P#YH_\
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M@N)5WRD>ZY*'ZBO6JIZ;I.G:/;-;Z7I]K8P,Q<Q6L*Q*6( SA0!G '/M5R@
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M_76?_P!&-7H]5K#3[+2[1;33[.WM+9"2L-O$L:#)R<* !UJS0 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT'P)KEQXMA\5>--5MK[4+1"EE:V:%8+?/5AD D\GJ/Q.!@ R_A=_R4KXF?\
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MCGQOH<D6N^(].%S&5>UL;2-DM0^<%G<@N?E+ <<$_6@!?CASX \.?]A:V_\
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M^6Y=FD^S;,MUVJQ5?T KL*K:=I]MI6FVVGV40BM;:)8HD'\*J,"K- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!E>(_^0#<_5/_ $-:IZ'_ *I:N>(_^0#<_5/_ $-:IZ'_ *I: .@/W:%^
MZ/I0?NT+]T?2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /GCP?I?BW4OB'\0O^$7\0
MP:1Y>JO]H\VU2;S<RS;<;E.,8;\Z[G_A%_BS_P!%"LO_  61?_$5R7AO5M=\
M#>.O'%P_@KQ!J,&IZF[PR6MFY4JLLIR#MP00X((KK?\ A;.K?]$U\6?^ ;__
M !- %?XZZ192?#>YU.XM()=2@\B)+HQC>H,@R >P.3^=8OQ,\(>'-,^#9U*Q
MT2QM[WR[4^?% JOEF3//ODUT?Q-_M'Q5\&II+31=06]NC!)]@,#-.G[P$@H!
MG( STIWQ.TO4-0^"YL+*QNKF\\NU'V>&%GDX9,_*!GC!S0!B_$&X@\"?!R!O
M#MK#ITVJM!;RRVRA&^:,LS9'<A",]>:Y^SU+X&6_A]-+F0W$GE[9+Q[27SF;
M'+!L9!SS@<>U>D^,_!D_C#X:6NE0O]GU&WCAN+8R9 65$QANXR"P]L^U95O\
M2/%EK8)9ZA\.];FUI%V%K>/-M(XXW>8 0H/7OCUH YCP1X\O+/X/^*FAO)+M
M]#9H;"YD7YO*?Y8B<^AR<'M@5TO@#X9>&KKP38:CK.FQ:GJ6J6ZW=S<W67=C
M(-W!)XX8<CG/-:^F>'_$OB/X=ZEIGC6[B^WZDKA4BC0"U4_<!V\,0>?P SWK
MG?#_ (J\6^"M"M_#FK^"-6U&XL4\BVNM-3S89D7A"S ?)Q@<]NPZ4 2:W\.[
M+PQ\+?$]G+<G4;**.>[TZ&YBS]A.UL!"2>Q'/'.3W-5-)EM?!G[/K>)-*LX+
M;4YM/C#W,<8#N[/L5F/<@OGFM73O#OC#5? OBU]?GD_M/6XI?LFFM/OCM%*M
MM0<X!)(!],#OFJGA&SO/%'PPN? FKZ#JFD3V]EY'VF[MR(G<,2K(>-V"%)'_
M .N@"YX%^%OAH^#[&\UG3(M2U/4;=;FZN+O,CEI!N(!)XQG&1R>M4OAVDWA3
MXH^(_ MO/)+H\5N+^S21RQ@R4RHSV_>?^.@]2:3P]XL\7>#-$MO#NM>!]6U"
M>QC%O;W6F)YL4J+PF2/N\8&3^(%:OP]\,:Y_PE&M>-O$\"6FI:FHAALD;<8(
M1C )'&?E3\LGK@ ''?!GP5H?B'2=;U'6K&*_*ZC):PQSY98E 5F*CH"2XYZ\
M5[M##';P1P0H$BC4(BCHH P!7FWP1TO4-)\*ZO#J5A=6<LFL32(ES"T;,A2,
M!@& R.#S[5Z90!BZWX3T3Q'>Z=>:M9?:)]-D,MH_FNGEL2I)PI /*+USTK:K
MF/%/B;4]!U/1;6P\-W>K17\QCN)X"VVT4,@W-A&X^8GDC[I_#IZ "O'_  ]_
MR=#XL_[!4?\ Z#:U[!7E>A:3J4/[1OB?5)=/NTT^;3$2*[:%A$[;;?A7Q@GY
M6X!['TH O_$K2/#UYJ&D:AXM\0I::-:,S'3'R!=/CKP<G'' !XSTS7E7Q$U?
MX:WGAUI?!M@\6J6LL;Q7EE:/ D?S#[S$#\.,YQ7=_$'1=4L_B=I7BW_A')?$
M6D06GD/:0KYCQ/EOF$?.?O CCMVX-9OQ O\ Q;XX\$W-AH_@G4-.TZ(I++]L
MCV3RX882.$#/7YL^@/X@$_QBCEU71/ D;3O'-=WT*F9#AE9E7Y@1T.3FNE\5
M:5HGPU\!ZQK?AW2[>QOX;,6T<\2_/\[JH))ZD$@\^E8_CG3M4U71_AU):Z5?
M.\%[;2W,:V[EK<!5SO&,KCG.<=*]$\6:!%XI\*ZEHDKA!=PE%<C.QQRK8[X8
M _A0!Q'@KX5>%Y?!5E-J^F1:CJ&HVZW%U=7#%I"\@W'#9RN,XR,'C/6N<^&L
M!\)>+?B-%YTMVNEPH8VE;+,B*Y12?90!^%:_AWQ;XO\ "FBVWAK4_ NK7U]8
MQBVM[FR&^WF51A"SXP@Q@9/X@=*S/A/:W^I^,OB%%KZ1_:;@QQWB0ME4+^9E
M ?897OTZGK0!RG@KQ'\.Y;:ZUCQW,=2\07TS/*+FVDE2)<X55 !'3GV&!QBM
MWX?^(] M?BZ^B>$KF63PWK%L[M:2(X2&X568[0W(&U/_ !['88VO#-]XI^%E
ME)X;O_"^I:YI<$KM8WNE1>:2C$MAD'(Y)//<GJ,&NF\):CXW\0>)KC5-6LFT
M7P\L6RWTZ=4,TC_WV.-R_3CL,=20#D/!OA?06^-GBZU.D69M[!8)+2/R1M@;
M"G*CL<\U[97D*?VQX0^-&N:E)X=U34--UI8$BNK&$R+$0%!+XZ '.<^GO7KU
M 'AWQ ;64_:'\-MX?2R?5!I1\A;W=Y1_X^=V[;S]W=C'?%6?%GC/XK>%+*.Z
MU2P\.16,CB.2^M8II1;DG + MG_QTCMU(K4UW2=2F_:-\,:I%I]V^GPZ8Z2W
M:PL8D;;<<,^, _,O!/<>M>EZA86NJZ=<6%["LUK<1F.6-NC*1@T <9\-/"-M
MHUG=:^VKC6=1ULBXFOU7:C*<D!!V&2?3MP,8KD;ZV^&OAOQ+K%[XTUVVUS5[
MJ<OY<T#2FV7'$6Q=P&/?&!@<=[OPUM/$'@7Q5J'@R^L;ZYT)G:;3M16!VB3/
M.UF VKD=02,,#_>K#\%+J_PWEU#3M7\!:GJ]]+=-*FJV%OY_G X RQ^Z,C/7
M^(Y&: (/!E_H7_"]K,^$+:ZL-)OM.?SH9(VC25@'.Y5/\/RKCW#5IKX5T"X_
M:&O--FT>RDLFTGSS T(*&0LN7QZ\GFI+.#Q=??&_0O$FM>'9K*RFM9;:-(LS
M?94"OM\UU&T$LWMU]JN^)EUCPO\ &5?%4/AW4]7TVXTW[*?[.B,KH^>ZC_='
M7 Y]L4 36_\ R<S=?]@,?^A+65X!T"Q^).O^(?%OB6'^T4BOWL[&VF),4**
M?NYP>&7KQG)Y)XWK;3=0;]H*?53I]VNGOHP07+0L(]^5^7=C&[VSFLNQM?$G
MPK\2ZS]D\/W6N>&]3N3=1?V>-TUNYZC9U/8>F #GJ* (/%6BVOPV\?\ AC6_
M#2"RMM4O%L;ZRC)$4BL0 0O0<$GZ@>]>T5Y$;#Q'\2_&FBZEJ6B7.A^'=&F^
MTQQ7ORSW,H((RG4#*CKVSR<\>NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "+]T?2E
MJG<ZA%:##I(V/[H'^-9[>*;-3@V]U_WPO_Q5 &Y16%_PE=G_ ,^UW_WPO_Q5
M'_"5V?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?\)79_P#/M=_]\+_\
M50!NT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_PE=G_ ,^U
MW_WPO_Q5'_"5V?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?\)79_P#/
MM=_]\+_\50!NT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_P
ME=G_ ,^UW_WPO_Q5'_"5V?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?
M\)79_P#/M=_]\+_\50!NT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5
M &[16%_PE=G_ ,^UW_WPO_Q5'_"5V?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?
M_?"__%4?\)79_P#/M=_]\+_\50!NT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^U
MW_WPO_Q5 &[16%_PE=G_ ,^UW_WPO_Q5'_"5V?\ S[7?_?"__%4 ;M%87_"5
MV?\ S[7?_?"__%4?\)79_P#/M=_]\+_\50!NT5A?\)79_P#/M=_]\+_\51_P
ME=G_ ,^UW_WPO_Q5 &[16%_PE=G_ ,^UW_WPO_Q5'_"5V?\ S[7?_?"__%4
M;M%87_"5V?\ S[7?_?"__%4?\)79_P#/M=_]\+_\50!NT5A?\)79_P#/M=_]
M\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_PE=G_ ,^UW_WPO_Q5'_"5V?\ S[7?
M_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?\)79_P#/M=_]\+_\50!NT5A?\)79
M_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_PE=G_ ,^UW_WPO_Q5'_"5
MV?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?\)79_P#/M=_]\+_\50!N
MT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_PE=G_ ,^UW_WP
MO_Q5'_"5V?\ S[7?_?"__%4 ;M%87_"5V?\ S[7?_?"__%4?\)79_P#/M=_]
M\+_\50!NT5A?\)79_P#/M=_]\+_\51_PE=G_ ,^UW_WPO_Q5 &[16%_PE=G_
M ,^UW_WPO_Q5'_"5V?\ S[7?_?"__%4 ;M<5X@^%V@Z_K+ZPL^HZ7J<@VRW6
MF7/DO(.G/!'0>E;'_"5V?_/M=_\ ?"__ !5'_"5V?_/M=_\ ?"__ !5 %'PM
M\/-"\)WDU_:"YNM1F7;)?7TWFS$>F> /? &:ZNL+_A*[/_GVN_\ OA?_ (JC
M_A*[/_GVN_\ OA?_ (J@#=HK"_X2NS_Y]KO_ +X7_P"*H_X2NS_Y]KO_ +X7
M_P"*H W:*PO^$KL_^?:[_P"^%_\ BJ/^$KL_^?:[_P"^%_\ BJ -VBL+_A*[
M/_GVN_\ OA?_ (JC_A*[/_GVN_\ OA?_ (J@#=HK"_X2NS_Y]KO_ +X7_P"*
MH_X2NS_Y]KO_ +X7_P"*H W:*PO^$KL_^?:[_P"^%_\ BJ/^$KL_^?:[_P"^
M%_\ BJ -VBL+_A*[/_GVN_\ OA?_ (JC_A*[/_GVN_\ OA?_ (J@#=HK"_X2
MNS_Y]KO_ +X7_P"*H_X2NS_Y]KO_ +X7_P"*H W:*PO^$KL_^?:[_P"^%_\
MBJ/^$KL_^?:[_P"^%_\ BJ -VBL+_A*[/_GVN_\ OA?_ (JC_A*[/_GVN_\
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MM8H+A7?;@NH X8'L?:K>BQE(QD4 ;A^[0OW1]*#]VJEQJ$5HOSI(V/[H'^-
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M7_XJ@#=HK"_X2NS_ .?:[_[X7_XJC_A*[/\ Y]KO_OA?_BJ -VBL+_A*[/\
MY]KO_OA?_BJ/^$KL_P#GVN_^^%_^*H W:*PO^$KL_P#GVN_^^%_^*H_X2NS_
M .?:[_[X7_XJ@#=HK"_X2NS_ .?:[_[X7_XJC_A*[/\ Y]KO_OA?_BJ -VBL
M+_A*[/\ Y]KO_OA?_BJ/^$KL_P#GVN_^^%_^*H W:*PO^$KL_P#GVN_^^%_^
M*H_X2NS_ .?:[_[X7_XJ@#=HK"_X2NS_ .?:[_[X7_XJC_A*[/\ Y]KO_OA?
M_BJ -VBL+_A*[/\ Y]KO_OA?_BJ/^$KL_P#GVN_^^%_^*H W:*PO^$KL_P#G
MVN_^^%_^*H_X2NS_ .?:[_[X7_XJ@#=HK"_X2NS_ .?:[_[X7_XJC_A*[/\
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M .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\
MA*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#O
MA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"
M_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_
M .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\
MA*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#O
MA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"
M_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_
M .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\
MA*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#O
MA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"
M_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_
M .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\
MA*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#O
MA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"
M_P"$KL_^?:[_ .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_
M .^%_P#BJ/\ A*[/_GVN_P#OA?\ XJ@#=HK"_P"$KL_^?:[_ .^%_P#BJ/\
MA*K/_GVN_P#OA?\ XJ@#3N+99LY%46TB,G[HK8HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH
M QO['C_NBC^QX_[HK9HH R%TB-3G:*OP6XB& *L44 ':JL]JLPY%6J* ,=M(
MC)^Z*3^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO[
M'C_NBC^QX_[HK9HH QO['C_NBC^QX_[HK9HH QO['C_NBE_L>/\ NBMBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW!NN(+BZ+%[==N-JKM('.?F!!YR<D58G\-SW,E]"\D:VUQ8QVL<BL=\6W/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img101536035_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0!0 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDN-@
MR7 W+]T$GJ/3MZ^U/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWDRJ^/K@T68%FBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y/\<M8\C1
M;#2(V^>YE,T@']Q. #]2?_':]8KYV\<O+XS^+']EVT@"K*EC&Q&0F#\YQ[,7
M/X5T8:-YW?0F;T+GC?PQ_9OPM\*W03$L (F]?WP\SGZ$8_&O5_A]K']N>!],
MNF;=*D7D2^NY/ER?J #^->7:I\$KS3M)N[U-9BG:WA>41"W(+[03@'=[5H_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW.CV=HT>GW(<2PF:1@0R[6P2Q(R/0BMFBGS2M:X6.,_X51X)_P"@+_Y-3?\
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M3(=.TZ#R+2'=Y<>]FQEBQY8D]2>]8.H?#;PEJFH-?7.DKYSMN?RY717/J0I
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MT=%8<\KWN.R"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 4/,?^^WYT>8_P#?;\ZM^1'_ '?U
M-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='
MF/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1
M_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\
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M -]OSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\
M=_4T 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]O
MSJWY$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T
M 5/,?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY
M$?\ =_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,
M?^^WYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\
M=_4T>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^W
MYT>8_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T
M>1'_ '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8
M_P#?;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_
M '?U- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?
M;\ZM^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U
M- %3S'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?;\ZM
M^1'_ '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- %3
MS'_OM^='F/\ WV_.K?D1_P!W]31Y$?\ =_4T 5/,?^^WYT>8_P#?;\ZM^1'_
M '?U-'D1_P!W]30!4\Q_[[?G1YC_ -]OSJWY$?\ =_4T>1'_ '?U- #;<EHR
M22>>]34U45!A1@4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]/UY-+ETN%SLZ***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR\T[QCK.L320-;WP41JC$N,8Z@C'ZFNGHHI-W&%%%%( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** .8\(>'+SP^^K-=R0.+RZ,T?E,3A3GKD#GFM'Q-HO\ PD'A
M^ZTP3>4TP&U\9 (((S[<5K44[N]Q6/.+[P;XKU/3]-@N[[2A_9KIY,48<+(
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M**GF86"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-U=VJ-$CS/'@QL.4*J@'4 YQNR!DD#%<WHVOV][IPGU+Q]]BNS)(KV_FV2;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6UI&H37FE)-+&99DD>&3RP!N*,5+8)X!QG'O3<; G<TZ*@^T2?\ /G-^:?\
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M(_!]_<Z9]LO]-F5OWD<$[1A_1OE(!&.AKI;/3]7^+'BPS_OH+&)466224R+
MH4 A<X^9B"<>_/K7LOC'P/IOC*SC2Z)@NHC^ZN8U!91GE3Z@^G8UKZ+HMCH&
MEPZ=IT(BMXA^+'NS'N3ZUV2Q*Y;I>\9\FH:+HMCH&EPZ=IT(BMXA^+'NS'N3
MZU>D3S(RFXC/!(ZTZBN-MMW9H1^4OF*W9%PJ]A4E%%( HHHH **** "BBB@
MHHHH JW%C%<7EI=.SA[4L4 (P=PP<U)=VL-[:R6TZ[HY!@@'!^H(Z'WJ:BBX
M&3_8$,B3_:KNZNI)8&MQ+*5W(C=0NU0,GU()X%.;0;5DG'F3*TKI()%8!HV1
M0JE>/0=\YY[<5J44[L5C-31+?R;Q)Y9KB2\C\N::4C<5P0 -H  &3T'?-,A\
M/64,^G3 RL]A&T<19A\V1@EN.3U_,UJT4786*U_8PZC8RVD^[RY!U4X*D'((
M]P0#6%JWAMYK6=XY[J[NIS"CM)(J_(L@8D8"@$#/3T]:Z:BA2:!JY0L]+2UN
MGNI+F>ZN&01B6<KE4Z[0% '7GIDU?HHI7&%%%% !1110 4444 %%%% !1110
M A (((!!Z@U@ZCI\=K&76 O#NW?(0K)[9P<BM^D(!!! (/4&FG831RD=^-TA
M:)M[@(K1O@JHXP.#6QIVEQ0E;AXV63'".P;;[]!S4MOI-O;W33J"?[BGHM7Z
M;EV!(****D84444 %%%% !1110 4444 %%%% !1110 4444 %-=%D1D=0R,"
M&4C((]*=10!X_P"-?!CZ),=0T]6:P8Y8#DP'_P")]#^'URVUW[7-/);6#_VK
M>Q?9Y)5EW!L@!BJ;<AF^IZG KW&6*.:)XI45XW!5E89!![&N?T7P5I>AZG/?
M0!GD8_N0_(A!Z@?KSZ<>N?3I8Z/):JKM;>?J>)6RR7M;T7:+W\O0I^"_!L>A
M0"\O%#ZC(OU$(/8>_J?P^O7T45P5*DJDN:6YZU&C"C!0@M HHHK,U"BBB@ H
MHHH **** .#^(?P\@\66IO;()#K$2_*_03 ?PM[^A_IT\,L==U[PQ?I:?;-1
MMDM9PTMDMP\:D@Y92H..<>E?5]<AXM^'6C^+KVVO+DO;W$3 2R1 9FC'\)]_
M0]JZJ-=17+/8B4;ZH\J\-^%M0^)GB>ZUK4&GATHS%G=Y"[$9R(D)]!QGH!^5
M>^V5E;:=90V=G"D-O"H6.-!@**+*RMM.LH;.SA2&WA4+'&@P%%3UE5JN;\BD
MK#)(Q*H5B=N<D>OM08P91(23M& .P]Z?160PHHHH **** "BBB@ HHHH *JV
M=C%9-<M&SDW$QF?<1PQ ''MQ5JB@"C>:8MU<I<QW,]K<(I3S8"N64_PD,"",
M\],C\ZK/X<L6MT@!F1$AFAR&R6\W&]B2#ELC.?>M>BG=BL9<VB1R2%X;NZMM
M\8BE$+*/-4# SE3@XXRN#[\"G/H=DT^G2JC1C3P1"B'Y<$ 8/KC /U%:5%%V
M%BCIFE6VE).EOOQ/,TSESDY;M]!VIMYI$=U>K=K<W%O+Y?DN864>8F<X.0<=
M^1@\GFM"BB[W'8YFW\-RVVJC[/=7=M;164<$<T;H6;#,2""".X.<?0]:W[.S
MAL+2.UMU*Q1C !.2?4D]R3S4]%#;8DK!1112&%%%% !1110 4444 %%%% !5
M&^L([@-((E:7;C'3(^O8^]7J*$[ <DMTD$J(UNVR(D^6[<[CW)Q[>E7;&PCU
M!S<2),$SDEY =_Z"M*[TNWNYTE?*L#\V/XA[U=5510J@!0, #M5N785@ "J
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M\ ]5HKRJBCV7F'U_^[^/_ /5:*\JHH]EYA]?_N_C_P  ]5HKRJBCV7F'U_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUK%J$MI</-+>@CRRA7R\YSDGKU-39FG/"S5_7[OQU.<HHHK8X HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .U\(?\@F7_KN?_05KH*Y_P (?\@F7_KN?_05KH*Y
M9_$SVL/_  HA1114FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&5XD_P"0!=?\ _\ 0Q7G]>@>)/\ D 77_ /_ $,5P,85I%#MM4D MCH/6MZ6
MQY>-_B+T.KT7R;+3;:&=1NU%V!S_ '<8'^?>J6@6[6GB9[=^L8=<^OO4]WXI
M:WF$.G)"]LBA59T;)X^HIRZKIO\ ;T.H"<*KPD2C8WRM^7/_ -:EKKIN7>G>
M*3^%G-N[1W;.APROD'T.:W]8M#J<^G7D(XNU5&QV;_.?RJ.6V\-L'==0N2YR
M0-IQG_OBI-#UJVM-->&Z;YX6+P#:3G(/''3J?SJFWNC*$4FX3:L_/L:<%R)/
M$YMHO]5;6YC4>_&?Z#\*DADU*X2=-7L[>.T\LDL&'7\S7.:'J$5MJDMS=R[=
MZ-EL$Y8D'M4ECJL=S;3V.K3LT+C,<K LR-_.I<6;0KIK5[W]/F3>''L([F!3
M&TEY([#)Z1C'7ZT:;;QS>)+Z21 XA,DBJW3.[BLW2)X;/6(999 (D8Y< GL1
MG'6K-EJD-KKMS<-EK:=G4D#G:3G.*IIW=C&$XVBI=&69)I-8\/7%Q=;&G@E
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MD0'&#C//04^9"]E(QZ*M:C:"QOY;</O5#PWJ",C^=5:9FTT[,****8@HHHH
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MY+FY*W(5H0JC*@]"Q^OI1S(%1D8:(\CA$5F=C@*HR34[:=?(I9[.X51R28F
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M-'_"(:A_SVMO^^F_^)IWCW%R5]^4BGU+3_[/N;: 7C/-M/F3L"<@YQUZ4_\
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M&H?\]K;_ +Z;_P")H_X1#4/^>UM_WTW_ ,31SQ[B^KU?Y3GZ*Z#_ (1#4/\
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M&H?\]K;_ +Z;_P")HYX]P^KU?Y3GZ*Z#_A$-0_Y[6W_?3?\ Q-'_  B&H?\
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M]1GK25GT!W1:&M:JMP]PNIWHG=%1Y!.VYE4DJ"<Y(!9B!VW'UJ3_ (2+6_\
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M+NC*\2?\@"Z_X!_Z&*\_KTC5[.2_TN:VB*AWVX+'CA@?Z5R__"(:A_SVMO\
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MH[:YDO8O*)V/:R;<@G."#Q4W_"(:A_SVMO\ OIO_ (FC_A$-0_Y[6W_?3?\
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M=9?9_I&?/J(N+&>-PWG2W/G9'0#!&/UI9;^)[K3Y0K[;>.-7R!DE3DXYJ_\
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M#_GM;?\ ?3?_ !-'_"(:A_SVMO\ OIO_ (FCGCW)^KU?Y3GZ*Z#_ (1#4/\
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M/\* /0Z*\\_X2;6/^?O_ ,AI_A1_PDVL?\_?_D-/\* /0Z*\\_X2;6/^?O\
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M?\_?_D-/\* /0Z*\\_X2;6/^?O\ \AI_A1_PDVL?\_?_ )#3_"@#T.BO//\
MA)M8_P"?O_R&G^%'_"3:Q_S]_P#D-/\ "@#T.BO//^$FUC_G[_\ (:?X4?\
M"3:Q_P _?_D-/\* /0Z*\\_X2;6/^?O_ ,AI_A1_PDVL?\_?_D-/\* /0Z*\
M\_X2;6/^?O\ \AI_A1_PDVL?\_?_ )#3_"@#T.BO//\ A)M8_P"?O_R&G^%'
M_"3:Q_S]_P#D-/\ "@#T.BO//^$FUC_G[_\ (:?X4?\ "3:Q_P _?_D-/\*
M/0Z*\\_X2;6/^?O_ ,AI_A1_PDVL?\_?_D-/\* /0Z*\\_X2;6/^?O\ \AI_
MA1_PDVL?\_?_ )#3_"@#T.BO//\ A)M8_P"?O_R&G^%'_"3:Q_S]_P#D-/\
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M+3-NCAMBHB7 PRGH">A]J'S75PT.DD7Q#:V^GV&D:M86I2SC M)7C\V5\9)
M*G^8Z5YE<"47,HG!$P<^8",$-GG]:ZFV'A);JWU5;ZXM#%MD;3UA9SO7G"R'
MC!([_I7-ZA=M?ZC<WC*%,\K2%1VR<XIP5@96HHHJR30T&S-_K]A:@9$DZAO]
MW.3^@-?0->9?#+0V:XEUJ92$0&*#(ZD_>8?0<?B?2O3:Y:TKRL:P6@45G:[=
M36>C7%Q;OLE3;M; .,L!W^M<;_PDVL?\_?\ Y#3_  K(L]#HKSS_ (2;6/\
MG[_\AI_A1_PDVL?\_?\ Y#3_  H ]#HKSS_A)M8_Y^__ "&G^%'_  DVL?\
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M /(:?X4?\)-K'_/W_P"0T_PH ]#HKSS_ (2;6/\ G[_\AI_A1_PDVL?\_?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH [CP;_P @B7_KN?\ T%:Z&N>\&_\ ((E_Z[G_ -!6NAH
M**** "BBB@"KJ.G6NJV,EG>1B2&0<CN/0@]C7EVJ_#35;:=CIS1W<)/R@L$<
M#WSQ^M>MT5<9N.PG%,\2_P"$!\3?] S_ ,CQ_P#Q5'_" ^)O^@9_Y'C_ /BJ
M]MHJ_;2)Y$>)?\(#XF_Z!G_D>/\ ^*H_X0'Q-_T#/_(\?_Q5>VT4>VD'(CPI
M/!^O2:C-8+89NH8HYI$\Y/E1RX4YW8Y,;_E[BK'_  @/B;_H&?\ D>/_ .*K
MTVS_ .2AZS_V"K#_ -&W==!1[:0<B/$O^$!\3?\ 0,_\CQ__ !5'_" ^)O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &MX9_P"1AM?^!_\ H!KT.O//#/\ R,-K_P #_P#0#7H=
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_ __ $ UZ'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!P_C+_D+Q?]<!_P"A-7/5T/C+_D+Q?]<!_P"A-7/4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!W'@W_D$2_P#7
M<_\ H*UT-<]X-_Y!$O\ UW/_ *"M=#0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!D^)O^1>NO^ ?^ABO/*]&\0Q23Z%<QQ1M(YVX5!DG
MYAVKA/[*U'_GPNO^_+?X4 5**M_V5J/_ #X77_?EO\*/[*U'_GPNO^_+?X4
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M+K_ORW^% %2BK?\ 96H_\^%U_P!^6_PH_LK4?^?"Z_[\M_A0!4HJW_96H_\
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MRM1_Y\+K_ORW^% %2BK?]E:C_P ^%U_WY;_"C^RM1_Y\+K_ORW^% %2BK?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9\^B6%Q<R7!CECEE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:"<5C^$M?_X2CPM8ZU]F^S?:D+>3YF_;ABOWL#/3TH VJ*** "BBB@ HHHH
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M?:X+1[14##RRC,&)(QG.0._X5GW?@;1[_P#X2!;L3S1Z[Y9NHV< *8U"J4P
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METJ5R[:2FH,MIR<D; ,XSSUK4D^'.BR^#[#PW)+>F'3VWVEV)@MQ P)(974
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MV;36%PQDG,TA:260G)D9^I?.#GVH \V\/>&O$FB^*-+N]&\ W.@0&X5=1?\
MX2!+I)X3PV^-CR1G<"/3H:]>UN\ET_0=1O8$WS6]M)+&OJRJ2!^8KFM'^&FF
M:7JEM?W.K:YJ[VC;K2+5+XS1V[8QN1< 9 X&<X^O-=FRAE*L 5(P0>AH ^<M
M.\/>)-8T2WURU\$7]QKMS$)XO$*^)460N>0PC)VA>VS'3CWKL?'7A[Q'K3Z)
MJ.I>'7U^PCT\+>Z-%J'V8Q7/!:0%#A_[H )]O6MT_"'0A(\,6IZ]!I,C%GT>
M'4&6S8$Y*[ ,X/H#6MKW@'2]<GMKF*[U+2+RWA%NESI-R;=_*'2,X!!4>F*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%97B'7[7PUI?]H7D
M<TD/G1P[85!;<[A!U(XR1FH_$OB?3?"FFB]U!I&,CB*"W@7?-<2'HD:_Q$T
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M(L?FSQ;8Y\J&S&<_,!G!/J*O4 %%%9^MZU9>']*EU+4)&2WC*J2JEB2S!5
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ML+E,9SG.1Z?C0!JT45GW6M65GK-AI,TC"\OQ(T"!200@RQ)Z#J/SH T****
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M+QE"6D)X/.>A]  * .$CUW7+CPTFFVNJW$-WJOB>YTX7KL9'MX0[D[,]"%7
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M #3*?;>JK^-=GX0\/?\ "*^%[/1?M7VK[-O_ 'WE[-VYRWW<G'7'6LOP_P"
MXM!\6:EK2WQFAN-_V6T,05;3S&#RX;/.Y@#T&* .OKS"UTS5_B!K.O74_BG5
M])L=.U"2PM+72YA#S'@,\C8)?)/3M7I]<+J7@'4TUJ^U+PQXLNM".H/YEY!]
ME2XC=\8WJ&QL8]R.M '+7GB+Q'_P@5W:OJS?VQI?B&+3?[01-GG+YB89E& <
MA@"O?'.<UZ7X<T$^'K![9M6U35'DD,C3ZC<>:X) &%X&%XZ>YK!/PXM(O"4&
MA6NH3AEOX]0GN[@>;)<2K('8MR.3C&>WO7;4 >6:O_PE7_"XM0_X1;^QO/\
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M9\=>([OPMX?CU&RM4NIC=P0>2_\ &'<*0#D8;G@GC-8.L>,O$7A31+5?$":
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MHA98HR SD#[HR0,GIR0*\VL=3U#Q_>26&H:^/#P7/F:)9[HKXC ^_)(H./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC%O!.7&",*",C&:U?#_Q TK7[Z^LOLFHZ;<V<7VAXM3MO(9H?^>B@D_+]<4
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M]VMR\U&R/CC0[<7FH^=<VEQ)!'!*/LDJ#9EI!G)89&TCU- '2T5YR?C/X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***ANKNVL;9[F[N(K>!.7EF<(
MJ_4G@4 344R&:*YA2:"5)8G&Y'1@RL/4$=:?0 45R7Q)U74]'\'27.D7GV.]
M:YMX4G\I9-@>55)VL"#P:P-6TGXC:!I-WJZ^/[?4?L437#6ESH\4*2JH)(+J
M<C@'I^8H ],HKEI_'^@:9X:TO6M<O8]-34+=)XX9,L_*AB J@DXR.0/2K6@^
M-O#GB>RN;O1M4CNHK49F 1E9!C.2K -C@\XYQ0!OT5Y[KOQ>\+6FB:C-IFKQ
M3W\%F+B%#;RLA+@>6&(4 9+*""01GG'-=)X-\1VOBKPM9:I:W(N"T:I,XC9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQKX3B\9>'SI<EV]J1(LJ
M2JNX!AD<KD9&">X[5T5%5&3B^9;B:35F8WA;P]%X6\.6NCPSO.L ;,CC!8LQ
M8\=AD]*V:**4FY.[!*VAPGQ?B\_P!)#YDD?F7MHN^,X9<S(,@]C47_"IK"?$
M>I^*/%>J6A(+V=]JA>&3'9@%!(_&NYN[*UOX/(O+:&YAW!O+FC#KN!R#@]P0
M"*GI#/-/&GB'^Q_&6EZ58?\ ".:5<"Q:1=5UA,"./=M\J(C&#QD@L!BN9\$Z
MA_:'CWQI,VN6NLRG255[NVMA#&Q&00H!.X#@;N_TQ7L>I:+I6LQI'JFF6=\D
M9RBW4"RA3Z@,#BD@T32;5P]OI=E"XA^S[H[=%/E9SLX'W<\XZ4 >>Z5!%;_L
MWE88UC#:'*[!1C+,C$GZDFNT\&7UI?\ @W2);.ZAN(TM(HV:&0.%94 *DCN#
MU%:T%E:VUDEG;VT,5JB;%@CC"HJ^@4< >U,T_3-/TFV-MIMC;64!8OY5M$L:
M[CU.% &: /*/%6D^#=6^+UY'XRDLTMTTB P&ZO3; OYCYP0RYX[4OAV#POH/
MQ-TNQ\ 744]K?6\QU:&UN/M,4:(,QN7);:=QQC=WZ#OZ7J/AC0-7N1<ZGH>F
M7LX4();FTCD;:.@RP)QR:L:;HVEZ-$T6EZ;9V,;G++:P+$&/N% H RO'W_)/
M?$7_ &#I_P#T UY_J>IZ.;7X;:M?7%M<:!:@Q7,P(EBAN/(41[\9 (8'KT->
MPNBR(R.H96&"I&01Z51M]$TFST^33[;2[*"RD)+VT5NBQMGKE0,'- ' W>JZ
M-X@^+WAF3P[=6M[=6L-P^H7-H1(H@*816=>#\YX&>/QYU_B[_P DKU[(S^Y7
M_P!&+74Z;H^F:-"T.EZ=:6,3'<R6L"Q*3ZD*!4UW9VNH6LEK>VT-S;R##PS(
M'1AUY!X- 'E/B/6O#.M6?@[2O#-Q;2:E'J=L]I;VH'F6D:<R;UZH H.5./TK
M&C-_9>/?%T4OQ!LO"UU+?>;Y=YI\#_:(2H\MEDE89 '&T=,>]>TVVCZ79W\]
M]:Z;9P7D_$UQ% JR2?[S 9/XTS4M!T?6C&=5TFQOC']S[5;I+M^FX'% 'C7V
M/3]+\%Z'>2:RNM^'X_$WVF\NET\V\*J<J?W?0QB3NOR\X%=#<:WX=UKXW^&G
MT:[L[RYCLKH7,]JZN"I3Y%++P2/FX[9]Z[7Q1I.JWN@+9^';JSLIHV7]S<VR
MR6\T0&#$ZX.%([KSQ7.>$O VJ6/B"#6=:CT"S:TBDCM;'0K4Q0@R8W2,6Y+$
M*!TH XZ>WBN_A^UM<1K)#+XT9)$;HRFY((/X5V^NV\,?Q>\&R1Q(K_9+V/*C
M'RA%P/H,G\ZZ[^Q=*\CR/[,L_)\_[3Y?D+M\W.?,QC[V>=W7-3R65K-=PW<M
MM"]S &$,S1@O&&^\%;J,]\=: )Z\7N8+FX^&7Q&CM4=W_MVZ9UCZM&)$+C_O
MD-7M%06UE:V7F_9;:&#SI#++Y487>YZLV.K'N3S0!Y-XY\1>#=:^'5KIGA^[
MT^YOYG@32;2U ,L,NY<80<QX&<Y ].]4/&P8-\4 YRWV+3,D>O->O6OA_1;&
M_DO[32+"WO),[[B*V1)&SURP&33Y]&TNZ-T;C3;.8W:JMSYD"MYP7[H?(^8#
MMGI0!Y]::IHV@?%W7IO$-S;64]U9VITZYO&"+Y(0B15=N!\_49YK)L]-M/%R
M_$<^'_+_ ++NA#]DEB3;')=QH69E[?>"9(ZYS[GUC4=(TS5X%@U/3K2]A4Y6
M.Y@610?4!@15BWMH+.W2WMH(X((QM2*) JJ/0 <"@#PLZNFM(WQ.=7":7>6$
M.Y4R5B"8N !Z;IVS_N5I7]I,GP>_M2Z!%UK.L0:E+GMYEPA0?@@05ZPFAZ3'
MILNFII=DMA*29+46Z")R3DDKC!R?:I9M-L;BR2SGLK:6UCV[('B5D7;@KA2,
M#&!CTQ0!QFC6L$GQI\3W3PHT\6GVB1R$<J&#;@/KM'Y5P7EVECH$<]W"HT.R
M\;3->+LS'''DJI8?W0Q6O<TLK6*\EO([:%+J956698P'<+]T,W4@9.,]*PO$
M>@W\VARVWAB33]/N))_/FCGM$>"[S]])1C/S=V'/% ''W&M^'=:^-_AI]&N[
M.\N8[*Z%S/:NK@J4^12R\$CYN.V?>O5*\]\)>!M4L?$$&LZU'H%FUI%)':V.
MA6IBA!DQND8MR6(4#I7H5 'DECX0_P"$D\?^-)O^$B\0:5Y-["NS2[WR%?,*
MG+#:<FNKLO"NE>"-'UG5$6^U>[>U=[F>_G,\]RB*2(R2,8[8Q^==3#96MM//
M/!;0Q37#!II$C"M*P& 6(ZG''-3T ?./B?Q3/J/PRD63Q-X4LK.>$>3H>DVH
MDD&3E48,<QD=VVC!'':O0K>&"X^(O@AW1)/+T"62-B,[6Q&,C\"?SKM8_"GA
MR&2:2+0-*22=665ELXP9%;[P8XY![YZU=CTRPBFMYH[&V26WB\F!UB4-%'Q\
MBG'"\#@<<"@#BC?6EI\=)8KFZAADN-#CCA620*9&\YCM4'J< \"I_BE>W'_"
M,Q:#8NRW^O7":?$5&=JMS(Q]@@.?K767.DZ;>WEO>76GVD]U;',$TL*L\1]5
M8C*_A4DUC9W%W;W<UK!+<VV[R)GC#/%N&&VD\KD<''6@#Q[7_#7B/P0-%\5W
M_BG^UK30)$B-M'ID=N4MGQ&^"C?-@8X/UKV=722(2*=R,NX%><CVJ.ZM;>^M
M9+6[@BN+>5=LD4J!T<>A!X(I\,,5M!'!!$D4,:A$C10JJHX  '04 > 37MOX
M;\/7:^'?&WAS5= C:63_ (1_6[=5D'S$E IQ(S9S@$#M77>(_%\L6OZ##;PZ
M!H=]<:6+IM0UQ"# K<&",_+\P/4$@8[5Z#)X;T*;4AJ4NBZ<]^#N%TUJAESZ
M[\9S^-2ZEHNE:S&D>J:99WR1G*+=0+*%/J P.* /*/AIJ']H?%3Q-,VN6NLR
MFQB5[NVMA#&Q#8(4 G<!P-W?Z8K*N8;B7]G;0WBF,-O#?I+=RB#SA'$)WRQ0
M\,%.TD'@XKVVUT?2[*99K33;.WE6+R%>*!481YSL! ^[GG'2I;6PL[*S6SM+
M2"WM5!"P11A$ /)^4<<Y/YT >/6\*ZIXF\-M=?%?3]:GAO%EM+6TTB$R' RR
MEH6+1J5SG=A?7I74^%KRS7XG^.+":X@%S/+;,EN[C?(H@&XA>I SS]:Z[3O#
MVBZ1/)/IFCZ?932##R6ULD;,.N"5 S3KG2;-KQ]3AT^Q.KK$4ANY8 7'! !<
M#=M]0#TH \FMX9I-4M?A>P9H;+5S=-GD'3DQ-&I)Z_.P3\*];UJZ2QT+4+N2
MV-U'!;22- !GS0JDE<>^,5SGA+PQJ]IK>H^(_$US97&M7D:6ZK8JPAMX5Y"K
MN^8Y/)S78T ?./B?Q3/J/PRD63Q-X4LK.>$>3H>DVHDD&3E48,<QD=VVC!''
M:O0+.VM[OXF>$9)8DE,/AMI8F(SM;*#</?!/YUV\?A3PY#)-)%H&E)).K+*R
MV<8,BM]X,<<@]\]:NQ:980SPSQ6-M'+!#Y$4B1*&CCX^13CA>!P..* /&/%%
MDWD_$]+6 F);RPGN8X^-T857E/Y;B?QK6\4Z_P"%=:U_P&FB75E=W$6J0E#:
MX;R(2I^5L?<R=ORG!^4\<5ZI%8VD%Q<3Q6L$<UR09Y$C :4@8&X]6P..:I0>
M&]"M6W6^BZ="PF%QF.U13YHSA^!]X9//7DT :G:OGGPY]LMM+U:QO/B7IWA^
M9;RX%]IM[I5N[,Q8Y;,A#2AA@]^N*^AJS+[P[H>IW:7>H:-IUW<I@+-<6J2.
MN.F&()% 'FD]G#8>!/AW;6^HMJ-NNNVIANFMF@,D9,A4[&Y P0!Z@ ]*Z8?\
MER;_ +%T?^E!KL;FRM+SR?M5K#/Y$@EB\V,-Y;CHRYZ$9/(YH^Q6OV[[=]FA
M^V>7Y7VCRQYFS.=N[KMSSCIF@#Q*<1KX :YNXS)I=MXRDFU!=NX>0)VR6'<9
M*YKO[37/!VK^/;)M*,>HZPMC(/MEC*'C@@!'RR%6QR2,#!(/I760Z=8V]O+;
MP6=O%!,S/+&D2JKLWWB0!@D]\]:BTW1=*T99%TO3+*Q60Y<6L"Q!CZG:!F@#
MQ&?QF]_X3U66+7?"GAK39&G7^RH;02WC<E2'C) +,>X7'.<]:LZ9/9V7AGX5
MZEJQ0:-;^<L\L@S'%,5(B9NPP0W)Z&O7_P#A&M".I'4O[$TW[>6W&Z^RIYI/
MKNQG/XU.NCZ8FE_V6NG68T_!7[((%\K!.2-F,=>>E '.:!J?A36/&6L2:'&M
MU>-;1"^O[=]]O(.0B$AMK.!GD#IQGM7#6\,TFJ6OPO8,T-EJYNFSR#IR8FC4
MD]?G8)^%>MVVEVNDZ=+;:+8V5D,,T<44(CBWD<$JN.^,]ZYSPEX8U>TUO4?$
M?B:YLKC6KR-+=5L580V\*\A5W?,<GDYH E^)W_),O$7_ %Y/7,_$NR>+X3Z5
M'9L+2RM9[-[ADMQ*L4(QEO+Z,%.TD'@XKTRZM;>^M9+6[@BN+>5=LD4J!T<>
MA!X(J3RHQ%Y01?+V[=F.,>F/2@#QBWA75/$WAMKKXKZ?K4\-XLMI:VFD0F0X
M&64M"Q:-2N<[L+Z]*O>+=3N/ ?B;6_L<;%?$UHIL@H)Q?@B+'MD.K'_=->DZ
M=X>T72)Y)],T?3[*:08>2VMDC9AUP2H&:LW6GV5])!)=V=O</;R"6%I8E<Q.
M.C*2.#[B@#SS6-%B\.V_PWTB'&VTU2.,L!]YO)DW-^)R?QKE8S?V7CWQ=%+\
M0;+PM=2WWF^7>:? _P!HA*CRV625AD <;1TQ[U[?<65K=R027-M#,]N_F0M)
M&&,;XQN4GH<$\CUJMJ6@Z/K1C.JZ38WQC^Y]JMTEV_3<#B@#RB#28[+X4SZK
MI>MIK7]F:L=7@N8['[*A*./-5$Z;<>9RN%YP*SKC5ET9X_B;&CL-2OKZW5EC
MR7A,>RW!XZ;X%/\ P,U[G]EMS:?9#!%]FV>7Y.P;-F,;=O3&.,55?0])DTZ+
M3GTNR:QA(,=LUNAB0CH0N,#'M0!0\%:*_A_P;I>FRDF>.$-.Q/)E8[G/_?3&
MMZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ 9.W@>BCOO5+5GH-!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img101536035_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img101536035_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H!L<# 2(  A$! Q$!_\0
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M=*_[]2?_ !=)_P +P\2_\^6E?]^I/_BZ\THKZ/ZI1_E/+]M4[GI?_"\/$O\
MSY:5_P!^I/\ XNC_ (7AXE_Y\M*_[]2?_%UYI11]4H_RA[:IW/2_^%X>)?\
MGRTK_OU)_P#%T?\ "\/$O_/EI7_?J3_XNO-**/JE'^4/;5.YZ7_PO#Q+_P ^
M6E?]^I/_ (NC_A>'B7_GRTK_ +]2?_%UYI12^J4?Y0]M4[GI?_"\/$O_ #Y:
M5_WZD_\ BZ/^%X>)?^?+2O\ OU)_\77FE%'U6C_*'MJG<]+_ .%X>)?^?+2O
M^_4G_P 71_PO#Q+_ ,^6E?\ ?J3_ .+KS2BCZK1_E#VU3N>E_P#"\/$O_/EI
M7_?J3_XNC_A>'B7_ )\M*_[]2?\ Q=>:&DH^JT?Y0]M4[GIG_"\/$O\ SY:5
M_P!^I/\ XNC_ (7AXE_Y\M*_[]2?_%UYG11]5H_RC]M4[GIG_"\/$O\ SY:5
M_P!^I/\ XNC_ (7AXE_Y\M*_[]2?_%UYG11]5H_RA[:IW/3/^%X>)?\ GRTK
M_OU)_P#%T?\ "\/$O_/EI7_?J3_XNO,Z*7U6C_*'MJG<],_X7AXE_P"?+2O^
M_4G_ ,71_P +P\2_\^6E?]^I/_BZ\SHH^JT?Y0]M4[GI?_"\?$O_ #XZ5_WZ
MD_\ BZ/^%X^)?^?'2O\ OU)_\77F=%'U6C_*'MI]STS_ (7CXE_Y\=*_[]2?
M_%T?\+Q\2_\ /CI7_?J3_P"+KS.BCZK1_E#VT^YZ9_PO'Q+_ ,^.E?\ ?J3_
M .+H_P"%X^)?^?'2O^_4G_Q=>9T4?5:/\H>VGW/3/^%X^)?^?'2O^_4G_P 7
M1_PO'Q+_ ,^.E?\ ?N3_ .+KS,TE'U6C_*'MI]STW_A>/B7_ )\=*_[]R?\
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MN3_XNO,:*/JU'^4/:S[GIW_"\_$O_/CI7_?N3_XNC_A>?B7_ )\=*_[]R?\
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MM*_[XD_^+KRJBE[&GV#GEW/5?^%^>)?^@=I7_?$G_P 71_POSQ+_ - [2O\
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M_?N3_P"+H_X7UXE_Z!^E?]^Y/_BZ\L-)1[&G_*'M)=SU3_A?7B7_ *!^E?\
M?N3_ .+I/^%]>)?^@?I7_?$G_P 77EE)2]C3[![27<]4_P"%]>)?^@=I7_?$
MG_Q='_"^_$O_ $#M*_[XD_\ BZ\KI*/8T^P^>7<]5_X7WXE_Z!VE?]\2?_%T
MG_"^_$O_ $#M*_[XD_\ BZ\KI#1[&GV#GEW/5?\ A?GB7_H':5_WQ)_\71_P
MOSQ+_P! [2O^^)/_ (NO*J*7L:?8.>7<]5_X7YXE_P"@=I7_ 'Q)_P#%T?\
M"_/$O_0.TK_OB3_XNO*:*/8T^P<\NYZM_P +\\2_] [2O^^)/_BZ3_A?OB7_
M *!VE?\ ?$G_ ,77E5(:7LH=A\\NYZM_POWQ+_T#M*_[XD_^+H_X7[XE_P"@
M=I7_ 'Q)_P#%UY0:*/90[!SR[GJ__"_?$O\ T#M*_P"^)/\ XND_X7]XE_Z!
MNE?]\2?_ !=>4TE+V4.P^>7<]7_X7]XE_P"@;I7_ 'Q)_P#%T?\ "_O$O_0-
MTK_OB3_XNO***7LH=@YY=SU?_A?WB7_H&Z5_WQ)_\71_PO\ \2_] W2O^^)/
M_BZ\G-%'LX=@YI=SU?\ X7_XE_Z!NE?]\2?_ !='_"__ !+_ - W2O\ OB3_
M .+KR>BE[.'8.:7<]8_X: \2_P#0-TK_ +XD_P#BZ*\FHH]G#L/F?<VZ***]
M@X HHHH **** "BBBD 4444 %%%%  :2E-)0,**** "BBB@ HHHI %%%% "4
M444#"BBB@ HHK5T7PSK7B%V72=.GN@OWG4813Z%C@ ^V:3:BKL$F]$91I*ZN
M^^&OC#3[9KB?0YC&O)\J1)2/P1B?TKE*49QE\+N-Q:W04444Q!14GV>;[,;G
MR9/(#^69=IV[L9VYZ9QSBHZ "BBM#1M$U'Q!J"V&EV_VBZ92P3>J<#KRQ I-
MI*[!*^QG45-=6LUE>3VEPFR>"1HY%R#M93@C(XZBH:8!114DMO- (S-#)&)$
M$B;U(W*>C#/4<'GVI 1TE;&N>&-8\.):MJUG]G%TI:']ZC[@,9^Z3CJ.M8])
M24E=#LUHPHHHH 2BBM_6O!?B'P]I\5_JNG-;VTK!$<RHV202 0K$C@'K2<DG
M9L:3>Q@4444P"DI:>EO-+#+-'#(\40!D=5)5,G R>V3Q2 CHK7TSPQK&L:7?
M:E86?G6EBA>YD\U%V *6)P2"> >@-9%)-/1!9@:2E-:V@>&-8\3W$L&CV?VF
M6%-[KYJ)@9QGYB*&TE=@DWHC(HI\4,EQ,D,,;R2N0J(BDLQ/0 #J::Z-&[(Z
ME64X*D8(/I0 E)2TE !1110,*0TM6+&PN]4OH;*Q@>>YF;;'&@R6/^>_:D]
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M3Q$^@)IX;5(XO-> 7$7RKQR6W;>XXSGFI<HK=@DWL<Y17;?\*B\<_P#0#_\
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M%Y<> _AEX=T32I)+*[U!/M%W+"=KDA5+#=UY+ ?1<=*\S\5_\CCKG_80G_\
M1C5Z-\;V$MGX3GC;=%):R%#V(Q&<_J*):R@GM_P 6BDQWPDUZ\\1W&J>%-<N
M)K^PNK1G7SY"Y0@@$ GGD-GKP5&*D^%NG1>&[?QEK<T2W%YHZ211C&/N!RV/
M3.T#VQ6+\#03\0'('2RD)_-:30_',7A+XA>(S<P?:=*U"[F2Y10"<"1]K 'K
M]X\>AK.I%N4HQ\BHO1-G,CQ]XH76_P"UO[:N_M'F;]AE;RS_ +.S.-OM77_&
MO3;=;_1=>BB\F75;8M,@&!N4*<_7#@?\!%,GM?A':7;:E%J>J7B*WF+IBQ,
M3G[NYE'R_P# L^YK7^-FI/>>'/"9EMA;RW,37#Q!L^4=D?R^_P!XC\*?,O:1
MY5;?R"WNN[/&*2EI*ZC$*0TM(:0!24M)0,****0"4444AB&B@T4 %%%%(8E)
M2TE !1112 2BBBD,*0TM(:0!24M)0 4AI:0TAGO_ ,*?^12T_P"LG_HQJ]AM
M?]4/I7CWPI_Y%+3_ *R?^C&KV&U_U0^E>94^-G7'9$]%%%0,1NAKY-\7?\CI
MKG_80G_]&-7UDW0U\F^+O^1TUS_L(3_^C&KT\L^.7H<F+^%&-1117L'"%%%%
M !1110 4444@"BBB@ I*6DH ****!A1110 4444@"BBB@#Z7U[Q%9KXX7PCK
M"(VFZKIZA"QQB4O(NW/^T  #V('K7@GB_P ,W/A/Q#/IL^6C'SP2G_EI&>A^
MO8^X-=C\<B5\;V3*2"-.C(([?O)*V8#'\6?A_P"2[+_PDFDCY6( ,HQ_)@.?
M1AZ5YM#]S"-3[+W_ ,SKJ>_)QZK8I_&W_CV\,?\ 7O+_ "CK.@^'FA:'HMMJ
M/C;69[&6[&Z*SMES(!UYX;GD9XP.F:Z#XJ"-=7\$+< ",-B0/T W19S6%\</
M/_X3.U\S=Y/V)?*ZX^\V?Q_^M3H2DX0IIVO?\PJ)*4I-7V(KSX>Z+K&@W&J^
M"M7FOS:@F>TN%'FX]L <X!P,<]C7F]>H? W[1_PEM]LW?9_L1\W^[G>NW/O]
M[]:\YU/R/[6O/LV/L_GOY6,8V[CCIQTKII2DIRIMWM8QFDXJ2([.TEO[ZWLX
M #-/(L2 ]V8X'ZFNX^+5W$GB*ST*U/\ HNCV<=NJ^C$ G_QW8/PJ'X4::E]X
MY@N9L"WT^)[N0D<?*,#Z8+ _A7*ZWJ;ZSKE]J4F[=<SO+ACR 3P/P&!^%/XJ
MWHOS#:'J4*^E-,UA=+TOP%;RD>1J%BEJVX\9,*%?U '_  *OFNO7OB!<2VGP
M\\!W,#;)H8(9$;T81(0?SK+%0YW"/>_Y%T9<J;/.?%>CG0/%6I:7C"03$1C.
M?D/S)_XZ17N/@A5\.6'A;P_@K=WT4U_<C&"!MX##U^91_P  K"\5^'4\:>)_
M"&MVT1:TU2-5N?10@WD'W*[E_P" TNC:U_;GQ]GD0@P6L,MK%C^Z@(/YMN/X
MUA5G[6FD^B;?KL7"/)._=G)V'ARS\5?&#6M+OI)XX'O;MRT# -D.Q'4$?I4/
MAKP3INL_$C5/#MQ/=K9VCW"H\;J)"(WVC)*D=.O%;W@O_DO.K_\ 7U>_^AM4
MW@3_ )+GX@_ZZWG_ *-JYU)14DGM%$QBG:_<S)_!W@/0;HZ?XB\27@U#.7CM
M$RL(/0,=C9..O3Z5A^/O Z^$;BSFM+S[9IM\A>WF(Y&,'!(X/!!!'7GCBL7Q
M42?%^MDG)-_/S_VT:N_^(G/PN\$_]>Z?^BEK1.<90;E>^_W$OE:EIL8/CWP;
MIWA;3/#]S8S74CZC"\DPG92%(6,_+A1C[YZY[5TNL_##PMH,%KJ6IZY>6NFO
M$N5.UY9)3SA,+P /8_A4?QB_Y '@S_KUD_\ 08:D^-S'[)X77)QY$IQ^$=90
MG.:@N;>Y<HQ7,[;6*[?"[0M>TB+5O"FONUFDI6Z:_P #RE RQX5<$#G!Z@]1
M2:5X'\ >(IY-+T?Q+J$FJ"-BC2Q@1N1U(!09'?&[.*L>!B1\$_%F#CYYO_12
M5RWPF_Y*;H__ &V_]$O1[_+/WG[NW_!#W;QTW,W1O!VHZSXPD\.1M&EQ#*\<
M\O)6,(<,WOST]21TKK+GPS\,=,O7TZ_\3:H]W"WERO#&/+5AU_Y9MT/N:E_X
M1[5_$/Q?UZ+2M2FTT12LT]W$[*43(X&TC))QQGMGM4$VG?"O2YY&N=9U;5ID
MSN2$?*[>S;1GZ[L54JCDUJ]MD)1LMOO,3Q]X&7PA-97%G>&\TV^4M!*1R,8.
M"1P<@@@]^>.*Z3XQ?\@CP?\ ]>;?^@Q5<^+1M6\!^$VLH)+>T* P0R'+(GEK
MM!Y/(&.]4_C%_P @CP?_ ->;?^@Q5-.;FZ;EOJ5**BI)>1Y37JGP?L8-/AUG
MQ?>K_H^G0-''[MC<V/?&!_P.O*Z]^N[/PWX7^&NF^%_$NHW-@;V/S9OLREG9
MP0[ D*PP"0.1R!6F*E[JAW_+J116O-V,;P]/)\1/AAKNDS[7U2TG>[AQU+,3
M(,9]3YB_0UXY%%)/,D,2,\DC!411DL3P !7MO@B[^'/AWQ C:-X@U.6YNP+8
M17,9\MBS#&?W8P<XYSW-8.I>'HO#_P =-/B=%6SNKV.Z@ST^9NGX." /I6=.
MIR3DDK+=?J5.-TG\A)_A]X4\+6=N/&7B"YBU"==XMK%02@]_E;/.>>!Z=*J:
MY\/]&L]/T_Q'I>KS7OAJ6XCCNY-H$T"%@&8<<GMC;D''!JA\7#.?B3J?G[]H
M6(1;NFSRUZ>V<_CFL:STSQ)=^$[R[M#<MH,$A^T*+@+$'&TY*%N3]SG'IZ5<
M%-QC-SW^[44FKN*1[)XQM?"#_#G0H]0OM0CTQ(T^P21*-\A\L[=_RGJ/85YN
MG@O36^$DGBPSW7V]9=@CWKY6/-"=-N>A]:Z/XA?\D>\'?[D/_HDT1_\ )MLW
M_7Q_[<"L*;<(*SWD7*SD[KH<UXF\&Z;9>!M&\3Z+/=2P7?R7*3,K^6Y'0%5&
M &5@<^U0?#KP;;^+]7NDOYIH-/M(#+-+"RA@2?E&2".S'IVKI?AK(OB;P7X@
M\%SL#*T9N;/<>C<?D X0_P# C3H0W@OX(S2.#%J.ORE &'S+&>/RV!C[%ZT=
M223IWUO9>C)44VI=+&-H/@K1=;\'^)M=2>_7^SFF-HN] &14W+O&WD],XQ7;
M_#BW\-#X:ZX([N],<MHW]JD@9B/E-N\OY>>,XZUC?#S_ )([XR_W)O\ T2*C
M^&A_XMAXX'?[++_Z)>LZK<E)-[-%PLFM.AG^'?!/A/Q9J.O6.D:CJ)>VA673
MWE=!YH*#.]=@.!)QQC@CZUYW!9W%Q?QV,<3?:9)1"L9&#O)P!ST.:WO .O\
M_"-^,]/OV?;;E_)N,G \MN"3].&_X#7J=KX,BL/C3?ZM,%33+: ZF'/W0SY'
M/T8.WM@5M*HZ4FF[JVAFHJ:5CSCXB^%](\(ZM::9IUS=3W'D"2Z:9U(5CT"@
M*,="><\$5QR(TCJB*69C@*!DD^E:?B369/$'B/4-5DSFYF+J&ZJG15_!0!^%
M2^$=G_"::%OQL_M&WW9Z8\Q:UC>,/>U9+LY:';GX=^&O#6F6T_C?7;BUO+E=
MR6=DH+(/<[6S]< 9XR:K:Q\.M+O/#4OB#P9JTNI6EODW%O. )4 Y)Z#H.<$#
M(Y!/2HOC1]I_X6)/Y^/+^SQ>1C/W,<_^/;ZV_@3N^U^(-_\ QZ?9D\WTSEL?
MINKF<IJE[7FU[=#6T7/DL:_PU@\*1>"/$#VNH:AODT]#JY( ,'[N3)B^7_?_
M +W05Y)XG@\/6^J(GAJZN[FQ\H%GN@ ^_)R/NKQC':NW^%__ "(_Q"_[!H_]
M%SUY=5THVJ2=_P"K$S?N(5(WED6.-&=W(5549))Z "O;/%NL?\*XT?P?H-FW
M[^TD6]NQ&V"X&0P^CEI/^^:XWX1^'_[<\=6\TB;K;3Q]JDR."P.$'UW$'_@)
MKK/%EQ\,?$OB&?4-3\2ZJ+@8BV01GRT"\87]T>,Y/4]34UI)U%%JZ0X*T6S&
M^-.B1P:]:>(;/#6>JPABZY(WJ!SGIRI4CUP:U?@9_P @[Q9_UQ@_E-6]>V6@
M^,_A3<Z3X<OI]0;2%#6[SKB4,H)"_=7JNY1Q_*L'X&?\@[Q9_P!<8/Y35BY7
MP[B]U_F6E^\3[GC1KT;X,Z\-*\9?V=,W^C:I'Y!!QCS!RA/_ (\O_ J\Y-2V
MUQ-9W4-S;N8YH762-QU5@<@_F*[*D.>+B81ERNYK^,-#/ASQ;J6E;2(X9CY6
M<G,9^9/_ !TBO0O#C?\ "$_!?4M;;]WJ&LOY-L>58+RJD?0>8X_"I?B+I'_"
M:+X2\1:8H#:N$LI,<['))&<?W?W@)_V:R?C+JD$>IZ;X7L?EL]'MU4J#QO*C
M /T4+_WT:Y^;VBC!_/Y?\$UMRMO[C4^!2L\'BA5!9C!$  ,DG$E><'P9XI_Z
M%K6/_ &7_P")KT?X$NT</BAT.&6"(@CL?WE<E9_%GQG:7<<[:NUPJG)BFC0J
MX]#@ _D:%S^UGR^7Y ^7D5SO?A/H>I>"[/6==\11MIM@T"_)/PS;23DKU![
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M0:*0!24M)2&%%%% "&B@T4@$HHHH&)1112 VZ***]4X@HHHH **** "BBBD
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M^(&GPSZK>3PW3.DT<TS.K#:3T)/((!S6OI__ ";CJO\ U]+_ .CHJY'X9?\
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MGD'CVZ:[2CJKKJ94TV]'9B?\)U\/O$/'B#PE]DFD;+SVH!Y]2R[6_0UD^-O
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M8[.]\>^-K#3[KRML,,B(2JYSC * G)YQGMSP*X7Q'KL$GQ%N]=TUUGA6^%S
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M3DT7XRWNIQ('>TO8I@A. VU5./QZ5U^HR_##XAWAU"YU.XT?5)5!E,K>6&(
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M1WJ!;>]>(,T#8(.&P2O4'/08YK9L_ 7A'3KZ.]U'QSI=U8PMYC00E2\H'.W
M8GGO@&O,**QE2;;<9-7-%-)6:N=5\0_%,7B[Q7)?VR,MK%&L$&X8+(I)R1VR
M6)^F*Y6BBKA%0BHKH1)N3NPI*6DJA!1112&)1110 4444#"DI:2@ HHHI !I
M*4TE !1112 *2EI* "BBB@84AI:0T@"BBB@ I*6DI %%%% "4444#"BBBD E
M%%%( I*6DH&%(:6D-( HHHH 2BBBD,*2EI* "D-+2&D 4E+24#"BBBD E%%%
M(8AHH-% !1112&)24M)0 4444@$HHHI#"D-+2&D 4E+24 %(:6D-(9[_ /"G
M_D4M/^LG_HQJ]AM?]4/I7CWPI_Y%+3_K)_Z,:O8;7_5#Z5YE3XV=<=D3T445
M Q&Z&ODWQ=_R.FN?]A"?_P!&-7UDW0U\F^+O^1TUS_L(3_\ HQJ]/+/CEZ')
MB_A1C4445[!PA1110 4444 %%%%( HHHH *2EI* "BBB@84444 %%%%( HHH
MH 2BBB@84444 %%%% 'I@^('AOQ#HUG:>,]%NKFZLUV1W5FP#,,=2-RXS@9'
M([\57U3Q_HUCX;N="\':1+80W@*W-Q<L#(RD8(ZGJ.,YXR<#G->=TE8+#P3\
MNU]/N-/:R"BBBMC,**** "D-+2&@ HHHH ****0"4444#"D-+2&D 4444 %%
M%% Q#10:* "BBBD E%%% !1112 2BBB@84444 )1112 *2EI* "BBBD AHH-
M% PHHHI (:*#12 LZ=?3Z7J5K?VK!9[:598R>FY3D9]N*]+U#QQ\/_%$RZAX
MC\-:@NIE0LK6<@VOC@9.]<\>V>V>*\KI*B=-2=^I<9-:'=^,/'UMJ^AV_ASP
M_IO]F:';L&\MFR\I'(W?B2>I)/)-<&:6D-$8*"LA-MN["BBBJ$)1112&!I*4
MTE( I*6DH&%)2TE !2&EI#2 ****0Q**** "D-+2&D,0T4&BD 4E+24AA111
M0 AHH-%(!****!B4444@-NBOK/\ X1#PS_T+ND?^ 4?_ ,31_P (AX9_Z%W2
M/_ */_XFJ_M.'\I/U27<^3**^L_^$0\,_P#0NZ1_X!1__$T?\(AX9_Z%W2/_
M  "C_P#B:/[3A_*'U27<^3**^L_^$0\,_P#0NZ1_X!1__$T?\(AX9_Z%W2/_
M  "C_P#B:/[3A_*'U27<^3**^L_^$0\,_P#0NZ1_X!1__$T?\(AX9_Z%W2/_
M  "C_P#B:/[3A_*'U27<^3**^L_^$0\,_P#0NZ1_X!1__$T?\(AX9_Z%W2/_
M  "C_P#B:/[2A_*'U27<^3**^L_^$0\,_P#0NZ1_X!1__$T?\(AX9_Z%W2/_
M  "C_P#B:/[2A_*'U27<^3#25]9_\(AX9_Z%W2/_  "C_P#B:/\ A$/#/_0N
MZ1_X!1__ !-']I0_E#ZH^Y\F45]9_P#"(>&?^A=TC_P"C_\ B:/^$0\,_P#0
MNZ1_X!1__$T?VE#^4/JK[GR917UG_P (AX9_Z%W2/_ */_XFC_A$/#/_ $+N
MD?\ @%'_ /$T?VE#^4/JK[GR917UG_PB'AG_ *%W2/\ P"C_ /B:/^$0\,_]
M"[I'_@%'_P#$TO[2A_*'U5]SY,HKZS_X1#PS_P!"[I'_ (!1_P#Q-'_"(>&?
M^A=TC_P"C_\ B:/[2A_*'U5]SY+HKZT_X0_PS_T+FD?^ 4?_ ,31_P (?X9_
MZ%S2/_ */_XFC^TH?RC^JON?)=%?6G_"'^&?^A<TC_P"C_\ B:/^$/\ #/\
MT+FD?^ 4?_Q-']I0_E#ZJ^Y\ET5]:?\ "'^&?^A<TC_P"C_^)H_X0_PS_P!"
MYI'_ (!1_P#Q-']I0_E#ZJ^Y\EFDKZU_X0_PQ_T+FD?^ ,?_ ,31_P (?X8_
MZ%S2/_ &/_XFC^TH?RA]5?<^2J*^M?\ A#_#'_0N:1_X Q__ !-'_"'^&/\
MH7-(_P# &/\ ^)H_M*/\H?57W/DJBOK7_A#_  Q_T+FD?^ ,?_Q-'_"'^&/^
MA<TC_P  8_\ XFC^T8_RA]5?<^2J*^M?^$/\,?\ 0N:1_P" ,?\ \31_PA_A
MC_H7-(_\ 8__ (FC^T8_RA]5?<^2:*^MO^$/\,?]"YI'_@#%_P#$T?\ "'^&
M/^A<TC_P!B_^)H_M&/\ *'U5]SY)HKZV_P"$/\,?]"YI'_@#%_\ $T?\(?X8
M_P"A<TC_ , 8O_B:7]HQ_E#ZJ^Y\DTE?6_\ PA_AC_H7-(_\ 8O_ (FC_A#_
M  Q_T+FD?^ ,7_Q-']HQ_E#ZJ^Y\D45];_\ "'^&/^A<TC_P!B_^)H_X0_PQ
M_P!"YI'_ ( Q?_$T?VC'^4/JK[GR/17UQ_PAWAC_ *%S2/\ P!B_^)H_X0[P
MQ_T+FD?^ ,7_ ,31_:,?Y1_57W/D>BOKC_A#O#'_ $+FD?\ @#%_\31_PAWA
MC_H7-(_\ 8O_ (FE_:,?Y0^K/N?(])7US_PAWAC_ *%S2/\ P!B_^)H_X0[P
MQ_T+FD?^ ,7_ ,31_:$?Y0^K/N?(U%?7/_"'>&/^A<TC_P  8O\ XFC_ (0[
MPQ_T+FD?^ ,7_P 31_:$?Y0^K/N?(QI*^NO^$.\,?]"WI'_@#%_\31_PAWA?
M_H6]'_\  &+_ .)H_M"/\H?5GW/D6BOKK_A#O"__ $+>C_\ @#%_\31_PAWA
M?_H6]'_\ 8O_ (FC^T(_RA]6?<^1:2OKO_A#O"__ $+>C_\ @#%_\32?\(=X
M7_Z%O1__  !B_P#B:7]H1[!]6?<^1:*^NO\ A#O"_P#T+>C_ /@#%_\ $T?\
M(=X7_P"A;T?_ , 8O_B:/[0CV#ZL^Y\BTAKZ[_X0[PO_ -"WH_\ X Q?_$T?
M\(=X7_Z%O1__  !B_P#B:/K\>P_JS[GR)17UW_PAWA?_ *%O1_\ P!B_^)H_
MX0[PO_T+>C_^ ,7_ ,31]?CV#ZL^Y\B4E?7G_"&^%_\ H6]'_P# &+_XFC_A
M#?"__0MZ/_X Q?\ Q-+Z_'L'U9]SY#HKZ\_X0WPO_P!"WH__ ( Q?_$T?\(;
MX7_Z%O1__ &+_P")H^OQ[!]6?<^0J*^O?^$-\+_]"WH__@#%_P#$T?\ "&^%
M_P#H6]'_ / &+_XFCZ_'L'U=]SY"HKZ]_P"$-\+_ /0MZ/\ ^ ,7_P 31_PA
MOA?_ *%O1_\ P!B_^)I?7H]@^KON?(-%?7W_  AOA?\ Z%O1_P#P!B_^)H_X
M0WPM_P!"WH__ ( Q?_$T?7H]@^KON?(-)7U__P (;X6_Z%O1_P#P!B_^)H_X
M0WPM_P!"UH__ ( Q?_$T?7H]A_5WW/D"D-?8'_"&^%O^A:T?_P  8O\ XFC_
M (0SPM_T+6C_ /@#%_\ $T?7H]@^KON?']%?8'_"&>%O^A:T?_P!B_\ B:/^
M$,\+?]"UH_\ X Q?_$TOKT>P?5WW/CZBOL'_ (0SPM_T+6C_ /@#%_\ $T?\
M(9X6_P"A:T?_ , 8O_B:/KL>P>P?<^/J2OL'_A#/"W_0M:/_ . ,7_Q-'_"&
M>%O^A:T;_P  8O\ XFCZ['L'L'W/CZD-?87_  AGA;_H6M&_\ 8O_B:/^$,\
M+?\ 0M:-_P" $7_Q-+Z['L/V#[GQ[25]A_\ "&>%O^A:T;_P B_^)H_X0OPK
M_P!"UHW_ ( 1?_$T?78]@]@^Y\>45]A_\(7X5_Z%K1O_   B_P#B:/\ A"_"
MO_0M:-_X 1?_ !-'UR/8/8/N?'=%?8G_  A?A7_H6=&_\ (O_B:/^$+\*_\
M0LZ-_P" $7_Q-+ZY'L'L'W/CHT5]B_\ "%^%?^A9T;_P B_^)H_X0OPK_P!"
MSHW_ ( 1?_$T?7(]@]@^Y\=45]B_\(7X5_Z%G1O_   B_P#B:/\ A"_"O_0L
MZ-_X 1?_ !-'UN/8?L7W/CFDK['_ .$+\*_]"SHW_@!%_P#$T?\ "%^%?^A9
MT;_P B_^)H^MQ[![%]SXXHK['_X0OPK_ -"SHW_@!%_\31_PA7A7_H6=&_\
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M#_\ )N#_ .+H_P"%1>.O^@'_ .3<'_Q=?4E%'UVIV0>PB?+?_"H?'7_0#_\
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M-P?_ !=)_P *=\>_] +_ ,FX/_BZ^K**/K4^R#V43Y2_X4[X]_Z /_DY!_\
M%T?\*=\>_P#0!_\ )R#_ .+KZMHI?69]D'LHGRE_PISQ[_T ?_)R#_XNBOJV
MBCZS,?LD%%%%<YH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKZG8/XELTUC4=+,4_GV%J+J5MHVE#V7G.?J!5K1=6@UW1[75+5)$@N4WHLH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%( HHHH **** "BBB@#Q_X;_P#(OV7U?_T-J]9M?]4/I7DWPW_Y%^R^K_\
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M!3D^6%^89]#_ /7KTJBBE*?,K D%%%%0,**** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** ./_X6/H__ #[7W_?"?_%4?\+'T?\
MY]K[_OA/_BJ/^%<:/_S\WW_?:?\ Q-'_  KC1_\ GYOO^^T_^)H /^%CZ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN39[F=IG_)7M<_[!T'\ZR8[&VU+X@>/K2\B$L#VMKN0DC.(E(Z>X%;-_X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C
M_P -_P#D7[+ZO_Z&U>LVO^J'TKR;X;_\B_9?5_\ T-J]9M?]4/I6M?\ BR]7
M^9%/X%Z$]%%%9%B-T-<=\//N^*/^Q@N__9*[%NAKCOAY]WQ1_P!C!=_^R5K#
M^'+Y$2^)'94445D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !63XBUZ+P]IRW+VMS=RRR"&"WMHR[R2$$@>WW3S6M135KZ@>>_#S5]
M<U3Q+XI772\4T+6VVT\S<EN&#G:HZ9QMR>Y%,\>7-Q>>,-#T.+6[G2+4P37-
MW<07!A(3&%R<@=5(Y]:L^#O^2B^.O^NMI_Z ]7]0\+^%]=\:?:[^5+W4K>V"
MFQDE5D1,Y#,F,]6[\<]*W;2J7\OT)Z%7POX=@34HM2L_'&J:S# 6#0M?B:)B
M5(^8 D<9R/<5DSG4_$>J>++G^V]2TY=&8Q6D-K+Y<>50G<X_C!([]J;XATJS
M\(^/_#&H:'!'9_VC<_8[JW@&U)$)49VC@8SGCT%=/JW@/3-6U"YO/M6H6;7:
MA+N.SN/+2Y X^<8.>..,4<R3YF]P,V7Q;?2?#C3+V)5;6]6C2WMD7C,S<%_8
M#!;T'%==I-D^G:3:V<ES-=20QA7GF<N\C=V)//)KSB75;.S;4?%B6X.D>'X_
M[.TBW!PLDF0KN/;)"Y] ?2NBT[Q#X@L_$NG:/XDM=/5M3BD>VDL2_P CH-S(
MVXG/'<<5,H::?U_PPT=C112,I9<!BON*Q&+147E-_P ]Y/T_PH\IO^>\GZ?X
M4 2T5%Y3?\]Y/T_PH\IO^>\GZ?X4 2T5%Y3?\]Y/T_PH\IO^>\GZ?X4 2T5%
MY3?\]Y/T_P */*;_ )[R?I_A0!+147E-_P ]Y/T_PH\IO^>\GZ?X4 <IX=_Y
M*/XT_P"W'_T2:["N,\/1L?B+XS'FN,?8>>.?W1]JZ[RF_P">\GZ?X4 2T5%Y
M3?\ />3]/\*/*;_GO)^G^% ',>)?AUH'BJ\-Y?I<I=% GG0S$' Z<'*_I5CP
M;X-M?!EA<VMK<27 GF\TO(H# 8  X^A_.M_RF_Y[R?I_A1Y3?\]Y/T_PK1UI
MN'(WH3R1OS6U/,/C'HFO:XFFQZ7ITUU:VX=Y3%@G<< #;G/ !Z#O6+\%M O+
M7Q)J=W?6<]N]O;B(+/&4(9VST//1#^=>T^4W_/>3]/\ "CRF_P">\GZ?X5LL
M5)4?96,W13GSW.+^*^O7.@^#M]E<26]W<7"11R1MAEQEB1^"X_&N'^'?Q \5
MZQXILM(NKN.[MY"QD:6$;E15)."N.>.^>M>I^(O"&E^*;:*#5?/E6)BT963:
M5)X)XZ_C6-X8^&6F>%-=DU*QO;M]T)B6.;:2N2"2" /3'3O5TZM%4'&2][T)
MG"HZB:>AUFJ:C!I&E76HW1;R+:)I7VC)( S@>YKG=*^)GA/5Y$BAU189G(41
MW"&,Y/09(Q^M1_$?3=7U+P9<V.D12W4\[HKH&12$!W$\XST P/6O&_!O@_5E
M\?:5;:EIEW:HDWG,TT)5<("W4C!Y&**%"G.DY2>J"I4G&:21]*T5E:]>'2/#
M^H:B9Y!]FMWD'3J <#IZXKY[TGXE^,;66*"+57N=S!52Y429)X'S$;OUK.AA
M9UHMQZ%U*T8-)GTS14*0R;%WSN7P-Q4 #/MQ7%V_Q1\*2WDMK+JMQ;21R-'F
M:+Y6()&0R@C''?%8QIRG?E5RW)1W9W5%5;:2*\MH[FVO#-!*H9)$*E6![@XJ
M7RF_Y[R?I_A4%$M%1>4W_/>3]/\ "CRF_P">\GZ?X4 2UQ_@'_F:/^Q@N_\
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M))\Z0>P"\?I2>4__ #WD_)?\* ):*B\I_P#GO)^2_P"%'E/_ ,]Y/R7_  H
MEHJ+RG_Y[R?DO^%'E/\ \]Y/R7_"@"6BHO*?_GO)^2_X4>4__/>3\E_PH EH
MJ+RG_P">\GY+_A1Y3_\ />3\E_PH EHJ+RG_ .>\GY+_ (4>4_\ SWD_)?\
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M\E_PH EHJ+RG_P">\GY+_A1Y3_\ />3\E_PH EHJ+RG_ .>\GY+_ (4>4_\
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M%% !1110 4444 %%%% !1110!Q_@'_F:/^Q@N_\ V6NPKC_ /_,T?]C!=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>EOI^GM,T+2M,3,P+9( Z@#L!7(?$SP#K'C"]L[C3KBT6.VB*&.=V4EB<DC
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M"N/\ _\ ,T?]C!=_^RUV% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO=>M+;1+F>#2[2^2WGNH)"OGS'DID'E0 ?Q/TJJ=-S=D)NQ[)11168PHHHH
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MP2J^/R->0Z[=2P?#_P 9Q0H[-<^))XCL!.%RC$GVPN/QK@_AW8-J7C[1X 2
MLWFL0<<("Q'XXQ^-*CA54I.HW:PZE9QFHI'U+15#6]172-"O]1;'^C6[R@'N
M0"0/SKQC2_C?KBR1PWFEV=X6(4>46B9B?^^A^E94L/4JIN'0N=6,':1[M12+
MDJ,C!QR,UD6?BSP_?W#V]MK%F\Z,5:(RA7R#@\'!/-8J+>R+;2W-BBBBD,**
M** "BBB@ HHHH **** "BBB@ HHHH *X_P"%O_).-)_[;?\ HYZ["N/^%O\
MR3C2?^VW_HYZ .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH \?\ AO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7F'QJ_Y ^B_]A ?^@FO3Z\Z^+NFW^I:5I"6%E<W31WP
M9U@B9RJ[3R<#@5K0=JB%+8J^.M/NO"/B*#QSH\6Z/(BU.!1PZ' W?CP,^H4^
MM1ZUJ-KJWQ/\$:A9R"2WN('=&'H0WZ]B*].N;:&\M9;:YC66"5"DB-T92,$5
MXMI?@S6?#OQ4TRW6WN[C1K>9Y+>X$;,D:.IX9@, YX(/?GO6M.2DM=TF2U8Z
M_P 67OPY@UUT\2I =2V*6WP2N=N..5!%8G]I?!O_ )YVO_@)<?\ Q->H3Z;8
MW,ADGLK:60\%I(E8_F14?]C:5_T#;/\ [\+_ (5G&HDK:_>.QPGBOQ786/A_
M2=#\.74%H-4B @N)&\J.VM^A?+8QQD#OU[XKG?&K^&]-\-^&M*T35+"XCM+]
M&D,-PCL>#N=L'C)[UZK?^%]"U1XFOM)M)S$GEQ[X@=JYS@>@YK@/B'X(L8K?
M2/["\/*7-\HN/LEL6/EXYW8'W:TI3A=(33/3;*_L]2M_M%C=P74))'F02!UR
M.HR.*L54T[3+'2;46NGVL5M &+>7$N!D]3BK=<SM?0L****0!1110 4444 %
M%%% !1110 4444 %%%% !7E6A7<TY\2^/;^^F9[)[BWM;7=^[1% P,>I.T<8
M]3UKU6O)I?!MCXFU#4HM!\7B+2[VX,U]IT8RP<'YN,@@9'<=AUP*VI6UN2SG
M8?"_V;X:_P#"<M>7,>OB;[6DYD/(,@4 _7.?QQ7NEC<&[L+:Y9=IEB60J.V0
M#7)^(O TFN1Z3I<6H-:Z!9JJS6B#F7;C:,_0=_KC-=DJJBA5 "@8  X HJSY
MTOF"5A:***Q*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX_P#_P S1_V,%W_[+785Q_@'_F:/^Q@N_P#V6@#L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ./\ _\ ,T?]C!=_^RUTHTRP6^%Z
M+&V%V 0)Q$H?!ZC=C-<UX!_YFC_L8+O_ -EKL*:;0&7XCT1/$>@76DRW$D"7
M  :2/&X88'OZXQ7FFF_!6;2_$=A?#5H;JTM[A971XBC$*<X&"0>0/2O7Z*UI
MXBI3BXQ>C,Y4XR=V5-5N9;/2+RY@B>6:*!WCCC4LSL%)  '))-?(TMK=+>>1
M/#*ER[8V2*0Q)/H?>OL2H;BTMKL(+FWBF"'<OF(&VGU&:UPN*]A?2]R:U'VE
MM2+2K(:;I%E8KC%M D(Q_LJ!_2O$]3^,6OZ=XEU*&W6SN+&.Y>.))HCD(K$#
M!4CT[YKW<\CKCWKR#4_@5!*[R:?KDRDDG;=1!R3[LI'\J>%E1YFZW4593LN0
M]'\*ZO<:]X9L=4NK9;:6Y0OY:L6 &2 <GU&#^-1WOC#P]INK-I=]JMO;7:JK
M%)B4 !Z?,?E_6M'2K%=,TBRL$QMMH$A!'?:H']*^;/B+;ZI)XSU6^O;&ZAA>
MX*Q22Q,JLB_*I!(P00!1AZ$*]1K9!5J2IQ3W9],VUU;WD(EM9XIXCP'B<,/S
M%2UQ'PETTZ=\/[-F&'NW>X8?4X'_ (ZJURWQ,^(6M^'/%T5CI%TB0QVRM-&\
M2N&<DGG(R.-O0BLXX=SJNG![%.JHP4I'L%%<1\-?&&I^,-,O+G4;:WB\B18D
M> , YQDY!)Z K^=;VO>*='\,M:C5[O[.+EF6-BC,,C&<X!QU%9RI3C/DMJ6I
MQ<>;H;-%9NE^(-'UH'^S-3M;M@NXI%*"RCU*]1^-:50TT[,::>P4444AA111
M0 5Q_P +?^2<:3_VV_\ 1SUV%<?\+?\ DG&D_P#;;_T<] '84444 %%%% !1
M110 4444 %%%% !1110 4444 >/_  W_ .1?LOJ__H;5ZS:_ZH?2O)OAO_R+
M]E]7_P#0VKUFU_U0^E:U_P"++U?YD4_@7H3T445D6(W0UQWP\^[XH_[&"[_]
MDKL6Z&N.^'GW?%'_ &,%W_[)6L/X<OD1+XD=E1116185!>V5MJ-G+:7D*S6\
MHP\;=&'H:GKS>X^-?ANVN98'LM5+Q.48B*/&0<?\]*N$)2^%";2W/0K6TMK&
MW6WM+>*"%?NQQ(%4?@*Y3Q7KFHZ;XP\)V%I<>7;7\\J7*;%/F!=F.2,CJ>F*
MQ/\ A>7AG_GQU?\ [\Q__'*Q+OQSIGC3X@>$/[.@NXOLES)YGVA%7._;C&UC
M_=-:PHS3O)=_R$Y+H>QI;PQRR2QPQI))]]U4 M]3WJ2BBN<H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KBO$'PZ\+7A?4&4Z3<J2_VNUE\K:WJ0?E_D?>NUKSS_A5
MYU>_>\\4:Y>ZEERT=LKE(T&>!Z_EBM*;L[WL)G*+XZUKPYJB:?IFNP^+82V!
M%Y#F8#V< [OKEOI7H7A[QY9:UJ']E7EG=:5J^W=]DNTP6QUVGO\ D*LWAT'X
M?^'+C48-,6"TMPHD6UB7S&W,%')(SR1U-%[X?M?$6K:#X@,TD1L5,L:!1EPX
M! 8^V.GN:TE*$E>WS$DT='1117.4%%%9/B)]<73E3P_%;/>RR!#)<MA(4(.7
MQU;! &/?VII7=@-".[MI;F:VCN(GG@"F6)7!:/=RNX=1G!QGK27=Y:V%NUQ>
M7,-O"OWI)G"*/J3Q7G?PSL;G3O%OC*TO+QKVY22U\VX88,C%9"3C\:EU"TC\
M6?%IM*U*/SM+TBR$XMVR4DE?&"PZ'AO_ !WW-:.FE)J^B%<[VRU&QU*$S6%Y
M;W40."\$JNN?J#4=WK&F6%Q';WFHVEO-)]R.:=49OH"<FN#U'3[7P;\2M N=
M)ACM;36-]I=6\0VQEAC:P4< Y8=/3WK,G_L7^U?'O_"3?8_MG_+M]JQO\KRS
ML\O=WZ?=[XIJFGKT"YZVS*BEF("@9))X J*UNK>]MDN;2>*X@D&4EB<.K?0C
M@UYS]LU&Z\">&_#"RR)JNKVZQRNWWX;8#YW/OMPHSUSZUZ+9VD%A906=M&(X
M((UCC0=E P!42CRA<GHHI&=47+L%'J3BH&+147VF#_GM'_WT*/M,'_/:/_OH
M4 2T5%]I@_Y[1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\ /:/_
M +Z% $M%1?:8/^>T?_?0H^TP?\]H_P#OH4 2T5%]I@_Y[1_]]"C[3!_SVC_[
MZ% $M%1?:8/^>T?_ 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\ WT*/M,'_ #VC
M_P"^A0!+147VF#_GM'_WT*/M,'_/:/\ [Z% $M%1?:8/^>T?_?0H^TP?\]H_
M^^A0!+147VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]
MH_\ OH4 2T5%]I@_Y[1_]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:
M/_OH4 2T5%]I@_Y[1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\
M/:/_ +Z% $M<?X!_YFC_ +&"[_\ 9:GU3P7X2UK4I=0U"SCFNIL;Y/M,BYP
MHX# = *J?\*V\#?] R/_ ,#)?_BZ .THK.TJSTO1-.BT_3_+AM8L[(_-+8R2
M3R23U)JY]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_P ]
MH_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,
M'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_@'_F:/^Q@N
M_P#V6NPKC_ /_,T?]C!=_P#LM=A0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6?K6B6'B'3)-.U*$RVSD$J'*G(.0<@UH44TVG= U?1G :5\)
M=%T7Q)::Q975UBW<N+>4JZD[2!@X!&"0>_2K_P +?^2<:3_VV_\ 1SUV%<?\
M+?\ DG&D_P#;;_T<]5.I.H[R=R8PC'8["BBBH*"BBB@ HHHH **** "BBB@
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MTM?,BAD;YG>5LYR22QP#C\*T]/L;S7_B+=ZWJ-I-!8:,IL]+2>,IYDC#][.
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M^,GVQ7>6,LDUA;2S+ME>)6<>C$#-$HKE4D%];$]%%%0,**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCLMV69V&"S>F..N.@XZUT-6;;M9_TB#T2BBBN8L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH *\F\+3VL6B>.K.Z9$UPRW;SJYP[IL.TCU&=W3U]Q7K->6_$F'X?G4
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M/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\
MOX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__
M #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EH
MH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^
M_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=
M/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\
MOX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__
M #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EH
MH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^
M_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=
M/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\
MOX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__
M #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EH
MH BW3_\ /./_ +^'_"C=/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^
M_A_PJ6B@"+=/_P \X_\ OX?\*-T__/./_OX?\*EHH BW3_\ /./_ +^'_"C=
M/_SSC_[^'_"I:* (MT__ #SC_P"_A_PHW3_\\X_^_A_PJ6B@"+=/_P \X_\
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MOM,'_/:/_OH4?:8/^>T?_?0J6B@"+[3!_P ]H_\ OH4?:8/^>T?_ 'T*EHH
MB^TP?\]H_P#OH4?:8/\ GM'_ -]"I:* (OM,'_/:/_OH4?:8/^>T?_?0J6B@
M"+[3!_SVC_[Z%'VF#_GM'_WT*EHH B^TP?\ /:/_ +Z%'VF#_GM'_P!]"I:*
M (OM,'_/:/\ [Z%'VF#_ )[1_P#?0J6B@"+[3!_SVC_[Z%'VF#_GM'_WT*EH
MH B^TP?\]H_^^A1]I@_Y[1_]]"I:* (OM,'_ #VC_P"^A1]I@_Y[1_\ ?0J6
MB@"+[3!_SVC_ .^A3EFB<X21&/H#FGT4 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+\BYM_T&M]"2BBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JG?:3INJ>7_:&GVEWY>=GVB%9-N<9QD'&<#\JN44 >>Z#X>T2;Q]XM
MMI='T]X(/L?DQ-;(5CW1$MM&,#)Y..M=Q8Z;8Z9$T5A96UI&QW,D$2Q@GU(
MZUS/AW_DH_C3_MQ_]$FNPH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_X;_\B_9?5_\
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MT8Z_E^I.[.MHHHKF+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_X;_\ (OV7U?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_R+]E]7_P#0VKUFU_U0^E>3?#?_ )%^R^K_ /H;5ZS:_P"J'TK6O_%EZO\
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M //QJ_\ X.+O_P".T>Z!M45B_P#"+:?_ ,_&K_\ @XN__CM'_"+:?_S\:O\
M^#B[_P#CM'N@;5%8O_"+:?\ \_&K_P#@XN__ ([1_P (MI__ #\:O_X.+O\
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M_P#/QJ__ (.+O_X[1_PBVG_\_&K_ /@XN_\ X[1[H&U16+_PBVG_ //QJ_\
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M_P#!Q=__ !VC_A%M/_Y^-7_\'%W_ /':/= VJ*Q?^$6T_P#Y^-7_ /!Q=_\
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M:_\ SPD_-?\ &CS7_P">$GYK_C0!+147FO\ \\)/S7_&CS7_ .>$GYK_ (T
M2T5%YK_\\)/S7_&CS7_YX2?FO^- $M%1>:__ #PD_-?\:/-?_GA)^:_XT 2T
M5%YK_P#/"3\U_P :/-?_ )X2?FO^- $M%1>:_P#SPD_-?\:/-?\ YX2?FO\
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M^:_XT 2T5%YK_P#/"3\U_P :/-?_ )X2?FO^- $M%1>:_P#SPD_-?\:/-?\
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M@#S"3X<:JOW+JS;ZLP_]EJK)X!UU/NQ0/_NRC^N*]9HH \<D\&>((^NG,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAO\ "H'TZ]C^_9W"_P"]$P_I7N]% '@&T\\'@X/'0^E)7J'@'_F:/^Q@N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'GW?%'_8P7?_ +)6L/X<OD1+XD=E1116184444 %%%% !1110 4444 %%%%
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M&&94)R44GK_7<RY?A#XSC^[IL<G^Y<Q_U85#_P (!X]L_N:9>IC_ )Y3J?\
MT%J])^(6E^'_  S:V,FG^%/#NZ9V#^9ID3#  ]O>N&77[%>O@[PFWUTE/Z5G
M1IXBK!3BE8UK8VC1FX2O<S_[+^)%G]R'Q(F/^>33'_T$T?VO\1[/[\_B),?\
M]5E/_H0KLO!T^B^(?$4.G77@OPLD3J[,T6F(", GOFM7QO%X9\*WMI!!X*\.
MSB:,NWF6$8(P<=EJ7&JJBI.*NRXXNDZ3JWT1YS_PL+QY9_?U2\3'_/6W4_\
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MW?P['_X%G_XBFS?'5;F%H;CPM#-$WWD>ZW*>_(,==\?A;X+/_,#C_P"_\O\
M\54-Q\,_ =K T]SI4,,2XW2274BJ,G')+^M'/0_E?]?,33:LS@_#?C[1]9\<
M6L5SX;M[:WNT%JD2;9%60L,,1M ]L^]>X1QI%&L<:*B( JJHP% Z "O+;/PU
MX"M/&3A;;2I-.^Q9'VB<31&3<!_&Q!..U=E'X(\&31)+%X7T%XW4,KKI\)#
M]"#MY%17:;7*98>--<W(K:LZ*BN?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZO\ ^AM7K-K_ *H?2M:_\67J_P R*?P+T)Z***R+$;H:X[X>?=\4?]C!=_\
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M_LEREU#A;L8D3.T\#GJ>*V--G\:_VA#_ &HNA?8LGS?LL=QYF,<;=PQUQUH
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M["BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% '/K_ ,E"D_[!@_\
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MTW3#(;#3[2T,AR_D0K'N/O@<U?M='<+%RBBBL1A1110 4444 %%%% !1110
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MV*BMK>&TM8K:WC6*"%!''&HP%4#  ]@*EH C*S9.)(P.V4/^-)MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\
MC1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9
M_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\
MW[/^-2T4 1;9_P#GI'_W[/\ C1MG_P">D?\ W[/^-2T4 9PTLC63JGGCSS!Y
M&W9\NW=NSUSG/O5S;/\ \](_^_9_QJ6BFW<F,5'8BVS_ //2/_OV?\:-L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#@]>XK2K#U&U\0R>)=-GL+^WBT>,'[;;NH+R'G&T[3[?Q"MRL7TU&<)\(_\
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M% !1110 4444 %%%% 'C_P -_P#D7[+ZO_Z&U>LVO^J'TKR;X;_\B_9?5_\
MT-J]9M?]4/I6M?\ BR]7^9%/X%Z$]%%%9%B-T-<=\//N^*/^Q@N__9*[%NAK
MCOAY]WQ1_P!C!=_^R5K#^'+Y$2^)'94445D6%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7!?$R]U,V=GI-EIVIW%G>.?M\UA;&5
MUA!&4&. 6]R.!WKO:*J$N5W!GC/B#Q-!_;GA 6OA?7[*#3IV\NWEL=C2+M4!
M8QN^8C%;^N7IE^(7@/57M9[>*X6XC$=RNR1&=,!6'.#\PXKJ=<\-_P!LZUH>
MH_:_)_LN=IO+\O=YN0!C.1CI[U)XG\,V?BC3%M+EY(9(I!+;W$1P\,@Z,#_G
M^5:^TCI\R;'.?&%A_P (!+".9)[F&.-1U9MV<?D#78?V592K9-=6EO<3V8'D
MRR1!FC.!DJ3RIX'3T%<O:>!+R;5K*_\ $7B.XUD6+;[6!K=845AT9@"=Q'KU
MK:UG1+W4]6TB\MM9N+&&QE9Y[>+=MN@2ORMA@,#:>H/WC4MJRBGW&;=<)X _
MY&+QI_V%6_K7=U@^'_#?]A:CK5W]K\_^T[LW.WR]OE]?ESDYZ]>*F+2BT!O4
M445 PHHHH **** "BBB@ HHHH **** &3316\#S32+'%&I9W<X"@=237FT]Q
M??%*\-I9F6S\)028GN?NO?,#]U?1?\GG@=;XQ\.3^*O#[Z3#J)L%DD5I9!%Y
MF]1SMQN'?!Z]JYRT\!^*K&TBM;7Q[)#!$H2.--,0!0.P^>MJ?*E>^HF)X^AA
MTNZ\%/%$L5E::K%%@<+&O 'Y '\JV/B7,D'P[UEI& #0A![DL /YU:N?"R:O
MX2&AZ[>/J$F/FNP@C<ODE6 &0",X_P#UUBK\/;Z]EM(_$'BBZU;3K1Q)':-
ML88CIYC DO\ C0I1TN]@-W1-'M)_".A6VHV5O<M;6<&T3Q*^QUC R,YP:WJP
M_$FAWVMQ6:V6M7&EF"<2R-!N_>J/X#AEX_/Z5N5G)WU&<'\./^0CXQ_[#MQ_
M.N\K!\.>&_\ A'[G69OM?VC^TK^2\QY>SR]QSMZG./7CZ5O4ZC3E="04445
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M\QT;S?+WXVG/3(_G6]2;7(EZ_H'4****@84444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M671M0MK;3XI6.I12J"TR97 7Y#@X#]UZC\-ZBPPHHHI %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \?\ AO\
M\B_9?5__ $-J]9M?]4/I7DWPW_Y%^R^K_P#H;5ZS:_ZH?2M:_P#%EZO\R*?P
M+T)Z***R+$;H:X[X>?=\4?\ 8P7?_LE=BW0UQWP\^[XH_P"Q@N__ &2M8?PY
M?(B7Q([*BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#DOB=_R3G6?^N:?^C%KE/"WPJ\,
MZOX6TS4+J.Z,]Q;K))MFP,D=ABN\\8Z-<>(?"=_I5H\23W"*J-*2%&&!Y(!/
M;TKD--T#XFZ3IMMI]KJF@"WMXQ'&&#DX'OY==%.35.RE9W):U-[0/ASH'AK5
M5U'3DN1<*K(#)+N&#UXQ6-JG_)?-$_[!3?SFJ_IMG\2$U.V;4M3T-[(2*9UA
M5]Y3/(&4'.*MWOAB]N?B;IWB5);<65M9&W="S>86/F<@8QCYQW]:7-9MR=]&
M'H8NN_\ )=/"_P#UY3?^@35B^*)M3E^,]O\ 8M+359K.S#V]K+,L:C@DMEN,
M@G]!Z5VFI>&+V\^).C>(XY;<6=E;R12(S-YA+*X&!C&/G'<=Z;XM\&RZW?VF
MLZ3??V?K=F-L4Y7*NO/RL/Q/KU/%5&<4UZ6!IG+^*X_''BO0I=,N?!,$>YE:
M.8:A$S1L#U'S>F1^-0:Y%>77BCX?:5KL>"L0:XB=@P:8 9R0<'E1^?O6O?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8W_"7>&O\
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M_P"$'TW_ *!=G_WX7_"C_A!]-_Z!=G_WX7_"C]UYA[_D=E_PEWAK_H8=)_\
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M5<;_ ,(/IO\ T"[/_OPO^%'_  @^F_\ 0+L_^_"_X4?NO,/?\CLO^$N\-?\
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M&Q__ !5<;_P@^F_] NS_ ._"_P"%'_"#Z;_T"[/_ +\+_A1^Z\P]_P CLO\
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M .*H_P"$N\-?]##I/_@;'_\ %5QO_"#Z;_T"[/\ [\+_ (4?\(/IO_0+L_\
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M_P! NS_[\+_A1_P@^F_] NS_ ._"_P"%'[KS#W_([+_A+O#7_0PZ3_X&Q_\
MQ5'_  EWAK_H8=)_\#8__BJXW_A!]-_Z!=G_ -^%_P */^$'TW_H%V?_ 'X7
M_"C]UYA[_D=E_P )=X:_Z&'2?_ V/_XJC_A+O#7_ $,.D_\ @;'_ /%5QO\
MP@^F_P#0+L_^_"_X4?\ "#Z;_P! NS_[\+_A1^Z\P]_R.R_X2[PU_P!##I/_
M (&Q_P#Q5'_"7>&O^AATG_P-C_\ BJXW_A!]-_Z!=G_WX7_"C_A!]-_Z!=G_
M -^%_P */W7F'O\ D=E_PEWAK_H8=)_\#8__ (JC_A+O#7_0PZ3_ .!L?_Q5
M<;_P@^F_] NS_P"_"_X4?\(/IO\ T"[/_OPO^%'[KS#W_([+_A+O#7_0PZ3_
M .!L?_Q5'_"7>&O^AATG_P #8_\ XJN-_P"$'TW_ *!=G_WX7_"C_A!]-_Z!
M=G_WX7_"C]UYA[_D=E_PEWAK_H8=)_\  V/_ .*H_P"$N\-?]##I/_@;'_\
M%5QO_"#Z;_T"[/\ [\+_ (4?\(/IO_0+L_\ OPO^%'[KS#W_ ".R_P"$N\-?
M]##I/_@;'_\ %4?\)=X:_P"AATG_ ,#8_P#XJN-_X0?3?^@79_\ ?A?\*/\
MA!]-_P"@79_]^%_PH_=>8>_Y'9?\)=X:_P"AATG_ ,#8_P#XJC_A+O#7_0PZ
M3_X&Q_\ Q5<;_P (/IO_ $"[/_OPO^%'_"#Z;_T"[/\ [\+_ (4?NO,/?\CL
MO^$N\-?]##I/_@;'_P#%4?\ "7>&O^AATG_P-C_^*KC?^$'TW_H%V?\ WX7_
M  H_X0?3?^@79_\ ?A?\*/W7F'O^1V7_  EWAK_H8=)_\#8__BJ/^$N\-?\
M0PZ3_P"!L?\ \57&_P#"#Z;_ - NS_[\+_A1_P (/IO_ $"[/_OPO^%'[KS#
MW_([+_A+O#7_ $,.D_\ @;'_ /%4?\)=X:_Z&'2?_ V/_P"*KC?^$'TW_H%V
M?_?A?\*/^$'TW_H%V?\ WX7_  H_=>8>_P"1V7_"7>&O^AATG_P-C_\ BJ/^
M$N\-?]##I/\ X&Q__%5QO_"#Z;_T"[/_ +\+_A1_P@^F_P#0+L_^_"_X4?NO
M,/?\CLO^$N\-?]##I/\ X&Q__%4?\)=X:_Z&'2?_  -C_P#BJXW_ (0?3?\
MH%V?_?A?\*/^$'TW_H%V?_?A?\*/W7F'O^1V7_"7>&O^AATG_P #8_\ XJC_
M (2[PU_T,.D_^!L?_P 57&_\(/IO_0+L_P#OPO\ A1_P@^F_] NS_P"_"_X4
M?NO,/?\ ([+_ (2[PU_T,.D_^!L?_P 51_PEWAK_ *&'2?\ P-C_ /BJXW_A
M!]-_Z!=G_P!^%_PH_P"$'TW_ *!=G_WX7_"C]UYA[_D=E_PEWAK_ *&'2?\
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M#Z;_ - NS_[\+_A1^Z\P]_R.R_X2[PU_T,.D_P#@;'_\51_PEWAK_H8=)_\
M V/_ .*KC?\ A!]-_P"@79_]^%_PH_X0?3?^@79_]^%_PH_=>8>_Y'9?\)=X
M:_Z&'2?_  -C_P#BJ/\ A+O#7_0PZ3_X&Q__ !5<;_P@^F_] NS_ ._"_P"%
M'_"#Z;_T"[/_ +\+_A1^Z\P]_P CLO\ A+O#7_0PZ3_X&Q__ !5'_"7>&O\
MH8=)_P# V/\ ^*KC?^$'TW_H%V?_ 'X7_"C_ (0?3?\ H%V?_?A?\*/W7F'O
M^1V7_"7>&O\ H8=)_P# V/\ ^*H_X2[PU_T,.D_^!L?_ ,57&_\ "#Z;_P!
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M-C_^*H_X2[PU_P!##I/_ (&Q_P#Q5<;_ ,(/IO\ T"[/_OPO^%'_  @^F_\
M0+L_^_"_X4?NO,/?\CLO^$N\-?\ 0PZ3_P"!L?\ \517'?\ "#Z;_P! NS_[
M\+_A11^Z\P]_R/1S&IZBD\A/2I**R+(_(3TH\A/2I** (_(3TH\A/2I** (_
M(3TH\A/2I** (O(3TH\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10!%Y"
M>@H\A/05+10!%Y">@H\A/05+10!%Y">@H\A/05+10 P1*.U/Z444 %%%% !3
M2@/6G44 1^2GH*3R$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"C
MR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"CR$]!4M% $7D)Z"B
MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'!R">,=><U:%O=Z7J]Y=6]F]W;WI5V6)U5XW"[3PY *D =\@]O3/U#2-0O\
M3-;N&MU6\OXDCAM@ZDHJ= 6Z9)))P<#CDU2L+4L6FMW=QK\.FEEVBW$TCM83
M1ER6;@!C\@P!R<Y.1UXJ]?:P+/6=.T_R7;[7ORXC8A0!QT&.O7G@=>N:CDT^
MZD\2SW2L\,+V*0K.A4L'$C$@!@>Q'48YJ*YT^\BU?2+@//?) \HED<QJR!U
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M6VLG9&>-3N*#"[B23CVR:T*EVZ#04444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>alvr-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-14T16:04:23.5053+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" xlink:href="alvr-20221231.xsd#DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" xlink:href="alvr-20221231.xsd#DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="alvr_PrepaidExpensesToRelatedParty" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidExpensesToRelatedParty" xlink:label="alvr_PrepaidExpensesToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alvr_NonCashLeaseExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonCashLeaseExpense" xlink:label="alvr_NonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alvr_AccruedResearchAndDevelopmentCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedResearchAndDevelopmentCurrent" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alvr_DeferredTaxLiabilitiesDepreciation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alvr_DeferredTaxAssetsLeasingArrangements" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesDepreciation" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsLeasingArrangements" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>alvr-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-14T16:04:22.9556+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="alvr-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="alvr-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:href="alvr-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidExpensesToRelatedParty" xlink:label="alvr_PrepaidExpensesToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="alvr_PrepaidExpensesToRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecuritiesPurchaseAgreementMember" xlink:label="alvr_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_GrossProceedsFromIssuanceOfCommonStock" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alvr_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alvr_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CashAndCashEquivalentsMaturityPeriod" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShortTermInvestmentsMaturityPeriod" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfIndividualSecuritiesWithImpairment" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_CashAndCashEquivalentsMaturityPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_ShortTermInvestmentsMaturityPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_NumberOfIndividualSecuritiesWithImpairment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LaboratoryEquipmentMember" xlink:label="alvr_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alvr_LaboratoryEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_USGovernmentTreasurySecuritiesMember" xlink:label="alvr_USGovernmentTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CorporateAndAgencyBondsMember" xlink:label="alvr_CorporateAndAgencyBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="alvr_USGovernmentTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alvr_CorporateAndAgencyBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_USGovernmentTreasurySecuritiesMember" xlink:label="alvr_USGovernmentTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CorporateAndAgencyBondsMember" xlink:label="alvr_CorporateAndAgencyBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="alvr_USGovernmentTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alvr_CorporateAndAgencyBondsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestmentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesLineItems" xlink:label="alvr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesTable" xlink:label="alvr_LeasesTable"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseExpirationMonthAndYear" xlink:label="alvr_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_WalthamLeasesMember" xlink:label="alvr_WalthamLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NewLeaseAgreementWithBpBayColonyLlcMember" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SubleaseWithAmagPharmaceuticalsMember" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OriginalSOWAmendmentMember" xlink:label="alvr_OriginalSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondSOWAmendmentMember" xlink:label="alvr_SecondSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseTerm" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UtilizationFeePayable" xlink:label="alvr_UtilizationFeePayable"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidUtilizationFee" xlink:label="alvr_PrepaidUtilizationFee"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseCommencementMonthAndYear" xlink:label="alvr_LeaseCommencementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AdditionalOneTimeLeasePeriod" xlink:label="alvr_AdditionalOneTimeLeasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceToBeReimbursed" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceReimbursementPeriod" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeasesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_DevelopmentAndManufacturingServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_LeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_LeasesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_WalthamLeasesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_NewLeaseAgreementWithBpBayColonyLlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_SubleaseWithAmagPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_OriginalSOWAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_SecondSOWAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingEstimatedLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_UtilizationFeePayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_PrepaidUtilizationFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_AdditionalOneTimeLeasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_TenantImprovementAllowanceToBeReimbursed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_TenantImprovementAllowanceReimbursementPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LaboratoryEquipmentMember" xlink:label="alvr_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alvr_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_BaylorCollegeOfMedicineMember" xlink:label="alvr_BaylorCollegeOfMedicineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedExpensesMember" xlink:label="alvr_AccruedExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CancerResearchAndPreventionInstituteOfTexasMember" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePayments" xlink:label="alvr_NonRefundableLicenseFeePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondLicenseAgreementMember" xlink:label="alvr_SecondLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedMilestoneExpenses" xlink:label="alvr_AccruedMilestoneExpenses"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchCollaborationAgreementMember" xlink:label="alvr_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MilestonePayments" xlink:label="alvr_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RedumptionAgreementMember" xlink:label="alvr_RedumptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AgreementForPerformingResearchActivitiesTerm" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchActivitiesPerformingFees" xlink:label="alvr_ResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AggregateResearchActivitiesPerformingFees" xlink:label="alvr_AggregateResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentAsPercentageOfNetSales" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alvr_BaylorCollegeOfMedicineMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="alvr_AccruedExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="alvr_CancerResearchAndPreventionInstituteOfTexasMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_SecondLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AccruedMilestoneExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_ResearchCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_RedumptionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AgreementForPerformingResearchActivitiesTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_ResearchActivitiesPerformingFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AggregateResearchActivitiesPerformingFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_EarnoutPaymentAsPercentageOfNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecuritiesPurchaseAgreementMember" xlink:label="alvr_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SaleOfStockOfferingCosts" xlink:label="alvr_SaleOfStockOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnderwritingDiscountsCommissions" xlink:label="alvr_UnderwritingDiscountsCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfVotesPerShare" xlink:label="alvr_NumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alvr_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_SaleOfStockOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_UnderwritingDiscountsCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_NumberOfVotesPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnvestedRestrictedStockMember" xlink:label="alvr_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionToPurchaseCommonStockMember" xlink:label="alvr_OptionToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForGrantMember" xlink:label="alvr_StockAvailableForGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForIssuanceMember" xlink:label="alvr_StockAvailableForIssuanceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_UnvestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_OptionToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForIssuanceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForGrantMember" xlink:label="alvr_StockAvailableForGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OfferingPeriodDescription" xlink:label="alvr_OfferingPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_OfferingPeriodDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesLineItems" xlink:label="alvr_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesTable" xlink:label="alvr_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsCarrybackPeriod" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsExpirationYear" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCreditCarryforwardExpirationYear" xlink:label="alvr_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_OperatingLossCarryforwardsCarrybackPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionsToPurchaseCommonStockMember" xlink:label="alvr_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnvestedRestrictedStockMember" xlink:label="alvr_UnvestedRestrictedStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alvr_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alvr_UnvestedRestrictedStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevateBioAndAffiliatesMember" xlink:label="alvr_ElevateBioAndAffiliatesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevatebioBasecampIncMember" xlink:label="alvr_ElevatebioBasecampIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alvr_ElevateBioAndAffiliatesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alvr_ElevatebioBasecampIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ManagementFeeExpense" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>alvr-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-14T16:04:23.3727+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.allovir.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:alvr="http://www.allovir.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvr-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvr-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvr-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alvr-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100090 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments" id="Role_DisclosureShortTermInvestments">
        <link:definition>100110 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100140 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100150 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements" id="Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements">
        <link:definition>100160 - Disclosure - Sponsored Research, Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>100170 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFundingArrangements" id="Role_DisclosureFundingArrangements">
        <link:definition>100180 - Disclosure - Funding Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>100190 - Disclosure - Stockholder's Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100200 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100220 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100230 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100240 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" id="DisclosureEmployeeBenefitPlans1">
        <link:definition>100250 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100260 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" id="Role_DisclosureShortTermInvestmentsTables">
        <link:definition>100290 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100330 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>100340 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100350 - Disclosure - Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100360 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100370 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100380 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Nature of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" id="Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails">
        <link:definition>100420 - Disclosure - Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100450 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100460 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100480 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Sponsored Research, Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Stockholders Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails">
        <link:definition>100510 - Disclosure - Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100520 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails">
        <link:definition>100540 - Disclosure - Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100550 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100560 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>100570 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100580 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails">
        <link:definition>100590 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails">
        <link:definition>100600 - Disclosure - Income Taxes - Summary of Components of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100620 - Disclosure - Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100630 - Disclosure - Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Commitments and Contingencies- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" name="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_AccruedMilestoneExpenses" name="AccruedMilestoneExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" name="AccruedProcessDevelopmentAndManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_AdditionalOneTimeLeasePeriod" name="AdditionalOneTimeLeasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_AggregateResearchActivitiesPerformingFees" name="AggregateResearchActivitiesPerformingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_AgreementForPerformingResearchActivitiesTerm" name="AgreementForPerformingResearchActivitiesTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_CashAndCashEquivalentsMaturityPeriod" name="CashAndCashEquivalentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_DeferredTaxAssetsLeasingArrangements" name="DeferredTaxAssetsLeasingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" name="DeferredTaxLiabilitiesRestrictedStockCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_EarnoutPaymentAsPercentageOfNetSales" name="EarnoutPaymentAsPercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" name="EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" name="EffectiveIncomeTaxRateReconciliationOfficersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" name="EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification" name="IncreaseDecreaseInRightOfUseAssetDueToModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_LeaseTerminationEffectiveDate" name="LeaseTerminationEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" name="LesseeOperatingEstimatedLeaseExpiringMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_LesseeOperatingEstimatedLeaseTerm" name="LesseeOperatingEstimatedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" name="LesseeOperatingLeaseLeaseTermIncludingRenewalOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" name="MaximumAnnualIncreaseOfCommonStockReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" name="MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" name="MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" name="MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_NonRefundableLicenseFeePayments" name="NonRefundableLicenseFeePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" name="NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" name="NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_NumberOfIndividualSecuritiesWithImpairment" name="NumberOfIndividualSecuritiesWithImpairment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" name="NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_NumberOfVotesPerShare" name="NumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_OfferingPeriodDescription" name="OfferingPeriodDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_OperatingLossCarryforwardsCarrybackPeriod" name="OperatingLossCarryforwardsCarrybackPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" name="PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" name="PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" name="PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_PrepaidExpensesToRelatedParty" name="PrepaidExpensesToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_PrepaidUtilizationFee" name="PrepaidUtilizationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" name="PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_ResearchActivitiesPerformingFees" name="ResearchActivitiesPerformingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_SaleOfStockOfferingCosts" name="SaleOfStockOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShortTermInvestmentsMaturityPeriod" name="ShortTermInvestmentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" name="TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_TenantImprovementAllowanceReimbursementPeriod" name="TenantImprovementAllowanceReimbursementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_TenantImprovementAllowanceToBeReimbursed" name="TenantImprovementAllowanceToBeReimbursed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alvr_UnderwritingDiscounts" name="UnderwritingDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_UnderwritingDiscountsCommissions" name="UnderwritingDiscountsCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_UnrealizedGainLossOnAvailableForSaleSecurities" name="UnrealizedGainLossOnAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_UtilizationFeePayable" name="UtilizationFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alvr_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_LeasesLineItems" name="LeasesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" name="SponsoredResearchCollaborationAndLicenseAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_AccruedExpensesMember" name="AccruedExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" name="AmendedAndRestatedExclusiveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_BaylorCollegeOfMedicineMember" name="BaylorCollegeOfMedicineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_CancerResearchAndPreventionInstituteOfTexasMember" name="CancerResearchAndPreventionInstituteOfTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" name="ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_CorporateAndAgencyBondsMember" name="CorporateAndAgencyBondsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_DevelopmentAndManufacturingServicesAgreementMember" name="DevelopmentAndManufacturingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_ElevateBioAndAffiliatesMember" name="ElevateBioAndAffiliatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_ElevatebioBasecampIncMember" name="ElevatebioBasecampIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_NewLeaseAgreementWithBpBayColonyLlcMember" name="NewLeaseAgreementWithBpBayColonyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_OptionToPurchaseCommonStockMember" name="OptionToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_OriginalSOWAmendmentMember" name="OriginalSOWAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_RedumptionAgreementMember" name="RedumptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_ResearchCollaborationAgreementMember" name="ResearchCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SecondLicenseAgreementMember" name="SecondLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SecondSOWAmendmentMember" name="SecondSOWAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" name="SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_StockAvailableForGrantMember" name="StockAvailableForGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_StockAvailableForIssuanceMember" name="StockAvailableForIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SubleaseWithAmagPharmaceuticalsMember" name="SubleaseWithAmagPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" name="TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" name="TwoThousandTwentyStockOptionAndGrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" name="TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_USGovernmentTreasurySecuritiesMember" name="USGovernmentTreasurySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_WalthamLeasesMember" name="WalthamLeasesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock" name="BasisOfPresentationAndConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_OtherIncomeNetPolicyTextBlock" name="OtherIncomeNetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock" name="ResearchAndDevelopmentGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_LeasesTable" name="LeasesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" name="SponsoredResearchCollaborationAndLicenseAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" name="CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_AccruedLiabilitiesDisclosureTextBlock" name="AccruedLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_FundingArrangementsTextBlock" name="FundingArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" name="SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>alvr-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-14T16:04:22.9115+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="alvr-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="alvr-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:href="alvr-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:href="alvr-20221231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="alvr-20221231.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="alvr-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments" xlink:href="alvr-20221231.xsd#Role_DisclosureShortTermInvestments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="alvr-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="alvr-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="alvr-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements" xlink:href="alvr-20221231.xsd#Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenue" xlink:href="alvr-20221231.xsd#Role_DisclosureRevenue" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFundingArrangements" xlink:href="alvr-20221231.xsd#Role_DisclosureFundingArrangements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="alvr-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="alvr-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="alvr-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:href="alvr-20221231.xsd#DisclosureEmployeeBenefitPlans1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="alvr-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alvr-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="alvr-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" xlink:href="alvr-20221231.xsd#Role_DisclosureShortTermInvestmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="alvr-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="alvr-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="alvr-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenueTables" xlink:href="alvr-20221231.xsd#Role_DisclosureRevenueTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="alvr-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:href="alvr-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:href="alvr-20221231.xsd#DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" xlink:href="alvr-20221231.xsd#DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="alvr-20221231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidExpensesToRelatedParty" xlink:label="alvr_PrepaidExpensesToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="alvr_PrepaidExpensesToRelatedParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_15"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnrealizedGainLossOnAvailableForSaleSecurities" xlink:label="alvr_UnrealizedGainLossOnAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonCashLeaseExpense" xlink:label="alvr_NonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncreaseDecreaseInRightOfUseAssetDueToModification" xlink:label="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alvr_UnrealizedGainLossOnAvailableForSaleSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alvr_NonCashLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnderwritingDiscounts" xlink:label="alvr_UnderwritingDiscounts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="alvr_UnderwritingDiscounts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedLiabilitiesDisclosureTextBlock" xlink:label="alvr_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="alvr_AccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFundingArrangements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_FundingArrangementsTextBlock" xlink:label="alvr_FundingArrangementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="alvr_FundingArrangementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShortTermInvestmentsPolicyTextBlock" xlink:label="alvr_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredOfferingCostsPolicyTextBlock" xlink:label="alvr_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OtherIncomeNetPolicyTextBlock" xlink:label="alvr_OtherIncomeNetPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_ShortTermInvestmentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_DeferredOfferingCostsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InternalUseSoftwarePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_OtherIncomeNetPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecuritiesPurchaseAgreementMember" xlink:label="alvr_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_GrossProceedsFromIssuanceOfCommonStock" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alvr_SecuritiesPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alvr_GrossProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CashAndCashEquivalentsMaturityPeriod" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShortTermInvestmentsMaturityPeriod" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfIndividualSecuritiesWithImpairment" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_CashAndCashEquivalentsMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_ShortTermInvestmentsMaturityPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_NumberOfIndividualSecuritiesWithImpairment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LaboratoryEquipmentMember" xlink:label="alvr_LaboratoryEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alvr_LaboratoryEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_USGovernmentTreasurySecuritiesMember" xlink:label="alvr_USGovernmentTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CorporateAndAgencyBondsMember" xlink:label="alvr_CorporateAndAgencyBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="alvr_USGovernmentTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alvr_CorporateAndAgencyBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_USGovernmentTreasurySecuritiesMember" xlink:label="alvr_USGovernmentTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CorporateAndAgencyBondsMember" xlink:label="alvr_CorporateAndAgencyBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="alvr_USGovernmentTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alvr_CorporateAndAgencyBondsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestmentsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesLineItems" xlink:label="alvr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseExpirationMonthAndYear" xlink:label="alvr_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesTable" xlink:label="alvr_LeasesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_WalthamLeasesMember" xlink:label="alvr_WalthamLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NewLeaseAgreementWithBpBayColonyLlcMember" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SubleaseWithAmagPharmaceuticalsMember" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OriginalSOWAmendmentMember" xlink:label="alvr_OriginalSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondSOWAmendmentMember" xlink:label="alvr_SecondSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseTerm" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UtilizationFeePayable" xlink:label="alvr_UtilizationFeePayable"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidUtilizationFee" xlink:label="alvr_PrepaidUtilizationFee"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseCommencementMonthAndYear" xlink:label="alvr_LeaseCommencementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AdditionalOneTimeLeasePeriod" xlink:label="alvr_AdditionalOneTimeLeasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceToBeReimbursed" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceReimbursementPeriod" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeaseExpirationMonthAndYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_DevelopmentAndManufacturingServicesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="alvr_LeasesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_WalthamLeasesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesTable" xlink:to="alvr_LeasesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_NewLeaseAgreementWithBpBayColonyLlcMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_SubleaseWithAmagPharmaceuticalsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_OriginalSOWAmendmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_SecondSOWAmendmentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingEstimatedLeaseTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_UtilizationFeePayable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_PrepaidUtilizationFee" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeaseCommencementMonthAndYear" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_AdditionalOneTimeLeasePeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_TenantImprovementAllowanceToBeReimbursed" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_TenantImprovementAllowanceReimbursementPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_TenantImprovements" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_VariableLeaseCost" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_LeasesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LaboratoryEquipmentMember" xlink:label="alvr_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alvr_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedResearchAndDevelopmentCurrent" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="alvr_AccruedResearchAndDevelopmentCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_BaylorCollegeOfMedicineMember" xlink:label="alvr_BaylorCollegeOfMedicineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedExpensesMember" xlink:label="alvr_AccruedExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CancerResearchAndPreventionInstituteOfTexasMember" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePayments" xlink:label="alvr_NonRefundableLicenseFeePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondLicenseAgreementMember" xlink:label="alvr_SecondLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedMilestoneExpenses" xlink:label="alvr_AccruedMilestoneExpenses"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchCollaborationAgreementMember" xlink:label="alvr_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MilestonePayments" xlink:label="alvr_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RedumptionAgreementMember" xlink:label="alvr_RedumptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AgreementForPerformingResearchActivitiesTerm" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchActivitiesPerformingFees" xlink:label="alvr_ResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AggregateResearchActivitiesPerformingFees" xlink:label="alvr_AggregateResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentAsPercentageOfNetSales" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alvr_BaylorCollegeOfMedicineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="alvr_AccruedExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="alvr_CancerResearchAndPreventionInstituteOfTexasMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_SecondLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AccruedMilestoneExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_ResearchCollaborationAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MilestonePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="srt_MajorCustomersAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alvr_RedumptionAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AgreementForPerformingResearchActivitiesTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_ResearchActivitiesPerformingFees" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_AggregateResearchActivitiesPerformingFees" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_EarnoutPaymentAsPercentageOfNetSales" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecuritiesPurchaseAgreementMember" xlink:label="alvr_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SaleOfStockOfferingCosts" xlink:label="alvr_SaleOfStockOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnderwritingDiscountsCommissions" xlink:label="alvr_UnderwritingDiscountsCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfVotesPerShare" xlink:label="alvr_NumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alvr_SecuritiesPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_SaleOfStockOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_UnderwritingDiscountsCommissions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alvr_NumberOfVotesPerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnvestedRestrictedStockMember" xlink:label="alvr_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionToPurchaseCommonStockMember" xlink:label="alvr_OptionToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForGrantMember" xlink:label="alvr_StockAvailableForGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForIssuanceMember" xlink:label="alvr_StockAvailableForIssuanceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_UnvestedRestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_OptionToPurchaseCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForGrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForIssuanceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForGrantMember" xlink:label="alvr_StockAvailableForGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OfferingPeriodDescription" xlink:label="alvr_OfferingPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndEighteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alvr_StockAvailableForGrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_OfferingPeriodDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_8"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesDepreciation" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsLeasingArrangements" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="alvr_DeferredTaxLiabilitiesDepreciation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="alvr_DeferredTaxAssetsLeasingArrangements" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesTable" xlink:label="alvr_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesLineItems" xlink:label="alvr_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsCarrybackPeriod" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsExpirationYear" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCreditCarryforwardExpirationYear" xlink:label="alvr_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alvr_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_OperatingLossCarryforwardsCarrybackPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesTable" xlink:to="alvr_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_TaxCreditCarryforwardExpirationYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionsToPurchaseCommonStockMember" xlink:label="alvr_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnvestedRestrictedStockMember" xlink:label="alvr_UnvestedRestrictedStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alvr_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alvr_UnvestedRestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseTerminationEffectiveDate" xlink:label="alvr_LeaseTerminationEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alvr_LeaseTerminationEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevateBioAndAffiliatesMember" xlink:label="alvr_ElevateBioAndAffiliatesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevatebioBasecampIncMember" xlink:label="alvr_ElevatebioBasecampIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alvr_ElevateBioAndAffiliatesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alvr_ElevatebioBasecampIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>33
<FILENAME>alvr-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-14T16:04:25.1335+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncreaseDecreaseInRightOfUseAssetDueToModification" xlink:label="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondLicenseAgreementMember" xlink:label="alvr_SecondLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsCarrybackPeriod" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesLineItems" xlink:label="alvr_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MilestonePayments" xlink:label="alvr_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CashAndCashEquivalentsMaturityPeriod" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_FundingArrangementsTextBlock" xlink:label="alvr_FundingArrangementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_WalthamLeasesMember" xlink:label="alvr_WalthamLeasesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseTerm" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SaleOfStockOfferingCosts" xlink:label="alvr_SaleOfStockOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_GrossProceedsFromIssuanceOfCommonStock" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonCashLeaseExpense" xlink:label="alvr_NonCashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchActivitiesPerformingFees" xlink:label="alvr_ResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecuritiesPurchaseAgreementMember" xlink:label="alvr_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionToPurchaseCommonStockMember" xlink:label="alvr_OptionToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseExpirationMonthAndYear" xlink:label="alvr_LeaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForGrantMember" xlink:label="alvr_StockAvailableForGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredOfferingCostsPolicyTextBlock" xlink:label="alvr_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SecondSOWAmendmentMember" xlink:label="alvr_SecondSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseTerminationEffectiveDate" xlink:label="alvr_LeaseTerminationEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedMilestoneExpenses" xlink:label="alvr_AccruedMilestoneExpenses"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OfferingPeriodDescription" xlink:label="alvr_OfferingPeriodDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnderwritingDiscounts" xlink:label="alvr_UnderwritingDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShortTermInvestmentsMaturityPeriod" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnrealizedGainLossOnAvailableForSaleSecurities" xlink:label="alvr_UnrealizedGainLossOnAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidUtilizationFee" xlink:label="alvr_PrepaidUtilizationFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CancerResearchAndPreventionInstituteOfTexasMember" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PrepaidExpensesToRelatedParty" xlink:label="alvr_PrepaidExpensesToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedExpensesMember" xlink:label="alvr_AccruedExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceReimbursementPeriod" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfVotesPerShare" xlink:label="alvr_NumberOfVotesPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesLineItems" xlink:label="alvr_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TaxCreditCarryforwardExpirationYear" xlink:label="alvr_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxAssetsLeasingArrangements" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedLiabilitiesDisclosureTextBlock" xlink:label="alvr_AccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_BaylorCollegeOfMedicineMember" xlink:label="alvr_BaylorCollegeOfMedicineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AggregateResearchActivitiesPerformingFees" xlink:label="alvr_AggregateResearchActivitiesPerformingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevateBioAndAffiliatesMember" xlink:label="alvr_ElevateBioAndAffiliatesMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OriginalSOWAmendmentMember" xlink:label="alvr_OriginalSOWAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfIndividualSecuritiesWithImpairment" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShortTermInvestmentsPolicyTextBlock" xlink:label="alvr_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TenantImprovementAllowanceToBeReimbursed" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OperatingLossCarryforwardsExpirationYear" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EarnoutPaymentAsPercentageOfNetSales" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_IncomeTaxesTable" xlink:label="alvr_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnvestedRestrictedStockMember" xlink:label="alvr_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AccruedResearchAndDevelopmentCurrent" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_USGovernmentTreasurySecuritiesMember" xlink:label="alvr_USGovernmentTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LaboratoryEquipmentMember" xlink:label="alvr_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_CorporateAndAgencyBondsMember" xlink:label="alvr_CorporateAndAgencyBondsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_DeferredTaxLiabilitiesDepreciation" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchCollaborationAgreementMember" xlink:label="alvr_ResearchCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AgreementForPerformingResearchActivitiesTerm" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_AdditionalOneTimeLeasePeriod" xlink:label="alvr_AdditionalOneTimeLeasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RedumptionAgreementMember" xlink:label="alvr_RedumptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OtherIncomeNetPolicyTextBlock" xlink:label="alvr_OtherIncomeNetPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NewLeaseAgreementWithBpBayColonyLlcMember" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="us-gaap_InternalUseSoftwarePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UtilizationFeePayable" xlink:label="alvr_UtilizationFeePayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_StockAvailableForIssuanceMember" xlink:label="alvr_StockAvailableForIssuanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_ElevatebioBasecampIncMember" xlink:label="alvr_ElevatebioBasecampIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeasesTable" xlink:label="alvr_LeasesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_SubleaseWithAmagPharmaceuticalsMember" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_LeaseCommencementMonthAndYear" xlink:label="alvr_LeaseCommencementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_UnderwritingDiscountsCommissions" xlink:label="alvr_UnderwritingDiscountsCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_OptionsToPurchaseCommonStockMember" xlink:label="alvr_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="alvr-20221231.xsd#alvr_NonRefundableLicenseFeePayments" xlink:label="alvr_NonRefundableLicenseFeePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of right-of-use asset due to modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Right of Use Asset Due to Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in right of use asset due to modification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income Tax (Benefit) Expense Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in registered direct offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-commercial License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License agreement terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Permanent Difference, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, permanent differences, percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ROU asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of payroll deductions of base salary or wages</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Maximum Payroll Deductions of Base Salary or Wages</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum payroll deductions of base salary or wages.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017 percentage of limitations on net operating loss carryforwards to taxable income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Percentage Of Limitations On Net Operating Loss Carryforwards To Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of TCJA limitations on net operating loss carryforwards to taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: interest (5.00% - 8.08%)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, long term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability &#8211; long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards carryback period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Carryback Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsCarrybackPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards carryback period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of common stock under the employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under the 2020 employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserved shares of common stock for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Unvested at January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Unvested at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value of restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum earnout payments received by investors for reduction of earnout payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Earnout Payments Received by Investors For Reduction of Earnout Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum earnout payments received by investors for reduction of earnout payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents maturity period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CashAndCashEquivalentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents maturity period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_FundingArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_FundingArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_FundingArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under the 2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_WalthamLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_WalthamLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_WalthamLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Leases [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored research, collaboration and license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Collaboration And License Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Collaboration And License Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease interest percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease, weighted average discount rate, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, convertible preferred stock and stockholders' deficit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Convertible Preferred Stock And Stockholders Deficit [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 SOW Under the DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Statement of Work Under Development and Manufacturing Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two statement of work under development and manufacturing services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating estimated lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Estimated Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SaleOfStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SaleOfStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SaleOfStockOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Options vested and exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable weighted average grant date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Contract Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated exclusive license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Exclusive License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A&amp;R License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Options outstanding at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Options outstanding at January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options outstanding at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Permanent Differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, permanent differences.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum threshold percentage of eligible to receive tiered royalties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Threshold Percentage Of Eligible To Receive Tiered Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of eligible to receive tiered royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative increase in number shares reserved for issuance, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty development and manufacturing services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Development And Manufacturing Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-qualified stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research activities performing fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Activities Performing Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research activities performing fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease Modification under ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued upon conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal-use Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum paid percentage from grant award proceeds until which revenue share is payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Paid Percentage From Grant Award Proceeds Until Which Revenue Share Is Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum paid percentage of grant award proceeds until which revenue share is payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored research, collaboration and license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Collaboration And License Agreements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research, Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. current income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value: 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively;</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock available for grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Available For Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared or paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnout payment obligation for number of years from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnout Payment Obligation For Number of Years From First Commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnout payment obligation for number of years from first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second SOW Amendment under DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second S O W Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SecondSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second SOW Amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseTerminationEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseTerminationEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseTerminationEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Termination Effective Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedMilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OfferingPeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OfferingPeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OfferingPeriodDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering Period, description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, vested and exercisable, number.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for reduction of earnout payment after first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period For Reduction Of Earnout Payment After First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for reduction of earnout payment after first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, tax deferred expense, compensation and benefits, restricted stock compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Restricted Stock Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities restricted stock compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Restricted Stock Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments maturity period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments maturity period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in registered direct offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to services with related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnrealizedGainLossOnAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnrealizedGainLossOnAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnrealizedGainLossOnAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par or stated value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding - diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidUtilizationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid utilization fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidUtilizationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Utilization Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidUtilizationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid utilization fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancer research and prevention institute of Texas.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cancer Research And Prevention Institute Of Texas [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CancerResearchAndPreventionInstituteOfTexasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CPRIT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant and Equipment Estimated Useful Life [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant and Equipment Estimated Useful Life [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax rate differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidExpensesToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidExpensesToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses To Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PrepaidExpensesToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses to related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software, Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense for cloud computing arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change Order to Modify Terms of SOW under 2020 DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change Order to Modify Terms of SOW under Two Thousand Twenty DMS Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change Order to Modify Terms of SOW under 2020 DMS Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in deferred tax assets valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accured member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance, reimbursement period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance Reimbursement Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceReimbursementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance, reimbursement period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Basis of Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, valuation basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of votes per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Votes Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in registered direct offering, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, upon vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award common stock issuable upon exercise of outstanding options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Common Stock Issuable Upon Exercise Of Outstanding Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable upon exercise of outstanding options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base salary or wages</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Salary and Wage, Excluding Cost of Good and Service Sold, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholder's Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards forfeited or cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value: 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 93,268,069 and 65,170,332 shares issued at December 31, 2022 and December 31, 2021, respectively; and 93,093,243 and 63,565,886 shares outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax rate differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets leasing arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxAssetsLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options vested and exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and amount due to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BaylorCollegeOfMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Baylor College of Medicine.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BaylorCollegeOfMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Baylor College Of Medicine [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BaylorCollegeOfMedicineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BCM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AggregateResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate research activities performing fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AggregateResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Research Activities Performing Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AggregateResearchActivitiesPerformingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total research activities performing fees, over the term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevateBioAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ElevateBio and affiliates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevateBioAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Elevate Bio And Affiliates [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevateBioAndAffiliatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ElevateBio and Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Intellectual Property Transfer Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual property transfer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation intellectual property transfer amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share issued to investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income (Loss) Before Provision for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value of restricted stock granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OriginalSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original SOW Amendment under DMS Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OriginalSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Original S O W Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OriginalSOWAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Original SOW Amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, upon vesting of restricted stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable license fee payments first year through fourth anniversary of effective date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable License Fee Payments First Year Through Fourth Anniversary Of Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payments, first year through fourth anniversary of effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share issued, average price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net losses attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of individual securities with impairment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Individual Securities With Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfIndividualSecuritiesWithImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individual securities with impairments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability &#8211; current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalization of R&amp;D expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Common Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, depreciation methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax (benefit) expense:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance to be reimbursed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance To Be Reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TenantImprovementAllowanceToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance to be reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued process development and manufacturing costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Process Development and Manufacturing Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Process development and manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnout payment as percentage of net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnout Payment as Percentage of Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EarnoutPaymentAsPercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnout payment as percentage of net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement by share based payment award fair value assumptions fair value of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Fair Value of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation officer's compensation, percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Officer's Compensation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officer's compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period of cost expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life, Options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable License Fee Payments Fifth Anniversary Of Effective Date And Continuing Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss), net of tax:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of property and equipment included in account payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment included in AP and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities Operating Leases Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Accretion) amortization of short-term investment (premiums) discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease, lease term including renewal option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Term Including Renewal Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, lease term including renewal option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation officer's compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Officer's Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officer's compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, vested and exercisable, intrinsic value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life, Options vested and exercisable at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Options outstanding as of December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Options outstanding as of January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Exchange</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (loss), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reserved Shares of Common Stock for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income (loss), net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_USGovernmentTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. government treasury securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_USGovernmentTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_USGovernmentTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock option and grant plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Option And Grant Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Option and Grant Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of common stock issuable upon exercise of outstanding options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Common Stock Issuable Upon Exercise Of Outstanding Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issuable upon exercise of outstanding options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CorporateAndAgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate and Agency Bonds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CorporateAndAgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate and Agency Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_CorporateAndAgencyBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate and agency bonds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Options outstanding at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Options outstanding at January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Fund</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax (benefit) expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored research, collaboration and license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research, Collaboration and License Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development grants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Grants Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessee Operating Lease Liability Payments Due Next Twelve Months, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax (benefit) expense:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement for performing research activities term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement For Performing Research Activities Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AgreementForPerformingResearchActivitiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement for research activities, term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts of $22,238</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit at the federal rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AdditionalOneTimeLeasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional One Time Lease Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AdditionalOneTimeLeasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional one time lease period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_AdditionalOneTimeLeasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional one time lease period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested at December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested at January 1, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating estimated lease expiring month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Estimated Lease Expiring Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease expiring month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and consolidation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets and prepaid expenses to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RedumptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redumption Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RedumptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redumption Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RedumptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redumption agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OtherIncomeNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other income net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OtherIncomeNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income Net Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OtherIncomeNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (Loss), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset (liability)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum discount on purchase of shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Maximum Discount Price on Purchase of Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum discount price on purchase of shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes paid, net of refunds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset (liability)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum annual increase of common stock reserved for issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Annual Increase Of Common Stock Reserved For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual increase in number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting fees to members of management and board of directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Deferred Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Lease Agreement with BP Bay Colony LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Lease Agreement with BP Bay Colony LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NewLeaseAgreementWithBpBayColonyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Lease Agreement with BP Bay Colony LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalUseSoftwarePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cloud Computing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contributions by employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently adopted accounting pronouncements policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from purchases under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds with certain investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UtilizationFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Utilization fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UtilizationFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Utilization Fee Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UtilizationFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Utilization fee payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Available For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Available For Issuance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_StockAvailableForIssuanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Available For Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevatebioBasecampIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BaseCamp</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevatebioBasecampIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ElevateBio BaseCamp Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_ElevatebioBasecampIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ElevateBio BaseCamp, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, upon exercise of common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Business Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credit (ODC)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation intellectual property transfer, percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Intellectual Property Transfer, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual property transfer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, upon exercise of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored research agreement, collaboration agreement and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreement Collaboration Agreement And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collective Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeasesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease with AMAG Pharmaceuticals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease with AMAG Pharmaceuticals.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_SubleaseWithAmagPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease with AMAG Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscountsCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts or commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscountsCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_UnderwritingDiscountsCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss &#8211; basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amortized Cost and Estimated Fair Value of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit at the federal rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-balance sheet risk description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable license fee payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable License Fee Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alvr_NonRefundableLicenseFeePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable license fee payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares added to number of available shares under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification" xlink:to="alvr_IncreaseDecreaseInRightOfUseAssetDueToModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SecondLicenseAgreementMember" xlink:to="alvr_SecondLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages" xlink:to="alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome" xlink:to="alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OperatingLossCarryforwardsCarrybackPeriod" xlink:to="alvr_OperatingLossCarryforwardsCarrybackPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LeasesLineItems" xlink:to="alvr_LeasesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_MilestonePayments" xlink:to="alvr_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment" xlink:to="alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_CashAndCashEquivalentsMaturityPeriod" xlink:to="alvr_CashAndCashEquivalentsMaturityPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_FundingArrangementsTextBlock" xlink:to="alvr_FundingArrangementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_WalthamLeasesMember" xlink:to="alvr_WalthamLeasesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember" xlink:to="alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LesseeOperatingEstimatedLeaseTerm" xlink:to="alvr_LesseeOperatingEstimatedLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SaleOfStockOfferingCosts" xlink:to="alvr_SaleOfStockOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember" xlink:to="alvr_AmendedAndRestatedExclusiveLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_GrossProceedsFromIssuanceOfCommonStock" xlink:to="alvr_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties" xlink:to="alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NonCashLeaseExpense" xlink:to="alvr_NonCashLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember" xlink:to="alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ResearchActivitiesPerformingFees" xlink:to="alvr_ResearchActivitiesPerformingFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SecuritiesPurchaseAgreementMember" xlink:to="alvr_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OptionToPurchaseCommonStockMember" xlink:to="alvr_OptionToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable" xlink:to="alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LeaseExpirationMonthAndYear" xlink:to="alvr_LeaseExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_StockAvailableForGrantMember" xlink:to="alvr_StockAvailableForGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCash" xlink:to="us-gaap_DividendsCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DeferredOfferingCostsPolicyTextBlock" xlink:to="alvr_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale" xlink:to="alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SecondSOWAmendmentMember" xlink:to="alvr_SecondSOWAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LeaseTerminationEffectiveDate" xlink:to="alvr_LeaseTerminationEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedMilestoneExpenses" xlink:to="alvr_AccruedMilestoneExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OfferingPeriodDescription" xlink:to="alvr_OfferingPeriodDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale" xlink:to="alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation" xlink:to="alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation" xlink:to="alvr_DeferredTaxLiabilitiesRestrictedStockCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_UnderwritingDiscounts" xlink:to="alvr_UnderwritingDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShortTermInvestmentsMaturityPeriod" xlink:to="alvr_ShortTermInvestmentsMaturityPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_UnrealizedGainLossOnAvailableForSaleSecurities" xlink:to="alvr_UnrealizedGainLossOnAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DevelopmentAndManufacturingServicesAgreementMember" xlink:to="alvr_DevelopmentAndManufacturingServicesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PrepaidUtilizationFee" xlink:to="alvr_PrepaidUtilizationFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_CancerResearchAndPreventionInstituteOfTexasMember" xlink:to="alvr_CancerResearchAndPreventionInstituteOfTexasMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PrepaidExpensesToRelatedParty" xlink:to="alvr_PrepaidExpensesToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember" xlink:to="alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedExpensesMember" xlink:to="alvr_AccruedExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TenantImprovementAllowanceReimbursementPeriod" xlink:to="alvr_TenantImprovementAllowanceReimbursementPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NumberOfVotesPerShare" xlink:to="alvr_NumberOfVotesPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_IncomeTaxesLineItems" xlink:to="alvr_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TaxCreditCarryforwardExpirationYear" xlink:to="alvr_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DeferredTaxAssetsLeasingArrangements" xlink:to="alvr_DeferredTaxAssetsLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedLiabilitiesDisclosureTextBlock" xlink:to="alvr_AccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_BaylorCollegeOfMedicineMember" xlink:to="alvr_BaylorCollegeOfMedicineMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AggregateResearchActivitiesPerformingFees" xlink:to="alvr_AggregateResearchActivitiesPerformingFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ElevateBioAndAffiliatesMember" xlink:to="alvr_ElevateBioAndAffiliatesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="alvr_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OriginalSOWAmendmentMember" xlink:to="alvr_OriginalSOWAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate" xlink:to="alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NumberOfIndividualSecuritiesWithImpairment" xlink:to="alvr_NumberOfIndividualSecuritiesWithImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShortTermInvestmentsPolicyTextBlock" xlink:to="alvr_ShortTermInvestmentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TenantImprovementAllowanceToBeReimbursed" xlink:to="alvr_TenantImprovementAllowanceToBeReimbursed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OperatingLossCarryforwardsExpirationYear" xlink:to="alvr_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent" xlink:to="alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EarnoutPaymentAsPercentageOfNetSales" xlink:to="alvr_EarnoutPaymentAsPercentageOfNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_IncomeTaxesTable" xlink:to="alvr_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter" xlink:to="alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:to="alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_UnvestedRestrictedStockMember" xlink:to="alvr_UnvestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption" xlink:to="alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AccruedResearchAndDevelopmentCurrent" xlink:to="alvr_AccruedResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_USGovernmentTreasurySecuritiesMember" xlink:to="alvr_USGovernmentTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember" xlink:to="alvr_TwoThousandTwentyStockOptionAndGrantPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions" xlink:to="alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alvr_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LaboratoryEquipmentMember" xlink:to="alvr_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_CorporateAndAgencyBondsMember" xlink:to="alvr_CorporateAndAgencyBondsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_DeferredTaxLiabilitiesDepreciation" xlink:to="alvr_DeferredTaxLiabilitiesDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ResearchCollaborationAgreementMember" xlink:to="alvr_ResearchCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock" xlink:to="alvr_ResearchAndDevelopmentGrantsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AgreementForPerformingResearchActivitiesTerm" xlink:to="alvr_AgreementForPerformingResearchActivitiesTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_AdditionalOneTimeLeasePeriod" xlink:to="alvr_AdditionalOneTimeLeasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear" xlink:to="alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:to="alvr_BasisOfPresentationAndConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_RedumptionAgreementMember" xlink:to="alvr_RedumptionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OtherIncomeNetPolicyTextBlock" xlink:to="alvr_OtherIncomeNetPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock" xlink:to="alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance" xlink:to="alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NewLeaseAgreementWithBpBayColonyLlcMember" xlink:to="alvr_NewLeaseAgreementWithBpBayColonyLlcMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalUseSoftwarePolicy" xlink:to="us-gaap_InternalUseSoftwarePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_UtilizationFeePayable" xlink:to="alvr_UtilizationFeePayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_StockAvailableForIssuanceMember" xlink:to="alvr_StockAvailableForIssuanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_ElevatebioBasecampIncMember" xlink:to="alvr_ElevatebioBasecampIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent" xlink:to="alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember" xlink:to="alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LeasesTable" xlink:to="alvr_LeasesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_SubleaseWithAmagPharmaceuticalsMember" xlink:to="alvr_SubleaseWithAmagPharmaceuticalsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_LeaseCommencementMonthAndYear" xlink:to="alvr_LeaseCommencementMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_UnderwritingDiscountsCommissions" xlink:to="alvr_UnderwritingDiscountsCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_OptionsToPurchaseCommonStockMember" xlink:to="alvr_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alvr_NonRefundableLicenseFeePayments" xlink:to="alvr_NonRefundableLicenseFeePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024135138464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALVR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALLOVIR, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001754068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,463,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1971007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">1100 Winter Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">433-2605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the Proxy Statement for the registrant&#8217;s </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Annual Meeting of Stockholders, or the Proxy Statement, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#8217;s fiscal year end of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, MA, USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134701600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 106,092<span></span>
</td>
<td class="nump">$ 201,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">127,703<span></span>
</td>
<td class="nump">46,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">5,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PrepaidExpensesToRelatedParty', window );">Prepaid expenses to related party</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">243,052<span></span>
</td>
<td class="nump">253,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">31,633<span></span>
</td>
<td class="nump">29,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">277,079<span></span>
</td>
<td class="nump">286,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,004<span></span>
</td>
<td class="nump">8,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">20,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">7,165<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,338<span></span>
</td>
<td class="nump">37,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long term</a></td>
<td class="nump">28,222<span></span>
</td>
<td class="nump">23,475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,560<span></span>
</td>
<td class="nump">61,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively;</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 93,268,069 and 65,170,332 shares issued at December 31, 2022 and December 31, 2021, respectively; and 93,093,243 and 63,565,886 shares outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">690,753<span></span>
</td>
<td class="nump">522,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(468)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(465,775)<span></span>
</td>
<td class="num">(297,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">224,519<span></span>
</td>
<td class="nump">225,266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 277,079<span></span>
</td>
<td class="nump">$ 286,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PrepaidExpensesToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PrepaidExpensesToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137557312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">93,268,069<span></span>
</td>
<td class="nump">65,170,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">93,093,243<span></span>
</td>
<td class="nump">63,565,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134570704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 118,870<span></span>
</td>
<td class="nump">$ 120,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">52,332<span></span>
</td>
<td class="nump">49,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">171,202<span></span>
</td>
<td class="nump">169,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(171,202)<span></span>
</td>
<td class="num">(169,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Total other income (loss), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,876<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (loss), net</a></td>
<td class="nump">351<span></span>
</td>
<td class="num">(2,452)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(168,975)<span></span>
</td>
<td class="num">(170,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(265)<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (168,710)<span></span>
</td>
<td class="num">$ (171,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">76,654,856<span></span>
</td>
<td class="nump">62,782,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">76,654,856<span></span>
</td>
<td class="nump">62,782,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (168,710)<span></span>
</td>
<td class="num">$ (171,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(313)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (169,023)<span></span>
</td>
<td class="num">$ (172,005)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024133684864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 353,064<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 478,272<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
<td class="num">$ (125,103)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,931,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock, upon vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, upon exercise of common stock</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, upon exercise of common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(171,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">225,266<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">522,479<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(297,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,565,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">41,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock, upon vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,912,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under the 2020 employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in registered direct offering, net of issuance costs</a></td>
<td class="nump">126,425<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">126,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in registered direct offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,458,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(168,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168,710)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 224,519<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 690,753<span></span>
</td>
<td class="num">$ (468)<span></span>
</td>
<td class="num">$ (465,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,093,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139425872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131079104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (168,710)<span></span>
</td>
<td class="num">$ (171,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion) amortization of short-term investment (premiums) discounts</a></td>
<td class="num">(1,076)<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">41,315<span></span>
</td>
<td class="nump">43,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(107)<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets and prepaid expenses to related party</a></td>
<td class="num">(3,028)<span></span>
</td>
<td class="num">(1,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">490<span></span>
</td>
<td class="num">(1,102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Income tax payable</a></td>
<td class="num">(879)<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and amount due to related party</a></td>
<td class="num">(12,622)<span></span>
</td>
<td class="nump">20,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(142,052)<span></span>
</td>
<td class="num">(106,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of short-term investments</a></td>
<td class="num">(228,806)<span></span>
</td>
<td class="num">(76,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="nump">148,328<span></span>
</td>
<td class="nump">262,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(80,478)<span></span>
</td>
<td class="nump">185,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in registered direct offering, net of issuance costs</a></td>
<td class="nump">126,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">126,961<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(95,569)<span></span>
</td>
<td class="nump">79,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">202,513<span></span>
</td>
<td class="nump">122,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">106,944<span></span>
</td>
<td class="nump">202,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_UnrealizedGainLossOnAvailableForSaleSecurities', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liability</a></td>
<td class="nump">14,717<span></span>
</td>
<td class="nump">26,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncreaseDecreaseInRightOfUseAssetDueToModification', window );">Reduction of right-of-use asset due to modification</a></td>
<td class="num">(5,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses', window );">Purchase of property and equipment included in AP and accrued expenses</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net of refunds</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">106,092<span></span>
</td>
<td class="nump">201,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 106,944<span></span>
</td>
<td class="nump">$ 202,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_IncreaseDecreaseInRightOfUseAssetDueToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in right of use asset due to modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_IncreaseDecreaseInRightOfUseAssetDueToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of property and equipment included in account payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_UnrealizedGainLossOnAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain (loss) on available-for-sale securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_UnrealizedGainLossOnAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137534576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of the Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AlloVir, Inc. (&#8220;AlloVir&#8221; or &#8220;the Company&#8221;, formerly known as ViraCyte, Inc.) is a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. The Company&#8217;s innovative and proprietary virus-specific T cell, or VST, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. The Company is developing three innovative, allogeneic, off-the-shelf VST therapy candidates targeting 11 different devastating viruses. The Company's lead product, posoleucel (previously referred to as Viralym-M or ALVR105), is a multi-VST therapy that targets six viruses: adenovirus, or AdV, BK virus, or BKV, cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, human herpesvirus 6, or HHV-6 and JC virus, or JCV. The Company believes that posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Posoleucel is being studied in three ongoing Phase 3 registrational trials for 3 distinct indications - the prevention of clinically significant infections from multiple viruses, the treatment of virus-associated hemorrhagic cystitis, or HC, and the treatment of AdV infections &#8211; all in allogeneic hematopoietic cell transplant, or HCT, patients who are at high risk for life-threatening viral infections from the six viruses targeted by posoleucel. We have successfully accelerated the multi-prevention study in recognition of the fact that prevention best addresses patients&#8217; unmet medical needs. The three Phase 3 studies are expected to complete enrollment by the end of 2023, enabling potential data readouts from all three trials in 2024. In addition to the ongoing Phase 3 registrational studies, posoleucel has been studied in a Phase 2 proof-of-concept study for the treatment of BK viremia in kidney transplant patients. Positive topline results of this study were released in February 2023. This is the first study of posoleucel in SOT patients, and the results of this trial will inform next steps for this potential indication as well as the company&#8217;s broader SOT strategy.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s pipeline includes additional investigational VST therapies that may benefit high-risk individuals. ALVR106 is the Company&#8217;s second off-the-shelf, multi-VST product candidate targeting devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV and respiratory syncytial virus, or RSV. A Phase 1b/2 POC clinical study of ALVR106 is enrolling patients in the U.S. In the preclinical space, the Company is developing ALVR107 to treat hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infection. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study after completion of the posoleucel Phase 3 registrational studies. ALVR109 is an allogeneic, off-the-shelf, single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. Data from the POC clinical trial of ALVR109 were reported in 2021, and positive reports of ALVR109 compassionate use in immune-compromised patients also have been published and presented, including poster presentations at the 2022 American Transplant Congress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company was formed on August 16, 2013 as a Delaware limited liability company (&#8220;LLC&#8221;), under the name AdCyte LLC and on July 29, 2014 the Company changed its name to ViraCyte LLC. On September 17, 2018, the Company converted from a Delaware LLC to a Delaware corporation (&#8220;LLC Conversion&#8221;) and changed its name to ViraCyte, Inc. On May 22, 2019, the Company changed its name to AlloVir, Inc. The Company has principal offices in Waltham, Massachusetts, Houston, Texas and Dublin, Ireland.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 8, 2019, AlloVir formed AlloVir International Designated Activity Company (&#8220;AlloVir International&#8221;), a wholly-owned subsidiary established in Ireland.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 9, 2019, AlloVir Securities Corporation was incorporated as a Massachusetts Security Corporation, a wholly-owned subsidiary of AlloVir.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 10, 2019, AlloVir International formed AlloVir Italia S.R.L., a wholly-owned subsidiary in Italy.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2021, AlloVir Inc. formed AlloVir U.S., Inc., a wholly-owned subsidiary of AlloVir.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, the Company completed an initial public offering (&#8220;IPO&#8221;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,687,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">317.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">292.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and offering costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,859,139</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of convertible preferred stock outstanding.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2022, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain investors for the issuance and sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,458,095</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ElevateBio, LLC</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On September 17, 2018, the Company executed a Series A2 Preferred Stock Purchase Agreement ("Series A2 Agreement"), with ElevateBio, LLC ("ElevateBio") and ElevateBio was a purchaser in our registered direct offering in July 2022. ElevateBio, through its diverse platform of technologies to support cell and gene therapy products and expertise, provides drug development and manufacturing services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of ElevateBio&#8217;s purchase of our Series A2 Preferred Stock, which converted to common stock upon completion of our IPO, and as a result of ElevateBio&#8217;s participation in the July 2022 registered direct offering, ElevateBio acquired an ownership interest in the Company. The Chief Financial Officer of ElevateBio currently serves in a similar management role with AlloVir. In May 2021, Diana M. Brainard M.D. succeeded David Hallal, ElevateBio&#8217;s Chief Executive Officer, as the Company&#8217;s Chief Executive Officer. Mr. Hallal currently serves as Executive Chairman of the Company's board of directors. In addition to Mr. Hallal and Mr. Sinha, two other members of the Company's board of directors, Morana Jovan-Embiricos and Ansbert Gadicke, also serve as directors of the board of directors of ElevateBio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">           </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2022, the Company has funded its operations primarily with proceeds received from the sale of common stock, research grants, and from the sale of preferred stock. The Company has incurred recurring losses since its inception, including net losses attributable to common stockholders of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">172.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. In addition, at December 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">465.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes that its $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">233.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of cash, cash equivalents and short-term investments held at December 31, 2022, is sufficient to fund planned operations for at least twelve months from the date that these consolidated financial statements are available to be issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 Considerations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development of product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the recent COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted the Company&#8217;s operations, including the interruption of preclinical and clinical trial activities and potential interruption to the Company&#8217;s supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay the Company&#8217;s ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay the Company&#8217;s ability to obtain regulatory approval and commercialize product candidates. Furthermore, COVID-19 could affect the Company&#8217;s employees or the employees of research sites and service providers on whom the Company relies on as well as those of companies with which the Company does business, including suppliers and CMOs, thereby disrupting business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which the Company and the companies with which it does business operate could materially impact</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. For the health and safety of our employees, the Company has implemented work-at-home policies and we have generally restricted on site staff to only those employees who are fully vaccinated or essential to the development and research of product candidates; accordingly, the Company may experience limitations in employee resources. The outbreak and any other preventative or protective actions that the Company, its suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay or otherwise adversely impact the business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is still assessing business plans and the impact the COVID-19 pandemic may have on its ability to advance the testing, development and manufacturing of drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom the Company relies on, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or this sector in particular. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies on or with whom it conducts business, were to experience shutdowns or other business disruptions, the Company&#8217;s ability to conduct business in the manner and on the timelines presently planned could be materially and adversely impacted.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139187520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the Company&#8217;s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#8217;s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents are short-term, highly liquid investments with original maturities of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net".</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> individual securities with impairments at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#8217;s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records property and equipment at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.18%;"/>
          <td style="width:4.918%;"/>
          <td style="width:45.902%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for long-lived assets in accordance with ASC Topic 360, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 360&#8221;). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognized any impairment losses during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#8211; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#8211; Valuations based on inputs that are unobservable and significant to the overall fair value measurement. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company&#8217;s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> deferred offering costs.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cloud Computing Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is  a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Loss), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records interest expense, investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in &#8220;other income (loss), net&#8221; over the same period in which the qualifying costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants restricted stock and stock options to employees, consultants and directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee&#8217;s payroll costs are classified or in which the grantee&#8217;s service payments are classified. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black&#8209;Scholes option pricing model. As there was no public market for the Company&#8217;s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company&#8217;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Privately Held Company Equity Securities Issued as Compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Following the closing of the initial public offering, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#8209;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method. The &#8220;simplified&#8221; method estimates the expected term of stock options as the mid&#8209;point between the weighted average time to vesting and the contractual maturity. The risk&#8209;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is determined by dividing net loss by the weighted&#8209;average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti&#8209;dilutive. Therefore, the weighted&#8209;average shares used to calculate both basic and diluted loss per share are the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no off-balance sheet risk.</span></span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Exchange</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of certain intercompany transactions in September 2021, the Company determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (&#8220;USD&#8221;) during the year ended December 31, 2021. Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of operations and comprehensive loss.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder&#8217;s deficit that are excluded from net loss. The Company's comprehensive loss includes unrealized gains (losses) on available-for-sale securities during the year ended December 31, 2022 and 2021 and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia during the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (&#8220;ROU&#8221;) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. Options to renew or options to cancel a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 16 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139172432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the amortized cost and estimated fair value of the Company&#8217;s U.S. government treasury securities and marketable securities, which are considered to be available-for-sale investments and are included in short-term investments on the consolidated balance sheets:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.595%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.972000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.972000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.177000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.372%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">337</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,092</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,568</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,821</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain short-term debt securities with original maturities of less than three months are included in cash and cash equivalents on the consolidated balance sheets and are not included in the tables above. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, all investments had contractual maturities within one year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139300400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.396%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.396%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,751</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,129</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, there were no transfers between levels. The Company classifies its money market fund and U.S. government treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its marketable securities (corporate and agency bonds and commercial paper) as Level 2 assets under the fair value hierarchy, as these assets have pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of prepaid expenses and other current assets, prepaid expenses to related party, accounts payable, amount due to related party and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139227600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">       Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company uses an incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate represents the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company estimates this rate based on prevailing market conditions, comparable company and credit analysis, the impact of collateralization, and the term of each of the Company&#8217;s lease agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DMS Agreement with Third-Party Supplier</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2019, the Company entered into an interim services agreement which ultimately led to a Development and Manufacturing Services Agreement ("DMS Agreement") with a third-party supplier in July 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The DMS Agreement specifies a dedicated manufacturing suite for the manufacture of AlloVir&#8217;s products at the facility. The DMS Agreement initially expired upon the later of (1) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and (2) the completion of services under all statements of work (&#8220;SOWs&#8221;). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective June 2022, the Company entered into a First Amendment to the DMS Agreement to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the expiration date to June 2024 provided that the terms and conditions of the DMS Agreement will continue to apply to any active SOW's. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DMS Agreement (or any individual SOW) may be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminated</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> earlier by AlloVir at any time by providing 190 days&#8217; notice.</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In March 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over a total estimated lease term of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In September 2019, the Company executed a SOW for another dedicated manufacturing suite under the DMS Agreement with substantially the same terms as the original SOW. In September 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over a total estimated lease term of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The SOW calls for a fixed monthly payment through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options.  The use of these manufacturing suites qualifies as a lease under ASC 842, as it includes an identified asset for exclusive use by the Company at its direction.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company entered into amendments to both SOWs under the DMS Agreement. The original SOW under the DMS Agreement (beginning March 2019) was modified to add a new termination clause whereby the Company can terminate the lease upon entering into a contract for another suite at the facility. Management concluded that the SOW amendment constituted a lease modification under ASC 842 and recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset and lease liability in February 2022. The original SOW under the DMS Agreement was terminated in October 2022 upon execution of the new 2022 SOW under the DMS Agreement. The second SOW under the DMS agreement (beginning September 2019) was terminated as of the effective date of the amendment in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As a result of the amendment, which also represented a lease modification under ASC 842, the Company recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset and lease liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, the Company entered into a new SOW under the DMS Agreement ("2022 SOW under the DMS Agreement") with a third-party supplier. The 2022 SOW under the DMS Agreement contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#8217;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, fixed batch payments and other related fixed costs, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.25</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> year lease term ending in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, testing, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lease </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and commenced in October 2022, the point at which the suite was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 DMS Agreement with BaseCamp</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into a new Development and Manufacturing Services Agreement (&#8220;2020 DMS Agreement&#8221;) with ElevateBio BaseCamp, Inc. ("BaseCamp") and signed a SOW in November 2020. The 2020 DMS Agreement and related SOW contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#8217;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, and other related fixed costs, totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease term (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease with a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal option), that covers costs associated with reserving capacity for AlloVir, as well as cleaning services, utilities, handling and maintenance of the manufacturing suite. At inception of the lease, the Company estimated that the exercise of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal option was reasonably certain to occur, and the Company was reasonably certain that it would not exercise its early termination right, providing for a total estimated lease term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expiring in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating lease and commenced in February 2021, the point at which the new facility area was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and a lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company prepaid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the suite utilization fee, which was reclassified from prepaid expense to the ROU asset upon lease commencement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, the Company decided not to exercise the one-year renewal option and subsequently executed a Change Order to modify the terms of the SOW under the 2020 DMS Agreement. Management concluded that the amendments laid out in the change order collectively constituted a lease remeasurement under ASC 842 and recorded a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related lease liability and a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million reduction to the related ROU asset.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Waltham Leases</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2021, the Company entered into a new lease agreement with BP Bay Colony LLC and a sublease with AMAG Pharmaceuticals Inc. for the lease of property in Waltham, Massachusetts (collectively, the "Waltham leases"). The space identified under the Waltham leases is intended for general office space, research and development, laboratory use, and light manufacturing. The Waltham leases have been classified as operating leases and commenced in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the inception date, the Company has recorded an ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million for the lease and a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the sublease based on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 30, 2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> end date for the Waltham leases. As part of the arrangement, there were also variable costs for common area maintenance fees that were not included in the measurement of the lease. The agreement also provides a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million tenant improvement allowance which is to be reimbursed by the landlord over the duration of the first </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Waltham leases. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the tenant improvement allowance has been used. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">option to renew the leased space</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for an additional one time period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with written notice from the Company. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has no reasonable certainty that this option to extend will be exercised.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.231%;"/>
        <td style="width:1.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.824%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,683</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,818</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#8211; current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,165</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#8211; long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. Cash paid for operating leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The Company&#8217;s total variable lease costs, such as materials, non-fixed batch payments, testing, storage, knowledge and tech transfer, and other common area</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintenance fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, related to the operating leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average remaining lease term is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.93</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The weighted average discount rate is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140711744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.383%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.513%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.397%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,830</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140725152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,416</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">559</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">504</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,685</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">828</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,985</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139422352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sponsored Research, Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock', window );">Sponsored Research, Collaboration and License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Sponsored Research, Collaboration and License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2017, the Company signed a License Agreement (the &#8220;License Agreement&#8221;) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#8217;s rights in Subject Technology and related patent rights in the field of viral infection. In May 2020, the Company amended and restated the License Agreement (the &#8220;A&amp;R License Agreement&#8221;), pursuant to which the Company obtained (a) an exclusive worldwide license, with the right to sublicense, under certain patent rights and other intellectual property rights of BCM, to make, have made, use, market, sell, offer to sell, lease, import and export products in a particular field, except that such license is non-exclusive within a particular subfield, and in addition with respect to certain patent rights such license is limited to two particular subfields, and (b) an exclusive, worldwide sublicense, with the right to further sublicense, under all patent rights and other intellectual property rights that are exclusively licensed to BCM by a certain third party licensor, to make, have made, use, market, sell, offer to sell, lease, import and export products in the same field. The Company&#8217;s rights are subject to the rights of the U.S. government and certain rights retained by BCM.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the A&amp;R License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country. The Company may terminate the A&amp;R License Agreement in its entirety at any time for convenience upon a certain number of days&#8217; written notice. BCM may terminate the A&amp;R License Agreement in its entirety for the Company&#8217;s uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BCM maintains control of all filing, prosecution and maintenance of its patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the agreement. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the agreement with respect to the filing,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prosecution and maintenance of the patent rights licensed by the Company. If BCM licenses the patent rights licensed by the Company to third parties for additional fields of use, the Company&#8217;s responsibility for patent related costs and expenses will be reduced on a pro-rata basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the A&amp;R License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the original agreement executed in June 2017, the Company paid BCM a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the term of the A&amp;R License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee, but beginning with the fifth year after the original agreement date, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize a product under the A&amp;R License Agreement, total milestone payments could exceed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the A&amp;R License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company also entered into the First Amendment (the &#8220;License Amendment&#8221;) to the A&amp;R License Agreement. Under the License Amendment, the Company assumed responsibility from BCM for the filing, prosecution and maintenance of the patent rights licensed by the Company from BCM under the A&amp;R License Agreement that are in common with the License Agreement. Further, BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in such patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company signed a second License Agreement (the &#8220;Second License Agreement) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#8217;s rights in Subject Technology and related patent rights outside the field of viral infection (all fields other than those covered by the A&amp;R License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, the Second License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country, provided that the Second License Agreement shall not expire later than March 25, 2040. The Company may terminate the Second License Agreement in its entirety at any time for convenience upon a certain number of days&#8217; written notice. BCM may terminate the Second License Agreement in its entirety for the Company&#8217;s uncured material default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, BCM transferred to the Company control of all filing, prosecution and maintenance of the patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the Second License Agreement. BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in the patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the Second License Agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by the Company, to the extent not already paid by the Company under the A&amp;R License Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Second License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the Second License Agreement, the Company paid BCM a non-refundable license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the term of the Second License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee of (a) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the first through fourth anniversary of the effective date of the Second License Agreement, and (b) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the fifth anniversary of the effective date and continuing thereafter, but beginning with the fifth year, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize multiple products under the Second License Agreement, total milestone payments could exceed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the Second License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreement with BCM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into a Research Collaboration Agreement (the &#8220;Research Agreement&#8221;) with BCM, under which the Company agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021 and continuing for a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period thereafter. The Research Agreement requires the Company to make payments to BCM totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per year, for a total of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over the term of the Research Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collectively under the agreements above and for services provided by BCM the Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively, and the payments were classified in research and development expense in the consolidated statements of operations and comprehensive loss. As of December 31, 2022, and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in accrued milestone expenses are recorded under accrued expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the consolidated balance sheet.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CPRIT Grant</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2017, the Company was awarded a grant (the &#8220;CPRIT Grant&#8221;) from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;). The CPRIT Grant required that the Company grant CPRIT a non-commercial license to technology developed under the grant and pay CPRIT a share of revenue on sales of commercial products developed using CPRIT funds equal to low single digits of revenue until such time as CPRIT has been paid an aggregate amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the grant award proceeds.  </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> royalty payments were made under this license agreement during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Redeemable Preferred Stock Redemption Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company entered into a redeemable preferred stock redemption agreement, or Redemption Agreement, to redeem shares of our Series A1 convertible preferred stock held by certain investors, including executive officer Ann Leen, director and former executive officer Juan Vera and entities affiliated with director, Malcolm Brenner and former director, John Wilson (or their affiliates). Pursuant to the Redemption Agreement, for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of the first commercial sale of Viralym-M, the Company is obligated to make earnout payments to such investors on at least an annual basis. The earnout payments will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of net sales of Viralym-M, which number will be reduced to a high single-digit percentage if certain events occur. Specifically, royalties due to third parties for the sale of Viralym-M are subtracted from the earnout payments due to the investors. Further, if the investors receive at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in earnout payments from AlloVir during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period after the first commercial sale of Viralym-M, the earnout payment percentage will be reduced.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsored research, collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140034528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Stockholder&#8217;s Equity</span><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 3, 2020, in connection with the closing of the Company&#8217;s IPO, the Company filed its amended and restated certificate of incorporation, which authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value per share. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of preferred stock issued or outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a par value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 26, 2022, the Company entered into the Securities Purchase Agreement with certain investors for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors in a registered direct offering an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,458,095</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company's common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share (the "Shares") at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per Share (the "Offering"). The Offering was made without an underwriter or a placement agent, and therefore, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> underwriting discounts or commissions in connection with the offering.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following is a summary of the rights and privileges of the holders of the Company&#8217;s common stock at December 31, 2022 and 2021:</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Rights</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The holders of the common stock are entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.</span></span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dividends</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cash dividends have been declared or paid.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidation Preference</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the then-outstanding shares of preferred stock.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rights and Preferences</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.772%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.741%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.144%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for grant under the 2020 Stock Option and Grant Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,253,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,812,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for issuance under the 2020 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">454,302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">611,354</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,869,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,445,714</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024138964576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,014</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,343</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s 2018 Plan provided for the Company to issue restricted stock, restricted stock units, incentive stock options, and non-statutory stock options and other stock-based awards to employees, officers, members of the Board, consultants and advisors of the Company. The 2018 Plan was most recently amended in July 2020. The awards granted under this plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contractual term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had granted </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,715,415</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock under the 2018 Plan. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,042</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options under the 2018 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,616,772</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock granted under the 2018 plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares remain available for future issuance under the 2018 Plan. Any options or awards outstanding under the 2018 Plan remain outstanding and effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Stock Option and Grant Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 2, 2020, the Company&#8217;s Board of Directors adopted and in July 2020 the stockholders approved the 2020 Stock Option and Grant Plan (the &#8220;2020 Plan&#8221;) which became effective on July 28, 2020, the date immediately prior to the date on which the registration statement related to the IPO was declared effective, and as a result no further awards were made under the 2018 Plan thereafter. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,008,734</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. The number of shares of our common stock reserved for issuance under the 2020 Plan shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. Accordingly, on January 1, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,528,817</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were added to the number of available shares under the 2020 Plan. The awards granted under this plan generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period and have a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> contractual term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there were an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,858,755</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,076,516</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of restricted common stock granted under the 2020 Plan. There is an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,253,680</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Common Stock</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted common stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.112%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.084999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,632,996</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">348,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,912,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation cost related to the restricted stock, which is expected to be recognized over a weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.54</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.350000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.35%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.372%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.316%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.535%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,051,906</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.48</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,284,164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,945,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of options exercised were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted average grant-date fair value of stock options granted during the year ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.76</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. The weighted average grant date fair value of options vested was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively. At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to unvested stock options, which is being recognized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.20</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.07</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.06</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;) was adopted by the Board of Directors and approved by the stockholders. The purpose of the 2020 ESPP is to provide eligible employees of the Company and other designated companies, with opportunities to purchase shares of the Company&#8217;s common stock, par value $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initially, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">611,354</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock in the aggregate were approved and reserved for this purpose. The number of shares of common stock reserved and available for issuance under the 2020 ESPP shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by the least of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,222,707</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such number of shares of common stock as determined by the Administrator. The Board of Directors elected not to increase the number of available shares as of January 1, 2021 and 2022. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">454,302</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares reserved for future issuance under the ESPP.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP allows eligible employees to authorize payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their base salary or wages up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Market </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) on the first trading day of the offering period or (ii) the last day of any offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares and compensation expense is recognized over the offering period.  The first ESPP offering period was shortened in duration to three months and commenced on April 1, 2022 and ended on June 30, 2022. New six-month offering periods will commence each January 1 and July 1 thereafter during the term of the plan, with the administrator having the right to establish different offering periods.</span></span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#8217;s shares at the discounted price. The Company makes no contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering period, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#8217;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,052</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> common shares under the ESPP during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at an average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Cash received from purchases under the ESPP for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of compensation expense for the ESPP during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139266576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Income Taxes</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.144%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.037%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.231%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,045</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,586</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,955</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provision for income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.185%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.516%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.709999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s income tax (benefit) expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.492%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.225%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.602%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit at the federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,901</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase (decrease) resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,603</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property transfer</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,540</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Officer's compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">695</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,069</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, the Company began applying the requirement to capitalize U.S. research and development expenses in the period incurred, as required by the Tax Cuts and Job Act of 2017. During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company transferred intellectual property rights between tax jurisdictions, resulting in a deferred tax benefit on the basis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difference </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in our intangible assets.  The additional deferred tax asset was offset by valuation allowance, resulting in no net impact to deferred tax expense (benefit).  The transfer of intellectual property rights generated U.S. current income tax expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after utilization of net operating loss and tax credit carryforwards.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of deferred income taxes consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,374</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,537</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-qualified stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalization of R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,661</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,419</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,791</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,419</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At December 31, 2022 and 2021, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying consolidated balance sheets. For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which was principally due to net operating losses, tax credits, tax basis generated from the intellectual property transfer, and U.S. research and development expense capitalization.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal net operating loss carryforwards have no expiration. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_fb8a9d38-01ce-4a93-beea-aee65bc7b04d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior tax years.  In addition, net operating losses generated in these years could fully offset prior year taxable income without the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the taxable income limitation under the TCJA which was enacted on December 22, 2017.  Given that the Company utilized a substantial portion of its net operating losses in 2021, is expected to utilize all remaining net operating losses in 2022, the net operating loss carryback provisions under the CARES Act are not applicable to the Company.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused state net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The state net operating loss carryforwards expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had unused foreign net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The foreign net operating loss carryforwards have no expiration.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development tax credit carryforwards that may be available to offset future federal income taxes through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2040</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Additionally, at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had a federal orphan drug credit (ODC) carryforward related to qualifying research of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that will begin to expire</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2041</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company also had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of research and development tax credit carryforwards that may be available to offset future state income taxes in the state of Massachusetts through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of net operating loss and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax expense, respectively. The Company has completed several financings since its inception which may result in a change of control as defined in Section 382 of the Internal Revenue Code or could result in a change in control in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> uncertain tax positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accruals for interest and penalties at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for the tax years December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as the Company was incorporated in September 2018. There are currently no federal, state or foreign income tax audits in progress. The resolution of tax matters is not expected to have a material effect on the Company's consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139228832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Net Loss per Share</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.745%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.351000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.674%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.545%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,710</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171,962</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,654,856</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,782,126</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the amounts outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.485%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.319%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.721999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139320704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Company entered into a lease agreement and a sublease agreement for the lease of property in Waltham, Massachusetts (see Note 5). The Company also leases an office space in Houston, Texas under an operating lease which will be terminated effective </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and an office space in Dublin, Ireland under an operating lease that expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. At December 31, 2022, there were no matters which would have a material impact on the Company&#8217;s financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and testing and manufacturing services, which can contain purchase commitments or other noncancelable obligations. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of services provided up to one year after the date of cancellation. The amount and timing of such payments are not known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or we may be required to make royalty payments under license and grant agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time (see Note 8).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139410400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company entered into a Management and Administrative Services Agreement with ElevateBio Technologies, Inc. that provides for ongoing services to the Company in areas such as information technology, human resources and administration management, and facilities. The Company is billed monthly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2020, the Company entered into the 2020 DMS Agreement with BaseCamp pursuant to which BaseCamp provides products and services that are used in the Company's laboratory operations, including consulting services, project management services, quality control services and cGMP drug product manufacturing (see Note 5).</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, the Company made a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million prepayment to BaseCamp for future services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">year ended December 31, 2022 and 2021, respectively, related to services provided to the Company by ElevateBio and affiliates. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company owed ElevateBio and affiliates $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively and had prepaid expenses with ElevateBio and affiliates of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Members of the Company&#8217;s management and board of directors received consulting fees totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139232416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. Employee Benefit Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company made matching contributions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139286992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the financial statements at December 31, 2022 and for the year then ended, the Company has evaluated all subsequent events through February 15, 2023, the date the consolidated financial statements were available to be issued, noting there were no events or matters identified that require additional disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131248400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_BasisOfPresentationAndConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements include the Company&#8217;s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> operating segment. The Company&#8217;s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#8217;s long-lived assets are held in the United States.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents are short-term, highly liquid investments with original maturities of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net".</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> individual securities with impairments at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#8217;s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records property and equipment at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.18%;"/>
          <td style="width:4.918%;"/>
          <td style="width:45.902%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for long-lived assets in accordance with ASC Topic 360, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property, Plant, and Equipment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;ASC 360&#8221;). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognized any impairment losses during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1 &#8211; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2 &#8211; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3 &#8211; Valuations based on inputs that are unobservable and significant to the overall fair value measurement. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company&#8217;s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. At December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> deferred offering costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Cloud Computing Arrangements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cloud Computing Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is  a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_OtherIncomeNetPolicyTextBlock', window );">Other Income (Loss), Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Loss), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records interest expense, investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in &#8220;other income (loss), net&#8221; over the same period in which the qualifying costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants restricted stock and stock options to employees, consultants and directors.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee&#8217;s payroll costs are classified or in which the grantee&#8217;s service payments are classified. Forfeitures are accounted for as they occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black&#8209;Scholes option pricing model. As there was no public market for the Company&#8217;s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company&#8217;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation of Privately Held Company Equity Securities Issued as Compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Following the closing of the initial public offering, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#8209;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method. The &#8220;simplified&#8221; method estimates the expected term of stock options as the mid&#8209;point between the weighted average time to vesting and the contractual maturity. The risk&#8209;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss per share is determined by dividing net loss by the weighted&#8209;average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti&#8209;dilutive. Therefore, the weighted&#8209;average shares used to calculate both basic and diluted loss per share are the same.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Off-Balance Sheet Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had no off-balance sheet risk.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Exchange</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Exchange</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of certain intercompany transactions in September 2021, the Company determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (&#8220;USD&#8221;) during the year ended December 31, 2021. Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of operations and comprehensive loss.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder&#8217;s deficit that are excluded from net loss. The Company's comprehensive loss includes unrealized gains (losses) on available-for-sale securities during the year ended December 31, 2022 and 2021 and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia during the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease Accounting</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (&#8220;ROU&#8221;) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. Options to renew or options to cancel a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Subsequent Events</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 16 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for further details.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses (Topic 326)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_BasisOfPresentationAndConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_BasisOfPresentationAndConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_OtherIncomeNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other income net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_OtherIncomeNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140094976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Life</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records property and equipment at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.18%;"/>
          <td style="width:4.918%;"/>
          <td style="width:45.902%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Plant and Equipment Estimated Useful Life [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139300400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Amortized Cost and Estimated Fair Value of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the amortized cost and estimated fair value of the Company&#8217;s U.S. government treasury securities and marketable securities, which are considered to be available-for-sale investments and are included in short-term investments on the consolidated balance sheets:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.595%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.972000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.972000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.177000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.227%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.372%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">337</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,092</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,568</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,821</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,481</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139357360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.396%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,641</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,703</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.694%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.23%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.396%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market fund</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141,378</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,751</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150,129</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,818</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Totals</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,072</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139228832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities Operating Leases Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of operating lease liabilities at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.231%;"/>
        <td style="width:1.944%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.824%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,525</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,308</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,683</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,818</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#8211; current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,165</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability &#8211; long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140747632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.383%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.513%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.397%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,830</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139307600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,416</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">559</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Process development and manufacturing costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">504</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,685</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">828</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,985</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,152</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139260720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Reserved Shares of Common Stock for Issuance</a></td>
<td class="text"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved shares of common stock for issuance as follows:</span></p><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.772%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.741%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.144%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for grant under the 2020 Stock Option and Grant Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,253,680</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,812,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock available for issuance under the 2020 Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">454,302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">611,354</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,869,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,445,714</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024135301056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.065%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.645999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.622%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.043999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,014</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,632</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,343</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,315</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Common Stock Activity</a></td>
<td class="text"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes restricted common stock activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.112%;"/>
        <td style="width:1.171%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.017999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.084999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,632,996</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">348,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,912,210</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes stock option activity (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.350000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.305%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.35%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.372%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.316%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.535%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at January 1, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">480</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,051,906</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.48</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,284,164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.13</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,945,832</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model</a></td>
<td class="text"><p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.492%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.151%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.608%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.142%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.07</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.06</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024135300928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Income (Loss) Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.144%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.037%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.231%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,045</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,586</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,975</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,955</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The provision for income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.185%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.516%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.709999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income tax (benefit) expense:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax (Benefit) Expense Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s income tax (benefit) expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.492%;"/>
        <td style="width:1.234%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.610999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.225%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.602%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit at the federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,901</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increase (decrease) resulting from:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax rate differential</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,603</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,018</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual property transfer</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,992</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,540</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Officer's compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">695</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,648</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,069</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">730</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax (benefit) expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Components of Deferred Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of deferred income taxes consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.932%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.619%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.012%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,374</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,683</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,537</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,538</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-qualified stock compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,028</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">235</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalization of R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,661</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,646</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,419</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,791</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">350</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,419</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,175</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset (liability)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137555856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.745%;"/>
        <td style="width:1.683%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.351000000000003%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.674%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.545%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168,710</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171,962</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average common shares outstanding &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,654,856</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,782,126</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.20</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the amounts outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.485%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.319%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.237%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.721999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,922,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,155,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,239,106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,866,909</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024130900464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (168,710)<span></span>
</td>
<td class="num">$ (171,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(465,775)<span></span>
</td>
<td class="num">$ (297,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,458,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,687,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,859,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share issued to investors</a></td>
<td class="nump">27,458,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Net proceeds with certain investors</a></td>
<td class="nump">$ 126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137491040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_CashAndCashEquivalentsMaturityPeriod', window );">Cash and cash equivalents maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShortTermInvestmentsMaturityPeriod', window );">Short-term investments maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NumberOfIndividualSecuritiesWithImpairment', window );">Number of individual securities with impairments | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation', window );">Property, plant and equipment, valuation basis</a></td>
<td class="text">cost<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense for cloud computing arrangements</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Off-balance sheet risk description</a></td>
<td class="text">At December 31, 2022 and 2021, the Company had no off-balance sheet risk.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Expected useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_CashAndCashEquivalentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_CashAndCashEquivalentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NumberOfIndividualSecuritiesWithImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of individual securities with impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NumberOfIndividualSecuritiesWithImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShortTermInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investments maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShortTermInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentBasisOfValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137412880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131073216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 128,036<span></span>
</td>
<td class="nump">$ 46,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">127,703<span></span>
</td>
<td class="nump">46,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember', window );">U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">99,288<span></span>
</td>
<td class="nump">25,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">99,036<span></span>
</td>
<td class="nump">25,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember', window );">Corporate and Agency Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,748<span></span>
</td>
<td class="nump">9,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 28,667<span></span>
</td>
<td class="nump">9,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131571776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 32,641<span></span>
</td>
<td class="nump">$ 150,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">127,703<span></span>
</td>
<td class="nump">46,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember', window );">Corporate and Agency Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">28,667<span></span>
</td>
<td class="nump">9,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,641<span></span>
</td>
<td class="nump">141,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember', window );">U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">99,036<span></span>
</td>
<td class="nump">25,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,641<span></span>
</td>
<td class="nump">141,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">99,036<span></span>
</td>
<td class="nump">25,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,641<span></span>
</td>
<td class="nump">141,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">99,036<span></span>
</td>
<td class="nump">25,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">28,667<span></span>
</td>
<td class="nump">21,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate and Agency Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 28,667<span></span>
</td>
<td class="nump">$ 9,818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alvr_CorporateAndAgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alvr_USGovernmentTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024129474224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,633<span></span>
</td>
<td class="nump">$ 29,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_DevelopmentAndManufacturingServicesAgreementMember', window );">DMS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Effective June 2022, the Company entered into a First Amendment to the DMS Agreement to extend the expiration date to June 2024 provided that the terms and conditions of the DMS Agreement will continue to apply to any active SOW's. The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days&#8217; notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease, existence of option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lease, option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days&#8217; notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingEstimatedLeaseTerm', window );">Estimated lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear', window );">Estimated lease expiring month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember', window );">2020 DMS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingEstimatedLeaseTerm', window );">Estimated lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear', window );">Estimated lease expiring month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_UtilizationFeePayable', window );">Utilization fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption', window );">Lessee operating lease, lease term including renewal option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PrepaidUtilizationFee', window );">Prepaid utilization fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_WalthamLeasesMember', window );">Waltham Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the option to renew the leased space for an additional one time period of five years with written notice from the Company. As of December 31, 2022, the Company has no reasonable certainty that this option to extend will be exercised.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeaseCommencementMonthAndYear', window );">Lease commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AdditionalOneTimeLeasePeriod', window );">Additional one time lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TenantImprovementAllowanceToBeReimbursed', window );">Tenant improvement allowance to be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TenantImprovementAllowanceReimbursementPeriod', window );">Tenant improvement allowance, reimbursement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_NewLeaseAgreementWithBpBayColonyLlcMember', window );">New Lease Agreement with BP Bay Colony LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_SubleaseWithAmagPharmaceuticalsMember', window );">Sublease with AMAG Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_OriginalSOWAmendmentMember', window );">Original SOW Amendment under DMS Agreement | Lease Modification under ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_SecondSOWAmendmentMember', window );">Second SOW Amendment under DMS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_SecondSOWAmendmentMember', window );">Second SOW Amendment under DMS Agreement | Lease Modification under ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember', window );">2022 SOW Under the DMS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">2024-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_UtilizationFeePayable', window );">Utilization fee</a></td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption', window );">Lessee operating lease, lease term including renewal option</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember', window );">Change Order to Modify Terms of SOW under 2020 DMS Agreement | Lease Modification under ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AdditionalOneTimeLeasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional one time lease period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AdditionalOneTimeLeasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating estimated lease expiring month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LesseeOperatingEstimatedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating estimated lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LesseeOperatingEstimatedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, lease term including renewal option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PrepaidUtilizationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid utilization fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PrepaidUtilizationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_TenantImprovementAllowanceReimbursementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance, reimbursement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_TenantImprovementAllowanceReimbursementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_TenantImprovementAllowanceToBeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance to be reimbursed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_TenantImprovementAllowanceToBeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_UtilizationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Utilization fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_UtilizationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_DevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_DevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_WalthamLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_WalthamLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_NewLeaseAgreementWithBpBayColonyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_NewLeaseAgreementWithBpBayColonyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_SubleaseWithAmagPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_SubleaseWithAmagPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_OriginalSOWAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_OriginalSOWAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_SecondSOWAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_SecondSOWAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137394592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 9,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">12,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">41,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">5,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">35,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability &#8211; current</a></td>
<td class="nump">7,165<span></span>
</td>
<td class="nump">$ 6,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability &#8211; long-term</a></td>
<td class="nump">$ 28,222<span></span>
</td>
<td class="nump">$ 23,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134613216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,934<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alvr_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140261712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131128320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 6,416<span></span>
</td>
<td class="nump">$ 6,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">5,678<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent', window );">Process development and manufacturing costs</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">7,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 13,985<span></span>
</td>
<td class="nump">$ 20,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued process development and manufacturing costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131318448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sponsored Research, Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,870,000<span></span>
</td>
<td class="nump">$ 120,735,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=alvr_CancerResearchAndPreventionInstituteOfTexasMember', window );">CPRIT | License agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable', window );">Maximum paid percentage of grant award proceeds until which revenue share is payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_AmendedAndRestatedExclusiveLicenseAgreementMember', window );">A&amp;R License Agreement | BCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NonRefundableLicenseFeePayments', window );">Non-refundable license fee payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties', window );">Minimum percentage of eligible to receive tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_SecondLicenseAgreementMember', window );">Second License Agreement | BCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NonRefundableLicenseFeePayments', window );">Non-refundable license fee payments</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties', window );">Minimum percentage of eligible to receive tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate', window );">Non-refundable license fee payments, first year through fourth anniversary of effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter', window );">Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_ResearchCollaborationAgreementMember', window );">Research Agreement | BCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AgreementForPerformingResearchActivitiesTerm', window );">Agreement for research activities, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ResearchActivitiesPerformingFees', window );">Research activities performing fees</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AggregateResearchActivitiesPerformingFees', window );">Total research activities performing fees, over the term</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember', window );">Collective Agreements | BCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember', window );">Collective Agreements | BCM | Accured member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_AccruedMilestoneExpenses', window );">Accrued milestone expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alvr_RedumptionAgreementMember', window );">Redumption Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Sponsored Research, Collaboration and License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EarnoutPaymentAsPercentageOfNetSales', window );">Earnout payment as percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale', window );">Earnout payment obligation for number of years from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment', window );">Minimum earnout payments received by investors for reduction of earnout payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale', window );">Period for reduction of earnout payment after first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AccruedMilestoneExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AccruedMilestoneExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AggregateResearchActivitiesPerformingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate research activities performing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AggregateResearchActivitiesPerformingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_AgreementForPerformingResearchActivitiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement for performing research activities term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_AgreementForPerformingResearchActivitiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EarnoutPaymentAsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout payment as percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EarnoutPaymentAsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout payment obligation for number of years from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum paid percentage from grant award proceeds until which revenue share is payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum earnout payments received by investors for reduction of earnout payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum threshold percentage of eligible to receive tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NonRefundableLicenseFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable license fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NonRefundableLicenseFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable license fee payments first year through fourth anniversary of effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for reduction of earnout payment after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ResearchActivitiesPerformingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research activities performing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ResearchActivitiesPerformingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsored research, collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alvr_CancerResearchAndPreventionInstituteOfTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alvr_CancerResearchAndPreventionInstituteOfTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alvr_AmendedAndRestatedExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alvr_AmendedAndRestatedExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alvr_BaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alvr_BaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alvr_SecondLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alvr_SecondLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alvr_ResearchCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alvr_ResearchCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=alvr_AccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=alvr_AccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alvr_RedumptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alvr_RedumptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131429408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends declared or paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Net proceeds with certain investors | $</a></td>
<td class="nump">$ 126,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_SaleOfStockOfferingCosts', window );">Offering costs | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share issued to investors | shares</a></td>
<td class="nump">27,458,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_UnderwritingDiscountsCommissions', window );">Underwriting Discounts Commissions | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_SaleOfStockOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_SaleOfStockOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_UnderwritingDiscountsCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_UnderwritingDiscountsCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alvr_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024137642944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">14,869,885<span></span>
</td>
<td class="nump">13,445,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">454,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alvr_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">2,239,106<span></span>
</td>
<td class="nump">2,866,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alvr_OptionToPurchaseCommonStockMember', window );">Option To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">7,922,797<span></span>
</td>
<td class="nump">6,155,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alvr_StockAvailableForGrantMember', window );">Stock Available For Grant | 2020 Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">4,253,680<span></span>
</td>
<td class="nump">3,812,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alvr_StockAvailableForIssuanceMember', window );">Stock Available For Issuance | 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">454,302<span></span>
</td>
<td class="nump">611,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alvr_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alvr_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alvr_OptionToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alvr_OptionToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alvr_StockAvailableForGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alvr_StockAvailableForGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alvr_StockAvailableForIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alvr_StockAvailableForIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024135203008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 41,315<span></span>
</td>
<td class="nump">$ 43,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">14,014<span></span>
</td>
<td class="nump">20,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 27,301<span></span>
</td>
<td class="nump">$ 23,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024136436416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jul. 02, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,869,885<span></span>
</td>
<td class="nump">13,445,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,315,000<span></span>
</td>
<td class="nump">$ 43,975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 24.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.16<span></span>
</td>
<td class="nump">$ 13.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Awards contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,715,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions', window );">Number of shares of common stock issuable upon exercise of outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan | Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,616,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember', window );">2020 Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Awards contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,008,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Cumulative increase in number shares reserved for issuance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares added to number of available shares under plan</a></td>
<td class="nump">3,528,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions', window );">Common stock issuable upon exercise of outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,858,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember', window );">2020 Stock Option and Grant Plan | Restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,076,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember', window );">2020 Stock Option and Grant Plan | Stock Available For Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,680<span></span>
</td>
<td class="nump">3,812,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,354<span></span>
</td>
<td class="nump">454,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages', window );">Percentage of payroll deductions of base salary or wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock', window );">Percentage of maximum discount on purchase of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_OfferingPeriodDescription', window );">Offering period, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) on the first trading day of the offering period or (ii) the last day of any offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares and compensation expense is recognized over the offering period.  The first ESPP offering period was shortened in duration to three months and commenced on April 1, 2022 and ended on June 30, 2022. New six-month offering periods will commence each January 1 and July 1 thereafter during the term of the plan, with the administrator having the right to establish different offering periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Cumulative increase in number shares reserved for issuance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance', window );">Annual increase in number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under the employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share issued, average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Cash received from purchases under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Base salary or wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum annual increase of common stock reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issuable upon exercise of outstanding options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_OfferingPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Period, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_OfferingPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum discount price on purchase of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum payroll deductions of base salary or wages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award common stock issuable upon exercise of outstanding options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alvr_TwoThousandAndEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alvr_TwoThousandTwentyStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alvr_StockAvailableForGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alvr_StockAvailableForGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024130898144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details) - Restricted Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested at January 1, 2022 | shares</a></td>
<td class="nump">2,866,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">1,632,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(348,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(1,912,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested at December 31, 2022 | shares</a></td>
<td class="nump">2,239,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested at January 1, 2022 | $ / shares</a></td>
<td class="nump">$ 15.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">7.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">17.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">10.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested at December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134682928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Outstanding, Beginning Balance</a></td>
<td class="nump">6,155,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,051,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(1,284,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Outstanding, Ending Balance</a></td>
<td class="nump">7,922,797<span></span>
</td>
<td class="nump">6,155,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber', window );">Options vested and exercisable at December 31, 2022</a></td>
<td class="nump">2,945,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding at January 1, 2022</a></td>
<td class="nump">$ 23.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">20.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding at December 31, 2022</a></td>
<td class="nump">17.81<span></span>
</td>
<td class="nump">$ 23.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable at December 31, 2022</a></td>
<td class="nump">$ 22.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life, Options outstanding</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Contractual Life, Options vested and exercisable at December 31, 2022</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding at January 1, 2022</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding at December 31, 2022</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2022</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and exercisable, intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and exercisable, number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024231605360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 32.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by share based payment award fair value assumptions fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134731968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Federal</a></td>
<td class="num">$ (113,389)<span></span>
</td>
<td class="nump">$ 49,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(55,586)<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (168,975)<span></span>
</td>
<td class="num">$ (170,955)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131059552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax (benefit) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (246)<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (benefit) expense</a></td>
<td class="num">(265)<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax (benefit) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) expense</a></td>
<td class="num">$ (265)<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131557856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit at the federal rate</a></td>
<td class="num">$ (35,472)<span></span>
</td>
<td class="num">$ (35,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">43,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(1,603)<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">35,406<span></span>
</td>
<td class="nump">22,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer', window );">Intellectual property transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(6,992)<span></span>
</td>
<td class="num">(5,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation', window );">Officer's compensation</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock compensation</a></td>
<td class="nump">4,637<span></span>
</td>
<td class="num">(2,464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) expense</a></td>
<td class="num">$ (265)<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Benefit at the federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(25.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent', window );">Intellectual property transfer</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent', window );">Officer's compensation</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent', window );">Permanent differences</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax (benefit) expense</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation intellectual property transfer amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation intellectual property transfer, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation officer's compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation officer's compensation, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, permanent differences, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024131551344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 9,374<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">12,374<span></span>
</td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">25,537<span></span>
</td>
<td class="nump">25,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_DeferredTaxAssetsLeasingArrangements', window );">Operating lease liabilities</a></td>
<td class="nump">8,074<span></span>
</td>
<td class="nump">6,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-qualified stock compensation</a></td>
<td class="nump">12,017<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation', window );">Restricted stock compensation</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalization of R&amp;D expenses</a></td>
<td class="nump">20,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">89,647<span></span>
</td>
<td class="nump">53,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(82,228)<span></span>
</td>
<td class="num">(46,823)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset (liability)</a></td>
<td class="nump">7,419<span></span>
</td>
<td class="nump">7,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(7,218)<span></span>
</td>
<td class="num">(6,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (7,419)<span></span>
</td>
<td class="num">$ (7,175)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, tax deferred expense, compensation and benefits, restricted stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024135269264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">U.S. current income tax expense</a></td>
<td class="num">$ (265,000)<span></span>
</td>
<td class="nump">$ 1,007,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in deferred tax assets valuation allowance</a></td>
<td class="nump">$ 35,406,000<span></span>
</td>
<td class="nump">22,268,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_OperatingLossCarryforwardsCarrybackPeriod', window );">Operating loss carryforwards carryback period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome', window );">Percentage of TCJA limitations on net operating loss carryforwards to taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Orphan Drug Credit (ODC)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 72,900,000<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_OperatingLossCarryforwardsCarrybackPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards carryback period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_OperatingLossCarryforwardsCarrybackPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act of 2017 percentage of limitations on net operating loss carryforwards to taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140338288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss &#8211; basic and diluted</a></td>
<td class="num">$ (168,710)<span></span>
</td>
<td class="num">$ (171,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">76,654,856<span></span>
</td>
<td class="nump">62,782,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">76,654,856<span></span>
</td>
<td class="nump">62,782,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140365280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">7,922,797<span></span>
</td>
<td class="nump">6,155,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,239,106<span></span>
</td>
<td class="nump">2,866,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alvr_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024140725152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies- Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alvr_LeaseTerminationEffectiveDate', window );">Lease termination effective date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alvr_LeaseTerminationEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Termination Effective Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alvr_LeaseTerminationEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alvr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024134562512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Consulting fees to members of management and board of directors</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevateBioAndAffiliatesMember', window );">ElevateBio and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to services with related party</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due to related party</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevatebioBasecampIncMember', window );">BaseCamp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevateBioAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevateBioAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevatebioBasecampIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alvr_ElevatebioBasecampIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140024139254560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Matching contributions by employer</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>alvr-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alvr="http://www.allovir.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alvr-20221231.xsd" xlink:type="simple"/>
    <context id="C_51750031-7f9c-4c75-a085-4599ec0a8c7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-02</endDate>
        </period>
    </context>
    <context id="C_7a663255-07b3-4b0c-81df-49da0711cfc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0aab4b39-a49a-4d2d-a277-8f923ab3d97d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a2440698-340f-405b-82b8-2ee426f49c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b229f14-0e9d-4a8c-9c99-2fac3bf93e45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="C_6e1405d7-d3f6-4118-b825-18c83ba250f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SecondSOWAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_eb50bcd6-a9a6-4061-9ef2-e7d4b30b505a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alvr:CancerResearchAndPreventionInstituteOfTexasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4638e48c-caee-470f-8e9f-fd72016b2756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0b872f5d-6e7d-409f-b489-675ef849e5c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:RedumptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_ca1c64ca-7e9c-446e-8772-b18830c91079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1809599-290d-4a09-84c6-6e1cc69305a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_617f4174-88a5-4f52-8e3f-dafed24ab46e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_05a46537-0f3d-403a-bd4b-9b51a77c50b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_871ad9af-02db-4352-9621-2c92ad7156c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_26adca99-ca18-49de-923e-a278ee315f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_edef2090-5f5c-44a5-91fc-85d5605d9a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_51a0554a-094f-4ada-b6e2-8ae4cc043eaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForIssuanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7dba3ee0-797d-4488-a999-52e2d13730df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_48c024c0-d687-47ba-9b05-7f832db9c0ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bd837554-2d0e-44a4-89f5-21197c0c9b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_160a6c1c-126c-4390-a8b9-a1f7c5589625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:OptionToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef1fea4e-8882-400a-ae32-d746b5237239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-04</instant>
        </period>
    </context>
    <context id="C_50437763-ff2d-4d51-98a3-8c880a8fe158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a2765896-7ab5-4950-93b3-5422a0d04d3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_929b39a9-292b-4663-ab90-74229b474881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_530cd7cd-8adc-465e-b494-4eb7a45191a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_6cb1ed55-c237-4a84-8a95-212c9e28b1d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_34bd2dd2-4644-4d61-9dd2-0ea6e25b44ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_09a37f2c-e1fe-4c12-9a21-29a9a69ff02e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_5a13a2d7-5fd2-4d62-8f2a-c04d53be3758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f54245dd-ad04-435d-9405-f93c21c6df54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0de4aa3b-f8d3-4a15-88ec-81d1af1626ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">alvr:AccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe20c7f0-e4e5-4327-8d78-110f415bf544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_e1ac0558-7793-4cbc-abac-375855874e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_75215896-db5d-4536-a304-39f269881d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForIssuanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6d7b88b-a721-4583-9af3-cdcbc9a426d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c3854674-c6cb-450f-a8f1-f217cae5fd90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_05b6c22e-9c40-4013-83f9-51bb3313e591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_56bf8742-8a30-46a1-808e-e166b1e6b639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16d12274-58f7-4d85-a851-cdb95fe02f19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ddd9b411-5433-4b78-876b-16099390a62c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7d26fd97-1281-48e9-9f0c-80658a0a41dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c2c0042d-4a48-4498-a1f0-1bd575db97dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_14bd8057-2b3c-443a-8b90-b6382cbf114b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-02</instant>
        </period>
    </context>
    <context id="C_de179e1a-a46a-42ff-ade3-641aee56fdf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0369a67b-84df-4183-8524-460dca6b72af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_232cbeff-83b0-4296-a32f-459b4b6c2711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:WalthamLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_1176b604-ee17-4ddb-be7e-456b15cb96ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SubleaseWithAmagPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_ca8bd669-1d5c-4b9a-921e-86a2b0097299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevatebioBasecampIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa412a85-c19c-4db1-b1d6-89d57a67aedd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a42b0c01-30a3-4913-9e9a-d46c91274d8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6b58947d-f992-4988-85a8-62bc792aa149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db4ec574-667d-4e70-a4cf-db9a6e572237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_ed61a91e-38ee-40bf-89a6-4063803306fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6dd688fa-9bfb-450c-823f-914d71bdb20b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:ResearchCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_35bb2d87-2273-4b9b-abe3-66c79a568333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5df06e65-2e31-4282-a0c9-44687c839727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62c6f492-44c1-46c2-b513-632f27ed7e91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_235f6d4f-ef0b-4fbc-b567-efa82b6fd888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_34017843-7cb8-4d00-86bb-8889a840a88a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_978fec4b-4bb3-4327-9bc3-a12cff64e534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:SecondSOWAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_dbf392d2-9387-428a-99dd-65df376878d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_477148ad-c1c9-490f-97aa-87c51b482f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6bd4967c-de1f-4ce5-9073-2145721fd38c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="C_9cd782a5-8539-46d4-88c3-5b91917b87e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ba9cbb52-e4cc-4b69-b43d-08477c237f07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_caad09b2-8a5c-427a-bf14-b4c5d6dc2fac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86f2f458-9d81-4153-bb34-15b4a600c6f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alvr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="C_ddb75e86-804f-400d-952a-974d942d169c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5b6e5424-0ab6-4de8-961e-ab8143059eb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_75223583-180e-4986-994f-4bfea6c4561f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_2ac4b804-48e5-4500-bafb-20607b67d00c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e73a754-0c34-4892-ba85-21910762594e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_51c4f488-3970-4c54-84de-f12cde7d10db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">alvr:AccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ebbb3c52-5b08-40b2-b326-8098da241ddd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_f0711afd-ddae-4cbb-95eb-8a59378fefed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_227c3050-c341-4701-9bbc-1a6d93036b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alvr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="C_a1c6fa03-2ee5-482c-8fcc-3134560afe02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_c1a7c8cb-c126-4a75-84cc-77ae967326ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f2ebfc16-1156-46e3-a10c-6844f6815d58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f6f1e4d-56e5-462f-b160-b281f07868df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b98a7795-ec31-4702-95a8-60d00f9f4656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_befdac74-700b-4c42-b7e1-ec0012c1f70b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_62600b73-3cde-4af9-85cb-8d2dcf5152ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_89b61897-7cb1-4529-aa9a-3dcca0317455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alvr:CancerResearchAndPreventionInstituteOfTexasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4c070771-4f77-4eda-b36a-c12f31943e25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e238b96f-4a9e-4feb-94c6-0c19c3005824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:NewLeaseAgreementWithBpBayColonyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_2423b8cb-2946-470e-a22d-8cdaaa80af94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_364b0156-c9eb-4a54-8db9-564a84677c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0a071b5e-8a39-4f87-993b-1f4dca7d0685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ec9f3cbd-6e49-4297-9fce-29d9733f0dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_868e0009-9125-478f-bcb4-16998a2eebfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_b7155aa6-ec63-47bc-af6f-62110067cad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_260a042b-801a-42d1-b1f2-f77d80a4d46a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8351b805-5c1a-4d38-8217-30f5d6839ca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1b40c6bb-4bfb-4418-9f73-133bb83a5cc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fc2f8cf1-b175-4168-8c12-2ca0ee568e4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_028feb25-e5dc-4693-838f-892bc643344f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alvr:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_de1adbb2-e1ee-4eaa-9635-a371d6880799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d003b5a4-37dd-4bf1-a824-7458b10262ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b2d19e85-a506-472f-9db8-0cfeb581c0c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_276e92a2-b36d-49d9-b698-ebe3737df111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_64a704c4-3d7f-4e2b-9ec5-bfbaf9960234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_f6f0fa23-53ee-473a-93c3-d9f513ff687e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3d1dc62-3ca8-4a65-8d93-bffe388766da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2c5c0b15-4d90-49b6-b481-28b693927667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c580b793-4a8d-44b5-9ac5-f169ca597d82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:OriginalSOWAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="C_f3f9b887-cf21-4bb9-8973-a2512cec26c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2690d392-2fbc-4b1f-8ea4-61ecf654db96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alvr:ElevateBioAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c8f5f95d-8c74-42da-8e94-481be7b2c583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e6a30e50-19aa-46ea-ad75-47a4021abf20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8e51cc0b-f9e3-4e56-9d47-caa41e9a1eab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0dc312bf-dbc1-46c6-bfff-794105b41f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_183322ca-7ab4-457e-8a32-87ac4df2d1d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:OptionToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8964311a-67d6-48e8-930b-0c03d707e7e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79512046-91c6-49b4-ae01-0e273533c65f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cd2342e2-4156-4233-ac5f-e78b1c441b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_20d83d46-ff82-406b-8ed4-fbca2c534f99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alvr:StockAvailableForGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alvr:TwoThousandTwentyStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d14225a-1f51-4be3-8682-e3fe75c16bf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alvr:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ad4867e-83a6-4c90-8517-df9e8041faad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:SecondLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_45693ffc-b960-4db0-a592-606079f137e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alvr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alvr:AmendedAndRestatedExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="C_d21593fe-88fc-485a-877e-34bb4604b4f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e64c980b-ef3a-4f68-b295-dd082f470d79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alvr:CorporateAndAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b319269-2fae-4e66-8b64-b20a04c36873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_eca66d82-2e78-437b-aec1-7a4f3bee0629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_95a486e9-ee67-47cd-9f0c-c1d735435df0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0c3fe01a-8496-428e-84e7-1771deb6fcdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a68d724b-186e-40cb-914f-9f396ee8efa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76cdb962-34b7-4488-9b22-155ce39bf6f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_afd1f979-2cf1-48e4-85ce-a45e00e28ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_be903c41-fc2c-4418-82d1-61c35c6f02d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0a765caa-d973-4579-b4bc-2ffa5b45e639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_4a87737f-16d9-4518-9638-fffb2170c6fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001754068</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alvr:USGovernmentTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_Security">
        <measure>alvr:Security</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Vote">
        <measure>alvr:Vote</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>alvr:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_871cf843-6bae-437f-95c7-ea585ae4dff2">0001754068</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c1ab136d-680d-45ec-99a6-7401e7e06c0a">FY</dei:DocumentFiscalPeriodFocus>
    <alvr:OperatingLossCarryforwardsCarrybackPeriod
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_fb8a9d38-01ce-4a93-beea-aee65bc7b04d">P5Y</alvr:OperatingLossCarryforwardsCarrybackPeriod>
    <us-gaap:PreferredStockValue
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      id="F_794d01a1-aca2-4aae-acbc-307b1688cae1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_e33bdda4-f497-4a6e-b92c-1b3e161d699e">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      id="F_6fd272f4-1070-42c6-9b05-cfa962784023"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_6cde47ad-fcdd-464e-9335-ba901086ed11">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_21d51f43-038b-4eae-85e7-07333f45136e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_8f2f4b61-d25c-44cc-b16e-5139691b40d9">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_a81cc9df-3ee5-4cc7-960c-ec4c2a93aae8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_b1556e8d-2cb5-41db-95b4-90975378ba22">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1138fef4-741c-4a92-a1c1-afe60d9d737d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_ff45a5f7-dcf1-4b7d-b262-0c31b1b1a5c1">001-39409</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_a469a160-7f39-485b-b5a1-ee2498b0a8c7">ALLOVIR, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_db18e5a0-3206-4ee6-97a3-5d43b0d8af1c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_265f8078-69c1-4673-96fc-bbd1af857c00">83-1971007</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_6cfbdd36-6c19-4504-9cda-7487f8b7e168">1100 Winter Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_a79e3fac-1aae-4c49-b076-5ec270b5ddb0">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_960184f8-2475-408d-ba36-d29aabab76e8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_671f395b-2ef9-4fe6-b6d1-629d89adbc77">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_93950211-ea59-4d61-a926-b65bb4e4cdb5">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_ffca941a-8a89-44ec-a285-e81c35a19912">433-2605</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_939aa3d1-ead6-4779-aa4b-0053f70406c4">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c715749b-1e22-404f-9883-3b456bd61f0b">ALVR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_b5c8a673-1fdf-4a51-b4f8-7d5be0060577">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_0c87c27b-8a21-42f1-a243-87c0c4c15db4">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_88522d10-f496-4301-915a-d24ce886b274">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_526d85c6-ba28-439c-93c3-4d9df3877e7f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_de284ab6-5912-4020-bd79-a2b2560b1b59">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_ed3fb1fd-e761-4916-ab53-7165987d1b10">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_33fe247f-6204-43ce-8add-e0990042026f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_e3779a8f-3a2b-4ae2-8654-17fa4f15737f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_91d11fbf-d184-4987-9680-7d31188415b1">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_52d5dcb1-62c3-4991-8f7a-6f5d50666012">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_566792c6-4d6e-48c2-a6db-0e341f5e7ba4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_afd1f979-2cf1-48e4-85ce-a45e00e28ade"
      decimals="-5"
      id="F_613e7569-4bd2-43dd-880d-7aaddbb01936"
      unitRef="U_USD">143500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_4b229f14-0e9d-4a8c-9c99-2fac3bf93e45"
      decimals="INF"
      id="F_2f8cee16-e078-4f0c-89fe-e71d55699e6f"
      unitRef="U_shares">93463200</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_52ac1a76-eaf8-495e-8b89-5b779f1861fd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the Proxy Statement for the registrant&#x2019;s &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Annual Meeting of Stockholders, or the Proxy Statement, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#x2019;s fiscal year end of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_056f5b64-e63f-44da-937c-e4bbaa989d80">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_bce8e2f1-4653-4724-8c76-edc490dea756">Boston, MA, USA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_89cad007-6ab0-4c87-9574-108c8aa42c9d">34</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_6091b339-d4de-4085-bf46-7eb5564079db"
      unitRef="U_USD">106092000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_30fa7c52-4242-42fb-a6a2-d7e10b1359bc"
      unitRef="U_USD">201661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_9440b6a6-2110-4c09-abfe-19b46eb1826f"
      unitRef="U_USD">127703000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_6d2ce892-2fb0-429c-906b-bdd4961e5ceb"
      unitRef="U_USD">46459000</us-gaap:ShortTermInvestments>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_186d8d03-8832-4eab-8d91-d2370667c64b"
      unitRef="U_USD">157000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_ad19c65e-8a7d-4f6d-8461-8ba1d246f0a1"
      unitRef="U_USD">50000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_28291d5f-2b06-477f-8628-be1b8552c817"
      unitRef="U_USD">7100000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_446a1cfc-2a4a-4dce-bf61-2ecd5608600e"
      unitRef="U_USD">5178000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <alvr:PrepaidExpensesToRelatedParty
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_00f6b081-0f79-4858-82da-7edf27c3fb01"
      unitRef="U_USD">2000000</alvr:PrepaidExpensesToRelatedParty>
    <us-gaap:AssetsCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_f82edbf0-d324-43e0-a561-2b30a7111e6d"
      unitRef="U_USD">243052000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_3ccbc708-5137-4452-996f-a0ab6c5b2bad"
      unitRef="U_USD">253348000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_5b3d6efa-47bb-4ab5-a000-72069ed7a93b"
      unitRef="U_USD">852000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_39fdf307-bcfc-46b1-bd5b-7d770cd6948c"
      unitRef="U_USD">852000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_9905dae8-2164-4b84-8c1f-2963f78901d7"
      unitRef="U_USD">612000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_f1e00437-0fff-4546-8476-ebfa91151f76"
      unitRef="U_USD">1102000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_8665e047-2a37-4f82-91fb-c3674434252b"
      unitRef="U_USD">930000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_72f7512b-7508-4c08-876b-3af49821e1f5"
      unitRef="U_USD">1549000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_fceba8f7-f64b-43f7-810e-f3fd92e07c71"
      unitRef="U_USD">31633000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_e5f1c53a-20d7-4dc4-a131-eaaf0bda5a1a"
      unitRef="U_USD">29743000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_512b5a71-bb14-43fc-8470-828545fbee89"
      unitRef="U_USD">277079000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_846a0da6-9956-4269-b138-71ed5bc308b6"
      unitRef="U_USD">286594000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_d413d2ad-5215-4297-aa4c-977dd550addf"
      unitRef="U_USD">3004000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_f2405008-fac4-4249-b2df-b1c91514e7ab"
      unitRef="U_USD">8361000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_61d02d58-a153-42ba-aae8-36250499be16"
      unitRef="U_USD">13985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_7e9acd1a-65d8-43fe-8d29-7d9f59e2d366"
      unitRef="U_USD">20152000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_69925b54-d1e9-4e5e-b6c8-fdf82b95197e"
      unitRef="U_USD">128000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_9563bb1d-7558-4b06-880d-ebb54aaac307"
      unitRef="U_USD">1007000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_2d2d0667-d997-4e7e-9bce-b1ca7b28f449"
      unitRef="U_USD">7165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_aaa5a1ec-02da-4b96-bd57-cd7b479c5d0e"
      unitRef="U_USD">6591000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_86900308-431b-433f-bdb6-1b42128d23b3"
      unitRef="U_USD">56000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_659a1cc2-be6b-4783-b948-338adc8102f5"
      unitRef="U_USD">1742000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_44e7e260-c0ec-40a9-a470-2a21139de866"
      unitRef="U_USD">24338000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_e1efe003-078e-4c6b-a4e3-4aa143a0ac5f"
      unitRef="U_USD">37853000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_40f4affe-4142-497d-93d3-53c6504836d6"
      unitRef="U_USD">28222000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_402435ac-71c6-4008-bdf1-64cec6650ec3"
      unitRef="U_USD">23475000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_fbc2500c-c936-42e7-aa3f-a84cac86ccbd"
      unitRef="U_USD">52560000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_fd6c080b-db9a-4765-88cc-ad39d64fd3ba"
      unitRef="U_USD">61328000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_bc1611e7-3d25-4bae-b862-5d813eb895a3"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_e5061c65-56f3-4a34-9ebc-07eec720e511"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_fd5da05a-0832-4961-a6cb-3bb7537d7277"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_551045f9-1df9-4b41-a2e5-a7a29fa43892"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_fca22031-4860-47ff-9de7-7f297dddb72f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_f6ca3a43-4197-46c0-ab0e-140d59f4d2e8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_e5177103-1748-4224-923f-307a7d72d742"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_2b867970-5102-478e-8b4a-58b8304270ca"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_b744cb67-0b12-4b51-9523-64649d17f6c2"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_dd832dcf-1a62-4375-9fdd-6a3a5f096f55"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_08ebdb70-9f3b-47e0-89a8-4d98e01beba5"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_49054fae-d6ca-4fd6-afe8-43832a2cc29a"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_f3e0c9a9-7d0e-4704-8c37-7bb8966597e7"
      unitRef="U_shares">93268069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_b91d30da-fa0e-4b54-a429-5feea5bae738"
      unitRef="U_shares">65170332</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_679a9860-90f1-43a3-95c8-112ea29fa227"
      unitRef="U_shares">93093243</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_29458ea4-57cb-48f1-9538-327285f734be"
      unitRef="U_shares">63565886</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_d35c8f99-0dca-47c7-ab9d-522d88d48671"
      unitRef="U_USD">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_e310a5af-1e8a-4af8-8308-58248a6aac2c"
      unitRef="U_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_94a2fe2a-06d9-4826-bf89-f1d2bb84d112"
      unitRef="U_USD">690753000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_7897ba96-124d-47dd-89db-27e648ce5358"
      unitRef="U_USD">522479000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_d19de77a-7931-4f38-a49d-e78e23574c8b"
      unitRef="U_USD">-468000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_a20607b3-3ee8-4220-82a8-87a7e900205d"
      unitRef="U_USD">-155000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_cff2a947-28be-4130-b344-261bb20057d1"
      unitRef="U_USD">-465775000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_e05cac42-6890-40a9-b996-cc79c8d83768"
      unitRef="U_USD">-297065000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_08ecc282-6ebc-4bc7-ac96-99c8f42e3d62"
      unitRef="U_USD">224519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_c0f67e11-fd1a-470d-8dab-36982300504c"
      unitRef="U_USD">225266000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_9dc23fb4-c1c3-443a-9138-7f15050effd4"
      unitRef="U_USD">277079000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_42f028e6-212e-4fa4-bd49-a06a5ab3d954"
      unitRef="U_USD">286594000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_d751fc35-02fe-4bcf-8a61-f58111721f6c"
      unitRef="U_USD">118870000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_9882de40-563f-4924-a0fc-043805309816"
      unitRef="U_USD">120735000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_7f0e2a54-08f5-4ef7-ab83-a782f20d904f"
      unitRef="U_USD">52332000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_d494156b-662f-45fe-a1c8-826eedaa584e"
      unitRef="U_USD">49083000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_a985c5aa-a4d5-4661-b919-277809227ed4"
      unitRef="U_USD">171202000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_ee28448b-a321-448a-9ae4-66ce6ba18318"
      unitRef="U_USD">169818000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_fc37b3f3-84fe-4d0e-b375-def4ba70ff3f"
      unitRef="U_USD">-171202000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_d99ef5b1-7695-43aa-be54-392b1e621523"
      unitRef="U_USD">-169818000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_ecfa5f46-ada1-4f9e-b633-67d3681195c4"
      unitRef="U_USD">1876000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3a3a7ebb-44cd-483a-a966-a230b716b2a9"
      unitRef="U_USD">1315000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_e9fa5954-7caf-47e8-bcc8-69e756625e19"
      unitRef="U_USD">351000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3bc9724d-c05c-4a3e-af1d-292bbb7ac2bd"
      unitRef="U_USD">-2452000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_0fdd139d-5ee0-4e37-aca8-113241cd47f6"
      unitRef="U_USD">-168975000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_11986138-0a0a-486a-98e7-17758ee0b1c1"
      unitRef="U_USD">-170955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_379675af-bfb4-49c8-9e3c-df249fc26ae0"
      unitRef="U_USD">-265000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_88db3043-1aa5-4098-9a81-17ca92170734"
      unitRef="U_USD">1007000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_ee5c9cc8-2ab1-445a-9ce7-8b8d148d53cb"
      unitRef="U_USD">-168710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3445bf02-84af-4f59-a082-fcbb521262ad"
      unitRef="U_USD">-171962000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_9c14df31-559b-4625-b0fb-1727c82b0474"
      unitRef="U_USDollarShare">-2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_f724a988-07f7-46f0-98de-6a2dcaf08bdd"
      unitRef="U_USDollarShare">-2.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_732baf6d-6a2c-45c1-a7fb-c7e23e72f7f7"
      unitRef="U_USDollarShare">-2.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_82cb6689-0c19-4b4e-a6ae-09fb974b4993"
      unitRef="U_USDollarShare">-2.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="0"
      id="F_1a4614d6-8692-43b5-9b44-ab4bcdfb96b8"
      unitRef="U_shares">76654856</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="0"
      id="F_e7c6ce53-f7ca-4aa9-b600-e7622343bd4a"
      unitRef="U_shares">76654856</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="0"
      id="F_ef147c7c-0d44-4774-b903-421470b754fd"
      unitRef="U_shares">62782126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="0"
      id="F_89a56ba0-4463-492d-a988-dfc1264c94ff"
      unitRef="U_shares">62782126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_7b919d42-0bb7-4947-8b36-67194df3454a"
      unitRef="U_USD">-168710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_dff536b3-09e9-45e8-a2a3-d4b3a8692597"
      unitRef="U_USD">-171962000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_9a2493df-7a9f-4ea4-a4c7-9f63199f35b7"
      unitRef="U_USD">-313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3f5678f6-10f5-4c25-b18c-8c629836d724"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_6934f83e-b26f-4f7f-89ff-3f5e1242dc94"
      unitRef="U_USD">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_5f74f192-9b85-4154-b10e-369cf0bf67d6"
      unitRef="U_USD">-313000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3f54b4ab-7823-41a3-9027-b06bd3918c3a"
      unitRef="U_USD">-43000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_2cf1e897-50b6-4fde-af31-07267fa72720"
      unitRef="U_USD">-169023000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_fe24c4bc-64cb-49f7-8898-a34cf7b05723"
      unitRef="U_USD">-172005000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0b319269-2fae-4e66-8b64-b20a04c36873"
      decimals="INF"
      id="F_543f441e-4d8c-4037-adef-8364e49e43de"
      unitRef="U_shares">61931255</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0b319269-2fae-4e66-8b64-b20a04c36873"
      decimals="-3"
      id="F_a2188dc5-6497-426a-b84c-489313ed8358"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a13a2d7-5fd2-4d62-8f2a-c04d53be3758"
      decimals="-3"
      id="F_2e6e3fc0-6d49-4ebd-b3db-b325791105f1"
      unitRef="U_USD">478272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f3f9b887-cf21-4bb9-8973-a2512cec26c1"
      decimals="-3"
      id="F_aa818210-1122-4d44-b17d-9c1c29ad5844"
      unitRef="U_USD">-112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_16d12274-58f7-4d85-a851-cdb95fe02f19"
      decimals="-3"
      id="F_5f04a5c5-7609-4fc7-ba04-f7d1840ff36a"
      unitRef="U_USD">-125103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33"
      decimals="-3"
      id="F_9e7905a3-bba7-4ce1-b7df-0ed9f830134c"
      unitRef="U_USD">353064000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9cd782a5-8539-46d4-88c3-5b91917b87e4"
      decimals="-3"
      id="F_c585287d-86a6-44a4-82be-af9807c794f9"
      unitRef="U_USD">43975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_93f7e5be-7bec-463c-953d-7467b7aca813"
      unitRef="U_USD">43975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_c3854674-c6cb-450f-a8f1-f217cae5fd90"
      decimals="INF"
      id="F_66019cd1-e91e-48f3-847c-1a0be303056a"
      unitRef="U_shares">1609479</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c3854674-c6cb-450f-a8f1-f217cae5fd90"
      decimals="INF"
      id="F_5524d3a2-be3a-40fe-b5b6-a5bb6e520daf"
      unitRef="U_shares">25152</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9cd782a5-8539-46d4-88c3-5b91917b87e4"
      decimals="-3"
      id="F_6e1e33ba-3406-431e-83da-ae18975893dc"
      unitRef="U_USD">232000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_bdf0380b-d973-4d23-a186-59214d361754"
      unitRef="U_USD">232000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_e6a30e50-19aa-46ea-ad75-47a4021abf20"
      decimals="-3"
      id="F_2ddd2b33-3f34-48d5-9928-92ca98c76e89"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_7b7c8c47-2092-4835-8caf-452bd6647750"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_e6a30e50-19aa-46ea-ad75-47a4021abf20"
      decimals="-3"
      id="F_1447c880-0a83-4427-ba55-9c1affd9cc5e"
      unitRef="U_USD">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_7cfac677-d31d-4894-8794-9a89abb8c16f"
      unitRef="U_USD">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_8e51cc0b-f9e3-4e56-9d47-caa41e9a1eab"
      decimals="-3"
      id="F_66e7ae0d-c65e-48e7-b97c-1f70cf094bad"
      unitRef="U_USD">-171962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_c1ff48b5-5c67-4a01-bb4d-7119daa624ac"
      unitRef="U_USD">-171962000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd"
      decimals="INF"
      id="F_1a995a8a-6271-4031-ae12-0fd8a9cf59dc"
      unitRef="U_shares">63565886</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5b6e1fb0-20b2-4f1b-82b4-b09207b1a6bd"
      decimals="-3"
      id="F_ed4cb229-0792-4545-8be5-df96a8ccaa44"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b2d19e85-a506-472f-9db8-0cfeb581c0c6"
      decimals="-3"
      id="F_0c4b6dd4-85be-4e56-bf9d-f26a1484a7da"
      unitRef="U_USD">522479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7dba3ee0-797d-4488-a999-52e2d13730df"
      decimals="-3"
      id="F_bda90048-0d51-4e59-93fe-be7bd8bfb87b"
      unitRef="U_USD">-155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b6e5424-0ab6-4de8-961e-ab8143059eb0"
      decimals="-3"
      id="F_ec469ad3-0ac0-4187-9e49-5441c64ace3e"
      unitRef="U_USD">-297065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_2fe1754a-bc35-4ecb-bc88-718ccd3d0c8f"
      unitRef="U_USD">225266000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333"
      decimals="-3"
      id="F_8079880e-71d0-4dde-9bf7-75fb2ae6835f"
      unitRef="U_USD">41315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_27d29c01-ad42-418b-b9ff-6dd1f0caffa2"
      unitRef="U_USD">41315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9"
      decimals="INF"
      id="F_cdfee90b-2d33-4274-bf46-a412c8fa2966"
      unitRef="U_shares">1912210</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9"
      decimals="INF"
      id="F_0eff21db-c255-44d6-88da-e2db21c0c8f3"
      unitRef="U_shares">157052</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333"
      decimals="-3"
      id="F_1479d817-3011-4f8b-820b-fadf82bfab7d"
      unitRef="U_USD">536000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_9bc47767-52aa-416a-a637-eebb0e646aad"
      unitRef="U_USD">536000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_f7be66f4-78d2-41b7-98f1-e3a14da6b0c5"
      unitRef="U_USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9"
      decimals="INF"
      id="F_0baf3948-6cef-4bf0-9710-cdc0bb3d197f"
      unitRef="U_shares">27458095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c1809599-290d-4a09-84c6-6e1cc69305a9"
      decimals="-3"
      id="F_79e8000d-d4a2-425c-b0c0-fa75e6fc22d9"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_35bb2d87-2273-4b9b-abe3-66c79a568333"
      decimals="-3"
      id="F_635601f9-0b45-47bd-8f95-60da1561b04d"
      unitRef="U_USD">126423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_ea208eef-8d80-4e9a-9e64-53f05596cfe9"
      unitRef="U_USD">126425000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_befdac74-700b-4c42-b7e1-ec0012c1f70b"
      decimals="-3"
      id="F_078319b3-8e7a-4594-b9d2-2c1fce50cf9b"
      unitRef="U_USD">-313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_d5fd1198-357a-4fb7-a23b-0f4eaec19c89"
      unitRef="U_USD">-313000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d26fd97-1281-48e9-9f0c-80658a0a41dd"
      decimals="-3"
      id="F_80129229-c8af-438a-89a5-cbac70d18d89"
      unitRef="U_USD">-168710000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_3f6836de-5af2-496b-9002-4284565666cb"
      unitRef="U_USD">-168710000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_bd837554-2d0e-44a4-89f5-21197c0c9b79"
      decimals="INF"
      id="F_e4280abc-e410-485b-b75a-067e45e26708"
      unitRef="U_shares">93093243</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bd837554-2d0e-44a4-89f5-21197c0c9b79"
      decimals="-3"
      id="F_f53be03f-b051-4642-b4ec-b84ef3d3169b"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dbf392d2-9387-428a-99dd-65df376878d8"
      decimals="-3"
      id="F_8a1bef56-30e2-4f69-b77f-94a33038b485"
      unitRef="U_USD">690753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_235f6d4f-ef0b-4fbc-b567-efa82b6fd888"
      decimals="-3"
      id="F_39775a9f-53de-4aed-a903-b444c010a36f"
      unitRef="U_USD">-468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_76cdb962-34b7-4488-9b22-155ce39bf6f4"
      decimals="-3"
      id="F_2aacf8d2-7968-42ef-88ce-eee5343b2af0"
      unitRef="U_USD">-465775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_30c7d2d5-6369-47b5-9ea8-9e7b1abb120e"
      unitRef="U_USD">224519000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_0231a1e5-f7f6-4719-a0fb-cba5d277fe32"
      unitRef="U_USD">-168710000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_7073045c-376c-4ac6-8480-493a459ca30a"
      unitRef="U_USD">-171962000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_37bd9eec-a96e-4d59-8a6d-f2b0d8ff7dfd"
      unitRef="U_USD">723000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_50932c04-25aa-412d-97d6-87f04b36851d"
      unitRef="U_USD">189000</us-gaap:DepreciationDepletionAndAmortization>
    <alvr:NonCashLeaseExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_9d63a6c6-729f-4fe2-b825-b1c3c80c51cc"
      unitRef="U_USD">1842000</alvr:NonCashLeaseExpense>
    <alvr:NonCashLeaseExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_01bbb995-db1a-4799-bedd-b01f6a2ee519"
      unitRef="U_USD">928000</alvr:NonCashLeaseExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_bad505ae-8ed8-4652-a2c9-9c2e161c6f94"
      unitRef="U_USD">1076000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_d744d1f2-47bc-4bb6-9c85-a414e96a9c8c"
      unitRef="U_USD">-1197000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_90870c9d-0a8e-402b-9a3e-712f88e3e4f3"
      unitRef="U_USD">41315000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_7f55f491-cdc3-439b-8467-dd166b3f9306"
      unitRef="U_USD">43975000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_ff82c071-2ad0-46e8-90e6-eb3c02f82be1"
      unitRef="U_USD">107000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_9c902bb8-be41-4508-aa8c-6f5435ee87c2"
      unitRef="U_USD">-400000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_f82b81d9-97ee-4913-aee4-37210ef4c4ed"
      unitRef="U_USD">3028000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_81c69b1b-6171-4413-94c6-440115388490"
      unitRef="U_USD">1241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_fa86c5f2-ddaa-4b5f-a077-b0707d87a559"
      unitRef="U_USD">-490000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_a40805d8-7441-49d4-843e-def7cbe12686"
      unitRef="U_USD">1102000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_e5d103e1-4ce6-4bfd-a4f4-cdd30d126344"
      unitRef="U_USD">-879000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_85021ce3-2138-4a32-ae66-53ab2c09a1b1"
      unitRef="U_USD">1007000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_8d21cc48-797d-4f60-985a-0f93047dd805"
      unitRef="U_USD">-12622000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_e24c55a0-b7d0-4a92-b199-e40c9ec3eee9"
      unitRef="U_USD">20290000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_82bef789-e268-4586-a569-461b2217b486"
      unitRef="U_USD">-142052000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_cad954fa-0834-40b5-ae2f-009d7e8a07f7"
      unitRef="U_USD">-106319000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3393d2ee-b185-407a-9ee4-72a08e86fea1"
      unitRef="U_USD">26000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_7815f897-c737-4336-8767-018bdc5a0a6f"
      unitRef="U_USD">228806000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_7f9768c2-8472-4be5-a6a9-5cd057361a13"
      unitRef="U_USD">76591000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_d63c5d93-d34c-4533-b9ae-f14a2dd8b420"
      unitRef="U_USD">148328000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_3199b48c-42db-41ae-bca3-698694af3b73"
      unitRef="U_USD">262600000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_7b03fa3a-8fbd-43e8-be89-be48c40b7cda"
      unitRef="U_USD">-80478000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_64ada76c-fcdc-431b-a60c-e748779c47de"
      unitRef="U_USD">185983000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_42f461be-b220-4f4e-a80a-773b58941eaf"
      unitRef="U_USD">126425000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_efa1d099-bfa6-477d-94ba-bc74b8cd84b6"
      unitRef="U_USD">536000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_c2e4b456-0a75-4149-a3b9-2543bbc84918"
      unitRef="U_USD">232000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_c103372f-bf35-4caa-b8c8-348e73faa0d7"
      unitRef="U_USD">126961000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_2838b9de-5f71-4dc5-9eb3-7850b8f8b334"
      unitRef="U_USD">232000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_e24a8d5a-a520-4b68-845c-6ac8dc8bd76d"
      unitRef="U_USD">-44000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_877901c9-67f6-4af2-9ef6-406dd951d722"
      unitRef="U_USD">-95569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_8d41a394-546d-4669-b096-9439e31f4586"
      unitRef="U_USD">79852000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_a64062d5-8cc6-4803-9dfd-eb23dec191b7"
      unitRef="U_USD">202513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33"
      decimals="-3"
      id="F_7c1cf2f0-f8fd-4a25-baa6-11edc8357c14"
      unitRef="U_USD">122661000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_108ea805-c67c-4689-8a5b-5aa95f1cdf7f"
      unitRef="U_USD">106944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_18269c55-b4ed-4b4f-9430-bc69d3143509"
      unitRef="U_USD">202513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <alvr:UnrealizedGainLossOnAvailableForSaleSecurities
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_83a9a217-ddbc-44aa-9c92-425114d9439d"
      unitRef="U_USD">-313000</alvr:UnrealizedGainLossOnAvailableForSaleSecurities>
    <alvr:UnrealizedGainLossOnAvailableForSaleSecurities
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_f718d492-abdc-47e4-a116-e3651a8c9229"
      unitRef="U_USD">1000</alvr:UnrealizedGainLossOnAvailableForSaleSecurities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_0b9cf0b9-797e-400b-839e-915c0536c9e7"
      unitRef="U_USD">14717000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_b0b3191f-8c89-4970-a1a7-b8be5996a276"
      unitRef="U_USD">26386000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <alvr:IncreaseDecreaseInRightOfUseAssetDueToModification
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_b61932db-092e-46df-9b35-105a7c935e33"
      unitRef="U_USD">-5506000</alvr:IncreaseDecreaseInRightOfUseAssetDueToModification>
    <alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_47d3d7d7-fadf-49a5-a692-8f59f8ff433b"
      unitRef="U_USD">104000</alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_2f974019-4879-4425-9df2-bd5abfc3dea0"
      unitRef="U_USD">899000</alvr:PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_f71caa11-2d4e-4ed9-841a-3cd19dc7926b"
      unitRef="U_USD">613000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_d4d110b0-7e8c-46df-827a-9ce59f3962f0"
      unitRef="U_USD">106092000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_8111443a-3e3f-4f2a-8c11-7eb766d5dddd"
      unitRef="U_USD">201661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_b60135e6-dd95-4c67-bba9-19966a08d03e"
      unitRef="U_USD">852000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_cc0f3a0c-adb6-4121-a147-3c40509e6b36"
      unitRef="U_USD">852000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_ae405765-abc8-423a-bd2a-91263336ddd5"
      unitRef="U_USD">106944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_09d2ad3e-4129-4a1a-ba2e-2f1bf506ba30"
      unitRef="U_USD">202513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_eb34d6aa-43b8-4348-9484-a7c710b6ae69">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Nature of the Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;AlloVir, Inc. (&#x201c;AlloVir&#x201d; or &#x201c;the Company&#x201d;, formerly known as ViraCyte, Inc.) is a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. The Company&#x2019;s innovative and proprietary virus-specific T cell, or VST, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. The Company is developing three innovative, allogeneic, off-the-shelf VST therapy candidates targeting 11 different devastating viruses. The Company's lead product, posoleucel (previously referred to as Viralym-M or ALVR105), is a multi-VST therapy that targets six viruses: adenovirus, or AdV, BK virus, or BKV, cytomegalovirus, or CMV, Epstein-Barr virus, or EBV, human herpesvirus 6, or HHV-6 and JC virus, or JCV. The Company believes that posoleucel has the potential to fundamentally transform the treatment landscape for transplant patients by substantially reducing or preventing disease morbidity and mortality, thereby dramatically improving patient outcomes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Posoleucel is being studied in three ongoing Phase 3 registrational trials for 3 distinct indications - the prevention of clinically significant infections from multiple viruses, the treatment of virus-associated hemorrhagic cystitis, or HC, and the treatment of AdV infections &#x2013; all in allogeneic hematopoietic cell transplant, or HCT, patients who are at high risk for life-threatening viral infections from the six viruses targeted by posoleucel. We have successfully accelerated the multi-prevention study in recognition of the fact that prevention best addresses patients&#x2019; unmet medical needs. The three Phase 3 studies are expected to complete enrollment by the end of 2023, enabling potential data readouts from all three trials in 2024. In addition to the ongoing Phase 3 registrational studies, posoleucel has been studied in a Phase 2 proof-of-concept study for the treatment of BK viremia in kidney transplant patients. Positive topline results of this study were released in February 2023. This is the first study of posoleucel in SOT patients, and the results of this trial will inform next steps for this potential indication as well as the company&#x2019;s broader SOT strategy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s pipeline includes additional investigational VST therapies that may benefit high-risk individuals. ALVR106 is the Company&#x2019;s second off-the-shelf, multi-VST product candidate targeting devastating respiratory diseases caused by human metapneumovirus, or hMPV, influenza, parainfluenza virus, or PIV and respiratory syncytial virus, or RSV. A Phase 1b/2 POC clinical study of ALVR106 is enrolling patients in the U.S. In the preclinical space, the Company is developing ALVR107 to treat hepatitis B, or HBV, infected cells and with the aim of curing chronic HBV infection. Preclinical and IND-enabling studies of ALVR107 to treat and cure HBV were completed in 2022 to support advancement into a POC study after completion of the posoleucel Phase 3 registrational studies. ALVR109 is an allogeneic, off-the-shelf, single virus-targeted cell therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. Data from the POC clinical trial of ALVR109 were reported in 2021, and positive reports of ALVR109 compassionate use in immune-compromised patients also have been published and presented, including poster presentations at the 2022 American Transplant Congress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company was formed on August 16, 2013 as a Delaware limited liability company (&#x201c;LLC&#x201d;), under the name AdCyte LLC and on July 29, 2014 the Company changed its name to ViraCyte LLC. On September 17, 2018, the Company converted from a Delaware LLC to a Delaware corporation (&#x201c;LLC Conversion&#x201d;) and changed its name to ViraCyte, Inc. On May 22, 2019, the Company changed its name to AlloVir, Inc. The Company has principal offices in Waltham, Massachusetts, Houston, Texas and Dublin, Ireland.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 8, 2019, AlloVir formed AlloVir International Designated Activity Company (&#x201c;AlloVir International&#x201d;), a wholly-owned subsidiary established in Ireland.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 9, 2019, AlloVir Securities Corporation was incorporated as a Massachusetts Security Corporation, a wholly-owned subsidiary of AlloVir.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 10, 2019, AlloVir International formed AlloVir Italia S.R.L., a wholly-owned subsidiary in Italy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 20, 2021, AlloVir Inc. formed AlloVir U.S., Inc., a wholly-owned subsidiary of AlloVir.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 3, 2020, the Company completed an initial public offering (&#x201c;IPO&#x201d;) in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,687,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;317.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;292.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions and offering costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,859,139&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 26, 2022, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain investors for the issuance and sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,458,095&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ElevateBio, LLC&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On September 17, 2018, the Company executed a Series A2 Preferred Stock Purchase Agreement ("Series A2 Agreement"), with ElevateBio, LLC ("ElevateBio") and ElevateBio was a purchaser in our registered direct offering in July 2022. ElevateBio, through its diverse platform of technologies to support cell and gene therapy products and expertise, provides drug development and manufacturing services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of ElevateBio&#x2019;s purchase of our Series A2 Preferred Stock, which converted to common stock upon completion of our IPO, and as a result of ElevateBio&#x2019;s participation in the July 2022 registered direct offering, ElevateBio acquired an ownership interest in the Company. The Chief Financial Officer of ElevateBio currently serves in a similar management role with AlloVir. In May 2021, Diana M. Brainard M.D. succeeded David Hallal, ElevateBio&#x2019;s Chief Executive Officer, as the Company&#x2019;s Chief Executive Officer. Mr. Hallal currently serves as Executive Chairman of the Company's board of directors. In addition to Mr. Hallal and Mr. Sinha, two other members of the Company's board of directors, Morana Jovan-Embiricos and Ansbert Gadicke, also serve as directors of the board of directors of ElevateBio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;           &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2022, the Company has funded its operations primarily with proceeds received from the sale of common stock, research grants, and from the sale of preferred stock. The Company has incurred recurring losses since its inception, including net losses attributable to common stockholders of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;172.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. In addition, at December 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;465.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company expects to continue to generate operating losses for the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company believes that its $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;233.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of cash, cash equivalents and short-term investments held at December 31, 2022, is sufficient to fund planned operations for at least twelve months from the date that these consolidated financial statements are available to be issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;COVID-19 Considerations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The development of product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the recent COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted the Company&#x2019;s operations, including the interruption of preclinical and clinical trial activities and potential interruption to the Company&#x2019;s supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay the Company&#x2019;s ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay the Company&#x2019;s ability to obtain regulatory approval and commercialize product candidates. Furthermore, COVID-19 could affect the Company&#x2019;s employees or the employees of research sites and service providers on whom the Company relies on as well as those of companies with which the Company does business, including suppliers and CMOs, thereby disrupting business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which the Company and the companies with which it does business operate could materially impact&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. For the health and safety of our employees, the Company has implemented work-at-home policies and we have generally restricted on site staff to only those employees who are fully vaccinated or essential to the development and research of product candidates; accordingly, the Company may experience limitations in employee resources. The outbreak and any other preventative or protective actions that the Company, its suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay or otherwise adversely impact the business.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is still assessing business plans and the impact the COVID-19 pandemic may have on its ability to advance the testing, development and manufacturing of drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom the Company relies on, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or this sector in particular. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies on or with whom it conducts business, were to experience shutdowns or other business disruptions, the Company&#x2019;s ability to conduct business in the manner and on the timelines presently planned could be materially and adversely impacted.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d"
      decimals="INF"
      id="F_441d3c91-36d1-4892-8ba0-4b5f9b30393a"
      unitRef="U_shares">18687500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c"
      decimals="INF"
      id="F_c9b65d07-0cd3-4750-a96b-102fa0309124"
      unitRef="U_USDollarShare">17.00</us-gaap:SaleOfStockPricePerShare>
    <alvr:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_8dc6db35-83bd-4b55-a8d8-4e3f3007277d"
      decimals="-5"
      id="F_fea47833-02a1-45cc-8363-e599c37f050c"
      unitRef="U_USD">317700000</alvr:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6"
      decimals="-5"
      id="F_f055f4ad-9a94-40a2-b77a-cb64b73ae4d5"
      unitRef="U_USD">292000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_64a704c4-3d7f-4e2b-9ec5-bfbaf9960234"
      decimals="INF"
      id="F_6d9c7587-d64c-4cb1-b660-685e4aa5d89d"
      unitRef="U_shares">39859139</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ef1fea4e-8882-400a-ae32-d746b5237239"
      decimals="INF"
      id="F_40e87e71-4336-4007-beb7-ec2cd147f89e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="INF"
      id="F_4ca1f934-6ff4-4f8a-a4c9-0fd12bcc1f2d"
      unitRef="U_shares">27458095</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="-5"
      id="F_eb755bc4-0e8e-419d-b207-eff0ba55c5c6"
      unitRef="U_USD">126400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_97c625f6-c0f0-4fbb-b511-5292da2adceb"
      unitRef="U_USD">-168700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_f959fad5-74a6-4fd9-afc1-dac5375deeb7"
      unitRef="U_USD">-172000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-5"
      id="F_eaecedfc-2056-42c1-acf1-8c5a09c86d38"
      unitRef="U_USD">-465800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-5"
      id="F_71e65ed6-4739-4dde-a40b-02b252f56a84"
      unitRef="U_USD">233800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_4d494699-ce55-4552-8bd0-2c9afc87a454">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the Company&#x2019;s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#x2019;s long-lived assets are held in the United States.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents are short-term, highly liquid investments with original maturities of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net".&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; individual securities with impairments at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#x2019;s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records property and equipment at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;cost&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.18%;"/&gt;
          &lt;td style="width:4.918%;"/&gt;
          &lt;td style="width:45.902%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for long-lived assets in accordance with ASC Topic 360, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property, Plant, and Equipment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 360&#x201d;). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognized any impairment losses during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 &#x2013; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 &#x2013; Valuations based on inputs that are unobservable and significant to the overall fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company&#x2019;s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; deferred offering costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is  a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Income (Loss), Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records interest expense, investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in &#x201c;other income (loss), net&#x201d; over the same period in which the qualifying costs are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants restricted stock and stock options to employees, consultants and directors.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee&#x2019;s payroll costs are classified or in which the grantee&#x2019;s service payments are classified. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black&#x2011;Scholes option pricing model. As there was no public market for the Company&#x2019;s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#x2019;s board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately Held Company Equity Securities Issued as Compensation.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Following the closing of the initial public offering, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#x2011;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method. The &#x201c;simplified&#x201d; method estimates the expected term of stock options as the mid&#x2011;point between the weighted average time to vesting and the contractual maturity. The risk&#x2011;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share is determined by dividing net loss by the weighted&#x2011;average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti&#x2011;dilutive. Therefore, the weighted&#x2011;average shares used to calculate both basic and diluted loss per share are the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had no off-balance sheet risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Exchange&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of certain intercompany transactions in September 2021, the Company determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (&#x201c;USD&#x201d;) during the year ended December 31, 2021. Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of operations and comprehensive loss.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder&#x2019;s deficit that are excluded from net loss. The Company's comprehensive loss includes unrealized gains (losses) on available-for-sale securities during the year ended December 31, 2022 and 2021 and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia during the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Lease Accounting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. Options to renew or options to cancel a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 16 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <alvr:BasisOfPresentationAndConsolidationPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_082b02d6-2ceb-4460-a915-c57b3db6e075">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements include the Company&#x2019;s accounts and those of its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.&lt;/span&gt;</alvr:BasisOfPresentationAndConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_091f8fff-3a19-4768-b20b-f0f106f72e22">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; operating segment. The Company&#x2019;s singular focus is the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&#x2019;s long-lived assets are held in the United States.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_7d48e717-cbbb-4605-b8e1-a177543a8067"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_db4f5705-8f2c-4671-8709-bbfab7c51b4a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_99a5e1bf-5baf-4b7e-9b14-91c6fa005a27">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents are short-term, highly liquid investments with original maturities of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or less at the date of purchase. Investments qualifying as cash equivalents primarily consist of money market funds, corporate bonds and commercial paper.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <alvr:CashAndCashEquivalentsMaturityPeriod
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c812e48f-6080-4230-b817-51eabddb5c36">P3M</alvr:CashAndCashEquivalentsMaturityPeriod>
    <alvr:ShortTermInvestmentsPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_3a0d9895-00c0-41c0-bfd9-8a8e37f96a8c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments consist of U.S. treasury securities, corporate bonds and commercial paper classified as available-for-sale that have maturities of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in "other income (loss), net".&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific identification method. Interest on debt securities classified as available-for-sale are included in interest income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; individual securities with impairments at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</alvr:ShortTermInvestmentsPolicyTextBlock>
    <alvr:ShortTermInvestmentsMaturityPeriod
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_d0afdd83-844b-4042-8d9a-ebf81d272e82">P1Y</alvr:ShortTermInvestmentsMaturityPeriod>
    <alvr:NumberOfIndividualSecuritiesWithImpairment
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_d0dfb81c-7e6d-4403-ac3f-8bb375a9a003"
      unitRef="U_Security">0</alvr:NumberOfIndividualSecuritiesWithImpairment>
    <alvr:NumberOfIndividualSecuritiesWithImpairment
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="INF"
      id="F_4444ad3e-74f9-400a-ba00-3092fb77e373"
      unitRef="U_Security">0</alvr:NumberOfIndividualSecuritiesWithImpairment>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_205497c2-556a-41f0-9eec-aaf6fc176d86">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#x2019;s leased Waltham facility for a security deposit. The Company classified this amount as non-current restricted cash in the accompanying condensed consolidated balance sheet at December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_5e70e9d5-be25-41c2-9818-162aab7bb5aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records property and equipment at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;cost&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.18%;"/&gt;
          &lt;td style="width:4.918%;"/&gt;
          &lt;td style="width:45.902%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment. Expenditures for repairs and maintenance of assets are expensed as incurred. Upon retirement or sale, the cost of assets disposed and the corresponding accumulated depreciation are removed from the related accounts and any resulting gain or loss is reflected in the results of operations. Construction in progress is not depreciated until it is placed in service. Property and equipment to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_b51f1ee9-e0ca-4dc8-a380-d889093c06cf">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records property and equipment at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;cost&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.18%;"/&gt;
          &lt;td style="width:4.918%;"/&gt;
          &lt;td style="width:45.902%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentBasisOfValuation
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_cece726a-48b8-4b03-bdbd-631570568099">cost</us-gaap:PropertyPlantAndEquipmentBasisOfValuation>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_a415139e-be1b-4fa2-8558-0ef091e056d2">recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d003b5a4-37dd-4bf1-a824-7458b10262ac"
      id="F_5176b9ca-e7ce-4343-a8f0-0885047169ec">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7a663255-07b3-4b0c-81df-49da0711cfc1"
      id="F_99262ae8-392b-4d3d-83e7-5e5a54f4a7f0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_2f3aed44-2e48-439f-8e87-3cbf8f56b342">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for long-lived assets in accordance with ASC Topic 360, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property, Plant, and Equipment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;ASC 360&#x201d;). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognized any impairment losses during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_474636da-be52-447f-83b6-cfa7de8d7aa6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="INF"
      id="F_7a3ccbf4-5f65-421f-aec0-aa4fc3de2a47"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_ce5924bd-deaa-4735-91dd-8fffbbeb53f4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1 &#x2013; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2 &#x2013; Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3 &#x2013; Valuations based on inputs that are unobservable and significant to the overall fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, accounts payable, amount due to related party and accrued expenses. Certain of the Company&#x2019;s financial assets, including cash equivalents and short-term investments, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other financial instruments, including accounts payable, amount due to related party and accrued expenses, are carried at cost, which approximate fair value due to the short duration and term to maturity.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <alvr:DeferredOfferingCostsPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_6ff6ad0b-b662-4189-a233-14a15982c0e8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; deferred offering costs.&lt;/span&gt;&lt;/p&gt;</alvr:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_4c91218c-ace9-49bc-9306-7c1d44d658ab"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_e2976660-7d89-4b9b-ace5-8e29dcef3a3b"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_4a56f542-9d97-4a9a-b448-2eb995bc4c4d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is  a service contract. Eligible costs associated with cloud computing arrangements, such as the implementation costs incurred to develop or obtain software business applications used in the normal course of business, are capitalized in accordance with ASC 350. Capitalization ceases at the point the software is substantially complete and ready for its intended use, and after all substantial testing is completed. Amortization is recorded on a straight-line basis over the expected useful life of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the internal-use software cost in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement. Amortization expense associated with the Company's cloud computing arrangements has been recognized in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_2c5c0b15-4d90-49b6-b481-28b693927667"
      id="F_be240c53-2c70-456e-a76f-1db50b023aa9">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_94ede637-7e03-47f1-91bb-a80ccaed075e"
      unitRef="U_USD">500000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="1"
      id="F_06a12b87-f75b-4118-a46b-443844d9b5cf"
      unitRef="U_USD">0.1</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <alvr:OtherIncomeNetPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_0c1f624f-39ee-455a-b06f-e7a0518ca082">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Income (Loss), Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records interest expense, investment amortization and accretion of discounts and premiums on short-term investments and foreign exchange gains and losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in &#x201c;other income (loss), net&#x201d; over the same period in which the qualifying costs are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</alvr:OtherIncomeNetPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_2e889389-5e8b-4806-82f5-23269c7a7e78">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <alvr:AccruedResearchAndDevelopmentExpensesPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_904bed05-19aa-44fb-b45c-9157b61afdf9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</alvr:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_7294426c-89c7-486d-8cfa-b4a467df1c53">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company grants restricted stock and stock options to employees, consultants and directors.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes stock-based compensation cost for awards with performance conditions if and when it concludes that it is probable that the performance conditions will be achieved. For awards with only a service condition, the Company expenses stock-based compensation on a straight-line basis over the requisite employee service period or for grants issued with performance conditions, on a graded-vesting basis over the requisite employee service period. Awards for employees and non-employees are accounted for similarly. The Company records stock-based compensation expense associated with grants of restricted stock and stock options in the consolidated statements of operations and comprehensive loss based on their estimated fair value at the date of the grant. The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the grantee&#x2019;s payroll costs are classified or in which the grantee&#x2019;s service payments are classified. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black&#x2011;Scholes option pricing model. As there was no public market for the Company&#x2019;s common stock prior to the initial public offering of its common stock in August 2020, the estimated fair value of common stock was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#x2019;s board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately Held Company Equity Securities Issued as Compensation.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Following the closing of the initial public offering, the fair value of the Company&#x2019;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#x2011;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method. The &#x201c;simplified&#x201d; method estimates the expected term of stock options as the mid&#x2011;point between the weighted average time to vesting and the contractual maturity. The risk&#x2011;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_e2e067db-4878-4133-ba96-647e7725a034"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_19ff5c58-6bb6-4548-96d9-74f94196bc1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss per share is determined by dividing net loss by the weighted&#x2011;average common stock outstanding during the period. Since we have incurred operating losses for all periods presented, outstanding stock options and unvested restricted common stock have been excluded from the calculation because their effects would be anti&#x2011;dilutive. Therefore, the weighted&#x2011;average shares used to calculate both basic and diluted loss per share are the same.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_ad5f8eec-bf07-41dd-a1f4-513734e2a411">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1a85fbc5-e8fd-4368-aebb-b6183997dff0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had no off-balance sheet risk.&lt;/span&gt;&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_fe4aa380-8bd5-4a86-b40c-ec5249781887">At December 31, 2022 and 2021, the Company had no off-balance sheet risk.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1b4ffa75-4936-4820-a94d-c8c41b0db2ca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Exchange&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of certain intercompany transactions in September 2021, the Company determined that the functional currency for AlloVir International and AlloVir Italia is the U.S. Dollar (&#x201c;USD&#x201d;) during the year ended December 31, 2021. Prior to this determination, the functional currency of AlloVir International and Allovir Italia was the Euro; however, due to the immateriality of the transactions that occurred at AlloVir International and AlloVir Italia previously, the impact of the determination for the transition from Euro to USD is not material and is not considered a change in accounting principle for reporting purposes. Reporting currency has been and remains the USD.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the change in functional currency for AlloVir International and AlloVir Italia, assets and liabilities were translated into USD at the exchange rate in effect on the balance sheet date. Equity balances, other than retained earnings, were translated at historical exchange rates. Income items and expenses were translated at the average exchange rate in effect during the period. Unrealized translation gains and losses were recorded as a cumulative translation adjustment in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in "other income (loss), net" within the consolidated statements &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of operations and comprehensive loss.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_aee79334-9544-494b-b6cb-848663be8d40">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Comprehensive loss includes net loss and certain changes in stockholder&#x2019;s deficit that are excluded from net loss. The Company's comprehensive loss includes unrealized gains (losses) on available-for-sale securities during the year ended December 31, 2022 and 2021 and foreign currency translation adjustments from foreign subsidiaries prior to the change in functional currency for AlloVir International and AlloVir Italia during the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_28d46eaf-cea4-4de3-9e96-2ab28b456619">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Lease Accounting&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. Leases with a term greater than one year are recognized on the consolidated balance sheet as a right-of-use (&#x201c;ROU&#x201d;) asset and current and non-current lease liabilities, as applicable. The Company has made an accounting policy election, known as the short-term lease recognition exemption, which allows the Company to not recognize ROU assets and lease liabilities that arise from short-term leases (12 months or less) for any class of underlying asset. Options to renew or options to cancel a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew or will not cancel, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Certain adjustments to the ROU asset may be required for items such as lease prepayments or incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has elected to account for the lease and non-lease components together for all existing classes of underlying assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_3901e81b-913b-4bba-8e66-97555360dbd8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. The Company did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note 16 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_6fe2e821-1eb9-4cbc-abf2-cda7e9945919">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <alvr:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c384804d-c36d-4d4e-b962-b6a83adff9c6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</alvr:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <alvr:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_7d0afa87-3891-47ab-854a-61372ef51a0e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;: Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and subsequent interim periods. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;</alvr:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_859e6597-58e1-4f7e-bdee-0ded60bb2207">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the amortized cost and estimated fair value of the Company&#x2019;s U.S. government treasury securities and marketable securities, which are considered to be available-for-sale investments and are included in short-term investments on the consolidated balance sheets:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.595%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.972000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.972000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.177000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain short-term debt securities with original maturities of less than three months are included in cash and cash equivalents on the consolidated balance sheets and are not included in the tables above. At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, all investments had contractual maturities within one year.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_5cdf6fe4-2902-4367-bfd7-4ffc965ca4aa">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the amortized cost and estimated fair value of the Company&#x2019;s U.S. government treasury securities and marketable securities, which are considered to be available-for-sale investments and are included in short-term investments on the consolidated balance sheets:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.595%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.972000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.972000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.177000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.227%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;128,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd"
      decimals="-3"
      id="F_00544887-557e-4a98-b735-7e52c4ff609e"
      unitRef="U_USD">99288000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd"
      decimals="-3"
      id="F_c39c7259-8974-45e7-8127-912f0a9016c1"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd"
      decimals="-3"
      id="F_75c07062-15d7-4830-9c01-11a9e2f590fe"
      unitRef="U_USD">253000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd"
      decimals="-3"
      id="F_e2644ad6-5f7d-481e-98f2-eb4cd2a5701a"
      unitRef="U_USD">99036000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"
      decimals="-3"
      id="F_7e176d23-242d-4395-b7b7-106cd112dcbb"
      unitRef="U_USD">28748000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"
      decimals="-3"
      id="F_ca830549-1328-4d5b-b7df-d33258384dee"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"
      decimals="-3"
      id="F_d88ea18a-a25f-42b3-a07a-62c3b200bc62"
      unitRef="U_USD">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"
      decimals="-3"
      id="F_99bb731e-51cd-425b-97f2-54bc7dc95dd2"
      unitRef="U_USD">28667000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_672b6e03-d88f-4263-8d22-3f442a23d520"
      unitRef="U_USD">128036000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_00812119-6d1a-4698-a489-62bd6991fd74"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_3a16ad06-6d98-4eda-a991-9517efddeada"
      unitRef="U_USD">337000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_abcc81c2-cd9c-48b1-8697-2fde5e97611d"
      unitRef="U_USD">127703000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb"
      decimals="-3"
      id="F_63d4dd2e-801f-40e8-8763-d13b8a16cb5e"
      unitRef="U_USD">25092000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb"
      decimals="-3"
      id="F_3424268d-740f-44c2-8fbe-ed7353a07130"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb"
      decimals="-3"
      id="F_6b9602b6-6271-4fd1-967f-65d7e4af9e4e"
      unitRef="U_USD">25072000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0369a67b-84df-4183-8524-460dca6b72af"
      decimals="-3"
      id="F_a06caee1-6d07-4219-a40c-948c8a1cf31c"
      unitRef="U_USD">11568000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0369a67b-84df-4183-8524-460dca6b72af"
      decimals="-3"
      id="F_4d5aafb5-dc93-41ac-972a-c6b471bd5102"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0369a67b-84df-4183-8524-460dca6b72af"
      decimals="-3"
      id="F_e4cdfc81-33e0-4f00-973f-6286acda210f"
      unitRef="U_USD">11569000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"
      decimals="-3"
      id="F_56a5a16d-fa18-4e7a-be75-fdc1ad8355b4"
      unitRef="U_USD">9821000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"
      decimals="-3"
      id="F_59cb4dde-26e8-4db3-bb0f-bf3755de2b53"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"
      decimals="-3"
      id="F_2b7ee88e-0075-4dde-8cd6-955fb38b24c6"
      unitRef="U_USD">9818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_ff90cf25-d0b0-42dc-ac2d-e1a9d01723a5"
      unitRef="U_USD">46481000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_d9a0e57e-aa05-4b43-b29f-974a0b27b8d3"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_b1fe8868-19a1-4f4d-aa52-2e1f6734dfc1"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_7c0d58d9-ad61-45b7-97ca-c61ab967d4d8"
      unitRef="U_USD">46459000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_28072613-cbb5-44e9-95ad-32ec13bbe302">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, there were no transfers between levels. The Company classifies its money market fund and U.S. government treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its marketable securities (corporate and agency bonds and commercial paper) as Level 2 assets under the fair value hierarchy, as these assets have pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined using models or other valuation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of prepaid expenses and other current assets, prepaid expenses to related party, accounts payable, amount due to related party and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1e644af8-faa3-444e-a66f-1170b63d99c5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.694%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.23%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;141,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate and agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Totals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f54245dd-ad04-435d-9405-f93c21c6df54"
      decimals="-3"
      id="F_ae240cf2-9be4-4546-853b-cc99205f3ec1"
      unitRef="U_USD">32641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a42b0c01-30a3-4913-9e9a-d46c91274d8f"
      decimals="-3"
      id="F_c03c6cdc-200c-4fff-8ec2-eebb56b160e2"
      unitRef="U_USD">32641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d21593fe-88fc-485a-877e-34bb4604b4f0"
      decimals="-3"
      id="F_cc348110-92f5-421a-9e1c-58efcbc59d8a"
      unitRef="U_USD">32641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_0523d6e4-a559-440c-8234-bd2885cea3d7"
      unitRef="U_USD">32641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b98a7795-ec31-4702-95a8-60d00f9f4656"
      decimals="-3"
      id="F_290fd80b-73d8-4024-9bdc-7a03e630fcbe"
      unitRef="U_USD">99036000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4a87737f-16d9-4518-9638-fffb2170c6fd"
      decimals="-3"
      id="F_18bfc422-4767-419d-9cf2-0c6ad67f1043"
      unitRef="U_USD">99036000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_477148ad-c1c9-490f-97aa-87c51b482f68"
      decimals="-3"
      id="F_88bf03a3-2c0a-4798-a5af-ff250c30fa3a"
      unitRef="U_USD">28667000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_12c8446d-ab47-48d2-8bf5-a0c7f09c4fc6"
      decimals="-3"
      id="F_e90e502d-23af-489d-8334-047609f5785a"
      unitRef="U_USD">28667000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_d21593fe-88fc-485a-877e-34bb4604b4f0"
      decimals="-3"
      id="F_b2c18409-d91e-42fd-8d4a-3e89b54de012"
      unitRef="U_USD">99036000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_ca1c64ca-7e9c-446e-8772-b18830c91079"
      decimals="-3"
      id="F_fba1ab7f-32ea-46be-8a23-73ff7fb7e82e"
      unitRef="U_USD">28667000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_d4365ae6-4f0d-48b4-bcf1-4d6363eb55a2"
      unitRef="U_USD">127703000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_62600b73-3cde-4af9-85cb-8d2dcf5152ba"
      decimals="-3"
      id="F_ca8d09c6-ca1a-4b21-8898-8b242795fc81"
      unitRef="U_USD">141378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0a071b5e-8a39-4f87-993b-1f4dca7d0685"
      decimals="-3"
      id="F_4362a2dd-a33e-48d4-9e49-fe707a6b7487"
      unitRef="U_USD">141378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a68d724b-186e-40cb-914f-9f396ee8efa8"
      decimals="-3"
      id="F_94f65673-2971-40de-b388-1d76f3a99d93"
      unitRef="U_USD">7998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0369a67b-84df-4183-8524-460dca6b72af"
      decimals="-3"
      id="F_5575af7f-d0ba-4a39-bbb8-79f20aad29bd"
      unitRef="U_USD">7998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e64c980b-ef3a-4f68-b295-dd082f470d79"
      decimals="-3"
      id="F_13bcc465-6bad-4494-ae58-8da271b405a2"
      unitRef="U_USD">753000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"
      decimals="-3"
      id="F_9fe8ed21-92d9-4018-8439-236b20b36d97"
      unitRef="U_USD">753000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9"
      decimals="-3"
      id="F_f9e3dbb3-cf00-4934-87a5-59bad2c67614"
      unitRef="U_USD">141378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_eca66d82-2e78-437b-aec1-7a4f3bee0629"
      decimals="-3"
      id="F_d07550a0-5d08-4212-b392-8aa7af5e607d"
      unitRef="U_USD">8751000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_c1769aac-d33d-4243-b720-13b60f6c8c54"
      unitRef="U_USD">150129000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f2ebfc16-1156-46e3-a10c-6844f6815d58"
      decimals="-3"
      id="F_327b78f1-cbca-438e-b7df-f281d82aee7f"
      unitRef="U_USD">25072000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b3dc9f8e-adfe-4e45-bc77-d258f45102eb"
      decimals="-3"
      id="F_243f4e0d-5c7f-46f0-96af-96305eb914b6"
      unitRef="U_USD">25072000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a68d724b-186e-40cb-914f-9f396ee8efa8"
      decimals="-3"
      id="F_d1aac99d-e8d7-48c9-b6d2-4a8a1dd763e3"
      unitRef="U_USD">11569000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0369a67b-84df-4183-8524-460dca6b72af"
      decimals="-3"
      id="F_76cad6c7-065d-4ca1-973b-ef89ec076bbc"
      unitRef="U_USD">11569000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e64c980b-ef3a-4f68-b295-dd082f470d79"
      decimals="-3"
      id="F_d75537e7-df90-4063-b968-e71bc6a27ec4"
      unitRef="U_USD">9818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0b2bb03b-55e1-4761-8f11-ea6afd8e002e"
      decimals="-3"
      id="F_ff0fa5ee-50da-4b47-9b37-86043284c1a8"
      unitRef="U_USD">9818000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_d500694d-beb7-4dc9-86b1-7980fe7c2ed9"
      decimals="-3"
      id="F_9e5986af-f623-4820-b703-263bac3b72e4"
      unitRef="U_USD">25072000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_eca66d82-2e78-437b-aec1-7a4f3bee0629"
      decimals="-3"
      id="F_12f43f3e-55cb-46cf-b680-57a4b1701bc0"
      unitRef="U_USD">21387000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_63bd5d7b-3f57-4886-b08f-493a04cbe8a8"
      unitRef="U_USD">46459000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_5b0fc353-67af-45e0-ad2a-ca5f85246fca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;       Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected remaining lease term. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company uses an incremental borrowing rate based on information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate represents the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company estimates this rate based on prevailing market conditions, comparable company and credit analysis, the impact of collateralization, and the term of each of the Company&#x2019;s lease agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DMS Agreement with Third-Party Supplier&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2019, the Company entered into an interim services agreement which ultimately led to a Development and Manufacturing Services Agreement ("DMS Agreement") with a third-party supplier in July 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The DMS Agreement specifies a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility. The DMS Agreement initially expired upon the later of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and (2) the completion of services under all statements of work (&#x201c;SOWs&#x201d;). &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective June 2022, the Company entered into a First Amendment to the DMS Agreement to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; the expiration date to June 2024 provided that the terms and conditions of the DMS Agreement will continue to apply to any active SOW's. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The DMS Agreement (or any individual SOW) may be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; earlier by AlloVir at any time by providing 190 days&#x2019; notice.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; In March 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over a total estimated lease term of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In September 2019, the Company executed a SOW for another dedicated manufacturing suite under the DMS Agreement with substantially the same terms as the original SOW. In September 2019, at the inception of this lease, the Company recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over a total estimated lease term of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The SOW calls for a fixed monthly payment through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal options.  The use of these manufacturing suites qualifies as a lease under ASC 842, as it includes an identified asset for exclusive use by the Company at its direction.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, the Company entered into amendments to both SOWs under the DMS Agreement. The original SOW under the DMS Agreement (beginning March 2019) was modified to add a new termination clause whereby the Company can terminate the lease upon entering into a contract for another suite at the facility. Management concluded that the SOW amendment constituted a lease modification under ASC 842 and recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million reduction to the related ROU asset and lease liability in February 2022. The original SOW under the DMS Agreement was terminated in October 2022 upon execution of the new 2022 SOW under the DMS Agreement. The second SOW under the DMS agreement (beginning September 2019) was terminated as of the effective date of the amendment in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As a result of the amendment, which also represented a lease modification under ASC 842, the Company recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million reduction to the related ROU asset and lease liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2022, the Company entered into a new SOW under the DMS Agreement ("2022 SOW under the DMS Agreement") with a third-party supplier. The 2022 SOW under the DMS Agreement contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, fixed batch payments and other related fixed costs, totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; year lease term ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, testing, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lease &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and commenced in October 2022, the point at which the suite was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020 DMS Agreement with BaseCamp&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2020, the Company entered into a new Development and Manufacturing Services Agreement (&#x201c;2020 DMS Agreement&#x201d;) with ElevateBio BaseCamp, Inc. ("BaseCamp") and signed a SOW in November 2020. The 2020 DMS Agreement and related SOW contained an embedded lease for a dedicated manufacturing suite for the manufacture of AlloVir&#x2019;s products at the facility because the Company directs how and for what purpose the suite is used and obtains substantially all of the economic benefit of the suite. At inception of the lease, it was determined that, in exchange for this dedicated manufacturing suite, AlloVir will pay the supplier a monthly fixed suite utilization fee, and other related fixed costs, totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lease term (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lease with a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal option), that covers costs associated with reserving capacity for AlloVir, as well as cleaning services, utilities, handling and maintenance of the manufacturing suite. At inception of the lease, the Company estimated that the exercise of the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal option was reasonably certain to occur, and the Company was reasonably certain that it would not exercise its early termination right, providing for a total estimated lease term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. As part of the arrangement, there were also variable costs for materials, non-fixed batch payments, storage, knowledge and tech transfer and other common area maintenance fees that were not included in the measurement of the lease. The lease of the facility was determined to be classified as an operating lease and commenced in February 2021, the point at which the new facility area was substantially complete and available for use by the Company. Accordingly, at inception, the Company recorded a ROU asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and a lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company prepaid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the suite utilization fee, which was reclassified from prepaid expense to the ROU asset upon lease commencement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, the Company decided not to exercise the one-year renewal option and subsequently executed a Change Order to modify the terms of the SOW under the 2020 DMS Agreement. Management concluded that the amendments laid out in the change order collectively constituted a lease remeasurement under ASC 842 and recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million reduction to the related lease liability and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million reduction to the related ROU asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Waltham Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2021, the Company entered into a new lease agreement with BP Bay Colony LLC and a sublease with AMAG Pharmaceuticals Inc. for the lease of property in Waltham, Massachusetts (collectively, the "Waltham leases"). The space identified under the Waltham leases is intended for general office space, research and development, laboratory use, and light manufacturing. The Waltham leases have been classified as operating leases and commenced in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. At the inception date, the Company has recorded an ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million for the lease and a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the sublease based on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 30, 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; end date for the Waltham leases. As part of the arrangement, there were also variable costs for common area maintenance fees that were not included in the measurement of the lease. The agreement also provides a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million tenant improvement allowance which is to be reimbursed by the landlord over the duration of the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Waltham leases. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the tenant improvement allowance has been used. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;option to renew the leased space&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for an additional one time period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; with written notice from the Company. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has no reasonable certainty that this option to extend will be exercised.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of operating lease liabilities at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.231%;"/&gt;
        &lt;td style="width:1.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.824%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability &#x2013; current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability &#x2013; long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease costs were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. Cash paid for operating leases was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The Company&#x2019;s total variable lease costs, such as materials, non-fixed batch payments, testing, storage, knowledge and tech transfer, and other common area&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;maintenance fees&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, related to the operating leases was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The weighted average discount rate is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <alvr:LeaseExpirationMonthAndYear
      contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd"
      id="F_184a4750-093b-4aef-9b3d-cf5a98910deb">2021-07</alvr:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_9e73a754-0c34-4892-ba85-21910762594e"
      id="F_b88c224b-308e-43e2-8065-e7acc398582b">Effective June 2022, the Company entered into a First Amendment to the DMS Agreement to extend the expiration date to June 2024 provided that the terms and conditions of the DMS Agreement will continue to apply to any active SOW's. The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days&#x2019; notice.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd"
      id="F_1de91ede-01ee-45dc-bc42-d3aa9fa64623">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_9e73a754-0c34-4892-ba85-21910762594e"
      id="F_d250f3a7-e225-435c-89ef-4aadebb352d2">The DMS Agreement (or any individual SOW) may be terminated earlier by AlloVir at any time by providing 190 days&#x2019; notice.</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_ebbb3c52-5b08-40b2-b326-8098da241ddd"
      id="F_f4177193-6b5d-43d7-8fbd-21b8e41bda0f">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_276e92a2-b36d-49d9-b698-ebe3737df111"
      decimals="-5"
      id="F_85dfea28-a48f-43d8-b319-afaf5fc5b9d0"
      unitRef="U_USD">6900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_276e92a2-b36d-49d9-b698-ebe3737df111"
      decimals="-5"
      id="F_33e0776a-f69d-4165-ae6e-761621818b7e"
      unitRef="U_USD">6900000</us-gaap:OperatingLeaseLiability>
    <alvr:LesseeOperatingEstimatedLeaseTerm
      contextRef="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274"
      id="F_dd7837ae-7927-4102-83c7-dba6c7b189af">P4Y3M</alvr:LesseeOperatingEstimatedLeaseTerm>
    <alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear
      contextRef="C_9b1f0b8d-a99b-4799-ad4e-5b06354ad274"
      id="F_9bfdd5d4-7244-4118-aee4-ed49046bf653">2023-07</alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c"
      decimals="-5"
      id="F_a7453421-51cf-4225-8c52-94c37fe9c3db"
      unitRef="U_USD">6300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c"
      decimals="-5"
      id="F_bddd4dc1-7c0b-4d4d-b8ef-057f4519621a"
      unitRef="U_USD">6300000</us-gaap:OperatingLeaseLiability>
    <alvr:LesseeOperatingEstimatedLeaseTerm
      contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99"
      id="F_e758158c-dc4c-4c0a-941f-5bfdb224efec">P3Y9M</alvr:LesseeOperatingEstimatedLeaseTerm>
    <alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear
      contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99"
      id="F_8a7e6447-7cbf-42b9-9ae8-4fb84ba6cd2c">2023-07</alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear>
    <alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear
      contextRef="C_20d83d46-ff82-406b-8ed4-fbca2c534f99"
      id="F_8e8a8778-5397-4d4e-82bb-f303b5200227">2023-07</alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c5351c3f-424c-4eca-9cd0-1ff24d10674c"
      id="F_ef381cd1-150f-4dcf-8b93-04df9649b6f8">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c580b793-4a8d-44b5-9ac5-f169ca597d82"
      decimals="-5"
      id="F_ae74877f-c549-446b-9f3b-4895ee7927e3"
      unitRef="U_USD">-1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_c580b793-4a8d-44b5-9ac5-f169ca597d82"
      decimals="-5"
      id="F_816333f2-6b73-49c0-9b7c-f063a621f046"
      unitRef="U_USD">-1400000</us-gaap:OperatingLeaseLiability>
    <alvr:LeaseExpirationMonthAndYear
      contextRef="C_6e1405d7-d3f6-4118-b825-18c83ba250f6"
      id="F_20ed01b7-4110-421a-b887-57998c2a3aa7">2022-02</alvr:LeaseExpirationMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_978fec4b-4bb3-4327-9bc3-a12cff64e534"
      decimals="-5"
      id="F_ac87ade0-98fc-43e3-a602-6a156b144f2c"
      unitRef="U_USD">-2600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_978fec4b-4bb3-4327-9bc3-a12cff64e534"
      decimals="-5"
      id="F_19d5c3fa-b4cb-402b-8931-c1f2ae552c3d"
      unitRef="U_USD">-2600000</us-gaap:OperatingLeaseLiability>
    <alvr:UtilizationFeePayable
      contextRef="C_75223583-180e-4986-994f-4bfea6c4561f"
      decimals="-5"
      id="F_61a9b5a3-b7b8-47ed-be0f-cdf5afcce4ed"
      unitRef="U_USD">16300000</alvr:UtilizationFeePayable>
    <alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption
      contextRef="C_0a765caa-d973-4579-b4bc-2ffa5b45e639"
      id="F_d0875904-909a-4295-be4e-b87505c854c2">P2Y3M</alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption>
    <alvr:LeaseExpirationMonthAndYear
      contextRef="C_0a765caa-d973-4579-b4bc-2ffa5b45e639"
      id="F_c71c7e70-ece3-44fc-9fc4-5d6b8c356ec1">2024-12</alvr:LeaseExpirationMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_75223583-180e-4986-994f-4bfea6c4561f"
      decimals="-5"
      id="F_ed44a703-1e25-48e1-b0e7-6bdda03fb3ab"
      unitRef="U_USD">14700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_75223583-180e-4986-994f-4bfea6c4561f"
      decimals="-5"
      id="F_0d664e19-e186-48a6-970e-bc68ae9d8772"
      unitRef="U_USD">14700000</us-gaap:OperatingLeaseLiability>
    <alvr:UtilizationFeePayable
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      decimals="-5"
      id="F_07fe028b-3f76-4034-bb7e-edfce7c8d53f"
      unitRef="U_USD">3200000</alvr:UtilizationFeePayable>
    <alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption
      contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7"
      id="F_d8ff1362-a6da-4427-9275-2697d00f559a">P2Y</alvr:LesseeOperatingLeaseLeaseTermIncludingRenewalOption>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      id="F_84fb0668-2cbe-417d-9aac-87bcfc19b538">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      id="F_db4e0767-fac1-4dad-9756-55419be4b479">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      id="F_02fc4f89-5978-4745-90bc-96ed461dc501">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <alvr:LesseeOperatingEstimatedLeaseTerm
      contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7"
      id="F_f4245d8a-379f-4e41-845f-b2ad223ae2c4">P2Y</alvr:LesseeOperatingEstimatedLeaseTerm>
    <alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear
      contextRef="C_871e7fe3-7d71-4c59-84ae-b9c9532b21b7"
      id="F_3c6b16ad-fa43-4462-925d-85a88ea06292">2023-01</alvr:LesseeOperatingEstimatedLeaseExpiringMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      decimals="-5"
      id="F_aa7d7597-11bd-438e-ae67-762c7f992fe2"
      unitRef="U_USD">3100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      decimals="-5"
      id="F_5265585d-5f75-4231-8169-80751d949ce2"
      unitRef="U_USD">2500000</us-gaap:OperatingLeaseLiability>
    <alvr:PrepaidUtilizationFee
      contextRef="C_db4ec574-667d-4e70-a4cf-db9a6e572237"
      decimals="-5"
      id="F_4e1c3522-d50d-460b-bf01-e9ead91a3ab4"
      unitRef="U_USD">600000</alvr:PrepaidUtilizationFee>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_2423b8cb-2946-470e-a22d-8cdaaa80af94"
      decimals="-5"
      id="F_9fd08420-8bb4-49c6-9b37-5b116d115d3f"
      unitRef="U_USD">-1300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2423b8cb-2946-470e-a22d-8cdaaa80af94"
      decimals="-5"
      id="F_b62c81da-1c12-4df1-a4c8-378d8c73910e"
      unitRef="U_USD">-1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <alvr:LeaseCommencementMonthAndYear
      contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"
      id="F_54cb1455-a94a-478f-b6e0-558e4cc40038">2021-09</alvr:LeaseCommencementMonthAndYear>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e238b96f-4a9e-4feb-94c6-0c19c3005824"
      decimals="-5"
      id="F_19b3f93e-9979-456e-895b-27764273c100"
      unitRef="U_USD">6000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e238b96f-4a9e-4feb-94c6-0c19c3005824"
      decimals="-5"
      id="F_939e66c6-6303-4a65-adcc-f0f19f827141"
      unitRef="U_USD">6000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1176b604-ee17-4ddb-be7e-456b15cb96ce"
      decimals="-5"
      id="F_be5f1d4c-6a90-4955-ad92-7e23aadb119b"
      unitRef="U_USD">17300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1176b604-ee17-4ddb-be7e-456b15cb96ce"
      decimals="-5"
      id="F_87bbcf18-a749-4364-b417-8108aab18f1a"
      unitRef="U_USD">17300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"
      id="F_7d30c054-60ac-4c16-bcba-9cd471ca94f7">2030-07-30</us-gaap:LeaseExpirationDate1>
    <alvr:TenantImprovementAllowanceToBeReimbursed
      contextRef="C_232cbeff-83b0-4296-a32f-459b4b6c2711"
      decimals="-5"
      id="F_f4c8c91c-c818-48c2-b5a7-90da360d63ce"
      unitRef="U_USD">3100000</alvr:TenantImprovementAllowanceToBeReimbursed>
    <alvr:TenantImprovementAllowanceReimbursementPeriod
      contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"
      id="F_d416c2a0-c023-4da2-bcf2-263606c25e94">P2Y</alvr:TenantImprovementAllowanceReimbursementPeriod>
    <us-gaap:TenantImprovements
      contextRef="C_ddd9b411-5433-4b78-876b-16099390a62c"
      decimals="-5"
      id="F_b2aed9fa-b1fe-445c-be98-3c698f9fb406"
      unitRef="U_USD">900000</us-gaap:TenantImprovements>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_48c024c0-d687-47ba-9b05-7f832db9c0ca"
      id="F_da3e93b1-2aa9-4d56-80be-ba22c7e016b3">The Company has the option to renew the leased space for an additional one time period of five years with written notice from the Company. As of December 31, 2022, the Company has no reasonable certainty that this option to extend will be exercised.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"
      id="F_a2c6d896-4d2c-41cc-b220-e193465fe34e">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <alvr:AdditionalOneTimeLeasePeriod
      contextRef="C_13cfbc46-42ec-40b3-9d81-f9fcc108c637"
      id="F_b305a6b9-1c15-4024-a50f-8b39d89a5630">P5Y</alvr:AdditionalOneTimeLeasePeriod>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_e6c4de93-e071-4eb7-9642-223325235641">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of operating lease liabilities at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.231%;"/&gt;
        &lt;td style="width:1.944%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.824%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability &#x2013; current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability &#x2013; long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_6794dfe1-4ee4-40e6-81a9-c98645b64f5e"
      unitRef="U_USD">9074000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_54c0dd69-daaa-4897-8bec-d40ceca6bfed"
      unitRef="U_USD">12525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_a30005d1-e7f5-46f2-8e72-ad56e2d2b9f8"
      unitRef="U_USD">3229000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_17e65d7e-12db-4174-9932-00424d6c675a"
      unitRef="U_USD">3308000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_2f59f3a2-f71c-4b66-9bd9-b459494fc513"
      unitRef="U_USD">3386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_f4412a40-eb10-4741-a7d2-8e51856145db"
      unitRef="U_USD">9683000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_b0cc02bd-506a-4d55-8e6d-078ff5921af4"
      unitRef="U_USD">41205000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_02c1ec9c-f28a-478a-8c8b-f82f6cd6cf1e"
      unitRef="U_USD">5818000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_041d012d-f709-4993-82e1-9ab629f50d02"
      unitRef="U_USD">35387000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_9caec006-6a55-4b38-853b-431de79296d0"
      unitRef="U_USD">7165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_4044d9e6-2726-4a30-b9a3-19721d6316ed"
      unitRef="U_USD">28222000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_bb883dd4-7960-4331-873f-b2df4088496c"
      unitRef="U_USD">6600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_e51e2a41-2e91-45eb-a10f-0d725d64b635"
      unitRef="U_USD">6200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_5fd7160b-9796-434c-942d-1c55c0b3d652"
      unitRef="U_USD">4800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_70251c7a-6682-4a40-85f7-46ce5339f620"
      unitRef="U_USD">5200000</us-gaap:OperatingLeasePayments>
    <us-gaap:VariableLeaseCost
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_2cd400ab-d8a2-43bb-83c3-6dc0d900c527"
      unitRef="U_USD">3700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_18deab9c-73b6-4222-ac7c-f11c5195fbfc"
      unitRef="U_USD">14500000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      id="F_9f8858ce-018f-45b1-9b3e-0d49d0eb59de">P6Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="4"
      id="F_41f0ada1-7ea0-4183-9b9e-01fcf4175b5d"
      unitRef="U_pure">0.0623</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_358e6510-9750-4752-ac2c-09dab5db66e3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.383%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.513%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.397%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_46d71f9f-52e4-479b-ac78-6c772085f1b6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.383%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.513%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.397%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_028feb25-e5dc-4693-838f-892bc643344f"
      decimals="-3"
      id="F_b5064c8b-6234-4768-9fab-c173c1803550"
      unitRef="U_USD">1395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e1ac0558-7793-4cbc-abac-375855874e63"
      decimals="-3"
      id="F_83ad9c20-6c20-4a37-b56a-f6717789ed13"
      unitRef="U_USD">1395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4638e48c-caee-470f-8e9f-fd72016b2756"
      decimals="-3"
      id="F_f1b8ec8d-e88a-4ab4-849f-67ded89b4e00"
      unitRef="U_USD">435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a6d7b88b-a721-4583-9af3-cdcbc9a426d2"
      decimals="-3"
      id="F_bb719b69-2202-4ecd-9794-26b20b390409"
      unitRef="U_USD">435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4c070771-4f77-4eda-b36a-c12f31943e25"
      decimals="-3"
      id="F_3a6538ea-c0e3-4e12-9c94-42cf33765ead"
      unitRef="U_USD">104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_143ede05-80ac-4804-bafc-ac62c5f1f9a2"
      unitRef="U_USD">1934000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_9b31d718-0228-4573-b24a-95b0925cf93c"
      unitRef="U_USD">1830000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_babd15c4-2cc4-44f1-86c1-e9ee188dee77"
      unitRef="U_USD">1004000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_89f3ea25-f39e-4eb8-9142-ef105eedac5b"
      unitRef="U_USD">281000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_739816d0-1a6f-4372-adc7-56cfba3f538d"
      unitRef="U_USD">930000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_930d6e78-424d-4da7-b181-115e42038afc"
      unitRef="U_USD">1549000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_2b047b0d-bd36-44e7-ab02-6ea258550f25"
      unitRef="U_USD">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_e9348b98-e878-4f6d-b27d-10ddf2841b67"
      unitRef="U_USD">200000</us-gaap:Depreciation>
    <alvr:AccruedLiabilitiesDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_f2484b84-a620-4946-b4a5-90a4d781e8b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Process development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</alvr:AccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_a08e4594-d71f-4cdd-970f-0960d4b94d09">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Process development and manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_1f50a029-a188-4d7c-ab5d-42c7a8b623f2"
      unitRef="U_USD">6416000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_621f8e4d-cded-47b9-8980-402172f34083"
      unitRef="U_USD">6867000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_8bfb3fb4-a93a-4b01-9b7d-123e5aff4e92"
      unitRef="U_USD">559000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_05d8400b-8427-4bcf-8320-25829bf1a344"
      unitRef="U_USD">738000</us-gaap:AccruedProfessionalFeesCurrent>
    <alvr:AccruedResearchAndDevelopmentCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_b2510725-ae1b-453e-abbc-11fa324027c9"
      unitRef="U_USD">5678000</alvr:AccruedResearchAndDevelopmentCurrent>
    <alvr:AccruedResearchAndDevelopmentCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_f4e3a166-17c3-483d-a6fe-71b918de466a"
      unitRef="U_USD">3573000</alvr:AccruedResearchAndDevelopmentCurrent>
    <alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_0d4f730f-99de-482f-9ca1-f39f0e42ec91"
      unitRef="U_USD">504000</alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent>
    <alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_a3a21971-f9a5-4aa5-96a7-a78fba544c2b"
      unitRef="U_USD">7685000</alvr:AccruedProcessDevelopmentAndManufacturingCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_7b8f6ad9-af7b-42e1-9be8-e55b81b8e282"
      unitRef="U_USD">828000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_d7a11651-aa6d-4268-b291-fc21a37af03f"
      unitRef="U_USD">1289000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_c022d70e-5c32-42a3-b84a-968cb6947b34"
      unitRef="U_USD">13985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_5f05366c-6058-4d3a-8864-24ae5051f3b2"
      unitRef="U_USD">20152000</us-gaap:AccruedLiabilitiesCurrent>
    <alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_6e392c18-a92d-40b7-9c8b-7572aecb05dd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. Sponsored Research, Collaboration and License Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Amended and Restated Exclusive License Agreement with BCM&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2017, the Company signed a License Agreement (the &#x201c;License Agreement&#x201d;) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights in the field of viral infection. In May 2020, the Company amended and restated the License Agreement (the &#x201c;A&amp;amp;R License Agreement&#x201d;), pursuant to which the Company obtained (a) an exclusive worldwide license, with the right to sublicense, under certain patent rights and other intellectual property rights of BCM, to make, have made, use, market, sell, offer to sell, lease, import and export products in a particular field, except that such license is non-exclusive within a particular subfield, and in addition with respect to certain patent rights such license is limited to two particular subfields, and (b) an exclusive, worldwide sublicense, with the right to further sublicense, under all patent rights and other intellectual property rights that are exclusively licensed to BCM by a certain third party licensor, to make, have made, use, market, sell, offer to sell, lease, import and export products in the same field. The Company&#x2019;s rights are subject to the rights of the U.S. government and certain rights retained by BCM.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unless earlier terminated, the A&amp;amp;R License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country. The Company may terminate the A&amp;amp;R License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the A&amp;amp;R License Agreement in its entirety for the Company&#x2019;s uncured material default.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;BCM maintains control of all filing, prosecution and maintenance of its patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the agreement. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the agreement with respect to the filing,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;prosecution and maintenance of the patent rights licensed by the Company. If BCM licenses the patent rights licensed by the Company to third parties for additional fields of use, the Company&#x2019;s responsibility for patent related costs and expenses will be reduced on a pro-rata basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the A&amp;amp;R License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the original agreement executed in June 2017, the Company paid BCM a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the term of the A&amp;amp;R License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee, but beginning with the fifth year after the original agreement date, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize a product under the A&amp;amp;R License Agreement, total milestone payments could exceed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the A&amp;amp;R License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2020, the Company also entered into the First Amendment (the &#x201c;License Amendment&#x201d;) to the A&amp;amp;R License Agreement. Under the License Amendment, the Company assumed responsibility from BCM for the filing, prosecution and maintenance of the patent rights licensed by the Company from BCM under the A&amp;amp;R License Agreement that are in common with the License Agreement. Further, BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in such patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with BCM&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2020, the Company signed a second License Agreement (the &#x201c;Second License Agreement) with BCM, whereby the Company acquired a royalty-bearing, worldwide, exclusive license to BCM&#x2019;s rights in Subject Technology and related patent rights outside the field of viral infection (all fields other than those covered by the A&amp;amp;R License Agreement).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unless earlier terminated, the Second License Agreement will expire on a country-by-country basis with respect to a product upon the later of (a) the expiration of the last to expire valid claim of a patent or patent application covering such product in such country or (b) 10 years after the first commercial sale of such product in such country, provided that the Second License Agreement shall not expire later than March 25, 2040. The Company may terminate the Second License Agreement in its entirety at any time for convenience upon a certain number of days&#x2019; written notice. BCM may terminate the Second License Agreement in its entirety for the Company&#x2019;s uncured material default.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Second License Agreement, BCM transferred to the Company control of all filing, prosecution and maintenance of the patent rights licensed by the Company, and the Company is responsible for all related costs and expenses during the term of the Second License Agreement. BCM also transferred to the Company the right of enforcement against third parties for any suspected infringement of any claims in the patent rights or misuse, misappropriation, theft or breach of confidence of other proprietary rights. The Company also reimbursed BCM for costs and expenses (including reasonable legal fees and expenses) incurred prior to the effective date of the Second License Agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by the Company, to the extent not already paid by the Company under the A&amp;amp;R License Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Second License Agreement, the Company must use commercially reasonable efforts to develop and commercialize one or more products in certain countries. As partial consideration for the rights conveyed by BCM under the Second License Agreement, the Company paid BCM a non-refundable license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the term of the Second License Agreement, the Company is obligated to pay BCM a non-refundable annual license maintenance fee of (a) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the first through fourth anniversary of the effective date of the Second License Agreement, and (b) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the fifth anniversary of the effective date and continuing thereafter, but beginning with the fifth year, license maintenance fees are fully creditable against royalty revenue due in the applicable year. The Company is required to pay certain milestone payments upon the achievement of specified clinical, regulatory, and sales milestones. In the event that the Company is able to successfully develop, launch and commercialize multiple products under the Second License Agreement, total milestone payments could exceed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. BCM is also eligible to receive tiered royalties at percentage rates ranging from less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to the low single-digits, on net sales of any products that are commercialized by the Company or its sublicensees that incorporate, utilize or are made with the use of, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the Second License Agreement, BCM would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement with BCM&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2020, the Company entered into a Research Collaboration Agreement (the &#x201c;Research Agreement&#x201d;) with BCM, under which the Company agreed to pay BCM for performing certain research activities under the direction of Dr. Ann Leen commencing on January 1, 2021 and continuing for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period thereafter. The Research Agreement requires the Company to make payments to BCM totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per year, for a total of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over the term of the Research Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collectively under the agreements above and for services provided by BCM the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively, and the payments were classified in research and development expense in the consolidated statements of operations and comprehensive loss. As of December 31, 2022, and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in accrued milestone expenses are recorded under accrued expenses &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;CPRIT Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2017, the Company was awarded a grant (the &#x201c;CPRIT Grant&#x201d;) from the Cancer Prevention and Research Institute of Texas (&#x201c;CPRIT&#x201d;). The CPRIT Grant required that the Company grant CPRIT a non-commercial license to technology developed under the grant and pay CPRIT a share of revenue on sales of commercial products developed using CPRIT funds equal to low single digits of revenue until such time as CPRIT has been paid an aggregate amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the grant award proceeds.  &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; royalty payments were made under this license agreement during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Redeemable Preferred Stock Redemption Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2018, the Company entered into a redeemable preferred stock redemption agreement, or Redemption Agreement, to redeem shares of our Series A1 convertible preferred stock held by certain investors, including executive officer Ann Leen, director and former executive officer Juan Vera and entities affiliated with director, Malcolm Brenner and former director, John Wilson (or their affiliates). Pursuant to the Redemption Agreement, for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the date of the first commercial sale of Viralym-M, the Company is obligated to make earnout payments to such investors on at least an annual basis. The earnout payments will be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of net sales of Viralym-M, which number will be reduced to a high single-digit percentage if certain events occur. Specifically, royalties due to third parties for the sale of Viralym-M are subtracted from the earnout payments due to the investors. Further, if the investors receive at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in earnout payments from AlloVir during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period after the first commercial sale of Viralym-M, the earnout payment percentage will be reduced.&lt;/span&gt;&lt;/p&gt;</alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock>
    <alvr:NonRefundableLicenseFeePayments
      contextRef="C_45693ffc-b960-4db0-a592-606079f137e6"
      decimals="0"
      id="F_3bb5810c-2b80-4bfd-bf1b-491461d924a2"
      unitRef="U_USD">250000</alvr:NonRefundableLicenseFeePayments>
    <alvr:MilestonePayments
      contextRef="C_ba9cbb52-e4cc-4b69-b43d-08477c237f07"
      decimals="-5"
      id="F_0dfa96b8-9c4a-4ebc-ae63-f1f595622355"
      unitRef="U_USD">40000000.0</alvr:MilestonePayments>
    <alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties
      contextRef="C_871ad9af-02db-4352-9621-2c92ad7156c5"
      decimals="INF"
      id="F_f2838d63-ba52-444d-8c1f-cb34193155c3"
      unitRef="U_pure">0.01</alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties>
    <alvr:NonRefundableLicenseFeePayments
      contextRef="C_a1c6fa03-2ee5-482c-8fcc-3134560afe02"
      decimals="0"
      id="F_96abd253-0595-464a-9f27-5b6a04b5c1cf"
      unitRef="U_USD">125000</alvr:NonRefundableLicenseFeePayments>
    <alvr:NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate
      contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223"
      decimals="0"
      id="F_67b656da-03f0-4544-b4ba-82a80f07ecaf"
      unitRef="U_USD">20000</alvr:NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate>
    <alvr:NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter
      contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223"
      decimals="0"
      id="F_c9d7e516-b0ca-42f9-a848-ea41213e7f9e"
      unitRef="U_USD">40000</alvr:NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter>
    <alvr:MilestonePayments
      contextRef="C_58e1e3b7-65b1-4635-80ad-d5bfdb1cd223"
      decimals="-5"
      id="F_e4563281-55b1-4aba-9621-8c22472b4ba9"
      unitRef="U_USD">30000000.0</alvr:MilestonePayments>
    <alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties
      contextRef="C_6ad4867e-83a6-4c90-8517-df9e8041faad"
      decimals="INF"
      id="F_00e0acfe-e29f-4e62-a585-90a6896f8ead"
      unitRef="U_pure">0.01</alvr:MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties>
    <alvr:AgreementForPerformingResearchActivitiesTerm
      contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b"
      id="F_60dd305c-dac2-4437-b4d7-68e37d3bf782">P3Y</alvr:AgreementForPerformingResearchActivitiesTerm>
    <alvr:ResearchActivitiesPerformingFees
      contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b"
      decimals="-5"
      id="F_fad7005b-a136-4036-99d9-6de67d14bc14"
      unitRef="U_USD">2000000.0</alvr:ResearchActivitiesPerformingFees>
    <alvr:AggregateResearchActivitiesPerformingFees
      contextRef="C_6dd688fa-9bfb-450c-823f-914d71bdb20b"
      decimals="-5"
      id="F_cd7b9fcd-aea1-4669-97a4-62aa15a116e2"
      unitRef="U_USD">6000000.0</alvr:AggregateResearchActivitiesPerformingFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a3d1dc62-3ca8-4a65-8d93-bffe388766da"
      decimals="-5"
      id="F_65be6ff7-f9f2-4075-93ed-73c1bbc39d46"
      unitRef="U_USD">2500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_34017843-7cb8-4d00-86bb-8889a840a88a"
      decimals="-5"
      id="F_e3b00940-63a7-47ee-804f-4222ffd1106d"
      unitRef="U_USD">3300000</us-gaap:ResearchAndDevelopmentExpense>
    <alvr:AccruedMilestoneExpenses
      contextRef="C_51c4f488-3970-4c54-84de-f12cde7d10db"
      decimals="-6"
      id="F_6711571f-d31d-4249-8efd-0f50f2b34347"
      unitRef="U_USD">0</alvr:AccruedMilestoneExpenses>
    <alvr:AccruedMilestoneExpenses
      contextRef="C_0de4aa3b-f8d3-4a15-88ec-81d1af1626ad"
      decimals="-5"
      id="F_bc6adf9f-bc73-4403-ab29-6f19189c67a4"
      unitRef="U_USD">200000</alvr:AccruedMilestoneExpenses>
    <alvr:MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable
      contextRef="C_89b61897-7cb1-4529-aa9a-3dcca0317455"
      decimals="2"
      id="F_9179a0fc-e20a-4283-9219-30ce41301664"
      unitRef="U_pure">4</alvr:MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_89b61897-7cb1-4529-aa9a-3dcca0317455"
      decimals="-3"
      id="F_91af4be6-cc4b-4fac-b635-b43df1a534ce"
      unitRef="U_USD">0</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_eb50bcd6-a9a6-4061-9ef2-e7d4b30b505a"
      decimals="-3"
      id="F_0bd7ce08-a582-4551-b763-f2ad071b0c1d"
      unitRef="U_USD">0</us-gaap:PaymentsForRoyalties>
    <alvr:EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale
      contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2"
      id="F_3567350b-78b1-4797-9d4c-1db75f41f857">P20Y</alvr:EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale>
    <alvr:EarnoutPaymentAsPercentageOfNetSales
      contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2"
      decimals="2"
      id="F_14b1aedc-c6ad-408b-aaf6-1347117a6203"
      unitRef="U_pure">0.10</alvr:EarnoutPaymentAsPercentageOfNetSales>
    <alvr:MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment
      contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2"
      decimals="0"
      id="F_bd457253-b535-4495-8b7d-a51e6a8403c8"
      unitRef="U_USD">50000000</alvr:MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment>
    <alvr:PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale
      contextRef="C_0b872f5d-6e7d-409f-b489-675ef849e5c2"
      id="F_b146896f-2db7-4dee-b126-438b8ff389aa">P3Y</alvr:PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c668a608-3266-4c31-94b3-53f05095f3b7">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Stockholder&#x2019;s Equity&lt;/span&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 3, 2020, in connection with the closing of the Company&#x2019;s IPO, the Company filed its amended and restated certificate of incorporation, which authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; par value per share. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of preferred stock issued or outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 26, 2022, the Company entered into the Securities Purchase Agreement with certain investors for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors in a registered direct offering an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,458,095&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company's common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share (the "Shares") at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per Share (the "Offering"). The Offering was made without an underwriter or a placement agent, and therefore, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; underwriting discounts or commissions in connection with the offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following is a summary of the rights and privileges of the holders of the Company&#x2019;s common stock at December 31, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Voting Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The holders of the common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Board out of legally available funds. At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cash dividends have been declared or paid.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidation Preference&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the event of a liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the then-outstanding shares of preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Rights and Preferences&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.772%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.741%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.144%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock available for grant under the 2020 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,253,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,812,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock available for issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;454,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;611,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,869,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,445,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c"
      decimals="INF"
      id="F_32e983fb-98d3-42d5-a45b-06fbfa1aabb4"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6bd4967c-de1f-4ce5-9073-2145721fd38c"
      decimals="INF"
      id="F_1a0e0760-1d82-4166-9e81-bc0e480490d4"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_c08e5b47-5626-4b0a-9e44-88120b74cfba"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_b7ca7bad-9364-4ef4-82b5-b423229eaf95"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_2655ea68-83ba-42d9-aa96-3cba4fff5143"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_3511338e-6b74-49ab-94d1-abdc9bbc8813"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_03363e59-7ef1-4adb-bb12-091bc90136fd"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_58530541-b5e4-496f-9cdc-4d8d6dd69f33"
      decimals="INF"
      id="F_7e16c6ef-820b-4a70-940c-5785f0b4e391"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_499b8119-c41c-4a21-885e-cad67c2497d3"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_cc72ce7e-234c-4ecc-b9ff-160eaa3408e7"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="-5"
      id="F_271aa4d4-7e0c-445f-9f31-81af54b4a6ce"
      unitRef="U_USD">126400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <alvr:SaleOfStockOfferingCosts
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="-5"
      id="F_eb73ac62-0e83-420d-ad7e-fd06183f782e"
      unitRef="U_USD">200000</alvr:SaleOfStockOfferingCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="INF"
      id="F_b63fa698-2168-45a3-818f-4e2d75e4fa09"
      unitRef="U_shares">27458095</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_227c3050-c341-4701-9bbc-1a6d93036b5a"
      decimals="4"
      id="F_a90b2f39-c1b6-4a53-a1e8-6a561271c1ee"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_227c3050-c341-4701-9bbc-1a6d93036b5a"
      decimals="2"
      id="F_9270d2df-d643-4259-85e4-8cbe979fd1d2"
      unitRef="U_USDollarShare">4.61</us-gaap:SaleOfStockPricePerShare>
    <alvr:UnderwritingDiscountsCommissions
      contextRef="C_86f2f458-9d81-4153-bb34-15b4a600c6f3"
      decimals="-3"
      id="F_51ef9db0-a1c2-4d95-af99-63859004f0ca"
      unitRef="U_USD">0</alvr:UnderwritingDiscountsCommissions>
    <us-gaap:CommonStockVotingRights
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1bb3645c-07c3-4c64-bb40-61ecb7a30950">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.</us-gaap:CommonStockVotingRights>
    <alvr:NumberOfVotesPerShare
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_e4490edc-6014-44d4-a1da-4e91dbd578db"
      unitRef="U_Vote">1</alvr:NumberOfVotesPerShare>
    <us-gaap:DividendsCash
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_67e142a7-8c71-41a9-8502-4f1d976dac47"
      unitRef="U_USD">0</us-gaap:DividendsCash>
    <alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_cc5f4db8-ba60-4ad7-9b5e-3cac4d6811bd">&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.772%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.741%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.144%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock available for grant under the 2020 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,253,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,812,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock available for issuance under the 2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;454,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;611,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,869,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,445,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f0711afd-ddae-4cbb-95eb-8a59378fefed"
      decimals="INF"
      id="F_a6c6783d-fd01-4b71-b21a-d448ebfc781c"
      unitRef="U_shares">2239106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_530cd7cd-8adc-465e-b494-4eb7a45191a4"
      decimals="INF"
      id="F_1e469503-dc10-4c98-9ea6-18b457c937ba"
      unitRef="U_shares">2866909</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_160a6c1c-126c-4390-a8b9-a1f7c5589625"
      decimals="INF"
      id="F_24d1ab0f-06a8-475f-9c48-88fc8c7e3151"
      unitRef="U_shares">7922797</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_183322ca-7ab4-457e-8a32-87ac4df2d1d3"
      decimals="INF"
      id="F_9df289dd-3542-45ef-8747-4d0e030b96c0"
      unitRef="U_shares">6155055</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea"
      decimals="INF"
      id="F_0b93f245-5892-445d-b058-f3c7fd5329b5"
      unitRef="U_shares">4253680</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79512046-91c6-49b4-ae01-0e273533c65f"
      decimals="INF"
      id="F_af715a11-33b3-4a60-85f4-e4eb6819584e"
      unitRef="U_shares">3812396</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_75215896-db5d-4536-a304-39f269881d56"
      decimals="INF"
      id="F_7e131673-7ac3-474f-86c0-58986d242dfd"
      unitRef="U_shares">454302</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_51a0554a-094f-4ada-b6e2-8ae4cc043eaf"
      decimals="INF"
      id="F_37b768e6-1a2f-40b9-8665-e2169daf835d"
      unitRef="U_shares">611354</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_aca5b3e5-a34c-4491-8260-1ce806b8b938"
      unitRef="U_shares">14869885</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_cf1fbca2-a890-483b-80cf-7a89b3e7a722"
      unitRef="U_shares">13445714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_75131eb7-bd3c-4e7b-a4fc-d3054436762a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s 2018 Plan provided for the Company to issue restricted stock, restricted stock units, incentive stock options, and non-statutory stock options and other stock-based awards to employees, officers, members of the Board, consultants and advisors of the Company. The 2018 Plan was most recently amended in July 2020. The awards granted under this plan generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period and have a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; contractual term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,715,415&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock under the 2018 Plan. At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,042&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of outstanding options under the 2018 Plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,616,772&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of restricted common stock granted under the 2018 plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares remain available for future issuance under the 2018 Plan. Any options or awards outstanding under the 2018 Plan remain outstanding and effective.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 2, 2020, the Company&#x2019;s Board of Directors adopted and in July 2020 the stockholders approved the 2020 Stock Option and Grant Plan (the &#x201c;2020 Plan&#x201d;) which became effective on July 28, 2020, the date immediately prior to the date on which the registration statement related to the IPO was declared effective, and as a result no further awards were made under the 2018 Plan thereafter. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Plan &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,008,734&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares. The number of shares of our common stock reserved for issuance under the 2020 Plan shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. Accordingly, on January 1, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,528,817&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were added to the number of available shares under the 2020 Plan. The awards granted under this plan generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period and have a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; contractual term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there were an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,858,755&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issuable upon the exercise of outstanding options under the 2020 Plan and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,076,516&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of restricted common stock granted under the 2020 Plan. There is an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,253,680&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares reserved for future issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Common Stock&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes restricted common stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.112%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.084999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,632,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;348,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,912,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation cost related to the restricted stock, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.350000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.35%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.316%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.535%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,051,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,284,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,945,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The aggregate intrinsic value of options exercised were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted average grant-date fair value of stock options granted during the year ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.61&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.76&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively. The weighted average grant date fair value of options vested was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.61&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022 and 2021, respectively. At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to unvested stock options, which is being recognized over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.492%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2020, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;) was adopted by the Board of Directors and approved by the stockholders. The purpose of the 2020 ESPP is to provide eligible employees of the Company and other designated companies, with opportunities to purchase shares of the Company&#x2019;s common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Initially, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;611,354&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock in the aggregate were approved and reserved for this purpose. The number of shares of common stock reserved and available for issuance under the 2020 ESPP shall be cumulatively increased on January 1, 2021 and each January 1 thereafter by the least of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,222,707&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such number of shares of common stock as determined by the Administrator. The Board of Directors elected not to increase the number of available shares as of January 1, 2021 and 2022. At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;454,302&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP allows eligible employees to authorize payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their base salary or wages up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Market &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(i) on the first trading day of the offering period or (ii) the last day of any offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares and compensation expense is recognized over the offering period.  The first ESPP offering period was shortened in duration to three months and commenced on April 1, 2022 and ended on June 30, 2022. New six-month offering periods will commence each January 1 and July 1 thereafter during the term of the plan, with the administrator having the right to establish different offering periods.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions. At the end of each offering period, accumulated payroll deductions are used to purchase the Company&#x2019;s shares at the discounted price. The Company makes no contributions to the ESPP. A participant may withdraw from the ESPP or suspend contributions to the ESPP. If the participant elects to withdraw during an offering period, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw or suspend contributions, they will not be able to re-enroll in the current offering but may elect to participate in future offerings. The ESPP purchases only whole shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157,052&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; common shares under the ESPP during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, at an average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Cash received from purchases under the ESPP for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of compensation expense for the ESPP during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_17b47bd8-1eca-4961-95dc-a1d134aa8d32">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.065%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.645999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.043999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1b40c6bb-4bfb-4418-9f73-133bb83a5cc8"
      decimals="-3"
      id="F_a755259f-4d00-4e90-ae1f-5223e4064536"
      unitRef="U_USD">14014000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_34bd2dd2-4644-4d61-9dd2-0ea6e25b44ad"
      decimals="-3"
      id="F_dcc6aaa0-485f-4e9c-9d90-e538dd0723e5"
      unitRef="U_USD">20632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c8f5f95d-8c74-42da-8e94-481be7b2c583"
      decimals="-3"
      id="F_0dbfd26d-cc47-48fa-b0ef-5d390d1df2db"
      unitRef="U_USD">27301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_edef2090-5f5c-44a5-91fc-85d5605d9a25"
      decimals="-3"
      id="F_51956062-1bf5-4bf9-a589-6ab86e59b15f"
      unitRef="U_USD">23343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_40decdd5-5fd4-4166-a526-789ae6afe630"
      unitRef="U_USD">41315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_1dc48e83-81d0-49c3-9ce6-b2832e25a09e"
      unitRef="U_USD">43975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a2440698-340f-405b-82b8-2ee426f49c94"
      id="F_846a03c1-763f-4e98-bc11-0d0130fe2dfe">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_a2440698-340f-405b-82b8-2ee426f49c94"
      id="F_5fb85dca-2195-408f-b0ff-b3162661b738">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df"
      decimals="INF"
      id="F_51269357-9d16-481c-928b-f64ac62745a8"
      unitRef="U_shares">6715415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <alvr:NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions
      contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df"
      decimals="0"
      id="F_812ca4a9-e529-499a-a660-aace17ef62ae"
      unitRef="U_shares">64042</alvr:NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_2ac4b804-48e5-4500-bafb-20607b67d00c"
      decimals="INF"
      id="F_8a725b4c-98fe-4323-9320-1a03e460f628"
      unitRef="U_shares">6616772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6f6f1e4d-56e5-462f-b160-b281f07868df"
      decimals="INF"
      id="F_87745d56-a85d-4d5f-b088-ee12db52a3c5"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_14bd8057-2b3c-443a-8b90-b6382cbf114b"
      decimals="INF"
      id="F_7637436f-e31d-4184-9180-2742534d079d"
      unitRef="U_shares">8008734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d"
      decimals="2"
      id="F_37f8885c-717f-4013-886b-a36af40d1619"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_929b39a9-292b-4663-ab90-74229b474881"
      decimals="INF"
      id="F_cd2a0826-78d5-41b7-b96d-85270826b164"
      unitRef="U_shares">3528817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d"
      id="F_4aacfc48-b163-4f5e-ace7-6d2337dc104a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_51750031-7f9c-4c75-a085-4599ec0a8c7d"
      id="F_77051206-c617-4ad5-8904-b753d498f740">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions
      contextRef="C_a2765896-7ab5-4950-93b3-5422a0d04d3d"
      decimals="INF"
      id="F_d5a7e735-272a-4377-848a-d7e7ff6005ee"
      unitRef="U_shares">7858755</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_617f4174-88a5-4f52-8e3f-dafed24ab46e"
      decimals="INF"
      id="F_1f9409c9-038b-4bc6-897f-207a41315173"
      unitRef="U_shares">3076516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e5c615ee-7ec1-4521-8323-ae396ba0a2ea"
      decimals="INF"
      id="F_bdd12195-84ed-4b29-bb25-598c7fe5ffbc"
      unitRef="U_shares">4253680</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_1136fccb-6d94-4738-8e1b-ce0430fca691">&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes restricted common stock activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.112%;"/&gt;
        &lt;td style="width:1.171%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.017999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.084999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,632,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;348,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,912,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805"
      decimals="INF"
      id="F_96025857-eef4-439c-ae84-04f2ee9ce458"
      unitRef="U_shares">2866909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a98375b5-9ac1-4ea5-b963-c5149a6f4805"
      decimals="2"
      id="F_c434b1fe-aeb0-40c1-b48b-fd0517dbe97e"
      unitRef="U_USDollarShare">15.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="INF"
      id="F_b1864293-d0bb-4283-bad4-26a470b64ac0"
      unitRef="U_shares">1632996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="2"
      id="F_8e24ae45-2631-414c-bab7-aea63c7e7f9b"
      unitRef="U_USDollarShare">7.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="INF"
      id="F_71ab8862-8f69-46e6-a3c0-7e5f503a3559"
      unitRef="U_shares">348589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="2"
      id="F_a5fc25b9-5287-4356-bd71-31e6ce483ccd"
      unitRef="U_USDollarShare">17.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="INF"
      id="F_e53af4ab-28b6-42b2-9b41-f85338372f2d"
      unitRef="U_shares">1912210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      decimals="2"
      id="F_808ab6b5-0ec4-420c-ac06-fc8440422242"
      unitRef="U_USDollarShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0"
      decimals="INF"
      id="F_5172353d-adb7-4d7d-adbd-f136d7dd0471"
      unitRef="U_shares">2239106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0"
      decimals="2"
      id="F_e22f281a-8132-44be-905b-2324e9c18f8e"
      unitRef="U_USDollarShare">13.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_95a486e9-ee67-47cd-9f0c-c1d735435df0"
      decimals="-5"
      id="F_6e9745c4-ac42-4222-9534-cc838e7302ad"
      unitRef="U_USD">27400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b7155aa6-ec63-47bc-af6f-62110067cad1"
      id="F_2287d40a-ebc9-410f-b203-28af1d6623d6">P2Y6M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_5c761905-63cc-46d7-8bf0-b3a39c96d663">&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes stock option activity (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.350000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.305%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.35%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.372%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.316%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.535%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options outstanding at January 1, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,051,906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,284,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,945,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_f3d25211-6e84-42b7-80f7-fd6e44c3728d"
      unitRef="U_shares">6155055</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="2"
      id="F_c08026ce-c4aa-4441-989f-8e721ab57de7"
      unitRef="U_USDollarShare">23.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      id="F_0946346e-3599-4213-b8ea-3de56c4eb5cc">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_5ce2d2e7-9e31-4e26-9621-cc45feeca4cb"
      unitRef="U_USD">480000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_0ebb54f6-5bec-4bd9-92af-e2f0c0cfcbb7"
      unitRef="U_shares">3051906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_596f08d8-d11b-49ef-a6e1-cf23549ad2b1"
      unitRef="U_USDollarShare">7.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_7a2cd143-e6f4-48c7-ac29-a49f51a2f44e"
      unitRef="U_shares">1284164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_aa03927c-9d43-4bdf-8160-736fd7d81f8d"
      unitRef="U_USDollarShare">20.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_5868e17c-f4bc-4909-9f4f-576b35a9cbb5"
      unitRef="U_shares">7922797</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="2"
      id="F_a6c93ab3-7216-4c83-9470-50b27ec69fa0"
      unitRef="U_USDollarShare">17.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_015bf2ee-70d9-40b4-995d-026a532e7847">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_8a1007a4-ab2c-4fa0-ae50-c6dd3d4d012e"
      unitRef="U_USD">786000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_a5f08aa9-1708-45ff-b7c3-0c0851362a17"
      unitRef="U_shares">2945832</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="2"
      id="F_66da9c29-783f-4944-bfa5-ce663ac115d7"
      unitRef="U_USDollarShare">22.10</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_eefb63ce-e6c1-4874-b81c-aab713a61468">P7Y9M18D</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_bced49a9-55f6-4750-a783-953da6754128"
      unitRef="U_USD">88000</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61"
      decimals="-6"
      id="F_ca0d114a-363b-43b5-830d-91039f914faa"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0"
      decimals="-5"
      id="F_3f274da9-1cc8-41a3-870f-603fa9aaa1bc"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61"
      decimals="2"
      id="F_01edbc5d-5afb-43aa-acca-7b204e3fce58"
      unitRef="U_USDollarShare">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0"
      decimals="2"
      id="F_f5c51b6b-ad20-48e3-8350-3de5b2482869"
      unitRef="U_USDollarShare">24.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61"
      decimals="2"
      id="F_7eca7835-6e63-405b-a793-5fd1c7493281"
      unitRef="U_USDollarShare">19.16</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_be903c41-fc2c-4418-82d1-61c35c6f02d0"
      decimals="2"
      id="F_849c99a4-edb8-4e2e-a672-f4200df59571"
      unitRef="U_USDollarShare">13.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_56bf8742-8a30-46a1-808e-e166b1e6b639"
      decimals="-5"
      id="F_91746a7a-edd4-4753-a490-1807ab817332"
      unitRef="U_USD">50500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0dc312bf-dbc1-46c6-bfff-794105b41f61"
      id="F_b9d886b7-29ce-4b12-bba3-26bae4b74240">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_795da760-b64a-4f92-b318-509e722f7ee4">&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value was estimated on the date of grant using the Black-Scholes option-pricing model, with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.492%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.151%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.608%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.142%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_3092cda8-97dd-41b1-ae92-f4fa498800a8">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      id="F_d9c684f1-a2f4-4f8b-b22b-14c91b40449c">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_9b7801ac-80d1-4f43-b6d9-e1d460186077"
      unitRef="U_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_ba479bc5-958d-4e0a-9524-3280fe4c2cb3"
      unitRef="U_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="4"
      id="F_35a0ea2f-9f6c-47a5-b10e-6fbfc9aa4e74"
      unitRef="U_pure">0.0200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="4"
      id="F_80476c06-79ad-4d1c-8ee3-7efe40c00267"
      unitRef="U_pure">0.0087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_ea5d4dca-2d02-4b13-b2d9-f0721b331455"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_4938fda3-1c02-49ea-9534-b10cb7a2cd9f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_49a70158-7386-4d2e-9767-2c83b923558d"
      unitRef="U_USDollarShare">7.48</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_e6291f40-6840-40b6-8091-fab0fd725848"
      unitRef="U_USDollarShare">32.41</alvr:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17"
      decimals="INF"
      id="F_c1c5a194-d756-4283-bed5-b5e3faf7cc3e"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17"
      decimals="INF"
      id="F_67249b30-67dd-4789-ba57-469017fe6cdb"
      unitRef="U_shares">611354</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alvr:MaximumAnnualIncreaseOfCommonStockReservedForIssuance
      contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17"
      decimals="INF"
      id="F_79d3ae23-cf55-43e6-9be1-668b79f307ac"
      unitRef="U_shares">1222707</alvr:MaximumAnnualIncreaseOfCommonStockReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_fe20c7f0-e4e5-4327-8d78-110f415bf544"
      decimals="INF"
      id="F_f6d1bc6f-17fc-44c8-9287-aa86cb451a29"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8964311a-67d6-48e8-930b-0c03d707e7e5"
      decimals="INF"
      id="F_198d5a29-449a-472e-85cb-88884e6d1c90"
      unitRef="U_shares">454302</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alvr:PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages
      contextRef="C_fe20c7f0-e4e5-4327-8d78-110f415bf544"
      decimals="2"
      id="F_ef875d24-1227-46c4-80f5-5eb50723b003"
      unitRef="U_pure">0.15</alvr:PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_09a37f2c-e1fe-4c12-9a21-29a9a69ff02e"
      decimals="0"
      id="F_7fc2b82b-cec4-49f9-b1a0-c7f1244f6e6e"
      unitRef="U_USD">25000</us-gaap:SalariesWagesAndOfficersCompensation>
    <alvr:PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock
      contextRef="C_cd2342e2-4156-4233-ac5f-e78b1c441b17"
      decimals="2"
      id="F_bb960f40-20bf-4ac5-ad1f-f8b0e7075196"
      unitRef="U_pure">0.15</alvr:PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock>
    <alvr:OfferingPeriodDescription
      contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149"
      id="F_82e29622-be6c-4d3e-92c4-88b5ca43a245">(i) on the first trading day of the offering period or (ii) the last day of any offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares and compensation expense is recognized over the offering period.  The first ESPP offering period was shortened in duration to three months and commenced on April 1, 2022 and ended on June 30, 2022. New six-month offering periods will commence each January 1 and July 1 thereafter during the term of the plan, with the administrator having the right to establish different offering periods.</alvr:OfferingPeriodDescription>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149"
      decimals="INF"
      id="F_da4421f8-829f-4c09-95a8-6e470ef70aaa"
      unitRef="U_shares">157052</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_8964311a-67d6-48e8-930b-0c03d707e7e5"
      decimals="2"
      id="F_ff239178-8920-4a0a-aa12-5db34f278218"
      unitRef="U_USDollarShare">3.42</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149"
      decimals="-5"
      id="F_d21f7e27-3276-42da-a813-afb13df41c60"
      unitRef="U_USD">500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6b58947d-f992-4988-85a8-62bc792aa149"
      decimals="-5"
      id="F_527a8057-1f52-4c5b-8623-b9931b8ee2ca"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_536baa45-bb41-4408-b7f9-8fc3d3d939ec">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, Income Taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Management believes that it is more likely than not that all deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes liabilities for potential tax payments to various tax authorities related to uncertain tax positions. The liabilities are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions, if any, are recorded as components of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income (loss) before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.144%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.037%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.231%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The provision for income taxes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.185%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.516%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.709999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s income tax (benefit) expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.492%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Benefit at the federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase (decrease) resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intellectual property transfer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Officer's compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company began applying the requirement to capitalize U.S. research and development expenses in the period incurred, as required by the Tax Cuts and Job Act of 2017. During the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company transferred intellectual property rights between tax jurisdictions, resulting in a deferred tax benefit on the basis&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;difference &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in our intangible assets.  The additional deferred tax asset was offset by valuation allowance, resulting in no net impact to deferred tax expense (benefit).  The transfer of intellectual property rights generated U.S. current income tax expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after utilization of net operating loss and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Components of deferred income taxes consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-qualified stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalization of R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#x2019;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At December 31, 2022 and 2021, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying consolidated balance sheets. For the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the valuation allowance for deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which was principally due to net operating losses, tax credits, tax basis generated from the intellectual property transfer, and U.S. research and development expense capitalization.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had unused federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The federal net operating loss carryforwards have no expiration. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_fb8a9d38-01ce-4a93-beea-aee65bc7b04d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; prior tax years.  In addition, net operating losses generated in these years could fully offset prior year taxable income without the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the taxable income limitation under the TCJA which was enacted on December 22, 2017.  Given that the Company utilized a substantial portion of its net operating losses in 2021, is expected to utilize all remaining net operating losses in 2022, the net operating loss carryback provisions under the CARES Act are not applicable to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had unused state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The state net operating loss carryforwards expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had unused foreign net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The foreign net operating loss carryforwards have no expiration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of research and development tax credit carryforwards that may be available to offset future federal income taxes through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Additionally, at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had a federal orphan drug credit (ODC) carryforward related to qualifying research of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;that will begin to expire&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company also had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of research and development tax credit carryforwards that may be available to offset future state income taxes in the state of Massachusetts through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Utilization of net operating loss and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax expense, respectively. The Company has completed several financings since its inception which may result in a change of control as defined in Section 382 of the Internal Revenue Code or could result in a change in control in the future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company complies with the provisions of ASC 740 in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; uncertain tax positions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accruals for interest and penalties at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for the tax years December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as the Company was incorporated in September 2018. There are currently no federal, state or foreign income tax audits in progress. The resolution of tax matters is not expected to have a material effect on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_643b098d-b5aa-4c6f-9fb6-7c0b2949758b">&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income (loss) before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.144%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.037%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.231%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_e4bb5238-dcd6-4ea3-b343-e5bd4851e843"
      unitRef="U_USD">-113389000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_33088527-2862-4e14-925c-b2726a1aeec1"
      unitRef="U_USD">49045000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_3f24be7d-7c6c-4db2-9400-3f9c716aada7"
      unitRef="U_USD">-55586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_58dfd34b-9e32-4915-a213-06122f157720"
      unitRef="U_USD">-220000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_43a1b7ee-a8c0-4015-a90b-ca10ac931b0b"
      unitRef="U_USD">-168975000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_5fde1240-6b60-42ce-a4db-cd9a22947d7a"
      unitRef="U_USD">-170955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_66b8f7bb-f64e-4d88-9ae2-28e7c88c66e3">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The provision for income taxes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.185%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.516%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.709999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income tax (benefit) expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_58ab5ace-2df7-45bc-b7e7-6fab0c59735b"
      unitRef="U_USD">-246000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_da81ca19-7c1e-4752-ae26-302e3489cc2b"
      unitRef="U_USD">987000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_98066ceb-bd83-4c28-bf72-b15e9c1d9320"
      unitRef="U_USD">-19000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_f9f22678-cf4a-4f49-a6c1-b0280fba13f4"
      unitRef="U_USD">20000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_90177bc5-f5a3-47f2-b55a-7c8e353c45e3"
      unitRef="U_USD">-265000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_56a67925-7c1c-4220-b175-0c235ef07ce3"
      unitRef="U_USD">1007000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_e1cfb668-43f4-4fef-bdfd-8f8b67902735"
      unitRef="U_USD">-265000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_dcc2a7ae-168f-40cc-be9e-87c3bdadcd61"
      unitRef="U_USD">1007000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_97570571-3fec-4dc1-8be4-d20db2c25440">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s income tax (benefit) expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 relating to federal, state and foreign tax jurisdictions differs from the amounts determined by applying the statutory federal income tax rate based on the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.492%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.610999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.225%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.602%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Benefit at the federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increase (decrease) resulting from:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intellectual property transfer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Officer's compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_9be879c2-6ae2-404a-a6dc-dbe99b02a8e5"
      unitRef="U_USD">-35472000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="INF"
      id="F_77b08500-a2fb-411f-8bc5-396f02ec28ff"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_b608704a-9fb2-4952-a1da-e200ef8e979e"
      unitRef="U_USD">-35901000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="INF"
      id="F_818cf265-31d4-4d83-a08b-730712568a7f"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_7c47c283-b1a5-4f5d-ac37-6f30ffb8c6ab"
      unitRef="U_USD">2177000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_888ec4e4-a7e4-4d99-b7ed-3da2632ceb5a"
      unitRef="U_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_73c00315-343d-46df-a01b-33b3a125c39b"
      unitRef="U_USD">43786000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_750269b7-5894-4d3c-8721-b1484f7f0507"
      unitRef="U_pure">-0.256</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_c153c40b-c681-45ae-bf5d-bb698c540ad7"
      unitRef="U_USD">-1603000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_34690417-840f-48ea-b4d8-54124cbde482"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_bfdb8106-6ad4-4034-9a15-14b632bc8567"
      unitRef="U_USD">1018000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_20ef116c-e690-46bb-a51c-c128727cb2d5"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_3b794836-d4c9-4efd-8f3f-b8f14dea1e8e"
      unitRef="U_USD">35406000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_09c17626-d245-4df0-b9af-ea383a616a63"
      unitRef="U_pure">-0.210</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_289e89ff-a5ad-443d-a055-63caa6df08ea"
      unitRef="U_USD">22268000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_9b83ce32-5310-42bb-86cd-ad14fd29ce30"
      unitRef="U_pure">-0.130</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_719779b0-1da7-4523-a118-b0702e5f098d"
      unitRef="U_pure">0.000</alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent>
    <alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_2c12ee38-dae3-4fde-b2b9-e85f61d82c73"
      unitRef="U_USD">-25538000</alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer>
    <alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_6657e95c-603e-4bb9-a161-004bf0a4c75a"
      unitRef="U_pure">0.149</alvr:EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_a5318c3b-51ad-4629-beed-d20138c30872"
      unitRef="U_USD">6992000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_7ae1ac5a-c5e6-4e72-85c2-fbd93b515350"
      unitRef="U_pure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_71bac5c6-cd62-49b9-9877-ff42961bf9e7"
      unitRef="U_USD">5540000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_ab3ca4e6-0fde-4a99-9244-775511ef64ff"
      unitRef="U_pure">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_fe9c89c9-02cb-4771-b920-63b411b013c2"
      unitRef="U_USD">695000</alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_ab290961-aa8c-4c2c-9c3f-5e1b54db725b"
      unitRef="U_pure">-0.004</alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent>
    <alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_39842107-d902-4876-8987-83166b13251a"
      unitRef="U_USD">2648000</alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_9288b7e4-b317-4448-a85c-547bf5843aab"
      unitRef="U_pure">-0.015</alvr:EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_0eaeec96-9667-4407-b21b-7146c7bc913f"
      unitRef="U_USD">4637000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_b87731d7-0851-4286-8e72-311a2ed4c68d"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_e1fc8e14-896b-45e6-8f73-1e498929fb5d"
      unitRef="U_USD">-2464000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_b50462c1-586c-4e63-8470-223b62ee8a8c"
      unitRef="U_pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_3850a573-c1b3-4971-85b6-e9520fbe303e"
      unitRef="U_USD">-182000</alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_1ec74d50-3dfc-49b8-b368-57c73e35509f"
      unitRef="U_pure">0.001</alvr:EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_88d620ff-1e4e-43aa-873f-701ed367f9af"
      unitRef="U_USD">1069000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_aa326f5b-6094-486e-8a08-e5b9f6799a75"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_f562fa13-2899-40d2-b2c8-41800aaf0d6a"
      unitRef="U_USD">730000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_bda89450-7ff1-4d13-8880-0e7a26a945ea"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_90bdb08e-09e8-4510-9095-97f9b88be7c7"
      unitRef="U_USD">-265000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="3"
      id="F_00595212-d86c-4b96-b3bc-e778b7a5c20d"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_407b86e5-8a4c-40f7-85c0-b799c0bfc751"
      unitRef="U_USD">1007000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="3"
      id="F_9b1be561-f3ce-416b-bba8-1a75d705213f"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_4adb9049-0897-4d5a-9d06-08d74ae07b3f"
      unitRef="U_USD">1000000.0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_c11b225f-4830-469b-8bc1-523900cc20e5">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Components of deferred income taxes consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.932%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.619%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.012%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-qualified stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalization of R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_cdb33b2f-5ede-4870-a98d-6005259907e7"
      unitRef="U_USD">9374000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_8ad0109e-b62d-4167-8dd9-2b93d90ad4cd"
      unitRef="U_USD">5460000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_77828cf3-9ea7-45f3-a177-e387acc23bf0"
      unitRef="U_USD">12374000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_81abb09b-93bd-4b81-9acf-32a8031bfde9"
      unitRef="U_USD">4683000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_968368d3-e942-45f1-85dc-bd685d9c5684"
      unitRef="U_USD">25537000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_ea81c4c3-1520-40de-8562-af0c3893945d"
      unitRef="U_USD">25538000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <alvr:DeferredTaxAssetsLeasingArrangements
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_50bf3b9a-902d-4483-8fca-bbc4095ab65e"
      unitRef="U_USD">8074000</alvr:DeferredTaxAssetsLeasingArrangements>
    <alvr:DeferredTaxAssetsLeasingArrangements
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_ebac901d-6ff1-481c-a7b7-2fc458362b8c"
      unitRef="U_USD">6865000</alvr:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_3ef97fc6-1de3-44a3-b172-e96a0567ed3c"
      unitRef="U_USD">12017000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_c6865561-95f3-4748-a366-7cdf9091dedf"
      unitRef="U_USD">8028000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_927da998-4a3b-491e-8c2d-6e4de1fc9c43"
      unitRef="U_USD">235000</alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation>
    <alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_69aaf7b1-fb00-4eb9-9826-27be08fe02e1"
      unitRef="U_USD">1778000</alvr:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_32c76096-f152-4909-ba93-8ad7b55e3568"
      unitRef="U_USD">20375000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_47af1359-4615-4736-a40b-52a485555d37"
      unitRef="U_USD">1661000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_e31609c3-3980-4915-96d4-16fc3d5c4e87"
      unitRef="U_USD">1646000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_3d0b2300-db5f-4af2-bcd9-c86642b894c9"
      unitRef="U_USD">89647000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_4b4e6239-1122-4aea-bde0-ad5dbc3e5f71"
      unitRef="U_USD">53998000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_f5eac029-0ee6-496e-adec-63906715f7cb"
      unitRef="U_USD">82228000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_15f185e3-effa-43e0-9fd8-446c3f98f797"
      unitRef="U_USD">46823000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_eec70a8b-0110-4029-8f28-b4c9a06b85aa"
      unitRef="U_USD">7419000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_521c7b42-2e05-4c86-be22-54a1ca16e21e"
      unitRef="U_USD">7175000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_51548adb-4871-4604-aa79-9a704050eed6"
      unitRef="U_USD">7218000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_b3754e58-ecd7-430d-b00f-ff08d8ad676a"
      unitRef="U_USD">6791000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <alvr:DeferredTaxLiabilitiesDepreciation
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_40b5d9fc-94ec-4eca-884a-71ce316109c8"
      unitRef="U_USD">186000</alvr:DeferredTaxLiabilitiesDepreciation>
    <alvr:DeferredTaxLiabilitiesDepreciation
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_01a58330-3a11-4074-b43b-a3e32871b7d5"
      unitRef="U_USD">350000</alvr:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_00005017-133b-465f-a395-eac60ef0fa0b"
      unitRef="U_USD">15000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_fc645e90-d038-4e48-af62-b9bd6e61de94"
      unitRef="U_USD">34000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="-3"
      id="F_19b17e36-e515-431f-a2a3-0e11c3824f7a"
      unitRef="U_USD">7419000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="-3"
      id="F_eb3ad673-923a-4fa9-9e36-8e1179a0c7f7"
      unitRef="U_USD">7175000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_7c045369-7462-41b8-90cc-1cbb9ac774da"
      unitRef="U_USD">35400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_fc2f8cf1-b175-4168-8c12-2ca0ee568e4e"
      decimals="-6"
      id="F_e8c7f8b2-cfd9-4012-82f7-f6b8976921c7"
      unitRef="U_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_caad09b2-8a5c-427a-bf14-b4c5d6dc2fac"
      decimals="-5"
      id="F_80430bc7-0c5d-42c3-b172-75852b31e2dd"
      unitRef="U_USD">13300000</us-gaap:OperatingLossCarryforwards>
    <alvr:TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_81f607c7-8deb-461b-af8d-f94213946da0"
      unitRef="U_pure">0.80</alvr:TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ed61a91e-38ee-40bf-89a6-4063803306fc"
      decimals="-5"
      id="F_b08b9216-cbb7-4767-b3d9-18bfc1ba2f3f"
      unitRef="U_USD">3600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0c3fe01a-8496-428e-84e7-1771deb6fcdf"
      decimals="-5"
      id="F_af3cafac-d143-4771-b473-d58a8d39396a"
      unitRef="U_USD">8500000</us-gaap:OperatingLossCarryforwards>
    <alvr:OperatingLossCarryforwardsExpirationYear
      contextRef="C_5df06e65-2e31-4282-a0c9-44687c839727"
      id="F_f09e632b-d3dd-4244-ab06-a65e54676af9">2035</alvr:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ec9f3cbd-6e49-4297-9fce-29d9733f0dee"
      decimals="-5"
      id="F_91c403d0-4388-42ef-993c-0da9f762f950"
      unitRef="U_USD">72900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_de179e1a-a46a-42ff-ade3-641aee56fdf6"
      decimals="-5"
      id="F_aa7b5e1b-6aa5-4f37-b4f3-d0af1a9c54a4"
      unitRef="U_USD">16800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_364b0156-c9eb-4a54-8db9-564a84677c30"
      decimals="-5"
      id="F_de7d308a-bb88-41a3-a69a-18118aa33672"
      unitRef="U_USD">6600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c1a7c8cb-c126-4a75-84cc-77ae967326ea"
      decimals="-5"
      id="F_d8cb3a77-1694-46b1-8935-d4d234389f89"
      unitRef="U_USD">2800000</us-gaap:TaxCreditCarryforwardAmount>
    <alvr:TaxCreditCarryforwardExpirationYear
      contextRef="C_05b6c22e-9c40-4013-83f9-51bb3313e591"
      id="F_11763bc2-b347-499d-a584-9103765323f6">2040</alvr:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_6cb1ed55-c237-4a84-8a95-212c9e28b1d9"
      decimals="-5"
      id="F_a39a58b3-6cfc-4182-b4dd-089c18c00f08"
      unitRef="U_USD">4800000</us-gaap:TaxCreditCarryforwardAmount>
    <alvr:TaxCreditCarryforwardExpirationYear
      contextRef="C_de1adbb2-e1ee-4eaa-9635-a371d6880799"
      id="F_4229e006-0cef-4112-a999-6e435b81784c">2041</alvr:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_260a042b-801a-42d1-b1f2-f77d80a4d46a"
      decimals="-5"
      id="F_dd923663-2bc8-46b6-883a-ed778d8593f0"
      unitRef="U_USD">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_fa412a85-c19c-4db1-b1d6-89d57a67aedd"
      decimals="-5"
      id="F_eaf08ef4-6279-466a-abd8-e044cb128ce0"
      unitRef="U_USD">800000</us-gaap:TaxCreditCarryforwardAmount>
    <alvr:TaxCreditCarryforwardExpirationYear
      contextRef="C_0aab4b39-a49a-4d2d-a277-8f923ab3d97d"
      id="F_1bb08baa-1aaa-4e98-b75b-8414a7c10333">2035</alvr:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_d18372a5-405a-4273-9923-c3a05a1c8559"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_3be07a36-b856-4e1a-9651-e0f151036c51"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d"
      decimals="INF"
      id="F_cb3d8b49-eb0e-4871-9ed5-af4426fc40aa"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_50437763-ff2d-4d51-98a3-8c880a8fe158"
      decimals="INF"
      id="F_5ca97a21-b7b0-4f79-9290-26e9c3b2b20a"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear
      contextRef="C_05a46537-0f3d-403a-bd4b-9b51a77c50b9"
      id="F_e5fd9b05-6e8a-4198-a863-2bc160850a60">2019</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_f6f0fa23-53ee-473a-93c3-d9f513ff687e"
      id="F_0e2b1836-10a0-4fca-aae3-195349ee4670">2022</us-gaap:OpenTaxYear>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_fe138e6f-8234-42e9-a8d6-93d06f71c049">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.745%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.351000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.674%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.545%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;171,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,654,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,782,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the amounts outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.485%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.319%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.721999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_fec107eb-1e75-401e-a2e9-76ecedeb9917">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.745%;"/&gt;
        &lt;td style="width:1.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.351000000000003%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.674%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.545%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168,710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;171,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average common shares outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,654,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,782,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-3"
      id="F_17ee79dc-582f-4189-94f6-16c2f70d55e6"
      unitRef="U_USD">-168710000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-3"
      id="F_4c1865f7-4df4-48a2-b567-ed367381351a"
      unitRef="U_USD">-171962000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="0"
      id="F_9bb870cd-6d45-43c6-8dc6-5317065a6de3"
      unitRef="U_shares">76654856</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="0"
      id="F_e5a669a8-80c0-4b0e-beb8-fe693ae15c2d"
      unitRef="U_shares">76654856</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="0"
      id="F_efe0ffb9-981d-4c22-b072-09be61fbc585"
      unitRef="U_shares">62782126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="0"
      id="F_7ae82f4c-ff67-4597-bc67-32305bc47cf7"
      unitRef="U_shares">62782126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_4275c259-8233-4027-99b5-1e9df231fb30"
      unitRef="U_USDollarShare">-2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="2"
      id="F_11d9bbb5-4865-485c-829c-a7ad61aa7741"
      unitRef="U_USDollarShare">-2.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_b9f8099e-1e64-4f5a-88f0-c4c4963eac0a"
      unitRef="U_USDollarShare">-2.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="2"
      id="F_f2809a87-237c-49fc-8635-5f2800909d3d"
      unitRef="U_USDollarShare">-2.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_d183e72a-c912-4a90-b730-ed206105f51b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the amounts outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, the Company excluded the following potential shares of common stock from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021, because including them would have had an anti-dilutive effect. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.485%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.319%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.237%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.721999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,922,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,155,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,239,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,866,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9d14225a-1f51-4be3-8682-e3fe75c16bf8"
      decimals="0"
      id="F_71ce8c97-8303-46f4-ae74-d07666d1262d"
      unitRef="U_shares">7922797</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_62c6f492-44c1-46c2-b513-632f27ed7e91"
      decimals="INF"
      id="F_4cf9e730-f67a-4a72-aab9-15da0bcfef5d"
      unitRef="U_shares">6155055</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_26adca99-ca18-49de-923e-a278ee315f05"
      decimals="0"
      id="F_b2986f71-81b0-4b2d-86f2-6d339a3b57f2"
      unitRef="U_shares">2239106</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c2c0042d-4a48-4498-a1f0-1bd575db97dc"
      decimals="INF"
      id="F_8e419922-b2f9-4c19-b895-1d5aadcb816f"
      unitRef="U_shares">2866909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_837da6f3-bc42-488c-8279-49f3cc9e6c98">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The Company entered into a lease agreement and a sublease agreement for the lease of property in Waltham, Massachusetts (see Note 5). The Company also leases an office space in Houston, Texas under an operating lease which will be terminated effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and an office space in Dublin, Ireland under an operating lease that expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. At December 31, 2022, there were no matters which would have a material impact on the Company&#x2019;s financial results.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Purchase and Other Obligations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and testing and manufacturing services, which can contain purchase commitments or other noncancelable obligations. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including non-cancelable obligations of services provided up to one year after the date of cancellation. The amount and timing of such payments are not known.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or we may be required to make royalty payments under license and grant agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time (see Note 8).&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <alvr:LeaseTerminationEffectiveDate
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_d71444c4-0abf-4a22-8542-8868da423047">2023-03-31</alvr:LeaseTerminationEffectiveDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_7d8a60e1-6a28-4e00-afa8-b9d9528f376e">2023-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_74108bdd-3ee8-4d7f-aa6a-7ab07c299f20">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2020, the Company entered into a Management and Administrative Services Agreement with ElevateBio Technologies, Inc. that provides for ongoing services to the Company in areas such as information technology, human resources and administration management, and facilities. The Company is billed monthly for such services at cost, with mark-up for profit on specific services, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2020, the Company entered into the 2020 DMS Agreement with BaseCamp pursuant to which BaseCamp provides products and services that are used in the Company's laboratory operations, including consulting services, project management services, quality control services and cGMP drug product manufacturing (see Note 5).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2022, the Company made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million prepayment to BaseCamp for future services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;year ended December 31, 2022 and 2021, respectively, related to services provided to the Company by ElevateBio and affiliates. At December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company owed ElevateBio and affiliates $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively and had prepaid expenses with ElevateBio and affiliates of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.147%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Members of the Company&#x2019;s management and board of directors received consulting fees totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_ca8bd669-1d5c-4b9a-921e-86a2b0097299"
      decimals="-5"
      id="F_dbc86dbf-b026-401c-8a3f-ab72e0abe693"
      unitRef="U_USD">2000000.0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_8351b805-5c1a-4d38-8217-30f5d6839ca6"
      decimals="-5"
      id="F_01896b34-c673-4bc1-a1cc-5dcc0f49c93a"
      unitRef="U_USD">3500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_2690d392-2fbc-4b1f-8ea4-61ecf654db96"
      decimals="-5"
      id="F_00d78958-cd96-49c6-9ae4-a2a16a1d5440"
      unitRef="U_USD">5900000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_ddb75e86-804f-400d-952a-974d942d169c"
      decimals="-5"
      id="F_f71d7858-a95e-49c9-8099-344e25950dad"
      unitRef="U_USD">100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e"
      decimals="-5"
      id="F_91119f35-17e5-49d3-acac-0cb461e5bb68"
      unitRef="U_USD">1700000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_ddb75e86-804f-400d-952a-974d942d169c"
      decimals="-5"
      id="F_bc343fe7-078f-44ec-83ca-2b4471a1780e"
      unitRef="U_USD">2000000.0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_9f8eb866-255f-45f8-8309-4b6c1f2f239e"
      decimals="-6"
      id="F_f0ff1a03-ecfd-4885-b8ca-dfa6517453d5"
      unitRef="U_USD">0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:ManagementFeeExpense
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_fb9a1b4d-14ca-45a3-80a0-a31bac66889b"
      unitRef="U_USD">500000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_55d16a93-afe2-43dd-96b1-07a9dbe5bfff"
      unitRef="U_USD">500000</us-gaap:ManagementFeeExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_7e0b48ec-81a3-4458-b9c3-e07a641dd4e8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. Employee Benefit Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective January 1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. The Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      decimals="-5"
      id="F_f64e19bb-1186-4bba-ab67-c33a141cc8e4"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_868e0009-9125-478f-bcb4-16998a2eebfa"
      decimals="-5"
      id="F_c15c3476-df82-45a1-b2d7-4f2297874380"
      unitRef="U_USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_ff35b1c7-5c8c-421c-b26e-66dcd752e033"
      id="F_970e28b8-2f15-4e3d-9a95-8427f9ee11cd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16. Subsequent Events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the financial statements at December 31, 2022 and for the year then ended, the Company has evaluated all subsequent events through February 15, 2023, the date the consolidated financial statements were available to be issued, noting there were no events or matters identified that require additional disclosure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1NIN!EP'J.<SQN1K1Y_^Y6W/_P-02P,$%     @ ]$-/5IEQDJHB!0  A10
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M!P9AB7%58) .#$S0+<_41J)Y%K'HU,$ 8JH"(X? KHC5XS4+SY"+/R+B$&(
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M/LBY*,Z\B@?%M_FQT1-7BJ?Y[8;1B EM /^O.%>'!_V!ZN1Q^C]02P,$%
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M/U<5F\B$:L-6:77T6M5FOA3K,*+7(]BM@O(-'<W^\PMVK?_J7#Z1LKT .$T
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M&QJ\0L(1O6"8L 3@PWT+ #]1D]B,44EU=66F$!QQ1^PHV8\86&#!F"^(4ZU
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M0=855<P; M);NT[J',*435!?:0+_&GF*>.J,/94HO;=%!_.9QXCW) ENGX(
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M"@M0Z:YU0\4^H"-G"!>7V;/'E]GYQ>5DM4'^*;[H!E5!KFF#O ='Q;[#A)&
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M9HDXZA=)&QTN/U7[7/V=VV8WU.3R-;.6(Z\K&&)%RSE'61IU2U$!"P9$4VZ
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M.(RM-G@;),*^#%AM^ZHS^,4F.X%/RKO2-N6RD1?-7=F,\MURSQBL-M:L"A=
MJDUER1*<;\L/IJ,3T2<U?;6!& VN (U=1=N"_=S8$3((@++O3=\76(CW!Y*$
MH$HB( R':4VRE9X^>RQ0LL<38U-V !OJF4Y"T!+'EUVU60"J.UBZ'2.7M@?*
MMJ @>,7^)@<$YMQJ=8[7SJ&WFU7QR^W/M$A7[DB,<!(P^9U_?X"I'0#2G0$I
M[BPX^1PG<EB0" OL&MBD?A[68S@L&(<+YK\7_,RKCZ8:R3X6;U<0<?H2J()5
M[F?969<DYB,1SX5CR7J J$JO[L9NI^RN!")( HF$R_'EW#:-:]?G#: 2*BH_
M F?S(GQ1O)>-7O6#W;)0$U9$903<'Y%=.@,QB!WVHDV"'@"POXX6$"M*F+2@
M$B&Q,&$KY;5QNQ/$#!O0K5RMX'XHB^Q<1\"66U$%A!$]%5YM;+FTC1VL+D5R
MT[A^[/A$ ([PQDQQY!W9A4C@T3E[4E% \^"8C_#UP$U%/79$I?@<ZU3365=?
M@&/*EA@#.#M^>B(4_"MROD3_A/V 2'A,O:>@K$J_B?+ 9WOH+XB-*3ZT4(O@
MD&H8<0C_(G1@0_@!:B&%G=NJ0@W  ,2RWXCEH1]>@7S0+WS\\$U%/YCD&X*X
MWP#&<ZBT[:+8P)^#T6@LGB'X[K"^H)#9PW5V#?PV8(,!V&(:,-X[8XJMN#T0
M@89TSX0V$(D*6@=ZZ'6RZJ\XHUVQ021-.P4/2A:&V (B$C;;#[02]@&V\/D'
MN.^KL:UA&F 3@6G::NGPP40)%;L2&(?^YY/^C)-F0-P&!&0G3K9DL2"E!-;<
M0R]5>OB';5Q4#;@$7H38DV $SB%ZYSV.*F+#1BQ'+",27[:LK/?0M@4XX_#]
M"!%3M"J[CC<#?DK;%61GS$)(2#096QP%JAF/K!'"J%PYLAF19<&<CA0TV[_.
M;"@FN2.+QESZB!Y7+P'"!&&AU2HG^*K-<DB!8K:W1.#!K!U02+:P_A<\??(K
MP#&Z1-!7V'!KQZV*6$7&5+\A%2&RR]J(L;4GEPUBE*_2)2_:X*GPP<[D9-E9
M%D5KAC/O]\@YDB- U=>T#$5#-1D 0F2_@W&!Z2AL#99A/Y&WVQI(9TVL#JXR
MM%9[@)-/,@51,@7:^L4$;$#JL"BQ+3P5*!+#9RJ5;.?$-F#J+;$G81Q6QG:L
MQLU'L#7Y4XE#P,Q>FZX/"]F!O01Z2!3NGHE!4(@IV!!&Z.LH- 5YH@ULHTHG
MY+<BE5@Y6/+]@A?PZYL[0EI%K]=6+:3H7G[:[ZEJW5-DLA\B[GN*0?NX'""3
M%]J!#LX$!2;OZ7^MX]WP*.G6A!@L&A%%K+T0=YGM$I#ZV(O!QP]7$,*?  $.
M1_S+VE54K'=XQ3,'6H?]CK5?IX]S<$ 2FA&_BXN1"CQTU28/@.QP+VS8"$S9
M?E@$1Q1AC/BM30-Y@_,D(@9M,N!7MJP()D!?"]N%)15C\*7K!K'%4<?$,.O_
MLVS 6EMHEDHH)(LK,O<>MOP0R7E9$8C])2A;>+=XLR-J3H^IUG(:-]5DK^NI
M_\6A0"%)G4]1[UU'SIQR-%E*=ET7Q3_P;@HV\6)7DQU*GC?^>=J&^9(^I4<1
M*OY&CH2!^B)?E:@]]IZQ*<"F=,DYA:&J(@IB=?[6&_(:;YC5V!3D O:>%L#,
MSG NQ[M""T+>"B1V]_W7?[JA#Z-Z?76XV,K\B4XU$@?$$SQAH]+_Z4VY)"M&
M[\8O/Y<O,XR(YP)YI=A2 QC3)T(=_*W*=A4T^)!$:*YB2M=B[[8EG$Y8JI(I
M?R=.NIYW!ALK<2-F*7$!7QY>''AZ))>5.)+\7]L)*)2G@]9B!DD<4,BA.G\L
MA5"K#!T\ZATGWP;XOZ)ENH(T\B+31+H*[!&Y^G7P,<$Q1"VP*7LU./)V;"1N
M2?E"?,6M(S]?_3GZ0)[,(F=A1'(#:4$RV.QCP6:1/<K\3645]AC=*HE8+C@=
M,72CJ"!+.06W[HRLT;HA D<X9RW."J+8-64EBY-BL11(OIN7!JB1I8GX(!0=
M\T7$L2%,LAGO3=/ 6$8+A7??4!CTAL.@&\%TRH8!02M&Q31BFLF3W-R^@,'<
MP58_^>)R$<Z GZ XAD6N"4)>A-["\S$KHA_$\$A4D\2P7Q>/[&=1$Y M3LPN
M4\RUD!NK-@VH$==7M"%A[. PGC[!+,(S"#X(F0 XP.H2$2>-) &B/5>D&OA<
MCRS VK+W.@N4FGF)+MB(+@WLJFEGP?2,GI!3I98!SA4_E,,P%],*LW!42^M!
MRNN%>CN2RIICL063.X$>:J>E)('7._BVBH%:KH'4S5!G^QC^!3JR:(S\=>?&
M7<^JBH@ D*&,FGU*C0N8&G'"@O<Z<6%2K[&,\2,]^0GB1;$/*F+L<W2+4S;T
M@@)R:T0"K:2\7@L-);7")^_)4TX9A/VB@54AZQ$A33]23L2J8.N)CJ$M0*->
M9:)A[^$40/>>UXAJU=, VT3>Z0^]'7AI0Y0B48 3ELW#=3%3AO+MI^W^][3M
M+\RR/XHXB+<7E<-7UU .\X]E2@'/>:6P((J"$RQ\#YPYE8N-!1<@[A4GR;(&
MEAU5&J=ZD2D$ A+-1UG0BV*:: CLI'XV?*"R>.26I*)90]@6EK[_+,CJ02[K
M/E_PT=@>OGU1O)U^ID$)_ZA&7!S]$H%79;$'.:6<JR!&93N#SY5.PK"DL:V7
MC=F3N.50<O:5N=[G-2' AHR\B3RGQX+%/@3_ %2UE/.IZC2+LT14H8'&'W=0
MMN2<6.94J:0,8R2YE, N9HMCJECM>J;-Q!"!"4/D26Y/Y"/5Z.:CJ$,)Q!8$
M$8*_P?_:F9U4+0+<(M%\8#G<D@,RPZI;+37IL'! 2*4$$)2;I]Q4F9S9LKZ#
M&38==&:2O@],/8-5'*WGD,8G5'UH2D >/I^1#ALF2-@F(KX(",N%E5-7YX@!
MNWFYG1%(($G1)>XWOOFZ8&7PQ;/B#9&WN.+?KZZ>L18I)T([MB'W\>OHZ!^F
MA[HM[.3+.>7\0F%XW(EU2I.@P9ZE.C0-VZE,4&%]H#8'\_HDF#EL!$EOMY:J
M /-P'$"_F%DB'N8AZWDT2%I9#95NPHZ]JTW3)U48A"58-9;L$E40%004MN5H
MI88'5PU@35;._K<IEIZ<Q%*J(VB;3)$2C"DX&FFS<P!(YWF5$SLBO4.PVO1[
M+!>E'H7B@(^0@\).=@(-'IFH>5Y6D"R&NYZZ,@F(L2+@L/B_QEH+1C?L:4,*
MFKU?9$WY8+SM'\)1*"%*$&NER_,JE[1D3W9SXG8XXYK*0*08I]93 UWV#K""
MT@F@).G_^'R2P:#G*!S0H\^*_#3)!Q$G&.1EK@#N!=6":=O/D?@H:6>,SQS,
ML;(Z38HODH1]FJ]>Q*!H5^Z%SU6?UZ,1)TZB2]*>^Y!9I0R0KX$@3(37S1'F
M? XH@NK=O>BS'Q87B/N/P!HKMB#\8#F=P.BJ?>$@-1=JKWC!$0S\ZXA5V W/
MWX%WP"6=$JI@6L-9%".B6ON;V#K;U>>"!V^W-;QE29+T<"(JB7=RH?6UR5NR
M.&<SH=JI2@!+79==G8BMBBH=XW!M+[UI4I=/!S>,P9EEDY0 OY_^BVG(3B&Z
M3RR6.T1E'R5T2=A;%^<,%Q&;'//8!<&4SS+U+PW<!/)\WU*T27"_X#Q EBXL
M=W;@"@5D73FR,>NR65!DN()>P_K$A+'Y@9'*>$J)NS(F48A!WR?%9,G\MN=8
METPD,S"]*,ANUQP=UQYFYV&6W(4D2CBB2E_HI'."ND@&RB?=K ;3Q8_2/-=D
M-U:@O='E:2'UT&)^YWC:DT$M]92@=JW9GA ['HG<DN2BPA,93'/$7#L;.5@_
MA2QR%\LE2.%:BN?%&,RC[M[" "Z3#)S=;DU--&'Z4'U]4W9KYJU8S _%VCED
M) 7?+/GEBW))%8MB2-#E9)IX,7&J:@I,CQP'BK-Q8UU(BI4^OJ'$YEK!^11O
M([IM^%%A#L&0&#UP#CC]G(*,WJV&>ZT*21[5<A\"[UR%G4NROMO@.5"VW:LI
MK8I4E#!M[-J2^E%6FTC$P:+)<1;"\>IESL(>(&1UQA$/ZU4.[.)!EI0=YV+Q
M;M=H\:SG9) G<$L!44/E[TX2'_X5KZH\,F>;HSA;]_DEU<;U.062^T>\U=@Y
MV\I/$<,]&QJH<+5-A(G&:'L/-8)J2,]G'23U +C%1I4L[^R+QD4X%4:HM'U8
MC71#6K/D?"X=09-%DYJ!Q$2Q9. S-I,<N93C)2D22F9S?,2I;$5T7VXA%K2+
MA1"%3[U(/4BB8MC)4LH88@WL^V(2+CO!8!.D^-6F+)I(YU_[DPS+$1$[&TE6
MR1>7@BK\C^+RXO,"$4GCC1=]<O5O)9K$8K_6^O(;J2\?JRZ%PJZ>=)%6.+.:
M]HEJ.'T5JN;X<M[QXL= #0./-68'#IH @!O-=1TKE&OR*S(C\\],7TO:XA&M
M6JRU_*1-9+S]RZ2/3+R"[.NTS2RN)7:"54UDE6,[I$L$8R*RL.66OEHZCS(E
M1MD=Z:33-J[Y]3@PU;Z0))5MNMZUK6G.O?_%JT.)#J[Z<"ZA!NT.6)C*"U]:
MY87\;N%MPO@&"F@!EH?O3*'TT%G6D;RL5_%D$-4YG5EE6[8CMAF8MQ<0_$HD
MUFA;D]"=(E!2&][('2W!M*[M#/7B2-A;W[$.AA\J7$>/K)W3_IC@,TN>21T!
MK_4U"_X +!.9 PVI%"",Z%=/^F>%>(2\+CXH ,6G?)Z+(UIVBX_RYBN_ZS1U
MS:VA? YPXUT):1C[XT?QI%+,!G0!CR)5?;38OKM,K4-Y8MG(UZD8S&D>[_^G
M:1?N3 WE5]>N7<;TR@G_)"SZ!E:?/:SA#Y95Z-F863WWJ4JPUI[\H%",U#?[
M ;*3BQ$;:FH@XR*/V$]5@E+\8:WIF/(A8REF*LB#PO[#6*^3QL"DGZ^C:*PV
MTZQ$>IC0<YR'G(+5:=?@ YKX#F/LI*5O+ENPL5 <G>0#"2;\&T_ W"R5*LZN
MX@SBO_C:WA#W+04X1<HM:Z/GK(U>)-K(\WK&/^N.\]])OP8K,Y%N_LGYAE H
M9=#*[8UTR[6$B=*C7D(5U_6'[*F]%,>4I/@NW'H"5Z;63IBDWYD;1:RFA5>^
M\XA*IO0-IU94 6F=NW-+5EXAW79D,:^O2FHT9G7Q_00*KO%F/K>\FS-_D-*C
M1_RT!\@IN1X.6T!RV%5-,7E@I'R%8-KP<P)7"]D5ST/+G-^IR_I_W1:<+_A@
M9>+IST2@?I_DD\YX0Z*=@)H3;O;S&NLHLHYYB7KRI ?K!+?^ 5%EECNTJ2I-
MRS.'?<L,YY&FJ0<<VTHSP.^"/(T$P!>M3!Q$3XY!-"9H(MBKSC5-ZHK%-B_W
MB9<#PWBCE[_/4K4RVM!SR"82:>REI4C0EO<C< XPI:Y 0**>6K>,#O)$[-AZ
MWI35!X+X\C^?W58;1Y,UNIC/_W%*CTM6@[092OUZ-R[A4H4F90U_#D85W'9+
MKCI#B17I,:?Q&B=%_3HAV:#S,]F+0//-N!ZA#A%\7"XF_5,Y5K(7[SFSI;G&
M:68^ +ETI?0$!F5-R%>N]9AC;*=X7OC$&N7)V>3$.8)%5M)+TW5WL< R<U)N
M>;OG"N3\A,8AJ/J5SL/X0+:L1=M1%6KY+Q/K20C7_:_D'--9O8E8FH;5O322
MPHV&\^/[AH3+J4F$[:]$54E;5RKG6[);Y*!PRF'FZ!2^NW&].:$A>G,,:PQ<
M='=G4B*\TFCE$QU8#<'PS=:09]$B<@4##:-L3C4!$>IWPHXZ"$>*U2/X)L_$
MADI9\3?LA8@V?L"S<O9.$GU_IP8@K^]>23;Q-K;EOA9[!7*G+@GI!BV\BKJ&
M]E+A."$[BVE=YDB)(Y>M7$+2LI#6-K-.YXF$30*FIG<%:13?-+97U1*ZR%/7
MCKIZ8"8)ZW<.,9NOJ,<. 9]_FMDJ.H3<&>3S1$'1 -1DT>Q8"0S)(SS 0>B4
M.CY%(#NCLP'2_<:>-&_$3I_,[DAIH'8%3I[DR@&<Q.C28BYQPY#MS7T@G5F7
M7?#^<W#H8-Q2)- D1Q-4Q'8F2H$<H75N_4.6*"%Y6C,R/BG2,V5((GP:Q#?\
M__SIAQ+B#'-PYC"IIMO:6IE%DI5I?QXWP'/7*)65*6-.Z*7X4[VWV)DJD= 8
M!WC4R^IL[^W<BG*'(2/%DRUV:B8ZX_L$U5SQ?,S/?CYF;TFJ(<0\+E(8&0?S
M93T"+MA:'RF2MRAFTH8T4I]6G!IN3*9<AYM'6UC&-_QSWV1\CKO^*5@3Z* P
MJFQJ53K/N)F0>UJDSUY?XHQ:IA@X>G&F3UKG>(BQW!>2Y,_>]N5F1V&TD0%0
M3G-<<%*0\H-TZ.)V0YX.S117&A\U(P'?&NW4I(?ZC6:H<Z+P;D3N\+ :=,\?
M2F#/)=EQ8 BX7LD#DS'?Z;WY6\;6O1'[%O)BL2ZC>4/VS&"?/0%#\6J1[3!A
M<>K_Y!2EJ;,1@!3 9,+WHX[$)&6MIJ(6:VDLJLJ1[2,[W\QZ?>QEHE2\XH%Q
M"TNO_$*T69S"%Z-=BQ.DX'13&OR"65T>T&Q"+_K/>]<7/C/\<_G1G&ALUK3K
MP$^%I%#2]QE;K52W'*F!?/D4?F&V)[7,R7JVUY<7L;B%'8^.7&H62K/HWK5-
M'$[)W]$2Y.9QK5[R)2#L<APDR'9)MW'L<9P9WIP6+75FTZIJ.SY+*AR0U#8)
MHJ7,#;]\X$%#EZ;$!*:5/%(GIC6H-H\$'M!+HQYBQ#"!E1[8SQXD#;?:8BNA
M$R :&HJ"HM]$@\3W97@;FI&T2TW)C<R "_NRFQM:"/UPU$*3'=S!T]@/I%9Y
MO)"TF'0'$XNH%'L??P99G 31CF@_2WA1_!A'A=5=SE(LQW>EW1Z^S9%4T32)
MN7/4/L65-ZP8XLPD,<L[C>!]=3=]<GP@;\779OEE[:?6/-6436)W]V$#59S+
MJWEF?TL.$'?Z,S^:UJR G:'\8-J9WBCR<NBY%;:3TN$\$EV*H=B7R"/GI.8$
M%A[@"5@)X]5\D86JZA0';*XCD!?%N_!N<!"X[ 2Y:#0AGR=?V-L[@LJ%I.7V
MBX/$=G[A0E2"/MDQ<:LYM%-7-WDX;!3&LRA_E)PGFBLIZVGP)W6D,M!0B#ON
MN$?9\W=,UMZE@8U$&!678;+A YF<G.ON+9,9+Y\^IJA/THHRY)T?YU[<FT^)
M5,9?/FG9C[VT5N>YR( =8FZJIO5#VB.2+<0#A]*9U\F>GU^2G>.(ED&Q&^<X
M#%\:X4%E2\8AS3-P"Y&H.!GCD$6Q#^MTE4B.IKDI< 3P-!8/C;CVERJ$$#S%
M:XJT659(<4>H^H/P%SS!9/8G>W\NL3AW4P'/:1$FX]4-+V16\R>XZ,Q&;U>K
M\^?:]G/+TX[\U?>S380Z\:&,G4!,'HPL3+Y_F'6/ _<4RL*)7<ST'T['-(_W
M^4%E)/.".<YX*(\+SV&:5;P7!BO#C]5LA,_1P@748M'*U'K/#9YA2TWWOTQ+
ME7&#H0^3I4>6G^1[M*1"]R)XA'%!6QOH0KV%5%-GR<;*O(HZQ.2_<J],.M 7
MN$7W4'[$$DZ=2UIA;,>>ZS,)F99F[S28\XTQR;<'/3SQ'@(:$!99%#^YW]A=
MKU/S 3M\&,YGV:;)(GA".%'D0=B6$9Y3* ED\%O_6ZU8=)],/O9+6& 5P.T-
MKWQ[ \\32 V.V=HW7:6W#&5W"^'+6[HTB:$A ";2'N.N4"Q:P<II2E&FF2MI
M$+J!)?[%=G(3@%@4S>Z$;Z@OJ?1WZG D_9(FM[MX.=/M2S]K-&U&.=*+<D5#
MFB&=G(2*9:Q#S4$,[)P&^"X"?*^IB5=CYYZ1:T.Q\R)M![5;7X!,!ODS1#/Z
MPE0P?GXPNNBV(/+AO%:A^;!JB"YKZH5Y]YRWMK$EDB G6('?8 \48#'8\IE/
M5A.$FMOU<=;TXBT_>>S+P'(-4$\]*/ZS@.N0;1+W9,NJD%G@]F5&/I-L^GO9
M;'$LVN'$,2.HT<NS%#&^S.V%23)"(?3QXTN9'(K_HNE<7S!?A/;<DH>K9<(+
M/$PE=GP[A8!N1(GYP&S_/@30U*L6<X_2"'*X#@?-&L8?.\A,UN-]O";%K\?U
MC6FWE%8$H@,+-I&A;PX[DU=E[D?Z:C_9S4L9M5PI^<8M)7T,QT.<RF0[(=WB
M9ZKCE%Z\]BDZSU0L$TF&_B:+#J=]H$CW:$1M^W26M9]H@W*&!8^=I1PF+'$(
MZR%/<@MJFWB>W!R6#-9G9,W"DI.7QJ0C);^O(_E%]AGG!5_,%&K[]'ZZ5"EI
M0S;'EZ&Y-KFO3KF\##,1TPGCE![\"=7KZ9Z^K@B7E\U!Y#LJ0O*13ZB6-IG)
MYFP>W1QCNA!#T5DJZ_UNSHRD*3Z_9.9E_+6?KV K& <W'#T2HGY6I,'7[ 5*
M#[.PB7.2ME0&_IR7>L6I?SH3P-W_C\9_J,=07!1OI"OZ]:G+$[YZ>KV0!].2
MW\++'.6)=S'=D';A'O&AXMTAK*7C\\3E,OTI44(I%] $,'W02"%'%HZ&J[(F
MJ4KW*8TKPM1QMXU;<:NT=\%^>OL^N& Q_>KOK?%]+?YW!C1O>RM#CSM?&3#U
ME[GKK,R="KIB=%_XJWP7<C&<+P@E\9;LI@?5IA C$[&+.!9)H_Z3 # /6''$
M3'%/S^#%DZ^]Y+GL"0@0LJOKR2UPGTF.Q3>SZ)4'- X<LK<7Q=O8*P;TF7M6
MT_&SBBC4>/J',=#T:JRYVEY2\A];O4A-ZT)4J(*X\/2#J*AA7QR,T7(4%  *
MJ4@!9Y%DEJE7*5XC>HBXF(W.[X9),9[:FBR=Z_-RH6:M^779)F0U#X<"Q*6,
M$!&A5'AB\YS+P>[]!$(4F4]TH,6UF<7;PUF=.%.8ZD'5<P$%W#VQ#$.FM5:W
MR;OSPR9Z8KK8QQ^:K3&E).^2KD^1KDD)DVJQE21B&D6![ZNER&N_TRN-1";*
MFE(@(8I@D4VBR%R5Z>1?2$#*J"<%W:"VIF$!@Y=%O89 I'%E/VH]@31H[):*
MU[)QX8H7\K>.^EN]F$)"#E:=V4S7A#W2UBYO1A;^YBZ=PI8;('FDR'\$3FC=
M%FK?M(C\7'LPPRI-STVH8ZC^"B&7BJSJ1X_YD-X=W%ITO\_$AL(.JPLSJS X
M;^&'0(M7=P<35O%:*G\M#$>8O,!J4,;UGBR<FA,7,T_FZ_*R0JIR79=>7DH#
MM&/WD'1?EJ:RM6@VN=)!*LDA(HV#K_Y8(BM\K!A7T+C<R2/-7I#Z*!'Z@XWX
MFD=.J;(\QFV3$S\BC^O$$@_.@":57EW>U.J/\(@YN>S4/HUS_@.4**Z^D#&C
ML6-&JBFP;#CBYH1T>F<W&-A1,4+V^9[]76V5H'_)E[_/P_KL!:FZ<T.2%FIB
MSC79YE;G?OOB.;>C>1?B^YO;Y_'*F#!D',:$*2KA7EM7>Z-1UHZO[I[4A6+)
M0#N'*([FT(<<80F^WXO)XSWNV?,',L>^]YGKF"^17C3*Z<G9^@!_=NO"'CHZ
M;A*LH>0,(Y?Z=>=M\J>ISS4"/C>'E>]#T?N'<;O#<]U0O 5[/_>QS2U]1%<T
MW<AIKB^OKL7;VHJC^RCIV_GA[?-;>C"2(4M(&Z-:F8,KF[BQ *Y;<Y (/2R9
M51U@J',-N-%;&VJ?,Y!5M!E[Y4<76"HE1ZNV4;T,O@?/U"D71GKLQJX?]8Z!
M6_T##U>77SY:?N;YP1_0LS^H>J,\=%P0_@%EG+R@/7>GGA^*_P(W^)41+_PP
MPC, ZK\0C!*K>W:ZN7W/WYQ?/5DD O,Z%BF8.ZZ?:9WCC03?C_2NMNLO/BN^
MSFYABB61-R&A/+MN<E]3 "&]R"U\F-[?0*.>&JUZ,=%KI[C3ETG(+9S3FQ"R
M@-=G"@(L^7[J6;*G$^>><WNR2EHJ-,FO>8FT;X M6]J8'WP^G07=$IL>WMH@
MG@;#$?]4@*;(*8U0=@U=B3.!*&E!8%;.P,(CC2O;='QL]L:"'!54]PA:Y5B?
M] JZJY0R+2P#!+&-MCP$LE>?)X%Y8H#8$;1;WY.D5Q:KAA'!H6E?KX9MVM(E
M2/ZC=9PD?!M_E[V:4$ V]^<R'B=_YH2T$/\Q%QXE:@?YBR?AT\+_O9@;^3,I
M\7'Y8S,_EJ3$R)%>X=7+BR\_/Y-HU_\RN!W_T92E&P:WY1]ITM!T] "^7SE8
M7/V%-@A_1>>[_P502P,$%     @ ]$-/5I3<N";O P  50D  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&ULM59+;]LX$+[[5PS41=$"BO7R0TYL TG:
M8GLH$#3)[F&Q!TH:6T0D4B4IN]Y?OT/*5IS6,;J'/20>DC/?S'R<&6J^E>I)
MEX@&OM>5T NO-*:Y# *=EU@S/90-"CI9254S0TNU#G2CD!7.J*Z". PG0<VX
M\)9SMW>GEG/9FHH+O%.@V[IF:G>#E=PNO,@[;'SEZ]+8C6 Y;]@:[]$\-G>*
M5D&/4O :A>92@,+5PKN.+F]&5M\I_,%QJX]DL)ED4C[9Q>=BX84V(*PP-Q:!
MT<\&;[&J+!"%\6V/Z?4NK>&Q?$#_Y'*G7#*F\596?_+"E LO]:# %6LK\U5N
M?\=]/F.+E\M*N_^P[73'Y#%OM9'UWIC6-1?=+_N^Y^'(( U?,8CW!K&+NW/D
MHOS #%O.E=R"LMJ$9@67JK.FX+BPEW)O%)URLC/+^U(J<_& JH;/8H/:$.%&
MSP-#V%8CR/<X-QU._ I.%,,7*4RIX:,HL'@)$%!0?63Q(;*;^"SB!\R'D$0^
MQ&$<G\%+^DP3AY>\@G>4G@\?,#/ 1 $?O[7<[. >\U9QPU'#7]>9-HJJY>]3
M+'0^1J=]V ZZU W+<>%1BVA4&_26;]]$D_#J3 :C/H/1.?3_<%=G<4Y'F0SA
M-#X\E @K65'[<K$&P[**6.J:F/^#8.B8U61)BP)RJ3MBR9Q3T]#6BG$%&U:U
M"'+EU&]EW3"Q>_LFC:/IE8;'X?T0UG*#2EB78&B\Z%;M0#]?B\4DCT_H C@Z
M\6%;\KP$II"\T[0H4)%7(R&CP#:,5];@@N;7A69DR8]2LZ#6CHN\:JEL20#M
M6#"6A6-5FB V=.M!5KQPF66L8B*G8&S[Z<L!E2S6&:J^; ?ON#63K29/^CU<
M]SP]"LJQ^E'\1%0-?H6-WV V\^,T)2&BOW<0CQ-XWVV'R63PY113EX-;J1JI
M*/8N\S6*? >9I-@@3OWI*(6$L-(10=%Z,ID.'J1AE?47T08ADS1R#I-DZAQ&
M\=2?ALE/N4?_8^[QV ]G,0FN@N*KCH'0Q6//IO'K!-0UJIRS"AK64+11Y(\G
M*9%X@'(;LW-,S7S2[/6)"?)+>U'Z3-9HXH_2Z/ERNKNQN^,9W*(R[&6A%78<
M':6XY:8$J?B:"XJ4VNAP0 U$W:>)5V;)58A0=V/WQS+.F2Y=[$Y &G/4@K]8
MR7U?"&E>@%J[_0!@&=W2$*X-_%3USMR6 /C JNI%&Y7,S@CA!FS[,C>;-/F0
M F&'3 WAU,@,CIXZNLFU>] U0;;"=*]>O]M_,UQW3^6S>O?!025"_&HB=$6F
MX7 Z]D!UCWBW,+)Q#V<F#3W#3BSINP>55:#SE93FL+ .^B^IY;]02P,$%
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MZ+TLZ@6$KBWI[[8AU;%Z-!JP/CKVS$NR!-@OF7W7L ^[_K7&>L2]\#8<2NZ
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M*[_G DG?JJ0)=U2W'*/D<FU\6DMZ\!%*7" +T!\.TSMI=>@.P0OKBLH#O,S
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MSD:^<6U^5*;D^Y9S4U4FY\>5DBAZ: "^+XRIFA^T0'L!]_6_ %!+ P04
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M CPOC/'I"S'H_G/$\_\ 4$L#!!0    ( /1#3U9_TB_"0 <  &L2   9
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MOVKORJ>@[O/7X,=@B *")%T9JDHKP;;:"=\/@H,20SY?-VXARLQG%:5781>
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MM;=Q0.]#'D.A9EZ\%9'J"YE)I40+QE:&^7+<*J]9.M!=T! =M=N?3I.OFNC
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M$$<SY#X.H2%_M*F"X6 >3F!\SG.L9N"ON@0T49L23)B=G@%2UZ4.*MYAB^Z
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MOQ$*.[33$78P8 2<UMUX 9F32RII..6[/JG)[X$'>RG^PUXSYR,EQS %_U&
M9/R^.:6PN<1W30-VP[6%ZE1!BL#;3NL=U.5'T&6?-72+' J#255=VGVS>+'<
M)5+3)N:*"N>@I7U8KY^O;M]?_9U]R-6*Y^PGKK\(2[GHU]=2/TEQ= DE9VLL
MOQ>A^,!(O2^!6(VE$\>TMMRS8;EG@W*/%D 4KZWHFN7"R3WHF9OL*$_T.](<
M-#!''?JYM0+%];[>F$ &@MF*TGT] _VJ8T33,#8 A?O.UTM2X"A"@'D%BN6L
MW_BYII!NITO!QE'@4_AGL6-&?CTG2OLB^-AJ2.]C+M*E>C^ WUY731U.,T9
ML>\U5+R/6WC#U9S1V%[1=V$&QVUIMNV<90_D&R0%*.?+7%/5H7V"^ 9A0W9]
MB!8K\%&!..$IX#=I?0* L*)$"$&&?J%J;K4:G"%A#I"&H+$W1Y'A]H2' I#Z
MDH=7XH=HA8U];5S?W*;WL9:AB4?KIU*7UD@4LW68$P7_(O#ZUMTBRE7M!TC5
M0]JKODWH.A;=EFF^8VNMBLY""G]@ J,$A=])<A]] /1H^EMDV-92]F'#RR-V
MHACLTT?3:+&N*:@Q313>OYB][YRI].*M3(I%C03ACXEQ2B6J:O<N'["*8@W
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M7IW=#*[?C.A]?N$WK;:V\5F0)'-C/M&7GY)79R$QI%(5%T1!XL^#NE5I2H3
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MT1]M.;G9D*.&4E@^7_^7E+A,R[M&@Z_T+IE:XZTQV%4&;XWP_V0-%T8M6WC
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M/UE NP.X7RA,W\W$7;#[")K_ U!+ P04    " #T0T]6D+3B$E4%   5#
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MN;V^'40I6B3HFDUK!$;=] $YT)Q-&ZNL;%]1;,K H>HLTB'OIZ6!%-O*!'J
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M>E$<'LD^9?]RPA2K1,8RKC5X\QJK]#@+A#)A0?")M"F:RUDT4]R 26=W%E7
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MY9>^V?.?S5PU?=_L^$<,\9L6#]#WZX;<+?T%"_@_I/K\_P%02P,$%     @
M]$-/5E%,T\ZS @  T@4  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M?53?;]HP$'[O7W'*I&F3N@8"=!4#)&@[;5(KH=)N#],>3'(A5AT[M2^E[*_?
MV8&4:927Q+X?WWUG^[O1VMA'5R 2O)1*NW%4$%7#.'9I@:5P9Z9"S9[<V%(0
M;^TJ=I5%D86D4L5)IW,>ET+J:#(*MKF=C$Q-2FJ<6W!U60J[F:$RZW'4C7:&
M.[DJR!OBR:@2*UP@/51SR[NX1<EDB=I)H\%B/HZFW>&L[^-#P ^):[>W!M_)
MTIA'O_F>C:..)X0*4_((@G_/>(E*>2"F\;3%C-J2/G%_O4/_&GKG7I;"X:51
M/V5&Q3BZB"##7-2*[LSZ&V[[&7B\U"@7OK!N8@=)!&GMR)3;9&902MW\Q<OV
M'/82+CIO)"3;A"3P;@H%EE>"Q&1DS1JLCV8TOPBMAFPF)[6_E 59]DK.H\FB
MN0PP.2SD2LM<ID(33-/4U)JD7L'<*)E*=/#A7BP5NH^CF+BP3X_3;9%94R1Y
MHT@W@5NCJ7!PK3/,_@6(F7%+.]G1GB5'$:\P/8->]Q223I(<P>NUQ] +>+TW
M\ [U^VNZ=&3YV?P^U'&#US^,YZ4T=)5(<1RQ5AS:9XPF[]]USSM?CK#MMVS[
MQ] G"Y9F5BOTMW;M2/+CQ P>'.:U@AN9XR'"QR'O"X1+4U9";UAKJ;&9@\JR
M]BUM0.@,\*F6%:N10!"DQE&P^E!^-7_XN#+D3E,I@MAJYX^2&-0?H5?&)U\1
M2J3"9&">T08OMNSKAKUBC3K?E_?RR5489 O".20'I[R W"B>)6YX,O5&2#E_
M9?@-7_\/EN.)[ZHFKO?:00\V**P[N1%+8P7YW%?GH'$>NJ9X3V<EVE68)@["
MTVDDUUK;@35M=/H:WDR[6V%74CM0F'-JY^SS( +;3)!F0Z8*JET:XAD0E@4/
M7;0^@/VY,;3;^ +M&)_\!5!+ P04    " #T0T]6Q>R='YX#  !0"   &0
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M6OJZ4D!SYU1R/PJ""[^D3'CIV.W-5#J6M>%,P$P179<E5>]3X'(U\4)OL_'
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M/TVQ4H<A&1R1*'13Z,N0D/$0BOFHJ133CEQ2PU0)^;2%VH06N=W$ W[B#<>
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MN#&;UR6C<.H@ 7R?"Z&W"U30_NDQ_1=02P,$%     @ ]$-/5KHAOU\1!
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M[@^Q1G1[1VD[5M7^7H +C;<,WRSQ6@?:!>#W0J%]5QTW07=1G/T+4$L#!!0
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MY)Z$]&ZD!TU)Q3,=+7_^"3O6+WWJ53"WA!7CZ?/27NCQ5;?V^5@ER#)]2%@
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M:)F*Y;N#SLORP:EGF'T*FW%#)0:E>37MN+_;[G0VMQ:GLQK0<@,H6E?"(^<
M&R5\7/_1JY0Q:K!2D#0/E.:#T@(H6E=-NU73ADU((VZPS/99"N&Y?DF;G;V_
M@Y;K@]("*%I7PM:3P6939MUU7-!>L)"B/1755*=715 +!I][,-@]U0_4@ &E
M!5"TKGZM!X/-)LPGP:6\9*OQ;<>)Z143U(/!YW[(!+ON>4)"ENJ#T@(H6E?0
MUJS!9K=&/R'1O^BUR:L9,E@V4+L&E.:#T@(H6E?<UOS!9O=G<_RDS/=:X; T
M$,IO;CI;]]WWS5[E0<V?FG;\#)TLYK,%GBQ.4Q:R7!^4%D#1NJJV'A VFT ;
M&N:"*48E6N<BC(FDZ'XG*"T,O%X-07T@4)H'2O-!:0$4K:MS:P;A5]R@_S%7
MJHB+H_R:7CNXFULK<[F#%00U>4!I 12MJV!K"6&S)[0I='H9?Q6O?7;>_W6J
M9KW^BKXRESI8/U#_!Y060-&Z'^-;!\@V.T"=3\@'IF(44J$(R\Q*UM3..X;M
M3$^GI2MSZ4-U!*7YH+0 BE;I.#Y:2Y)2L2M7_4@]M\DS5:VU:(XV*XONR_4T
M)\<]?.-7ZX-:3+5<Z3,1.Y9)E-"M1EK7KI[(B6H%4+6C^+Y<L?+$E>)IN1E3
M$E%17*#/;SE7+SM% <TZK.5_4$L#!!0    ( /1#3U;O+6;>OP0   X2   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;+U8;6_;-A#^*X0V#"T01R].
M[#2S#=A.AP58UZ!&MP_#/C#2R2(BD2I)V7'1'[\CI<AV(C.9ERX?8DKB/;SG
MWGCD:"WDG<H -+DO<J[&7J9U>>G[*LZ@H.I4E,#Q2RID034^RJ6O2@DTL4)%
M[D=!,/ +RK@W&=EW-W(R$I7.&8<;2515%%1N9I"+]=@+O8<7G]@RT^:%/QF5
M= D+T)_+&XE/?HN2L *X8H(3">G8FX:7\W!H!.R,/QBLU<Z8&"JW0MR9A^MD
M[ 5&(\@AU@:"XL\*YI#G!@GU^-* >NV:1G!W_(#^BR6/9&ZI@KG(_V2)SL;>
MA4<22&F5ZT]B_2LTA,X-7BQR9?^3=3UWB)/C2FE1-,*H0<%X_4OO&T/L"%P$
M!P2B1B!Z)- /#PCT&X&^)5IK9FE=44TG(RG61)K9B&8&UC96&MDP;MRXT!*_
M,I33DT7M/B)2LF!+SE(64Z[)-(Y%Q37C2W(C<A8S4*1'IDG"C/%I3JYY'4+&
M%6^N0%.6J[<C7Z-*!MB/F^5G]?+1@>7#B'P07&>*O.<))/L /G)I"44/A&:1
M$_$*XE/2#T](%$01^;RX(F]^?$L6$%>2Z0T.EAB$ND/3^<MQPR>X#L7[K2?Z
M=H'^,Y[X^+PG_OH-9<FUAD+]W67S>J&S[H5,8;A4)8UA[&'F*Y K\"8__1 .
M@I^[S/)*8'LV.6MM<N9"G_Q>%;<@37!BW9+46D'5'B3?'+Z<U; #"VLJV6H2
MCOS5+BWGPD?2.F]IG3MIS:G*".4)B<T OE1L17-DHC"S=1VG2)>)I(N:&[I/
M"IM/79YT2AY)>=!2'CCU6F1"ZIX&61#&5Z!T\5*^;MR0;(#*+K9.N2/9#ENV
MPQ?&+>,)6[&DPI*IZEIA$GC-=$9845(F:SM\.U!):A,,GT1S\"B:73/V&%RT
M#"Z<#&ZDR3B].2%E;LJ0B583J*71]X1@O%9U\<<]E'5%V\R-'PO5682=4D=Z
M[5W+^=U_X9P KAFSFG8!.A-))W'W(@@AL+I_Q2C8 ZR4*6XZ Z*TI*;YZ!G1
M9B$B5AA/YBNF#L.L@00E(*URDF,;I$RHF:]HE!)L9T2H4J [ZX!3P2-M' ;;
MAB-P&N"Z#7N2"]01=><XXLN>89(<UGO6  \=>>"<LJ_P3H<4.A6^@A2D1,U$
MB@/C)1.\W1J&SV:J<\J^AM%6P\BIX;3 XLJ^UH$$]]CB*R#8GY$X%Q7N,J(H
M*[MW4BDI7X*M.9WZ1T_,=QZ8O\<DZGGGNR1.PP,TM@U0Z.PE)N_O3>RBH6W)
M!,R^#8.\<U-HD(R[#UO:.6=?QVU#$KH[DH]IVKNE6!YB3%1[SI),W6$JJUBR
MTCB@4UTWZ%03;"_![AEMZVJJC^DU3VQBS]&'E&](1A/"A0G%#C5.N[+=O?:Q
MZ;YM=4)W0W+-<=/'$T,/RQ59B%2OJ81.&[U2>]*P_A[-3KCM=L+!_]7,AZ_4
MR#1V^1YM4;CMBT)W8]2F>+MYI=W!X(;IVZZO<W-S2_Y;@O[.R;H N;07#HI8
M+]9GTO9M>ZDQM4?Y1^]GYK+#GMBW,/5-R0<JEXPKDD.*D,'I$"-7UI</]8,6
MI3V_WPJM16&'&= $I)F WU,A],.#6:"] IK\ U!+ P04    " #T0T]6AV"*
M4WX"  "8!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R]56UKVS 0
M_BO"@['!5CO.*UUB:-J.%5H6&KI]&/N@V&=;5"^N=&[:?U])=MP,&A?&NB^V
M7NX>/<_=23??*GUK2@ D#X)+LPA*Q.HX#$U:@J#F2%4@[4ZNM*!HI[H(3:6!
M9MY)\#".HDDH*)-!,O=K*YW,58V<25AI8FHAJ'Y< E?;13 (=@O7K"C1+83)
MO*(%K %OJI6VL[!#R9@ :9B21$.^"$X&Q\N9L_<&/QALS=Z8."4;I6[=Y");
M!)$C!!Q2= C4_N[A%#AW0);&78L9=$<ZQ_WQ#OVKUVZU;*B!4\5_L@S+13 +
M2 8YK3E>J^TW:/6,'5ZJN/%?LFUMHX"DM4$E6F?+0##9_.E#&X<]A\'D@$/<
M.L2>=W.09WE&D29SK;9$.VN+Y@9>JO>VY)AT25FCMKO,^F&R;I)!5$[6K) L
M9RF52$[25-42F2S(2G&6,C#D,UG;DLAJ#L[ZW""S08&,W!C(:TXN60[DPQD@
M9=Q\G(=HV;DSPK1ELFR8Q >8#&)RI226AIS+#+(_ 4(KJ],6[[0MXU[$,TB/
MR'#PB<11'/?@#;M8#3W>Z #>J1)5C:#)^5W-*EN9^)+*7@QWQXY-15-8!/82
M&=#W$"3OWPTFT9<>AJ..X<BC#U_)YO?7L_GKTOJ2"P1A?K\D8_0&,L:=C'%O
MH)]KJVYJB]O:>HED/\R0/ +5IH?0I",TZ46ZI!NE*2H;VM[<]Z+\9="F'<?I
M_\K]] UDS#H9LW^3^WZ8\>'<AWNOI0!=^)Y@B ]3\W!VJUW;.6E>VV?SIF==
M45TP:0B'W+I&1U-;D+KI \T$5>7?WHU"^Y+[86E;)VAG8/=SI7 W<0=TS3AY
M E!+ P04    " #T0T]6?X,K_T\$  #U%   &0   'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6R]6&USVC@0_BL:7^>FG;E@2P;;Y("9A%Q[F6FGF9*T'V[N
M@V(6\,2V.$E >[_^9./8&,L"&BY?P"^[CYY]+.VN--@P_B06 !)]3^)4#*V%
ME,M+VQ;A A(J.FP)J7HS8SRA4MWRN2V6'.@T=TIBFSB.9R<T2JW1(']VQT<#
MMI)QE,(=1V*5))3_N(:8;886MIX??(GF"YD]L$>#)9W#!.3#\HZK.[M$F48)
MI")B*>(P&UI7^'),W,PAM_@:P4;L7*,LE$?&GK*;V^G0<C)&$$,H,PBJ_M8P
MACC.D!2/?PI0JQPS<]R]?D9_GP>O@GFD L8L_A9-Y6)H!1::PHRN8OF%;?Z$
M(J!>AA>R6.2_:%/8.A8*5T*RI'!6#)(HW?[3[X40.PZXV^) "@=RK(-;..3*
MV5MF>5@W5-+1@+,-XIFU0LLN<FUR;Q5-E&:?<2*Y>ALI/SF:+!B7%_? $W2;
MKD%(]8FD0!=HLOVNB,W05:)LHG]ABL9,2$33*?I#R$AIJ!Z]IQ%'7VF\@LST
M$^5/(.EC#&@"X8I',@*!WMZH9U$LWBG<A\D->OOF'7J#HA3=+]A**#PQL*4*
M)J-DAP7QZRUQTD+\!L(.<O%OB#B$:-S'Q[OCNKNM)"QU)*6.),=SVW14ZVNZ
M4F%_5GJM5;"Y!FJFH0FMB_'71^6*;B4DXF]=V-MQNOIQLE5]*98TA*&EEJT
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MS/4[(?3S2?%.9?T.[?P_4$L#!!0    ( /1#3U8\"U]?M1   $#@   9
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M\21GYTE:\9X]%^^9L7BOXN+.NH^3I763Y5:FEW)7$1NYH45,8BZ)>23FDUA
M8B&)B;.]^IR<[17Q_I.F!XOX_+F(SXU%_'N<5UL7*]GW 6Q4AM8NB;DDYI&8
M3V(!B84D)L[WMX_G>[6[_R1[,CU4O/9('24?#=F >&4]-,&+7%KQC^HWM]+*
M99U&J4V,4N;KSD/CQ@4-K7!4<U'-0S4?U0)4"U%-])3BS'J4<5Y8MFVMVQ1D
M8BWCQZY/TXA:,;UK=K(E^R>[9ID4BVR3EE;UO.KWU?,7,NT\<&)>U."^(347
MU3Q4\U$M0+40U<16L^V=#__1F]',>7D(A5JLWA6.Z@K'?/3RTU?K\C:7<GVH
MU(WC!Y<ZJ;FHYJ&:CVH!JH6H)E MHC2]'U1F:B.AJ8VFIJCFHIJ':CZJ!:@6
MHII M8C2]*Y0\:EMSKC:0_)2I:C-QIX5I\MF^Z^S0]! %=5<5/-0S4>UH.?O
M6I]I\GHT[^P&-$)%M8C2]&Y0D:IMSE0_MOL/V7W3"F56-48ITZYSQSZ8I<%=
M@&:LJ.:AFH]J :J%J"9Z:LV[N9'-6;M6M*FV2.HSRUY9Y9VTKK+U?9P^6M5F
MN\RKG=@DK0HQMOPD+TKKLMJ:7]9;]'5UUL_6-O-5R3:_D_K),?5OGY8UL>[S
M[$>RE/4SX[)Y>GTLJ6@^^A=9VIZF65C93<=B'I+5JGY2M=.]:=CX_G[UV/RC
M6O'V9&3KZ^<__JUX8WW;&_U+EC?/2ZJ%5*NPB5?U<W^UUO&C==VN1I+&]?Y[
M]0VT2F1N73]:EZM5]GM2#2R;L66REO7#[:NH]_WM\U%S@.(??SMS[/D_K30K
MDX5\T_DI _V=]4\9E8+;YAA\[WB%_"LIJC_:0M;OMOKP>7XC.C]_T*0<U5Q4
M\U#-1[6@YR]=YINN/UZ(KH1 M8C2].90$;IMSM#WOH+-78 FZ:CFHIJ':CZJ
M!:@6HIKH*;?_C]].T.O7&U"=!F";SP-H]PASF<J'ZJ4?S)?0]!_57%3S4,WO
M>?.=-G7I;#(T[D<U@6H1I>D-H$XAL,WG$'A%U;Y-@_=$K.A)!*CFHIJ':G[/
MVS_>!H_GV]RQLQ?0TP=Z5FBR7:'QX142Z I%E*9?I*;.0G#,T>_+!FAV(^LO
ML?YC@V9Y:$^@FHMJ'JKY/7^1^OJ#[J-Y ;H>X;^\'@)=CXC2] Y09Q0XYC,*
MC-=6F,<.KG'T% %4\U#-WVJ[)TW-QB_/K K0989=RSQ_N4R!+C.B-+UV5>[O
MF'/_(RZR, N#*QA-_E'-0S5_J_55,)KH=RVSHX+1I)[2] I62;UCS#SK;YF1
MU7OZBAD97,1H4(]J'JKYJ!:@6HAJ M4B2M.;0@7USH0X?<5!PWE4<U'-0S4?
MU0)4"U%-H%I$:7I7J,#>,8>HWV2^KD.SV/A-@4;UJ.:BFM?S;MF']MM]=#4"
M5 M13:!:1&EZ^:LDV3GF@NJ^8_5F9'#]HU$QJGD];Y>A_M%4&-5"5!.H%E&:
M7O\J+';,Z=VQA^K-S. .0&-B5/-ZWK##^9*/KD> :B&J"52+*$UO 177.N;$
M\&<.UJ,9+JJYJ.;UO(?M8>WN2>W0*[91+40U@6H1I>E=H3)<QYS9F0_@H\$M
MJKFHYCD=%S/;+P\>^N@R U0+44V@6D1I^AR0*J8=F\.X(P[TFX6AE8YJ+JIY
M6VUW-@EGNE?IZ#(#5 M13:!:1&EZI:LX=FR.8[^7587_=WLB^XWL/!'4+ RN
M=#24135OO!]ICIW]2D>OQT:U$-4$JD64IE>Z"F_'?>%MM=$B7\Z^]&IG]]9*
MTL5JTYQ3^G3<ISU7NK,KT* 7U5Q4\WK>5\-^+[H> :J%J"90+:(TO5-VIL V
MA\1?<ME,5K8YXKN!G0B;G0F;G0I[O'^RP/Y7 SO'-3O)-3O+-3O-]?]% #Q6
M ?#8&*5=_!&ORKMX;;5!<&>=H]DOJKFHYJ&:CVH!JH6H)E MHC2](53V.YX2
M9T2,T?07U5Q4\U#-1[4 U4)4$Z@649K>%2H2'ILSSB-NB& 6!G<$F@?WO+KV
M-C"C9DK^\:BS"="KA5$M0+40U02J192F-X'*A<>#)N(^>(7]X>D]S L8W"-H
M8MSSX@]<=.ZA*^&C6H!J(:H)5(LH3>\,%1>/C[BZ][@9;LS2X!9 XV%4\U#-
M1[4 U4)4$SVU]FUG,IN[N&CFD5&%UQR];!YK/J.75K/@9O+Y.+5B=9_ K-J\
M;RZHKS[4DVQ9?X+?U//+M%=E/B3EG?60)V55QMNKZJV;/%OO3J7SQKIL)K)Q
MY4*NKV7^?"LW?<*=>AW3>L7BHEIP/8OX0N9EG*3EX],D.4FQUSKM9#C7]9D7
M,E\DU2OIO*J?>N?UOE>!^-@<B'_<SH>^7M??@LU$!_TGB)C-P9\ :%#>\WK;
M^<^Z;O7GH>OAHUJ :B&J"52+*$V_:YP*SR?F\/RRX_.E#5G:3YFN=C"30]L!
MU=R>ESL]F']XZ'KXJ!:@6HAJ M4B2M/;027L$W/"_DVF<?65D*SK&6O:KX=X
MM<H>XGJ7J?JJNZ[/,D_6UYN\Z+R5[@>S/[@WT/Q]TI&8[YT%Y:'+]%$M0+40
MU02J192F]X'*WR?FG-C4!Z]4"S2_,'Q1H+$[JKD];\#AH-Q#U\-'M0#50E03
MJ!91FMX@*G:?F&-W4X-TM@*:O:.:BVH>JOFH%J!:B&IBLG_.PM[\!A&U2+WJ
M=VXR;<[>_UT^M+F[-@=NM??\X8OU(7ZTKK)5ECY:'S]>=?8 FLNCFHMJ'JKY
MJ!:@6HAJ M4B2M.;1>7R$R27GZ"Y/*JYJ.:AFH]J :J%J"90+:(TO2M4+C\Q
M)]?&*Y+,8P?W IK(;[47YQ3N[3VCL3NJ!:@6HII M8C2]!I7L?ODB+F[S5<D
MF87!E8[FZI..VRIW5#H:HZ-:@&HAJ@E4BRA-KW05HT_,T>;7S76;%C1[ 9>?
M+@/KRUV<KZLE;LID$:\Z3] UHX.+'TW44<U#-1_5 E0+44V@6D1I>I.HS'ER
MCNP(H"DSJKFHYJ&:CVH!JH6H)E MHC2M*Z8J>9Z:HUCCCH!Y[-!>0#5WNG^)
MM3W?F_[40Q?JHUJ :B&J"52+*$TO<I4G3\UY\A%[ F9A<*FCB?%T/S'N+'4T
M,D:U -5"5!.H%E&:7NHJ,IZ:$]//>7*;I.U=@G9NS[=)ES)_<6NA_]F&")^R
M97)3[24T)Q*V3[S\>F6=39S.1D'39%1S4<U#-1_5 E0+44V@6D1I>C^IA'F*
MW*=[B@;+J.:BFH=J/JH%J!:BFD"UB-+TKE )]-2<0)OW&M" >:OM;OR\MB<O
M-WY<=*$>JOFH%J!:B&H"U2)*TXM<)<?3(VZ_W;/7@*;&6ZVWU-$X&-5\5 M0
M+40U@6H1I>FEKN+@J3D._BKK>VSW[S-T]@":%J.:BVH>JOFH%J!:B&H"U2)*
MTUM%I<K3.;)#@";+J.:BFH=J/JH%J!:BFD"UB-+TKE )]/28VS1+-=M'_^6<
M9G%PA_3.J>V\'G4=T'+1]?!0S4>U -5"5!.H%E&:W@TJ:IZ:+_<]=G/J7ST$
MBT;4J.:BFH=J/JH%J!:BFD"UB-*T;IJIB'HV(K:X9FA8C6HNJGFHYJ-:@&HA
MJ@E4BRA-[PJ5:<]^XJ;0YK&#>V$_?W[M[,WDZJ(+]5#-1[4 U4)4$Z@649I>
MY"K-GOWTW:/-PN!2=_;.*NHL=31H1C4?U0)4"U%-H%I$:7JIJZ!YUGN;::?9
M8_C>;/[7,T'U'GHUDX-K'TV=4<U#-1_5 E0+44V@6D1I>HNHU'DV078$T/P9
MU5Q4\U#-1[4 U4)4$Z@649K>%2JFGAT34P\Z]-HC5E]%D]=VUZ&G*_/(P=V
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M-JU2-T5-NSU,>W#(38(*F-HF:?_]KH$0:"AM)/J2V'#OX9SC:[@>;AE_$&L
M29X"/Q0C;2UE=*'KPEU#0,4YBR#$.TO& RIQRE>ZB#C019(4^+IE&%T]H%ZH
M.</DVI0[0Q9+WPMARHF(@X#RYROPV7:DF=KNPJVW6DMU07>&$5W!#.1]-.4X
MTW.4A1= *#P6$@[+D79I7HS-MDI((GY[L!6%,5%2YHP]J,GU8J09BA'XX$H%
M0?%O V/P?86$/!XS4"U_IDHLCG?HWQ/Q*&9.!8R9_\=;R/5(ZVMD 4L:^_*6
M;7] )JBC\%SFB^27;+-80R-N+"0+LF1D$'AA^D^?,B,*"2BT.L'*$JSW)MA9
M@IT(39DELB944F?(V99P%8UH:I!XDV2C&B]4RSB3'.]ZF">=*<>*X/*9T'!!
MOCW&7H1K),_(+ZR@%IEAU2QB'PA;DKK(TPE(ZOGB"^;<SR;D].0+.2%>2.[6
M+!:8((:Z1+;JF;J;,;M*F5FO,)N >TYL\XQ8AF55I(_?GVZ6TW7T*#?*RHVR
M$CS[+:.F/@TEN2R:0/[>8#2YEA"(?U5*4^AV-;3:J1<BHBZ,--R* O@&-.?S
M)[-K?*W2W1!8R04[=\&N0W?NF*0^B8JE #L7JH2G:+T$3;U1-HXYL-M#?5,4
M5!'4MXT\J$2TG1-MUQ*] 2$N\"7AQD'L4PD+W-OHA^M1]?:HHIKB=0LL6J9A
MO.1:$67US6JNG9QKIY;KM-+.,Q)"I:>= PJ#@ELIS<,8L],>5-/LYC2[]9;2
M.>-4,OY<O^:U*,<6>T-@)<&]7'#OX[9\KTD7&@(KN=#/7>@WNN7[AZ5G#SHO
MZO.-H!+104YT4$MTS((HEL#KZ=5B'+LN#8&5Y)K&_M-M?%Q]9M@-&=$46MF)
M0A-C-EJC&5RQ_MKVRQK-@GJO!)6I[ML(L_;[C%4:"LGCI(EM>6$+%W&%EE0W
M2(WV#4VAE87O.P?3_L!JK6U+CG:B(;2R$_O6Q*SO38ZNUO9A@W30F-0_\UA-
M>N%$H8YS/RE?>:$@/BP1WCCO88/!TQ-2.I$L2@X9<R;QR)(,UWBJ!*X"\/Z2
M,;F;J'-+?DYU_@-02P,$%     @ ]$-/5JI&73=I @  S04  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&ULK53+;MLP$/P50@V*!$BCAQVW<&4!?J1H
M#BZ,&&D/10^TM+:(4*1"4K;S]UV2LNH$3MI#+Q))[0QG5KN;[J1ZT"6 (?N*
M"ST*2F/J81CJO(2*ZBM9@\ O:ZDJ:G"K-J&N%=#"@2H>)E$T""O*1)"E[FRA
MLE0VAC,!"T5T4U54/4V R]THB(/#P1W;E,8>A%E:TPTLP=S7"X6[L&,I6 5"
M,RF(@O4H&,?#:=_&NX#O#';Z:$VLDY64#W9S6XR"R H"#KFQ#!1?6Y@"YY8(
M93RVG$%WI04>KP_L7YQW]+*B&J:2_V"%*4?!IX 4L*8--W=R]Q5:/]>6+Y=<
MNR?9M;%10/)&&UFU8%10,>'?=-_FX0@0#UX!)"T@>0GHOP+HM8">,^J5.5LS
M:FB6*KDCRD8CFUVXW#@TNF'"_L6E4?B5(<YD"X4%H<P3H:(@-X\-J_$7F4OR
M#0OH QD7!;/9IIS<"E\R-O?G,S"4<7V!(??+&3D_NR!GA DR9YQC@$Y#@]KL
M#6'>ZIAX'<DK.N*$S*4PI28WHH#B.4&(ICIGR<'9)'F3<0;Y%>G%ER2)DN2$
MH.F_P^,WY/2Z1/<<7^\OB;XD"TZ%>9YO\G.\TD9A3?\ZE3K/W#_-;/M\J&N:
MPRC 1M:@MA!D[]_%@^CS*=O_B>Q9$OI=$OIOL6-2D31GOHI@CZ-(P\EB\337
MCL8.HFT677U,P^VQD5,Q21?C]85'G5&!VKB!H4DN&V%\*76GW4P:NU9\<3[!
M6>5'RQ\:/^CF5&V8T(3#&BE1)BI2?GCXC9&UZ[^5--C-;EGBO 5E _#[6DIS
MV-@+N@F>_0902P,$%     @ ]$-/5BFDPG#P @  60@  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#0N>&ULK9;?;YLP$,?_%8M54RMMY5?XT2Y!:I-.V\.T
MJ&FWAVD/#AP!U6!FFZ3][W<&BM) LS[L)=CX[LOGSN=SICLN'F0&H,ACP4HY
M,S*EJDO3E'$&!97GO((25U(N"JIP*C:FK 30I'$JF.E8EF\6-"^-:-J\6XIH
MRFO%\A*6@LBZ**AXN@;&=S/#-IY?W.:;3.D79C2MZ 96H.ZKI<"9V:LD>0&E
MS'E)!*0SX\J^G(?:OC'XD<-.[HV)CF3-^8.>?$UFAJ6!@$&LM +%QQ;FP)@6
M0HP_G:;1?U([[H^?U3\WL6,L:RIASMG//%'9S @-DD!*:Z9N^>X+=/%X6B_F
M3#:_9-?96@:):ZEXT3DC09&7[9,^=GG8<[ GKS@XG8/S5@>W<W";0%NR)JP%
M532:"KXC0ENCFAXTN6F\,9J\U+NX4@)7<_13T54<BQH2<O.(=2%!DH]DA962
MU P(3\E@^70!BN9,GJ'A_6I!3D_.R G)2W*7\5K2,I%34R&75C?CCN&Z97!>
M85A ?$Y<^P-Q+,<9<9^_W=U^Z6YB-OJ4.'U*G$;/?45O29_HFF&L&$V; ,HD
M^76UEDI@U?T>"[!5G(PKZI-X*2L:P\S HR9!;,&(WK^S?>O36+C_2>Q%\&X?
MO'M,/;HI*L:? $C,"[WEM#ULF(DUE)#F:G1_6\V@T=1]8QOY$]N?FMO]L$:,
M0C_HC5[@3GK<R5'<I> I2-U2*",IP"A=*^'O?=CS+@[@AC:!&XZS>3V;=Y3M
M%C>'BCAKLI? %CMFA?U/C2%Z0T0_" \8AT:N%[CCD'X/Z?\K@3$F<)^OX2UH
M6:=8[;7(RPT6@QS?>'_(;4T.L(<V@1]ZX]A!CQT<Q?ZN,A!C0,'@8Z%SF,>A
MC>V$%^- 80\4'@6ZXPHKD';M$KIV.488#HZ![5[LY:-E'%HYENTY!Y#F7N/7
ME^XW*C9Y*0F#%/VL\P!+1K0763M1O&KN@C57>+,TPPSO?A#: -=3SM7S1%\O
M_;^)Z"]02P,$%     @ ]$-/5JM]950G"   Y4<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&ULQ9Q=;]LV%(;_"N$-10>DM3[\D::)@22BL YM$23M
M=C'L@K%HFZ@D>A25-,!^_$A)EDR;IJ/B%,E%8CLZ#V6]A^31*TKGCUQ\*U:4
M2O0]2_/B8K"2<GTV'!;S%<U(\9:O::[^L^ B(U*]%<MAL1:4)%50E@X#SYL,
M,\+RP>R\^NQ&S,YY*5.6TQN!BC++B'BZHBE_O!CX@\T'MVRYDOJ#X>Q\39;T
MCLJOZQNAW@U;2L(RFA>,YTC0Q<7@TC^+PZD.J+;XD]''8NLUTE_EGO-O^LV'
MY&+@Z3VB*9U+C2#JSP.]IFFJ26H__FV@@[9-';C]>D./JR^OOLP]*>@U3_]B
MB5Q=#$X'**$+4J;REC_^3ILO--:\.4^+ZC=Z;+;U!FA>%I)G3;#:@XSE]5_R
MO3D06P&*8P\(FH!@-V!T("!L L+G!HR:@-%NP.1 P+@)&#^WA4D3,*F.?7VP
MJB,=$4EFYX(_(J&W5C3]HI*KBE8'F.4ZL^ZD4/]E*D[.[M8\+[B@";JE!25B
MOCI!2J64W'-!:NWS!'UD<Y5,%%TN!:4JKV2!WJ#+)&%Z"Y*B#WF=XWK[UQ&5
MA*7%;VJ3KW<1>OWK;^=#J795-SB<-[MU5>]6<&"W?/2)YW)5()PG-+'$XR/Q
M@0,P5,>H/5#!YD!=!4[B9_[P%H7>"0J\P+/LT+4[_(ZN-^'^J24\<H?_4>9M
M^-1V.-SA$9VK<+_:^< 2'C\_W'<<R[!-NK#BA=!)]_='14(?),V*?VQ)53<[
MLC>K!^FS8DWF]&*@1N&"B@<ZF+WZQ9]X[VV"0L(B2!B&A,5 ,",11FTBC%ST
MV4;^2N^$/JB);JV51O3[6FMOT]A)[*LQ)"R"A.$:-JU@NCQXF/G^Z>G44S_G
MPX=M 2U;!MXT'&]O::@S;M49.]6YOKG]\ 7]UW9$LNF(2%*1%39QG,"^XD#"
M(D@8AH3%0#!#XDDK\>1E1N()9") PB)(&(:$Q4 P(Q&F;2),G7W]$_G.LC)#
M:\(2M*9""2[5F07B"[041'5Y\DB$^H_@<TJ3 I6Y9*I673$U> LU<.<E1<6*
M"(I8H2!/Y#ZUCM[.O>B;%Y"P"!*&:YCO;0W*HYUA&Z@]0^W35NU3][S+GT@J
MG[1057>V*>4D]%4*$A9!PO#IWNRY.[_66TRL6QA'_UU[]-\YC_[E*Y*MW]_N
M#ZMJKKVZ_F03PPGL*P8D+(*$84A8# 0S)/:][KS:>YF9M6D7*!= :1$H#8/2
M8BB:F0];/HOO[/2?>?Y&T$69)WIJ1&DC_()2YRCLIO96&Y(6-;3ML3,8[Y^@
M8-!68RB:J6/0Z1BX"R66TD+R_(AL3DAOV2!I$2@--[3M)!AY]<_./ K5KBE<
MYSGY3B=#"9?7%:Y1W-*4+9GND)*K.G9.V8-ZR:@>MT55)#%J%QC4:@*E1: T
MW-",6M9[Z_F[ZOX,'\GOC"3?[23=T3FWS:>'2RHWL+>"H$X2* V#TF(HFBET
MYTGYXQ>JJT"]*U!:!$K#H+08BF;F0V=@^4Y;Y(?KJHG%-1WO35K7[M9[ZPAJ
M/H'28BB:J6/G/_E'#*CGU56@_A$H+0*EX8:VG:#A@;KJ9SA)?F<E^6XO";BN
M K6=0&D1* TWM*-U%5"CIKJ=5>6[O:IG#*\G:,%$(=&3FHV17 E>+E=HP4LA
M]76]7"DO"B*>JJQ8+&BUE 0E1%K]8??N]-8?U.H"I>&&9IP]VWKWS["Q@L[&
M"IRVR'/T5_(OCDE=%66J0I<L+UF^5&FBA@*RD%38DL"]3WV3 )06@=)P0]LV
MET>6)(!JU$R"SKL*W-Y5>YG^&:=5;E1O[4 -*U :!J7%4#13XL[6"H*7.:T*
M0)TP4%H$2L.@M!B*9N9#YY8%;K>LZ^D++I!HU^GH(9WIXNVD6@1B5=Q-#JM"
MP5;\7;LC>ZL+:H.!TF(HFJENYY8%SUUWU>JIZW>]B%//SFIVMQ;GP?Y2H\!V
M2G+M;KZWD*!N&"@MAJ*90G9N6.!>HO6%2Y+:NN>NG">(J^),UUV'^^UX3]V)
M75U0;PN4AD%I,13-5+?SM@*WMZ4GX*:(WIIQ#Y=>H(NN0&D1* V#TF(HFJER
MYWP%TQ<JO4#-,E!:!$K#H+08BF;F0V>H!4<69_W HF@WLK?4H+89* T'^\NQ
MZD4'>^?,^QN&H;FA*5#GB05N3\PQ+*O?E_-YJ3MS1K/[ _8&J,<%2HM :1B4
M%D/1S'M6.BLL?*$572&HW05*BT!I&)060]',?.A<L=#MBJF.+DK=T=LK5\T
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M)":JE<$#XL%+;AMK3AQLM]WX]5P[699V:052'GAI;.?>XW..;YT[W AYIU(
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M>"5VMQG;Y(H;E=,81@XF P6R "?Z],$/O:]-PO\3V%$8NG48NN?0H[NW'%,
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M4/7$US^A\J=C^&).I7VB=67K.2@NI.)Y!=8*<L+*-]Y4<=@!^.$)0% !@D-
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M77.C-A3]*QJZ;9V9C8T$!CNU/;-Q=J=YV-E,DFT?.GV00;:9@.1*<IS]]Y4
M@PU"))DV#PD?]Q[.U?TXBF8'QI_$EA )7K*4BKFSE7)W-1J):$LR+(9L1ZAZ
MLV8\PU+=\LU([#C!<>Z4I2/DNL$HPPEU%K/\V1U?S-A>I@DE=QR(?99A_N.:
MI.PP=Z!S?'"?;+92/Q@M9CN\(0]$?M_=<74WJE#B)"-4)(P"3M9SYQ.\6J*Q
M=L@M_DC(09Q< QW*BK$G?7,;SQU7,R(IB:2&P.K/,UF2--5(BL<_):A3?5,[
MGEX?T;_DP:M@5EB0)4O_3&*YG3L3!\1DC?>IO&>'WTD94$XP8JG(?X-#:>LZ
M(-H+R;+263'($EK\Q2_E0IPXP*## 94.J.G@=SAXI8.7!UHPR\.ZP1(O9IP=
M -?6"DU?Y&N3>ZMH$JK3^""Y>ILH/[FXI1'+"'C$+T2 2_"@RB3>IP2P-:A?
M@<$UH62=R OP^445D"#@GD2,1DF:X#P;@QLB<9**"X7Q_>$&##Y<@ \@H>!Q
MR_8"TUC,1E+1U1\=126UZX(:ZJ &$?C*J-P*\)G&)#X'&*DXJV#1,=AK9$6\
M(=$0>/ C0"Y"!D++U[M#"QVO6GLOQ_-ZUQ[<)")*F=AS O[ZM!*2J_+^V[1D
M!:)O1M0]?R5V.")S1S6U(/R9.(M??H*!^YLIW/\(["QXOPK>MZ$ORHH"6 *Y
M)6!-8L)Q"CB6Q!1W 1;F8'HT/2\NO;$?JBP^GT9D-)NZL#([XSJNN(ZM7-7
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MKWGU0+)==5-:,JGN7=7C5EV-@6L!]7W-F'P=Z,M7>]F>_0M02P,$%     @
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MM_?Q0FB\W>TPP?<72&. WY="Z.W$;%"_Z,9_ 5!+ P04    " #T0T]66_9
M*1L#  !\"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6S-5EUOVC 4
M_2M6)DV;M#4?0( .D("V6J5V167='J8]F.1"K#IQ9CO0_?M=.R$%"FB5D+:7
MQ';N.;[GQ!^WMQ+R424 FCRE/%-])]$Z/W==%2604G4F<LCPRUS(E&KLRH6K
M<@DTMJ"4NX'GA6Y*6>8,>G9L(@<]46C.,IA(HHHTI?+W"+A8]1W?60_<LT6B
MS8 [Z.5T 5/0#_E$8L^M66*60J:8R(B$>=\9^N?CCHFW =\8K-1&FQ@E,R$>
M3><Z[CN>20@X1-HP4'PM80R<&R),XU?%Z=13&N!F>\U^9;6CEAE5,!;\.XMU
MTG<Z#HEA3@NN[\7J,U1Z6H8O$ES9)UE5L9Y#HD)ID59@S"!E6?FF3Y4/&P _
M/  (*D"P"V@> #0J0,,*+3.SLBZHIH.>%"LB332RF8;UQJ)1#<O,7YQJB5\9
MXO3@"RZ4&Z$4R4&2:4(ED(]D(C1DFE%.+A@OC,]D"E$AF6:@R.53Q(L88G(E
M14K&(LT+3>T_N9N7 /Q6\TYJWJ'6DLTP=L:!?!4&F2)HJD7TF @>@U3DW05H
MRKAZCUDH@U(]5Z-,DZP;59)&I:3@@"0_(+<BTPEFFF&:VP0N^E.;%*Q-&@5'
M&2\@.B,-_P,)O"#8D]#X[^'^D70:]3]K6+[F ;Z[W+BMC(>30D8)KN(M,_=9
M=I31'!7G*J<1]!T\"Q3()3B#MV_\T/NT3^Z)R+;$-VOQ3<O>."!^B LS?NVJ
MO*0R8]EB<S7^N$%B<JTA53_W&=8\I6$G(MLRK%4;UCJZ6K8,4\^&P=JPN3$L
MVC!,S FL#3/'@MV(^SPJ)P[MQ.:Z6 [:W2!H=]L]=[DI_V5<Z+=:7JM5QVTI
M"VMEX5%E#]D2E#EL[O$E662:!S? 4:K7_L\3D6VI;M>JV__%!FB?TK 3D6T9
MUJD-Z_RK#=!YL;"#H-'UO7!G ^R)ZX1AU^ON; !WXR)/02YL?:,PMR+3Y755
MC]8EU-!6#COC(RRMRDKHF::LRVZI7#"\/#C,D=([:^/FE&6M4W:TR&VY,!,:
MBP_;3+ \!&D"\/M<8'50=<P$=<$Y^ -02P,$%     @ ]$-/5F+]4M1( @
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MG""0D*-CX/3:P 2D=$0DXW?+&72?=,##]9[]F_=.7A;<PD3+'Z+ <AA<!ZR
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MK>AX['4PQM8MCN''KX9Y P:6!S+]V5KCNXU7R/XZP/9T7X5@,\4K$9LIOM:
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MQ6Y;<%GE^1#*IN58\6S[WM_VG<4?_P)02P,$%     @ ]$-/5G=+<84& @
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M&^IM!'K;;+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M3*5/?C_JIUU1]</L=+VOUB^'>00V/$Z_XX\S?J__RSX$2!\2I \%TH<&Z:,
MZ>,<I(\+D#XN0?K@$Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4
M606*K )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*
M%%DEBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR
M:A19-8JL&D56C2*K1I%5H\BJ460M4&0M4&0M_E/69VN7?QP_///6U-TAGPU_
M,IJ] 5!+ 0(4 Q0    ( /1#3U8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ]$-/5CS@D[_N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ ]$-/5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #T0T]6*+#$_W8(  "?-   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ ]$-/5K]6>BD:!@  SQD  !@              ("!N1   'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /1#3U:S7#PL!@,  /D)
M   8              " @0D7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #T0T]6F7&2JB(%  "%%   &               @(%%&@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ]$-/5LZQ/WM)
M!@  72<  !@              ("!G1\  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( /1#3U;[*\>?&P(  !\$   8              "
M@1PF  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #T0T]6
MH-W5> D(  "[(P  &               @(%M*   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ ]$-/5KEP?E_O%   F3<  !@
M     ("!K#   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M /1#3U:GB$L&K"   %%G   8              " @=%%  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #T0T]6E-RX)N\#  !5"0  &0
M            @(&S9@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( /1#3U9(*5)2Z@0  /X,   9              " @=EJ  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ]$-/5BJJ1WY)#0
MC"L  !D              ("!^F\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #T0T]67+,>6NL"  "@!@  &0              @(%Z
M?0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /1#3U8$
M+/JTOP(  .P%   9              " @9R   !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ ]$-/5N.C@RM+#0  *#$  !D
M     ("!DH,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /1#3U:0M.(2504  !4,   9              "
M@=*X  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ]$-/
M5D=\VBR.!   \@H  !D              ("!7KX  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #T0T]6+D<[W]P"  !-!@  &0
M        @($CPP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( /1#3U;4XO&>G (  /0%   9              " @3;&  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ]$-/5IQ"\J-O(@  5'4
M !D              ("!"<D  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #T0T]644S3SK,"  #2!0  &0              @(&OZP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /1#3U;%[)T?
MG@,  % (   9              " @9GN  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ ]$-/5A[ON0N< P  3 D  !D
M ("!;O(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #T
M0T]6T/M>SKX"    !@  &0              @(%!]@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /1#3U;NI'LEP0(  !X&   9
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M970S,RYX;6Q02P$"% ,4    " #T0T]6NB&_7Q$$   T"@  &0
M    @($7#@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M /1#3U;D.]SCK@4  ),E   9              " @5\2 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ ]$-/5N\M9MZ_!   #A(  !D
M             ("!1!@! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #T0T]6AV"*4WX"  "8!P  &0              @($Z'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /1#3U9_@RO_3P0
M /44   9              " @>\? 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ ]$-/5@(;&AJP!0  3RL  !D              ("!
M=20! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #T0T]6
M/ M?7[40  ! X   &0              @(%<*@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( /1#3U9.Z].10 ,  (\,   9
M      " @4@[ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ ]$-/5F,O$%Y* P  LPX  !D              ("!OSX! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #T0T]6JD9=-VD"  #-!0
M&0              @(% 0@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( /1#3U8II,)P\ (  %D(   9              " @>!$ 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ]$-/5JM]950G
M"   Y4<  !D              ("!!T@! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #T0T]6WV-13_@&  !H,   &0
M@(%E4 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( /1#
M3U90U"+^( 0  +<8   9              " @917 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ ]$-/5HTL[[\P P  Y0L  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( /1#3U8B9W;RM@(  !<'   9
M  " @71W 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M]$-/5FR%8UK. @  MP@  !D              ("!87H! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " #T0T]6HKT8V?0$   @%0  &0
M            @(%F?0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( /1#3U;ZHL&0'@0  '@/   9              " @9&" 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ]$-/5I:ZN#O6!0
M"2,  !D              ("!YH8! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " #T0T]6+\I'YC,#  #="0  &0              @('S
MC $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( /1#3U9;
M]D I&P,  'P*   9              " @5V0 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ ]$-/5F+]4M1( @  @04  !D
M     ("!KY,! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M" #T0T]6VJ:AN'0#  !-#0  &0              @($NE@$ >&PO=V]R:W-H
M965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /1#3U9[6U#[;@(  ,L%   9
M              " @=F9 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L!
M A0#%     @ ]$-/5J+C2]DZ P  [A,   T              ( !?IP! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #T0T]6EXJ[',     3 @  "P
M        @ 'CGP$ 7W)E;',O+G)E;'-02P$"% ,4    " #T0T]6"BB",OX$
M   W*0  #P              @ ',H $ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ ]$-/5G=+<84& @  \20  !H              ( !]Z4! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ]$-/5O\GIW7C 0
M;"0  !,              ( !-:@! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $8 1@ A$P  2:H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Sponsored Research, Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements</Role>
      <ShortName>Sponsored Research, Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Nature of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails</Role>
      <ShortName>Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Sponsored Research, Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Sponsored Research, Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stockholders Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails</Role>
      <ShortName>Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Summary of Components of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Commitments and Contingencies- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="alvr-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: alvr:OperatingLossCarryforwardsCarrybackPeriod -  alvr-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="alvr-20221231.htm">alvr-20221231.htm</File>
    <File>alvr-20221231.xsd</File>
    <File>alvr-20221231_cal.xml</File>
    <File>alvr-20221231_def.xml</File>
    <File>alvr-20221231_lab.xml</File>
    <File>alvr-20221231_pre.xml</File>
    <File>alvr-ex23_1.htm</File>
    <File>alvr-ex31_1.htm</File>
    <File>alvr-ex31_2.htm</File>
    <File>alvr-ex32_1.htm</File>
    <File>alvr-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img101536035_0.jpg</File>
    <File>img101536035_1.jpg</File>
    <File>img101536035_10.jpg</File>
    <File>img101536035_11.jpg</File>
    <File>img101536035_12.jpg</File>
    <File>img101536035_13.jpg</File>
    <File>img101536035_14.jpg</File>
    <File>img101536035_15.jpg</File>
    <File>img101536035_16.jpg</File>
    <File>img101536035_17.jpg</File>
    <File>img101536035_18.jpg</File>
    <File>img101536035_19.jpg</File>
    <File>img101536035_2.jpg</File>
    <File>img101536035_20.jpg</File>
    <File>img101536035_21.jpg</File>
    <File>img101536035_3.jpg</File>
    <File>img101536035_4.jpg</File>
    <File>img101536035_5.jpg</File>
    <File>img101536035_6.jpg</File>
    <File>img101536035_7.jpg</File>
    <File>img101536035_8.jpg</File>
    <File>img101536035_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="601">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alvr-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 601,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "alvr-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alvr-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "alvr-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alvr-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alvr-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "alvr-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 573,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://www.allovir.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 6
   },
   "keyCustom": 74,
   "keyStandard": 300,
   "memberCustom": 31,
   "memberStandard": 27,
   "nsprefix": "alvr",
   "nsuri": "http://www.allovir.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Short-Term Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:AccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Sponsored Research, Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements",
     "shortName": "Sponsored Research, Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stockholder's Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1",
     "shortName": "Stockholder's Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Short-Term Investments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "alvr:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "alvr:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stockholder's Equity (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholder's Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Net Loss per Share (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Nature of the Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Nature of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_d4bf8ec6-0102-42a1-b91b-bcf0a769f2a6",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_d003b5a4-37dd-4bf1-a824-7458b10262ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "alvr:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_d003b5a4-37dd-4bf1-a824-7458b10262ac",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails",
     "shortName": "Short-Term Investments - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value On Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "alvr:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "alvr:AccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Sponsored Research, Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Sponsored Research, Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "alvr:SponsoredResearchCollaborationAndLicenseAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_89b61897-7cb1-4529-aa9a-3dcca0317455",
      "decimals": "2",
      "lang": null,
      "name": "alvr:MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stockholders Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_58530541-b5e4-496f-9cdc-4d8d6dd69f33",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
     "shortName": "Stockholders Equity - Schedule of Reserved Shares of Common Stock for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_f0711afd-ddae-4cbb-95eb-8a59378fefed",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_1b40c6bb-4bfb-4418-9f73-133bb83a5cc8",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "alvr:CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_95a486e9-ee67-47cd-9f0c-c1d735435df0",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_58530541-b5e4-496f-9cdc-4d8d6dd69f33",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_58530541-b5e4-496f-9cdc-4d8d6dd69f33",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_a98375b5-9ac1-4ea5-b963-c5149a6f4805",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Common Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_a98375b5-9ac1-4ea5-b963-c5149a6f4805",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_50437763-ff2d-4d51-98a3-8c880a8fe158",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock-Based Compensation - Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Income (Loss) Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Income Tax (Benefit) Expense Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Income Taxes - Summary of Components of Deferred Income Taxes (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails",
     "shortName": "Income Taxes - Summary of Components of Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "2",
      "lang": null,
      "name": "alvr:TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_9d14225a-1f51-4be3-8682-e3fe75c16bf8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Share - Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_9d14225a-1f51-4be3-8682-e3fe75c16bf8",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:LeaseTerminationEffectiveDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Commitments and Contingencies- Additional Information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies- Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alvr:LeaseTerminationEffectiveDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_b6deace2-ab0b-4cd5-a4ed-af0a2d79a13d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ManagementFeeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Nature of the Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alvr-20221231.htm",
      "contextRef": "C_ff35b1c7-5c8c-421c-b26e-66dcd752e033",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "alvr_AccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses.",
        "label": "Accrued Expenses [Member]",
        "terseLabel": "Accured member"
       }
      }
     },
     "localname": "AccruedExpensesMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_AccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities disclosure.",
        "label": "Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_AccruedMilestoneExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone expenses.",
        "label": "Accrued Milestone Expenses",
        "terseLabel": "Accrued milestone expenses"
       }
      }
     },
     "localname": "AccruedMilestoneExpenses",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_AccruedProcessDevelopmentAndManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued process development and manufacturing costs current.",
        "label": "Accrued Process Development and Manufacturing Costs Current",
        "terseLabel": "Process development and manufacturing costs"
       }
      }
     },
     "localname": "AccruedProcessDevelopmentAndManufacturingCostsCurrent",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development current.",
        "label": "Accrued Research And Development Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_AdditionalOneTimeLeasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional one time lease period.",
        "label": "Additional One Time Lease Period",
        "terseLabel": "Additional one time lease period"
       }
      }
     },
     "localname": "AdditionalOneTimeLeasePeriod",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_AggregateResearchActivitiesPerformingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate research activities performing fees.",
        "label": "Aggregate Research Activities Performing Fees",
        "terseLabel": "Total research activities performing fees, over the term"
       }
      }
     },
     "localname": "AggregateResearchActivitiesPerformingFees",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_AgreementForPerformingResearchActivitiesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for performing research activities term.",
        "label": "Agreement For Performing Research Activities Term",
        "terseLabel": "Agreement for research activities, term"
       }
      }
     },
     "localname": "AgreementForPerformingResearchActivitiesTerm",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_AmendedAndRestatedExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated exclusive license agreement.",
        "label": "Amended And Restated Exclusive License Agreement [Member]",
        "terseLabel": "A&amp;R License Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedExclusiveLicenseAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_BasisOfPresentationAndConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and consolidation.",
        "label": "Basis Of Presentation And Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_BaylorCollegeOfMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baylor College of Medicine.",
        "label": "Baylor College Of Medicine [Member]",
        "terseLabel": "BCM"
       }
      }
     },
     "localname": "BaylorCollegeOfMedicineMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_CancerResearchAndPreventionInstituteOfTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancer research and prevention institute of Texas.",
        "label": "Cancer Research And Prevention Institute Of Texas [Member]",
        "terseLabel": "CPRIT"
       }
      }
     },
     "localname": "CancerResearchAndPreventionInstituteOfTexasMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_CashAndCashEquivalentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents maturity period.",
        "label": "Cash And Cash Equivalents Maturity Period",
        "terseLabel": "Cash and cash equivalents maturity period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMaturityPeriod",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change Order to Modify Terms of SOW under 2020 DMS Agreement.",
        "label": "Change Order to Modify Terms of SOW under Two Thousand Twenty DMS Agreement [Member]",
        "terseLabel": "Change Order to Modify Terms of SOW under 2020 DMS Agreement"
       }
      }
     },
     "localname": "ChangeOrderToModifyTermsOfSowUnderTwoThousandTwentyDmsAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_CorporateAndAgencyBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate and agency bonds.",
        "label": "Corporate and Agency Bonds [Member]",
        "terseLabel": "Corporate and Agency Bonds"
       }
      }
     },
     "localname": "CorporateAndAgencyBondsMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets leasing arrangements.",
        "label": "Deferred Tax Assets Leasing Arrangements",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, tax deferred expense, compensation and benefits, restricted stock compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Restricted Stock Compensation",
        "terseLabel": "Restricted stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsRestrictedStockCompensation",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_DeferredTaxLiabilitiesRestrictedStockCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities restricted stock compensation.",
        "label": "Deferred Tax Liabilities Restricted Stock Compensation",
        "negatedLabel": "Restricted stock compensation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRestrictedStockCompensation",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_DevelopmentAndManufacturingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement.",
        "label": "Development And Manufacturing Services Agreement [Member]",
        "terseLabel": "DMS Agreement"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingServicesAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_EarnoutPaymentAsPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout payment as percentage of net sales.",
        "label": "Earnout Payment as Percentage of Net Sales",
        "terseLabel": "Earnout payment as percentage of net sales"
       }
      }
     },
     "localname": "EarnoutPaymentAsPercentageOfNetSales",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout payment obligation for number of years from first commercial sale.",
        "label": "Earnout Payment Obligation For Number of Years From First Commercial sale",
        "terseLabel": "Earnout payment obligation for number of years from first commercial sale"
       }
      }
     },
     "localname": "EarnoutPaymentObligationForNumberOfYearsFromFirstCommercialSale",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation intellectual property transfer amount.",
        "label": "Effective Income Tax Rate Reconciliation Intellectual Property Transfer Amount",
        "terseLabel": "Intellectual property transfer"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransfer",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation intellectual property transfer, percent.",
        "label": "Effective Income Tax Rate Reconciliation Intellectual Property Transfer, Percent",
        "terseLabel": "Intellectual property transfer"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyTransferPercent",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation officer's compensation.",
        "label": "Effective Income Tax Rate Reconciliation Officer's Compensation",
        "terseLabel": "Officer's compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOfficersCompensation",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation officer's compensation, percent.",
        "label": "Effective Income Tax Rate Reconciliation Officer's Compensation, Percent",
        "terseLabel": "Officer's compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOfficersCompensationPercent",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, permanent differences, percent.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Difference, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_ElevateBioAndAffiliatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ElevateBio and affiliates.",
        "label": "Elevate Bio And Affiliates [Member]",
        "terseLabel": "ElevateBio and Affiliates"
       }
      }
     },
     "localname": "ElevateBioAndAffiliatesMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_ElevatebioBasecampIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ElevateBio BaseCamp, Inc.",
        "label": "ElevateBio BaseCamp Inc [Member]",
        "terseLabel": "BaseCamp"
       }
      }
     },
     "localname": "ElevatebioBasecampIncMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_FundingArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangements.",
        "label": "Funding Arrangements [Text Block]",
        "terseLabel": "Funding Arrangements"
       }
      }
     },
     "localname": "FundingArrangementsTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFundingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_IncreaseDecreaseInRightOfUseAssetDueToModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in right of use asset due to modification.",
        "label": "Increase Decrease in Right of Use Asset Due to Modification",
        "terseLabel": "Reduction of right-of-use asset due to modification"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetDueToModification",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "verboseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_LeaseCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement month and year"
       }
      }
     },
     "localname": "LeaseCommencementMonthAndYear",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alvr_LeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "localname": "LeaseExpirationMonthAndYear",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alvr_LeaseTerminationEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Termination Effective Date.",
        "label": "Lease Termination Effective Date",
        "terseLabel": "Lease termination effective date"
       }
      }
     },
     "localname": "LeaseTerminationEffectiveDate",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "alvr_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases.",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases [Line Items]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases.",
        "label": "Leases [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_LesseeOperatingEstimatedLeaseExpiringMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating estimated lease expiring month and year.",
        "label": "Lessee Operating Estimated Lease Expiring Month And Year",
        "terseLabel": "Estimated lease expiring month and year"
       }
      }
     },
     "localname": "LesseeOperatingEstimatedLeaseExpiringMonthAndYear",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alvr_LesseeOperatingEstimatedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating estimated lease term.",
        "label": "Lessee Operating Estimated Lease Term",
        "terseLabel": "Estimated lease term"
       }
      }
     },
     "localname": "LesseeOperatingEstimatedLeaseTerm",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_LesseeOperatingLeaseLeaseTermIncludingRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, lease term including renewal option.",
        "label": "Lessee Operating Lease Lease Term Including Renewal Option",
        "terseLabel": "Lessee operating lease, lease term including renewal option"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseTermIncludingRenewalOption",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, convertible preferred stock and stockholders' deficit.",
        "label": "Liabilities Convertible Preferred Stock And Stockholders Deficit [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_MaximumAnnualIncreaseOfCommonStockReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum annual increase of common stock reserved for issuance.",
        "label": "Maximum Annual Increase Of Common Stock Reserved For Issuance",
        "terseLabel": "Annual increase in number of shares reserved for issuance"
       }
      }
     },
     "localname": "MaximumAnnualIncreaseOfCommonStockReservedForIssuance",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alvr_MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum paid percentage from grant award proceeds until which revenue share is payable.",
        "label": "Maximum Paid Percentage From Grant Award Proceeds Until Which Revenue Share Is Payable",
        "terseLabel": "Maximum paid percentage of grant award proceeds until which revenue share is payable"
       }
      }
     },
     "localname": "MaximumPaidPercentageFromGrantAwardProceedsUntilWhichRevenueShareIsPayable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum earnout payments received by investors for reduction of earnout payment.",
        "label": "Minimum Earnout Payments Received by Investors For Reduction of Earnout Payment",
        "terseLabel": "Minimum earnout payments received by investors for reduction of earnout payment"
       }
      }
     },
     "localname": "MinimumEarnoutPaymentsReceivedByInvestorsForReductionOfEarnoutPayment",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum threshold percentage of eligible to receive tiered royalties.",
        "label": "Minimum Threshold Percentage Of Eligible To Receive Tiered Royalties",
        "terseLabel": "Minimum percentage of eligible to receive tiered royalties"
       }
      }
     },
     "localname": "MinimumThresholdPercentageOfEligibleToReceiveTieredRoyalties",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_NewLeaseAgreementWithBpBayColonyLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Lease Agreement with BP Bay Colony LLC.",
        "label": "New Lease Agreement with BP Bay Colony LLC [Member]",
        "terseLabel": "New Lease Agreement with BP Bay Colony LLC"
       }
      }
     },
     "localname": "NewLeaseAgreementWithBpBayColonyLlcMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash lease expense.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_NonRefundableLicenseFeePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable license fee payments.",
        "label": "Non Refundable License Fee Payments",
        "terseLabel": "Non-refundable license fee payments"
       }
      }
     },
     "localname": "NonRefundableLicenseFeePayments",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter.",
        "label": "Non Refundable License Fee Payments Fifth Anniversary Of Effective Date And Continuing Thereafter",
        "terseLabel": "Non-refundable license fee payments fifth anniversary of effective date and continuing thereafter"
       }
      }
     },
     "localname": "NonRefundableLicenseFeePaymentsFifthAnniversaryOfEffectiveDateAndContinuingThereafter",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable license fee payments first year through fourth anniversary of effective date.",
        "label": "Non Refundable License Fee Payments First Year Through Fourth Anniversary Of Effective Date",
        "terseLabel": "Non-refundable license fee payments, first year through fourth anniversary of effective date"
       }
      }
     },
     "localname": "NonRefundableLicenseFeePaymentsFirstYearThroughFourthAnniversaryOfEffectiveDate",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_NumberOfIndividualSecuritiesWithImpairment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual securities with impairment.",
        "label": "Number Of Individual Securities With Impairment",
        "terseLabel": "Number of individual securities with impairments"
       }
      }
     },
     "localname": "NumberOfIndividualSecuritiesWithImpairment",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alvr_NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issuable upon exercise of outstanding options.",
        "label": "Number Of Shares Of Common Stock Issuable Upon Exercise Of Outstanding Options",
        "terseLabel": "Number of shares of common stock issuable upon exercise of outstanding options"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockIssuableUponExerciseOfOutstandingOptions",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alvr_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share.",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "alvr_OfferingPeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Period, description.",
        "label": "Offering Period, Description",
        "terseLabel": "Offering period, description"
       }
      }
     },
     "localname": "OfferingPeriodDescription",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_OperatingLossCarryforwardsCarrybackPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards carryback period.",
        "label": "Operating Loss Carryforwards Carryback Period",
        "terseLabel": "Operating loss carryforwards carryback period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsCarrybackPeriod",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "alvr_OptionToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase common stock.",
        "label": "Option To Purchase Common Stock [Member]",
        "terseLabel": "Option To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionToPurchaseCommonStockMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_OriginalSOWAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original SOW Amendment.",
        "label": "Original S O W Amendment [Member]",
        "terseLabel": "Original SOW Amendment under DMS Agreement"
       }
      }
     },
     "localname": "OriginalSOWAmendmentMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_OtherIncomeNetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income net.",
        "label": "Other Income Net Policy [Text Block]",
        "terseLabel": "Other Income (Loss), Net"
       }
      }
     },
     "localname": "OtherIncomeNetPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum discount price on purchase of shares of common stock.",
        "label": "Percentage of Maximum Discount Price on Purchase of Shares of Common Stock",
        "terseLabel": "Percentage of maximum discount on purchase of shares of common stock"
       }
      }
     },
     "localname": "PercentageOfMaximumDiscountPriceOnPurchaseOfSharesOfCommonStock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum payroll deductions of base salary or wages.",
        "label": "Percentage of Maximum Payroll Deductions of Base Salary or Wages",
        "terseLabel": "Percentage of payroll deductions of base salary or wages"
       }
      }
     },
     "localname": "PercentageOfMaximumPayrollDeductionsOfBaseSalaryOrWages",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for reduction of earnout payment after first commercial sale.",
        "label": "Period For Reduction Of Earnout Payment After First Commercial Sale",
        "terseLabel": "Period for reduction of earnout payment after first commercial sale"
       }
      }
     },
     "localname": "PeriodForReductionOfEarnoutPaymentAfterFirstCommercialSale",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_PrepaidExpensesToRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses to related party.",
        "label": "Prepaid Expenses To Related Party",
        "terseLabel": "Prepaid expenses to related party"
       }
      }
     },
     "localname": "PrepaidExpensesToRelatedParty",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_PrepaidUtilizationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid utilization fee.",
        "label": "Prepaid Utilization Fee",
        "terseLabel": "Prepaid utilization fee"
       }
      }
     },
     "localname": "PrepaidUtilizationFee",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant and Equipment Estimated Useful Life [Table Text Block]",
        "label": "Property Plant and Equipment Estimated Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of property and equipment included in account payable and accrued expenses.",
        "label": "Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Purchase of property and equipment included in AP and accrued expenses"
       }
      }
     },
     "localname": "PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements policy.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_RedumptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redumption agreement.",
        "label": "Redumption Agreement [Member]",
        "terseLabel": "Redumption Agreement"
       }
      }
     },
     "localname": "RedumptionAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_ResearchActivitiesPerformingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research activities performing fees.",
        "label": "Research Activities Performing Fees",
        "terseLabel": "Research activities performing fees"
       }
      }
     },
     "localname": "ResearchActivitiesPerformingFees",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_ResearchAndDevelopmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "Research And Development Grants Policy [Text Block]",
        "terseLabel": "Research and Development Grants"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantsPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_ResearchCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration agreement.",
        "label": "Research Collaboration Agreement [Member]",
        "terseLabel": "Research Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SaleOfStockOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock offering costs.",
        "label": "Sale of Stock Offering Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "SaleOfStockOfferingCosts",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_SecondLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second license agreement.",
        "label": "Second License Agreement [Member]",
        "terseLabel": "Second License Agreement"
       }
      }
     },
     "localname": "SecondLicenseAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SecondSOWAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second SOW Amendment.",
        "label": "Second S O W Amendment [Member]",
        "terseLabel": "Second SOW Amendment under DMS Agreement"
       }
      }
     },
     "localname": "SecondSOWAmendmentMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award common stock issuable upon exercise of outstanding options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Common Stock Issuable Upon Exercise Of Outstanding Options",
        "terseLabel": "Common stock issuable upon exercise of outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockIssuableUponExerciseOfOutstandingOptions",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by share based payment award fair value assumptions fair value of common stock.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Fair Value of Common Stock",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, vested and exercisable, intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, vested and exercisable, number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number",
        "terseLabel": "Options vested and exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options vested and exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Options vested and exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "alvr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, vested and exercisable, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Life, Options vested and exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_ShortTermInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments maturity period.",
        "label": "Short Term Investments Maturity Period",
        "terseLabel": "Short-term investments maturity period"
       }
      }
     },
     "localname": "ShortTermInvestmentsMaturityPeriod",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investments.",
        "label": "Short Term Investments Policy [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored research agreement, collaboration agreement and license agreement.",
        "label": "Sponsored Research Agreement Collaboration Agreement And License Agreement [Member]",
        "terseLabel": "Collective Agreements"
       }
      }
     },
     "localname": "SponsoredResearchAgreementCollaborationAgreementAndLicenseAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SponsoredResearchCollaborationAndLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored research, collaboration and license agreements.",
        "label": "Sponsored Research Collaboration And License Agreements [Line Items]",
        "terseLabel": "Sponsored Research, Collaboration and License Agreements [Line Items]"
       }
      }
     },
     "localname": "SponsoredResearchCollaborationAndLicenseAgreementsLineItems",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_SponsoredResearchCollaborationAndLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored research, collaboration and license agreements.",
        "label": "Sponsored Research Collaboration And License Agreements [Table]",
        "terseLabel": "Sponsored Research Collaboration And License Agreements [Table]"
       }
      }
     },
     "localname": "SponsoredResearchCollaborationAndLicenseAgreementsTable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_SponsoredResearchCollaborationAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored research, collaboration and license agreements.",
        "label": "Sponsored Research Collaboration And License Agreements [Text Block]",
        "terseLabel": "Sponsored Research, Collaboration and License Agreements"
       }
      }
     },
     "localname": "SponsoredResearchCollaborationAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alvr_StockAvailableForGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock available for grant.",
        "label": "Stock Available For Grant [Member]",
        "terseLabel": "Stock Available For Grant"
       }
      }
     },
     "localname": "StockAvailableForGrantMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_StockAvailableForIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Available For Issuance",
        "label": "Stock Available For Issuance [Member]",
        "terseLabel": "Stock Available For Issuance"
       }
      }
     },
     "localname": "StockAvailableForIssuanceMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SubleaseWithAmagPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease with AMAG Pharmaceuticals.",
        "label": "Sublease with AMAG Pharmaceuticals [Member]",
        "terseLabel": "Sublease with AMAG Pharmaceuticals"
       }
      }
     },
     "localname": "SubleaseWithAmagPharmaceuticalsMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alvr_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "alvr_TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cuts and jobs act of 2017 percentage of limitations on net operating loss carryforwards to taxable income.",
        "label": "Tax Cuts And Jobs Act Of2017 Percentage Of Limitations On Net Operating Loss Carryforwards To Taxable Income",
        "terseLabel": "Percentage of TCJA limitations on net operating loss carryforwards to taxable income"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alvr_TenantImprovementAllowanceReimbursementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance, reimbursement period.",
        "label": "Tenant Improvement Allowance Reimbursement Period",
        "terseLabel": "Tenant improvement allowance, reimbursement period"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReimbursementPeriod",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alvr_TenantImprovementAllowanceToBeReimbursed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance to be reimbursed.",
        "label": "Tenant Improvement Allowance To Be Reimbursed",
        "terseLabel": "Tenant improvement allowance to be reimbursed"
       }
      }
     },
     "localname": "TenantImprovementAllowanceToBeReimbursed",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen equity incentive plan.",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty development and manufacturing services agreement.",
        "label": "Two Thousand And Twenty Development And Manufacturing Services Agreement [Member]",
        "terseLabel": "2020 DMS Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyDevelopmentAndManufacturingServicesAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_TwoThousandAndTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 employee stock purchase plan.",
        "label": "Two Thousand And Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP",
        "verboseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_TwoThousandTwentyStockOptionAndGrantPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock option and grant plan.",
        "label": "Two Thousand Twenty Stock Option And Grant Plan [Member]",
        "terseLabel": "2020 Stock Option and Grant Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyStockOptionAndGrantPlanMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two statement of work under development and manufacturing services agreement.",
        "label": "Two Thousand Twenty Two Statement of Work Under Development and Manufacturing Services Agreement [Member]",
        "terseLabel": "2022 SOW Under the DMS Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_USGovernmentTreasurySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. government treasury securities.",
        "label": "U S Government Treasury Securities [Member]",
        "terseLabel": "U.S. Government Treasury Securities"
       }
      }
     },
     "localname": "USGovernmentTreasurySecuritiesMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_UnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts.",
        "label": "Underwriting Discounts",
        "terseLabel": "Underwriting discounts, amount"
       }
      }
     },
     "localname": "UnderwritingDiscounts",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_UnderwritingDiscountsCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts commissions.",
        "label": "Underwriting Discounts Commissions",
        "terseLabel": "Underwriting discounts or commissions"
       }
      }
     },
     "localname": "UnderwritingDiscountsCommissions",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_UnrealizedGainLossOnAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized gain (loss) on available-for-sale securities",
        "label": "Unrealized gain (loss) on available-for-sale securities",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnAvailableForSaleSecurities",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alvr_UtilizationFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Utilization fee payable.",
        "label": "Utilization Fee Payable",
        "terseLabel": "Utilization fee"
       }
      }
     },
     "localname": "UtilizationFeePayable",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alvr_WalthamLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham leases.",
        "label": "Waltham Leases [Member]",
        "terseLabel": "Waltham Leases"
       }
      }
     },
     "localname": "WalthamLeasesMember",
     "nsuri": "http://www.allovir.com/20221231",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address Address Line1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r296",
      "r302",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r254",
      "r582",
      "r642",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r335",
      "r522",
      "r549",
      "r567",
      "r568",
      "r581",
      "r586",
      "r594",
      "r639",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r254",
      "r582",
      "r642",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r327",
      "r335",
      "r365",
      "r366",
      "r367",
      "r498",
      "r522",
      "r549",
      "r567",
      "r568",
      "r581",
      "r586",
      "r594",
      "r635",
      "r639",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r327",
      "r335",
      "r365",
      "r366",
      "r367",
      "r498",
      "r522",
      "r549",
      "r567",
      "r568",
      "r581",
      "r586",
      "r594",
      "r635",
      "r639",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r296",
      "r302",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02",
        "verboseLabel": "Lease Modification under ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "(Accretion) amortization of short-term investment (premiums) discounts"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r63",
      "r159"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r165",
      "r544",
      "r557",
      "r561"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r110",
      "r483",
      "r552",
      "r553",
      "r614",
      "r615",
      "r616",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r5",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r623",
      "r624",
      "r625",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r197",
      "r198",
      "r199",
      "r200",
      "r209",
      "r255",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r374",
      "r375",
      "r376",
      "r398",
      "r399",
      "r400",
      "r401",
      "r413",
      "r414",
      "r415",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r524",
      "r525",
      "r526",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r96",
      "r97",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r137",
      "r161",
      "r188",
      "r241",
      "r249",
      "r251",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r417",
      "r421",
      "r441",
      "r593",
      "r637",
      "r638",
      "r688"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r167",
      "r188",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r417",
      "r421",
      "r441",
      "r593",
      "r637",
      "r638",
      "r688"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r257",
      "r273"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r53",
      "r273"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense for cloud computing arrangements"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r157",
      "r571"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r42",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Total cash, cash equivalents, and restricted cash",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r35",
      "r41",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r117"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net increase in cash, cash equivalents, and restricted cash",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r188",
      "r212",
      "r213",
      "r220",
      "r222",
      "r229",
      "r230",
      "r261",
      "r285",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r300",
      "r301",
      "r304",
      "r308",
      "r315",
      "r441",
      "r569",
      "r606",
      "r619",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r279",
      "r280",
      "r563",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Reserved shares of common stock for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r623",
      "r624",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r4",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r4",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value: 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 93,268,069 and 65,170,332 shares issued at December 31, 2022 and December 31, 2021, respectively; and 93,093,243 and 63,565,886 shares outstanding at December 31, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r172",
      "r174",
      "r180",
      "r540",
      "r546"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "auth_ref": [
      "r116",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.",
        "label": "Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk",
        "terseLabel": "Off-balance sheet risk description"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Changes in Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r621",
      "r676",
      "r678"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r395",
      "r405",
      "r621"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "U.S. current income tax expense",
        "totalLabel": "Total current income tax (benefit) expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax (benefit) expense:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r621",
      "r676",
      "r678"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Amortized Cost and Estimated Fair Value of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r621",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r621",
      "r677"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r109",
      "r396",
      "r404",
      "r405",
      "r621"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax (benefit) expense:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r125",
      "r135",
      "r390"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r621",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalization of R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r674"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset (liability)"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r105",
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Non-qualified stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r107",
      "r675"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfComponentsOfDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Matching contributions by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expenses",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r239"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r339",
      "r370",
      "r371",
      "r373",
      "r378",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r81",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "terseLabel": "Cash dividends declared or paid",
        "totalLabel": "Dividends, Cash, Total"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r11",
      "r287",
      "r288",
      "r289",
      "r293",
      "r294",
      "r295",
      "r487",
      "r622"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Amount due to related party",
        "totalLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r181",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r210",
      "r212",
      "r220",
      "r221",
      "r222",
      "r226",
      "r434",
      "r435",
      "r541",
      "r547",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r181",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r212",
      "r220",
      "r221",
      "r222",
      "r226",
      "r434",
      "r435",
      "r541",
      "r547",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total income tax (benefit) expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r190",
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Benefit at the federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r671",
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r672",
      "r679"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "terseLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of cost expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r151",
      "r176",
      "r177",
      "r178",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r228",
      "r265",
      "r316",
      "r374",
      "r375",
      "r376",
      "r400",
      "r401",
      "r433",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r483",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r437",
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r113",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r297",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r438",
      "r495",
      "r496",
      "r497",
      "r579",
      "r580",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r297",
      "r328",
      "r333",
      "r438",
      "r495",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r297",
      "r328",
      "r333",
      "r438",
      "r496",
      "r579",
      "r580",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r297",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r495",
      "r496",
      "r497",
      "r579",
      "r580",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r299",
      "r313",
      "r423",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r578",
      "r630",
      "r631",
      "r632",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Expected useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan Drug Credit (ODC)"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r39",
      "r60",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses on long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r189",
      "r406"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r121",
      "r130",
      "r144",
      "r241",
      "r248",
      "r250",
      "r252",
      "r542",
      "r577"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r189",
      "r406"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r384",
      "r388",
      "r394",
      "r402",
      "r408",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r191",
      "r207",
      "r208",
      "r240",
      "r382",
      "r403",
      "r409",
      "r548"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense",
        "terseLabel": "Income tax (benefit) expense",
        "totalLabel": "Total income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r380",
      "r381",
      "r388",
      "r389",
      "r393",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "verboseLabel": "Increase in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Benefit at the federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r672"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitExpenseReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid, net of refunds",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and amount due to related party",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.",
        "label": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Other assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets and prepaid expenses to related party",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r611"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Cloud Computing Arrangements"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r30",
      "r238"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r122",
      "r132",
      "r145",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Operating lease, existence of option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities Operating Leases Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "totalLabel": "Lessee Operating Lease Liability Payments Due Next Twelve Months, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest (5.00% - 8.08%)",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lease, option to terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r188",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r418",
      "r421",
      "r422",
      "r441",
      "r576",
      "r637",
      "r688",
      "r689"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r126",
      "r139",
      "r593",
      "r620",
      "r633",
      "r682"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r156",
      "r188",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r418",
      "r421",
      "r422",
      "r441",
      "r593",
      "r637",
      "r688",
      "r689"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Non-commercial License Agreement",
        "verboseLabel": "License agreement terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "terseLabel": "Consulting fees to members of management and board of directors"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Fund"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r231",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash provided by (used in) investing activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r40",
      "r131",
      "r143",
      "r154",
      "r170",
      "r173",
      "r178",
      "r188",
      "r197",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r218",
      "r241",
      "r248",
      "r250",
      "r252",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r435",
      "r441",
      "r577",
      "r637"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net losses attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss \u2013 basic and diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Total other income (loss), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r241",
      "r248",
      "r250",
      "r252",
      "r577"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current",
        "verboseLabel": "Lease liability \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, long term",
        "verboseLabel": "Lease liability \u2013 long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfOperatingLeaseLiabilitiesDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r468",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r475",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease interest percentage",
        "verboseLabel": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r474",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r74",
      "r171",
      "r174",
      "r179",
      "r451",
      "r456",
      "r457",
      "r539",
      "r545",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (loss), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r32",
      "r52",
      "r182"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r3",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r3",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value: 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively;",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r129",
      "r142",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid expense"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts of $22,238",
        "verboseLabel": "Net proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in registered direct offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r52",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r94"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r154",
      "r170",
      "r173",
      "r184",
      "r188",
      "r197",
      "r207",
      "r208",
      "r241",
      "r248",
      "r250",
      "r252",
      "r261",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r416",
      "r419",
      "r420",
      "r435",
      "r441",
      "r542",
      "r577",
      "r590",
      "r591",
      "r616",
      "r637"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentBasisOfValuation": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).",
        "label": "Property, Plant and Equipment, Basis of Valuation",
        "terseLabel": "Property, plant and equipment, valuation basis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentBasisOfValuation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Property, plant and equipment, depreciation methods"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r62",
      "r158"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r140",
      "r543",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r334",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses related to services with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r334",
      "r486",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r484",
      "r485",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r99",
      "r147",
      "r696"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r607",
      "r618",
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r562",
      "r608",
      "r618"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Common Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r6",
      "r81",
      "r138",
      "r556",
      "r561",
      "r593"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r151",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r265",
      "r374",
      "r375",
      "r376",
      "r400",
      "r401",
      "r433",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r473",
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "terseLabel": "Base salary or wages",
        "totalLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Cash received from purchases under the ESPP",
        "verboseLabel": "Net proceeds with certain investors"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Stock issued under employee stock purchase plan",
        "verboseLabel": "Share issued to investors"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Offering price per share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Share issued, average price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerSharePotentialDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potential Dilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Attributable To Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Components of Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Income Tax (Benefit) Expense Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Income (Loss) Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Common Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r336",
      "r338",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r86",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value Weighted-Average Assumptions Using Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r162",
      "r163",
      "r164",
      "r229",
      "r300",
      "r301",
      "r302",
      "r304",
      "r308",
      "r313",
      "r315",
      "r581",
      "r606",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r609",
      "r610",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r609",
      "r610",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited",
        "terseLabel": "Awards forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted average grant date fair value of restricted stock granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested at December 31, 2022",
        "periodStartLabel": "Number of Shares, Unvested at January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested at December 31, 2022",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested at January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "verboseLabel": "Weighted average grant date fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares added to number of available shares under plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "verboseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding at December 31, 2022",
        "periodStartLabel": "Aggregate Intrinsic Value, Options outstanding at January 1, 2022",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding at December 31, 2022",
        "periodStartLabel": "Weighted Average Exercise Price, Options outstanding at January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Cumulative increase in number shares reserved for issuance, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRestrictedCommonStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r343",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Awards contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueWeightedAverageAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Options Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Options outstanding as of December 31, 2022",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Options outstanding as of January 1, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Life, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r127",
      "r128",
      "r136",
      "r612"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use Software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r188",
      "r212",
      "r213",
      "r220",
      "r222",
      "r229",
      "r230",
      "r261",
      "r285",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r300",
      "r301",
      "r304",
      "r308",
      "r315",
      "r441",
      "r569",
      "r606",
      "r619",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r74",
      "r151",
      "r176",
      "r177",
      "r178",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r228",
      "r265",
      "r316",
      "r374",
      "r375",
      "r376",
      "r400",
      "r401",
      "r433",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r483",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r228",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r74",
      "r75",
      "r81",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering, Shares",
        "verboseLabel": "Stock issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under the 2020 employee stock purchase plan, Shares",
        "verboseLabel": "Purchase of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in registered direct offering, net of issuance costs, Shares",
        "verboseLabel": "Common stock issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock, upon vesting of restricted stock, Shares",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Number of Options, Exercised",
        "verboseLabel": "Issuance of common stock, upon exercise of common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under the 2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r3",
      "r4",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in registered direct offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock, upon vesting of restricted stock",
        "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock, upon exercise of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r4",
      "r7",
      "r8",
      "r51",
      "r593",
      "r620",
      "r633",
      "r682"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.allovir.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r187",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r316",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholder's Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "totalLabel": "Taxes Payable, Current, Total"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, Balance, Shares",
        "periodStartLabel": "Temporary equity, Balance, Shares",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r258",
      "r259",
      "r299",
      "r313",
      "r423",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r630",
      "r631",
      "r632",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfAmortizedCostAndEstimatedFairValueOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r197",
      "r198",
      "r199",
      "r200",
      "r209",
      "r255",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r374",
      "r375",
      "r376",
      "r398",
      "r399",
      "r400",
      "r401",
      "r413",
      "r414",
      "r415",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r524",
      "r525",
      "r526",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSponsoredResearchCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r379",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r232",
      "r233",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r471",
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r211",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r210",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.allovir.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.allovir.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0000950170-23-002830-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-002830-xbrl.zip
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M^Z,O8U@X/A.Q'43$91[>'_4H:(F)34 %B5W.E ,-^DH)O0J 6PR$[B;:?I0
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MB8>Y;]V8DB01@H1@;GD16%:Q6'N1_P*I#%8HYOTH<OR8"L(=M'836Y$DHI2
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M-&LV&J@%QW87F=T#SD^",(_5Y.]05%Q'!([R/6)[,</TRY+$@8R('7F>I_S
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MA>CW1<MW""?MU3GZAL2TS(-8_O/?K[&@ZIO*JF4FQZ,BEU:N#U6V+ "H;()
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M[P+X]J\)Q2SEV]9A#AL*?\%$6^/C)LLOL/#")+8ZDUMDZ[FULS!I)G-0A-%
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MX,6L3&>[1/.*K-%6+>J:-FKO5E5DJ5BVJB^TJ2\FEE?*H9]  ?S*G N-^.N
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M!Y[*I3H$_W->7&G5>&+N$[3=Z6O)^F* D/("&\".IQ=MV(MF35" BVX@S,W
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M)9CK^)KEY]2@(^+(F"HU<9C^CK!96XH=!HGK#" 7==("2-5+61=GR5F8#GB
M>B01]4!$WGHX1\A)PGEO7F>.(^)6N:EQ?"?*4Y_'@K]ZK1<%OZW&2UU>'^F-
MTZ K.][65@YXL!1=<L<74G5-Y<HT95.100<EB0;4.!>$EA:)G2.,I05/J-VL
M^F,KL_&LJQNQ'E>QK@[7L:X.[Y=U];LOUD?G /#W<9@O46LDT5IY^H4OIN'
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M%_*"$ I"X[U\K$H5K@4]7!$^/',HS:/#9Z]63KLTH7TY2=7%JFB+?.K7T:?
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MNGZ.X-HDB\9X:O\#-#RB$:A-/!:H-=JAOL\X"]*L>Z2:JWPLG9.9JHU:I%)
MNN'FF-?8G V7".+?L8 :Q"KEBD$]#>X2PE,N)*W(&)Y:-].#N9NK^QBCY@4F
M(%581#/\VV]A5N-E/]H>[7@(Z>6:@._9#D*1L*[R5V/JQDT#3++IR^U7]/%^
M&B[SNH+'7ZCX%;]J_Q#74#X/YY5"[R]+!=( FZN7A[C/^=$_X>OA_4:!GR4Z
MP_%2?U\^!)^*FU'0W</!B\-=Y,/XOS]7\9H/[0T'V\/]QH?@'T7[O1)+E4U?
M?:/,B<7@8&]1!7"6$K"Z4!WM;??V=WO#[0-425=H,7D0K\$5CSJ'S_)M]I+O
M-/Q%M\Z3Q]*F7?'4EL//PJH?8$3WTD=T7&WKCI26W%LZ4\.'LVKNE,GYN'%5
M.,>S4[0W71H?M8@]H.%\IR+V9ST?8ROV9\^[Q.M&2A$FAT_XUT^CGZZY'!NG
M]N9)'*?*R^3F)9@^JXM@Z\_@7V F/[^E>#$N>7\'K(5]V-YOF/+>8/_%WFW,
M&4QP"@^]I#9W8"VO787PNP_I(SV8L%?^5#ZT7_LA3-651L@FF!9>6C9 6G:V
M@ZV]T?>;%5YC>1G\5AG\1<V]SO+R<GTHPF&PM7OH72'O"FVP*W0T5=X5\JZ0
M/Y4/275,+;2+) JV-@^]]GDY'^?I=3,_%Y/M<.?5YLWB&U$ P5*%!4'IPJGJ
MO,D?_O#[$[V1DK.U,_3NJI?!AY/!(V1W]BK+B\OUQ&5W.]C:?^&]5>^M;K"W
M^@F&XMU5[Z[Z8_F0K3A2&#-"YH\F!9()!$=S1?_PQH87H6NF\X*M/>\=>0E\
M. G\#[[?*RPO+M<3E[UAL'5X"[D\K[*\#'YS0*=,O(WEQ>5^;2P?SO$">6?A
MG+?$SCAFIAE#K":EB13F.=CV=ZZ7V0>,=?Q^^BAN7%__M!GR,CH(MG9N(8OB
M=9:7P6\N]/S@=9:7EQOHK%W06;M>9WD9?$BPBM=97EYN + ;!5O#?:^SO P^
MG P2.[S76EYBKH^Q"[:\SO(2^) TJJ^]G>7EY0:^(;B&7F,Y$FB^[L7M#L3M
MM^-'K9Z\<-RISP<NWP8DM.]$+7U_.MO?C ^=S1;VNWSB9K.)P9T)<Y$"MZSJ
M&#GLJV+IZQA\'8.W;1_R/GG,IH:7EON.W>P'6P<^L^]E\"&]<:^QO+1<_WY#
MA\EK+"^##PE"]QK+2\M-(CRWP/'Z!$H6O.[:_ @/M:YL!GA\1,='=/R)]1$=
M;VT\!FG9W0VV#G8''I'CI=#'=+S.>A320C&=0Z^SO!3ZJ([768]#6A#U/+B<
M.P?^%VD 'E_GW&]TL;^_B?:#+<@="F#K_);U N3_SM8ZO*4HS4,?KP#[63<[
M>&L*C=4NX(/@8V9^"LY#IRUX=9Y$JF>^.TF*LJ)^XD?Q*?<,GZF,?O';\2DV
MT4[*QH,B6+5*/X<^5^9S%:C)!/8T6M(C\DS_*9RH:MD:#780IZ(:>EZ65X$R
M!"'XI4*5BSPK58"MGF^GX?9W-YI_=%KZ^M%.T_9=9*O9G-ULF].<_M+>]+>R
M7QV=RI_ZAJUU!5ZT5G1FC/Y%.%5L,_7#"<SV99B>A\ORU4_!SP]YHVB+Z@;W
MZ^TNV2U>K^"$/9[[]5::/E]?<1QK#8#JX#2!^R6?@G+X).J[Z]Y]#-,*KB,X
MNX.]G9T[OG/NWS*[JP/Y<8)618>=(C<_&2)P\QLC8KP,RN0B.%?J*U@?.5@H
M.A/7"_;V@ED8!V%P_ G9J4\^]<!B@%F5\, DF\(?7NP]:QH1O0 ,C5@MD@C?
ME&0TFDDRK0L5C%6:GX.=<Z[2,V=@YPK^%N5]QGC#M\AL":L@52$,ISK/@SB9
M3.!3<#>>)45=PK*0[4-S+='$ CO*/&_K<.?9<QE5C.93CO/*4U5'*EV=;U_/
M5RPPO'VSLL+)E#3Z18YKBQ<T+AQ9<SAY.WX<[KQ.JV0!MSL,$#[IX-7IS_ED
MTH=G]<N92B?.<&['YKI-SR293X.RB/[U$_QCN#W<V]G?WMG[W^%P\-=B^E,0
MIM6:O^C;AV3R8+2]N'@ED;+=[3WX 6]*?5L\Z%R[S96K;LU5*VDS;DUO;J^_
M7GYAM0,2&IQ8!7 R"T%7C8)%D>>3/OQ_A#[4HA(C?(MM\^<O2;?EX$&':=K4
M<:C6FJ>?#WV<E J?#2IF7Q0,?')5%7MSZ8XW_GT&1M)9'IQ^_A*<J*($=TG!
M'GLSZ?%(S!V;22 A%,0FXZ#(SY(8CFV1Q%.\V9/Y'$YLM<0_OCO^8LXMV#8I
M&-XJ4V![-V]TD+02;  P5Q8L;V2@Z"?C>Y.L!ELDA'^PLH"_56PB@'JHDI1,
M#; ZLG*1AA3V :&=!Z"Q4@PI30OP.W702(_H__Q_%Z/MX8M799"?9SQL,+;J
MC!\+M@RHK2HO5 RF31ZH"U@V^, L/P_2'.:9UX5K&?&K9/QLO-F9GRO]?1D!
M:$R<&EAZ(%HJ*!<J2L"DQ&4#NRQ*BJA.V5#Z(D^NT(XKHR*!IZ 6':L*E&3&
M]B:M30P3C7&!\[ID2Z^OGZN?,@C PAWN6_U;S<!2A-&!M0:#IH&204FA%G@E
MK/TD*>8R:*,+J .EW4W:/YCP<&B?C-9>O<!G#$>LSF_'6O.:>[VJ^TQ1S."D
MR"=)ZA7V(Q*4.U;8&)'7QEB8A>D2#C*>81A+2@JE6$H(')4>.&-E, WAS!?6
M"VT$]$O0@J3*PHI=NKD)F#LJ$:/FJ"'PM4O0 6D*^Y(J- +CP:U)YUVG,WR<
M^)8!1ML^3GQG'J]7BS=95[DOYSG8JWE!QFN'LH//BTT'&K-4I$:#L"Q56<[9
MO$NR**UCBNG97^.G80EGP:^G[]Z0>8:#0=LLC.$9X.G"H^CK8"E]/GI;4O"O
M4)-4N=$_ B+HX-]'UN&]8+03Q*!V9_"6**H+U--Q33/ [Q"KPZL@RS-EPGSZ
M\^<4851S^ :AYSG$QSP01I63G8A/,N_ID5..EF%9YE$2FDBC^4X?GEE,\1Z
MN01;7]["_SSOT<3W+ALLFO(Y2(<V5N&O1V\Q4IH7'"G$54,;W+Q(CYM>$: 9
M/]K?>Q7\6H1@4N_8E\ *'@9;PYW!X;/G8)AB,C\!@<4EQ_OK#!T8O.-X8EDN
M#TQ52'L)RY*@SBWJ!7D$L$UH@;,W$O*O)K)R]$'<3HK\-I\:YZ7JXS5;\5,O
MT,Y/5,EK@Q^0G:'EK4#HQK5L2]4]YVM9TEX5W-"E%5.EIRVA"2PD[)@)L;,6
MT'9.-<OQ"%\LS&F%^3L^D>/Z@DVT('<.)(9M).U)D4_Z,T$))IB;SL$.:X?
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M*O^*/9_A*<Q#M<SB(I^KUO=^T-/H'5./)O!H@CL\BJ\U&9_+_4"D$*9<R'K
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MA?$@.\3J5F_;>]O^6B#:1J$.Y=_07*#(F6Y#@9&S=I,9H:KJ?TNTS ;Q.!3
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M3!,,'-&/AO+\!$+>82W*J3Q6)!-F0TGA=9QJU9Z20W3,83PJ6Y!H?O7 G*8
M]DG%^),-^+U*(+94%WDU\%YB%4#,+L=..E/B+(EZ37>Q'C#0<*\)/5G#S4PX
M^BZ:8L[8TLN<&XR$C2WH_])"9DZQR T&__J,_7+!V.FA,^3=HE[PX$62NLP
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M0S)NY_EF:VUSF1%?^)G"T#"K.PKS6F8MIBO'1_-X3CFNW, :+POP<6) +3W
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M*U<M?=G-563$N.UI"[WYH'L:.--^KOA$^7*7[WQI#R1JN:6\#$![L'\ITNR
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MP_?GNIG8>>GRD]4*SKE6JP3#%2%QKWWC.? \_?4<?R VQ+1*9#G&.[8?=29
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M:(Q7*E>[V^<TZPZN'XK;T,[:)M ZE&.]TE#8A(HC"IDQ"<TX9\6QH=34:,.
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MA9U#B=BU_3Q;P* R5>Q!6' <M=@2,T9;IECWH9J[CIO6IR=CDEH=$B^ID5=
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MS9Q612UZPX'/S!PV _7$+,S$VG+/+TTB5SMP?\SGS,@QN&Y)ZZC>]%E2^ ^
MT"^XKB!%\62$QMA]Z;@UDPRCMEO#EC?YTOD'X[;E:7]_MOO[&LZ>Q-N$&-IG
M&D<C!FWQ[JTP3<>9 >G8,7IN$U[0S'CB64YZ]"CAINF6PY98(O+?N+P5!AO\
M6@Y5W%]/8?JGM;RG#H];='A\/75X3/SK'V)R\?MP>@CES>Q9MX,(8R_(D6AF
M2J-^/(OISZU]QN'S&-1E9H6L*'[/N?*G;-2]"XBC_7?7%.W26$E\4$\.EL+6
M"R]U2[]B;C4ER.7Z8NC.G@T%:[2]9I:RB\P\HM/Z&F:>O ,]VXO7G,5EUI>&
M4Z_*3^T9WU,RNHC4O4^+J@?TB-ESZ[//@=ASK'4IHL*T)$3HZ8][H6,.=2@I
M+7*T8X1+4I0E56'45Z\BK<_>6^JJXC^=ZY5'N1EDIGQ)N*Z">8Q%1M*&G%,(
MN<9/*@2:K,5MBRZ#\Z/R(KCXN,Z=U<)^G>@,>*DIA=T)]%W3;\7"]E7CBLV\
M:UJ)V"\!(-/,$A;A7DX8_*/@:DODZUMKLNJW=%OOO@Y(%G4?;?;]^?,^%<!U
MA+GV44=F2S8V'?T+9EE7Z3>N_&-?T=Z^*#S_TR.W*//0%_^#*^GQ7Q?'TV)]
MYZYM!6>%!.8U<A-6##GPGGUJ-&'N'W=<R@V:LIP.5G[\YSYW<C0(<P%C5*M*
ML1HQN2'#+.DP3H%%%&!\'O;$GTV-(B2CLZ>P_#T'J^?VYE^)%1I"#Z>M_LXR
MRRK>*;1_V+-:*4G(D!*->]G9\ SZT9WY-HA6AOTGCB?>F6D6>%A-38AA6"*G
M6GAFWKYOXDZQB%D];F/F0:$F&]5YSP>YX/J:@YZ!P*RH:[Q[VM[EFZ[[BI&#
M]NVXX6V#0AXD1/F+X 6Z]HE5;#=];L\DTT^@)_KL>7;^ZFR$>H<_!"&3WBB!
MJ>=?2VP0Z))^LJ*!,!5@9&<F0,_%N9] C,"A-\4D+L>JJ!@@R"PR^/QC.'J
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M.\?\Y7.KK#'REF5EUF/2I".TYB8=@%V(< _%%-J8R9Q8;L3KE7+OI]56\-*
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M["%V@\QYX!D\P.P(370'J20V%ZMQ]&W0+[?/+ZP"TDKSLH!D-@_<+BZJ*(U
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MU_#XFD&F+YIH[PTI=B&9:V:1FKHN>&H$":S<64X8=$Y;Y/ QD70XA=URTI_
MF2*+*B%K[$$= _D/(7(<N2Y'\G>_.%_3W34S ]K<EBOIMA3-?-2=DMF=C[K[
M..KTF JE,Z.'\N<?%8QH6GXLUE<UF/B%E?<;=Q5GX86F_,**?OH]/0X?/WSX
MI1Z'/WYS\=W2BIIE2U%O)8LH@9<S5=0VELH9Q=4\*'_8UN5JZ!8OG'&,Q%K*
M(*3D_.E/[.A5Y=,$*^F>Q8#:1O"21K/7Y'A:QB0OW3+B->;GUE61X0BX<A:[
MH(SJ#0A^)7F=/N *H2_.)$\9:L=\T5(2P5M<1>+Y4(])4.-[YTP"85TUQ-+#
MLH=0H_)<P!)G>22E?X/+Q* K5O(Z6Y.A=#VTYMIHS.S#HC>YQYF^:@F-S/%!
M-T-?,FN]F<ZD$"IK:Y"K4JCX7Q53*9J0UO3A8"IF-3'C\@(O<1QH#5O+W9Y)
MG<,T4 $#S$U9^?NO T PS[;99=%)=>-?0[WV)[%WZYJA54)^S(V*9-E?Y?E\
M:JDKBE=A-";VXSY=&$GF%$<[I<D8ZZ>I+!.7':>]W8*Q(LVA'QJ#*^JF?D \
M  <HVTA"SGC-Z,AUV;C7>A4P$4I<S=.>PB'!B)31WBO;];#M2-W>:=^%NX[<
M,!:19 U!K@F<=<1."GR<JI$(\2U/>_H*;BTIJA9/[^P%8;ED&:\O]1]T[ L0
M=O?=46]@ACS^4LCCIS/D\6U 'F>W='9+/Q"W-#XLZ8V@6P*LHXD?%[(%YQ?G
M8V>1;AP]F&/JHOC4<\^$_ESBXV[Q<JB[*U"-LG+#)#\T!8_ZJ')>60-(Y(:,
MRO7:@K8T-;ZEU[5*Q?H@]%-9^3S%6,0=C0=4IQXAH?B/BZNRRMVL!?' PYR6
M)GT^HD-AYW+Q,P15\' ?"RB3K8U978L#Z'Y%V&1\JD?,X#N;1U\QX@O<Z!Q<
M9]6@Y1]\V*:_6WR4%QOVHA(!PQ+'(F](OXHI<Q/?(4G1[)S]04<C_[5K<N<1
M\1_B*5V5X-82UE;)[?3P'O#2KIIN!V1PMXQ]=:2?6O>^=XJ(-#4" 6H4':D>
M*X9%T6!#&%-N\=[(Y<55[UXCNFX@Q^#)\"PN$=G4Q]98&=I#0TFH$]K;9!9N
MF3][97#9 JF_CV""5(O_F_,B2]+<RD/4U 7BC-$C=%^:TR*G9 OG\^<^SI^)
M2MNXI5L*_ZGQ%X64Z<YP-@7^[)O#K"N;=3C?B1WU8>/XJ"6%F8S"T&_S)CV=
M!3-OTOO<I"*W*$I9O99!L(^&>I.5(@%2R.F6;%JJ7]$KO)3=*NT)Z$9E":*\
M#F)HT3\E;V<"V.[[P&CZ,70S3^&I+91Y<]X+RVV=N=@&[5LAL6CD"&X7+G!B
M.E]6(H6-IOBDS)>MT*1NNUNVK&=)06G1$/ART0.T7I"[\NCJJ=)FK"DW2><3
M1Y1C&61ZXZW7 'RB3QG(2,PE&$&X R4/60NV&)\OV9JR?(C8KIL*&(-V'R<L
MH4;/+1UZQ**H<_1!_H!2_%!=,D33^LZ$AV,!VTW)X$29''P\Q\>*4/ZCHG (
M.J(,L)G)T*Z@36Q/HF4A?62'4T?&'O>R:BUVC.=2F'+B<OAU<<N;$+*-)"8/
MT>WK@ME()? P&DL#V?#1R=DA#,#ZX,#B6>>EM.K'W '1>)Z,VNZB7:1/>/?D
M_"@3+WQ!<1J>.#?W^O.LSZ8OQMMB&;QAAEXU\Y2$""8)B!59D E8!M?VN?IB
M(E-_]I:937]YJOZW<E3^[D]/4]E#I.;=AP+KB:]9X:]UUK;(GP2PC2 T0 05
MDDBR?+(-VE3:%2F= BM7R:36KNFZ4OA+W'(VGA6T#X<Z7O# ULV A$S:D:+L
M9)860U<,A5K%<O#XP-AGPJ8/=VU'8L=:E!4(+?2LL*Y8.^RNW(HV#C_""B0-
MR#:V(V?Y_P0M:IAP\0E\IFT= ^2#1Y'RQIBZ>^=ELAAV+.J!'#XLPD?\SL@;
M2 F_B\C3^ "" 1= 1&R()ZKH7='WDM0>EXM!@.:>O^<^4H>'/6Q2;B\D)UX7
M_4W3OK)Y4:^F;MR)[G9BJ\K<;IX>[&C3AYT5T"UO21@7^RB$GJV_"K<SH 'H
MKL9<6W]WKY(3(U /IKN_?^E,23>XL7F_QX0J\6LYL/\]N%6-:R;8#F%]ZZ]:
M$;R5@L+_='%$V+DU@Z)^=BDRMVO[*GT(FB%[\22N!\I:/BDOEL<D74PA=BI,
MX#VWDC1MGW\2+-J<5]\V==D'I=B@?<M!V/6M"-X#,1$D+A4.X'6'%1U'#Y!L
M# )LQRVA?^9<I8+D/SJ3V:(=JIA<,D*VR^0<FU&46.3U)WYU6VS+8>M1#7Z:
MO*,E)&6Z/()S^L"<,FN+X9IXZ:[OU\&GL@Y^>/9G.XV^^^YE>)"7LM06Y[F;
M0<S,TZ$"2U?M7!0A3AOYAOHZ C-@.&VZS" ?H01U>V>%>^ _8-T?;R+RK0O:
M]< 7&6N%='VQ$T3)SU(7> YQ^J\5P.F>K?7=0M)ID^Z[,R*6VUQI1$,@8I<3
M8_*F%WTV<8"[P[B^%$X.V\P[ME_370= ]_!*-D-B 7JQIY;)<=.T]E06 .F@
MZ:&SSI9V8KV+C^"#F"2TJ8M+Q@H #;%&8W94]Z]MJ6"U%<5MUX0^-+$^I(@T
M&7B9'[EB)'/K,6^MT/K)503G&A#"6>Y6>F>(%1/'5MX,<X+D4IL2PNJE)+[$
M)LX,O^] $=E,]?ZV$]U"3! *%-&K2<Q^V&M\[2MTW!?6?D2;@@Q(?84KYTEW
M#^L'?FUWZQ:0_[W8;!@Z',E>D%U//DT-B"L]7%[">1$T(;>JD$E.\=P=Q,9$
MW^5-K2Z'N-DM>/S8V7_IGND_^K>;J\8S-.K&CF;+?=,W\]M^67IM>ALJ0LCX
MHM-MDL2LNS&YR<X+'9" !]T?<#JT!<EP\P*AM=H,@;5Y7L(JY$'BA_9#6J",
MKMWY])Z(&<4MVPZ+9$MY3U3CS:0J"26>F"#[L$?=\+#%.00U[>X%O;);:+"5
M89Z;]G\ZLQMGB^^:F^(:@TK>P&UK4?T_KL5<PBBS==KY8 A/78?2:!>OPBWZ
M!W=5TB.?.,MK?351DH0]:#K"8-ZE/(['Z[DTMDV/>#(CP/,8PR)NJN^;/1SP
M$6"FG4/;UI+@.9.3?&,\B:3( %9NL2^RMC.H8WA"_TB1NQMU2D)%USUX]+R:
M2QP37N,A(_K*LKWU71C9!4BL"OF2>0@AG<.(=/((O1'&3NY ,B)UR@SB5W6T
M%3>PK+9$2'I95+NP!BG 5^3[<%19QA'/(![94G?M4EVS!X& -0(GN+%NR+Y]
MU33R8MV*[AI%R?!/.&G=R77M1ME(MLN6+UY3N9,!I.V9FZRLQOE0M[Z*:\0M
MDO^-$#=L'P$N&B\F>FW>ZU?_UM.,A>Q%=*(7DVD$!?8NA<YB&6.3/9S%PJ>E
M>'/2?Q71<"&(]/XA6UT.MD],C*[I3;XW$J:%?)<QEBZ]^V0D'XT[*)@S-.[T
M;@!E5ZFM,%H(<Z%M!MI6W+:SC$KA+M_LB]BOX#%7"P-(>'4^WVN--=P$\%2#
MQQ7WF_YK:,LN+P,66KRF&WL3+M1XD71GF3#R3>&;= !\RD-"W-T-;4/12TZB
M8'V%I3M=UWV:+A)$"P-IUN?PQ[;8#;T"X7/T1DFXA6:FVM:),*-($[@E 63:
MD*GM[ T(][E\79)9GMDV;,;@!.BF"/O/G9;L> J68R9:?=NHX\]FU/$[(UJ=
M8XDWF=<?ZL77SD611 4Q@ ^7=Z&8O)UA,K0^93%QICO/&QZ-4<H]1D9LE-M<
M!1RTJ05ARNO" 21V%AV"=1P/XN!(NL SD\7T9Y9.T\ON?;.NL4\M/GK^]/ON
M8Q"#\4CHC;P]C R.4:P>X0X$Y;Y'6BIJ,0*] A(#\4-//JF+PBL)T#7;MFM*
M]Y*;S0,$VPDT-#NXFN6E-N7/D#PIBFG:+CR6)N2B*73.DV&(([>D[#1=(C%*
M^@A*U1*/,'X6+S0B3TKF+]9<COK7N(<;7:!Q8XL1LA*>3%[>:UM<EVXL&B09
MB2N[@G CR<TR;Q'SC_HL)'J,M)=+.I8+-_0\DA9IHBWQR2/;$TA#QLL:TX$W
M'2M+IV#:3Y91<O)@Q7K?"ME.]U*E7(L6M(,0%1XXB,#R12"0-?]>TE*HBKK0
MT<48XG6Q_=]]],:Y-)(S5@67F %E\9PO"//R%(&X_-,0@A$Q"_+?9PMG*;YW
MXWHL#^?^]_G5B^_/%TQA^HRF<NV2Y+74!-<%^LT\C[__M;OX15,-VU69D5JP
M<Y994FP32U%W%<.?)"$MOX8SFL&_ZV)L!E1]:(WQ#0]!5^47BVV&FLV2BZOF
M1ESSH5][,07D)$KOT@G'OD_+\=Y^7AY]$2&HWW@&))!R,\E)]2 +%YB:7>R&
M[19KZU]#K@2)SM]TIU%N&7HT!:R'K21DV($:N_+05,(][3$/)YE%'2K9M!)+
M:*:4"PZV#C,=3T'LU)XMSJO^BC8U+@S)THQ %Z8ULG7.*X.$6*!"VQO_HP1$
M:J.CAL XM4JN)KXIO_]\.O/N1D%N+_G-)!&KAD\>P$:[%*FL-S8[%TU]V>(8
M82RA=15++C&QKKL6+1P"VF#?99).O@[CB&5%5$VKZV<MM;?O'?T-:+ X1HY8
MO0_TU#;->E C+=\1LBLA-G'_OQH4I&"=.[?#"WR8:*>6QQ'DH;336:+F&\&?
M)">+1>V'-.<!NA#["!K;1G5 &6D2O7J1CJ4MVI 8B:!>$;[(XS+BP)S?M1YR
ME/?0]R&%@ZZ79 YN&_C8X_HT_G(X\COCG"0?RV!8*=_<N970D6F[KX=F+$PA
MA=<,,3_18^&AA*;3@'V#Y'(.2W11YL8_TY+/@(1?4'Q9CG(WRU >3VIVT?7&
M2:*\["Z;UK(&(<L DCSGAHT93&'9 H,I3YT.N07/9WJ8)YQ22C-$Y#1++K/-
M[A!NA?-%JA XP(6.S&=8T@@DIL"+ZG%N<3NWMPJ,P:8OPW5RN(AB'SH<+-/M
M3EQ%.!M@:C2'J&=.]#8S-_K6?5W(U?KB4K@*G,'W/,:R;,*O1(V*2S].4*.
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M'P+0W!,92C27H/<??Q5K:3?B%_BSGM&7VH)L>%C_B/R0_[362WB[$FY37CP
MJDBF?M&MW4S+D:W.7@V+C=+\@?!82#^HSF=28+>YCVC"HN_'\EW1\CA07DIK
M$$M5]#1/4$U6?U4DR\9=DXA5IOJ28%"B1,_8,>*G3&OM,06$PAK\.$-4O$SU
M-$(]).Y>E])15*UQ@]]8"XC9RG3>P@!=&$D?SV)HCL4JSIKR$#5.\WE]?8ME
MQJ*^S)3Z(::OXK,T;1>M!QZM]MZUZPA]/'S=> ;;VP?C%7=OJ'N2+#5#CU10
MNG?=EE'?GQOHKV.5DQ&*0LJ](D=ML^\IL2/H96\CUHIYR"HF@$GO8,N>B"R&
M/R6ES(R"^,XK;6?K)RYD<L:S4ES(H\\_>?+HB[//['<?PPA]^GOI H"LR.*R
M:E9,OUP7]5 8Y1*:AK#?+AE@M.-)QWI@<L[G05LK.VK-V?V?%#'%D)F<FCI4
M!K$P;I6J@=BHK]=K>-0-.\ ?NA%\=2GM0_]R$[*6S!&@!KZ=8Z7R@ENX^9E/
M:IERW$BI?7K&SQ:+KPN(EA0+L7[>[N$6:LUP8]R*+[+:\P@M\K,+RUTI# *%
M47%!X%"PI93; @!5A&J%[7(:>UNQVP+^0]EMG0DMSXHSN9CY*E2!_,<?W$"2
MI*I]^QBF0^"7?N'?NJ2=J5\I)6G9AV3NT(W"QA@:'*-4I>4!*VQ=98+,V;$.
MS!#1S:1[!#=^'T9Q8Y==7&SV;EKL7(;KKH8V+X(GUDDWQ#7[=P2$;?$:EV_K
MFU6L!S!Z!0DS7SPO&J=?LM6T&4,]9 AJD]S37)$HNVX&YFLCFD)J32KFNDZ(
MIL?&0IS?C7-="U(\PM=T&X+(QA=RG:=N+YLKH#A8H6TKD@@[>KSX4)?U?7'8
MAN&/]7B-@VH)F[OAF9JI2,8#LB0R2+)SU).6C#*2 @O(&Z9&S ]F+TNBW"$-
MB<>81*2I1C:DLP.=KP89Z9 .LWNUB$E\4AC/!"YG&07JQB\R:B*:0FAAF/Z@
MD'4<Y9UG8,&'"BSX8@86S,""DUB*";#@CF#EN$%;,S_2HQT1^JM@RPB4\ ?J
M.P1<@CGV_7XW IGBM-/#9Q^W0_K*?9Q<NM&<BQP4\=$6DCZPV56!/)Y[0*O,
MB1*Q;SZ> F1*\Q$2U$-M7Y $L-*<A/1N.(L%DF'N4IQ?"+%6E&88UZ>CF1FA
MV-SJ**&(XZN&C&A!S_"JD';;^.6DQ]JXPNG>]EX"Q5&?UA3;7=12I@=FW$6F
M\$)2@[%_R92QM,:+L-\S+_J3T3EO7>^CT-!]E>)NZ6ZYX(*!GQ91O4:((A=Z
MNCOK;!<!!-%MME$$2$.(B[(NVB]7>_8F:T_SN..(W:$*O(^:0I=C-(DD_KL^
M0DP$*CC_FI0BCS'GJ$-IZ45%D&RM<\38'%7LPL;Y8F8!K%>@E2[C$6VU/+*\
MJ+A1=ZF5%$M.&C@@,.<)L6+4GN=F*6GT]I"/IO4Q7:8:D-(W[?4RI'=\5%I9
MTB^,,B%ABWIN8:GJKXLQWF9,^1?&;05@HYV.>-+=NY5&;-N!F"1PN[2R8630
MLC*=A2M&P//+H:S$6,418-R!495*\=B&OG.Q2/+/$;/=ZTO4RRD"85TV>'.R
M#7PW]UOBI?O@>L/D^QCD5Q =+=='#\GO0H^A1%:GU2!V]P>96\;>A0,UW?E%
MN*0I 24>U0$!KD24>H8?<."LP.@3%>QB*IP1_;25DA0;)#4Y^V5"_!OWS6J7
ML1>.<&<VE?<*[\&,ZU_ARTM%[=LGJ35P^"%-ZEF.&X7OQIG:X"%)]!^^,@))
MEJA;M,Z*/W[X2)GY*"@-0(B!)>505$G>+B5N*@2WD2F)FZDU*XA-F->$329B
M,AUUA;%*Z/R*"<9K'<]7[VM$/ZL>SJJ''XCJ84IX@"3M=M@>T.(MG'5B_IE9
M^92U, B*^&]]#?:Q%_RJ*;;/\K^G]-[GO78O"J-Y#KX_CSO<%OU5D[N!7NZQ
MMTR9>[3C_HO-)@2I)NJ=2RRF<E7:3%S65R XA2NQ$9PY(MRRDM^AGDCBR08M
M*?^B'S3OX%-:3?,.OH\=S,1(WKU^ R*_Z':3L98*1LZS'7?"!Q40*$6M&B]P
M[.VZD@',U>%&373>@J>T'.8M>"];T(M'=0;%$4YPXJ-^%A!3>F@F#!XJYQ-S
MC_-HG/?6*;WG>6_=Q]Y*VV(\3ZLJ+/J4T66V(Q28=/*:"5H&SJ9T\VU!W$>F
M%7:)LNOYLX>_7WP4D.#N]U^XW^R&MANRVH-WGY:L371N2I^"WKQ'-Q0V,Y"Z
M,<%^UNEOO_QX)#U@H\0'H,-XV:#O2FI3:ZF?1=QY- [F*#<+MP,O6?%+I27S
MP?)T99O.R<Y-;I,O18DA5"J,X3V>EX!C:H;>6/O]G5>%[ZL2AW_T*LX$##P;
MK-/9/+/!NA]_' V#XH_[2JS?MQMMG18+$$+GY]^]A"D)>_! ?*1<2Z^<FC9B
M=U_5T-E6BJU//GWX5!S_Y_IA]?S/CNW*_[:V],MQ8K^5+?:[/[TLB3GMNZ"O
M>ZB>:/CFI1=8$%"B]# 6ZX%GAJ?-[^(NTJS;Q5V:YQ?G5/+XRU 7)N7Q*)+R
M>#E C+!0)0^WU,!II3P5S)2JSJ.'7/N[VAGG[H#BT@ 0^&KO'I\P7.MM,_+W
M+M*/!&I".WBECJ/$77S((/8H8W>+L_$=<,EH(R"MNW9'*,!SHW9P1R\1PJI$
M74?SUK3<18WU,$,36#71-8H5R J/0L'/?ENL6NDT_BS,H*AXG ^7< _"'UB!
M&EII34!9W_>!^(Y^4WGT1^](!3W60-?>V]'HI?^A%D[X(I\0[\9R 0)8\>&J
M+23516/.4@_ HW:27EJ!MC#;)BKFV7JM+ =)L=#CI2/A6#;YH=0G#^[S 7FQ
MQ<M6LF5GG$*#P$T&S/)(XU=+?PM"L-(FPJ3W-^)D=$:R+C!0O*Y5UCJ'1W2)
MPGL8/\AM;\0/73T@KLE#@9T#BGK%??O^%EW2LBI'2BH>\^*1S279\)<*CY;]
MME1))Q5WPMKPZ^7F""?&W%[XU@UX8H^F7B=UMGY8]PV*^X\^@5F W<5RH#25
M&:@?VV&[(QA*#-0W?HO_( 8*+45U$$%"1?V!X0D!PBISO_3;HMRN!FC]J/9[
M["MPR<*(Z!#DQJ,UZ!Z06TU90)*;>?4S@M@N7KY86KE=2=G#[K&.%,]=F0PC
M<-=[P>2P5P.98>G5\;R^D&@X67>%*6MSV=,],FR%:LKKX,HMF4C[@A)K/01O
MV4$PNA6)K[+<F=J7\>'E^7@Z3\BS*9'A[(:R3X2]1G,I+1>CU^??&"1@>[6\
MF"8HE.',R*0OVN,I,&\WI'>JE5PA\WW<U,I"N!K1;D2K[O%GLNIX\ML!]6DB
M@HBS7\Y\9YG.=S LG0_SC.CRHFS7>%8<!<(O=0,&41?38GK66G-5TA@;6RP<
MV\50.NFR@43)EF$W"5UWL*UN286;4U$:V2WWICT>UA\R\EC?RCHT<"->'B9H
MPIS;@L35Y<H(O06=@_:VI6\)&NNAK8I%S,":%_)&58!V*QYY/A1FK5.A/?&W
M..>(]/_;.;]M=K$X9"^%44)@C]0"9&[[7X\>+U;:$>C>'G8@&V7 $UOF\%.B
M;9ST7&9[\$E!,M?9=1/"\Y\FI)+5/;&#6UEH;D=5B\=?'!?;3)U-E2?+WWQR
M_B>X?.K1;"4G2CN9==XW3:_JK\)5LS2;9SLTQ@FQF2O"Z-K<BH$Y,HG!UGDA
M;9C<H<K&+L.-$DF(S@<O29=8Q0UH)N$8O.E1/K?LO$'+SA_GEIVY9><DEF*B
M5?R09\:7K_,82;4 +5#:1SW#+J 33.E,]XGSU,M!YOFC[\Y>G"T>_?'SSSY>
M>K"&F%H2S&2Y,S_9&E6H980IC4Y4X]*7CUB;[I91DO/%"E+6%S^O :-W'S'#
MQ\9W;3Z)SU*3H_=,-RQ_">,*.U+HB7EN2VG2_6VU6<Y;Y8VVBOAJ$6#:4,$A
M?>9QTM*7T>RB%90Z)!VS<8Q.$'KG]%4O$ ]@MT109 F@M(;C=AD52D,MY]$R
MSGYX$'%I,55V>0FL=I\H2;N-X(LBL2,6J=NYB_\>B2@7>'387_!@.90NN=(4
MX:AX8V3&0Q#JIF();Y64"S'#'12C(Q]02*F&OA@S!+RFE.7\H*=/SU4ZTUT"
MS> V&LNE/'[XR4,O/!YU]H^2G%Z$'/( ]=GB.^=I7L.M#I 50-PE=&*[D9^(
MX(%-O*JP0$3\$2^&H1I5CH/7JHD?@M-5)ONQGSN:R1_^^>SK!X^^7"!S7VS+
M]9ASIR^V8,1!_Y>7F03B_]'O/4X]J*VOW,)(7M?CQ]ZI):^OC8@AQ2</Y2.R
M(!]/71 M15N1:XUH8!]+&E@9$Q_;NN#:!U4^6))_S'YVEW,S^**HRF(3O>''
MW RCHT>/D.FU;V&5L/WGTTO=DL6A6S1(F8;EYV+V'=I@R& C!#'BA2JU" XF
M,/06F5"#Z1^7"9]?'B]N-EUX.=+.YWHUW(@B :9.F14DO\3T/E6.!2T0;V"5
M&&NR<2TZV;%1QG+K&S),4X-:2&2$H,2TJGVC:1>W.?#^E+VER*@F?Q'?L5N#
M;(RQ; X_>W"6,SD^3A5)<)/E.#*T=5/P8*1QZW;@,K*-D$B*AQ@U-QUPJ@S&
M@77:L"+@4<X(64)&43::8].QG"U>FL&NEZ\=L.T,I"NV1>_);FD"AITX28*_
M0>MOTF-XRUL2E@EZ*)=*2$K.=J'+6:#,J8)[2U_6AV$APZ>\W551KZ^0XY<(
MU^?LC)X\\("S[6@+5A.<T[NX,&!\/6P ]:3J=@!L2"WSLTTU,+O2LJFK0  !
M_=%,':L87#K.H0PVB'V7\2#2K <LJ5@H2WJ0!!9O]D=G=>Q0'=D1L64T*%.6
M1/=9%^6_0E\VQFGK7T$(6N^0S%K(]8?^:W (ZHITUP).A%KCOFV(;Y@S*HPT
MPJ_X_ J)A4=C\FIQ@162S#F\;*0'.[H-A_GMU^=*A)-51DM3(H43YQDD$SBJ
MYL:P"V&+?"4UQ'3<L0!+*"'[62&F(P@K3;V=V;/^<#WKE//92M*!Y4_UX ^:
M%6,*7#((8-M->MMCXF,MNO9[6\>&65"N &?NHZKQ89G<O <M46NR+_8ERQK&
M+0@W1'&!]1@>"G_'[K$S.V*K^F;:.*U8(9&4*RBXW&$C',Q-\E!+4SV*>R,/
M$9PCK-32RK::4Q1OY:K<N>?O;R34D3E3=8Y@)0R0%;A0Q:=D53+R;^RP]!4D
M_C:T=5CNG,.;S<.':Q[^=KQ'.? -A[W)DDS?*!\Z^30>V.&7\FLJ"X)XC**W
MH9MUV_0A)!2&+?%+QE@G.?_.%C\A^U^+-O:";-V67XJBS:G<@15\//],T_JO
M,K_FCFZ(=VKO=\+U<3F4.=UI>G()\8J_KMS'KJLE':O7FSZV#49A,;& MTZ<
M9TO11\;3YLSV19@!X0@)DI]47.BG^2V5]/8(3[OX>3+GQ^X:F9*8ZU*\HH."
MDK1MV5$"KHP>L;+1JPK.A/B&E&U(B$,LRQ@<'@K9"'',B ;$F*\E!*S=[/5*
M61>^BH?/=F7PI''<B8,D"2-VM#NW2B A75&)((X ;Q//TRX+QCBC-I79.VQ[
M3][*;0?:"9]E)W4J+<[[*#8@L_DA$NPXT,+R)%\:@BO;;$H$H9<3Q?T(<0GP
M$2?GH_)C$)9"U#.Q+O)<71PQRHKRJ[J;= -$^*+D@ZZ33 A  )9H\@D5-P(/
M"P\OBD"#O4I="7FPKH-UMNLT(0B\G@S<GC;'[#4[KPLAJQC(U):X/#[  WHP
MEP!%E&OU7'3,FLCO!-[]41E-C2!<%?0H*C(,L=>'F8EF)U3TQY@9QJ^0<#AA
MN^A,Z=0+0*G>*MYS%E*O+K1;N=<"^:-.V2QET4XZ9DLW\JO,DL5YLT5L)X_.
MYZO(U%'6B9\GALN7\+\]+.'OH#SE%_)2$]9LL=5O7[JP6PFO-35 8BF97GMB
M.Z+ (X6@6"AT W$)E#61WFO+5<2!398WYESXRD'CQ@?^X\-/%\^0P%1VH^<&
MR2.]%"1?4^[0@.R/IPW(XB6N ^)7@;EB*-\W.7C4M*G0)Q@??A**2>Y)PBY+
M**NC<_>,#XPZ.W-[S$L<^RS>_,MBUVL:S@-AC'/K,'GN=6@TW?HP9KGV!SY>
M7)!P6 UE)>:X&U8XQ\IH#B65$IJ8!=V4U5F>,2\;#>\SNR-R4%K^DB_)!04+
MI/>UI UR94A.T>%0!R@!D9MUM-YL^:*IW#[Z\O$7EA-XV1 )^])(_<[7_8$A
M[]2<"?S$=G=7V--%<C\KA(-<RU[SQ_WU7,_4[^/3X3E7O&%GHV2?OS!6&>X9
M2;]:E\FX"47FS_*H5D;LPPQI>L_9A[];*LA&153\^=J=MZH2>-$H2"L:C/.P
M-F'):<^Y?^$@OAV_:;IF6V0)Q=>:I T+AN.F,)B<9(7J_7'WSZ?ADM7[^&&\
ME@(6^AG<U'*[^)99S1=8.,G>X:[&(W^;73>8W+\;LM'%IM_^?<E=7.D:DEV4
MMO<\'9W<K<3_7#/!W1FU]WL]P/@\X1D(SW?%?:Z^,4XA6U9BA-/5:?/FKO9#
M>YEY>T/R;%-FN&@\XQKO]G5T] 6&>!%.\@5J%[4YV^P/ 'L3J-&Y<[4$Q:6O
M5S4>?/>YN19X#P''F 4W3E++R%MV[A3*C[T"V>;N8$R2-=,6"^=@G,,.%A&U
M)2%X@@@ N(Y70?LO2 &6ZZ3*R)5\2V92BB(0'&>5H/&5!>GX<D=HV0OW-DXM
MM^*YGR2OK)?=6UY:.\=1Q-%Z8=@7H=)51NGKU3ZDDCF94RI9T=-./J+SV"K/
MF,4[QKUXS.??%$ PXHKCJ]GZW90_TQ<'QRCT*C3.]<[QL4<]M+)GB^=10Z%4
M4P@,7:KOO64XK5Z#%S2EUXI8E?NY@=L;C57A>VX#9WN-'S3>2/3ZMAI>(!Y
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M:8$Z/@)J-%ZX . -E#GN]MY^4T?!K"9RY_G\;G ?75PPVU^=EF[([ W\>MX
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M,F%N@&9E8&:(.3^(2O9AW90\DY9=E</.#Z/KA]R2*>-JVNCZ&66<RS4+1 Q
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MZ1,V5J=8NNOU;J86KVKD-AL MWOYIKN4V#?GO</7=RMVZ,V;EM=[I#NVE5<
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MKT1WF3"&%&Y4@R1;Y6@P=H]E>NQW](0*Y0XIC2]2\@D]B0[<]YV%'=PWA?I
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MKP"-^[6CJQ3=2=68F9A!>((I!YI)X&$_R"6NO3/W> M7L;D+L1G5=6-GG$.
M Y0[LN&'')%/U0F#W!KQW+O=7"7H;MVW:[<IFDW=])O+_,K9EM#J%-I J24T
M-GE^B?!H%:+[LZ&K$-W=W!W*0..MGWS.@J%.7/CET;7$DL4UXBZ0FX8:<5Y<
MY371J7()F60S<(Y/D+@^D *1"=HTI;1;!=94=AEC;S;]F!]',UP)Z$M$Z#,H
M7T$"8V((CX;U]]!I(._"*"[VA=T5->M_BGC_U_]^5X<>W8PP;^T@YPD38 IE
M7YS.R::]U#Y>?*0JWWA=>=DT1=#_K@:]#9'Z#KO+34(\0-%[J(KZX][S(*DL
MCD+,M(M8: G,-#= R:4 "G"$%$9'(<WYYA^4&!@J_ZFJ:\SSZ*WWTPG"9:?D
MCBZE=RRX+3+3-2%2?I6FLO8'HA]XZ?P+,1D)WEJY(%N5,'DK5V3,1?DU<5'^
MR!QV+R,7Y5?@H@1M9+@,/4_DPUP@JIP?FWR^^9$N8W[#6W@X-L24A[\E!>GX
MYO2CE)5S,SQ(6LFL C $8SLS\&N\PK>>_ 4V"CM45HF;<=>.QI>8XOGH-HU7
MC['E-:(R?^T*"ETUO:?TWF'Q2GT$<Y(NFZKXY12%V>:7$;05[4!"\EM:?F_=
MJCM=W_--HCO,8RQM)FR8PHCH\#6[W=!F^/VUPV]JQ\CUG/A:9Z9(\>:/&Y']
MP_FEE"<XWSRC+_,MZ9I*!#[@>[2)VX-?RNFPXO0&$.\]6,K=VUP%(1/1%MG)
M]803/T(6FC$ALSO7=?NA,IG)T2GA95339@W)?;04T08?5UKTWX46_=.5%OWW
MH$5?G<#?NJSD)?&DA8K4I?\?KZN(;243O__**U3J&I_.7)!)16"%Z31/1I$^
M10O^T\1][:^GWH"T 4Y:U6$"+DMO@[TAX'S!A=>[K,39K EL%0/-#EZ!DT-&
M5NQ**+_UBP#&(H#95P-3V5R!+8:^*F/0_-/M:4G]7U?]^VB/_4MI3*4CJ[P(
M"%T0^S"&VN7DCQ % P__$L^/&>5WCI&:[<C&CS&9/#'3!R#D/AXX R97YEXC
M5\-AW2>>)Z)D_O5\ZZSW= *]4G6"!*B_[".H?-NT/*67;D]$2VT)<3!NJ;N"
M@!6!^BVZN/ TQR_"JX. *LQ"\SMWQ6"ZG2N/$'%_@M[(V&U]"7*D>)T.KMWY
MBY7_SG6YYM[LN_WBZU D)3Y=L< U-7YNN@YS1E%2@>DR9I(46W=J2&==-HAI
M.8B=?8:H+G&<_.8#=5_>_-1#S;F3QKB'N 0.SW1^P-QC(U*;/CONS34*&66U
M%[<X7HNNP@]"65D.7>)TK*:FO&Q3^ _Y?]B_\I5;3LQ()$/#>:CY-!//_8N'
MJD;7M/*:5GXD:66P^WDE%%H'*&A=BY;W:9-6P;@+P=@Z=F>X[!'I;V72JX%O
M+G@V4WN\BM5]VN)5K.X$3;,H,_ZW77- ;:;V_JG4)\DK)?DC9W,5H'NUF:L
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M;&8I&9K5Q*#FFZ_^_BPS;5&!%FHKG/3AO?#;V.>0X0\=9J2<7$Y8:/^0Q(Y
M4Y8H04"8@++=#8<.\7L7L,%@S;D6*%T<<3)@/& K3=5V;:P3.K,BTN9-*T#=
M+F91+KV?R#AW4!_Q%>PW:5]HQ>B!:F&P@<L<,>J!K"<T]QC2TW\-.6U:&0G[
M1X]I65%KYXJTL2:TF<^9?7."DL7(H^D9L>_.@KI#Y, RD9JV?"Z+<IU$(%$B
M8N@0:[L3"F$C(W++>&;,Q(8-<3"AZX@Y94<1AQ@5M-.E@X+D><5!Z7;>34##
ME=G4L@L'4&X6/I:'IK&D!4QF_93[]--F/^VZ$;5$V^2%.E>12".YZ'@\BSZB
M,\O7DI(,(R;TJ6_8S<ZY-^-%MRL\>;#1\R=/&.B)Z=XT)$46@"2)H?6!;\((
M%9JX.E9X=EGH8%IJ+K<7E!"+)P-@ZX'XT[UDM;2,0ZWQ+1&HM.YFT?J%,K7H
M3Y]O O^+;GN4 S[AJ0U)M"_6P1XWE15N-N XPU^M=T+$$A 3(+33S#?ME>-.
M7S,I!C$+2T#XI9B:0U,Z[I7,:V0&],0E"MJ\Y(LXOFH<C73AVZ9Q)Z]3FQBL
M2*J'PZWL<YT6GL*>**;2*.Q1XD-F3""!Q?RVP(4/ZYEQVN,-Z0G_WW_R7L8>
M&HH^) "B7I*PO725]/VN<SZ/$SMP@\31*8KGU)Q@>UB)J;LZC0YJC*'HB&@K
M:^L"O]Y,<,G=A'UH!0L=AL>FHGMUZ-ZQ,[G*?8:A)E@E;\82;\ @"^P!6+IX
MH-P#+TPF#\.2JDVB= O,41#"W@.I,.V.36E>OG8$G8>AE[8D_9)]1M B4D-[
MW]WJ(4<$W:$6/$--_V "@S4R^-U'-7)G&OHOZY B$JQ;::=Y)?W&4VN/CN'-
M,_)J*AK$Z&7\53B9FP]>//]P\^3/3_[GJ2096+=60M*@WDKLZ N9'PXIJG+O
MSOI+(/%J*8/M+MNF%MAKX>!W,M] 5*N8=,C!^ =//F3/VOQ5VM[JQB1#]ARO
M2#Z$IIIT)%DB\2]^"L._DID,)=GT@E7P!T\_M.HM@SUHAE$/IU\M<(XR8S*O
MIX\ ^L%RY@]U5;XA4;6CV8T^;9U70,G3^0_*X12[K\-3> (7C_2*LV3@\<(1
M:F[P@./E6<O%JT[&8;+%(K-$ ^>PMF8<C')Z@*&MS"_JIBM!W81J)_)Q;9H9
M&F\9IT'_+0<C>HCQ$9L6!4Z.HO1^_#1I**FS.D 5$7L498?8)\94,JVD"HV'
M\1TT#?=3ILLVD1NVC,ZKC5+1,9&<RD>8]-Y7)NIKJ14TIB:9-6-/7%MDE-M.
MA]M7>%IU<_B1<99"1ZBMY79^G;D\#/92G!Y\R%N#<N>(N5:>UI 8W'00Z+:J
M#9Y\Q*$M/?&TG)'Y< 8]O1*C48:+3H6TQ$X5S4(DK1XX^L(*1>/S_3"4<112
M[C"]J3-U' NW[Z^;FQ[:O"D0O/XA<VHG5I#N^>;;YMI!A.AC3SXZHXO-72C@
M&&G^#*.ARK=R:_))Q,6CWCEQB_;EWON/](E,Y,T+KG>LRNX2XUKRU%_V:UDU
MWEMHX>VSS[!K2P083)T^V4?FC?OSEWO;F5ZFT4-IIY94IT#74@5./=4S*(ZY
M6L$',P6M481GPF(1YV2#->N,N%N/R;L.1\Y4-3A=Y7[M(EZ!;ROP[3ZO.0/?
M.D?&-)HS3BFJMM-$8Q==*6)": :B?6*]D"U&PRD42].G5-N4!.J*$;]/YV&5
MP;N204Y:&Q$D:HZ:J;ARE= E[]8&0:"A767J_NSO*E/W1J9HG$9(?[H:)FQ)
MIE8L]_NL@R_EKR57'#-<MT(0OFO6-NI0TXIVJ22_#!$?$66WCJFP V\FQ_6S
M%%\KJN/Q8K.?K-CLASPGY(\[B+\+#G@1I(JV]U=Q[!SQJ7]EY\(^'P_+N"<;
M\,?;-=R\\"XU3XC[ D43^#U_V.[\F%=4&WP9<W"\0UIN?W08[C^^;V&?[]"2
M2QGYGF=4A.6W))R1\EAX'&F*"=5M0/)HL#^C@33"KLWY_*W;8Z:?S/:3]C-F
M^64>3*J3KST'#^:\OF>O0L^G1># _ZP'?\":H1LCS4A_;$O"\5S6A(6D^ 8#
MFLJ.%$U.E-I51?^53L:\<(=RYX\U@=D'P5I>T+FN4?73>5+2"%E>H6N _HUA
M1X:]VESA'&;']%G& 8YT*:WUI7/[P@B^<B\1 ;\SX@%E.YU,J)D6JQ?@.. 1
MY^Z"E(N>OH,&7R(#9PY<BDD$- @Q-05)T]M9VJ(7B^\\0?^8M'5<@FE^VV+5
M?K>JS7#LJ%9[B"L2:.BX)!T*N83S:OQIE_*F(&VNT*-A2?O;4?>"P-("K_AN
M:('UHI(HSV3B;@'3T7%NC=EDH(.6X3JR@GK =JPP'6/KFGJQ+^P7]\VF//1V
M4S$C(!3NQ[S]\XW!0K!/DU@FQ]5;]FV;*/X(5A83, @'N]_'DD&H)N:\S1"F
M-=1\O%8!(Q08V4':2P2Q(D@G(=3.T#?S\ME9D(_85T:'R1+_?Z!LXCECMY]_
M__-W7Y\]^?Q#J@R'9OLH:>+=-#7-)>C"I64V@5^(TL4;+6H(5246UE\!MDM=
M0=G&ZZ!FS_^\('3&KN(?O#9*?MXWW2YO:T>$MIVK>K^T^/V_\UK_N<VKYFV.
M?[;EEOY14A>#J_4&@"7YI=WQAS"(G6RDK?,#YH$)[04!@-@(2%?4Y:GS2BNO
M([&Z+D?9%F<$+2> ^0F$W#\V!Q?Y"V3I_'6W;0Y\%? @D1[F2 "K7H&Y8=H?
M;UE<^'KHV\!<2%E-H2=,AO;RZ'3@EKS9WN8==ZZ1EA4<2^"5'STV3\JHO<)K
M<\%E$@+8OX9>S9J<@'C1=XK@]W\XV%CI>KG%C &\@ 7]GH(Y)$M!"]8#EA!5
MN9?'0SD<8,\L9<?D6;T1WG; +RMHN0SC8/"]J@)\35L]W!7;Q<P:*;H5KX]7
MY*Z0U@MBGA?,D'FQ3IXI".NR3 5)L@'(&"HZ'D]HC1M$%Y-LZE+6T40HM;N6
M6\!M[,*X!LF,'ZD]B#!9BF[![)&\!2AFQW* 7>"AX5WZECIKG,QI6#UC4U?#
M]6@-UTLC[M9?:LR0@N0/<-I3SU?G\H@[19XBBV4$\OE?^3OLQ*?$C)^>< =P
M.25<H;^80YD9D#P">G_=.*2+AN/2+X4K,M$+@D'+)&(83^H,U,]YPL<>9-_&
M+Q+^RR!5,VF,Q!]+D2<J+7:>0K,,9&"H5YRZQVBN2%N=J"1XX8PJ".,RN$^B
M;T:QA5W^M(N]19TLUFGP!&U+ 0:;&\IJ.&_>E4^W(EO/6V!,:7@4=!H0/2X9
M'&[!<LJR),-,AX[W#%.K-#W6.EWG?PU>0/:ELQC*S$92O.9USD\H\.':55E\
MHF0O>;Y55P;BGS WZZ($J%8[W";SVTQ@3>C&'?$D8MDT$-<0VD3F/ESQ\::\
M,]ML0?&*/J61QSRG33>ZX=DTB>9?U>EC5:>C883L5#*VF]'5G4NT*<F^Y#7F
M!B,&&NIQNO*:PPQI)U*?!#[ ;,E4LS6C3.AB)*O9HN1!H:3T2NSKOBO%@Y_%
M18<?!5_NTGD_1R(<_P#B[=BQ0:-<+'^4=4]B%48Z/%TL56>TG$0P3HL5Y#9.
MH4)CQH*[VVR)8(%G3]=-;55]W G!>C<R^%:R5MQP:#,7XU09YV,>F;)8*9O>
M@;Y(&P4CV#.FY.)YW^5'%G(9JH[,,O4&-3QI_F!;6:U-MP-,"V+BKQ:3>I%K
M.#Y5Z+7A:<> 8:PED@=SKM]_B03&B5L.X/1NV.FE#GOKYJ&A^,+[GM+AP%EY
MR2=X,WILZBZT!7%;0^62!@F*&>P@/&KAGN_T#U-E:<C=S)-$%C.0S<L<V^3Q
M>#[ISKEXH;-@[&IAK2P:?+]!_!^:QZ;C@L5XBFS9O+EVM6K>XU:S;UE0B;]H
M.Y054Z%V7,L.RY6)Z]VJ)\[Y)6_8SN $8[W&.@5]M4E4,:]/O$77"54= ;M:
M:IQB&RQ)41O3\#" LKYJ*J8[X,>.6^&?DYE%6._9?;!!T,C/\0_E,HE'=.(Q
M.LC(UXG!B>&ORF8;!_FFE<L+M-\UE&DBBJ1_<<-U*Z>$NI5FU'*(:CC4,@W]
MO/[(^B5C20CE2:FD8O9ZO<L/U,)U\JYD60U<KN;9VLL%$@SVYLDIZ2F8"DVR
MY=Q<.4EMI32M*A'!QTU2BG*FQ5NBUC8Z,:,,&$Y_3+TAF(XS+SG]555G^P$I
MR[EE:8ZNU='+_Y >TCSMRNK\\E*B$N)U;"F?6'$7E$R9IIW$@9#%LD4_*_JJ
M?P94 IF"*HK R0K W*/N(YGXG#W5$#M!'^07Q"#1RP*S9ST;M=^3*.X_!SCX
M= 4.KJ2N]]%5?8WYNPH'4"+LE,U0*_Y3+D=TZD;&0%2Y\HY[A2F?>@A4F+;B
M)(E;[\XH^0X\F0B).(TO+*5&=B[FAJ!W3*"I*8!K%VXO)#^17RFO E1#\B1$
MFZ1/G6]J[YDTUZ 8VI=U:8S2S ID0A"/>(53NM%U8 IQ%QIY^0],2T(9B4A)
MQ&/CU3YJ^_L:_SP8J7W/]N,'ZI\LV+,3>__&&0GS#GS>!B+:&^5Y29:-#%SE
M_FZ4A)[*K'C [-I0H48\7?)]\NJ$>C.GR.+#B6]2UOG..V<BDN%FWAFD5!I5
MRO,^GYG=WC<]Q19%07 AN#?OUA<(^ J0_&Q04)^;J9X0^)LO2[S$L\<JG;S>
MGY)J 0\AS+A%18O%7+DH#]O!"S(3?Y!^-4/M%3L@3O;TK7BYB&-D P*3ABG0
M E\NU];) 0W7,I1XL?TV][=77W TN3Z^*LA3J%"<7$M*OOX4^>]U_KT039 +
M3#EHXD/2L>;$E8JPB <L4-H8(P_WIJ*=%O8PIL96-FQ)S_ *<\*;9S8$GUQG
MT1/ZH']T-9'5B;DI/81@3UK)"N)!8L5$@=]+;O=SFV>4J2= R6O@(DXX_J]>
M/GN=I62L<RS1WS[7Z4I>/7SU?S^C EC@C'(!HJR\*-.7"2P(9>#_04]1[D"A
M;/F0-Q\\*W[^T%]BSXB?Z;?\ERZ=5Y_-$>1ZQ(+B#IL=955]@%E3 Z=_K@_H
MTV?^ZA_B(?3!+;G//FG$-^F2</-.HW<FAT7C6_F6XO^\$WJG0!2- %M1+!+&
M7_H=/Z/D"Z\'"VE@;PF:)7U%>N@-DZ)\_.5D9;) ,[WYP*_UAQ.2Z<T'SU_2
MKZ=TTIL/7GQ%?[%$TD+Q_<GF ]!(\V+][;E^X6_/Z0NLN^7\,'D0^VNZJC^\
M^N[E"Q_^^WUQD;"7B+MG#PR=X0;UI;#.T+[@S 8_-A-B?_4S;HTG$QIO,[XR
MM6MJ6\UIC>J?4DO<0;[/.Z;(-!F<.>KK&<9J00F1^:1KB@U@R!.(L<K+IA%*
MG(7V2/ZV=G5."5E_G^3"ZAS>H/V\2ENFEQZY2K^CMB.ASN8OZ,_ZHKKCK_U6
M!>9=O3/DUR*$':\-*8M"!Z9Y%C;6 GBW\$(<B.%%IP^)3"1#=*BH'-:;-</L
M@O].ZN%_E )_K"$>FQ.T D,B,$3RM:<P1IVXCR>RW^PMGT_"I@T?W7YV1 <V
MXB>+9&=1-)3V[ NP/>HD$?93U,DR*-1-7W;=0-QK?H^<L^T3:K+Q762,^*/A
MST+C[5]Z6\KSZI-1+"$%MHA/;R)L(Q.LFK!8,QT\R=R7H([DQYY,/B&LB8][
M3AGR.SZBPS/LJ%B2!_G%5/H14^8<M3,/W_S@XP])N568\]F>IL!CA>U;+F*$
MF,0'WR>CC,C4<_BX&>J#ZT/ RLS3(,%G1L9YJNG)29&B5&?N$;@SF1>*:9*Y
M<+!OF8\9QX(B:EYCLC"$#BJ[W=!-YW"0WVK4_.1,,IVNWG[LAK4-X[7%?Y%F
M(F;FY]\96D4]Q9/WM*B@A"62PMA*TQD!,"4CJ A+ST6:;FC;YD)3BY0+.<#=
M!:6@]]>!)<R[AN+OTR;2B2KBFK@#S^A;<?MEG3/VTZH268GA2,3T>9]+GE*I
M2W-,6/#K0#"FF%L HG$.S>G>>BW1*:]^)&1D""1&HNO;QH8KKFSQ*3DS'.UI
MJ5F]O-F5\^L,S*2YGO<.AFI?LG8HV_3F.GF:2\+Z]%PCVQZ\-ACY P:M/P7J
MCE"=.D*74T":S/(7(^:/S7735D64P0^4&=2_TZX'Y:V/)(@(#:"LMN@^_#)Y
M/L++ND A"D@L1&U?M@?VN+&-G:,AO U%*OGHU7U$1:@X&3UA1D%UK(MT_(#1
M<2<^^]C4%-VG']!14=]\_?VK9Y%OW)_C(W'G]]*?+LL^W2N&XHV>-'DM6FZD
M@63=N0;I[TG3PF<>K\5;D#.I+23T",0@"8:X0ECAH34@8/O12(&@,U2ZYT[>
M.;^Q>FEXNVX#Z(<T[G64&!R.TKC9A*4A/7_://GL(W_[4Z>RSR3!@1LWG+$H
M:L#Q<@KLFEHH7$VJBB</(>$J@55@%R=4A?_2X0BBSP8U6=@@JO>*.D;O;75*
MWB:.)L).2GA6!-@&% VM<='FU\FYD/E&E'K5 2HWK2%J(9QN+& T60'J( I>
M2X '.BXW S2?+!""!NPNPQ1J@G-BY5.>Y.D^9%*TX0@S.7YZ;;HS?8-Z\X5Y
MF=Z/4PJ??]FIMJ6R]DC++HN%.QPITRH^ % JTI&E&H%\$E3?>::W%M1'& 1]
M.%T5GILPT$ %;V\D,W^ZG6"1ZNMU%5M'*>^P5.C;/LDQ+=MP#$>-0OLF@?L*
M83<U2+=*]SUS N+*Q-EN*DP9\60#G102SGQT(]R(GTV5"/ET5-_R3ITFRNGX
M-V**M!1FO# ,\?#+[0[J[=%;0"9DJ@=KDB=/55CW,\D&&<4>E9U9-I[ !T]"
M^)(E]K06"7]FY:3 (QES4<ML$-CJ9-K1M>D:-NV5<ZD2)Z/Z& '-]%9 @['X
MS4JFMPR7U["M%/::\3!T;W]EN3,+CWZVO_G166Z-F4TF,P4 7>B)A >G<+R@
M(Y)>FYDDDUXF3.TS"@+ZA;U\G!?+F>[B)*$0=,\?V:E8J<*0HUN(7)*H80%%
M@8R51$BKT0 F7I[@I''@)'1BDG53G2O*MK9=0=>2-5 WSGM5@?)[=H>+QO'T
M)QD^,V:@CEIN]NM89F10>(PB@%,U29]R//=M'MS WS<OMT;HIFJ+O! B8DD;
M2X@5E"2EAPB275]"%!4+%B:VI1@\X2T,L2&7<JF-81+_>5W5"#J1%1V>)9O3
M02(8@JJ=1J3A\*G;.1N*-M1?"P1;#/9'K6N8"  UJXDPA,\AQDP&):'X&1-F
M1P'E/4,AM[=C'?S"\$+G.A7MB" L3+K<M#F6U0VM:%A@+Z6%E8)X77=,H'35
M40"O-,6F<@6A*R])S'&Q)2IUHRXS64L?%'I':UB8 $!Z[HT[)9OL3YSK^H9]
M"W&4DF76+0WF?&R]1>O2 Y0 [NN2!%U^7&=3/G(PXL<K&/$ALQC^YQC(26J.
M=!XK<YOZ$Z)8,S),N0HZ&]LD;F A'F_9S7B[Y)Z-*6+1[&1N*E5,I3&*3NZ,
M7ZO><$*B8D9EA'HJ^=X*+PR#$,T'T?$7W8-I,K^=+L^8:&IV40-"1[X/UO\<
M3BV]4/,FION3229V179<">9N2H=AXI'Z@?);#IWAC\ZRK,"<Q176$; +O;":
M/IYI5 ;*$7+CU\;_+QCR8C.']P*;$0M#DCWF1B?F*"FFT(=YSL>$ B[FR:7Y
M5FAY+ L*\&WQ\83^:-R@:^X>8'3E[RDF*[KW89M!.RAYN7,_S7^;FEG9Q_%U
MAE<JBHB1BU_;"RALD9HD,\-&,Y.\ X8CWTG?5Z;M<6+< L,*?DT&Q:] VU19
MF$":Y(^J?$O#)(BFQ6\I>O?\0OH'\SYJEG2;9>-,JK5*F0+K.2,B*52^6+ZG
M ;'>-;AR7HASE)+* _V=AB+S?TW:,HLYRTPJ06^<.T;DKUP9E0*^=FR)Q"/:
MZ7DATZ^HKF2CM-8:<W+=+[RL>:;.<*$<)EPGDHS%L:I*V2/#=1+U*#A,N#BY
M/0F[X?\$;G^_F3FF5EHV!=ORQNF]YR^_E^CV^:OONSB>>WX+F7LE=&Q(1EUF
M;/-BH+VB"E.TDV&#@:>*W99=U:##0LIMOZ$Y5N<7AY+3=S$'RY08M[R.$FQ=
M4_K"OP+!L>7%DLU,;J?ONLBJ)D1JB@RA_([*4^ +)?<N.17(;[QZ\?)'EH)N
MU%_K2.($JX3,[20;J>"%8@.X:#(NDBHZ?-%9Q;2W]%"4A_+'H5K*Y3;)N4\$
M^+$YGVLT&59T3(X7!KIS$STW:J2=^V5K[!5WE$<#BN8O:6L7/1)+0HQRYJX<
MHD4^*HIOI%!82R_(_EXTA>A4E F53O."<+:I+CV2?J46> 8B_?7E#]GFK_2Q
MYZHM?T@^\=?G_@/)]0*F*KW0ZQ^RZ<-RPI7:<73 MNED)D8V'R@R!:(6E TU
MPF@#[.6UP=]VZFLC=(7IW43)0P5R5+P)7B2_9'KBV&0^\?@Y;1M1&QG#<]!!
M0JJX.Q&,/DT:D-%ZHR:<?M!_[T'00[*A7@]T^YX*/W35O:-:4%%R706N2>64
M(J!G^"HW]Q&>5-*SED0SZ68TQ$>QICK4F#'+E=#XWK)@/]7(1_S8,[]2F+23
M)\>-:YW*8P]H+0'7B#VII@0W$L)^<0X"X IJ/1:]$P<*PC34Q*._*X]XJ8Y@
M$^30$2* 86$[;JY(+PWH((O;B88Z2[Y>=P(3G<.AH1;[F1<1&LX&_E)JD+"
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MJV#=ITU>!>O.C1,R8VB6-)&!UEB-1:)<924]S+&9,M2 M1YB$.?4G%KN7,U
M?OZGLP-A4ZAE,J%D%=/[=&16,;T3^P<^3)53&RD;41V%S0D[1FB4R\R4 J?A
M[I?XY2IF]V?+5S&["S'CY)Z*64S\G2_)QMHZ]!M7_+./UM:ANVL=6O&G:2$D
MA?2S-D R'SED  8TI<\V.*5GMR//X1(K_XEFSW?P:6OI12:Z6;?L]W*J6C+*
MLV.%-EJ)2/OF0Q+?+50 E,94>^P3UQZ#SH'E [*6'B:; ?7I^\<LOV2YS<7.
M-Z\;KIH[6<> &I#F(+G*N!JA,0<#[&/&+,F4:?K,/CVZ>$LABQ-X8>P2GQ0;
M=(:=&4*?^%.CRL,(/X]Z 3A<&?$J]0C+!( =C'W8Q'Q/4('N<I-,[>USZA1G
M:,$1]%0]H4H!@$TZDVB-U3Q)=>Q\+<R_YYKS]PEP%M7V0%-P*+O0$*0MUW#6
MCZY-J>9"@TG=U..!>8;O,\X>X]8+.]/0]LDQD-!6D?P%13P96I*VM$<JJK7V
M_V .^OOO9B,,O[=S31>Y=$%\1DU(VC_ P\S#\8Y'WIYJ-'Z%BOG\L+YOOGXV
M'J.N$P^27^]9MS&?EG*/&AE)"/("%_=N-\B0S805$L,U_(V;]I=<U3YV8@6,
M@ 9H?T?=:5ZI$W68_>)T+J$9PCD>$3_;;H5ORA+-?L#<FSF-F<L;<+Q?\+H\
M6L9X&781&Z'YTQ6N@,439E;0F$F#'3U#4'G<W'N^>1DU)&LNIJJ4@<!"H<SZ
M4J#1R;U!<1A)Z*E!B#\U]@-2]1AI*ZQNU7'@MB&8520QM*=:4@838VX- @\S
MH[C1,2,R5=+1E)T@+XQI5$_NE B,XAW)J\D'@7X[IM<&G@*DH^+WP \ KD#[
M "T((7+1,*D@-=^ 6'^HB;L%^S;4[.@40D8C;"],.\],*+V,M!DFX]!Q#*CY
M*/+XAUFUN_ +.I8##TQQAT,@F\RMWS,_)C89=SP>Q1SF(0=&^M:%]E0Z:$)0
M/W0!!S=/;%:XO0LQ?>>J*WYYXF:7\7NT[^!PSZ3Y4V]IL)XI$E<Y!NH1IWRM
M!X^!Q[.3I&^>)2&DIH&]96Z _?0*OW*B\Z&I74^]<K.CG<-Q'PUT9IP3<<T)
M#:2.;,["O&83TJ@.G!WZ_,XYSGRAWV/&LFK16TY97AZRG"5%CK"6,X.PBQ([
M<,ESQ_:EO(Z$2S[DH*JE'-]D1O7,2&H[0T74Z-Q86A.@!0+N9%IMU/"DDLK0
M*#U[;!]A:"$>%VY>^'/&*_$%")N0Y'Q?OM@KZ.=7D>&?]NTKV;='Y_C>#?1Z
M:SE9%>-7G0(7.-=(S00Y 0M"+>Y.6Y*;WJ_&HB^"-H# :"\S;P*;N+3-'XE
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M?_?:GZ;G@_AS?VNVW>89M?9*CNOU\[\](Z^\V[@ZYT&<]>;I1T\^%11ED4*
MS!#.""%6S3#N^O3.<83W,P;.? 5&3[MO_2YN>(NHN1*-@/O-QW_Y$Y<9]Q6-
M-Y7?/GWR)TE,!O2U7I^N6H2;D@]/\V7"!!5Q9NF:'W_T)_CI!6T\54/]*Y#H
MB:[[P+VE*:ZXA([*Z?RN18PVD&G@VS%QD7[4V'KU +"2HNV>/WOUXD?:!<$:
M[88.!2]7-==+KS9]K8@?$D 3EE)?!$J'QQ74 $\1?F,\.,'OLG_JSW@MM()
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M<XIT3?0NA?51M_&D^QJCUE#R7'^QF3WMBKAU][89KU'FI=NF"R#828B0GET
M]=M'^]$D)X2UJ5"MZ,$6)O,WU$H@SM*V2AQR1^J =#TB4;XSQ+"B8P@>$']H
M4+N]]P3@KC@ZI&J53 R<)DFL9.V_U?V=NG724[*F#9[,JG_O"NXAQIVGSTDZ
MBTRTOL0I,HF3P,.,I9IJ#V0C98*@1,WDQIV P/O\C;\RTU1P91^QV1GFB([8
M>68HIEEF7;9B\AL66KF_(TO#%%'GH._%?BKL.B5@1#9=; #8>4Q,IN0\ZDS,
M, .%#+>=?/U^[+5,(0QTSU1,VO1S)1D+I>!1_9KSU@U2>&W!#EB5^_>TGPCE
M./8-Y](P8R'47)@;%ZZ46]JX9^(-K;09@3;CTY4VX_%H,]9S,1;EA0=,R*6.
ME-!3=>(=8FL5=U)F<\D8*">QBA489-HH9\9) >\K!G:.0OAI(4K:DN<8"J-#
MVP7B_9DFX:O-_]1%T DA;2_YKL()\IO6V4RR,VFWJ. :#YN_?/%MX$.3[@YV
M4%'5.N8GOE8@X!+>1CTF]2A/",ELJC2Q^D0'19H$->45_R)D?%SGI72 I'Y9
MQE+'3!4$5TA?LYG <3D\$/X%_X)=;U81#Y)H)TJ]EP>MS.5<%5#'(>%?GL\5
MC\O2L^>:IE7/'?ECQC'ZOE:E7RC5G?@;?A'WM+E$! +Y)LF$;/>42D9I?><#
MCI;2TOZ0)X8'_]VJH3F"LA 76_!F5&LB.G:DIW1L_"(J(P*"J9M% TB+([1P
M-74ZXS*MU%AK-C8I58K?K.ZX>*)L5)C@?0/Z<Z(LT#1>L$XK%=&*:EQ1C9<\
MY__QWZ@P;ILC,0I)X3P+>70],>"F:"E#CQ(3PYJ.\5]"190Q<YF/=/W_AS(]
M_\=GY\OU*1M* AJ;.X_E[ VX/>;T[+1<.Y>@6WL*+FG!KD;BL8R$.)'*L\KA
M3@<5,BJ] \.48'%&\-.Z2+J)-'NH%,= :?#/QAFX"2O%+[0Q@6;IEQF7U1!<
MTJ)<#<&C$*9%&$QF3 !E$B8QM$$KS.Q?:%PHHB;9I_Z/DVUZGH>&$SNM#_[+
M6_#,3QGVT^PV2Q*QQM![2" EXE1ADD36F8UHBB!,:/@7&S"5'\1854!&:+3E
M2FQU67MEM4^/0FP5!>M@#HX]1RXSV$_1P<B8/!FU?-@/D;@>*6K QCW0A/T"
M"[9NWHM:2.OF?:PH0\O/3:R7VV;+=J-=F")B2%HR=DMUV9PC3T>W:<5<-]LE
MO?AULSW&9J/X>>_R KCIC1_\7;\7$8&NV9:FRLDJ+,*O<XXH((M=MVA"(<RU
MV^ 1L[1K)NVO2&D)ULUY20MEW9R/=1*&R#ITHQ%59&6ZW#JW'1CCE^/0]+ZH
M:6M0:JR?U57'IZJ-7QWU4VQCSE_5?1=^+WEVEOM=F4,N;6FMV_FQMK.*&H9M
M'?M+9IA8+XXLY/>#7/SSBEQ<!;\N827^BS4829$R8UU* M?<YA7 ->C.WS=M
M_X)P@E1D$Q%=&(___.CCCZ,\(UF0.9U'@.\%07?M MB/56^G^'%@S:E#]C8O
M*^Y$3.1L 5A$?IY^7U6)+BWY\V4/9@+0#R!['N^A *+S#3@S/T [(T42)5P<
M[1!H:6R,H+0C;#9#%YI",30" B:MBM*YPTW=U^CM%8X"TV:00./F&G26._4-
M)]!"ZZ>HSE"M@ONC1_T*38!=S:!"@3FMNH9>%#T_>H[FY_3@'-<U! 8:AV9Y
MP(< 2(UW64%_S]DJ77L?F;3=C09AV7$O\L^U51D;%<=KDAN>R=Q8E@H*,I2\
M"X"CJ7QWBCM4(@L_NLKEG5_C=Z[RXSWXA]A3L;&JFCNMO95=-S"EP$Z$9F.[
M,'"VO. WK_=E%['%M,N0V*<!^YUVUS;:/ACZ 0?)<T1S&5&22L'B#8"?2Q0.
MZSEBKZO-UT-+6S)C(# FN6RWPX$:?;94#.P$31T)BZ[G^J(S&16#L@?MW.Z&
M0QS7J&<[[_K9H46<=GAB-$M+SSO$0T;'Q^A)!?5]*00)OYWS^D[:+!_<9_RM
MK05?R%S_KAN-*>E12_\OM^OEZ-55[X04Z+F+01P#:II,*_8):7*0C%NB9"&Q
M^IO*O>#2/]A9_O>'UR,"EBOO^2D]G_9D6C(52!/LM!?1#][;;<5->%>'" [5
MCTG'JA=CRP+':58U*)N")[T!Z!0GUKKK$W-XC.E\Z)G!Q2+%V+7A^>GLOO=-
M!3-;MH_,E5]\^UTGK;1^64JCOJ7Y42?8L#J90&)*NH5]8!MBI0")M1]7;]([
ME/*QL$]#O"U#'7%/IK025KEM,%-H4@OK7KANVY;7S B''-F'VY<3PT^=&5^B
M^P+LG/XBKT%"]3TSCF7\P^)EZKW1E&41M]0[_CC F\"2$K[=YG>!9XRMEC_>
MNQ D&J2%I+8RH58IMW[LQ!Z%IQ-25="E?O7MJQB#(-/5XC79%^U-PE:H4[U+
MB-X3T/7 D@%JM?WKM]^SH_C7U]]?82Z8*:OT<9-WQ83:FMU #KX:[U A ((\
M)UDDNAI/?.?&;5432M?$^Z0U!DW>-+(<4:2*4QB 9%J>3AGEFC8;(\=,7<P[
M<LQ<)=2G\DV-^C0,)0ZRO;=VB-9'C759;"\GX]V X^T6_$-<2J!?*T8N0?&E
M.-Q05SC#'(MT $+3E)')?]._Y$.@QG/10U\;A-;BQ5J\N.0Y)]ISZAB&'2B\
M'03#331A+VY:_W$DI.2D 3)/8ZM^HGB[+O*V@)55?D&Q*VS: Q\C0Q%B9D_]
M:6_C3D3I%UN35KS ):V7=8\^"NR5DF_Y#3NS$NZY1"C2>G.=90JB2)*8$<EK
M.KBBS,F-._9E :;$4]^\(2I@Y,AMH$C!I?A,F^N!B%WI*V]<Q,6GK<!22@#8
M:(G"?84+7-K*6G?SHT#S E1@)O"QL4IL7DLB%-E?/S?DNCC,P>]E%_W'?W\=
MPU(KR2N!E7D?>*V<;D,D%2._SJ\#_O.U8YKC8],Y!'T#1ZT+##$[LM_TP8^#
M7,';]?*V)";4.A=*W-RN("9/87HVBAB)K[G6$!/>WZ%I \/+A$A.8_!1XT4J
MB^+=1O"83]C6%@NK2M2;R=@ZQ+\M9K+PQQO_UN0DM7CJ ]YF*\(MG2O_[<>&
M"6N='W6%[3+)_21$N/[!MG'#;5L0/581@2?=I8:ZEM\@\?0E@A%K6?796@##
MWY@7M\S4GR;;T:!0_C0$#0+-O:.\!X:DH%2$*BK1&OG5!U:_AI-@Q@9P"O"S
MEQWQLK &R>9??JL0^_J.:XZF4)OIJ)# 6AP8)Z, &'C('1GT';3H_*XQ$61S
M3<U4_;.C5%XW19C15YMZ &#IC-$W'<>42YX>F:/#13.FPIAI$K2VHX^+<(J1
MX6.(A"?\C:\VK^5C= GSAY&+4ZO@VNJ #*LFZAE4-!QC IXY2T/N0G<U/4DR
M."9/VA!7,,,6A-J@(KMA$L@@<_]F!NP#V8G,5D1H)Q=P).D/K.JEP'+V$;U)
MT1%#Q*'I-\Z_G>9 YSDA!/P#EG1]2OJREQ$IV;Q?4:CZQ0M6O] JP5(MAI_!
M+2&G2!)MID83WY.@HOB5" XMOE4[8&2&GA_\X'UC9S];L;./B)U=R?A_"4@F
M5D9/[P$P\Y0J]K\]7D:KXO:0T!@51Y6I(N>,;^F' J%CZH.B.#X;9*4Z:$D#
M8J3=X/*]G/J_ =7E"CYYV@?=%TT=X9"A;!VZT'<IKF+.;27_;"O1VCRHBI2%
M7NP9H0 4 (">V[SC; T5Z0')V(5?$/JL18X^*,)I[B6F]D%>87-!WI\E'2 2
M=INR<@42KBS 048]P&&892<DNF\9Q,^L7Q240HZ+/_.&_BBVGD;N5\H^H"^$
M!=BO@_A!) 'CNJ&B]IU0BK$_[%_A6,?,/I+QK\D1+JD:X=BG%FJ<)";@F#F,
MD:3+T &@/S-C,ACZ((<V3K7F(E05P^ROB+.YHWH,!^T]B:<1%+!20F6SND@8
M$<4:!AIKSK</&<(@YSO._#+ =U>V!YZ\.I()8PZ;+>Y2*#L2/SU' "Q%)RS'
MUVU9 'FL^A" 37'W*+X/O*  6=+UXU=[SBT:HB,_R@G.]T> +99]^:FHVN95
M5/O-1/08VA1T!DCO"C01?&A$\Q06**EI4L"A208*\'29\/P.,]MCH[1.!(PI
M&_\5]U:R>N&*TY<RD[9=\QC/]KA(3).W_)HC")*/"4PLY1Y' /["!^!W3?LF
M2,KM. W0N1%-HD4S)M3P\W+:)+)&2UHV=C:K96KR(J+UX5VH@A/6E LQM"S$
M U&)OQ;&F5H$VB$ELZG6KJ>'"OST-GUI1#Y%/R8F2NQ3%HIZ$S.MF18F:_(W
M#)F6D'24@TH*78*N/'?IIBUOD-&WF1QN<Y]<G1I%*#MC0,S)HS3AM0 %>%^V
MBI_=##<ILI/]209L@=@/9W ?$=6G4K0H$<6#TD\)>]<+JTKAGP="_01=K+SP
MQUB'\PV$NIRK<][$[KTI?N-LJ;+._5U)L*?LT(!""L A12RU(ZK>$"IU$X -
MV>;8W+G6?(&N6'L_HJ4%SI=6F<;5P+UC _=Z;PV1?[5GUPCM]639WN$,YXQF
M%?A4>9$D9W$"CCT.+94X!5?:.BE1:&.7=;^COZ:.2"BRS(M?C?LYJ84B%&B2
ME"+)T%)",79<G)9\:'93HHQ\JI;5Y]V;0)W;BD5$LL)XV_ OZ$C 4[+IXA1P
M,)Y@GEM\NKEFU509C)*_?K>V0XU-I:RY*4I70PX]G;+P2>OXC9=!G#<4JMB(
MR<=$]:/VN!M8=E7 ?=N3<F'"8HR0TO[PN7'2XYN@EMCT_KXM%T4Y\-!SCC.E
MFZBLZ^:6!4K#JP^+D;25M2#-&//_>O7ZV^__3Q:G$LT'"0(,!!34[%B-]>08
MT*FTJ)S&-3V.&JWZ(ZP+X>K>Y14YQ@K>/Y :.)?XO3=].$K0TF&G!^5F"(1+
ML"BKZ&I#Q0T47NP/93"X(K5ZS':&2&ND5C\&OZXKOA2M-+J[HOU-  =;Y?KU
MR'B/1\8T;"1K2G+>J8AX-W2$]RV3:E&_J9HNJN7XZ^?:_3"S_5#F.C =$76A
M]-Z&2Z0?^HTY[ \_16G,!_!%T\8O42-,VS:M#^8IMO=WA'#/;:E=$!1&\@P^
MG.=<.4.7?78V2Q'TP_*BA<UP /U,&2*1]VD NM1K ?M)A?>>!Z#FAJV,)$#]
M\-J!M];5YGM5*G6LA.!'P] CI _\+N)&95=4)Q0>#^76GQ1H+;DM6W::%5UF
MWHWT9HG\*?O:RX0)XHC_8MO.'D?A,MGBBQ>R?<R4;:F H>(7PT%.P;C9LBE@
MI\AR4'(:O43<5<VH"2AM25>7-\$G3:S$*8@2633JV>;-&86I&?<)BXTN?UTU
M,BR33R^:&E#;_MR&F^ZNN28E=!>-+QT.#3Y_S2VL (@>/1S/^,GD7%84GBS4
M/M.ER3_*6VZ#K2J'OG>_FVFK<9%:B'+O2HZ 0Q]^E^]XTEFXPQ^(8Z_ -/K/
MEI@E:ZFIS+ [KS8_2*/]..X.6 +* ,JS1,-C>GZ[-][%D"RG/]?*VD*P)[,W
M MDLC3CVVR6OS_3?2VV$LY <*JL$G.3P_"'M?[F-8N^!0X'00-.=%P[C+^QZ
M9L_0;_JALS0GQ]R[ O[@QRYU)3Y#;)HLGHWY[TYA2\7\Q@^31(8!BC28+S8\
MH'"U*6^0T9!66U/6H4=.+Y%VS\7MZ0 ?&.JAL]TEP@+1GXZ.F^$2@S8VSFG#
MWV@%A@UA:U5+OWU@&/\::V1V5+#8H?BE[:3,P0,'=].5WJL3N9O .D$XSFS4
M@1Z'3A;KP(E4\=UEW;*V[6U9$/<?S%G%(%/D/CA':A+J?_O[*[KHKJS<-+OK
MW8A*6D4G1V?,HH0D>+@;C#9;47BNH., @L0O2,!'9-]V;.7](S1MH4OYVO5W
MSF^7V(FIO@'PI:9%GP853E4?R;3 8\=MO69]GZN'2\Q-NKO,#NXDDIP6V^(:
M.]-%.S)956-#RU@6-.%EMY>C2/'1(7T8D-$IWEDM-^J)Z@FJ+4J+Y&DZTIBR
MGYV#_)>+U%5*S'77DFYEL]O%!T.N8@@NI0]-;R0&#QQ!-'=QE,D(X7W0=,7:
M7=IFF#'=%8F5(Q52G=A]8[]>55H1$H#F!D!W^>+(SZ_\Y-7*XO6-30B'FJ$
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MW?!""N[R[_JV.?$_K'+EC 2E_V64$C*\"5FRM*(NB)$RXR6X*FD_H57_&T2
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MFG"6YA U(:3@S(>HX<N_)O.'THE>C ID5#<&^(3MCU#MZC^ZJ_#+;Q('&'T
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M27ZH.(>B8B4$E(WZ:479!19VG SRZ$&TD.$FG?:)T=35-Y6;S)6!UDK&<9)
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MKA0K9S$4$(=QS(--F0P%3"D%5C*5?L7.^\YM=+&EKHX;\4^[X.L;2L+7(BV
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M<57HH?L],A@UX?(1BC; SNG^$OZ 3%('$FSFF_?O8*LR-.>NX>EI.:GG&-+
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M!!ENW&,/S_NCAJW#WL9&IQF..5 $E82"5T]FBG*!\/4\@ ,G%?*X"EG*-'?
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M&[_+/^M=)R0R.4X&& XR)2D?[(>:0D2EF^&CUS1]/H9+,L%-9<7DXUX0HNY
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M')&FU+MX6=![3U?O&7!@;+SC..HUA=-US[<L)ZD.LVHEIUO?:>I4H@,CA$;
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M5[FW9UF1%6XPX)XQZG-:.D!L]9Q"D 1;Z :?'C8&GU)L,A,.2U'[84W\%+,
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MH LX,'-@YKUB9E;(!F&Z*EJ!6I-LLYA]+6;S+8DIUL$L1$J/P0*HP%]].NO
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MC<<I.HR>-#?_QLR#+D&M2JPZ57)2RLK.5+,@!5:-R4^3K%88SUO:;&+7"+C
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M2&Y$/H%[%F61U),JFH T2Q-X3+PB(D#0??9+)[#W:#M%59F*3+$H.AZ<FJ^
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MBT52H,$E+%0*>R3 4RI+!'30U1:_-F*>)G99BE1UERWIE?F]9V91^*TY37;
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M_)I:7&TSK#2D>LVDJOT2VQ:+Y?45XB6(Y 8TD$Z9B9RB&#2$MRI%SA$_@W-
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M) 24P_"KKB[:D /QRGJBSSOK7(C@M@]![K0U@!,!3D0W-2\X$:9R!IP(<"+
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MK&^6(][R"O8R<2GQ\=>T6*F '*G-@UM/RT(\MX8QA!I&2$" ?P% %M@R#+:
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M4I<8%YF\_VIDB201L=YIT[@?)V)2S^9(^\_V0!SHG@9HWW%].# ,"6PQDBT
M[0<"[;N]SWY@4MD5MAB/Z;$=A&[H?.:$$L=S&DS??TB_MU@@N7<QR8IK#8!7
MELG<3!FL@?+?4I8SZVLIX3PK^5WT_IL>B]0@=X*?@=P? NZ[4^EZY*KI6UYI
M"=@#]%\K<%WR%CDAM5=3!LW=$-+<#<!U@.M@@8 M?60+P/6!P/5NKXX?F%1V
MA2UFP74%TY>(W0Y=^:N$;^K'P/[,LLL2*3AG>XZM8/O9 '#[J03$57I[:?SC
M:)U=IMSZ.\LRELV+?'3_<= J/O_O*2MK28'KVP@=V^B_'X'H.]-S>5)F=3T
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M $8?"$9W :-W1RJ[PI:N8O0!5, =/ V@?SU2R3"5"2OR:^O@8+<%7/[@3@S
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MYIQI>6QT](5"80U:X6D59T4UN^:]C]6 S1DI6585*S=PR;(IJQ<77QL"F"I
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M!I#N0?BC4B2B+(7BK03S(^O?YH<$XBEKXBE1C#V,A8\<3EQ$(R90%'@$N3S
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M! =P N#$+'#"B.W9?N0@1P@]#]=& 6$!"GSFB]"VB>W>V<_\HI#8>X(3[+H
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MB-U'WV,_]@YWB[I.N/)_K[]D6S?FT>"9EWF@NB-X7G''YD;"S27J23&+X(U
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MQX3=7OA0PN99'OQK8]Q:3H=[K<%B2(9W&T<#, )@!,#HW1DS&& $@&(&*(*
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MH5+XP4KA*,0AIP394>0C&E(U5\OQD.?C4/6I4;>=G/U AVN!%H9)60!I0)@
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MF8I4-WI1=V8U/]ZH:3!#($UGOT$B"HK2!"Z HNRAHC1"Y$QGL$%""*K0!"Z
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M?3<('7YGT=5+1I[>X\?I:0./NW$O'4% '/#D0!\91W PPN_/@SZ0&SPY\.1
MGL"(@!&!0P]&!(P(R)/Y\F06P<&(O#\/^D!N" =VS0BM#P=&/+&=P(X0#WT'
M44X<Q'#@(3<DF'+'P[Y+VQA@"N% T$<PCK37Q;>_YY+FF;PLM\Y9FEM2Q[!+
MEF8LR@220HHJ*;_R&K&4_SH5E1EM#F9QO3/P#'H1C"8W^/@=\_%!GKHL3V81
M'(S(^_.@#^0&(P)&!.0)C @8$3CT8$3 B( \F2]/9A$<C,C[\Z /Y(9L8]>,
MT/IL(^&<D\AQD),X%-& NR@,28!"$K,PB'U/!.'M;*/PF&,+UT8X9 Q13S#$
MN*_RCHS:!+,H(7>:R _KL2C5%L12C$5>I9=B/X^+"[%,4?R]R'B:G__*TOR@
MJ*K#_&21E]@ITTJ^M)JFU"MW3ME5*TE)#(MV0&F91G"PU._/@SZ0&]P]</=
MGL"(@!&!0V^>$0%W[TW=/3_RXR"F/B)V2*2[Y[@HB%F"J$LB[GG4]UV[C>)2
M</= :<'X5ZA _5Z4\FMR2XIV*?+XVJI+EE<9TRJ)\7].J_I"OM.,%@FSF-T9
MZ 9U^$:3&_S_COG_($]=EB>S" Y&Y/UYT =R@Q$!(P+R!$8$C @<>C B8$1
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M<4K$'?KQ*1%G 3L+^,LM8!7G*@A81J(8+>!<I(2'D2!^3C77,F R.TBZL+.
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M>)5H@=VUPD[!JU%5P+->9=-;RDMO;CH)SPLNBGG1WCJ_];%AP8,6Z$V?32>
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M27.EYSE^O8&5-G#.P!J&ZS"3I0)^+:ZOT:F'6P#V<UN@8>Q]+-JK_NV5AI7
MGR5NP,>KREK=K5<7S9]>7E?7AM_G1:[A<;@YNL2=0 BC_UK"]^!K(!3V[ P^
MO4$#?EE?XD9>:X64\TJ-!CN\\[Z-!RK#U5ZY-"UYX<:K13?+/(=3"<\VJ]I\
MH%FY7-8U7 KTON(WN.;K GT#\*2RNS_Z!;QJ893$!O5PI8-C@V^J!X2<#8[-
M;'?KUR<0"&Y@';P2OH<Y-$$ R\2U[SE-R^UC]+\:<][QU*BE;&?>H@*HJ)=
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M.89W-PA1IU8Y@?\';I,:\^#-9G=09//\6:6GKPN.]_BS4*6^W:<@3CQ@V,*
M/3B$L ,:H1=0M;%4 QZV3_F(>*@&XL-:S+I^T:)>(BC$#422P*6%U61Y43?]
MZA "#41"Z5V<?U@]?<T\VP\U^PM S["+T7PE2$NXIUXTW1O#56MBK84#PHF/
MR$6=6I7;^%;4%<"$VBS$T$-?WIXX+7#PB-B.8;$H%MJ<,!#G\Z5";NU8QA 0
ML%%;7/;LL<9[18^9KCFBJ!( OQ5]Q(@^I/Q-H9; CB<==$SZ@[BSA :DDF'[
M 0*>#1!F!UO70'B @X?0%X[K J0KF"BW:PPO^;*Q<M1B11!<?%'JY?4 9E[]
M^AZP)!SI.=@>_\-1KM=\]>L /[Y_\T>?TK]Z4G-; G3%X[Z^[K<+P)FGG8P(
MQ+^'WOOSLY4N7#/A8&>L*!R@ML9J9NW]?G)A1%FG7-=WP8,T&V[IEL%A[YZN
M#:$KC?<&->G];'78S_:UK6!&+=>8US.F'-Z7%]=&B2^-B22OZ@H>C5];*S"0
M58,UX;??O'M%5I*[5P&KETTW#6*)_A^\H1%EO6)0G0P/\>)FN5@ Y(5S><-!
MQ!IA6I1HHIA=M9MIXE7]]P?J;2#F[A?Y_3%EG7UYIVT&7 8OUD,5LM+4&UZ#
MH=5LK_ N3G^[(&?5'R2T-+/FBN$A<T8M<S1 OMK:^'= A^YDS[RS\S_>O"(!
M._%>H5)<X8B-HV9%]FKW6:\R<$=7VQQ8D;_HE8[]N!E^S0CLIL$M _Z#Y>)7
MC1] $_P,'EX@GZT.+W!^9;&*T9V+)9P'V#_5NT$:#&*H62=VK))OD(;=9QVF
M1)L2WLF<A5/C" ;:?%BKS#-0Z(A2G&GCE)KWD3?6_P?*I/1.EY?PEEZ0S#R$
M^0@]N/=*S_E'Q*.](V=><%&@-;WR]*U<CV_?GO5^Q1]F@'D1G^!AQ$@!V!+H
M4_3@&G.BX7G_N00L'C+S-+HAEN45+R^1VX OS)=!*O1>2;S#B7<.$ S HYT9
M%:3F'MFF;(=7Q@0T=',9U+M^%5R#$8>KO\BJ!@ZVR&OX.L@N<!-DX]6;63%\
MSPH[CRPL\5?0]6%H%L=FGWW#38?ND$Z(J!>@4F2Q,,()C$)MU-U_\3D(Q.L9
M/*EIN+P".=,B(/U'!92LRIGW07_B5D>]0H$"?WD#\!=^?Q!6S-+'SG8Y'KXZ
M7S%0UA.\]QAW+-;_^@:CT66O3E\9S6=LT5, "#?(66?;G+7WJP->XVA0@VE+
MJH^H1-%95J@"[1J H[S7)'!@MJE_%-+?'=,O.J;GLJU0;++M<WJA$;BV"#_/
M!@(1M03(GNXOB$A0,6Q(G/ZKM\,OWG<L$2G9I[JC^(*/XKOJIE/A_O9AW)22
MVR(4'?K<NSCY[>3MR7WG#$4>7/LPUX@CWA<1S^(W0SBTB-:$ _2R12\TR2VN
M^4*AX,AU:'02&7KYVUBY]R.85._"N&>,"2H1;MJ([PJ-O'E_OD;#P&'P<O)J
MRZ_2+#O3M:GF:F_:F2M+ZE*T* U4)%E HD0%A&8L))G@/J$BSIF(_(A%?#M%
M*U,R42**218)A5?&A&<J(U1'>>3[:9BF.^70%VTE_WQC*//*.*C>PV(K=7$%
M%E #;V(^VJP_:LQGP\*C-^]^N;_B.9LE63J+??_.XJ.)LY)G-P6E%5IOP#K7
M)F0$FSOS3/;$-N. Z29-TM:_.CZXK^\4$TFL_)3X4D6$IK%/.$L$"?PPYW[D
MLR"DVWR0"$59DDJB=) 3*G5,F)]&) QHG(9!KJ),[O !G^OSW'##>Z0,L('A
M@>W*.U!2O/]DDP'^(TA/COB +P"0F4,^ZR):>(A!SL-[-.B(J"0&,-V!_MR!
MSC6G:19%Q \Y"/982A#7241TS)B,TMR/??DM@IW/;^H?_XY$>=_1Y)>ZND8Q
MCG[_\_S,B"9ST.^L*DTVJDKC>V5[!,<^/=I3#S>8F_C,T/-6:ZF+&X R[J3?
M>]+].,XI5X1Q1@GU>4A$FG(B14)%&G%-=SNZ*"KR3,N$^"#@"446$2P01,C<
MYVG"\I GVZ)[WSE_8^'J>Z-TSSN=>Y#S'C*P(([]O*-@+W6[%NLV,J@PP\X(
M?N/'_XA^(9MA)^$U6^M31NQ3F""7_7V%>&353+3TTUF;!]C0WQ>5#;_+>=68
M-$T;7 ;#T23Q]K_#_TJ"B4DM9BI@]'L%K;OH38%= 1:K/%N#LCV^A/U;I6^N
MXSPFR.WD]#UR.E%,IG"4B4JH!+@L0.8FB4^2+-:4\UAE;&=X3T)YZE-)2:12
M@-@Z%(1I&1.1"YXSEOAA1+_(U%S'U!"BK,B\]CY_HPD:L5D6LUD0L:.5W4,^
M69N???"?+Q:@"K%11,<<N->><<H;ED.1KW/,1SGQ+I;"EA"T?<;?/IXU>=,V
M%<+QUWVN'%]GJ4X![$=1 C@(C%FA14JT#*4*:)IG;&=P@LX#-!0TR;(LQ.]P
MPG44$I721,1AE(81V^:O#_H:HRSU+3:.:6\M7YVO!>D7<A!IM$0NPD8N#9:^
MEM6+8)V[5<Q *6WXHF%3]">3]_?5]8RN0\31=8A(-\MZO0<WB7CNBOB)5\1.
MO"6"H_XC=#C8UQS 1JOH3]\#W 0S%E#I#^ZT3+F;C$$G]RMB9[)_73S?9'^&
MX69\V!R!WL+FPT2A]\M:FCSQT\M:VUSS[_&;__8O$?WIWNO,%3_8W'D).(QC
M@K2IGZCJ9E4/5'1>/AM+YG,31W,VR'TVB.1!SB)*DCRGA.89V!-4,N+G*@B%
ME$$>[MCX69*'.8TSPE0&QDL01T0(N$40"\H3WY=)OM/Q8Q!&>V<*Q>$7@ZVM
MW?^F-%GG=FG?:-&'Z0P6-_-9_ +,DNV@LF$%?@EL<XFE!!N^6A>"^PPS@/$=
MQT)2 H8Y]GUEBH@0K'*=Y[[@<2QCN3/+Z!N9 3!&4ZBN"\YO7?SHO:[O8H>O
MC4X$87)R=V?YJ?-#'XT[GAB"ZW2TLYGV^[C('PO,Z)1W;N_KN;X!Z?=S4<VP
M?&-<Z/WAK^&*F0Z.6C]7!J0_ 0@UF8UP:8U0]#3$$LS.W6=$]EX4VR'8_BM;
MN'5F@>O6N>R^M?YK!W(1O*[_:#+J,4W,/K1&?WRUK+M"2P.T55%KV:X#JL4J
MW38,3S:>VEX!R2ZO#&Q0!3K[];IU$?KPM;PJ@72778N?OCK4E%_BNK!H<]WT
MR)8.VW NMB"HVP)K)TV'%"QV5O7RLJ^9-?MD.JSP<HE]$6S9*[S1#18H34P5
M/9R+3YZLC>)CMQ##8VA3O/"H#(_MJMR]YPSX',_HG3PTZ]* U^%8V[ABC6.7
M&!7>K#C&.]J@<-F5E7QF-1P[RA<+6YC2U7NO&.,>!IH-V8_+OY9%;9.=,0F]
M;JZ*A>EPC0V[^MMV J3+![HJ=.[]LFIP?6YJ\.K-=0YZ7R$/V!(][C4%T(G7
MR"7\T@J7N@)#U@B0/N$="]9-N:#)I7]5P+7>KR?>SUA7SVL%/[\ZL5U,M(*5
MO^+ CMX_^'S.Y[.]6V57_-I(/ZQ1[E8\ZSM*['05N.,+)]ZO\#_[I-T7A)NM
MOW%VQ8L:>P9TH<-U-RU1X3O GRU9P,#?:38R> H>!OSUHBBO.$BXCY57H8#R
MKHV@;QYR_YGW:U7C)OYG=<-+\OI:%'4A*RO83LL&[M-Z?^>JD'^:QF)-95\)
MWVAUD_Y!N[??)/SGRQ4<^/L&>?MWTX'F#/O%U*6#?A,Y)(^LNU!\2%G5RG@'
MK2R5)C<-#\L%!F^!:1OO]X7I@+(NI;WX?5V\@E$!L.MG$]/G7W#J7A4-)G1T
M76-_+SM/J_')<E$M$<!YK^'W=J *3KL*?Q#+?<3$:N<-3O2^OU@*.)6%A'V,
M"?7W!E5&O(UW;=JF 8'%]R#HYTM3^_KQ2AM59#-B;.^ TFJQ#C3?V)Y0LG,#
M]1WC]-J'-[-=3$"U-WK8V-!,P6D[LNS5T7Q-&+E!&-ND2W:$06Y FP* _:T&
MY&%3.O&.MAO0U0,&=YAWLW5<1^2$>8",=5&A_<U"L(G:4OPWHFIL;5LT?]H#
MO]R0*1WBARO@X,UO^P[!YAZ%7O5H$D6U,DRQ2E?!EM6W@^XV,T\ $Y15NVH\
MTH*Q.S0\A2U;!%NB!V0EO-S:W)6F'Y=M'@N'';^\T'@*L!:K]/[4MUCHTE1E
MJ>?&P&UM@R;3[&W0+GB]SIFU7HJUQKFLP-8I+:37E\LY7\L!P_%K=FVTZ=PT
MZ!4F^0*%=]\GU:M6G=.Q1=16!Z]F +UM8Y7A5I@.<[4V5LU&V\C!X[!+$ =;
MSBQN^&6=Y]B\:*.ST%:'JG5W).QN!A?8GE[FA;&E%U^@?X";;2RJNK?\=(TR
MI?@?WO9U%2#ONL?M7^ZUS2T'"NQNU S[XOZ%4GA--[.0HLQK#L=G*4US=.NY
M@ /<H$TRH)A=-#H_C*SD"TL>T\OJ]0VF1>;[I6[?3VW/KADIN6XN"9O8(J.L
M> +U13G#.V.?JDW%TE$-=VAS&TQ?29#LIF]-_W",?4XHI7[]?TXF/_*<KL^K
M\D%;,6  7MM^3T8.\Z;HDR$13J"T0K_,2A;-NA/*>]'(FT:W:Q'7P =-SE>2
MLV\/9?!E7R+27@_[\P%F1Y\&BN]E;3U+HIMD@$+"NC-?:6F]NE&P+R$!01E*
MS:Z%TGJ]*('@*, >6PF]"I6N*KG6_6.[;(+-"MZ5G+RL^:JYY\YWMO)%=]LU
M@3!=FL]K%/S&+PHP'+O6P9N","K,?F #5-,I92U[,;[;7<G;MBY #9I,[BUO
MVA58KYTKQ$6 [XL LU0F89PG1/JY3V@N!!%Q$) X9*'B(5=2BX,,0-'MFQ*[
MAK\%XCT\P(MR'WZZ/]*;9,=?=[G*^#$6BS:LO2,$##.Z\WYO*2:+6<Y53%+*
M$SCOBA&>RX H+N,HC976(MW->,BT[_N,L" $0S[-<B*DH"1(&,MX"%_)^5.>
M]_0EU%T^X+P'&UYRTUWBLWK11#4 'RRO$9UC),3,%FF=IOALKA"'O56Y)*$?
M ^>$P#1<Y@')9,Q])K-$1=DVYXA$:7B+D'#A"T(E\!VG6@'+^3Q4*>-!M-.'
MY3>-EH%6KWF-;6J;TS6Q7EE:'9:=:!*?9,?.3IL(S#;/;S;\9!MS>RQ>7(.R
MGAGA7\!_VB"N?(GVY'1,+F=H/9[S:W/N#8)W)TOODZ5IH)-8*Q"C:<0(54J#
M7 0)Z8<BC,,\3GBVT\OG:V3I&6^N\']8!WD#(A(LMM-275Q5=?M!U]=O3#ZY
ML3X/TQ$BBHY?E!J;&/9T9O[KZ?76VB1\W%S2PNYVZ?J=CT'/U1T I;!SP\R$
MLW;E[\1^Y-@ <&"[FTSG%F=O-7#=1SV_P5E.97LUF/K213!LJ?-#)I#;.3,W
MO)CW=K38"6RXN/UC!!_[AOO>1DKTR,95N@C^<^K7H4O=QEUVXA[5$@0+L*PJ
MFGJY:+NVDB"A=6V'P7%ELA[QI[P;S=%Y&BV"PT@1]V"OE+[&Z11Z49B?<*)'
MM6Q-::[Q;):K*1W+9CTVHEEBT*3I!OQ@-=QJDL3JIA9]-@L<M(2W6EU@7($
M(60_:^IR7@D03SC!I;JV\^EVKMD)0 S=L6M/H2F/PJ0UW)95X.JNR(V9:\%M
MA_'>.3N</#2X3]<(8G?NS'*QF)O>]07@[5]@^_0GCNE\G0VZO2OFS92>\UN]
MO1+,_[+1EHZL^%QE4?K^>_4X'F=-=9IC4=Q4&$';NK7-YEJ?FVX!W=T'(;NJ
M-BY4H]0*#"N!'C$3."N;6[*TA]*,15F='MO3]%JO)W?8B3X +S"@TPTE7):]
MLFEK#D?<A #-X!5\4C/KQM>8@VH7#5\R-QDX>Q>]$WN+BABKK("C&XPK_;7D
MZ*A&]SF>(JU6*P/5>:.[%UT3&!0U#@V0)G#59>KVN9L?S9Z9#7M(_H%AU8T)
M._W\LIV39]ZO&[RU_3K]U"P;+GCX"BIA(FQ[XI"KR$,?@=1[) N<X&6-:1S7
M53V8#M,MP8J2_6O00)GJ5FOS4F8(V_H/^3J 8"AMSXO=YSZ+NC8G[.-5AVC6
MO>;F_>$;#O^JFCY*T870S9'8[;FK*OBL#Z0,Y81AVZ(_Z6>_GC>#09@=]\%E
M_5<W M'_W^!TF9"//<V8)UL7W4 ^.'55-S)JS5RK:,]_+^NB4:MK]W4+[F-)
M>U^Q:#??K%N>[N@TT -6AD[27'=M15Q;D=T7R5Q;$==69.J-(B9'_7>NK8AK
M*_+UBM@9^*O]':9  H)=HV1L(F)2YNZV5SLS:<Y%9>:&FB'#6W6&*WS=342S
M-BD^U=HX7<^07'=)3<MZO8;==*("+5F$KICE7=6@5EMR90R]WBPTHSZ[@=(V
ME&1GT5LL;).JC"'9M& ^&!.EQ+GW!L*OW[Z??6V'4=_ 3A1V_A<:U$W36>2=
M(;Q=:KFR+O9Z2W[J:B)PX.;MYBNBE6H*.@N3 6NR:OD*E/>KP_O#/IG-1)?&
MRC]B"O3@-K80JQM]S4W95U6OLF>Q?JI#^KV+ME_ S$1-UK8(.E^Z3/JB5K:R
M;P?YFU'2/?#'T67FWE?%PHZ-'9H;^'XM_U/;L=W-PE;_[7<FS'H[TUH_L\[@
M[)?T$?/RUUXE:U?8=+D^3VV25H8+"AX^([XMC)W>P*'8,*+11[7.DAP<H5W/
M%IY<(U,P>M9NN#BZ$;ZV6;+-O9Y]IOH:JQ2Q1GLM%(:^@*T:V^Z0=^MK^JS0
M31?&;-=_,?. _94ILP2F&3#U?6X-<RV6#IBZERY4@W[,=5'ZML3KI/;6"YUX
M[RK<\V6-FX,CJTOTG5T6F,3=R1TSE)C/;S&]U21:Z\ZS-E@9;O!-55CA@XOK
M6E,;VEJ*K1,_=WV[Z%4SO7I*VT%7;FZUJCZ60!,K7U?GPHAW\VYK#=(/@F],
M;2E>;NN<EW->;^8UP)MB240W\G>.]?H:?2MVB;):='VR,-F\T[KXM;6?=[V.
MJV6+*S2">.V#;6S=Q68FO-F:\G;=M7LHL'N2%^W @05?Z 2Y_:1S%@[]4Z:9
M,):)K'72QIJL<EBM=V.)#_5-KK[=^:*NT6]<]_-GS;L +>;&NS78T\Z]O/(@
M#V,-J :W-,-6'+&+#K];FNG+\+LJ;M!\_W_AWT/E":S"[MU3^M9?BC*:,$:D
MCF-"XQ@G22F?A)+Q7&8II_%.U/UK<ETOUL4*ZYK+]QU,^@#W_GEN9H[H1O(%
MZIMZJ;]S$=9OU3TAMNN^ONY&Y0V(,*Q\[<DP04OT\1G$ST+AARH!CM""4)K@
MB*D@)C).1:1$HOUT9T[)ES"(F<CS,]94G.?O!W/93TMUMLI3@-\-D6[OXI15
MK$N=M@]=]3^#KV:P*5FL3QSR_[DOCQD2TX91AN0<%Z]]94;#7KTUNCR'PPB&
MCL'X(&/MP4QV! ;,MY>/%;O=%_A:!W6SZN>PNC7*18_/8I"<\7MIRGHO6I/F
ML>K/@*-BO;^?GKY?=6G8:VR/5KA\EM>.X/Q\_LA8,TC?@=3E8(;4*L"-MM3^
MR<"F0O=TWF6IR#YJW-UEAD'IOK.FO:?@<VL9KD^N1H>7=;,5Y> %ACTF_WU+
M,NQ-[!PC39X:1;$@S_(\)Q$/&*%IDF%354%R/P_\)$]#'88',3/T)9ZFW_J:
M;8N:OA [/6"MWX"=7IYQ\G!TT9'/>U/:C&H'E)X"*-V);Q[*"!/73^>KTI[&
MGC^; (Y5<*A4N&E1LJA*W3>:*&UW>\ LC:G_Z:(/#2(=S#,R_3**1M:ZQ>#"
MZBRC^W>=5HY?[+H$X6?"IJ])TU-O76V$A00XC(M<\S]MWT_\BW$77E4?C4-R
M#D(-'[L*Q'2]$1OC5=:U>3XHM]V2<U>0<E]!BJ*93H.42"$ WB=^3$2F \*#
M-(UIQ#,_V2F+_:HR\*X5_NH8=E)PL_ZD^^,7S>2"(WNTE2?5-M-NG.Y!!C)<
M@EYQV"BY;) #A^&*W=#(3A<:$U$ (0A?(\V5GN?>'Q<?NNZW78/<+K;9I3MJ
MWEIWNO9N"C!D"'!B!3<TE;4V1;RY8[%W,;]GF-_&0^_LTFF;A=[1JG-0,H/N
MB$T\;EMZ] 6-BV6]Z !V)UIP*8,H[^EZ'.?.<^95>4GFIFM&W_:CUK;29Y\1
MYX#T%P)I)6@>IR"*LCP$ 9.D <E2GQ$A<BY2&0>"\D,(I=\;?9Z_!IB D8S&
M^>4?'2_^;CENM>5'@7O'@G GK.A03U@?VDH;W>$^0:Y'-( 13>->6_G%^LYI
MS;"A-.@MU"J>[D]<CQJ7UXM!/LZ@JL%V0D/)/FBZMN[MM-W'26WT$;7"_=*H
MR3N^TZZK-3OULK\XL\N0V+<<# V76)VO;&K#^CKC9#0CA4^PZW1Y:3L+WOWV
MJ+=JG<]7Y6&KY_75)YU"LW?=J%/ ZAYL=.+]658?2]"8LET.RE;Z5"+L--[G
M"YB$KWXQTTP6VF_E/KY.9(S'.A YB07/"16I)DP$E+! )CGW_9B'!P'J6#6.
M8;G-XO$O<RX]9*W.N?0XM<58FFX"<?C#@()'H6JGZ6)Z,#M,7(NOSMYN?P0L
MJESU1YAY5["<^2TH1KA&;;1+,#J]J@O8=M EH"?Z08F/--[P#FDKLR#4-,M)
MXF<^2,[()R(+0) &F@NE1"RCG?EH7YP0L5_4_FK?^?:]T;B[O@]0^BO?Q]1/
M3'M5Z[Z5Q=!(WN#Q(W'EU-X<795; +"?(X,=S=9<\!< *1 L76;J#CNM>WF:
M;NJ-20B%7=28SE[_J5O32<0T6Z\7E?'6B@K^L.7[\1:@PFOGG?A"V1!Q7[&,
MQ<3W)<B& /XCL)U@QC,=I3E+>":_63;L:]5S/PAS:.H10G5&9R$9ANQY%%!J
M+*!IPC+]8G_'IX%,-LX)=)8WR_K6]KHW:.9ADMF3<[#5B[RP\;E54(T )""F
MX[)Q7IADCDVD9#0-?%@^)692/L^5RB*242H(]6E(,L4XT2+/ A6FH<Z^*?WA
M3KGXDA!3/[ODN-'2B7>Z>]C7[&/GR_"Z-IP!:(<7M8=!9MV-GT2$M2R[&0+*
MN^1%EP'5M;5<>;EP&HPIJ,#@=ZVONND(A>G@ZWV/E_]@PUC\&OUK_V/J'RQS
M*RW:X:*,IZQ N-;J2VR[@H%PA>(.L\&P5L3>8N7BA =>%\OKSBLG,9+>?8)>
M1>ON,PY,>[PQRQU;+FW<I1Y\L5CEEYD7,S,V[=MMO,\,>ZF;#Z?I@7/E>H?*
M5K3G>'"$FPI#F W&2M>S$+!F% LJ0,QCM1265ICC=JW;*W0TO^D'1&*KJBV>
M^*P&,].4!H=V,&T2CRSP7@4W11U;@.3KITSQCFT)ZCC0P->H2VM;>%34=A#)
M)]#!6^7,_>RI9G6CKI9V6)%M1Z>T7?0 YPET'<5Z?>-A-N_<X[VM!=:8-"W0
ML.KVUG;"ZN^OL2[0S#4H5=$%F;N&:7CUH J\'5!DZWG5LC6GHEG?KJN"1H+B
MBQL1!3MIBL=<OLL]^2[*5[G( &:D.E&$4C\B7$8YR82(TI@S[OO1-X.4/MGE
M#1 =* ;&_,6*)?X+]-.;U3'=RGXQ%]U^4?K+_M>D\']<19JD-&> Q7Q.!+P:
MB7P6YB)-P5#=><TOZ7;_Y*]95GN2?(XTZZ=8[>=0E!I@LQ9PQI-T)&^\?YX%
M-OH_DA?\?"&L:W7F6IWM>1'F6IVY5F=3;UXU.>J_<ZW.7*LS5,2/'TP*_9BR
M5(8DCA-.:)#[A&DM">=YDLL@353V38'F^]-Z?EOUZ+HO[<<%FAX]-+,FA$G<
M&9<,<1&FY\VHZ<N";3DY-FBZ7>BNI7;?;MJZQ#>\;8,&?)A!L%L8M74!#H*N
MFF+U($_P\L_9JNRKOM&V2FR.([EJ,$Z-3]N;ZQ:GJ&/V*S9=:KL9(KV+:@ZF
M'&RLNKN80AMGXW]A9T)^[>5<6I^8O7MG -_VB]OJ^[1^8=O:RB3)XC)!T))N
M-/3.>_9SY[>J_14FU:KMHA%3,>TU5UJW>\>XO$!3]?&U8JQ37S,5$Z'1%16
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MDM%B[]GM,O+7'5%*XUNL:-%XHEG/V4H?D?'M,!V\?2CZRP7X?=L(*G,!?B[
M'WY)]>"H_ULNP,\%^'MU\3VLS%R"OSSB]\NVNUM(=MD++MBA$<953<O=50B\
M&CI<:Z;6U>,O)GVTW>V:URQZ2RT&N2UZNC7Y0,L51>3<VC/+27O5^K+K!JVN
M6C%?&5>W?':R.28K3^RJ]--8G.AO7O6WMO[4Q1&DH4"ZG4,W;=OZ-3D:345.
MW>UXZI:;3H%5EP:^+H<<-^;.QKR'.+O"-,6RX_8(NC'2,7'N]KJI>6J-%&5C
M3=4B!2S94"M)@.O693-58UDE/DT69:SB"=1NVR^$-73&T=3Y<3-9)$:J1U_:
M;G[1J%U.5EO,BVN:)*<'-=0P,;5O%NMZ$H4:<B1K=EE3?;EU/5;GP'7NZK/&
M6.K&\R4BGJ6TM,6OPDV85%<C4[C)S6A:35((?)"V1V_*? 8LXS:]",E7T%;
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M.,I56\UC76ZO462_[;7'--TXZJB-NRB<@6@/1?=N(,HXULS!$E@AHNN+E2
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MC*@LO0-"^ !;!55 <.Y 2;0F#!)-/#PU"/JTLC*#T)[(O)X=>\87&5]D?#$
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MLY+,2C(KR0$HR6R*MZ:X)26CRC% /+2 "$V -AX!8EG)2J<I55L.?\VL"[O
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M,RK(J*"?C'(ZJ&" 6CW;O)EILW;K.2VR=NLQ<5Z,=LLV;Y?C[9UP%B,@L96
M0!3,75)*@$NF,=0ELW*[VZ;&6L-2 TH= H0S!(1'"#C%E+?"08A=MGDS*NAY
M>L#^FO'V:<?)#T KIYP3!!YX23Y6L\#__<ELZQEO#@LZ'C2):EVLXG,<Y:JM
MYK'7:Z_!8^[A_DWH\RX*9_S90]&]&W]ZZ4JK=0F,AQ 061(@N** 2JTL-BR
M2[*)/RV%D$D2;I/3'!!K)!!,(\"E@-YQ@YU]YIA+W[N]?Y65,@KMB=#KV;%G
M@)$!1@88&6 ,!V!8R"F%"@)JH0 $(PQT*3$02G'EJ6.0;Q6T.*,8LP(#['CX
M3LDU4,X$@*&(+[5SD.%G!ACBC%.4X46&%QE>#(<6&5YD>'$B\&* \*!OS1BR
MDNR-8,Y*LC^TR$HR*\D349+9!F]M<(,XDTH98,O2!AN<E$!S# $J-8.>&6'H
MEI.?PF!W<U8"[W'XCJ4(2*%*((P04 GO$'WF1H*(AB/',EOA)P8P\A38YTXB
MT=78'DU$?;BLIC,0],55,9K<N'IV%85$'@([%+B91_ ,8<9+'L&3R9.E6I9J
MF6TR>4Z8/%FJ9:F6V2:3Y[3(DZ5:EFJ9;3)Y!N9E/50HZH5X68\<"OKS_,-Y
M\:D*9SN)'M9B%HA0SZ>WX6MF/AW-1B[7\0U%XSUAU*IGE,B!^Y-1?CD<WX;C
M2\PU%QX!HXT"I!0.:&X]\%@@*[!RCOO-<+S'3GN#&$"(,D"8*X%"T  F2&QZ
MB*C=#L=?W*C16.FQ^ZF:?E!C]V$A^-\Z/5O^]&8^G8;U'B0HC^D9Y+BW,?F>
M2;>342E9O?>'%D-B@*S>3T:]#U ]]RTEO6?,>3(2,6NG_M!B2 R0M5/63ED[
M]90Y3T8B9NW4'UH,B0&R=CH9[91=HZUK%)/2$P<MH(9[0)B'0#+EP_\K(75:
M(J+9IFM4E]9(+QQ0UCM '*% &\Z!Q51X0A'$3F?7Z-"DV\E$Q7/M49_$SJ]J
M^I>;1<Y?B8/GXJ.AH+V<^C6$W**<^I7)DZ5:EFJ9;3)Y3I@\6:IEJ9;9)I/G
MM,B3I5J6:IEM,GD&YF;=/TV,IH<=9Y@879Y\=L4^\(J\J:ZNW-2,U+BX5M=N
MVI^ 85:!.2C5HZ!4CICG?*[,6Z?"6ST[]JQ<^D*)DSGTP2N7G([5#6]"2ADI
M+7#"<D"$D4 SBP%10B%K.2M=N9F.I5CX+"8:(,$<(-!H(!'Q0/I2,N>$\ZH7
ME:H(G5'6W^[163AE[9RU<W\HD;.M3T:]#U ]9]LQ:Z?^'7O63GVAQ,D<^N"5
M2[8=6]N1,Z,L,QQ 1BT@1B$@>:F!\T(Z SG3VFS:CK!D4C&N@2#6 X)$"03%
M!! &K5%,<ZQ\MAVS<.I%*4^.,?=?-+VIIM?55,U<H2:V4)_<Q-P6NIK8Q_2^
MS E7_<$7#Z7% R:VP?,XL*VNQB/;[^&6)T.<!\VFW$^>_H/$ 4K2 W@@GI)7
M\VS%GC!MSXX]:[>LW?K)**>CW;(+I N?<TI+[CBP7D) ("N!EDP QY$V3&'N
MS-;<9<>(D0)&/TFI0.SM##26%%@+!?:$0\ME'UP@\DP@<4@/2$8'+U#H]>S8
M,SK(Z*"?C'(ZZ&" VCW;OIEILW;K.2VR=NLQ<5Z,=LNV;VO[>@^]HLX!"FVP
M8S7A0.J2 \$@*;$@!L4T\(WPO\9:PU(#2AT"A#,$A$<(.,64M\)!B%VV?3,Z
M&$BZP/Z2]/9IQ\D70"NGG!,&'GA)/E:S( 'ZD_#6,]X<%H0\:%+5NEC%YSC*
M55O-8RO97H/(7+GP32CT+@IG'-I#T;T;ATI'I8@MY#W#)2 "0Z Y+ %F9=AC
MJ3EV6S$82R%DDH3;Y#0'Q!H98*M&@$L!O>,&.]N+&$S/.\I_E9\R%.V)Y.O9
ML6>4D5%&1AD990P'92#L2>E+!R@U&A!F/-!,0$"Y(AIQB+2!6YD>1C%F!0;8
M<0%(R350S@24H8@OM7.0X7Z@#'16"IY11D89&64,AQ899624<2(H8X HH6_]
M&K*2[(U@SDJR/[3(2C(KR1-1DMD4;TUQ5FI+;3"F2T]CST+!@(;" R)+!8G1
M3FPGGE 8S&_.2N ]MH!8BH 4J@3"" &5\ [17O0L).R,T/[VG<@HX_&Y)^'?
M\5+M.19R3LOR;\<]E_^>U[.1O^T9$@A7WGTQX[G==S3A_7<?#,*//9FEZ!^X
M>?(3Z(YVX!M!=.6.+-CI<I&]=:T^N4:@ >4#[5ZI\6=U6[_^KOC7;[U&C^:O
MI[M%NAK;HQW]Q2^_O/_'SW^<%3__]N9\UW7JWY*+58&2J?^8H_SM_<=W'XJ/
M[XLW[W_[\/Z7G]]>?'SWMOCIY]\N?GOS\\4OQ8>/X1>_OOOMXX?.%?+]F_#E
MT63N[ _YMCSNMCRW4;ZJBULL^MO\*CS%A)_MZ*9_X&6 JNUML!\FGXK9I2MN
MG9K6A0NG:(NWSK@K[:9%B<X*##%.G:W"/\*/X;-35WR._V]2%;.IFM3>A6]J
M-_OLW*08NQLWKL^+C^&9;ZJK<#ZWA1FKNA[Y8*@4HUE=7%43=UN$0_[+S0H_
MCTVSPO_^//]P7GRJ NJ?7(75A4<[5<^GMV$+G9E3J+KX)3Z_0.&?M0O/"M\.
MZXP;\&HT+6[4>.Z*RY&;JJFYO#V+WPA_K%WW^4MUX\):PT+31VTQK^,)Q-,*
M/[1KN@ZW+*YU4D3C)WRA^7U=?![-+JOYK(B;BM]7R294-MZ(N.B[MYT>$H'W
MZI:^-WO;AZ5?F(T)5C\L#P$_ZA#B)N/61Y/K^2Q^0(5]!:I6D<+QQTEW*ON.
MXZP(]]=<IF^Y4?J:'4V=F8UOBVH:/K_\28=[>).V'M92^;36J0O[GL4EV+#[
ML[3;E?6/ZF"S!L$4[NZ"3%>5#9<K/KQ9Y9(&5RY0Q@86^Q0.]?RK4O4>8N+Q
M4/YTY$2\U49-I[>1".HJK'V6R!C6<JU&MG!?KMVD=LV-;4AC&I=$>^7.MC\Z
MJ\(-&*MTP=1T%J^I,<V3K]5MO"MG[:L*&Z[#YL<;;C%F&IEX^?[KZVGU9705
MV2DL(URFY8VJN^?$RU=?AKL'XO4J)FHVC_?>KS-)?/YXI/1HG!CU</#SR+0J
M-M7HEN8,-LS?PW]W^".VK_P]%K)PDK5O:7UD5$-O2EH"QI4'A#H(E,4*&$5]
M;+C*O%&;/C+O2ZJ1X8 :80#!R "-F0.,66,YQ0Z6Y::/[!<7Z.7>!]&HHC#Y
M)6@-5W\,S_QQ7)F_OBM<;8+<#.P?;LH=GJ"O" ,Q(&%P5,1*SXOFB%\,P&8O
MC?3-]^,B7XUF80MF[^DNN"[ OM4[\3(.^]B"O/F_C3->U4E)1S5J+J#(J:NO
M VR,G_SC_9\+-3:-2,M$K[DM='A 4-"3I +#GNJHH1NX%=2?GR=%V+PFZ."(
M:(.:OVFQ952R)NK?J;M2H\ER15&+GJ^^,ZCZ]MFS)1QN;'3Y.OPYGEY4Q/.H
M;2<-?!TWV"(^($8GTC>7CV^T\=;^O_*B2H<KT>##\+8K]=?6YM1TE("EGU97
MRU>N;68#!RP.]-,DD#Q D-G*4A-8GP3C*2XIHMJOG/CRF]O'O7JVJU;%O,%9
M 5Z;:7I1L QTH'[U.6YDNO;2T:0)]"0KI8LE=4O>7FQ ^!WD[LS"K26O+[=9
MVAU+65"H;C!__%UXRBBZ'%P]:\V.\-2HQ(O/U7QL&_,D$"R\)/ZG>6+<CHJ3
MT2,&G 9>_W_-?1ZU1Z:*>A0X3DW;^Q*-M X_NO^9AY6UR&_CO*-5L_AJ(.ND
MN@H0QDUN1M-JLFW3A34G=!FW$UZ]?MQAJ_&0DZ726)(F,F0\_H" 37S$-%'
MM$]+!M[4A8^$?ZKQ;=A-LK"+4?B[F<636MUQ(N19Q_7-1L-'G I&6'N;MGB@
MV:[Z-'6NH=B+E-'IY3:*P72&KQJ1$RS+X[E6?OU07'2GGAP'X1Z-IA;\GJR7
M#_/KZ_%H?2!UME0??^P_3XI?H]>CB-?_;)4EBN3F#(P:9$_5"-#P\^@J/O F
M.3C4DES)KS$?-[P^O@U<9*/\4,7;Z'FIKM.G(A_^JB9S'UBU<:1]Z!ZUI/SW
M__)/)7F]=AO2;WYH[H2*<B3<BL:FK=M;$:72?\[#>^,N3B2,ULC1=;:H Z)H
M'&0J:!X[,JKQPJV>:3T/ZUY @N7?DAZY&(^K?XRF2W$7S'\[-U%MSUJ'F(F*
M^W;7VX.6FXW4.!QS@#:C>#7FUZVF3B(WON![]$.QBP"//:4]1C,21!%.(8"R
MU( HYV-'DT!D3Y44$D'K]%:-A]:Z-!2#8'$+0*#&0)>8 0&EL H39*WMC&8U
MOIF^2O;;N[CE) Q_#4^[O)C8_^/4=#TS)(*"J_C7Z!QVD^%+AY:G,%J(W4W_
MR$FP6I),W^,?.IAW/78) H;[O!!VC<\XW/ZPSTAFU[KT/E?3OZ+0B@QE7G]X
M_U]U\V_[^H?SI^0$+83!<<1K"84#I'0X7&A&@>/*F%(**O 6)TC'2\4I ="4
M!! A R<H00%&@7,XPU22K=X^N]Q'[Z_C<7VLWGT)!VJ'?^W?>>\:S_U_SB<N
M173N4HW%3Z-I@.87X4[8)A33(.=UZ1E^^92"T3J)G'4 (A>N [4&:$,PL*52
MTBM&&-Z:$OP0P7C7=7CW953/HJ7TWG<WXV,RD@+?K M,754!;T]:5^/ ;XU+
MM__$)67KV&A586,&AYO=\0F)@.)F%'TGR5+MS*XN-M=9=YWYM8GZ@W@U;4I"
MPH\!WB6;-AE_#4L&$?N_ZR<5K193Z(.@! YC&D0K-4#(@#2(4@%>Z))BBX\M
M6I<,-/@[M TLOP]@-5(X1D##Y8G.AT#E'P)XO2VT>TI2>X(X1[($3,<!>:7E
M0'AM ]FT< 1IJZ#/8O.@UV'6[?'416>P"9*MJF\[,ZSQN@4!%YX7?]W(SFC$
M(0F#;+VM.T.MF%2S $//OW)$)WIR&TZ*5J^, JM<=S@]>1>3[VX=J2U<^6KI
MH][A'+^-S_CG8PB: 9[W[AH.0:UW"@N@2*S<**T(8@Y)H+SRU!NJI=UJIX Y
M<Q*K*!!9$*?22J"9%,!I5_*26X\0VA2-ZT+QC[CA]_[/VEU$TNVMV&!K%1OT
MSHJ-W?LK2P<Y9PIX)L-:4;"=E&,.<(881@()S=WA]_=+=P$/LC-VOJL094]E
MRM"E0GC .'%_$\Z8Q2Z1BWB#70V&!=Y>270)B/(IP:/EHN0JW".)>;A6,-CE
MI>' :L4,UTA(M84HI$8>:F&!DE(#PF7@,DM<!!BLI$19S,F&AVH-3KSK#B%=
ML0@BUFX-J)UY9>?3Z*4:/GX@YYB>N/Y+N:9GC=W5I" ^Y0V6VEM++0$<DV#*
M(!14@',$.$LD)$Q[1K=<"8>]P>_:C;] SVMYVE?[/&*[#P'&-?G3.X)07YR9
MSQ)^"R9A"FNH29,Q>7< 9)GCNR.R6,]U/0L&5!/-2/F-X2IVGHHF]%Y-1Y^"
M79),T9W+S##T.6"HXH26!"- D0DP-'ID1#2^)3$E]TZ:TF[YN0TMPZ?+^'%B
M '%& 6DL!,A[3"R"C!/3%QBJK;7$QI9C!@;):6/'4^$\@)1[0I$,6'0K#?3Q
M^SLT#"TS#.T7#'6<"D2% =;$*V)@N"($^:"0O=48$^>=V;)NH!6E)0QX+W <
ME:B!"$H?>&T4#G>.>"DS#&WO07G.,PP]Y@T6BCM&" ^"44=)IR60R@E O!8D
M&E,6'_D&9QAZJE>[R7:) #,HNW'=P,S"C[Y$<!GI&4ZAS8 ,L"[L[=/EDU[]
MV!^%<P%H*7G$! X(K#7P)2PUQ1!BS//5SU?_6[9YUN;5V28R&[#+4Z(27PID
M+ *(0A^;^GL@M"P!)-9+1J1F?JLOT+> W5WAMC_<Q'U6X[VP)+;9J4_A(L\^
M5R RY6G?XV!B)WH653+&Z_,BR?18,K&H5-SA)ZB+F.O>YE36*;,^XO7&>W#Q
MX4TA"$X%P:.8_YCJZYMJ@IAL'+]F5VHP4@%^'9,4XFOU[9H+0,U257-3XQM6
MF(MN#Y_*_)/3T[F:WGXU9:M+U:J;@HD@ &/FWCZG40,/5AU">]U+WVL7/I3*
M098ARQ^*SRJ6\=OFPL0%V.@*"A>VZ,+?T80T8Q4OSN?8,F#C]IA FD6D?*4N
M(V7@IKTUB#SEH\4SB6;VFKNL<8MMI?G^JB;J4[/V\+5TP5=R=^)6%X<5/Q N
MRZSUQS4+:'9EF@VLL4WR;ZTXOK)?ZTZ_EN,D8#P/#"42$!+PFO0QIUE(ZEP,
M'KDM+[NA FH>]"51PH;O:!I,(D.!1TP:126W A_)KU4'V1'^]0T.+H%8698>
M Z9Y6+DT$$C-#?"0E8IAY"%AA]_H-SBX[K-%=$Y>GJ<KB-&YZ:H$F\X43:.!
MNUW;HPWY_ "I&L7G,D\H/NF]F56-*Q[C5@BF2,'"#^^2=$U_ON/)S1KJ6,=F
M=WQ.[9+KZW& 'S87MVS8X19IQ+8MXXN_78K3I_6?8.@L1'%V%D(P]@I00 O!
M >52"H-5J=26$<D<(I!:#FSI61/ZTP)3@(01I58Q+Y+E4HFF?=_JU3YMJ'U>
M7$2D/'7U?#S;NM:++C?CNEJ6L]X+,>R-F67H<"=T,((KZX(>%=[$TH\2* :#
M@E6(,HT(\=N>4<E%$$XDX NM@UHM<1P%;<(7$3;>,^)H27H''9"T-%C^07"1
M.-$'8@V$+!$PR&/E*,6FM(??Z)&@ SYG&3K<#SH,LY=0MND/8M.O(KT[J[ B
MWKO3-$]UQ%]#A%\O-FXPX]>>D\202KW8 @4B7K1V$0YNX@O'K> MM#/)G;!Z
M9(WWJ2XNJ\]-_[CPDL_1V+^>3Z^K]L/-^T=U]&(UO08K';=2;^3-Q&+(#NIV
MC2"TF[A PN[WZ5$!+\PVTV1<ER4S:M#]2NNZZ'PXB^#8?3&7:O*I.XK4X.Z.
M$SM;I-6G.J+4#2,MH:T15XM03A/8:?.$9J.N4T3A77A(\T>M9@'#+/N>+/JT
M=0*K^9BIZMBL+07]XT(R4+D+J#"DI*:J!)IK 0AW<9HO],!83Y4WQA&WI;\Y
MQ;BDH@PV!W2 2,& E,0'=>Z=8H90AOR:"?+GDJ _.?=[TQKO(&DM:'=>RVEI
MZ$4_G:?,D8:"4PD)D%"J8)I*&NX%<<'6Y!12(R@Q6P5V4'%&C5+ RNA&"E9L
M0(7: .R]HII0Q\H[XYL-M.L24WY.GL_PZS8JU!1@G7"Z"GX96=.KZ5>NZ?7U
MM%X7PY'ACD/@3##+@BEF@/2& &J9%J:DS!ET@*O]4KTNB\[+L?;XM._S[I+G
M 6[DHDX=:1>.H^DT@KS&=;32+3OYCV[4=-1V  M *P'!F)02?CD.L"L0&>R"
M:^$Y,0%S\BDL959-U:< Z_Z:5)_'SGYJVD;/7/AXUXQ[M0MO=745&Z=-74"+
M*G8\FJ@ 7",R;%L^MYV\%]'@Y(U..#VUWVZP_RK$;<R%1@ZUOU] ]$WD6\5R
MYT4;[.1+#J2N.ITU2#,X#XG)0V)V#(EA6T-B\HB8/")F8$,_!D?]W_*(F#PB
MYCDU\>FXIAM$=R+J>#$Y)8#=K?R*QNM^78UB#\^NV>?241Q![+ICN&VAUTYH
M6?11CNA].S'RO+@P,= ;\.WX-E55+ES%N8;R.'Y89PE1')8 N=C02C@$-'0<
M,&VM@J77I=JJH7R('_:Y:RBA98PX)(%#89E$J+!6'E:M#1/*22LXW_(G/GY_
MAZVA1.2<O[CX<&ZV_33-MH-4A[OJXG\,U_B-NKK.8>PC=-E.J6'PJR'L;^F8
MW32?W:;JHA5M0]YW8W>C9N['4;6@=+ #)^:\C8UWOVQCX/'M,9-ET7TAX(+?
MJIN%PQ4N(N&;EZG)_&X"I:FJ+L?"!QD+SV'O0\ MR+V#6&A0>A[@""P)T)H[
MX*PWCAMA:;G5 LIJX@SE!##&+2 Q@J2(\<!JJ9BC/( 5_D1A[_(<GSKN>)ZH
MM_ >E0P#Q:P"A,3,1,PIP$QR"Z&G5&YU^A <N7";2L M1X 8*H$@*B!;:20M
ML<9(\Z-$O7,UY*!VN1KW_OXI*]6)UY Q ;#1P8I"079)I0P07!MOD-2TW"KH
M?8BHNZN@-][H]SZZ*Z.4.NU;7$V:"<0OXA:WN9A/*9K#E82<\? D$\2L5>$:
M<\H I23<84<TX?)8U_C%U*6'._P2)/%Z7?H/9TT:@8F(HV[3&E1=5V:4\'6Z
MZ[%D)IAY 5@;%18>#9@(^UM(G\K1/[L Z\-_36P$GF!_:QB>-2@^CMX[*X+)
M8!- CT!^-9^AM3MV6 YW&BAKINNBQ=6B6MA]B9.WEWD.3\BQ$'M#O)" 2AY3
M2PD%$FH#)'.6,&0-A5MY5IEC,\=^G6.323X-=*XFP:2Z+8R;1@= 3-:IC)E/
ME_,%.\[8]X7+U *B'=H84X@6_!(;0\3V\+=K[0#2W,^SE:[PC:OD[@YS3SHL
M 1-JA0(EES[P#T'!&*$>:*QLX!WEL"&'-F#NV5/N9%@NF"M-W[43Y[EG:BI7
M&J81"_#.*Q+3<X,U+C&U0% EA%.08;D5*3KL%7Z)G;4"ZF@KI4^\N5:JE#YZ
MLNM)Y;AV W@W$Q)6Z^O1WHR$&$!9O#GM\%FS$W(FPE=<XTH%(1H@.T!(QWE+
MPL6A&QQPA@WW4F+OMN3OM\#VXV<BE.?HY+WDB6%RNLU#+SG%C%(14 7UG *"
MRX"3$0NH 7**K"32'..2'S8=!9_34[_>ZX/KPTJNU<CFJWWGU28.F9)B#"R%
MX9HRJ('V$ $GG;(2J5+I+1/PP:'-WQM2K$<X#W*KX<X>'"=UJ]>R#[8C_ UT
M:CP6*Z#,3ZNK!0L$V\Q-:M>U[%C"F]1WJU$''59+3;5R^M!3=K:,MSD"SPC8
M XD63J4TQ*3UV&WZM%)J3T#%[G_FX17CM3DK;YI$D_?3U->B:OHUW:Z,<FUO
MU'KSB^TLH*_UEEQIPCF.UZR:SSH[H\UUJ=(2 D7&31^U!-ZW6U!&@V1IE^0>
ME-\LS:6W,!P:!$)K$ELS,B!UR0'5"#&+$+7;B2HXX!DMC 98$@9(3+-5&%L@
MC%5*":B\?)[^2N@%-&O8VTYI$Z,WR#W?_KMNOPXVIT!6 600!L1Z%'&) "47
M5AA>2@2W!T ^^O8?M8T:.GW4?H^68CFK_&FRRO]+C8-RORK2O:XS"#PX"%SM
M/-LY0>_()&\]J1LI_K\7/ZK;\+5Q%;[URR]O6MT0T.!*MLW%KQ?_4?Q^J<*.
MC M&0Y!!=9,IWJ5B+YR]U]/HNVWZ^[8WX"P@O[I6YG(>N"_ N^]7(5RS[)1B
MWEV8]*RZR3IO._+&8UYMLK\$FNM?BJG9R84=\5U<VZ< =*<1Z'H_,NV#SE)&
M16K''C=KEQGV9P%ZZL@A58#6\[I->1Y'>JXG1S3+VGCWI;IQA79NLN'/WG!F
MU]O>["<,<5%B-"*4 B6)"BI*>*"9@X!2X8@Q!,+ME#Q4&J]-U&C8F3C2O@32
M"@2\],8@* PK-T-<L71@Q09\0>&L=:X\^8#6YM3+2,]U4739>!-:FVN2JS4?
MATM1L,&\+!V0DDM *'- 2!H@)^>,8%X&AMP:O.YP*;1D'A E'2#>Z3@@DP%H
MD#0EA%3@8^'2!U=KRE(ZQL+B6 ECA_\X>-V:.!# (^D%YHALI6X]?G^'GG@)
MCUVLB2GMRST]E:KWSH18QS0-'LI"ZW'&M*,>66( 4Q("(B/^L!(#'CA7*:M1
MD&I;J -QIADDP#G$@P%N-=".NRCR-*(F\+MQ?1%:@FMM?!R%SN.XEI(1H$E8
MM0CH2"F-A-\>T_OX_1VXQ)R_Q#F]';,O#!ZM8FEG=(H_)2SGMH0&4@(85'$@
M+V) &YUFV1&.3 #K?FL<QT-@^3)A>:TWY-N UM >0&[5[:E@\C2\L81G 9*7
M\+0A>>QKV@R8Z6[VNI7ZZ!RTH^6++3T3Z=5-GG.TEK-NO5.W>F*$D<@ (X("
M(L)@H*GB0$*K2@8M*\VVH[J,%7G> U'J./U',J!*'/ SE9IH9@+*1FL6_<=(
MY=G/5Y$JB4BQ^N1S)/S'ZD?WAQM=Z?FTCOVZ<_+4O?1.8IO (LL3C4T#FB-M
MP_"CNDV/G"Z.MTM'',=*GF!1+RN5[;R1Z(N$R]&TGCUID1Q!X=XH" S$92R2
M"]?0> PP"Y<P_(4ZN97[\6#'TOYKN+B"\;>_AW55-I<"G +#M/=YAQ;;4]XR
MP$TN^E:7Z&QM8MC ]Y4U]]U6,5;.RCC "OE@]Q%J@@4H!2@-DR+(0$W@UNQ+
M:VU0T0@!2LH@9C470 0[$B &I2PE5 QOS;O>DIKU@=+EY,FKZ5;ZW*FMHX,[
MA7UB4Z#=?=F/I7-5Z62I$<!*R:!S*0,":@>TPMAP!Q'36U-B T"$F!@(+!,<
M$!Z-3 TIX%Z4V&IIH%'W*7-MNH-\K-Y]B>&VX>O3CQLABR>N6%;8,"L"#B<6
M!RB$3) %&$/@D"P)H]Z59 O%?YL#8)N4[[Z,ZED,U;WW&U1=8W]=5;&\?#:=
MN^&3N\U\G%5-+N32&+5-D/C$454S"CP.'A_%<X@1\DD0<^%9Q74"ST]</*Q+
M2!73,F9;T3C+D0!%8;!/=1FNM%24E5M1K0=;#Q>+W;Z?N+C*=/M?@K'@X]CA
MEV MI'25S]/1+/PB^J!BTD?*7E\OXLO&0__WM9U%,*F6C11<UTAA=MOED(_J
M8BG575)@3;]#O>Q%8L\?P !]/)6=M[;7"XT9?W9TLT.!;*?S?;L"<<P0&\ P
M<#"6X3O-@60$ XS+$E-<4K:=-N!]234R'% C3)R!'C$7<X Q:RRGV,&RO ]^
M6L3A?E4Q/6QV^S%>T(_A13^.*_/7=X4+UM5US'=LH%/.?WS\]6J/>N22*-^L
M%^]"\_'/:K<;=(![WI+T,0H3,PQ]%8W1NO@^!5JJ>:TFMO[AU2!%Q3/-Z-C#
M&5\;TO%-(NS>0SJ:24C%WV=)X;5+:C<R=G[V2LUGU6N="J/2(@,'O(*OT\?!
M6-U6\]FKU"3B=?,Z!--!ME^(:;CJNG:O:G>M ONX[HQ2IZ'FV=]U:PB+6,QC
MNAG5HT;@O>J>L?+!\$F[.+[T6@'/<8G^%L_V7V?VC@^B<TG(O3X'[_,I>B[P
MMSXN_##=M??+AB/:&[A[U[M%"X;\#!-X%K119+K5Z]T^+9H;S9RK5\VTJ_B+
MW=QY$\!/3,-N;V]@@=>KBF7UCJ"5N[YDI^[6'HN?XJM/0,VL-:6YWG^1[D7R
M;Z=O<\JO]V&'9Z+G<T\P.BXM)M5P*'$RA_X5!M@Y5.NY")'4Y*$I,4 9N6>Z
M.Y?$>A=M,4< @8X!@90$1@I&J&;$TRV'MF;6A5U@H#34@!A+@2+. N6API9+
MA4K[((/L][8KUMNY^RV\YN-G-[YQJ1AE?PBL7 N!E7>&P.09Y&1O$"P+J1X(
MJ2, .4K/NO]E(#<0(;4V$?SA?+E.\@SDGA-3/)06648^PZ%G(#<\&;FG7QTQ
MT%HF0>QA 8B0' CM#+ $&F<4TSZF_3X=D(LUQ!\_5P?!;PB?4;R_*4863CT0
M3MD3EP%< ^!H?QP1/>/,80&X;.0.X- S@!N>C-S35;N$$%*+@..> L(\!L+Q
M@,TL90Y;K*7?:OER= !W.;VC:>M#(%QYAO'^//0LG7H@G;(++B.X!L&Q_G@@
M>L:9PT)PV<H=P*%G!#<\&;FGYQ=WC%KN ,)6QSFZ!$A98@ AP<0RPSC=:B]S
M; 3W4S6?'@C E5!D%UR?A5-VP64 UP XWA\/1,\X<U@ +ANY SCT#."&)R-W
M SCLJ?2EPL!S9 #1+([2L!)H0B61Q!N*M@KUCP[@1C>'\L"58O_@I"R<>B"<
ML@<N [BFQT6@A ^JHC]NB)[QY[!@W$%-W;8L;'%:]'I6U-5X9(OU6]PSBIT,
M<;["*/<E3X:%/92\^UIW$H05@<!I! 'A! '%;0S/4B0H0X3:K;;8QX2%%U$U
M'!0;RC,F]@]>Z[G$6WU9N U9]#V1-_!PR+$'-!J@L/I8S=2X[:1PW4J'_K@]
M>D;?80'&;%H/X-"SWV]X,G-/AU=H#,3: @J9B@TZ:<!VS +(A?=48J3\5E/L
M8P*\@V Z@LXP/&C11)9* \!H^QU^^)@./YP=?M]^2:)<>)4F8DY=/>N/+Z-G
M/#HL#)>=?CW&>MGIES'AW9@08H.<D09X+-($7@6$$1IX@3TSEAF/CM\8Y<^)
M'=4FG.;,V7=?3/CHQ57\Z2  D9X)U-^,ONSTZPF@W)\"6!X34)894![&-;B8
M?]H?UTC/6'58N/*@5OBZE,7G.(I96\4IF_U&EM_ E$_(?__<'UZ[/X4S..VA
M)-\#3@FR$&$+/(<2$"E+(+!#0"K-L/046H@/ 4X?.LCX0?F(]*P4O+?^R:_R
M34:@S^/2S&'GYW96KJ'*XE_^Z0N&J'Q=F/ET&C[2'Z],SV@]+)AYRN5YIPL>
M<_'Q2X6$TBAG(&2 *4H!T:4 @I8!Z)7(.BZQ9'9K--L!(>&;1O@?!!GR,\1R
MM[^7AO)R<F&?A,Q>E#>N)I] T 17_7%Q](S:P\)YIYS4<[HX+^<JOE2<1R A
M5CH&,,<,$%5"H*4J 9(<(\M*Q [3YWD/SONMFI@#0CTLSG <A=I3)V#/Y-GS
M8[WP[SBU[M^WY[+:T<VS307\%BU\W)& WSP\]-%G<3JS0U>#V*:J9W7QV4U=
ML5";63WL2F770I36$L E@\'X+Q$0O/1 8^L)%()(9@XQ8'==/;S[<NTF]?Z\
M=;:F$NB=*H&=[^]2,? ;780'C".MU,3F>WSG/784.:P( MA)! AU&B@$/8"6
M8VH9T:RDF_=8,.$@A!)(A&E,V0O7WF@"$)-2*.R<]NHI[_%^7',J]SAL/XU_
MOW5J6A<N:#E[PE.< ].&?Z 3V>!9,77UM0L7\\:-;\^+-ZJ^+*[5R":J;HSJ
M#KI7U5EDW3V!QUL>8* &,NC>H'J) 9)@"Y"AU$!=6D:WDC(>KWJ[LK&#R"QR
MOC\A>.#7/>O>>U]D#C$-=U*%6R@P(+'SA:"> \*,"P:,] QOA9(>KWL/>I'I
M"U.^+T7W;BJMCV'_;ZJKL-W;)D(A7]?%+!F.-VHZBKZ*50LRO'AN+HN@RL+%
M"4L(5^FL"'<$^-&7<'Q:S<SEHI?"63%S=;R>X5NS:JH^N;/BKTGU>>SL)Y=6
M-'/AX[.IFM3>3<_2KZI D6EXV=55%#53IW:1I(]G7JQZ+P+GN"]F/+?N6WTZ
M._PK#W1D+!W1 [_-/X$384NTVE:X<0C^_7(1^KT.#-*X6D'J7?=*C3^KV_KU
M=\6_/IMC\.GND*[&]F@'?_'++^__\?,?9\7/O[TY/YA .>J2BZ\Z0S/U[WF4
MO[W_^.Y#\?%]\>;];Q_>__+SVXN/[]X6/_W\V\5O;WZ^^*7X\#'\XM=WOWW\
MT*A \OK[-^'+H\G<V1_R;7G<;7GN8/[C-7&.*"S.]TK%'@L3-3&N\,[5)Z*7
M(R@>!SP; &F5+(+LO'EXZV]C"81* QNL54!*K8$H30F8-=!*" W%_!#.FW^T
M5DDR>=\$F^0@YFYYOK^09N"7._MM[C]_2%BGM#2 EYJ%^X@Q4(8;X!$R%$GJ
MM=^*_7V+W^8X=QB1\_U)OZ=RB5]DP&33:7,B&XZ^I^9-@8CJQD4/4=AI!!D+
MU5O$3-EB5._<\V,7MI #;19.5PG@A:#". !1X&825!20N@P_6B(M=)I*>Y#.
M)>ONV_]J3^*B.8@_NG-(?_P83@&M<3^HG7EEY]/(",,'ENQ<E@O8OID9=1*7
MO958:G8JW+LEKDYD7XU/?$LN=7V$BL"R[E@":8#'M2?)%@6Y9Q4"W"D("!)E
M$*$R2E1O/$&<:GJ$)-L-$?JV)=D?@6*_NZG9S+F]GD_= FD!O JUR-<R4_8W
M>Q_X]?_;X?RC3QEPV9E.^[^*XN_AOSNX\YN25_? A9(*QRB"0'(:IQO0:#5@
M Z"T*EQSS9C;&GKU+9;O[]/HEIC=_CY6D]G%Q+[[G_GH.@;:XCT?5W6XS1_#
M&WX<5^:O[PH7[O5U='5-Y^Z.+.RO!*'$@'Q?1W6PLO.B._\$RQ>'?Q:>-!N@
MD_CX?$&8Y<A+#\)U)H$OI([6M #,<(ZAH!YI=E2^>" WW".YG V('8XL?=>X
MP2VY8>)FD:;UJ([HJ?+)6O?5>%Q]#FKZU2"52Z[*6(M9%W]/-2R[F@ZJ^:SJ
M.O_$14:2P]?IXV"L;JOY[%7*%'G=O [!=(KM%\(]&*OKVKVJW;6*,+L[H%30
MUCS[NUU%TS>C>M145[WJGK&G=+IY+9/GI0BL_MW^XJAV?7%U7_\4/J?H@(\[
M+R4_Y.(X_-;'?:5*73R\2/VY.M2@7G GVL.=;\(C]72TX$HUJ<&CRY;#L<>_
M)B=RWYLY=X=Y+V**TTETV,;7!_+(]*<%SH/[$/?]6GR%R0]*TD<U$1F.>#X\
MZ9ZJB\@Q^?G[T22@YVH>U(&M?[B?K,=9UK\(6;_J<,\R_H1E_$L7VCVC1!:T
M+T_0HO[P9A:TSP6F<T>^H7NL?U&!>]2LFMXN_=6Y3U+N^Y;[OKV(E!1-(2-Q
M !G#90Q',@&D5QH8Q$N#!"PIW2K*AEAXIS$%CEH#"(MC(DKA@9!8&T;*DA!_
M[W#D?TRK>G]Q]D.:OJ&S4N;!M+WN^?:RT<%S%WWEVY\U>=;DIZK)1:FL-!@"
M%O\?424'FC(%/..(<R&=15L)=PXI RD5@/.@Q(G1!JAP(*#D5(1?<^+8_V?O
MS7L;.9*\X:]2\.[L8P-,;=Z5U3T80.YCGA[8K89;X\7^]2+/5NU0I+:*5+>>
M3_]&5A4I4CQT45*12@.V*;+.B(R(7QP9<??"HF3)7Y$E3_.8#CPN$-O?3$'A
M[R0JD"9E['\")$&!'DKI>B@0B%'>*H>\BD/&M>%(\2(@F3OO5&&XQRM./9=,
M>:XLLMI[Q',,_KR'<X++*2;2T%S(%X "G*61/4D1]=:P[Y=+GU;_'A ]F>%#
M,</&Y*0PLD"48HJXMR[V\.6(@C7%AA68X^*F&=;2Y48I@W1.8X/RN$54!X:L
M ^>\T)Q*1Y,93HHHY>E?G3\^JB?5M!$]H!ZZJ,;?*E_7?8F*W;42JV<KH;>P
M8<>!_ <4RB5XT1?97P\OF)8"?':-+/8,X 6AJ+  +SBU@;%<"J]7NDEPBW.<
MYX L0I[#.4XCPR1<@M# 2,&9I^(E OZ8]S;<?^_BPJ3A7CV^V*^P0,(!KT!*
M#@X'[*$=GS72WA-93:8MI;Y?HZO=3@B]6-O*)06]>B2)*?J>W..-[C$!9]9Y
M+)#"VB*N,$=&!XNTE=2*0$*A5^;F/:39XK/4PQ5LIPYR4D5[K(IZ:.3WR]]-
MJW\/B)X,\:$8XL(PXG*B$*94(2YRA@SE&A7"X((*&PJV,C]"8,[R7#(4 G6(
M.T%0H31#RBHPYRIX(M2+&&+%<#+$?59%*1%^X-[Y;[ZNWV3:VNGYM!U/Y3P\
MARUU%,8]":VE,'@*@[_:,/C/:4C$MJI!;1P1EB-JX3^<!X*4M 3YPGNBE/,^
M7QD9]Y"XQ?&U!GV_H$#A\]#'#X"@CL_'(#S_K_E^([K:$;#"J02@3U;^&<5@
M>P_'5PO-]BNFDL!3 D\)/"7P],+@216!>4T%"JSPB'NC4$$X13X0++QWV@JS
MBUA3K\ 3521!IP2=GK5&99$UW=5VA[X69Z>0!3;MW5)X:26Y91Q17X+6RPJ"
M'M&H(=QX&D?I]!KM]5LS/*:'U)-VY]W&X?X#Q@2T.J"5LT(1Z3 B6@8$ (HB
M[>*$.FF#T2P(IG8RRG0C<OKL=P.>BAXG]&Z5G-[#I]ZZQ*\>S>Q7>"E!C@0Y
M$N1XW9 #++63/E>(4Q[C-#I'ABB""!&>4\R4#D];1[0KR$$&@A<)=!P8Z%@,
MN<#G.-SU;^L'L*?)N=MG"-]AY/2C:7$X(Z<7X\^9_W'A1[7/ONLZ^_>4*=AB
M3:C!/#<8-*5C$G'N\^B64B1C^D )@4/LA/#X.>R+[-EH/>22]1!;K0<^RC?:
MCCU?RAE<8!A9%,.5:?EN6[Z^8%R90B&O(B(*$A8RS1TBV+E %2=&KE0)*:D\
MQKA !:$"\5P%9*SAB,@"0!'UW@3]#,N7'OSRA=?/)F<^N_*ZJC,/5LUE!_*.
MB].4LSANLY'5Q7%P>_Z"@ZSR]86'A7GIAU='Z]ZJCX^=+<'2=:@3H.E?X?^[
MTJ1SQ=3=9=9ZF'+%C>)(RSB%H. 2&:X%*K#F+E?$*[,RA> ^9E4/+ZN8?:^F
MWOU6:E,.RTGIZ_=E;8?C>EKY4[CNK\.Q_==/F0?U=!&Q)1R\Q479CC3)ZK"]
M_D+-&R,?=[O$\J.L(WSVH869]<ZDXTD??$DVUHO @]R<#2*@L?)<%!RYG(28
MYHAM/W% N)#8<5-PM]KV\R'(\JL]\VXZ]"=A51Y.H_MY3U&X@]LE]T@6GECA
MSD2A\[CJR-"ZK.-^E'%HK'\8#X?C[^7HVYN]-"(I2-%18A;3:4(ZZY(Z>CH9
MS\)F\2$CR_';YG TU%?CZ01N\<.[M^WM"&ZHV)T ZV"H+VK_IO87NM(3/R-0
M$PQNK_W3NE*>R[(N&W&_>C.[QH:"GO:V,C_"4OPETG93>+%[OB-)Z9V.PW<Y
MBAY)T(8+_^SNTKM]4':$.=O!@]Y2>Z4>6WJUR[W3:?IQS_:UOQPO]FG,O$QC
MYE_%F/G%:$-_9#2-FW^IW?LO;SO[I9_W39Y_+D?@&HVGM1ZY^C'[_@Z:J_T1
MQV6K2Y/5?156-X;U^R.;R=HF]R8IVJ1H#U/1DO[(9E*TJ2E9+^HW]S ;].'\
M8CB^\AYT^'G,![75>+$TPOB1AV.?<T[7CFQP3Y([_=J(LM/-\3WCQ.%N+]FQ
M!*5-(SU4P1NZP >!-:8%TD0IQ%UND3;"Q2%IN59&4A9VT@6^*P>8V8%?.ZW_
M;EI5NVKS(0><R-XV^NB9+CL8 Y*,>7]XL4\"D(QY,N:'9LPE)4%Y#J_AP!SS
MW!1(%0HCCBG):6 <JY7BX@=V]WIZ8Z[DYGT\29?UP)BG.6\''K3Y4HV#KVL0
M/#W,@O>/B=&\4)XDP;HT5&,_B9Y0V?XIS T]5TTP+!B.=,$TX@8#PC)Q*RIE
M7N@0N"]V&6)9U-H?06GO$I4)T=^^'$D1)4N<+'%_.'$P1$^6^% L,19.<0P&
M57&:@R6V 2E&,:)"T<($HAGG.XR//*4ESIE*EKC/BBB5M!QX=.0/7WM=V;.F
MBL7Y2S\<-UWP^A.Y[QF/]PN:I7CQ'A ]0;/]TYL;IOI107!.!=*>&,0%\T@;
M8Q$A03-8$S2W*TU![A,D6>R+,]/<QR/W_EIO[S1.,I#Y3O%9TD;[KXUZ1O9D
MCOO"B8,A>C+'AV*. _=,$RD1R2U#7#&PJC)XE!-3$.4\EU(_)E+RO.:8#43.
MDCGNLS9*Q20''B[Y4HVMK^O%2$D3.8$+3 -(Y+0J1]] H]2/V@J4DEO]00\I
MIKP'1$^0;?]4Z8;DEN,A9SB@HG >(!N%3U:3..DW8,^IMP79502E4^8+< W
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M3&*<H=@L10GFC/DXKK[,*3OCV_&<GJ>^.E]R]5'M[1LWK>( G=J/]E\,)F=
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M!\7$"EP01&,AN$:X '3!M=/(2$^1TIY;BSGS^L6#2Y*0 1,\P86#4GFI*NC
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MXG(F.!,NX/WMKT59,2!XIYLHGU=/)L39$X79,[(G;+%_V*+?X>4>->]*X.0
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M\O5L--'?JW']V,(#-L""#(K=]H!/VFO_M5?/R)[,=U\X<3!$3^;[4,RW*&3
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M>[+F?>%$<OD3'#@TE]]8[WBA"R1$D(CG B.=QZTO@CDM<\$)70$PO7#YGZ!
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M[&.>2XLER@OM$'=@[I7W#.4^>(XMQE2N9)E>/(3T=! !'ZD\082#A@BI NG
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M/S.5-U[TV@1W3Z";AUAG2^,8VJ/L>+)68^PAVY<8LSAC=\_?:]#"G#8(-5I
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MA*<]+W.NEUD36 2>(*38^G32;6RQG?9:>!V*%^!I?]5SW9W<@M_/*O^QK6B
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M@R"783N9TOPH9ZD%RB302VIEFM!+[)28S*:/'KTDJ]];?2'RPJO<(H&91]R
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MA12/;"9KF]R;I&B3HIVFHB7QR&92M,_EUCQ^[&YJ7_G,M=U[E03-BT=(=FH
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M5%W_&+"S]CS[5,UFF?$9O%@[>A[>KNN_$3IQ'*)WW%V]@ K".;<<86U*P.4
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M=]&9&X>]_O;^Y6;2K=@^\X7R+TRXQ7<>]AHYJP?_?18(=QFVLG-0075NE&:
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MSU6!@3I7O3\VW+8*R;1S50LK9YG;]&\XY.FC0:W&(\);7PZ"IK[:T^NK7=Q
M& ]KJOTOP&>F=E?_\2]_^??SY<7L/_Y_4$L#!!0    ( /1#3U:>7?P%)1<
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M?ZN@S";J\C#80S9$G$E3IV>+;!:[,X4W>4V\?ARQV28,AI1SQF_'U\N[6>>
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MY*]!K.ZM+?'1=BU-0#@( A26@1M:P3-,,/E#)G9CN42#!N'0PG@+SAEU4<W
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M_7WZ+23)K0H)W$F7&+C$ZPOU@R\_W4;#K2WDM$P\^/\W8$I+1%WK'%8#4<_
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M!9.B1\FY) E=^ B<4\YE3.C"0\WOY5P.A2YXU'UH[N55Z,*H!V><>^6>M2U
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MS(_8 %;J9R+QL.0$0RD00BE#P8A>X,H(=5&S(-"7&#\E, ETO0UCT";T^5[
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M0KUKR+U<L$-6Q(Y?R;W\KF;3+W!@N9>2=8A>K#K"W$NB:LS[CB_-W624PD=
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MFKJ&-UHX_4 NU*JG:_F(B=*JA]%]N>(/("O4VN$7K0&P-K6[MMOQL&(R>?K
MQ29-(=,SML;</G; F^#-JT(E1<7->U7MI8W"+YN+L HUJ!4Z.)2GU)6^YE=
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MGVBT[.4M/9"(LR V%OW(]DE!E+/Z2(F?65$C:"JTA]8X]D$$G=4OPY?RMF2
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MLSM-\&O&DKGN0K[;BX;Q?@@BUTROX606"RSC88,EWMS<A).[2$<3+Z:V/,
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MZQO^R7L+UOE:]G%AQ4&+J.B95@,#4'>)#R7I#K*[<O[WP^UN>LAEPS2:8I)
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M:6JO$3'[&6+&!15!B>[BM;8'W"1URW01T>Z )Q+]L_'J:GO"G*\[\FGRBO8
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M'B-]VCA;8M\)=N[C0NW0@]"VU2KC;)6;#K3R-GK345X,RX&X4]::10/E+A1
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M2,)7)+9QD"*.'"[*6O&.,[&)C2_%A2O0,R)9120/_W)00U4KR=9!V$*(6(G
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M,P,6'>ZN=YH++??Z*.B,<*.RQ, 5S(]Q:*9^!-&3!B6OM6Y"E3*M_],@\Z!
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MG_'V7R0^3>[C3[$?K+9XF&"SG?B5X=#?O\;WSW&>PE%\_PI?R?9\;;*LE"^
ML!6@J<S7P,#'>8^>Q4\DQW5@S]3WQ'(5JCN9A/N* ]9 Y"((7T59.M:3+5R(
MJ9IR,V#W6/3#+."3A6\7<QT/=1T#!?;Y(XU)+K3<_9CR^,+6ZFH;JJ'Y)D"5
MK-+="#&TN&T<@BV+N4'68TYB0S(-=Z=+%%$+(FI%SFK(+4JMYGP'@;PHYCU)
M^$MBNERD"/,GS% %QOW=MFN.A&'2G%/?@0,[S!P[-8HC0U*P=&?.E\LD5[W6
MAF5?"EI%\,3R?6]D[97[6_(@@R6V,F*-K+WD7UN"T0@+7U,[#=+K\2$YN!"V
M9-B_D8=N\>V@7PK4(D[9>E*E.:;"/OP< R.MB)T"12RPS(T /&=XY[(;[:!B
MAS*"NB0Y0K4#3^+@W[S6\&]8*%%D<X@32R-K,:!HAZ&=K!J+7P@O2D[OX_GR
M'WF0T,94N4'GF9@%34 Q#ZDT#IE5FVG8/N.L,1X>RO-1,5O;6/,&UO#L\;Y3
M&[U)R@A8)GW2^#['D4_]'(9A0( K&_4%[EC ;MT8+2VG:$K<"1HPB91(N[(L
M(Y_9[]':8KL,#-PW6&*V>VO>TP@^[:LU?(8O;-LHP_F6!NO'',2+OS729I//
M18)BLL)JQG[DVGR66VY:Y5J\4,&M-DGA+2*E:>PVXK3*J_[][?]Z'33Y@E,G
M2!<KY2>RT<YL1M@L>+NI>8Z0U4IG1<'O1O%+"WX+-]@C3FII)TLHX!_CC*I.
M00//I +Q]P6I%AT4;!T]1I@0NU L?@'[C"W>8J,+<VO7MU6C]"VFWZ&6P(W[
M<X:QRP\^;O1_IJ_L3X. AZY,]AV5/I!C$\@.UI\F!C87;]P0AS:;-%OA+-2U
M34Z=</+B'I>O#!L]OO(1%E_?A9>$ 4TS$?X;Y(J6M%3$<@3D0B/K+V7F59EP
M:_]PEX__]WQ81Y#^UJ+P;Q4S3L00'"J($;U=#0<'Z^549(BQ40S8[C/-%JO+
M.%G1(,.>XT-\8&WG"EM "1& CQ:8@)_Y!:(MQ'Z/E)$EU>/PW5M(7XYT^F@A
M,Y)OX&?,,16P!5HY?FJG)3A3'NN=/IK#ZG1;#!'^+"85K14Z8^HQI \;;!7)
MF]<O5EJ3C@-Q(RM& 5L'J4&+U++LR>.6JZIBW$9XX#Q<<D7O$ZOFDJ=BW2AZ
MO:%,S)=NR^Z8LOCE5\W$R1V:^B)UKR8YW1)]G')\,K'KG>V)7"W!Y1*Y7K26
MM!4+(%5;)NN4I5[%%#ULO]H[/2^](&%'Y>E6_?CG@":(";6]1I#A 7V1D:)H
M#ZEH,I/D\_Q'Z\V1[7!6 @MH8<_B?5>[V_GVG$?^%>O6#5HBNJI$2P([@,DC
M-UNPS_9.G..DYIBTEF*.A:7SW ^R./GLK0_U5@D*!$E8-$58_<[ 8(PH81JC
M4K+SADB;K@AQ[&OZXE7$%<Q*"S5Y:=R EG?HR],_N*:[.46=J/;+U#'+TYFN
M?*-33&KN.^W8U)W-5O[K?0=U+0H;A*2$:S/#2,"$14_<W,=.UH?GQW-*TJWQ
M#HE]/>FEZ]8Z/D]62;PF\0A0>M<T32E5++":5KX#[^.+MXQ&A\8J.>$9*5X'
MHRT_6<Q-X?2/B3?]JQ'LQ(H=:ID==EP\=BO^CPTGBNJ<(&,NW*=L\?3N>WBK
ME<UVVF5^\>*LHAP6 A#SE!N&7G!+2>1/_DJDHZ-I=LCG5*%G6A>1C@PTL#&0
MAFLT2F^?H0LOUS?;1V72&EE>!Q&]RNAZJ$.NJ 6V5UM@8MEBC^@5*.1GI$88
M.5M)7":6WE1!8WG]<IN+I.B;)%Z!(@ OW0LOZ=!4;YGDK5/%SB=CI'J;9:B2
MBU-PLZ*V>Q<)+^2/,:IEMVA\'(QPK7EG9X03))SBY%EH<I;.,',%^4@L\5&
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MYDTJ[K#PA6I)HA0W/1FT:W)-=2>>.K;>PHEY#),P/ZSSWVC;HG6%GD@'DW5
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MJ#$$L7T$ Q(#[3<U3U&@'62I'F?6P]1CH*;4O&=/KUE5A&GT]$Z_WX'^09E
MUMO?LOQW5O->3TY+H\]A6FWISF>:D7C_BC[X#7]#83L#*/7U5K-6.IT"MH:X
M,:R&EJ1J5"O74?NV[.N!*M'75I4UI/S2"3(9JRVR.QHB;R0>]-%A;S$:H*[T
MJ3%C1F08P%MS?%\0 H\*7L.;!;K>YL 'O[-%H@_OA2W$9"F3I7Z+R]>KJBCI
MNYJSW<[T9V&WZ5<]3B"#>8Q8PC_;@2!/A3Q1,JF@*LI 3*NC*9R)WY,>V7AC
M^\)'$4#4K0!D<963T.8VTW_#5OU'7J':BM_2HQ>G=-6GCS3N&^P,D4W:0LFI
MA+#-]72214EG"Z;T#ER:=C/,K\8POG2'HLSP848KF134^D;#NIWYF19)H !3
M*6/W?9QFRS +B&P&9U !=AX=Z.%C$K,(UJ=,Q"0_Q00,_MDA3,!PU-HG8XAA
M1[@HD%)NOY4?5I2B9GI2*Z>X&V!O%$7,/?$E2\&\Q91;8;9N?6I+&^P;N;9H
M]CCM$>6C:U$;A1_\CVETW<!W<S;"7EU>MI+K&568@-'#'>CA;KT8U)">)%)K
MPW-]X?1[6),F.6<<!&G2IV[ >/B*-^3O;7C1>BK:O !$O'L[=+5?B"%[)0W,
MTQJM1Y#%?M(M>67R;^+),O9U&@G_1&'?^/!B6Q]Z#^.<ZTTSI&R:Y_S<TZ:
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M+,,"2G?:0(Y/IX(=@4"OR@V$K-I-=AT&HV$]ER+V#XQWX1$4N1'^TFGPFW0
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MP^[^L#_/'<U1/2-I1/)W4+[2%QE17,!<XZ*P%FCLZX#H)J#B--AG'@^[Y\Q
M"&[]B&]..*X6F\.J<!P1='G]N=0,9HW2IOUA5<?T1V>U$?<U),Y(:XD\_<LP
M 3?4XRLA"M'#%73L:HM_.3?MN%VVWX[FV%K2E 4]'^+B]QNJ!ZB4S#FJB-H&
MQ8X=Y@$VA7#Q=^>A6%IB3[]Q]S5NQKI&,(,4JOT7\%!P][[C&$Q"&%MOH_<1
M)&\X$\>TW['/MC*&NU">+P_&+_U6]2,(+2*P!325AIG4"GM\ LCGI -@;VIG
MJ6LZK#O4=T W_'=:"JMT9ZYSAB3&;9;2T].C3+FZH==A^(TDR5_2[#U]I$IL
MEG* ZC;B;F=C5' +_GP_93*S5%MTAYVHOPOR=OL6YC'<?<*N4%C?_%8C_#/2
M%$X'V\J']D5G,04'F(B(I0(CMU0QT;&=M5ZLMUM=[X!F=N;'4L46$+P%A9G0
MDY/J $>.O=27=6!!EF/Z+WTW.:'-K!]N\BK,TPV/FDH'(?W;*HW8$\*=;SR:
MG/'8>C-[VB]]S[B^&<?Q7&]K\/(A1G*/PV'K[./"G=RY8),0QG[^PP*<.O ?
MN#_?PL3(2:RO4NLK/[0SOL+;S'6"A[%.WCX&L-/:M6;P__QSS=\=_=>__Q?Y
M%_H_SY3"O_]_4$L#!!0    ( /1#3U8Y;?EC;4\  ,D6!@ 5    86QV<BTR
M,#(R,3(S,5]P<F4N>&UL[7U;=^,XDN;[_(K<VI>9LYN5Y:SNZJX^4S-'OF5Y
MQFGYV,K*Z7W)0U.0Q$F*]("D;?6O7P D)9+"E00)$-1+7FP #'P(! (1@8A_
M_?>W;?CN!< DB*/??CC[\:<?WH'(CY=!M/[MAR^/[V>/%S<W/_S[O_W3O_ZO
M]^_?75[?W+V[ Z_O9GX:O(#+(/'#.,D@>/?/CY__Y=U_G3_<OKL-HN]/7@+>
M7<9^M@51^N[]NTV:/O_MPX?7U]<?EZL@2N(P2]$'DQ_]>/OAW?OWQ? 7$'CX
MY^\NO12\^]O'GS[^_/ZGC^_/_K0X^^5O/_WI;Q\__OCKV=F?_\]//_WMIY\J
MW>+G'0S6F_3=/_O_\@[W0M^.(A"&NW?70>1%?N"%[Q[+C_[?=S>1_^.[61B^
M>\"]DG</( 'P!2Q_S,<,T0S^%I;3>$N"OR7^!FR]V]@GY/WV0V4^;T\P_#&&
MZP\??_KIYP_[7LP6^'_ORV;O\8_>GWU\__/9CV_)\H=W:#6BA'Q;XB-E\[>C
M]J\_D]9GO_[ZZP?RVWW3)* U1,.>??BOS[>/9)[OT0JE"#7PP[_]T[MW.1PP
M#L$#6+W#?W]YN*D-XH5A_!) LI@(_8]G'W\^^Y!Z;W$4;W<?<(\/#^B/;R5#
ME'_/HN55E ;I[B9:Q7!+L$6$DN]M(%C]]H,7OL#WY9 8H?^M/%"Z>P:__9 $
MV^<0_/!![X0>4\2GF("+^=WC_/;F<K:XNCR?W<[N+JX>?[^Z6CQ*34=^&+.3
MN?<@^O4&I('OA9IF1AUS\&D^+M"?GZ_N%H_SZ_G]U<-L<8-^.[N[O)A_OG^X
M^OWJ[O'FCZO;^6.'!57_1D\P'*B+L20.ENB_R_T/D_GJ8N-%:Y#<1(]I['_?
MQ.$2G0]7_Y.A#2::OHZQ+9RV$N=K_Y#1[7 Q>_S]^G;^51/G'PUGQ^0TB3;Y
ML?N<]D$MN_-2].=\=9XE00221.YT%78?AOC';+OUX&Z^>@S64;!"Z*&3WO?C
M#!WUT?H>[2P_ *I34AMTH(EN8I@N -S>1"\@28F44)T69XAA)G'M!? /+\S
M9^#A_[>9!7>,8:9QB[ZLS%3U3L,0>@_C9P#3'=9]T='QC+&Z ZDBY8)1AID*
MVG\P \NKMV<0J8//Z#W0UGW&9SP$2WR%]*"_N8C#T'N*(;F#(%1O Q^3-5M#
MT&I+M/_ ,  \@!<094!Q5HU> TFH+,)FC1F$6/UJ)9_8(_0TA0HC'.F*9R+J
MI3H/M$\P >=(2BXOXBW>J J7?<E!AIG(383:@H7WIBRG*#T'4@)!>ALGR3V
MCQNDBJKJ@/3>PY".UGD;Y-H,$G7H/H65-!"UT/LD1AI*8(;X/H@N!>EN@>1(
MXOG$*JDL0?G#]"Z/KM#(\0Z <Q"!59#>AX@&!8G$[3[4_>(I ?^3(9:X>FES
M,C.ZVW0YZO62--!E296LA?<4BF?<;51S]T*YV2D/9/".V&I&$B,->5]L-0=:
M5Z-WQU:SD!K+R#VRU72X8PQZI6I%/K6O@;N)LA 6C&#REM).Y$H,-?B-I=5,
MF/V-W%Y:38$[AAE+_&RY##!'>&'%9WT)4B\(NUKI98:V24G5"(6^#UJBS.*
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MJ :6ITIU[NUGS%&B@TGNJI1D0$HQ<1P))B+5U<"4JGQ_&6^]H!D>SVEH8@4
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M<R;V+#KR2J&8SZ(,?^(SBKB?D6QYY5.+G*0R@)=YD#&:FSS)A!*4UM( P9]
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MM2"HWM;$7;NIPKV!"O7QNKB+E?J5I![8*(&TX]NYU:VG"J+ZC:(71./4"^U
M5'#OJ"5%U*H4.,ZI0YSO@BN8HZ^1NIX\+(9W'*Z^1:?LG=EQF%MRI>+J./I0
MSCBO-DP96F'^-8<Y FO\84>!%II'AGB::-!'O3_VBP._[J3>GSVY4H#TJ-O
M>T*'?6[XR%6$67IP63>TA9$YJ_?S.. C<KIPNYAWT])7K+),J,%=C,1)==5X
MSC-]XQM)D'0<D"%87VZ7:9IWAZH7BT .\#LH>BH#1H(#GC>GTY &(/@<1V"7
MQP!=9ZS0 D%C0P55CV$4[#-!)VNF09'W2C.B]3=1_?H4EN586-;Y;O_/WP,
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M$)#,ELL@G\I-M(KAEGS(BL3<.7U':DC5N]ELHB]S+1[XZNTYR+._?XZC%,O
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M'R8O, /P>ABX!AR6Y1KM*FS!#Z(LB-;S9P )W,5R59<(_2-) Y\[P78CC@,
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M.H80/I+#98J2 K?KO@LS)<DQ_ <&?6M7%.Y!'5)5T/?:/^V0C)5<[((-+]'
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MF=UP R:V;&?:S3_J-4>&T8D]0C1'C9]02P,$%     @ ]$-/5O61Y3\V"0
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M!J)XT^L-6M86T&YFRJQH6P%^"P%_L!6 ']Q#QS]- >:B"L3E4<6Q@,L=L^M
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M0&PF&,GR-BC#$[JHR Z.@4L^YE,\S^T-4:]E7KPY>=-KV1=V_@=02P,$%
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M4IJ;IUY+OYUS\J;7,F_U_ ]02P,$%     @ ]$-/5HE\P1\V-@$ 6)$! !(
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MN9I&%TD</;W794#;VMF.(-!IB*'DASP?EO17 JLS=7%\EJJ#GHN7RWVA1N"
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MOU>@:V>2T<_-\4?IF?0+?9HS)  ?#G*YTK 5*5^G2/BX*__CQT4E55Q@!X/
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M0N :[UI&:UO*Z.?R-U\/>7B&"U@*I]%L+?VWVO>IJL!J7!^(]'+-DE<75W-
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MSE?UA"IJ:D)">8;6RA.!*Q+ J#AJ1]Z@'/$UO128H#BEQ,*47B(7([4I\N^
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MXRCIXO1:Z+\1%=/!ST)&5:SN(2(!+G'_, C;T?\3+HU#OJPQ&[6K(CNBITJ
M-/"(GKZ:O8K7E^)_+X5LP91AUDO7I=<6&@/1)0[ 9T9J6\_-0UQ) "/#D./,
M"QEG>KE^T^N.3>KES"OE GE)#N7XRWD9['M_<+-T@#]?%Z<&9C?W8?':5!*Y
M9ADA"JM*EP=\R27A#,$ELULD2]9T<9H?%VVWTC]AHRQ[.^&*%6+JJ9^L=EPR
MPFK[G]A[Z["XMBU?M!)(",&"NP0)%D*">X4D> A!@FN X.Y:"01W"!"T<)?@
M#D$+=RW<W:VPJE?L['WV/J?[]>G^WKVWW]?W_#$_OE%SK&%3QOR-M19K[-HI
MO3C8DTIMVU;S.]EXV_Q7I4[;H?O3$X%'^W[P^V$=(_,0ABNH1[3\%]76O1FY
MZI-B$Z]QC7WO']"6S,Q8424QE,B..U\N)B*OF0\=8Q>U9-[#QR,6?=<8,&A3
MW3FBFE&2[=04OD7S,^WY#M?6-!SF#9I<\OH4>,<2'78]^OBBSK2#,ZRE9'KQ
M+#,?AENOXE%(RA XTNL[&U[Y6+1E;P -)86ZOTJ$;T;,)=O9<NW^+&:+"6Z#
MDG\G,-J^DOI(%/S[W:LW1DS#05HM$^9'",!=8_6J$#VP*%E;3*ULR=6;"-T?
M3YU)M#E':GYN!X_8.UO6XQQJ0YN?U0^P' FZ4(K*TUM]MN7<F(+D%,4N *]]
MN,&7R]3PKV8X[3I'&@GP%I[Y*P:SWEFIUYD^%OB"5L%PEKKAG5TN,U)UXCI%
M^B,ZO4J4S^F3B>N;H:?KYR(D!^4B^+P1SGG,W-'^TA:?+]"WWMLDGO6[GA6U
M+B<'6.]GF]ETJ*.^MN#$6>!GL-NQG4$ 0O0W]@_2/,A('?@L+8J][CP5S++H
M16.07M%-CJ--BY+/2K0Z0JL9<^9MXU7?;Q&V%=Q4UPAB-?-WGS OR_XF'>GA
M0G=0S'^ XWM*32SKDMZ<QQT#]HG? &AXHC_D63'*W;*93V8=MT\ 8HL=M*K7
M'XPJ2)@X&5GWE]888=+I>4=:FX7 <!& QPT:\(8H!.!51J9QO_R@XYCFZFI)
M'0QTR(*A:ME;;"'T1CK=ZGN(ERCI'CJJBL9A<2NSE8!SN!:G<&^NN>Y4R^=@
MNT0$H&Q3%8P/7"D$7MV>5!].I+A;5,2 4)NY3*6GY]*[O@Q)EZX?TWAROY.+
MQ]MC->XW6HQMK:[ T&)M9U2P=R["N$E\\T"0 KE;N[NJ5$U$7#,>5H:8I4S!
M7+<<@][S8D8\#O&/<C.PY:-(M L\[5YMX^=O_+AL9NR^?YCEPG X&1(P19AA
MZCT9"8HK]ARQ>/QC>)>-[>>CYH?BWS<_ PA7P.3UG%PA9DN"!D9O1*UL"8R,
MNU@@TY'H"(!C <QLF2<*S6]W85ROCGC\T+_GS9>V21*TG&;AYD(C8H5O+@+H
M@KQVH;"JAR8( .YJ\O3#(PF"W="!$2!L@WO4W?'C63*U;:8,:3^.)5W1NW[6
M^0 $ $^V*R"]RH5P=>^QC\UGN5P4:D4MI[_<'M7*?L?N ']S8MXYXDDT"_-K
M[BG6-&-GV(FYVETT?'J7J27UHRT?R?*7?3F8<+[FG$PN3-MD>B>6)_308+W;
MTL_X'%-N45V N)V-6!+FA)TL,N@@X^;H0WL$,UI'<WIK=WI6@ !\@7*-F%75
MMHI[]J'>OZ<_)TYS>/+>[I0@8[5+!!3.JJ6Z[ #&R(I>;EVLJ#7!W\5]O?ZM
M^:(E<5FXRO6LV/#' 9<G^H%*P'+HS1Y\S) .;^CK="7ON4C%&C((/1L( #%]
M4PS/BXO*<RG(_(</_4!"Y&Q4![>[ @/K"9?0[1-BOK_68_K&9>XC%?*#GPJ2
MR5*:$*PC4;T4/;7>A$0>O/F@B5+0QH>(O#E3(+XGW;/(9_&L[,+#A/T*3(,4
MC8(E #"$L!B).UZ[5MVX,<)]5'D4FEK# @WW%VRL,(NPFY,&JQ^K>3C3P%$_
M-"UU%>ZFU-+J$#NKGR^&%F>;DBGGLJ)7F4>1JZG91.MB/^"G+G25"#JU*78G
MJ!F[B\K+<U!'P_]PSO0N\+G99UCJLB UR:Q)C !+'Y=UC&"PX=M0V!TE*C?/
MBAGG(,FH5S#<9PG/[QI;+!T#^._TYO4".<SXM7+XKU7(MO4'W-$7^EY#R S;
MR[:Q3#*A,M5O"!H-]28L7VX(K%_$6WEAS?LTLK9G%EQ]KG5CKEQY&M2)1JU)
MMOOWQ=FP(+A,,P+PHPZT(5YN:ZD8!&VI#(B%\VCK  ,+GQJYX+^3)%Q^+Z+0
M%MZWYPQ9W%?W)(:!%CTDE'^,U@.7 M8T'/'D[CQ^LCQ"8DBZ<#AX8)9V6!5X
M3?BD& %XL.^_"W5X,S/QT,>GCFI*YSN%[F'RV KOMEXF##H)8X&O;;[QUW54
M()%\QX-]1V_0?IUO/3?>?3@KK?S:=R=I(&<C+?"X[_\S5/\_T4HJBA\:>]+&
M,SM8"#_+")!._:3WV65'S'Q(EB=ID"+VFI7]/C+8V-17%XP( *%Z"4SE39!H
MU&L95#)S/[OI/7/\<-=UX9?[&@2*=E&S@9T]0^Z"&3!'TH_#YN/C_*J</I_X
MZ4)7QK18FSTIA[AQJDR@!H[GJJQKK"5\PJZ)RJ<$=C+5JBWC0I2+-YZ'EJ>R
M/(()/J(DCHXD[Z50O(1EM4?M+8#*P_T)'N9E:DGIW?1?CDY6*,X(/0/YP3:3
M?4/E6.RMX\,:F\I!%@1A#=&JB94ODJ5V[BD.UQ,OSN*_OW),RI*P<O!J_%B'
M[SV1VVXE+\%5YQ.\:_1J^%K4Z$Q6N5LP1[03*USITNNYQ(*9X,L#H%\]I_.Y
MZX< W\7!#@-.P:0,[V \B?>L:6D^S QF&T0ON <>&(O0&WJHR 8NB9&H<<C_
M/)G)H% 28/]2SYWREG&D/$?!9E@-/0)2_?0=$%/EM1C%445Q2D&@>E9$]K8C
MFV&N.L3.L@TO5 !WABKE*K!M!$X)4WRK-CXM$71^6&YIX&A7X?O@7@!=*%]S
M45H@P4IT% :I*[N?/1B[]:FZ;#P4PGK?N@!";S,3/YH6*%NYUV'G! <<5&9[
M<.^N11!4<?)LTG/P/06A?&A:5'/FA7^V1D*Z+B L;]LX[RQJK]W 2'-#W7#.
MM_;I6>"E;4>$/P:%Q5L+TGYGJ.!9EG$CY;"[(&:)"8^9&44!:4L9103$UDPA
M,-G(3-/Q^2D8;8.*IEZF044V=,T^6+RHO_4A.M]"Z K<H8Q "I69P*R2ZWV>
M,&!!<2.U<NP[Q5[5@@Z6L^_"S): IJTFKC<+ISAD2RD8SI]/QOC5'@>[Q(+U
MK>_<J^<&J_-4"=^CPLS'QP@N5LUT1-4(N"V(92<L1'IRI]H=L&V)1 <OO4>I
M,_4VY['JZ3)G"\<JPTBCWRGUT'42;Y!$:&D1,'>Q/B$2DY5X6SJV8U ZRI9>
M70EJH/"FV][Q:-<SH<81>I%J:I*S>6D3N"5T86D446GPR!I#/U78+.=V6 U:
M.AXZL[>6;$NHRG*\R"%].^=YUG_<Q=<O.-XW5LY;&:4^TT'O9?"B,V3H6S#N
MA5*Y@JV5(V?RB!#68B'Y^U $0&[XH]>6T$ZX(%X-B;#4CJP]E_SK*+<?_!:*
MBQ,^W$%5M77#=,>S58+M=)#J\TX%-.[\=&<[B8-K-J+H[%93\GT.S#(/U2,0
MOOHWY")2-E<6%2-0"OXYXDZX.$NG0!;B&T=!;%:'Y_?1A43XG>#X#8&B1<//
MYO_7*2Z&596/DC1^C;%8_&B&/$E")E3&Z[FAN/'DC70$&,*M_^8@],OB.%NF
M2?ATISAF8MWRB!V>S6X\- TL5&BVP4J'IGU@Y'<MPR*;M]G%U?F<0=G W!4O
MP\##E/$ QR=C).V'!=G\SA"__7M52HB7#$JD9\:$!'*62T]@T))KJ)H7+)17
M!DN@XA;8I/!#\YZCK;#&C8J0.4LH-IC5A3Q&[9\&=T<O8WJTA -9MIE2I:5F
M7TRV-AUX?LE3G5+3WNSB;@AT<>SLGZ_3O/-9M&M10D>Z-IX'3!5H;U\IG_T]
M6$3\'0_5@WZ[N>(AF;AS#))+=A][.>RNI_&R7NKU/Y_ZJ(4N"#@\2:DY4/&S
MX@[;-0OAX&WB>)ILX]B_VH'-&=I2M9$]P#JW5$K*]4*SY6  3P8_I"@T-=HO
M%:W0ENV@K#G,9IV25!2^D?RR*69'15\,-S&]#..)0ICD2.KP_%O??I("+3(>
M+X;)3%7=DU/*K>2@15F<UC*99U'9F061.2HLO;9HPEV%\<QVPD6") )A7M>"
M^:9^"HTC=/$'NR(FCFBKFS_Y=E@_K4$Q>DS8BO2D4B(<ZVV9#/4V1'.-4[L:
M)BE"BEO9'TR9RNM,;XHQ!K1%+"V]I4,)?SF[#5/1$B-8999Q)/HQ12>%1%]B
M]KJO63&]A!\4O=I>-/*VW!,Z&QKG863X&#<D=XU*@=-*.#GTQI!IIV6"R43@
M25RJND>L3&G@.,6*/^2IA]26W'A]\?+$90C:S28"\,UAQP&K/:EB;KY\NI5G
MOFZ-QMR#\\.[[*>C<VFF6Y DF.)/;=*):\HT'5,!=2E;BPE[_UU2=P/W:<F!
MT>-V5RP?GZPX0\*DD'K'LT-,>IO@.XH0"NN.DK9 __0[2KHX+4G2=K:N/Z0[
M1.H6+8C;2FA-SW!G+D V1Q\F-KI%(572Q>DPQM9+PJ353)^P6,(M%Z?'F8['
MQ*BZ*X>M5-^WM>X1U" WAI>E+\IUD,F*,E[-/DF8S2#Z58VR?CC_GJQ,H;.5
MQ"$!!G:A'N%P]BQ;>,^)GA=08#0MU$3[?-21?Y;X9R/9P6EGS4AY]7(U:5M1
M'QU.ZD<;F')'9M;4UJ5[)?$!^J[A3^<N&IX'=-G"+_.5WJ],U^GILXL=[$4M
M3AH&295IJ*[J]A-^7PD5C/H@X74MP%V\^R5+XB9U[>)VLX#7=-AHC,KWL>T1
MO7!H0C<6H66!%L5AM04^IU_5Q)%%NKC\H5SNKK-9Z\3=]7?#RS)?ADU(,_1.
M?DL1$K^G"*] IER2__J3"?]'VIW7O:#]JG6)[\AL8M5?>('$0$ZG7"Z__MQ1
M_%?GOSK_U?FOSO^1G8!I6W4.*<;D4VYN^?=ZXO<$_OO_F^N_VK_:__&6LQ:M
MZ]^Y_O!%U$L\^;>A8M$HS)U<E__)_R?RPP$!(#&AHE"HLMNO[A"KU^$$%^O!
MQE[A):P&UMW?L5(TB*!]=220AET  :@$F5$3..2O&_S G7SI3 XP@M11;]RS
MF7":<!J.>[:756UWK5"C?SF1+L>:R_9I%Q97&Y1ZPC7'/$A#+U4P>5?@BT D
MD$X.W"8@7.(OES/=OM96)M%P6(/SBO.D."&_XC!L;A"T@V.% )0IE_;HD3(=
M"[_3U'ZFQ"P0(5$*W7(DSB:*'1\!2V8JP\4+5?ITPVWYN"NRG,LTAOV))HZ^
M0Z[+ONWK=)Y<OY 7*KP)H/(0VF.7#K\*<TVKQL)9<BCLF'1P]NQ[O-SOCT]Z
M&9I^6K1'NE3C\\3K320CJ<KK<(F28I'"A]^2LL*T?9]$.[A:KGR3%S.P)) 7
M ]PV0HWW#6'O?L0?O9=^4U=9K"S\^9PQL$SM<C9H2UVXO> -NNK],)N?,QG/
M!RI?YODD1I_1ID=ZV\Q\R9SX&&*I+LC_1:]QF$%W"WWWL3F>P,T@3H5JW;CY
M4T/C/08'ICNV)8(%NB?/NA_HM 7F\E38,51%&V5K88F%#E&<[95TN,6 :I5
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MZMH^O6XPZUZ)E,HT87!T(5F-"Y42R1@Q<VK5)AP5DG-9G6:/M?0[K\(644(
M\'>O\S=,AC-]_2QWVJN>Z &D?I(^J67C_#E'._9!FU) ,@UX-&RW&E:$PWA
MN$-%?: =MKBJXG6'>W#;[GF/T70IG'!(Y9[YB(:"CHLIV*[3 OYHZQUPV$%0
M-2S#=.#Z4(NJZN#20F/G'O>#99X8>>A"V[NEN/5BTCXG>Q6"DK&5T>(20NN3
M+4BDZ<;A]("OZVYMS.=I+>P6?IXJN!#@QNQ[XPA[>9=[W;14BN7<QW"<P1.@
MCP>^O.:TJ N*J!VFW9MY%_KW/^'WJ[+C1G7(:M:4NTRD/'?+X<?K#Z</$(!
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M:OW0,[X0/LN"D1,EQR+<P.Y+EQ\3R]K"+O=][GO&C;XZ@ZK#.PS:VS FV(^
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M(&R3 L!1'P2,Y=-AF%J4TZ+3=)T;QJ\Z"G,.?J@*:Q(L!"1%^3O^XUNA$C4
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M )TA!O#Z.<("^0[U6L"[.$/@36( :;9E.D >;!;UKJ"6;D8T[^V4/IFR3'1
M4-QXGVR5R=WS7MG/:^G^L?I.^YQGH$$1%DX*['H^L?U-+O.O8?J(_!12+*@=
M[K0'.26R/&?S,U3_OW+#^#]^_LZM^K<:_=_+'Y)1;B;$H0^*"P59Q%*BMR$G
M<RIS7[ @L5C,$?DQ&T[R(\.=#O!&M.S/2K6EU L>/+ >0.;UTO0_*R%I?M1_
M-/JC5N(_*/_'H3S'-C@GXQ<Y+2U1[*TC5CY!71MWR8"=TIR.*I=!)#+MX]6%
MF"C'VY 88OV(CQRMQ!5YL%[5 RSH' ,:2ER59XJY'P\_O((%S>I/*L<[=6&&
M@K=+1MB**#!C9ZJ('3 1_$DP? .%*X"A0%$/+"G!6!"-H7(\\&9;/3C267NM
M%4+G!BQCJ04'&#SPX<#C&D U:9[\(&!Y_*(FZN0QPU<O'XKI10,$>(G3YR>^
M(FN&W6MGZ("]+8W$!ZY93'_P=O*\M+LQLBSEF, 06&X4L: (P1.8#H"[# O"
MX,$/^_:HW1CVPV&O#W0YFL 5>P#@Y$_ &UL7 " I@%WT)=A6Y@_ %P!@*$<C
MY"5_T:^ Q&> $8"*.&<(<!A>$X7:6O4:IYB2;1&9 ,_Q $KF)US%W\/UK?ZJ
MG=P%T<RZDZ<77$C0EV%;.9,M(M];72(DIYYW=0+M&53C'4Y=Q:,^L!6ED+S<
MZSDF7 $?D@-R5I)@0O)@03<* %5S+@4-]5'0;]MKWY<(3*MW!U;76/TV=% 9
MPQG*C!]%H/L(0/?X0S!\/T K]R5>IM6[2+ @X4N"P(H/+&<1?(?Q9ZIA(O,7
MN,SAXWNA1RV_U#C"@%X)P*..B%8,#RE9 7&RNS$@M$R7CCD69F=L8)CG@!(Z
MWX'AFSR4W\."CHFM8&=@_<=)0-\)BG??4^QHH9DQC "^]>S?\<F^!%3RC7%@
MT3\W=S:4V5RS^ZCBW3**'6&@#KPD>J8YGJ0 W6;?(@;/B7^$39FES,H.SH_Y
M?G>52$BK-P,J2$[QRR!HPEBTU4+L+/S*LNYK+9O<\?&TE&2"=]_[D)6-K/@3
ML4T*HZ\_IB\=!Z#6 ='IJQV%ID]O7!D^C%=41%'?(R&5\=VU&9?#@H3SD#\C
M&[0X$US-7^S^>JG8/WK^>Y.Y_MG#^[?6G,[Q 3IL).74$YALJ33_A:")$KYQ
M5Z0:?.C9M+RJTCV7 -=7H,Q0CGE[")4QDB+;@"5O68(5L0>_/K),+S]@ @^R
MSK-9_3PY0[5C2^7SY38QQ%%R.0&T:VU(^WWEFD@$)C%K)7Y?4]7#VL'Z7/6X
M@*0=LVUG(&M<P_7K9*'+;3=K#PR1J^N^1#T?W<VU/E=HF\KA40>N;=W,?<0]
MSO1*=C<GNW@0#9U5LNT]C%?O?[9K2JC\(.O132C=++'!?:DQX=:))!]'G.^6
MNJ=%+V_4Q?4+1]MPLY3$=BE?<N^^1,4:!9G7+9N.8Q@5F""R5E2RE>._5&N.
MZ)\<C:C9'C8?[7V.A,Z6V85%:#7H8NJL^.L4=4J4+BNIL@PN[NC?DKDM^8R0
M?=9?DCY7VOLD&S7!7*XG;C+!'2)87?)V+IFC "SB_%5N(H_FM#%\.EAB#.E3
MZ!Z):APY>#E?E>QAL[X[5#^0'G?_:PGK^@@+WE:<923^003($V]'UL:.>4=(
M+EUUO>T3+O.@*R7B./F]#0S*^L[&B;23;"KB:S/CU+80_S<#RPKYS2P;KA/5
M>L&0K!2)-58))SE*)^]%5KPY'Z%"LD?]+N=[?>F7$+[,")L/0S;S<3,:U:<S
M-RIDOE.WDA,:.Q*/)2GCEZD8\,ZX[RD6>/K0R@^)6>1$W+MHK-Z_3OK=--8<
MDN(X=U383.@.,H^%#-8^F'E/.[VJ5#0Q#,GQ*>;FXDS"CV92%1>(:Y@N;A2^
MWHM?TF>@9D,9NGM"0NMN)XO@=A$=O6I[['Q0<B'I3EX5TH.*TV^8U<^A_^,A
MKE9,SY=/R\B1^'";IU41R%4)YJAN^3E<X2#C<*,+LU1&EKC#''=1<<TMS5+?
M!4<BWM5.^I>8G[[M=DHZ\>6?K^8**T(E7Z[<(CN<U2ZO*8U9*V"2QX(< X0-
M0YZ;=0Q4@;@N""W>'V@A<IDA,+PR_CB.F_6Y[Q!S%[5+8%@09P7C)_PDMV5)
M^CQI]UOO<]P3E;;P@_FY2]WK"LH(#FT*GR(*F;192"UN< 8I6%!?WPK7;!DQ
MJ,O7=1_0-*2RUK10&.2*B"BK/3%5HPEJGB/]ZD[KY-^3FTJB9:/:P?]R-^ZM
M3[4<S;3)B$>$-KOP\E#@DR+F@=(C%W@H/2V"=:A,:*%R\]A0GER0UO0.S5TU
M6_!0L3#'V$R=[3]_AQ?16C.C=I?T=#HE4G(FZ^8P#^]"-T/,S$?TUN.HIR$*
M2QP]F%LP*Y^*)L-AN"FF#X.0D!UU\Q#>-CL9]6CE[??CXX.\K/8MRFO,'%LZ
M7HAPLZ==1>7I4.'-R\BIQ5S"31@?<!G5?XP%:90$LLCS=2 NC4B>BV,K>M,H
M9AS\1"MYDH%2:B:%T,!]S#(BJPTVW\#WG)'#<:F3.K9KKHAU_8")/^K?>O?7
MYP[?I&<FC03H6O%">0Q8W@VF1X@%F8LJYG)11^L%-)B*\^K;?&G1+/\\UCU]
M(X0P<C$MAYIUN]!\@HZD#4RLVZ,D':986W97EC2KV5:RM3_]@PR=>-ZK2J0M
M6G83"Y+9;.:5S5]Q8U6H Z'[\O$I20[3=K&@K  _<3*9+:+"DND<_KE0+SWA
M-%Y_QU2A<(N%&_)3_LEU1 :?ZBL&=U'6)_)BG=9OX[13\&PUJ?'QHQOSH\BA
MT8I3^HJ/ Z"KTXJWU*VUAI=RJD ,CP@93*R[^+I8E?7QI]<C+&:4S$?H-"=T
M;%GTBB9NTCK;1"<92[92,JYU? %Y:5!,3]P<XJ?<TE\/V#D\UA>5#;UX$T9<
M].Y.H2EACUAV3!M39))Y&23$I:K^NNRU#^"7?*?2>]S%DC*)%<IU81M$'^74
M':N^O6-\QAHK25\LUC>JUR'63<HV6%.\"NK@IPO<J\_.UC,<D5_0>]+RN>60
MR?%3NY!8))%[7 P_HGJ+-6B/ $ZF^UTI37S5<,0S0,GY<OF]PO0YM8#+.Y.(
MHF5-FC<IP1)TRYYN+UWD+N1'[BCLV%GVCEY@>YY*\/S3%=?89$O<[SE%K />
MP@63*,^#0+.MPMIJVP3C!-K ))_B$?5N1"(U6P8]B+K'@(/FY,OQ+H9X,^+Y
MF'6LO"^7[ZA36@-S7?0-D^>6&%+'2[;IY#CK?%I1[G8ZB _%6W11;V;/#Z3W
M9U:6UVP1%4>Z9X'F-54._-N9A)B@7U@BDN%IW]VY6QP/*[3J4U0KR\IKRRI?
MT[I&:F#(VPB%CB+EYPY2232+A^Z4L=LQE;Z50S@E>C2H"LB1\US?FPY6J#*P
MV>R\C^E&>NL[G>9]?+(Z]+1\N]!6,-V[N.*MC+"O0TTOCD'L;T>;QNZ=&&G%
MR1.+LW-66P1E.'Q.O0X+*H<=TR!>PT(8U$U#,(2G#',>/!GB[$HWE@V.MG-^
MYF,-*/'-*O&%/E"ZD<D7!!3E1U[WNV;H4OUVS!R4\/LQ-'09 .Q/.#M0;EW;
MRTXP=3WN9\?)2GX]JR3.QDFTII3MFM5_=MH,@$O)07^K8+\6E& C-  E#QJ
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MEQ+8CK&@ QC#X?D[U9/6@(T>X#T'#:I_E1:/A-< MF<#NQ&X#D B8<U/JS5
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MFC,@CE?(GW&1R$"+B$8% L^N_<*%*U3E' \-6,&[8L/HU=6SL&][V*\@2;;
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M<Q+M\^Q]T=1@Q*91?IF:_OS6YFY9639<Z3(BW,[&N.:==A)%;<B;I2"R S0
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MK)(.,V]&)8F4ZW!%K9AZSBHZYR%]BQJAS%LH^N8453@JTM?I:?IR>T7_?6Q
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MA^7!Z4YN5[OQ,/SLVD:->:,!W(,-P/=^C-QL&VY#![GT*T'CQ_@(5V!(CN>
MMS8!6X1O<:TW@V"*B?[JSKTCO;-6!);!?G +77^^;&)#O0?GT"/ TD^OC+WH
MJ4U=PVLPZQY2$'7J_6P;_FIEB0W4&7U+1L;8B#6/QUI*,'?3&/>W\=@B'2_N
M0[9IJTDOL[K:RIHHO!!3RJ%Z<87SB4+6,N::N1_[V5^* \-8LQ\7EUAT)!LV
MDNC-FEGQ!"?Y:1E]1H6$37PI?.+H'E[UT"%BBB-^!"K!"C-;#S$:E++CT%Y\
M<3?^Q'AV>WB*UTB^G]SYV<CS,'C=S+>.>]%2[#T^]DN,GPTN2P=NCN6*N1^D
M7.3-CAV<7VB+V5>?LMF?9?!_6FWI\M8U(K9;@&%_E>#V)=JT*?U9D\;NG''V
MI@<14IN/]&OI+::2?G1=OI>QV>>'80ELME-V;Z#:._'[Y+(+3D8S0]X2,AIB
M\<DXOKG8S_R',G_>SL-+8.]^_I<P^-#GJSR&1W-6-5.5-UE($["Q3?>"&&3N
M:0"G!1CFZC +O0",*!S]4J"L^*S797%N1M;^A##DU X(8S-"L47OT!#O_00O
M:K0B7UFIJLRH--[]K:BAW ;8Z(@&!*BA 7 -\.MIL-LR&G MY^J$[(_5%G]*
M[7=U#:BOY:C='M1UC,WM4KT,,KZ<C4;>2D0#POY8;O%[CH&_9^#5'VH;+FYT
M7-0R("BXKY);?G?[OZNW^#W/^;_GX.\*07['-,,?9?:[HHO?,YWU>P;^6 KR
M'ZG]1VK_D=K_K5+[A[$$:V>[OHKG::RY,YI']_Y43,72_S2H8&06>BA\64/6
M( C\)PS@(>5&>I"-1N"%F[\D,W9&TH+[(:=700*V:(O00P9(^QD-&O#GDS"$
M\6F^C;2NS_P6=:!00 /P>3'^5H8>&O!+$(%^B&0-:/7N0(3ASX2Z3MRY2P[N
M+_W\6_S@JB]UUA?B,]=QX%7@P<5;!&6RWN%)Q_(GR\H9"*L^ IX=_W9Y"+3T
M'7!U3/6WL,C(SO99= KQBLL_>XS^C+#SVU=A"KE?8R=*P#LN)&@ 5W+B+_&2
M1&8P#VJY\B*JZ,_66;TTW%Z2X6"S +Q0=Q6ZL$(T9Q*?.8^C ?OC8*0!;3RR
M?5R4NV[[GZV&&""EF 1P=4@=PSF&>[AK_5(KK26*-4';)F)$A7(HSN&S3DC^
M5V'RY!(*=Z>/K,VQ%Y'<OY/#4^?/VFQRP75K,@SP8^ZRBXG?E33J%,;M??OU
M]>Q2^8].^%_4"?],TK\K'OV_5"G]&TV;3L-)C(5ME@J?E.V6.DTID_%ISYOI
MTMC?GZ5@1%G'IC'UP\B1*_S7SBQ9?^W,\C3SGYWJO%)20XES*S:TQ,4'/D$<
MBX= '=CF'!;(N5%#F4_-\PA=!>2/7ZV@<D"ZY)<Y,D1KE(4MW1&%;G(?Y_3[
M/=WYO^\VZ.@W9J@I*[FT8,/.M[T64AQ22C@?'UP3<D-1H%J?ZI=XAP2X5.1Z
M:$ZQX=0R#CFC3E60[A1[)M87;(9[^])K3WX":SL-]3AU1E5E/.YVK84M0Y4B
MH\/WCT6Y\9KS>13,Z]6YA5D";PX9WL2F=4X^6]Z.]OW2!%Z23;J34KH ;N>'
M;OL:M4<#V"WX=NQ>QT7P1.3?DH -42U'L64$(WVS/$!+YD500K+V#)/:$(T#
MP_X+F95#NL!K%S\4:$FZ1;V'<6M4#4U8NAJ+V'<I("IX\].;U(T/](SZG"*<
MIK_R!'P0'F*B=8Z:*(&"0]6M)![5P@9#,@=*04]DUIL>.90S*0PQ3Y.DB]"Z
MTAY*TG51K/+ZR-A3;+8(#2_(9*CX"C[_5)_^4K\V0?K1R\>/G7O?$!L>IRVJ
M4,TBI!>GWH7\8&X9MU]/QF=G_<3^ N5\*@[H[5O/SR2VR.>V61SGR*VNEX1]
MR]%1.=O6CP[Q\7;,]XA'"I9M\%KJ]H7LWFZ?PA=18G JS22 >9Q(Q,^,*>6Y
M/(S3M!C2G4SDBBSZ.:W4][Z\)+JI^2E2]M$5FB6#5DUKR+[4&>-%_W!TIZD6
M&*ZN> -?_!6YG>8!DT3F2MD!,,TSWI?Y5E@S^8+!4$27FH>-=(27=72V<;)H
M*&/Z0T+:,#IM=QQ3:E_'^1O-C>-BC#8)4[=[F(NJN<S?]GT0UC=.I+W-_OG
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MO[?A0P,H6R-<Y;FY<@X'8C],*N(YB96Q1[E%V TZ#^ENH!ZB 7V\<.)+3W&
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MI@E./-A/BDBJ"2)BTK-*7-WODNC.]#N+OGW']$0T/2S3-.-;TUB'%^^VFX0
M;#^T4]J@\:/X4<+ZXZ7E:W?"/V-)N=@Y$7E-Z$6Z[7>"B8_L"7CYO ;SG%R*
MAHD'J-L<'3#>(K?*N24K]J@8L$0:RGEK3*NVMBX0/_N043'XY87SUWNDPK11
M7B2ZKPA>=EF8?_A*/_TYXL&#DY>/ <CKGK5OCPS<.VNHP1%&W2+9=Q/5SM;Z
MY$',;X7IM>)[1&4%+8372P!>OA1]EO^T:42='GZD22>U2L".5J=(?-E)1$/@
MG,%3)Y\I&0Y9RO54@FO.4>-8.T=:(1[A&N-&7>X-^$/+FRZ[]*SWWB-%6DPK
MZR-XQ0[2%6FC1!R3CU1"='-+"CW,HJIL\[L<[1U@65L"N?-67RA9=YIY@P+E
M<((DZ6S_/HWJ7X-7AOX*7OEH7S7YPVG^@/=Z__U(U>280E[Y"0)Q-EXU^GBJ
MJ^CJX[&!QZ/\S\RSK#^,V\J/D$!D)Q@U;.4G2)(CQM]E\46JTJB7V.UQ<$$;
M($F?TQ_^C K!H09IF.<D=YYCM\T+U\*5\G[LW9(N?-;:%)WY >P)SM\U4/I+
M]=W!0,E<5_!/+;<X,=[.V=AG0O>F&A&BW2,>5<K:N:IW<NS@9[VXWSH<:!)G
M9R&>$QM.$I8[KE):(VD0<E7]W(!_[V3^ICQH\2HDA<9O9!:SAVGY%'V9T*S;
M% 1]!UYZ%"XN\>W3E8ULK%SUVCCD=;?A/99CL+U9W_#N^L6H2"92F7UC>EG[
MB_RP\>WKJAO7?<X^+Z-("07=52 R&1<[6L.0%LOCL&/A)T*E.JV291SPP:SE
M-/S.(4?[+YA7=@F4'UB37,[.IQ+EMW5GBS>6TDF.5JM@Q%!UGYYJ$4B\+9+7
MN8%49W@+7"(=S:SQ2!]_%#WT!J^[_>XX/3GQ1_=2KZ$.^GM&_C-KJ3/TN=S9
MDPD:-0*QGL6?HM?P(V*^KL^TA+1,\@UPZ7E "&4'1Q43?ES35ZY(THLB)Q6D
MEU-155LP^K&9$.T.=K^>4VGB,T6*-^+D\*1ST5F27ATN*#O!C11<#"T^FNU/
MXBQ=M!JEI/HN>:_O->XWW&:@/F12C!$>C]2[$9*_36V88\J9<X?DK%*RPU[F
MZ(S\,."0WJ-,L7ZJVIL=SW[O&$3)D0OH<N1LYW"Z]N16A9 P?7R_->HF;"H*
M0@,FF=Z^ZV#8F:YF+<()TS2C.G,G[*C?'.+#6O?BM:8NBT ]HJK>O-=</ZK-
MF8P\(.AY:Y0H;&/;2[7R@5?G (&KTXPP7NQ/<J%)J1FUXR(\B;MG:1[+\BD=
MES"5Z">R+>QHB$"P8^$&_T8-W#R#_W@\J;&A9>)+K*<VV6F4W(OTCOE&0MY.
M:J[J@X?Q1=-&U:_OZNE]_)@ISEN=^A(W'@F$E7R&+YRTQ"]Z'A$^&"5E3%$'
M!3?&:N+<)LEAK\4YT#C:CNNI')$!.*,$(7?]B,?O4K$&JNY6!R$#RO#+,GT4
MHA&R_#9'%[2MYUAE&46S_0Q[*TU#R8/0YF*CF,W6FWLW0]1KQ2FR'!%[N&>W
MCKP.,(:7ZL(N;W,U[Y!_B^)KM&:GXNH9?:GF?G#TT"'&+ZL;DF1GZ)RGA< U
MP\Y?[9P^GNW=&K3]\2H%]YX3,57/JAZYNE+7W,VB#?,M7;J$@J6S:H4/):GE
M9Y0OKA7>N,'[\[7)IGY+"2Q/9K+ZDFL0<SOU1[GMKX,3Y#O(AVA:7M"^QHIP
M-)B@4"T20G(H/]ISI*=$Z'WQ4-$Q4&O??AGK*BM9U1OLX'4D"=8=J81QQ1@O
MLY>12UE<N+:7LWYOT8T%<&11]?64.1OPD\]9]=7,+WZF&.YJ@ W$+X3M-,DP
MU5X[&+SSCD^37H<P=<5$^"S:*VR[74!0@A,"9U-QM0?C^*GC&4B]2(4M%@P9
MJ<X.:UZ2UZ\N]/KD=TTB><W*K*E?[8[7WGR8!,S >^]/\-/A!RYCU'0^4FZ)
M$]B9.Z/WWJ[$;E?[$]?.ZL%:M+BD#3VAO:I4:GSQ"9'&=UOL#A'PNZ-Z#AN<
M[.?="GGQI_WLZ<4#/U&4.;"A$ Z,P7^8:,)T(%4ZU."4\]XD+A; D&.CJC"H
M?.H='(L1?+;QE;K2+PMMPLY!A*@:O##8TC7,S6<4;# 8"=12V:OXBN-'55H8
M!EBMC@98G@LD%>C*,*]V=>?1R'F"7053G%GO1>E'.!#3FLR4*BTI4AVET2A9
MV3T3>5&NA'W#X/L;2H.?KX,6 'X4C3( ,ZMT^LK1Y?'EB#X^K_CQ1/7B3I+Z
M-H(L@$\='9$?I'_6AVG8=N\^83[(G=J&].;]48M6B^K(@-YV$R'<5%)0\Q=_
M7HXC41"GL_K$%\_([B\/R-A)(#X0MD;9)T)B*\D#8TTDN589TRTO3FTO/XQ!
M6D[5ZP;29F%-RRR4/<L&G.18'1G!7G=/,F:NSQ?7W !7T]$:DIB:#NZ<::-.
MA0;%*[I<J?>B[:&$1(?RC9YJ\WN,Y)$D6/X2;P-Y$9K!Y%C2:J.<QP8WMN72
M5O6\4]QJW:2P@]FK/\@S"IV4>NL@W,V*N6*J=":/-ET:34 X,[ZC[3MO6453
MK(9^TCUF+[^")25& L>..#6L*[>\NLO\8JH=?EK7OG,+UMO'6<1*]3(O :'P
M1YODBC:3T^!U9%;[]9HLMZH WY9,*<\^/BG"ZGG0P/9?2ZPN'E"4KIG@YV0[
M=T\R&S.W6L*3U#27"G%[VMM!_^D*FI5=9YC3M:^ZS\XTB4:Y2;'7)Q? FW_O
M1J\P;?JG\RF,@_:DIG5R_UA;3 7J*Z"WB1,GDV<4:L)!SBIT<R.K@/^GJB2E
M'Q4L-V-)#Q2ZL])0E[[VE'E@;J5;)^_U8WR>[8 C"L+$P*,B8DI#CV0RQY/9
M;+8W%O0:IL$$W^J64MZLK*=JR<@ */[5=+B3O\1]5(($CKK.^8!(YZS=JJJE
M\#_M[,U0[BW3D;X4-NZC)5';]+L^>O1V>'1&KZ2!)W7VAMG70^<Z 7(+JF5*
M)"CW7X/!EJ1A2Y;#YA,:_-(K/;UGY#Q-N9E*>SCV>F)[)JLW_GN[^O< J7](
M)7D.[(PNY.D$W_"+/A#[B/%KY+W'S9L/5S]T8WZ=H+IJ2!]/54#\_'>]ZK_\
MUJO>,G0FRSJF4"#;.G1 UEKZ*MTLLI!7C=]R@YZA!?XP/T& 9R7=],/E]-3%
M51_Z<8'81H'W] %+V_ND6^]-3.@5UA2(YR*]*X#K_$<WPI<:B0FL;O_0>:@0
M3U#U^"S')DKEB*X03(BPZ^F@UKWZ_YK.)Y_1V@)4$,1R[J\H1;;6@UF5TUL1
M-E<MJ=<Y_IUABK3B?5[5LA=-ZY_$8C-<'F!DLC.Q!>GT42D7E*!_MZO%"7K,
M=,[N #: 3 5F<'JD4J5)^'"4C!G5'7CK#$!^\I9I9VLQ! SX4D=5RE;>_U:.
M0_*3^JRFN;_M/',<R6ZI:*[GN"(O/A5P_GK*S0*_FW?'TY-9(X_-OK35<415
MAF*90=:SK(>8N*4*=J[7;_9P_WF\W7 9KN42&B#=B,+6[XF"C"U?8K<U$*9^
MLK_]/&X.1^Q+9@?J604:X*]5HS_;Y0[BK]ZB?Q23Y2H^'D%B* BK6DJH75J@
MG#/:KLBHW!P1K_G8K>'0.]A9?DO!\*:0T,415@I<5%*/F&'S/+<^TYJZY^V]
M<FU2]H>O.<,"A6=D1>GE<1G3>709;IK O!'?4!=?SU>[(,U=Y:26=U^6NW8_
M7NK_,"V\&2M([P#R[J:6ZU02[.KII"=JH@XN'L%)46A*/9-O,W$J>JR:BOWA
MZ:!7( C8;D@,CRJ TW-3>[1/J8R9U01\B9K\'M$KS\@)26$D\.1046;%3D&,
MP-" #GKZX1T()_N+"_&YR>P"OG2?LGIM'D:"3B(Y8\/&I>AK'O;MI"H"P;F7
ML8KQKSZ>'2C4$<DMF$3EY3@O4#;Q%'L4=22[YH9;G!0LC9-:W1UXUG[]M;)V
MP$^M+ZSM ;N2^%<MN7 C2X/S@H[O#N+WK!+[=A*O*'F\\@KI$G_)7)*>$"$H
M/^\3-$QT]Y )]6KU>-]L>#7+??Q,'UJ8SACO(I?GPUK[8$&]7IQJ.<(/$(?L
M\N)W0@.(=PBCW]J&<TW5F:>UTN.B1*Z[4JQ UX=T7YR6DU^F4Y/XMHI+A;&6
M.I>S%I<8J23L>'[0GY.^1TFO\3WH )=B*.VN[A RF+L5=K^UNX#UV%10=*.5
M#/*E+F/'P!X5F+B N+VP+'?"58L&/%7<1^+9P_,L3^_R7?@!840S85!PA6OK
M^2TC\*(T.))ANF'A\OJOE,+EZIQ5:I?1 ,!N?BG+Q5T]-" SYQ2%(X@8N0PO
MP6@=M0LTX!H-TK+:.^0_Q/Y#[#_$_D/L_SRQ_RZ)MAL->+,-/B)O00/:WJ$!
MU,#?W>M.M(.=O0<*,R[C@E@!0]P@$86=AU"]#,D&#[/UH %88TCV3ZBN231@
MXY$O&A! B.(#_X%:J?W^$V%P76M9S!C8^*K9\*V*OR;GNH#/<:;1@,4GX&!G
MX.^>*OKW:EGP])-3ZXK15.\FN)S/'C, ?'4] RQZH_4(K_RWM-JUUC\14)3]
M/L]!Z^K5\*M6R> -XKQ?;WC57CGC"'<,#8!1 =OK6__,$F2E7'SG0 /BP4:,
M66C 6W=IC! $KG)[_UM[WQW55/2E&PA5>I4.DB!(DR)(J"(2>N]5>N^]214$
MA$!"D=ZK@/0.2@D!I(0F':0$ B(H703UX?QFWIIY:\V\NMY:K_RQ_SSG?G?O
M[WY[GWO//;OZ[]Y>2/&MC^]JWJ+0OT6!E?OW40BU?/B7.3R?WLXAF/^/.0J_
M)SO)G>'-1OS=V=OY^=^#47)PE77X\.]]['W89)R2VR.NN+T/<,3F;5"(4%%_
M $]D1&^C ?J+XM_SQ>OZ7>MO$;RWC-A@I;CA_,U^"X,^^Q8&_';5;]8TZ_;H
MDW]C4UNK$<0:3S4JY3VAV.A_0(W[L^ORP7\ #_^)?&__I<CD2_VW9'CU;-XX
M;#E_OW]D_'#AM-SIDOT?-%Q/W((F_VN"_MMAIC*#.2\^L/\@=%?T_O>8H5BZ
M"JE<.;[%'S!G1/-OZ?Y_[6R?_O.19"/_]CE3*''EEW77/-O . 0<7$T[79([
M7]Q$;+#VTB&3F?^/%JS__9/5_.L#W+!_ /]JQ+TI?Y,G*N<DG;8C7&P.'!M8
M>(X VT;>=3BWUC_O,#?0D"5H;S5>J:+S*)KZ#Q=F[\IMV<HK5I?4+KF3BF6S
M62/(6UT2G5N.7LX@FF5]>EIR4!>N*@MN#9U0MJTN3X#KMM+\;[3484OW@#!W
M;,2FY_Z/:\-+Y =R>E2G*YLRCN 3]LB(O8@[IZH_)50EWDJ>WZ!AU<0;WI)^
M*Q/LJCJ6+S8>,@K,/2AST</QBN2G[OP#,)9Z(/N^X(/E^QA+?!>1<ED3=J-7
MR*>]8A+XM#HFS+'_\I% (="?+*.LW8B<FB&]N_$KOO(1O%2J05\GTT$"$))S
M0L'RX\.UR_97>L&(YBT/XX@QA_.?Y)\+R_VL&T[JI 2Z\K+&S;WFK@I^44VZ
MYM1VK3?Z1@@JY7SF3+O4]R+<42EQ]CF0'&I]:3)>'V=]PS=7V.=0951W _F^
M.?N5V:!3W7Q-$(3GTWC^*^07H-Z7RE BQ#0$M"N4SO6Z_EM(<ULB.(XV48R$
MB<= 9Y$<4#FM&+9T(?^_J_/9_RJ#\I1$DOY7SRA.Y"D"_H_V?OHO35QYQJG@
M@;:TQYVFAA&.<X(>,Y0L]9O!A;A0+W3EQW"E@YW"H\*]T(76.2/QJ;6544]O
MZC'2&-=2TFB^2K*$#&(+][EMU,9V0FQ!LALZ#Z=_I%[^>SO2L"69O[7D!"FA
M!A_C^0-P"F3[%=YJ-"1'<=2""NT5L-Q%5R?Y'$<<*WRNKZ_SICML5:(C/SA6
M&J^,[_OT]0^ X 6CXPO7*K.ZH7RD+W*-27RDANZT/+,XN%)C=\E"#7@IW,CX
M\^>"@?VQJ'D;C@?]^EY(E[OGA)><ZNE;^S2MU4"91,BG!WSZAA$A,G&)IX]^
M-/5#?S'0'QEB@2<K&KE;R/&L&.5DYD]8?CF.DH:?<:"K"%K_")=-@>-PBIL4
MS=JUYY:S?A)A8]=E2?",))_#,\M6S.4? .6-?%AM@G1 5:A9!<6N3P3O+E>.
M68*I25DPV,-D+8'[BX;?S!AX[8M<QU9]OB*?3O+G[-D?-:B%<([[ZX#Y>< ?
M0 UZ@KN;??_F(*/<P-'J+8FP!( 4X3H5QO?]R&3IH7^+4PE+7?5F[J]O\H<+
M^Y8OR]7(R$=.;._\6&Y?^TU4N>%)*%XOZ6)T#+=FMJ=Z]7.7_?IA?;V6Z?F&
MD-"#J@1:5Q87.EK VU( A;QF/2%5?$;PJ>@7KRQEZ^J3X?#:6ZGI^_(?-BW[
M__8/VSW_C.?,M.EL"G+W6[V:.D[[/;474=CKEVXP4%;T[:ZM9'JQH72SD1+L
M2P19:PVGZ>S'WI1YT=8/=')3.;N"9]W7!)Q''[=PY;!E]HHO:!0#!T6KWG/Y
M?JQ!S*3U@!>VPA847S#,BWNL%,P3R%8(.=LVMR:T*[G?>?RVB*[]HN3W<R3V
M]V $^F_C/%PT=.Z< '=F8-?MTGA23C9C;C^"M-6UA.VW<6WI4>?Z'T#J]GF]
M14E#=;;^FX%:OYE1IV&3MC\ BH/;.E..:%^2G&V90F2#W/'-;L1@PPU?0")?
MM&_Z&N8(;9@OH9?"3Y>JHTC'%?O?T>[B_WDS_( XXC-T9?8K"(NDPBS*3'JY
M3-#B1.;T'L^MWY??*<NUY&I.W7#'*Y22DD"K^R8%5ML<RZ2_R;RH9TD=D]"M
M :&(UBZA4]<P* 5@6WH[SUER987OB/G9B757_O@B^RN7).?,&F^6$2ZEY*>1
M:5W5P(H=0K(?,09^ JK-/^(FUZ??L9KSOAQQ4+S*@K?S]^$*^::I$,:[']G%
MRWM*PT?>ANWP:--TD^0O<?-"GX ^LWQJFZD=%WW&:6]2?II7EE3W84X(PBI%
MI:DAN2S38613KNP(S[OI1*F "RKKF @JPIBN$ QY2ZN/FIXA2((&,K7EP9@V
MHHT0-B6]F8EWC71KF]$2W$3AF*]W;?,(^K"!4-8G17LAP;$V)V5WB@"&@:2
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M^,U(XJZ4I+<9OT'S%71[UKFBUTQ-.+P)TV@3N'/I&3I!'FJ'7X,G):3/1O\
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MQ982EIV04<4I-D4<867TX (MV;7N&:8K3T%AV@+O N7%7&>\((L?@_"6PO3
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M;I?Q+405S!L>>F.S^M,8)K6*627][F?^1^^[ ]M3/"O-S<L<A05W5D78(X,
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M*PE>+75'%B.5OV3UI?_-WI6BW9!E9KPRY 3 Y2;O(\5X"!-\*V @7_QF>AE
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M=$XD-FVV_U-SKTQ2=-ZQ5EW[U3EH",P*YT K+>JAVV#H-WQ5R!@,@//:! .
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M'F9N^=J<-$:+[<>S96EO;7Z<'UA.G3O)?9<@90P<M%O&1Y17-WRMZ@>EE&,
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M*PYSOHZX<->2((:6_9,W[L#:B)G.MIH32"3BNF1?6Y*7O;S3P7HZ!$Y&$6$
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M;J@"U7QI>>7A**%15!_H&*M4\R4OPA]K<12MCK7H_;M6[[P&:^4$@M1G/6/
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MQZ\ (W*>YID(NVX?!MO,_%TW![>=A@:VHNG6[[C""X\[\!)O*ZM8!*S*<V
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M*D=NJQ"_K7:)A[^P3L58I[>UU=/SWR+:E'47(H= +^Q%3=/J13VKEMIG*<>
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M3W^@V7TQU)O"S@%+?? ]+>>NEV_]RF]?J-LJY3.=]7.FQF!O,B_"3+H3_TU
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MO286+EY[2Z?>ZQ;7PU\&R-6;8H74R]''(?0CC%9'M5MNE35&>!!-:D%<QB#
MZ!"VJ&6IG9:I(<&.;71-*;VOW96'O$E[&""\X#6OEB$P>7<NY)(GL\;=8$YE
M=#LS8;$7IVZ RMFL)U8,M<08#@$>E5Q9-FF.2M"D@(:.\X:-D"XZ 0G/0%$_
MYDDX6P\W=&O<OM7Q45^3C'#!4_7&=:]"P785SU\_H?L\'UWYJXW:T>N8O%AW
M+90_Z9*N9&/(O64/U%!SD,Z<,+@0XEK-I.'0W*$ Q/GZ,16M:+AQ3O0V$9MX
M V#8N6U^O]\ UG-R!B_IC)VR09O)<]^,!A?JHK,1FE_SK%U3^9X\G/R)B;W=
M6H5+$<K]VAC(S'' K LBC%QK4DLX0GK^BZ>_[JB6!"4&-\BY7A(TRCQDZUSQ
MDCU,,\TR8LKUP5Q-$Z9_:_+XXYM-RPT#(M"5G+IBA$'?E!):I'J8Y*SLNS*9
MD6$=Z-=UG?IDL#]GMI+HGL+HXO!13T]E!3CN:[:5&:/]8%G_A^BMJ%R5;!M?
M"M72=2$RLJH:@;,(6.FR-&,TT.Q[7]$#Z>YYZ/'FGV1XL#.GF/+@49JROC1A
M/NG.RM84XCVI\.,"7UM>A9P5L2#_'"S8UKRQK!(C'EX#B[9,'EGB*7I'=7_R
MP_>'Y(SX2WDV$3< OY(E!!KN#'_RME!GQ@ 67LY9*VM\2U1Y)P=/;#J;E< 5
M#U!G<6L5U5Z5"?&@J3B#7'2X_@XW99# %ER*%TY$$5E/:J5=)WM+$S2%6=\
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M<6.@\PK&^?F?"(D,I\^6(3K?&*;HHPZL:PJ?4A,H\,=JH5=\X/DK3H&Y@#+
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MZ<R8E+K^@1 WOD+1<>,(4CQ6BRCX[0CTP"EDC>9_9YU]<R.!J'4F1L8N>[?
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MU<8WG<7\A39+M1\?M;W;$NS>B?0&_-E:E5?E"Y[<0F.,ZX.AI#],KCBC==#
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M^2@:WQ^+V[C/6R\%T]W$P.Z;#SV/:A*+Z> UWX03?-A<27I95G>#!KW9L%5
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MC2,KP &61>W<HF?NW3->P8H?:?)>ZVNNS1>'MX]GL\-W" !B][QJ\V;Z>*)
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MVY(T*Y59FJ&VKQQ3_?Q$/$%=N'.W2VR.(ME@ 8ZXPL1HO;MFT=F"%%?S2\T
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MVV A0$P^V0[NFV>G4-[]YS'Z"XY/^RPI8*%8A1!R#?K[MO)]C0*5MS9?<)X
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MLRI@\-[EV0M.^CKEQD0CEL-07SXHJ3+(AWI<(IA1S((W9D<]S6EO-E4W.4"
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MN-&EWG@_(RDSCGC#^D3IH^ KJW4!@0&#V3.D?O?(AP^H-*=BS3$W.RQ0\QW
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MX\@\M%R)O,J7EU\$6KPW9(B4+9@TW=I(#VS]S_P$XMA"N+*9.1'G=V&<?!,
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MH1^US8-1O2='/%9NO!G:LSUVHH%\I3>GLRUBYY@^>W+NB_4,*E57$G/Q=56
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MK0_/0HO#QP^@UEOX_5!NTA66LU_4P+IS9]8Y)_?=/O38RE&OCID)6+D1X\O
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M:K$)#4_TBAF$AGVBKLAZ#0  ?A*I6"W_8T?Q'R\(]M("^3<#IH0L ;C788_
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MN98._/?&G7^S$%KU%HS%2PV," 2DW83#$R\,#O-4%5'OPDFO\\>( &/!:GH
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MJQK3]L\> 5_.,=-NSA[BBBY5'-F7*,0$X/^6Z"(5.+$;2*X8ND%\DI'$)S+
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M(![6<(B>T]"2O!V^Y+R46A%C?$U8WK8[$7"/02SOS/BG9)/W5S1@'"R<4_;
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MN]+]@TANLI9)?=F8I78XLU99>OHU8BV2_53Q[1ZJ.3EDVJJ1=_;,(_C6=H9
M86(A:VA_"O/C.]&7&UR&^A(39KPXUHVY!J*87BX4:;,WH'V*]X;@F#S+$D3$
M7H5I%M6=S%SOS$0#T,7]78DS(1<+[5Q2[B18,R7/2^S'G3)WCB3>B-G_!/\=
ML_%R+(ZFFW\YO1I(N K1^$@I8_K5U1S97Q/NF2!'/!->R>QTVD_$\'"TY@_9
M)"=HXMQ>,DN)BE(S=1-V%- VI_-VWW,@\/0F9:V.)H=X@V>&337**HXKXH^'
MTA+EY/@0K(+D/0W$AT6L5H7N[8L,H;@:R1<G"_/2#D\)DJ7@I<]TI2L])=,<
MT&8YG7U;VN(H&^E7^@&7I8TB&5P+C+ AE[4>W&S_\]^_11O:?!FID_V1TTAA
MW4N0W#834=7ORZE&.<,2=&W:M'I.,='4]XL1D0Y];Z#<T3=WUB)U'4[ *Q&R
M@_H(J&B"IQU>@C3CW4@8>DMUY4UH3A0?8O'W#S2"F[S7L+(GDB?5:EOC9?;7
M68]+!9^"ZM$Y6J2=#+K/L&G!3CFYV4QJF:Q/R)XZFU&DQ=[NI)<O+GSPE:-L
M2&-_BO!Z;T8U.,()G129[MJ!M)TWS/Z(2X[SF:N4FK@WGG=/U*;CY(DJL6KU
M+W$]4CBI'77A'<P, 9P!++^+0!06YQ>WM4_$R[[D/4PZ5EP:J7H>/==PR6RM
M7="W_H2/-3 L3&&<;IPSKX%EA!CV$"YWM@#ZM=KLB[(NQXV*7VD+Y]M I64=
M]F[U,^5TBMC[6%E7:3Q') )-PG>'5::YT<ZCNE@V%9'C>FU4\=5\<V?GGU!,
M@C%*JTU(23/F2>Y\)Q#^1;9#Q: ],4TBZ@L\=:5I6XC.HCS#W51T715<"G.%
M*2T-K=B-:4%$4>W$JG RNA/?*<EQ]MJ1CWSQ/(7Y,LT_*+?]V?!H@BN8.OHB
MZ4M(4*@NH8FT$8/ L'#TVQ!04B+$QWVN;>Q,#]@HU90YK3T=\\QQL&3'>%9%
MVL73)$Q^',VPH$-N&XMH?::M#7=8]VV*K&2L07USV.(UP3!+=%"+<5[<%-8D
MEP#<\"TSVH:<VNZD>FMN\ZG6E$,/F*66H.;Y_FKLWN'%U3+&RY 6:$!Y/Q@M
M??O #4T&0J9Y-ML=.=I(I*DEZS(J%$:^L'6QJVDBA!ZOM&L8D.^6[%%W$UHZ
M#^_?^' -GZ7BXQ.B<-(@Z()S&MU'.ZQRXL-1,";\>$TIP.9;LLQMF+IO^I-R
MOM&B4A_8)P[:*7>V'8'F] VN.0*Q%*LKMI$S+-=W9T2-?<?WR1+&K1UO:C7R
MRQ<R:^^6SF+J2I5+YA &0MC#=1J!\QS[=%@Q+[9OW"HXC:;.<2H7WI.>_/SQ
M[.3I8D'C"6<\R>$IO'Q!GNMR0MZ18,3OR>#^&]!F!E:/2*( (C^<%"_>V:=L
MR_V=,MEPLTL'(C=./,^4"#4.5O\(B/B9C?X3U:>+XFI76S8GH*^M*&"F-N#F
M>3G%%^L-*_>(7>_L&S38D8>VT)Z$E[Y\GG&J2_O%"ADQ*S]E(^/0V&_@]?H1
M8%&[1<\D^#<VTK^T/_XIU1@FIL_-'_LK/T3MRF*L.=H#\'$NRHBZV69[Q9:<
MX5EVZ:V)4(P7MB4ZF%^;@MP\A)]YM225SQ"HV<"CO*"7%.QTN1@_,>:=]"<*
M"P[E367>"QMU'JS#[C[T**J=[X,1!W#]#(#PJ'>T$&>!73O4@NX*%,[M[U/F
M(['DPB'16NZ4%C.C-W&0C]7M@^4RA@-Z<)OTTE^8A9_4?=:Z\2_(DZ$;JUQ7
M\-NUSG86A7+;[*H$?-'F@0O,1<E^O#ZD<423CGG7IC<I.<+$J5.=-:%SOL!E
MUUI[G2I]!U'Z-:%T<._-SF"XV_!)?Q3OREUT3Y1^Z<4CP,/29T3]_M  TRCK
M'';E(!;U?K*Y^3I%+?-TR+LI(%1_@IN/.Y-Q\0$I,<DE9L<GLL6@IGBI">C!
MD8B8@/U.9:O_#/,)?",OZ'EHWJQS+%2*MT2]AA%"AKJL,[-(4-?85FL>QE;-
MG"#K1%)CGCJ%7EE$)5SV/;>@@T4W3T<K@VSE$0 &K8_5=DTJ93"OWC+PLV=D
M^;G,B%R7:B\20\DI&B==ZS]!K2,S&OCX/GH)I65WS;C,>?IO #T8Z 9R>H_6
M ^G.2W]<F2I7-=8V0AJ2%QU7?5)E>4F=,93X=[LMJ2L'XEKX9:7A<@Y^ @M@
MMX?4'/,<ZS0?!1C,J6?R5?5KV;X#%&],$]6 #LZ\^_ ]XT_J#FU#+PTC7NU@
M. MXSXAZK:9 IRPU]8UKVAE 7>UWF^WM;X)J_3 +Q,$_ J[D=)7>RW\0E0M7
MRZS5?FC[12*-^65#R=GFXF[BCM7-+L<ZNC# DD0"/W5A/5A:I&'$Y3#-V:K1
MU5H 39-)@-J9";L]20K7V>=E<[:3?R*DC=F'5 16.#]Z2+\-%\G.SP-'5W>0
MKL?(TAU3I[5(XD[(ZN(PR"F=>)A(XJI3_WE05]T.KTF__\ZT=1X!9[P5K13G
M3&<5XG\XQ .8-^>QO[&H]^[R(T"M3:[$WE)^^;IM./:_;>K]+8&$Y/U-'>#T
MC^$O?SA\4O])4&"P"1(RMEYFX>&U@N^J-CHP]G2PFC4DG@'<24%92VK/;'<\
MU.>L/;2U8,Y&RK@*QPBIGUSEJ"]?K*:M"5$L"Q[N,PCIK]3IWHF[UL>\'?+V
ME<Y7O3WMO[F)%Z,^LOS,6EY)>\P;8:Y?B;U801JC-B(RUKV%ZK)T+@S^IY"A
M\: *)31_V.\=L_9Z##M,6M1->N8.*/'U"74@JAHP=C+HV./+(P"R1C3!M<E@
M5I0_$=O"-N;^"#B?[F#8N9"4--:N GZ8J' =IKU4;^O<N2RUJ'<X.#[Y?O&T
MUM7\12["]"K%220_;2H..:Z:5PJ9N'-\C5V<Y7/X9=V(E+#&&==\1H*I0RJ/
MQO%[.F6-!Q1?WG4CASP9UQ:C5864+VMV1PE&57[V*>ZC:&<F[6<BD$T1JK&B
MCX0,\M^43+\Z-1U7I&%KK5M,I4&9N)]44'1[ _5W4(YQOUFN91] 7 5X*MAR
M3RRN65>7IRXO\8J$L S%QH:"5DV"7P'QMP?5<N>IO0SQIA<\64"?X8;TXN-F
M9*+$+,U83.]X>;^4S4OE9\,:A<L%,\EAPB/V$R,^M_EUT \G_+UD+</>#PG6
MY D%XC;E/%W9G-Y9^=.O.!5J)CXQV+U6DQ[:OXR=@BE5E<[;S(C.IO%Q"(7;
M3E2*"8(> 0*;&9G:YE6?UW8$6<*W*?T"NCV\F^6(T9S6)?2+BJX>W":,X(O#
MEHPUO82(C*"$;J/QLR^N=AQ,?-(+1.X/IQY<^Y*1",*9E,0]U?-R&L%!15!&
M)0L:'#\!=7;_D([-R;$/XUK)Z0Q/],N=J.6*(:6BR-%KS&'2D'*'N5#]T)S)
M?9;OR9KBM91KJW1X#I5RF\X>#2F<+>,G%PVY1IX!6NE*+0JR1'TFEX8^[RZX
M87?LQT[C;JH%A@VWKU8#\[,HOQYACAUA_@*.M[[Q5!22S^7Z*OT(P"'19$/"
MJ!#,N;FXO -NCFC^<'XNFN3>(5?./"J%K;D]EZTS;C :"+DXQ@RU.Z"UFU')
MIG29KU[-[GKMWU"15D^=89BZ,<#*.O3?T_B+*"*(M/Y]@$=9X]"B5(KCSU])
M<)&BV%V-YM\YYO@*[WP=K+,\WE[T_2-@-R_'(B44?-?T;G97#R>@K]?R$6"4
M\ C8<IP\*_9-IR;<5TA_D!(4O3G[*_E,]*#\YWM:MBCIPO6>I4*RR?XZ>Q##
M:3\AT&_$/S$:#6_3>W-XE44LH2\,CT(!YZX??"^'.E8 F::,W]D*/ZE KL$V
MX 6L'E1@?B<#8G;5>2<2Y!G7UT6\H7];'X//VO=]W2#K:@3CF=W[6]B!M;(/
MN<D*6@/K>7KPVGYT<RUYH):KLRQZ&;-2/R5I&4,[2M,K8">'#0[)/7?<4!LG
MK?_Q.4JQ=2O:=*5]LN"75[7\UVO.G+$?!6:*B+^JSA^ 5@>\1\/92%2/SB$+
M/Y\4A'"8.7J^23O>M]E_Z#2WB/["4QN(\=G^;8#<X9UX>6^!%3AWVR1KM?\$
M,?BL^<LQJ(KLQ98(9,30VCV+<O*-GXBF[D?#2)(?#[O>?L"LR'7?40L3Y07?
M4=,OE7I7=L7S1ELGG8*<]VEB7_;[X5).5]II\ULI,)=R;?9\\T;L7R%G2 G7
MVG[?=[U%0YM%QGNI$PPVG5!HC3G$$=0?GQSJK0AOZ=H ]1>CD_-%Z)C(6TI'
MR9=8B7[%&WBOHIY15C>;.%##>"[9UW.C8_;<47/*V[#F!SH(LYR81O0V/,2_
MCBB?( 6I6;72W9)23MQP<M<3:I$FD7_VP)5Z13WSGKXVP1##N05GV2TC5Q\Q
M\3PBN*L5Y))P':"7&^>I=J)*C:_-V3_5_?0'Q9=M/0_X^1FQ;NTD5\/953#6
M1K59\9E*0[M(89(N?V_2FQ(ZFH&XJ&,"34/QKC!Z_7>('LJ^K2$,Y9T N36F
MBJGRV@7I]S$;(RK1]CR!7I]D;XM:94NX*E&ZCIG3/L>VA/G6\B'.N1TS3-#<
M&3E!IJ;BG?Y4S5'MEUCA+*X)+"TU4&I[BELVNA,PD\SW27", 6-LFJS!26\3
MCDKGLJ#5JF1M4P.4_N$3*,QPMD=&V+.<@F .J 6K0BN099YN2"-=CK7KA'Q*
M-&>B:XC.8]!U$VAB"9!+,X_@?BZ?$(AFREW\?VQ!&;TU@APA5.M;QM?#W"UO
MN8*P$ FUH-6C KT4RHVHEXG7!!R63KDV967;':N#[ H@TRP<&#]!<-MF5?$C
M8/E-K7/'(E-39KG&-[O,%*K@/\C8='M3A9QF1BHMN9"*VL@D=?:38L8O@$L/
MXR,@; &\[[#<Z#F]W/R5'?7EDW;"45@];;PWZ826Q9K#AD2,:H)S""3L^077
MCAFGI!-%*GH)I25)7!#%MZ*I^/^<I\KL81'%.*)X?G^6VWRK,.E6B6?5AAA<
M8=H5[)]+@S\WMFO^R/ZR_-MUHW- IGP)W'@GB[]FPIX;_&%:*I$V<?OTFW@?
M:;!3W^8=4\"G2GL[*-<:;$9P@.G+I%OJG:!(2]&.=LU29Q&SFKXLPU %J1.1
M,((/:5?SC@V\4_?C*GA5._+B9@6MV[A&#XE3NMYORB &Q<=;94MNN)(MLWMO
M;FDF]6I2)KWSIO$J5@D$:2XB4*7_Y0-K"_;5]0)S75S6>4>)PFGFG"_:*27(
MJ"PHNH39KV;,F55'<209F7HZT<LYGN>XJ&1^FW1=+_D)5[0LWWXP\[$(?A^F
MCIB=X2[V%<*6,59JQ/I])28[@X+.**'G#L]L]+AW=T0(?7MZV<QZ0\Y*Z[)X
M()'*-;OX";,&;*\:7A@?XXT3L&PWI4M"P#P?$;X\4_E.FXOZ4ID#Z]'N#^1'
MR=DYKXY*DM= 1/F[5]X:L ?JL0+#P5)XT,/DKX?:ZV;C900W"VT9$M8=^]WF
M67&F7,U8JE)^K<6:DX\VVVK+1\3L*XS>R[3H!ZK9C"3QF=-2YRN$&BR?)PM_
M8L-=B*0DY8G?/>JJO@C!D<Z$?;KZU,&KC1(Z6O$^A?/N#[$UET67V'G]Y:VK
MP,Y&N2WO5X59]0O$OIO3L73G8#GZ"G>$AX7BP@+H7=<D<R$71_%;@^(^U&*4
MO/B>"6/>(4C0W9Y74QZJOX#]>6^+LJ3B5P;NFK=9$_"=MWC=S>I2&!_Z@@+O
M7O'>BO1U'*7+")60N!0E\U2=4Y&F54GBBZO%CW/P?0R#O\7%HE:-B2 .13K"
M[6>VHSGU'=2A&.E-;WSGL5IX:. S=:9JQFKI,Q\!_NZE $:V^)"EZQPB&-"4
MK6P#G(7+VM:- I'$VMQI07@4X7)9D<PAJ9=O;\F@<_Z#%Y[^HR O?90A/P%U
M_W;+"^/J^WC,FD? *!NS[5VC9B1]-0574U+^I*W%R1V"R4OH.[)/KOH/C,X8
MAE.XOD$B)Z*;+=F#[EM07;9J5A(WKBXJ5U-<)S+/^//O$90@5PF5[_Y/<XG]
MOC;P4H[,&^!D<TDTU9SWV SCZJ*E7C+-Z^@N"+1TY^,(^,'BWW7Y<2KYZ'M1
M6U-#(Q:^]NA^Q59Y!&#X"9?:_/4GHO^CK _U.]ZPYR_[26;I>Y$_%+K)&<Y5
MAVM4G7]0Z*"E$=&&K<!3J;KH1\";JX>D'-T;T;N0U1NM4"JQOY'BDGYCX9D[
MS^Y'@+'[GZ'8><=4 G\3M""-"@4P-!WC1Q<FW.:_<MS=\<9< [)IM!KR*B5O
MA^DXYDVE31PW6V 2;1.P/%18&9'>\ 3<G(]ZMA+XH7F'?%G7<BB2.RQ,4)76
MP/8M7F$]V&RMMSZ@9EV[W!))>H6K[37K0?YR9BW^E[6'O;[C_6#"B/313(XT
M(16R&?GS2LQ)LI7I\D7F0YQ"]O-*GQ@1;VT,6D:.QAVGF4A0!4CT&?_$^;VQ
M&-VEG.1PO7!28]"-MIL!NS'52DR&>@AW5'BOKR7%0%/:&KA,N9&]I-&O(Y*^
M'-3QCZ3@^0'+2B,T_L68+&X4)/$2+]9N69_)I]C2)VHPZ,D0^[QB Y7P#W;]
M1(WZ[J9:ZY<UP3:L_=_VEP<=H"U3VAZP%>E3ZC"TX+@F#VH,KYO)BCMA:T\W
M).J$6.CSKB8=IYI"O@<OL V#L_2/^Q;YQ=\'<_89"8 IIT=?QO$?I2O_BUR]
M/\(]GZ9=>>3H0];O4%UJG:_#;\0.O.E'U7Q>5AEY'8?O&Q_%;"U].O&?N8=:
MKUU?S[4Y(9I(5_E&^+]CK!AJ*P7O[].V06(V^!0[.T[IW;XX&@0[$RP5* +=
M''R 9,/YQ\H.C <Q.AD<?.?(CI*>&4M'<8^ CJZ9MF6ZAX%;ASM*7I* &J%1
M-HL'S@V7)OZ+;7UBNNC:88I?MARZ-EH).\G>>F_JPLR]U+0Z:-=0J39,X('"
M KT:D^>B@GL$%U!_\6_KMT*#=,FKI768J+/3C4=+8;S;RX<D"*O=W%UBPXJR
MPI[P6Z4Q1*K],G(3&YVC.776=;=/TK\'*^<L^N9L]>:HCAO74,L&P\L$MKL?
M(6TK"Z+W;A.ZNNU%<^+6=H0QSU4HZ?>>2=L5S,TM+BR^?ZX?5?>**Y6Z#@75
M* 0.GAZ0&Z O/*M^V3M=;HY=D6/!*62*D7TZ[L?T*3)Q[X!ZSP2Q*.GUVG,$
M\YAAIS!>0Q9E1M-D2\K&YQ[/(G$>+CIW(!@W_I!;-:.22BYSP#+[+1W8+$[%
M72J[IZ<]VSG33/'J+-MV,GL/&M7']-,![-*KVS:1W0^S-5,3D L),=R>VA]5
M?I<M%LZU-GEP'KO0_R)X['[US?4WGY>+W,1:63V1=DSRIE&Q78WJZ/=E#C5O
M<?M]M8NDNZ1TEZISR0,$SCR. L(7*5AJRTQ[>&V);C9AQ?!MU2NG=/MTW(OK
M@4%<TR'C2C"-5OK<._5P"2>M&X<O=ZJA)_J*DXA#SJ,AT=2*)<FC\^00ZS5X
M[RE%V]O;$;^=Y9FS%7[K]P_;H(U<@=#NI4$34Z;-JW42#0TEYWA(>41B_ADD
MCF9H7%_"+"E0]6::WO:<*---4H*$/X9(L!)L!;?Z/,3J]L+W.IPQ^V=;J Y,
M;4>1>[76H&HYD$_09Z5F0W8..TV/2F"$;?\VK+$I"G^K"5OH\L#F'!R]'CJ0
MSTMNE[H3?[]V0WZV3WLRO#\!1^\Y!A%FF(1::PPH7=! ?V@'W:F,H<2N)#>$
M\B",0SA^.5)<]6Z&/ *>5OI6H*YL9$"-L/2'?"]<RBSODZ]E[@8>-%UI!D75
M#;BN;=@X4ZZXBVOUIA\R]"]=Q&@ CP O&8K^V'6C8:-G1^445TK[/V3(-5(O
MKX%+UBMXA5H,>M__I\F'NM(KTG@.RX/C_^9A'7-ZS]95\GI-XKL_7?8.HS)&
M0#%7VLO[2NWZ!J$P9^E)(34??/=W%7V)/II$;6NF?[2.LH^ ,SZ@A&OY]G_\
MPBIF3?./^%$J^C<L&^MNKIZ">!;4U7O:L5"L4XHNRG0*.TL1G(CJS>A,25")
M<H0B3EWB#I5_WTD4^%9:WBQQ+1,%:2,;ULE\RQ%!$=^RE"8G05E,;U=;V''<
MR@=)7XJX$)<'5-IL"[D,CX#RCS=E9L_?>CY8-"/^A7*U),E/G3JM=%(MT$*E
M-F8WJZ]G^+.\-P/*ZM>_8Z.,:^T>9WU8@L"'3.$EF7IZGLH*,6&<KYW/635&
M]^046E^D8(S475H">?F?<*#XE>FJ.?GVI\FE,&TH+$[:XD]YQ4,S7>\&.4]D
M'X(A'^LA27>5 JATP>E!]TR@8_<\9BQQ2[3$T_?6S_FHO;6)7Z@]I\8:B\2C
MXW;O)E:RV<\J*[_"']0,RO^A"6E&8B3X[+(E[5!<R?_0W:9[E\HR]SR][Y/,
MM?'DS4R>KP#L@)O)>I]UOI^F[F7?@EQ63^K*-RIE,KUJ4J^OY?'T0@1/ D4-
M+ KQZ%[PO0.MX__JZ('/R%9CY>CD_M]RTS1[8@6:3/[BIN54S.KQ?JF]D#>3
MY1&J%@ Y]+!G]W)G5UP%;K_\^C/RDI77=P'7.VWXZ"+'B;^6EWF4U <<+W5'
MI"V:J7KL5UNUD[L<Q"X7R.2.[(:;A^DE]9[09X"#MO9XI,SAG;464=Y!J/N#
MA';1E@?,Z.T$\D#0KV^X\71$[0>%S8PM+LN0_&1_<J_- >83(@(/<R2B@HC/
M&O;0ET>1T>-=-OZO6V.[4AK=/AN9J?+!]WX^TUJSO+NH./TO&F<BF;D+GF$;
MMWI1JLDC:"55SV-H:/*,$WF4*X7+"B::^4WR!R9[*KD1Z-Q#^ZT?A#EG?5[V
M@($5ND13)6X6;.%G#5PMO':#X<V90Y>L D0DQ>2=@2))0HT\J<*#!L-%"%E.
M4Y?F]Q%W.^=X/0C[O4W[@U73&#X5:IGBD-SBG[@[]/EO_G.L'(#MN>G/KA ;
MU=Q_ZY-UN=!,]]P3L?]6A.=AL<=5\7'P%[ VQH=%M$N;1T]B3W</AO>IJ?5(
MFXX1L^BTC#CVLT/!]+X;&9VAGXB\#[L5&@(MS!R5GR;6*+-)@QPYQ6B:Z\K-
M3][@5@&'J1AR2TD+P]#@.6\7QB0\U#8['DDB+X?1,G42*[%D';U_B(D_FS46
M(KW5EG?3R%!O:6[[96,U?VA>C A GNVW]""'<*657U930W%DOT'Q"%6>8@7R
MKPIO+Q(?&8:'N:'=EHEGUV9(M?$>Y#T<R)/-@S;!-*,QKDV&'_0]@J^_ARDS
M M>@M(MT(^]&$1D8F;LDQL>T8+-%EEONQ?:/=6$SEU;N#CT'>1FW&Y_+Y!?L
M^Q\!:<9K+Q2WY_>Y[CE&Y<)DRG-.XF7U+$FBS!$E:VE0@_5>D!W+N<<DU>2Y
M?+_)+%WRQ-1 '#X12=6HDB=*HPCD\RI->6-J[4VH5O-D.01YS@N(OKM-B:1E
M5:R$>+Y1>(0:9F'7JR INB>(N:N&\*3J="]']]9@EKX[&WP$<!H^P_.'^<T9
MG!QPT'^"@J31K8DQ(B,!1>/_$.[]3\M@-+IMC>PW;C*.>@3D+C;:;/C:_0;
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M7?B_21+[:Y4MS,*-\ZV]@,\Z>BD'@JTZ/SN-AWECS4Y'TC_-;]3*%$8L#)L
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MG?N>/'-"T*7M68&%RRN6G!L6$ =>X)E.?K.9"DN=VJ8HP=2A[H,T)V:3&+G
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M3"[T*TQ.6\?7'S8K> X>+GV]-1OM='Z?>/X327//*#UBC'B'9TT&?1/4JA_
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M5Y[$S;31OG(],US:8O6\X&,OLQ$A:3R.7H-B&1N+,:^>PEA*NX*;(D,"Q81
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M:3[;2K-1?8?("X5R[W'(2'__H,\[W]"QS[21/U9'V$H%EW=*F&=M&A,J+?7
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MW)G>670*6$?9)L@EAUA$2;*+;319LAT[/7^OFFO.&%#Z^G,]-\(L(=:DC/Q
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M6LN9,UZ"[J[E+(=3[O!;[K3[SJ#A:B+%$V/9' E\N5'VL"P$F3Z(U:LOYZ;
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M]M2<*YO\9 %]T^@P^H9Z8C=&4 46P4==-\)'BU]&?U1L-3!D=\&FI ;Y(A*
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M7QRO4 8V&]$/%X++[N9RK)LL:R;5(6GTA][AO 33<0:'S,%B($^8=^H/AAH
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M]0[I)N:,WS2(OJZ[EO"?8P#!(+/SO#]6?OB3*&ZT)W*Z.">(\'>LI520;=2
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MM*6J.6A_N>LY'Q6QTA5E5X4W<N>?-Y.U1<>/MSP<C<FJNLF$3U]6O/] I:V
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MMYUY&F>8H_W306W[P9<W_5\P55O&VA_) )Y'O5D/[&2ICTV]M@,+%NV;X8E
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ME9>0Z>Q=A.D\J#+[83A*LM?!,%#OL.5)%RW:4LK&A).9=3[S_MJV .W0JH?
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M/PP4QROH*=, I]+\6B.]%H]Q"A5[$[*%>4:[2OW0>AT4Y*GOUF-.8FE7J3N
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MFW7'!-K'"_BE?O9,DK3!NQ'>;KMSI-::'5RKJD%AJ_O</H5[Q?\;=Z%M#;O
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M-D2UV:63;DG 5& 9!K)DE\(@\R8]XD3U@]]-GEZI;G\Z(%_HK"Z2;GAGBXL
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MMX -#V91U?71]A KK0Y34,>(\:0IS>A?J-;#E%UX+AG[?-Y)&6OID;;81\#
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MS=(]0H-]=26?W"5BZ"XDJ^I2O\,_U\>^$><F8A5? :,[E&7( O$6[9A2'BW
M9.;J!;Y.7M2'O:P.8'F:@*72F8JO6I.)-(P(+X<V+[(HC?.N)FV<7AQO91D0
M;.!@CH.D9(PQ\(+MM%#8K+#J-K%GG<1K7=U&*&3\V2((N,?.\,9[;ZY&>(BA
M>XXP[@"LL^HO36(H]0+O+WJJ)T&#^^4^)#(U['2,[&4!CX[^+%6M'E+OMI&V
M3U5 5:TG FMY^/GB;706JQ*SL3^\":^CS>X+E9L9CGH$4MG?<"%M4AV^&?CG
M_R:.-L#YR)AJ$0#IOB0-@?M)KJ(#3KKI*V/ 2L[X!7^F4F?*A;#6%/Y9_"WR
M,B]Z6L5NTK))A"#R77\#Z)')_[;^2FK_+DKYHA0]6,58S'JD)"_+9.TBS7<+
M))4>W0)_KOX:!<BHU] YTOG4U]OOF?>ZO:Z7B@N;W7W.@4K]+Z&C5QB$Y.:/
M6K1D3\!C##*Y$ANJ$/&B=@SU1=Z1GWI3)3_1,V7 A9+,-*!Q!<!ZTYO!NGKI
M>P8(VNE+#4#U/!\1>?8)LCY7*SYZUF780-5IY!@4Y"RYGUS^BY@I,2_11\":
M-6&X44I;#L,? =;Q1_'?ZX 4&>T^4CM/!G^C&.?^F20*)F"O"#1]]NKD-28[
MX<!Q_^P/\W+7'$G+CM0O(I]ZP45*<1WBT/N-"!]F[CO.]#BK"2PPKYYM3R-C
MF7/U;^[!5<>6[C=[4*ZY6OC_A ^75U+;DL.R.]/BX_B Q@\ESVX(&?,"B''*
MVO\#EOQ_IPW#_[8U?FDA_UX9,Q+EQ \%#<)Y(#E-C<OXN>;ASQY+&R>XFPC_
M\Y$S3@S*F<C.E'="MU<G:I;]HRIQHK*6<CY=%X@T(KO 8H>%1*A<5*]^REF8
MU\:H!<XQKU*Z1'<=XO.)%F 9;G[U+X<=92R46%TR:@,%&VBQ?8H+Z"';C/'O
M%U!V?(Z5 ^T=HTE-?%\&$$2D<PDQS!D]MR0<S3W]K8CV3MD;!8#R?]&H0E'9
M]SM0@]QE!W!>K6%\"RLCHFQN]?QW^1E, _X@GVB@TM(:4CAC-#/;765DA*A2
MH#_5P05T_G5D2F?UY^V0-PKY;-R#M1^(,VHH?JF DU2XA"W^^VL4E:Z6$*@K
M!'P4Q0%WY^"L.7Z&KX);Z*(\TECZ/S1$I9I#S)[=/9Q[,/T&,<81(:YC<0_W
M1S^NC)SNO_Z-SC&R&C%6Y_GCJ8NRF/1:@40T$#X^OM0YS*"JG,( TU1BM!6@
MDOUYI_#_Z4V1_X-6X6MZ]/T<O>\E,W]YD%DMD*6;[;V>YZ:NW+&5U=99-(LE
MW/?Z8?Q7_ABABJ^_4FL\A2BY29-Z_ICOD^JQS2.R[V_>AYYMF5%7Y(>0D?R$
M-K?2(_=TE9TJT$XWPX-TBL-F.4R_4:W4+1>HL/)6]"T0@J[(B?;UALZD*!?(
M#JSDK3^ L=5P%^3:,C-E&\)OAK'%E?:ISY0YC62PRI89KRC7PQ7HK-<2=XS2
MVKLS)5]/\=5>J;&8(&UJWZ5RO:H2Y.%1]*RQ(D;5\X!!JXM/T4ZG:$+5FD;-
M%T/.-HQ.."NKGW!-M2MAXYX8:?CWO270U"D_V^JWZO'319GG"R^E]\J:C3C_
MB-T)DC310- S-ZYP0^=]T;H,=$ZY"?[!Y,;LOTN:&;SDLA@F;>A*XE"A.=CV
M7KVFV.GDG3D(_%.I4USS^PW(/%4DD!Q[.@P*&:?-#I[(BPE+D2%GZTN5V=-I
MFZ#K.OW=N+54?ZUJZ5YL'TA9SK/J7<&B7C5+3USS(-Z%T+WW%7!:KMWMZ2,W
M'C#&B/Y3[)'R\;<]Z;2+,F^2@!@ZK=<YTL<=EF1",*TZ=<AOWD0]D>[P;H?@
M12)[W?Y3IM[DD8$%UQ&J8NS6*XSU5@CK./7F&X(J)Z=\&!/%/1&!X_YWSQ>R
MOK+PCS>-X ;? O<TXM7%):IC;X%YRAS\R0!NVW/ZL)X6":?ZH@[;3<G2/:*'
MPJW-9"UT'>AE -5TQ;!GHMY)M/<DR==@5(4R$F;-SCH]XN,G(1K>@TQ$!=)@
MI^6GV!I3K<L_'?.(/AU^U2)GR;[9MZLD7NEP))).D+PR]'P8R?N*F_IY/_/W
M'\:L[WDCB'Z"3W<E3]( C8?8"=6CXKKP';Z#PXI^:J2( -WW=";/HM,+MN*=
M;'*A5C/UR4WXCRF%F[3T Z%BWOM+@(_%<^^1JK) RMTW6%643FK4F9%O:)YJ
M 3QFL8=(N:[:._UX58Y58(W5LQ#FK!V#8*$X *OER[G_B7,N\(\T5;T7YY3_
MW/DW+J"L22;]_00H.+*_O#().3&<K 2K"D_F'-!L0:(6T DUE25A'7^GM!;#
M'WMZ"Q"/.#OP5N0&!KJ580SLD COKWJE$"9"J2%KOT=_%V&SO#^<M\!8I0$+
M^;6>[S=8LD95P[3-T4$$;XWR9:R(C*V=]6("2$Q20& 6.,LAC7B!C2APJ+(/
M=CP#,0P]YY?81-S,#V1JTQ$Z*6\QMV4*&H@$TH$E88X%U/23$O[S9:I%0U:Z
MLQQ.(D)?=\D(Z1BAO<+=6(D#4#8E%J%<"8^9*1R-D8.6/C'@>^"$/_K.7/#G
M&K(.:CL6:"/%BJ>)1TT(>)U8;@:)3"/JVX\:K4<9-)#T/PUX[*DGO54?^7T=
MM)$V%6ANE:,M3=.(.<T45#>@-WF/6MHS2ONY8%K=GOS,34#],(4GEM_8-:W8
MJV1VAX7QF]%O>A8T$YNDD>*S*@/KDR]H/&+<!+,W>V_!4CF546T,L&P5#I[D
MW>DEU>R5CZ]>B:[\U"3T+\:&3*A.U9;SO4U3;557BJ>,Q*U]>F#CF!B&VS#R
MIL==E_G9F(<,L:G]Q*+]A,'C2MZRI*7J/HQXJETO^.7WG%U"^P&L>Z#7&O\#
M8UBV9AC*7V)(*%^)Y7@YHL'9.=W^#[[[,;!,RA<,A*Y1W)4Y.^?&;76.HG>4
M$/*)6TJL,!2Z>#R''/"EX'-*9ZAA?)>DQS0LH7TMA2%3PQ!47PKN-+4E%WLK
M6M5-\8(C$@GQ4Y,_RI"-(@.[;P$*>VF6&&5]X7M"<2*;-D:+NI(RM>DNP--F
M;\1:8@:C14/@/7O=N0@$[^/-:4/D68P=3P6%)%I1D%%+&@=T'VT,2-PPSP*G
M@6$7]88108X'SD[O&S,+&TAXQFDL\ X(5+:"@&O0$S\'WUN *,4$I_:/>1E^
M$B(7HO2IFJ8_H\Y]8XVH>9(\NO4HX4:E)^&/5],M,![U]/-2J4V^GUN4\[IM
M8*U')!I"B^BQ3AVVK'T@0"KEKU0.6,",4)\+$U;+[#%[/C'R7B[U7F-&+9BY
MRHP.O.J'O8.Q.%G/>E\=MLBM2?%W(9$);"9FQJ:Q<P8S+]YGN1"HZ# %L2<'
M&_-%T0=VAF+(^MJ?VRLT['KU]U^'6<&R>G@KP(\J=GU2F@NWVV=<YP;]\_K>
MH-<[?RSIJ,QTQ1-J<N-.>/ S[*2=P4]ZG?UMO"S2#QSY<P06%!LX*/)/65WD
MROZ 4 $Q)7/&9@4II02?G>W.BX6?H#WGSW^9=TAF/ P!P*']%68=*4U4B\/U
M9;9-(]'P I-GZ.'<4NEM6L:Z;KZ2C6"\+ '! Y"J\B2<]^$*?GANGI'W]*A=
M8JWMPX#GBIOSRT!*KY\F_DP;KQW!^3C#$$VW!!2^4$I),SWG';\XV[9-DG%R
M^N?I9A6&Z]786?,BS96D;MMD^4O(N0.1N>! Q;V%(!&7')+N-3HF=U-1E :Y
MH0.]_X=$V* IAKC*U*C? S]UMISWIVLRVP?&]14W[\,)J<DLGO$63DQ$CZA/
M7PJ#.(3W(3H*5[E*9"(,DI/87.^<$B1)B8WXIKIZQ>1$U90TL(OAR8@,<K"C
MJ[LYI1 )FB&DVY78A,-Y Z9?3]6V/E?>3-G32AS_EU1A=!_A<#66"1<BP&A\
M\-._$$F:F8.%7SK$B&VJ543KO'BE5\29&KBN(+C:.G41?;;3(E_<O<.7:I4F
MJ[?K1$"_VB[P+4B*1;,U1FW"J;*"]%%=U.;'RZ<A&MN@88\$$EAHKX25-"OR
MVJ!\)Q"B(8'L4LK>WW$FWY!GI%B/I5"7F,[=G?.QGQ,^SV2G4FWV9K60)-!J
M1[;LR6,3"K&2"O!1L'VJA&*!.<5\A,BX"M5XSEPE ZLX'D[&&MXH07;$F92#
M"A)N=L\A=4LSA8BE;L8>7T2%1_RI_%K<P,PZ=-@A[*B\+K0$:Z31-G7#YY#B
M$SM&D+5\0_$R8=#Q=&Z6'5,Q^,)AY"$V70<3FT(C8FB_4]BEKIH_RS&@?O&Q
M4O,>0'S&B+3Y(,T,<^A>ONO1<. 10WO(YWAROHW^^+HR.7PQ-H/119U,7I9A
MF0CN.Z2G/#D.>66B.S#\![T/I],C<Z4%UK-1'1Q.AR:+KC*DT-^''GO99+M5
M\L[EV_&\3A91=T Y+!PE.0!51,XUP-9L_Y]/X?X_,A"A^M'T#-BR#!N*#K Y
M_Z2IM.X-.[[^H>AED[$U:E%?E$-<^6#GLO![?FM=0EDF&_H+N0<OTHVF86Z&
M\?*,<H08YCG1V83?EFQ[R-;;F&4G[FT2;S!SF>1@\9_OVW^J_:7QM\"'7G35
M7Z8N^2?LW(S'^6;TI/ZP?Z<FUI*E_$W-+1 6=SXC/7\+W*V<!?><M&37.L]F
MISO!A@5CD=&94P=1F\<2EUM^"I6+=O3+X?OE:V%YDX>&2Y:L'"61L]4-[(2L
MT"$/G4X_^2P0B4U'T^?)&*K,MLHZ ^-5;3_UG.09F];W;ZK6_ /VNDR9;D9K
MXND>7[U]@/ZJ8E+)EKNM),9%5>"+(J%1MTNYTOL!M_7\_<WWDSSS/GHQ&>'B
MFM50H8TJ_T6VVDPB_E[>R[_8D+-6KLWNV?,J5A]  NDGS3 &/XR]84O7G2@_
M;!LRMV=3_=(=V1QJA0;;;##^L<4=TSH?5WWDDZH)SU5#03]2@O::"Z5VL[)1
M4F2ZC;[^H@83E39R*=%S.QS6S/E/./229OKS[?YFMQ3?R2M_]4ELF@.(26R1
M]LWRKP%V:=FW> ^'E8J$M0X&UM2Q7U>69;INZ$??^W;5+:OZ+5 ^E7L.T=%J
MK4DP]LHA4QB]ACI++34S-_L6[F!F[:OUYVJ3(ENF=+0$6QN=?"UW],XJ'QCO
M+(&.AE.=/DJUE7+L"?[@#%*.J1@GE;@,[7%9HASUXRQUN)%,-X+_:&J*T?FB
MS'=>GTPP%L[0MJE^^.4=9CIZZ"@VJ2^ [B!Q(Y@/SHTVN3F1+4*!;X  VAPR
MT^;I4XCTN21HT;1S[L#8VT7-+?(PZXN6FX-BF\_15L2U/,J$7Z=5PBO8.3_I
M8,5TJ(SGT(N(@#7<_ ( (/.QQ'H_L'>(2LUP[70OTN*R\GC>4%[I9&S:YFMV
M\TVSVN#B'N7@87ICWATY1YAI?9RO1;R,IRW\HM12 R@?N-RS(#2?+W=H@Q<H
M%504768F[>SC&-5EOGS)O'J2@&RX!6)U/>MER+[[QMA:PRH@OR!L!$^^:C+:
M%,JQ;SO(Z(^=@BJC+Q_'E!C,D;"1<*Y/E)GHO+.[_B5P[T+_0R_M10_@P_MO
M]OD&D?4R\X9VM#'YOY)WFJ"C$+-(,V<^_H7#WOB3,Y(IP@D^9"LB\3X.DZHY
M<2U%^<"@/S\*2N1@&;F6H7S'+R_,(O_H6:_4[T9,]#!R:_7TT!5"7$DUU!B7
M+]LC^!0W]K2/PY\$\"0KMWNSXU B_=VJR1?017]_0T[8X+=V5C*=AJZ!6=P"
M^N-.Y<Y:1';6\<KY%(J_2M2??\]2*G>E1R3DFOCIC0F9: V/VCVPXW^<:;%;
MBJNQ:1ZDT=3]6*RW#21RW/MZK,4952[3-2:'GY'%D&+R8FX&);:%]^&WTOT>
ME17+>-]CG&T?T4CS[(XTT];2!4,#HG2Q[VE*KHS*PSD?B9@)--P-/=,RPW.M
MS^=!>P[IZAK9Q"4[O69?&%U-:;R<2^Q39<@\!FUKQ5'2+"H0]-F(P+RJR!1)
MF%G+JFN0>X?P.,Q2=NJ4U[U;QBFYLRY&.N5UT_L(CI@(%D]MHH14UL3$(-A:
M*^"C4]>:M[3HGS*A6Y6UTLUU_*U!,9 G2'Z%$<T:FI41'3W??</2VDXMTK3Y
M56JUCQIC@AAWG=X@%-Z\)$D(]Y,Y$N%]?PNHJ(0ATDJ].92L+G#Z<(ASPN^K
MO)D&R.2,O\<*_=[G\7BR?I0:#I8H#W1\1SU]1W6ZBS0V&A>02-+8B@;.-C"(
MK(!'[6%J0TG5AO?DTS\O35#W?J*YZ@APA*Z[[M5X56[/^>][ZC6UAL$7&HY7
MTC;(EZ4$\M>G::@3"T5['8K3U6L%^>*8.AO#O.[YH9I/$EKC!:>IMFX8CVZ!
M2#_5@MWZ[^I'O*=))@M$L_"PS(/5=]T/?DFO "3-KL'1P"5US1FOK]+8:TN=
MJ3+'U]GN:+U[U(>%*$&# "!D=_KGG$[K9IY-T2"E@O24C7C:$\IG1/ ^NI\_
MKT&1&*4PYT,PM,3^4K@^'*Q\2/ELT<ZG@MG!)"^8Q6J!-, Q0 AG#C:-$&FC
M..J8"IU_=2S!<8]C%2_]RQVY&YX[1O%=]8;3R29CJQ.6DP53CEJ=<I^:'#Z0
M"YS[K=Q URYKTZ3+CUZAQ#QH3T\*[1T<(1R?C&.\_4Z7J^6S[KJ)G;$7> 3P
MA2I+<X\+D8AVI 54%758G<CC_]K#+R_#_Z$<&U*FPI3*C@R2O.)U>#59MMY2
M-;E_4&XY_'LETX0&EXN'E !?GBQ*"!33 'F$K-WALY'CT"P8ITE4[K/6=)-C
M7-=+P+[B@F.<X]%S\XHUKGD)(O-*%N_B?IJ'9I"LM1&(GPT]W^OT8<X\XE><
M0@MMLTW1['N].-.\=]$2E9U=(6V)<!$[S2&SFQ3.!*G8ZFE-ENW/6=8]<I?H
MW6116%#4&*^ZYD(9P$M)3/<TKX3N618;&X(*=?P:^G"^)'GW:O^L,-,8%X($
MH@)C":-XT,XV=:H>M=%G5-V>"'"*["(!RNVGB^^)\7 "--?@^MDDI&!BWK"Z
M$<-3AQ1I=WC&VW5 ('5,0;"<*NX8BI#+(3.?N%;*W9WF=R[<DX#N;S\?,S+A
MB,V;#..(]EAB'8,<4"_YFW8^27.N*7-VBT88X_ZXX]Y,W )=]YF.-9DUMEM^
M"&;8P@9V&1*/P#SG=YS30\*4'ZN5E.C5N>[%GR&Q9O(3E6";-8BZ[UV^2C2<
MD[I:C=;]'ODC?,$+==>^K> =62:EJ!8CRSP[GQ_P2:$+),_^1H/JD\=:ZR74
M=++R%G /AWYA)B*-MJ\ZUHUU\39W!7*J0URS%J:CY[:S:!NP9('ERQWVT)1H
M;S[^_)^---;IZ_P7P5RXSBX^[J8]JX&_*3W,+H]";P&%<L"X?;),J#2PUEZT
M#NEBPVS=74J_M=M]/W[0<!P.$N?G@4I*ENJ?M,&X]!1^]@_B!@<;B\9;5;5C
MLK[F=ZVJFCUP>&)[\FUY\2YZY4/=^#S#HYG$63<!\0K5SC=2E3%^7D[(.>'T
M.$;ONCG)AWA.N,2,*\Y,1\]&*FQQ9QYA'H>Y>I'D2R S.7]M<T13-KTX?D)'
M7$*JS)X1W6_&:+>%8L"^79@%<>9\$F\T03]S])8+;*'9[#558FZSAJY*D:EC
M:?+LS],\R.UCSB5S?8KPKI9>CHQ,LSQ;$V/TT;/YMS.^HW>IEVXO&M@5RG0$
M<]BG9<5.#/KRMOZH:1AH&W?)?M;_"><$9W03[L0/@7"$2*9_,?>-.%XUX+AO
MY6=C'SJYPDQ8X,V9$B==>31BZOL@L+9,>'YP[['I-_U-'N R-@%1YT%B2!;)
M+%&%Y+V!B"I-I"C0K3H=4%)(#?3V5MD#>[69YFD(NS,3)24N=*4S98K[S>$A
M6GGF+U$S&J5BPE+9LSRPK:?6-NTHG5&UPW5,\6A45)X?^\*(V[<R';\HFRI#
M[%R^OEAM1O-?V/NJJ#JZ;LM#L 1W]X,%=]<0/'!P.UAP.+B[!G</;L'=W3VX
MDX.[NTM(Y_MO/_1#]^C1#]W_Z''OPWRL4;777G.M.7=5[<W!L\A@;^O/!XS7
M,XBV]A;\01N4I_TH,J;<VM;FP=1P105=254CWDU\U H&!A*D \ZYUMQD%C^'
MRBU8V[UV=]^#OZ7:>II;\E6 /CRVNH#@>JM/$I>70U),XL>>E.FUM1%9ADGH
M+Q8[;OI3ZK6\[6I#;%C%9LT$K/OD%0AC?_(!)P#P:ZN&SB?0<LLNLE2#2[IO
M;\,>!3P%$"\?:B*SVAMQ=Y0J8GI^HX+X@"$O)<2_SDZ#J+*D;:[:IIIY]#^.
M'H\I8) I5]_W0SM0$!WT+ KWVI(7AM7VTCHW?9MJ0;43^AH1@AD4-@F:OTF_
M_?GO%]7_#\!05%RD=2+@O4B47*&ID8@BI%*E]D!>S5_NK(3X,?>5Z](OQ 6S
MQ%* 6DFOI._GM5"AZ-KZL.5!R:!M;\$R&(+OV:!DT]7^.<;#K7:]-*N L&<(
M)*[YUT41ON)OK611/<CE?(D!$Z^$MF73N0H6&B=L'C X'4H):MAF7#;WZGQ>
MO-$Z5)80[CAQP,G71BZO!GVOY?L#,.<325Y6%B-)*;@<ZVUKN ;YY URU>DV
MSK6FB.E(#<E2MI&@IYZ_:*P\^LEY9;'LG"K_2-?Z:@*DP<,8J_'/#8CN,(P1
MU$C&@1F%D*-T$%<?%ZO.-]#3=ABGQINX/^1H(/6P/P?I*71V\*3,@%<D2-@^
MYP%CN)%*<@T!B  8%64QG$8?JG[]V8,Y;GF3UOI,(YD<"C)'?I*@^'D-R25_
M;U:?K1,]A!.9"!N!::-U?M*QSYR)C3<=OBZSRF($;V275:%;\M*-T[?+UCM.
MJ1]3S(%%^T9:.W2EVY7'SY(AG853158IHT[F? /Q(F)"NX[\B,"2\@8E1%Z7
M37+D#7?/)?&V6:J_582@.4;:<09E]\S[@CQ+X8<[:W\;7KQ3X5&Z&L]BJHR*
MRZ?!0I7W_?R"L7 /.T(:=S@P 26/C/WI30&0O(TC95W+^[#:E:'3E7QU &IU
M5K\_@E/B>JKXI7FH-^=7!]."(P>=7D=VGD4S#X3WO:XT8;L[V1P.X'DE!!-?
MLEFCR^/#=S]Y9E/(*< R\E537Q)DGP^X)U9>*2YQ*QRI]<G"["A2+/?,5-X#
M(7@_KP4QC_0Z<6 B2]SE/RUPGY Z7O>:S)\ZW'L% ,M9T,0$95#XA4CNN-,J
MO#DN;;O+LD JT[GI5S'ZDO$[ZSY:C(#A8U27!B4XU_M+*%C2S@;%OA?K6PS?
M/$-^@#^ ! #OU$7UZ+4%PEVK7&\LD'1R++!+K[KB)PV@%Q>-@13E^[/G]'DB
M/UIV"#BW._S@..,I0ZK6/0!F'F0>\!]PI_K]32)H=NK7HG6+4N;&0)PF!$M8
MJ1\'MI<K85-&"B[_!+[P$;$/RCC^;!:/6ZY@94-SG37T&#Z*F UZ,?!:KYK8
M\B'R0Y/8>K)^L+2O@)"00:+@**HGLE8Q!!?_CGK*/;2GB_!*?1Q?8#T>=?5R
MDSHXC1@V$^N'+4DVFC17]:8?JFS>FD7UCSZHR_R9 Q-\!IDQ28IJ9K4BSPYI
M>6Z^/]]OWBV[P(;PROW:Z?P0+X_%[8^?Z_ U]7/8C1S>)NU]&/-K9TZY5LI/
M,F2$6JN+;L[!7J07#2SV(!*8.5S/",#N^1OA(\^+>LO\.1>Q:T>+M*R>]CS/
MI@1IKC_![FN/^7J;%]C"NI*RL5DA3IQHF&@WJZP 8'(SK?9WZ*+;!G#N=H/[
ML%5'#FL-A)A=#]%)9"MQ0;%6L?*7Z,$-FFFW$U2,&NGS4/D]P>@K[ 1TH9S[
MKH=.YR0EA,_K^#/%E[LBY"E3KJE(0[6]^RT]GY!>?ZWUPG9R*EVF!)=!%@7V
M]@)'2Y=W3A_>24OIDOB[QA$XNO,?0ZPB  6%A_=$3-CBQ;V[PUP7]B>=&1S\
M8V2RQU[.)<ZB:)9D1,TM03)U8*TJ.DBXNG:&4[/J*-\A'PG2?+X_V]0W+F Q
M3[:UWXS.S=F0*/]3CN_OI[6<SDD!+[5LJLNJ\.TQZOHEKL<+2JGU@+3DI!>.
M..G-?Q9I]F[M0O6Q+W^?5>XG%TA"G*Q)I!ED]FIV4%M2GEK>[AU6<&FF_(68
M/;8>&P2SR#XZ'^KM1O"Z,46-:T=TN:$D>!(=T>>BB**Y_[7DF(%:#<P<C.P?
M$:10)B]BTLRHXSC<)VS_#]Y+_W\%3<PKUJ&';*392MK:^@B/<U-Z(NLD,00/
M0*#LV<@%.!MC*6=@':]V8:_I12@525XZTU\"E]J+Q,0'(BTGA^1#*/3SM6C-
M[*3M+6VKDD%!7J,-[&5"Z2A.\_U6'38!E%O)L/OJLQ7Y!X!EV>:=KCZ.:25@
M>NNV..;X(43ZRVMUC-A!R1_ R:(I8=#V8B)LN54Z?CA7)(]A_H/2G X?_U$*
M7'RVH%M5CNX52];6;X'%YZ-L&=OBB'7L]ZB=/_CT'X>]ES!+'U>TFF;/F5X=
M-I&7;T>-+*JJG)\6]ZF^??T>W$^UT^4HTAA_Q2D]Q]I!O,58B:_:'2J/[YJR
M6 O6K8D=,[[N(J;S#.BE Z8#[JT8)QM5O?*]Q1[]"B3*CCEU&MPL^;,WZW7/
M(AE,AV#C/$9Q(8,/#TT;6$+($/C5*_#JF"M=!#_2CURI]ZLP_8:W$P WEWC(
M-J-\-_;&(>8P7WMM"/^NJW)-^0$!_Z3[ 84F!G.C79@^\U*^"-6"LP^^= N>
M_6#AV*XL5YZXFUOOR.B0@#$I_P0YDJ5 F;?$579\J=6<KJZ?V4H_6FY.>U(>
M:FVX:G_4#I"0,?L6YB1),SF6R #JC=/:EJVMV UIE[6NY2"N65?B/P;'W1UZ
MHB8]FX=6,)V?F[6UAJSA6>['M8\\/H73)4Y:P$I%/!VZ/WR^8IXXSZOV_KS8
MP"\R?6):?&3)0,T.&\R!&Q7^X=CC#P"FVF6G4U7S$;?\..[8%AJ2X]D4I-2T
M!I/)%![:TZOWLQ]X\M=NV>9WN T1L88+T6S)"AEF<R^:+U1&J4S94 >=VK4F
MRU50&*)GS-_><4^[URLMW$WA6&1CS=Y];"BY8-9_?CY?]KW]S/8.Z/>!.MLS
M1K@7<'QG@*EC\5P57[PJ+:A0]F5:;*:$H:*\Y7R4@("T7N=NIZTXM%$4S5OB
M4J$C_>ZMLG#4BU'*A0YK"B40&+]OKRTCS#XD? R&D&.XEV\;1'$5;-NH@F9L
M:/SCS>TUE(;8@Z-CO!N/%1&%E!"K9O2-?YQXY@1Q__;J;VLJ=J@ :UM*:]2V
MM/)_EVI%)8E^E:8P_ -X#A8F[R=CN!(-^7JE/ASMXJ5@=,W:J .%MH#YDJ)'
MHO%$?-D3?+QVXM#EYAOM3E<RWOO57YQW_>(+]:D07$2_W^5_TEQO8!S)&!+(
M[BSPYEN 'VBJVSC.)Q[9C(^G66G5PD!GD#M I,I.$3B(Z*)[;)?Y _B6HS[7
M$"E:SR__\7ZTM6 32/($B1O8=!JR@%TLI^OOHJJ]$DEQ(16=>!'-HJ88:9>E
M7Y$=+I*T7\<.54_4N8H-N'B5*%T#:U,C++Y.1+8LJC/Y><3([.3\ :AK/#+F
M/ODB=[2^+2X0GSF!$).6"&5<VU&OHKRK/!-7IQ$KE-4:HGE?@'+--2\V>Q<)
MA;XS7JQIG->*VC4<'M6$2RZ'^U>3]<;;&P3N0?W,*"_.):?:^<T)3"B"'*4;
MB:.3@%WS&L"# ..W&!#VQ&4?)W[8K<;"^WZ(/,N)'S4O!VPS\?W54?;=05M7
MI^F6 D@FI[\;JU'8\1F\G-]:U]J!KS1*3,).0*QZ,R7DG(NN>06*81)B=#$U
M9PXI+MG01["PX5JQ$U I?\@@)$%9$H>(0BNV6JY-0R>B#<;27-M,S%$$,5<U
MXQ\+^G*@!L2WR]W-=RL&35KR/"_@B6B$5=3X3.\RAP3!! BGWM508MECOW;M
M4H=#N;MGOT+.:5,35"N>)CDU-'Y7S3IJ%_[^M4>X[?J<$9DX<G04HY=8GA*6
MFB$J6R2P_#"]LZL[7_MX,9)J96V()DJ&;07T)>*:F5C/CLB=^"\?7JG=EFHL
MV9]2H)5=)QY55/3C6%^J0 SJ+4^A!Z!9YS5YB4?28HBG1F6Y@H,MQ3ST TNX
M.-'.>+#8$' EL>&@$."E@'OPQK18O'!7C7C8QGUZ657,UYT-]D#B_66L-X"%
M9C\0\*B9JP0CB?.?%O!>8\3"4LLK!CJ]+K 87U2'2&7)AB/2^68)%OGB5;A@
MU-4,Z4D!.,?TW6)(N]Y.6Y#?+LX3H,]M(2O@63I.*-?F]TS,4.EA"LQ5O[MA
M/4F Q^!BY16G1DV&G &BUM$<B/@S-*DM7Q;+Q+ F6MS.'LWG*)OBDBP/<CDF
M.=W EKKD*3R.3TGM@ ]%8C<#9.-39YI<"BX5*HN1.6W;L X*%#P:#*;[1N-X
M+B9=IS6$5TV':.-#8.B?G )ZCZ::&.J/?+FO$&,ZF*N/V[B[LDR+1_D@,N<)
MYM^XW-<O>JPS 65H[!.>/C@P![P"!A&OY-N=8-7+]5B$UJ(3M/H)LR6(#35V
M0(CA.)MZI\#!',GHY@3V((;[A?Z2MZ0=G+%2H[\4\RY*?/+4^;!@N')4+0!+
MD:_Z4\E!Y%1S M9YME'R!K&-Z<B0^*G/(>QH-1=BV^-NFU&RS\<H7XJ6R#K%
MB.EJLK/&;EC]=MV+X [BXD>EM3'XA=]W9SL?6SKGZ6Z*XNC[ I?_JM6(PQ+8
ML89R=!)O47P=D>BM%QL_:8]UR$??U90I6Y+=@I"7'NR5YTW0=BSJ8[?.HX)?
MD<$$6G&UGEQ"6.X'' ?6[Y5[I8*..+!CCCXGLR6Y:!+;BN$E)W\ :-S,=%^:
M;RZ*M+XYV*E/4G_R,$(4\UH0Q7%WTU70E+R2#C4*]%%5"*@\J,L6"]S'@V4@
MSZ\1"G1_K?%JHX<=,YM[==H&$;H;:R]P\7%UBBJVQ76FZU-?4]"+QZ\:8OZ-
M[H>3]+&Y\P[E8F^UJ\&+T(8Q'QU,[CI=K<Z1@%%V[ZJ8#?IA?L0J22]N8TM?
MHOI9[C5SS>84UY:%;-XL$T-E.9:9!L#[G?ETP#X7Z(-5VV1QQ<D;<P@RN%-N
MX&CZ%WAT'QEBG"#!PS8I>\RWLP$+5 S:-@]M('_\?'HKC[R\)6%G69FQ$(TE
M]%5^P'$PR=,3K1-4/B-&9LSKS]I0R=FC8Y:9 XF5FM?P&FUF,"1)\<9.X&7?
M-%D\"+EEENO?9HWB!F?8L8PIO=#],ETO'O]%B-K#3T#7@OOKK\>V#<JSTO##
M%M(N7P5;UW1'+-@4KA=[_/=/[W&S+F\4KUB#;]>D);JGIWMMJ)?P4FO7*<%-
M9DS8=NN*G0J>I#@P\C)M71VSE>?<S((O E?S:39"=QD_^87L]-$)A#R74"MB
M2: ;5CRJCT;]0T3< T5@9>X!O/VUOZU+X_@D%+;VY-BCY]:*'G;88"N[';%?
M>HY2'K\S4?-M/E4>3;*>UF]GF4Q$'^?9Q'@]?ZF#?X<<XS"E!NK.*3_-7'%!
MV?(VU=P:OM?"T%] KR8)2)Q/#-"?D@0X0$-"2Z:NC*46=YHFL^R*%>#J[90;
MEW=16T>? R*&?5@'UY&O>&J]MM;(-O1G&SW>YN^+SFP*F[_'?@^Q1<J9.HKQ
MH8T [-Q." YZ%H>Z-%Z1#C9H"B39D59&41"<)N4I%?:,)2C*[GIZJOFA,S66
MVR$.Y[I'?@93FKYOE,:7Y5BC?<\<_-(M<:)7:/H8])F,8C:[YU@G)ILPR./9
M^>U+ 6FSX:57E!)BYBO53#%15[V/!T66<X@ [K<U)QP53NP_@%B*G9?&$_6,
MW$,-,N(9FX8L'B!I95M<7HQ6@J-6]FZ";"7#OWWMZ-^/UAQB]R(#E*.F,6/S
M^S4#I2P;:V;9'@]T5^$D--#M,4# BG&*;OJ-[H>"'WY4PU(;K/N<:-T\./'W
M%*_@U<5BP15Y5&/#(Z_;-E\EW8S+]V3<_&R2[QL3:M:(!*84"6CHB(O^PF01
M^V;SO[S!>=I-G;O<$S\22#E/O;KF/P5U3PR/-L]U:LR+?'1GE<<B7G.E3V<,
M;7*^-C''HD/A":8#_ '@L5^(D?K@3A@\IBK,>Z-Z51[IO&HL!B*8SA<$36%@
MSG^_2I!^D)F0=]ON).Y?)ZQ=X.XTHVE.(;A?[3!5Z&5 VXM"V;WK(5%"%)<T
M<?<:)&*-J-!Y^#Q/U1$ AN#":X,*& '2VXQH-]M3 =;</'/G0I*V++A-/".[
MSHC3;:4&B_Z" HSA5P]A%\Z=O/W-.MS'3&[/@Q7H5 PR=7TOX8 XJ?>P\5-Y
M55!_),;D)1'J1XE^S]A[W_(J"?@-XGPU#R3SEQ6<LU<'G>9UFIG;,SA(*O[5
M'X 9QC?=(92(WC DJ6FG!&DYP$)^*]QCX68:=]X/NC ;A2T_)M3JO93;&_;Z
MN\HUIP$B4$C#CE_%AJ2Y-=KT-7F'YR;,&!DZ 'L08*FL;^=P138,7GIE) ^^
M^W[.='[Q(_">'8^@)*H&3B!$7QK.F*\J2.TQ<DL8#W+H0FHFZ&%M(E,L%?&I
M][LM -#-2_+:.NRMA*@L:7HH0CWS"OIZ?X:O%'&](2A/*ZYZ^-->[06#$>MA
M.S;0^;?A$:\^19/\H$_4NW:J)H<0>Z0HM]&=3H#+K:;@-K."C5V'2&EU-+_M
MA08[0</-X"%01/_BR3R[O8P9O$WW[?;CA>'\W??*HCIGV0*+U1H67GHE?.9A
M.EN'#1R8N1G=LYR8#LZ21]<3_?J%_ R%!I6YGV$K!; OH]']UU5.6SD#$!".
M!?Z<E4XF[?W$;OH!^_<$ E[24&KXH9EC4"7 DQEW]/ / -N;N/JXX,N<RS)M
MAY$ZT&)=^&!&GA[U$1NL>@(U;>J&Y$TX-:NTAQ>&D#/'[.H7VQ-+*^[[<Y54
M_)8&SS5D9"![G<0R@)^ZIJR%FBAWAUQWWR'"=M'/-TX(RK36-'>U7!=UYYS>
MCV!^'WF<%%&R%YX$W/VSSUG<3(=J\:]'WP>5^5<Y;F*+._PF7MK!O.OO+>JA
M%H1\U*B_;]*;B]Q?^J #.DE- N-8$D5_ ,.KXX3 *!-_-S9 4%#@APF <Y(F
MY8]7E4N-UC+:C.*3Z5$WH,UG]]TH0<^/+H <,72N49<U65]V\"'5 9'Q8:7S
MM+6^Z8W<^5KTFJ Y#LPO94F';+BE1E2C@T$)E3:LX:\54S9V2>J8 RT]FR@[
M\[LOTXCFDHYX&S@=F&X5T;3H&"O"*R*#Q+I WMRXZ-!+H<6I,"&%_$>= 7V(
MYS<->W9HX;7V5'X)7/,F/:Q.Q$$'[TX.JGMKH0*Z1L2Y3,A!+$1JT_/,'DWX
M*J*ZREOZ,C;DCK+8"KJ*H>_P/5 HF'/.==KU#C'308Q4 7?8G7R 5^>^>-N!
M^5A/1^=81#V#0B^?*J(?7GJ<?U(14OO/5FE+K_(%[CH]!O_<W76OJ=0[87A&
M[9WL,Y)MP'8T_J".U_JAYS?-N#SHH+B&Q.'/'LS'",!2?D?SIRO; K_+A#GP
M@K?\[PP/FJWHZK>>>A./P4\>5NPC ',2EZHI[:OND%=A#^:BRK)!2R&-[;T4
M2;L[TZ; ]P3&<;[*B6=BQ+<:Z"&OD*TI?*;B3PM4[6Q_ !5B%3$%2Q" PT64
MN@'J2<I$GI5.\$$X<-ZFTHY6FV6W":_<MLQO(<XAJWO];Y62Q!U_]-M&#_96
M]:%)B:X8='+VKPTK&!I *W2#:?'AE [KHG17[4N5AU1"V,&Z;&M[#$(QB$:?
MWDGOB)%RXXX;N)>-*5^B558]NBE';$J8"\6#"%#K)#])J8?"V=M+;VF\$I;H
M6:TCS;@@'WFOE&?P%:8HY+FQ*\GV -#[_'GIJ\P'## Z/F[)%S8N-GZOK"*P
MO4XFDX:MI80!7I4W93--5[\*\G1;EDJ*I+WC'!,R;.HI8$Z&M:=PBC*'^O-8
M5''X18K -[>'+!I@@BOJ&>K>SC_ELHVL]MH7S[/#N0TZ+SUW9159VI6NK_?"
M1] [V9^_,[SMO<B,,JZR>'>&NT_T!S"H1Z<\:Y/3)W"KHH<J!R5,'678I_/F
MP9/<=1TA\5PJ4F 0ATN4D9&9K_\JRP=+%S#Z2@]SJ^&;4WG45A5.5F_J7&<Y
M*V6J_3.96,K17@R8=\R(L#%PKS,<=ON!:P,SN;Z[*5VK C7(KS!XQ^][#\Y*
M3*:9O\ Q8Y)=N#Z&GM0&2."G3]WV5J7Q-PE*8ZJNOO<KPQ,]=$'+Z7INVZ"@
M5]Y2/W.KME4VO3\ '+E82M!#T\>5I2YZV++\EJDP?9J6.5]"*Z*W #^"9!6Z
MYM8HI@@)F0(@15"<@LUQ-LULAV"^9"DD_9M&'*Y!MF+%@#E208*/?RYJ!"-R
M_S]_]$;FIR@@JT;<_.2+_U0G\))L^ \MBO]WM!BS(F.:=4%'A:3J&(1AS5L>
MJT!NFS@KVVU0"#X2Q!D&#8E/:+=?Z4=O7: L'Z>OUV.MC*%XV>IS%&TF(SH.
M(3AZ;J+1P^;FUPD)_T,0#6:O?"M,?;'*QHC BN*99'_@%6[9>>W0+']?"76.
M&#W,O"9S\=\G2JDN^W7D2M0'\O(@ST"11TEC#/3XN:4(P\?'5V+G2_](I[B(
MENRR36S2KKG<PU@'=.[G@]<DO7;_5R=.K7Q,E+X\3_U=7&Z% ?V5"1\?XY;
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M+HV%CUED,T'0-?"(<3HB+'%\J,2C\4J &$EJ#)/SX1N#.]H=,)R;D,5,VA3
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M^DTGW1"KUHPQU&SDE6Q]JY)+KXOF<,A8]S\>TI?#VD>*=;YBEE=VTA8\V];
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M<F5]XD5&?T&J?DM*/[>U9K;SLP@CVX=+KFQ %V ^1AN^:3HG>S0&RU\N21G
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M;;8J"IT!+:"%XDW[Z$A'A/ R.VU+GC^OYF8O9>MU):.\]$N]K@A[Z_+=*YO
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MQG^ST:_QE#VG <4GYTS4^0^@_.T!-%?)=^P:>*J31B#C/I6R(C[DFC(TO7P
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MZ^7-;'5(5M[('Q&4^W9&=H91Y:WF/V8^(W[V6'[8#0_Q.L)#E'\UZ6L@C7B
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ME*_['>UG]1[FJQC0JU'@2;^MC!NA.U.,%ZT&K<ZO?CWV?ZV!?:KBVS*2^Z#
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MWG\\! D+"PL7!Y<"#X^"]R7-2][_V^/I)X 0$WD*#8""] J 3(B$0HCT- @
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M$/<Z:E[1;&M=L^3_]RG]"__"O_#_&'SBTK7+<$?9MGGNS$A3H'O 1?T6RXT
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MSDP#8RKG"?#3__B#V&ZHR[)M&*?>J2A9!EW4]Z7#)'/[)G9*!G@D3?[@SJ.
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M R=] C#@/^\AX] GP#O22;C'*3<:0GNS$CV>&A1EEA8YIOUYG'K-A6"F>V3
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M6,9B#_RL]#PI4O 3QT4QL-0MYF&@GM2U/F S)C/C4*WTW6-%0.K=OUN?74\
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M+ED"/?=*Z'C8S]Z]>!EA/>L@,!_6--=(YY0%%/!10-?%$(<T^PIX!W1_5ZE
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M[-#$-P0T+F(HAFM2+\15OALMK1_=G<94ZQD)Z]E7[\45MV+D>2"%2!$.\TV
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M3JE#JG++U#9;(G1JA72,-\[$#2"6D@M\^0+--6KOP$ZUG;*WGN8 AX^5E@W
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MO1WD]1=/B4IH5+& WB7AJ;!/V.'*GO.YS-[R0CGBR3FY[_,5AI,[9?_;R5-
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M$ZP3PH5:*4:Z2MJRO'O"*NVT2E2#7Y9,[(L<$Q^Q\Z[G#=Z&F#QXS_.B.G+
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M@JLLTZ7!V3S4:NGROHFJ9D+B//\GE>*7J@]U "3:LA4R3:-'SA3^6C"/-GB
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MTU^@-KRCF:EJK%&>.Z4D]WW@0-&=3Y_-;TN$/.D,Z<8QG;B;@-C3JD*&%D9
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M3N9 R&OU_O%#OL*(#BYB#N!+B(QDHT5TVQKGTF(GXU&6OT $I4C*EM[P//X
M38S'W@N9W^./]$%G)<EYE44@9[OWTV^KFV1-K7:2D5YAUN $()$DOT="\,68
MZ1<P21#"GW! !HG9>!4U=J"6/7A_A"6 A:#-R$7&^GIJPP@H(JB+NP@5>VR$
M/NCWO&HSJ6B;+"DY(8?4M;B0?\ON/ZI9=Z(O@(I^ZN]  ,Q]*C\X*@$Y._9)
M-<53ELH1[Y@0%Y<6T4;/8_:/]3][^I;>_'^/C]+'GNWD,\59?5^2Y)PV<0BU
M3P315TL%.0+-7@RC7XOP7A8!6]_*B?6NX-=66J@BILMF"#(QE#$JB;RA@MVA
M".S8)=XL!3AQ )-,A-A$3V=:IV^7H-YU]62FA Y+V=;&4/=U FV>74=XP:+5
MP/+R'S_+T09</&P$TYNRN@')1M9UG\CU)!1>3B2F.KS[2XC(]O;ES&CY1JF3
MXMV'/GF(P]21'IH[Q( @_J,]C9OYV!T<4+#0+!;L.A:LR^KLLS%%C7LFG2NO
MB[O:"#0%70>_Y=4__W**X9[M- RSSZ%"0KAYI$$2T/<,2$?JPA^GHW_IN1?P
M=SX!T%PW(68__V8L6<]P#]R8@VY[1FHN1#FL?:O:?Y2UL>P!HSSCQ&1UT%NS
MS1G'0N\?UO*A$2448SHIP[]8'Z^Q818_:0-1=S*$LC?LBC5ORJ0SI_,BR'[L
M3G^TZ<644CGW<D2D.O4BI=M)*S;[M'A#ULU-6-@$:?57TTG<$OK<G(F? Q52
M[)C[PH.P0^$M2!&RO=G8,"-$(8?"_9HI(T?C91QFO[0E]18\;-DT8.UR!=7A
M#^$E3:/24MF<FXU'T[=)):4" M<6EL0_&*K(4JP^KNES0(1(FF>:A>%S[4H/
M;,!.+ R' MRV5"R\,+[!,.<+>'D$:M'3L2, 1V4@>:P9H60W,FVYE;:;EG;7
MX&*#/]@)?5CF#16Y/8.U<,-*_CA3F8,7#K@Q"/J6SZ&Z+ .,8;==33Y<I?^=
M?]'(:Y["FR_D]Z'T7R#^ ]&+[[EJ9YKM+#:,IXW"NL_ZK]9AE@;"Z\WOLWVB
M_5:CM7IPK MI^7MB:0LMGSM)5%1;_+NSHX77^O"YZ?&;68X'H_,3^93(>,.D
MBOR'^+L<^UUHBV-F355M17"/L05JL^'"H!B^B'J$=/NQ M4X@G]7H99S=@<9
MEM71$4V@2WZ=Z1$D:K\2XV/B83L0IVDS ].96^/& 9SG['FBT-"6M";W=G(:
MEH'M6/,+ NN:,2_L5(MK"R3#T)"Q&Q+O>"IM^VAP@BV3I_IX@2&D?VS64AYT
M"2+ZQ7S$$8KL-L#>ND%O($TD:-MN,/[R$H52<9?1)T80/%@CJ-_%QY2]F<*,
MH[D 7=$T8Y>FTV91K:\U)%73/-^TE$#X60XLN7M D)PQ#O&0E*YL3F;^::L)
MR@E+NV% HX4-GF4H/?'$-FTL#V*P9$2+B3[0,,>C2L+1'X!Z&M'8NP6RN8:D
M= "1-BR W4)L(G*EXR 2@8K=_J^VW1X&1D^ 5K!7SU7ZV[8IW+$N()]#\5@C
M?U(YSI D ?XRZ0HWNB?=$R#(GM\*U=FU3Z)F('#R#;X>B^:U_K&\PJ8(*?OS
M2+<YE>P\8JC4,KUUS(<]Q.C]D*XII!]#)1H;H;QV59;0 ]T-<A<M=1::ZYJ#
M<-\VN^:P=<^:4YE8S+W5ZO$\.#K()Y/GN703)/LX-=)1-55RU#JYF'^NJWRA
M( !!&'81]#!-=O3+WCNAW$]6"8\=>JPL+9UD>P)H91IY"\A<C5Z-=4.? "'+
MK<LY)BL4;$O[%J0B\)RH/'TK!B^EX'1U,S0N4=\?(*^&M&(TU<89UJ5\;([A
MQ=CBBR: \\2!2N:K=3-]<'3<8TIL:5?[YC(L@>0II"=)/&UM<FM8#.)L33-%
MULB6M-3W4>X,*LI#&$2#%\E$IYO@N!.^45QYZU4MV>AUA$3-[^((],BY"R^.
MS#5V]K%<FVM&=727Q LJ37FO5OH3Z<?D!D?**W7YBUHD3?<E^S[7*__)FKT2
MJHJ(SAF&G"72Y2^?B"P'S,M8[&(S-"=L<O>ODYVGCLT9C:M>88.&7M7HHOF9
MXK=GHO.?HN98;:8I*#X!_ _FNNL"!R@;[MZF1O7"_\CFB(X)6V+I6^FK*-4)
M9>FS64<V,1)WSIEAF)@(%(-E\T5U)/1,RM_G6C6:,K<H*3T'#4*^ZFNFY[\"
MC @=#,[>4H><0XF"9V9%8B6(X3]'S0MV;!$"+A1"SQ1(^@*8@)_EWG:N_.I.
M*#6I0[)X\U%B./Q\DY= D#U]!M@5/^1R1B37DK$AEQ!\L@9)P5@PC2[3HX03
MJ*A\!8M#+NR9!IYE8EQOJG-S2]1/)H"?BQ!'*1%$%" LS-M+E@^)>1N7NZ"6
MXX\' MD'LY(VB8P G!D*;5M?G'*N7F7M.RJ:S:5;7$ 9.T']AE$2/\)[V:-C
MIWB/M)R"&.-/-KA2W(2[4Y@Q5Q<7Y8+-:_KG6#%]2=74 F!"HLC:Y&L/,/<U
M[#7<3,_F-7)C+>$7OGPB6++UU-2/D1;6,$K*,N6CDTI633+4K<+0LK"8).]V
M/8+E@-E@OQDYN:<I&L)M6E= -:WB.'R(0\V,/VN@$^N5>IEXC1QAEUYK.8G*
M9!7D"6A,Z$%:7]: OD/+<&.@D+*5H (NGZ.Q7@>?S+8X/6*6(AY(*CUV3WFN
M@&P:[^A<<FZ/>^UNIO/%)HED"$&FJC3R)(RHC2YBJ0_#^N6"M+##[JRE![=I
M)U]K_(3\B@YH9-C>UF63#T<&*DNK68/J 6=^-S90Q9#-]6Y'O P<CF5A!=P=
M_G *"T)8#@8>P\4,UD3B^W:#=->Y<5?'N'Q3W"> \10#HWDFC5."Q:O>AI^=
MWG1--W9BL9\)4Y.Y4J'>NIW[I8J#B'M.F[SW)B_DL.!KQ^T/G>K= D.@'.P"
M1ERQK^ W\N-HRM IFD.5G#G"C;NQ;JSZ&DF*-+6EWW[/ H\740Y+C@T!MA4L
MLDEW6JJJF9MYOQ\DF#H5F$ =E@=U&>9P"RG+^'2CGH$3VH%L)*8[R62SF&%>
MSY>"_9#D\-P:VD_8W?(J>&0.45P(V>BEA"2=SLFKO7^Q5#/%:OO;04(?/L7\
M;JI*SQPROEK9UU2=CHRFF$Q9AFR :VTG>B78,;1_,U4[?NMW@K!=7*[8B%2U
M==[OG0H>=LE8*1^RI"E7O 6:/D_]6'](O;0AJ3'UKTK]XK6=+962<N!$ZG%H
MK#!3HX/NKG#F<T:RG?OMVM2*NJ0NHH"J#O.(+N<)4(,&%+BUT?:_E4][FYIL
MMW]5JN?S'L1!IZ>8@P-CX^,++\@J76!RJUVBQQ>?8NRR!=EKG7HQ4'$;WK[V
M0 O;51K3>;*NLN4XNV9ZX5S[P;K*@O13&DNN@JC?9%-&<)6:Z>/;4Z/O)5FH
M:- #PZ0<N0EQ>@DXAJY,@)_?8JGCKOAD&#K,%,,PLS!40_B-8TW#6*($K[FW
MD\.(1GU=X/'RT?&7"!,#(FU>;+:*2_)3$]@1*TXMHFXR/'=.FB#+4BO+4MT&
MC_<[XU^Q13XCEAQV_!J#%? 4.-]4J-%9*%:)$B7]E1]O2F0RQ-,(11+*I"4+
M<)-/R=Y/%F!$2\C74.O>M:,N0<:*/7CO(_T0GOL$,.)*>D@Q?DA?6 9O,7^S
M=2+.8YU+3WL&$63=7./J][(W#B0UK)TA"94%X2(P<+#(?59F%\^NE4?5HNQ,
MB940]?X*69(5T\NK%+=<4!,[+J]YOY@,ON[U8<CUOCG#;F-=8_(D$A-CG0M6
MLVXS*)#(5*!,$H'$+/??36D/&+YQ,T8-\JX)!7N(UQ(Y^"=:)B]DLDFHQ?$3
M1;&(D&;"3C::_8^<'??/.;&VYV1F+P4E'N5>,?(=#]X:-8#=&E:6.MCU;535
M5FTK"3I@$012UY2;3BT.;[1O::UTK3 TE\MRF :QOUHJ%XH@4)$COF[H]0!7
M9WGS$(T%13-EK#\!Z/IDIW<G,TVHZJ;G6):LH%K7YA;E+4[&IJ-J3OW5X'7D
M@BE9^ZE+$O8?T/)% \@4!:TO*U$F$222]5'7KA:>YR@6.B%"ZK*!_N) (_>Q
M]71Q;[*UD$"*D[]EQ,8@\ V11&C%??[.%M^F"Q6Q[DC!#3=P6B'Y7*V/7FT>
M5/55T_M4TZ7<KSI*$C9LMX $W/(W+^[B2*R]L;8WKD#<U,7TY8_;YFN;C[(8
M%1];086;)^9&Y+9L")Q[G*'KI>Z'5TY6C 4UC=7-\:,;Z.R>?1)K@>W]="I!
M)'NP",JG<MM3-T$_8A=%ZJ(7/(*YI"3K^+UM(K"CLL/.TOF5"2,#!,1+#_"N
MY_)EZ\#!YAL1^,8Q(KY$&9Q5VWB\!'V#O#Q']2<F0C2/R[(NL\AN;N"$^COA
M)(>[A>QPWZ\X7.?H5!?GX2U.-IZ+W1K46YU$6L8*Z4J#/A2-$OQ)LK3M@C*^
MD@5PXPB<%NMRVOSUJA*5=YRM;4R%Q*'T)\Y;6-LR/]IU#4CZ*07YB 7Q/L[5
M/H_;PV0Z3E]3[N3:'TI+-1$T(>S\5N*1SW8[E?5+^#(:[R4X35^V*F0'5"HS
MBGBDKKJ^G:;\7NW%]P'A=[SX8YHAYAHKL4+QMSE\N=^2;5]H'#%A=&<Z#/GY
M1)8"; G;NGYQ$@W=Y87*-SP!%'S/)Z%GLCT4N?4!,8K*F\)<B*A^-6N7I>7(
M>\PY8T[\>YYDDQ^:5"@F]88P^!(2]"RW3IO@!>6=9^MF:XI;.'_26\@/@A&[
M\!HC'$R^,6O6\^"?C#"EE.R[#BLP)12JKTJ$UZ[,.GQ[=^BKG$H(:/HM_*OY
M! BM"7W0[NPVS5HH8V1>:UJPHY>(H#2/6RKJ?GW).?Y)A+AJG_ 9>C$R?Y[5
MG?JQ,3D<(X:3.[3$4<6'/<0N23J.G0[@I;)E'0$QPV*N25WR-V2'7!%L-=0U
M06A8/AH82V-'H4FL9VA+BFFE8<,,F34*-93<R$\8N^$+B)LR.+'*HD3H7D3]
M'-#J4)=]P6*-'^&:IH"ZMRER>A2?4B\0U9>40W8^J<J?UH;+X$4X\X_MN[1@
MUP^$QZ%.N4O5#$#6;TR)2T$%7]+7UB)S=9?5;H:4*@B5K_DL4N4=%8K4EV1H
MG/N4HLU?<'_QR6"%;$6GTY<^?W)IDAVWWZ9N0G8&-Q:8+*&C%KS;QD*:%6@H
MJ<9P83:IOF8KX>NRX32:4TSW>]K(<F0_V#"C3MXYZ-WTLE@K:.?G.M@K(I#H
MKQVFZ! /%4G;O-Y_1U7G&/^+?[,A3L7 7!^_W9;WD!*H_X_-?S #B\YO.^^4
M9S@5L$P;C7*='&SN,OA>)HJ^""_P<SUUK>QS//%1C[[!O?O8E'3I5!FR,O7I
M<7RR=)$N6)LM]GT[<W^0#1V0A^;XS&]U0H2XS"_[,-JY3G6.,_+'S>PY%)'"
M=Q(8.X19'8/,5O;C9-2:;Y/8H&-= 4%SCV]F>V:F^S-(G  R.2'-^+)):I(-
M(D(PH((_AE@[/_'W_8CXGE0399Q^.1YI&SJ5!XK+ SM8;%]3?;Q==A</)<JS
M-75N8D6F]9S]^=QC:XJZCW7/OA$Y[\:NXC2( ^P(:8*L.%:#G@#SKZ5AM3S2
MG>NRL9)LMVPE;"[09E!W TZV3KGB\J!C<*Z]\?'GH(]JO_1,O!%H"*!=MNGL
M@?M:%M@PH_NM6!#(:6]&CN:84^.RDS1C[H_9'6D0]7SB@O00+H]0K>9><F^T
M2V$:$H-1W?22+,VB)95$791$93R^))LOCCS2YRB77_4'!9DH#^@RH>_'S3D*
M-)L=HZC>S.M")L(RRC7&_V:ZN\X"(^W*;V0_3?Z XM37AS$8&=$EH:!3O9!4
M$)-^.1<R7%ERRQ46;0FSS&FJ[GM-3O0E]BCZ)TZ3., &ZIFR$8YUK<&ERB<X
MC3=WKM5#!0VK9 M4P:<C_W(OF)P7U!&*U[7OSF%9]_&0\B$73U=]8=AGVLZ;
MV!>!I[VL+ 30<1H?ZI!MRH8J(64X?7Q,U=@<@R7#$>851$[\\E6VSS78]6^K
M7D6$V_ZW>4$>^F 7ZKCNTRIQ.\PW67H\NJ((?B? O4RTS_*GC[ENQ9IFGF\B
M>@P2Y EM?">-X[1LU>>K*?2I-BW16*=WLH+DSCPSLL/1>BW>97Z%P[W-F>Q_
M&T$.>)F)5+LL27"!C073OJ\5@ TS?*A-V%A_6IL6D>%Z5+@_ACV;X!13C1O'
MWS]/=?S2YTI?0XAHHM=G?9&1V]KE322[E/!V3HD3OR>#VB-G\1]V!XW>1#Z^
MY].957B(;Z3[(_H7(3K]:T NZ2_AN;W_UHKY_T;YMXD"_Y]R884WY)8)GAO?
M_QZO@-T>/\ZSCP.-)CVYN[QK.XISE<.&Z97+7]S79CV-SS!)83RJ6>S7UQ'_
M!" ;;!@1/+H<"Q("M":8<ZG650S9L:Y3H,6470L"5C:I;O^R[>CC=;)$;LFA
M:^-A]/Z^5<GBB'&!-'J2N:9&D><%CPZCCRZ1[58<=(&2Y8![SC7WFX:W!;XZ
M%#Q O5(.-AHSM?>EK#)6_*4;\4GZ E&I811[<V[O&;"Z>;"KAG83AH^%FN\$
M*E0E65ZF<?;4O.Z^BU'5.\^./@\::%?DUM6=DUQGU*K5P3!SRYVH56!"?'](
MJ,R/^S'^82CM)%ZGQ7LWB!CE8N'_SNW_7RG_W:S&_R]+""B8<8Y=CEA_9AY]
M5]$+;-IVB?'L7+0-/7(<#N&7XYG[452WK1-6/^YE(C\!H%"K!SA&KY/S)T X
MV1\O?@/^9F-W69$W$B5/@$;:%T^ *TC*$T 46>?NOFU3\H\7RL)_J2_[$;-8
M^#@$T/90FO<$&'\_]_@$8+Z9^-/5#/K?ZOM;]=[,3X _BOA'>3G%_EJA\+^D
M_9>T_Y+V7]+^2]I_2?N_(*U:\O),RTIVWD/ZQCM(PO)VO;FQE:;*V%__3*?&
M0:1&A5;$1@LK_Y?]ZI.T4 !VS?\Z>>N_6I2!W"SJB[)V#@+6H.[<K7C@JX+L
M0JK3E[*:^9'L5W)XPWWS;1!&S[DF_(6F[5$WEW0M@(FZ<YU$6W/@)&\91;+U
M1S*SZN1EX_:!<^@'Q5WB=>G-]#B4=*X));<"X)V,/IA>C!VT#_Q,P?>PWD))
MWS=;=IA *%["%7.(3$0#W0#IGA&@I\N_-@&D+0BZ.1QIH@;6;J BRYTY7*5D
MJ1_@CH/QY!?+M:C)G&B&,#':T9S-H]#@36 G?Y1;U-+C,YOO2A_EBU(I?>\W
M%$0L/(3MB&<Q;469LC@Z43IGIAG!8V7"E=MJH.-M'[(6I,>=? (X7#YW.!)-
M6,YPB$!##6ITG2!!:R]+:SXE;/VA"(E1?O'\WKBXX'TO?FX:X\P5.^JQ8P$/
M B &7AY!T-1!4&E(HA(\]*N;!5YYN::281A'!( E384"H](LF]6WP8RZNL]&
MTF;J7R1\36P;?L."<%HFK#"3T=L8&<AHH$F$'Y%=6+"7@!G[JM?K*#]Q]6K4
M6_ %LG\]T$ =(&D@9/ QB'QMC86 U-_:U==,XX*FH;6UIA+B(7_+F=&3H%HE
M $2+^ +OM1R(\,8Z$P4S[ 6+2-$C<U.C[UPW>JYTZ>@MQZM*S;+,<= "VP?B
MH+?OK]%LD9;"T+:5)-]Z"S(Z$$G,&$S!-31'X-2;7*53&M&AV404.8\Z9RU^
MJFEJ;J[QU;I8:.SC.Z+49PN"I=*]+T''&=YG:WX"8.PDBR7$BM08]17&?U;C
MG@.^VV@Q5O!U*=V<KAV25=_U@?!)7G'JX;3Y0\8;B,/._/Q$2-/$75JS"^36
M'R0U)[[/<+XVO@+S6CS:V=D0Q\I,)$YLF6]?A>%:?4N]Q"]"+@,3PJTPJWUI
MA<C*D3"76C@@;[HQ*"3AV;$:]SKZ5?"C )RIO&'V$Y+3T@)&XEJ&%ZE;OG59
M-DFOK,MBMF\&T*3:%SOL0-.#&ZU"!-"MD\N^.TZNU"=J+C</T3^DB^W0ZKUW
M6@?HI.2_J+L'[P[0!)52-#?61ARJ2!ES37%\/$O,I79Z!P?K,[YE+8$([\U7
MY*V]2'15^?I=HYI_[YOI-U3P0MV^PK#[VC;\9AJ1P9R+V#5G'*?[@?2RN%.U
M5,'B=[E>K/<#$[FVH.(@?-@R>1,ML8(>I]*#Y% M*+CR1MHH4=R-7&VW>U#J
MU1WK^19,NT"$K0GLG$DYSYECL9N5J>[LW#5FPNGQ=U[688E=M2RZ>U(IJB@W
M@ZE5V;C:-F33/N L'%Y\ C=WB@.2G_SZE[Z1)EHVVQ<XL%$L2'"P$W0P;N96
MT.Z/>?MZK_&#%/VC\.^P$._1<W5O2-V2[&43+2T-&[B2 V9*;(=[4ON(2XH;
M(AE$  ;G;G."9>@_,HB=0T&U>&Q:4&<72_VPI4%])L(OOBF0Z/,(UK"M"&D.
MF+UIX(OH)1/N=.P&/]5IIIP9XW-FU8/]'?6N]^=6RE0E!FQG%;0=O8B]'/<6
M5U_)NF:C=+0T&&=+HH9G)Q,7-L]SJ6WYB3TDX72]36"+LYH[02WOIY2:3Z<U
MPI\ \[ESY#5XJ-8G BPM]7%1,MUU#*]\Y44L$3=1SG!&'L.YZK+4S.8.+2OW
MYS#ZKYD99H\8Y^(/J&S5?/%X]%RCQS>\!65"+OHFAA]Y6B>%:VMSIDKM@_.D
M/BNGLD;G).RR6:U(]7U<.XNR9DWYOKP*,A5"F*.9^8D<VJ+T!6<_?1OZCI*E
M?_6@NE)JOHW-6QY->J ?H6@&1"(QI12ASDA]@4N04V=7$R85IA)$68F0'K>C
MRI>7Q9GQZ@"#J\SB)W\U\;737&+(3U)N:[U:M$/"^TP_?UT6E@4]OB< K%<_
MO^H3H&+D^C'2#'! 6P8O#24!]R;GKI2ZP6FH3ID++!#2NT.+V5W>^ X,C,[V
M]V_"Q:IPT)?*C/5I6&2+%4.AVOL7S=$'R4%0JN0/K!DLY$YJ0:,2.(&VHI]\
MHM"ELYHS)!(4I^X%UY;M[D"?FYK;4@8;94/KHM^*H83A#=&8D&>M>Z.X#/!R
M)""YNJ.OK[YF:BE"E;@]'Y0MK:MR46*H*MOS!T$HPC:W >O6=K%1Z.I9S6F6
M]Y*EHB5FJAI>P08S>JWI]'B^M_A'%)B\XA(!>8KM1[]"WPBS=JSI3SB$7N3?
M&%T]N@3$BIF<US0)K%+[QJ8U_*IP<\I$Y:,?J?E/:I),R-$8F+%^ G^8 86F
M+6_?KZA,:FHU?V7#-]!M5><7?8F' M ?E1[(1)>;=N 7?+O Q)QWGN6B'P R
M-6^J4"&&G8ZB6W9!RS5DO/81X-[@#]=^!!\N'B(=JY2I==[MB%6(IWVMB?;-
M)$N(L;5;<KYU2_%"E+]R^JPQ.L=54/U^45U,@3"5[#OEBC>?&?THYQO[5F8A
MLL"Y;F"R17QZ;);:02"OMC25M;9T3AJ)-[(W-^9 _]KG@(S0,HYE\@-'U]R>
M9G0;DI%<2%;\7 S3R9+,&'%(R?LPMJ^ (<M=_$QT\:*ZY/!<__CHI:'MVJ7.
M%9B:M',<Q@@$8GI;YXUZ>MGUDI'U!]Q5Q=DIA=3EEH'ZU!['<F3:._[^1*MO
ME0,H:OX$>D@CP(9Z+=<YF9@#4+$'=_=$CP7#J+9(N-%)9>KYHBQFC'0OFX(&
MX"=A/KAH826W)KZ*XTPS6T"ICXC#/)N OQW*=Q;#OLA3+ES3VMAZ*ND#!PU8
M<#O,"=GYT&@?H\(R$J4E99E)VB)R6>".9C!UY([YLOG:B"B<Z=CTBUL2B59?
M; 1^%&"@G1@E%4T.X!J'LWVFI2.^MDS?2_FYC2]W>;E)#B6!:9Q-EJUW/-BN
M4D2U_8V8H:V\]+"EU<9$+:,[F#"I&7*&+/J*<_$7/3JTVXB=U)$%VA</%\$B
M @L@+13GG"]BAXF!(7>=2^RS\R#SXVC#]S)=?0*8:6LM)GUWRV?Y0]7D\(.[
MO*,B_'>H=@K3)Y9'#%OQZHS$?>P/Z:+XUM;*4D!]#%=O:9)#B?JQ( U[7%6^
MKN[KCR#5)K%=+5G:SN$U77X,]$+B]*TIRIK8[D?:,V(\U_1<"](,*M79R@5M
M::OMXZ^:_>^C2+Y:<@?B:Z?9PDSE5>M37U[9#%#%=K!UT.6@=7(;K'!CL,!/
MHAVG^J2> 0^'D]U2%(B7)'&FNX;/4',^LUCDJ=S!4+%HOD ";.+W[RORMH5*
M3->>E9@9G2]V,\+1SEEME0B#,1.'7>:[P*1J6#P= !2 JSL>DG59?Q4@HM^]
M/PE-M*-=ETT0<>TGW'3M3AM4(Z#''Q>U0+,WX9&VL2K>(<X_]%5S":7D0=(\
M-J8OS":)!*3!)!DUKC:\]7O9$M-W]Z+G 9=D'(4X7V,S0EDL@3;2$WKFBT>0
MB5:L.&W!4<SNY,8<![ /@TRNLE>(XP/2U;WOS69<7FNM#JQG8,UK/WS'&M.H
M5"-O:.)6>A].A5Z92Q7/:YEDCB5"!0!/"*A8%"W?..XPXLK5Y7Q_17T>%HR/
M)QZ+H,]V#-.$A4XB I_;TZG1M=-?Q7:LTFW#$3X L,Y,M1OXP2OP*KZY]4[Q
M#CZE"*0QL"'(=?NNA*3D)_VJ0)%@)]/-]NJ;-X';E)X\=]DT?+:@)>>@3V?*
M=820;*-;@RSH */E"HX_HJH":YP4%M:HYPWE*WB^<00W<1>% +WF,X9D ^[;
MT1**WSSVR?5XHGT]9G8!OV$C5100[!Q"V"XL>J6'E\H$AX?.IR#U&7/J2<7H
M'#,RPW3>#O[E;])D2?46?</6RNN>YN,(>0HN5A8V%G!5%O';@^_K:6Q>J5WN
M=\:.*&@28RTY!U!Z("C'J)=>LLTFU)EQ$^2OD[0KLL%)"C.?V?_,MK"RH<G(
M#CSC^EJJ95K%0>]4F%)@&&USD9.RY%LB"3O4;ZE\"?CM:%72P@TYV6Z^EZ.5
M7PHTY[NSY6ITJ@=%(URH)5(B_+WWFG=O@FSIM>Q5K8C,DKFO>AL>TG"3<";%
M'PJ%UMDY0NNEFSQ9VIP<EU(W?;S1Q0NH6B"!Y\C2;U7JZU$F))=]-VU(NR@O
M<+8?L=U.\ Y4=:#)LSF53P!=C=%3Z(I@6Q*]0)$!/R)O^R[<"ZE^'GP.U5BU
M,[R <BOCYO2-%489G&]:4KXV< 4%V\H!_-Z_ZKN<^I^_U7)Q%W<@<,*96^8L
M>/IDM-#)R7)*C'JH!B5FN+*&@OB'(DX%HN*"9FR,W?LU,\G.VPA(\E4YR;TG
MN9L:L59#!&WX:D+U$(T^"FOO-L\:&@ ;YO 2F+*J<<AU.]N4:8(W%X->H;&<
M P2>\\<8.L1A&3-,)'QH%^YTP3\$>6*GPSU/W(#DA[1A&TG*>;.Y]ULOS7VH
M;*VBHJ3(PV]>>NX)1*%!_AOA\_\G):L!XGL%!8$+*--75-Y1*148.@B*(OC2
M:6P^4FHC"^+)N5AM/P, )2A_4G8CV/T#: =>G+R@3UL<8*9V(R8^=4+>%(+\
MU0BB!-DY/@=' R@1AK#XX7CP![UM^F0F*J<8+CML&=^</T[Q:\I=X"Y3ZMML
MG:6B(>!T+6KO%V^4$@HC'LX19@U0A19T-I8DG%$1(:'U+-]#T#"8$!EC>(]&
M]ALA/LS>Z<>[/=?%&\),>M%O6_CE=A&^$(9ZL00*VULL^NV+D%;GF,P2XGA7
M3NFR: 09J]55OV2PM:E/18EM7W/$<2W<M]4:RE:7]2 =FJV32$/ CRI8$A:8
M==>XRJ7:)[J15?^J[IND#6(K8I_>L+46]!&:AFE0AWH&Y)D"ZZ[C58M1>^Y]
M00DH?<-?TJWE$3ZWMP_0M,@6I$GK B<G)]7CJB:T^"GZZ_=(Q+ %T1PA-F$H
M6[:N&:%4L^YDY7FQ5JZ-:<T6ED)]H;Y5W$/?G&51?.U\5=H)Z#)# /NONQJ5
M7$ 6-MO:+;>>9_5IUY:>+==U)+S[*@[H\'M\N3,C/=NQ@Y;>>)@>62J!YB@O
MSN 1AP'X5%@LO&OZJ1:JBUT:0I6VD,;E]$*KO"$[;,+>G&L*%='K:9?)@BX<
MA.^[X]-G?0[K(SI=AISTB]G%>'7->$[,=,WILE)5=*G!CX:4B#C6RSSX@ -S
M>T%^N7KIHR^&28Q*X_R#Q^XY5$4QW;LO(VG27:>=M DGF3\KRH:R;"K:QZPE
MZ*I/O"]^@?;)6Z5#$T/"]4+S[5>O<M-S?NF'@KE8:# 3Y;3 ZKM:^*@ EI/-
M(>26R(1S"]@6I\:7.VD.N1^2+4MQ"W'J,5H&-;\.\<#R)[Z^L$MU&W_I<!H1
MS'%8C%OC0MEDZ+(5OR']-CJ!2#HN<2"N'>KD7K^)K>8L*SYEM7*[,BOFQ/ 6
MR2AY1UW;@(8GJHGD9@_9P*>]?2-[VN%N9G95<J*FO[S\31THQ<_&5C>$0^\]
M:@=QO%ZI3Y@N<72OBQ723=VGV _5$%EI*X>T][>_8I 78WP1LY.J=X2(O1M4
M +"C@,THF"D-9[PN"/#*:7Q!=G<!R^)C@AW?HB\B/6%UG'C'729,^Z9/>.@(
MW^2CK#23W@7AY!<;F"6)@1=Q8PCI!/4"=IJ+SLLQ UD6W(3S;81.\W!KA8EE
MI^[#7L4+%Y:+J39U I]/[A5*]Z,U))W6]\2/EF\71"I7CP.N)4;)O.+Q <J!
M+V&(HYOJX2,*U^4H@8UNQ066N"X4YX9NX('2X<)1G/LZK36#34>;V$.%YQE'
M1QPO:BG75V)"XR%<B<L@N&/L&,KRGNW<&I%G#">!.833E.G$HN8(;>5<CHOC
MSNO61ARK*HCU_4>OYC=2VQ T27GK.FWF9"TV$DG)J?7Z*O ;]VO@M<0D=MBE
MUAT9<T<_#VS#EB)<Q0U"EW7A)WWV)T#6@!'*7*R4*@* PTQ]0*5]#44_5?\M
M1+C*W'/!V&G+\W&0)G"YKJX_O,ZZU]JNTG4WUZYXT\\+WILC!=^@8;8T>0>N
MM?&.[Z5B;H(UD.$)P/+K?3HL<9A*:.1K,T5(6GXXID2#JP'%I&P[A=1F[SY*
M48DC<9F07)_U8(0U3)-^OH9IY1!)CK;&"$<"&O?K)))0UJUKJK/)[PD?IG9F
M/P.==8X*D?Q<!P]*2:6A_6AS!%3A[9L"RH1H$(?@XXWTQ1\)5^PI;L4V-(F8
M%?@XYJB#*M_\O%VV7B"6O-[89V30!S.^!24=.PQ<=H?(S@KSL+G?)9(4?[O+
M/O;KM88!0*?<J;-,\6R6%J!\ UA5[53U,<IUJ@<4DGJ5L%.(@';87),5T]F$
M<PUI.[S$V5CD8+0-+BGL,F>!TY&.S>31<8>A<)6?]* A[)JVJ7R,$6([ GWS
MK,:J!A4JC*ZB,.)9>VVNBQHMICW3;AT=G2> <6UT"OP[G$39^,5^Q;!E>&L^
M(V_.XV;.'.V\S 3<+[V9^]0=3.W560&J<,39@&+?>O*PGSM9D9T:#(Z?H1[1
M6[)?]9--W];'2!LZ]QLP4K(Z0I5U7WO#\ZGB9FP<%MJ?H'3D[FV8UH*E:<2;
MILDP@J^,W7-)4M[<KJ5NSE'TEF[*IA%NO"N[+-B8HFH%X<2#VY@V)!GK[*V_
M=>6YC)[*^,[W*:*%F:J**:<H83P!\N1>+ Z\W?F5K22%/\I7N4NP4]2SGD9!
MQ,@VPG!FE5OOQL'&>]ZOE-T*"J1,_5FD\7+XPCF_1W%((!(;SYI!:E2F%[79
M((#$ARJ=/WELQOV]O3#^0:SF@$!\U#[7&$F1,#K]& 4@,]52O];N<DP&T(;G
M?<^+$C\:_]EH]A-CV>% (HB%MUNDE?+S,A#@#0,' U+E<\A+(:Z$BF^73$E;
M;]KP1L]7DRK8*I#0OR+#UE[424&UDKSC7%P8<'FA-FKI/YBXXK<EMH,ZU(O(
MNW95\$- Q]I=EO1KL9K&@N:8T5QT"5ZK6]8[ JRR'EJ732*?+KL>@ 7D:U[;
M5?R=BDWAYE'(5D7"%E(_#>PVP";DN_%:RZO>1^@C$3BP&?+R2WWRN:F!"B41
M-W_,YP>_<[]1]A%;SS=G1K5>F?L:X>DIU.EQ7@501*;-9@HOQCQ- LI7+[++
M)-'Z=@ ^L1%/ .666(6IW(:027 #$(;<WS#M*P#]2^S #S8WQ9?.S?RY'?IY
M"SU@""IK=[R9@=TVBZJBZW:]T6%Z;1^--]/QB<7+HX@4\,O:@Q4""ZMC*@G#
M6*_C(TT7:SS*F)+N%UUIW;/)-SMJ"L&EY26,0,4)\];Y,PT=E[/&(SWL!G':
M56;R\O?HO#FD?,D],7).4G<O2Z#NC?[H.&.IBY2OU+4<"X!=Y8"*PQ& V<H-
M^_MIIIWZAIIO*4' ^@"F7"GC+V$$%*J(#P#^;UL -+#VSBCT?!!$'ZPD:ZK/
M*O!12%6)14*059/I>]E-H,YK9PGZ%LZ:1=!0G]722A(W<_2;\QVM(EB/*6]-
M0P4!E!7(&<G2%]Q)]+H#PMJC+J@H9T<([5JP_PH(1<6ZR%.%EWDJYAD%9/A>
MTA/=@6\LR@C/YW$"-\ #N='*8>9+Q](*5^B#Z#QCG)9D:/N*ZJ80&^B1W\<H
M:9-T?3)&WRJ_U*W38=XQC?:$/FXD8L>![,"9MIK>),["QFY3R@\&0"QSZFQR
MV+3,M8P$2H3B)\#'V&<;'(][74K6/)&]^0A0%WT"V&>8 ;H2VK6)TK>-8SK?
M*ZUI2>)!\S E:2T6)QGO<*H'R%&V=@M'9[_G:YA!C":OF+E>[+_1ZO$TT#VP
M111@\[M1Y<P((087?C=SM.DJY/#4Q76BM_5QPV*I(G\"F&8CI:)V1Z%SKB^$
M#,%_+U>_29X%I?Q"<>(&GO>9$VQ;T0E3CO;CTV5RZ+[^20 XXE1 -VWL/EW2
MDF1;>O^J3[!V&'(>( AT-R^M62,V)GY5Y$[TW2-F$DK/RQ@_SM9%G3M<(0-K
MNQ##A;88@33 2TE#D[QE>6)E?-K:LHD];85UH=!8SU61.U1:'X+TRMRD==/R
MU8+1RZHE3)^O/_G3-(1Q4ZJ9\K$8A[$Z]W<>OII_<$D<> (P7!M[K?QZW.')
M1"M30-JK,G6\M:E^][(YW9R1>)*J\,VHIDP)F<W D.7 P  O)Q4IP<119FT@
MO0!CZ4!3>%B$VK HO*2>[0\QXG@:3H4NU]*6I3DDF\(/T-*!N\^F(]8H\151
M A7ZH\!M.@4RE\A:A8(#4_!&.%-_%V7SU1Q;<6B@BE:ZMJAHU^LF7\]C-+YD
M0,AJ!REI;8OO,3T>%FAX:K&P(2[;9]%QDQ 7ZGW,^PH@8-/>?6L58&]!(0NL
MJHU&+?@&"JR/[GXOUS0CQ@H@*>X3723@'-9P?S]35O. ]01XQ/0'>9AV<_G=
MB3%1TTDQ"30S>-&3M%?K&ELZ%^Z>_3QJ0J;,+$FNF.Y-OIK0-F(908HCEE(T
MM G;%B4^?9Y6ED,["8GYHEIEN2[@>M?UV?N_2"NHXV*M:+11';]"D^8=X/SR
M_(T+97#Z:>Q W6*=*%S"+V1WD+B->>_6B.V/PFS4N#UY&J88.!7J]@X:TS.H
MZ\%23,T]\;PYB!$1*@I*72\EZ2/\"1N8@QU\/.!CK7+41HH344>&O: H%:*D
M&\5W8_1V[)CM\WRDS@2 _6(T9D03ZX/WOQ@6AU\3!82-O0F@%C10DW4QNX^M
MI^6EVJ6:(7G=>WI(F*IJI4^=&0-5YY8EIS8,5& RB8!GRRGLI_D_[;QE4-O=
MU^\='(H4*!:\!+<2/!"L%&]Q=P@N@>#04JQ0)%"D2'%WM^!%@SO% L6A%"M0
M:"F4ZW#][WE>WO/,/.?%<\[,G9GU<B5[K_7=G^_Z39+->A!;4?I[_];"S.EG
M, T/W $E@41)1''OA';ROS16'O:.Y*?UP('("&-]63Y<S'3S&G:F36MZQ3$0
M/[BO8CL1*#,*]:FDSXOT";8\J:W-SWC%;LMC^O6[,707V#\"LB>#0,6#\DP'
MK9C6+-<.Q8,LXP_6-VI&DJ7C"BA71W%X1VJ?MRJK ;6]A^D@Y)B ^WL-Z@6X
M*"ZJ/O;.>0GNX:^:?).KX[3 R2PTZ*6.LDH/2R2+?P,NXIA;*XDMCO-,YVM8
M,;!3O2MYJM"+)6L.8UXI0[WW*9O?KW<UQVAYP7>UP#W.;_HXCP_DWN DY#0D
M\)$=H%$Z?>4N?JM2TP7.\U )VA 7#,_%%$? ]K(B;_:5I^9\:,!$T(>$9S6U
M8HM-,SL=#;,&[&UM$EDD2<T:3\&U ^VA7.'ZGI"#4-+#-V+%KTK7G"],(MQE
M!BRD;I!TZI-=':W^?/!=:A!3@\&'\)^<K4ZFJUN?2DTF!RRGX!+EJV53S_9)
ML.5O.B@?K/-':UW5][?<YY06*H#Z*&.E'DR4@Y)34BBFGDR1A@N"^S#BUN2$
MF-X/-8<.P>%U@F5FKF;!6]!1!JXT.5]YW)2(4#(LJ#:>TQOJK=N TZ+8H?#U
M+EUSAVW%_2XWH$4,W,H3%V5XS^:JIS/O=N7*U=3S3@,G$=%6H4NFR(?]J)Z5
M7 &7(M$UXMPC5BRET,54=V78IJJ/HRS3YG-P*5$)(3W/"YM&56ZO2B/V<$^1
ME9CM&:CHD@2F*'9L>5P6SKQ;;C!NJW*3UT.T>_O@;7<LA1Q=/UJ:YV_.&,8Y
M)M?FU;^:$2CL2].LTMD)(D9W4HQSV7[4W%=5?7W%G%,R23WARI*[]$M\0A]G
M< ;]R!R@Q@K65L ,Z[JLGD4[_'A;Y2^.%/W-/E<KR-J.^KS!3P+BP*G]LCH,
M&:/M8PJBMSX/N39,K;8D)HYKK[9OC)Q9;P*NZK]/)>V'37R39+=+5!/%FOEF
M":R?J:FAI'Z&\+"A#LN)P=OY(#EV@),\7!94^X8BG] ZEL\URSX<"UZZ^"<
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MM+<'-&NR?Z1@&\1+R!A>%L!% -A3YF-;&C8MK?!)6W5\7YBF,I^BNXYX8ZO
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MDR+%B0Z _T*U0,E1O+T,#7O,'FT'9,A/M'[23'/SUCP7'Y&[4FIQM.A7O_X
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MFM^=<VL#@OIO,WF2&"JC'II<RI0%WU8;VPR;PLXK/QY<O'J\UJ3BUK_/$;"
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M'#N>C_%%4%^2:C5=,A7=QP3==NM :[/;3N).E+%-UF2FB<;3MWU4=T5P,E4
MR4.)^5#Y3C)=8GP#CV1VA0,1PPSL:4-%2=J2#"DA<@',FECF.W/7Z47_ !SZ
M09=W$V8J^'[NMUGM1QO^6B[3Q(^(LYR?/2N)XOEBD\"7?LD!HY.6<$0<=9X!
M1*:Q<Q"D0S4MU7.6JK]H[K6S!49O:/U_$9"9G>YU"T.VW_OG4UK\=A:LJ89M
MN)VY$B1U;']QT!6"/-(BO4 RJYA':'H\3JJL.=8;IM,926!*EL3$5X\];_PA
MR:MZK"2MWY'$_GG5F-A,3DQ?6G#??8 +EUG\?-I;H^R[1,H&F]9N(.7-%C5Y
ME-4#+S3(O62B9+YUUCL9-<_43L9_7H7/PFVC.*()VY %I%$W/6_E"7 1\XO5
M\:1(+X^.=?;ZB81^*/8<N1H.%"OADYQI&6=[")6(YMN1[THC,=3&U&!*+%AG
M(F(*@'9>DFJM<'_;VL_->;$HD=-?R4,V")!0?[3#Y+DB$\G\P^GE&ZAF-:IP
MCYR,93RZ.$%\QU7(&AA L*^K4J-6Y 0^E+6V:J+F!NF15@X.J?C;)$_.YQ*T
MZ-)?74S[)9=TA#'&NZ?VM^N%W4[N:;5)$_X\Y7BOWYZEF>L:#NMHSO%79G.*
M(< A*:Z'X&Y&V<PD!.#LDQ(5S.3G\"]IHZ)\FV+R]3/%/'?XW@,/^__XR\5.
M;F&<!4NZ%!Y9WAR)ZF4H@+>>GT OA!X#F0)V'5J=*O9AC3QF&(F\0-$Q_:F^
MYP>%Y;UW-W+1E=K?= N5.;LHZ=[Q (U;MT#NO<R:QK^@CUU6"^/J&Y2OQ[9=
MHVO=!76)=I0_""OM\QCV0?$9]U0@5]M5I/0ZOMUU&GW[,6/-BH$I#A-I!'1G
MH=VO=V*7_LU%BK*U'M&UC1J?S)_Z7F3D6=[<R7SO+HWPNA8_"O;JL4,\#Z.!
MNA'V17,AUM3H1GJO:Z-BWTSP>R_VT-XR=:J0M";5@V\\F)(+^H4\LB/2N0!/
M$J6WJYW_X/K1?TQ7=8]-/GZT6CF>!I$N_BY_0(>S(=:DQ#C!C[RMX7E&^B-9
ML?$4[UUH$5_\VN7269!?]?R6K[M,S>A\G[-$8F90<8@_BX^0];KF9N\]HY&2
M$@=G^,C!THMND6:! -.U/A*O4;:S0+^F)Q&=? M>_I[!@156\LDO,KFZF-74
MTJ@IK,LRO#08[Y9/0F4NS7ST]FWL8"[TA#TF?6E/]D?8,:(,"S;8U]:]YXD*
MN/JD6Y'.)_O) 8Y)H!?)&EDV(CG%V47@&[51QM.3-8>.1]P/V8X6SO\ G#K;
M2.CZ_.%/$RL !1;+T#^G<HGE=G/P.O<)^M1C(W :\L9VF9>\FNX4-UD-+;6S
MVO*MQ(\&_+DALJ5ZT3 VSADZMBTJ7TB1_1FRR^@)1@=+R?Y22?M^;S)W HL*
MV$EPFC"+T;==$P_@\I.B7RQ,<* 1;CZB_:#7W97,%6,Q$B7!ZTDF(;2JB4-.
M)G6.D2RA5Q0X3')4<'.\54,J77X"?_B<F[L\W<.G&RO8CPZ^_IB^E';9N04C
MJ<WR8B?(EU.,T"_YL:I1BL% ZR=%A3]IK&%B*)59(]J)#B*&H=:&)U3>0@W3
MJ,AM$<P8:0$8'7U[G/1A3&TB. 4B\P%^-S_]'GO F\I[$-;FS9XT[L:N'+P7
MQJM5T'?J20BB[E22=:!1!LZ>UOR4K,YO$QY+07\_22XOZ.LE&3P!^*R]>EQ@
M+IQ&.](TQJZV,7)C8HX\8>C1%4=2FJW1K_V[5;#<%C.Z.KUAC=VEBRG)/6G)
MB<$D C#>*R><<O8J2]%G9C?,(<VUI$6(<\4"Y)&.\\L^]J!,MFOQWU4W/M3X
M="+\VX;2]2RK;TA3'C\@TB]U/:6/2[KC%F%P\*,MJ<;/ O="1WM\S]:-Y,"U
MB@0G)5'QL<LWIZ)/D4GO6=[O"E5[?R6"ML1*C@VA*-"84&AVPVD \Q?JNLBA
MDJ8ADL6&MHN[LH1)[;OX-J"0U^ZF8^J?1_^5'<\<[P^G-'ZV0ZM0(@#"I#UG
M=Q_$6R/LPV&\]QGZL2U8Z?$R4=4DHG/4*1YLW1F04K_)B+4DR8HP^ZC[("P[
M\??MHE>W6G=!RC&_9.\7E:<M90^.] 136PHYW=ZU)8=T+@78)'2C?*]KZ+D[
MB1G_!'AY-'7I62H(7<#":#2T1UN(0%YITC'3DIAYI.[P5CL(A=)Y^[)U\\9M
M9*+2OXH;*R.GR '<^5G'[.=_CL%_Q]G92 X,OQX>.)SFX1FY4]E[NM8EB,?<
MCW?:@3-M,N*$9NXF%";=HVP>LK-RQP?Y29 X]B& M/T2%Q'=K@/"]]0,/"7
M ?RJZ>#N?-Y@Z"J>?,U7G A2(DDJYTM*X_5>:OV:>V7T:OZ,O_ 37#"_W1G?
M9!%?Q?_*UJ+I,!3 1,!H6$)E[@<9$24>]1DI:N]$OJQ7HBQ+2370)>8+W9!%
M1(3C2^L5_A@?<+[VZ8S1+SZO-PO.)Z*3&,-!A,O\_OD?,!FJ0'MHXIG/8!C>
MJ63>CE7NC[00Z3R(M; GOLRED?V<Q9GL/-.(\N5@,=TOQ-Z-G>_1AEQ!C3K/
MO_KYF4/:/"KX.(]Y5!^+"DRW0W"+\:=H.\\I4&D1ML#*G+71*,%SWXK8CTZU
MCD]IPP<:$N Z7CYL]J&BWK,!+JZN(+R:GV 1_H9VFL^"HPQ^U(JDQ7Z['URZ
MRP\%@AW=X1QQ;NQPD\)+4*([B*0SZC5%]F;8D/.LB@@Q2)@4-#I;_?,?@)R<
M YA%Q$'"S3K($;F=[_%8V3?],RE<XG/&4(U!"2D*3J,X&T! -_U9K.5?CGJ#
M!M+%$U4%:MG6+OK'&<&!B-HEW/;G0]YA4^OMP^K-?Z@'>&S>Q$$+7^3<?4A-
M'9F:[=P#.?5Q=/?5C/%<"C4*HQ.H+YH2\7HS2-M!%,?#5].')H=;\@*U-J^C
M_=1UTMA1@](?(]J+^/530LG6V^\M.*C:,TRH?HY3E)D0$J3D#'U((HR!R'ST
MN5.3O;)TY]23-C=;9_?^6S3]_-Q#)Z.?7'E3B_&*ND*)UL8V*J^D-G>WNJ0O
M2K+')N(B#7+G;V@68)'[?=NO,[JY89+FW..VGS%< N+6NF;M0_>S-B$6DF%"
MA[)DT<BBRW<,6^7Y:G]Y,IB4,Q1#\@[YXVM1XN,6]4PVT#(%MT&+16T,G5(Z
M8P(^8,!+LL;T/SV)W_)[716S>LHV-RQJ-O3YC-"+<&VO$8,(FX'-E4KA]3D#
M%M0Y1Q>9DJCMA.MM-? /<!%(Q,T#3&XR3!A//D>5M Q@ULT4>=?^%KSPRX(1
MC"\K]_Z%3)O/2D3JZG\04>1#/\'>7E-C$-I('D_*/I/LH^O=75+ZC[T=S&%N
MV8BY2Q(D(HOL$83$J=8;"%4 HP]^DU;DRFDMU^NV. W&60^:?P!=3T= WC3C
M[F@"A0_JW[X5%\^8T-%WQQ__":\IE$N5&FQJU^?%AMB$FPM!L^]J<J5\2S\0
M*]<%Z&K8/2DN,#=]EDE\X2_KU6NW28)8R/SF5#;1/\1P1/2L>0L.AU:@YSCC
M55<'*G!D;IA>+U@M?^_(EG 67(C4,13H3K4(.OC[>:[Y7WL2^@=0SR'<<[O@
MY#?5@';O&\[L2SA.9L"%Y>]<5N[T%QW;TF:NC&D=J#S!T*(T"7E!CI*,*0,
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MO1%\R_Z.FX^/CY9%6%R(1XR3EX_G'Q=!0$='Q\+$(L/&)N.AIZ+G^=\>+]T
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M =Q9#HQ"P_"3@WC2PRFX)-0_'<[XD%7W,8H9X3MI;!-^0^,6U4X16Q7L[@7
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M]( )!Q@-XP:"RKV2]>=N\.HV!TD4_D0GIUMM[&P&26[IG.OLBS3U/LG-]O,
M<_#F9U6;4^KX>$)_$XX @@(T [^&?F"]<GTKKL\/U.^#@;\ OWCGV^F6_#93
MF$%-DDS-=)BI<%XC7*B':VQ5>AIVSH@9%5)ZNQ,UANW7MPQB!N?P7MX=.I]D
MY R!XRK+3J;M-O@6&.<,J4 A>!Y45$%>ZJ3B0?OU<-LM:GF3^9_SU_X.1FQ+
M48E4<1NF\G+&_K,PJA> J [!7I2O.Z:[T+K9(',U2#X>CM&6S\1T2.YSTRTF
M=+NN#,W4,JID[ -^VH2R-<<>Q-MTV[_"'+)'.;HP3._"@8.VK9J:H)*1(*;:
ML+Y731]S/^Y\CME*3,YI6#IY1IIIV,0TLK'VPU\NBS9(3XL)CO.7/A>=GE3E
MB88W8@K\"!CJ6V'U,N5@%55@FLW 0WOS;BN^W7_2^*::%J;A+"*_74ZVGC%V
MJL9B'-1'1]M/>(^QJ0;PDXY0>1Z(&-#-5V2KHQ6 Y(3N#I.=M1$OPER[%W)(
M(0/[/ZQ9,MT]*=&KF,@V!A2H7,/(CR:UM,;)9,LWP.76N7ZT.4:.F+"J;=R;
MZ0_5M(\]3(PW58'@]@VV$.7'2>S#!8J8_I(,8!'ESH07\G!QCNNB4+4Z#+@5
M*]^ST)IBF+60[%^:4!+\(QSPR;5%OM*BJX\Z4&K!NA-BVH:=Y7H3OD7U9L+C
M:0$+U3YF(:Z"JJ!M2==#SCK"CV-'08+)"!9R\;YI%ISTGE-WP:;?7&DKNVWD
MH'HQ(^(#7<#4XJ<$] RGO^6O![ %DA[>KE-LQ^6[C4LH?FC_ L@;2"9G<A]#
M"!('T,[4M.M 9K7;H(YPIAS*>?JZ=BN<,0$I/23D$(0)>77YZDJU>E45@<;?
MIQ9P7T8)6NH7P$S@;:J5GVES[J-@[T(+P^:IJ94H26_\5*#(XN(S,:RZ'[_/
ML\0K9.%*$]7VRI5*HSCO3+7EEG@9EMO]VRN_]]80]*>7<DQH3L8IWTD7 X%L
MA]5)DEZ5GQY'UG=EV[8MC?\%@ %S58?T4_B_ %*!1:M$W$IQ-??^@#[\X*S@
MBXRKR6B!A0>ND&MJ%L7$N!\'"MWWA7T6B5?6B5>"]\0..^"AN 9Q"6I*32A_
M_M&[Q 8]5P'4C_"@1G%,BI-J"2I;05.TT#[620HIO^$J)\Q(X;%<XUWHT34Q
M?LJG69?.?+LG' )*LV^D&]C1<A&](KQ'KD9O8OM^?L: TCW=;5YDN9=3!$14
MP7S!J)'V_&T6#J@7=%JLDJ@. 4="NP%%E:M_PP)_6,B1;@!;0[RJ6NJ[/TPZ
MUZA6\E/\[NFFI/,.8@C>O]3*,Y_>;_-TV;90:A/(4R$Z<9_;%6IP<%8&OE,8
MA+&\ !B8<F\>_WK.U,/Y$;@89.#B:SO? PC>>/G1@<)DBI>X!T,TR'6HT#UU
M4J=88%KY4UX4&W<8D8;4J[] ^T?GS9;T/+Z0 T"D(?N?@Q[^EN2W0$BF\4;?
M4_HM5QU#8\#TOL.:PO/AD-(B-#?R!0#&ASS:=5D\FC+KPZL%QTXVA21'*V>3
MTAD-HXX713#84B,&%O4" /']"S[LBWH$;RQGP2ZGF^U+3N^3G'@V/9MV#/_*
MJ^JF@T3T9)W5G]/3"F7![UP=!V%/^VJQD 4E=<EX(2^*58Y(CS\?MJF\"%=V
MSS\J+";Y_8.IF8I>-.3,S+3#QQ]86+2]DX_YEZH"1FOJ5Y&B'^[%:PZ7#N8V
M9H[J9'C.%^,NG50P,_ %UK%RB1%F>6;*9-J=:N5>KCJQU.1"F])>?2[1<6M$
MU 5?=#R6J<%R]\S7.2:.O5'BWVBC"%<X\BS02H8#J[QKPIJY:5GB[[U1;WXB
M1NV(^>]<P*1? '4O@&V#V\U&[]S+S;'E.L='%N'U!STS1ZY<$-'2:@>2A?"@
MG%V6H9*:%5N2AL::L0S0D7F@/YJ(^ZVGIQ!&?I**MT,Y=.QC0ZM-_3HK\'!N
M9]S;+V%C"\1":ZP5)JP&EEHQRJF4=<K!@Q46P,J@]C3D[%Q9 >?"9#PCIY5#
M$OT8YT=*!*'U"2Q._URI?^X;K_=.+.?J0%H Y;>& ?A%HU06.Z.MX_<[B;[K
MJHS,:*,@#5FBH#=YS;%ZVZ2WUO&58EQ/Z?M/O[;-ZI_R'=9? *=GPD,+9=PN
MT^AMU!U$&IKO\J(.Q$#;73"9>N:YYX';]HD:[P#']#G"K*T''ZT8X^P$>S<W
MO9@70._?RK84^ )@Z7HT<:,AAG44>47K1*BTU"3U;KLV,E@2, I^F4!!/QNP
M@]P0M'VX8IPNR8OJ__EO#6% 7@E0[^HH0WS^K#(F?;8W,VF%_3SA 0LQ4$9'
MC*O2]&1%V=3L<)'B8Z]FKG6NQS: 5I"U&%4BN_2RS9@3]$].549].6_G^2NM
M+D?O^@0S+/'8B%J^-RXK?'K'$R5,=<,_-YMB;/+=%"Q+I/EO;>C+=<<=A_3B
M3450L>W,,28E,2_Y!X7^0,\0A;ON\C!AE94W*H4MQ]IZF3"+'9S4:COUH[LT
M3=NKB1X&"[I$\G@I503D7+OS&Q/=L0^S5G/\Z N8-N$&DX> <[5"@N(W;7SH
M129Y[>%7.P-9KK7+-EIJ>"RX',,QN=UL@2)'[<Q0&3FHRLQ22M+@?>>N%MZ'
MG-&^TENALE2,1#T;X<0U#>V&?W5A;_^#H6BA<XSE0RTU-"%<CNZ8Q).@2OC1
M^Y0#R$\0QZ1)7HL:*NP%H B-:O?H5?9=6G1=58[9F5<X9LN&Q4,I#F0%152_
M)L6^W[0P7B<+9<)8HL,*01<-VK7(-0TI%.14MB/5;3FJU\$FV#8:1U)MR;X;
MYZ_05%A"8M<F<!(ZT3NF: S%>).7\.K?O,N_PG_6XWAW#:@$]N>0BC@4%IC>
M>W .OMU^EX_X O!RT4Y,3%QLL(6-#5HHP_Q:-[)Y"NY*R>H=*+%VQ'%1D22_
M50:2'\KT!Q#.\4TAI.YLHE\G>IO]B?'']GLLFBSQ^@WS[<5NEP<YTTTZ54A_
MEG^DXW>?^6I-M*GRA 8J\O&"YG3]]&-M@J(4TW7,51<A;OZ)U;'01;6E!PSW
M)K\ $(ES'3VANG=2*@&3VK^;FY(D^>W!<0()52*?6,Q RV>+4>?M%I[@==K>
M7FR/Z<*957M,+&>20=11'HD+51Q9;]F)2+"-6_$"G&O'@&_D/?FKK-G/)MW6
M#D3A$UX3E,>VLWM)':VWK2B^N%\;."RTIRQRC6<->V'<>N_?47E\XDW,E5G3
M/?,^Z)7$/Z&AGZJ:*#N37"Y$)^[#(D6V#/%-')*X.70?UQ2KLRDLDW" V>ZH
M"/8T^7QMC2'5K!QE*%Z>U@]!G_!\=U,Y20M7G?;3 WO,LH,<=[[_27+(X<,,
MSKIV"52*WFI,+CIN>F@]%O&OW!XB^O*JGXU.4]F:,GC G9;$3S+OJ!/5-YJ:
MH7?!W)GLBJ[Q@SW5KB76HOV:>$/&W+A9BK*XX9T,# $EOUAMUZ2/XM[%7G?0
M02"'#'\J9QZH )W(!T%BX2HE^+Y^<<,M4C^37\\/JZ.@ !D.GE4: D\R H_4
MRSO1NF;J-T.5!1HP58I_,"NJ?S"C:Z$*AI\($H^N5U\0/\L%I); U:$T4>[C
M@KJS7U&=C605QAK1M[ C4./"@JO*9>;$;*M@ E!.#E+%1:*RU3753(U!::9?
MV*$Q<=E#X(,=:8C*3?YQ)Q74+0,K7[BI-1.K61RP1KD9,C_K1P.5:*K"EIO5
MRE$>YDC%\B1PZ4X*T%R_1/'>SU:HTF-*R]%] 400K&U)4*UXI1WT+T:"G]ZO
MS!Q9O ;OJ\L401,DY Z$3MFF_2R@2+IJA$-@1XS5(<X\??9D!:17GWG#4.-0
MF7*/C#U[LU6'9*$Y52O9NR11G]Q0K#$PO4.#<XI7*B9=.C%A._S/%87LYY;>
M))\+@I*0PFEE>AXH6@I9XTZ^%']/^S8_+R8-I>W>M.Y:_%([SW?G5,4H:U)P
M.UJ6X',5PF8QE"/0U@0++#QYIFY[1SF68C+([T*4GZ9)AI\P%M];]\P&ZY/I
MA*3?6N662/NZNK*^(SFG8@C-JJ$6Q7+?_^UG4+!VV(5T3:D\8-DLN*TG=YRY
MH(M$W<S(N,B/'Y7.7E!Q+G!7,^NE>K5-&YFN,K^I65L_0U:2)!#Y,;D,<HK2
M%])/.(>0@_(VAQ :T%8*UYF_-AJ[X%5K2MK['#$B7<_TW>P[IRIJ:55?-RMA
MMPB=1O#M!\G(_?;9[JY+XX87P,/)WS(\WTZG<#)ORC]VDA!V8MH!38<SY.#K
M:^ZA&SA8JB]]XED:[L;<#$V>W6A(CQ8#@;O(5@\[F6/=%:PQ/C8F6);5#$(;
MY &A"7)>%<I&W]H9H1.W_N9_2.X(_ISP/DW5[J4<S(KY!A"O'7<1NV5RX:T<
MB?AAE_^XK?[QA?4WSA""O)6DC,K@0HR%N^.)>I<'5ZR[&451); (9J'*AO43
MM<L-YU?\(KT4M2+M4X"\.C0WS@]SFU+9D<#4X%A@%G P)JNN)21$KQTB/O@&
M6AW-'YW[+:*O:]7QYU%B;;[Q:^W+X*8T,K'DX&':2J<<P9J9"GX%\UGW9??T
MRROQODX(I1C %WIN=Z2EJZ1HUQ:0YUBS"?=] ?P(?-[XFU+[W$3 0RL#3Y("
MZ4UEH!?/7UX CW\7;$7G9('V$N?O^E4IPL/,M6#J]RF=K[WO!COD@&HH?4!"
M8J.V0D4T<6W$)7@WO%P-'!!L40CC56N+0GM>]*3-9G^4VVG[.?F3C*S(3P]R
M,]BUM?](9:6<*2S;FW?C#@@'> H)P]G28?Y09=G9=D''@I.D$2#_SS=)]Q^/
MCW(D#IGP9XOM"K)*5L1O2&;FCAIRPU8<2K>_\X_Y%L]N\,1-K\KENY8.V]^*
MBWJ4/#-X/3MB*8,*;75/G,M- *-D#OBE0E0X!5E;>K2^.[' P4 \]HIV-D]/
M6ZMW7^-B6L:&1UW>H7Y\\-U.W[9WM3$CK _$5\-4M&@E'2;?%[A//XG!ORF+
M%?R3JN*V1#DK(Z/>"2L'KPL^.CP<#QZO<'<"-2@(*5X #0W20].Q;FH[10L2
MI,<T]#.KITV_Y732(RX+D'UB\$/0AB\^0N/CVP6>T>9>594ZNO.?523(8JEB
M[LU5&?A4\>8XSS1?8!^1&@;V<.&MK^73==!8*JU]09FBA K# ;]DE=Z.&*P)
M^)"T<V^K?=MX-[UFZZGKG.G)8'3R5<HDGI[H%6-PW/K#0GS?"X#ZY*&J+1#<
MX=2_."W/DB[076@I$U*!B@JA;IN_"/F$BS@6)-R1+'DWJL>\U77/^=#UY+?Q
M C@$J2IQC!O8<+@);]9ZY3Z35"\'UH,"P0Q7T-N._+'-NBJ!0,_X-I/J>#^S
M[2XTY9^KU$H"V96A&_?.] 99 CCHJ@BW2$?ZBTUX1UWUF,:FX]3M;UW("U)#
MRD+1>I@@(E'I.\P#C?E5-H2KH\FK*@Y*K0(Z*5V?V528A8KJ?S=^/&\7V!",
MLEKPTRA=EB]XRBX&*NQ0[NPPLC@"L'+;@3]JH1%Q?MZE:]5AG>-%2U+.!ZK!
MG9F1V"/72%'7DX2VE\>=I//L'"^ 16/#$2J_F\_%2%#^/3-4N$;AH8=/>&SY
MFJRY\VTH:T?/9<_]^U1V+V30H;^*.:823X;2GOBIG<V&.!0E;'NX77!'"&R=
M53;D289YUZSI'*2=PQL<]\1&.Q!X:<:7^W "A!]7QU1M00_ZSS@GW[LZ)93)
MW>$_34>P_\']B5I=:0@U@Z>/LSRWKKP 1!:X%3<60-S&Z]"A./=51S(CF)D4
M$&BPB]ZZOX7;WD>'O880X\&4P_JZ_:^FGG3G'1E#31I3X+TKS "$F) >/=N#
M$*^'N6?)5LCK7]7RA5[!G#_G -JDB?1J' K#S/&OO*^%X"=?%PK3NY-7E<'Q
M5/Z=+,("4"4J.FI!@!)M/]*9ENK; :;.FX=0G]P/I<S2K-J)4S?$!V:4DKL?
MXI^[+%X 4Z9ME:_W?<<I!H^/N5BW@5Z[:6(6%L3(\=T9X "!P.'(OUYHZ 7P
ML\-U>B:/U8B,A@C6\M/&E&3VNJU<1?&@,=JB7F-0.ROGAU.@T@&!H@0=7+.A
M:[I^J+%)\7.2+JN$SGMT3\8@-;4 MC;(7; ;+3Z<9S8-B.GE^+IQN#V*KA9U
MI(] V/%7E5&WZ>LNB'Q4 :2H=<]^18MLS2ML<OU38.M:P*>'14WGNRR2@I/"
MB<FA#=&N&7XC29Q#O(+6CHW-[,$/OG%$ *^1NRW<2G.[' 98Y)86,' ;O>)O
M_6V-=D)0LJ3 XO"^%!5P-;S]N_/M44(?E&?C0/<J6;E#OVD,=P/C765,Z/"@
M<]QVE<K69EB"MRC<R,UOLZUV7W#H<=5"-)!*,^93/C57(%NHPX'M3N"WW[#
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M,6!M_2)I*7XF@074HA^;C0HC5!4%391:EF8<NM5%MBP#OE^S MY6#4CU\KX
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ME/!U%]T.4U) YSGO18L/B_/8<,6G@]P]N2QX,NV;^E"JH:LC!>YJP/ZF&F
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M[#/,02?%4<"AMMV&W8H:DHZ?V57NKXG+0ON_/HJPY-#BC]#GSRO!)INM:'K
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MZ1*@@.1[*&"/ 06TEQV"@75WBGJ7/@;&RBK'7CFD!2+G=H1OYV9J:N9=0N]
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MZVWVJC9]K>9!(1:)[40@&=G7$RJ'V5K+HMT$!QVJFH2N="SMA67=KAQI58B
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MEZ);0_,'6[)#OX=BW$:KO(Q8/G"E[.LL<$4@D<H;U/_3XK7;@7=+<"IY1(L
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M%!<(@G(&>L1* L*Q,Y\XNN43'A%V/,40BR4(QO$3 0@I\P>_%T8 8&_%@ C
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MJW*NO. ?/;Q23<UV%ZS. 0_RQK?U:IZFDB.(,3LW4R3_X;N&F.J.;>_\7S\
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M<")_J@5FB]1_N*2+21X;F]5(,X6MDKC< 0SZI&@!NQSBBL4KF+C.(O]\ZSL
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MR?O*X1[!9:DSG:E<2;$^YT<U82<)M&Z:J<M\;#-XSI[@^]OS&O$>*]G0V<$
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MWNE0FI JO,4I:W6A(O*T[,4VI#F=$SN3(YZ[6$W_RC4I,?>"@;V\;>X4QC/
M?69+^ Z\O.[]-<[RW_X8A 8Q?]9Y6B&.B?)>CR,23ZUMCV,.>E3.H@]CKL$(
M5R5KFI0O6':P;E.XN7)RZV'&RQ@T^@AGZN\I_LT!J4)D;^86 CY.#\YAFPT0
M4WG7HP>.'VA*KBY8X(\N;&Q2& :I-T3/='K;V+4AN$RO7XSSCY\0C#:,[2_S
MQIYMU ]"R_:P+ T3+4^R5@AMDT,OM.;*@U]^ Q!_8?Y!CC-?6&[V_C@?8XQ<
M9%]@H65=8>,UNE1=D?_6&&Y0.1!=)WKMD0723^IS,L"T=U_9)[@5K$(1D88T
M5D$RK[0B/@64E@7.I05CM#97VG.@%Y4+1KOGE'/.J.$@VZ_R/J==24E&OBXY
M?VF%^RJ(NG/T$ LCYQXJ$K7%7Z2%3'5^'3VZ#/5&(1K&2>#^/9+/)\_TIPK@
ME%>*7 ?X_Q!=8Q>.OS\_M&1T!! L-W3T GP)=3*8T;@83\X#.L7VUFKG+D^[
MG!/:)2+32-#W"H.$-+,\K2,\*JTV@LFR0T$Z"3F=7Z_.2T1&)A2RPPW+I<<(
M@$@MGW?%NU=>^MV__L85+2]1 FJZ7IKB,@I$.SN-2S]Z(X#C(#\GT$ZJ4W:0
MY(N_V8CR44DO**=V^_C/T3:\%2W5 [POFCI3-<1<Q&2#N;UMN<>]GDZT3U.,
M'F0QF=LSIMM:9Q!E,)+&/;7U^#U<2CU$?8J1;7G\D(;XQAE5Z2S_*_C3V;4#
MR$?N:''UW;KWL(KDM$*U +^G.@&>.80\:@#?BX>>T></0<P=(&J%\2'4C[TV
M@(%/G?PB8:!@)!9(7Q7O])7U:>< D+J\B,%<UM5DJ)LY<.!9 P/=QR1C##/G
M5A$Y[R.!X2_^KX2894FRO_E_H5!S6A1L7Q-.A81A&;UC5J!3R.4&D]O._SHC
M=/Y[&,TK9!DS02GEB)DVZRHN"Z,8^^\+U"8J^I-\%^V3/Z4UD-\X!3H#B8M=
MK$Z5\9NJ+DGCXDD99_6R !<P,\8#*45AG(>MSNEW<2VF&B43-P_\PQ M["=2
MDBH??".5E??/R^@;?HUV<8D3V48_DR9"\JU[[*,QH,BVX/T*SE>,W16/X Z?
M8!"%"=.Z%A/YGZVK]E[[1 K&JKS]%+5F.?/0>NTYH7A/%V.5[:6Z<[%5:X.U
MC#>X^:_/R'$&=S.);FC*;.X B)0K_)KZD'K^4%<27]U/(69G0,&\,KB2-)KD
M&^6/8JC6R4(7()2G63R+@*"K@;V?_HG^)S4"QC!Q!N0=X&$GAQ[E#XK4(9F$
M8/YF5+YN!"M1!O\GF"0M1K3?F':S+A@&SF(<T<6!%:]D\_]F='Q37AP)Z$"S
M!?D(KR.ISK>^$2_V=BDV)DQ[V6O0@1=Z/V.J.QW[C]H_'6V'U!1^AJK[E, C
M\\^7<A-'Y%2!&BZ]'@)J0.[L&ZFCMK"BF,_#[^OJIY?]H'*JDW)T-HF:C[8/
M J>O9EMH*7_ G(H@#+\.I^<%MXX-+9G=G7,38G*H<2ER_A]#-VF@W^L&XVP9
M;GJEEE.N,)00].:\Z&46440+=PX$.> CQ9FQST418Q8\ZA3PA>*RNCD(Z!7<
MD_'X:#LJF;E\Q\GP>_M,HZ6\^DZCPIOS,7:O2, V\D@^=/^&5SB,:?)7E.+/
M'R8Q/Y3#F#;3&'J.1-C$'T\T391RNS%(8M=7?6<S#,N,O4$<3?OV.)T#J+29
MJY>X8 BA=9+![M1H03]':A.KQXH9/\=0L$U,[IH)N$,+O[T+A*/7_TP6^3?T
M^)%EAI8%4Y!0I5T%2R7XV^*$-'53V)<:SH]&E7/<')0JJOV,5@UDHE5K&[@U
M =U)G>,?=>N-B6[H/(N7;5S^"NU[NI97O[%26PRE#@'BQ$)& .+;@K/W0$^
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MP !\Q?_Q5P7^]S$#*"8DE 5+>@>@3/.@M;H#6&A2-]I1B;UFIY)&4YVC&^X
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MEF.*D-T>E).NY)MI=?6S064.O3,4-$[H%=4*SPY!O&*K!2T'9J7QXSR&N3Y
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M,QYZ^*)9- #O/8Z:D=KJ/#)S:"U=(%60R\^M^O%>4T_@]5R9U@LC_.,;\*L
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MLR<$0@O5*A![+OJ'T_8YUO3???&+?L<W"DF&98/>3+AW$.VUT!R69AN@S;O
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M &2O>B+ _%,#_'.#@86#1T!$0G[S%N6U0RTF !8&#@X6'@X! 1[^5>K[*@?
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M#&![;;/J1O*::31&^9L2ES*#?_S!^O\!E^N1#_V+/KSF>92&9V9K6\_?]J"
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MX$L/=H;,%S_)7/CN)O[11JIV1ELK+!;HX;&8MS!CV/>$6^;L?W*! F)RY*&
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MLLZT=8Z,<U.?-,&"GW!_F@-222&<$Q[S?:3H+PM"Q!>X*;H288V[*BOD3CR
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M:O$O/[J$CB&A?B\91)J)0'U\F,?+]3#O4D\GY/9*#$]85X\GF,*4F!'X(TQ
M=9&*-=>\'OZ"$^V!)_L(;R9U;8K<@9$RM(13)U2<^T+=L/Y6]XDC3APLC'50
MU5O8'WT91L/ +8")U<!S^(G>LO;XC.AL@O0A#=B9@:F_:K%4'GMJ9LV!O81D
M$XU,:3Y-[F?6LBX:)3GG(^WD8UJTMG3?')8D.6(Z+O%1'DEO/=Y;."#_7+ M
MOL@ZG:S.F]9P2)=CBO^3*E%UB-D?L 3?/%&I]3I:BZ&]HV>AF&N>E;D;5?@'
M+;&%M$:U<1('W\>IB-9[+1;]#EL+\-G&65 -%(#:Z>Y:<+BG%'@1^G-_RT#T
M^ U"=3HHD7,G UEX.^?UR$^N$T*0]7VN+/Z2-Y9QZS#&N_1QA>N%9_7>6TVX
M"^.>]I4,ZYAECWI_6;U&[XTB:>T/$V*6S-9?:7EOZ8C;8I"*/!D8VUTG[YQ1
MD&?F\_4<G+)!8C6U+)>L#O80Z N70!T2[7,&ASX0+D"RN-(*G^1"NA7@@+4A
M'-)G2A_&-A(=C) 4V) J]%K>UF9:K*.7WGA4V#]I/N?1?S+1W+*8ILP_#LH8
MQW5,9#2Z6;9^4U+GTO;Q?+4^V _-JLFUM%J:@([9K.^/UI>!/QA_.V,!$.JS
MO@?7'G:K2ZV#NM@=0U66)'PGQV@D@+->]06SAYT?WF'U\E!LU\$[JIC?IH:[
M!>3@VE$?9"@@FKGBE7V\QF;FW*?4> +9LKZIW<H>#T9=#_W-$3XC8 O3\N*0
M2$>,)T'_/&);=$5:]FMLGX..F=<?L"JRK1RU&MHI.FBSPW<87R^ _Q/! +O<
MJ4=2,X=8AIA$N!Y&J,_3'-=8'3?8Y\G9+LZQM #;^,S=24HT>4,UP_',S.^=
M.[:(M1X1B$'0+Z:+@$/'^1M?:SY(@'^3*,"QV-(1R /P#$C"#YC SGT'F5$G
MA3MOG<VK+6WB; Q<=O_Y([[OV.1<0KIC>[>)GNYJT!4W>B ;C(^-/\-HD87K
M"\"';?S1'O*"V=;(_<["P?/;]KW=12!H50GI0%<5ATZ&GW6A(/] C5 PLW:Z
M=*/6'P0OA0@LNA':K7:I0("X?YD16BVPC%E>-:CX5=[SY^;047M&:=>WJX^Y
M>H,$J8>;=<6JR4EGF-!&S=PP>,RQDV2PS,( O+;&\T&D4B( UQ<'%49)4<RV
M!&98YXG[/'AUL2E1+&B4QG'A-!SX6"SRS)!=75TW?4)96QW(P[2%+[6E4)QS
MH#PI-P24Z.J5D_U:/<=Q;\.)_-Y;T[&-:PP=F;*@ 3<CQT-,Y/QY>N5 R\9M
MNLG3YG!$6B<(+'V*M*/MHJ1DJ;5A+*PQ<;WJ-VK+*:O:6*^.#6]&B0H#.)<L
MRM?T\):9KO%T29'E#.]2.#P/,4(V#-E.O=)R41PYL0Z(S(8HBYT?3PWG'AQ8
M4Q7C#E43!XP[61O&Z\K\1I#JA'<09\+A6FZ&2XC::/_VH1VO**N#&JT%]E19
M^-3<?B.\S8<FBZN%L[M \CD7GSNCL3J::X^@'VBUE)TAD*&H24 X'GPMC!G\
M,CMMT&B*KVX@%K"/;_!2JR]QKAXJ("R<D6^IT,V#CUUIB>^+@BVYH7VM.,Z@
M]8 0K4JB+3E]L_S.M$B;J;?2H(^+"A6<AEPRHU)@JS!R0O1Y6D#8[#99-7M9
MY)*  #=L&!/1D^8W6;S%I#C7\FQ 6"E$3/0";4KG\-55(V$[)=6_N[93'22=
MK(UH8Y&5:.=M++)4O& Z"B9?'?6)-Z4BM VGI2WA<DLB1#;,A$UJ9WW7R$F>
M'5P[K2B.+G?:U2=4OZ&+T:,M7Y;?[33 59):$G#0*,7S9#$IP) %<7><<EFP
M3>J;<TQP$N1FI2&+M%$$)JO57J,@#Q'\TRHB994KV8?XH:?OK[2%(D>G]5#%
MTN\]3W2"9(YHLV04%X,CTNR["5F^;X"9M('@'>/';[&E[1+P6/>S4D\H&]]K
M"J;?2?IK276NLBT:\6$OKCC>E(>$XVS'Q^'&*'^=9KRVY6- $X)!*-5<Q*<*
MB)4^&E>R)A" V_"H_3F[.64,OJ&Z4I/:=H6I3CU!J[\NCPW'R:TS_JWBCBGN
M:LO4LD]*IY!3=)IK$#64FYV+JDO4Q8<16F[2,%6S79?P96&DO)\A=2O6.T"K
MGNM"3VO4UB%@(XF0%Q,*P(X)%*94FI0;K'=#Y/JQ(8?172W+'%>05QI;J$X_
MXH0D.%CRD)!B7G)PN:#?05.;"+-%Y;] #DZ]@2U3%(NS.PE(S(:X2Y\?L_7F
M+I:5.OTV?SOB)$DR6+H\'MKVKGU&ZV5+/*"<I)X5=:C45R80YT5U6A&8+KVV
M6?5I]]P]M&"6Z89F:N-1MU(,-5SF>/'. :8?GZ1$3&7*AK,$J6JFS+BQSNF-
M)$G_9PP%WUZ=[$3V4WX"0HS@:WM420$OP8S%!"="T=WF4\J"-9JYBO4%;2LW
M=DV]+Q_KDMP&":@0R8(ULD.I5Q>(LWTXSIUX#+-$I%ZN&LEB."<L']0R<CL,
MITO+3C[0?#2((*>9V2HJ<5%VCEL-'T >Z#S0*5OO!B'KZZ2$U? (=#GYU'MT
M"I\6P5V7%X?+R/\M^Q18\OG%F#%Q//+89I)U$@(P&E^SS^\*(6*/SR_;*\"L
MSMUW#??R%X%^X2+E^>%63O('X;V"[-+3U]:<-=.V%+7^SE4?^_[UE-5OO#>.
M:^7FWHY[^JZ/59YCV,S"6$H=7G*L.R90=.RL?ZH0TB<<6I)/\_3A4G?0;XRG
M)P7V;K7%7%CF 4EIXCK-@.4V(<7:3?TT*1M5?1\H$P0\+P_(&ZI:V)_[)-/N
M]B7 /0KRGEU7L4=<VU=HDU=>?^,LA.P%M\I2Z[E:0%V)H]WL9[3J&P31?LJ8
M9M*;V?TVDBD??M1*2RYK:^)2@JYJXIA^)VNE\+V?*RE7= SXE)U^)(3SMQW3
ME"\35SYGPM[F()TMGK)#VB+;UCX<17'R?_@MR7\#:#VCGF^?]J_('D_N9]L_
M")^^Y$?]T]6?_B_)7Y*_)'])_D,D1':R$M)45VOY^<7TJ+0=!0HPXCC_/P=N
M8/I'[Q\E S;73/(GMC065 G4]:K, !JB'>45M_PX WM%E>LR^66-Z:W66I:=
M-E%-G!)*N! UI"QX3+]X(P)25:/S02QT%21Z=X"'8:"'H(3G#6Q(*?S/_\-.
MI/\RV+S&=TUB>?ILPW)L$/JHIE-Z"V0PMW*.H8_P-FJ6 1-Y,(V$X!M'#.U*
MOZ4E6K@Q!A<$C*J8FO0X*D&LNC P/4!R3:+>6.&WGFT36=^FV"5ZDQRC6IP0
M>3JN2Q>9*%JCY.K2N#^_T#2A)W48/IYB5.Y+.O9Z\8NBC!.?X-AR&!1+J;Q7
M<(S&L/ECOD]/4; (^TUS.3 V*?'.>"=ZCYEG PP4].2TRM2X2AE]]S6\O^^$
MY"?#+4;ZX.<_6O71%4T44 #CH)VTCCG<5,X%0Z28S+S]:&V*M"F\E?U9WDBT
M] X#C%V Q$J"?HH'?Q@/#VPK4RGCJIUJ&;EI$Q2@AVH0YM$_^GS*LU<K1OTC
M3\ZM7ND@ >A4M%,Z"IN($F&+1-#W!O\NO_C(_=F&@7B$SS6A>@MS*;A%W=#%
MVEV1/E2A=_O>7[AWWRLB0RNJ*]^Z58V(+NF7AQ\!D\;OQS&=8N+T%R4X* "N
MO L%15:'R%J#PC3B2SY/UP:B0PL(>7!K+7.J9N^W;!A- F]Y>=Z5>2S/4ZVQ
M?PY*K,C;3"<Y9E_\8_WL< :*8!Q%$82_\#^!^.8D,N\NPA!\.4?T31O1H%J"
M&&X7W<$RDI&4=(Y9">?R6.Z'+@=6!#T;,79.]BE2O1*[%EZR[4IRBU=PVLJG
MI@X#!L[&:$P-XO,C\$_QG#>$A[H2JDWINRP40_D]&O?WJDY21W&#@T\,6?)<
MTJU,E7T'PTD-)?QK#Z#N^)R96GY+1L)[IMSP^W!ZD=(R%%S&S%@I/QB"KJNE
M[*G:X90#8_/FZ0"*B%M^36:FCD-T:4;1/T_%K]6/37?V2E(9V@XDG8'MZ]O?
MQS9_"LUY*;[#7[]E7TI\_'"X>3@G^[A?3EGK='%2MW LQ7#%M8G<N8V@D^I+
MMY;>/@]BD>_(T3H"':[YM8ZD@/#"L)=.*ESZ0C95@94YNYN<QO[2*TX2H@PU
M!N;IO$<EI-,R;552M@8SLS:&]C$(#6S').\\J8SKW/9(KD9MU%QUB.Z$*SKF
M @L3SX0K>E\"Q''4)#9>4S4B,(PS[_PEE"MS*&)(C0-;J&=E!,?.;NC-H)#_
M/"\4\*8F&F4?,2_'*JZ_0,X3O@[^1"W"*9;YEH<7GJ2;1^#MX4TD,Y.Q7.R8
MNL4=KDL,:Q.W&FHI>S\\G.:T15/K<^1->4[9YP-GB]O#A%L]K2(#4;>5XQ'/
M/XB*\U%R'[9LOYR: 3?3@!)8XZ62YHSO#B[7/FB54'Z9#*9F&^D1<@]H1IG.
M4YO5U]%U[[JTDNC-\2Z(9FJQR<>[I+I_P^@>\>X*T.Y>(&!O18H?I.S-V?2S
M!E-SU)+*T,$$&QY^3\#8O%TKCR:D5O.,8_G'B:,=Y;1F.NW4N+'L3Y/ANJN$
MSD, B<>VT<]L)IED]S#7Z9P#OK7<9*]%O4$<>WC6AECA3\'JJ!I!5UCQ2Y\P
ME,$V.I ?:EQ:^95F";;Y!U-2(:N3(]/?P504=X T=,2Y,5Y* >7S_E!.NB?N
MK,X2O=\U=5CCMS2U=+2N.ZHK]?0%T5Q!'8,\>_)'7=6C),\1A,F=N>L#4SK:
MSQELL.M'L-(-"&BGI1+RR%MHE]2$/T^?Q!TM$5O=#<W-S$(.)RE7@K^N&?6.
M?".5PO#W!O#P%)-^G+G9#KR22=\=-(M8'&,FKW=%C07^SM+_E(Z\O1<MU3%F
M[;?752+@E6KIOE-V,MKRQU/SLD=/?W@^]=[7H\][,]*ZZZ1D57?EXUGTE78G
MMAG3!B'=UZPH2O)81)Z'J8C,Y)=F4"<*NQ\%>3#\2 6M8FN,6Z!W]!L>TD6.
M!Y//HF_?).DIY'A_.(&_(\=V$*RRO D3_0_F%4@L)=VH:TP!YE/M-2H:E5BV
MD75I6QEKF,+/K@+3:&22#4W3USS'U%>4HL1AA&%L&YZ7"U" Q\U3\<E:BCMU
M&6F6I3LJ\V]\F5&8:$QMWHUY$CIFCJ.C(^[ZEM9Z SUNM9#%."(=;EZW,4?P
MPEU)TT0*3L'<V?7!*9-=[-+F'T9JQ+"O5GV2M'"PVED$XP565B@W%VG):ZTM
M&?O..+'X0^:[7P/S4@J(]]IK]=HFIEY./=?<Q*A8^U*06*MX71V\+R7Q3Z3M
M<]?0S)ADKA3 9N#WP<;@]6$=;'1/(^?^RX.5)C1I5Z+E[V=,-HQ/>0T-*VLF
M0YJ*> 0\\":7B&S",AVSU"TSVW73IT(#I"1?Q-A:4"^&'ZL.E]W166>E!;;2
M>?<KKN\:D]<.EUP##U?2P)-G2F5W\2$2HAW[DN2J&M?85.&>S/4KOA4GSL*)
M_ML4(IGF.P"LE>NSSY9H":[6C1RC'_?JO[%&671\5N,<0 BOH*+=@_M=*BCS
M\' DGE1V(\BVR<K!L*=5XNZ*(!/*<\B[.C#0<:3+.>,L:S=L[[@MVZF^@.^+
M+"A9(;8O;CR^<5\^=ZK]8Z%MWN&#(I7:HZ)/W4JC4D]<QFV3<1Z6=2'K6?&J
MN&U9-;*6G"#;-PJ8J)]D,7%]P K@6#8?.*]0W,M&O+C?)HM8IK1/G1;?7PS-
M'Q&.BGL:K.N>N;KBVR!9F"L+PM0.N/5)ZW3;$;+_B141E)YF)3%I9\2.0B*B
MG3=4^(N#?^Q/ECO%"E<LX"BF8VMF0BO)2ZB2.B-3E#BFA-XR9MS>WVG;I[3@
M@@X*\%57Q_ME".2V3ZJQ7_K$OHX[5O<]ZUI0V*6*"( :>V^J.($.(\BFJ;!%
M=:'+1*=A09L='O-?[\SN3Z;=!G/'X&X/B#/"V#@Y\$^A?-?:*.N93(H7XS ,
M^8/Q65)' ?ZG,F4R7?V]$N6Q461MP%)WH5!(QNO@0;-PY)$XJ9A,\O=N )-4
M=&#KWQZZJ."XF(^\VK4D_-KB5/\NZ^BP&)3TQ&"%\U%+IY+W@N>7X<:X,,39
MZ&J3*\5Z$[X295>+CHYS*#78WG %?>_R8-R8.(S1FLJ&!!]133E:])1A3_UW
M"WC4;FW*M<XY."F'@FA_H=_JJ.7=EL3DMJZP@M,<J@/8\U/&"\V]>M;W#O'/
MU[76(/:!+K,J5U[K_?0U_7.!<;WL&!)=W,D@!M00)/)PK4N@#RT-''7X%08)
M9'Z<S9)0I[WIL?Y=T2,4<%QT?2/XDN:6]5FU8/A=!FY8"&F&P(N>V0;D1SX&
MUG-05*5OMWM&(@@*>+<L/-7\2100%&V]IS+-LEW-'6;L-)>);8;%*H*DGX)?
MOM61SOE(%R4U^_&Y\]X@+>JA_5;CP8MT73X-DHJJXEED;3O.@)0LH[Q3D7<+
MF@>RSQ1FAU]&N=#S[H7/K<F&;4ME1<HV-W8H\%(EN\12*=;$\F63,X[T V!F
MXO2%?&0AX2^4#;XTLC&)TF%MYL1$"23CCT)!%X*59?3RN:7?5J,^3[0Q6?*-
MA^=/:;';VQQCC^V,P8].PX/0O?U:YK/F^[&6=611JWOA*W!XV 8*9?KC AIN
M![>2[S""H0!L4$T"$Y)6RC.GB+9UJ/!1J*GQ\YG8^M&\%\04=Q36F'FO9%(<
MMT]#41P'\*]#N6G6EHD:<V"JI=D=_T_PCBEI+CD5QM>;SDR4GRI<B0[ZVA][
M:[*E,G(PMB45?*,^_&AN8+35V]VY_?)KL%-0'A&PG7J+ \.),V"JN:&IP*-&
M #.1XT?N+[DEO==C)]?@N >_IMR@LR7\2S@>("V.JW:D4%>=@)]O?D5-)1'3
M-]9/(H]#BB@I2 L[BZ,J52O+>_H>>7>5DB,<SY* -9JLWDCR.A/%15$<@/-O
M!&Z*9ZFXM4,EPGK08Q?&*A1P-..57V@(!4C4\:8U4#G70P$5.D^5LEC/QW;?
MKJZ*"$HBO,.J:\!?DCECN5 CV) +U)GR]8=-G(9&;>2)P#"W=^7IO-@:LW\+
MU$!ZK=\TCC.*XO]EB3X!X:4->.C:G"M1:COJM')A/<?\O'1@&_/0T5K>(1'/
M6;N2YD5SRPH*V)K$>#QLDFTV::E)7M+Y%O^652^33";/,4M+9U\VEU^&:595
MC,'P10G=&=RB2EU*'8'/8E9=.\VDIOV=\$G66^"W=E(N@<'"6]SV-E[R<\%#
M3<[E_3*EU=&IFL3T+^ZV)IL247:778(MOSOUF\&0$^T[+Q-U/3&JJN51^PQZ
M#:F5S BL ?*@@$ZDS,(4"; LD%J[N=$4^W[8X1*#E:Q2CPO,TX'?K^!DN?IV
M9(]3^S%A\@;?]-&TMT7.GDIYW&*BV4SQ9]\LJ@0,/LD12+RI<49HTEV@&6^$
ME2E_\I=;QB;/H/%\.2_^N%*5A:6C-0>>^GP]J34E7LR,L24\(.LS6%+ Y.&Z
MQ%%#'#%'<-O^0\UAMM0E%S8?%^L\L>L^ EJ)AIL9#9A, X@AY1)SM/<3"M!X
MU[9^M(Z[Z5#HN:7VF.<O_'5^BG.7E/=<,F;7:DE%OVFG( !I!0JPE"PH/+D^
MV-^!?.^_<YIZ!K[CZAP#M8'K#E[TBS(H.=+9YLM2,ZJ?$SR&_FPHOJ/KKYL,
MWRS1 V&NC*-F=MHDOOM"D7R@VC*(:1P45Y^*&@W#4]:.X,%ZTYCP<$_ L2V
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MOO-)GQ]%&BMH+^;K'2JJVQD]#O2V8EI3 LJ%&@=*S9B7V<-EAT(ZSO3H.=L
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M^Y$&W?7SAA6%-\Q% CR'8$2>,,\-( :KO[J*O@$BQVZ 1Y)=AL=7)>#%F1L
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M'B::BWR\HC>AQW:A.<N^VNA>M6K9/?B4RE'I=5?$21;NM]NZB0O"G>+:C)=
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M\@TDZ"!"8]7(9K4W%SH1^(TWAY7\@;4>G]B<GX@_$A@&L:BA/^387(44P%=
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M6EY[72M2@3NP I?+;)8?CYW535#.'&*X78?S!'B)_-QVY[#X'I]LQ]?1MW_
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M;CPVP9SHL-<ZYGSC,3Z:17GZCF9I'PI-X2S6KUO77^(>8*Z</8);:^.8_$C
MVWXX39M%OL$JZ S0K@>-IP<6L&NEGY<>#<!FYV'7]&UDV1_4M](VA#A*Z:M,
MO46ZDB<B46C#6=G\6E&?O_1C$'D"79#XYUR;<DDRQ,BW)N-P5T'*)K>+M0&W
MJ*VI+Y\(:Q/4L568WE^/XM1K&4NM53S:E<9&EJ!+Y)K:@HVJ^=[-1(./9O*;
M@JH?>53:G0'\WWU'F[]'^7=7D.OO&]LEJX*L./5*AVC[KG$)NI79'#1H>@S_
M7<HJ@(%'924[K5C3;@](;V^7&Z;8I%;;N<H:A-UQ\K7L4IGMR_J$])1,&$QH
M38VJFQ:X'+U*E_$(TZFDJ.V&%<\ML1-LCZK:B#K"@K@)8AS6*=[MW2U[D]=,
MM,[03QPT)([HW8TPXJT$7S8"3%V'O-335KF9NN<O8WB$8FL'GTVQJH*3$6/,
M_MP:/Q[%X;N(;Q]%J F?;#VP#G]\'EXVKVWQ;)WX8?WZ_-_\WLC' &]NBG5&
MU@F8S)H&F>TLLO?;C;X[P?('98<HRN3A/&SV6?[ F!M&#6-0 9KO@6@C;TGW
M5(!E1]N!6#5>!22&&)XQU$0_Z2'.LHPA"E_0$1?V(G"#LMO*P8OIA"'J'I<_
M7V,G=9/9X(>,)F'RW67%MC+(^ R):_EKJ\.*+3QAQUY@LW\8];\ZU]63(MIJ
MA.DGAAT7X>/"UHAELD%346!O8&(/J-_!+@\U$NY#PUC_XL3Q1H;U,DYQBT^$
M3WB:0PZ_F3! 2<ZXRMS<_I>>X>Q<U_-Z:/3GB-<J\[]?XTB>91.+-:$CUPVE
M='K?-Z =JT_N 8/7@OX+<1G7 .X^(X)'XO' MC!W0G/MB51?1_F[GB92"LH5
MD&I4.3:=2Y3K"./4"#CK[EU*8-M2VSU@3%47IE !KE&;_$K+%G0/J.<F,(L>
MN<C70=NEET_3K,?X[F#^SH4UK<M6HX-1Q$;5*'XU[E^)CG;<M><-%@HVFC5]
M'B0-VYLCZAQM$0Y"O$0^KX/?C=?U"Q4O?% 37(2+*W"PB-U.J"10M'<Z2 FD
M/P&<IR(VT.$U(_> <&.?BJ>_PNX!3 R>]K?'2P\ Z^C:O9P3ODR+>AFY%LUS
MK(@D' [$:/@T:7)'BM6D@I 41L^>*'H^DA*GM7A T ^DT/()TVU"@%1G&LM!
M=!;-/%ZW."Q2$=D2%IV/HOIV7I)6<6@(?+<U/VS1Z';]2*'S0//-=7H0\9HU
MYNC-BXI_O!4!8@ =K'RYUJ8\\1FZ=NKVN\"&0'2FP("6*3I$6("@FO2X]VR=
MR \C0SF/^E^;FC5>?C;7V2?JXH>]D!T?PFQTI!S*MZH6:=D;YO;J<SROF?BX
M\=NAJ+P0-I=Z13R:/JDBS)D2PAL%:"\?&'30N%(H=#DO.?PC[N52P^6P*UHW
M'FS20:L(10X? UM@C<!W0Q6TP[L.^H]#>SWHWL2)WW3%:<B\FYTX']BMNQ4
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MI-BI?NT<6^.:OUE5X\GQIQJ1OO]Q2FT3#4.66Y4^6,#@:(9S [*>X4T8>0^
MF-+174<"$'[$<C1H#R/'2!H5^V-/V.HFD6U.'\3<)."X@<PSSCAEXYC^A,@?
M@ LW#BZPUK</MA/J3+/;E),X=GI^;+G"? +;8JLN?F^9 5_A4)KTK^6T\ZD4
M!U<G;@DX;B;_C6!+@'5Y 4XZ!(Q20$C<OC&I/M#444/;.8>Y5(FTVY>/SK\9
M>24"'JUGWI'C-%^=^&@@5;K"W0Z%3PZ,!:)H:7V#ELFO!R(X79:DDG:;_+"1
M8Y=A7.W2;@4#PFFV?%C<1Q_\CSH],"<,9RBDB7R8B^0LD_4Y>7UCX?;?73V(
M6 T#1I=^+ S#(QX*:@(0UF .LK[SF5*]P^DAI=2J>IDQ]VQ8WSV VI8&$6VP
M+_8QS&;'_G#^Y3W E\,<62WSG_R3#%]'YK:@)B+/NH",P#WBW47CW(?8C5E^
M]BQ)774F?'N;P !W>BI 3#JL%2N;%BF?\4GZ]6>)ZV2)1(ZLL9SO(C<<\>AV
M[GDCI.$OVY&"[J8?I5T)V&E,WW)/%LI].E(MSL:]=<IF54#*-7.N?[\(<2A6
M5;)200H-@^\!\Y>Y0.Y9'\DR.00/ ?2ISWOE89Q\NCGAJ+Q!J$"U&H'5JP(+
M"FGV"<ERDUZ2[^B^C;_OH7QR":%'&-&;?L$GE<= 'PED<8@#S:G\K[S&ED]-
M8U:>5$1PY<0FY !8;T??+K2ZQ+9Q;M7HZ/N?VS*C Y^Q8/P>$2K<&C*,[3EU
M$$\_-")>+XC;N'=!KBFXO=L)O=7@1VV;_L[_<?VPU"\LX0OW0?$)OJ#PS*?M
M4EXNB1.5;LFM%!F?*TWV+BZ6>([[P2[<%U*FLB'KF01 &0[24WA.,,_YQ&%&
MUJ/?QTU_H_^:5JQ6!!R8[\>YK 9(Q,HW2-=)3K\I/LA9M,@[O92:XI5^=;9&
MM^=%@GY;HD1W4?W)Q=3L!YZL'E45\T?Z<:?N7:AM(8JR]]?O&Y[6*0G)(E5X
M]?-4@VX&2Y;1BFVZ',T=#OL)>$HP9T/U8:J$M&W*4E.H>"2'V\]!U0%1>AFJ
M7*+7JEP%/@I()10F7H$#864]C^@@=R#M( A%[(3>Z!*GN4$:^3@@OU'85WO8
M@-TO,XC>OQO^2KA[ZG5U/6]5#7%11$EE?A$JQZOFBE@F/WF2HV4J^\^M[8X.
MZ1'6SDH0OZ-OJ&UF<AZ-+]Y4:\D:?C$&@ QL2V.T&TOO2?+<06,[<!$WZC"D
MAU8,B1:IR*,2.G;27*JJD!L@_+<@[1AA_<'N?&)&&OQT\^\F)U7CX6^Z $<B
M#@7=7X*'_@H92C.'-]?401'/5T<RB15>R>[A>@'@[<8RJ)P^GTS_@I%[0)Z<
MEXH9.KA7GS+2=:="J%*4^Q!N^JO44OL-CLCG9V';8Y(^ OE5Y<5[9I.W=: F
MX;D?:88'T=$DT>NHY<U)'/]^_[\O5IGO 34^:U>/*R:>V'8RAJV?ATPL<FDJ
MAZF0+-M_:C"PI-?UA]1*N+%<S\&@E<7M:/_J)?T>EM,1\U<*9(IZ69&9 %R6
M><G<&VYDTGA:OJU73NBZ6-[OGNW';TNXB3$[.0_91,=U1/=EZ.0J"_O]@7X4
MLOZTH6*;JJ5L1B$%%O< V/MY*Q0#V)N'!D)T#]#XK,)-NYO\7T[KLG\20)AQ
MJK[EC3/U] (ZWCB=#:09^"$MC7T__CJS=TN_I-Z?W/S86I3TJ7)WVN8JJT!'
M.Y% 0H,@^ YWV9D=,QB=Y.3@A !B+BR)=1:YE13'$/]))L<==;AT@HXLED.$
MMU6A&SJQN4D((WE-A\U0$:MH^=?8-^Z):!T#^ 0 8M#K06IHG2ZA/=V\^)G[
MY+^.?01^,@Q)"10\)D%O#*XA$ZP=)+\U"4_8"):@COIUS>F"L:+7Z1@K =HS
M?7M=I.V?7H3VJC.&9L_]@6_ZEB36*M'KLL-*=@W\L.8$J3H)=<?MN:8&Y_I&
MVK'#AN"@U I)I0GZTS6A>6L_ABD)H>(H0II>6G%39VV^$88T,T_S(R6A,$]D
M4\_KJQ';>2G&Q@34FC?].$G&S"!17_9?NDG<U(4E12EZ'\[(75K"JL&]ZMO>
M$WZ_U*ICQ%],F5^/13 -Z^\!DS'N-+&!A7MCQ1E+ZFP7/OM.MI@_\#;5 QP+
MK*AWG%\NKH840:#**2JS!U-[XQ\H8H;I8K^2! &;11_"R>0>D+ "YW2[QMZ^
M"];Z[YQ<#3ZMKV!^R%%.G^J'O4C![[$<M*']J7#=ERQZXQ([J_P?C6MD&)0@
M&@Z!V0*MC8PHGI;Y@N2):$R2=%Z\BR&A'7]*1*QT<&N%=61)?#>Y#%PF"3#@
MEAX6ZFJGV;<MVUH3O6N@)5=OT9_[$EMF09:*R;6T(>:IZOR99WV6ZMI$;2I[
M M=!2P^6<P%#KD<NOK _"HXC]E?YIGQ"ZK\94<%S3J<R]MX2 -#VSWE7Z"H0
MQ5!Z6URV$S?A.;C[#LIPX[I,'N  D_J&L>5>D>A#@CJ?K6$&M<Q4%=:)=/-1
MROSK_<$B\"9JT>K62^X>D/O$;BWLK'P%X^QE13Z-0?]SX5];0GCBA,W,Q;8=
M6"1+!@,.3PXC6?"B,M<Q D1S@?RH/^-9-BCO;A=;!U(9[$F=;W#M-V3/V)K&
MHKT1E3>*R1S53R$O>L=FSS_/;C3CA7$GKS/R0?,V3F$-TH-2C'?+Z!2X5NO4
MZN5[BOD(U[''D!1GPN^QO(\E)6'DDQ"7;C\JY+<?RGDVQ(MC3'WO]0I\O'"<
M%>F(, 8 SL)7L'"A+A)(+,]C&'R,X>?@08^WAPL).*)0_511RY%OYM&*TWP5
M;SN&P 1\(L)YN 16*JXB"A[:P*MC?-EIFA\ ;/!BJ$3.]RP>U=Y6EEJK@;P4
MN5YLJVUZ?-8@[R(&ZX"0@U&%*OZLL3EDTHL8<C^YWXMH+>+TN@<V10.P 9[R
M];*W61+BP=E?NLY,RRGGTF<G8(3.2R"4OC6E#H7VH:U%3>SZ\CO*K8^K\KS=
MF41=(1[:]P!"'V:;(B.;QBN9V/$]U^9D\N84G'>B&E+V?#N\'&_[_8@G)0RP
M'/?3+72BJ$>_])<75U$KFDK6R="9A+I&<-X]WZNS-192\="'*I_8<VU,4ZR-
MJ'276K[18<[Y=K,@E>2R7J%>W.LK6 :P\ [UDT*=&KJ@,8R, ^%&P-X+H'G>
M[B^]GF<C7UGJ<BY2$V H(7.Y7X+'0!L^&R^MKM\'WU=^<!V@EP>@G$I[("\
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MHC;1]V]!!18DJ\V,T4S KS3=F  6*LR[UD(/"A/4AL,]P##EKQHN'\*!5J4
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M/_.3 CW0E&A-!S67FWX^%P6'$DQ4&_W&?AW-G;#(KDP0LOH7NW8<%SV;)8#
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M:21@WZ&3R79JGR8F)=2'V:FRITAYT]@P:F%=*XX@2:8[A;F3;V*N8AC%H<R
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M !,   !I;6<Q,#$U,S8P,S5?,34N:G!G[+L%5)S/EB_Z$3RX)3A)<'?W$"!
M"!JDL1!(H'%W"1 @>(  P8,['0CN[N[N[DX#3?<C9]T[=\Y9\]Z;-^_>=69F
M_:O7K]?J+OGVWK5K2U5]B!G$"H"O**<@!R ] @"DAP^ F =D  PT-'0T5 QT
M='1,3(S'V,0XV%A8V&2$1'C$5.0TU%3DE)3/Z#@8G[U@HZ6D9!)D9N/BYN/C
MHV$4%A?B$>/@Y>/Y,P@2)B8F-A8V*0X.*<]SRN<\_Y\+H@4@P'@T@@H@([T
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MNOS,1[C4MA4!X$+$K%>S&^NFEDB?<>*DB&+[<3DXQG#Q>&KKGMH,]:M S?)
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M1_Q@L[T?OVC,C)/D\M!-E6_3$Q:37K^[]]EU=4?:9H0<?Z3#&_?=U$V*&$0
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M0?(^Z"'W'4FJ@/-;""90,Y>/46N0A+;$L)2UQ7]ZKW_/'65% QKX];!$3A#
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MDO#3<G:P4E Y,,L%6I=-O*H!DWQ>DMZ?,('8@JX5\_+!()\2C&"ULNKZ<,K
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MV)[],_I'8C75UVJRQ,!_(R"M_.T@P^DW OCEX+O3RSK(.@;_<Y]BUPP!O-]
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M;FDT&EGO@@UL//C6!'/1#G]4:/8M6(V)@V906D/;Z>#D^>?I?JNF&VW5Q8:
MPC(@[0),QIGXU[(,][4QY]ID'9N/=G.8!C:PAF&B/L+?$NNY*:ZF/O__YRU/
MG0ZV>]DKL\M5J;MG.BI-A0&#IL/W;7^=?OD"<''P+\\O_M>3< #YXQBY;M:E
M+IBJO%MI_['UW].)_XN02W4OJJ\Q%P+F/!\ %R^E:;+^Y9\B_=<3!NXFUS5F
M_P/ &./^Z\R87L6$-(V:O/<($<K6]/_&C1E'E4=GVY%ZYQ'W ) EWI_^EPOR
MOX:(W]@)8JCZ*6EDO&$G[Q&4T5U46+86(=N7)BTIBRM=*!!,XM\<;G-3(GLM
M-HP%"AFW3F]Z1#DZGH[V)YQ5]GE)KK/]NCJ+"I.]3KM=& T _0*K][(GW3H*
MRLR %UI.O'9#2)=-C6-2/S:UI#ML=:9DC9NI/:F%^P#UMHT]E?KKCU^@\'>]
M<NE&%R:CZ7-0I@P7*-/4X(*-OU)5Y 9XV1VCY@% (\9ZO>]J(E.AMA[H)2LE
M1//Q="'382%KR66-K.K/SVR!E6V;FX(N(4Q',9K.B(!<)%L387!4G "'?<NN
M>=WK7[[?8[GJ[J0&+Z)*2P]T6^6_-C4EHH7Q()+F49;3_2Z/.[.L.5:6\UA>
MD5M)[59ZQD7Y:CA#5>]V>185E,*H+FB*E^<X25\<#@]1?S_Z[#1^REPK(=:S
MRM\ ITI<:O^XN*_\FOSSJ<8[/T5GQ)UHU'7G*M3(*&(W6 &D/\\KFHDG[Z,1
M@C0BC:@4+XV"E+SI:E<?E6KOFG:OA'^7LC[M=1S<&:ZCM;]M[2)]A&=H^X<8
M_9(LC;"5"/<G1BU2T[W9G;OC+U+[LND;8#N9UAFX8EMRS\1;'@ HRW/A!X;)
MLY4!',=;8<H%XC<H\RCS+S)I\&=\)Q$!O.=4W1_F&"29$33[&W?^4WVBMBM&
MU%7"*:^\8CMPFW(K#:__R,UQ7F K<W$8+2H-75N:R9ENYQT*II]DIJ;$)8N+
MTK;'+E-DFN)/>,3U# _##PEI#'Q5X>?\;*"9^Y? &],6ZN#<; ;[)KY'%*KK
M!S@%769M@BG]OBD7[&L]  K\%G:U[ZMGWC\ ?*:O;B[.%M>>!VD;7PKN?=D\
M5U0W'04=>MP$I%U\)>QW07/I?C5$%$5.K2Z#T:%LRK<^1C:4,\K!10Y6CS\3
M_1[W)[RI!.G?V<.9(PBV)61>N/+*=MAH<N#+O/G8#"<#:B9GK^#*8<2$,5$-
M*S3)%:6+>9H"LRRB!-A'(0"4U19L-B@-N.2P5I^7S/PCR:J'E.\M:.'8V#%6
MW/+F:.#74!K_EI0<#_584P[2/]//8^-L:WU%;6W=R[-BI:Q4<\%QQ^^UO-=:
M4+O]51!-0MGP[6D;VI'_ R"OYO)"XK[#Q]Y(MW["]9K+D6&) @8X.'[4JKDL
MW:_[8PF5 7QS^5&%AJD-&NJ=<FY95E.R4]EG<%A^J.:?K#:44P-38GAH4R2]
MYP(::6GBAY7,ZA*)N\.A=CDH9A>^+8>+D_M "[XL+GXUXB9]K*$U>^! + -H
M^#I?+&'Z#-O;:5BOMA[<[CG#E^;CT^T3#3^7!.6U5#]#U.+B+WI]L0?=,]X=
MF:W2KIHY;JO#K:..D2+6#>Y#?JSW!UP:5QE+UP\ +J[Y]U?9HXO9<[.E/ESV
M :X:Q)Z=2[U.94\)5X=^R65^\-._(B[.L]--O_I'I8"5;T]S3MT:GOM4_H[)
MLY;R"^,+VN.5:'.OC&5L&'MN3"W_X0GC/*?Y^;>LRD&<P!2Y/24RJ61O[9\R
MVLI2/N=GXMY>E8H&+8K+%TN_KPY8P^(J#.W2OY@N=&XYD&NL*IP4>,^E^FHA
MDK:>MTODJ=VN:IULXRY?QFI4EQY/53GO#'PKE%2U]2ES=MY1W\_P3NU?H=6
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M!](CRVPU'P!%W+\UN1\ [R4T;LV&#TUF6-GYO0KW.A735+[5)+T+KEWIG'L
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MMMSYZ.8._8\KXA9YPU)&4K0+/M><G3*!L@,B37F9W$BH%):!9^*,1?-O%X4
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M;U&_ARV#7F/H6V[>H6!I.H)GK"(0<1C?0/])N45QLFKYL,TGI[?.PZSY2GX
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M!$%[FZV[0R^[P=%U27.QN5Q-/?(%?5WQU9X9>EAXL%H]D&I@C]B<YYR?-S&
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MLS@77&VF.NVK 37YR/*F=LB/8=4DA=L$3$?W$PT@Y#(UVU9-LH(PM&?KC4=
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M> X(Z;Z\H0)H3[I1?SG<-,VP@[)A^I@HS"EE\BTJ&3Z?;NXM\C<7IL?(ECA
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M[)XD>JH0%<\A3V^+A7$9/A?%^82CGZ*=H@,"&'LN 6N$Q/> +JT\H<('1H1
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MM$IIPUC,0"Y6:*/IH/< 5$T\LLMC)=L6$?/S<=-4'>7ZD5W.\A%L@\%=U>=
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MK22D G&_VS?2VUDV#/Y5^ZE"0S1#D& UPNI&?8US5QST8?$V:7/EEG)QJ8]
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M%F=2L;4E?3V@]/%7#JTEK:.AT^\* E%);G#6%>X_<(M4_L)*48V&#,Y1TGM
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MU+Y"1*T<^@@*'S9=5D0>K""BQ7AK:)LX<Q*"$3=T[U_/SM7*"M:'(,<C!KX
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M !AR<]N&+$#FR6+2VRZ%U\7_6#9,[I=3<-5EMK(#&DE[2K!(8<<BZ[")9GS
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MW ^WWQTH$F*_^>Y)VT+)/"W NI16LK,LI $CXGB[5E#;<D[U@H(RP6U5Q5Z
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M(5: IT3.&43\6=;:,533LQ35%C:D?:,%P$Z(Q/VO'>Z<FAIOCWR/K'>L7<D
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M[]T>K_O>'J-?]_N=&O.OL_8^>^Y=:ZTY3XV"+$(V >^EQ"3% %#O  "HMP\
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M6P;30MQN27G<MNNF/$$^&$<,&P5*UA$[&[_")R'5Q-?4^](F2>@& K"' +)
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MKL)0*UG>'%9H>6$X9.[.[P GYR2FZD8GD/?*">"29%X/OMV/04Q$FPZO^@T
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M*Q%KL#K*8L$)/&$_FP+.S/5;VYP\\UK9@TU+&8\_L^B-X_M*F]Y#SB=%--D
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MJ4Y9['Q/66$E!A*A:P1+[/?_J<4>_RO$8O&Z3K+R>Z=+B605#D8Q6TP%4H7
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MRD!>+_Q:U1W$=#_FZ20ZS+_NQ+67&E!1C7M/DRPL=JZEE-8\KTA &G)W 2>
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M>=3#<UY\&3L./2?F%F1FO,7*E#*-;EN9A>"BS.X*X'--%32=5KS&/NW LN[
M>]AW9-B+**1-52^:K^S5U)XS--D5^#D'?6-=GU(K%QAH<.NF71!5K.@,$IY3
MW31XSOZ]0C1'C=-M6:QX$6>3C.FXDZ[KY!?^89S\LZ^[72NXPXT@/&^C&<GC
MVC2_RZZ&MM0M R?_% %Y4@V<=K_8A7%7Q?P%U=E-VXI-?XG5*&Y'%J5I8XT
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M8L<%*59 E7*:%&4G=H/#D0K?[:7<65@IP[<+0WIC"1R2"W4L$UBJ56I( ^B
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M:^_#2C8.HH.NP=JU?\92&&[<$=R7,%2%[Y*5+VZHC<XWO",144YRP E@CBH
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MTJQV?3@>SML?3U1/U>G2A87P'0"AM$RG#ND#<@+M4R+2CD<OFSKVH"?@N]I
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M;RY=0&[M>,F0MW69'?G+6#S@2X=&0Y,S4<)[0 D=@.R592<5UJA3%T[SG/'
MQC%8&WT6R86LOBG@=Q>[WEUM H60OJE>=O!2\^"T5VLW_TJ$]8= KU5N>?ZA
M%GW602+J7^!\-;>*E0N.#!$RZ7L8Y^>=]Q?S')Z5,AGX^ 5F\&@E>!-:O5]L
MWK@%7W,6S4!<)OWZ'8U@A>I!!X>,!P+9_A!'_%6="]=N?_"[59ZRC-*T9>=8
MM0\R5W\2O&9%Y?+6(_"@P$JG[*.B:FB,C2WS?,\/N_?U2+S+8<9$T .\B>08
MS/O+%_KM:ZS,UA:LM'V!P0SE6Z^>=+Y+4=0CDZR6"NF_XC_OR'NP=$:=<]RP
M>B#C8/M2LP&WS", #U,"N?YJ!P,/3DSCE>>/4=M':S&BTF@.[8Q/3;/@Y_7T
M<CL[@%>1AX2'S[FO/ V/W\_*J%0Y9AN>)?*/1W;U=>3>WM!5.O2>X77$/1![
M]U4(57M99DG9 6V[X6!B:'VSH(M[!:.\H+OO[M0USGQN =E9.>9NY[NOAR_(
M(U"BO17.HL#M."0V0D"GUTH'>$]T\!]E:&#>]$+,G9 3'2$0B\4H<R'/BEB\
MC? E'9)Z)E?1J7VD97E+Z8ICUHE_<XONMRV-3;9KEJ':!RUT+5A_0E9DXU%U
M%:$[MSYK#DJ$3BG4BQ%%?:@B_H$;JFD0$B5TEVWY@IQBO_F>.2->+IU>,TSM
M)WN7>-5C[9_YYZO3"G29<O30V5LUL7HW#N[OMM1I2Y%8E!R<M=+_ #3R1,,Y
M#\V%9*DN_P=P6"[JAD]4-%;5_N9:KA$4"L?2G>^0XL'!5\>L77SNE&L4O6TQ
M]J7108Z94K^ANV2^8B9<]MLS0<B332)?&JN?T%26[2%.15J,C&Z(&L77>'Z5
M#G=T\;8\:)42AB8/KPCHX<B7B4'NZ3EZ*!12$PPP+\KLQM5\9C97*G-(6=AO
MR31+2L9?1$,)7A_;R1K"PVO 4PC'!S\AMD9^R*@^YP(*7!HW"S;@Z6AK=:_Q
MN1L/4R!L.A64F@.&1+>P(J^-2BK]2@S@!>HYOYK5Y@6+?#*>-H>UM;$*[<:A
M?Q>2:!+-&K3 094OCSYE(X&=\\#G%L,LTRE"T[[V]+M)CG^N/C^_-;='X4C'
MNKC801^$VD3Z.6=^VU_@ASC +M\MQZ-<.8Y8UVV;6DW.F<<EETI33XD/$GQK
M_MZSLD&G)O(@5GO74:D.?,6P2-V$U/?8M0E$N6C\!82]$L#=?B/X^ZRH^K.Y
MNK+[Z<[P"]-RY.2.2M/YL&?;Q<0CIU4_&0N__ .S"/W6%MKF$+N.9@,CM:^\
MCYQ3,SA\_&10_[73V'$0JVQ+/(RK=,%)_*)$:WHWCO\U%3U)&6"9X(4B_5]M
MLY6<#6C99#247V[7 -;:"=^-"AQ7UBE7(]&H*01@1S*Z YCL$&X/Z<QN"<\^
ML,@QG3[O6&&XWQ%-VH-D,',3]V4:X[KBA/9#@7Z!BBV8G:_-8G\LM-2;&B:]
MGOWE2DTR_79=X#3W4$Q9]5Y2#XC%?K961X7#Z=HC\RTHP7_ZU_7>I^M!_TK_
MT[\0DCVD!D/DH3B#\ZF%Z7_Z]WIB('_A_9OWX9*UJW& +3X8CDN'3NL\2'KE
MP_TU?+'SU[:M4)__<X9"+,E=CMRXN.&>QRJ!8+4JOV2].1>1T;?S1@ABAB\@
M7-Y7+Z(\L3:?=;SCP4EIP9!"8$:4\7N3"^?^HA^Y5'X==_,$=WG]-818]U,L
M UO,;CA65;V_B_P!IU$_TUNJ[ZB7E96LS8P#8.B]_T([Y34P]WF!J-A\Z0J"
MV9<N/DK@XE;^G7<Z_F$*3_UEJU= C*)P[XX.6L]X+^(^TX"*CQP<?ZI%'N2W
M]$I@30WN#1R 92O/G$T>PHUT<&H-CN3^ ?B-NZY";"L443'V'07V,0SB60Z
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MO?G-<""IJI.;S 1GVHXSA7KZK'2';1D(KH-'?1P)$25_G/AA1SE5J^!9_L4
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MS\73Q*JC?I+XHB! J4KH['%DY&"$DQ'F;SAO9=^+W:+/^UWG/X,,S.<;'H;
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M!.OS\% ^>TO'5#G"&R+%+VV9\0$JYLMWVC=1EB+!04+ E+%G%68E)!"_\0]
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MVR_UV&1Y(9']YV&6'KU]Q*A>FN3^8(#]*M2AD,1/Q-R:?(]6UP^H_@.:6^F
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MU<\:8G8I?HJM\11H86J5P%9^?$X"RB5)#TEW+2^*$+'=.0VN@:/-3B>M<".
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MF #@'-XU!<FOR?VX9A-\ZS=-O>364%U#XW\U_OG.YDOZ5!^"""B0NU^_U/E
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M=4XE3)7IYTLJIV>:3=2[ WN#BZ.:XMP[BS.>N&8<VED/EQ;<4/05ED.^N@
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M"GH$A-R$9A6)3H1>;%>%?0K[ECF9I&VPW GV \X5_L@;6E^!B&4>O4.2&T[
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M7YLHL1*1ATD\ GRKBUA+SV3#YL(3]L0IS?%G/ A)H"5+);;%%;$HWU\2/72
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MAD"$2%1S>+B,'EM%?E$2/Z)#]M*ESQ>!- K:L" TM94#/OSNG+&>64Q-7?T
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MZ&; K:I!)-HG/PA&O6UM4-Q6CM^*/=$GN876E>&X1EEL7W\3&X?_MS_5[7D
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MZ(, .-;G#1J/L&H00J0/]6HR$0_WTR/J!-B>F$0[HBU;9:")AX@)TJ5T4#X
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MITM;HW]0$[0R@HO!<?V%Y0 2B(QJ+F/S#:7C@#<TVIEOBF"0G?NYE;"8J?G
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M:>Q@UQOF4#412!RJ8:^N6-U3PI<I$MP_/-;P>>H[D.W[ # Z?@#D3#5G!M"
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MA8@G@"[#P'QG9Y4#Q;T%'9K34"^";'!97DI"\=\/>*6BBM6(/66'R]&/T$J
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M(XNHI>W <2[[[['^6 [?GHT/B7Q+4H&311?MMYCEMJ^H6\:R:S;&*-0XXP"
M7!3'^Q=]=$ODJ%8L-B$"3$B)94O23^=F&S6((EDD@X?[#*S%4ZMK,W@%;5 T
M6LG;/9VXAXQ\'<ON,CRQR7-8,^'X9W) ]Y>H\#2G,3G*2L-)T5<%>YJ-L7KM
M(]-KN\<";N_<XQ5B/!K$QJV"(7^HOF="<:.?]XDMZRC1\+06Q]@>!C8"\SFM
M*Y9. G^=/0 HE@L*X>=_ELIA;?,5B&4Y'A&BP>"-\YD-I[D6 BKDVUMLY]\7
MZ8R7G/@ZTMV*C&\7L;]IGPR*1*M&F"*F2><-P<2R'?#TPA!SSUR0A62PZDNB
MTN<;NQ3CS/62;O!SQ;:PT4S5V434I#Q37I)VLQE#&L]F1I[SADHI!]\)38%R
MCV<[%=OR_;M^,1.E%AS&>+D9:C; 932]X$V(>CR$=!X9+VO@UN,1_+OK.XSL
M"W/MI3KR!=X7^'5@W3K^JK[A1X[5U<NN98[5HS7K,C$>_ST1UXJ ZK3X3%YY
M!06>787[1R_5AZ^%8[;&ND&7S9N;-6D"XDHX8>18Y^4V'ONBRH7(X=[)N[G)
M/R!SJX7C=LK'RWU<]N=\,":/[/A:?[>=N029-4F;O<FN30^D<536_^<_3 AX
M/8VP])'?6&W[TD<R3.-.C7@;OEPN1T/1"^7WKB;V[UU,SVI'76RPE-IF?&C#
MPVT.BW0_DLZ/]8QH? '8@S<R?I='?GQ?TXX<!>5)I-/^\-#-#F--QGU=C(:+
MGN8\+@IK-5#NTM4L+K#D5],W>G^K]D9W56^$R R -D\Q/B0$L>76Y&@#FMC
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MQZU%$%2F'#[?NV8#6?Y$)SWZB,>7_3R9_;E+I;KWP#41ZH3SR\O'X+U;;M-
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MSLKO1&, A?7S"X"]E$))^K2'WEV(20@\*"._&.P$(6L1@\1[<_Q]ED?0V,R
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M$C&!XA2]/0Q5;*++Q];%_<+>?)_/U"/OI3UD,^8\-R5F4VO4:=M^IEGKX[,
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MX0:,W%_9.>D\THXG9N[]AH8#N3DS^?D.,Y<6C6!;Z$*PL$7OV!5=D6R0,+(
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MH$2SS]OONRTD D"SIS;\GE-'JX-5%_]UYPADC8*T/]Q%4Q#U^_DJ5(C#0EG
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MEZ2AW"9L&M^8:"L]B56SM->>DCN9YYUZW*:C;OLX4,")!=EF:@Q8LO-6AM>
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M?LEK*9KQ:L-[>2^D@N;;*; "^TUJ_->9[Q].4/R5<')7#$*9UYBQJ]<WQ;>
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M&<GW+U+[L=6S_J<L7D$/\S'^B A$7>:@5^WUV[,(P%*S8#32 Q<!?#F]KD8
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M4Y0D2?A]E8\<Q,^!1(Z?^4*;\3!K=Q,%:I#$,T%*<*- M=!=6LU0FPHXPM4
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MJOTA@\<X2S4DT-9<*Q1()QL%BF>P@E)"Y@&>,@>?R%<9('=1H!R/+-B8ZM[
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M2ZLLZN!&*>6:B\\4?Q*XMB.I*%"L!0HTT8 DZ?!:M'E^' <Y#$!*^6D@8?I
M;W;IJX1[%@(<P9<=B':B^ZWE9+[0Y&^Q&ZR^;Z81+DPB>T)A(X#DV?_!<)!?
M&2Y1[&:$0D/78TL:<,6L(&1[4#1SP>'O5HE$-<9M7PU EA/,&^<VT#$=VJ>L
MW:,[J JG0ZK#BM6VL*V@U'N/'!.^+)3O_R@?N1SYUPE?Z$T>B ^FL)4,**=6
MT^LAP1.G$A!CEZ;!,DO1& 2Q$X!$@C?/JOQ+S_7Q/_ %ODDC;)LP %D6,&]"
M7HR0TER^NJ&,U4Z%_S;.N#57*KS6'P=& ?175B=S,S#P:5ETCE?C.I4=\E_&
MK>&^ BE$EO4,*(5UIJW[)_TB=; :'_(CZ(1*7OH2Y'=%"R*G]G/C,K8WW._I
M@PF!"U83]7S'">B?D5#"H;HN-5GY5T_I$8K,JPCL-<V%YAE:9/UX!FQKRR\[
M[FAAE>4GHJ+_A:BR;<\9U5\Y*[W>;F*J$4D/9[.)85$UY=N\-%71^7Q(+?0
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MNS$:J^PG85=-Q'@&>/$@#X)-GCI6!YLK=],IBQ 2/#*)!K2E^?3&,09@K%#
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M[Y2@$T9(WO5=5:66@?M#.O#.>3MRT_&-XR-J@.LO\7M!%TD83_?C9J01-..
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M/@2SPLD:I+EZW'OBY$ZNWJEC9\T?F5/O3Z:HO2$)'B9YR[$R#WZ4.@:H*;K
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MNN=P6G"_&F#Y2[Y<"AO>._!$0&S?)K0]-T]=VAGI[!N]-]M>SU%Q-6KN")]
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MWZ55T\H_T84;(3OMIWW)435-38>MVC^0IMCSR% BNJ H1PZC5TN52N@@<_C
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M@;OQ1&#A=>)[/''(D9L 2? 62YKG2_F++56ZV$5OFH@56=Z&.,=#.T8;]*:
M,Z<;0%O!)N&[SG.;*XWA'1X++1]']3Z8Q6TG,F3_:2@X2@TY8]6J$16MO/6
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MF@;?G12"G85]E'= I\R&JTT+X* '6AT6N45_ 6YS0:[W&PTJVF^%RV\'.$\
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MQ_P.TQO]Z*+-$]DZ:W-7'RX1#W')=;<ZS@SK&XYL6ONCSBD_!9>X#^9^F*G
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M1HOJ$%'+PQ@)N_Q"=D_;V%A1P.IOGQD&X(\!1CM:KIAMJR,FT\A([*)M'N7
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M^!A#'WJSQC+HI6'(O@-VJD]:>C?6^:&0I(K97??BRGXH)RQ.?4^!X6,<]G
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M?Z1'^[ZJ 6[4A?8&@!I=QE<XC#<$C:CT.2LD>NN^_@1":L.!R4-JBEM=]#W
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M_ UH-P]<ZIW9@KZ$'/??(6F'V<XJ;\&IAAXKG%5RC<W">NIXG%X:+ZYY?8F
M&';,"R8_-:E<4("D!V1>H^J<.KL=8]9^:([R%!7C!Y#>TY6]GRPIQ>WD.40I
ME[KB+6V?QH92/?==G7PA98#TC?;DT/J**Q/0^"PMY>R"4AQD385:GF3VI0D2
M1VA^;*RO=7=A>DB0\\1%2PT83^6_)N83NR%7?&HPVUJM#Z:Y"#MKN;"1W&(.
M@HXJO\\Y?8AZX2J9PR^'6205-A3E[(/8P01\VDP1MZC2GV=1B3ZE(#Z$*WO8
M8M3Q&PF MXMJQMG9ESMQ@:<C%/;P-V\*ZI. 94)TRYQG469"(;7?7@5*\=ZR
M84M!'CWASLF?Z_04O&\HO4X)BB)^U (.]W^?J'98 '#Z."Z(X!!,Z)11XE2]
MV:Q^D(AYB?=6JF@86@B+*9!,?YFF^MJ@TTO89'0?#W2,!7C)/UW*3N8LONIN
M,)=H1,WZ+LESC%(F5H. LF(J>4B<(A2<<9)6X&.;I_)U3D)R^BB(UQ:,+$Z-
M";D*E0;[9#][7E;J6K.X.UU?1#&NC/@.4<%'IRK9T$ &,^B@'K[0@U3;"<<X
M%K9S]>$&Y':RGY,Q;2,@GMC+E(KDN74 2.CWMVG_,8NE>24;G5:D4$5*U48)
MW%A68=2:Y*'#2,&?.ILEDGF0;K\! 11H=7&E,/K+1/<ZLTANK1&=W[1$&R?J
M@%W$^L1;B(5TSY!<$P8_<P=9&-:G;JBQ.27R($-!"T/88#S]M9$+D>_/KXC<
M1FT!#09NP&"[([ZGV"=<\7&3/@Q/_5"N-RHIB3^9T3_;L>'V%"L#'UL1$9 M
MTMF5,2!I1@AV;+6O@2'=2--(#1V%"H35(@<NWL-\&10EM'^VM']0Y<M220DJ
MM\5O4;PTOFQ9B)-_20SM+X 'T+9FSZ5--:$.\K*@ID0,(TV&;\ A<?_^^TE[
M(=:U%6%INJ"ER".F4C8 N-M_"GC)H*\9$^R?4O>IQV!PPVV4?X!C+<@)WH/N
M(,*H5^Z6&9[..K#9U<G6P*F'[S0<]K&'DLK/$N'I!TX7R"M^_:JN3]]>N>Q/
M_.)!D*5N27!A7,QG:6\BH>:O8BSLW4.!@&+U*P#479G_W5WJ_[_]O]((_L[]
M#U!+ P04    " #T0T]6%F+/M=X% 0!A,0$ $P   &EM9S$P,34S-C S-5\Q
M."YJ<&?LO&587,^W+M@$@KL[)$!(<'?H) 0/P=V")- 0W#U T. $"-I(<(>&
MQMU=&[>&X-*-.Y??N??<N6>>_YR9N>>9;U/]K"^]]Z[:JY:\[ZJNZL>YQS4
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M(Q8D)=/U!U7R8VG;+###UY0#)*!"&D$OK%Y:D(U16$H#1/.P5&F..)J2K8V
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M5YLG6=,LB8&157)+[U#O8>@M.1M]C38>;+?=C=8MRRU%\Y5%[TW8>)S'?;K
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MXUK>KQOX4T*:?JJ0&>PC\&#)5=D*R7%;KW>OGS/-@A4OHOXG^4KY[^2+-GA
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M[O3#5!5N57#GX>C;+OJFMD0%)%.ODP=0.D))?N*X/+T/'YGX5O0K4RN?R+E
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M4ETA];?5$AX?%26S)&_KE8R]*$:LD^(Q3?N@E/$+ SM2IO)@&&&C3,>19_#
M8$6<^X&TBHXY2M+V8IG8LOR<#X9LE2XGK*YVZNU$F6^_=<V/??6^W-P3T5^/
MZWC7QAX%#8<V6JTC MNOH041%$7U^D:S!GJ-!>@Q KKZ(MPK0T^Z>5?+/:7@
M&C4(+NRA8L(L#LE\A]IH+DOI+^*83U'=/@@?D7EI=>6LE$3< PB'B[_ERLM6
M?^(\85?P_WV:;D;<W:0U4HWM/K<RT4P^:3&>NL]$T3<KKW:#Y6O4P?+3RJ,,
MG98D5%!S->R@6HBR/=4HDN)0(AJ1%G7<_M$9'6 0W[A,NYGYDV ,P=!!A'P]
MQJRO61T\IU;9$#^T_OJ#&?/7?N9/K3WGW^N)@ARJ!SWDFE/UW</'Q16Y12,[
MOA$DQK-C]'<;-4^"V_FIA\*O1^L\T_9GTVOCKLS3@8]_\:%FXBK<60- ]FN>
M5ZY,<3Z)V\&GOCAW2!,%*]XNH1;2#1@EA>U%JN;=9%,0;. "^8940P6@T4M"
MSY_\RR7=JA!FXYG2CGR3T$DH_.9H<#&#?,)]T,H))[O,S#,"'>WCIB-P;M<@
MN6$E0__]4:7>@FU<KP]XM8C9K#&*7:.A"$O%#P7-R@&8/8C*;\C1X<OPXY@K
M.FFU241>QHUU=0BN%#<CM=/06,=S3BVV9N)TI84HFQW;GJ6\$*L@F=P/]"EJ
M87>@,%Y DB]];N;7;.)I;Z9M.:;.A*[VWS'!QWG2&$#</)H>IK4#L75#XO&/
MHOEV=_/AAICW *.1U0CYU$6&&_V?#DR#/<*JGC.LV+7I/K2HI*<=PNPM4U:C
MC0)6N7=Y2L' (L,EP6;E]-T&<]L6'B5G'[!0RQ-$ -QXO$PJQ[+&*R.J?]9(
M%%HG48:C<:D&>7%>*M""BQAJUTW3/3K?"&5V(_Y &I5_TF>*]W9_"8]E<#R2
M4F[N*";DP!5;>&N'*.)3L;$!;&%^*TVC <":5^D'H)23D"8Y)OPDJ)V-""8F
MGWX_N@^Q@8A+SY9-O'Q.L4V)=EV#<90Z>HP-(1TJ7_;!N1+<%W9+WK!^== W
M^CX?%0?.E/Y9P^@M@FM%45YI C)^]G5U\N"E5/"J?O%%*32>.*K#C&;DCGY_
MR2^U6W1TY:CQQ_9U= Q0$;21$D]CA283$Z]O9WZV/?M5-]%8K&9<\%.Q=3V9
MT_8/VVNLZ-%?.4#9I#9&?VG RHV7)O&;J4;A*:)-&7V&$A"]$.$4ZEN>.6;=
M%#OL+\AM\2J+'TX-_H-N%"1'R%I"F-LJ+IZ1KN)WQ4>SG=@!/P*>!-J_MK\*
MHT%+V-;CL+[DR:0EC9J/2V/0=R%/EY,U!1Y3175QU&+R'^E/Q>ZI'F469TO:
MH8<4+)%L1I$/Q#S+KC=9:HK3*=(5=I:E5WI:EODS!A<AHC%>SBES:%G%K4>F
M+FU[Q$'"S'/TK%@%[]G$H]^":]H.8C+>BC62PN?.19KK?"H^DISO1Q["8P[6
M!\8-^(]*@2)-$EH\V$W>5SQ+U2 G?LJ<7/?)'2V*24Q? .<!OM7N(J3@_:I,
M7+>4BLW9/SP&>[Q\#Y!T)U?'$4'-VE8/C(M3=%N,+/SY-@\&NHBMV%&Q.LE^
M6O2_DUY /'1&,Z()I&0OOE_P7,PFY2[HR6Z(=_C-R0SAX&*DLHQXE\U/C51)
M6MGR7Z1!^LFTIX75>]CSS,AB?I&FW@/4J\;V)0?75FEE,5\]KE3^@9["?F!<
M6;1_T.0^#A9?($CA":TN^?R$);]^#L37X;!>L8 P ^9S=W?4"^<[,^VS:*X#
MW\BQ)YSUD.0/OYJ%7S<9:3-K6ZP-VM+G!Q=:%9<6C#EP]/E$<R?1+WY]K8I3
M:.54I&B&/U=F0A+W*"OEN$O@>KR>>CP5Q'DV7RN)K_[Z;VC3$U_]B"^4'F^:
MOT2#D\&DWI6?;%EY!!Q+=JS#19A8E732J[Q2 ?%_J.7/0_QY;(Y.4NY\?I[?
ML>P<M$-/[P'GFT=E7=\XV0S>?\BD2N;>B<[QO\56@ ^41AV=:]*=RAK:9@WJ
MK):YZ1M^[N+G'=<MD/<9!.[1 VX_[5]/JF?K[R+9IC[\3-:Y;60G[MD1)5O3
M=@.9V5@T[-7\$&LX_*0:-#R-O[4/6LV4A=>&O4LX["E"Y9FX++U+0@*A9DE"
M=.]*2QL.72*/O+6NI6!N^4;Z$*]0C/XLFLOB:50A(<_=I7S#XWO ;0"3R.XV
M.*XL69Y!M^SEJKZUD>M-/*=)Y1VNJKR3G8.[/[-)N(7Z3\908M3=01$K:][8
MX[!5H"'4Z_J*K+N#\HHH^QY0GG0/&-&K[[P)W%8UT--?Z +6U8:;8[PQ%_U%
M:4":"I4:^[B9H4FO6CA[#XAZ(._?6?\$L@QSCN,QLLH[*$B8D!@&WGS,M34N
MDA\FA/4HG,%OPKY1>]6!T+9>R[],+&=F^RU5\O)OIH&$OMT68C._[!?#!DB_
MH6G5"1!GAO J$ND:,+6 %=]W1R!]M:U9S016.&9.HBB&&*1%\#VCEU^O- \,
M; =XQ<B=M! N(0(-$89E>L8[S^>,MRZ7+%JL09/P)H4<-92;;XL0>'W<R'2A
M?L0=91MD:<?1:$E?OZ%IO>V99[J?##/1&WRG="O_5%&[*;9CK7 .9-K8K4WA
MI?(]@!(#P>_;)+3;>Y852O&6XNTH>:/$NW*+HH5N$*=L[JO/,K7W@&&^.9P.
M]YXU*ZY/]X#U\KN8B#M:U)EBAB$U!U)$@\JD_9GQ\]FM>I^HM>3DHU<$&66D
MPB097]?%/OI'+Y5>&!.XRE-B;]?ZTC4H\E_#!\/@,N9Q"G%\T@PP)70I*9_/
M(QQ5$9J565IU8_ TM_UJ&\8*D"G,6$#)*3"C,&=?D;0SPLXAC_%JXN6\0;7
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M^#O]"080KI6,X'!V$S5H'!I5-S_K"IK@*E_[A"LL5;#7S'T24';I =8EH_Y
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MU;<P[>7=Y?'?'M,O@=!2LD_U,M9V\R4FCIH:MYK51JU;*K G0*F-F'RY/NU
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M@"U8BE"+]%\QM[HJ@D0F)#@XFUM='0'[^=(_%6O_%WIG'Q8@$G9L])U$B2'
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M=T,;[Z]T$N_O JA2Y<CE" ZB),$.Y[<Y&?&IL[VKT>_V5=%W?>(NGEW.?T[
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MNEPK.<0*H4*6%BED<($Y.GM"G4!7CFGAH8EXYY%[%L'%TCGD.5Q0K1HMPY\
MNP7;_S(&()_-$D^F9TF$V<*X4"\:L*=[UF\17[<SZX-AC1X+D>O;M1:G.^:2
M+THPVV9J%=#"\!)-T4)+4"TB0$6V),+8R*$8MCYN8/DJ@BTR*?GL0<RZD&B]
M^EQ#LN,FA,<%$"2Q" 23P1E#\H=.)"]NP@U445)A][XRY_GT5$TVY0X<CE1W
MF1D_ BX*I5_=RUUKGCX!"@.OE"10;]NTZ389;LD /5&_,:#A+3D"9G-P5T;J
M\TP^!SEAQOSO?7V%>#<2>BI;&IS$?Z _^K+%WX*0II1X+4SO4"5VQ/'9J4_1
M+K-146E+Y#]\->X)$CI3_-S.XK,93)98>7-R=M4#A):GQW<PFDS47A#]SN8,
M0Z4^908R84H1JO]C:Q JI"NZU;HUIQA78RJE!QLF2GVCN\LFB:D:S%,"T>>>
M (=IQRN/;D"XNJU)VF?'(PPUZ]TG0$P1MWH%E1#-J['H.K$HV?RB*TT,=\+.
M^;])9.I_G\%0)G@=9VV?[Q77ENB9!)G3'_$6=GRG?F,G\24JN,'AKM'US'G(
MA\T6?!(>IM_I<Q76>8F_9)UX9O!Z*J9TM 23^5A995!&6<:($2DF27;BGJ9L
M[Q8U/#N!N^]>R-G5U=3"^M626OOO!;D7P<*6*9;CA7+INE90P/%>AZNSA=\'
M$1!P.)/!Z8!4TKDVA9H!LQN 2K0CR!=\S[?ZP'RD-%Z57U+B2)C3BM.UKH[6
MYJ)@A@R'<CKKY(YR%Z6^<!.*),F=>$7_17\@R3 "96Q$V-AU)@)P]@2XECDO
M0_ ZDX =YR<N["HXP9(]YRBU$EYQ#C!AR2%S!D-O>DI<DD2)CR\KCQ.? -W)
MB1E"UQ&VWN;)YXL5\;]B+_U_SJ%^G ?!\VPNTG"\,-L?"9+ESD7>L.BMOP:J
M']'"1[D@XBM.+(/N@0!;P>D<O[A[D3&S28?(+-ORW7<U<$]*XYH^H>. AKIT
M[)^-?'E>>=VW]&'%$"739K)H;9@>Z2MI NR&B!A9TF$19X.<H;"LM4"\O:LD
M(^Q?1I#A1UW60^).3,M+P@]?T5^Y- +^"+\<\O6'AII8>MK[E+]J"AFR2W3I
M>4LMT<T5G270;<M@<.VZ2H6_:Z8^Y29KV0CG#/<:@),L5@<Y!+E"F;#.'HPZ
M@"<ZP?=ODU1,"@S3XQ>L"78+\]0P3XO>E8M2Q /DACD7;M6R@Y\ :"H1?ARV
MEVD8NW@W,ONW8=GTL!H"/$09]G66 ^H0N1?70SY&Y2O+.'MSPF3*6=GS V:.
MP<CR6 &J2  F=8R3;>MDQQ _GJQM&)E(--B>XFMOYPG[^\TG0..@G)U''[P:
MX-T3?/"R/8"[O*+QN&DY?'.20#:3MSYOKL21!'L^E:22">"737G-8V%(UB-_
M<@7F:1(=>7P[#;0Q!,)^K'\WCU;?<G!R$8=3*>HXKCY#LV;"X^H](ZLY;NTK
M.OS-RD90^L6<06I+&//]$LE8W@F=* VD2[D(2YJP%J=UGSH$([2Z'IH^*D2I
M$;@:B+O=@G-P;YMKP\?0^8:QE'9R"-ZPJ"C[EE=]7I>C/Z''P8?L7.S;NZ'C
MD4ZLO>KH5":6;0]*9J&_79KET](ECJMWYHTZ2WGOU/3+=?MFT0Z"N]R T6FV
M1=8P0?]S(_N200LFLP4=E]@03C3:X_1W;Y.> -2_WM^NI-VBE7&$RYP89:T]
M 4@'5D>(WL80W+(;^Z)MZGWJ!2,WF.=O\Z/48SJ&+B%5-H3M8F.:C];WO?8O
M=7WV$"O-@A%[[\Z+6# ;YHNL_.K*<@@6>-<\:U735U)P .2FP;.KCR0?3P>*
MC?:(9W2,F/2T9]058HK6]_NDHG2BPNE"!"]*>)\ D,ZT2P3'!TJ6=,.7RDK>
M%U6P^?P^ ,Q;:]91W 6)44B.XCOI50%.DKE[<)&WV$X[;J5W _BV:;X&SK\W
M[)R,XBI*_7R37RO+MQN!3X#,\0:R/.<</4,;#Y_XT<.&"@),;S[V67+  E)H
M#*JJS9]L;L)X,FRD9R-ZAX^R)8)J<FCE@?85++&C;9_!T?.\,;KW,!AL55(R
M[O<'AW**SJ.8"[,'D1=*_RJ!Z*/#ES:LQP"$G,+[E2("/!Y>6&AD>\0.P#34
M$M^(-WT; H[JA\80WK=23J&;T+[U.><^[LV&""Q&>^<.IR.\N2#\F:V5&MXO
MV1DHCYR.HQ6>*R5#RJ50^S"US>R!$!^Z%-5GS4HR.PF*6X;E.#(L?$HO#:!'
M-D_L70'-2*( "'^(#%LX,,3X<#RZ9V7QC;!?$OUR[UKH>$SF.RN:8WH"R,8$
M5C[8*&4W3:@?/8J8WVK31I6TY%-(V2^ZVC*,_T[F82M$K=NJ5I_M<B 055U5
M%K&1" -9YC)-:?WH-!2BC%\*C=@<PY%!D P-47E;C(BVLID9I<W?)B+;EV,8
M)J[I3KKVA:!R-D$W"T4C1%"[D^![)I;@%658.3[,X9).ZY?>_4]O,18G*Y_8
M\I*_/0K_+!- >C9SN<+(BW"ZTZ0 ,EA04W*08&JQ"+:<JMAAJ;K*:MRZ8YG9
M?<\:\__\A#YF]"> UPZJQ4W:P]C\"?^#C4_(\A9$KZ5QGGB[,5!X]#]G[_VS
M+*'"&/9F\1:W!*#9DL;0K]%Z-Z4DBQH;>Y$.D:-;3]8T7 ^>(46:+H98)>@9
M,*U'A_TZ>T?%)H&:'(7)@MADL_LY3(]=!8BB(0G4ZA.QT4\/T)B#VK<Z]3J'
MIFA&!X\6I&,0:J1B\)*X*B$Q(/Z(R@][([&=F1Z_*2DEL$YG;Q22U27>(RW9
MB[ZCK9\@NE:X$N'G0L@OPHC$'*%-8HIKHRGMT1Z1\1(8>D8Y1?BEN"1$AL<9
M[\U7(A+8BP&!814)\=YFBZ!#NO4@)G,I3?$A$$Y(L5A_^I<%&7'FN$HN@D4K
MA-<. :KB5T4U+Y\  Z]$]S3_R,-%9(?>E&MCX:"MJW8ZJ"F&2;R3A[< _27^
M:0>RNQ2D))]UC2. C(BOM5D=&J+U7$HNR*DV-#3Q[F'$Z(?D ;14@V30L']#
M:60 Q;'D?W3H<<F)=V5G0F(PY:3H :S_6<<&,#%FI_\%"1Q,3-9, /6_+61_
MVWG^-OG0V6XN(OS5YN_-WP<R-VD5)[U:^S"MT?@H(J:HE9SU]O!O">Z?SZB7
M5'D#L=,X+=NU65Q84A2F^EE+E* 9\V,:*V /X8((28BUG9B$I-NU2WFD>A*_
MPSG-)WJ7#KH(C^U'4>=C:B,]Q"W![:T5$E%&U3UY6=U;6^?;),JXN)H\-('+
MR=[J)H).X7.RM_=!\>1EI(@HR^O(.O5NJF4@\L(5 1=Y,.@^:_(<#DH>FN+^
M-1")ILDZ3F)AE1%QZ=?'ZYP:&00@&;E8*[)*)*YQ:>H+<QERK.<OV3K=B'U]
MG038(EGW?P[J#,/^V>RU@2;C>[G0P,V+IAE_7+.)SUQ_LJ->?QS. -E/N0A2
M^< ,CL(S'H<F3,#^'2BO9PUX#3U=0\]+O^IRAN11SV0I+3%O]:Q9YVMZS+J
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MYHA+4 <Y^5M;ER)(DJQX"G3I)F[HY3%C$,M<SEG'MM&M<)5CS@M/K$59IOY
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MB<<@%NW@0XT)[CU[*OGJ";O1G.IB!4+CE-1"=JXC[;A?LS+I9K>!%SO6;YX
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M$0,)3G^>#9HPVYJ@K *T40C;W^(9(%++"O6HU[)&35^2/MI][<7/W5*$)U$
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M#:O2W<?U1'QON+%]V/2'!C@0AH^S)NT<M*[):Q<DRKJRK%^!Q)C_;6"O33J
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MGXR12IX*?$^))-FSP&U[Z@$.84RX<^AP:?#N"=[@BASO-;0/\7OY]7PV:-T
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MXDVC!&VHND>;N\6+,H<X> ;SFF&D^=QL9L3:V*S::-8A('17G<(_5%:?J,R
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MU_T&R?WHJ3RA>)?T-=TR$%G(UWFQQIH]Y&_QJO^B_[:$^;SP/P!02P,$%
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M_54!M&Z#JM?BJ:]8;Y+Q:[O2X??"JB]<7[A"SR)HB!ZZRTC%G+?1_6X@E%U
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M#C2=='_S'IOABF[?SR))&3 ^D@Z$.4!9UJ6H&GKV#<HH*5.^-&L:_3Y65-H
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M07454B$(D^673U/^"@+(&)I'_(&?I35\-C0BZO8-^&-W/V1PL6JDOZC\TL-
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M;U).;WNRK" 4NS.G5\AQM2;7;Z&U63 6D<U52C!H@XG@ *G?*IN/M+=N.&,
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MF3KKM;VXMYY9Y]U)%4H9+2I;AJA].JO>"A4W_1/>U.W:(QHX]+4_C&J#A3S
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MCGM7+)(ME)$5KA2_MSJ.3&98PK+'5I.F4&0_E/"SDC<NFRYP@# [B2Y!)O2
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M75+EV-JK:Q&8C]'&CJ'#N,* 59B69)'VT\K:#7D=CXPTF=VM3)'Y^A:6;AR
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M %;7'IPC_WHLU6O)4>XNMYP<0;R75F0=P4P6@2B>P9K )1S@]E-U[&03A05
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MJ!?.Y#:.96L9?&@7237C$8:7-GXQC%_TS]1$_"5P4_MC?9(#H$*>[,,\_7B
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M#LN0-*3EJN<%,%I/=>21:/TN_=.:NK@Y\\)VJRA*BL-+_06T-@ZP37?]=W"
M2_KES=SX!U>YD5C7=LBGZ7_I?U"Z/P76N@%_H04/Y=B?H("G$T<S@=#^&;H$
MG[0F258;6F;8L&$6F :KY %!U$ V-2U"C9]S',O]O&4\D?M+PON/9:'3?\:N
M?_^DLN^:IZR?]&)@,M2<M!\5,Q4#CWI&VJFJ].BON-"Z];+35:1& =9D91:G
M:G]YKUA.>J7 ,EX;W:H>1);QW#6>@[&;O4OHEP(.R9G_$]:E?[";/7Z\4WHG
MG]_5ZTXG;VA,Z0W"H>&)ZV!Z,&VI#N:17Q 6N.(_A9$MJ4I3M*=_AKIK36_E
MKG*;C#'JF)8U:G*>#WR/0Y?UJ>+(R[MXYR\__^W+?=UQ@/NU32WV2_,-UJ_*
MSH1G*.@%#7F5G)DW:#&@HK*%>ZJE U_-!4+%FJ4+AIWG%U_+AA"1M"_&Q&5L
MXG<*-BO^/^R]=T!42;8X?!$%D:0(DFD4$!01R1(;1$! DDB0J 1)0HODV"!#
MSB @2!)$<I2<<\Y18D.#9*1;4@--]Z^=W9G1>;.[W^[;W;?O>_Y1?]QSSZU[
MJNK4255URAIY!W(:)2U?6GE!1\S.LKA61A./SI?S$,*4PAN6B5\T6L:!UD+V
M2)6,7(F);K%Z<?33,F]._I4S1-$3$>)A\K1M%]P5)\1N?!*SFS\.9F-?&=T=
MVWD,<6RZC07J _<+%EN2KR(F M)<=AGO],]W.G47/S'I%ZE.O 56DZ0O_0?Y
MD>I[(>#JX!(>#%YZ6HL%O*"KQ#KJ,U]VH//<AD.O<3^P<5_]9E\BW@CJVVEE
MX#%O>$C:AP4,<.4MERNIW2@J/*,;"\Q.Y)[C2$O=O?,W[LO^9Q:2P@M8H)-@
M93WEB&Y,G/SDP=C [P"#A)*>6\0'<L,^?YILP#_:@?^)Y>>CF^]^WB8":#K6
MY4^B[.Y6C^T1.)26Z0]3ZO>%>-V2>*<9RJN=GL#'4)P78!MC&V$[H !\\4;B
MM\_=8C+T<6<=+W_Q7(#1\--]I@4WS)GZF <M\Y*U=1Y:K:[HS(>>4L.7P\98
M(*IWOG@@.">M^FL-LPVGW740 C%U6[V:<6"+G?DPS8=Q9WFJI%J,Y[S84 XN
M< Z!\/,H.]VJ%#4?A5@>BVPE6E+>V^P6$#@+?K*RW==+!+_RE?JH@[[HO8J+
MZZZ^^:]8Y^7M>-NK=GO.<YSZ1$55UDL=NV9K)6;7Q-PM?]%/DZGUN>6;C2-^
MU]<CK&.;U*KB7#J?3F=B\!(QK_#2_YXMJ0;&\(%#VD+P/.CHU$2FUFO4!XRL
MU0"*$.-5EB$^P"V$.;5W0ALL0ZFYTO_M$6E&L#=T24CHQ$T(\U/9JL#*W!DL
M$#$#V]N$'5%,I$Z(JP0<Z16>S+H6I05=)[_[K65RK820IR@TQI#0XDD$^;.0
M$(Q1D@SP0J<5PS6<EUZ)&1MB@SE (!7'US4ZWO#*I* .Q856&)%A(N-MOO4-
MC)W6<NHC-ER(%[%'[A'E;N[M9J ,G))'>UMC@<UKF= U$X$ZR6;</)#Z3]J[
MFY/@EYVY)H@%S$<+\_/F^\5ZXF,%!MYK>TM>6LVRMMDJS(]:[H=S!C"8LOFV
MY'J<G1^3+SNA@SW0%[0V:!;=;Y_6JI)YM?+^_-\]NO^!Y3N]X\( HQ;3I_PB
MVW#.H4+#Z&U3' G>!B:M[D40@,0"*%W,+2R0IE3@:0=%!O65CZ,5%U6"ZB^.
M<M=>R#4OG[)39GH$CXS8ENXRIO-=,D86OOCS7B:XN\S""=F(?C4R)7"%VE&P
M//OTI0^ZM ^F;^ ]3A>-#\07=<;HE]G2-83!FN=N5I8B63DM4A5/B8>E173V
M+-O;1X1XV77.VVXDX/0X88ZTV0(,A J_<Z$EC47>+O,1:55@>F!PL:2G9"O)
MM0[\]]?G(N?%R5510@P3Y;=ZL@TMVC%*4A$"'8EKRX2P@Q(BQI.:!!N?3'):
MY^CVA/HD"%>!;^Y:<[.P:4#;?K9"Q+"OV#Q^2&2_9YFN"O*D/!*QZJSS>1SA
M7##<N=:5$>QD%M.\*?N X-P%G\3=@7))49C_5.W4MA>_DNRG@P&NG$"]O:>&
MKZ(_W[M:K=.$T QF]W>G>F?!9[V3GQ]C.CWB\JD8%:T["JC=>WCKLA?S'D'\
MOC-X)01ZT)E*Q)&%&2!$(\,QAY0>R>2'BZ"3+QRG%*Z#/S1A 3%CG.J5 9GY
M8)P[L(![$! 5%+Z)@ [08('M2+G)>2R0S(,%8%>\6-/2C\5 .^W@XR6U_\&J
M=T"7H)U]+E@ P)F3E^HX?ZW0P )>]A#)-97CBV\&&*,NE696?5K& HT&#>D\
M.,]IYG#PVZAE)H(;[8=[7?@45TUL'4'M3N-J>/Y]1@W_R>F7?&A%?2SP&X%5
MZ^YRPY^@GS?&HM343GZAY1>2'S(%LE&!?L,._ZWM@+R,W"\-2O^54DF*/ZA%
M]?2KA]!?NTKBEY;C!<.QP.&I:9QCH*Z,!88[K5RK8-129X?RD93&F*L)4$3X
M(=JOHOY7_'\A*3^J_C=633D:RM+?JC&@1Z*>]=\Y,V";S(KX'%)]C&IH_1"<
M+]$\T.W7;V5WXWFQC<DYOJHPR>/Z9!_&)%N=E3!61&$P:7T#4('8W%_(+Z.!
M.Q'? O/>D[6-[)R'>A%R(G8>E$DM#IPWO\9 !SSA2HJ8.B?/(-<+N0&:]6,^
M3\8KSJ-9RS5O3:V#NA]'E_^*6B<VU_(@&M9%8X&>Z"$@'[T0&6+;4?4.<9+G
MR8.$!99M\=*F#G*7%FYNB\-Y@KL"ES4(3_L:QK$ZY52#PJW=>>:E%CP>S*VY
MJV4VCMNN==EL3MS@93%A?IQ-L[*Q%4$VLA!;+%&'@$F/WC3A54;0+-F-!?'<
M4:F:UC>U,R3?O58K,,\%NE>)9\/LPYN%H3;2]Y_7#EHS!](BLAY+ U+KI'S_
M>8/^H^H?5?^H^B]4K?Z /UST@I;X<Q[EOWY@H&]B+Q="MDH]U39W_U)$:5[N
M6/&07-5M4*B%)F%HZ34QI?DZ73G?EWT.-II7.O"=#^,D)D]Y<3H3:R$):A86
M<YS]VHG9J^/Z2OVNR.N^R%%WA 9G;XT^%]&\ZHW3Q1>T48N8"RHT.CKO*H)9
MITP_9;-=U>CB@&T!Y+<915Z0/C%/H;/O([Q?,836S[04>5IH2M'"^UJ(U5=V
MML<'1KL6?L?BZ&:N'1(,%PR%$W,)KH^T5%/:T13<5.74Z[FR=?FY"CZ 3#1.
M-#D'[$W]HWO\?V<DB=1VM*5\X3. -H)WS^1?^^SBTH"@+ESMQ3DM%1+VWSIM
M:VAB+'"YJF%CLF&7K5"J4.)W9M)OEA#.251UO?Q[QXD\&.<G$4.PP!,E42R@
M>#E_O>GW3MN_ZJ0:K0$+SC4E'1@#[PKDN(*.,G*3?P=()?/ZDV;\\QXT//-_
M88:W?W?Y;B& 7@&I%>3 360Y%87RG"RC=^EU="R:Y<QO?HG'YMTHELPW59-P
M.-%:#0FOI9KW@-Y1XAV&DO%OWQH=?LYVUP4/='/>+A%*;C>J2OB$/=B3O2]<
M:*$L[_5:]189&+D^@3@(DKAL:%4>6]WPTFAD]\#H:I5N#.3&X\A&B4I0Z!.+
M.194<[5IJD^3B$E$@*KLE@O3(\>0B\=S\ HQ\0*T2LU$_N,)=Y;,28NPCH'*
MH#7:".O;C104+HVKKH.$:?_H$>+O(AIK8]_'_"Q4['KZL(!7'536:$B&JFKG
M[3=,2ZCRN[">R\%W,8\!=;A$'"<6<#+(PW6TS]"OLXR3^MA@\3C24PYMCIFH
MQ"P91F(!.L>G(&WO,ADC+& U WW!W8D%0D%3!Z"9X"_@19G7'D:G/;EQ7,G5
M<.++OWURPZ\B-W[L:O3#TK"Y.P'9=F<:KV<*!SU\159') FFJSHIM#WI;&#!
M\#\*WS@OF)5GN.46_EGF$(1,__7''ZC'F:W5M!M^^85.;#3_?A<G0/LAT7Y#
M)MA7NV_R(JY[0G\O,,]-;'LP%EN+S,W!%UF(;$7O5&[O7!<^X3RS5WA1+D<J
M4S XW2/-V22)<+^T<IK^2@7XZ5XD5&=M@V ;(W<"PC0YP8X$A[WX[=<<Y(WM
M<AY-3M\&,Y=56S0Q?4J_[RE;,/1_>NG@NU(;MS#0JJ2EBF1;#H8_$B*N"<0"
M)3;WS;U;GVG #R5I@5-\ WI[5..6=.-O"=O$Z67#%FU2[#('^(LVU:M&O3)O
M=VY\'"34EWFBM&AX3K>/E<\Y129,^V-Z.JR55IOAO)3-V2P!,)W%+6<MK?'2
M-QM<#RW&MSC9,IJ[A0 %O^O*?.$]_'C#:@8R'@4H6(OG^1)D&Q8(N+%'+'SZ
MHMX:ITED3MLUM8!W()XGE0X'NRL3YG^K1=^ESJM\K=7AQ$0Q-J)6.@33YH6W
MW[#Q3>\^0:@8UAUI6>NMA#OTA),Y4VN/Y?/LOW&S^T3!5]9UCDQT/A%#B=>6
M!Z.GNI,?YW?'VPOO&3G:M10M#FZ3%^A1V=KP(+)/4TD>;XWG*5V$]&T$3:!L
M%P[MR8E:;1PX0^]LJUXY6K: .6TS4E]6T7M,5M8UN3;B+H+*?;<62^<[UAX,
MEWH^8/'\N#8P G*SOK4(%-C_G -__!\5]YR][H^P (O "AH?"TCJ[*Y_KUZ_
M#328_^U PW%CPQ?Z-YBZ-UC@CLXNW4HV$J08@P5J"C6_KM2M_A)\92BC5--A
M4OU6Q&EB<-\P7? $]XZ?@:PU(!>H%]%]]\-"A-IUTH*N*P_^?K#RZ!L.0;O0
MXS,PZ.JTPMSWC\#</\C1_YL.K_]_O99/8&'[7 J5.V]=T)0*B\:'\9N?[3<B
MGALEF;"Y[(J3KTS%M1C@%,!/'^ 0OY7*\,VCC((W3M99NA=\2-:[:8R+Q.4^
M?9QXC[)K*4^F&7E77!+E<B4*KOCRZ6-=NW+X;?R0W9P+J(NR/AV0Q;.GD9:\
M=XPB+[RZ>T@S(\M7 ]@ESW+@AX\^*[LZ^KG;_<(0Y&'ODK[XUFL+O\6="'7F
MY-J=/J[]?+<%B!^&;12VL/]F89+B]A 7/)8V:L7-Q2U1-O6)D[VX2Z%&SL&X
MX%1,R+Y0T;O]D;=AVC//NV7/II(S3M0SLOO6$C%5$#2XN-B^NP[C*IL.O,'Z
M^,6=EA .X4/;D:!]4E[$NHA2TEI(NPVS?!!3;I54QT+"HC%*)<V;JJP_L\!@
M[7F1>6E-+GP_-[Q:<)&5Y#G1E9HB ,#S$L'[FVEIOXL#JXW;YUH[R=0.%U*^
ML:K4H15,/'^V7:YR_?J>$:K"@(D&D9R93],::H%G+SV4DN:S%<6!WY]7.A!<
M3U:NQ'Y/1+#J?:.@3I?#JT@6D(-*;QUAC8>567,R&9*M(RBNK5ZPOOS-@Y=7
M_=K[!SW7)[7/=YS B1A18M&-# 15"UN>X]/-GIP3M3)N#EGK.F-I90GU'YGE
M>K:(UP6]VPG9"W4^GVDO7@"'.):KK[^86ZV_NI/,88H%XAZEJ[9RE]^ZW>YD
MU]D%[/ZO,<H)N60H-?U??;<4VO >"W3\9!B^(^"M>P1!.\N@L "?.DLZ*3(V
M*RTHNO37W[YCY>A:4]J)/H9EG*H&R?#UJVQ[OG+I.MD>]JH&:0M!OX!7L< ^
M<3T6&"J/J5AA/VA0:*\*A;6[FDZETSN7'E<FWW^>-ZQ+!0J018?BV=NHW?^Y
M+J874+?=U)O^0[][E*$D^8]*G_P?7KZ;4Z;.;Z3]6^MI1^TMIHT,[@QMXXOJ
MHG01S*#F,BO.UJDE"3K$^-N\?M_A_HM7&VUK=XE1482+DDS4<,[" -4U$7+_
M,LA9 \/ZX*PF!\:3EZ6YM@Q2KZY-99Y^*<S*)*PW 5FH [=B>)&S*<%H^8PD
MNA;%P!'ED27AB%H?DNV(LXNC9,'>35?]DA92 @UXBOUU1L4LIRAFF1.(Z45?
MW#67?2C4FWE[[P8T8@0Q5P4O)$&-3S0S<=?Z/PA6]5T:<6!5"MGTN1$F;GLB
M+#R//_)UBQ-GX+@ITO,#?*W4@^Y3J3CO^"Q;] .WRWQZ]UK1D=N'MP@-YB>L
M]0J#:TVJ3\<>/4TRGXH+X)8[8@OQ3!+K(D>D[HE#>0$^,5&XAY;R&%KZK7/R
M9_I)?C>36OT[9^_*:BM$.3'?)N&9+MQI]U%#^>0X*]5:6>3I2-/?G7AN;FV2
M%WJVZYSI\7%W"++=@Z\]R)EW1Q%!'<S>4$6-81G/8Q>*SFJ._1+_@)\QTLX;
M"ZR?VO:';#4LW/NH'T_U./@.'DSL5,069$P)L#\B*R1K6#@F-9BA"OIR^O6U
M]2I:YF.?C@4=@0XT9T7L] +4/_V-XZ(E*$66S7]5QA&GY.]--DU)B@?29NT/
M8 %QG/O:8(8V/Z5SG>O;!%F"_Z?>_4YJLO^6-:QVHDW7/]#FX+Q*5R<-YEL1
M:ODW1:@80M(N7ZG8"VQFDPYN+8-9IV!<Y;" YP#JMR7MDK],ER7YW=B@OY3
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ME-:W8?P_2M#T<P3_[VK WXC=-VOH<C211R8'J-AM_6SDQF5E_4&B*E%Y\S\
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M"5/C9TTK/79J;7TM=&EZ+HPN5N4X)=,-.M 7.WFD651HL;P;F6*IQ +>%Q*
M+]:R(&*<>>>/%(#]5)K;!U9.\D>[QTG8/CH/T>_OL$"+V,-KL,!A.A8X +#
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M\J.A69V%X,5A)E9<5HP0)*5Q&<^E*YFRQX*R(J?+_/H;SH)K3B' 5Y-\BY'
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MB]4;5*>&OKL]DV.EVS@95=O.U,9VZ8MZ6S<#I*TP(19XG: /H=IX2?TQ\V.
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M:.O91Z3N%7]8:[M'+%.H,)R^V^X,%$:%;V:@Y\VFTC1@Z>^N*)(@P"UZ,2F
MRJO]P[ 1T+424N]^ 7DS45EG,NRGJ:728E)N];Z@1_7[]T[QS=<GTL_EZ'M]
M$OK'+MAF&4]/B6_#S8X^-'?MU*];.(K. %R /YU_)_QP;7B/<[0N\2MC^Y8#
M_/(.T)=-D*8R55@?L[H%D9LE&/K\*GDH-$@=L/D5;5)N"G;#O1^M4>:<H;N'
MB6M& ID]!25,;TCD#OO5!]'R+@4",3!\:=_)[=LG\;+<Q\NFZ7'1XW4^N]\9
MBNT?D.)6V4Y!EZ9>U-5_+ 5;JLY5*2@$NYI2)@0R[!F/10OGD*'-C^##9C7O
M:Z2[!?N%K<1Q[#B B5,?^[,? E36M4AV:%0@)U,NJ_-9WKV[SH$C]"V/-WJ\
MW5YZ0:"CDZZS= ;$*!=#5%'UBBW(L<LK0R8C[?''27/>8^=!+.>EK./$R9:.
M)V#:'F\&?A@J,L)3BH?/VCC6\8O?MS$L"/I-4_^*)%:O%;I\M0/B[_)UD*)E
M35K<M$_OT G$8@TCSJ3P9FJZT,#H?W!CAQ$H[KY"3!0T9SQ_!U!2>W4=> =(
ME+WW:M\6&"_YC9=0_:$"K58K&O0<A^]-'%(3"+M4W2:H$]43,VU=?BRL3\4,
MH;3"@#;KC _M$5[EGGGQQO.O-8J3L!,M[5*HWOA_.!KVM5H*YD3'4)UJ(<2Z
MZXU#(V&P*>,U! >U?IH@W8WR>- *9@MC=*JH]QV L%4NK3J_0%]PC-IE-9&L
MYO&O1N+1<O1^)VBMM.[FE>:TA<:L!YS/'ES>^.94G[X?G?V(U4"Z!,RS1AD+
M-5!'J42=E <P?1.J3'MRT0"@6XT%X*SV5_<"/'+PCFR;T1:K%\YF&5JU3L.>
MB J](#F>;V4(KQQ0H7T](N"3 H^)72KGQR"\DLZ__C/]?SI*)<X&,A:B&W31
MD2C\V\=!)-\+?'S+;_)'8&JM"\.B"\ZOXBP[)(^"5BG1M?>O%V_X#O P,0A%
M/@AVT9_U)UROHC.5#6V5+_E>NN>,''1\MZE>49,9UO" 9"64YYZDPFO+@R9$
M4+:W&!UW@"=RY+>2NQ2Z_F)-TT=\3&FZ80/1_'%6OF%, SC?)&2SWEZ_0$9&
M"H^%V>I63_""?OFWO-KNQ2S?3!<::]?T"'H25.>OAW2PYQ,VDW=QCB,-".X<
MD0Q$DN)A9 8+36:AI#2F18A#M[J&^O:VCH=AC+81%#[BUF-#V.#O(X"WU_*-
M89TY.$PN1(CN8LVR.HK?PTY?:;?B:D55W$CB3K>:KJ0U5FPZ(J<TT@E[LLU_
M"C!,6DA\H?OF9$UW'-(/\]6*NZ:6C9.A,=[5[OAY2@M>;:P7M'Z8\H3*>9WI
MV]D8S,;D6A5E PTUVF,D.FV"%9B%0]='ZB#BBUL A;#9=FD[K,](E00!WEMB
M=.G7UJ3#$U$[)WYKBR]#0:G,[CMN[_W>&&BL$$>8TS0C-2/R*W:K'7Q32YT;
MO,7$C+RMF!:_<T"HW"3&1*J*P$$][2QH[U+[;)&6V,/+I,;7,<*8,UH+."X$
M\MM(+.G]K'O>B&DU68'B+7=G=(2*@)37>H&QCE 1X-P[I57\9XP<5'1G!Y+:
M#S*6NUL$"/SY4-*9#1PZ-3$21R<[SF_'YE[".Q74#E2 [LD+,YKL)A;8@6/0
M-4WN47S02Y#,L_/G?5@MM0?Z5@NA%ULPCU]$Z&X]I$"LA46VUJ&T,U?@8%'=
MU7J=+A2&(_X@">.D\U=&Z2JMU!B9_[,F)'M5[E[&'V=GYBH(Y\.!Z(7GW /@
MQ5"RQ'ODSL7/?H@V6<U?N:(=L7T1JSM]2NO9U-S8\@-B+-\8K+9.W:?" =5%
M>R6#7ZTE1%WCNP"3=E FL5?"B<-4@J^XA>;/<] [TFH%R/-8H-G*".E\=_-L
MR"E(P8^JMZT-_CG;23</F<YRA I)1H<8=Q#[/Z\,ZM*!@N=[D&Q%A:4E$;2L
MH+Y'RL]PZ6PWM88Y*@$X]$C;[\:,41Y9+CKPBK<=/"6#C@3NFZEL&$8QD."D
M]>Q6@Q9% B^DR@-.4LYI9LZ=7 (,<Q!216-:. =O#[FG3ZGO-EBAR<SV@X]6
MD"P.&R-X8.7XT#Q=CJIY^<.)UN.EW=D,6!J"8\I:$"&;L;M9S:W6]9&8L\U]
MLK[\,THK&B:-\VH"Y 04\RY7"GH.60/C@^JT!\1$'S=>1&\D- <190?CH>X
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MN>"6B"!WQ0?"(>A'8G\Z@EN%+"7VHV=Y,5S_[.($_]T:QMW/_P%02P,$%
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M'8A!+)7PJ[H;DYY'#4;RS7D*BY2!=Y,1_A]H_PW9_S-@0?\E9/\;L/\=UQ(
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MLZE>QM/<E58'22"+>@>^3&.#"]KR"ZU8M+EI^+WNFZD8K2C2IB" G&5'5?O
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M.]OU+<&CG(.OP#\"XN"L@T U5%-*]<0VS2G[_S"P<&DS1' ?OSCE%,-<E<]
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M-11/M.<(D^YJ0&5?>8'M%VQ_T)O\4F<>%5SNTXL_4KYGA_<3+R (<@/-[Y/
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M6D) G^"5J85.OELQSJ""5+8HFZQ0H?&S5V4Y^0$NN3:GJZ2?S-QP*C@UHH-
MK'/^D,*BU,42V55P\TXG$OOI<N]28;SYO8(AIJ[WB1D .*;7#G9<;:1WYXF]
MVA9N['XT59PW5H-95+!]-/N>HQ4S(]%3D;]G#)6@7(#)!H@JF6RI;N$3'-?(
M.U;_Z)/G2AXJ1AC\[E)=0.YTBIQNLQYKB=2_//I,G9>L)]B*#6G["+_;P_W&
MQ:OH*?S=_#8EQ&89";VD)SC.1B6:E-2/!EZ4[I$O39/=*U5+W/@E0+AYJ0LO
M9/L2NCRPCL/A)O&:X_L#GR]-:F'\-"@QX/<3WU<\/*Z$:,I?/Q] \U?XA/U0
MQ(QJ[.D6Z^BK9N<=5QQ'P!=OG+W&&"M#C;TID$XX)IC*;648@="%UJ&9+PU0
MR!M_3-[*A7/T4K(GP29D6G_/V)V>^2QJ%GWJ;;):S!Z;:P;\,]3N>P8 ;#KX
MFF?,9NS?YY&6ONU<,DP3B=RFTKC3? 90(P14X0)!MKSZ[RI-FQL3F=W3?[S!
MBBY&>2>F4FBI7*=A77[JG<+"O_NK3P^A_TD"J6!V/!-IEA+MQTK*G\"0$!R!
M+YQ<@?VR&P*F,)'^2/DW>C[X*BN%'K\1(E_B-H5@I1D+IP.K>?^0!5(2=UM.
MQSE]03R]$OCU=E2;\\V;QU%13*V=W.0Y B[DJY0E*PK!L[0!4Z=YVPSK2P_(
M":O6D[M^V!"P]'Q=I9&=BE)C:X*93O*?S(92@RS+7S?4\QS=J]B?YT7UO6D+
M+4E6W*_[M^73G,_6T!0N18GFVQ4WXX*N.% /%Z[OHJ]KVOM&#NQ6?P#0A%;R
M:OVH'H3G'H!5Z\9'9/S<_:)H?*1G)UUGZ%DEEV79;O>CBMXZ"OBKDUMM$M9H
M*?>2CXDC7+@MALKEE#"2SY\=T0OY>]8X7C_X-0?K1"L1KBGG4?B9FU V=$D>
M<?[<7FKU-@[7:P.29O;;N7RSQ;F0_T^!QJ50'5AQ$Z];I_+A;)]]^-!!#YN[
M=-=+_2@'57C5BY@+$!0<D.&TOH<(.;39^7,YB]C-;OEQZN@B/ 8RS-=BB-T]
M<+'^J*U* 8[VP0!AHKCI.C]Q4G E4KI[=9B:]N2N8*4=^J918PDDE>WEC&@/
M!P(M'9+1-/J?I@&O@A<M^:K@$EV453'VKG]YEZ-80LODJJ[3S,>WF@;FQ)-E
M*NC5,$>NVQ<%&RE$[%W\"7S8?AWZ8[LNE]-PKZWM&N'\B0BW&W)I;FG<-NSL
MT6*##<J^=W;B?"ARDHT1?5,"B>MJ6*+)FA]V(0BI_?.':,> ^G7!4TKQAAW:
M<:\XWN^I<[,PQ2A_'F\I^8\M,B9!'\3(W:%>*1HENNWVUN1+'A>"N7'&%ZR'
MG5?WSX :/K4%B9V5BL[C+. =K[8AG*=[*3SZ4E^131BL4Q"V/6;J^.=G3(%3
MO8KHG)ULUUWV?H^W/]:@V,^.&'IU>A%/8]"9Z.F$BDV+&UUIMT M<=YMX8&S
M'P#6$%[BPSQ;!;T<]:RB89?P?VOONM3)/NUW)E:M>"_!!=HBF1C!K49^>GH&
MA+JOO8:%_?KI(]$\R5[4X%WZJ=N(Z5NN8-<P*_ZAAC@9!%\#IG)==9U\[?Q8
M-7SQ].=D\6^GT$K^?4^VPE0R*^CL\KZ?G'?[UR(D3LL0NS<CMF3Q&2 3F"UY
MMG@KN^4H07G;V9W#.=,F!H;*EBY.>#.5XB>.1Z/-O6FT%'-I\M,\6R<0%2F'
ME/=*_!76N/Z=SJ25#J5))C;(PBWSC[)^8#T/\A%^(H6EI";QR/SKHRB$#+/^
M^2,_\$&LZW I+T5.O>"\W.%;(86"'JTFC$KOHEY,43JA0W>;C #Y<7<SX(8N
M[GZO[/^HC R? 5CK>K6($A_UHI5%QJB5VRJBH2TI*!==EQK/J&FN0CYSKP/!
MH3'A,V"3;HK=[FF0;3V7SG*IFZ+V+4&L#":UMVOEKEI65H8_X</G6;/$&0N7
M&_\+I_)G@/'4"V&O5H)/QYAN9Q=EEIC]C3C]BC$83(7Z#;U(D1.:-+".VR;I
MN>V/D/<1<'OU>9<ZW#>&./*7LR!=$)J_\"+\&=!K+:K/V%!NXD*34XN%^NTO
M)I,0D'/GM4MP\">PNC+[,\!B+9J:T:)R=L=/X$!/.04OSJWX[_+?\5,&VP;X
M]]X2+$DZ+\NJSNF6Y6< ,:*FMT><O&7J4F:.N:U&N]4B9J7<5@ISR3_JO><E
MU'U]TSBR3;I\V0 QJBM?:?=D&/'.PQS]YP8J>O/QJ=$HL6HWUD="5EG*4&G5
M@)^.@ J;V6A3\@>M9J<HN_98[:Z[FPB^O@[Q-U/^M3C2H@F[+9[IJZWG1#/(
M_ZJ082HA4%&3JC6=Y2.@B=4OZ^A,;#-T9&J"Q_/ICM(J3H0#;%L'YO_]G(]&
M:F] Q[+1*L5N]6\@>^6XAE. 5;ZA# ]8YO1K%I63BOJH'QV"\KC;_^^Z]9S?
M^G6G@,.0ML58\Y&*X7JAEW&?H'G:1FS65%(#2R7M9P_#G_[<()6MN( K%2I_
M<W^+"4NROZ+G/*?LH]GW7#%E_BU@:,-4GC^V9-X1)O54%&]#MBSKXH=BX.2<
M(A%D)LG#^HA1>5S>UMD?S?[T3)QFJ9OH7>J2M=I7X3!V'4N8B5$ .2DKQM"1
M&*@/*D[X$K-+T0NT! O\DLSD/'5J"0>+5/JT;;Z@"H3GAIU#;^--!K2Y8MC%
MP_V7$7'\4&5L]$DO8[AD;-:%B^Y"*/^JW(1?J.2P'AO)TXN"'PH&/OH-/@-^
MMMOZO'N)5LM\_U:.IQBOI"V!T*HVX\W0&==;NZT?!@RM4(H41V2\KJQ_A]H/
M1+]6$ [==WX)$-BPDSVUR$O.2;,@9T">C)UC=[IKB;EJFO:;?I)Y]*G=T(;K
M0<)@"!D^[W/&MLDUX[OVX]R.#\>-:QU%_S?S8?-[SA1#^4D_LL @HSI]\QD0
M3LLX+VJ('R%J[4*+H#'3(4E)C[S(W[W5E#P1_G><,8V(VHI!Z^WCUV+NK09G
M7$ 735.<J\_I =$T?5?(U%[1"R7:R8B;S8[&,D0+!R'$_8(<VB$U"DIA.0R@
M4,:@!SCZBNQE"Y<5*LZZRUM/H>2/ EW_21"PEYINKPKO?YFJN 0W6EDJ>G.^
M"NP,HR-$)A0ZG"GT,*:ML/M6/UU%7Q_*;I$RKSO/2=.E&C VN[V6[@]+ZF\I
M*C8O.Z(\S=X]^&J/4[%!IX:AT?-OO>;"G_+<[PV"$S'3>VR-,XR[0^CY6V3?
M6I"N=- TIV.NK;Q;H^B\X9KGBT^-%CW,(J%(#X*OW%$_4_FF-5-1A1_R2S/Q
M\T]F%Z2DI F^?2#@&; C5.&_4.-_H+D 0>ZEY9N,GA<>.VW+4%AJXY1B7*T>
M)J??'1>^$KM3A0UN[E5NM"L\;:LVU:2PO]&0M#_K>^WR'UF=;$H9E7%3'RG?
M2&8ZTO8_HK"M'*@'.8QQ6S5@#UJ:)/GJ9D+,:4X4*QS+VR;T(["B$4*_4@>1
M:NC=[97L[CRBNX3^+5-^)_0%G>C&!M:A*$G>BXA1:^J RS233"N2]M<K2V7M
M>R!IJJAV"4W46VNU&1CDS9>MVG_^.E,KVJGWNWY.7*(]Y40*;.U KTO/L!F>
M6HQ.G$MQZ2OR"<Z>Y=K*\GY>T?!/O R!(IJ@(+7E Z@Y=W.@FKD_<.N7B^DU
M@6/-K?GZ6->'=OYM(=JZ9T!$)UZ]/Z7-O+:>VUBT:C=23&AO2Z('T< <[Z81
M:X'8*2$Z^LCET3<?K^KZR 6%MMAYXN8,;5U+G2X/)!ED ?4XKU,?FLU3M@?D
MK_/S6@V-VBUJTGRSG*Q#RY-FJ<C,.9YBTHIP_.[P@1R@OIR%G -=TEC@NHA\
M-ZJR"/75-=2CFY8$OA:'.IY=8C/96QPE3U?/\F0=)B6SH!H8+[21<Q4NG()*
M"^8US,AT7]DXK:Q_*99I9!%E$.<9]6DH^?O$8=I+1YYH<;R5_7S\GO:J;N'Q
M)"A$;WY?II&T(>)'QT0=/F.XYO9QULV89_U$@!^3>"Y3B(^DG5.AXD5UJIJ?
M 0R31<<7J=]+-LCG'5EPFP!M:I+G-!GW&#LGQ3A2UV47,JPX(ID1NR&K+52)
M]R$22,C7CBX#VXKQ&CR%C[%<V E[QK;MBP6<7PW@@?L?')@*2ZU(*2LZ7L_4
M*?'M8#OP8A#*(ZE]$*0'!6:ET,Z=2!")XDO$N&9JUN0(5MDQ6$0KR,EJ(3LR
M( =W=5_?0)GV-RUC^<;P0(;ZQ@T.-:'ZBMKN+#^=4K^V?]AP7%?5#LL6E.:_
MZFA]>E52L*S%!DYL6Z]-21IR[A$D$^_Y@GZ *KF!CVWE%=[CJW!W_KDQ SZ]
M?7/!M*]4?G'*?+:]3#)G#"%3;T$H.FQ^ROEC//":@F)Y9$MI,+OY\%3;Y\TF
M[L</"'^7GX9*MC=J$4%MG_O%G0(3-8#3A7.11;-&;>L!MT#NE@//SA[LYI,'
MCFWO[Q0AO_48JK=+OB81Q VI/Z$?>!E5.E6L'O''&XYA1-#K3@I^66ZDIMVW
MVC\^-LSME0A?"@]Y,_]V;K>F*?;QVY??/)P]YSA4SK&M@\<&W0B5K77\X]JQ
M324+%C8FD8]U%;&E"WBOLK9G_5(*RGK42DE 1DN)^0QY2XNCL)0*4N,ZE/GY
M*88OTBZNU0/!2!]DNY"G.P*KF&#%/>V6O1WBC0OL?"+ZHV9XTR(\$=EKW)C=
M*+Y[$OTSN397&7O]X]R)NQZ3TXG6(KGB#QPIO.M12Z&5QX&B05NKBO!TY"!_
M0I+R \)NIT0T933PF*@GK/B)D$WE'BS=ILCV.84;DYM@Z*"K9*01.8MZNU&O
MJPX!WA[35J\7IX-31X#!=&YN+9X&!%/Q! %K^[F5UMI_Y^MN*XL*!C-H3R.!
M-/9,:?U>2M&QHS8-O[HGJ-(7N1Y2P Y;-Z&7;!Q=\[6+A]?SM?HK#*IM<B39
M<D(H<>TSHG>^X')$(.P)2'GX&Z7IM0W_SUN>EAU!,<WJQ7@\616%C8F>=6IP
ME;7I%JX[4=$2-1.C-0;Y@*8CM[=YC"%K_&YXN[UA/TMK.X?3PHTV66ZM6UL:
M8_I<*I^%$*.6;_DM 'U3!88>6B?V<5.\T->C2'\,<NAT?TOD4C1WZYYTXW0:
M>=:FN5%;\B#^# @Q_73!UH.1RB'V_0M)H! =45+P<FD1Y&,/9=C+ /<_M&3\
M/2LD0H6D1_IL(S.42!2J-,35^D#'1IX!;R[$[;RI@5U15APG#_+6GBC:I!/7
M=I-_ J<ZY]W0@R?]-*-@58HS5_C?[U(*KT(KQUHDN70L0PTU(HAQ7G%UC7E)
M])PC'>5@/LT]3>>,&]??BAO_S<ZD$M@72?:':/.5/;#!9=*V;J]R,6U>?ZJ5
M&V\M6(+;"YG3!6$] [*T8BL8U?+4ZD^_>>I%&S:\\_&,%/&.P^_%L:96[67-
M>QM0]O,G &E2NP@BT4-)&I%_6+MD/;\%^P"US^ T?S_ZCV95QAER:% <ZT>#
MB.J_\PM\2BN.&@6ITRR/T0=<O&X&A0@-HUP?&Z47+[=#,\$.;]3@4M_[O0@!
MU-IB>E&+ Y@WS06FYPU3FT"\EQK5<&1\-7_^#)#B,]:I:9CUMR*M:PNU:$R]
MYH0WRM#J95&>/KQ[8023'6\-$6%'>_VG3)Y_U9A=Z-;D*5 _W/W3N#H/U3NK
MW!X]]5O0:JB.E2%<'J822J&F0Z8'("7,TN:T@XJ7/RX)C%W;6@ZS&[9D[0\\
M C]/NQF^M>.?QY9GBI1\^R$0?43;NNM\F.+ZNNC!,M$Z#U8WLS_N_6I<Y29V
MVE_O;_7+DE0"]R48(T8U(X_67B%A@^2F2X2PN &:HON=1D)C;L9$/L@2T77W
M3#.[852C;[M)#4)<;<W,\#"6N/I9YD,8E=FUZ\\>);OKF>W^Y$;W <-:G-"#
M/? DSI?GZ$W!+O<BO:+7OT?YVLOKN$5-,KC-A5A5Z&%E'"]D8:DCY.T\WV7B
MUJJFK5U!]MJ+6#T="XY+H_M*N[+53B0#B^J&K4E@VSC+C-OMA,G3,92L_)&D
M , 3ENLM]K$<HS6JK T*L@J6#?% &^X)1480YZ/K?>6ZG#/L?[LJ#*S3LB%2
M_-44Y*)P \VKL<?S 3%E\ZD%W>:P(_/8$=,4\\]E\!4 4K_;&BG">[L3\[BZ
M,+70^C%U 9.Q2U>.,*^1WEI-$I23FVT+F=D,/<O?>K,E@;->&%L@9TTR_$$'
MQUX+L)$P:XI6?_U;TVP%6M"QY6FVE=(@I.\+[/=X!A#6^7H_$0A,F\IOZO8!
M4)9;\0:?7CGZI9Q-]U-/B:KE#5.5:LM2X."C$*QHYT)4)!&AI*UHO[;$_,CJ
M(BB4\GS6+&2$L$@DJ:DO_(4O%7;Z)M(+B[)CK,N9?(Z+#KV\'[Q]A16QM:KO
MS4;8,DBXOLKTX38-\,3.3?FX8!<=9)"FF3C0-.1,C^RQ$+]%,VRZE04.#%0B
M9C9CF]VV_FT9XZQ)T_36# V=J29^ (QDO98<\+R!AOWK)GMZ!T/M2-KR;AJO
M)JJ+\B2;J&^D=@I,J N0K7=MF=P+53RH U_Q?'%/MG6YNPGEQ1#'D'6AB:DQ
MD#5%[5EE1:*76Y9G;,G:B?:^QYI$4+DY.6U8;_VHE77P@O?('Q1J?@=&$2$6
M./U($7=[(VQHQP8-3P,1@:K[/"P4)ZW.3K/(_5[[83XBEIMV:.L*-<-R848R
MU$/[Y<"J TZ0\$QDP>;8G^7F+RH9U]55TL3:F+__BZ^< =$CD;H_6$N&&3:0
M=!N>Z"?/SL0G["JM9U2R/)U6Z?G] O;:!K?'R_WM3 JM)T4&+5W-K!NR,+%.
M>W)-$IW6XQ2&I_Q(()9]2RA$!QU,"5?X;'J:=A4$34-<T=S_$H:A32:;)[-[
MI_[TS*K_G N\@=]])$TV8R@-U54M2>'QG%&IWY0!R/.9FQ,$UD_OIK9G+^==
MD+G4:MCGM6@D24*W9HH0IIN]'TMUARMT]0N^M+F,>(S^ Y W0CWSNY:>(I]>
M"1=6!EE3FE?'UTG?A& /VVXS2V1;GBS4[BE60K4%VDUK\]IBC6/?1-^0&I&V
M-<W\^EKI.F.WG),9((7FOU8Y@?;P):[_+G2LS.J?7@5IE=->W7*P'2O_X]3$
MV)WJ>SX=J$6@1I3[YTLLT/ W!+R0/]-)M$7CT#6Z'+<I62 ]:R=U@!C'.P=L
MV?4,(+%M,RWMR&0,7C0\X:!,#XFBH_D@2+V=9?J35Q%7Z]WPX">L OT:BU8?
MJ4GU ?I>-/F.%0/9SM''M0N>1J%Q?QR+>K=G ,&A'\5,QVJY(<8;MGK(^_&U
M #PE1QY(5&\I/-3U&C;-7[7_WGA)W,,Y>&\YVA*=MK['QQ0N>[T>H?U9SHAA
M.D<N@B.!GI![\72Z(8Q"V4G+6N\D7&VX=L[NZ3W":%^Q8Y8^\7RD=GD/&8T\
M5?!+VT92\'JAJQ\UG#1W*YM63$7)DI.'!/3VU-QDEL#(O! 1W+._:5184A6R
MJ2]8%#F]M2B(ZR@S39.%LT,V4>G>B5_ORWK?+>]9?'A8: T7#1[AML<@WOU1
M_7!;4J[ %67#X>U*;;8\E^U&LM.2.V@GC+T0KCA5W!DJL5NKN&N/7(IL+7BW
MU0KRIUKJ# R/A-IRV)VZ.W">X"#&N3D]U;RSG,8LWXO)%2RM%*IQ6+@1:\<*
M# Z1FDO 8B:N+405[#]\$TNSQ]\W^K[VOB:I6PV1,ZRW-<>6L:DNHG,ZKG'5
MC4+P"7;UQMZ\Z5W_R=@=:)CA90:AB8V8!>,W8V^,:VY_HJK&_>A8NSU .M1_
M(D;\,MGRY5!ONB=.;=3SP75B;(X7OP1DE7_U,BUV4M:QJ=:V(I%K-!N_B+SU
M0=Q2;7V'1^DT?_A+NN8@>-'69C^X/=T1 >MHZV""K>;\3MU;M?](0&#7[]CO
MM>&E7A66PI!Y?'M-S/I.A/3LRE= )5G:NT1/7Z[74;=(@\%K(R?%3M?P(PA-
MBP*%.@C4Y2<D=4,K.//FNWW"B::FK\H/!##&(Q?_P1@G]Z6VU]FO<Q1(P3_S
M#!-$%^^URLZ7Z8#58J1G250\^[,;KP?2KB>JGP'6NH_E[A/,$X;W[?S[0N7U
M%Q/!N\TMB/2\]=5_;*?G2]C^WNQ=N7\H;ZHH(<\ 19@&%]OTL),G)QM)W:=7
M'[;?JZP"]VFL*D,=,T+<;+^49-AEFY/L>@$''GF^S.;7S?$.NW:_PTJB\.FC
M.-#?54/OY)M#[ \D()@5&SH2AZ%]_SPEM91^W,J/._J"!*0*S/+F*PH%Z[VS
ME4CV)&#-%>SUIP(*,[S#[&OPS9@='A2=O_!X<?56>T<O5[X]<7;X"#CW->^C
MDVV.8-U>Q"<V.L8^9[+C6)Z,^1R\@NR,:NYRXCKQK+RF2JHMZ=3"C?()HA4=
M TD[:ZZ(K>A;J"-9SOK:N4&4CT^@A?HS &/E&6!AVE>T@T;_UWWCR2W+<<YL
M2?%;MARTN-)&X/I.*]O)WWV7[72;6ZZ+4"I6Y57-)9#<JH.QIJ5MQCY]HUXP
M?8U?J<VRZ;)B@@!,ZO4,Z,G6UOCM?+U Z5/13$X?A$$_^UKR3IL*]J[/CVJ!
M)LU1-SGEZA:?>%O:^YW267;(_CE#['E/A_B4J(F+FT,1[Y:^(T6JU?69P;;C
M#ORJ&YK3EKNY'_D@PGU<>_!$06G24"_ 0Y+IF<RN/)4PZ&_SSV5[QR&2?H#M
MVRZRF;YGV_;(!;P5&*>P<!3KDAA9'W%=RNARA 7Z<\41-5IT("S^>PFGRJZT
M(-3)45Q&EE7CH>U:(J[>K>,-W#PG>),4CM?KA"2WQJ"U9+8FP^D7+A'JTL)'
MDJ1_8%5,ZC"E(_X:3@6IZH7;[/57;*?\-95)\C17C_G;=8;Q /*J338P_#'3
MTH+%DA??$\GR\]7_1([GWS^?0SU;M^AZ3BAO'[\RVH#\/I/J3W>W^N(S(%9D
MJTU[4 */"4;,!<Y0KME#XOPT?+$7\YW!).W<58SKLDH7/M$[BD_%P*WD)E:Y
M@Z7U3N/\"^8X%E%<W]=[N(%T59<UY2Y:_A93XC1/0,*'CR27*-78MY3GO1HA
MA&VGJSH]!08YO5>GSO_Z)&IALQRWS=8$-/ X'MME#S_!_74^B< ZQ)5Q8$9H
M<B.F;:+G;<;'T,]?=^.*J>^UP560MS,:,$%8>W1/SU\IC!79/3NL[F8*"N;F
M"?6,WN:I]P](L"2-F?/]M"\-BYL9+ ]%IF^P +O50;*BCR)JFJ8LSH,>H )Q
MK>QUT[$VKG)$J#CM$2W-3!N'2XG^NF@4S8EJL_3*JP8_ T*N;@936)4FPG.S
M?!T;\DI?[!-J2WI!]C9NZ^A( !E];"0^;?T>+2$L-Z)*E _W*6%;SO5>:^74
MEJ,@^I,'P3_4#4O $]_DPSNXQ'>W;!?UR2O0/W]KFM8$QT&_ 1SBU\^ /CP5
M8\EH%_UO9+SF(W-)K2N1]F,&PPA<%&Y(N'K*EDPBR/QB-9FPV=[16PWBQQ!\
M'94HF/S6%WJ\JQKX1PVX;Q2Z 0Q;AP6O&QD\ \"^C:=<&->/F:/+P5G[3F/\
MHYO%BT\, E'/@/K&LPQ=O]%K6]]+\X''U4;+8IN(K7?-8^LR%6&_V'6J>":@
M+YIF6_NI,_\9,/6M&''[(O;&Z)_:<U\4#G3+.,S(H<]DZ_S4YYM;YDFGQ>67
MIO7.Y>D"^$VO T*9H^+,O[ZC_]HJVMMO;,]^>-REZ=OWA:(R*>TI$')(L]X_
M.D3E,X AS__^A3M/IC8]TA2I_!W5X/0]YPM\!KB.!'9^7BB%5/4\ V!)"*5+
MB0;?3(^T^W.0'W^\WYFL@=>L$1',59P*EG] 1H9=(DDOO\<C_9N[4Q.4]'!,
MKA5MS;B0L=LD +JE]N_Z?N*_2=H)Z;- K"9P#8[5VIP"5=H1>ZWX5)#8T9XU
MPIQK[T^M$7 'FFIDL]# 6Q6[)G3QGB:1SL#I;G^&%N#WPMK&^(V! P_6.WLM
MJO!9K*/<S?JZ=7SUGC3*E+XG?<\$0^'H@=NAEZ%Z)'+*'WD>1I8=*A37[;4X
MF,AFRZ8.IB-2[P?\&!&>3(TE_)G@G^<?<2M4 T[_A:)"& #^2]1X/RK/,7@$
M3IX!E4'.).P?KJDDG^K9BKL.,_I/W8!$+\J&Z@363W&Q[3(5F;I_P'4%;92%
MH5^K!'"TL3T6[SV6*(C/[-@MMYF>G0D-SM>7ZJ5QO#?6/YW\T:/=>N(,1+*S
M6Y>?MX#06^.,4CC_S&[U._,5*R?;:'EO3,@'B;>3KOV!2@,@DHV\/ <@J)Y>
M>U.-.IP"&QZ+))G.Z4>7 Z--G<:^P!QZ51"??%0\*_X34E6GG&U&*G_;VENS
M]8567&Z<9MH_'7>W9)R#<26AQO03KM/TC_G4S=B9A^'B\ :)'U4_07\>K&$_
M(%%&PFMII8]!\.MTXE^L.E_14%YK;'@O6&_:O3V7@ITV9/N6\#W SE8=NX+^
M?EO9273*LERJZ5,FBC;+*=7K5U=F*_*4Z/?@>M"&S51I*CI+G-]KO]LB=\/'
M/C9Z [-+MIVT2>/\H4%;WNJ,=+5"_ A:;-.''3\1YI)8MZQ?5_WUZZNN2KKV
MO;]N]F]O,A4:_*A_\T0T5<_Q6O<X32OS"IL3A=N!#H=01O9CD/Q>0QC3ZVBM
M.S\Q3-=E6[BNZ^R4'R_$6SYZ]WUHA= 3?!$;V)?H3^D?(Z4(WYOCHRN:.>4/
M0+\O$N4PN%YME8CQ$L^';9^^<-VO<(?KJK1=48=KX]I]$6+\SM8.,=;!V Z:
MPR?^V'=FZ94<FX;5*V_#1O9%="%#Q[$R/$K?3,9(UQ4E5(7MQU?'F;<O]#!<
M97NPQZ:CX]IW']I]:V?@-V7/ "*<4UA<C\S^H]-KAPF#6_2J=K#5,P"5Q$VG
MRN=CI7QI 8-=L E2@"B:!</I-3#;;4T4)@=O2 )_Y7CJH<L<PWGSC^<B(=J>
M_%A>JQ@=H]BU):9'^6PY_H%CQO;D"7BH)NE *>]$E@D*I<J.HI4_7P8J_ ,"
M"8"#2D(KH9)BF81>IL[_C/YNC@&?")X!>(N'XOZYUSH/G0(68VN(X<%]@^*X
M)PK);9$2-VSO]6KCOAQ=4]K=!$D&2Y37,E[SKF!IK>2"2P_6+_:8] Z#1O3U
ML,Y0* ?T5.O43%Q*OXG*S (];,(6.0/^(JW7(1-]G?@,\U=H,W:N- <F]9&<
M-!V./ZM0 O#O/P;.D!SP/P-PV=E%L=TV5\%ZB1>Z]JA] B(Z/W18 #Z#>]2T
M@D=@M)D-U[%OURUQ$<6))+C7D&_1MT[-!_V*+I?D=W-3*91@[3+?%D\B/B'7
MM[!@'K^)NT7F-VH[^"9UP"-K/_1GP%#Y%O[=@<0ELN%$F \^7N#&<B[NBA'5
MD+W/%$,0Q_M3IR"NI-N]WSXDL(&;'LJYD^/*]]?:I.?X*;LIS PFW\>YN>XR
M&+6R\E6-/5RQN)7?[_C]M\UAVO]]<UA91\8G_SK3M#<NOIS[:_R#_T@.<I 0
M=B^L3NQJ=^*Z<=EOYG6<P\N*:Q(:]Z">]X\1)\(G  _J3U])_#82GWF;S*B(
M ^@*PLK"]VHTRJQD]J6L[Q]F1-VQ\_D">P8\,-"BM<?RKKI8B<_A">]*#CUH
M.]YMM>E_@;^_N^FMPD58$)JU*@Y&Q-/*&6"$S]S\^,^WW<W6%\L0[![2WY D
M?=VV!C,!M7(+J?Y<\F&&;8D43_Q>7+1U T2:2^G?KN,"'24&.#H-MUR$7W[5
M UHJK0)GDE?)T0\-;9M5%<\IUZ$Z0\+1S^&/AA6@U^)-U+E]_Q!S1RQ58JVM
MM3]9\B(_$*M* _YG<Q*CNX$%]>J,D6N4G"7SOPSV@B9:++]$D/8Y8"H]N$+Q
M;!>E0A?]@R-BS12/X.I)'Z$"A,W0DC6_M0,5=3/%^_VY'Q=@K<AIS3(E/>6=
M$FG;H$B6BI'_RM\;N'RD-PWI^[4FEX]@HO\+>V\=U7:TK@F'8J58:7%OT:+%
M70K%"Q2*>PL40HH37%HH4"Q8@18)Q:%(B@9W*5 (+L'=)6BP,)PS<^^YY]Z9
M6?-=F3O?6O>/)__LG;V2G5>>9^_W_66X_6K8P. 5O74Y3;&):'B^=V"K,=#
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MC 4_[0.E1T6:;$]"@(5;Y^UR(D_&>*_SD^0:&Z&RM3?$[P=0I@IA:O3&VR-
ME,9J<P%#_H[MAY6##9F 8NKM9(PPNB![?M,5(9*?A-.]OY1EW\ISG^RZU3TQ
MVB]3?96_[(/PLS*Y)8I)_Q<YV]ENAO*UU7;SJRL HGP9H89/ZL+,<ZE>-7.?
M!G)])ZI7FOA5FB.[N4$WNJCEQ]^$IZ3751$J3O+8J'T9D*7BQ*ZT4FY'$7#D
M(OEH@X::2T6?I9QB)36=/]][?D4'Y510:A]1./V"N7YDU>8-IQ(I'87!YHO6
M2]_)K&NQT1*>1BD>I(=O^PL?E]%;0.>,7>KJ1T+B)HC4D>^E 1BH(#QJFD0C
MQDU1AN':K(%+YM6.GOJLC=K:[^-09K6'LE(-[N+^WE:]U"OWUSD\F?04R'9@
MLFURI3?<<S!8^"/7:K02/[3X4 :4-/3Q2JSK#<1_!A*T*#AACL9>P@]^+G +
M>'RG 4Z><5M::YW!4Y;<?-;JMF6?H/(SEG9F_ B8FYK'.'11TU,OUOOT@B@%
MQ1<QRCDUJ(E8GZ6T/4_2*F%1K.91)^L9X0^21;HJ<A"9G91Q_G>'7EU1&7[&
MQF_4QW@,J/<GV,&ADTYZ>SC1>^?;,JC()]"[0(4.7]:#)R]HC67?&U,/)<IZ
MT;]X)K&S'\#%HDSR[!*T??9L8'8"1=IU&M41=OYR^%3A_8.GC?55,TZYIW25
M_23?MJ#K]5*Q7PQ$DSV)^1)+16ZV*U4*V*!."D7,E>S>]#;NO\ODND1'- ^Q
MU9]W&RD15T'([0@AVCN:*+'(/;",GW+RAL'8GO03=X<NNPICEN-\G.#8T#D(
MH*=6YMB@2$'-1,9R45O(M+F[(%+VJ3"&&#-RM[N4AJX.!"!7BH'ZB*<<$@8&
M=XY=K'70E0B<YYNT$J."QT]MM:\"AZ=[JIA2DN)$UZ6/[K?2G,">QCLN'R*^
M9,.#0?;=\ _#;>)/7T9'/'!"2/24^@JVGS-12;\ALN9G_T*F4L3U45_]Z]-2
MIUO CZ\SF"8-1BIT/KS>().O,M_A8:^?UQFX0<.E)N_[C+T!;P* F@,?Q]"X
M")T]T=$IZGM/B:<^9I>?QPB[/YI3^K=[' FIO*_A-W0@G?,C?_+Z(<?O@["\
M\(SLHVD3"1S(-A9+@CP+Y'MI2YC0G#?,=.S:.NBA@8"*M9-<0_6+1*8W(>C4
MP3Q./J#)1,OUO1R.['V+0XYHD<R'.Y-G\';$[C91.;E[LMGG/Y;,<XQK@6H<
M<;)-)\>\38V5XFS6"JLDM=@BN'^2D?JA71MQE%+>QE,O/S[Z26CE<7Z](]IO
M5H-B"LDTJ%1+F%^>UXUZCA4F1B+/ZGE:YH-T3N7Z/6Q?,CVH@@J23^CF1KTM
MB1(-XC.-+5\7IQ/'FJ*W.6W?.%ZNE\JDV#J;9QDY44CL=2UZ.=+&Q?7M[*,V
MA\2F%+:%Z8<[&DTT[MIZM7IR</;)A'9\S)?TBS3V,MU:O/!OX5L %W!"L)]&
MP,H.< OP*R@O2U$@KJ:8"^A7%!%S](=<6M( A[93YZ%#<S0>?CI@%X6R"<V&
M7YEB'(RU)=08?C1XJ:HN848_N&\M,J#,])4BW?%1,LXJZEJBS&3R3:P1BJ-3
M8U/7-LR<_B+P@RW-5Z6/GG'W\6EH=AV@93D8<J_/87C$USY,T55<#X?5/*_U
M.]<O&=.RT#L:D^ BCV][![L'C^1$6)K@1]'#MP ?07?(]>(*JDRJ0XX\-ZQ'
M3W+5)#F'MVGW8Z^=S8,9>8'@54> G5?1<M7^+6"U:2IHZDG+'3?0:,,(C%S+
M+1T\,MHFTZJ8M4"<N<4)E7908/?C$#G1N[AV/&!1Y^,;;MHET;ILWBATD!4=
M%M[#0Q@*J;GBHO2K(I&"1X,]V3\OSS:HI<$Y+U'0C#(5?Y;@LY']+J]9XWG%
MM5=1T2%P&=*)QM3CCE1(XIU"G7>00XK6U+C]F71\KXYPJ*A9<VUC_C0)D02+
MC*"U1A4:QZIC+-5:4.SYPU/2^*_'O@D+WA.J5L/JQ?&U"GSZM?#-:T?0+8!$
M1$+4 \. CBCPSEZ?YY72F"!RIR1V.6M5(@"D2^VSL)((0+/S)AH#\C:1Q5L@
M8)&#6#G'=VF3 'CJ6TO#52LW.0'C!?R/3,15UR05FIE7Z/$HZQ*D-WZ/+*?S
MPXBE\#=)3KQ\R93@K_X+S%R2,5/7)-JO^@M(@9QY<*W+V.]'^9>ILD+H+[S7
MV(S52S4);SR6Q?=?2B7?(QUH9 S_]5MZHB6\.NW*\IYL94F&^IE]TCHXN8NW
M8$KJ?H?U#U;Z(^X_8 ;)(\3B?J4/V)'MIX/DK_K@>25D+XT5GLJ'E:,NO_3[
M%4"4\C:-"?-]F39R_>@G. G;MP#Y*,>YL^<P:=<\8[06HE.)S[:ZD?-7UZ.B
MI.^7?(18\2%0/]HBYV4:N26Y<8\+Y[)4.E/<VBNRZF@>_V>LZG3NC+YD$-])
M*-I=N25E&1?VF4]>TCF\;+U9P?V8Q5$@]D\(.E-]<Q*C@1\9M/M +D%?\G7,
MR%Y0EY'9P+:C_5T>\&ARI=1@X#;V%E4=T7*4A_!&&A7+[MI\:J79YMI&'V@X
M8S-1?N&7J^RYKIQJ=KY$\.?O@L^WC.2(K$"QGPEPK#>2^%Y;U_&TUU*AV$J8
M<#D..U0\ZJL;0YV81?>EDX[/G3R[ 9N2&\)^]]6=!$R%FU\,CC3L^NZ7KY2*
MJ8*H _L++>8MVCDB!_M(11V_777:%:Q,C=4;QE29&RHVCB<#>7^4\\"![HR]
MS%821(W')PAI<!E5]_--=6'N)O4=XV&GD39*AG>#@L.D*?NBHPW2T(_@'3W'
ME,YF3K3=LJD0V/TGLA.5(;EO],K-_*GH1JLT%-#MYMX-Y'KHHNV,#JJ5F-OU
M2I7K-.<P'"LMT806O)O\F";A[-A8N_]QX]PQ$2JQ-Y$]AF';HG6\6?MIM#W9
M_V[&:9]GS_]W*<)E+S[:/3.KC%0^I"-UO2#+M*?8NT>W!1[/#@*RD5)$Y9,B
MFN0)VYCXM/ DE[\OAPU[P!XZP"EIYYN6,LS7!$4JY0<H5MR#TTCN6\]!)+8,
M=Y\=(Q&7UTH(;K/3#11),I0>LR"F<9.V&G&]R]1PL@.=VH%RDZJC8_*V?4OS
M,]DSBK>.+((=69NKCT;\B:[#.:2#!(PGD0515(M+8[3/6";_8&7:>,<;!A(Z
M8H=-]ZY ?-_5$OJ<F,(HT8+'F@WCSC9BJO"4\SV6]XIPLN I&GPO;8O\[(S[
MU=P7&%QU1Z,3)F)_^8:):]>?]D=;5,.F"LN<1J8H JQ^X8',%$^ CDJD?Y!7
MEO>"YO#;$6<G*S"0_4JFY3MK![#UBXT=?K+LN&)[RMFE=M==P(:7#9L["*FP
M_?PV\XC3X)U[- EI4!X_Q-EJ",.!-C09H\D>78FTA[ZE>TZD_Y'ZM3;J@7_\
M6<W:R,*/NDR^FY<ARQ03&2O:CZ:VR;9I0YN*5<XT-+@%6+)7^-0 +H(2UB=E
M97+TF_Q+9,O6'KT%4%G;B_,-.M'8903Z9+VN!3?).0(C[AJ2'((_@U<KI2EZ
MK(,6H:_I=>6:!FE*%SD%^:Q]"C:$L7@&U G/<;D!'0\QG&8C&@<R7B]0S9EE
MVYKY:3(J6LUD%T7.A3,7_$^#?'PD*)P[H5RCUP+$Y0T:WS?J@_CFD1/\@L:F
MS>,K8X'O:DD)3-'NAJBDF/7OQ6B8,;1/U-7=C]F>N2].)ZKPP_&P+P8/+LMA
MNEDQLS4*XOXY<]_&FK+(*BTTQ_4<]1L?^\?>F('35PI]!G5=?[CH"3\=T.1\
M)MZZX5?M+_-ST4F4C^[+VL%E0>_64PPXQ1FEH51;6T/\MKC-%LP91JS@)UAS
M)"!._6$CLV"BSAE_1Y8U@?]A5Y[#N0DFS?$=PC; W:FO>X7^Z4&_6"")+PF>
MSW*UQH"8SN'^=S#;?GE0F8IG3*&&IXW]'IXJ]R"YS0J3UARWT5+VZBC;F*=,
MBMZ=_0%];]:_3$CF#9R6@)Y )F8&CK&PFLT86U<W[A4%M<\=KAB_\*.GS4V&
M* Q(FCQ*+M$F9+&C.3,?-U1L0Z\LARW>L1S%D%L %J0VC1E_]ZKTH81DN-SY
MK$>.<EH%Z"*(K*[_^)K4;++1-M^>R29F9/MR^] )7OTK:B!9GSX9F]F:\1;P
M:KD$[=59P\A>D;#</QBS%-<ET]3^(9F*J;U_:C(%7='[X5IM:<Y.MWG\@W"$
M<"X<M"?2UTB")<[Z3%R"H>Z:^R?:T3HW?!QLSF7NN\:7H5-V^B[7S'&0@02;
M#&' -%&9P:F<(J93!.<F+PEDF7>0O 5\\3@?!1,:\3ZU#;;?PTYS*]RU^)!^
MSS,F)ZM;9GL\MM./F+]#$G>BU+704K;01J^.TCY:O5G6?A@B^5%T0P1ANC"S
M92&(#LF?;U "%[;;5+^A>Z=$IMJY04U_]W74>T?E)8/:?RFK(#=N </%II*O
M X3OA(':!XC=PF7= D>7.<W &/:KB:Z;\HM=V7;_H]K>@+K6UY*KD9.Q/9*$
MZ)?>W^8$@1NQWP,#+KH'<M"5&!F),FLU; R57>2@!*V_V2V@U;J,?>95PY@L
M 5+3(>41+[1L\C%;W<UZ6YSZ5?3&#,PAUEIS)G\ADANJ@9(!_7?;Y\V_B=49
MA74&.IANBV(T?F?.6V@IV:$5S&V\^SMK4KOSSGHB>,WUL8RR9^GC(M5:-X7&
M5E+7K]F<EP8LNPW$4M_#EIO>^W%.=PWL?OH1PO5"F2^K$J&T@Z8]V11ND'+4
M.M )8X![O:7T$7O<R/S$FP.;1H9;,E+X@!QN6:336-+_54?)G1:77$<>UUWM
M%L 2L'&-?9<R3;9 J=H7= =RBTR7]X;P-9"14G<SR/\&K.R0?UMEMJUW>"=E
M(.T(),NW4A7ZKC->(0NJ8OV1_!&>W^F>GFEWO5F@8&S[2%ZGU]%+5F6P)<^J
MG9.7G3C":0Z4B0[N7ND.O#^Z@(?? IQBW$USO49LF!5$5W&7>BV7_:SWJ]@6
M];7Q2@[5EG40M ID3O=;KM_2^9RPOIUV_<'V6=6)C.YHYYDAE+OE<-?5C+"?
M,]F8(<F_@OH9M<1@X-LI@W%ORW#P#O^COSQAI'K7O<=1-DQV+,[:=^^E(6%#
M]"J]';+N3N ]:)$[%KLCAM66XWQ[,*T4JFK9A D1/QE"M;JQ@]5I1Z>T;Y""
M(5)=;>P=XZ(5&6:TC+2.4+]S0;W3/7VZRR1L %2-L7H]4!AE$%6\8^@K6^!_
MAG1*^N ?Y1DQ-3='+J5!@8-K!JG=&/- I.A7-:/5EHI!/N=IO+K4!^1%6 1\
MK8^4[[?MQ:N+6X(E+ W1V$7%Y=OSC*CNM&6Z"^'3ZI9?S:J=V3.O0_J\8J_Z
M!-VX@LB].S0.OQJ4%M*8[^<=94<^),Q\$ZR"S<(Q:\B[#.R"=?.3F-E\6?Y5
MZQ,9G?');#(5'=N)U([@73!M;.$M[O6CG9GV<8[24.*(WD,:'6H18-Y%>H,E
M.!SOZ=-J@F6.G!\B3='0!?DD=HWB-$\HS8-8WG:H'OV&R\YH@>\$3 #5703R
M\ELT#WKU58-N6SU>K:ILU1]O<1&2T>4+=A^D+X_:!U)Y#NDH4<2_4")_C?6O
M +[8ORP0<D_-O([QO 6<[K=</C94;O%X?6]X5D?%]>_,^>_@#N4XA%VS>B'9
M$#.!B)OOWG!3_U*,TWTI]WA(AD\9)+*PMVN.(/?DK1*Y7O3_K$;T-XH]I0A$
MJU,Y*A(VDN=YL6&$DY>(0P&(A^3$N7=)=?CBPL*$"<W9_U0J 20\MW>U-)B*
M1(J5#*76UC:YN6<_%-I$#$DI&ZN2U/9=1:-2807 OW2#X\;\3 JC0#9 U/;5
M9'HE6*_&?SZSU"#Z:S^.X6,4E5Y#&"^=TNB^;4W]^$'"8V%!<H_HAV;!DF"&
MJTF6Y4PJ!R@-&KY.&%7GX>?G'3,.3^T6B?F5=W;RFX?$-_&T=&OHZP0TZ-.C
M5)4*'0L0".9 =JV!,@[6*%5 SKR"+".[V-Y!9AY^C/J-LU'(L,V$-F'DO 5D
M TL"W6X!J%19F-@O/Z6QTP?<"']W7+3G^"G_(PM[) YE*X^)7X76*#3M5R/$
M-?;M:**Q%Y1]DAE-6Y^T-AKD8(9%+O:P9?"%/UX?(YV]'*:>Y44O.W2_=>,]
MPB"[$=XZ:8#?&6^"*/5N RM]K*V86'_ZK(V^HHC^4R^-Q'6,VV0]INS,I+O4
M=;E4 ='I6?\Q;%)9[5Z6>2O6ZLK&(M1G:]!=[]= ?_(M8)2J:F2C:=@,#U:\
M+:D2+<WFYRY</K,=3R?5H/CD:$072Y<J?Z^'YH1ZP.LT^L=RXKZ)UP/.[!]O
M_Y66^%>8C03]7O"Y!=Q)X2'*>I/U1(SR%0*-C_E8A35RE@T9^[O9 /L?P_]K
MF_P_ +UA)R_?MLTPN)@.R.<DG(9>%U"B\;+OQ3K,2?#&/RRM]1>RI8HJ0 GV
MNYY-EX96*AOYO'4CD>]V/X*<5BL!]YBX(J1_GDL,T+5):H4LRZB8_A+*/5^,
M>,I#!$J@3J+^O>H+K1X>5GJ5N[K?G6#ZT *I$O36U>[96WJ4\"N](VPB>K]C
MH][% 69O&6E^00W7@FQ'/ .ZRV1\9I(7LDE#.@I?D__0OEIOE%D,$.N8/'(@
M< \*\D=]4>JZQH!RK='DBU;Z"X^\G1!=M!X&AA7:]#J#B2'8 "\^US%&B=+(
M9_4);NO-67VEUI$HOC37,N_SCCN?MOTVM;5V4)#>[>E,?3^K_G%\.KC+LTI'
M7;=>XQ>;U;^EV<G=]Y]%C?_ VD.L#:B<(GZ,-%FA+ Z!_U Y![7=3.QJ$!?$
MF53MI[_I1.#<6RF@H:_<--*:[OY40CI^MYAKI@5WY>0)G3;95N;;!I\<G:<:
M]+]^D=(5_>9299$+]QUCX :;#*LYOV^AB^_U]&[Y>,VR3"S7V<PZ>D![-"F*
M-S*C>_2-#PN+ANZCJAD]=GRT:^347VZ>EV,OG_GVK/'? AAAK[/3R]\X[1PI
MZ"TG082,4(Q-/T":SJY+.Z6F*@FS/D+ (1K;8X%@5II6?&A0IGCWX7[F<@N!
MOTRJ'X,H#9C F79SJZ*<7=R41@DI/]?M>C J;9BOH_MSVN0O]V.E^SZEM>/2
M=BM[+,:8SI:1#Q[?;&8O/UN8):AN*X];++JXGYZ5R6J2ZH8KCIUH'. [4,VS
MUS8(*I6PF@ZM!C,AY+RR5@K*2$#SA<40MA[;'QE2I](=W:)>90ND)VG?7UY^
M:8S(#YCFL=:?G[\9!(WN<#G>FUCIK$'NCKPZI_PE_+Q;]6C4]>(;D9TK/;A;
MRJ#43M>_EZ]+R?A7=B3WT^!_2Q/#W]5X>E0/<%S'G&<>DMY@V6/G[2DQ%/[=
M;,#PB_\'_@[ZGT"B21NCW!!T>6YY0U"<8UG/G3YV1W% \%L #'P7Q5+K1:ZR
M/U)"EB.E_K/;,/[GX/X;;9W4^+OX^U'28NQ_6V^;'5GP$^CI.YC)%GKMR%M2
M>\SR2!"?9I!DA "_=E,%_^G')S63)VD#M)KO"-&FFK%_YCQ,R3Y&ZT.TK?2.
MA\[RMP*?CHK$BIMH<C4^8%0M<UR%Q^N=."9PU8R&A'63D$K3'H^%\F(>ESSO
MCD?VP,AME-I+%'68HTD^DG90."]S9-Z4!YQ)7[0<1BU<I'EYS#'.9V#.Y&@!
MNR<MY)N7 Y/3NV49JYPVL7^"52=L\'%7[%ZS6JC\^0Q1D8XT%^J\E(6Y2E,:
MIJV&:M2@H<]_$YAO&@&VXI37?I^7$!M;!YBV@ARC:7*QG8+& Y*.1^%S-]QW
MFN@%(WT$<_V8YD 5K7]<:.1"O[?PYN"%%T./WR^R[OLSD^([\HRQ=CYX6;;$
M:Y54P3:D=!3<==J*P5A%.ZF'"Q%YX[G0D7--4[IO5L%+UL'6DM1Y. 52Y&&X
MU&311$2/4S>E3TX2,3=PM(X56W;V\>B(]M79PI(*%)H0M%!SQY\]K324E#8*
M<C//]UK:8V5D6&\!+8X8<N-/O!14_SCI']=XCU.E9^'K>R=2 F>N.?]A-:5O
MCX9U?+:V.&ZNG ]S$-IJ<@<S0:&4_[7R_[651>AE7:BMQU4Q'MOR__X95=G^
MG\3+5Q/XX?ZVN>CL*[W*T6B,4YI8HNMZ3Y53+[UO[-<A_'^M:OAWP;^-Z]$,
MVYO8F+RZU$4^*4_OLPWM!0<)1,FZ:>MV8J3?"+>0;*7*I3L^28*""5CA8H_,
M5/LD^2YHTNQ[VS>P.2":#CKRU$C#4(\ RE4S(V3][_)O.<=\K%\5/J_FOIWZ
M,OGIJ P?>TC_.!\I,C[0T<YH^BV91B.A+<Z.,*2526 1C!!QB 3T#S=*Y:$#
M)=YH?5HY]CSP>>^3'DJM/[NK-21.F$[B(E&J_I_T@"/G?U&&L2'RSTHU?N#F
MU&9#EO\QB=&FU01/$4-<=[3N8ORJ<]+I+8!NUK[2PN*%K?5;AC8-J2+>Z;7X
MN1?O%:A#"5H'!6=#/D4U/QC;!VL3=?'N-H/_/$: 6&O;XKJX56H7L1+('T/6
MTXJV3*I;O@S"L]F^'@TX\#HQ-V8LZU)$L11SR3%7WA,85&&AGQH2CLK 5JL<
MU<FN->MGF^MUBUF7HF)[C,]<R4A(1 3^0:+144F13*QH48D2*8&+'5'O.\'6
M(%-"??-Z@2H9<<_UY>U;.;:%&.;V=C%4DXWO4F.6+8#GAG@3Y'5@.-F+)YHQ
M5+..;:8\K36FP<\%6D2CEHD-)A;4)U@KD@<)OQ3XH==DP:T0^6U:)IZG=O8X
MX3(D^-)Z#8=0&!NTZ(?\F:+B6)D%D(_6CHJ,-:;>J-T1.2WU:Z8;VT-\]1XB
M AQ+;6*&#&H76MK1U)HP@O>R3CX5+-&6)Y$R)#X4U/@.7J#M];G7YC'9EA^A
MI2!A]QN_F=A/_#4 ^\>6A=RA-489QA@TI7H+V'1[C?]K6%5+(N_N]PO?2\X_
MF0[(9ZK^<CV*AVIY[]K@;&87?9(7MCZ_M*YJ%ZD2>EVG3_^8SHJA%!*.0\_8
M^1JGZB\!0T_,T.!,M,+<'$'1U*A1KV;K\B5D++&5O&;RN86IBCM(V+V-*QQB
M]$VP'OJ9K(T<BY>"'/Y<_C!WM(?NS]530Q>BF&"7NFT7@M9=8HU_XFFZW-QE
M:U8JA<* *CU!\QDE5IU>UT?2L+7NDD4J_\=5)!N =%_L-__,NQ79YJITE>A3
MR%CZ,&8.@UA>;5+R^RX$/3]$1/[]GB[Q-YX(RBL#RJTZ-]X"/@9M$LHS\#MP
M[OUO^TS_ Z S("VZU>RCRSHH)H7+5/KBIK@@"'$#N\%8HO(\=#]#BR@W?V8B
MZ[VN;P'(6\#"VBV -LMG.4-R\"VCA7_9WA"%[:6=C+V;:NU0$8=]5YJ>H=0M
M@ ":<0N0=FHY2+H%+!?> CXCM&X!4#'+\[Y; $I?=D1F0+; \L)X6,?LX)K=
MU^L:57\+:#:\!406E5R_L0[P8JC2,<./6Z34[SDN0# N>ZMOF7>E?>VU57WB
M8^M8&,*C_5:[<".(CX"I'_@\=U<G87Y<F=" 1[='^IUJKO'#$UL)O!RQY!WO
MFK 79V'F2\]]?2>4DI/<P!1-1RNC*X.O'I:SW0+F>_HO'D"D.$L:#9W*#]@6
M/;T\^P40N@X2WT=W@7-YW%M!.QBLX3OC?#UM6G5.6L'6;8ISNE*M.\EHSVO=
M$#H; -7WH=#"YE"X?V!,Y94B!#2!YC!T%M.I%^%-,N/BW%/)!]89Z?VZ/DLZ
M<5J(/1DL+LS^]13BUT(VSV)AQOK\?KHR1)Z#@11N\L.Y##\D]0V8L_:XYN"8
MY*!I5,97=X.V'6X#/;O6JH]<JS9LH@WM+ :[6$60QU;\J8N">!4$F6SNL5-1
MNOQA\O8@;G 2ZBEP<##T%"I2:N<R;.HMS([,>?@/S75I_Y+6UPW\/?7GQ++?
MY\RI_1^1N+307,W:FO>/@2$5C/HWO&9Z7>ZJX;M*B\6L>Y<-L%ED",Q=N-L\
M]:&:BC"*6$&TNI8M3)[L-Y;3=9D*@SWV#X9G0GOR6W>NR XBU)N$/9F@4AT^
M03O#.IF W[0]K"#B1_J!5A - 7QLZL55B)"?X@3S9)6W"!W80^T%,=V*AU-N
M\;,>&J+[*R,?^5<O=:"N9GOG47LEUX[YWA927JGK*$8U6WQ"P(,_=2L),]HT
M]$2CUI/@AAM+G9I183\"1QXGI4HSLVW2QU(?5!Q__OK5NA#;-.;Y@R2YT6^Q
MYSK&0OH6\"O^;B-686KCC?I9]F)D,]O(ZKRO(V4G:JL/C.QHUAO[%[\>SJ*C
M>A[/_*[H8,]J8M!2?&;'' DX4Q#24 7:8R.JBR46EO4'<]Z%PDYNGL[;QZL(
MPC)$T2V+&JTG5@75.B.G14[5F@H,7"<F^96P4*JW>O7*/-:)JP:X7@RU%Y^Z
MM?$I-HL+3/B*V?.?=JW&E3:HU1[3EEL)I(.M!X4&WL?B;W*#O)P9H4\AV[L+
M:FOJF^V!<M[1N>1.^%PJ06_DR= 6F*-E36OMYEHQ-R"\Q<XT7\D@B0C(/$N.
M.RNVN(C5NIR+>E_@GK?Y\\Q-A;BKZP]ED7#(4WY1)4WTINI<'"E-M\-<<OC;
M I,>9R!]^=-7=JQFJA9JI ;Q44Z),N>/TTE?&#CO\H*E:$I@5L:E^>8P.@^6
M2\9%R(OUC]*C7;%%7YL/;[JKO:0]SR5M.[V4.7%R-5Q_Y2P_#\?%YB/WI8>0
M@I9!Q3=,'3M!()?]#Q823E$_$X4?J*1!GY/,POOP66+5$_@)-H=-^IW/@+;&
M[R$^K-!U8UNOZ#"%$2FJ)^K1]USW>DM]LB#+!$^2L'N>?@7+W&?!>8V/RQ\A
M JS>M*MIG,G3+A;Y+/!E*%QU;Y6OK1QJ:W9GW,F!&P*;J37U'BWXEO,@(;/>
MDL'@9?9@BAC#WTF'#:^?]^JS)OC06]$;FCHN!=".=&B6PRO(9H Q]2,"+(&[
M>[:#[HD=<+-3A G;87<\7Q0PE\[ 5$HF\SW9P%-I-F_="FY\73SE%X,$#)O8
MZ?5CUVI>?J4S0(0KCV=JKDN\_2_"+XNBFQO]Q^4T4E-V@=X<],N5[U$6N3R[
MN\([-[IGVSNOKZ3#0-2.L%(]Q?6OW'R_OR/>(ZF XB3*VB;0!T/6\ 3J/39%
MUN6E?(VZ9&<Q>\WEUS,=%-2LHJ8<$KU_PMM-N(&P=V<5TL[/,_+\OINX<W9/
M'D?YI'T$8#<P$Y&(_R#QX9/^@'P5+P+-;^ '/$ZT/MOB[7L<ATV-C=]^'%T@
M/F?*^'@\<.ZMMZ5>?8.?#P \QM/<[^JDSOWA*ZZ^C!N-'E&0'XTH?LC)"]NS
MMX[/;\XSSSYYB2&E_SC.;>P?"\'7!@\:CDZ6R[;J12!)SJR4Y;+31HTP89AP
M0KHUW[Z&&(!$;1%KZ#4^E*^E5+,0*&M05-)?L%VA08K,KZ@.QL.C ML_C!6W
M*NSY1OU0,CW8-S;\82]51RFQQ;9QE'%W6^[]!_=R'H@6+GH.:A>)O!MMG6<L
MKZ^J"QNT%.R%FURDN*ORHEG(BB7NUXIS ?"Q(7@BPAE/^Q7+*4W\W50^E*AW
MCTI_$IKV>EP=0.XB]0!P-$-'N%"^&==5/'M1X9V/,O!A^5(E3QCWYP<S72S'
M.LX]7^O(L0847XLMF"^$8F#NM&T<TYT2W_,!+FLXW;D*N'K"W_M:M5NBC04Z
MPD^X>6@1\%/*[E%43=-K)U:NRN>V=OJ\5392-EC!6KXC<][6*DVFY3)9[-L>
M=4D3AH:/?H8:&N"06Y$3%3$5_7@P3Y%FYN=76UT,JNUT#\H>\':\WK)F9DJ7
M5[]'QQ)M8QV]_LM)Q!RD/0$'T885Y7>?IS';EH>M:"4(,;_4_4TT7,G-_V<W
MQ%7\-W59A\;PKH<]:V0?AZ7(GX1>'AA/@MBKACJ>GKO=;P5X4+ST5E&B:@%>
MW86Y'?];0.5-F7/EQ?>YAM]S:QM> QDM?NL[ P W6E@$V,\/%6 =]--LNJR8
MHN2SB6G7.XI\,F&K9@Y/FJM-]>03&JR*[7EV3'NF292%;8*,8\F[:I!1-#L+
M>#7F%L#IULJ8%?ZBVTU;G^.3OY1(6[+&,],;ECT-LH:T/HCCS'5G;&"GX^R:
M/ ='N42SOU0>@TQ)8#\F>M(2]&Q=[')!:& N?>/@&))1#N'$CIIH5"Q#.^SH
MC;*T9.K%E:9,OX=R4AJE^EB(7F4+?W#$];).#'8UQP]C1Y$U-\+'>:N?6*\5
MS\QNLP]IML3U1KGIE8G&J>*SAD"Y#8X[D 8YO*LIR4 A"_F:XP/6\!@-"NI!
M+-R(WVV(0%Q:BT\%]D>:O+GN-/D -9&!/RF/GC-0^4</5-DLVF%SC WA8R_M
ME*JHE/^"\&HMVS2B*$X$(W*BDBRKQ.A>6_-\BFUY1?+L,C!K.>(D]KZEVK+:
MJ_H9'C&!FV3B^*+0!7_O5^%T<E\J5C-3Z T=H!3#.?5BA X8.V3J(;;K$_WO
M24G?#3W'?WO^!MS3\CU^H[1TPT=H+HB4,O^U]8%VP+];5N?^:W=HH %+^ND/
M$MJ#SOJ;I+%Z(D,QKTE\PRM:"Q6&BMD+2[L[E][]W,+V@H5Z P?BBW@P4";3
M-&LR7CW[3J)E^'VC*,:C/(YTD)D-BSB^6U"@V]W J5$@9[YT"CJ4")8TZ]OA
M+H[05R@NOO?@^0,\O=BQ\0Q^E?+A'PG<G!G^DX(:K!6-%:IS@ONKE?0 "0[
MG4/C;O][G#C^3297CTP*9QZ)S0>URIW@_B!)J2;W_/NYV$IX_^.(+Q-EVS\U
M/3,?2VYJSTW>V+3JVOCX?*HMLL:%1%02V@3Z 9-$D8=C'I7*&:5U-3^JKJD4
M>SYSTTR,(/_\PQ8!S?IF%:P\4M>&+PV04D>'%]U$FNZ9=APWQS_@KBFWB:5_
M51)X"T@45[N'RYP M=H)!@VUX=R3I%UIE"G,+UWFKV*BL[^L['+8K)$T(',Q
M5HN?'$QDM0)X=Z_LF,< R-^83PC;>3Z(%/S3 R!]HR\\9Z<Q\<['HTE]\%+8
ML>RLLB1+V^Q1[N(0+I(K)KDR;]N0BO*,-BEC;&*@QGLQPSQ;@H4(JR\]9'(D
MPZX8B(R>?#CM0 D7G)'M'2%(0K)OA &N"T+:3GX0?M5S,5,$W]-V%G976'G&
M^H'&R#=8<NSK_P>:+ZKVB-4N?IQ,64.@E1RPS?W4\C%00'TX+:-+2S#2B"F+
M'(%6KXJ]V+\%_.7<J  J,S!!6WE%NB_Z4PQ*/0/JIX7G/*?XG6&H-\G_E/*9
M2(F<:X9;'ZE9(H0+Z6T BEJ0TFVX4MAKFXD+J"O:<%Y21A#2!G4G93HN7 2R
M-ZW#"Z9VC\OP$>D?Z.H#9*L3F:(L7$P8N'S(Z6U)5(Z*X[T--2+UXE2><+9]
MM/LM?DH!(Q>0SWL7P:+KIL!Y+R/_.F*]XX5]>B8T,_[3G;200=Q@.;58'N;*
MLM?UT/).[F HAH=5>!H2]^QO 8B6KO3JFJQE4&UT/%(>('XQ";R.*+H^(+\;
MJH:MRZ%_;A;F)/YQ?@3+$[_ID=KP+L $E 8)W *Z]'U*I36"7!^F:E=TB[\/
M?F7E&T>7NOV7R93/>O3OP^+_#"R!^C]/R\*EB]+WP#QR!L7]2P',G,2@!'R.
M/X%!)E/9F:Q^CWG,WY<..&O*L;!@R&*8,'<1^(C[%A"C"<H"UA@2NCH[5N@/
MTOG1VUC7E=)RKL6^8_ M->Z]V;TS]ASFOQ#VPO4PJ2^,-(8>3@]^#0IRJ7/B
M[/T4XKV6RT,.)G: :EY*O%D7:+O6- >ITJ+X^MY[Z$9.2Y,6J*=&JK&:_1S4
M.G*,3F9-Y8A4FH4\^'6*5YPA.E""&Q%^0QV$M[(#K4.8P)6D"-0UWBLRY)*9
M];M$1-@"I&R.(;BZB1U(O5B6ZM1]]^0GWP+-4&B##/*2<-K*J/I$3O--9,!N
M.RC*U@?0O1N?648J%V.AKR?_)4M?&8 ->&#"6?$X/3?!^>6=7A54^%>>Y4A8
M,J 3'/$5XS\,_#$<K7+M<$GUAS^CO* @9/AOW'T%5%S=EF81W$.">X*[NR?!
M@[L3"%HIW%V"0P&%!0CN#L'=W1T*]^ 4! DZ_&_-O)[WNE^O[K]?S\R:6NM6
MW:I[[KGGG'MJ[^_;>Y]]_<K7"6-*I;;\X/;U-VHF;4Y C_,%;A&]?-,K;[=T
M*QO JWB@XA.<#>V7C $^/^EBTX&E\P6S5 UN1R#G1549=53N"Q-\6@Q9JG%C
M5YS. :; /FR>6-/GF41Q%52?\?R9E+!;_@2H\?WL[NDX=IPANF;0LE7 #3=C
MV?2!&#\.*Q5(/6Z+M$'P_2Z<P>0=?'13YC%\)4 S"#X/%ZYW]0#?D.0FR+40
M2!"KHV-D5?4,MWO\J3@_G.-_3(<W$1<?4^+_:>V+D%AYUMO"QQQCN#;NZ@P"
MV=V1)>RX Z ^-GCQL9&1%P8@7+B=%]T]'D81+8QLI=Q%;.5LK/GIFR+OI"Y6
MLMZ$(<'5,/KAN6^(#QQJ\C3<T]=!UZ>/,FMA88GFM;)#J=<-!]%8VG5==E++
MK%P=VUH%D^*$\X^$D[7="+=S<::>CJ2?7$=1OKA26M0!1QY1W^/5A][;(^!0
M*_<7?OD@X5=,U $/;?U7!"D3^]._.$S^G2T&PN'_3/?P(L1"$?A>'=>XU@1+
MD-;#]0^MG5R7)9JILXZ\\(?(KJ/)YEL)J@4U)FY.ZB02SPA&W5^=O>'HR0QS
MO&X+)!,Y5/PZO:#V-?.8QOR/B?1/,RS^22?=5JT =8!%6HO\9D,.Q KG4^TD
MQ.Q=00R'Y6A].F%<<Q7/PGS&37V?(/$A5#-6+*P,]"4W1?OT<=BG:IBD<(CJ
M1]U-?,RBL58,'.7K&,QH+ /WVXB*J_DP-GL<4<."W(=$CH%MOL6<84\;X=?]
MI,YX76Y O>G/L%*H:&!%>5&!]]=EN6@?&RB1:Q )M;FYL90K1DPNF\+RM1/<
M\/V'EV+^M23NVPF(_4D()M18XU2"009Y\2]E =M@U-U&%I]3U<HF&.+L/?ZM
M3_$C2=)1D>D;")_V^$B?E(;03$/740=RL "EAVA5+A28H@_U/J@*5A:08ASH
M""C-=3(6I[P-S[+8 +J5%S3-L%7P ,- HQ7)WCOW,>DZ>*8?E FWZ(CXB831
M -TS+,;3ET9P>>',5$Z)@<-=C^M+0GBW9B\?Q$M-L]?<["G#;W>G5DRGUY3
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M$J!V\&\.DCEHS>'_RJWYKU?-4$0LG19:DMXLQ3#S[\:7C![XGO,L/0'FFYX
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M5?8=!GYL9,'@C=UL3F,]Z98CJ)\@F?;-AWIGC$,WM.7ROIT@GA-6C6UU](N
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M#LHN%EH&D-Q(9?+FZJU_:;A?#06^AMK*MM?9L&TU^&N_X&) X*S&0H,U!S@
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M%2RPS$_(GZ07LV+I<1URW"(FDECD<1ZJT%KRS=SE+J[FP!\O&L.5K*-<@'\
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MF AL?T7<V_#W0K&> +IR?)ZQQ'(*Y699QY]C!%5MQ@GQ-HT6G@!XOGM[*D^
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M3B[1&VH5),M.WD*$068(=_:16NJA5=G9]!HJ?IG&</MJ)/4C8Z72-/R,'*Y
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M#97D% 3E2+$(@7>;,,O \'18GW3+(K4F^HM)J=*& OZ6AF!D'=C""M]"0CB
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MCC!3P%[E=F2O-+2Q@R\&OE:.3_?+O5'H6%DJ'G@S&1-Y](/,S;'XIU !-BK
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MT[M1T/I'T];S1^<GP L/JAMFZ_KQJGUNN#HIM7D#51DK5'/E54<9-^^&=7;
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M?OQT==/31<9ON4N(@TR)]@22%!Z]A18[#RR:IV(G(I&=UL]MQ=+E,<L*$
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M.U3$>Z4V1GF]:AA2Y_F;(NA+H&7,Y!07:)B E7NR/7XR%$_:QRKTC@$("C(
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M(SZBPBKC>JM-/RQ%WH$67I#AE-7EH=W^]G!1\0_39YJFE*J.LM6<'U/4:9&
MDU</=?W];9<"JN+E,\4J"Y"7KRE#Z"VBV:T)2\7$%? UES!<*9J%+=>;J68_
M-DS.3 [5-"Y?1=E2?#S?^G3L_"8Q%$VR#7!*0TW\+9S_'_;>.CBN9LD7;%EL
MD<7,+;#%S&RQQ:P66&1ABYG! HO! HN9F9G18I9:S!:TF"5+S]_<V9EW9W;>
MVYF)C7VQ<?_(B.P3574J\V15_K*Z*FMAUKOK$7;58\W3HP8\N=-&'N7B\B/_
MWD]A6E>K+MR.6[GT2D]/5C!8Z[3R@3#-8J3W )8N6L%R"A'W0EIR]H8<SFJQ
M*:G7H[R\T,OG9,#$L<N=UO64-"4RVE[*:N#E[%Y[G7CCI>Q)^)_\G-]??DZ?
M-J\(<@0!#V;YX*=9.Q&&:]_AKN9_C@Q$>OZ IO:Q>H$BA&$I/4Q/%GN 8^#O
M/!W 8^;L#ZIK>DGOVF(161\\J_$U]+NI+/L/!FNI-U<^*?83R7),]>E&O4S/
MW>E:EZ^;W=J5W<3)5?I\%(MTS71V/ -]AO<BNSRPMKU69HW]=+>.!,!'!X"9
M4H8_^E_<R/Z?S2#Z[ZYR&V66&S@O&X!XI_ 4/MYN_-SDD&?L[V<[ZIF*T0N_
MX<^AC2A0**4MHTW^YU/EE/]ZJAQ^6".>8#Y:FQ[N,=6'@J_@;[!"<%EWZ5EQ
MEKJ^,62-7+XC+HF@%\$U]<V8Z)'LD=>BD7)#/<(A<R0F\5<)HC%U.PT@5O9-
M#P664/ GOG].*%QA+-ONQ+48>GTY;5$S;#3/<O%2'\@#&CA2DO(-BF7W=/U1
M_EX0>XNOP,/L?##\4@#/W!KIF[$',*,]%;"F@92C;B3:#5M=4%B)*U[J#^B&
M;>#_ ]+MD:^O"W+]>5DP5_N*A[+=$Q0[DQY7K=[1=&91!7];3A^<P+?J2LFN
M>?B&4OV<1UAY6[<U=1T!5E101/LPR"2N]Y L:QO!<%"IAYH9U&&(\$\8\&UJ
M_ET21&,.XE,$.<.B906=(>\+\Q("8<8]ND*23ONV%=)YB)@+2.<>U:O<A/I6
M]F6)S)C>+S-XM\"($E* ";K'/3/$P>"7!1:T=JE=NN^T2SQ?Z03<7 8]!@ *
MDH#]<,![Y&ZZK&[5:5$R)]*"S- M*(/&^7I1R;K@W51_EF7K]_)CX%+<)SJD
MKV\.*&'@986N?LUGH'_+!UG%6]E;:K)981WXS(!R?SX<)\/2-7E._TW![:D3
M$SX\W:FG%;]+_/ :BM;7ZQTJ1LL=1@\XJ C$D&E___0U,_;N"8IJODF=3/LX
M8^LBT\!WW?;>!<D?<TVHE;,8P2&4FKKD;-V?N7]B*D^FC:28,?L L;GHKT/C
M*C**]+#QYX%12KH7&&%9^QY51(.KF:YB,,L!-PEC=OV>?UP+!+*RW+<+61FP
MP]L'QU%HC&+)=I_* I]2_Q;M\-F%)0"%D3JQQ'!JY*8E*5.J91+S-=BY9]#Q
M!9JIBU34Z]L\G+O">F= #PV6YC,1#?,CAMQKFI(P2)$?X'WZ@YH<Z!VU,9+K
MXK"TU]]C&O"HEI>S$Y!E1V^7'*9R)^9)71QZFB5^=22=:*QF%(LI>8M@\>;W
M7SL_V&46M#-YGLK?9N7@/-+#CMC9N'P\#PG*$?/)7STL*=8=,O&P%)!E@DBS
MQW+#-,B5)GU!WSB:A!7TG/2<;)QR]F*2TI=:E*T.?+1Y:&+[2^M\ BFHZ9F*
MUE+_)!;O*X!T6;<B(_%H19QY0WUVQ[+?9,P4GUX\Z4@4>'&F*BK9-, D660F
MYI O^IDIH%D:F/D%P]M.W#>WU3K-@CE/O3GP?:*^J48<+."G8SG'ZCLDH;#2
MQZ28@F,5H&YAFKD/";@%ZPC^^_L;F(">;%264#F_K7?1>L8,$6TE6SN$40=Q
ML3'&^9@GUJ4X]&]SU '9GV$@2?YO=SNIEW5'-O5=+^4M#(Y(^5W"OT3B2YKM
M(AS!=$_P;[="0H[64=HLF2H_1[O3J,9+?@C10BRF.)<$.':].ZDPO?>K,) %
MHZQ)%'ZJ^30=^*N\W7]-E)=P2$\+A/_X_17@K,;,M-G6$ _91BIJBI,35*4W
M<Q$*$\14C49@B['ZI_P"?Q3S3D=WQ;VKMZX'C*JF9^58/P,TTM7$2P!H1Q>1
M.*D>0PI.:SP<MC)@&O5.4/R*V?<8XT)%1<)5^5G$TC.[KVM7>@2K1QDQ98&H
M!K0N<(,R'^0RA^"B!;!UW'PQSR=RW&CF#T(Y(]*^*1I8EN>Y.1W)ZJ4"N@H.
M%QZ%$RT+(>]!UMJ:!$$D&:6L[%Z9']8DP';P&>VN"U/2\.UR6+S;RJ7A_ !$
M@/K<?_/OG/\<X0Y9/L:$<[5!374V?MW&:F^,6!(I%,ESL&JHQ?>ZD \<0OP%
MB!C29@7U[;B_<>V7!D[L+QR65U)$. ]-JOG7!!-GV5/X(]A[VEO-=X5?@])4
M')-M2VX+ZLR2D*G=]XW?Y.71FP+CHKK1I8NST4H9:)_Z(8H9P&D]O:8TE'PP
MCO((=5TS8VEIJ7PC#*^R#$GZVS2YA7*NX@(OPHQ(EKU1DAI!U8]+$X1_K2TC
M#1/"$0&F<FM<E/ L(%Q]/5Y.'^JM*CBDP8PE -L0+4D& N%R:9+K2O/^%Y&6
MZ8:G%7EM>9"VY08XF1\\-N@J4%U&Y5U3B?-%G-"#^EX!X F/.\D2Z=Q<#Q7V
M*FS%7I?8+VAWQ6Y?(O=H+Q#?$GNA8AL^B%-==>^2: KI-6SD'"V6FM%%T09F
M%&H,0LN(XAV:34V$?- !//3E(OC'/$2(P94W\A^_[8=^F?\AJ]8RKRA*<2U<
M[YZFTSQM-$NV3&7B4B)F\?*9#@D:*(5T,/N@C+"'.Q:EI;-PP_#D@RZ/(@]"
MCFI/YK'GZDE5AC%3UU+(<438'J*CAB5DB;;#U3],F[QU_>$!.YS@L3#N1-IM
MV ;T,A,/]^"UB9MME$&4EG021NM<;(@B&M*:9^%<"+R<_X)WVZB$3<V*>%9?
MCD3R"D#ZO]9Y_I/TWW7^_\^I&6HXT 0Q[U?@^'C)-)'L9$OF$6;'SF-.G\(W
M.-.C5>C8^Y<UQLX)ZG@@]D<Q]"5-=2\X2>T?::'J&YKPE\;:\WY*#^I[.QLQ
M\$@"B:V1'[Q"'5PS996A])#67C#N!(G @5$5Q0B&.6%:))WZALC(>"HL6-);
M]=*D'< L20D(#'OU::X,6+QPD;LF?(0'KX M,VI0CS-X?7WUV*YH]&!YHFCT
MC4(!C+*NN DY/5S@BLP$/>R413G-1=+7!317Y@)(W>^4OEL=W^G]'0'!C,XO
M)TY1'7R'X_HS#65H5N\-!LU-4!X<AQB5<.*X.4*D8;YO!K(CB"'X<]*7$A76
MF>3E2UWLK7'@AM-3>.3'!B0T4*,.P<:+[G0X"5->S+D^?HESR)4]\+-<^YWQ
M!2R\O64,8/,>(D!KQQWLE7#A?5  N-9K4>?<G_Y\DNJ<XR+GGF=B(5MD,>?T
M-4)7<2UCUEF*:6[Y+*,VJ4^Y@X;RQ'ZL$G^3TU0?1]6,W0-4%1\35;ZH#=4[
M)0":( K1PSJ&5YAYX>5\259F/"8^>.-.AK^Y\]V>P/F4 ?'C!>Y^P?DKX,G7
M8A-453?)W*^*3:^'CCPAK++NS^_)$-MT(5Q0 OF5Y.FM&5%Z1.1I.,F8$\D]
M'=LB (.Z6_>9>6LJ?O7S>J 2KL>=)CZB(LM>>=)CONOX[@$O6SN"_DI-/)(W
MR57D9W]G3BWR7$/W,N6%!@%0E+S4I?-*?: 2RZ?OG#]-9-&1FRD5R4F)"WW*
MJO]K-YC^-\]>_&=H\YI45PA1^0+(<TO4;?D'4(3UY:^.U5*J T)D?F:*G>GO
MX<#LQVM;X_%;6;&OZ.MV%E1TW,R"=)G6QB.EV+\U<#=O!(OV,WP6\+%"H_[8
MVCGK;6=\;E73L#/D9.92G(>8^%6^5B\N6-C8=ME?_3/8 '#SH<+/"*' C*9@
M,FUWQ+_W?28MM1 /)2)9GF T&L#C)C'?;1VK?K%!7D&7>$W\Z4E&S]+"+'.X
M%AH)!209,GYXASDTYM@\0LKSE=G%.LWK%0 EM*UDBM^-($Y;40$+UH#ASF*L
M=M":81L< ;RGGO0[,KDR.Y(R4_ :*G]"?T"1,F*B^\\5]:X_ 4QEMUAY:',,
MGF:J2^:2'6(\PH/M&W-[F\!"R6%)_8ITXN1&?,A7S]$>([>(+&1I.'$90A3Y
MI[.US8#07>\.#]Q#3F7$%$X>A^.%U@.(MZ21F4M^GQ79D/R56;C,<@0P3I"=
M/ZB-(ABPN?M[=76*T[QA49!+$*^U:[F]0LH#.&<L1B581>S=RXK+0]K/#'.$
M!(=I$/H'5[P",&T*YP212W1!*[).P$SM=T.$CGUCJKXJBY$+6M^\B?.6&[\Y
MY=Y;#:*D-'AI>=B4J^A38UQA:3CB+S:XU2LC$A<IKK^;<P')KY"*RS.,+K-4
MV-I @:WD[3W.1EAU# @CA 04D22!")T1'F56GBY["WG&C'F)*R>N8_F?JG>"
M6("(='06@S" J]257']600P[H:( 9P&O%-,0]Y-<K6C)#\/BD8$8% N__VN^
M_;^T)_F_1/;"=--V+B)X&[)V=LQ2P6F6SW75>OG;,H.>YA^*R!(W5$3)+(NT
MK;0@0R$W;5'<IPO;CY>71WNFD:>-FE^'WOD*JS4H?[XKSFWH3.YIU0H*^>'+
M)2_?YI)JR93Q63W<+*X0V\3D35DL+-[HY\B@&.5<?\%MGP_7]]1:_MIZA+L7
MV(IQ82 GNA6-IH#(N'ISX?3KX@J;,Z+3B?GZXZG;=<;,(_&%2NR?#GPZL#N6
MAC\\$ -%>8>K/OUIYD!YEIIHO\/-RZR\/TB]*7/FZ5- JHPVB.H'KBBMY--P
M-T.THA0,=>YY\$2%DYW?[SRF^8$_H\S$R<N*J2B)*3OC JIGU 1PK11%))V4
ME00XO+!X#=]TO(^[00&1T[HDW7V:'9COY5MN$)D?5B%   8?E0U76O=!;'/P
MTO) (P5'RD)-X729'UND765^T'XX.1 ((16SB4N(W._0# =<1F1PJ,9/ATN4
M@823MT$1RYV3EJU2(1+T.I3HD?$[[KPPT1P!Z>K)CVI'W$0-T*9G8&M4?^V2
MZ,P1]WM ''6SE@"5=IY3/0?66,J@O2*ZD&(X $/"P"S[GEC&+Z1\<1VO!JQ?
M<8K,<?C+G*7E]D9_^3"FMX,['' %_3!QU?<*.(\YCC^\B^_[_0T]RP>'M6[<
M=K0AL3V;AQ6N^7-V7*R#O\.T9>M"3KEUU"U8V-H'BR#,\@R<'ZA3"/Q,);SP
M-H^/L3T>\,O:-QQP("@ %B1Z!82;_D&%T=;WZ[3.%#)=YF%F2@ZQ4M+VUGG_
M1<# \*^9K!;E_^Y:/G]^@SD5R-^71L,)+<+]YN57-L &<F=:%M+1?@7H E9S
M6ZJ@"GXO/A5^9R&O@.WBE[G%5\ !9/'EWN[E@S^_+D/JWSV)^;O"L 7_J/Z/
MZO^H_H_J?ZN._^]V>.Q31"AWS.>UM45SFHGZ2R$1P&7N/BXJMM-GP^<UYZ;N
M!M-X1G\''#%DM<RY%.\SX';4* [$==V71CRI&;X"LJP-G[;^_ (<6E1:_]T3
MD0:N5\##;<,KH)/XKQV^Z$GA^UU__RSO'TW\HXE_-/&/)OZ_:^)_RC4Z_;ND
MZA4PV5#U^WSC68,YS<Z#N8P).O.A/6585'039N-0E)3.ZM^&S0K9MP6Y_MA6
MCV^YJ[+_-UQY%I9[R&SO(Q"2L3U"E:,>3:#EG" S]#9<(-X"5NMOA2J)%2]N
M2UOW0C*V#9'U?CD<*1K7-O,XK#)TLN/>[AA19_,='&IY.UT@RIT+I\_H^158
MH;:$#/+T-;]<;$)5?F^+<(B2?IF_Q@$;BFEWTEQ@N;M)1Y^O<(WW7TF#P;85
M3>.I$L'Z:Z$E)XB^B2#9"V.]D7+(T<+%X6(J]V*;1MIXF-1HAZG6A_Q(V/1B
MBB!14K*_M:4#02@2KLL%67$L-<2UJ%&)GK5\-7T.;B:@L9>!IIMNUQ?#_.E\
MWA\9='<%)7:8)!0N)(M"Z^W01\K61^UN6[IFXN%#F)YXS )&)MRW_?FA9;_H
M(9V!2>$ A7_F:KDFWXGER!<,<;++0**.="3K"#1MTM-O 63?82H:?.")M:8T
M@*U=8%MKK=G&)<:W%^L/1V[#LO#<+@0 DFN^LCE FM:4RI^"3*H+7+S.^GAW
MZLW2[F *CS430,U;9 IS6$%E^/&_O:S,LJFLQ%+3[6<PWCY<"B7?!T*QH6/-
M?Q6!_G_)#1N^$WUA3N@K0\VRB!XVJ"\BYDY> IQE8AR*$JW\<Q]P_J4W7$M4
M')GA[ ZB*'\30M,PI.&7M\+6L<(7""%5R"\.*MFH;@2&"=Y)W#)1Y+^5495Y
MHC8?= UTT'[!^N.GM^C/&Z(;;NWJ?$I0/(2__&XV[O*"%1*BAS7_MR962G5Y
M;W6'=VFYXGP/7?C8@5VR_L"GQ%+<#3C(&7>JVKD']?)+AX'K'\A(%6\9U,-E
MW[ CQA;N^$M)<<0L^ N@_;NO\B]<R3%1.C]SA%>I'G4[=ZS@:8V_=C!<+$=
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M[)"6PFZA<>U?H,;77S*WER9;3   TG6[W7 .1TJ<, >Z10&G2GVO !2QK=_
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MY5:;%U\5=<;"Z24#Y[MBH& H(#UNJ.JRPO-<:ZXA"_.9?LIWUN?]7')_C>Z
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MBG09Y'>FCFW,DG<R,M4:?V6OE#1%(A^<,]U5H8&NWD@A2/I-OWGPMD\MGX:
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M"73U.#30(^BCF.J8__]- %!+ P04    " #T0T]6^8"0"EC_   M/@$ $P
M &EM9S$P,34S-C S-5\R,"YJ<&?LNG547-&7+E@$=[>@08*[>PC!@[L3W IW
MAP1W"!K<O8(4[NX$)X6[2^'.\.N9-SU_O%[SIKOG]<Q;OW/7M^JNM>\]=;[O
MW+W/WN?>U\77=0"6G)2L% #F'0  \W8 7I< $@ D! 1$!'@D1$1$9&0D%#0\
M=#145#1B'%Q,/++W%.1D[TE)*6E8Z2BIF*E)2>GY&)C9.;BYN2GH!$3X.859
MN;@Y_]$)##(R,AHJ&A$Z.A'G!](/G/^/VVL7 !OIW1]X "P,%> =-@PL-LQK
M'X#B;9SP,/_2 /]'@WD'"P>/@(B$C(+Z=@$8"_ .!A;V'1PL/#P<W)O5[\T.
M@,.&Q_G (8Z J_(-D<H)CS,H(0^)^G---[[JU#D-EXES,#(* 2$1\7O:CW3T
M#(S</+Q\_ *"$E\DI:1E9.74U#4TM;1U=$W-S"TLK:QM7%S=W#T\O;R__P@)
M#0N/B$Q,^IF<DIJ6GI%?4%A47%):5EY;5P]N:&QJ;NGI[>L?&!P:'IF>F9V;
M7UC\"]G8W-K>V=W;/SB$7EQ>7=_<WMT__(,7S!O/_];^N[RPWWB]@X.#A4/\
M!R^8=Q[_N  ;#OX#!P*.N KB-R=<*LX@)+S/"7DUW<C47*KG^";.4R@$--P;
MM-!_4/L79O]CQ(+_7<S^3V+_R@L"0(.%>9L\6&R &.#V@3X_$.6?^/>!(7'+
M>-B1CVT%+KM@IA$$%OVO'](_\4_\$_])J S MX45/V\H*MM&#'YG.GD[B?H*
MB,-68&JEY*4'95[%11@R@>?J1[/4U%(4!&6#XKFM8 =(T(?(FD$%,$-#![H:
MA0>GM$PA^)MBF$^VFRQ&FVBZ;B\E-#<Q>Q94D8@H,OM<D/:69#G[7W5PIWA:
M8;U;2CA6KP"\!>G9:]F/-7IGE 7Y %.7'S1!V='%[;9]#R4W;"'7(E]XR5$]
MK"8?/7M>"M6RZ A2'15WP?@[8DC79]AWB;<JS7-N#/8L+%OJZF;*J#43GK"Y
M:J\ /RU,ZRTC"IN'F0.(18GP+=ID+:W,("S--7EPU;?M[;GYX%W1V/PV@@ R
M7ZGSD#%TT&>SD#OUYI!WC=5D').;_LG'$-Y68+6G.[K%+%\2M^1-=KF4N-HI
M$E5^$;&XD2L/4\9/K>]'%*0\/NF :6;CVG#RKYWM[B^?_#MUK\^0#CT$)W]<
MK4@=ES4U_1!*)B(>/OFR/X%R 4]SPUL*$KM+@J(_4<9K'T '68L$S\8R*V4S
MS6*WXYVN>/I? 3W]T+/0:J"]KZ1IQ\CVJ7H*?'3R*7YJWHW=3 SRL 'R,/4*
M?;F[8%%Q7J%XN03](\V?B.^-1/J6.5\]0&2S+PQWO_K>SS:08]91X4\,: L/
MZV-N"0RI7..S%S$TVG\'4B^5@KC.,2.?S$N/9JS)*:>7[%3.$C<V+W29]^RE
MV/\.( !.?;2*53-)R=+H'//;A#;%8GSE"SUW]Q1G> 0H&S6BS.3"O1B1#T44
MM%JAF/T.Z$M^K:JX?@E$#IS=N*"2,74SS#[-"O2/22VS^D.W&4Q)YY@QU-#L
MZ,MZ>?235KBF"/]]N@(V7U+RCK C?<+H#B:;5,%1JPY\U2+S"_\_X>2R.?P]
M[Y!@1>[I(/G<E@S\-R2)X$GK_ [?UH47.L^O$@%EP^XL?P/[>PH3&A]9XEIS
M2GF.7I"A?IW1KAP^I"8DX4NC3=_=W?E*;T0ZL2&9^R.H&;>?59NG50Q-H12;
MKMFDK4 2*9DUY46TNLZQ#Y.?"%M-$;,1I V7;6V,\(]/I&H^S/I/(*9Y#/R
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M8*,I>#!K5XW%_.[CO<BH<7R?*WGF D^5K1A:FR7/;,N/.NN%H7Z"$RIC"]C
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MWOX9A+>Z;'WV;G^!(Y"2=>#+MYE2 >*5M7:[._<U_8::9)['(=;3KX4#YX&
MKVB8+6U[(A4FD21-VCN^#AOCTGUO_10K.:#=-)([6@_#!@VPE[2;C*Z_ @B/
M6EE\I3=1/6:^AWF>*"/XNF\07D].M^-$VBC Q^KUD>-G7QPIS-;;IAU?HPNX
M2^PR<+28DB@*P()V;43X>@4S7Z@, OH(-4$>:!9,GG9S;4U!D^,IV]D*;O6J
MN]],?\SY\FQ623$<[S7_N4;U&(K=O5F,V%1[7JFHQSY27?'$$,_=OYD7#!V7
MEG6AP1WJ9,+QP)+^ENF] )04M2 0:">177@%-)C-\:S(\8H:I9)E)0U14IQ@
MK2AM/#-)]PFZ0AK#0/5WQ 1ZX9$?XN-S<_1A=5U5.QK)XGAKSM?Z#'@'2(04
M?+[&KN)#(NI),<NB>/YT_-J<_W."9\L;IA[QZP1F0S-X0Y8?<1O.*:B+[ 4\
MJZ(PLEG39Y6-T1G6SU!]:/37?1+/G&!-/B*!-%[<8D)@^^&F=.N\)/Q*QPTU
M -.&E^&;[^Y7_;!+2M-N>G7C'%#NPX*').D8L]/[DF P@UV]#O.U4;V-MUFH
M$N]S^KRJ#!U=(H(T[,QET<P3&X@NY@,4H\#C&X?5>X:"'X+A=UW(\1X8832Q
MQ:TV]&_JC7^[<RI]!?10\*:R[)0;HIZ!>X9T"L3H]7G5*0P'0*,; ;A&=U$R
M\VXDXQS9(Y_>(\&6_YBDE85+$3YWY,=?F9(60J6.?P7\<-"JA8X/-)=,FLPW
M1D8XD6Y\+X^VM.>GVSGTLQ7[>N?#?@Z\"2O3[Z'-V%^69(;[+?&6P05EA\5Y
MG^T7I(?$$@2@W,49Z,E38!WRLA4O\;N\K9.<Z[$(3^?\5U5L=U*G@WUX"RDR
M\!F0>W)#Q:=GCFA_GED5:2Y4TH&8C=%QH0'!B1KN>)[V<Y7W!3A;1(=(@X>V
M)?F1"LO?)/%4 ?F1]/]1P*:=AX6Q"8L^U!D,PT:-%G#[J^&&"!S%"^S6^RKD
MOPDHOO%8Q:ZPP]T%]#5[AT0MNJP)QCL]<]*^C#I#N .IS5PMLI[5YSUG'&SW
M$SG6 @"CO/S",($<P]5!P@*>G5B%4)A$S%H>4-)OCK76V,4!_NNW0.([QNPL
MN!?&8^UK8+F)3NZ#S:U\_U:_  M=AIB&-]I;M%1<<)4LN25@LGE5LM.I\7GP
M?I'%<4RW46\]X_3I'$!6T]&;3+HY6I,64L(SUL[W0GA8,)7F2E)>!,#MGP@N
MH1?4ZR>' MM[)1L&?GC+O_"CGS'(5-&IB*Y_I54[#)QQ:H?B-_,/PC8(:=+%
M^O*5>L9.]'/_K=K(@ 3PN6X'S41_4_(^W"_,RNH9S(FAV[3W@A*DOP+\W]PI
M>KY_,HS-$OH<VT'[_?BW'E$6*MG.[Q4$CK@TC^K\2-]NT]29)P$OVZUQ-0,O
M2MY&1Z0I_-CS3X8%1"^XJS579V%)<0A&5MXQ8TS<"U*;#,:TP:0 KG@1#'_P
M/I[*6,_05I6K&(&!X6* [1$!]._?>+F#$RJ1"4&OL*"E3*>%R/)L;"A"3OGA
MGMPL,\Z@AO-T&[1.@< E*]=1:<P[X_1?GCB<P2ZNG'?C&R>?-[$I,T?ASG&Z
MR-EE*'V"183F*@PP^U.U&B@@#_UM[NYF."T^,G$NL=G?UMWW2-TV6]__PW%&
M?*W-K:L]+Q7J9T X.O:I0QVQ!!.STL/+TOZ8%,>1UQH:DBBY\+  C)X*\>)%
MR/*HBX,Y$+^OF5.>5*[R7F [*&E<-Z]U'YFTY-^2=N2]4M_RY28+U\OS6WU*
M#/J4'\+$!!\KI'<>LQ?1)HW64G_^"C!9DOKB#A5R\*!.L0=0!(D@EE7^Y5;0
MZEW#O#[AO=E%_46_Z6)U.-ZN?F,LA0B"N^;9=R,]EW"![166959D/Z *U23_
M05[OPEZSF^$0)BQ1=<?V=0:AR"R#&UH8.\![.6OIWOU$8[EOZZ)YGE) WEIL
M\P!W$\&3W-2 M8I K_P.D9$KD\+F:".8R4J5B$HF7_R'S"QCZ17 M>P?&D5.
M"=-56C_L@@)\O*Q=G@OLU6L1/M>2+SE*30U-N'1MILJ?A^:9G]]<]EXHV-GO
MXL"[65P,G*8+N3QH6?\CPCD[68E2UIP/I)L6'VK^7M'].)R?R'ZN*(+,U.2/
MKR1Y;I]'&(EK,-M9>U(8R?NE<8;*3)H&2Z<NUDNTO:(I/]:"@!^=:^.XM[L1
M0E[D@I1B6^"$]QNG&P,/+1C!FUSD4.>):5/$#<CL*U&ZV/'+;F/RKT;;:# _
MR677UG1K^1L!,^=7P'G,2EPX X@Y'I4'?"'<EG7_8$KT9.WJ@&%HO<HQ[Q91
M&%1U%AP^1Y1*-*@L):9F((+7G*;]5NI)_)?OO/WW8-LB22)+S4@5/#;F"""3
MY3XLJ H80E1Y!8"LQ:YP%>SAL#QS>F^UD.$[6HL5N,-LI,F6[<;\ (@T\S]K
M!QU0Q[DC2%7*+#V,\3]M)RJ)Z]-(*"^(DD/VIZSXY&^BB/+E*R(HL4I&..A&
M/_B+GM^[Q NZU[GY5?3YJC#:U!9Z?Z'8AU:JQ(_?&/]U5D\*%2"BSMRCCIR:
MT?JC)21I[H96R)D0+SY$E=*TVS+/0X$U;(X!HLUJ\U;GH^E'^[JKR<J5JLHQ
M2$T6RC%A<Z [7PL4YBHWM!%UG#.[*&G IOH2.#!&+$,2=(_@W$>:C4AD.'Z+
MFK6"WP7QC%,&&DF9=32WACZL]SJ*#E'7?ZW@O&<=JGX%>%1K8V=N416_3,^G
MRLVY%92-')@&,#XG?(O[UAAKQZNXLM2 L$W>&WTI7??-I:ER:1)KO\6MN[%C
MGOM1IPMN4&2$&N!-BIL1)=61H](ZN\N*GNE!+OD;8/Q#F:QN(859;)TG"JZE
MT%_H+2C651Z?PD0N!$!8,TA]JZ*!,9</JBISRZRNL$93&=V@!<W?O#9+[]?U
M2U)(_C0X94OC[5^/?[0%U?:7ZX@,?+Z7=PRYD/HTX#)$7.W2]]N&K];3Y40M
MP'+RN9@0F!G%&;<R)&&?^&&H>XMH^WK]+9++KS!_KCE4&VGT_Y"]JI'"WZQL
M3O-4BJ%=GG2U!1M9+6D;,ODYO]F/5\%(/_'TA<7@>"OT1H8*K$WM.2+UJ/@4
ML]V *:5OYC0H( B*8#NISMZ=?]D-8%+6\P@F$;^1#!_""DV.QWFZP)X@B3;&
ME54#+K)ZS&IQ[!YFS(,KEB"'M=93UL?Q?52A L*#]*1U9ZI.ES A3'\N#PR/
M=.98'-A<4S)YKE(U-Z=5WE=3I9X9D^XYI'+L"9L*%+V5+$:2>.IH_QG[+?\C
MB-S=117R:&K)YJ>,-M].[BF/4U5Z5Z9S%_5EUEYS=51[YM326"82M="=TFV=
M=-XC3E$8O3P>^?G/NL=]B-:<Z:RO)'YR[A1KI6]%DSWZW&P\-I$4FGOXMHEV
M4&,ND6G2X@%1<76_2TFV)S#_TC*%OV#(X()=)=$10:F,TI^'UG&RW!:UT$8W
M;XYF3#>O+A0;SX= K+[<[*DU"DACR3]H=ZDP>\WB$A#%FCNWNLI"C0Y$$2=&
M\TUV)JU-U!+]0:XDPN[#M\SJX:I%!&DH*S+2\ZM0B]U@XQX^7=3/'\1O"\<Z
M5_&PNP__$$4*,UG!#72^?U*P-EM(O75/U4R4FS;486G"^3CSF%=#84]R%W02
M2O->Y!>X9P\HZ?B@65(YF&>ENW-:1CNFY2*5ZIAFJBZ91%_D7FKL\9..)K8=
M$7_*T_MB2V7F_<-&;2.NS#D:9@I9'YUB,X!BX&?NGX\L@Q%7J/)AC<T+W$,6
MT2>>VZTQ.DIY<-OJX]76J+;PHS8IGU<W&B08FA02&_,SUW.*7'3A(&,>+Q\(
M" AP>Y\K6'5]%B+JP/Q=$4VWXZP@2S^OS6?XHHZ,'A=KMY_U'$,U"3M[MK($
MBLY<"8NFI+O-^,>$@K9 2_GV)MZ;EN3,2P9CTT@W"WC_\RZ!+6K1] IPEZ?H
M[FE/;\]-CEV*GNTODHAL/IF[I9T30 @B+,L"7;;L%@DYN9^1QLRQVS X]$OS
M\^5?+^PT34X,/':87@Q1DSXS<A&\/..O!_O5"#-]WM]M'KAHK\>7^1802()N
MQ,GRS752A]TE/1[;G;NB]XCQJXJ'*XX2#=;Z*]HS'5>'X30KX!R(9=:LUQ+:
M4KKW1Z-C^;==(<NL;GA:M-95-JI&2_MGO$>+U\2JFPJ1J'KY]Y%.T<X@G&V,
MW19(NF3>6Y&K"B.)I_Q?CV^P/GZ;Z)__N@G]L@).4T6@?/$R=DD<&@0++FC8
M<I4N':HY\ II?\5%D%GT;59YTH%S%-B"!5L=B.;,C6E876OJ'AV\ M" 4SK4
M1HW1<FS&3356&WPDEAJT!60RB]I.@V1>I.H)-AN-)!4DH_SS7&SI@F4*!=5R
M7 "_6 8? 7<&C>]'S_ZAR?BIME7]+L+8[45SOYO@JU;-E6O7+:-QQ ?YC3%$
M0\&,YH1DQ"H9B2THD8<KK"<?&^)_RQ98+8*4D;K[Y26I(F\(G X@;N"?S./X
M;?(XA (T]%T30E#UXC\L%G':4HG&/.9+HD2^G:W83VU.76?9MIJ1'L86W?EZ
M>H><1M0CYC[J]90)C28$E%='E^^K"$,J36;JH[!I3@A2-C:6>]E"S'N=AGK)
MTZI:UC<6J'ZISVW.MMD^I\S?3J+QOICGF[#C?8^@9O:BRYP;S-#C$'H/]62%
MB!V?NXG(SB@F&([P>M[T())(8=F3^!O]<H+-(Q9H>;#SMH\+@ =7WJY9I^CH
MH@^A$FNG$)ODT@^?97IG5*]2-L[,*( CY<=M;+<33G8#/P\H_[!D1J'<:#GG
MOQ[0%"/X.PFTFY]O3%K1%TXH2F2,D)!RH@2.80%%9.U(HW$3)/:^Y7E\FD[]
M\H>Y?HXRC0IE3"RBI>9)]F.%TL;T0_M\D6W%(8&: 2-S!2#DYS$<9B<)]NQM
M)1,F*=XO%9\EVP-8&Y.1^3EC(U[>"PD[2E**-/8)F6V7QHS5J+[Y +..C%.2
M7PS,3GO=@K!4WV_?YIGW]+NU@+!;WH#U,C?-2\^E_Y ##]/2(+B9D*,MGU8
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M,_$!9JX?BT695<RD(<P*@Y 0$$3B%5!PT=HVME<L%B;B.>DM0*1_:%7-I+&
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MBRAQ\F>:2 ?7Q6 +F-,SX IEE7 U;"\\ 2X+H[I]]RA!ME\C?<U,YOQEQ6R
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M5[L*QNE42-MZEF8&JX4TDD;31<>"4Y7S'99F9&?W]8SAJSU:^^I50[ES&35
M$!]=,OYC.?<Z 6N'"X%IJ>!K99S/M$:^C1AZ@%A&AB6Q(4R=VI>%7L+JBGAH
MTC$^:#*"G[C>K2K,8;"'QG,R4*>Y:$< ?SX43ICUN6,805#%2Z4J/D/\8O85
M^I366/S:!-$4#5XI63^O':::A36"MX.+39+>PT4AND;/PU<=\[I.!L2YW7[K
M\//QA)==:#(B?VWSX^\J&75):JI#'&ZSD4F/@"%Q>>;&)X"V*8?+8ZPZ<)DL
M80$9$"N<H!0K$.= W3.98("F9#V,WK"*DW=P69T@.@V@V7IS<&\UC_3)S599
M7M9TKS6L4.@4;2:?);QX>?C*4<\X153T4XNN*&=I'J=[U="0A4Z#JRW)5X4K
M2V$$_Y2T,'KI,7[%64>NEQ*4\#2LRCO@(U_DA)]U]5$7KPTN93P<<LLXUQ/6
MR2<: RST[PV24KXL2<YN#HC.;,F$*855B06)T4 Y?F;"6O67F$%5T1.*&C&%
MT89/WF^]9/871#L@S CZZ.DJU,#"OA@ZRGJ6*\3S]?Q.:=3^W&7;JD?]5$M$
MB<O=[T=[$$41XC^5R']KJ4T-G#8$(G789)(M62G?4;WD20$?%N3DZKS/SU&?
M'6J7PN)W0]:[P3?-.)AXIR0\P@R^T3@(]Z4[O 2\JAH"\X_K/:I0.K2L\):(
M0?K=V._,.'Y0,5$K^%_>X5>EO[JL<!(ZZLKJ&HRS[LT'G:6+D'-QS*A7"5$)
MF0KK<2>N E%5%DKF=%,6U2!WG.%ZTX6A.!VLVUVU3X!:N]1UQ>Q3O.QC+PL:
M6AR+PON\<Q#D%J4B*R4>$#FBKB"SOOSNA6<^< /N"7"3\".+ZTV]VLZ5:E+S
M=ZD\WQ\T)4*]"T;'K)QW>"WJT]NS1)/<%!H=U/S&XTH1G2[<4[U:G9[JD0U1
MZW+W!@-'D9OG)-_U2)*B/=6B]J='G;;6%8+MKFQ$5@[Z8X4T<K%Z.+=/<B:@
MAPY5)0RW!29?W8Y7X=BIW[Z/*HW7G5LY84?RT7^T3CCOWR=.[+A#+[ZX<\_E
M>AP:1+9$$X+"#%7+UW6)/%R^*.%T7=/^Q$SWX$GP+)ABG]4(W0WP8!78%3JC
M!!#(SGB)O=9T6>:CG+^AA*RW6+KL?)??F-N9>0X_C"8W43^E'$WFA4G#<6MN
M'H=<$0Q79$S35.WG"P>6D# P\1$VBCP!)M^*;F*\\.P[D)"RM4[OR 4;.\R<
MC9A>ZZ[M76;HOZ&O>9/L8NC?U)&>F^WD=Z\6=<6QHXU/$(3!\$57.H(6J34+
MX&B$68+4D*S0R)$GB)>%3ZXFP4UPJ5B^.[[.LZ27&M\T9/T:1Y2R!S7.T+P
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MN@8GGW(?#I0+665=X4_-_>V94,QKJ;#@FU#H_C7X#4P5ZXB.,?_+4H[4U>-
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M 31#*N>OQ"BBU*[QW/[,KYK+[:%K9+]'<?7'1";A0WYV <RD;,ER5]E*:+U
M9</HF!28N-8]TW4%U0DA8[LV)JMR_9'747R+*5R/!=E_DP=AYF0$$<+1NB&
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M@++;"9+8J/R9&.521H+%.*M)5BYQ0<B+(/=V5U_P]ZHS+M;C)7+'5'&UH<;
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M3P()M+>4=R5!;9P!%K=3Q\ Z57W:K\))>.6'N:F8EN,F"^^#/NN28E&8VE0
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M5M70VT'N8Z1@BKV969^8Z=.9GB5O&,<)R"G#\YS=LE%NE@8W<N?('@6GISV
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M58M5S46:@(:$SNL"K:U9$A'J[1VV7-#?_HMEL4M?<@:">$O0L6GKS%$F3^)
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M-^K+=$\,5'L_!<:2?:>(5S3LE/7N]P%&24K]Y?:*$3<9Y["ZP$)YF;3-HSN
M'FL'7\*LH_@DMJZ7*H![_-GDX5P^>P1+DT8G7L6%L?_@'A'C+LGJ[5-LTONH
M/F1@.)?25]U)5<76%B>@X9]4>Q&']S0W_83L"6,L7L40BA/0%(^0PSUWC!_H
M78,"% 8?MB"=XG\$__96^@*/5Y+\\V[Z#MP4=WG/\U)M#9L(UJ"PK:%)U0F9
M<^'/= 02L3]T)A.(/D'IN3,^>C].=:$U>ZWA6[E T_')IH^WGV[CNKI8\4AW
M(Q/8AQO[SXPHG1:LEU5>5'-27Y(=[NMT=[<M]LCEMF\B1G\L/(_\9LO[:<(>
M1PM4*Q W_ZYC("O,+FZKZQ[7QS:NA96M,_)]<J"B2>8J2J:E .<',[W1!42S
MAG(LM8."I/U,'^TS/?6-,='"4(E%'Q,+C5<&U\901I:RY"QE2]NO9T;NYT[!
MN4P-L%:^E2 UV]+6I:BOQ5_ZNE.HC)(EH]=E8NPZ>T<^]1SN0*P'4GVDTSP$
MU)Y&U,6NL/$->]L//B?3P,V#IJ*=;R?0_9-[7IHQP)&MG;2B9A[:UZ#7$,GM
MO%/  \ JVZS'<!SILPQP^8*\5SDV>UN=NFI J?&+1%*=U'V=KM,Q&JB$@X@N
M>K!OC-36%)UDATQ)=<.?_^-U<I3DDSNZ14,FAF=IY7U6#"GI3?<*:P-*^L3,
M%.X@>_?([<3]&TPU$A:J$U(]WW([*V]LYU9JX-T4].50G*+LF"F6L"G$]"HS
MOA>(VR$\WR#MF$>X6YL14EU,WW"8H-)%%1 FO-OQ^"5FVN]<VYEI?I7OND4Y
M#F$,[FLMD$JX*1YD6>[S+067GC[BK"2%^*L'[1<H0WGH]/J*@\E]%F="&$VC
M%[J?1U+4W5;(FYP>Y* ]\EC"Z-YFPXO%[NWP\]&72U$KAO-.Y/)0[.>^5!!J
M.EW2DYB=Z(%A!0G?DX"3A(%#Z2Q>G/X17P__5:BX:FM:%:.D:TV%VA/7TKIJ
M';Q3@#MC^?)7_)F:PNOW\!RM*0IZ#KW0CTTL+Z.<^P%B/7Q7719B0I.PWI$6
M;2I39,X>_ B5=0>PWK_JN341\5WWVM7K7'T0<P=8?:4"2RO  )>(F!" XR]^
M%.J':3O/<9.H+@* :(TO\-\>,9IKHR-KB;<2&8FKT&T=3;XN5G[M4BD"<!'B
MR!$.BTC/2?;@WTWGJC7T5GE"/N+",=H?M-I0^EX X5()_;2&Z+H#D#&_P>C"
MN*MFWP]9V[#6\+5U%5.Q/'(FG(B QH5U,#>CCT+L5SI)/#@S%TT$;M8Y3\*D
M<QU,>X*X(!=&+>CM$"$IS6$GY)J"LBI)J)=9\->CD+EK3C9%=&"$(*.%1GMX
M?RJRDB*DI:BC3,Q=C$$0P/-#WG-'R6=?J)UIK(^.:RDI(!3J6,#WX_%*G+/O
M0V>ER68NCM7S$C)HR<+^$E?+#%1PX.25@R5<.4047R<K^-EKG)7LZW%\TD?J
M4W[RZSD/ASW6I$R(&3ET3.OFD O?E*1!? ;BFZ+,S[LVV\')& 8OT'9/#&CM
M2'>J$8D-TW[?2$B28WN_?&Y41^YG;-^#LRQ@[_+OEN)FWW.8Q)7F@='!\?D?
M?07CYJ&QQ5'(OGZ2GX1!&W4YUANNI^7O_W3/J!"73^ M^X?ZI*9[@#T!E"Q#
M9PQ<35YAJMZ)$+2(K=V;L$_?VMM_JU%O]XAT7H^?P8%VK\OZ,/9,)L0CR^73
M3/V<&<;Z7%-?\+S1Y$D]WQA#09B&H//*!GGFO\#I3 ;73CRY(=G[+U8*GM\^
M1138S.J&30/2](^9&%!L);3[(T83?ESE!KT!E[.1/!Y1\TWOZ)?X2,BY@9P/
MLEJ;-ULRR3(W<$,14"%(P,,E;,M^W^7T0)%T6#^;B'UU;^@?8VVW+7-%H\Q$
ME2-0]JLI5*H:^E0\)_I,ZBGWJUYZ8^YGX-82I+3#'FT0P_E&THC[T,IB#JG,
M*O J('"<-!5YG:,S@,KH?'<K)*^'9LIS"2S>\V&.L)HXDU"EK/;NSU=/>D.F
M^"$69TQL*)<L<#6@QI\C"MY.L[Q_ ;+4G3 R#'1Z0OU2?R5>XZF&8Y:XEW1"
MOJW,[Q8C3QDD]<45;1R29^O$RC[1V1"7Q1H7V9SS $NPW]O!T3'KV*;@5KZP
M;'B_BK3O96&3?9@F&:7LRC/1,Y2Q<(1UZ>]=E_F]EI+SHK4ZJI8K\>XF"F5Z
MZN#@X*-(P$F[TBU%)];P<NR:M?-WA].Y%2SGIFP+-; ]L,S3:;258?M7U$[7
M7)W .T"/SDW$EG_(R<$=8,[$D>_8<7$K@&:PW4NW@^E*)!K._-"_PFN>R[SA
M6++-_K?^X6*V6VNQQ ??U:,&2._;V=OIN@.JD^X-;^\3R9&VPS&:^1VW=,!V
MQT/V0'1(5)C6^7[4?!I/E/^Z2'K7X447):+7*5]^+:/,_(I_WXOJ!Z(TZ2+N
M02)EY':N&&V_FT]XD-!]H:AVU9Z YTWC3'^NAYOPRXVZV;,6V%8XF38\H!H/
ML,(\9$8F>]3BH:,5E:;)5SIGHSAF[93:SI%2A*<T@!'F8Z.,V_Z).T 106MD
M[U^'Y77+F;1F"O= A,;-77=>VG8&'-S2#*X;?L/9SN;YK#G=P6IS25G57&J;
MX@7RZ%V@?_%6[,&.(F+"4)2^6IV(<?\[1K<N0%*')S3%B5ZU>%<X_D5J+^9/
MJI;R<-;)6^\!0O.AQ5V3++?5HWKL:&^?C-W\N:J*0UL<C\1%LD2C=;3#;NQ9
MZAHSOHGI?H')N*2\2YX=['Z(-P5^MM@XA>+.?$RO)!U@O?X.0 N)4T$31I1D
MSX)TJ_FXTSRJ#/X(M/Q\_4\1>)-F6VJ 7T)/K0 BTY=.5E.RU+LVC-(EDC/6
M7-;.;&&(I0-0;SQI=6=KMT%B>4;0,T6%V,\&'3.%4\%7[TZ$N]K,O#_$I?#R
M99)=9\XX)J&OM,)U$8<>1U2+8-UT"^\4X5I0H1S#O?+1KJ0G +1&@ UN!H:[
MKGQ^I_-18;AF6\S!H</,=*(G 4"3_[79=>[&Z2"H.= *!GGM\*@O;BU&];WO
M_ [7&3UG!$X#YXO!0XO!H?J$6!71C;/A#E:(UQ5;UY+$5,#T=B!84, [P&29
MT[%OP-7+FG:'4^DMUM?S(EUGH&;-=U%+%6' @3C]8_Z&O(GY1:+<KU9?:^8Q
M%MK9)<XI=QII]KT7@HW $J/7#0EO?^V2V\23<$/H,]A)]#B<H-@XM?1Y3<0*
M-LV[S/NK(\O4*6I&ZP4;Y'[;X( RFRA,QQ0/I,H127'IY@9>(]1-?)A!(JOX
M"*?6%3+JS&>@*WT/PT Q;VCB)SMU*.CKJ9E2,U\HP%_V1^?P\1%;S6["KBQM
M8XL)="TN4OSPNZ1&I6VZ#CRK,HR>.(YKN-K>X2-9=_>H."8[>7B_K S,3'BT
M/BV4L5LEZ&\_1U209-ZDD/:0-K!-\2#.&2@*,ZI!'_V^-JT WP'LEF_R\![^
M83*1[.3QDJ@;]?(A^5C#@?5L9**8.7TV;:Q>5*H2D$H$^/5JM*K EL,97\DE
MQPZPY>=!T)@W4C@G=1&UC?Y%%?VL?6(3Z(,(NT)("]0Y!>![,).<@=4TY)H,
M91X9@6NZQ71\?[SS>O@"E_R'!K?/]>_MG+<>1U_:U*3:O\UTB+?!I\W#AYJ:
MJ&S01B1)3?-)<-.&%5^=.\ #R(<V\8N+U/1,9'%%:8O4XD9"I=QYU?2#J)X@
MF2R '5C\6<X:,;#:SCD-I5I1;S@G'^^*:Q8=?2Y)MRE-)T=9G\T=<C_QN<7L
M]IN8QR_+OT0# #N<K94R9%BOJWL.GS3@?_$>"8I._?W7^?B&Q+2KNS3"&'W>
M$\JL#V88SYR:XLL]4?8@ $-5OIV<Z__XZ>MDS[,-"F#!^$!,]HCO7_.L,2H*
MW+?R?]D[&D&@_$!]-80/,1[9# R7[&0PAB0?_HH1BC08Q'GG_;92/VMNFSV6
M5UP7!7 ^EZ$(6"PU! 7V4*YS!DKKQ(TV338H,:F+"#BN*FGZOY1ADD0>-N9C
M7Q(]D"\5,+9[5Y)3.Z"H->]K'BA^Q/F F<P[0+0%P[F81@=^7!=[[_MQLG[-
M7]6I,)BYYY*,T4.L]6;-QE&G$AGT@M7MJBDBY"DZOPN?3>&2AKB%R*[H>J;Y
MKW620L;4)B05*@WW4T MJN?@HGI#;_,4H07M<K1V],G06(G_$15$S4^5,?/\
M\LNE8X7YDY2?EP#:?';S8*W>%XQ*/@6Y$-;#,6-CKSX3EAR3Z2=?>QW8YHO:
M/'>6?>W! ^OCC44 #0R^!TT;Y[.B(B,-RIFTEZ;>+LK:Z@F9;?:$2_A>SKYK
MI<*-'!&2'GF@W=2D9QE.YC=05W/7_ \L\R0.GW]L9A".ZRFMR3S<-:&9V)CR
M*/LE+/MU[HO:,Y4=WMSLP)<; 4"LCQI'K\ >]4,UDI9O_:N1ZS>6NL/'O;27
MW.HRR%PR'#^-RK]:$/+6Z-/?$OCQ:O9U+<%/0=V7N2&!/I _=;&NG'53;?(>
M;NBCUVT8IG;?57!&^/'A)+TPM1<)?ZN%$=6[>/HG&A_FJSY?2\[8<Q^&A_G9
M>A7LIFH)3NIGB![>$V!H3/GE&K2!%J=KA6+)P/M2#W>SGW363 OZ]RQ_R"0N
M<5X';A'*\(E> M^YR#*8A@A%93A%>"+54J!K&8NLAS\-Z&\I'K/7Y='8I 6)
M=F\'SW8Z,!/N(F]AQ79,+/]LV-+.OIQ9NR25[J]2;OA(V^-='O"'!#($ !3
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M.3'[S;-'"\\X8L^@0""8>*65F1Q9F_-2XKY'E.#MGQ3>RMS 69WKI19C^:Y
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MU]9Q39(.-P?]N@R\Z-!;MGM6Q:TUYCN\D3OI:F&BZUE"_D[/U;M.(=ZLW^,
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M\;PQJ$Q8; 26L[]]ZF(]M0/)8/<#+:2EO@^#.:$&/K F-\N_5R'&+N7=23.
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M&"X^:!2"^O^"SYVTA=L$[N4&JXU>]0/<W;2SE%%1[\,%6R&T?8%++''HM$>
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M7N#0&2L[KP-+&L#+[WO2YPCXTB6AL&^GT"93, FGOJ0ZG:]7]GI_WD5>4ZP
MV*,Z%9GPSB'@X$CY6?;[Z/FX8.B S5;FR5H#WY>7=&^H,47 %E!MF__V&<O_
M+:\MSX$.TJ@!(T8Q@U0GN_=1'$IE33C4=!5R<D]/Q;5E934MX']2X+:"5N9>
M^KW3_Y#2 N9O.P(X#"&PHWC-!TV39AIL<K^G)[5BP?XSE(F:1&+%_TF4WS5:
MYD9/4+ORX8?\GC-&EI2S]?ED1X*U2_5(\)8V[,*VDNA_8&/%#;2FMX+TT>"H
M41M'TU7:T;0W1TUT(2&KSW%+#O OU&B\(NX8!_2,DDT? ;B[R<Z<>K+S[J%=
ML1(K?L5?!XBHF:JH*JR[Q2*N(^+\;/GM4UK&BA0_^[;:F^([R,D\PQ /VG0\
MN^SW92C(/= ;LV4H*=3=8+%F;U3G_*56C$_XFFE:(%V;R*E@Z2V<L?8T=HWL
MC^[$!'!M4N1 FL&W0(:\\WA=BVKAS3)=1;<<WUBTXFVB?1W2\JK@$1#B]LWA
M]%=3#-?+F#1JS#!+Z6>)XB%S6G446@T+BM9.$'RMXG0*7,2SR(XO\@#?3P)_
M^=5F(#$-Z>802PRSA\]URC2G$JID&&F \SAR6TF"^0X>(WG$:\Z9-8&O^#B'
MERM/'LSWL/CV8N<ZZ$-Z;HGZUK@'NR@UU.S]G7CG?]4WW7W0R,4?V!F&%$$'
MA#WWQ6^-\K9B,+6;*<6R(@J-)LB84G9G1&EM]OFZ,ESL!M+S;'T$5"A2"Y=^
M#^QQ-E1QRL0UJ;-C@@8WSM7\9!\!)@>/@$M,H\"20Q_1>C2DS-A W\"&(J??
M]<U+G5]-YV3RG=2 <&#E.Z.>_1IFYF)+T^!\"^(#3<BERJM)M22UAIGCG)KX
MQ.MI_=R!I:-D3*  1M?:88OP5TD>+RLUPC6]]36]7N?;L/%?).Q!A<2ZBR$7
M63A>]]Z+Z-9' $NET=#DJ?8C0([+7<PQKM!FJD[,*-/6G)1^+*6*4TFMY!FV
MBJ>U?;'>L+TOA&"\+80(?XB>RGV;@0#@K?;UJA+_2"N <*:-'PIY5<!0Y'"=
M<IWCG9)0Q.=D5/PD)%GD+XB&/] 2L4$IR]-'RX-GJ.R_^\<SS8_H^JM2'%>*
MHHX%QL#T+,/5B="R9*IUH,151;HU]O:]"I3L68WBPP5&$GI6D LHOQ!M_7G&
MP2DZT/5$ZX![HW 3*LT@>"TAI8PTBO!^5=.R$8% "2\[<:>J"2%+,TK^;KRC
M2FJY;]O4?@>%H3WUT!M;1=,5QV?<YC4ME/S++4T<G[8_CG8S[R(:_(_J47))
MI>O[>-9;*V7BK_,L_XZ/UPP["4B;]!V%A#&W7/2[9I$@A4K,X;B"F7823\9A
M+Q/%]>F?S?7C\IF[1>LG]K'3LV/&9JV#.B-.(%":8?P. 8L$VKS7S4PA:&VG
MBI5>QOXSG&$ZA<IKY=_G>8SLLEVW^-D3+6?'AJ"A<ZE:SOMLJ1-)X_A6O]6]
ML0'):^^U14%PBE:M8:\G5QV/*\ 4?YR*A\JIC;PE^F90#Y#59K2+EQX7;DR<
M5R_O^;#68JUS6V?VGEOJ+'[^A!R[/AF6FGZM;V-RD<\WNB-'Z9M5_OMPL!D\
M!4SRVNLS(ECHH-<[R&)LG3UUVO4B5:RK!XSBMZ92R8QY44](7YYI@AVHA/L!
M>US77/PL/A=&[?9;?RD&'I3O5%[VK)]_.&N*7"*1FS2HHA;X<PGAWE^CC1&:
M,/<H;92T>+;N;-S"R+R+V>"C#LS6LTL3^H+R-$KO$Q9:^+2FNYPIMHL*YDE\
M_HW<L(E12B/+_M6D2AW*Y5Y>DO'\$5!S&BIED<*R0I<*_65E>7(3;!';/-E\
M%2.O,"OH14&@IEK7'J:J)?Z#0A8XAX/U.<K7AO-D9GT9=S.8M_[EMR>E<=+
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M:M\S^^\E%O1_*[._$_LGKQD 'CH:JGCH1 !9@#RTH[, 8>0&NCQE0P(HE)$
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MVEVIV(EJ*K%!F94GJTI.DW4GLEI"+KRMPMD=,^3(1R1* !2A;=W-3N.NNDA
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M=CO7[Z>^OX7^O@M'[8Y^/BF3/-FD\*Q%S!1[%SLR?Z?!YS6W<YAJ3Z,K8@B
M/O5RUP1G!0G FX,!.P6W*]=S&*2(,[_94FT%-$?7"4_!75C]GEM^?<BL'A$D
M&7"D,OVB&VJ]C 3$[;5"XFR9U\T! A&!=]$S%>D3-X:N^IBU]IJ1@+[=HL,O
MW<53!=!:A'33/=13'E4!]ET)PM 4\M#L63L9D0GKBJ0]Q_"!:5=&.N_E^C7K
M"(+WY:]6/D2Z!V+PM-W@GXJ1O2^JD#9!T4THBR"1-!7TC#]C/6I8/10)9$!4
M2Q#'O^8HL%\\OA7&H:)F:LXU&-K 6_%ASJ[EUOA&J\B']_N\I-YU9VVT2[1X
MKE.3J9.%?OB72G#6VEE1_\P]I7[$@6?YW.75X433IM:1;#5(IC^Z\MOAN@7E
M;-UJ 1U7?D)N :?#PL2]%'7.AU$#(X:7N[YB $$@4^>+\V=B#$7EJROC<\HK
M7-*WQI" [*TSY]GBBWN 3+BG&9R3(9C:SM1K _?]1YX36,;! R4&]K8+LX^R
MP2X-"_D7 _7^1<J-[GV'O)1':%*$;68!I C.A;?'^%D[CT%Y0OU/W9KYVG2/
M8M?LR#GL9J.I^+-,Q]!09 )*V9UL8312M84<MWGRBWS)"J(B:J;\XS7#P*<N
M^?3/TH??*!2-BBH'_/1RTM&[#)*2(UA(B"@' N2/V1 2"K[1061^XD^7GQ,N
ME<V?:)G.19B]K'W1,;FA@00 2OG(8.Y2MBN!V/8>P^15X\PZ]2>/7WECS96O
M(P$O1K9F)L\VNZ?7'N"1?^RU)Y=M>/'J6\TJ;(+,>M\V]^+N8GG79ZGX5@\7
M#WK:2J@>&-]>M27.:\EWMI8''3!-T.F.$9!(&-)$DK\K2RP,))@#>M1X1#L5
M0AO"L"//(N)RW7:[GGOQ(50'4$QDJM=Z0:.]@(&:7)LKA!>[WJB&9K>IJ:&I
MO$_ZR#P=-->7V;Z /N08E;G"1VR"+R_NM4_"A2V-3A<9']4LDQBZ>H@.>NW(
MO5'5=/DLU2]X?X,Y-H*66$SJMAR=]VIX%U2#K>MBFHUE<7#PJLKN$,'D"FEL
MEST]R+S@L/]CDTJNWN3RJK-%-R\?3!CM1U/@9?@(<M4?,:DIDX/[A3\](?B.
MA2POJ<5A1OT^"K\A'9]G\,@;D@K*30RV0<3KZI-)RD"Q1WP 0@N8=B!EZQK:
MTN#%:3RJ5X?DPN:Z]S(HC-*\B=,"B"8>IVU\J*^M=XG0$ZR9X*K]O(]K,L(T
MWL0!:GR2F^>8@@2@?WTLT!UL=%N\?8=00SG/BZ&-GBE#C4\)RIMUMY#9/)+;
M3''-G9&4B@[:*%9"C\GB1P)]1B#CW7JBJ<<#246H.$8C 0ZM)ZK#AT>#"P$'
MBQ#Y^2:WN?[A)KK"71G^^([8*EMG/!#MT9$N?RC> OSDE,6M_--FARR>6^_D
M* BN5BP]Q[/^%0*6JGXZB7A2*W]@9PI3J@Z\#3>=S!ZIYJ@:)BT=G>_<RR-A
M?ED5$><,]K6NEA-)AX!4,Q3K)]P=#"P'UE[[E2_T5UGO-I)I%JY-@!QB$OZL
MN>P#,GA1^=T13NQ*7VX:?9Y011S; R; H:4-PI;^MAJ^+7,OL(>Y'0DXW5B\
MP--Q71FN?HX&4RO]$+<P](%?_DXOD[=]%3V0T:)9"]:%!#!&8R$!DZF!6_>T
M1U-3\]=;\E0X.96]Z;5,BB !8'P9.NNN\Q)$=,']X>Z#J;FI<S 6G*"IO/GB
M8+ C@ )FGP\S[6R(['_9'-V?NO?UR70[05M,*3\.>FP/63ZGR4YH8&\1J6[3
M?,1S0B!;)S"$^B!>9G*<A\VWSGFLDH01[ ]\URIO(DZJ"120)Q;\PGSS#XVX
M3@B ;+\%NQ'FNKQXF]EF@7%LO;[QQI2"*]715"6>];D%EMBF=+_9C@G]VPXD
M@$X(ED[VYP'(HN&5M,RS;9@8(V&>M7H!RUK<I_F /'519?CKS.7S8"D>:T<I
MJQ7<=]4XDUXU%8]5" ,3*P>\EWS<BE,V.ZZH!X&C<*6\G6,3F)WAF]7&>!N2
M^\$OGM&Z^%HXRG5C%OH9"6:&261FMMKHOS9L^/-HLJ#&%;9147HR2&P,4S\Z
M&)JK>841NG^+]T8GK8,XNV'\N7AW09X1Z9R%J#1B7^%N^4KL7L:]:L@KN/A0
MSAA?-?9)9Z1,.XN*:(]?96W@5Y_HIR:.&;BCALLL&=R"\_[-5E/,"RVZ4D/I
M(IM9I^71*Q3PV$.LP'I"1)B0$FHO.?MC+\E1B\TEO694NG;00#L9UD23/^U%
MHPB5>2L]]M$8GLPAR/7-4>F^CB+ RLQU_[&?!,2A]>VI;VYKBHW0Y4.\2E5<
M=C/E;XH/F2OITTOR8/9,L-3V $:(T1Y>&55]Y9R/*$,,P6W4$S]2XO8"+HQ9
M* K/(*J5XSZE7R_5ZM$4Y25%&9TRR_:BX;2/@+:6G3&WA8W,K6'W5BQ8JK'R
MX>2E>+[(VV: I?9<(W@!^&B5;!8N5@L9@MF78Q\</G*9$3TK8GS&O"YRR+>^
M&;%:9N&'VJ['2:[RG=]%<3=3#LPF<&7*:\GSDKOU@G57HNR+LFBEPN<O91)4
M"#H(\#7\2>'NA(1B3F%R3;#5Z(*>W$;0*\E),S%B9[ 8\ZZ)Y\WTKBZXQ[W.
M1=LXC5M@18(C)RQI GO?-@DD ,X<(#AZ.'TVFWSD*. D5;,4?[+<NB2\X]&"
M%]ZQJH8HX]<>Y?D@\<[U7%Y&25:18&&*K*I80M.VL<3F679^8K08[.VR/_-G
MB>K\]P5&\T#G-1S>%&M-LNC[']B['W@/8NC1OAF1R.9X9O'B@V7\MD$ RX0E
M%.O-*;[NHXT-\QV:X@(%T_;[#,&JRW29D!0;0VCEI>*BAX]%G\&$:(3T_A/>
M 0.Z>ICG,@C?-FD4MFA<5]U4;_S%VO+#)T+7ZLK3-JK5NR7V# 15C8/XJBN$
MF'8C.[I)WT3)CU^PWA=G^[ EWH[.' -4>;NJ-!.X; [<7.V]E#)1%#R_-XB0
M;JE!8!Q<FKX110*Z"Z;C^T\&#!GR=S9<4O+VO:OWAR:&7=<J0) )PEL*2]&W
MI<NS"I_' ^5+X@#\ 0>/WK68GB,!S4-Z<5X9A(2&.V\RJ!L:ZRN.7EHW &3@
M:=$-319T);4P4R2 2;:3[Q(S^HI"VMO=F'TF-QT)*"$1/;BC*9JD$"5D[7E'
M1]LRS@? -2ME6!KXN6X8SO!ANO9PG\5PMH+&K(X*3R;* 'BY4;?X.H !,0<=
M;QJYN^L@Y5_\* H7_36#<2<##*>\LBN9 <]/=87J%!_8V5!81_G6DBB3YP8T
M^&IX55P:J*5EH#RF8;=-<&OX3S!L-%L)L]EVA49*.*,$VWPW3K20=K. 4SO:
MB'H<1H5J@(?D@9.4L@GCS;Y6'V"#RVH#\<N]VZ>8(Z3"C0-U"0)!#Z[&=QH3
MG.$E6$O6\%=-3Y  (S.$EBZO7D==\^2WI.1#D@.O89 B3!"$SP4VG1X5O1 I
M8HB1 TNU?R5! J+YX+>:UL9J)DF>S,N[.FZ(9[G'B=+IO.R1?5?^-6;S;=AK
MJZ\']K .>1E:J&->G@.3V#,971=7JF^H9QX=4S-N1R02@ UL]U<U?#Z_0]W[
M3:0[T:RI./:$WB+Z<Q[L;6[@9YL68BCYNP\BY<1?'[E6?&&Q9IB_6F*[2OD"
MZRV6HR_(AYETKU<.[X^KO (?Y0"N2/FN3NPS4V?8V^$(4XB:P]?9RTC@2Y5!
MK' RN6?\?P#06=*439S\J%8R+\BKH^%HJ'U2&$@)1KQ/*\/N)F85Q(2]%^AM
ME)C9E4DU8]PM:;?O5.QBGB+$N3JTA/Z-FD*V.I,O>8TP.=;H,(!DRR<Y:.\T
MW;-3HR;5;(COBRS>K+(XUQA]&[VZ%^CNT"G^W=$NI\6=%.^Z47(]SZK'!')8
M=DLQ_ 2+O1"0%A21UB(%>40O,.SHF&YN?*Y+*"AP%Y.R.(,LN06 X7H*Y733
MDQ7*. R\ YS_I#0L@PZ='XRPG+QS24HNX9_^CGQB*+J!8/G+JC36?0 HLVH7
M6+N3E.1;<Y5M^=8S?P-=MLRGH&WQV_O6W6'9,Y^C_;O;W.ZI-/5H'#<[73[2
MA[=EKBN(%0[8R<C'-ZAEQ$-G]D/#W/HYI7C*\F)LACRX.QF&R<O\*+2*MTPX
MAQQQ[,7+QFOHP_M*<Z,#*!#?R)16FRL+(O;*/R,V?$FG5G/(G@UNZ1V3^2Z]
MN@KO[9)(ZW H)>]Y,HC^8L_[#/V4+!4)\-1%5',A3*(A.8,4>TC "M8(KG_M
M/AX;QWD0XM 3(3\(##C=D*$0M>CR 4YY7I7L.WO[2FPZ74G[EQ3"_(M@H X/
MO8NS6/-:'R%3GA.7AUE>@$VJ@?N.'^B;=W4G5[@I4A)$6L@A'N]S=B9'<-V;
M[K.X+3BIO'C[:L WVJ[5AU=7K_6TL,K6R+K;]V8UM(]"H[.8=V\X/43&6M=*
M'$6PKT&\( W8H4\MO7AMC3(ZKCV+K@:<MZ\O$#I2O3ZNS;<W_J4(^OV[?C4C
M:N<D3QS._N%&S,@(M?SM8;GL[]_Z[P23:MS'MODP?+W98Z>\_MPILI4=?JK.
M^/OWI>N#6D7K^X;QPXV_CERTZ^]6U_^#<OV-*FEFQ5"UT-%AKEN(ER6R6\?,
MA7#3I,*_$*:ZXICI(%)4I)2U"U%D]F8!*#'"'V)8BZT199RN:>OJ<'!4C58:
MJT9\<]OR24I=.KQI0Z%:9!_ _W'LZ8M00\,'#-YTHC>Y'YYUCZW4F])[@8%4
M]ME;BD/3;2W&5=S>N!GZ9W.^JT,$SBGK_?JC745C90K' M/OXP>YQI1B&^EA
M_8]L#8R./"U<&]95>LZ KR;/+FI##D[\Y>3O)KLD?ZQTDTOO.+)B0]PTT5E)
MMVU26/&7U_ES/T/3 NL3 6G@(J/>\V*O^,\RU!#_@[=+TP>\!^Y\<2L'EISM
MDD$JY5XL "P7G]/C6P.OI;]I5X.N9)N*X\ZU@69A)T J.,]PE7>3\M.\!?V'
MHF6KQ?%5 B^#E"C-7 2UI<1!6R;,$"7XG1;69G+B69E=R8EVC:"'7[;!#S<!
MK]K[O=U)$>6EXQ?SWK@SS7L^ Z'+BUA>HIIJKII0]Z1\!W483^E9O?7>0[SN
MJ)Q\0O'B!6*H>TL9-,#85[,N!+R@OZ8M2ARL/\8[;A0?L11@.9D\K+9\&&#M
M,?YJQF#"@-J$)4D<KE72C_>61=.DKV?+I10W#INY$.02VL5/&$+D]54!U62J
M1'C,/_&OYW)3R#[X2K.= GU^:Q;FL:GCU:3F[6QK_E32JA;C8SPS'5D=^&!\
MR.N\RT<!D5K@Y=KQ<#M'W^I<(/'8:#.-WJO7Q2=).-W.[RB"I]:4*8M7>\TY
M251Q5+.F4?PN59*Z!$0.]!A6@!FV(HP$O$Y5@_*F<W79TYIW]YD*(UQ[J'H8
M99RCP$TIX0MNWW+STTNMJ:;%SJ6U5B9JK3RD!'D3BPR-5!U(DD2.N4-$KJ:I
MVL7$Z:XX%RKX@EO8GTS;">[6S-!78SS@>MW R!P%Q(@A9(F1VW)2*HC1U+4G
M2- $ZDR.@>P]9@TS2CP#EP?18%R:PVYENG36>N,4EJ-M:%%"C*#'#Y?(NUG6
M-E^:&&,H^KY9)GAC:9:5:U8LX!P'!/B.N>F,%GSQ=YP62+ZW8TKJWB_ 0+@5
M0#9TN'^PSV-!*!2C0DN<8Q>D%W&UHE0'XD8M*"WMU:]!FAN>TKZ=*0.I*ZBL
M+]S7&M)S?1#I0>:^KY^D@;Y.46%M &3I$QK2)T,"V+>3*#P;UFO"RF>ZUH%G
M,60L=%XL48)QXJML3$U!X5^>CAA(/MD^WC*M;MDZ#6V!;':T8N\8!"27=)3N
M&J1X.PBWX#GS8F,QQMQ+.HQ[N*^ZS#5/8PS3\%XVG/<856V@H$DLGV*?;38B
MBA/L82Y76C=14U9;'C7<]9V3SF^T\>E^=5#53]*>(3%2,+Y'K44[;)A9Q7BI
MSNR.>2\S5<J":M>(\+4[&+(97K6OQ<(B$"U*MRHENJ5F/JQ=Q-H?D.WJ8YBU
M9THNI913$/IAV$_6U]XIN1;HZ3'QJ?25^'Q(]Z-*:P3ZD\R;PL:2*A.GXL(T
MEX9"OE8Z]F%)_-V>]_4C)M]1JP2'JL07^'?OF\K>6X S37(+\5$+S22.&,I)
ME[2QQ"S+D^M228?V3GSR>Y[UQ.:B,*[;N&+<O-&6I;\T?$&O?_@C$'1<;EXC
M)4@0[%S&8L)<GS&K;FDV>A_'\D_G(7JXF[1=FOBS';XZ%3VC@AHOB\ZS:,A7
M0E(3=M\K\@E#86NV#8N/[%]V#(F.=]3\+H5&C( LH^+>EN8'>R[Z\7%J/H21
M<)TL!OPIF-;G9Q9Y;1M/\F,$WJ>F$3@!6>)CQ,$2>ND37CY^M8EE@3W%<<W)
M9B!3!\..0&(XUU.K,CNHS<5!1B.Y;X2W"P&:.,L- C2P'-:8^]$M+H.$;WN'
MS\(BZH%/AY(_R^+I;NH]OVVXFU+YAT5M4$]0CMB.G-CV%[9\)YS2Z&")TT]^
M"F/"QN9G$Z/[NL>27Z2RA7A'N&[C,H#(-JI"*MU(U _V$XKM2FMX[!P_V=5&
M15 9>-YYV</LO-&,O@1/$4DNMJ,^ Q4^F:5Y>,NP6ZBG?*\MB3-W+093C/:@
MR[N,S#542MSQD96URT%EL5J9O6A#.MAOMBA%4S"]7HKP VT V80?.U0H@!::
M8+[C%@(^Q2-IBJY^?*K+ FVG'#0#U]FIN 8EB$O<B%??K(*9&V-U+%*=VK\Y
M31>R]22/4\5;.9#EIG!C%;4&!-%$U=THLFLE].,KVJ68"85S^]/S51LIBPS.
MB\SW&5(=*SJG'$EP,5BP'.2:5NE6*EFM+&)N+="-9#>.-ID^+>T[?A/97*?V
M-4__\)NEHP!@>Z$606%/+3T16NJEU:GG<79&0>/(Y!OVAWT=49TC"Q[D-:&%
MB:&"=E&]?!)P@U52,M>CE;1)F>(-W%;2X-$G_>G"FEJ; 9T7EWV2+IU'$B\X
M%]OG%;L?0=OKQOAX]N]<LKS=,%*I*%<VPHO#M!_<RAHQ&9P.E=S8$(*K<;O"
M0/HI5,0/<YO?QPZ_U-5<"\+>X?H(4UL5@XN7RZ07?GV;N\/ '2)_U EKL\@
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M0>OSMK>0QR?/H/A5+-90'ZY+, A9?'):&9$&4>6&XYQ3V)L 0*.UJ*,*B(A
M9?A^^&WM6_9IJ>G:*U3OAOA[/IHG7I>EO![.:%B:GU6\ KQ6)'?92=X*8IK3
M; >Q>TLL+\IP-'-TZ:X=S1+FI[4'0)R^#@7WI2;4K?R>A5CS !Q2X;DI]JH
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MRZ3K8?9\9$%:;N&#74Y[X4->'L)K"#FM;3.HEY-.H68,P\F'CXUFFQA';R4
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M777H[-STR5K'X0^G#'Y5MW]EI%4<+%:-I=_!UJ*1RY&V&*F1R\_1G O&E4)
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MMTG($YT%+&<<:6^NLI6_V:3:G)6S)<B7!IQ\$:!<"4S/R*;CCG*Z-]O)T/R
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MHA_VJ8T*$FE3D)UW!E8OIRL^O'+':%3KYH!4VD@+!RZUV2>6'3OGC5BG\JV
M8LM>1O_DX.?!;G@Y=R^+OD]7?+)^96C4.3P\?82#?6.Z9.GPSH.LV/TC\59>
MC;'&8XZX[E$S:V<QG%TH']LKE>X!O*%P4FU7)2'V]VVKE&IZF907E7H?XJUI
M8TKGEYU(I06_  &1>[XC1+7<]U0-W:DSZ'#?)T<S4QC-/VUO'*<K9B+=_$K&
M;ITK+"<M+]8PU*NYA0M6X78INY!255 TP!$]>C!$_9'"O5>>PD9@W@*<N9RT
M>8A!=(WGF=25+&Y2/  K6[:FXYAA266I[RPV!3A5?'7B"-M#6?$A'NCO=1J\
MN7AW-.MIKDH'2U&]>]A[/RN# H#1@Z&0%&.V>;YR"_#/$C@6S%;4O_K^]OR-
MD"/R]1K8&2"QV*$3=IRXEVN*[M#HP'9O0NNJ<9:3?-ORJ?_T.6PY>H9IMW<W
M$<FH%MS:TY!B[^V%G9NZQ,*L+$D%[+_MR__^P+@0M7""PX8*?34C/$AQ57%9
MO)[O;!_^#.;5.K]"[J=W5IW98'"Q4LX/T[1RZJH79G$O1?!=IY\T.P*O'+Y/
M0)>_G5SJ!XCDK.4((3_HU9NEIMG6'QNLWU.TEDN,/A%DX"V?/05I]/#H$JQ<
M&^X5*\_2:M0;?1>$GS4&L>?VLXP-($\7&\ 8[]62\=QW-A]N<8A\M]\IP2OC
MWB<\YCAC_JF0X8Z*ZO.CMX3WA9_#\$PUO'U$I'*FFBU4&P]@!VP"#9R<3)(G
M(W;ZMAA'T@0$A Z -:._3?Q?_,QY>YOS0M[S5Z05OB!9*2G)-M,+?6-Y@YGS
MY*UEEXS =& #%R5"1"%5PFZFFF^(5J=E4?B]2-C##],[*=MW/.*=V4J2BIXS
M1CM[ZOM0<6;S^Q9/R*[[/9U<N8TGWO[NJ/*)LL?76,/T:D/)&8ZWPXTNUZH*
M?4F'>:0LAOK*QEB!!#%>TI8]>_/#R;TRQ9#A\6L"^NE@CV:=&WUY^W&LHLP*
M_4PGCQK,5>QO?72>5'7%/EIK-N/D<&RTJRC.\TC76--X=1@B1\VT*FUF(#!%
M[?&5KA':57VE7',*X^OX*KEJ1$4\+"VF=,J*UG\X(B1_]>'U'>?\YU0^RP=D
M <#&>-I*.)=;E90AQQ?3C#A;X[DRK?5[G-T?(04/&>!Y_EM.D Q)T,MHJ;Q0
MOH43Z21S_2A;CZZV[2<*M6< +1LAL4#]1..@E6.GFVQ@;TQ!QOB4^/G!52:5
M+;V'BY="G<28_?4:Y+T/N$:<9CN^U-ANE'4Y6,6^S.Z86<ONIEN-M+M*E*9C
M?*&[DZ JWUSZ7KQWWAUM9S*:=5N1P\<*-& K*>U+8U(EM2<"=S16@:;/Q*.$
MY5I<S$6QTV?-5X6N55H!WS&6!X,VV3D?EP[C%G#?K;X/#XX7H)Q+M2U2/@@X
M_*0VH_\)3N]IDZLAS_ H4+6_6-BK\C)G!+F[RLG(1#TV9CIOY8PFOD['X_#]
MCD+1TR];P@EO/P-$&1X?T ^5&J4LCN+2>/OM=6HXJXH/%L5@U9CQV=/)001?
MOL9+>'5MSD]%<OEX,V:.0T&5CJID:&[@HCQ)AQ65:.;S>H48$4=8 DPZ*3JC
MK]B]-7IED@I.Q15 A>HB!*H77)A:WX%%Z'8$.^6'7&Y9H+Q.<$^S5..*%I+=
M^\&@0<#GR"=>E*_"6[ZF2&F]6J+ 2ZZV*=8Y;I]2S(]OW[S!4;6L'TQH862C
M:8=+ISO;<3YVNWVPV:_8EVLV$X!%LLH&+F!?O=S21./>2NLL;ZYM%-V<BO*9
MU2:>%([)L-XKK"P(D:",$+DT$PCP6%MF'8<0\'S2"UA3&MQZD_N51X5?U7%:
MR_K(XBYV(N_7P?:D1[W$VEV&TI'-#EXEPPZI11HJ'X/)Y(ANRC/"3A<M!#![
MJ)I[>0+)C&W%KO?EYLX519A&Y:T7<_$R2K\VN'&%)KA.)%C'34JF:(<VD'>(
M)Y 87,V^P86\8Y@N3].VL^JU*$B!)2BFIOO1L ?M2*[U922%I7_)P<$B5?S]
MK-7__&21+%<X=Q6:9G>:4Z$&*6]$6CGYUKG?B;43S3JUAS;34]6$\I9ZYX+$
MFIE&01555]03WH>(/14<MX <C[156+X-#_I8PUVA0(E(EMNN"</K> $N=?!L
M]TO!>,NW=#(>+VJY]:%"RP72TOG6F& .E"Y%8X^Z.B;;.@?M*JSBF L$@%W:
M:;GDRF)Y C ?#FW5&(J8ZP?4MN>:]M5ZH/M<I%J:';<"G5]SY*7YX%+07)6\
M*MA"ZE(S6!Q]:-8O00Q>_@"A!=.MWO&1GP^*H!TL<0<J'T6;#?G/BI(KP8F-
MCI\)>9:4/?YP3RM'][6M4FZY9@2EX&Q"P*D(9&[CYN[C /VDY?I%TU+_X-?A
MKABJ BMNQR>J9K,<)O2$1OP.L8T6GF(/6]5IMK/$4MR4QOR3S2#3?C,1+8R1
MC[:+.YO,4A"V$UR\QE]GJ,1Q'@ANQ)80ZK$5]#KI)B"\9C;VJB4,H\CM_9*3
MR?8Q7-L.R5K.C^F:1<AF-B4N#,&B0"!WOZ( ;?4@NR/Q%NST:GE0MAHX>Y;<
MFW,/RZZDWVQ3;.2Z3[):8\(SOWF,($?E$"75?53-2U&ZX(\9;4JM/?K'?;U:
M"T3VZ%91;,?%%,7SZXV7@Q2#//H,L+O%O%@[)_/K3:E7_+\MSAN8AZB4W1X>
M.0,4+X2,;5!7P28B)THI3\I;)VF=36U] ;-G@!E3A"3*_2YDF@<ZHQG-[%,T
M130F:Y52%$DDC=(LZ?SXQI#BC>W-?*3P&8")O@5Z,'<&2)*W_9\/]O^*_U_Q
MW\1YCA@?)ALSVCQXJAX5 ,#,O%5N!6=H8+.<CS-AWQRKDEX4.0/4EH+6GB7?
M?N.^)+=8BSSY? 1#]/Y\Z4^*$)R5?1G\RK_.P%H03U1B2R'S A?O&6!I4J$3
MTA+XZRTUK3+%LBCD;A8+TWE$Y3R [O\@%:7O;)8Y(F5OR!T]J1@6;.5%V6*?
M_3\P:)#-3*-]5[FF/P'J/!$8>?#Q@'NDVHZ+46_>@43*-?]?4 >*GE[40?O&
MW550M!)_NG]>Y:0 4O^3Q5G;FEVYR^A2T!_"_O>.(ZHP?W"2-SP?F3=532@0
MKV74VV6()Y,9.-P8*EG-2TS[:C*4-JQ84%)5RGC'=Y8I&(>6@()(G Y[5CB.
MTH40X;NYUB0D=>A;7.H^N\&QQ1 \3"*MPHCA,^HK>DPWN*HQ!$U'/D#8\X6G
MFPYU@+@#!,USHPR?&; N$%#@G8[[_3_L?75<6VV6?RBEM-!"H;BV0(L&BCO4
M\*+%M46*NP4-4J"X%2CN3I BP2D.Q1V"$RC%"1HL^=&=F=UY9W9F9W??G7=V
M?_/'^2<WGW.?^]SCY_N<>R1VG(!XL-R56 !ZH%*]/Q5PE#.Q^.U"T ]&IFNH
M"@QZ:+1V;S$M+G/%(,B%8LCG\3XJV=HR][46NZ$EZ(,9% >[OQ5;$//F<?>H
MS]-C-."#MFAD4*DSD&9+!8K BFN0(\FQ->:2[JEK-U["#+.[Q2HE"[4-H;U;
M1:WP?5,.J,*G\YGCD=)K#0+N)U?Y?G>P6<=N5>[-KL2W9/8N]QX!Q17-X1>B
M@Y4G:T[&]'=[[Y_YTHN"98]H\7_4+% -LSEYB'P&/B)@Y5?O5A=;747Q8*PG
M3<85@,Q>@VO251$)P8D\6Y;9-]K*7S4VL# +W,ZI$!19*7F^\GV_.G4R<GD1
M=ZC0;($B[+D7",I,KJXV=W$_K.>K<9H4;TN.67WX8L2Q(L'64S?F&U=!,A_J
M:Z;=&UN8'Y+:ZMZ_=<^1WYL:H1_$'\HS@"\)'6=KE!*!$BR(KG2>2,6YM'R&
M] $4).>&L7/-80$UQ7G:FR0.;O%3RFPC_$7E/2AGBTH1P9Q[F.W:[Z,8#KV[
MK:ENO3:R5P,DC67<[I./_0BGK]%% P*>;%QK70KX=/\GG.=:I.O!9^NT5Y?B
MRY+_O/#/"_]P%S0FCIF<O.CV5&K1 #7K![+MHG9"7HJRW_;!(=>Y@]5A4^*7
M.NBG3MY*F<8R@'\*WFVQU' -5BC_L[J&?_]&KY/4 LD?OY7-BA?8\F%Y9O-'
MURCST8 T>S1@L1U%_+(]:=R;;ACH;)9I9E1[5XULU8<L LPRGC>FT'\;JH@&
MB%R':BU!ETSSXI>'D2@4[7Y)L>U]K^S.4QC^C,M5/$SP$@W@%H;2)-MWB3KJ
MJ/),+OVE)W](]Z\\LIVN_=R@^ 42W):;Y?.?^[TDDL 2 7(?A+D]= OO''<I
M*'K6+M@E<T3&,VH]@Y'[']\\G_D3=/ C=H$#.%?L]U6,DN1[[L"7'=I=$5'U
MS9\?+M(3!'$5OO/=!EQN:2?+V_QIJ>J_0YB1^WN7G\ 4X-E(5##OM ;M\N(9
M$XH'#8#27A%:EO_A\-ZO3GCB*!*QR.NX:&KQM V,4 6W=8]<;Q#L H541+%$
M(C4HQ"\O%\&+YK]#@>/ I=" ].2]BQUQ9!) ?-GHQ_4;V/%" SP9T0!BJ4LV
M+UJ45UG+W@<T8*7@>H?MLZ^#@X'3JY/TGSCV4A[PV5DS&M \A@8$9V#^XLYJ
MDYT/DXCBGN-LDIF6WG,P^.6?2VN8.I[FR,JH*F6+VC%A?D1&'>B&8[Y:Z+4N
MLN#L=*R*TG[ZG!6Y?E3ZU;R&7AXU2!)U%=IW<!GN_W[QM3IM>!4NQ%:N)EG>
M6.^-8IU<@_PZ1B+X0_K+*RPE,8$)L0XC@UM;8%B#'=U3;SCXRGF0[V)RTB%$
MF?']DV+&2]:].S,;260>H<G)N545<H7\6&YW1."T3.N'Q!IOFA&*_O15$\YZ
M%M0Z"FXQK#WA66WO[MK7X1P#SM$ ?;KF_99@?/^JF>]U0H$M^8NEV16K E8/
M/JNF37>OVD\FE\U;B(E^J1Z&7(H6:;YD^'$*)=T_DZ%@[L4!AZ5-7Z?NVG*E
M31TZZ4H(OD+XO-&+L6KIDI*=%3]E;IV22!*-."60</"@CL!LYW/K LM3F&EH
MHWB!A<Q59FZ6=4O$O%0B9:;WF]W5HNB=AG'UTFA39]*.(4*]7FLN'7E;JXK^
MGA>"N#WWAN&P8BUS*&1ED49\YKWFWL-J.3=JG)R<9]]<*I:64FAE-0S\KFXY
M\E%$U"T/?4@RN4K+79?A&2XAX+E]TTS3G\:^1RP_6H\$4@B*;*<P)CG8M-NL
M;RYVIJ[^[&$2*$"V;B_L9D)S>;2E>QI=,'_Y=(PG.FLS6M_\-'Z#S4&[? XS
M1@O<F.',.XU<EQ[GL*Z:EY/YJ.B5JP<9G8V?7>>05/("MQ7).UI:+UYB ,,:
M+O8>(/DL<>=UM$(UQM@9Y3SB^ IQG^ED,^MG>%QO.#O(%B5K$(X&[+2C :^2
M^B=WG?%I[HE+^S\;WP9B?5/TL"]XN793;=W"\?#!%DIR*&A[-Q,9 ,=-M,Z+
M6(!OZ[\N^<"6;/BH)BT(VS\BCF/9=6&QB/8-)"N$-27CKVGO;U.D_CL2:\?Q
M$ TR::B#(@[2G/N%S"8W@O> 7D!I%2.F[@?K+%-IF*B9BO4WD3:+=3]P6Q?"
MX H+?*#/@7K2I/,U";);N0RRY?A^6$HAI7+Q8A^?"H#E5*4>A^#9E(KG&0>7
M/6>J'M]W\Z8#%;YWIB@%&&*?BQA<RG.C2/A#T( ?K&A # *,X-US4E_4NS8H
M8@G+J!=K7OU@G$5="WW2L3WVU4/VQZ&.S<-<#AYXK(8AK$.Q"O*YAD,BR-QB
M[6Z2V$R]UX;0YCHM#G*USQ_O^X&4%!EIXTPWO)E&QE8*O%A6FR(J;2I>Y]VA
MPQ7R:@_$+ JSGYO2,UV^&$(J\N+?7Y3!?&4=,]G%\SB)9W/M"^!F^NMCGF;^
M_3G4X^%12G+#(*6:VHB52:T[.*7Y=8"T#R=;(3 N/UF.\SH^CT28Z67<CB.J
M=1@LU!O1-:N"](5OR?5\*!>%E*XRA*T\IL^O):X$+Z,!]]M7)!!XH?9YD+F3
M4%LW:]?&#NEUAR]AB".4TR(>4DZC?*IZ0$Z]!5KGI4(VWOC,KP3CIC5] ";
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M\EV3NDB9QD"FQY_6+O/B< I%$?YG4\;-E(@GOH6;A"##0WE+RK/P]ED+##3
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M(XIZF'=]E)=Y/=!L1&N5@/1YK3%^ J- Z\9"O;S8-U%A^>J*H"NU*AE"+R*
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M.3QKO2L#GP%KM^V[=CHAU.MNQ<!$XL=D2SP[4X3"BQ04 1&?]\;5TSL4L19
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M6QZNFPBCSO&H)@J-R:;'I@J;E$@/%1$'VYV<P#J3!\/4LK@"//W]6UM%)EF
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MK@I-WO)BU6NM2_O-OZ*D_$@+>M=P/E5RR9'&@'3.997VB13V:T>Y-YD:X+,
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M#]_65@6_.Z0/:W0((+O+V=-#?9LXH?A29MBYC-)L*H;RH],\0V,12MTX21(
MP#8AH[8LF^F%DE+?KM_U,"$> %EV:W.$LIM"1V$N("7AL^@=,D;BT2F&K)7M
MOJ:VD)]3+4TW8=\3,Z6LG^2[Q&\Y"NF\C))Q(UM6!=Q! _".+78W<7&9]]B-
M"69;*>58HQ0FE&- )T08O,3K:,!^@S<->+@=#8C1H+VTJ2].?_!CTILJM(.4
M']&>*T<H3]WNQ\_JHX$;/O,P@C/= C"957$IOI)*VDER,)1MD#O:-FNB5Q))
M+LK/"F@7$)42*&8NV3BPC/E1*+;S@HED13J.[,,+NSM6UC>C0(,><"(,[W^
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MV1B1.;E6^;Z2PKK=6L9I&I.2LV%BYU*4:"]NL+OYFB?^#!7H86C\(FTPN07
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M(2O$^E1/T-L2D7S7C I?XV;'+X2*00<BF&&<$B('\W@=P^\H4QP5$9H%<1$
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MOBR;C>"QD"/=>H\2_HUQ!#U)JS)J>)H *!A=,CU.)SL-*^!ID^PZ;5"_2P"
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MJS'&0;\+#+R<\?1^V%CCG=@ U*A.WJW5+XJ>*+DE\JA[GN0)T2[F032=,AW
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M*5LM:%8Y%*NF.,>,99,RGH9FE>D!LWV8A@_MQ.J^[CX8(+U,6I0R'0TOT&%
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M\J CEC^*#'KB3^Q%SB&5RM.P:2^]JM&'OG/W*XFCM_#T&<BQ%=_S--@+1"P
MOHVVGT<2OXW5L:^I,\'O"OH.D2'):?[T@I%@8 ^C54I4E(?QP04(BNLG5LA
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MF+O\?=OXJ9'(;+=-U3?]%O/HJH@IT9&Y!D>L[->:VJJ&78?,(.%#.!W7*\G
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M[! U6X^]FCVKU*AKC+@<12TF=>&2_4YC2JS&B;EAPQA=&QE=,<9P#6>NVJ7
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M3%-K_M3D5D5#\E^G,:F8$$'QT3C"^470]F;<SJ6Y@D#CA@S#U/%*VQ?S G\
M=HVIW7;MS19\ ?]M<L)O(Q3I9@E#H=;FC$&A^>7[K7%JPLD->N%0%[+S0'\B
M,I-ACQ+:@GKIC1_%C.GI@BWM072CC,%QZ*PNBAM*073".%!<P;JQ4'(E,3]
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MXYK-$9:=*IG[N!R>FAE95E31YS&DGWG/#@JA14O#\1)<!'&XQ!Y9!.*"^Q8
MOA4E3A8_)<@: X[[(A=>^# K35S4!E-\71-%:/K@I$OC]'Y0D\8/)>O\FUF2
M2 6<!E():8SY42^L!N);#>Y)GI)#ER]VX J8!VL"\ M=HPHSX-7#(0^X85N
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MXH):24ZC,8$IC+9Z\CTF:=]^-.UP-_&-XG. 93OM>7%Y_HQM[=3DK#+.0D\
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M 'BC(\__BE-\3V'.Q :V< N$R]B;G7ZQ"*>P)(KAL83/"K#L"UK2C[=M/3R
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M=Z+2OE6%$GYQF$0CHN.!T)__1>UOS/YMQ +^7<S^D=A_Y[4$P("'>U$>/"X
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MM6UBF,6O?PXC 8HI_L2(4S663LG&]%P,'<;F))H9^V4YTUT3Z/B5#87I_-"
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M[]R]:O&V@O]72ZVF$"!,>KXKI:]\HY0XP"7J/=? \:F)U!>_X*]]CK'1NA=
M)$.8V;WEZ4V?F/>8EI<[!F2;,6YA.[.2TE&>W^%GKO/.#-4@]WIWN4JM\H_K
MZSK^8$_RY*7%5 L5;CR)NND!P<XK2M9BV)&C#T=MJ7[3P2BY&/*JA7CG> /)
MPZA]"N)H_EZO%7HJNF_-XG!QJ2361#-./3R\?Z\G=I27,<1;Z(X2WJC&:J!
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M+0;D?0J\L%?Q0G\&Q!JI/ ,JUQ]C+6D9T=C[&Y9:(ENU.JP8NXM$>*U+>*O
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M6^&08Y"BU/TA/O[)IK]HTM L]T'B'+,RG-T)F]A\0D?!U1\C<7L#OV-\I"/
M;>/<,,B[6/L@)K3RS/J$YJ\7/A@CW)FDT"NIN'Q*'U97)TI*K+\^LC=SQ.QA
MG_K+J'KL/ZX?D7U-JOGK*>":]1N?2:'^YH.&B)G%8^X30@+7-PK?.&A3^/TJ
M("Q5+#(5'E^*"G_4"GI%<^I,KX]_J3IIDMRE^F7H#I)G>YGM87\4VG\T[=:4
MK"S &"45I=A3OR6Y8OX8O+[]:3S-/IZO_FFG*K7ZP$DK;?])^)R-BJ9NTDL-
M4E>?N/>H/V<YEELGB^A/$1'C=F8PVE>3O_1?V'O+H+BB+FVT"00)%DAP:8*$
M!(?@3@@6 @02W$* ((UKHTT@N 4(D.#N$MP=NI'@%AIOW+O1QIJ/=^Z\UVKN
MS#>WZMZ9JGM_K#JGZIRSCCU[[>?9M?;:1FUM(_E61#O E'$5\5(."#C0!:^-
MO/!%RP-/GO&/,37YT9*V>%HUE$I?7;<JDR K^GW2L ^_IYEM_J7FP=3J/]HZ
M]K;R\X(_EB6<H\RHPC"A3&K;%)-HQWQY\_SV^5]'<\>R=OQTZGCR4^8Q=1 Y
M=&0AJ/UEQT2\JK59 [.$E\FJJ]MUV*58%[USU):0PX_O%3$3$7;Q7)JU,4YA
MA/RG#UJKEQ%XT;YO)Q?!NCTZU3OCRN:D;G> 5V2C%[-IYE_3K,I??'#Y2U>U
M6ZO+LN)(%TLY;PQS_6)71TA)X$S CBVV;A77SQ0T23&AMZLCGL8M%'Q0M_!V
M7G\ET>+]HI.RE-?3?"JJ+P0+=0KO0PTG'.R?MP1]K$Z"DY[5L'4+*&%.L+^B
MIS00]KA\^6=M0IZ%/ULJUNB2KWLR,DZ;3,U2?FB[M=?$PPX&W+$-[ 3\LBUP
MI7)+'79BO3=O=!&ID;PD\L5HES7E%@$C_-:AR*(9<KZY'JKWADS.F28OH=PM
M#T>J(PHIBRTN;#[/UG<X\H<*=UN>\$=M.;C&>KLU9V0^/-5Y96JHY/7BC\<1
M1SB]:[^6BS=P,/$G95'9];"/TF3A8U/;&>%)QC>N"\PBZ^H@&:C!*0:(]#NL
M^OQ[B(LCFOH'I>+"K@19!FFY$"7<N'M+3L'9,T@+)1-8._SA^NU5+YVSNSM)
M_,\42(($"^O&?7RV=0RE#5[*7A7RF9]T%W0=H+2P^Q-!2LA[;=ZQJM8]WECA
M/J6I(-L=\2+KP7]7:U75K9^M:!>Q=4:[G"^-W 'VMWWGIBCF-@J4.)862^=!
MHT)W@!#/YH9(GKIKTB<+-J[J)8V!3YIDWS<NL&JY1LU,6>0L7C]A<XV=G>V5
M9D )!Y>@#\'N/J+YTAIS1DS1U21OOQG%=4'%.FE*@4^9IRK\GV^/;8\,0+A3
M\GC*:XNYF=BE&MDS<IKI-+Z-\I3:>R%(GYB"5.SF<T,LF:S$NK@.NCK[J8?=
M: N#9&I;W?/1R0<8W;_FQYCA]2W(TI;'H?1%]HZAC][SS(13BE^=8(8\M.?:
M4";Q'J.FL=S[+C 55FJ:BU>7&%#SR)@4:LQVZ,N+6PY@7E-+$S6;8GE,NE>+
MH6A:BWTPCQY9FKWEFC.&-UD?4DIMV>PV]A]BC8!A;780B[;9D%25:0>%M0&'
M3RD07JM?<='S+DX^9WOZS:4I0N)G#+55&][0H@ZR5M55AN?/%QW7RS=6Z .\
MJS.[E.\ 7W5KS;$?-,H\N!&,[$J)'CZQE7%(TFO-D[$Z/B=:OP.0C3C)<!QQ
M@-YRYQ-_5Y NC+F1G_@T*\UM[6TY\D9$V)#@0_^F$=FIJ% W.DBS_?>8S"KQ
M-$7T2#*DF6K?G&/!3PS'1Z3.)ZEX9?F E\$F@^T:DGQ.?=-1<RFV?-&TV!+;
MMNVM XF1IIT'#V+@E[SM/:[D7BZBH7].J,1HZ$+PMS(AMO!TZXJ/Y[=O$".J
M"/G%W8['M6J/YZ2S;7\3Z/0:A>'\\;3:DB2A8FR379\>Q4.;]]+RQK*TUR/7
M4Z2C!14E?LK4:JU@!P7-.E]6_5W+F)Y%]W0F97 9J@0OU(M'%UY%-H:\O>BB
M8;BD#^0@?70C'=MS598"S2XUMKW*+4QJH**YI)IGBW&&NDX4PF%S<QXG]X@C
MM'5B?(1,BD-DTH)SKXUIP0<.F4,!ROT$-D NC^]@N(SX-))>YB^0S%=M=>BE
M\>G4M\&2X?0RX3749?]%YVF9Z2.T]HT*PI%2JJ+2,]_4T(2,8KCFL4?-0.-C
M?%:&W,;*=TC(5[L;-GLWG4W5H;V.LPNM*,IS;'9LUHR\A.5\8_U\MV7[AT^]
M&GI(<;8Q[&-UG.D&8E;\(Y^#<<I*R> $G[!HV%DJL_*1;M7 ('^N!BMN>N[G
MG1KO2C;;>+L82>X WT14FZJO(?.2EW_F;S)Y'0=Q^1NW\K]8+Y/(5/NRE6V;
MPML=S^/81Z^EEWF92%L:MPJ+\CD&&CSSIT,'S6ZDD4NI!6@*2;VD C]+^ZTD
M,?V?!YV6CZA$M_G3K!(^2C.B@0HH2.BA>[G;L!_$5?+KPI]!<Y8.'(NTK;28
M--U"L+D<(P-RNB)F]L&V;%F!/./PW&?_0XW*<F=/4_QON@WDUB:L'1/</*1'
M]CD/?\2^"S$1DZ2?NOZXT+;G%5POMOQH<8$TU%]D'.Z1,:JA0@E_[<(GOT[J
MF"P37BQ)A;SH@2_W%$SS]L;Z< R^P3@S*D[(=N(QU/1+@:JF6OD+T1JK'@V%
M.[OS:GF5K!4N$\)+A3><$<C0GF))N95(SE+3Q\LVX\:7@<=S N/#H1PD(@!1
MZBTAWYU"UH.B,EK<*G.9+J\5%,/!J8[F$ITUIE\IE6-%5*Z1+$;#I(<BN;P_
M;J_]:>-O9&LS#J=3^-,)>Q4>68N-'P 7*777YC89330HSP0ML-SS786[U6-T
ML\\Y>GC3-<D,ZIH 8_S;]V7YYM64N[[@=;I27P.5;KT YYLCZQR^K*#HKZ%_
ME&D^JSN_L>T^6&Z$6XDA[@#$.R) FM-4,7L1PUW^RP:53=$3ZN0ML?[KW +Q
M#ZUFV?!=()4;,?4OYAKAEV1Z"T$;E;^.MRJ9/EW3[K>:KV C_'1&M6MGV">.
M#A*&GKP)#C>*YP_1(F5/NRAL^&JB064-OTFIZ;]R+YFOEA2S"2,2H5KLDJ@9
MFRHI&5C.TD.LCY7YLJ$J7]>/YX)\?,)$)/W-^=;%X^)58(.D,V7ZRTK(:P15
MN+V%<9)(4C3$+F_EU0ON6LC:&I)B;C>#&#.!FOF%,&VXA)C%#EW+)*3? 7S2
MYQNOET+SO8[Z.--?];6S3K@9LRW9&W"&UJ=>O,O&8@E4ING"67>.FOR6J)@P
MJR97RN#8K<9A:$JH6K(8Z'"F#U_]>\:91CJZ*1-M@"XNAYBCR5&:54*KE%5W
M@,[V"XPX;?,>IW(9E_W^BO'O+MK>H/&/GR <F[[Z*PF(8<.WC9E:_/I_V\_K
MCCV]"IG2ZE=C<,49SR)2$M5M["1L+, 5A0CC!Q# ]I54=-N^=T4FTT\C2>NG
M+>2F./RB(_PP9,09D%RAZ$8.K6LE'2/7F#J4I(<=?/)H7=QBQ6GAY!9^5&F'
MZ/C=6)/N2H2J59<*ZZJ@A:T:U_H_SNQICBED6WB^=D!YHH0?O6+W:8VMFO1,
MJ+ NJNS<YBKBS\JS:3N[&_E<X&.TR5;/K$<U<;*X+3ZE_'>![4%/WF+BL8RF
MBDB8.$^;U5HRZJDX$2/39,;#</N-R!$R(J* =+E^=E&63:%QD9ZA@[<^SQ R
M3Q9LZW4<&.D<:UC%6 K.<9+68DU:IX=-.RM=$2P(XB=ZJ4I3Z[%#OV8H?K&:
MI&7#)$G[G5,<RKP2-$X:+H-_]=](SM06<;>^A6L79%L6L0H82Z<+1B"SC=:&
M+C]&D6/AU8LC2F^DD-*1]R E7=@SV$FYPFQZ83?]^@%5\L<?$!L58Q"MN.XQ
M(8Q\W=X^=<2[,76FNEKO\^L]$\O8BVUQ3ZF'KO].*!@_8/&T LV_KQ&+)05Y
MQR0C]Z#".K,"JI2I+R)F/OGOMB3:%S8 1>I!2DIHF]5RI=7S]*(%H[K$]<$$
M%?]))P+'EL#7,8T,)S%MG&."D(?65R(A7\:ROPW8.Y7QT,J?O%7N8HW)^+MC
MY'GS,N>C/I#"EEV1W)%2 DQ_=3B?Z5?KHU>_?U"D'X6.(YVKB\7JVAJ0279[
M,O(]<,(LARZ<067O [C^J.=H;5UGX@SX>._Q_+ZQF"8CG,EKZ('X2=JQ&./T
MV%[&@X9I"^1V70NESA77U]PP^0[P0WR:!?X+\9.9[&G)A\XBD:PHRLA*U;PE
M#6"R<Z3[3]%.>EPF$L#9^I>"5\&)RTXUHJ,A28]WQ4>CW"*OGSA:<6)Q!_Q
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M-HCL1,?O4T(&WI&3]J%'?9OV\RT,J(38D:K:(UR(%?I:$Z4T?S-:W[?AESH
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MUB/:P^#<95_'<<HCY=_I#K5-&^F6]8KDC4RX=K$_OW8^;U..>H9=P)G9@NR
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M>#1]\_F^/6PH)EW-Q5NISP_4ZRWIG12\HCJ$?@RLJU[*P?\);&'<P/T0]21
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MAWLR#P_5B6'F:QMX74@IU2]+E_BUDJ 0TZ)=C@/?\0)T$[GE2522YR-P' $
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M&=R/_OBC^03XC8?Y!&@#[GJS6D:"1]5<&'80_JR@1>D?'RKT& N=M,^GNI\
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MW]-0_F']O->-I\,6/U\V&U-S0-;9:105H"QVQT=OTNTH!M_PVJWPMGN9N+0
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M>Z;R7>^?W_67C58FSCV^L5ALRN-=_?6BEA6/<?-6Z<Y!/\@8O9;-K%P<]57
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M!F7M<NWR1-%^XRYYAN_ 4+\+IF=97.PQ;ZC TW;N'+@K 1>F(E#A\WE[C5T
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M3[-/9G^WI_9XTU_"A/%YCQW/!H;VLGZDC9._S&WT3X!?SRR_1:K4&U*87'L
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M+X7O;9"3$>FVN,]BLP7?UI4L$?,JDV7SP_B/,A3:SDI?[?I@;$>,(9RW5/'
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MLDG36@Z96&L?;Z.S;8K.D"CB+]J.0RU&V ]YX9\C;UM3.L.R+HZ,BF28#:%
M]+?;$N034,H -,0,9@5'0<;Z^F$'96='$2H75C"/ZR*Q]H5,Z_>U^E0GD\1%
M]?'^UH_IGWB(7)2E-YU<XTR-JG6-WIQ"JJ+R@K$7E]]3@@8X<2L6"4R<NZ*I
M@F+%>6RT'-E]EMC,?+EJ&^S1=@Q;:?<RAKL,)6NLL22RY:_IFZ.B%A8H174A
MD W=M5 4Y_Q++62 OQ:[I;"K0G6127[4.]G_[$@/_)<SX'\[%H-847>*\M/X
M\<G$R/K96D33HOYK+R:&_%+J@2KA:5_#,X:NV]=G'&7Y-L@*4C5*YE03WQL2
M(LC8_#]'1Z_Y$R'MN^GD(,I[;X?#FN'+G%W7)*GJ!QX3+?2[-=],B)/30CI#
MV>0[F,G(2HP1!3T>R)_&"+H^-9_9GP^P@37ZZSW.6,W_F/F[X"-3N^;8!7I.
MZ;S*0Q1T"[0QAW?Y<U5/KK>T1&[7-$\:_B&TVQH+_YL<N"..?W'T)OX#2F*R
M!T915'Z*>= 8TM3=LY:HXL[I?@(0,DXPG^&V!>7/[R4P*#WD^%ZP[\6X)GJ_
M2T1S\M;*UEE7ZCC="7-P XIJ3?E^=';@Q_PD[?!^Z_NOS;4U )>*XR? I1YK
MW.DV=!U>-50 *I>O4[>_1[A3LWV:&1[!L3.P-&YGSM(1M-[(H0)%3=SIGZZD
MYJD4Z@W18[\M_K$R^!(<],R06*+H!U NOF9^0_M+T/[&YS$^VXHZ8*0[Q*;"
M(\/M;V3"X%;+GPTDGR> ='^!]?HHR:[>8V8):%9E(K2MG#D!Z%4DEFF>28ZQ
M?W^Q+W1[#;A\5^438%V\^)!_>XRMZXEZP1Q/OYF%E.B<" QM/S/^[A[PZFN&
M=8C; ]/:A*Z<NVN9/")%G<<\FMEY'S1:)+WN2++<WGEG__4)T!4O [IQZA'(
M_KE(JNG(:VM20OYXGN,L19,DX_SX>J;%X/9TO(6]8"$Q/K)X"JI&O_A"Y55E
M1XK##GK4R%C+EW6([(7QZ?)56++CNJ$(40JYVB90(>1A0FX5N:3]V2QKAC7!
MFF5];-?3B:-(8KH 7<$\HE$9+8YP[=HRD ^\K:S\0+;KCF1\)_&U8_NH+4I,
MJ[*_ 6%@P]4V=/O,N%M)]-,S>$Q5&^-S/)21%IOA&F5>-/M>9J;2+T^5@'CN
M9:;63EL=%+R"_;WT=08\2IHJ$=56%R<^]V$C%E2IV.TOT!QY:2C:>:VZ3U%9
M^ZH!)HBG3F;ZO";2=JABT9G!]S2*FE.^JJLO[PE+0,6=G:*AK2FZ#I?S9!WO
M_GXD[KH?'$J8#0&+J*)7J\DX903$5H9_$U,I^YJPR/08ZNR*$DE04_"#/'JM
M6I*+=14\A;0\[=Y>ZW/S2[^!XNJE_/6ZE(4F,U+4#IW/+/C+O?P4+9S_)-+A
MB-U\!F+IHUVOY<AFX)5)++^<Y3N4DWE6_FI_X4^;Z#1?N:'D!T,K<;RW,\?R
MU(J#NB]BUU+.@T;0C;T!Q[)%)G;;+:3U3P#+$,],P8QFAL4;F( 3]ZKX.Z!/
MA,/11@,L0S@W^4,?HQVYH7P_72R&!!2^@O6X^ 0(95Z/>Z:S?@)8/63<])][
M_EVQ,O8_O&]VG:2ZG8F-69>DM7V&G9?#YLKC;HZ'0%P1GM-EI==-8*$Q!_?%
M<Q8Z J2!OBTIF@$9M7%W>?=6@CXMF+:N(YW"N'XI#E+'_4'J&6T4='+]VVG[
MMPJV2GY&&*F.CN!Q)[8;,Q:&<5IUGT.6^PZ VM58C^E<%SJ%[45/3K#4CQ(=
M$MSA'2_^M<>+(ZGT(-68XG+1^)6N_L*^0--'.'CB_9AR42\U[P52!YG8V8E>
MY'H5)2C#9Z@*?:_IW1Y);0NF1!ECY@D6%7<T,Q8/!FI[-P!?-K^!%)%. $*S
M]]U+K"PB'KWVL2WJ/8$>+VX='_.XYGQ*DIL5\P2N4U+2$NZFX%O[0VH.% @:
MH"8\)/;SR.(\0L, 3TV=C('U)P#Y/IAWMD4<OBPI*SFOWJNW_;=0ZWP>"3N4
M,9794PB =*+#*::V/FQM-,57A3ZWQY9ASJ;CN5#03^\5@=)'42),OIESVH_N
M)^/L+1C+R>%F[W@G)Y/NOOSRL.E7[9\V5^)!LNH!W,6&$UV*JN]MC*" CQ),
MTWQ* %L6$H4*\PPU3P)N9-2X@82$+/S.0''EJ+46N0U[56"&;! \@N_DB/K3
MY-%W@7(&1E9:2R0O*[%3D0!V?%Q$N*'YSP4$3#&JUX__8]CUE'!=0W2P(@/7
MB Y5]':@R +KGZ-[G3/\+Y,!</KQ.FHRFPJ<7U^6A^E:&B+<3.3ZB\+I:&>C
M][Y*OMKX)X>Y['2=/GIKV\RF+IO=<J?_Z8['Q1P'GLID]3# 0\=S)N5586JJ
MJK[L<76Y$IW4" @+<U_%5)NU1\R]%#%!24TSU*/GD6C:.'V$(^BM&5<O@)^=
MR):U&1TO1Z4#'4.2<7JV&^_5RD'/H/'#J65LRD$QJO[0D=KF>4LO^?D4,V/0
MU!. @V<4"[%J,'TO5[5[VY;J:"J1!*2LLU%TB ])I!1BD4)QPA?;#A1'B[IP
M1$:T]_JS_:J9M9JL2^-CH(R\QM3;UE&=YZ9C1%T2"%00(SQ24UD/B$RT)42$
MK4J-VUWV)Q0_CK9YI5SV-@Z($RL@"XFS($\X.$ .(86-36 6NAA/L9H&+;5]
MA36L$MNJW=G3'GXPQ-R5:(*L .3PJJN!_!V&6)9'%3,B$_*UC05AF[NOYR;
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M\[EP9@:62%8#!39\UI-9(_3C! ?OQ8C1VNVGA3ZVSFB)%!17$O^!7?X'=>]
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MKM'Q#F)<NW]_TR?U8_!R8-C9C>&*5;(N^AG -HS:/[^)$>FQ@3I.FX'%-"[
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M23S4ADW6GC,!DO<P$K,;2P6QNI^P/)O*<S=H^O WJ+S 0D55(R+<V<C(:Y8
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M<L!_%D^FB&:#LMT5BK/;1Y-J'B5LB;^,[Q7)$K:+L%HF-SHXNSVSZRM3EZ/
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M=STX)#/)/%.=01.1]D&\NO+Y9\_]X-'AH(Y1]5VC\FXF N-]8PSH5EY^Y^2
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M[?W0A'(I5.2SJ\W<&G;Z(V@QY? SWSZ)1#-6MUX=]N.)'"YO"1:L<F2Y0KJ
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M"CA];I\!7JX14DF;LFVL-SHR:H /E\_M.2IZ0S;J)BTDUA4UY!+6S[79K5&
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M3#B[ZGOB'T7X>U@[*0Q<-19"S1$O"$U5O1PCXG\L*N>6#<]SWMTB(5YP>V1
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M][A2"^Q$1B]N3#@90\!?)2KQ-FX7"K?\M9VOZ1(_?I8EZ[*NX&47U!SQQ%3
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MKD@6@'YB+S"N( ,,\B,$YF?\?LHUKL0UWI:%IF-64==D(+)S9SU5K2MN;1I
MNE87_1S88EK4#1J>:GZ%2P405'Y2\-].Z:)^9_G]:!)I)#CBPR.KL'PH!Y.C
M6UG^&ZLQ@;[&KQNJBBL"L8LF;W^**7/(YA5I#I$))1CU7P]?2C>_(;63)=+2
M)2\1*W(R?/?3>U:-+,8197JJJHQU;NUM;!PU2AE$4ZLXT66I;XFKH<J('IH4
M:#E<^WJSNM'T1"ONV4*RZ+=2 7U=I<_;NOWV1;<']P#3:)U)^5 5S?1=?J+]
M,Z[LD -^9<M=AI)PKS)^<6T:#8,<5]]T2]WW9JIEEQ,K-S?3[TWS*@(4;)4D
M<=6?_7=_65NW2J^2]G1\?&0WV"C//VQ1A':;[7HFM"1\HDVEJ>B@.C?12=GJ
M+]D9ZMQTCGL#(@FXPW#PX8U2;ZAVQ$K8C,&RF=TZZ[93?*U YW[UHS*_Z(-N
M,5N[;S*S"%?TX&-KJHJMHA:96W;]=Z*FDY^>L,Y"-BFVMJU_,(UZ(]F]&<US
M0QGP"(V@ (M"K'6^FI!;IGGXO,ZSRAC*+TR%(W457Z3SK/Z,T\&NF#D9A2X.
MMS[UP:O1RYZ$5!>GZZI_2PQ\[UI!A5Y=R2#$5D9_QAU/5[%&]BZ)MV)GVT/K
M8P2_83$Y>$?KAI<>%)W5T=W@HX.PR!K5$V[)69/_Q&&@:U@ PSV^_N03T8SX
MWH!!T<4#+XFVH5'5,>SAN!@'[7D6;G<N?/B1JG/P:64JOQLOH<"*0&67!P[*
M=6".S^%+,7:-< %@:JVG.9P7U]HKV#W7#0?7QZ8ZF"MG>0$$L$I]:I)IP_[C
MUXR6@PQ/6'>6SW<($'Y,(\7#/D2^?8U@W^E<0SB@R! -T1A>N/U!15*FXS_N
M!PX@")*"?+=Z-7_S@^X!QS_..D>F>UR6/W=V0'E%Y4EGPBH#ZY6R1%<]KBP0
MWBZ^-^<4?W)1,O]2ZAH1=H 8_NYT9YY]AG++)HI^#QB.>O#0?7+^I,2<'@W?
M7NT^Q$^[H@A^0]%1Z0F&X"DK"K%_DTC_K6C0WXLFG-Z]RMG%E8!Q8V7Y_JD#
M]U]UZ/RG#O P0^7O%-H%H"?W +3A3M'3U>+?O*5[P-4F_7\ Q@6]#4%4*<.?
M( C ?P$27?5T_Y>*RC(+_E"!4\3_'A"XLYIY?31Y#SB<\/W-<S'((/I-4#%$
MW$D_A!],6W.,#Z@@<XL1PZ-F(?;?;)G6.WCT/2!*]3?/KO?VRNH?1B"6$\EY
M)U+!N<UV9=!"^"?*/YA)^ZO1?U;SFT[3XIV;=TY,#>\:SA9=]7(W^4.W/\@S
MN?\U:]88//+5G;'%B.]1<]/?-+C^)P.-XD^K_&;:>%_*RN]^")C_"2= $+0&
MB?YI@C^I/M[NA@^U1/]92UE&(2-(,>:N:3C;]Z^2WP2QP-^T&ZV_E;S^%9<T
ML8/U@$GR[R+15=!?01D90:HQ7L#,=[X=\*/6VRMKBC]8/3(^(NY:OC]%_P&Y
M,$X"H?B0BUF]!\)[:,-EQ_*_$JA:\/^50)5PFIV;L_NU_^)4Y*'-@7>KAO\D
M>-VR':(^N!:B?Z<(70_%C,'SV&\\,J4>(MJ_LK9^&_8>\"^E#?E5B0W5\T7M
M.+</_PMKZ]\Y7V5IEGGG.D;[^2"R>P#&H[\H\9M4M4WQ=[:3]^I#'TST[N>"
M7OV14^E?26>_.57_5(!/V5/EW,KH(>O#J,1 ^D-D^'=0@M^@$-\_,1<EV8K5
M*&ICSZ+_*J X&C' _:UXS3^LY8(+TGFT;_I'[?]C2 I-/R]M"H=Y?7$W5 6[
MU_(X!6;.GX)0LE'J"HL'17"6Y46#2XQ=:57GN"G$OC>SUA%754Q\#F/(_:_.
MGFK+9 G7)/+!)K7)J$ 5"-?1&AG6K:EFYGS#_O)ACEJ7MG[&VI4$N+S?#=.>
M>>T?)]N&%^"Q-O],5O[-926FJ-,ERN0P1:)U<AV.0>W-3;)ME"/>T L0KH.L
M'S( @.FGC)0Z:*?1TF?M#\2^!R2Z+GL=.PUOA@W*4$<DJE^G%I-KW<EN3&*]
MM!:=$1!<+!'QWH/A8EN0;)@$$MWYHO;&BQT+2E]4K+D2![D]>X?*$GQ#XM!(
M5I4V@J)LE8[(MLAOWUI:D'ZJ^]G.R3]^1,,VI]@ F$$SQG* +M5Q38S\L6[>
MGM_ :23"CRE]^JQO./2P.EF+!1H">1X!?5<?8N_+ H:)X7.+$BWRI)J().</
MOIA@%1E OQPH9^)9+(,VO- *R%S=^=#TSE8ZI%J716.TQM3:PG(E^I/#L..S
M_H^]A&C#_##-[Y&WND<K8L@#5SFS44&"(=$4[Q-N4VHMQDR.D<,M4P8+HS9>
MR[138*'7;10SKF?* 7YQ+=)H[T[KF,'GY[I+YENX!L2&8I$(V>I6&-M[GSQ=
M'ZOF HFLJQV];Z K1LNM8)HE<*9\8X ]/6%B)_*]YFP82QO(*>M E+%V(/GL
MDE<UV?2UH*TP2CF$4XQT]TIGS@FL;\5\:L7C0&/NGIYSRG/"&3 L-+5:B/%F
MY D&U_@@U\A3\Q3@KQ3+1T'?K"14JI!V/<ZRD%. A3G0#*>0=4I/Z)7:(1<L
MG#9*]HF'HW<]=?8]0/2''V.*<0.H80H9)A2(ZQ5HCI"SDE";T4ZN&7P:>WF8
M>G(CU M7DUNS +O;=NG.,<7V0W;#EE[AO@XH+P2B_R?WY#7DYXQ+"#O1TS27
MM?Q$LT#'Q2$ F6R)UWSF:T/V<C.C0&5W%35&AN**W/E*_#7W;!*Y Y-;?FZ5
M4K!/9+DKZFM:I(4JTOBEJB9Q%Y;$Y :<FHV/J<U('N?6U:G;SCTIDI>M+VK)
M]]6;B0*U@E46&J-HU&YE9H8W#4P=>YEE1< I8R/F*<(:A&LTQ6D"4=]*7[M?
M.]$:+^ (HS)-I)A^IH_CF&7FG$ USV&42<1;X:7'"_5E3N1]LPB^K?H4NRN(
M2"CS>=?RKL^)I/3#G4>9RN"/Y+ P-8X:$O#X67^I280@95]_&_G67-8(-UKJ
M[%:0:]2'2-R2D;LQ)95,JR2U29;JJRG^[Z?)O? 6]FC/5(F)ZOFO)RPFNFY$
M(AJ V^+0R6!>EG,!-;W:BFBG+"L?E\EJ61Q=O;[A7TU@ST=15[O6^3)"WU2%
M?\Y+<0S&^1(W0\/ 3B"@'4.8];<<IUOF%9.(4W6W"=*T:N((HV0]S],SB'J"
M2<9+K)];=A/&E;D4"?+ 9%O(['S(268F54/YR52OL'K>4%08BAQ3^=9__EQC
MOL)K<?1XF7:32'EV8;^-$62+D);.N[A?B'T6/"TA)\Z/.5%?/.^$.?4F2QMS
M8#S[9H5<8EM(WUY$(\;BD)EHE.CJO5VL1[3J1<U#Z[5,]OUW/>-UT(1+#^FT
MC?H1R$:WQ85J*AI>\;JH>47+91:[BBTOCM9:TR[!/U $WZ]3I%LJ%?>,H&$\
MEP+,V#Y&'+Q"#%]&&L\#:U5A3C*U(X%!W'I(A,P>0R()(H6E.CM(Q@RF7R.N
M@3THK7GO2Q>A%K$'*JJ5*KH\4#/K=.+KQ!':+J=>8%TO#NM"E8NQ5Z:O9]?D
MK21=="VU"7V&9RB?^JW7U$'FVCQ382+CNK5C[Z-OFTZ'.SH-4\'(-6"AEY0<
M-G2\!QAZYNLT12R8$:RT-.GT@WCCMPUE?6M<910]MOC";V<D24@]*M+VX=%R
M!X?5JX4S>=TE_FP?R6WR.BX^61 =@+/)SU>3E+EKNLKKKF/#4BX6D4URKWB6
MK*>8-G0.0(O21$^N4:>QD4CD4&I$- F',E6,HY6GN'05O/99+V.-+2$Y8D6Y
M]C\\XSRC6@-M.]T*#?I))$Q96"K1N*?A/61M8N[P^*L/!O@U<<.=&NP_&\U,
M3\E :"]G[JR-ZRS,Z$TR-!K+523QJ/[7NK%/[1JLUP5NV%MVRB)@DP,BRP/G
M?,>@!TG9AS6!2,[5Z;#S2 &RMYURIQ!SDISX?6S6U31G9BRKOBEG%K7.R]:'
M8&*C)BVR7??IF_.GIMAGW O+[A8W;AWD^$DW3I+CMXV\^BF!RU\';Z;X50)B
M599T=Z8OE_".P'._IC$R4UAIQT-LYH=623]U862QL:0!0.7\U ::TS:>-G:<
M%@JZ$D/6;\G0/F1XA;P<DDR<6UB4BS-"[0((EL_LB9__:J;O(L<9L1'B="FZ
M!QCISBJ!!]&$2XBK]+@*AAYIB];'CD0@OA[BSFTW3(>?AZ3*GFQ6C1*O#%PD
M"2Y($D6L1]B@D <7YE>\UF6#*8F^N=!8S)"6]$)..CI9PL!1<%HEB725[WL)
M/)A6TW7 /'#]CD\2@M+J@_AV?*4F,<+:I-,PF7LY"J1#@:I_[=FC$6*DCA('
MI)%?Y5<HN\F?'=K> [YY,;(,"]769IS\$O2R-$WQP)R(XF;^"?(K"*&,D<+P
MO QF\18F"+NEAP!3WB4>6X4+&<\>)'<W%3@TL6_6];6O9TS*=\ I@IND&B#[
MI?X8BROU:)C1=$5'W]90.7:O!N)F86T(X)IJH[52DI<;EMDO#QN\$?=AV7"I
M8]S$$2"TP=L,#S'L*H%+7Z#Q-%AO"X5[>J?EY='Y5LAJ0PH%FT3=^,=DM2&[
M.*#6.V2G# H'V/Q8J?KW[WD+<AB-Y"[YP*24GFR\P"\B+C_K9U(_;P'B^RF=
MD4.<&V%!-5K[N:+62?W^(1U]UT\>19/)W,*:CNX!7ZJ[4]]63.YU3;M=)AE\
M/"63ZWR9@.8GQ;&2=KY6UNZ1EXEZ18P[QJ,X%ZH%OI&G8$G4NNV9'SD\$W6K
ML7@-GV."3]^&?3B;AL^<W QHE]C15=<KQ+=32U.9DI5@/NM;APAT=&Q]:/W<
M,R3*\\L-NR?U\X')B.D*ZAG$8*"C82IGK9$$)/!+6+6?E0WY^S3*96E9HA+;
M06!_VX'8>1ES<:"BRVP\PTG5@_,9*+_N"W_LN[$@>JOOF!*5Z9)GQ3ECT+VI
MUS9/H]!>F_G^LWAI@N]&K.A=4"\BM$CYBJ#+:9M:+UIQ*$6Y?^OZ^&[$(;T1
MZG)1$#'7*JC?Z)/'5U89Y1I@$% FO@)Y[-6*.9QK* ^RPYR:-*D3C+AQ0A3$
M-'*(P=)\7,"KAH\E>+^4G)NLAGI+.G@.>5<4A&OMCRJB\"-]BP%)GRLV??!(
MN0TJK-V+YBD?.^26L&=>/56HQG!@^TGPR?HRFL:B3'R0%I'DD8^FYH&5R)JE
M&^+ST4UJMGWE>.3(HTR>G,@0[2JI"W]4DOG-@KNC5\AJ<H"0KA\2VF/Q=I38
M?;W6J'O Y$,XV.9Z#Q@LE"KCBM/%Z!A09>%<;0WG3N=YF.RRIQ"+?YGL*EH-
M0P%%[IZ7>RDU7Q.K$A;PCB2PE*6?@C#LKAH1DG8H]X 9$:4[XDFPD8W36G3P
MG'#DQD8#K-@"R-7T-7*<.>N\C8_O'H":":0]% [^4:N;X:9++!K(W>PS='#Z
MO@((@2#O;+(6%/=X5A#Q$;4->G8/=]S(QSOEZUZ)'/S@DGIAS5*8&[&'\L.
M; :U=\0"_ 3*A)F=VWMD(&,Z,J!P]]V( P3I/;RM?#>ST[9NH7@NLISLE3F]
M)FIA%[)RKL!Z*C5!4]X:W%\?P6BZ0$($B!*GSL9-,4_R*-EEUP(>74^K;AG;
MHJ4]5J+Q'R$^DS]$=[>3FKJ5+E@"GBKE[<A^*I^1%F1+I2G ^GG-#. 7C:YE
M8I*N/BH+%0+ESL\ W7BF>+%;YTKROU46?S$YD<%<XR.S=]J7KFFRVR!-F5E]
MUMZ^^YH'9E"_:@=H9_NRSVVR"O26=O \^-WO,ONCNI9;E%4OL0H0Y5!_+GVF
MGH;(6HB%RUT*E^9$W/(@^:>G)DSUBE.404\*=M+&+HX;]?W'786RQC1SE++<
MO;H%>*)!63MQVR?#Q:S)0@J.XX7HC5_\H-ZN:P7N<>MMHQ(%.P(^P;[67I8(
M]>9[P%Q$AA>345,7#1(*RL&-O8"ZEWRC5I2\"Y^GA$&DR:H"_8>)6W9?O-:$
M'#UM(7A8*.&^E_?U+,V&[;4G]F5=B2$RD$?DU?&G"ME<_<7YIW&6>Q"S9\A8
MCS9<290MD"J5%'/'+L(&+RBHZ_M5B2\HL-VIQ<*6Q9NAXRPE.B #)I)B>7V%
MTI%B1S?^=HT+LD@)BU5#]*O@7H(&NJ1L/6GD"'J/"P,<EALFI \D0S,]>Z<9
MZ:<J^SG6"7N+>QZT>+M+G$>H.E=R,)WHCBIW1VO&%US2*KK5&3R"3FEQ)<_)
M9TJ]5I>#]\X;BZ]9SW33-?=&BVGD'6M''BL^3U05-_R8%3^<AUJBYQ$0N]1+
M86WMX.5"5E/R4DDHV.I/Q@FJW^?G3S^&7:9B86Z3DUT%K K.L_#@(4:UQ_NA
M$\1K#+3OO6&OB'PXG@F9WFB&P=SP-3T')^"@X!D6_7N F\T6D:M#P"FYHJ+2
MNAPW?T8(J8?R_#[=C0*T,N, BU5PQOO&=0GL:1IQY+Y!7E=<NX0S=8B96*YM
M)_"];\JW6?S7EYM%)<)V6-C!N0U%IV=T8!,M7<U:V9Y'TGO46%^+?H=F-^A@
M A_I<=A$IO@HVX$(N27,Y:XLMXDW2V&SN37E$<NE4[U]YW2-1#$\H<\]^^E+
M+!5-YWVZ2PU>JA]87/.ZS3^7!4IGI@]Y:2R(MOE+QZ:&.WP(CZ:20&6653#>
MAMIK5>X&RY=+>,99GUL]0I^N')\=3FCOD).-W5H4=IM@=-=&.JQJU,4@L[%.
M RJN0Z\KKLS3BES%LMQK\!:NH@8Z=8+]]V\ELX"<0%5IGT_F4*_\;WRS32*Z
MK>5M,#UN/?U^JPX52=PVN-HJRJV_C2_LL^\V5;-&4_%??R;;#DT^^#FX07]^
M5/W#88TN&;=X8[U,_TUAVN^(U_+Q)C7']T1SU)S?T>W/!?>XDW4F(XL-\.U%
MPPKB&?]M7TG]2MPQ=)> 8S$C6V^-_4R\=RL%L-1PK!YAVFM>!F)8OQ2UIW 3
M\M$N\4I7>XAVO0)_;PH,"-HU_]X5>/P-]W6@,H ,D)\"*".K?A/7%^ %VA*J
M@,?W%VDV3*6;Y.OO<BSDZ.J\I+.,NBOA8^KUCNWFKVDD"%?EJ>IUXLD@&0[B
MN4[PHP>>[=S>,45!FP)TTIV!+#GC9_< ;. :G+<6(#.61A3[+8*]U]LY"R/=
ML*M3:GK/I,D21[JQ-C9Q*ZVD\/1CVCJ2IT,<D.L>0*ACN%L!/-':Q>=8H!:N
M,A#?#&V#0>/GTTA)-2GLOJ,=!L$S8BJP]FV(]Q<KY3WBI'^4HPAQV MJ2D.N
M,VB/$M-+MX\/6Z"6AY 8<ED*'Z$[WL?"D@#]XXQ(!\B5K27S/$%,PX+N5F-V
M'T4T]7'1G&^4LR"$UO;@<'\/+-EU,=Z'+[, VISS$ J(P+0ND&(CKE#]XB>7
MD3-7,)RSDT1@?&##,R0?.V;A+W\/6'YG[L?/Q(362KBM$S%=I:<KZ>"UM6,+
M.VTKC(Q"J1\F#R[C+[Y X,5YU;'5[(O7,#6::T!-H_NU[,7[4#UH_..4^'J8
M"KC&Q5Y(/U5&P7X7&VR\7R&VT%LHLC7U]=]CX?=<@$X%+EDJZ<MO6+9GW:=;
M?$%4PLNW# !N@F^$:]RLH 8?ES*+U<;46F2QGU@FXR>EWSL[8M\]BL$45$;!
ML<M;7$S[6""<=&N=/=Y$V17DTEMXJ)_7DHE4]^B%C[HE0  5T%<UP@+QNW[$
MM?QBYWF!I>:+=P&#*BU"6&NDT</@==T/OP]('4T:\A65'6MJ&YEL6AD0QT0W
M%]3= _KEPU)@'8?(4">.Z(5^NFV_/2SZ<T@JS,&FP%T=T'O[/O,>(,OZ.J<N
M>7Q4$H_Z/X5PG >Y=!=\-T@F>G>;'255PZ\ZI)Z+M&ET;_YTA<==E^"9ZOM'
MBSFE]#5!5;C*^[)C3]N)GA+_ZC+HF; !R>G8UB/M_Q SCJ/[BA]2U^9R<0F1
M'Q0ADYN8'\(<$T=2HIPR3_[>:>1,CS/\2IW!?SY0;<($INT[#_>;O CUHW)X
M7F4VYXJU-FS;[)/039,1;$$5?XE!<V065VNPYD:>AEH']R96_W)H]$S[\TO"
MB#@03 ^*%UQT]9D$K<+ZPB,_!N/DZ?M]I4,-A[QGK2[8N/,C;6.VMG;IV7%N
M]5^ZM-/';?LYXYJ%8=92K7$?XF7K])H8# C.GU04\TR_T9]C^?GH[<#I"_:T
MFYMQY^T)ZQ]MZ-_2--5YW6PWIMS<:B(H<.9%4_%&GF;K1X P/C)5VY(1%C/V
M49XPC1ZRJ+'@%I#3[TE^; VT6=+O=]S^<K=@01'I41?!?#T?LDXS6I5E95<(
M#*=IA2GO.<$.M>:&@P_9N-$*C?$/DEZ)><BRD*.H]*[J3L5(F'PJ%VM4\56#
M:;503=BR;'VF;< O%W@YMH)3A^VO[SP1)WL 5&BQP2CY%*E<89-#9!)G92/X
M*T6=?I.I_^RR!,1QX 5Y353J\*N\G[JU6;;04$]K7@)H]47)&4TH<]'@&UX-
MRX&)NLZQ@+QU?[Z_5A\*67SKEB9U@]K)#W6*$Y0=O>8X!;R&PM@3%(BBCMH]
M@(7D%(*H;"2\P7<VW\6ZWL8:3TD@TY>@1E8;"?OU\N07E:C[3Q1S[F(+]\C:
M]X&:@H;T.:X0(W6%F5#QKO'O84RJ?PG^*H0^[F6\G*AE5QVUZ;ND]-5I](0'
M_*B]4,DU2F)SH7NF9&:0UU)'89 P9'5D*(D.QXVF7=")2X#698@)07M?A9 W
M^:'4?"!658AB'>2,GF;+?#^*)N;:-V_R5C0XJF;KISR[.4U\/WV<]8AM2:KF
M..UX*4H\R/9M ^\1W^&92$WWPO9<0DF+7JV:!1_2BW+1MTQ3W\<T=MW&@$PN
MPCBK&]]MB$W-6:CZ^^GI"=L0ZJ%EH<C-[C1#WIT1<->[UX=?N"":[VI2U9+?
M2D]"TOSD,,'"T>\UU7G2OU]5/LU@\J-%Z\Q^Y'=&>5ZJ+?NV.$EB\Y24N8A7
MD4VWMND0H2DT<U9F.#JZ-K)/T\#G[,<9/_,H<U/K0@1I?(\5?_?D<% &\;$L
MT+!WJAB&X#O:[?MDZQ+NY<7=7F<O+Q1P$Q*>V'XPTRTIZZ7+\.VC_7C'DCJO
M%W5:;<5#!#0_!"G09XZ7?17+<AK#O[Y)FC$YJSUCX!ZV1F1GLS0M$_@EU(ZR
M<Z%\6\M599H,%MYZ-;VJP!U]01=(^[-X3()8#+QMKWM6*JIQM;56O#]@7)OB
M2![$<-GZZYHB"P)*U]Z#['HYE*':1^ T)T3G]J/F??,#]-/7F$FL@5#7U158
MES6J4J[;J9[E82Z@IZV#GS1[CW"5A?CP?AR3*#'LZ7T%-I?Q?=Q%><O4>$31
M@86]G4$]?MXX_[#V5<DV=428NJH^,UL!<#PGZB_)"_Z"\RLQMZ@R?I1\4Q)7
M\U7YOV_9:V;<<MP#8MT4[P%E,JUGCPP"_^T@@NJ5X?F"OM+;[V&OI?[3%534
MH'%#HNG9R$L%;PN#4NT+A&%A;_CV@\03C%U6;.T[EV(0:W;ARW0C@!SL<[=D
MKE?KX!]5=RB[VNRJA&EMO\OXU VUJ)^&PYY&2K6$<SY@JM*R8".:C4W\5'!A
MG\W;.I<WF)N,0.ZH6L>9(!M-!FI#':2!_IR9G]2$U(0N\;!WZI)SP)5+,@J^
M_MX++3EQ8TU57=T0:/"&( N6T:2)IY]]96<?*W8I0GLTF3/X\CU5?0M[G081
M$1((PXQ!-;@;GL*HJ(L][SXLG]$Q1N;;<60%U7 (,6JX4>N81UG$Q#4Z'L^8
MS%AB7#0KFX\46,(N)@S1M:>. D36(8GQG^T*>WR_:9^&F[<BQX-<C.PN0FYG
MRF@R\0^^T;SQ=N;K5:P[+W6/>/DZ!]5.*_2'O%/A>),%74H&*;8V$T\D<Z59
M[IH1M6F$R>8ZM=#$B'MQ9[_PVH([SYPUHQF.^(M&YT3DMJ<>;;9F-!8H^=;(
M U)U+6/<+'+T(1+@D)]%70<V^]4VZV0@F9)=X302WR.01(K,PK%TJ.DQR]Y+
M4 *+#<3HA6Y;J:'Q8R5F#Y-AG7)O,V<A$IO5LR],XHYT!.((8[_$#ST"R,9.
MF1U9X1U)"JLF:\_+/K% OI4'$6W-<_>,/3J9)EW)5-'B8F@O9@VPE5T\%Y0O
M"V%S62]6>DG&]5I7RD1>,C5*PO1@?C$-*E<,ONI9FI8H+Z\?G5H#B5SN:T"I
M5K+%]+6_EC[CGX^X&%9D^@IIQ;@RWNH:UZ<AJ.4!6O\_[+UE5%S;LBC<A !)
M2$)"< _N[M8A"1[H8$WPX-+!73N!  GN! ^N#4$:EP1WU\;=W:&A']E[GWMV
M]MGGW3/>=\?X_MP?/7K5FG/5K%E5:\VJ*56$2:QC)5_ZV9]MH.VX#W<F";;I
MQ!Y?>$<E]!=C!=0&0W2'O5IJ+L'8GSP:!"C4X^T3%U?:YE,L5C8+&\[<<R;-
M*PA/-)-#\R7?U:SJ\._VFHU=-K^UU0X6%!0SP%W1BF_2;OM(*G$)U)IW7MU%
M 0RMIBN1-YTMOB ;'%2CC6FLZYU9;8OWW&)S=IV7QPYVG#](>!WSO+V-U/F+
M#$*+_ K*G)WI4@,*E/21&T.*/2RUMNBVU-KFN!V.*<12)<V2;+NKG8E9<O(:
MWM!=[^1X=_%.V@@?2[XGP>@H=IW8%DU%N0@!W5O,!1OY"K+(CN."'G?MZTD=
M3L^4CLL'04Y0J--5W'GU?5,QH8L1V;*N&D_N,:48MO(*Q77L'4JN5U:+1<3X
MBKYW9M;(DKNW84CC^7->,1[0J"C-52;=1RG:E$LY&3ML@LN\^NOC%^K[L)[E
MUH2K.%/,:./,ACA32S16_(.[)H:G"32Y* !)KW]3A:5K]N2T/,2@8N]\K\^9
M4^;$8YQ5RC8I Z>QY,X/ZM3GA-4L\6 12 /IFOHM][(]Q<3XVHW)'5VG"/*>
MD8^W+;$J3PL]':=<GJU1FFQZ<(A>H0!;[R8K*$/LS\"2='R*C$()(B9GWI&;
M"-C(2B#^:%R>-*[VN*P0\<$PAG$80.*V:3:T]6M@:SE8EVG(44&@*:8<''-G
M(Z98]K"C2H9NF2I&=#_\.U'!&U&@L_U\0IT;,94[1':4>.&^1_/TJ7:0H;FH
MJ5"?A;7_$78#KH6"L=E>JS)#O*RI 2ZO4D3W,X;)#S.E2UF1S ?\O U$Z^OI
M+S)=?)K"-OE/NGLL9LW=7:GOVZG;!47W">9(!Z7Y@X=WMH_DM=YP\*[SGFW#
M0F.*60 "D=XZE4O)H)P"A1>@2ZR)AB$V=H\S NLC<X%SU[YVY'W.-IJ9TDD8
MWYTZV:BDX$T.O)YL%RMR=@1Y:5-N5CIY+W+;6"?5:7$L<74/)F;:6BV5:>HR
M>HWS#3YB[7^AL!Z=22Q:*DUZ7ZKY%(N&85/[.C1->]/2C2V9]I(\(];.]6-0
MFB'56PI7%&!SQ)*[44==K6QHSDBC,$M&*3$L]<M[GJ#]'@8BW05%L,A:YK H
MPU[(QLQE9XB"E23_'5JP+38C=P.6[]L<K@W70O7&>CK00QV=JVS%4*7BN@K^
M,?ZBIZ%N$3CWA93OD*$ %YO4U[T*(DI5)7'1F171\W;^5-&T9*85^.3PLK$*
M&\1DUGE6N&&P?7"W(@#90X=AZI5NYPP6"2SZY&8^](YWFZ>Q?WVT7#A(?;_
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M_6/-F3^H5E%F*=C%UC,-[R(E,2MX6BO 6W[XP?P9^@_5U*0E*:+UD9;Y%4'
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M/;8;5X\C?'! >]:?(]M[10?WX@7MM\)+5Y &S>DI?GZ!A7G&^K:-H;D1*TT
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MM1EP+B>S8QR>X;)D:B!+!Z*OX8P:BA6M)@)'RK7[!41N'4+[B(&[D=(3*RA
M,C=TEKY.W.542$A/?]39_HWN"V=+&FE>=G)RQ3M42R07FS_$&?U;9HC*AX=N
M&?!K4UW?Q=+[?DRI>8[S#SPZ*$ C%+]G7@_W$_O'P*S9QV3-17=F;SPL/]<3
M^BHNFZ#%[N2<F:!$G;BC8SPE78W1_V2F_7]ZYAUM_8T7]LT#3YIF3^Z7HP #
M\EK^F?IG'-<O03C0<>Y)%$"2[??CI J=_]A!KRW^Q6/R2M?P-'Y_3+SK>^%"
M91?O)<,G/@CA7%F#62BP&=9Q9;%8*E@L/^MS" T/721=]9XA%1PO2HJQ$\G9
M/A\CUHD-+J!SJ*B79"-[F_'EFL+N@2U\^OE4/*7 ET-/_4./SVP[=/ D!N_G
M$4_;]75A&3K!\O(5-:WW P_1QD,>N'+G\V"\UO@RAS8<?_( 2]$2* 6'VUZV
MO&HHI5 P_0R/M2]B6+6/6+^(<QM#L!W744-HI:I9U_*VRSAI4GFK/\:7;%3S
MM18_" )W.)81Z7SQ-WXJV]ZFMPHVH$1X<=U/X25Y9\3C=$A:,<?B==$ZJUP2
M,[@AMM?.V701ZK:<W$&Q0NK:\6YV*0(YL*3+XF<FJ@1=]8F-='LR#0(-A3;F
MF8W=M2P<[Z--8UQ,(IXZT3Z\4$]7F.^Z_$Q=WN N)M=!BDV[T2',D;4L.IHA
M3C3P%N[N,)3*U3 S)?#D+!F"8U)UWJ>U&7%1,;(%F]WG_5KIMX(??U?YS61Z
M^BV<!<9X-3^"\&K&'CN5,^%=A;C"6J$<V7=7KW#YE>I*KZFN+&82W/,M[NU9
MC)I;G>P(X(O*N(4 :4;+W,A,@O1#C*#'$>0]VVM -*4>Q_NB(D$7#Q74ZVH9
M7RE1)M2X@9VF$I,5[!1A2>%E3+-@,_%,[&#8$^[+_GC?/*,"R;N;OINJ_*\-
M"Z[*@L42%50;*@PP#W J6][XJ:"?AP?W-[#G]^+D7,/?J\1[$.).\JLBZT8+
M\1%ND<PZ(84B7^@N(W+%XU8R"SYEA&QPT8]8G_K)Y!I$PT)GV+ <1:-.*4:&
M,^)\P+PY&;<?W1'"C,GY:7=BL/30@!H\3_F+:WW>GS5Y&<874?H=Y8QSP0_O
M++D6]F+-*5@,J/70978GD5A.M^CU2ZI)WOO*_.$]X#O^@Y:DNH%//;@U+^<7
M#4=D=G LD@,BE7!>:!]=6^CH2G8$I\^F/'_(DE;@&F<2OT,E=9!.J0B%O;HF
M$-RQ/P5S;1!86M-P^[0;"U*=\)&Q9)\YZFKEIPWVND8H:GP3),)W$Q>D"5>%
M*]"[3^:[YVNDA9B-I(L;&%G2G*_BKUPD?Z24.N+39-'1;#*GEJ%[;9>=?>,:
M5P7V86FW=EN:RA*6-&!6ZU!T./1PDSY;+K\?X0FB+^2QC6]T2%=9H%L[$G3G
M>*#'MF1IDT\F\^/S=(2M#F\]W'_!KQK2WL\V&[[,]<+*K7+U0<@4.+,X9>O1
M5<Z*W?N.X[Q,.=Y17SG^ )/CLF3/$BY:2J7QB]'H@AG/:MFI$$A\LD;J-^_1
MQY^MN&6/--?>47,BTB@:ZRR<EX?G8I;S&-,*POX8R- ;D830W)X,C4F$ =XC
MJ9HHXQ \9S&6LI*]LE-<UXK[W:OY5:R@!8N*)E(9/Y^WEU(*9:8H #G^.MKS
M$ S5:WK&K2 MCH>36N_EO"&Z_QA.__8#]!__?O6W69R*1:4A4!ISYW@/\*&\
MOI,I%XCG96$6L>'WMS"?R^]N3GDA-P.M@_ICAJ!:"=)H<=(26C<+:Q2@E2EE
M+W[S9BQFT[@Q+WM0@+,6LJ(+??OJM$J]LY]9[BX("E" /1,4 &D0^M<;(>I7
MG%732MH<2/IJ%. *&PP]XX%><TG_!62Y_J*]DU-(>/U$!WKMFP]$$C>@ $3I
M?P%O_-%7[,ZJZC>?W[N%-W>>CZ1<WY]% 8*4_N5&)PJ012B2QW+C\7P<TT,!
M4BWZ4 #,G[UA_-<[R] A[*01_)N!IA%2=&-DP6\DXR.  BSB0?]ZPZYAW;=W
M(V >.L\WA@*L:9:B #\24(#] .!?;PCI'36N.DK:-/R5>93_R\W_Y>;_<O/_
M1V[^96;%\-?&L\^P0"F*@S!+$W0/SHQWTL^?O[<]5X&GL4U,#DCB8_S=I_;_
MQ29\XT4U>&-0SXX_JCB9=:"(X'#DJY(4+$\:2)*SS:70(&M-RD5L6(SNI+&$
M'W19,C:A3[T]QE?<_5YM/!3[J>L=R$A(KWU,,M=,TPOFXVAUWV>GTQ\2V@RV
MV1N98B! '&](3Q@U+>[#:&CA@<4MRA\SJBQ^@/I,SZZ#3$+G'XC(1FDSNF;K
M1LAY[?8[90[S551^68^G9ZBSHC!>IJ+(N!@*]8V?6WP]LEN8?F/:ZY<S77S0
M H,)JCUN8<O@$K49DWO5EPFQ3->4K _$A]+2=%"V71S64 T<Y90%8I0'Q1HX
MRS[=V'&+5%]+*[7:V=KZB$>=3AZF),DOBTO+OH4OK6R.QT+&Q.?',&%)N[34
MN1Q[CK,,+J1SCW[Z.81B<^"+^\6]CG@]88D/'W7QW.ZUPA754C,%I\,Q6.U<
MZ9.?(*IT3+6B5R'NLO>D_.]OCH2>J6$KZ![TZE,E3=L?TI!YL[3%L-\#"Q=8
MG_FK)H!DGI;AG.0:O?Z8W>[Y6=0+/3[5/-<"3)+![Q;X77)R]]!.1B5$U<W=
M$V*O.F@PMO56W",<XVK+1-2(7U H3]/:SR3@A'3[N:T]55"Z-+4WX1!%'4LF
MGZ%+I9V%)5[.!+.8GI("_00[;7 &..RI&E! W*=AL)A-5)VLPJ[%WM*6X*#!
M%,0:0W4B?IZV8I&841@^,/'J;>(M+^FYT1Y][O@)WZ9GA6WH5K*%\=S5Q5UJ
MCJSKO2^MT42;6Z2'<JZ8MPW-AA+B&%*(I*&Q:YA8![#X+<Y?)ME7X?G8*8(Z
MFB*T^?TP!]Z/F$34[P4GY3];F[@L?Z(;#&XCPR+O&X71O)W;D[:HR&'E)]S7
MX40DYC\2OB4\V'7;68;>=W@U_6&P-CSG^',9LX,1M=P"//"SGG(-S[1VX[[O
M);<OHL2^]=EF'_XXD17>8I?AT4IZ1,\2;5WY@A2W>J(Z=R#(, L?3Z<=1A>W
MI0])FK'5KI]#Z^M7SHO+>C-6E=N2U.P?C1"3S=G-\!12GNG&K(DRJB)&P#.%
ME:U5F(;E#5]E&%P/XPI@T%!,V6N]R+2/9X\5M4M(B#4-KZ(+Y1L8LP-+,_Z,
MQ_>/Y8'_:QCAHN=Y*<TM/W7M[P\ _L>_Y^CW2309;U65? AY97B0<?F@ 7FH
MUUDP\ R_ONGF6R(Z=I"^Q8\"'/9 F4LE > _RD._W;SL?7S(O!X\-*U_E(O_
M\4 ^[VL,ZS\JY/POPO]%^%\(,T/N+%P&8,C^^VD+K+^.)U;_,N'_^PJ! .._
MF;C ,)%E0%AI)RO3(])GR5)&RXP$GWOFX]Z\V=Q0$KE)_[%P%;8/V)[T[?PA
MA;9OQH9(=?A=_=446>1?6\^DG:#SQ>6]'#(78$QG^Q8F'KVZ0#K:IL9G9 /5
MQ)'#DGO1/_;^G9NX?V2:1@1P^4O^L@4Y.R6-/#PH!,S5HDE=]\4<3[;-I4+1
MU8JMT-*2/ME(9/D>]JW\2>+OHJ.BL;"BV?5-2[*8=OJ%^=B@#XD/F_=<3OC6
M8&HQ=U(_&X3PONE?5GV(-0B3S1C<@)#DTCGFL7QT_ R6%6U#OW_6NK@9,L):
MN)O>A4O&/_?Q@HDWA%GK$8FLDI]:[&UPF4Y&B$7 /K_#I'$Y7!(=KIWG] 0W
MZ^Y#7?&/* #N"9]='7K47Y<?<SV-8L.B]+7S)S:$>6$G/-7\&T'<+/"L$A9'
M0#_6H]&+T>P4?M.7UPL>Z4?96CW0U(I8X;*3MKS(SBL6N*K:&B G&QXP;[/Q
M@ 6M"_@YNG42(J3Y8JB;"NU<;9NDU=P84M,0KWZ\O:UI:\X_P#]/U*.K=H<3
M$^,N+0" ?BLF@.G]GY9UT/Z;V2I=W]]6C:G^7>"R_WA6K TIO:]SZH,4L\XQ
MW]>2YXV%W-7R-='))"_]0;8LZ82_HD?6L/2J! 7XY@U=JV+QX%7-:Q$+VBC_
MBA#L.]/5I4<!4L@9KI$=?Z2V65ZP/M\?!.YVIR#M:KL'U2N.-8&=KM>(;/LA
MX+RK2\JUAT/HY2'#'RE^/J, JVTR*$ #-W2_\Y!&DB-OX%KITOQ43."OA: S
M72^&GVW1_-X62W<PGB<X],"_/,5^"#KO]A?,V;]B?O(;YM<G0SMNSD@.T).?
M"8S"40"OGX?BHU+VZD1!*("XL/35>20*$*(>!R[TF8?I-8\I3YJ=I)C'T!Z2
M>S2_8K=-+";O8?!/Q7<*&]$,GN"I_)DP: 'Z7]W]F2_H%Q+C1L3)74JEOL5<
M7$H[E'^R<I8UC#0[?OHFT7V,0X4$C[8([\NT7*#33Y+T_H4DCU](^C(43B*M
M*LFZ99.73ILB =H8AD;ICGKVO?J9(F@A],\TS##^F88>!F\MK<]LJ\$+\?R,
M:XL8;VPD*.#DE.!T9/I)Z6_<L,:#_JEE:./)OC3R;)WR= 5T+:2K+TD)SD2F
M;IM.'=UX!?_$W?6'N'?_T7;#C;AG.CL7E1N\.P>!W L_0Y^_GVJ>NY^,M:CI
MIO[1<=I:M6;(89-2^&!(W,/+@KV;?ZB+$ROEA?+::ZT,/N7TB:1L) ?T'[08
M_T[+Z4]:S%" TQ6]:Z$W/$CF_4QX;617VG8('_OV28XB@)AA=XS$PE#J8SW>
MEZD-MKX;IOGNW]"T-_ S95+#;SF$*'X2_8#R=Z)9NM;R+NHXE@GA*?;#/S,A
MI5][\$(O#SE^UYNV .!JD_1/M?F9*VJ.C9=-[J*3I<O=<D_!H=SL<MC$A!C;
MVWZH >06>$E_>0FYI&Q' 4"7TA.UL,WK4J?IJE[A_<2%['&E+?]M9F>Q)W_%
M"#K3$V?Z,SD][+#,TIKXT7E^!>PR.W:))G1O;L$-YB>@C:.&*+&,R^0;,QQ[
MM05X.']S,1L'_9GGI]Y#Y6?F)^#5>>Q/W8A5)A$ODC]_@>BKV@#^I5#IKT^[
M.N+5_U89]%OEVK]6WORELK7;8$,_GP[_Q@YBHU,R8D!IAW^^6:*X+$;[0U)3
M@YNB+WO32>2.&Q:2HPCO9P*NT'^(+N4OJ&^(5#[!N\0JN^%ZP[SG6?8O7)\-
M@/Z)1P>("LM,W1GSL8J]%_6C[4\K/;^_F[&I?1(9N1ZOVQBQ!C077[VAL/%R
M'_1/Y9"]H?VP1>]/M".%,?-MQ;KO&E/W6+ZS6I'E]#4 D(^_,_7&(3O4B'(G
M 7UUEST5 UT3K@8T_"JA9.:?$B+]0T)]#CHX2OL/,^*=HJU/ BN4NRB.7[WG
M=C7 DEO7FZ<,,91RZM_+N\NP;>. ^C_LO5587%OV+UH)28!@"0&"0P($MV!!
M*T!P=Y= <'>G"!H($B! @KL77KA;X0Z%N[L[Q:WLO;M[=_K?YYR'\WWW/MR'
M>JBU5LTYQF_,8;7&'!/0N*W#P^KL3!@C5EKW3X) ?XFMR5/E%R)<?R$2JZB$
M0 1M6JIF.^6W>XJ@UKLC-01S"W_PIJMN1H-X%.M_>O27S&[^-HV;SI.XTIQ)
M_LRZY)S?;B$HJ%?[.P6)V^XBYQ%4]2Z';HQV#[7;N0JLPQJW%A--2+ XA )$
M$S8%W%SXU> O+T)^G?0E^@^$@$N@RV*$_&S^E%_QVY+2FK&#O5W+E1,F:\KG
M[?_4>^G:ROB>?0\M_RD^;';$VI[NL145(Q%A-I0K<>BMV;H''#;=JOW&RSV@
M _0O9E1P/ B]_))U!E7^.+%KN0FAV$W_T&LX_:_3KL+^6G(Q:\K?&\($6@:9
M-O+O 6WO78OAGZ__-3#&@^6F:^3-OP!51@#*LDM\O.]>=<N.C&!OD^R?( V1
M_C8NN^*Y_.Z?4! B=X!.L?XBH6&A+?FU7[NF3-:IQ-K/)0EIC_*2,K_0BTZ+
M%;IKN26T%^F:OJ[/?IUFG?(<I8.>0M/>:ML]"T=!.SOM?Z@# ?Q>M3&Q]!]_
M+OSUBLK^OY6"^']ZKMT_TIA4F-EV)PW]Y+<S!)/3B"^TH)_)(0KU@2-%"R/Q
MRC_21A@@XS3)FMPTTW:_2SF@9'I@_7;^"$]>77O+F"?3B.2H>JT/] WGWBD'
M9M*217:]:/W3;VG=@-4JB).DN8KYBJNYYVQG'#4^X,&08VYFK2]_0K9@PRWD
MJCSV]'I$?,2-<?7[">OQP<#LS7+]*)Z+5>Z<WMR56C";88^5S_-14Q*'"+ C
MS=P4H9)O;.'I^@I8J+.TGIE]Q-2.8.4;ZY5_4?M5\SW@67?7->&$@\1SFN/*
M+_.%6]U]B&Q?$:U$937YL7G;LT!ROZH3\&;G_CH'28R_VR,NSCZLO@$ETM30
ME%5Z;7OZ>!_^\\I]X+C@,3.LIN@;.H"^QM(!301'Z5\OH5/C5PPMWZ-=4*?F
M>H_3H4<387D67X[4/AR+RI2J&4 6W)81/N\@F"/V\6*[+6#RDG*(]MF;00ZX
M5A:"2Y\0PI^4.2TGA>%RLWF]D4 %?!.3%\40*(')"T(:C9RV(J$C%:_'L%5Z
M,DC?.G\#@;7-1;7>:FO.UHB($7<S.4='CCWWI9,L$_KMS3;6_^Y,ZE.ZO%MI
MA:G'_ZWJ]/_T4_SV<@TQD5'<G3\B\A#IUDW0-3KJA7_H9;Y!H89_C:IE2>D,
MCK%9*F_&H*+-+$[G:\' (:0%!(9@X* +BSP)>8\[<\OO.[+>VWZXH'L7,GXZ
M*V&W1L!7NL[,*_:F.F1B^&QP-P%#%[8+MSD/*YZZL)E9NVTI#R4^W>HP4F52
M**/#H'9VJ76.2W?E;;N8IRHY>CP >=S^5H-!]3R;$G/G\X91.&#@/;ESI^EA
M\>=7":VJ[J6'[8VOJAM,!-3''A?:OD[$M$=C);^.V&F[M&@W$8PZIMT3V4_R
M0@W<'D[1_P9"Q? +5.IZ=P;&8.N8=G3_P*-:MS0)\= R-C3M7$N-(H=2N>1>
M!;IU./0DB7CPW@/B%LVS2)M@ZXZ&S?'\0>VLV=LT!I!DZ)YSI9K::_Z1Y$>,
M=!O5UF*I.TKFC60EA_> 8#Z@"Y<_T^DBK(#XV]<#@7GIE$C_U'UT+%YQ J0=
M;7?7?"@<^V5C=)NFX=8!UC?',YE4ZES/3\ ;+_/YG)4?F:-[['M8(A%2I;Y;
M3'U6]A>/5W53V!Q)6Z,#M K.X;4(!Y1[E6:8.KY[R^NT;(.[,QT8S35Y6G,;
M6Q&RU32R3RI*U.OTWBX1,ZE\I#PP8FGPF>:6>V-TME1.QUT>;MC>UUGV_)Z-
M5S$#1*GD=UXU10A]8DC0'K.&!KWB<2[ )PSPCV-HU4#".\$]?$J<W!92[+;B
M87,9J[G%@\-C_=/(M2I[BHE0+/Z]>T4HV^AG*$&:4/K!Q96[WW?9D,$V4F+8
MK9E;AEDMY5%+)NJ\5Y5_MZ>*;S[&AJ4A]P8_[WK"\N #!EW"%)6(-NQ+=PL-
M0Z7G8X]G'3(J9S<H"QZ*5=)'EA]Y5NK2CCD%E 5:> EFO>14(NDZJON4]FZO
M$Y-7Z2P%VQ2F:5<^[,EHD67CY$9M-KVLR_/8F4!P)[S"7EE1U=WL'H!<O-D6
MCP'<.>7E%R!#=G6!QML$A<>XO,FP<GB:I+9'_<9>$*GGIN[M^T%M;Z<-4D2>
M$EFLCDB>MII.V72LJMH3*!LAXT6W]&8.16TEB%1ZFL"SN9J =;'H&'E^@\3B
MR]@!L,))J_> N?=&^H"S;\-ZG9K@8"+_^Z<L-^=]VHKQR%'79<XX^'/3(:,%
MD4H5TLS8 DU0&X8YAH=<U1%NPI3ZP("N^'K8I+_0[I.)=Y1,; ?:ZPU%(*NB
M'P*#JW>!G;S ICKOOMNY)VS)B7?FC4&%LY<@C<IQQH<$J98!WXS4GPDJ\J-0
M>K-?&:<9K=-#XW<G)P[J*?*F&-S?!+EDZ3$LR4.ZX[D-^8PNB L<%S\Y%4N0
MH16"5X,D!9[5UP7'J.I8.7T05:6(59?2S^7_,L#O<554M6Q%>"%KH4/46AFO
MU$L>I7&[GBP=_EZHV<V0_SV8^F@_TK7;*_^2L^=&4^5!,>'2!#<^^A/7]]-0
MV$19HCE[C<W%/:#E3DJ6"W9]BV'UIE6&61@RNJ8_HGG92J/^.31&V^2T\/D]
M@"H)M,L'//52*CER*Q_5K^!$Z>37X1 :K@Z3'8Y@H-&FN=C;4@YLBB#$>G:7
MD'4/F/&,8+MKN'$Q/!P /LU"U9G5[A7.@XPZ2B7)00G#(58,1UL7 N8,BC@&
MTJNX W8GMJCDB]AB'!R[WH]*1]E3G@.#F$E))'19L]'6G[<;6K)=I;@FBR(C
M%4NN Y=H[Z#!&3=DMX&S IX+9^_B^DZO&GA59(1U;ER"V+TH=F> Y:'0_H44
MMC[].=9.UFTS#VZNXHV1A74!HSOWI/IYW,.!N(++^GDM;;F/65D5YYME,;:4
MY+L#[B0M]O;O-\ B'F2?&1S[J=OEEGJA08IJH6:^5_YV^#/H<)-YZLC/S3LC
MI1QRQ/< ,^"7A!O>7OADR#SP[.K8,[W^;B&!UZLT^2PBUZ+)^G ](M,KP>3<
M[L=5W<FZ6RA1]KM.?ADJU#H'KHLKT ]NL9RSO F+QA?#I\,K"C9H):/PKG/+
M_:DODH(4?GXM4.XMN4-8P*D6(D43:H29U)O+N3*CQ$!_4 S,!X5Z&,[G%K>_
MRX2=?>V=P^0%\ZKXOK-FT%TLG@70HSY<)0X]/;@<A2WS*2QLOM#:9)EIR?C9
MKGHX(%36Q?)$$N&HHI.@U"&J!18@+="/ [2%ZUFM&>!3"P',\0-'G=<;<K4C
ME/YN97,$WJ-$E;,E?+0'GZ]@BD.7'FVQC=PEA%@I5H\XP[O/NU^Z-_8QN5%@
M2IDTVHW40^5@C2VI.YIZ4_6#>T#JBV1COB;&"T<$(V-J@H@H\,F\EXU6;>-0
M[#I4M2J$P IC6"B;I4[]G?:9]@I.EJR6XQDB'?5]*G5]%5M83Y^Y'1\7:)/N
MUS.\SY!L)?(AU+F>X*1,HFON^!38T6$_C74N,QAJ"9.'($DF;U*TK;.@A-H*
MZ#L<KQ)O0)Q*>W-=E98XQAL.8HAV[&E+!%^7?U%'HK!U5<1]PB_'L0&(T6_^
M)MCU.O^ERYAL#S0MY9&&EJN4SLT'(\@/ZS<WI,0GZ-BO)8[#,5V2,RZ](0A+
M$L0'S)JQ2)?AL'XS3#XZ856%S9Q SW)2,T@P,)]H&&Z>F()#G="A:5S.]",,
M-ZM J]]BP[/J<9N-O?-1]3<[OU&P/A:NY 0IA:^% T/M;#!%SR=HK*K01JCG
MU "O,LV8QSU $V',U"*$QVWV'3U2OFBNRGVD2K2[]):KE,/I%(M!5W@.D7NJ
MXDK:(.-V#_A26,^=ZTJWT,Z#%\,91^FRWF-*NI:-R6F-%7NPR\(S%@=Z!M[/
MB3\TE<*]&_A^[336ZVA'2Y=?9D5_O,@L".-W+;*UJ#YT< 7MSMET;*0TW84E
M.*\<#8">OI*57"#_'LWEC4=I[]J5.7*EP!'6Y<:Y/\F7W=V\$R%I-!AX^P*W
M<$1P!1'B&PEUOSQG[VWP6;*7?2)'4)B"ZNH+1-\IR.TW/)^L__G:E6^!V=:)
MSEL?DV=BX982_N@>D.YT#XBI0>1YB=]KBHJ/J[:I+#3@60LHKH9M<.I?YQ@4
M86MIL*N9.<G1>]SE+YCIBP'IC207$0 STBVTBK7&QP5S,#Y5$S\3Q( DOI1-
M30N-).*F7*FQ-*$8FO!.6+D)>SHH 1G>[2CDC$[X6F(T=P[C>W:+SC2;J^OE
MQM&0O>.N4MQVIWMT"\3MC',H(N?Q+(\LE18IB:)Y+$[A%YZH+"&AG650GTPP
MQ)%P@+ZM*?LS%YIC7M:-?FU5[ZNA*'[M[T*QQMUMX$K YPC6PW-E%O9K<0_,
MLLF8,>.:>"MR4^"E44P0DV!S\&")7Q0+[  Z+)W'<)&N*1T&6SDF\7"_"I+&
MU) 49WVSP1<+G(=^;-F@]UAIP+^T4!PZC4 5SM9:>&0<:4.HP57PY%$YD_@*
MD6NG#)-FG!Y,89XG27J>[)#B<D(.&9JF(^; 1Q1[J]NT_^FXRB?7'N7"\E@.
MO\.!,U87[W AP+%!6&=X8X*9PY""+FOT?>Q1AE77S,6/9+>5K?FX6VJ]([L7
M'2E3"XX/SO6 (\S,!WNW[@J9ER.=)'@D]+J'NX1C>%'LL9876&AMU:MY]!=Q
M?'LYO>RU=\NUO 4':%MPQJ.!G\0*L[-;E?,DONN\3D[A%@$$* GA#Z,CHR/G
MRV[U#J\,#NNO*W1QX]JBIZ4(?X2G,ZTDD51N<%.I8_.7JJN!L+-KCAAXJLYE
M2GRV=G+FU&OZE#K9O@&03+<^#[#P3%@CO!KV@32G)IG_GF/$6Q$W:HO FH3P
MSR2=\NXK8&E#!8X[[Z;4F? <FQS!Q6*,RWN ].'4"#/E&-@Z374</F)O0B5.
MJC8W%?7$?>6DF/U([#:L%G8'DKL'9!#6H=D$3]""S IU724'-O2"]+V$]] ;
M];71?QRJN2$1U4"UU=#R=1'6W1Q6!=>+._\Y;Y507N7P(O1B1T7VK>RNHODT
MSF9ZR-BWS*S,5,"(8KSD>QP%D5?!>A*>Y/> ;XS%=[9R=X_4^B&G<:U85P^G
M[P&P1[]J?>V7*T4KJOA50VB*V&S_Y\UE6"V@X]>N'O"6/_:6V?Z7O64U_],N
M&YKT&CV<RUK&5X0C0X5Q[0YS!J0Y"T/RR"H:7",/\K4"WW49D2G= [:+D.2.
M!G*>Y!!?1!'L5?J['B*3S9/M@:[SSR&@7-?:@]UK%%<K??U!9U%,L9R<T;SS
M+,=S.OGO9/6%SJ%I8WD$R+[TA.)]+]Z2S@G$"'(PFK>H,#V<#5@L+T*]+="8
M<T)#V5_6)K9O@.86N8_M%^EP:TP&:^9MQ_=I?E"08+!ZW77#F3,_\*[Y0+%@
M OF+XU5F?=48F#%RM?+QJK&G-5(E?>AN=G3,SZPLUW 2(9LR"9Q@1XTF9\-W
MJ-V/4K+9#E1-ADY[$WZLQP[@T60)[1)Y0P:W)BY@U]?F7,][30C;;AJJ7PLF
MWP,4IFO33]F+TY0N].I22\5(ZE'1A9^GMH9N/ PT_^C^0359@1!3;DN& N^Z
MK+^\XR%'WS&#:?T3PY!BKF#& <-RL7CA9H-JA0-Y$FZ(EV <]>YATA=>N[&)
MO60_*RN_"FSZH1P944YN*OJZ\&%&:3R?J@5KB0NPIHA\@<^[W**BCV60V/6E
M5F'L.&=^'S#J&\H'4;;TKS<Z"$D2 [DAO+8K^076%,=%HAX[@]A-":['6EOM
M*70CG-/:[C4'IV 4,IF1920K<+[S' 249)U'U;B>&&SMJ*K[:H2#P+- 1A25
M$KZ^R[7J!N99UX1)PACM*&UE<_9[2;E>G:%S/TG(VHZ>RCJ/]'),L:B0&9*C
MP)KO%.N1J^8C#!;4W)2E3QM3^F3U16M(]4F8<6U1G!G(R<O-?H3<@&_O:[53
MLTS])Y=^2]U&<IHF+[A*81=;\I)!I<:/U:;^LS=E1<6L+P9MUPP$HS^WAL2>
M1O"_4CK^D":BTE!VX^1?>45>>RALF (R7RS@G(L<ET35*",!JE>,,<G4\][V
M9W4N^:B5DFE.'.^@R0PS!V:1=-P.=57VEI$'^RSL>1!N5:HRP8:FS6DWE4P'
MLX2$*:P5A3&7:WX6G3'O014HEY=,4$H,67]\[J8,KQY4."T*/SX?&1YG8J((
M^['XQ)SY8T^":$?2_&F(Z)+?E=5E.+U!#:^&"K6\[7"WC]@QQ_",I,,::S<2
MG4>DSJE)_XN03,M>=@412^._OS7YK9!D4V4=$;18IR8(EHJOB3I6AFD(KC[+
M +N+_%'?Y_O?_J[Y/_VH_?2T1WC\M[WP5E2$7UPMEOD]?=?!EUOYT%-U.+7X
M).K[B-HPJ?ZO3-WG5Z;^Y%6ZGP@Y#S]:BV9LC?YUT#2#XQV_EG[=&/6QH?&I
MDE]*3]H1EC^$&1/ZN/W RLG(KITKUOZJI.848^<,+$?DEC)%BGM<?I=T]SU9
M=:%N??6JZ9!A!1C VW; #L*XE3XIVN&('VLN0\]+ 9&#FMUO#&IJ-JP]MKP:
MG3G6]%"3N/PX4-B]>*[V"Q_5?I8K5[^Z!VQA$G\#5^%/V\$XU-J]B>/:N'I-
M['+-+ASTKWP'#*F_"[:H+7YL*!@^ [[8:$]&U=OE?WDQ,3&RL9L(K8^9KC\L
M2,S=%;5 TAUI6F(Z\BYGGKGE2K^+6DN=LN.:JM]E\[QLF9W/V5)X6MZP5JKH
M6QGTRB95;[;H)WF889!B->?Y"*]M'PKRNVX 'DE^488AT\^\.77IKI$9R6%N
M(<FH'&2"O0[WD&UO/43TDG,7)&4UG2!\_L6@FU1Y.&QS:OL>T [Z.ATM7S_"
MT2_52<AZ>!<*-/1=WR8:"MI[\LDR:C!9D/)H"),[337F3!/44I+$846P6J%6
MH;$9;QR68<;R(?FI<75%^/(>9*IGEMLNY9O^+OX[Y)2<8B*OQ0:!BW;W0D*U
M8'8T"WQ*)32=;0"RJLZD*& ?;51@7*$8;Y+'BD 3V8\#P[M5Y[V.NMFUI]P:
M48/0H@B!=YU@"R4<9T^JA3 [ 92C53&A]LS\[1=PL97Q";DS);HU$I_)Z F8
MU\-_U)/5)N<R6LIB#ULJ+[[GO&>7/B-OYI5NVN=F<A92B#-,JGS +]^4,#F#
MZ>L=!/VMAIX^.]OJLTDE2%E#,_*U5![EP9 Y'10U3[TWV]Q%]<5;]LJ1"B;Y
MJ,P\\A7^ZGS(CGO >D31MB[K<$30[L<;XI=J\O/^0#,VBM58SV-4ZG ?NW[=
M\F'V?B*1$?U@/NQ^.S.2CAF+\IAJ^Q4@><LDBRT64$[E["NC:MKN_JE)])1I
M%=>T0%9>^Q$*^Q%!C'I2?T-E6+UAL7:DIN(ET_Z"Q*C-/H21:>9&,./8:JU:
MP%:,$I5 *)&:8/!LN=9M]_2.6OIHEU#Y4$===$(.38P\YNE/+JM9GL^)WKAZ
MR[I5YS=DF"UW/[-GW.(=N02,*HA('*K=S!W:#7/U-/DSLRAC%PY?8"K'-DWD
MX((W+]R?E#MES0>\Q#N A! 7N#PB$T(!AIF++889& \;!'R,W5 /RZJJ4N.=
M8+VUB?1!Z29.?NQ8=2W=R"> ,[9D.8B(W+%W+O"O*+]\JKE@O5T($)HG'^,@
M^Q(WG1QD1#*>%%81R9AG&S(A7H>/*;A*?!2%NFDG5A&M:3/FF;_NM='F)8G&
M&[Q[IO-2.6H*K=\J9S[86(1$0ALS>:P?;6D/^L7**K/B""LHRL-'<EK*_<,*
MP6*JHL/GE"S3S5AOHJ,GZ95PHA2-(<B4 GP S!*%'D"9ZM06&AJ:.&'2QJ*V
MS!2;DVN&2+Z:;"1Z/(MUU+Y1$64 VTE?PIL#"8!5[#)B_09U[#M-W-$DD_KZ
MJ@^*#I9F-M'<\HKRIS7URFA*K30IJ$JX>2_0?3!9?>6(1[TIS1A-[#ZZUQK'
M6.&V6V:OB"<X0=IHMPLBOOF(BG&?[<@H5]3@)SJNB^H&+(9):8\F*'+Q>"?D
M(!]/'"A4/^L\N!M_1YG2AJO5[HTSYLEN-;^V5V3%),AY$6L?_#&.Q+FJJAJW
M>"6:=H2/:@W;\6#W^['=A>=L"A?\<:+)87X\9G3!#F>\4>:Q>#)IG$KX0^D0
M'.E+9%-JRKU3_#1)O1?N&%EEW.;T$XP<)"\UC[XW8MB@F,5.>_129:H]:Q69
M%1%\T.=_TM7]R,LAW#0[(]M5JT6 M$: >(2#MS>X*$JC:'&> %O:<=]=/W$1
MRUUW?,]*.+IOD=&QKG>&?J;KU8+-IY"3QD7.)_H9.]U[RCO3)M7EAZV7\)$V
ML=%/D "KG'#>'WPMP4\]@Y*5L<5)P@P7WL1W+P$QVC+,(CE+38QA:NL/-L(&
M_4J;_!.)DR7Z)<'>*>-%7$B]!:(G'VK*AMGG-,6^M.02?)#,W-=C]$UJP]]V
M;>'8/'</_PIV'=![4N7/7F?%OQ8U0O_EX^O]UZD^ZT)NJY]\!6J@'(R!$3:9
MKAA.Q\798G:>;]XQY& =1R%3N1@*C/$45YT9/R4U^3$!A@85[=VRF11??9,P
M<F!K^3(9%PPK#[6+[&KA<U=+NUR0"-EI+5^8,H/CU89,BWST2&V*&DI[UU[J
M4$<9?D66Y)",!MH+0]8YS/BFNTY6.85T#^!?)J#CG[('/N7/6NGSBQV  C-=
MO0\TRL?VEZ+PP:<[( &W-P;(VH_QD1GD9&>=\N.S4^[B<B7,SNND&C[+)9E1
M_R3ZA-2F;T+0<O&DMD$9D1?R'V[(C#QY/ ^A/@^ Y?K;/4TQ[%73 #V)2#?W
MYFB MXQ:B_BK,EK9<-1>B?<!^-!M);J1" XDQLSN ;KBYCRDW)J</%3]\+"\
M[4@^(8QWHL:JU XV5ADV^'QGW;A;\\16;TDP,;141CVI<D"F,@P=$'S"I4R9
M25)IM A&9#IN[DYSLF=;SN[LP.>[%9?^G'GG>.*P]'W]=BS+Z YF"S#X3MLS
M7OO$"_E#S1%>*6:<Z1'E"3+=*#:.E2+TW:-3I>ER^M)+G7L %1HBURARN =L
MQA7 2>M'*_0"H[=/3'FLLSPY/CYB], \>V_0W87/P'-;TRGKH?1]VOD4.VP8
M:EK+/]]4.+VE2I>]OG;^YKPU?#5Z$T!]F 5C3]F5D=F533/TE']H7)K0_V75
M$>-SUX$N)$/FX\<C*<&:T5,K 90S,"T3Y=>>KBK[<(FO*7&\=E #+_.<0,O3
M.V&1IB/I2MWGE4VUC3=\\ML+-64!N$^<Q0;4-P3FS$G4/&:$:K#(4F%%.HA4
M?#HNK.(AY;#1C;221*[&9IS6(B-V+)&8,B8+ZZZM!XRBX')0;OR5?[&_HP5O
M@D=,[$M(A &[(5RC)^5XB/2M/5 S2_'FU;L9AU>W'&Y6(!=#$$=60 >D>#ID
MMN^EZS3^Z\C$&G06>L*&\O;R&0L!=MA>D6,2N]?7MA$9XF!+KO(?Z?I]LO9J
MZ<DL],F-XXY-2).;\9X">",<7+4E(<?[VW LCM6W#E\&O.61"3:V=EAS%V1$
MER/8TQN\=>B%#]OA[+6$C.!3SF$-;4TM7::#5UG<TW+:#V=#CP%/\@;@+QOJ
M#O6^0*S>],J6-W"A@C R1?09"5HY6V8H/[D[]9/">J\A;=^.:^DG;ITR15R6
M) YV'0^>ZHA8O69I.+RY8GSZ(E3J)6^9.)PA8J ^*A][70TGQC<J-BKWO1FM
M#!7Y4YKT;^W%F8W/0%UX,'CUKS>%Z]/74G\[;;C&3HM"4RNY0 1'C:#Z_]+F
M;QP%0?*'$LTX#]3DQZS8"[CJ&I->!?"4DPVYQZ^L7OHY.$)O*(227>MD>+^T
M>3W^J#N?@F<1I=OG8E999%CQY=2>I^8,+'ZCIFTF2C^O9KS]E'=?0X[8XEGB
MW*6YJ.SZO&T[5C:]B?A145A!#[G&]/0.W%6[J/.6EZRUS&!/RBUCTOS(S25V
M>^/R$S'/'0:M*%:6_YB><%%3R+(%ZDK%#V';K@_VSY-R)NI%CZ?7)[;%;7 [
MVJV"_8BCH)?ELZ30PSV=0L+YM,4:O!E5-YN*H$>"3J'=!%"4>0CC02"$^47'
MFV+'7@N7<KS8A=87193\W7? .'Y)Y]$,*MW$[[$Y*4<A>W#B?I?S@@0;#H'N
M\CY6UJLR5W1^'N]WYT4N$H=WZSEY_)FV]?8?9HRP\]H%:OCO?'862.C'3\,(
M8:(5S[2*U$\HPRX2K^-;8YA-O&3[O'EW9 7VP'=>'<%[!C$H--R%C'Q>L>?+
M78>H)\] P"T=1H?KM>\S(]N3,;%LWT1,QP?YPG?D*'^2'XR#6G-)NL3U!4_9
M(R]CEJVJ8BWY-=GNZ#4GSGL5I#M><Y.H5'^\)%Q/(MH.RU"=^:EUF9/>33TK
M:I,*YO4S,B*(!=%Q7!"GI!;9*!^1S#J/ZC0+])L\C#.>B24')7_/"+(*F^#$
M[G3#ZGN(Y5[.^E6FS.WE060 =0'KECJ+!4]?"67D#^-P$?2H1X^>N3\/J?N8
MO: W1]5Q&GKCCM1,)JC9&?*5+4:,PN4#Y)@A#N@:&JWYO6M(]+.8N9?E>S6.
ME<Z/2V8J#I#L8#VRN7DV'4:E\8K+,QVZ]4Y=O$_T*<*3<&1<>><HR]PZ";;!
M V;OMH]V]D\\,QF01[/<O-96+RXP^/L"YAK<L;+<7W<>M]EEZZ5)_?@<8D1!
M</IQ5XRC5=<T[ESI1W]]%).WFD@7Q6&Q8EC,P#2G6N/: <K.BRV>LQ(QF]<F
MS[M^+OK:):KEU\MK7\Y(GWP,UYZ61G'"&/+E@25<FK2I4<N'7%_Q?77%^H%[
M:4R1,Z26Y:I)P$&BNJ'E]-&:XH:C:"FL-[$\P@ 48QALUP SY.G7W1PN*QG?
MQ=;2,BD-G^EW#IYE*U%T",LP);D9]G(^Q[*VH3P1?ZPK(I,1#2.>V#/9GHB<
MU>2V2T2')=OC5_56GO ]:WXFYKY^*^CA9.,84O5"JY7BY/FR3'L7)H#/D1MW
M3&<FIJ+*+KJ,0_4VOQ97'PD@UN VCIOI/!RO^JGRY:.M$AG'5DX:M+@K6Z\3
MX9U:;9G28H/!TL'C(GJ]FNHXE7ANG<I7K<R6JGJXZV,='&^BZ&#\(L8A2WBF
M292* FJZ(,UU")AP>_M:Z@LZ$U7HAP\%?9YGN,  _\@M=.UGX%>TR<L02F^+
MHN^)Z9GONCLV5<JJ3*.FYQ*[=GS4$Z.\++R?&.;OD>"]NH[6,%!G'[N1F7HU
M<Z=M>$#8D-[-.%NF(YG@8ENPR?OTE$8PR]E>)8[M5]GIYMN_5U#SZ36?VVJ;
M3C!L!3^N]_@DI!+4P_.\WX5EP7SBW?'^'[UJ&?8%U*#E$=OTH8=8MY\9FG;F
M@7>/U$S-<XY8Q3Z9:;FF]T\9UFLP9/$9V 503P61@:TH"D,(\%GX?+$T5TE4
MQ@H RH>")!9$RF.O#OO+YMH8^ZO-'CZJ:J.E?-'#"C4<C:=XR=5+TL'=^=P^
M>N@TG[[/TIMIAG;*RXCW\XBXBB#P$'O6VPD$Q]O_? \0<(^[NXFX!WPMBL@S
M $8F+NBVW0-X>*_I?>X! 76IH,%?A33>&?> Y<W_N' =2W&%[^6!=;MYL%F$
M](_Q4NZN?XV7\?OW;?6(U8]GN\"3C*;T:JQ+K5KDVZMMT,4V$,X4\>_??A$2
M!"NY!PR$PT,6@4O6FV0G&WGW@(7<>\!E[>_?!;*^P$7)_G^R_]\@FZPMF;+\
M2""%:NV[ Y10TN"U$6 5X/$"VD=O4+/V$KF7<>"'+%O(=]W/(CC*WW\OIAVU
M^'Q9G#%K<<T4DS7-;L;?F<[)GAE I/]SP!9U,P=B$VC.83"5I#Q+*#;P)JJ.
M5H#0(K)&B2J-8GCA'A"<#6JM@@&;+.X!7ESW@!>Z"Q,(\E@W;@B3POF&=8)N
MZ;T<;LZ;+D9!1^PIA^"SP8-I! <R?[0J'2=;)RM-,8Q@5_MX#W@ZHPV_*[X[
MO0?\ZLH)AOSYH-P?'2_S@7VDG5[A[_X8S^K/\?[LIUKYU]3 /WIH*H-^\(?>
MX%0 "<UYJ/RV.N>A"J-355]EA+!X.&Q4"/!S/867YZ3:%5IL>+0TI[1.,)(2
M=95IO(2N[RSDX+B5-7<W>C=;"'#C@4N:.RD+%?> QA0$B[GGDQXG.MI%DI60
M4+=;*3<[4*8NGSPJ>VYZ" !GR=^$OBY9KHA5XSKLM#8YRPGT-KW7@5YRZ<%3
M-.)$DRJ.,5 K!$&EV5]4BMW2ZR X2/F3 [I3O'ZD'(53-@3?!'IFUXR-WQD9
M3$(F-G6T>OD^=*,]01<JH0#$;&R[Y1]>)I]C**F.X=$[,.7A#,L^K1S'3JR<
M=Q7X.;BB>0\X!#LM'$R#_D0, >>H#OPNYT\XF:V"]H.ZE4KQDHZ0%4I'K7:M
MV><H%+44*J=EA(:D*.DGZ3_9\I]H[^?DZ>P0QG2F>='&KCLO4*P0 &7;((X+
MAV"._S;RTTI2IJU4V]SQ>!I34O:Q"C2"BC/?GGN 7$P5).F6U%*PJ?Z)*-:*
MHKDNSS@'/9C[]BN1EI6 4?)\SP@6W6-;AZC45;AW=:?YPBT]O\L_00&UEL-
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MH<RJV-42*-A"[((<XGNB/'JZEV+=6 E92$KV[$DHA1'PC2I83:%V4SE#?Z-
M>>?KC!2O3<7LG/ C8N]SC8?%_-Q\2OIC#$4YKHP'C.OQ+&A0XOR^U%-*I [B
M(EB) _WTTN\X1&FWH!@R'*4J(N'9LD@T#XZ=YIFIN_PGK^DU-;X#3Y*W71<#
M!$ZCJE5(:JA#L*NYK#3(_D',7S^1>)+ST<F":KSAK&+B:,.SM*<P^'-T%"8R
M\7B,?@^!.)VH( D&9_RL1$ZIWG\(FD/I1DENP3K%&C)GS_;PJO>GV W?[4(
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MO6QNA/5^,5^\1:A,R.%37N6FR[)_DV75'VL I6YZDUX]K"K5S02VL2XT^O&
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M%Z@R0FE7ZHZ\H>;-&KTT$=^M(W"[:#*(STM.&#LU5\+%RHL/HFPT0O/9F5R
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M9C"#M?).[#TC\J*9@7PK-QZG0NV([JV:H>>-V"VW#;.&\9X^UTPV_*P@(!G
MJQ#QJ6QO5CJSY.64/>+"'?=UF\G>8F.)4)K^[H]M>9%)-,@0-?I@"SYNOSW@
M$#3,H/NJ[_W7"@O=+-4+9+6YSRFV\9V?AY.,O'OT!:T&O^3KG"#SDLI5?SU!
M%>U\ "S>8DW,\,23)4ND^E<N9"199E47OHQ#E\C@U*^S"$X<E8KI)O5 !S^!
M<M73551JD,OV%$^<3#BHV13LNQ1\$W]T,J_%_Q)Z^VO-KB?!WV*&"BM^4P[_
M1?N=_ZZA_=>8X/;%%B6AWSJ:Y0/ 6.$!D,7M\J%Y\?6NHTGSPM:VZ]_!8,)?
MP:*.QO5282.[OTC(&678X_I_YS6^B'5^ 'R9RFU#Y(A>R9R6<5TWB*YC=IWT
M+,%GSVO\QF40VPC-"7WX;-+0&?]GOX:)!P#,[_6YJI0#>8>A-)*#&:W[@1'*
M:I_YJ)#ZJZSE,!#TU,RV=RW/#\,7>@2#Q>C^-I(0R8!N>=Z_\MQW$A>B:F-L
MH?@V[C55EC"1P&\T2ZRA/><TX-)(# 5R7"[[Y+!I^+F[$;3);4K2R#"_%4A[
MI.? 9LUQ+D#+:LH#0%&:.0FG5%?#,_+"45BAS?.7<56/U<&.P '-"?>Y0^G/
M6G 1_]8S!J^9##=+H,<V@<(;OM_$](WZK74_M3T]QFS+H]$!"RV[>5F\(B_'
MJ"TB]8E,:0)0Y[M.2W!MH>1B1I:)COIMBY;!(^SWSQNLQ]!8U#4MRSSL-LVZ
M5]C,RIR5(>[,B%Z+V%:&6B@#,V&2\2=!!,$WK)A"98Y@X(O$Z#0;')*C$B&Y
M@IV3HET2EQ[Q>X>RY.8U?97K*X6G<*FUYBL:&&UF_]1 G6-854(XW3<P@R_(
M ^-8-(!VY*-7_;#('$?G2'>$CP@T]01%/Z1N6ZOB*:>3O?A=V)3=^,2 =H<(
MU;AU+HE1QJPSDM).KG5_6]/(/7>7%0FRVDR'DPG08^TJIO_^!]HNT13X2XN7
M7J'&J.B/,;.>GF?9_>X!BHFTD2<JR;*HTPB\V5_ D:J#3[/VUD<C-EN=4Z'&
M=4OOQX>6;>A/E=]R<E%=1E2(8DQ-*5D)!A8Z@9X.J%+HON(;KZQ%+Q*(]=(>
MI4 ?394ZWH@(3\;-L8V;B6(XW;G6!F9?ZTL>S_G43A/CQ0CW1<7M3&OH-8?:
M"4F1I6@')RI74B;NWF-@-DYPSD^EAL:5UM)4+*2H1U5.'.H1!G10B-9-T B6
M<)W?D1=?N@X-MEW<[TU5;4\"B1(<QJ >SU.K!V=),>D)3B%35_[O"X?R[[H@
M+BF$(::Z[UC(;*B$;/GUSMZH:GX"*YN5-W#-'WW. ]N)+8*Y=D\Q)2H:E/^4
M.%0^ (PX'_G5<R@(V/X .&7:$[U8$T5\L=KQ!HV'-B,W8J,/^TW((:[."4I!
ME!*/SOX?T<3:OT03)16Y\J*GF,:Y1DG4%;D P"K;TGR,?*JI4G<3-?T# 9XA
MOK+7W!/7#.IWPFOZG/:^9H@JI%T-==4 1II&@2]_[R=*3/OI';.,WOI15?&>
M?F)*IW:4L$0&]HJASVO !3Y2BZ&E9S74]M(-AA="2ZKS;O.MS(0]*+4&GNDL
M&'*EO\L[64$Q4"UU_^O10K<2R(@Q6>9-_O8^*D ,><X3"[A"3)Q1+#6S3:Z]
MVRY*U<Y6HJ*XF##*=W@]C-XEOD5#NT46;):_'0QM_GP;VM53)QK98+A"KH=7
M*.=%BU3.#=E]:>AUVL9?EGV>VLC;[OE>("^5;9N>N'LWORYF.G2';7^Y$?;9
MEEK.Q+9H%_4^PB'67=:2]ZTBF&$:EO:K&CXMJL+'G2[;Z8,>YC ]VOS*TQ"\
ML+0D8V,=P$H;R$@0E>^^UI)D,+>7F'OVA=XF$(%"\+W4F[WNQ.O;.'3@'<%=
M:#^$Y 'PVUXTW5'@V_Y924=<OM6E-LVHZ>>HG1J-UJ W=;$6%3LD01F%-IQZ
M!AU\N!Q.I.;% T_U%0.NE!>XEYF6L4,6L>KOS#--G"-%-W+CB^F/B@I[*%4-
M?<-.(D]_P[]UI@BW6S\7V@@$XQU&1(TF&(B^';8O['5!,$7JOH;%B+]Y+5@^
M?3O%:6CQ[=YPY8A0CI:$NX]KNSYEUGFVPT<&8I@D_>N,DRZE\'P=_>0-']/9
M_&[XF!Z1"$'$8(F9BBOURRZ8<'&YVVI1:_3<.QI_[@@??,V0@XVT\"?%NR ]
M? .:OAH>F)DJ;O ,AM4+O-;(GQ-[R8BA/$@-C7<)_MW9@/8X0YSB&RDSW,;V
M+[&'G%4^3+=:Z1["PW6-,>EWM@?G9=(1;(:Z0VKY/-^D+"F3;,.VF3W%. "Y
MI0%4122-#4D\;#&9*64CFL2.5<,4<D4SAAMC'[S/4?SS;T-7V1;/Q!MPV]?E
M#\*Q8GT)CF8;@QJJ*^2[>0NZJ1M,5+ZZ4+Y:8,G<W<_25-W6C_5C0;_B6!PB
M1D$/4]XS22G!JR FC#)Z]N1,F1]QRL-Y,Q[K+4.'6CF&9J=+27->]G;<+N7P
M5EN(ZA..SS-QS+$6QEA.?VR1B_Q+3. # &=N>,TI_6 @/WNV-)>^O!A>II7J
M'(8H%?HH,UIJM*-GTX-;3T1GFZOSL1F]T.ZGGZ61?@=15\I3BSOPHRDG5!RQ
M9LG!Z;(.%]M8<%3\^+UMI,UW5Z!LSZDB$O=MV-8,?'\%PL+5!Z"/NCJS"#8?
M7,HJDSN.%]M&N#_EE%7R3=/$!+TKKZ_HT^V(N9>O$4V&4*)P.>P<Y ><Z5=K
M4.1B^PW6%C/Z&,]K3:DSCYLH.:C.&3??U@:4N(<>@F9HJGYD?R4JF+;7)^\!
MRYU(;>3VLLY#A.O)>!X #4W+$Y@6"C6C1S\C3>U8DY/7NS!$H*]2\P<*'[<]
M^A;#EFUO8\_/;!1LFLUT:XFR^LVFKGPKK9>[ E+MN(SNB]0R&]&@GG-%[-8=
MM\U=WC=%,GVT%2OB5Q=EXB?LH52C7-]SOB6]N5'=JNT$_N9^ ^PF_7A3T?YU
ML8Y#!VTJGXZAM\[@EFFLX2:V,3'?; T;=]LMUL]B)]^EEL:[@X_HT8U#X]GM
M#ECC\[+)HBEKM^C7HCX)3%$7]-L+3N6X\[:&.5DG7?7J ?R<B+>[:F^ULT.*
M,:KC/Y[(Q>8S %EGOE37-56(QY#HG+4R)TA>E/JW*C2^6N6I@7DYHJ+_$61L
M+/93.Y&. RM?.I+(:?M'%[3"%:VVZSHC5@MHH;_-@6=MS/?3".BZ E\9P\9T
MU11W?.-:^3#TO'8T42'QB1395B.+$4.H0AG0HB_-@OMW,?GSTS7Y^J2-$!28
M4X][E/BA^"ID&_NYUN8GW87OT5<H#%&M(:.YJDZYS4I=&E8\4>I:&-G?)!4T
M2TISZF#:(?<UQ=Q;W!;FUOBJ4E3_%U4I_G>-AK75H_NOK*)[.W[GS\MD_E;,
M5_R/HORX?Q3E5_RE*'^BI.S?9( A>JWYG7#%'6^<<RE,!>DQJ!_-P66A:/3=
MVD)F_,0Q!X> JI1"G-5 8DY<G;CXLJK4ZPR?586YVB.,E\'S U5OR*@._7YK
M/=M,<K+ >77P.N(FEH??G+Q;)*]1R8=MUM)[,YR0H'7OEZ&AL0>R34B:B$#"
M.:7>^?9X^!2S/C'THS.I+/<[J<"#D%+UR FKLY6#]/'<W$IH_,7\2'C*_/%A
MM/4:;LU<S)<F_SKTP5(V^_2LSIR4\64;$7*=N7YR%AL:T44<C-!MFWMV\V1.
MQN@HO86<\@RVJBL3%0635\:8NO5FXN+;3)G'8;,/ (]BU]"@D.)Y5QG,U1<@
M&U;[6B3\2LJ/!M5)*V4'C,3)<C_DXB4B-=6%OQ L7)?^GN^H>6UFQCQ]SJW=
M^HISSD;W;<M+^M4W:=K.5KX[BKLCJ1'K'O C_]Q8$XQAGQS1%2P1LWL?IA-O
M;G<QGBN]]&H9(%F#-C09S!H;(%*3;T/A'Y0RKJHJ*QRN3 Z]_HAQYI'D9]WX
MP0D1QT1S6AJ[UE9AZ<K\ZUU(* <!(9(?^M$O%"N9"%.)4B24\I+<Y(G4JVJ2
M?(+R]5N-\AG97T:O==,K.B+??9M^ "A!YRUG6:L&89\=OT5#Z9:"/V38;+N&
M;Q%!O!3,JF Z<5FYVB_3"&E(HAP_  !8_HFAP,!?)65X#X#N_)('P%3X ^ 6
M":+7>R+ZN$F&X.Y#CYN$I,Z8Y(*ZK(5=LM69_4+-KQ'^#)0R,*+V.N\;Y=ZL
M*PI*3I#QKI_\"'<3+WS5-X^(\LK=$]4R+WY,T3%=@L2R$ Q+^<3S^C:#>63D
M4.HRX14:H38]/;*]6+#,VHFX(O"K.(T'%HX"I=7T*%=QC =^7\W;M&5MBWQW
M116F>.Q<9]=9F\:*+P5, +BHWXQZ/R4/\P05  -=#\"8$_J?#B94E(+<G"\O
M 0+H>HQ9R%044*4S>6AC^,]C<+$+1NWSTA$Q,NY'%G,>)EAS(2RH[#][BE=+
M]U6H,M.G9FA-CV=VXV=AQ<DD6E(PEHB:CY3S?O979 >=*U_*ZMHX#Q5,^K(:
MLD-8F2%K/<,W&YM2VSLY>_E.42HY.##!CO1>?.S;K5T@I'0<N]EJ*^Z\1S37
M,R$CS,Z*3TS1@"<ZHT"4&5<ARS#S#<@/Y]X^9>LRL'P@%P-9P:WZ1NS\9BI.
M;]:N:PE'[PMLUC?3%5Q7_*[K!#EJM"F40VH#WU0MT)'(%,>8X_I(>^3"CECH
MUC?)E.O.'/458^"G+91-<Z"_TS#9%M&.H<:GHL\Q;UV%L97@655RW221,3Z?
ME=UUS55O#D1S7>K<.HR?67F]\]SGJ$60)GQVN/[U]*)48FSY >#?H G6MZI[
M=W7I,$^_H9$LD'WXDX.!:MWE0$<O:O^LH"LN#U1=><O:KTBX6]^<(!DA./=A
M_ JD<"<LP<[3>_@B^0'0C/&U:Y.YP[O,XSBIRY,K^#/79JJ%G'6^ENB7;KO1
M+&-";ZGCXJ":IDG6\M_ZUS-=&U1<C0F7)K47;#F<'WE$ZXV$REE$>#+X:PPE
MYE&'[N3&?>Q!/WY=7ZSJ:,CXF>4O=LWO?YY'4*V=%UQ@A\Q*-[[$V[G2(D1M
ME34+FE1FZI) FS.*?&(T4-.4Y\(]0;;UO8'3+\OJ[?</KE!75K+>6C5LDVVK
MIF_91GMN860OFV/SW_;*](+WC,I7FK][4H!)9D&.=-#?R_TJR697.Z<IN^P7
MF1ASEK'Q$U7'/^U_=?^,VT?1NS#B^6E#B.EUS@\/)VT<5!"KUH&^\$?!D2YH
MFDA?M;'=.,KH1=/C^[123?;*KBQ79P3ZX;:_@HO]&?0W&IY<"ZTSK>N Q@E;
MF-.S<UC,NU']7C=<L""V/<B_HOKU648394+NMND<B/ 2>U/2A>I"ZU/OD@H(
M/,8-O#G\.&ZM 49*1.S>!NP96$9L)7R*^,-9R8$SY^0\+RBQY]J[LXBN:D65
MSO<T(D@LH;XF89RQ\0G<NR)S'9>Q;1M6KJP9&_@"F6T0\SU?KK$#FUERMH$I
M&M9 G !=DL@RV[.*F=F\W[YW<6>^3\HIW,OL<H)R9H^8 P*BI3U*"E1S?;V$
M!2BT*/'0H9K<HFT7 IB"[^]T]>&*[Z:PWI;_NOE$_H4"VE!G$]Y7H<!'KJQB
M0C!X':49]_Z7JJWK *>-%F*;7-'A">+$[$SKT('>J4;62?=4/K_1:>>U7(]E
M]CQH">. /=LK_;5W:@+QJ=R-\31%9U%7<;JH>,T[:6E84()J,#H'.>KME-0R
M)8YRB10W9 73R18)UX1T_/8N-'M-7\'+#__#LQ=>MB3OA)Y_;!$-06ABIX"=
MB_:FU\H4W"[K,\1TT\/*6?H=Y0Y!DFU7>+/7P:WZG][EF)&Y(9^*,D\T'2OE
MXJ%4J#H\=>1'2MI+F3X^"IZ2C+>JJ^^LD$:+I'(*V/79Z[$:[!IJPU:?!19[
MI%N$&-*>:"4##%=GQ6;VPL,UK^_?T/7'S/]T-V^9+Y'VK=DSR/OF/OM'$*>!
MK#B37O0#-GUCQNSK9W4R\!&CE/@"U8C),O7IG[5E;!N&S&W[KW+>.G;%:6_G
MU&PP,+@Z/\-75?M_7@@*Z42B=4MEE'4-&M9OFB:(^?N#S<>E76!S$2SQS2+]
MS',I2WEP/C=W'6>QHF9 8+5%N+Y[0!>/5O3LW'Q\,+[.FC$;7M!3@&GX.0'[
M/9V(Z ,@L^T!X)OU $"_H+R6?G15=7\$)*R&[G+J,GANZQSN(C6_5H?^;'H
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M47I:Z008]Z"4B >Y)VA@KT14(F=.K&E^'N3EGAW(S\U#6<EI,<"P:6Z&5#'
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MT;I3'S8<Y#=RF]*H#BW9#9'-H6MRX1K!VNWAD@MHZV'G^S[6,HW3R'/57H^
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M$':G\"#F@%1\A#%]C.7,$*4%5PS&S*C_M./9_R\6ZL>Y_P902P,$%     @
M]$-/5D?ED7[,=P$ V,0! !(   !I;6<Q,#$U,S8P,S5?-2YJ<&?LNV=<$U^X
M+AJDUTCOH *B5.DM@*AT >D=I#?I+=10! 3I""@(2%=Z[[T%I'?ID-!K0@T8
MPN&_][GG['W/WG??<S_=#V?-[_V26;\U\\Q;GN==F;G[<[<.>*BBH*P P'H
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M%OJ>T%FIVEGTU($7->;I9+7-5-<[F4S 3V$:N.!%*(;C9[]B%AV$DQ,4_WI
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MD8V.GO[(+#OG87]ECRJ$UK2GW).=\8UJ5[)SORS @/)02!/M> =(MO@)F3>
MG%O.4WKFK]S_4*O^[?*- \ODXEZ2_Q=#:]+K>SGR<\I=[8I[P_E)?*H=7(/9
M*,OC"JKI\)P[+6S%91'T'OZ8*BX_GG#HY-@7PPH^,)E&6Z^2(*4W?0_[RNMA
MLM_2!M;%[@ 42=\I!T%!$D ">W,2D;@'S[WCS/9[M>+<W:G2L:B25@3;PO>^
MS^NN0TC1PIU('=>-6U7M=,WI+4J%&E'JGJ0S8$KJT9]9]3F'RBZ5&Z:5HGRX
M!GG@Z_DVD4)4V"E.QK&;=1KL%2],F?'CSM:A.-2B:]2'10II6XPXZ%X4BRJK
M9&^>VXFB,%-Y&_LC:%MK>;.Z9T<<>\]@C?B+&)2?FG)6#Y& )I"[=32/G]/7
MDWDT$:B4^(TWMT_M=F+_[PSK3\[3W(51^:B%#_'CW9TT=0<"%?TP0O8VXNWZ
MC_.N;"\P>WJXA)?C$]N%J,<P9B<CI$Q%2U%Q@-=GUW;+;%]O!3Y)/$Z6U"6Q
M 2!>'/"ODN/[H5K?!=$<*=\K]P2S6^F#,<R#9<9*>J=&W%??G*]2F?&L\:DJ
M.0DE'N]FU KQUI\P[\M2>(_2RLT>;R8[97ZETI 2]IF,]C"48W_Z8/VA(%;7
M9DQCQ7V<4'0P^DD>KCY*>5=_!D@7$U2CXZS-AX=/LYWA4ZOV8+BK_R%1_S.M
MY89T6C&]<:Z*P++1)E%\=AMW:/E]LTH3S(;RN0-TIS.(I@8QWXX>*!!^YK#4
M?7_-23?^&T_R3.=D)-F(LC"SV0DJ.9 /,X^@N6^%;V]O/R9B3L%'+BR@"A\E
MLBFA^D@YZ="+BOQN&>'&V6#&UY7FXV>&/</^.Q4H*.>^ B,&5S-0%'%@%,A3
M,U6OI'%C(B@\T6F=6 UM_*T(4PO\^U.U'&QXL88],#*YO#(0_\/CK_)2X^WZ
M.\R#/ 'M-GU%%-52?'%I('O'/-H4%F?>EQ%9&'2;R5C3;>O"U,-\O4@KY?8Y
M?JV/-(#7$T.$@(&U>_085$*WH2Q[?SQ;]+82ID' ]]P_RAR5)>Q-=)/699ED
M-_/  9@FQ3M OE'[N-8T3WV<C!/IJT6ISPY?2J%/-H."$G*/S"B1<SKAT$6J
M*29VG\&1H(]E:CX9.5!90J,_JARQZ6*-CS72"4(3:8Z2_W2A#PP5U 6V.(0S
MF_O1CQP"99'ZQHC]P5'7Z-Q']]G\!J5W _?=T:L_H0='0<V$FR= $J70?(>T
M#]W'BZ[L'=-UU1;C9C&2%S+C*-8\<T>91[.!-L&Q-,Y[C.2A//%+65%5 [+K
M9K/]#ATLB,LL^*CV&V1;HX][:5483*QKS(.8B85>Z1'&NS E,TB3X30_?X:_
MS0(Q$&#Z2I;Z=>7>V%_VT J2'[[=6LHF\$C\2K,F:?-^65;S)3"C0@<"/;4$
M+44/;('!\_92<A@:B7W9%G>3^JNH#M(_*]TNBQ?H >VPR]-H"EF?Q[)I3IW(
MQPC9"!!Y,=C7U,%N^JD4[R3&[^60C!W=([[C_.SE\U_.IE).NUKMV<42B#N
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MZN83(O/>?8![K(/9B; 2[=,T:QD+99YL2J*Z(*Z#RZ"*3T3XK!F>E@T%&L*
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MB3>E#PC00)%RD^(XM)_%NK&3\DFYBPO-W@*57..C$* $V]PO">7KF*$GLL!
M041EI#<6I'AO<Z7"1Q44^9KU;_,Z:W!]KO=Z)W 5E<S_<-GA[X5!S)><L<3W
ME=A;I(WGY9\9"SJJ&EKC#+7 :;JD,WB L^N9\^^%00:&+(9(X[Z;CI ATODH
M'F]7,A.NZS@N :Z%+>4QJBM\YMO243ZT^;IJ '$"2C&0!K'?2%[GP#LRH/NQ
M:F!+:W1P"(K]77\Z/II+4*EDMQ?7P)K<+, =-@ZTER5W;N/%CWH<?^P;2_S3
M,@[ (PC$!NG5;9<[D7-LRR/L>AJS61"!X[^Z$"9KH]M?32R2 #V1S-&;\&5]
M_8UQ/'L62J?(21Z9WRZOHB%!;,=+WX.VQ??]]65+T+K37I6LO1O*/"[,BTH;
M 8D*,WX +M$+MFV3G!U]D"F241T17&M5M&JXHL8+BU2(<J'E;?R>I,TA(:M9
MH=-.*G4'P$5!M)&D'9U^Q=<96<VOJ>X9T^%UZO5K9W&9O#KO(%JU^3(6J&YM
MS/'"34%X[@7^3QEX1KN\G8]NTLYD(#7BC;XEY' O2VXPXMBD^&P(?=#6T! V
MMBCE9&\523##I<@0H8M=A5VH*B_&R?N'/0W*6!'(@TCX)(+7V3HM:M(\DN#*
MIKC-ZD8F=!*;8^2.,ES/:PC_2_;"&?\X1NW)]QT)2SH7B6-/ RVT#R)6J\V9
MI;B9[E<?\0RDJ[0< 8WS8J7MY]Z]RG;J3Q#DU(K_=BQW="Q>&CS)ZZ*R92>G
M<Z'&-VXTS3E=3Q!XH#S_(>F8N\E.6@['Z]!QBSK)UC9BXY:_5]+W,CC)Z=+)
M=%N#?\3N.D$[C?VRK),B4 8Q'K--RU"44>Z%MR;#*=#,LLF:B1SU.M?>=EB%
MU?S9!OUG.K'%?POD"A\&/E@RT@AR\G1K5!_,(VW& ?@-L=1/&:QP7$34+SO^
M3NFK^>GRXP5^SMCWYIRV;F-KWJT"VDOMA>7B;Z[NC/)<UG&_>W&L/<2E2X5Z
M.Z@F0<]=A1DXTA>LLL('.YPZ8'A"9Y3&(BDP#?(]#/4DQVS]4W=71BZ8R+"
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M@W9J!PUK4=3:)F)H=LF(SO *$-UD$Z<F)?G:(V<!^.UZ\3YWD:;V50 ]IW/
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M4%ITYKFL82P'=9)3HVS9*$$ NY2[8">B7354L#'OHZ@39L#.):GI-=4^4.W
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M?I_6I4/RQC-8D]A?*HH$=LC>P=^\0\DS[UQ22B*!?EX\!"ZB?MH7 H01AQ2
ML-&97P9<9C'O2:#!9>+]7VEIXO^[ !T@8!@I.8N71ZT",5^'[:]"T'1 BF<)
M@4#B"B-"?7^.L$RX@=@[_CT  @.D8W#[E[%1Y=\>C!)NF/P##AL\^ EOY&6E
MP:W9<$Z2"/Q#V.KQ3_LX;03FW4]<[B>>#> "Z(UY9X#/ C?S;Y=S(>A+@ M
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M75*?*M#1[_Q-CA/D(:V]HS#K>!B_*@6/$.T1::Y6KQ!EL+/[(LU]X0:WF[#
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M([5 \EN B:<(B.3&?V#!"N\6\.6D,O)-0<]-:[T3U+S8"T'4*0]G"PJV*5W
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MO@50'A84;X''WFU(/[H%X-9'@K=SP!L$A(AL]!,;VCM<D[D%]%'3K>E-$CM
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M>D_!CO[+JLE:C?&LD$V*[AR-X"T63)D<BONVBK:N8NB:QIPSFIB1#KC[KGO
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M0M.%(=SASX383;"7@G4EU/FIKL#WDX>U_>*EVL/$^C1U%L)F+]Z1KBK+71:
ME#:*PJXJR];D)]8FK2A7!9A]7E?]H>P(:\\F$3&"VT4?:)A366A:KG"*D__!
M/O1VZ_6 5N1$#&A-3GF34IWI;R5!0Z0\6F0OM\SBIP%B2X_MO\D@_6^=>__J
M(&1'%O]VQ/M"]BXAIP(6XY]N <H0N1..$,@Q+Y(*#4F^!4@$MO+1G;&>EH5
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M-]]?VHUSSI,8A:^.,$G5),J<3#PDM%%*JC6Q*#7C2R.:SD'P%;KQHLY']'1
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M=-9&KB4!MIC3='Z\K_XU)KBKN9E,'?DT*'R6VO&+P/-DR3?"MX 'R!CY'<F
M/2P!B@C0D>_,];09^;V/8?X3&A';5+> E6<5QR?-0S1 @['6$+&:[W=8%HA1
M,746_@(\T?TL@7Z;JOZXK*AE'^DSB\S72)K"LG/@?OTF8^<8+GN^6L*;5EV
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M;1 =>T0:C/3C62,,9K=W8%]-TTG!#=,Q8R@57A_;IO\#TRLM#GSVMC02\ A
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M*--:*3Q#<92&C:ZH^)B8-10([92YW.J#GMKT??KNR(AYX>RS776>WS#-%B?
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MC"HORGF!T6W-#P)_*EU^QM>US(W9%^5C4C]395<Q_PYF,2'_>DER:_[Y'^\
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M5J]S+V#B-ONQ/0W]H_<?$$9()C&]DDI\*V5:!Q;^?EE%T[\726Q)053>QH%
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M5&5_[B$*[P &UE-$U9* F^#RFB\-EB(;:3F,A-<K=(_K;VCO[J]F^_95_CN
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MK:3.T3J^F^YRIFB\!5>G&O]VJ*6='>9.5\B';:A:T]4&NF<M:KT'[1S)4_J
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M@:J,@$>_+J5UX('6D!$"VB+LQQXCTC;1O3QAFDDZCN:3Q*M'^:1LGOS6P'N
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M<5OE2^\!QM5PV[/;._T^OOE;OGW$W&:X>1F!0V^Y'@4OX:#>Q6:;B]#Y&<5
MSHN/QS0A.I=<S[40(%1V7%3'(?-4=6W7=BI,JYG%,]'(*M3):6H90C]CH4 '
M/OB2TI\V04F:0#W\?\=I*V&GVWD'O(E$CWU6.;)=#PE")\CX$)W;( "(77-<
MG+QA04UQD8F8VK$H$ZR]""RV\,$=M[V1RJ%KRC43@ ?W:J$U+MO6#5>@[OX2
MCUXS_U9GV\[")J6J-:E:+B0QHGWWX*"4<ZG <!:X80OQ]?0IH?[ @ZMRE'9X
M<_/A0'V76@5/QROZLK]63V;16)9M<)[\6F/JQG&YULE325M4B;)G;TV[[77[
M)E?JLL)N3[KPEZM_64+/"/LOOG54>[P7@N1"NZXZTE/HKF:[R>(9&Q[+_4*X
M_1(L,EFA#,V] $N/>4D72)K;%\S(BB>2V]Q4^ML5$0=V(WV%!,E^OY0U>O"9
M-!>YV1:)=<]S^[BFK003%*,IOMH=H0"R8S7Q([/)PT9'O QL9FQ@!<BKA.2$
M9.^;A+O/6,RH&@C"\R])@G?D 3%A@G3@*<&8<57=O?C5,NQM#^_=L[2B3A$B
MU22;)Q'CV1)/:3,?5?AY8 8H7T0M4X ^PD=+8#5T=34?C)4BZZN&3/U0?"N5
MO0O6$PWKA)*9*N5B9$;DD"%^5=SD  PU)<<ZCJ@&CA4V^9-;%E#8RNXC,?U.
MI5_.,YJ Q2"WC5BE'>$T.L(NJ4/%EH^#MJ@>)Y1F;002PUTU@IU]"C</D9$G
MH:/!X6"P%[]+M5!",5KC3F&=P ]N;WZ\-S^O8U1B0;! IP?_PKO$@3=_D=\"
M%.H_L9-U%$^J-53#LW91]9,7!>SK9@0UR!\R='@((>N\? @BI]><-&IT_.X!
M3"U=J%$3&32378)1JEGEB>W5VMX=>?&0A5G)DF[+L]#G//8OK$D<PMM0L3E;
M!']M:9A?!"Z#]83:/M2,BZ3H'&S,R+.MJU*K-+CK1GU^D!2*\6=8V?E9Y4Z+
MI!>.P.$]9S";]E-6:_=T8(^[[SX+0,;3?M J0.'P'A!X6J^XG28,E,^N".FW
MO\X'OD.AJZ[TEQTB%32;8H],"%N'[H?<X8\["WL+]>KXZQ0'HM-.;=>+HLL!
M^*]I-V<R.-HY,"4?-IE1-T2B+BIIG?BL>N@>,,\1\?./K4YAL?;'W[!B2:T\
MI-S'<PN;.+M65A1E,_+]+A?[MB0W-/X'*DTD7WJ:I1,'A9MY^Z2#MB4I%,2/
M[]]/V2E#[4S]ABQXE,>AO$Z(F24Z>"71/S]]X<GI;Y'>(,8OV3%VCE$_XB_=
M[\Y8RG)6)I:2/8D7_E'%C?C+/Q+>_W9KP3'C2?-:QI2WV4,<'*%3]F=W://_
M2G?H?Q^O .'XR?F.9P+*6QJ28N,NM8T.B(T5F2='C#;A:=+6;YG5JERXBMDU
MYUF28PPT_0DQHUHK8;?NKP)ZOQYY)&_LOVX8,;$<L?RD3N*61R/^P5YCLSQ]
M:S5VJSUUT]CNVQWOHB(NFG"CLA!LL]O419ONAP71AB$67%)'Z?6[P+1X=5<&
M0A5EFAU\DY%*7IW@Y-.AC%AN/W&(E_=G\\K<W=R2W,M&GS6/DRV]([:80O?"
MF5Z;PTX[%(^EU>/2SY;/]9%8K#F]I.$R/Y;ED=-[EN.UR]U12:P8T>CK9\6]
MCK6"UZ0QVCO*#*@934D(MP!)ODHRKYCAX6 -T0CSVSK>J)VZ!DDL^\9$SNX]
M7*O]AO>%='/4?C[*OD)&0]DU4+5,A9B>\B[>$R<K!(QPE[(0YLN>L6;GT!,O
MDUE])G)@L4#R<:.AZT7I(M0>- O$UTQ1PISJP)6IF86!MN8R/)"@5CR6?1T=
MPX4L3B"[EPA:P:\YV8.P"<PHKLWXH4VAAK($/@&]QP,"YK:<BNM5"8*#$T5N
M6?-Y#9&*3O0;U'9%0OFYSH7+FD0O$S3YX6I'Y!EM(U4[.R:*URE2">*L83L.
M=@Z<&9])3TQ"=;<3I2LVK^GC%ZY3:::TMQ/\^:)#7V3C-@3/:6B*H+'&WER%
M/6D$<B>?4JC\ KKV,8 =JDQNG;!5HR8I?$G[#8(/8U'A0M\+;SM35T]*,TI'
MDNO,WZN%0;,+XXWLP<O7W-D7[F@#N4R7*052HYXQHY3Q,VZRDJ3>)?:FM6KZ
M\F3%M6MQ%^.-+UM=ZIQ>O8)'/KF*SHX[%=W."Z,-?$S]BW#=N"+&$D&AE*G\
MT;+W7<BG<GC&/H+EVR']%W+QIM!P-1J;,,D;AAN6QA*JYUR7CPSV_.1+W_/,
M)M)6>\;K/Y5-LXG$7M1<D#K3,WY$AKLB[I3QP5--Y_<"@;^DR&3Q:QPO> K-
M$7FR)E2KK 3XT:&MCRRLTE]HS5?!)RVO9FSAI1PW,7 A-&# M[6.SC]@@JOR
MF%.S%D)'5J7OK;T*#-@14E?3T2J?.F>M5^0X5_7$]=AR8GO%:ACUA%##KO@W
M<T=D/ %SZ2*W,?0*Q)I/S"[G-3U*W*.2;/3')BO_CYFWJ'\I^J@M^Y/4 ?V[
M&;K_>VQ7^8WLZC.,5N.Y;==[@-E+X8:RN?J]V?#;<0&DT,13_BS>QH@>%HRV
M!9Z#\[ %TV%GGCHW"?84"F)<W3>H4?8Z8SP3X1QV!:7TUZ+0JL_N(E"."H(J
M/G0[ -*[2)OIT7+%!4K'3+,_K^(ES)V-?LPL3C5.SEOT?02CH.3&BT:5GAJ
M?0;$*5E=**'LD*7M:OXLQO7)W:_V0=$JY@ZQXWC:2+)2#%TJCQ/P]JPW7^O*
MU9X*^\P"7P)H1GD<A7;)P>TD"W&VJ%8.;X+&]5771)B%GL74:IJ24\IB-%HA
M^:IIXBE9G2B,%UNN*KY)-YH'= 2=LHV@X](RR_9]B_KA89Q6MG5^!0MN)SN#
MUHQ2-WU327Y14#;=M@NH)+)-=/UL7HKF2;>0;V;B:&GMZ$CN.%\;N<#E8TF,
M'8U1GK\P-8,$?M32_Q4W^SZ7-@(AA>DSOF^X)N+,*[4B3G7!K./]?%..RJ0V
MDJ\FG.7-D1R:A. 1PD?-/C45" IJH"CH],ZQF)RQ_>8S;.)%'Q,QTYG73OCM
MJ0D=F?T]P-0P-1T\<8+[R,VD[669>_86Y^Q<Y2X7">5;C)\+G52!3M^%JD>H
M,^>.A*W1K^_P!T/#KI0Z9S@XV)7*P2[S0DOQ3 A-\SSN_@_C3L6SHN)M_+Y3
MZ31A2#8BED\-(X $B189H^3YQ+U30899<OMM[8GZO N77P96<'%SV$+%9;K.
M&VP/<PN!JW0FWC3/]P>WJ:X>:8,QV+$EC&^Y$UQ^ S[(;\FK>P?$DZ0#X&.[
M7B_RI8IG)"W=BF8S@PA#&%GE>AAZ<L*?HPOR=EZ<#2UL)W[87L"N'R^YR;WK
M:QY>-A&Q#HB/#[!#(0\/]R0]L>;0'CW-='&ZCA+>27QF+=[56RF-6%_#/B6/
M9+Y5B%-K# 874Y(57IAT8&6Z"7\83]1-5WRRH9B9TYTR)941'3"P"L?TB><M
M"^+8/1'%L>"!6&/?,02=R>WG7+_;)E[JI1_32T+("78ZZD]+@V#&:[*#DTTX
MXR_5)WB^]0MWN-KZ%D"'O8/6C4?793X'QX2] 5(NG5"PE-1'7K>F\QRB]7<&
M\5+XC&I6^PN[P+^^%WLW,]QC?U0HT$T#EYHMFO"AO5!LN\JI^U18[)U^1%&_
M>LU3%NXGRYSC1--H_7MF(66%@I?W&?,N.T0WFH+KC>P'R1:,J3 ;!]C,$ %(
MQOWTAC0W(_Q&N! 71T]G=C '%B"5CZ!7)*&HP98 ,*^9'@@(#+#$'$P&P(CW
MH1&DUTJ'MC.LME]'..LU3Z;\*XQ83;-MQ'?"7\3U>]Z:;VMOI"SO\IY2 +>L
M(7A^IH8J##\!C^6O,!6RIZGM==)E?<$E%M5B_$,&K<F1N7QE]KS]L-V&1ZNF
M1C&UP8?L7 2FF_G-SL_BIR[XJNDGC-QO ]>],WK%/CV(?#*7TP&W3NTJW'9;
M3%U+>/)7[=)MG5<O=,6G<\E0@Y^VZ*9>FR]4?SYM%+H'J#>-6I>*]-939%A&
MF3Q+08!BWSA@&%M\SQU_K%B[>@:L:ZKZZ2;5IKA,H:A2-UJZ7)M^Y,;W-J94
M\8T-SL: 0BKY8;_N& \XX2*#_ZL)II.WPAZ;@_WM^/O]MZ(DX[X*9PJ=(PTL
M61;)\6?9^9JT_(E]^BO6.WUKJ1D-RNC*=F_$F7W&!)^%,695L/Z9!"NY9= =
MA;7760NM#NKH!%7_V#&;?;WJ<//+O&#-7IN U_"?"_+7>&:N-7HCGMM;:)5(
M*9VCN4B/^&SJ)_!!14U88U!0)$K8=>]L?T#8A'?0Y..@S^L+V[OG*D1N;V<V
ME=./E5[H8E61-HVI%4?T-;O2>D3&9SLO>>.V+>!/KAR<1;^NJ2U/%I]/3)!_
M*A6(%FI3LP12S 8+^8;P%#B+LJ\.5J6X)M(C=)>BW0QQ/WAJ7#6YL["W3]MX
MK6,$\P /8K5Q@_59*&GXKM$VI]?EOMZFT!V\%-^YTQ@'/\2TSA$:K\?8S!.V
M&AC6Y>UB8H-V#=STVB)F_03*#!,TEP(WDB8$LM4&=NP(<.3I*U</92+8$(FH
MKD5'5D7[9C#B4/_P"@QB<H]5T:+;DO1"K!B:G@;^Y5W;:Y66J_3L_ 6V^?G3
MVX6?_2BXU'5H>C=>29B<J<X0;PSU23$JB]@+&]N'H#=UXJCGL\UGXV/J)))O
M[&=4CG&#A..RAPRM7,B,Z8IMS',#"QWK8M0<$N(E]J5ZC\C:#F<G!=M=:E4]
MD@U*+OBX[4D&#C(YX4L1>R[Z1H(U^JIS1THY^9,NX;$E\_0W[J)G3<0MQ6W+
MLW'%6M[?NUUIH]T3"FUY8E*-UM\M"6X*;FY/U/,[1_*Y"FB@QNVJ0ZW-50[1
MXW'R<^?<SQQMCM:F>E.?XV(_0N):!=.O@G%FYH[H#N[R&;Y BP6=4A#V*V5"
MFMKS1Z\6IATXS^T\'E11>_FB!=5S:Q$U'N%Y Q4A1ZWOY5\5V1I2>FV>_I9$
M.,[=B4*J:_/UMD%U[UZ2[>_$DZZPA?.AD^C+M72=T$.9ZB*O?JZ+\!E@@9]O
M >%JOR?Q.PO<"A_4?E6[='\#!G42 0I<]/C72K6SZ.,CI8\KG[=RYSCK*L*$
M98C6+CM[A/W)O3JIG?;#3I-7;9N8+UB4FFLJZB<:ZE/<29D^[E11E.2CFM+C
MBL4K."1TZ1;:@"_>/H4TO,C2&7S1P>."E]WY.M[,T ]/<HW*ZM@ Q2U*XZ Y
M !&V@'W(>A42"XP(#)63_T3GL.-&F4^X7?WR+#GW*_\$=\Y9%?OO=:GHUA)U
M)NVMS-F*5<ME-I/69 -_V%-HM[/!3B@[;6,5[,,1C5(78W.[^A7E3Y,Q]0FH
MGKG.L(A]:4OFXG1G$:3$9<;SE\\P4\2D(]2$EK*Y;**Q*:S,ZORN_EL,I6WA
M;[C!0?H%$5A/S!1>7543:9GEMQ/ :22%]Z8AS@\<J\>AK1)\=",J]J+)6FE/
MF9>*T3LZBM\UV>QT%L&9^NBD[%/=!/2:3;M3L:9FVMVW>6=XQZ39L-<!'1VC
MD- G4+78@KPP%2,("BXV"!5CK*N%Q@]#K%\'(2VZM,(0*$85 5TD"'M=8$PN
M&.CS>I35:1!W&UC14G 9-V.E*NML9)-$E_YTZC&.(/'FW/E9BI)RSYUG 1N[
M2;*BO$AA*_FE;?@NPP1DY"S"B8I159HP29;D[QZP EW_ ?M5#_=VWJ.YF\2W
M=S%F^,\DZ/_M5<M3TI6[5VQC"=7R',$O](=)9G?/AM_IKPM<4K*^V8Q+==SC
MULLE_*J7UD]:NP+4)YO(/: *A[#R-"I/*M0>#<3G+9H/ZI(W$<1*B!@ZIKKN
M\_8)Y<$+#18[?R(GNAF^FD'5:Z%F)F^\/G>*I)KBY!BN-"9H/2=.U]*EM<A-
M^K$$$(K3HJ0ZU/^V\J.4;MC69RQA[[D,OA! Y?J7^0'$.WNA_2A[\.0>@*O'
MGGW0Z1,G)&MNR5E'/_<%Y5(BXL8K!UXJ>%ZBY24,*?L*TS(>WJ?4,2#B^UG=
M^KR,AX;\I[@;^6'XY,]%+XT#8(JOO8DKQ-V5[XA'+7_ZD["6\I.N]Y3>+$7E
MS=!QUE=-%6D,L"1766;R( +!;JLAA_RQP^M[P*XO_D5QNU#1A:UF)3RCC5M'
M @YL%XFJ,;+C#A)9=DSG7OC97'E(RO[%_#:NI./S##;?@DN\)7'-L1TW097
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M[B6EKLNO*R]05+!SJ!;(\:>ZVH'%?U9KQ]P#.,1D7?^KB3V":1R\5 <TH3#
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MM%[5CU9%X>V2(X6U#T0?P5E,JN$_Q5RDNFA"5@S72CVQ;@ M%[T-ND94WI5
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M06O'K.0EAV5HOVX2^*[+P-SSQ4.#W+!&]Y);;P<XQEX)2N54KW&/2A_0B=*
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MRLJ\H&]$^=GBJZH/=/4IY:I<J04OL5SJ.<KRO4*<[FT\]",9'N5[KN? 4)'
M%$W>W3L _X4)P":.'63FVXSQHM.*D-FOBE>S64/6\/3;RU03"OY<.$#Y.2?G
M/X?+?4BQ,G7(CY*1C- >7>:.B#!UQM3D[Y]-<LD7%-P6I@9/<A*T*^PVBGS;
MXJ^W4_8NG(^0K3C\86:BX )R>N*Q_FU+^,TYQ)_7>J>2M5^_GWG\*$7A"2AL
M+8;E,US]#B!R]8 U%NV7JV]'1W@<Y:22J'@I8<4;ITL:%2O;WM-DH_Z3]J7\
M,BL?^713!W_O29-X%>HZJ@0Q4#/)'>5C]_QI0Q,0"W7OSO0;6<+UH-2FG(I&
MJ7U:%? 2HFGB[1%,OV41P<Z9:$*R:D"<S!,4&^,\FFW<@#:&>&=M<<$Z AH=
M/%2 0THYNGJZ=W[U9'G"!7'VL]*7FBH\%W=L.XW1\CON-+++!\NC.YBDJ.^"
M]D[W816![^T7CPJ-!D[)&NV1XL*P4+V&83<G@GG;<MW9HJ31#F'X*K9!5$;3
MA?G7NP2Y/DE+LL>(3-2"<GU3?=K64E_#6IKT[E2"?[=H&H!$31T5^K'H4CMO
M"T$QYC9E-IX1+=+>&#75V=4@ Z_)[_0Y/]VI6:0C,$2#6A*%Q8YBNEWOQ#3\
M;,^8VV[#]/>A4_KH<F#-!][R9JO?_7S]9%]4_P80W:B<8]"6UT^36I70E_W@
M[CO^8(92\JZ24J7]]3 W"*Z7_H+F,//8L9_.0#2?S2ONES('I)CF,7**#!AI
M=H6HT) ]40F_Y1>[OP(F-<>R&CZ\:D^0VZ"B-[GB.<Y%(F@:QD6-EU+U[].#
M_-C7;<:G0DPVB!T A-[4J^&Y@C5.2%/&4^Z22[^"**G*?LY6URWAJ.)&5UNN
M9S-RB=F33S!B#VM^8(@U+%FBOSB(1V4:;"2_[<R&%%9D5T$_EQ%V7_\0H0Z>
M/;\2RMEZ3[HO%AI>Q>[4FC2C#[&%4\ZWY67&1 ;=&?J&C(9'P[PZZ-# I'.Y
MI*4S-SSI*:3^J[@N"YC,+P,*R(3C;-<)_-;72/@FX34$0T>[I3^\ =C8UN/]
M"CYKN*#4G1/^W@AS>6;_ DH''PW/M]JW[3'&0PHG#*3_FM\$B<Z"P+6[)&U?
MG^AI_6)@3E?SX8-B>$';TV@C[?1+TEV+0(B(!J_^'_QA /@G.0'N-!<04]9(
M(U$QR%JXE:\S.-?6<PGX;-2M*[A1J;G5DVD3PS5UNM/K^] /<$<QP3+F><B7
M?*,M'ZR.3QX>.3L6-:F.&<DON:5[/AO> +;74A;WP@2,7C1&"_F*\647[7^A
M;PCYY9BY@K9X+N$VM3UW4K3PT%=LHA)FK#'.X<B;R@*.8+"CUF=C_X7-_!2H
M*,CH8TZG!&TSQC]NH".;0@K';WBT=M,HV[QL5//2-><NN4M@_,D](\^6]B0T
M=UB6Y*/EWXE#:R4((%U5V9#)KW_PFA[^C1+-@"ZT>55_I!DY\ =E6VP:I*'M
MTCBCB0P-'1K)%%P7A/O8=95%EIWCKQ5-V0A01@9D89EM5RTOHDBX.) *I\);
MVI%BJIE2]<E@B04E1H;=-/2I&%+SCSS2@A.@HA7A*Q*S/RY*2W()K+"(]QS7
M4YD]7;*)-8#T_Q.,>?]$[O_L_E^3$4F.DH_@5</U*NVDFR5KMKR0/=UM=MMK
ML.M-K\<71R&1AKQ/?ZG:LNRI]?5D*FDXG0^=U+-&W@""2Q?3S_$@JT4+E[)T
MJ*K+QS< J=++A%N?.JSH*MCX%\25=4:F7D3X7]3-G-*^UCE]>1*S&ST0OB*Q
M9(=FO@XR/F,5N $0R5^R0_Z@=[V-9YY9W@"6GY^00!*N^L2R1#(KOM<.HO6O
M[]_ZX9/72OTW@':-&\!#XQ:)(\H;0+=>,SI<[,\^$-C@;VQOE/!<DS8'0C;X
M;@!Q%9!]8DCK)$KM"KOY .AT_11JJG-F/-?VN[/_CW>VY9]&@_M0*G3%JWV)
M\$NZ*RCX)+UBX?WIJ6J*IZCNQ4^KW;2TA&W4GTE&-D8<O(M91<>7W3FCGY*O
M*_]@<O[\SYB<51P/)MI6FB)<O5WQJNKUQ,\LWX77Z=UNE?@*),,AX_\]O^BX
MGI7J#Z).W-N!=61!%NTAE]ITJ"2TU74(.\,- ,/\=J"%G%;B'8?R=16RYI!6
MXZ7T<_)*Z"4>] 80GOF/M](.^ 4EB_4G_^M&\TY<MZF'=^V'=1?^$;D!?&AN
MDSCBLJ%#4]'= $CD*])-UJ"NEN&=_P:Y?'9-<1L<1"C< 'Y.W0#0!6)?+W!X
MP2F\0(%_ TDL<:(&KW#UY:^Q;_>S#HWM]2FAS+GI[V7-_P#<.JJ0$,B&V8@$
MBE_BF@5J)=[23[O63Q+UCP!:^9+G=@4CC;T!!-S&._MOP$(G^-:G_-9%3O\&
M^D?-30_^</T_KE*R?X>&VVG9*NR(]0806I]=E5:5:S GD5#^W#%VNHSEL3^^
M&B!Y4_3O"0;5<7;XI?/7"A]&\W/-O_\Y+?^])((#XU#ASB_9M\M]\XQP5'9Z
MBJ]H<Z5JV5Y;_U='!L&N2V1.N./7D8/+OIR=/_]Q,/J7SZGL=OC&OY_];W/Z
M#ZBT$_U7$O?!1@D.7Y%L><(%YJGE18\S'/VM2^UE*($!6D8_$ ^LG*C'QOPJ
MBI/!TI+K!P#@S3@AT"K&SX0R3&A[SO8Z_9RKD$WU =^F[-BT6,.&L'N=Y9E/
MIJLBZD*A%5RBEE%20/Z(^$$X@/A8/1.@.1KY1OM[4<C\L:E"&XLL._'/;$0X
M*&^>X OY_%93U6M;X+=EQ5<J<XH'U[#G=^=)="Z4VJXA#LU[6S> *+H9#[K#
M*X<; $3GTOKN^"VH>@L6_P;_?P?5)SA)>U\G'(::EG-MP2_747DEOE*FCKD6
M3> 3W1!7]%'19X<]OMGCM%\>KYI=N(;ET4/8@R$F7+J!\OJ(O.)%W2=O-'Z2
M_(\_%L,O.T]!^[T63_XGT-.S?/ JW5I?CJW/Q*!,-,X+:10DR\=4;68C-GAK
MH<'N5C< 2:3:!:IY2?Z2M5#B'$<?LA!\ WAPU,,"R[J(2!2#_HMJST_B=ZG+
MMKW3_U8NL62H=VO%PJ/7EYQHG1P-^<KT=[^@YGTW@+\"MVO-@ZW!ZX")]-,E
M2"N,.UPLZR*4#4QK];=R*%H'"#G"K[P!-#^\)MG\I+'#/"=D/G4H\=?R6Q>R
MON+6GW//O4(;HTI??X?:B"_UTL*_W #^"F1>DXRG7V$42^RUW@[+YRTQ6/$4
M7_=$=/!OY72HDJ+;/9+&Y@;PGNR2=?1YYHQ:K0N\; WR-^#YWS5C]$66=L2O
M[;?*_JJR]1E/_Z(=3K/T"_$A7GL*7<DZ32%,YXD&]*2]B<\#=Q(.E=W..-"?
M_+]&?BL$F-/(\V2$FLU:3QX#WMK+,REF<AP:Q5*I+'K:[P7<GPR7MYGBA]-N
MW?L'36W7 >O7U\WHX;]>3)8[&$O)C1^1O$>4'DK XK>7IFG_=6UBL$]SW_4)
M[0!-[ H$5;@ML4$+V4/^8;A_O0 SW=:\O4&^IO!R<,_T=]/_E9O.1S6K(@1L
MUNF.QV\ G3#E5V4J(DHU%5'\\KAVE!R*K0'^0L5XA1LO;-]JNJ)3S#4B/:1D
MB=\0<VO4\V/4EK*,-U'9G/HD= Q.<1\JC(AXE_8^CO,Y3SX.5\D<TI9S"6W=
M9B9A'_X/#$!GYW8#X+F8%O^_5Y6_F_XOVK2@.-GFV;J:Q.GQ'U.<H75&5)@6
M2A+5:/2&:]W6D9F",4U-3+$8=CO+G<._:'\=SYJE_ #L>OX]/# P_/DWC.(W
MM:.+=1<;>*#O_ER@MD1[UQ^:D%8^JZMAD)LZ-O,E Q R3_R[X#]<\%H?*TM>
M!,M&%O-="9%D_C]_I_I;?LMO^2V_Y;?\EO_S@LD(4-Q@Y?*5R6DT,HE[5PM4
MGR@/7(RYHZ[#WDW#,P:,#S0W$8ZQ^^*'O<1K9\Z ,#3HC,F-8WS%E??6ZLW;
MV<'>L6HOY)NX+28'IC*S90E$^9=G!]H6'X>#5NA)Z$E6TIQG)Q*JP"315H<?
M"7M7?[RQ?':^ \ M6Z\&GP.?CY128'1@[D,KO\2)?&R/8WK"\I!_;4 7G_N=
MF/!]T]$]A[L&5Y][60P^ICUSQSI]11+&N/+DXY:\DH>4AR/(H,T3D(P]]R&V
MBT4*!Y/0&Y.V,Z<$!/K1-+8<"-GN?%1R%>L8+EG'@-7"&BAYT75&FU//ZDXO
M9(WI\NAA^<HC_N&N73^A=6BVLJ3D#"P.D2+G_2J@_6TDP0\N0$ SE8N+R&GA
M>#BO=PZL,='NRPA3K9YYL)*]65ZMF7/#'OX7&F&@"C1T%SB_G#QC9KAX> D/
MM>^PP/J,"?C1Z>U:NTZ>^W:.8Z#.0,@$PS<7AT7>?C\-YA-N[PKGZ8FMUF>:
M6L$)\G<^(S)(/4FJT4Z\DUW<[D2=@WCV/ -[ZLU+3/^74J<TP490N5KE83<S
M+3<.*0$*JG!O$34QYX::%7F673)A%FE)S+3 NH=T!'/%#1U\E>T-+>MG4/SI
M\*Z'+^_=,8T\6'<>X-)2S#+D#%NN#83WAK_@+^Q\>G_U3%9R=6\IFC^2T]<J
M64CG7=V08MY,ATE2T;;)NVPEN3Z0!_^2Y* 03?X/V\0DK+L*+:E]IK3\<G@U
M'@]^8+[CZ;>:FYH3"&%G]_UH9/V!:B5<$GJ0P(;A2"Y*Z\+RH5[VLCKNH9=5
MJ._ 1A(9U:JDZ8NXB\\'B'6, SQ&,BL=#0,#6;O[B98S_OZJ]U=C<-1<6+]>
M]T!8WPTW#S6-, H[FF_^VAF8GQ4_P>?9FPP/=Z \[ EX]N/"H%605.A#X36T
MJKR-36ISSDJP);NG(7@@6;GV:4/(^&K[*"NO7= A5J?W)B)"N9:SN/UDQ"DL
M#L,D,D9!S*_#$DGJ66$DZVSIWTW,09R(L<;V];U4H?"Z[%>0/,&4^"AE<>NK
MX,G3UX.?XN,[<9P3*1;5XQZF:I,,<D"%%ZY*N]4JK[+H*IT;>@\\TGQ6/)W@
M))JSK[[.>JODWE./<$M]F/^XO,E()JB+H>X,ZBR;]*YN0O,1@/&(I'<PQQ@T
M*PJL%AGJ<,>TC@YGP%_,:&'X]7.GZZB0;GH$3S$KZ?7A+[8HDH7/A:MYD@_6
M14*?U *"&N*[6VZGCY,,KR>A/*]*O1 Q]U=S^H,7QUTVYS1'E,&5HS("7RB9
MIF5:B8CE[DB_L[B87J3)%>J7-\\P6K9([L@,=ZK@S5NCITB4-MZEC@T:_V@^
ME^Q;6&N Y"A9+ _M3^W2E/8OT/N<UB+)F&[RPJ'$M,%?!<-16F&5A#XH\)YH
M(('YF[WB-)+RQ($IA>HX"U"G-G>VTF7=SQ4Q;F&@:D7N@FVA$ULB=\$=^@M1
M3>F^(H69G482',!JB<(@YJ$B8^NZ9-+$B"&L0/%+O$B2S0J5XGKN/N<ZD#4>
M-LS)E+;8^$CYL=4SB\B*?0(K*M"N "Y <"<6)(P%ZRB)I19XF:5:-"5[YQU/
MIZ0EQ@8^CKU;1K9=<+_P\^]9IO^)8T6_Y?]?P;F9_F]02P,$%     @ ]$-/
M5D^M1+Q)A $ P[8! !(   !I;6<Q,#$U,S8P,S5?-BYJ<&?LNW546U^T+AJ*
M%RON4*RTI+A[*<4+%'>'(D&*!PW>X@4*%'<G4-S=:7%W=PT:T@"7WSE7SAGW
MW/?N/>/=_][*F/]D[[&2N=:<\_N^N?=ZG']<![Q0E%60!: \ P!0GCZ QR6
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M-3/ECJR8&$*.A$L7&!6&*P8+G=;-F:\9*3 4#-EB>^=&'EZ-MW+FV2;-M=/
M>%?M" ?;S1T!MW=3 -(NU*C,-E 3C*Y.H..<3/S]3H.A<#2+D[:>1[Q_X]B6
M&AN.;&;T/$GL)P<3927Z!H$<FWJO@47<8::QOPM][&$E18=5E&Y_CT"- ^C9
MB88$%02DZQ)HY^QS,7SARJ-5+/59UF_DS;36PK'0THD A^)C=;P;TPT2=/#B
M5-,T%\K"FBPG!8'3KH&_PWB"7Z/S$V8P><51-Y-CSL2$^.!\HG^=79F&;D)1
MF%^3.Z)@"FUG#3<_ G!!-XO]7PMY#\EJ[(@6^M["!AA/\3^1#<>D9W6W"FYV
MA.6,BWUT9&R,UR@1:U"A0/E5DQ!X,N+-V0/Y.MO,8[O*'(.P?=5<)6>C]T[K
MDE1W_:]&^IM2A2"GGU>EYY7A$NPPNI2MI0Q)Y1E']G4<LL'O 2BO)4LJW2O3
M)8#RC/ ,5R9KK%_< ]7L*J2LXCYH-_QUU)41#^3U(J$GO2<@2O3E6HW7)X.4
M+WWF<L%,_=;]QN0MJ6!MX)(5]VC)K8KF]]_[!&(^5)M((UBPXJP8OU>A;3UY
M+JCXC\RI%JF:JD8/3;H?4&G](=BS$*ZC-5V1:Q.*B&4Q"%(C;;?W)AJ@5YS,
M=U)-M?NCY(<OO5Z$C'6!S/W(0A#-C6LL2X%PE)WYOO1V>&V;EDKDSXUUH$MN
M^R0\M.8_ L:3VH@W)8/9?:7<K8M-CGH^_FIX7X-MP.83E/T=U45*4J6V"ENQ
M+NW7UGE&:-8W-Z/W>\<W^FVA?^X&DO&Z1>GN4<J2=3QF/]W->1)*D3FWZSSG
MO>:_N(UP>P00[-\F03<R/ PN>"S-0_5?H9F&=6**73V)RQO@B>0#&7EWAL@F
MXF S2>AA]HPJ-F."5D7./E[YP_[KA379YSK<$O2^"M/NE23&4A5VVE6Z.-;Q
MG%S,[P2N (Y;8L1]'O0OQ)3IXM9]EEIP]F6F)TJ7>!1YI+G4?P?/6P:) WO:
MZ>$J!)2@J8,Y<G6#? ^H$'B:2-[*T/7AVC.+6 S/H0@L,GK/R>(Q"=VJE6'C
M6N_0.+O4KBE2UI)7:*')"O EM]B<B]]3F\UKB'-\5M!":LLJQNMNZC4J0C_9
M'IT)=C"U+4H2,I>Z%(LBE9M./3\+D<!KF-$3^W#K,L ?O2$3JDEJ_UHL"TZJ
M!JLO*@:O;8K O8'!I/DZ)I;A/(IAF 0,M&,FG>8153=U['[DZ]@+= <6%;8B
M>3^FKI6 193#72)-] '\+GIY0>1)MD1"WQVM/0"OKYFO*K/$W-?)SW$%J-J3
M2Y:%>.ZLQ@9A0T%2:-X!:\G>5ZHG=V)*Y^I_U;-L&D&4\?9N'$WJ$!I4^"Q/
M;GD!N=NP^O[HHKB!<M*L0?$UCEQ]Y+WE;YX?JB6CZ'(8+?F&\VU75 4_DK[]
MI7//4 0Z=]FOT\GM O<D4>&>FK $Y9PN7P>W^7G#96ZC'L\58Z&AHQ@_T#A2
M;T/7E_[<XQ'P,6RC@M<MOC8J38%EVFWH&%VS6)9'K3U7W<'P:F"6;_#8?QD1
MG;NP1V_#6QPKD583X1Y69%;Z[O/4F</I)B;Z^@\AS/%UF#'JNNJS%?"6W,]E
M$)&![L*@.L7[L]Z09RH\ )I8UQ/=3/*I.E 6R>^-2#R%\I$M\;K?):)ZQ&^7
M\5O?#,Q1=O$]0&EU!(J%LRP.1"$O;.:2PT:7M*M2]XG$?IX29C%5 G9K0;N2
M-' 9)"9TH0#Z]P]SE#)-BP</E]"Q_U?^*_]H,"+L:]'J4/0MV<3P_+45)F)6
MR_9UP>N60KZS/&')"$1[3BY<G*-VJ82]2% ^;4OLA*%:4LK8.O>P@\1=6;C.
MB.WTXG"!(L=T0GB92WY^.3.OSO,10/4(V/X0^]!A\91P^K%!61>,"H\ DVK(
M/M! JGABM]H[_ A(28<*K_3R*QO(!<>]4 7>J1F6VDM8*U>T\:A24NPU>%]/
M?N'QUAEY!)"N*PMNRO3>-$:OF#?>R7+!CZX'Q[:,(/U9)*OZ!9G!(*9W#2_N
M;EET@X85/F6I4$NTJHFP.7)0&9) ?3(SR+]="9\^#)%5%0VYIGLIN836'$3M
MEH#W'CXHN_YK15 &?R[;R,):@&NNZ(%S'-V+9_1RT+P<77A*N>-BO,:$3HQF
M RL-CSK0^/.\@$K.MFBSNW+"UI\"?R1<V?N3<D1$%Y!/"U?FI)Q3/TBZ=R#V
M""[MIF<?Z ^2'P$O8DI8(QQ,K1L5+&L_FPAQ+86:I+4+;<4(\2?_F[OWD%K_
M<,".8R:'1T"U]HB@OK;'N(D5W2- H*I@:87:M@XH=(J".NPU8\):A+;76.8B
M_[WW8O@P+C?)VB(@VYWYAG1CC?KJ<]UL[;WC"TU#UD0F3FL5*<1W"&SQ4,QU
M,S%M'2DXV*E4VD=BZ/&69^M"FW3DV#%W3KVI01QC2N/7-$XD\ @4_W.9X5][
M6A$1CX GMEZH-<TO*BKK&.0U@XT<\7(*3&FE/(_5@+$F%>[N1/93-V+^CI58
MBJ3/J6#MT?<(W=2K=.<DAZ<JV2Z<E[5ZQ=/X;<J+N5$,[$042 E<3^#\1*BL
M;N(4:X.\\E)?_:VDQM"X8LQ^F)YZ6+KA;%B\KQ2Z$-M92[<^W7NJ9@\4=M!<
MY(=DJ;J.O\:);I.,0I) 4O3$SF-Y0_K*7^40ZF43?:3!-,N47M+MF$Q(I=$(
M5?% !]\L]9ISA])7@62)$*K5'XM9-Z;3Y4\!)+G?;74I1"G)X3J5:B2M-WF5
MT;$H$EU0>-:R]Z>DY2!AY$OF<[BV+W_YTI%.:M&B$R&U&XB,A!>7N#$]LR@=
MOV[[>#:U*+92<H.WM;4NNC#N<SS+;R;44&.I[IAT5$4^LU?'5^^V)ZYF"JX+
MD!+N&=."W&YKN(%SEZ3B7K<]:^C[BRP[JY5Y1P[%BZ-!0D&-W?A%_E-ACAGO
M!L1TLF=Y%409X[8ZR)%JT'UCAJI@I>FBNO 3S^I^61PGLZS):F>8W=I'96W1
MLA)H*B$7D%F=-N09?L_0UKBZ[Q/HQ.6I/ (J.>\S2I<A5*:UYW]$_ H3WK1$
MS)CJ,7^W1WMM-$^39:AC;WZ?[F6>0N#I6@*W@&'L]05MJ4Y/H-\W>^7J]D\P
M6J+&S0?)J0B?&%VOG!2$2+CO3 O K*EWO[]$CH#GNNCQ5POSW"M5B0=L3+G>
MZUK\8?D1+_YN*0J19;<(NPVL'5'JE5P2F0N7S3*=*/U68%\/Z\).". .#B 0
M+F=[3S?3)\I0>.Q-&]:4?U@Q5'3HX>G8Q&*:81AX%& W,S+3EH[A4[(9Q!!@
MF=A=C%3VK2NG%>W)9 G:ZF[^T^#<3?8A/4=6#FU'Y=VR$.TOJ3X?N=ZCR@9?
MUOAC@-AU0S+J?:'&O4T&OI[LF.QS.1O$:#+IMS8_Q1$'[,[TT1SLJY5TS7K]
MT*0"S"P+3_1IO7XX,W['STH W&^= *Y<.[37.L,:-CDK3?(I>R7L)9'7.KZ<
M2OL,>8@C9RLA3($O6-@F\UA/!:5[L/P+-%;MNUR1HA,!K;IW]JZU.PRSL]GS
MFY@R[=7#J]JI?&XV!?0NPU#*'@Y=?Q-CT!34S,!'R$R.(ZZ_N'R .8 ['K1W
M%@VY$'_2[L9JCX!]9:.!OEC"%9MV@JEC^VV;@FF,V3@#7"8MZ@#$*>I!ECZ+
MBGH4Z2U.@6MCLN$DA[X/%K\!)>=SK@NB#9P]S.BF$3"D2_6.;OMI\]](7K&4
M^9/#5?BSL%XU")2PU_TIG>RLRF9XQXIVF9YN'65>ZDOR%"FGJHB+A$? >_U)
MKB@S?G)G@26Y\6DUF2^I-&,Q2&TQAHVB:2*6I%VY%TMY?BO;Q G' -:K,V-I
M,\D^ C*#>FC1RIIX^V5MWY?O)4S%6H.CDD50[XY>U>=*FVLX=1EE;*M2+S/Q
M!E!^/GN>L/0R:X!T2T0N4LS@?-.U<-F 1ZJQJK8EZD2B@ +R7L9C7*%GI4$P
M);UA^MHD++4RL@[+B0'&4O/68V1G@&_BSJ7F%LT"#67M[N9T-Q4(3M7+E]]2
M2_(T!=!MS[&N9WT3\8R:V(QY5=<1[CEDO^>A4[CCN!6W#QKV=8;:&0O"X.?7
MY2.T^9XFEF'LO0RF\[84GGN2 >7W"1FRJ54ZU>*38R83==3!3E9ENLM_1 :>
M6)W_NYF%TY=UH86-J4+F)JT77%KTZJ 1-T@PE6-BN:Y)?9&S\\WG2[I7[W+F
MW;HP7UHW")=E$2(I09LX9>+OG_:3RBJTF?2GXH+&,BE: '4\-L*]>+MP.][;
M&WTEIGNL5X0CQ_7&A]VX>]=WZW?8!FVL?\ ,/<T_O9R*?^&LV)698AI%<(A<
M:YT3[E'U6EP"$PG;!!<3F@! >*_HH\]<W;)=#<@$W9$?)PQ/;-'@+@J#I_.%
MZBY00>V3<_Q"U1L3Z5@XWB. OGGMWO7K79T/^W^0Q9U.\/O91\!1NN1(&6A@
M%6.*G_/%(\#^R)B%RB]8MI0QL7II .V5"J ?'R"VFV%3HFW[*_)65?K7'%^&
MU@+?O<KHR1QS.7'9=_$O>"X=Y!W;Z6N0.?F.*VYCVO]$OMZ()40:<.TV?Q;L
MBOPK+MA-%74[]T6_Y^;8*V&0T+4*/%2I7CW]MNZUV%_J1H[<4<&NE^[(/M_[
M\]N-3?"82G-3\W1!0WV0!I4,T78R&[8C&+5HCK;JXWETWVV0Q)M7WZW9B5<B
MWW0*Z9'&D%8=\F!='6AI_[!^PW=-E*! C 3]DPN2B(O8IURP0SP;>Q"#/JU+
MZB. [>X1L&6"C'7^UQXJL4XQ^!'0ZPJW[F3<G:@W,D1K"/V;8\7\ZQ9 X[-9
MF&^8H\Q0]'DTZ?]V>[GDO[67M4C4#/M"_^W#W?^5@2O[QW!&;GZ**=A'P4A>
M&*%3SLNM6!Q[^Z/.MI6FPO*K:ET8F[EZ@+A!XEC0-YIN.W]"9B:V4\G[1P1H
M,2CJ?)3ZIQFBF/C8RJN_<[>PA&&?#4PVGA$LF/@JPF,0H7]D'%HWQ(=HRITK
M5SXBOC][L*[SP1OHH<=87J;<'M_$5Y&/T2.$G"6:2BKNUYYP],C7&AB)3%+K
MDF?$O5;+TCCT.W)R4'G3#-)6!?IDRL V)U5Y9=J>?]1->N78U:Z.N36VHUD$
M3S9S/Q_EQ#=8,!HJH>:O8;*9?U:,'HC)&IAN@00MUHES#.A5^;#+SHJF>6X/
MO!P<*[Z2V*RNC46%@]Y[9:E,YH;OO(_Y\V?/]A#%_ M!W>O9KXQ12<4T1E=B
M>^NLR#_T-R>/@#I0RGDE,FGG$? K>NQAS/@R'^PI/RYV=ER&Y2!VTFZ=)''#
M&W7/ Q$)6NN6H*^;@=2N/ZFG]M5)KT[:I1@7"$VJ8ZM7_DFCRWYTZ>O<)B4)
MFW\Z'7:/ ,*\FFGV^,V%/WUY_B&AYI+Z"(*/Y[/A>0J[MHM:&;6- RDT[R3$
M!=V+[<68-NXY/Y'?B&BUDDL+):*,B='O&6BUV2V?*8='V7^!D%><E2/1N:NM
MI=X.D1RG$U*.>EVQVB!!PV+BD/4T DSC1X#-PI![Y7 UL]36VU+Y;M('PIC\
M3(@B0F1W$>>W+?NIF4)VG$>KRVLKLWVI<EK>3F/RB3.9G9A8-,_GGL :WA.)
M/&<A)%O);)39\", X.RP?)$5"+G@LY.\?EJ7&J@F?,Z:F4X@8N?'G0Y9L58+
M47Z09/*>\4H!V.+#!(=EXQ3?//OG.(\662[Y4>>[B#3=\=HV_VD#NWHUHP_X
M._C"&H=8V_XD#[_:*L5KR3F2A'\3D.P_T>(K=E6EJ7QG9_:TM^%LI/.&I$=K
MF).M<CT*V38/+UNFD*""WXQO+H9TW+F$Q+89*#%A)Q$(XO?GCH$;9>&LDWPP
MA[>156LCGBPN^!+F?N@*4+"J% P'>-AL*4C$=D)$4Q9XT"3/EZ/_P@&X<+^^
MN;"72:<:ZOGPIJ9FXIA%,.!N_./%QY(V+%.NL:$M(28:'2"L\D&N\:D*#$O>
M8Y<M7CEA@2$]%UZIQHEH1%MTGW':)5?-58]49L18LX\\S8_4)]>;TE\K7Z!F
MY&7?*PO-15F/E!F;;IY8I,&S'@',A6?W2Y![BL3H<^"#S(G&0_O 0P!P\NRJ
MA59#%82S9)DY4?4S*Z<+S3];4U_E:Z'-IR'\9"O2<A>!/=T!M"W*\AF9XW2Q
M 0='7UCAVL#Z6J2ZT>&;EQ&3%^Y?RI(6NZ:Y:.&FH$FDMRGLML=CVHUQ#@?D
MO(?RJ^Q%8&( 9F9T5G?SO5-7)AV,I-M/1RG"*V!I%\/27!Q;';NL6>!K(=R[
MYUA?J[B^8=G$]+-]52<K<\*\UFBK@;J2)@MYU3H=;@O<VZT',\+M@.R:(LZE
M^J.VC#@&82-3D:KBU=K7*C#9*0)QUGW#(^4,N+#D&6+@I#;=!G*O)PZ\ ]]"
M5^0V;D/Y#>J;6R9,;5,:>)GX?&)+%F5!!HH3?"/XRTL'25SZ_5Z,+%T6I]Y9
M_1&)><PG?KY7Z&2Q&5>BLW!W&,LCH);!E;0V7OJUU%#T5UQQ2,@]VU@? :7M
M*F?'+P?N5Q<.%E:V+$8MD2_ =/.5[K-(UAQP5)[=HKT.1[!=$XLN@?*P5)_T
M(P!++@Q2$]_SEVSNN/C!5+FC+\HR,W]K%FK.\*=P-F?XAKAS[8+1!G*]0_\0
M]*9=K*6MZER@TK4HV>!'\([E8=Y+;GJ9(23097(2AUH>ZF"NFQWZ7C9R0M/M
M68&5CJS<I^$>-,+O,JZN/L@^ ^G=2E03,*=JT,U1[TWURNH;C%7&T(DPX:U"
MA8=;6O%#IY!CZDVK/+83]9H7[5E,SL8S!#UCV 9K]_7B^//*+5^&S .N-[ 7
M)=G&&\[[PVW+VJ%.A5VT?VMX5?)V6=IA2!=0H>ZW.J").HG>QK\*:Y_8A]:\
M)]V:VL:Z"4'&IW7</LG&*W,=A=*G-)@][9LM*.AR%?J4MHTI*B>%2&V#%,P?
MIOKH&B\QWT1']=[C8S%=/ZMQ3\S9UN'82_!EJGJ8/B?_=HR!TF0=0CQ.%DD_
MVT3_-9,ULK.=M579F#*>-:J+2^NW[.'*P+K<EHF4K0A=2HXTLXC1#^VJP:4,
M"QKBJ,_%(+KGY[L=GC=05<4PGQB4[[Q,-&Y#ZKSP&1]P X=5'CEP_.[O)F>X
M@YC.9D*Q[@#;TEO@\Q0,'--X%5'WRL+R)]P=7GMHJKPHMT42;Z2E@7R\W QD
M(Y9)PSU,7XM[>\]>%']XGO<< W!%2FK7[ZP6,6_+YS77WW%'R/1$@.>?O"?+
M6R]"?HN'S!UG(9[/N9;:4ODWV+"[ W5/37'I+8.C>W+NE:F,XXKVD\+FE.MB
M%I_UW<@*+7MGC:O?1"ZXH-<U;631=&R[USQA@0MD?PC8#(]^RF0P9$[4:;=N
MSJZ==+SN=T'3]-4@1Y$F8=D@_OL@%<DG9&CPR;=%Q*3=9WB!:&;!:MN_[KZT
M2;Y]7FD/19\7]A1;6W=U.,\L7%(R/\_(*[DCC[@4?R6.:C1;)PK5T7P$A/CX
MG#7$8%%.X:KL;!5B2#1)*B+PE3G6>NBHI\>^NNUOIIC%VVQ$*ZR]-!8Z&W<V
M)MY0BL4P_@T1C-;?.YGZ:*FG*:3B)28WZIHY?V PE<R;/H<DTE^@BSQ'+'6*
MT&[A<1I%7&H\"3^EX*IO8ROOWAT-E/"'PO8>)-U4$7N"E_J;[AF"<K-BJDYF
MZSX^0_$RJ/8I.Q=>E-NO*;;G)LC;R2?=(WT^S-KGMB<M<D4R9^\]2>@8-LL9
MX9+ZM5T<+8OTR =YLZ<%HX;LYQE:=T+NGH,DK_LE[['FJJ,Y>FTE%\P7)'IV
MO"3DSH_[!>ZYM=QB\6P6<>.'"@[&%VNS,;F#+U$FJ[1TF/.6R^QBLTXJ<\['
M^BG/^&D/T.OSA+^',I^8=PI(1.'Y#$3Q\<,X0RJO=E#RD]C/Z1$VPL;^>?3O
M[<2M.U>I8.A[2_SB;,(57"C?17/LW48G>>&S)M%(+]"ZO#UTMJ^B(%7@8ERA
M]J4A2KR4^"- L41U<5@L4I,9ZI.)#1)_J'$H &N1(!LJ=X(7\N<;F>JQ6!_0
M0(=I0'FWOS@^HNY+>*T@(@(9M4!D65\[$=SC3 ?&/Q#)CR70'76&O52KP+O'
M(I>-]L#LK=.HT:<L_+HB$'T:N+.&!0Z:ZJ$3IH(>NRJ@*;-5=V<W_,&B0 M<
MFVW/K;!MIP<K+-?8:(>&#PF)98WF1LMW\7/DQ3M9I,9N>885)#(9T!IP=,F:
MQW;<UY:NT4INZTQU'-T^ BSMCI(W;D/B>CA";2AH@H.[D$<ZVD^UU6/EY<S;
MS>9P:N_RX(#Y?H@^R4&_G9K4YYF4/TCF1T"\0^$CH$WP(=KN8HP(,N1&?T-<
M]PA8=#]#>*19Y\\7)(8V&RS)9505224D(!+T+N%*[YIF.NH^3YZL_OVC)W:!
M?_([BK[G63KP]:CZ*;X(LZGO$_&(=_5[!!@Q/A6B/I=' +;;(^#$Y*LQP]0%
M2G.\O)0XBDT YG6E]G3M;W;CH>-K',O&>A<<V7ML3*;KXMH,XH_CT%4\CE&@
M;D9#=;\0>Y3U54FT9LF%>Z.!098$G*"WXXF::7GA5SGP]!^:-FI1VLS3X8O&
M=&3*=52#73<%OFY&.QKQ=!42,?N;BY75*L6VDKAO!8]U%-B!C G'Q=YO*NM\
M#-M\)Q NK#-0N/-RJM8$Q\:?=N4^L;#'_@_7*,^H7.$N\Q:LM$0]?69QFLCF
MO./Y(V#(T>0OUO(CX/@:M+D;_2IYJV#V51VQKO&=4]3W\D^ 0?EM(@P(U4TD
M! ON/Z?U,!6LV!#SUT=A#^#I*#ST5*@5$=U3ZK7QDS>KP$@O#"IA$BY^B*[A
MH8+;KR:WJDV((UR$#_;%+2U/8CG-]/(,<TKTYJ%N"GPZI5 -YYG8MR%6MB#Y
M#CA>Y@NL26*^%C_*#]YH"#XY]1]/)4&_P*?-F'NX8XZ=;'"JS9#4F(K)\K(E
MF;6F;V+"&6 */(A(T8KEL4-XTJ;L23Y[P@B=:<B_Q(O^1BW!'8?<0W<#/8)X
MKMU6Y%5*CD$KE5&Z=I6HDU74%P.*L0,ML_/8KR?7)B?RM65N[9>X[6!,C\OT
MK.GQL@I;44<.HUA..,SZ9=-$Y?L$0@5&]GD!*538$+*L'.Z^%4VO/>D&?4[)
M;"2[.F(!7L#"_/TI/W@JLV[A4,0JJ=+RQCNTW%/@[#;ONZ6?7VR;Q0$=ZOEH
M<'%%3N$!"'TRB$Q50+9?%A^5&S58XX3QX$+)351T>?]HCS,B@GXSNOO7<!R
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M*%MOG15CXCFVK:RN->*,I6"VG$QPUXWI:07!81A.1B_QKA>KA_SZ969BR_F
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M04G=%5QDS[\'J\G$1EBS/,=S2DIY8'TL['2@#^E6NB9!'-W<H0&S%+#FYVA
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MTU.I/XX>0FYY6XVKSD=;(J%;WHS'MZHGA]$$Z7F[@S8FMBVF58:L'L F>PX
M^<W&5A-E5S-VD-;Q4KS171G7GCX?4)8A[,? 9]%>/;](OU#$5O)Q$$IV$'KG
M'(<&2'!W(%T:FBEBXTRU._V^]0%NBU^O$?C(4$*.2CV'$YR*^Y*+2.5X^>Y[
MLIU"/&;S68#PAZ%*PQE//U'HNBWA !F>"\"(J13FQ=H>]@6N?64;I=]CDO"
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M/48D+5QZ58=8.5$GC<U9Z?&55WO%($M,+G-C],MPJ3/]7D.E>&A:OG,+SK8
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MY*+W-($ZE64)9?>N_O;7/U*;5.3Z.2;P@^&O0XI4CO=(QR>BYTIVET^QFM&
M4@\PXKE:(S\:0+=QHXPY^(^[#O5V9A. 9-B]L)/-W7$ 0*H[*WV8(0Q>LK.#
MZ^-[WQ9::E)4YPL?]#]G"'4'MPF^N=$T?4)0J'@Z2SX1!QP9C^Y:>AFUKP<Q
MKX]P)!+%0<R/H+AW4"0G'VCH*^#6FN70I39"E%#S<E^C>)&VP8+%=.3BG-RH
M GE?&1H@#)HH#0B4F0,.]'%:[/H02GYRU^TD1=%7#/=3;QA=CL#OURC-<E_-
M7FL2(PY?OU.ZX*Y_R)M\LO_=SJ')O<IZ=5826U>* ^E.!CA7T?Q2]OSW&:QG
M^,,&OSIGC+".=TBDJ?OZO'C13 <U""*6*>7$0RX2:S*Y>7 CMK27G9PQRFXT
M#2B>*26FM_XLQ*P32#0@A2T[,(]N!WR!.J$@.N.3L)ZJY<6,8*8N5WC@S33(
M)%_/8F 8 X_H#.2(;VI@R!7&<,JC'6QT:&7X":YZ.M-'<FV1U^ZDNMZ9D.;8
MRV )KJ<GN[/<BE[_%>52,S'Z:L'^M2(Q[4607;''>6=_7T<E;;:J15_2\YB2
MR8#<-[.9<DYY,.L;K+R>C+H6#$O6O"M35O8:X8;?.,)_6FG3'];+G5B*C2<&
M;+OENMB7&'4+.#2.H$:^QC/K^@JK'4/2D2"GCQ.OQA [I:\?91GQ4<MN8\$-
MC(K<*U6F7K'QR]CT]H8+G9T+[V4^D7-,2'*5)A!I>O/1&=X@I1Y6N&PH9D6[
M%-.&L9-ROG?)Z^I)$!7&>>#_2&O$A=GO*U8+R;I*SXE,A=1^>"ZPSUZLL+[E
M!RO,#W=)IG@C(*PP-'KA=CK=D! X%EY/W]?VQ4C\6<5E2M=4Y@F6:JS$!=]:
M3:ASWY%=1PI8SG]X323?YLVML?)"9VKBD_*6AWQWH+"4+[+*[B0J20&M)3]6
MMN>&F"2!L/DM1Y& ,1<O!<M6UG<;B^0K >TO#['/"R<W:/&YI0,ZOO<[G):L
M?]*\RW[LAPSP==D[7UO;]L)-*C2:R>;E6PPD5I??&S6C6'43=,:L&[.9)9V3
MVQ^>>CEK7TD0SN:;$2T3Y-/["Q'JFU.@I]?OO)HE+/!@1,7.B;GR,*P\!5L8
MW_FT69Y*;_0B:1&_<%&,V5>2<@.Q+P+[/0>;DL5+\WQ<P/L\HD+A9>]&JB><
MY8@A(FK(]^LQ<&?D@V/A6V'R69VK&*$3DK6"A_8,!@%[*.Z6J4:+(WV"L8[\
M?2_-+'>INU($67]2%<MGIAU_L/B;CM4Z^J&P'84F\@9)8DVBLG^^!)P,WD[G
M5K#MZ.AXU!<O$_D-Q[8L@4MK'ET4?J/:[/NV&&!XHC1CJRD_MG)K6\CTY-EI
M^6W-67>NGH:W 65-#9;VB<_IHF*FH#&X'CI#@ 9\,$KY=94Y[OTX*[$PAU<@
M9GC)>G/+-XM0<ABRI[*#HFXZ(1FS7'K=HUBFA1<HAAI!I:9FNW9*$=6[0GU+
M1P:K%^O#:4 3W.(V2-8L\I=*<0><89&A#G_6YYM]\M& XS#W[[?/+)L98UFU
M]KM:H7G=NZ"<^NK?%E&Z.T.QX]@7;:V8$\*UB!(#0ZQY#I_,#L_-P2D"&0_O
MVJ RZA8\M;8BD<',TP94\ZH<:TF+/VVNN2=F6$$V_&(C2J\S-79M![OW$54H
MH<XN77-5_?#L87H<M2N?W::>E98[YC+V>_Q#!K<[1W-4Z[%(!L_\,-6SE$ 6
MW)H5LG5$KBI1_I%"_]3RL6S8^RH%'[B+=GUU0,Z>_>\CFYAY,FTL@A8)E*13
MM^@)30A>/4_%="2!9/$R/XU?);)Z\H"^B_0R3D)IXE.TTH03%&@0"ID%P^>Y
MH>6_?&Y4FQILFZ62]BQ Y*8V5JTLCPY>YV:849[$T]&@EG/'&B@I]VRDA@0+
M936TC,DU:.$!'P7>_>C9)=?ZE$_^2!/?PP;L!V,]H"3VX)*=>9+H,!RE=,)Z
M?8%HURC-&4.B 2O0581@/9"/*61WB7_5_D0F/3)(G% NJD[^?RLORO?BE*RT
M6(&#LW4+=$*B\OY0X6W<..?48&K<RAX2PJ7G[GN0+"I&?8\ &%(/%$4.I==U
M)K^3! ,>RJYH;+[F,EM8$-#C,-LD6Q>9))Q3NE2"*S9IO'CGFD3UZ>9$/3^-
MZ586M8/<M;(*\@I46N6_OTJN2+O0)]]=R#BU[SMFL?%=_O!2+])*IVR67.N[
M*O8N=I9?M$_N7?3UZ$7T#.U06MI#3UQ7HFP33OD6AYU0]?K,W+</Q<6Z,:XG
M=^/J9.X!H>C?8O/0%10E+F XI7076P^$>TNC 2^I6?>84/VB?QVL\[>0G".!
MRO?]=3;V7]1>%4S'E<^^)^_2NINDWI9;M8(V_%"P8K"6>>RER:CS@J)SX$_!
M09@2E0MR3Z3FFXY.HAAWW?A.+!I@5J'2P(ARN@JITUML+G9Z&,BH#_B#)^AC
M9=J%$ISD>ZSOF5^T20HSEF-U7"1641:]7[T/E#30@ CARSNO7C0@+2%[=?@:
MBVGLOQ?(MU \Q](<NW-J'KOC\WG(64A>J4P&+%-'S63PF0D)HZGWJJ0KBF7$
M!KS*7UE1W5F__,@,W%8T)$;G2RUL96AXY9,]N\W[@L?Q0_3\>^.%HX@K<CKH
M<:G3GO-8&&ITN.=<:*OO J[8&+X[IA%B/J0>=+VA67D?M350]+ YUTXOLKM]
M_CW4V"T$>$*1,G2ZKM00OCOUMRMC4YCP*4;/L!4Z;EZ%P+U!:X40(AT;FW)#
M*; 7J2<:4'6/$>J!QTPXXGH5"SL*W,[W_A1MR^3(8P!TTX0HR.I!0[^A ;.D
M!R1M7?ZF!($7<7!H"7_Q6XD42U[8@-7D!=>BO$&W.ISPL.7NV/PLZ-(0=<6]
M54-D^>I27F/2R,Q]I&O-EYY\'0Q/J,GLS*-]9LATD>3[I?N-V9DCV<I7AWU[
MGW)]0AP37Z,0\I^_?GG07"P<(5?OIM& 9GP:>]0>&K",V3BVR*KTS87TQ?93
MQ536Y-Z]%)_>CVC @UQ+%4NPZ?$Q1=+G>+9BN,]XB[^/.Q"\PH7*+:ZK1\6Q
M\.T5GCJWK!N->?_C'>=0U+)(+PZ)0FGBP&!9O(57Z]^Z2_@Z/^M*Y%='%M9;
MGF19U R$+IRQ#DY0H0$WN^M^JK)G%TB%6"9=QTLDH>G?.\KET7Y;B@9X4YP^
MN8*]7*'F'BHDEW"]4A(R?H@YFG3Q,ES0EB3;@2"OY6D5HX\.D\B'QS\2_1^&
MK5-?/NWP/,S<!1E"6E:L"PS3=YH=+S4Q%A6$GDI)RYU",3OS63NLRD4*J=K
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MU_HP,Q3_8\JKW,IP.+.UV.0^&K!7#]D6;]JM_>']-D.:R_&G-K+C4]_@VY6
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MWT1<==9577<T'II@L.3EC'LSGRY6>:0N_3$C2!AMP! P]KUXY.]Z $+W .@
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M=7]%>YI['ORMIH7]]<N!#22^TG1 _O7EP7(&Q]D3(.1!8JT/]J!A4S*WSW>
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MU;QYXL1W]N5;#U7^\(E7 PX72)FO-S66M#1J)KGGZRDD[=[/D)/0P?5(J+$
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MPF'@,,&U07\&:.XR$)[WR1I] A2F_;6%-'#$#C189&/QR9]271L]T&:=<5Z
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M##\*V70?=P08\\;Y$44W[0/+86VB/%0X%JDYS7/<O;S?.7;&+O#,]<]BVK&
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M9AHV^=UV2I&12<U5P>/<RLI8Z0B_RRC!'++=E"X6Z-'188"BY46,G+O ,&-
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M!",-^!>)":?'0ZK^Z,F__S?W_Q#Q-@1CHOQEH$?G7!PJ$;"C?2G'J*0O&DJ
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MTB[0_JD\/NLVJ$45.E0L[BE[%JWH,"?WY&V;VMHIZ%1K#./+HZ_6;IYJY9:
M@;TWLA-DB?MZD-[9@NC.0,SD?%-HYI//9G2^)3@)R^#:?CU,J-Y\.-20P2IZ
MER5RS%)0(+P';TQ_V\[,C&M/NPY(B"I#]'EDTYT>%7U?E84*2EJW\V#(FG0&
M/G56[.@#H.-ESZ:6PE%_ ;TW>BC;SQ-V?$N*E&2WG_0GV88B.W+8N,]9A1 >
M>W/-AJ)RK?6HJ'(;D$-]ES<.^&62\]U(R!EW9O03D4@,%W(Z 60%HB?16L\B
M]NJ&=+GT;2J6E$4,"6W)SYP<2J9$;$9TB&J;&/+5RJX(9"SI*W;H97DXY*<Q
M?_H1;L"A>_]@\#PZ"^V!_,?3AU*'?#!\5=^P9M^CX1.<ZT?QB':$)M"(Y_U!
M9'$)V%0GIS,;:QI1N^)6N+J@#,ZV(6 U-1 ><W3TY<U>S%>;N% ZOY?OI>-L
M0L;6_<-)=:Q5Y]YU\A@8U9:5F#.58PI;L!2]P\('*ET\W[[P?74SW[_Z>N9W
M,"CK4"O*X?6EZ! [UCI--)%(H$H$C?>=(E(#I;?46[V;[BI"\S%AM9^OTIZV
MX9M[.,'W-W:!+4R(0M<&*L02:MH@E)V:XZKYE6'A8-3UF(<$88;8SSZG8]LG
M_D]MJTY%=KK+3;-TM]WU_?F%L79&Z 6.VCVRVR'VAE94F=F<\PZ)2P+S>D1Z
MT@\F=U-!?PPL&4_P@7078;ECG8B_ .K>C2/>7I'0F(+788Z3;R=EF7*LNW\9
M<[N<A3 %D6R=\7C/R_M7#IHB"%[(X\7$99CG0N &%.U>6^1=O.A#>$W]M$!^
M>?73L6K)SE')]['C[L6X I&GGN'OU"<:1K-@ ._95HWNF\+QR#MY;]+* ^]1
M#-V.!Y.8L^V'_Z8(S>5/OG=YJ& $A>L*C@%L KK'!_G<[T#S0JEK:V3?O5YQ
MH61$B";^Z3A_73XXIT>F!QX6!E,Q+X0,3(_>UR[40BW$EY3:'A3')SYK^U'/
M%I[*!_-M04=7,]R^,B_[F?@=F:![CCDZ'65>C1K!)BY9_5C:?J4L_A+!68SP
MJ+J9YEQO'//RZ!/?Q<,MQS/M%:0GN% QE@KK:G8KA5I73B&9(RFDQ#R_$@S]
M1,^<H;+L,71>ZB!&I?9H"3RW;-3AFPF /A,R#3@T8[$A3DJ*^VY)RTZN=GH2
M/=]%1WIZA@)572SI?$C/*K,AE+9P,]%ZU9.3FD^#GJ,>N33G^A= @D+(^(H\
M4DNR9O;%0=*5M*:VR'W* KF_@,\#P2%L.EYJXAB3;:_V6:MT= ZTVTC;@M4R
M!B(N1,_?Q@O3<_V(=GZ_E]#!MY1##XY30PH4%EO)=#O&2&Q#VOK+#$4,5TCW
M)P,#T':?C;<JYEJE9_75F4W?\9V.!>/!@A0KQY/$8F*S%:*?Q&325*][I0?W
M-N/7EMMHJQO?B4U>[FXY<UQ2<*5,?8C+B^ ]3Q1=1TRHEUB[3!U:-#;^:D@_
MGH$OB]E,+:42;%?35&YT=AZS-B?WSE:F.8G')+0V?WC-_O55_V_!KTV-]'HC
MI_9QWC_!,A^G+G$2G-Q ^/UN3+$%(1AG4AAHAZQBUD4V>OW!EQR2"IDROGSZ
MIB:]+@/,SB+V@$K?O:29S4MZ&O!PMW8]S\$DV/"(TYXQY/"PLN#6P'N,]YQ&
M0'2=?CA]>E9,!8$31[UO1'.Z'1I_8.N ^Q=@TV[]I.AP6X?E+=#.E$)XU'$^
M&PN)N1)2H&?9G<4N*U#;^S;1MTWXF.5Y]S>7:_E/'G1.\_,S?*VO;]8VZ=K+
MAK&6V%OT=3:2O+)& AMPT1.B8_,25/LQ-T\(#]J844#^\<6W('M0'3-TQB3A
M1\P>6X!I/VC))7NQW^90M=0?M/E(]!=M!;R4C56^NG'TCA!R<Y,L)1!S#VAD
MOS\(U$DU>C%O?HH=P;=[.'TT+S*26C_)-X11_:<$\1LC0$%CG@X%"9V^C#'N
M]:.=J[JH^M5/&C*C74W]/6G  T[J3# :_VR WD"- U?7QP,A#!/WW6S!(__H
M0%#P21SZ2>%Q\>8&@>QH(>P)B4W8M,].O(U0(2Y?K7/A>@()6.6EBQQ+XZ7+
MGF2_."<S,X^9D@+RLPD*G<FOLUDFV\CW19BSBI*]<V4<WJK;(FV>FEKQ^!F_
M-4N3#(OE_3/_OAPL=[-)@'LPYT66!1FV+>RW=BLR_D9G<O3I.6]06<=.TD(Z
MMID5V&,3<^YG>FO(13I_7_%7L_F$\8+E/U?3;[#7G.,=G[*(_:[Y\@B(8C9/
MK](VLV3DIHAE&JU2K/(2@="-!:X?37^D$]\_=_:D%#\PEIZH(Z^=8TGM;"8/
M2_<6;&AHJ-59W5@(SCK[B0/-:J0XF(EV7I'O%OFGDX;O'DM4')[Y#L[>^9NA
M4UYZ3<#]%.U$+F_B0F33K8H0E7[2,R]"\,T.VI_2Q91XMO/)DK#4*3E&VB43
M=Z?0?;;3IEZ"Y3%X^?%<NN%B(K/UY23*3G;SRO9(10HX!:_CY]@5%Y4(,DX?
M)U_S]1;0IQVIIBC=QD;]-Q>+!*EMZ]7JH8S'-&1X>W]F=7Q4$+0$6M-?D?89
M!=1X2F[UL3L?$S\N#:VYF1',LT3'2B:+JI_N1-958>N)'VT7WS&Y-QR42D6W
M-\8DQRXHJCU#4Z3<VFGW@C#G1/N8EUESVZ;C5484[EU;>W+?FBPK.N\EY@I$
ML^U4>C[($DA#YF-@UL)(IF:YU +Q^A /-F7F804JJP09D*S&-3)1L6/KBUOI
M?'\VDWXKMF;3E!W#Z6J=$RD4YW>M86X\;>S"GW=>ZV:(5JN];/I9C@L':OUA
MVWI#U:M]?=ESDC^12+;2@SX%<:?/EP2XML0HW@ZXC[MW);1EZ9D#\>C[[;>V
M8<)C^ 1%+DM\-E2$O9OM-+9ZV4W6/ZW3A0W9'A1PYV->1:BAU9&P2L(.$AUA
M5:V*GDAQXLX;B6('!Q!6;MG !)/V_),WH"WI#Z'R0G\^QY4.7%:(/WD$#<U^
M+0CBGU;US17$MCQ%3,TO^&$9\F.+MWM!0AATXOM'U]V^T@3/=E^]<3W2UYXZ
M9FYN;(!)?6GA)3('_OCB+#<E?QK<2Q4G?1T*\RY9/2C/M=$VHH;!FH,4.3A=
M];O?BGXW*XA4-$=D7@@)57IW7:<_9*W'T1C9N,.91RO(R6LH!!0.F#LDA<SM
M<>5_'1P8"GZ[\+Z:SV]M.L4.N^-W>") Q4TRS[GUQ0[<\;2117A07'3.QPL[
MPO3T.N8":_)[O]^UAX"@M0<E,;3X&]SQ<YQ&+UJNL5YJ3]*=S.E'N)T7G].@
M*:-48@1 3?WCSY"]/@%3)&0<I9P[68ALO>_+LBDM''^!!1=/7*Z5:_%H$+;[
MI>;4461+!0SGX#?&WF^V3VP.MJX_<7!SN"J(2/)ZE8+9*-2Y[E9R?$=:8H-$
M[4]]X=#0:@S59TT+QF*E^A+_C,'!@"82,Y>T/TK,[:>^+ 0<)3N%%3X6!*[X
M[>)B%2VUO-VFU2<G_9!LJ8$4C#KV 96@/+I3J&0*ZV"\4>57\6SV8S(8VQ%'
MT:;8PF54655Q=\:%5:%U*EC=*M"$!(<ZYE:BBI**9V?Y]#Q)L8)^6;:%4ZZV
M2\!PD:N"J]NWG""029#*D <)7N,7FF@S-Q*L;VW/D+3S$:ZLG Y'1',W\-_*
MRC_R[8I_A&%4^6@K&N!GN@$QP#(]S=]O=++-9XX=3!H$WV2;O47@M<0+#?8;
M<4>GGS":(,MYCIB>: OWU_&]=O(30$*;L7+-\_?.K-7V!9V@:U:SE3X95NJJ
M//W")D  @;1-3I@?@Z'-L_(%8\5\ QMW,A5/FAN5\1P03X#O-2LV(,AES'I5
M^+1P^R3\K9CLUSSKY@/]CKD&*M"I%+/T4G)")JD6MEAVSY25'EG>E5?/&4I0
M^O0<:''U^-A2+XN^<&G[C.:>U(!.ZY40J]5 E\+#\#^6Y2J0G(6(IP[I',^'
MY1IJ8]^=^)<OOXM9N-3\_"<4VR7PCY9<_D:6B7]PNE\P;?:1*@6(=/W\Q9?\
M7(<,43#@NF*-#&6LTX@<'2MG^0:!:9J^Y2[, Y8\Q<S&'A$0Q*4XGPJ8R(6
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M0-5^];K%-G>OV7Q)M_\AM('(0"' @:,EQ"";>Y0<ARY"UE/E+R#F3G7UN47
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M(_%ZC@$E7'PPN0J:^1TZF>W/@:_<C/7'J2$>:&.?ZX:@-=TDJ\JU@E]0&89
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MN>$K W0<: Y9B?*MX7?8U#1>":4-[_\XG[M7SUID[9Y"V#*0,E' =G+]XPV
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M;97N46]P"IR/)C:4)1D42W< @#=WNJK!%B!+>1'SI-XK"X4M7<O/CE+?UT,
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MOP!R5!J,J[#3"3_G=:Z'FW-*RMP@ Y!'?@S--!.?0 @B_OKWS;ER$.+3]%]
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M$5Q;+=MC(A99$7[;U-4RX]%IA"0^,(1)3XEX(F,<E7MH,(.S$ </JQ$H1-O
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M+"LTVS>8\PG#6?6]/LB56A]2Q% B#<)1WSL?PZ9\O.OLPY\,0O#< XC1@2;
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M4>MHF_Y(JSR6S16I$[+__M'*D'Q\_MO$B"-C6O[N8I 4O51)KC?FPK=^2F)
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MX.;%U-D:F1%L-+8WCFX3L)CT8RE#51+[G>1U?^(0=RJLR!PMW=]L?!>.\-T
M8P6XFM@G\\UT]!"SJCBE0YQQB+V+9(FT*>P#I*?6.V;<[6YD;Q.=[!W%+*HV
M=P@ROSUI,44Y2UP6H6:A"-\RA_/ )^H;OO[$(!<75I/TI'?ZIM4:V85)PN-0
MX,%<?)F?P/21=7A^$D(U5?]+6[Z=.BMJU,UG+*;MJ"^7R(CH]= 8XE-6@FK
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M>?(^?>S"<?3DB,ZB^HOFBL8\^:*1H#J^O#OG[=5UT3(.S]0JZVMYQ]J&CXD
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MT 8,YJ?]1GHH"(WV=H)C<0&.GJ=A(%@*1 H"T.#'&U #G  X@ 5P0, \R=*
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MN+O%/\!_05X"WG]#=B%]$3\T)?--^'T_P'/:]8)[>^#F_=T2/#P(^S?HSC_
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MMU'AQ:%7GN:AV9N?U[10!YU&-INLZ3QX>'CU"^)@\<O"1X9M7V+J5D2T"*^
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MDX^( !5]?AKN$^6D>S=-.:F)/T%>:[7'MJO^8$.357/=T]:7^ZI)ZQ.FC]Q
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M5,?=-8Q7:##;YMPX@B;EW2 ^ %<^'1I]5D.3MHB,<Y13PCL?BWC]3P>DL%%
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M2?>ZI#Y''=;2 9/>&U_[(0S.$>QL"W%>Q26+G+![,\6=K<WRIAWE=.:&G$K
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MQN&=5_:5IDPA3*OB=N+B6\0#"B($KBI>G+P=GBX=<B=K8'?@VDU]A71J0<K
MP"0,B,%=A*LY6/68/0[M%:'<)H:1,(J-$=W@,NW;<Z'!ON).)Q._)Z0,:WOK
M28W(W+G[4KBE)>>8+Z',FCP<""6P.BJ\\!$177+S6)$3D*[EJ8V'%BF0R%S^
MG/M@Y;WF"G)_>15YMR%Y&SGK*49(B9QJDGGW/=T1R\LKLMY#8Z+@Y7#([E&\
M@FU,<34,GIS7#>Z$$7.J$1CP0213/#>NXM[7A)).=TF"WGUNF]C<;))W\^[,
M9J<<!7QYC[CD%ZE$LH(PERSG!@^Y:<F2Q/7-0ILWGQL=04VOZ0 A!&G2M@_4
M:L$LY.\,"ST\HMAU+]/>20$/8K>!=,9TYS3P5XB*  O4G_*.[M?Q(I?F&;ZO
M7A@1]O9KSY*\3;AV3<63IJLJ5ZX?2L5@KEQVB5T[Q:?,T[[G2@<T,_$&C2'T
MV%W5/C8Q95,4W38R3@?4SVA&H /.JD3ZO3M_1$DLVI7Y=&)J]P+I@!T)RKSM
M8@7?!8H"2)PB)I;2 \&\1.R$2WQ78M$&,NN['S;+[EZ%/3>WQZ>;L1[-=A%)
M]A+@CZ>Q76^(/)JF%E,)3&;Z&QVPQ G.B;5NE.2O6ZT>GSKMJJ!!_ [GN>E-
M\WCDT:D]P: DJBPSV*F= %W.A$FN'U.T=9>0N+![YK%[E99?%56&A24-V+9(
M8_I;^-3N!8C#XZ<OKBL5"QYXK'>=;A!,MG]-8RE(__#!PG6,XVUM"W)#%=4@
M1CZUQ++>5!M@!('A)00A%&LT;^'1]CWO[W(S5KO'F;.%FV]>?S=%]7\S/Y9F
MY&SLQ\#/Z"%V@&[1HR_=5V172*G,AV(WF!LW(8_AZ(#]\$IP0KIXEVKZAF9Y
M%=N9"_/OU?\RGLKUL)2.W*]"G[RU<<AXL#\=T#C?X8C<6:!AQ\P6=('KZ+^Q
MG.+[+=E%JZG0(]4PO(CSN):QL=!@4:G4D[< 'C$*.X@Y\L"M.ER8UN%ZZ02^
MM*OEGTTCK>6N6]E=?0D=EVI;G7C_T $&C%9GRP[GZ(#YG %U:.FD (_!PH_)
MNKZU7]56NW[%TH.D=N:B@$@13<,0-U#=($>./>\UWOA B&)W^5IDNAS?]22S
MY]$A4;3/P$&>/[3UV?./N@Y9:<ER^[=,P\-K!GA -&D7L<+;4!+-+Y*= 5N)
M=MTT.N#13VZRHVQ47INSE\58;WIGRB3H=TJOX.,FMX&@'JEC2 .RA\F]@I)"
M!E_*9NKK7D1?*LTJ/*29'JQ;X?[<IDS@Z8 76QR8'33[#KE,1<1Q0VBSOJ)J
MRQ9E@_[X< [\W.#JA/YH+>]SDPU^!;_D.S]9Y.HO?)Q@F^M">TPO^*?.@'\9
M%!65^=I6 F=!/@YQYJ^-TMD0L./(!6OY$?*A(QUP2Y!G>C;<=<?U]G"X]X2*
M1J"'7GA9S>ZL!3KUA.:[F<9DK.B[.IVY87F/CQ\^^ESP$XT\J7,)0' ?S+2=
MNZQ]]F/(=G>G;=VF"^*ZOMR]UI.ILQ^7'G3OK][]=DRY88YPR*&KH'$+M=]H
MP/JQ8_B9.7=F^8Q,%[>7JNW-.P"KO0.126'7X:=38J;R:\N[:LU.-<8RZQX7
M9-@9(6%FH6$#UY*RHX^%?I153862M6J$YC9&I(Z_1I!,^VQ$$C"-'>/JKJ&J
M#E7N<B*[?GP7D,GT''9QK5+J<H/L/$BX+!D5-+=B;$$'V&U3_H)';N4A%PTB
MB>V4M7,WS2M_.B4?%V!-[20J+&3FJA\%,IKPEU,/3ZG]+&Q;A*=S'_-WWD2[
M?[".N3]E?F0A/8O%-460ZGG ](";ZTF+,T*!F>5]BY5*L@01!@T;W7BC'TLV
M>J\]RC0C7$18[)>I6=^:P%J9B^;CN),7B:7V/1)3-2(^$S6O5@Z\P+Q,#Q"I
MC\ 7__# 4M?T48V\Q*Z'_^@Y?I0?W ^:LC$@OE(EP_P"Y,&7*_GF\MKQ3E<%
M)U NN^)QG9MTP.(I[*_*T,[25X\RK)([RT$PAL&]NP4*&3?V-&X&#>,[:7+F
M^EVWVR?CK97L+WKN--,!(#O_S /-$#B*)ENG4\:(A2"*AZ1;Y+QEYY$ID& =
MLL=M2Z$EF[MB>ZHTPX7E81O62AY"M0H3.O:L2.Y79"7@"($A9IQ\[*1SOT6<
MHG&U]U";^7W,9:T]&^.L[C7_<NVP-U$H-HE:5K>34QZK6W+9$RL_Y)P*2NKY
M1;$E;IH_>868'FRN#-YL@T(\TPW=AZIPPG60P*]K^Y]M3A%99]@;]GX&RA6X
M#XWV-]Y1&CH"=@_!QEZCSGS%3X^L9,00_*KT'_V^7)Q<K/?=.4<;G]Y;H'LU
M'V-OMXRB](FK6;K]^@$)WNASSYX4>I#4N:0HS7;JLH37DSN:FJJ:=XO14O?D
M?[P[<3<_/L,0[)-YQ>,RB?]"E [KD9K/,G=H$3GVH#GYR9[F/$1T,*^!=-.&
M.7+Q-(]$BMD3"<XX+9,+HU+Z&CA'2I1J8N:7XM+US?SG._,[KC0QMZV@>>I3
MU1XA1ZC6'F8E-*G_.VQZRAVI\>KGT\J2U.X$V[S7;J>_*8D\<V@5?0=DKJ^M
M'MF")?ME?T3>J"E2T&)5B>E^EO[H@?>KK[\!4G476:G,.:\@DG<%S9VOA[N:
MUVQ;6.KU8VYPD[U[$K-8"RT4>=CWB$P3I /^XTG:(Q\+MY 3)*:,*V*R 8%A
M+6^U?PW,SJH&#W%;E6!F/1:[<)2(1;11N8CGAGY;2R#/!KKD9KI*MK-[0.S3
M ">9D3F!RN7M=NC 4[$XL=#Z,=/N!L)]<_^PL<.=Y/ZM#U[ <XUL&9E%H?%^
MF!M6TGC\FLT &FWWPM^E5W3Z!8*08,6C&GO>)KH9GSLP&(/F<?VC=2*KIQ/2
M0'CB Y*C^7F<09:5=_GY4;WK=\@"Y8IXD8M4X+S B.I\-#C9U]UVA@Z(R%=C
MGS[G)I.&=LU-]=09;"AFLV$[965=UT#051LX'*"TR6>?@E>2 Q?QN/49#&ZS
MMU)!8:7KP#,(]PE_.R >IU7X1"$_/"Q&A["X:7VOLQZ,F3CUX6B&IR&#X0VF
MYF^V^+O1 2G4G#.SQ)W&S"+\-]"M*N\:T&IHB^(<7R_/JGJUBG[^E !?#K8Y
M_MQK$?<;-N6(KXH<=,!K <:DY0V&;1YVQW:XR-6"__&QN/=!>H#GNJP=P8PB
M((K/V-R<A>F1$0'^(HDK"G@5T.DA<* ZP'EK8> MPR:\L:#T>?&Z0G=_F8F-
M^20Z8,8=.J4"0>X<@A>L@%7R5M&EG['2_>;ZU2YS*JW?)[W:)XMJ"YR<G #+
ME1\CR@48)!EMO,=[&.=OA.]4<,%$8'%ZU?5JIKA$ACI:K:[RELR9#O7T"TNU
M+9I"&Y/S!(MJ7L!/^O,,2F5GD*$!.8N%GJ],=0BVV ,%$W)&W@OW#X2V;CH@
M9)[WG<K[IP)F0")&(KSUF\S#7)"X%:1P?Y&9&#4%%M,!E?A7>]2^:&H=D5VW
MFPT+\0+C=Y,&Z8#.AE4(C<4S.7>)]7_8*NKYMSQG:!IUZ+O\8L?JU/*$T>>U
MO+Q#Z"[GU94]C 4\/T$-FL,#7"??GKO+6?(KTN^!1X3-D=!4?G/3VM7&DS :
M&X[CL![<C37 D( XERI7&1#V<-^7EV7LSE7V+7C7ZLQ-Z+:*"QT06(7$F=.:
M0@E6:T[3 KDE<$6ME=FG+!J1:(&PZ7ELTH 4&"46R/1'N6D+($[K]U?T_&[V
M>SK D>$C!9K2TK:K:#+4:[G,ACHX30[ECJ<#ADJH=0R_^;QQFI.0YP4^00>D
MS2^$QA+M:*]:#F26,5K:4#+(Q:JJGMJV61]+Y:8#>OT,\LYPC =2AGXA>X7G
MB<D[ 0?^?MF\'I[4\7K^5VCB*74V[%LE:E4G/&#X<B>"9RGB4I)K+%;T+4"'
MM7%7PH#R+,1_%(K(G59-QI-]")?-U+WEH\[>8=GQ*!WZYW1M:?5[MH2QQW'C
MSP,%'A""3TJ UM/H@'"J*F:Y@\-=8@V$_7P(M6U A0<&]_LR:-!U&CQ".N6I
M19,ES%./C6\S)$??P_)!G,P!T?])(5%-#/ZB+D;Q M+@][G["JEB1[<;+U7>
ML8,$ WL"/ 9O'LVYM@%RU)-<7E7&0.9=G1%_W*-?$(I5+[N6//\T),MCTS )
M@40JO[DC=>&0P-5L2 <<D42BU)9_(8:'HWZY((<C0 W*/9/@(%#C_ ^&# -#
M&*,9+=S:2@?X!FHZ,Y193H2L)_@\'6!?&Q'-@"\#L+]YQ3;9T8M9_*,CP.FU
M6)5) A(.P+[(0L:E'Q3A1S=#$J1%85;OT0*ADHQ7[VTGD1G._*+J)7)X0-LB
MP)/R!<PUHU1:@)P$XZV8VPQM/7G-J:@?6WTMDH$Q*S.@G6KBWRQ_-GSMY;9*
M!*3B.QWPVV-P/CN42F"$YUG,TPD>(IIL;,R$XT,9NK]U=J%!D9-$!S!UO&W7
M;W"<.W4PHX#1$DQN)AYE. 1SW]2H][($68!Z$>]N-Q)YL"5)LEU*[08:US"+
M-+*FE( XS0A7KD'&&_L3SACS,D 'S'B?7.0,G-+^IVK*D\B.(G-Z.E2"2=Q@
M7^8U_2@B$)>Q^A4] T9PXCAINTAF4:CL]I.^W([/V(B:XL>%+^"_PQ# Z:?O
M&J.NS.><C:)5,#?;WM*GF1MJTLA,1?[E99B'$<>L^4B<_V-%EQ@CM3<&Y+TV
M]C4')N6<-@&WQN$.!AG/$:/7-*YM,81'VG$C9K,V6XB^ ^,_/1L?<.Z(7P)N
MA#,:1\U- K=:?I>AY_=@G9OSU&7FAX6]8)[)(!*HA@Z(M(&.DT,PZQZ>=$ ?
ME-%EJ@J:E8J: <[B#O6[%_&$G0?@A1(F&07_ZJ0#G$9AL0'4:\BA%6^G^CI*
MF,JMNGBKO3:XR/3FYZ"DSW1 ">2^[8+>TYI4@PO@#-#>09$6'3 9[,9I?B#F
MO 4D-@?&&%=4(0]EW:CCU0&!- *HDSJ OO51EP]&JJ>0_D#J*_0# U;,"PNW
MN_>$<U3=.+(S"K#A@[M<GN#.]3QR:B%HEY.Z+=!/K2/3 C)$YNL^9#SO8:6:
MVC9OCIV;MOD6'@Z*L?MPL/[RH;LYH;^$1(:#5E;!08%FLG2 ];Q7QA[\7;[;
M"DUR97>]H&6NS[E:WPZTW3LZP<7+@"V"VD8>'1#5"!*OJ\JC@#%[#%S%1^=M
M962CQ6EI$BJ*U2^)7QE@&UAI47W 3!>MSU[&FTT*0"]9Q=5S(V?#V](Z]PZG
M!2Q;3]$!QLR=X(7&8)XY)<JOQ1+F4(,K\'A)*H8,98SG-YO45[1]CSCI9F(/
M'1 $)J0SK3'[A&G&?-JD3:$Y'0!HH -<\3SF5 @E H3YZQ'H@OR^K=.W1.TH
M1WH8(;,D8Q3F&7=Y+7555CIMEL_V4S^X516)5.0D>TA[#E)^,-.4Q]>0OS5Y
MR;A!I#NT]#7TP'L=#2$V%[%2GP ]-0L//WJZP6SVM;:(Z#CN;W55Y'Z.-YV.
M.A=BYJ<'#9JVOJ$$-=ZR0P?KVW-EIW_J7E@L,-@XM0OJG+"BCAUJ<1""ZIK2
MCH@D:7YS-2=%&\XT'7T&K"OF/N1'I=FHS^5DCON!"NVWK&F3=H5KTQ+\$:\A
M7P@ #[+ M)[ZX@G@;V G2H/:,.NI.ED-^6C8>+.$,S::F RYAIRW^P'N<SNU
M^*2'$H1K*2 _,-R$9= !_ H'-&2=I 88=J#27P)&.U/[K!,#I?/U[F1%#!<;
M).\!^TN?D-O=JT(K_<5D7G*(EGY8F!X0JIFK=&DW)"8)H-@VZN#L9%@] ]:8
M[K %[B87;86M9U./JQBH&(^-D^4K7I0^#SPS,7/QE5IC)!T05L[0#&4[S#38
M:=\@X$(HV&FYF D[OSNW!"O_$LTZ$_Y"/3)@O'4,VDNA T*K"7_F:,QR142"
M_WW3-+_:&CCYY3)Y'5J6S\) 4 <=.L"=,9V%GO^A%7L1>('E6'_];]JX\-I/
M,7+P,>2J+Y/XF)#<S"R@9&ZE8N+B9^E.RG#C(.]<(_2;>(/O,[@VRVXTT5G1
MIU>S\<QQBI4J5*PK8&:S8+_.3W@[\US8G=9&%SDA$Z5Q)N#PEH$_X TJL"0[
M0/,3JU<_/:FHT<F9W(7>$<,<9*X*0NWZF9'PQEIT2*W92*;PO,1V"Z^NHL"+
MA^_='S8,-A#NMC@>]JZ$^%9$F-N3H<Z;/Y-&5C</6^ M?=G.JFHB7BZ/^C8V
MUZJM/:J%=S;X'&5K%(J@MK_C7\S^*(<>Y[=GP%_>%&C@*T=UD\(X-TC713R@
M:.O.K[:9*:G:D$.Y9K!^8\2#?8I I= =U\HW8D%A02U+ E&/->"UNEA?;X;"
M)J%!%PMAAY730+ZK??X#9F*>?K+6>)JD0'QO(6'56?$1;MX*Y*?=4#3&QR/A
MN35W[5NZN7VFC68D@ &'OA1)&H,F=IB%K\Z,H1\3.;##JPW9@A&/P7"&'ZXI
M_9XUW/HWM6PSD>"E3"!ER',;ID\##<+HP^A3AZ[W1S;H@(R;XY<)A^V[Q_C
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MW'0YV5>/6XCE.7-N?L[IDM]V<3?I#%,T% &YKP<U);*[.E1E%2LW '&/.,U
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M8*I01Z>-(_&58R&/5D:TCY[= LPAC+V2!NY& -?"S4GA>M;IOP(4,W?E90R
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MX<9YJT_"[1UZ\74*/A=^'>_$5,A1USQG-A-6YG'G,YL/0?VW7?\VGX_P?/7
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MNPO96%P%\FN]9!;45*)R5UE=6#G^$"J!7-UL.S1[6D4=>>V;\V.]WD+U U&
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MK? !<Z2D$:U&H>^RPMF@?C2-G\"[O9&P)DW,F023#82Q!MN<Y112H%/ALV/
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MNT7!VA"[,>9TUO!)^*@T1WI/W>!CO&&#3J()IG!*'A#[+Q=/V>+@^#\&]#Z
MW=\5WOVRDT)-Z&5M N]:50!C/+T.)EB 5X'R]Y%X$PA9"\\AK!ON56*L+4$4
M240QJN=V+1(TU7AI:S/ 8W5KY3%.:GB3%P3_BY:.-P_V*F9T".4PV* 6V3%A
M>M=@0&OW0/X5C@X+4MA5^@Q#I6RQ00J:8#AG!]_U!;,NU7,^95U1-SDQ;UOE
MC0$;]%TVE VJK')A50$ _Q)*A-6!*@"OCPDS:@#XC0X5WI@EPAE*O/1Q8(+@
M[_ -IU4VB*'$QWH/=)31H'+TBVQ(/9SPD@WJM ( ]5#O=_S&VAJ8H<S'J@34
M1I&J&1MDKXM!DXL1K*K6O3,*YAP9[=T4SK<DH#GZ?^\8V?#0(<Y\$!L<;7-,
M%<W:J0.<MHJ,23YJV&82NKA5?YG#!5UJ6LNE=*IY:C9+Q2)'J0+;O(L?'V B
M@CES4MO)595FQH1M%G(@U6>B!$=RA\996Q$.)^Y0SA9&*L.+-\!//>K.Q]EJ
MLD%<Z3MUB#KN555:KG@*=:/A+ALT8XC!TX=A0)WB,\?G\*ZZU5Z&7-4B:ZL$
M\-8W^(HQK-3,X<6<UP3*U#@H&-Z5PADBSZ%2:0 W-J6@F=\00-TV/Q9"[P!L
M]+&4$^@%@SXV:+J[&KSD#02!_,8@9!.4"^<=/[%!E*1)0(L_?B/'>?.7/]D@
M0.63KI<#VI!OP8#AG\B1>=Y8-FC2'P#)>DQ+SH>TQ*20\V L8V"0Q$(QPX^N
MS 8=CV:#[@$U:R'$^,6YHKOP\0(X)7:\@5+'RG\''E[?AARE^J::(9@'^C_L
MWHJG[F):F=KF,# E"2V'YJ C[<Z3'Q6XM6V#4\;X4PU0<87>I3H9HZPRS2VA
M)..@RXM'U@7@XSO58:Q6;XHBR:.E;.LBU_XGV8RID*+7$\\M1#O77M@W^\(-
M*,N[.V_X\Y.R:@ALD K9DV.9[2F1RC^3!>#QS .C9M!(!64:C</W37M-(G4Y
M6RPC%[YQS8V74IA(LA1=F=PK,(T%;TF@.#\]&<5!<O, G#:-*87/MH_AJ:X$
M$G-Q"MA*_AQ@/+NTRY%A9SSKN;POL!]'U3EKPOG 61&L," &?U<8,%W&.R36
MA44V*!X0V#MO%#CFC=L#/MT/G),+"%Y(%(D-*HL;3R$7_8&/-.[5D/QE@Z@5
ML%ZZ^11\]3ZP1D:,3LX:N0"^JZ^\- F@+)D0#*P&!]NM-V'8('J':R]0DRB\
M5Y$&8W&-L$$3G7LG"^=I@MN%L\5SZ>DQ[N060J'@GPC,6#&%L*96/%8M3#K>
M2P!O-U<HZ!,GS*5MV* ,UA)>F,1A,@DQ0,8<F.J8'-WA^D:J#9<XV5 ;(5RE
M9D2P'&2VCP5"AL\)M-)O"6/QE!VX5Y55DS 6O>W!^N0!J)[$"O2WALG5)'3E
M"HV.>L4O7"O/Y03/T@O#)8JDT?@Y#^)B@SZ;^@?0"_SC[=<@V_!ZZ5*DFP4<
MC=B+5)#*P+%,,:<G,/7J!CV?$4_F-2^POA?:R0XI*NVRZ(EI9/*2LVDO)@1S
MF00  7*V0MQ@WEHXKM$,&QAO.92R'%_->D ("F;Q5?9P.5*$W0F6\TP2#C*)
MWTT0WCH[S]G.>]5XGJE!)PA@!*JQP+=A<G)W;1[V](TN!O]OZ6MLG#1+FC_
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M#K_J&124O07W)J+&5#TK:UL%GX5/; ][>9GL'HB.E2@[9("[Z"S^H"$9_$
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M[Q\,_O\[':PDJ 62P]KT2W9?E%%X-6"!694N/O#?'/"(&_R&"8R.P/&OOE@
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MO+$]>>K*S9H+&1\BU1[''FK*0?>9<[29-C]:H4'Z$L/\%$IV2 YM0*V%0W:
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MBR+^3&AGSK674T(DAD_*BY] M^2OE] 8<5J_/3+:DG4=R85JZ R(X$V0 1J
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MI2%6M!X7D601^;S$/&:MYM'7E'UD::XN7;)/L$BCY:,84P/%A"K(J+@.PL7
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MU6;KRH2PVH<7RCQQ9[-NNHC9N$1MNK-8E%J+O;VZGDF F,<L=E8S\5I"K^P
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M%8GTYW?,+?6E"?[;KI*9.C=33P3>)A[?<O\9^BOLS%UE47S?D).O5/>9<8>
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M>T3#N'CE'>$+FV?*B '[8XIR@R8%WZR'-7YY4I+TXMF3G/RTA1+-'BBM'UZ
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M]W8PWD\9YJ 5C=LXWWCH[&L3&XBLKS=W>[F:MV#K1SYFEJQ4EO5%-0%<7:H
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M5\&;/M7)KD$_ZB".TX$WV,T5&O]![V-75__1"KL .5A\:N<LM"XQ])),=AO
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M[]YR[/J>=MTI+]-H![(FM)'PE8HRJ8TW:6=URMR*9HU-;?-Q8YTL5TE#[@1
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MCH()\8U/GJ.26T9NS!9_%5OZ7JHAU!\7>#3\=P3+>9H7\V=)AIXQ&E-TU5>
MNN(5:RE0ZC[Y#-R&293V')]2YL!$!TZ#.;_Q)O!T*6K*H*)_S)B[VRWIO>D1
MWIK,C0L[@U7)X]1CU%(P/J3UY8Z2'J2ZJC7_<J+0:"1!O!"R'..QICB.754]
M!$J4G6%%1>2J4L7O.8]\&W:6Q3$3HE/.K(MR8A*_RNI5I?0GR%T(&%#P> (Y
ML*\9BJJ*L='_[DJ ,:;=//U\:%!I;&AD_A<P $#/!YU=4MTJ.$X-T(*2NP([
M\/7L/>N0->Z^"=\F27([2%K.^[7OF8Q!!*K$YR NGNHF#B]EM1G8:,0-8[7'
MKFGXI #S*=/3,9!7O_G4 [9@+C=A8]XG]X&W+QV?8/66=7F[[,):(R[?%[*0
M(LNW*^G.]TG_<9+\)@5IBX(>W5$RM_A50[F]5XN,F?LPMHC'&P7:%:SNM8[P
MW0G0%L"V?."![1+OP7G+&S\/04JJ(O<PHW3@IBO_59]4:29T?0?_^OY+_.+*
M-UFG:V-3-ER!T O97#4U)0%NRWM*$#])0F18$FOE]=K!"H\ZUPN_/"2MV(NJ
M \K]2I]_6+GGZ:LM8/UCR^;(_F$41/45C]>$4O9] >@B,FI[18A(LR7%_IBF
M _<8/SYNZ2/\%M=")P0E*^QHC:NH#XM@MX)]44*A=;S)RX'3V.6M_>UC@8GQ
MUVB%FVXW;6@W"4F5)C4H$4WSH_@P#LFBS8JR:=.SF',R/VQD2N^-RVX+8ZM,
M^DQH/$:/(AL(_'0@VOIF$!>-3 $/&-P%>1:UH^Y[0S.T\_EE&<-'[H@SO#WH
M+\@IR+*;&/=A4#=SKOHG&L5AJ3U&(>13:J6;0>*QZ $$.@VRLP<JKEM).H/>
MHUN*DF-?<L;=N<6"+;^;SWU8OACSH>@)['?_#HFS!]S@=Y+_DUGZ__U"-F2>
M(>D@S2?\H?W^U]"SM84$^87$J%X-WDU16C%2JP1!Z./C?UD]NY^42U-T_OLH
M%[%:0D-8+,K )&F;'- 9?W2;1[*PF6R6\&YII'F(8F^<$6&C[7S8APHZ\*L@
M,$>'#MPNW/A"!Z8T;5O)WJ)*6\]H2QX2]O-#2D_&.,<XVZNFYX>M$5.(74L_
M(H)<@43>G?-B+:!YQ>RM3E0@1I+[A&FB6&'/$U)="K+22TH>=&#'R:]_#SJX
M@/2%1?-KWXC\#MEQCBSL_+D^1 >"'],LD+@- (&BS>[VTH&/Q&2ED<<FA#G[
MK60+LI:@-:M$ATGT[J?]7XSO\?S)]\L.L:I'!RZ8D/R6PQ H#/]])(EG!/7]
M J?KK^,!K'2 \R["_2=G3R*[_R4ZD'MJQV["G0[ /9;I $77GP$3:SI\(TC!
M\K6@"KG[/PT".*C-NO%+20])8<=&65 RR;*3CM*/32..0QMW_4B74#AM5$K,
MO$I=QRAZSY<QWIH0Q=A1<YT0 <0,S4R@20G">)V$C.[BA3G9YY$K9=I@!L(V
M_-A98:I%:;JM^_F(8,ZH7,=$;"8M[R_GOKRD#X^E$V29FF1@<]S.7_Y2M0,"
MW3C3NH>#[K^>%*8N^F*'G%LA.S[N<$'?4EJ!H!#'XA/YA*(>ZK=1-/&CM="V
M1'T;CE:88'":77D?43SHAPM <Z$SB0QX_2VSVO_U-H,=K2[U9)F#A'AU><B/
M@6>Q$#=2'.-?BM%C^V5D/AW@M2C2IE+9:Z#$$B(\?RN3A'ZI3;U+ A,DW.VJ
MKZF,)3*HT6CE&SK@G:8"MG]17Q6"+M/,9/Z^=4(,:C$4%Q2^';P9S%">C_'H
M;9'1(>*TE[+.$D.I+/V%GT7PJ)-Q$^C>ED8T):L3;$^*WHOTD7T6_AJYPZE5
M.Q,4;G;8+ 6^^YKT&;O5B236SG/6AM;^$VA%M9#X9<,E.&&[YZ@\2OY+![8P
MC/F\FUDK/>IC1#6@5&$_<LXL0]O[,@.V[].!TN^(-9T2ZJKYZ^E&QJ-Q:?7,
M>L,(@?=DBUD(31!"^;4&W2NL3>SX=(I6.#K\S?WYPQWQ^1YJ3/<VY%T^9AF]
M(C.?PF ;OL&UPV/YHK.2G$8O9)0DY69$>W[0B#1<T+RVFNM/!_15&<@4HF2_
M%#'ILV#/CT 1S[FX>7@$+*V>EW%KIUALOL/""^_%[W]%_,VDN+GYU*E+4IZ'
M;R.6L6^@>*(@3TT>CUN7%&/)5%.NLS_#*7*99=(!!@]J9FQ$6P9$MS6G[J3M
M(QA3;R7_;2'W;.&C)T.0_]7>E44UE;79J&51RE2V"BJ26*7B@( @@P))5'Z,
MBAJ18B@14"E 1$!E3@A7141!B&B)"$I4!,0($1&"# D:@9)!AC!/D1F20,"0
M.?>F;_RKJWOUO_JA5[_T0SV>E9Q[SG?._KZ]=W+O/=..6Q0-6*FBN_-JIOJC
M?5N_6R<3'>,('7C _%84.$X2\/!RYDA%6+WW:B[GXE+@ZAE@QODZQ)QO7J9"
M1$M<PEQ\Z+)1]G/O#1B2VVP8M$19 &NZO"$58BA_D &#E@H9TZ)9Z"$2\O-#
M3Q'.QP!H,HY7(0KW$MLJ-3;!@X;GYG[7Q>3FVIH0%X#/)[9"C[VRZ0KMPBJ2
M@F=^6+U9A:/:&P@NN1166US^*RP[(D"%F(K B$.-#\_#<&ND6=;<SW]PQ*O/
MY"LJ!]N-!Z>&40('3L+X;EU1W.>J$L16O+P\@C5RFN'P#LN*A)'VSO.Y^H&L
M^:I"8X@VWGV[T1FB'2M1LO18_!4J1 #L1)[J#R5,/-)!<6418QE;GZ(/<).!
M$NR NPKQ.)RCJ.Y3(>:1RI#&Y2[@*;0M;N0:/FJ_3<,);"MC@J[DEPD4H0)+
M[+P/09\0R^PD/VBDK46@]/<:-:@0;ZY,,94.1((*(5\N,(NTN9[D F<PO$+2
MJHK=Z 9W\-_$=*DH#X28PL:N_L&ES=M246-*!BGZ#VPR[:X$;(-]L,55:!YJ
MH%>"@=^RS:DJ@L?S[?X#6^Y%@NP\0P"!W3*(L1#R7JE"=$ZS_?<Z'1=YE&*%
M9HIN6-K<@+=FO'$(>BLCPZM#$VG6@SY?N)_ELM#7XCTPV#U#U.\0.T+B<7EW
ML9T*6^IAX_I&9>G4?8$=D#\T 5&FZ!<!P3;!V;DK&OGR:ENGD2MQIHG,)+AL
M.ZS15"$^<RX# D?GV3R>VT%U;9")AK=:M>RCGT^.I7)ADO9_ 8]?/_CGZH87
M^B]';$%OAS9IBAB><#$>4"$4H=\/H.8Q"R&\CVI,YF6L8X.G"'AEKF=H2#)*
M'$X&I\O<F9K-N]=C.[_R/NUTWD^8G&_RH6/VZRK^/-LX9?QB-$ =[^H[S=)X
MYJ 4UF"793KJ_4H,.V,0!G&3[2G9<840LG9HT*U]9 "[VAWR:VDIT.P-KL:5
MZ_,O:FT'?CN&CB/]R+F]PT5&C=T?.CW'.P/79*5/*.QJ-7HXF45ZP7D3.Z.;
MMX$E\=.M7?(^:]C"9SS7V%@#D^(=-*'7IOP7G9?\)7"\C"AP9)M&>1!WZCRL
MN*GC'5J;$/%B(/Z9QG68,H#:4*6MC2X$XHER-D23%CV2)XB^U=3WQ*/!7=6W
M( /\)3(8-8E9,/WS IUZQ[7QRX'TZE] O+(1? !BF>JSH7_G_'D%VNB+6D)%
MUA:1^L0D_'I"./DCLMKM&+SVR8)&_/130%* G#4[B"  5/9+:8ZTPLY0^TR'
M(1&037R!F-SFZM8!KE4>T"R+$*Q:%Q5N]BN6IN PHT?9U.CX;MI?+=K_Z]9S
M1EA@,*EI:^J7FC-AH2EWW'R!I)$O#29:7:AW/][WN1=B$M0O#+VPMB7C&Y.I
M$*M2OU,A*#+?%PN5#N='=JW59MVN.?,B;$]MY_U/;://3C%<#@^U6+Q(*Y?#
M"30JX!P?<H 3M_!6\=T@B-:2NZ7_A K1 /N\,C&5AP)]YKU60[@\P9=H\E>F
M9"U9A3!3(6"B&]-40%EA]5@!MIO#>"4>&P6]'Y^G</-U7EOWUV1R[3-JCP,_
MUM=U[&YXO__&D<L_LHX$*#2IR<FZ^1A0E)%[":[O!QA6CL9BD79D9/MYO3H@
M<NY#THO,7O-) T0*I=WIS53[)JV]2L")*.E"6JECX\79+)#E3--'V'@8PS>!
MM9"!@]*G5HRM!1)Q2A><LHQ-Q8MI"W3I)8&/6^ 1-EQQ[THI[=/[?H.8@CC>
M*/D8?437NQRI(55$6K4_0:;-HYV[M%2(G@:B/:SZO,)A\D30_F#ZW]CHB/%>
M@9U/ZV*NQI  52M,.\E8*[G9J';4)U)\7V=ER;)R:IQ[E-M$O4-J3V6^)>W:
MW<,!J?L;4O?=.GNI7DX3L] "?P(5M_\M#%ZGP[\M."UZ*H,Y;&&7N%ZH+W7O
MZ[F-06VK4K@O+U?>;-C8&F$Z$VCXN\>R17FGXY7[0@#DIQWBF A#<YAO+^!H
M?RQ$Z.T7Z8<".SD)=D'%NPP?'JVJ/%'!O.C[0$]:W.%9U+ B_AI-//SPZI+D
M11"&&QE8,&<"L)%IX#[1M!\3^Y##,I2\?=/O71(1>0!#1NLF2Z^)4J=^<NQ(
ML4E8!EHK=>,,+#M7N^;+?;N@)_*%5;Y0F!)5ZU?1:%JI*'421=I(W3;CC\^6
MGH(+_XD/W__$_% / D2PQ4PQ PR13\KC>:VE5;"BPK(,1TN%=B=*PL7HI<@O
M]=8[QG >LW?UW3L*Y@I,@,(9D5S1VIM7Y!H(98A&+Y((2P*A0.667,. D(:9
M,(C\-<#X%A,_^V37%D4;."]"K6VWFJ^53BK1 HGE?:@9'LM[OH5V(!0R9 U/
M*@5VL(EQ3(5]$2V.I\@,'?:1Y$ AU2)MI4_CLR+,;['K(9Y_Y$-^4?<J8F(8
M0,C:9 M$&.RA/_<VAY4Q4E=*I,_&V.? O;H9<-3^YISF@.&N7:L/)4'HWN^.
M'S?"3+Z*.D!]%;3&>AZYUWN/^F<&G']F7M);6@'OPQ?YPE)WY;@4>_>SV!M0
MR/J2?^V5OK_9L%VDQSN3L*^F_:@M=X-N/HJG*.X=QTX%00N$O0%"VM<I]QZ@
MB3><6M<774ASJK0S*DM>JI%P^5>=DD'$&ZY_Y<I%VTFG3D(B.*#-)TGYA;>F
M=B^D#&";;(;=QOE'W_7>MVM\.Q4DAM#S:;[8-B2_?7CPT</U;&_K'?57U@!D
M9MSD ZD><YKLO<N]I<#+15G+T(MPLS-/K!5@.IM-<3]?3A4-'JUT;;NYX>;,
M02OR_.88)5$R&Q.;IE[=E>P6641\,3,#^%!4UWBAJMI?.'-2OV\M=D1:6Q>A
MQ_-KI+,/AAW3(<_3%;H$L/F? )!5>(DTNI6&4:^9&<P/P2GOZ-G3>4./:5[N
M55]QVXQL-G=YYH.L 8\72.R)+/!HM93//N[\;8XP<KI)3&4=8[58_+'IPOH\
M$?\V6H=T:?GE<"^GRE]K,CW&G8![.T^'>WRU)//X:YNS^T.R'M"SB$VXJS^1
M++?C@QOB7;N>7C8_<'Z^7N>NX%B"Y;K;9+.2R=;@$B@@%MGK]> F/Q,MZW/M
M[-%^F-#CJV=+CGRY1IS'(>5M,A&/I_N[=30L6E2NA<.PLK#%Q'O$!\6-(8LR
M[UY9\_+VR17I*ZW,T_K"R)1_1(9H<COVM6LL&MO&^SH5S6$V"893Y7TQP86N
M%8KM2<EH_>MCQ8-^%:9+.XOR/VJNS,_J'WAI'7BUH1#+1@G#MZA3Q)DL:YD#
M5J?S=E0(9CO-.GLXPQ[WT0X5G6'&H-,/:VZH$)HH$=@OL6<*2E4( CJ(JTL[
M\'V.[(W2ON!&4994X'MMD1:<3\G)/3TG?\0KZBM2TL\GO62#YCS.<1)A,XK?
M%PN7,)RH$@\:S7*JH06 P+P%/&7 [C+;O9_S#I>'[01-2T7:/%C@M]4]@2Y@
M=8H[+'_/1_>,'7>N=PCKLGLF2=FX%VBVV;!!J7Y!6V]O;L&S0@R[W?P2'FMZ
M91TYBZ+Q$N>O*Q"<)R]0[JX]55B1&)&6@!T"!#==C1:]"!I17FIF(B6*3/P7
M.*^ZJH!LPOHRBO" U*^D[//&H!,AJ76TG'[I0IT66;YK4.\,:MH?L]@A3,IL
M#9M-],\L=\WO(_C 8'I2;Z:LB5LU0=02>QV#,;A=2)_H1WUH.1[RFK&G3/&'
MI_OUQV>W,+(\??+$(CB/ X&KAU2((X3N5!(AA@M,[)NCOK1N]N;4AIIV-CN3
M%&.W2\%#E=_=&F._V* X_4/%DLO[OB.AI_AL8+$*48T21@C6RT?Y7&LA!'/+
M\JA4<:_G4$E,9.[2R-9-H^;)'9Z%-TX5;^I-L;WW"<H&%9DAWUNIMX@(;Y'4
M5N(![%0A$D@^F#'JLR%2@0\X_TF%T -&2+C*E8=>E^]_.U,8*K,%NB0E)4[C
MZ^ !D=5PC 6&A<K:N-7B7%-DHG&5PE/+6GS0[_X+PH/(7973F@%&&=-Z*&=
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M53R(%8URF&$M2F-(U 7E3! D2KLH%E,V%&D&)1NR89BA%1+8+'Q@"KR(7$P
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M8<%_'H*"@X.#CX=/14! )?B<[KG@?[@A>P#$V*@S&  TE!< 5&(4-&(4Y "
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MCEIO&3K\EZWMH<M#LAPPU UXM4HD<1AWG7K"R<^'!5Q5^@<LO>G@LHNA&JF
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M"N-82!XB_H;Q>KO[7N"X&%Z#!+#4/X5]]1(2<,]QF$>&(*CQ+1PP3,\T*-?
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M$ YZP/(WI>WNZ$R>AGO1["G/NU'\=ZUQS[$^*X.IW64S?F%1SVEW9KZ[\N%
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M@-8E17?1$P-)Y$@UX>"?OJLSH2B2_J0)2$!'<I7C%GZ@'FB+N"D?)#BGV-'
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M+[DH_U.1F'(0W-@,WHKRN?>)0 ) [ LBB4V68R.WV"-:6TSX$M(0YM\/'$@
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ML7C\8WB7C>WGH^:'XM\W/P,(5\#D]9Q<(69+@@9&;T2M; F,C+M8(-.1Z B
M8P',;)DG"LUO=V%<KXYX_-"_Y\V7MDD2M)QFX>9"(V*%;RX"Z(*\=J&PJH<F
M" #N:O+TPR,)@MW0@1$@;(-[U-WQXUDRM6VF#&D_CB5=T;M^UOD ! !/MBL@
MO<J%<'7OL8_-9[E<%&I%+:>_W![5RG['[@!_<V+>.>))- OS:^XIUC1C9]B)
MN=I=-'QZEZDE]:,M'\GREWTYF'"^YIQ,+DS;9'HGEB?TT&"]V]+/^!Q3;E%=
M@+B=C5@2YH2=+#+H(./FZ$-[!#-:1W-Z:W=Z5H  ?(%RC9A5U;:*>_:AWK^G
M/R=.<WCRWNZ4(&.U2P04SJJENNP QLB*7FY=K*@UP=_%?;W^K?FB)7%9N,KU
MK-CPQP&7)_J!2L!RZ,T>?,R0#F_HZW0E[[E(Q1HR"#T;"  Q?5,,SXN+RG,I
MR/R'#_U 0N1L5 >WNP(#ZPF7T.T38KZ_UF/ZQF7N(Q7R@Y\*DLE2FA"L(U&]
M%#VUWH1$'KSYH(E2T,:'B+PY4R"^)]VSR&?QK.S"PX3]"DR#%(V")0 PA+ 8
MB3M>NU;=N#'"?51Y%)I:PP(-]Q=LK#"+L)N3!JL?JWDXT\!1/S0M=17NIM32
MZA [JY\OAA9GFY(IY[*B5YE'D:NIV43K8C_@IRYTE0@ZM2EV)Z@9NXO*RW-0
M1\/_<,[T+O"YV6=8ZK(@-<FL28P 2Q^7=8Q@L.';4-@=)2HWSXH9YR#)J%<P
MW&<)S^\:6RP= _CO].;U CG,^+5R^*]5R+;U!]S1%_I>0\@,V\NVL4PRH3+5
M;P@:#?4F+%]N"*Q?Q%MY8<W[-+*V9Q9<?:YU8ZY<>1K4B4:M2;;[]\79L""X
M3#,"\*,.M"%>;FNI& 1MJ0R(A?-HZP #"Y\:N>"_DR1<?B^BT!;>M^<,6=Q7
M]R2&@18]))1_C-8#EP+6-!SQY.X\?K(\0F)(NG X>&"6=E@5>$WXI!@!>+#O
MOPMU>#,S\=#'IXYJ2N<[A>YA\M@*[[9>)@PZ"6.!KVV^\==U5""1?,>#?4=O
MT'Z=;STWWGTX*ZW\VG<G:2!G(RWPN.__,U3_/]%**HH?&GO2QC,[6 @_RPB0
M3OVD]]EE1\Q\2)8G:9 B]IJ5_3XRV-C45Q>," "A>@E,Y4V0:-1K&50R<S^[
MZ3US_'#7=>&7^QH$BG91LX&=/4/N@ADP1]*/P^;CX_RJG#Z?^.E"5\:T6)L]
M*8>X<:I,H :.YZJL:ZPE?,*NB<JG!'8RU:HMXT*4BS>>AY:GLCR""3ZB)(Z.
M).^E4+R$9;5'[2V RL/]"1[F96I)Z=WT7XY.5BC."#T#^<$VDWU#Y5CLK>/#
M&IO*018$80W1JHF5+Y*E=NXI#M<3+\[BO[]R3,J2L'+P:OQ8A^\]D=MN)2_!
M5><3O&OT:OA:U.A,5KE;,$>T$RM<Z=+KN<2"F>#+ Z!?/:?SN>N' -_%P0X#
M3L&D#.]@/(GWK&EI/LP,9AM$+[@''AB+T!MZJ,@&+HF1J''(_SR9R:!0$F#_
M4L^=\I9QI#Q'P698#3T"4OWT'1!3Y;48Q5%%<4I!H'I61/:V(YMAKCK$SK(-
M+U0 =X8JY2JP;01."5-\JS8^+1%T?EAN:>!H5^'[X%X 72A?<U%:(,%*=!0&
MJ2N[GST8N_6INFP\%,)ZW[H 0F\S$S^:%BA;N==AYP0''%1F>W#OKD405''R
M;-)S\#T%H7QH6E1SYH5_MD9"NBX@+&_;..\L:J_=P$AS0]UPSK?VZ5G@I6U'
MA#\&A<5;"])^9ZC@699Q(^6PNR!FB0F/F1E% 6E+&44$Q-9,(3#9R$S3\?DI
M&&V#BJ9>ID%%-G3-/EB\J+_U(3K?0N@*W*&,0 J5F<"LDNM]GC!@07$CM7+L
M.\5>U8(.EK/OPLR6@*:M)JXW"Z<X9$LI&,Z?3\;XU1X'N\2"]:WOW*OG!JOS
M5 G?H\+,Q\<(+E;-=$35"+@MB&4G+$1Z<J?:';!MB40'+[U'J3/U-N>QZNDR
M9PO'*L-(H]\I]=!U$F^01&AI$3!WL3XA$I.5>%LZMF-0.LJ67ET):J#PIMO>
M\6C7,Z'&$7J1:FJ2LWEI$[@E=&%I%%%I\,@:0S]5V"SG=E@-6CH>.K.WEFQ+
MJ,IRO,@A?3OG>=9_W,77+SC>-U;.6QFE/M-![V7PHC-DZ%LP[H52N8*ME2-G
M\H@0UF(A^?M0!$!N^*/7EM!.N"!>#8FPU(ZL/9?\ZRBW'_P6BHL3/MQ!5;5U
MPW3'LU6"[720ZO-.!33N_'1G.XF#:S:BZ.Q64_)]#LPR#]4C$+[Z-^0B4C97
M%A4C4 K^.>).N#A+IT 6XAM'06Q6A^?WT85$^)W@^ V!HD7#S^;_URDNAE65
MCY(T?HVQ6/QHACQ)0B94QNNYH;CQY(UT!!C"K?_F(/3+XCA;IDGX=*<X9F+=
M\H@=GLUN/#0-+%1HML%*AZ9]8.1W+<,BF[?9Q=7YG$'9P-P5+\/ PY3Q ,<G
M8R3MAP79_,X0O_U[54J(EPQ*I&?&A 1REDM/8-"2:ZB:%RR45P9+H.(6V*3P
M0_.>HZVPQHV*D#E+*#:8U84\1NV?!G='+V-ZM(0#6;:94J6E9E],MC8=>'[)
M4YU2T][LXFX(=''L[)^OT[SS6;1K44)'NC:>!TP5:&]?*9_]/5A$_!T/U8-^
MN[GB(9FX<PR22W8?>SGLKJ?QLE[J]3^?^JB%+@@X/$FI.5#QL^(.VS4+X>!M
MXGB:;./8O]J!S1G:4K61/< ZMU1*RO5"L^5@ $\&/Z0H-#7:+Q6MT);MH*PY
MS&:=DE04OI'\LBEF1T5?##<QO0SCB4*8Y$CJ\/Q;WWZ2 BTR'B^&R4Q5W9-3
MRJWDH$59G-8RF6=1V9D%D3DJ++VV:,)=A?',=L)%@B0"85[7@OFF?@J-(W3Q
M![LB)HYHJYL_^798/ZU!,7I,V(KTI%(B'.MMF0SU-D1SC5.[&B8I0HI;V1],
MF<KK3&^*,0:T12PMO:5#"7\YNPU3T1(C6&66<23Z,44GA41?8O:ZKUDQO80?
M%+W:7C3RMMP3.AL:YV%D^!@W)'>-2H'32C@Y],:0::=E@LE$X$E<JKI'K$QI
MX#C%BC_DJ8?4EMQX??'RQ&4(VLTF O#-8<<!JSVI8FZ^?+J59[YNC<;<@_/#
MN^RGHW-IIEN0))CB3VW2B6O*-!U3 74I6XL)>_]=4G<#]VG)@='C=E<L'Y^L
M.$/"I)!ZQ[-#3'J;X#N*$ KKCI*V0/_T.TJZ."U)TG:VKC^D.T3J%BV(VTIH
M3<]P9RY -D<?)C:Z12%5TL7I,,;62\*DU4R?L%C"+1>GQYF.Q\2HNBN'K53?
MM[7N$=0@-X:7I2_*=9#)BC)>S3Y)F,T@^E6-LGXX_YZL3*&SE<0A 09VH1[A
M</8L6WC/B9X74& T+=1$^WS4D7^6^&<CV<%I9\U(>?5R-6E;41\=3NI'&YAR
M1V;6U-:E>R7Q ?JNX4_G+AJ>!W39PB_SE=ZO3-?IZ;.+'>Q%+4X:!DF5::BN
MZO83?E\)%8SZ(.%U+<!=O/LE2^(F=>WB=K. UW38:(S*]['M$;UP:$(W%J%E
M@1;%8;4%/J=?U<211;JX_*%<[JZS6>O$W?5WP\LR7X9-2#/T3GY+$1*_IPBO
M0*9<DO_ZDPG_1]J=U[V@_:IUB>_(;&+57WB!Q$!.IUPNO_[<4?Q7Y[\Z_]7Y
MK\[_D9V :5MU#BG&Y%-N;OGW>N+W!/[[_YOKO]J_VO_QEK,6K>O?N?[P1=1+
M//FWH6+1*,R=7)?_R?\G\L,! 2 QH:)0J++;K^X0J]?A!!?KP<9>X26L!M;=
MW[%2-(B@?74DD(9=  &H!)E1$SCDKQO\P)U\Z4P.,(+446_<LYEPFG :CGNV
MEU5M=ZU0HW\YD2['FLOV:1<65QN4>L(UQSQ(0R]5,'E7X(M ))!.#MPF(%SB
M+Y<SW;[65B;1<%B#\XKSI#@AO^(P;&X0M(-CA0"4*9?VZ)$R'0N_T]1^IL0L
M$"%1"MUR),XFBAT? 4MF*L/%"U7Z=,-M^;@KLIS+-(;]B2:.OD.NR[[MZW2>
M7+^0%RJ\":#R$-ICEPZ_"G--J\;"67(H[)AT</;L>[S<[X]/>AF:?EJT1[I4
MX_/$ZTTD(ZG*ZW")DF*1PH??DK+"M'V?1#NX6JY\DQ<SL"20%P/<-D*-]PUA
M[W[$'[V7?E-76:PL_/F<,;!,[7(V:$M=N+W@#;KJ_3";GS,9SP<J7^;Y)$:?
MT:9'>MO,?,F<^!ABJ2[(_T6O<9A!=PM]][$YGL#-($Z%:MVX^5-#XST&!Z8[
MMB6"!;HGS[H?Z+0%YO)4V#%411ME:V&)A0Y1G.V5=+C%@&J50*40X7QJS<"S
M18>@3S*[1UDTOL/SYG;P':P!&LT5B@-5ZQ3==33GD37'9/#$*=R(:^M(K-82
M 1B!%\(H">>J] QMSEPR[7AC&*8(V!]/#?3YH(7B"%>?$L@6FAQDL*_'H7:M
MB=.$9'X$S[7<M=D?SMD<DKSLK'XN75*9\!"%WM!E9DHQ8B*;,"&5_I)E>D9K
M:I9DK23P\>K/_J%2(@;I''HCZW62Y>31AD2V-2IHYOBXTX7GDZR0(I!)!O;(
M2\P!OA \'I&/Z0O/S1=L@M>+G-LY%0Z%*VK?5-JBT[M]7\0< L9,61<0'A#Z
MDV[(O=XPXQ0KK3LVQX#*F>-,EU()N;BMW+.;='-=#C2?<Q[DZJ.[XCF851^P
M+"6L^AB(._&,FH3F=&$]V<9;W8W/#@'0FHJMS-^YWKUD/S:2>E*A1S@Q-?<)
M:^U!T,4[?6Q79G<+M,G$4:++:SSM+9NW9 \*)'M+Q;>JH>CTX6B>:#:=G=S]
M6_)SLE8<0@)!LI3["6>J;)4M.0QHSKKIO0PN'6O\C*$<;%O*3BH*9M9B6#]=
MGE35!!=H2OKC/U;SG9UG7H K19,XP"O$A,0D2J>OD\%?AM2V8F*/A*R%O-Z\
M[^#_Z)Q@LF']$T_X\D/W>OGD^+IJZ$9?P;O#5]U4>U-Z8ICB*N2/2BY$EVD^
MUI*MYQ(2&S@H)"0BQ[)XX!BYY%-&?_LW0/?53JM/S=QP7;+! LST\V>,%X[1
M))"$@;D;5M=2RZ7OL,AN@X XO'$'-N]R/$5 \E3S=;ZTE2)+]Z9&[7476T4"
M_Z? L2+>_HOW2VB2JWKGE2\NY%[_U!^!?C.+M[F2.NZ4L9BS]^5]X//NP5-Q
MSN2I/KM'$,=CXT@9HHPCC1EV,/%4L/6TH9IU8!XO9L2Q^R1*S@!O<LMF.>N/
MF&&N@-R*@4B5^TIJ53;)-2AAVJPF\EYNB4-M2B93(&5MT$1NF571Y@0OR% J
M0R;$]S7%8/W;1_ILOBBAKC<>6/0"9TG6DH%J)#L<-$?T5!]#,SF:@-=HPF;@
M,1FS^!Y1$\Q#SDTGW(*HMB%+^FP277(4ND1]<*%:R=>969.>I[737>8R%W8:
M$@36X9G6&CU:K9'/,]8W^["#":QN/%^K!H9JY@UHP?>!QSQ<LG)7.E*^YSW&
M4-'(3%)KC]+[$M5+^>0-[[8U&LHJDH=)"F,X,"MWZ5[HRAGI2(-\4;+]"FEB
MF#_&$!S-,@2GHKH:V I#"-6X4AV6M!1,VF=LOGT5/Y1[RC*))I1+"MF4-\[M
MZ5D?K>M76IS='TE_JFZF0=,('S%.=V.NCXVD<>P*?[BK_>[= L^1W;8BI9NL
MAI2E0<U1ND\TP[&^@7$/;DCW3]S$4,F\^)CX2N5Q!36-SB'UV:" ]+=UG0]H
MJAB?SJS7\)T66%C7(P"6H^/#5F74I:^":$F@G]1*/96;4=90Z!_FC'R=+SY%
M % #QG)EN2Y!4: #X&)_#)N=7#QK )&1O!5U E,DL3BZEY.%+CH%U<N,,6[C
M@@*&2%Y%:XO,Y'N&?+I!R: 7F^.E5DO5XWN6F>55U:'<(UE5]YWCZ>C#@IDP
M[_R$:">.R8KN<3/I/9K4#F.7J0FY[G'2E.Q,H>E<.9SVGN9:EN;5\7]7/ZJS
MN)X[*%4TI2$.-HF.KJ]P>?AFKV2][M$#>?@AX;W^)@J!S+&(6;)6D_6+7=30
ME"-;Z^=*=[8'7MJR8BAZG;D)2P^V>Q;3L]!X0>=-9:]2>(6^V(7;/O]MY[O?
MMR3+"#V#SE*7;Z0Q(0#6"( [&H,<-?.*M8VL@B\","$'HT<N1_M:4//QB0!&
MB/+PD"Z^Y"Y]3PT>B;:X7JCD!]3E^1E%A@G[R?1*.[MZS5QC5,EATA?!"TST
M$<E)KI=D*4)]O,J!9\[/M-'-(S%;,23U'>@7\KS$[28H:W8_V.=CY#BP"9@4
M)G/KN[Q0X%Q%IY3V<D4)G5?W>4=4!Z_B=LC3[H&3?X ;29BXW#LMG=&0:GS2
MB8;Z2+09E4H4K21WFU745Y*M:%P2RC%15NJK:2@3^>",.U^UC^%)Q-"[=_*R
M>\@\)*4G1O#^SK_3[E.EVQ2HST$E",?"8AVL/[X_"Y7&*FAE["6]JMY@:7/M
MJ\=C*UP=;H#$K7*5: BTUY]HS7-X#^I6Z122E2M(>61PB.^4S,;8YDG*KU9W
MG9#2'1>9*80>F;E$+(ZJ&^^[SY<V6U02BC()MMZCTF/MYWW1)603,?: .2.N
M72$CEY_[\DS;2.VFT/!L\^GU.*<8O JW1!6N-<^I;QKL&N]%C6L22_Q<(^,(
M_1EPU,]+#"\8/YKA)1U*SG)V3L%5B,C:$1#_-8%YF#VAWB?RU_!5"<5I?D+M
MHP-3LAAO D<GY;TRGF6N^R](C\"KJ,M.<HN=R\72TM^H9R\U;8OE'>?WQV>O
M3"T@12;#FD'V24&<W\?JLQ_T"N0U\D0U+U <F-3R%-66.SVCC02R. 6C!8S0
MX-VY^+P>*F'I6S.-@4[4 I&IBU7G:*:][RMHW/8RW1*3X>CG=(<G?&_6N7 6
M("0#0HV0(2]<&3CN>&EH1$](KWNX*9W))_ZL6;I"JLO.N*F0=_.&)D%31ECY
MC!P2RBKH_#BJEV:%^).V1S5E7IOZ7-)3Q:XS;[+I'!-W&)0VSY7B.1I:28&P
M:?^:A9R"067TT'+9PP_H6)4?-:BJ*<#2GE5Z#G;Y UQ$^[091,.ZF.B.;WO?
MXW?83&_*335#$8#Q^35&Y0(K0P\$0.=(+,!=%M\4],FG39XMHZQ[@FB8%5)E
MB3U2'KURLAV*93*0KZ[^0-F$<B6:E^4U1F>O8.48ZI<!'==U;J/8#TWQ&AH8
ML][2-4&]D5,C=I4SR.7,>+$>?*R.T20[3E>?/+>X$-/!]QIYH?QHI.@'U."]
M[=#1U7<\.N'IZNX#6NQ-<KV#49HCZ5[,7P=HI9,_NKP0RC8Z]W\O2;66&JO]
MU33>H^!Q9N 13_C;B+IG?!T/2/:[!B@O _L;X]>6KNN:<Z9%N?-V--RL#:*K
M>.1G[NKOAL795!\)BF:("9=[4G"J:V9'6W'7IW?IK]9 [^_QH9FL9S<\_*90
M!R_7=UA;[:ZO=2D&<KIP!ZF>])C5%+T)$D&U(&"/DX+ON%<M]N$4;99 &7HT
MEWACNZCI+(^?>[ZJ[K3$036J<FW[X;74,O"R/GYN 6)E>2A+]J;W,*:#7'?E
MI/GG %"=:'C-0HS=IR 7\S*O.Z_S-:JJ]+[>F*V$.]6WAF_/X*"#G_FCI:6[
M\Z43)P*"K%<6KWC=G/1+*@5J.3AX4Y4!86T?XKM']"*%]=4<0Z+IXSF"5>[X
M?4N)V.XS'<>7$L;.L[7D]01]EQ<C9/C'QW%)B6/CO<U*-L=MI]]D3?8/<+$]
M[M1]_GQ[6QY2*!PRMEI93 _0R+#%\)>/EJYAN:-9@F9]*D1Q^+9AI'%ZJ3I9
MK$:5J,LO#K/T#:\5!=$K0<<^LLHH C*NH:GI+OK( 0Q)&:Y2$7KM@K82 /;Z
M%RV,""A[\<4YW^HN,=>$S/GN]&C=DRI]O#?]EBC2Z)(^!5EOL=&9B*VI5O0S
M162U6U@EG[G?',JUB2APA3""HI7P0,]8&16JDN?;+-PMV1>KXJ<^XAA9/F'I
M[I74*^E$XT?%M+:#IE16"-A##2^GM_ TV*%"S5RB6:^9,<D_8M^A.;@O[H*2
M2-6-Q7CC^7);23;? FZF!3>\"GLDL?[*8BW$(AG#+U**]N-0N9MK,5IP8FB3
M=(5(C9X);2M7_PC)UVG:+S/?^"]^I"1:>R8:%>J;>7IF$1D_+6KQ\#WBGD='
MC<PC#DWGXT-#"XU.-;1BV>Z0\&D!?6JE6LHF]^91$6G@RUK$5IH_S6&)IH!J
M:PDUR QN\9P3TXLYX'=8C%O?!==*7509D?!M3@2&3FN.%&6@4^QP^(J9T#J/
MC3JP] +T!M[+44SP9ILXE6Z63KO@O3DRSK\;1Y"#4ROW[9)*8EV]+Z=')(BA
ML#+.UM(G'X7@K%U?&2,DHQ+%X/!H'2C-(,T\9?JHF"?*%;F.;;G8'()8IZ[]
M#4"<1M_SZ=FI3N%'>RC6FYT#\C+IVETY&^.Q42Q/H\0IO3 !'F6:-Y%OY^A&
M]FSR-,5I(AGCUV8Z</T5"&@^/.0#\O!WDO(MF[5&2*'Y/:6-YPT5^WI?0O.1
M1W-N[H,. 1?/3/E\_AX=X,AUGS02_@EX_<.-9\P^R[.U#N@,]/O7,DW(_<WW
MI3GZP0NXX/Y4MSX)N=&GJ0V1XTOD-9BBJ3YI!KJ97YH=.Q<N]0.%I$S/8RKE
MZ6VKK\P9KM.:H^VZNH]>;"OOGK@)FGT1*!B63O%QV:/_GB+LN*\??*7<U2ZJ
MT[MF:INSNSJQ/YA];RTWMVTB!LN0,I?^510=Y]L[=#:ZK;I\R[[+8-/[M1-$
MCI^&[UT93I?+$(2UF<?-J8:F6KLZ+&?9/AZQ!(O]T.)9ZC^28CL*+W_.%<2Q
MLBOX&9I=@BDNDCCF7%[7($".)9IB8N2KMEKM2TOJU2VEVS3'XG@@L+#,[5Y2
MU]0S (+==S\N+9LHCLF'HQ>C;/V8RU"1L;)##91+0OW$SA3:6] 7[B%Z+3@>
M8BB1.Z,]WTH879!O7F,64*3K7 UY^.6'U(#[([2:0O4.DU,!D_*1LMK;8_K@
M/Z)M%O*N^+GN)0- N4W99U<#S-$Q#7EE#XY=7!G.5PL #JGF;,HA#IA6L/*H
MPW>N>^,&\2VJ;1C6!VQUJ:R?);$-^/CZ^0KIQW8]!X>Z;&M,%.CEF+\H&V 2
M)(O2VR6C65;(2 ^R84=\?)9>Z_BH0YMTS]  $\#WHLQBX0Q"DF-IO[D7YG^W
MK8=5AJ"RO]M:B^Y5!A4"\!RRKH6E&&5V.4L1,!:LN+]UR6,V8WK&4RP@RZ?\
MY4,&N53'C@\*2J3-3XHQ<@0 3WUZLU1S.H ^@D$R_HG7RPW5+S%:=7YH=#1&
M*=MJ$5"MAF]DO>-E 7,P;3ES@CA4/6F6W2WI(FR!4PA7?*(*\;"IP%>B6!'Q
M'H,/QFH&409UDU_IG "7=OW,'=^>%3%/Y"SM9EL(J-4A 9SL=HB=7 6P,4:L
MQ<]N1?*-[LG<JVOPP5/%],:(TRGS'[Z$%5+>V!EESZ]_W+-S'9Z=@^2WE)@"
M^C]/-UN9RS/>?W$L]63&"]LVT^_A?6QKA_+)50MC31)#R6E9'U'G[NOF!!:[
M&0,;A<V.YTVG@SGCB7FV)TT7",!/7N.TP'7!WU9#:;VD] 8O/05%-MRW(E]-
MA $!B/!<WP)?D@VB0OF?M'!XL+XJ.[&Z0(.<%#[\3]1:ZIN6)$+(.)]Y9W6^
MUK<8S7,%_0 6KVYKO$]G&5GQ3RBE7)8+H)(124KIQ@B+T2CII.K:/KUN,.M>
MB93*-&%P="%9C0N5$LD8,7-JU28<%9)S69UFC[7T.Z_"%E%" /!WK_,W3(8S
M??TL=]JKGN@!I'Z2/JEEX_PY1SOV09M20#(->#1LMQI6A,-X0+A#17V@';:X
MJN)UAWMPV^YYC]%T*9QP2.6>^8B&@HZ+*=BNTP+^:.L=<-A!4#4LPW3@^E"+
MJNK@TD)CYQ[W@V6>&'GH0MN[I;CU8M(^)WL5@I*QE='B$D+KDRU(I.G&X?2
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M^BF;!MQCIVG?[_:=^V]<T#//0ID+N:3+5=":D:KGXZWYXWU#!, =B  02B$
M&/@J" #8C?IJ$;EMYZWT<9UGGIKJ= .+5."?')H.2AQ %V<ER%Q!C0 $9B!U
M!>4C  ,58;^4V8J'#_W&73CQB[LB[.^YPPI ?S)SC4B,;8*8=30*KR$Z2,UT
MJDC-9K]KEH.I"4"NKU1!\U6W=H=GQ>NH9%ZG7XY9K0E2(_L&_M:7"UPT- ,>
M[^HA )Y(%!-8)#1B?-G OLJZ_:'I^XY<6X,1W*, N(],8H=*X(,R;O#%V0\$
MH F9K-HG*%Q_\5*/FX%>3(%:^L:;UL=;X3=-" "QI.>3;9WC[=_%!A4]'Z;Z
MYJ$=>_2MA!OT?1>X:&2&[,U&IL9;([:8/9^8/2,@-\,FH:+SA-Q<+F^&W)C<
MLH=M$R+9P]JQK. >]@C U1G2=RW&:S;*O](VXO&_V_R+F>VOG8]AF46@@2+P
M'X;0C\A)_PI&N\Z:( BF[KI^?;DY?[Z+C%NM'$P]'DF:_$XN,6>%Y0_#Y?-.
M!9.:8?E(.5E)O\NY'8_"(N3H_>V7(HJ3K*%35X_ ,R1W%ZSX[SIOV?_^ER*2
M83+M%K#>E6E2_SJ<J*,! 1")M[JY L&?1<&)^O]"5JN;I$\J[JA4@NWJD&(J
MBI%F)/Q%;M4?/ZP@0[G]E0LJ["/2[J9V+MAZ:(><&6!97OA-%W*\AJF#:I$1
MN=AL.M^20XJE&P\?/B.XPH$.U,PAL>C<!#)K#[Q%#JX"Z-"!HHGH=/TA5E9"
MZ_TE?D'J\^VO656GOYE1#K9K A)?BR(-=#6ZN8SZW8KF)9R+XQ'@_BCX6LL:
M+?-QY@[S&2M4IF8>'"Q"@[1"F!-^(_6;%<':CV]I]E_T!#C>9%/B1_:D^]&>
M*\[U,^ C9)228Y'N(*4N;0(7;9W]X.XG35>GC,AII>TAR^7VT"-0,=9N*!76
M5X2^S#EI,O! KT%?0IFN$=W.&T9V.DNL7C)QTEF\PW#\V/,!T(6\]L>.F'N5
M1B/!H=:Y#_<+.W/W3NJ[;K:>:L27N)/C'ZR'S&:'8DD;LX=/E#V#"E6W+PU4
MSO NPIM0J>M#9E4=:<M9!TRR/YD3R(O1_.U9NZY#]NN@<R#R8#LX7I'/V-9T
MQ#YSHX@ O%8')(@C .'N(.G!@AMRN.CA#>NK__BQ/?,BVH 584(9ZI8DI8I/
M4YF:$3>]GN[O Q)6@XP(]H8%!2G*\*3."\.PIEVJB@4Q_6/#D,>[)R5F!0<S
M&ESC[K9'^& ]"&R\=(A*!$]H[,.-;"#.:S&TU((PXPN[18*136K<]-&WW\L:
M&Q+>?G/E9+:_[@X;C[,3JH5TW+"WB959N163NX'LOZ2_G-K#EE@QDX8TPQ^'
M+7HV<:F_R[Q?:%$$<3,DJ;3AW&W9^]"ABM5VN*E>XLRI/)(*4\*7KG>JJC;9
MC].UU66GY3_FNWB1:!?J^UE84?2P^&P^Q%UT<6 ' 6"\HC.ZE$BJZYN%]P]5
M'7.OPY\?0JZ?@!ZZFX.GYO7AO;6A$R*@N+6/AA>-&Y!WB6/?L:L6!H*IZ)NL
M,+<NDT)_1"2XV,->Y^BBS7]\J6V++7G:3-BCZNS6)GM0M72OH=\[1PSDEB/Q
M5+EEMD?J:HQ1MT,3VX4R!^75<<<<ZQ ;G'(#*AY/-;[6/3;*UD*G$Q[P_4AB
M[R<C:G+-26=176MM48+#(5BI(JH5J#?A&T<1J])D96+[L.6MQHNRX"_5#M/[
MFO/^7!:?.GH6/2N(_'*UGX6AOCJ#CM\]AAQ!(+$30%:/%_TL>PFIVF;SI$(R
M3DZ96S&N[PI3'PA=6/0ZSU/0%"T]W*?FI5CPWGQ)U25FW8@.4TQUQOD ?C^\
M=TJ:%8^/P3;JWTU,<UA!G'S/2>E.W!(6,W?#W?-WUNCQ'(^2^_D588]8UQP5
M"CY\P<1^()R_57M1UT'T$=)!5O"0)Z?:2'Z#?(VZO^Y 88[1$ENC;=\3:PL5
MDKO9.\,L->39Q IB*%8JQH3)"8HM"W]>D#'?DBA^?<,ZLTVA:?$A[N.'O.?(
MH_/W]?_]#Z<6X4,@BN V*OP1^]F/RV^O+'H/>YXRYOE+7=4T"]LD+BPL!P+V
M-HI9'<;<'^=MDSV$^2F.L3$.%K$O1%Z".):@;R[LU@#8(W5AK_@*ZJZ2[%I!
M..5)XL)6VJ/<P$<-!79<1KLXEED<.VQI?.3^)%W\PG;Q@+- 5L@U<8YIUY*S
M?77JX?$F[X_N6#Q8Z,P:^MU5;7X_UD1<[U!)NO@JD_RMJMK[ 8O$3;5D"V-D
MW?#%3WKL$9;3<[(+ZVMR3XWX10P!KH6$"]!8?VX+JS:!MF/>-@(-F2F+@JC6
MRN;"]^*.J_T@9RE2FLNE6HR@>3SG4/8[TW(YIJZ$JP@ -!(!Z EN9D5]]ZZ#
M!'69)MQQKW/W)552GJFCZ[,XFUQ3_ <6;"/NI8_>#9U0Q!N/BHX3OR.*->!N
M I\5LYY3NY'S&NV?=PBH!,-B6M]7'82%7@L[+6$IGTU+\4SPE,G9U!JI$3_A
M)Z<66*_ZL:G%W;>[_]4AMW!IU 'K%26PY5@K;VZ&%+/T:8:OY^?DJ0Z;=H"K
M!>'R>:UR70KL&9""/:3"K$&:B:X^'NHR.ME;Z*6O^OG"%OL.VF;P82I/5!ZL
M"N+)</M5J73UX0*VE'+GE!)P#ZU$<.**U\OE:)(NH9,4[&6=0Y[8Q6JZ*/F:
M-RYJRGSN[=@7A@HO/W(06].?D7*G&[J9Y4 EG SM"/O*/W^+)\8.Y@Q]L'#$
MZGNP]ST9"+-(#\.78I@)6G,I*"SK<V GT?\RZK$('T2K<'+\@:$A:3$VVR;Y
MB'/93E>?$8 YB%K^^Z.XOSV.Z[/,?D'(#MH%PWTKZE2U.1" "(5S^!024INI
MR\/I/>1#&6&<)Z"(E;6$=US02Y35][[Q;B,A7.<97(\SN++"!]]#3;(596F_
M9L4[< TJH,AFDUD\3L51M^ [S1I4(#/!D5:4='VO@/=]?AS\UFI;,H5KY!W7
MR,LVKI'A1)/L3-KP;R/OLN(?OJ+Z!K79E,U0>#1,IBAIS&3!-9*;Y17N>ZM4
M#$O8!(MY6]*8&0N91;,5-2Z'F1^X*I I#H??:LC.Y$,>2L0>,V<ER7(1?,T:
MR3L+2ILWNTQT),)UB0+2@VN#9K^?W<TLCYZ2G(,YY&S'>#(&8I%Q"O2^K/X2
M^BAEJQ?D1[H IUA'VPAL/LCV>>K.G(5AIDN?=&!43;<6T91"Z6.E$J>=EE@4
MLG3[#EN!]/^.-)9:B+EQ#G#%66.Y46X*ZA_9HZ-\:T2MJ:@1(:^-Y4+!X*A^
M'UBR>(G<_SLFU!9K>#<S.;LE)19<"AE+5A>T\JY# IG22H5M&W9/LQ),&&9O
M1HDJAY;=1SIQB1E1GCI3A#./3SA.Q$3,0F?$A,N#&IX$M-*QY]!YL8#]N?PK
M$ #L+;*WL"D7RX/UJXQ0G 5KT,-#:FSG%@NT!: _U[3O"]/:-\,FBQCN/SO;
M,#W005=+GX5;)K2&]@L,&\O&S"V?+C(85OLN4G'1W'W]G(\"=V(\2O;P?E!!
M759L_J0.!V9U18V4=)A'QE*]7%OCG;$=$0R8G=Q(09$5*F?A6JZ1I62DUC)C
M2M=T4CU**#8V*^L;:FPK=[VTGL7M0HEF:$-FY_R]'2O:F:A@2'6GHU'T2O Z
M20J.>].AG%]Y?KI9SC94*^GGG6 5XHB.!2H_3-$L=>>F5@&?&<=*;=IA2TL#
M/DF]AI#9L!]849JQ;?-WG(V4!BL&<+5-&BWSL;Z&4$+ M MIE$U,NO4>K.0+
M^Y_K.>!X@_7OH)8.X93PD?6N4<%GCGO3(Z%(C'IRNV:.]]N"02V@/(O-[TTG
M"BJ#'XY!P47MY\$.:J.KGH.=.#DZWT L.\WL'DUTQ0\:SOJL?+HU(#QM($P%
M?"38B;@QF\MO;WRD%N<NY>3HN4/4#EIXVTJ=PKW+S0=Q_;H$WK\;R%2D^/V_
M^CW3__+W3WT/U_T&_-W%%@5=V/;FAIY9DID4]C!_OF#4W]>I=KKCO1VX^_8@
M]W%F,.XH$0'8Q!ON)H$ >#P$K'&!_6J5HTQRZ;1-5<Y=@^_/+;]OJCDNPC1X
M1/""!& T,L+_,W^B\=%P!36&AK/K+D/,,)1OF)1W-QI3]YYU3_!SB/QUOM'N
M<]" ,0*PGRH!U44 DH>08.;59_XP'-C=5M'1"<58I7$'M\FA=%\+Y8-^/>6.
M!6\ YG(1I\IN/4.6.JQEO^WP8MZJ]O.K+5477?<:W1?A;2Q>=M>TE2(C:-=G
M8?!+ H\LG(M=ZIL3)I2(,4^RS?B80IN<:5/H6N2Y;.,6&P>LF;)5G]2A>>6+
M=[#1MOH/9Z!T>>PKLS<Q<\*$!AJJ$8T*E(Z5.UY2^XFGV_%35V^ICZ' JPWY
ML^_ ]7+0^6 *IN#^?1/7(+.UU2)*AVI]WU6GSP2TT0J)!E1V_2X$?>S-C@(6
MO<1XVEO$1^VZ4!>S3>77]&^O^H_+\=Q<]2NL;OZP[@_)[]%P+ ZB1*NJO_*D
M%LZ8_)"D]Y-*ODD>YD&C0P]>H+*6*LH;>%U9.L$MK,[X?<:4]C%'";E*CT)^
MN3Z==[]4_OS?AN=O ;@C\W*(K9X_731SJKX8E:&[O(U(\'M)/X!2]:R0)>C?
M#3]#6MJ_]13=.*?QWP3UKCH+>WDS B"<CD38/M1_3HZ84G<90YL<9\^M\7$@
MA]%4A>U]ZX5D.<I[QG^XS*SLK/99[7W4X'U"^:C@;[&OC.[Q53=F1R-!%'DQ
M$KWXP<7#?D'VKYRW  SG.@0)X0FUR\0<;CRS#6_<!X!7S\*<8,B<E-V<3/,G
M!Q(//=#Q!VY0WW[1\A:XCV^D;Y\*LF^O44_9NS6U7H?1(F6RM@%/<!" SJ%;
M3 YJ(5RBOD1# %:,;X'_*93I\N9=S^5%V!7'+PW4!U]A?O O", %&1#.$@5_
M!,8%#0(1 #JDM^TJ/^0E)O(<=29Z05/E=;<*J) *Z-IT3K#_4  ^\(8%P;_,
M7U A+V\(#!1I4"R%-^K=),G470,[#P=@HM=(22_WK\/^\(#7'YE[*9$N+-^Z
M,,64OCUVZP)P9TMK_O1(R!A&W@;Z3?[A+_E>L*B_R8\/U-'.G<*Y$HEUNG$/
M(T$:@]\&/L'Z@]GO9S(# I!B!9>X#7"Q<5I8L=*.]Q;!5=/VBG/5-8WG7WIS
M5@[8 Q[=A3IR_,29AXR"S_.G33&*:ZAO'.36F"YWWW6"Y+-G$0 =NHZ!S_6R
M2!?F_W0!)Z!I@_0/#Z:1'E0(/KX1!SLZ!QR@!2"]^Z,O%^>SD!SRTH'K,.+;
M$9X7H];*G4(;S3TW\D/.AJ9#X T*\$A(Y_K#8QAH*>SR/FBE#4FXA1!X.&8;
M '-']@:P@#CU\D@13=??@WZO\[@M@2_O(4?T-]8D@L8ZQ5+JL<>SR02>5+!L
M^!?0Q8M;91+7K ,$R+S-C@2#M+=VSAK?VDESF2%8U@)<U(+E_XU5TI/REM+Y
M16D?BE%K(H.\]6-OX#Y2G<-2T^6]7X8Q7K.""9$R6?^0.9>3OAV-]%T=S8O:
M3P3Y<XH*_*T8<N8HRK6&$8'^9)PW_L6HS?@9Z7C5H='-7=#11W8X2WK4XD#@
MX%VH,G(83OQKP3!"CWM_WIN3F&"<0OL1L !9K H";2"32]0+T.V<*'370L8$
M?!UW&Y/B%./,TZZSUV<O1-R!6'_MR0!B"=V28;\SIB*'RF[';R?-_10!>#C0
MC@"</$  NKXWP6I?'_P=>4D6*%(ETNG912TL=M#4/BSM#_W84?"3V,S?7W[+
MN@W^J@'<DDQ0<I#UG:W0+TYP8<!:HH\.]%+PX5Q:6:ZV V&<-/,] GG5;P1_
M/8I&+>G\[>Z+F;)< &A%I^8R&^Y;?H<G! &@@<&C4]4N>:^]ER^5?0!_O?+?
M:]9.XPB 84,\5?>,AZ!G=/9B703E\D](@ K=%O!R*M\5GL#0%B%G1>H$I+MS
M299.6%$9L\TVVFC8G5CP@KH6!.7*7S*1SQY05I:(D\'0V";**H9+J(F)FMC'
MQG1QV.MUG@BWRTGCATCFML]RCIID?R)<TJ:%?<C? A$3[3V0NZ8]KWHT-X_+
M<F=-G-SKZQX__PK.A;'9M'$>;KN[V*"[7-[DE+:SC$I,CT));.\1:CM=C;:(
M,K7],@JY+S]=X/&-2BLU?B.=YN:9"/.P?<B3EG&'Z#T]0XY'?(^M]^R\G"_$
M;>+/U9E0B-LKB05BO;F31+J!/&M+W:H?97]:?OQZ)^HS_VG!O&\\3^HB N!7
M^RXV3^,F^0S5AMYM[&QU,E0IW)DNM:CTUSF@?\+AS9 ]:Y_X*Z -KB$:+"$M
MK&U!I;=_ESYX3X833TJXSRTLN$*66#ZZG%)2;N4NY7J5Y\>H*NKVYO5B[3C"
M]0EJ[ I.-W.NS;11KJN 5VPSP*->JKT&%>KU9-8R-/7(VL;L3/%O.:WQIA."
M35]KY<L.1JOVJMVF;($S;[]<[A7!\U757F=MGITI;U>2T.&FG*%<C,6OY8JX
MU% 0,O0QTJ0%LCSX[W\Y](]6, MZ'RL]](Q=5\F$;OKS0D3/G<DP=9N@*"F'
M)[;O@Z*FR)14$D M+6--ZW,]<!CH-FD0$14B ")G.N>MR%WXP]@I2S;Q630.
ML/HDC[4/ITWXSQ)Y+G#QHRD"<+RO_WM17&(TS^\L!(=SA*F8XQ\+WHS73[5T
MX!X%H-\NS;F,1NZ#QH/'P@*!QS@P5>AM 1N9U)&IKET!U (9!ZY#(;_9$Y;[
M 6?W(6..O+;6?USXSKE,DK_Q#-A24HE!;DI=XZ!UZ*_R]&^U>E:UVPMQ?BL3
M?V#/':.>V$C.%G-1@\46W!KI=UM\O?7]4QG2]W'J7R5AD6PED88WI^JLW:#%
M3W^M<&< \1V*+T[_*(X/G0JD7^[2C6W]D7)8>Q" ?U+UOI5=)WG:S=KU3PK>
MU(IYP"(%8=/ H]>',AI(+[2 ?U3=F<W ?VK8N$QZ?SE+-\%4C-RC?;)OZ^!_
M+4CG_K6@G;X5+7%::U0LK_W2DV4;?+R9_2N&F\!%,[.F/TD/A11XQ=NSAZR0
ML'8/)[@'U_[?;/PK2:V40ZV6Y49(N P^J.3>OS@9 ?UV$\$>23K\A;P55X8R
MQ51,]D]+VQN7F2\OVW ^I=7K7FO>%JM'D%F[R19T:.^WM-=T6XZV^E6.1KJ"
MMKO@)B;J<$Z' !3E7K<[[U^S[8+@[B<#O\K(\CV'5MK6*5"3^N>6=%$E2 5A
M>:,X%BC3QL4$_Z2V3?TA!VB!/\U4C <D<?\[1B!)_>M;6N<7G7FJ[GU6(EP;
M>(@#T_3\:\E[&-2R<HAS?;$)^JT0CU1-71ZP1Z 2\/HP01._P^C'2/*C5M>.
MT ()=[QUM /N[=IG%?K%FQ$ZDS)KKZX?>1[Q.NA-!@8,?>/65Y#3?X4$](%_
MM\3_%X)Z9"/;HB1%IWD.0;M?G;\M45IKK!,QIG'5.E[GFINC*@&RE*^VZ>9-
M+2;G[_&LDSZ +5>!(\9\BG<RBWK7[!O$"AC7GQ!=;=^(.0QU1XF7BC='U*"J
MX-A9L!5T,,>:X71>!99D;RFJ2D5?I -=T!<0@"_%R=UE+KJ&I^ZOW)N"00LN
ME).)' 4UBTUKCO8?9(2EH:<2,3#/C1FR*AT+Z0J!(<6LO?JP)_(VCI%(8\OI
MF=+BG@XUX\MP!5&8<O2N SRY[JI,>MB)/#T4<A4NT] 0J+CV!F"[E]PL[V^P
M<NH<[LBG3YM0"_EY6TMT-^V%KL]GC]=?2E&9D$E1)DW>/F7-W:-<J_[FW/8Z
M3\$TT\%PNBDGN'>O?T?M^TJDK53QVX,G 0P^4?,SEFK/7J*3\MT1ECP%]FQK
M(G/6-<^F(4]-3G."FW.\<8HE9J:HT"4VD#I;1R[S511LRJ52A,U#&SQP[87$
MRF7K+?^9>_8U.N3.4)S[&I-=# FS#;T97,;3;ZU39ND;L%\%V\S3UN8=8<F\
MGZAHHC1SJM7Y"EQ\/%RHZT'&(Q#LV%U@;;1X'"F%$2[ !G!E#ZA_V4AUT#!>
M&8Y1[B,?\^+)S\7O. W>V\G?:BV;;E*79/4EKWAC;^)_\":L&?4>$U2]M0EV
M3;Q2B<42/]/Y NT/R']Y=ED9.#0U@%']2>GX48<M'_ Q"EW1L.EZ0/%>^7:Q
M?RR174-YLG("N:9$TF Z5M$R94NDW70AP/7TM1-PRCR[>KJN.P1L:9.(N52?
MKWB0]67!K0G;%$Z<;.Q WB?^@/R&;14^&/C:;P;CD:>"!@T 1R1ZM+%J*:CF
M5$;X=0NU[@@1>HLI-51>IA[@"'Z*U6J]#OW,:T]I=&75<D8V,74-KH 60J*:
M''N+;.I0@)K*F-2XYL@-&&6D7L;!D$,JAS?6(GL:+*!F^%2)UIK#>4!4$_RU
MGG,Y*.S.)B\1Z%%CE_'9BW+EILD?4JM9<\0N_'P4!F/L6 -$L8M@7_7&E*UX
MB[J9YJ<#GR.DGJR&?#\C135*Z0,X=!VBJ(\4I5@1P#C6Q4<L&505+JS2:I0^
M\>D\?_8097O@21@1;+F=BB3R<E$(]ZR!=K((>7JO2 MSYB,].HNA?@'9UB(.
MJ)?*@+F)$]<&X$/H:)NM2%0B%[O(E;GI+?EIX!71AV_V8&;Y> ^ZWUB[ALTQ
M +0/^LN69)4U?";<F6\"R%B^@Z_$!<%<R>D/[K^ Z*AO;!+OX62R_=/3YI]-
MTRB8T#X,S]FMG?ZK[]RG'_66X!KP':DSM;N>GS[SU,L4@UH$]2P<SJS*72;"
MU7>/>?1[K1/*O$?X(:Y&0?5(;/"@RN_36&//6?$SR:CN8QXCMSPC/F%>HVS3
M8S:%\76%@Z=SCT.M2N>=O74JDN?L2!Q]<5DR2!6;6SY/;AZ3.;7AX#AWM[9P
M:IK."<)'2V6"0!PC5[0DO&M**.N*$=[>L/=H'DMRI#P1N:WI)@)B'16%?;C?
MU9II.THZL'FEZ*P_)Z/EYK@#EV7J=LV-/6G^'_;>,RK*96D8'01%)2E!D@0%
M!$1 ),<!E2P..4I&8$!RC@,H(%E 00$!R4@2R7%($D0RS" YIR'G,,S<![=[
M;\^YY^QSWN][[UK?]][SXYFU>KJZJKJZGZZNKJI^-M''U_*8E?AK(?:Q;2)<
MO)^EISYU*\SZ:SAWYOGPSO2\Y+2;DROD%_72>?;H!8D GVI^J->KL=DB_AJ/
M&7&NR2\BOD'J8U;Q[$P?6R@B:HW,2I/FU3?Q<U,)=!$5UA^DK#G[VYL6UCGD
M6HS(ZF5&+G4LHW0U%F&4?.*\V@/.9#FC(9((SM0%F2>R3($.C722J$'7+ZH#
M:*:,2;0B,F%F?#Y,-K)QU0:-_$Z;+VM]A>2;I/*%U8.]5!*5M'KHY\\(EP)2
M&%G'-/MZF:K9:_<7A\E"1"47A%J>V8?6"50\0SZ=>7MK*SD[ QH+9=6LCY*+
M7%]!V*CK?;_?#4.8<"=HMC/='I5L ]ZZN+*"D25EW4[GSW>K:D+[>:CP-J++
M QP]/1%OO%'0].\H>E!QV1""]NVJMW;YE9=<9N[I_N.X&;9Z+#R]L4G.7USA
MFX&6F)M;!R]+(Z19?;BZOS9(6\96L]^XSL&#?T>=FUIH#F!:(ZV6 BV,-WEI
M:LMG:/^#0Y'VW6MN=L[?_4EAG"KJ=)4CPLRD\JS\IE]<1X)#)9BL!00ER&);
M$".>DN7[\-'[7XP(_<-6V^_(FP@ZSY+CK&L0C7]SU70:5TSAHAJ1;>AHH 9_
MK=68&2R#@):.S7.9$04,(3-E(6F#IE4)5)_MLRP[CI LCO8R^!2>.XTC$L$S
M#%?<?5NIXV7K-W<F%,V1I/>..EB)+SU;])\L WD61N<^R%]"Z&965S=[G(/0
M5.($? [@C40/C<Q)4$$U:2#-!13/;ESE[,K7XC7^7J&PE)D8XQ [[*#O\S_4
M[U P>=F]\*0IX6U5N809B;]X%?A.V.G%5>O+B6K,"27L#&J6U4.1\"QIF#'W
M.X)-J9/V\:%@$X[[]6[_PB6QC5+;=RRNU>]5D::(EOH]4_W7)"I$F=EA/$;Z
M).4C;,E:DLSRMUA%BI2?L8K_,,W][Y_S7C5LW";?[RW24;DP*"QPEWJ%W=.1
MBN/>R%G>HT#V&1@8O^YMS>N4=S,L<DJ+O.5<JD?O>PF?<2JT][E.O1^(92*]
M]#FX2'>IT#E,-$TG?7CQ,/8YAN*-8% &WEM;BF"C68H=WHZ2Z]>K/JT#>L3U
M!(D67KJC<?GC %I*3(F1H;9<$PMR*<;P&^IOO>LK9'RA[9%E[?)6\'V%K3Q5
MZX2G&NW]0<H,A4E9!D1)K=IT@9X:O,1+3WF9+DUFU4PEZ/QG88F9NB<?RTU9
M^4,@BKHHS(5,U<SG;S2ZK*V1F$OW43/TN6PW+]I,T5?>@1F %1;MRO1.E0X,
M]!4%A7&BODH\3RT,&)W>+Q+D%:_%'>]DZ#7=*S@%3R^DX!!Y.; ,P%Q\I4^%
M3ZV1<WGB/0]0PKZTVKH873@<<VDQSE50]\4,K1P]E,2,N@W97T?0C#D?]"T3
MD5WNT<9Q<?[*"1;DCDG172FX8_.,\<J(U'6>R':>E*("[8+<Z4$7SV1S;L%<
M'<>! ZT9"Q1\FVL%MK?,C?&SOE^RMW%$608^WHW'@B3Y/^CCO_IW=1#% [F^
M?#XZ,>WE3U0VS;6)BB4QW[Z\C3.19XX='#IFPR4]:1*YENF0 W$SK5>ZSS93
M?5/+D%]Y_AXNSBNO2"^-HE4Z[C61B&:=]/J,,+KA5_$Z;]1SSLNWWI6;<IHH
MM4PEUGIX:#=-0KP2K-I?*L18.Y>?.7'_':J4YX9G=*O03+5'FOQT##6ELR.[
M)G6K%!7?,=NY@J!$:!;4'EKNX*$9MW71),K!)N<"J(,Y65Q)O6(3$6$]/=]+
MVG2K_\UE AVGFVNL0J(AK+')UIJAH+E2PR #HLW]+'XZWOM!'&7SS![T^L%#
M#XHO^[1R?!ARSN.T4TI\/'ACI\"\(4;\BU/ Q;DKGOY:;*D@0L+_R@V0&N)Z
M"L5(OIH(7E4_B(5]#<O+8MK@P2NRTP JPM'WN(]J!CB=EPND2DO=DR\^__R"
MYY7:AQX\8GB$?-[2/LUZTK%O)GZ*U6I^1UT\B_;=>3EQR;Q!Y0NR+\6XT]P_
M=MGPUXG0MK^>%YR[1W^B?45KDQ\_"$TY/7DQ(^\#U'Z$VO<DH'M5G("',^K9
M3$5.*N&:W?T!,=E,Q2RK_3 7"RZ"UF]:KQPO,@80^Q#=>C=]RBN3 ,WG#%=5
M(E>1:Y6QZ21=D]HAZW78F.3/E 8Y"L()T!0Y**6\<7??$<56G_71)*8*QW;B
M5M9Z67Z[%H-SF_#0A8I$W?Z;U7'CKC+3$_<H3ZKNWQ./NIZPM)1*;.D-WORX
MI)5P<VF+*]&#+<':Q>WR$Q NX?6B<08WBLRL0YAB/Q=+97$YC^*=*Z,UU'0E
MUR5?7(_M)>M1F^3/E@:98D%-'&G CY W>)_[\$VY$W["Z21LHGNCKD<W=P:,
MXV[XY?,7KJH,:9<[BF4LQ%OUD_?;I9AB&V>J1=APZ<&7E^R7RT6<19Q5=(8?
M5USK>ZB %RU_HU(L*<:CVVNA0#Y]6#&/3E71'ADT//*.@)10NH)B-,EEO\L@
MS>]>+7BZCK5IQ$O;LCSE:1E45XTJ.LE6J(,VI$VJ36'H=[?7WP0PNOXS=P54
M/E.5\T!&^\4X.\MWC.PK&AN[?^6@F"S/1G=N2%BO[,&C3[\U\ U,5.-.]5R!
M_=J NX7A3^^#EQ7L6_W6J4'%-K@JZ2B#'[#"+VJ]A/WAP,CY>W=%71EXP=##
M4*L 7;1N(:[$WPNP1/:K P-R>-\;V$-*8D&_\23[@R6&H14LB./D78^:DK/A
MY@OW'PZ)G_X,V%58KR@6Q-0&6-8J:[E8T+V3K_L4L#>GWQ8C!*JY_X5_(O>W
M+IQ<AG_%S+X7AY;UI>"Z1_WNCP#0&Y+^$_1M H"*7@9/XVVQGN+"ML5@:(T;
MFZPAL"7:GZAS]@>QH'<^L^I6,(Z32%M CU?;'4JB%?]T-:AT3!F2,IXO77WJ
MQP"/R@5OJ.Z7GC69]Z)).6.';T"?9Y,R!/X'RESP-,Z6X ^? D".?B1EA[NV
MR%3MR'#,Z5:"I]8C;YP9V)F3P?U,E ^F2,BPH%Y>@/DO9V=HO^&>W=<  \SS
M*O$/_(6'@AYQAMKJ#60>YO -V&&LD#1OD,/^\#4 ?!C\ZHHH.QLDCN^0$F$G
M.>ML,(FWVI\>C70,Q6(H; F B[T* V9 P=D,,.CV>=>IIN0"WBQ$:_SB_0 3
M_R@6_6PZ,H!Y>O!F=?%[4G$6$JBXC/H"V[V,!76\A)]-%:U?/1(J:]"SP6E;
M71R>)]%]H*]SZ/2G8X,/+73FDH#_<$G$_\9NC'ZD:@(P*#V'FI@[ ![(;WC4
M';V%MW1!>@JMVCB8:$J@)^?21YJ/HA5(5QW;,F\4?D(+;-F=>3?,N<\F"$51
M&/P/QT5=/O@=10=7&S.PMW+)GOZU*G@Z&RA=_5GRTH;=XXC3CU1(L"[$@@(M
M9K"@8SS8W#?#LX#57TO<UL1+5MS%[4-KE-+UR#VAU3LW=V[YRH-=*&MX5L\[
M\WAS;SG'I F\+<Z[>WYDYB:Y9Q(/^%61Q1]1(,8+CP]YQZ[NR$WV$C=]SGL9
MKE6]WAE..R;&/JW(<!D:,#)\B=6;>OWB48;=$KZQWJ"*@9--38E]6BC['ZKE
M%T=&6<'?Y;[_=&98_$PO^5^_O3BE"-9>![Q=R SX,4[!Y1XD?,X >'U0_8:G
M(,2_=I;\=SU\[7Y3U8LHV7<,!\B=U-87<VFQN^F=42=A1\HX"[*G>^BE'2;,
M,<;9PP$+<H#=%JO$@BKA;T#T9K!)P^ZH>^"-HD79>(8#RNW_*8W\;Y+YK4 0
M45S@=>YYR0B<=FG\94GBWQ-M_MF3PU4_!]L; K_-_>/\FTT2\J]V\7^Z!=7^
MR"-3]DO^5Z=B@ +$@FZ>]@R!=_D+K'X]_/2[U0>?8V#H+^4 _W[N^;^<,$-X
MZH617H-@ZH#YWTMDJ>E;!Q#=S\:"#&( =7*A],_.YX.I5BAUM9Z7Z9VP>^>]
MY?P^Z_.A_--&P$7^JB?(%NXCUI&-4T]Q?7Z/C)-0/=[N^<%Z-FC]M> OO(?/
M%9.;.R)G5S=H..Z57U0[*5M,]B]9UM]KB^)#D1 OT[R?$[PPJQY",_%U!'P/
M2NTGI-+J&>F^PA&^V=8()[*BH7_S<1R2TWYPK0_"+.'XLN,I7B2Y@/!>3QWT
ML)YY$QE9*SC#;I-R0MP]OL9\MU5;=^XND7^OL1]:XATJY7-2E>;Q:L$VSY..
M)RM\AK10FD'!;Q)]3_D#-FK*Z\.^QE&T.C8GW^7@0L[$A3@Y644]S=/3U?]Z
MLP)>6?K=CH/,#]?BV,=!F\;KP0S\.LJ7J?13=76OS.MG'=JA_"AZ.<GA'ERZ
M:A+=><ZB[F@W"WQ_M'1!AZOYI5-_GV=MG7CHT:@Q9=$I,POA-#[&47T8-^J;
M[;,]+.C*X<#CS;VUNA>O#":MR'+=5U<9=Y[>!H=17[>',6D?(R--Z@\]\E &
M#%4Q!#5B3'?Z<)A)*L]14UU-8G XTC3(]F)X7L\Q9CW2_S7!X(/1IS;78MY\
MKAK'8,OV[DG?],GK\W.\DX=V,_@AJA-Z/J*J/ 0JM\GO!1K'-ZXZ(<>.50.I
MO(H&%@L;V>L@4K#KNLLTQ$$'RVZPCU;7BMOCRI4]8A5<SWTC-\)!#M2+:+SU
M]LAXXFZ.!3UY6'-UF+1"L^B*SHR1O7JN4,^L ;3@.V=RYK2XA6K]T#.^$#[+
M@I$3)<<BW,#N2Y<?$\O:PB[W?>Y[QHV^.H.JPSL,VMLP)MB/@%C3IKV[D=Y
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MNNH!_ZZ,,7<O[MVS.SX/F*)3HL#&AG6?O@AXAVLVT/BPS2*KM'CD_##LNST
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M!Q@\\.' XQI -6F>_"!@>?RB)NKD,<-7+Q^*Z44#!'B)T^<GOB)KAMUK9^B
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ML\B=K[JN^D&MN,DU"^D!$,[6;T/[+$_^AAARJ$&S@3[]O2A>)S'O1?,^\N*
MDEOVM 2P$0%[VIT)ZN8K]"UD%+IN&?X;H,%$BN,;ZGTA,B5Q#CCXDLO&T<D
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M;81FQTP\#=+.CV&?N(=78VID/TY,\L2YRV57&9]U$_%U%K)Y+<7:Q8:SM'W
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MRS@D%QW'Q_W8J\;YHNDW_3BKQ[@@[!HU(,5\6S*?;T3R9H:7X.=OH6>Z"J+
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MTK(K07'>O:#A,,"ZCT6FX7:R077RB^&GQ=KZ.1,?Q]9?.WXE]%<>S0GH@6A
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MB,F*/G-K00-:K3 .HE82OZR5[_,8T.-BKP!$?!;QF5OK;U^I@=N_CX#7)]$
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M)^-1W*1_&Z"P3%$M4\CIRH-D6+P WK*Z4+>I'0U8_VE2=L&^D75<LOT/NN)
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M^';L7L=%\$3DWY* #5$M1[%E!"-]LSQ 2^9%4$*R]@R3VA"- \/^"YF50[K
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M[CEE\?=P[-Y,>G><_.Y]4>V$1WD@-,$D9;:JV.U ]TEET"ZF7R;N13#MF$4
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MUD6E^Q!K]>@FY<C:A&[\-V2IDO[]&"\7(FDMSY!&9F5+C9DKSP20)[^; VE
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M6FMDJH'_H]I^<:OM_-FB'#!-+5[1X2\NW?OTNN;$R_?7^GFYO)*4GHZ0SX.
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M'#Z$8J)[.:&HQBR3IY$X*A9F0% 5!,LMVXD5,PX*%ZT>\P87U^7?J>L@Q<4
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MW?> SY(6N:UU)TYB.K %O9(Y7ZHJQP>&'\K%563^_O(L#B4!;@^B,M"WHQO
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MNP27QJ5QIW'GDN_,W/.=,V=FSIGGF?OK5C_KUZ[>>[^UWK766U5=_3CSN +
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MM]Z[F&QHA2I(DSP_[-@]G!N@%3F$,[\:%AQ8E?7/;4I<O>Q*E=-'R*Q3;.8
MB;_4>+TZ17Z/XO 6[9"W74S'8>U)*KR#@[&;FV"$;SD,%Y&_4'>K!0L?G.H$
MWDD>I]#PP/(F2CFS:^4/]!T1^0S?!^JV[G>9.W!34EI7 Y07;KS),^N"& />
M)S"1Z\AB%XM+40,E' BL$R[!YNFZ$_"ZG0WQ)W>,IL#2?&4F#\5P5HS8.F\L
M_@3H_>B\^.)>%P48YAY-;;.:X!_R]%DEAXF1-'3:$LKY.5$JH+Y$^H"]PKT7
M%]U<I4;!O;$95TD9UQQS]#88$/!<+$!TRD_&GO)#H\&'^^P..#L^[AV5LQ_"
M6/Q8HYO4V7AD=:\@R< )(VG>A]",[HNF#[Y+](P$]$ K55[$N8K"0V[DILI7
M>_2L'THM>WB()>]^'>N72]*CR[RJFY;M7GA#DH40[)H^6; AO?3@?G]+W3)&
M\6E-Z#JT3.NJ[!' ,*'S"'@JN\)L*5?$CX!7%P6/ !.S1\!;XLE"X[ATUN9;
M I"=>QIIHMJ$&+7E VN=KL.$9UTLW'R-1V"A7-3_<.F\\*;G%W7(_+):M8'8
MV@&:Q<GI3J-0J2K\\BXN^>AFA_0AF&V@B6#E0+4W0=(J45V@026MBZF_E4>2
M"84^[1?#C;9:=AZINLK<C\542,;^$<B-4K.ALCY\<_&T1M>0IP87]_DE6:'S
M%>1=P-%^[!Z%KX=P[P\8,Z7$SV'@T)V/CV#G(P!@8TPU?FBH)'$FB'4BT>8A
M3+:MX'1E6><CB>TI:X+!OS@23LR?^VT@824J?*9/=HWA#'7=C$\Z /BK601C
M,.-?(B/J 9IC8W*"/UG"H<*#>LI**/Z5?\L$]7RO1$FF=?PPQ^99Q,N@7V$O
MJ6@3MS$1Y\4X)JM'P:[-BH<.A)[=L0KF5M'<IW^(Q$B'-YG(#M3S<P3)Q4.&
M<L8.M#TNO"-I_*(62-6L:,P)T0WOI4H%X0Z1C,?# 5$Y2VU)<8:O[$2-XA5C
M%33FOXXT>PEVEJA5JX9>7-0(!OM0_IJ;3;91XR&4KIGH$VX_IV;S65,-SJB8
MC.O"<J)7RE<DR*0#*<?DKSP"VH#RHY&V^<U!0VXN8TW/X-4P,8X\I0);;4CA
ML#D>OJN.4,R7:_1;.O?2EB:'58_./;W]:C )Y<ZWU74P'?/\256><7.5<;_N
MM)J&[6O9B\F PXOQ#EJ1DUU*SZJH4WE\?\NB&6"22N%^DG^>E?M>K#;&5!]-
M'5K3:>\2V@0_%_XCP&[/^#6%7Z!LX:OXROE>5$850 \N0&RS*5U7Q"-$3.E9
M;Y#;+_NU;^QAPM*1T1@#*5_K'$4_!89/ISX?LCX_>]V?M6N07.0CA'VIT8WZ
M#M#/%J1VE?05ZL?/[K\P%Y0YNT5KS<L,D3RR(NZZ4VFX]>CPXFQ#&3'P<I2<
MLY"<;EIK2WO6@.B)8:F?9JB9V-]@P69M1+P$Q 6\I9:KOR@((JMSZ9^QUW_2
MVZ:%-C?%LD82-W.'W.W6KW50]@*[=9.L2^ VEC'T46AZBU\ /G$FHKXB"5N=
MR\1$'XCLW_%-NQSL,"[."#T"O*1*5".][P\SX*%WPBB5\P;?%BEJ4&/K4(G.
M4,UV_6S3:"]3"G;JZJOK9^]4IJH7#5:'<^Y3\_6-KM7?M>Z?LAW<PZ,=;2%M
MK=?$Y[3_T% D]:JD=^R0CA8"D!:_GD6:>)B8 4!NH<UI >#H-:*X^_#L$=!7
MEO\(@!T]]$&=U31IV1KJV$YMO5-]%_,\TWN]#UOFC'\5+XIW\NZ_>Y7?L9ZF
M6EZ6#=Q8?NX9,-%)(TQ1LN^B@*K,6MGQN_;/<S+4K\O3>=BE.3DSJAGCBYZ-
M<,D KD\BJS:F<:+J*_397]PZ\^A.]ZYTJFW27I9/-HD"2W[%SDW#W]SF.69@
MK*&F\::Q=;:\O'K H\J)3LZ>,2R4XWP$+.6?4O>U?2Q4+3@:(9[V3)9-?WN%
M0Y+L+#!"FC#.Z0)-,NKRIZS04D^*A?!4V2D<>@/W*,S=:1W\9,?L3B'5Y(F#
M([G[\-RJ9N@D2'UW8),MV6-XUM1Q8$9(B'[A<XOGL5P@5))&]S[-2'YN1\0'
M/YWQKN\N!3O:VSQNQR@=XF!Y!5[!8>M,,AH,LUH*7O67F\'=HJ?&X)3$GG;^
M_:.>:#*'@]/[_7]87YN=7!QL["<61EZ\*>5EB":6]:1*8]NB_%\E#W[8'7=#
M<G<:.LR7VX\EYG,D.][+?AE'=TAF98!$M4J XLY!W0^(875K5:NLCV@=IY8*
M62>=(UX+CIQ'D4T-86@9/Y:2%^8A!M_ -X@AT42@,=>QRH.R9-=-6H33#YO,
MQ>J+6-X 24:'@4+;L4= !Q#1NN^Y#,3I"PI1V^CB>03\PKD>._=1SCU37!W*
M.(*P.W59>&A%R<+W'0'G0VK5L#/@;:"#U9,^4<'%=ER@KUW'\=SJ7B98V*5A
MB>AD<>4H-CWI6J_ '+X239^5HO(#IB$$@E;]*#_4-!]OA:6=?HR6.25R1&\=
M_@DH?4YE?KZG0N8Z#CK$E1LG%=2^<"0_S M_'HP4JX.9A>!'L;VQU;VOAV+)
M5 U+C%JJT8"7AMD&[^1*E,ONGD$^UH-@N&8*!E,)1MGII;Q7L-<KJLB+GFOR
M/Q;V" UL+IQ_!!,;77W_HM!.AYNU<*L>]6Q@@PDHBI=LA.=?_J11M>DYGS2J
M!]E*-6'1U_-V>-,M/#'Z2$R([XI/]-;)A;[_(@B)@9G4'@E=:#U]H.D1L#I9
M*T%SE9_T*=F9/+<JW4%!X+"]]W8 AQ?>&IPQ*O;!_E5=K$:!6*T*&5)Y5=S7
M@R$;3((HS>1Z3N6LA2;NLGD@!<W/D7S]H7PEJQ=5O501=<)O#5A%G,&8LVF\
M[(2RE7P6D_ENN_74,EXCG>"0Z08>FR6&Z!L;QH8*.6N]MUJGQ+HKMSHY.OPR
MQ%RNT)J\$$_T'@DZDU S&9@;2YXLSSR/HBR)3#_Z7GSOFG$$@MXHN?,!HZD1
M^K/;??][QUK^9R_Z!V2*IG2X>..5"3Q%OYI56A%APBA:+F1Z%<^$*%F.UN]0
M=LC<&:TS_\X_;U;7,RE9!-,(2%EEJ#8W[D^B>6:DVIT&@#$@T*HD8SQ^TB=I
MDX5I.B\&\SAZ/5",7]FLW'+A&"Z/H+6""@99"U_4T-LR,P0X]L;=N$P7+]C0
MSI@\LW>%-YI#E%SH'@&@'U7^V3#:8\H'2;?6FRV\4]L0+VEG525(H7@PCH9J
M?3W0FNO HN[#8;AP_$^SP.^XGOD';LVL-Q=*HLJ*P_!=.J7.%P/#OZFHOKA,
M0H9;['3/E<I"]1/2LQ4_-[0TI<T["G7PILZ*!Z-+3!W0/+L"D09RV7/A9L)<
M1O!BP6[ES'U,5.E2UYJ3660<QEGJ=GM<YR5LBH^ [\$Y-K9.WYE^?8S9QR@H
M/MH_)Q.[I:SCS!P6ZV/ K;\)-&8KNA,_'DXL,!J"JY)5*K!'(GHDO *L JX7
MNM:HB]*NW H%PA T2],]QR-F+J(&O"!61FEY[3DO="&)K!S)HN[NNM8VP[E=
MUT< #7CM\OTCH-0%S%_VX5CP+C2)]MY+[A'P._Q4$B*)N,T$PX1;DV"YGI0/
M[Y7Q'IJRGB:6,L227_%-B.@1]_?3OU9 ZB<#'@&;#.JQ3%JBDV!ZP[+V1; V
MK(3?<HHKI\$Z[27Y]RWKEU5W0:Z21.#UE#W)\R'),_Y2WA7!.R\@^'R<=GTR
M,[$\[A0=05.$5I"WL "M)KVH7&#TD*$:^,/=WH<NIDEP%2*3=+O/;7N!YY':
M(KWPTO?&3'@$ZKOA8.%7Z*O8,L%W.UV5='(!)_E)^";H9_E:&4J>=WKO SH-
M6N/$7934H?:&7GRXG;EYCS>M4WAKD>PNIW[YIL]3!D_6@T@?G]\CDAB2V+QH
MB&.^+*WZ?T3:&V;;@F!X>M-2VL+*BO8&+5?0>(;;TZP^OT5QP3Y[T-KQ9QN7
MBY0@L6G86)P,<[+X9"^O118_@+TU$7\/#+PR79D'$R\O*HLOE%.+9\1(,XOV
MLSNZ/!QHO<A04;D)UZ_:5A*UYHMB7)H4R6G.QB*S%$+2>MM_MJ(ID/00!78$
M[9\#*</:VZ,IO[G??2VCNFJ$BZ:^Z^;VM. ,@D9*Z*8DO-1;1G>Y9::'E+@L
M,8XV<679),!:J!"\2[8$?2V?[0&7UQ, XG:4R+1FH-#J=:RS=T4]K>*TWT5C
MMDWL\Z-S S8=H6NK.DW)&/ZMVD< /A='"^[,'FOGK<K1/;["/>S95W I?GH!
M<>\5Z6JCYUS/EMX4/\N:;'R,XMT1/5+L']7ZFS1;,RF&#4'SX(V9RY#)?<(A
M!YJ;69#!X1^+CR';L[UFQAK'MW"5K!+/S!,<%W5H>)N!6(S7UU=(M;]1/,A7
MTMCT+U?=HFH[M\8>%KFM&8%;*5PWO9J?T,8]R21SO.2>)"]&^QJ'MY\(?%?)
M-7HJ#X\B0 &[*!J\5,(RD;O*Y"1P"+&]"OFMZUG[MGJQU$ W4VGS'5]T+HN"
M.G<*Y(]5L\T5Z?N:O^M[ORN@DQH?(T7KZR*COL7U&1*UW=S 4!!62LI$JYM!
MN7+TB@FUR&_VW^BBVMM>!I[7'&^U;4ZI:64'#IUTNBZ-QQL^,&C6U2KH[3BV
MY&69[.EK_]"TI8A/S7!H8$K]F/YG*AE8Y--' M2#IS%N(X0L)$/+TIKP5NI;
M7BW:ZB>4%"PP1WVQ02-?=XF;/ ,@74_<B?N C_?@IF,4&]E5P!\!;@Q!KKZ@
M..I0;+Q-9D^W8HTI=.ZC6N_4X+2/QLL&!J3]:GR%R14[<4-R?B4[^KJ1R[O:
M[IDJ&B.I&AX33$DGM/\:H=/FR[A<_%S(_?#!>]!FXRW3G#:C=.>@5I]ZUY80
MS4]J\1W92$/-[ -'9X]*\4.L4/O?"@>;T=8I%N91@6QXGT6FC-[IC9^EMLZ)
M1.7D'C5N_2EH?'JLETY;JJ)'A,Z$T: 4>;3UY)-?A'$@I21U)$!EC5Y8^O&O
M)6/]G@GY*@7"C9BO'65TJW(J2+GE#[<1/N@"(1/:B=.)Q]?3'A\7NB=\>=!-
M_FB>;RWC^9)F62<F>K= 2FJR@"+/X9AKST52;U7(&]Q0J!#&@;K*#/OA[UT6
MI(!8RDY\CEVM7NN?"B6RIR@E\;<;@D9F]Z$^6+].(9Q/T2%^@V(([@*CZ5\%
M[(Y\;(4%_S*U#[(DK-&\?"9%A[8>X)\*[&G2R+L"RS5!';#W*I=CXNA?L(Z]
MH4<5  AOY7WPF9[,[P'Z^6$X6]_$ZF4%D";8$ I]M[=R!S"?,YP5(FP;7*<K
MC63 P-=-)GNO%7YD^JDXLD7735E.MV NV))B4WA5UYZ285M\H4O_HQ/[- O/
M68Y<.E(6R4Y(<GUFF<3_K+:BSQ W%<*4E\.LIL+1/]?IO.]'D/=$HT)#F[GX
MU%G5)KI40T@ICI&EIOJ?MQ]Y%,203/CTYPP]*>$ET$A!V7<@KQ<@.J,6<X=:
MNLA'@%M1[=4B7+3(U.JW@?Q8MYB_7\]TNUN_EL;!=]56FA]+M,N*7+*<(-R1
M[J3I^ )/09.:BLG]4BLE%B4Y[-U]@$8:4BGZ4]KUWP.?#]-N3DF#O\$'VU3+
M% H5$_NM[?6)I:IL#/>'75*HB&ZT'@%?EA&W)4^:7 B<K)U2$47.W!A^],OP
M8H YLR[J?]Q(^T_8O]G ,3[5HZ@-.E-V7V6:XIOAS)&9*:$3QDI9.R^QGM3<
M^M/]VO7SE4.[,?E#QP1G\KN*6!N.SQXVK_ 2F#'$MNI+FV0#)-E??>M9_.T$
M4;3#[P4Y4.'_EL_Z&)J5F4^&G)W_(R5UYK79YB()7#483/C3UE'^4VB3:KEY
M]0<)'1/CWE-JVY$N",G\U9[>!/N9KF6"D""#3QP.0RSQ"IYJ/%C_$F35V2 7
M^DK^W."Y?;S$JE.P2095>$GFE6CG$LV/P9P=QW9.[LU8H[8S[*X8(Q/=H,FY
MR[ -'[+:AM+TX[W5AV10X;N+@(K7%;4?:/E#KV\0D":O"^J]?C';!T#31.QM
MIZJ30[YHU$6: 2K60LHQWFT>S>+>=O(\I;+BV($#"%Y7ZQ0<K86==\P_+'<\
MT3YF>)_A*H2U)63E;G*[7K,\GAFOVZOC$]5=-1P<5>09N*)5[[FD5UQ*X>,F
MO##**8M>IMU;3G:@=B=\E9A]!>SDV4G*-'0(UXXE(K1?HDQM]A0>J>4_5.N)
MD:WH"0_]_4R+#."-9+B9<7S;D92S9K2X7<ZW/_\K)DF\=S*(CH+8NE]HR,8G
M(OY,+'"U.PH6+L'87\HG"H*G*?6/6%@M:,FUK*7_YGL$1%V<R*V)VH1*&-8H
M0"MZWKVAO_9W.[SQ3[;(GBW)30<20QO.HE]C2K2:>!>57+G((Z@;I(IF>EUC
M8C6<6 ?3ZCY)T:;RAQI/),VA<R8(J5)TM0A=J8'R=S G_%(35EZ2V=&9.T'4
M^B][J8M&[L@]CL]V@O%>[(QS['*_VC#_61SNC4WO**>2%G^&!LFRN<%-2:"P
M:(VQ_5;9VYR,>N+U6=E\5Q*OB:5P$3JU%('R8:C^%WG6@I_*..][-ADF:M!&
MG5#S'ZZ0F"N*W8>;TXYI'H.%-K%$&_/O";+M?=IF[6S;>#3G&]HWH<=6W8T1
M>S,6U@<.>4OY:'!('3+O?AMLC$([+-?:?7/Y0T7 -&\_ 2<6K<OD _\[@V.=
M$%\91TY^(TZ6+12:3Y:R] L%J ]\&?JL*I<V]RMK&:M@(C$3T!J.[/B::DV=
MDJBY];<J3L$*83'LM5I?F!^\&7=-_XHE,UGW3YS>G/[" ;5BJ./,':5DD >A
MIVAGE4W"C6N23)7>?(5UYGQ'W.1MW"[0>&Z)4E075+)&T([)[I1YIH4"P&M3
M8]T=4S- YW+I?*#P51R_$\SHS][=XV&5'^]DMZG#]RZ@C@:GVQXXG"NIACT"
M<*&>U:ZFCK@DY(Y4/&_<'@$M7]9VY6SG)I^F'ZJ:C<"B$A*T7\DN/+QR=3??
MLU$,].WC3;.>_)QJ@U.,DAK#R>.G6G#)EZ>.<]IMRY?VY[JWW>6*![V^&A&<
MS!+G;U:'QSP[D\6*[WW9?F2<N/+S@<K$,R4=5U>!^C[;WTZ]G^&)#MISY-&.
M>$[+X7OG$%1/!^,Z8)220K#-/&6.^EB5V60!ZE0S;:>WP)=BOA(1+/5EKQCG
MH7W=$[!(8?P:PX'/S?9K$@@:8@]L?O<IZ6358$ IV2?RZ^4/5B)('Z2C);BB
M.5!]XN"HQ,2ON0O(#HJTT#5WFJOB7WZ^+?':<UEG(JL^EAMJXD*/M!-/MS97
MO<\.JAY\SFZW=E+R^VU,+MS]ZSQ3TG".C%"WVSO%/Z>JT>DG;#O+Y[>/@$I^
MI15E[XE.$_274US.9F$;2*1%%=^_9.T"6Z:JE7F-:N7YE81*,V67BNA6!+C3
MIU.MLFQJ**PN0- ?+&9];T #5"DI@3"^^VR_I$ CZ;F%XW3BI3L1&)\>E)J?
MD^_>.FK0+@:_=';]S09@KX_^1L?J6$)IZ[A[=]AP-J>'X](5G5:(9K87KNQ:
M=CS87JFZ18V+OQ1!'_3DP7=F9Z5I<]-+ [,<)9^BG].3R:]]+,R:P2R,SUSM
MI[SKRCQRUK\&M\_=IP?[NO(K;<27P'G1")@Y8I^3H4+T;P+J<Z_\5IF<AS+T
M29@85IY&.HF?'G6R(5JA&4*%V.K":'*_:%"),Q/1#WO';L?+?N)*R[I%UK]"
M--W\3 S%"73LO]6Y37Q.'G? R=N>Z%PSZA].RC]GTT(]YNJ^G&>C[5X621I.
MC"W7Z,:?IZ(5_^-3\7?F2PF+8\,'[*^'(#'3W 'SY9^'* ,"[LP#WVB:CWU@
M.5>,DB&D2TQ,G0F$<F ;VN07E0J<9/A:-<%F*2@+'O"&>[-V&DI8*<6:^KAI
MDGO/CF:UW<PYJQ2_@]SQ4M1O-APVE8#)VB5SPRH?$K'TX<(<SWY1XX<&#)FL
M$3$Y^",@9.GE5.G9D/><U(4VMYQ_OHK\7D"Z -+(1ZD]0ZZOK6,/K'.]J[.'
MC)6\E2%N[9[<PZMG-R[1\8?>O0&^@F4J$[OZ'X@^+'MK#?#Z*7Y7UAOSY<Z\
M<C.T$7$5Z+ZR^JA$L*V[OC;/QSH:2:%SCQ)?XZD:WKI>*WC_#=1ZH;CW(+*4
M[>T>;VXW-J='(U-G^L?'/:#H?('WC#8D8\%3KO-2O^PBY4:K*7%^6E4HL-&Q
M!V_UJ[$IHDBM@6(I+L^HEV[,L:H^2M:H%K^-:('+X:)P9TC%J?8]8_&O"+/5
MY1 0 Y[7FFC8;[(N-+3(Z'6BP&@_R9OS V^_Z3B7U0X^A8.-BG B*O]WR/G(
M9Q>2QL#N<\B5%NU,E43JQ9JOF0,+T=! B]!BZT:/TY[!(P"5#W@%@HK+P@6C
M>W;4A0(=7].EE-,$"HW4GV56>V7\F9^HD]DS2[IB^;N5GWZ^P?3PK?JI9"R?
MB#U]&?8-?$,)@]KX$XVZ*E6YY>XX&JAHYEZU#T],^@=$Z70DX=:Z<T+%>; *
MII#1OU,%H7Z7U- X#[TU]L%+5*+Q0+B\JVL]#HXJG.]MMJ/OFMDEF/)W^,TJ
M*;(IQNMUW&%$2 P[FS6=-#.J+(]UUY-_> DMY]WI]D.MR'S_2@OY3:/T16^.
M\R4M3A.MB\M%&)\0ZB^F=2N9_D> A3QMS@>V'!H]DW5<D86^X[1?J^)F'2+]
MQR7)^B5WZOH?JN3WVX(^U6,/?3VU@IC8GAR%I#%%M+4P-2D;D\<R1;:_T1J4
MW5WL79%;,WFO:S.MKY4Y-Z/?"4(^BV; E&CRN"PN,6LWIH(=/DP5['P<<6KC
M03,WB_[%*@NFH->7.(F? WLN^-!*^LH@./+"[]3=L,@V#"R"3#7HVNT(%7KM
MH6=3Z7=>?\>/_T$K2C+ E]<%Y.# &6$]9A!0P?GG&7J9JOZ2UO.OFJ9OVV@"
M<DMTAUFY#9"5\9?:[(LY0>WM"8QO_7^'7[>NMH:6B%'#=[:FIG6S@!XU?@5Q
ME X:?7MW0F4Y>RE33<]6_9P1I><XKU@X:1-BJ-?8GZHFCW^U>@%9'KE=A^)-
M5M 5U%),=16'K:M!E]= JOYGT,MO#I"?D,]--Y8%5R;PX<0L3T)*K- \D=1L
MY1?R!3_B2B=2CD6L=KJ]+])S]7;T7?7]?F 19[\M?(]!AZP@[I];;GGEL(H5
MT5K=GS%__6N8.%5'\C" ]*PP2M?Y1,&Z!DMTD<;B^-V[NF2CANDE'@[0JK7:
M"$*^R_6&T^6<^'"*&%K2'%_M/EW>BTT054!E2ZSI@Z0^K67KH^""PT8?^;_>
M&MI)"DZU*M+MMP#;)Y*,K_DZC)5+T>:C98R[BO-*!\N[-C*7F,74BO0(,9$-
MJ>?',R$9&*34=A]=,PDNGX]SW6-K<_WSVG<SO?H$.]2'J6J2(Q8^V\=!><9
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M*BZ*9NN\XD'VGC1?'P&O^QX!,]IKCP!I[PJ$AVK=N#\=9VG%P^&.69+@OA%
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M5PG"<(7/,>91/1NNPMCB4D=/>4HBG*VCA>&JMLO;"F+O>B^H55?[A=W@E30
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ML4;.^E?NH2SGPKW[FVM?AM.'4U;%(T)I8S2UX]%O-@A&N[*6+_6"4U9E8X'
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MFG\DY'G5/N&K^@?9-,K+IP/%K&XYVYROG\S>.P7L._NG(VOEL0/] EC&S=>
MT=C=+TPCP?V)L9R5NR_,.@JN^^ ](^%PUQ/\I7)HTB]!T@136IS[+MSXH%V!
MR[S_5&5KVQ_??SVI_F[,GT.;H:'$TO4]M/&W!U>'8&@W.=I(.]04/-B1,C-#
M72 ?BA2-\A5M2/C. 5#@0]/4./% 3<XU)**SP\Q9),I C_$T2J,RAZ#.QWP/
M'TM'[UZT/X1'-;"%9IYJKCT9:ZC^+?*DD_V\Y'X@C-/^_][WJ6N4H82";,'0
M;@VO9CV]_FT[M1\Q<E>8"@K815OS\6OZB&C'1P#TA_\MKD;V7Y6@XO26C\00
M/>_X\.59LZT75H#$*^D2JUA!6_I[OWI,#8:MK=^HO._ZVA?X 7F3XKX!H"+R
M9E%GQ_\-5O(F):M+(K$JY8\?J &/@#[%3>O&:])' +7:UOTW_4> 9)\.8=?H
M#?-?E[.NN$?::>0[H+X4L_WI8_&7#GOZ-\]_II5K#1L1_Z?B]H#P(5C/_:1I
MXI./N;V3ZHW*/.O,08+97[JIW&-K53<4C*!M,LLT=;\,96#I^I3%+.8I_')4
M^/HA@9%5-E47S7<D?&44$3^L\M!N^@@85X(F>9!*M)Z(5+.&VQ;5_L#MUML(
M43A7YO_=ZTD3Z*B7>VS^(+/Y5P3KKT? =M%>Q'^*LYZTG+(0(EIB'GM_[;MZ
M3?VKS5*/6Z[H/:PV*;YC:UIQIE5EM2_<KB8:8[;#D$9"I##.5%R"UN#9[#F=
M _'Y\!.>(FU?]ZA_&HI/SOHY7WGJZF:HHS_\%:E:?;37K'18U11-"6+Y@ZJ?
M"V_>3B.&]>RJ#8(#3NQ#"W47H5>=2<%EU [D93)^2QH1/X8;&P'-\L&%'M:2
MD]S)-27D$S"'$#C'O0FX\?M:L:?C'F(O0B27(][TD,HL&&%=IXZC\(>!LINW
M[KDO?\67:U?";_F3=J[8&%JMO^3H$@0':+@VN.K?)E=U_15]G7)Z!;*,$DI/
MI3=E_(U/@T)Q<195#8_&1?!#,Y4G499-(Z/C/7&.=$-K@NK;I(29MDN39V9F
MM$,U3,(P*B/E. #F7P7HYELRY:\WS*[XWNS.JXY_T+EAL0]Y*X2&$N7;@6 B
M$TII9VS:585,*6+X6$?MKC*)OI[/;W0B/' P-Q ]8%C'=E <4VN/;,*&N6#H
M6N$/)2K^4A;J7<=\>!5]MPU-]FBZDC\Q#U\5(9I80A(L$Z<*^/PKS@DF]GL7
M#1ZO+R63*^T.]]_7[EV*MF!9M]=/(KZ]@C#23_PP2V@) Q5$(4N?A(B@*?J8
M/ )DJP/*G#,DCHO\WZM<DPQ="^<N@*ZMM:%9X:[K16,@3"?9<H]+9E7_W];#
MK*P\K][_43ZN*7*RC\U3NK^^8@4<I04] I#PST.B;:U7VI&UI5TZ^6U8W!?8
MMS;O1J-UJOA+2A+X:]HF7^R.9K3P/ \NLW87/4ZR2DHLT/DUDI88D^$>AR7*
MUJU189&)>=ZQ<J\H7S>SWEP[32NM_?,[8U$$D<$SU;0(7$1I+-1U-)2">;+<
MOMR@<>(BL*QK\'L\S>7(0JGYU,K=]&@ ISYI.@C8.-E)\]IO.PEHO$P\.J:F
MYN3@I*&^_<YZ=L6'#U[D.DK6 []AI073)9J<J3Y;IJXB\SZHT#MY?A3\", $
MC<HW>9K'&6-R\2,E9#(KH#D@];4Q#=7 KA&D)U9RK9*T;T!Z"N7X3C!-P1#D
M=LQ77OK1GRE$KNWFH[Z!X+9VP!5>?*/7G)6 L_'J:R6U>OYE^!A-]:%G7PA"
M%*ZK+Y-XUZW'8*TK;FY4%8)2(>IY^M)(45AZIBDST&MC<#?I@3+1GW?.B*OK
M# >O%.!V1SZ'8$HY-EWNFBP@ JH4?JHOZ@Y/B#/ZQ;#-'ME!+NBE48  1O^&
M:EQ!,PBJXI8VD=:;Y6B__>+%$J^F>*G_P>,JIZ9U[GWF]IMM3_S6A,OB$\:[
MSY-'H!'M/[#OH"^?.@F,NJ):D/N\DOK\L.R?6<TPV1;)\"<#9]=A5;$_[BBS
MGU=X:#S(.3T"9J6V'@'FD-%HRE.\\?:]B,S;UQ"!^5*B\TI(_B!)>]?>W2C*
MP!J+-,@[]29+KBXRGBH7\&$Q(^L-C,QXJ2DZ("7BBH2BT) F$3QCXM'Q\'IE
M'=NFW!\7=%N(B/GY"-A_A?;P-6'$!_41H%3AWXIV&E?Y(ZUH\)Y8!O3I4O"F
M:[4ED"VL7OE-3#BR\7:XOC1T1!\?8 _60/_]^B,@:'D=%$'7>X\F'#F*BS -
MU3R^V$PVSI?!790RLGP?\[K$@Q^YN,?>!__XX# A7W_7O8J;^CHKF,S@A^XR
MKS#6H4C&1?*)_^]+MQ03DLUH0]1?'WR:BP[67C3+W.@C(P<Z*#:<EU? W<&A
M82W,+.5IPA??7P]A:WSV@5P'!!UB0U07?"-W(!2K^@2%\;J[8QYW?9QR%=:4
M<[?*!!PFZ[0&*XQ1J=$HF<67!?HZEDMH)[X)5\$\A6TU .YDNT^+9U*S@-=2
M0NZ7)>.63>[!0$?>]-56@<,R8S/Q-W,*DX/]^9]HC>L;#YGJZRC1CGCDA#!L
M12PI=L6(G%DZJ7$G'<W)%="(]W1QK'A_V6JORTY5GZ3V0-4S3<=LWGLD>OC<
MA=$88633,FZ-K<3O]:B.^[WL\8??:3</JVNRL=)HN=$:QB)M66[1KK570+C6
MHH(%ES6M'253]6E!_7\0F"^9,HMH_?"K<GW,QED0/';U8XO^%F+HO>-27\.(
M,$UX'9"N=HXTRUUE1?YLJB=-9:Z&U-(%M5 66J0(M3Q?(5+_L.7U\:LYVM0Z
MYKUU_/%5)U>Y!XMKR!1MU.TJ;]P+\6<_B7\;0^G(O<WJVUCFL'&NI65/WB<"
M[RR0A1)V:1Q:8O<UT";IEO[KI(_76ZI)[Z^FR"N*,E&!2N[O]A\HFI+SZU\G
M0^JKWG.^0)6N0N,_"-K3C)-\!+R0[NWOI] MU0W1%\-;H/QM1_. K/'PPL(=
MU[H>!.N5A+2PH L\,!!%94J.^.74^@EL=W<46,>R#9.26FIZD?WR:V[G4%U0
M,Z?8UC?;L(_R2I7WSMNN,DU6*R>7%F!V*SRU'ZGP.%)J/*;K@I!VW?J$D*9^
M1S2^BZS\3?]</,_E#Y^^N/7/8\2ISX?K:E-?3EP\CCX@V/_;Q_!;8M%SQGT1
M/@MWPMMW4:7V%!>5[KC&1=*P,U\DI9NI.:DOA6^/W#SO,T. -&S?4@ZW>M!3
M)L5-Y1RD>FQ,:!SCO)XY<:0<MF%;7X&B0UQM67?5?V@6L5>GQ41 3N^1]&<:
M%3&7?-B3/@:[WO-JNA)!;<IHTQ.51;_;VF#>.NHEK%BTO&,-*-JE(*CV-DER
M^3LJ_ MY(^9P%"G0ZTX%PN9:\%/:N1M(7F#51C65-\8-RZSN\<I:%-BF4?"\
M6(\22M.HH LJ%Z'TP.A6S%OZX^H+%$-,AQM3Z6$!Z+*8K;_]1P11>RA" X4
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M2$E+2P[=S3#S&WV>]SG/ZWO>..\YO^]USA]K7]?L:^V][G7O.SZ?=:_96V2
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M,@,*B'#906*@@-1"<Y7O/H'RI*>E1Q)):.*S3"G_9SD=B6![EPXH0%?[;(1
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MT[$8R[2)V^^94U[.PO8.>[$9M@FD+JTZ/N3JLU1HA6SZSDF7OVN)8'U:_<H
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M0P&_B)+^BZBL9 &9!'&_2D+YJZCV2]ST!;!?!?D;43\$_LM*ZQBKR+4E$=S
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MM,<TAB?(3:O=7)&ONV'B_-S'\%/3N5D#(P18%,*[GNZ=O]%(-_)ZK6)NBR=
MT%KF;5#D@^@W_:!WD;T.DW4"_T)-4J&ETE4-^7CO7;EV'[XKR3N[V[4$]^E]
MV6/H<KJHJ8?JA^2XMUY;7]Y6.77*M4JFCU^>*.BT+9/@++\?>9F1U!F*(VB
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M8'(HIYFV?X6D3[&TC\;+Z06?^\+=EJ/T956G [U\K3O+UD>!)OR;:C!1-_I
M4\$'51=9DTNZM!.013FX)OK\%&A]A8%T;6$6J>9'\3& A=L9QYZDK0J:5F"G
M38@EF7S^"Q"-?IC,DW-8C:2_*JWTJSF&C;=]LY:M^/EV6O(",Q593E8,PXU+
M?6+GF9F-A%RS8<(1V M/()$K<$B=7C8H-K58-N7NM3V%8R? 4;1ILK(9M6Q5
M'Z5P/-JN6#/<O2MT7\Y2:H>KW^<E]A$"\JH:\G3L/>>2[QZSR-]E.%$99G<"
M=S'4S9>TAG]JK\M:%QU*N.)@//U]/]NZ[C>H9O3]BBW&3GL01/O:B%>91/DZ
M[M2YQ'<W9F&1M_46^[51D6M=T2^9;GI&SPB.;H:E+I8WFEWS%T_\69(_SIZ\
M7C^P\#3XQ"%9'7#SM)<ZA8FGSDI.8+^V=RSNJP99+UUXX?86O:9@5$*(4/_F
MF[*)[SNG&7JH&:,GT<!69/^&1<H%GJ;,'W<LE_27ME-MZ<;+&W6O9JV!XJ W
M]577^VCTS\,F[]_6&-I[72DVI6M_=B\"H?+TJQ6F#V)_]?=5_Q3+]7-.!:I[
M[1A$7AF'PV'9S(* ZR+N_+L15.9=/=O[>V?L-/V>\#5S?7$#Z6\-GMP.N$W!
M2OO8"7GU:?G(P1 _S#FY&M%D.:0VN&!=<9^C)!9[Y28H)<X)KJ@*K4<P,*X(
MI1>V=5]J"1^O,?GK1#Z7^+QI+9H$AW@E,?QP'"57Q&]!X<FY9&2_>?E+/R8#
M= EY\]ZUR37"X5G8IDICEM6I@((,VYX;5?]D?-S2 45PJL1/XSGB\#?^V,HS
MU*0!5S5E/V?SQ'WN2R>!I(.=,5WCG+/X,-L7#@:M31I]F0.B^1NV*7QGN46V
MQG;*)GTT1(-EE(P6!O(37*7L3@2#>7IAK?U3P@%@@I+"?5V-6K&N)YF-^*U%
MSQ=@EO+8&&$*K?&XONBA&=OP5".++1*ID8J1S!"AM'O%ZNIR&6K&,J#;H2'W
MTZV)_FSDX(I'O7RVH[2(GB&-\8B3-C)PRW]SAYE_KK1]7E0):RC>Z5."8)$5
MM>ZI6<]%J$_E:NR$DL8T2F1ZWWW->H,]PAC0U. 3T1C*E!@WD@@]BKQ --O.
MHDHJ-+U^K8+*F9YJ-"1RPR(7SXN^8/Z#PLT? *$>V\*5@7XGK"C:&C6\F5T8
M9D-<"M:>[=LQLM:)[G>";@.MJ,3Q#E$Z>=1G=^=%C2R7M)G<[:!NH58?A9'7
M6HZY8-:E2G&6;0N=AW&\MA[/*DS;7)/6"1LNHPKJS2XH%"T3,E9603O#>1HM
MBQRGCA1R!#6ZBK2]\'('#KB@0=>5XG39YOK+B'C^O!)91!JA_BEG@!9BV6I+
M2**A=4%]5]>/+/%,\?B@ .MD'GU5B]>IIPPB>FZ<<@I3OF((\W.-,[>@AM47
MV1;8.VIIGK/N-DS8W6!D7 AEHC:=YKH_G>QS@C1K@G!_?I2UI>9*^RJ2< L\
M3+3[WD!\Z[?4VCE?P)^DJ&F@UX0A]\EM7')2M=1! ^RB3!ESNYS+1,"DO3GF
M5L2RK>+BMY.VTD(Z4SV\(,#C"+!* /V:;^A1)6=&QTV:G24!@(N*>5,!$5G@
MP2QPE**BOHPD)F]J27(&FC+OKC(O(#6U(2+X]1Q8F8[SY?DY90!U47'1)^GW
MRB[\8 MOI^(7JP;9"+9E^J?-0SG+R4+"11-8?,7D57[<Q>*=E:W;\=>IUACR
M%GB.W)-+#CED5: ?2LE:'&T Z^>M6L+SV^JA+XY$J:6COOYQ4_&3OWLI?)S#
M+<ZK:ESBE4V<4=#0*.@)K)=PJ"IK,;'#XMT85EQ<M;>$/DPZ$NOVR>P^>@I=
M)$5+->[FDH-@Z0S\U68UO/6*!Q9P>C-%SEB/D8.//W B7'3MW47*EC5KL#IT
MX%CW#LV :B]OYYWK;86P0*Q6@T23G:N1?&P83MH.>JD[/]<4M63/19Z^?R7[
M!P\=X2ZN&F<^DCEUI=0>)9TF&KV0\]@U%]^=RJ&= &%EXD8Y[B'<KZDS'4$=
MN#:D_ DWE;T'$VP61[G4S?/5)-]6-O36D#9JC67VZ[^X=164#>W&\ZNR=4T$
M4H%%FUKX_P#:X^OC>&R.YL1L7V058ZQVZS/*W1U8^F6_:A1%JXE3^Q%1&L$2
M>N/$=1+S_;LO8%M)&>]8A@#&U% 03*X$4E) 0=>W+44'Z/_-S XWWQ *3?HG
M(S8>H*$@.?4_MJWDDF7[7PV]6>#YN9?.GU/AG7LGH\PY%\\[C:#,.Q?OTJ8=
MR5^/N;[WFVJ)VKEQ,H2Z@SFF?.\5/)9@N0+6_)RR.XE*&RLOR\BMR&)KS.S9
MV6X+!A0&S[^%5<I &6XXYZ]L_]GX.;Z*H[):,5WAPO1J/$8X;>\@EK.U#ES2
MNG>9FT?7^V7Y U*CCVACI[W['M<D,NG)D*)C0J?84.PM)M=9=3]..>JW7GAJ
MN#HE7P&BVP$1+L/ORKR+E''TWA[(EFW)2SQOJW@U'*PTMM[DKEG74=?,K'@O
M2I#:X0J9XDLTJIT+'<6YO\QXZ@IJOCQI@<T"7*WNE!YCH_#U9E<P_P"8B->7
M@D4.\=F&HAM^\K8;W/*H-!M*X7%!DV76D.Z*K0GY&2M9./"73?AVV!KWN/6E
MK;.$=E!'Q;ARO^XJ)PXL<EC>1ZS<4B$1T-M*+-5[Z#X\).+IA4_\<JDD57VS
MNEXU^ARF'K&#VK%9K^S<I$>X(.=S&+-7V2$3X%A:\DFNF?=>(*H.C7:=8.*0
MY?6IPD-@82,? 4MN%E-OZV,>@;[^Z ]2D0<G'%P91#6G@$H>F$V<U]2)>A[I
M$>VPAU*K8]$*Q3XU/:.2AX[34"YLMIY\$O8^W,PND/YO&!AL2E]JII;IT%;S
M"<>[89O#6WXR*9%RM!(DY&';_A!M'E7O;%RN4^9PF:BO;=$Z'>-2+:)YF?PU
M@@^C4WSCCG3,$X?7K2<R)%'.U!N!_.',2"['Z^X$U>G=FVY+PP?WDB&3LC/9
M+(QT),'W2**:P=NJ>#TOZ+O\)S_Y?WM1[U_BG?N,"9 #E^2"(S+^R2R?7['6
M"8T/^$ A.FSJ0RB>#\+K]FYK!B/:N^)XLN;+Q"5_];98_5HLNB2&W[9R3$$6
MSBV].I'L6\M<E'*NHFRPT$@X^\7QG#X) R5!%N(BKH/@"WL,-WMX7T-BG6$/
M"U4V/[ZL*IFW;+*L3?"ZVHF#T!(./Z3&O8*;$\7R/6!1>E8Z76$[O2]1;7ZJ
MZZ95BWUL,M6)7WZ0UY!G"!DD#W<O=D)654Q@LLBB@S+HT;JF60DA^H89+H2?
M%['RQK9G[WZXNZQ3Z&C0,BSDM.J>(O49H4V9S9^U[IR[J4)_[WTUX-)E8)"J
M%B/:9-80TB[!>*SZ_@6NU26BM8/?$VE8%#P_60-J!UW$O!&71)P_F\@2I >P
MS;0H_5#JQI$>>JS;-4,0=>P9$;HKW[#:[0KY;&A,W#\^1^3)J$E/2$6/[!J7
M !)CK#&<GQ?E<0SROX_V"[+A#493+OJMFT*&V8?2:/M-=Q4,!=G;95/'D<&[
M^>PEJ_IVSU[<5A37=W"NBPI@M*G]E@S'BPO--@A"03B8E/-5+]TXEAX"M;=V
M"4@_.21SL.&QJV=P;]G$=^Q!1HYD,Q(*B/^'+3S^VD+5IR"<>!]"^U9C?+P;
M@*(14!$]>]%(['!ZZK!XJ8&!:MA8%EQKC7+A4WH>WQGYA8]%^;.4>_GQ&R6Z
MSE-?187I$%)FB0NQ!$E:VI0EV(S9VEEJ*!P*U0U-$?ZHX;%^F/YQ^J5Q5$1.
M?-,V7F6+K'L')-?+U)&6Z +T(>!S@_[9FGY8+Q21ES,J*>)YME6'#D3+4(N2
M,O6.!6FR3LC"RP.$G\43J>:FN2LH#GL=1)*J3:I@?LD6]@GA#%J')GE1#W[_
MT\GLY^+WSQ9D3#L93#M)V'B7LW^/_2]O !'!)& F93H =4F6:TF6^7\*J]TR
MRKS'X$^(+P^E N9 *KPKIB\/?:#^A#RK,:M&.U6Y,3B^+EOF+??[ROT#C\]8
M265(:BOM*Q]1[=0!/DP1%0)AOO54M6/U-XC0+CV FX'M;PK?)4-P2?E.[83=
M+\M?$:U>9+:C]4>J@&SP"M%70-Z1[J_J+S[\D<@Y[)$^#I<@] G6*$26QGG_
M^"<]P:,3H_GI(5?$I-'\0HBB<.Y6'(ZN=M?KNN:6&/F.>7;S\+ ^9U<7?<;A
MH_"[^Y(,W:Q!M)3^K/F-]\S#-5'KJ>'F>#=B/^PCN^J[.N:,V#UR/ ^UM3&!
M=;6<U:0,8X#MEBV 1)IO&EYJ)0'76^X\(KJA-(:4Y[SZ<6;/\PTLGI,S78(?
M1CDDFRH!XF=6#0OJL 9Y^_RT;+?<+:R2]BS&EE,+(CIQ'H-$IJ=\T_?C*Y[G
MUW"# 0$5>5]G+JHK.?0%G=)V%E;V6-GV1X_BK+GEC=W$T]9FI,TLHJ8=BO(,
M0[_+[TBPKYMPE(\#$./,=!!AO_8\/G?UN?_-^W 6.,*Q@L8P<C5Y<=MZM+31
M3J(N.V !OSK5>)FSY:<4$7&%VJ02G3'_R2%"+%%41P:D!(I35\%[":@#Q7BI
MVY+H3& F,*  QE20(XGQ3P)MP;_;!$DR_I/#[#\"\#\[+! 5_-UAX7_IW[-_
MH(&<!2XE 9=0O\R_#C)LX4I:'!EZA&6?='2$JS,.CBX8A+P@:$:'X&[:.*_J
MO3EE#4\,LL7V8E(CYKY'^@%RCY/4'$>+[HU"JMU-V+-=D9=.(/52P\G'66>'
MJDJEX2OCH?UZ+HU\34N8>W) 117OW(O6XT7UG4WMEC,-ZWXJ7Z^Y:>2QK6!7
M7A2H?P""U5$]KG\ :'*%SJP"D*$R_<$*'P?.VC3,O.R?JJ(Z&N"2B@Q6UU\;
M,7<4I%G [/<+7H8RM/(B/N>:@L,(Y%Q9E5D)B60QES]IU>4UT.N.&%'%/QVT
MNROS&FIS\7ZG,\$]X>E@KQVM<?#40##[.RVM<3AS;FC')%4G\;B.-1$7JH)(
M^)9?]#'G=DK0&@U8'Z^P=5779%JUA-J"N%0=Z8?>W?;<YW/63@QXB5=4VG/G
MB._,=Z77,988*NRRC:C/P>+\M#KEV*0IT<#JJP.^. 347N2E8X*2'>$7L%W:
M*H<C?;HFR$&#FZ&JZ+=KAM:DCL2$X#R[V8)MBZ@?"X6R.YE.YK.WI$IZ#J/1
M'-R3IT263:"5@,YZC8#D*TJDHST]0]&FYEB1[MH\SK+47,+/@M63,,8##")?
M#26&:#ZEP:8LQM+F9D:KN,_?ERG5(9"5>J3XZ9].=P6+S@VX0R_0^P.X73Y:
M*N7[%N-2[/IMJ[&*^V"N7R ]H8N:_]Z,F%0NZ0-&*+GOW<F%MH<C_<'*'X!<
M6I5S;W9L)FQ]F,YC+1C^% ^)@1S+][9Z[7TX68]%PL+-ZEC>3R4"4CVB-2F4
MM(\2'<REU*KN*VV=W*>;X!]KI#YG8U^X#.F'C-=B:IAZ4[S((]&]2V)</L/U
M_DW8Q0BW\S='N<Q_^P/N?W:45))]B=,1)2M,_!S% $D[)@L]"^]U&=K02FP7
MNT-H5VJN1I#7;:DKV9X^GIN>ODS@[$N,2R;.;TGF9YK&U0Q+!DQU<C_*&F3;
MLN)[+4=#]8S](I-54R, 3I/N<620$"..%,K[('W1J)?9\J\L_QX+VE,7C,_L
MH8&_%/J=ED7+@"$).1,ZPEH%JP:22=ML$O.80WLBBK^N>\3<#39M8A_S/A>>
M3O\!N-_RNB,E*,G^.&O*M+$#QO&-JSN8 ZUE@?X#>#!VOR0X/E>/,87MAFBS
M7OW7IJ2)(STFQMX,51Z45I'_5)$4]%+#0^B0@'.A[LH:VO;'2-(F!%KNH=SV
ME^(!P67;T[RK?AFE,>MIV]:VD5G[%JRH(IHP1B%1N(3<T+:@.JGGJ?F9.P6)
MUE]90J%#/ 219HA=#IPU5JSJ[ZHUN-V3RU061'.#/X@W8D5OGSAR3\Z#B.PS
M"KXI0#+A: \82\.GW #T;5/_5#/[G$QY'EB28%H[T112RJLF1YW,A1BHP?M^
MA-3A]Y&5J<(=<#[95M^C$'G3[H'2>I6TCBDQ+S584DQ%3$1'ZDXWZ$4&DWK9
MOS6]H)?'UC>@_[='#>XWM5&@Z9?F\PLUEY]_ +8D-2M&,(BQW(]]#HFE^*'#
M!^E?E]T(<=K-RSN_+X[!_O_TQXQ+;3QF6)!]XUZ[ISQJQ+IF2J,*QIMS!83O
M74]@]-J]TK\]UW!3[%+[NC0F<."F>$6,Z95MZ:RIQC2\QOO/G(QP$<E%*XPK
M8HSPS#(:IR:*+QCBI"JJH-#_I>$#/I*,.<C6[BBZ>;:]2GG\6D4(7TQ=D?LN
M:/T9+/H?S3-I:%W02)S_+DFL'WC>G)]Q820!5V'_Z_S.]NN+IEX(PLD-71/8
M]Q+O0?_2G9V !Y/.+@#ZUXB)_^H8E]HTD/Y7R[!_NMHE:$KB+RM%UCX@8?.W
MSTOEM:M_ /]GF$KZ7RV:_P!R@_Y30U"FWH:N$907"97^A9 7"<'V\J<U_\#V
M7X+&AL==JN '_0>4 [(X_O)"Y%*U-O]1=O8!YV64\58C<2EI/_UKJ(AF_,M$
MS'/A>E<6OR].Y%/SUI]M6_"/[(*8Q"3T3=C$&%M>Q^BGC_UC=@3:8GSZA9M"
MVYLB!##8A<E5$I7)]K_D TI*NF^*NF_PX.!*LNH;?+%'XRN>9Q[>M^!-\"ZL
MQ[Z<JM=*M'U-(\21G%.V?0 _#SR57>W^WOFM:?BJ3YGO\[[\/YS"%^. 7TH1
M ]\K5"72<SP<Y-T/%X[$_O8I?;[ZZVZ_%55]>6'O_=]LAG^Q&[274@B?KE0?
M]]3W!OX 1%-^/^"Y(\69,G5K?WVY<?T_;LS]ZT:^"G[IOOQ_7/NHOW00WU-9
M"W$OC$5F+/$Q]D%]O_2>\*K8A0G=I<+OS5]&;5";!#,[DID*OH7='X!'H*:C
MB=2#NBL$W:5TRQ?=$%M1DO=]V?^&)_TW_9O^3?\_I3+VZN192JX>)Q>\UVCB
MRU1JB#?://;O,=(EK**6*X_@TJ>HK[851/AW*3E_<^C79)WG +D5ZX4T5X>2
M'TR'T#4M6-&^ZU#-U>-/D+ (LUEO^)WXV6IKOQD\)^O?8M* 0Z$-@]T.<B7L
MY/Z*4M9SB,/"Z[W*3,2X2MORDO!VGSMV#QWWXE#7=3VY:FSUJL6@K51URO7T
M'X T5>\FIAY6\X3,\16;>3J=O4N6HX&0%T($G-!'%00%B<EL/NU$9.&/:6J_
M#:2I@^YH:1P0[>B)3K%=/6:4H;>[+0\AV@CM5,E6Z([G0QVPV?8>9I+"WT<,
M4UF@E!TSUF.DVU:>R>@WUM01OM(;>SL[&$+*"IA4@5L1(F8(R4)NM.DTMTZ9
ML)I<B/YFXW36'CQXZAYWN!++M3934'?6^"A4=4;^]&UC'R<TP_ CJPL">8MA
M+IS@E%V*QOS$QR975C;6=.X'BXB50F)@FO;0;F(9($DOYB </ZOM+FNZH\#S
M6[9O[U:-13@S%Q3Q!^HP']UDK95M+>\%\T.9I=8568UZ7#)@=)=6:)"QGGQL
M7@MEL9+6)W5TKR]XW]R36+ ;\16NURNXD0FNVS-AP4)(20H643"U6S=3GQ/
MRD7U;RF,+$TMCC-[CJ: ]$EZF4%IKG=GZ_'?5F$O6N"#.I1L)PN0TG9M*<Q8
M^FCH"<GO/(2.>1ZR6 ?<[6*F?J_.W;\K<1--L_;DJM$@C%CYUF=Z.^BJT?=Y
M1=F>KW=X! \Q^EUM@Q4GW!XG2C[RBTV:92V-?H9ND M55^U";7 KQ=_+TG!:
M#PI@A@?W3*T?QGW MW;4GUW9=RQ-JNQGHI(;KVC9L@KN1@SE=I7-J#8NJ*MN
M?!3QKL[T'P$VQV_:1G<'%"$T-FUM)6'Q)-Q<5^O+D8U.<GY;@2B,(R^8ZTGO
MN[98WI!9'L:P]GZ?+2CCKS=OQG0">B99^M<*:4A?=)MRJFRXPN;YNZCJ6B(6
M\B;BSW%(P>$_PA, UJLA*=V3/"NQG*T5LE)B^YWUYF!^2K;B/<JVEI$G;N:&
ME8%*SQW-)$$6TEW[@"5!#4ZTD4.$!W5K'NF8@89+NL:^WCIY5G$/=>$44A@A
M$!!HDFII^B;8?0"L%."(H5@':NC':UGQ7G/Y:I@KF%\2[C: GY6U#_&*W^_[
M9!U0=EI>KFN5;8MPGMOYDWB7A:(6\4JRAJ4YDRN\H]]V&57ZJ0+@"_<P8TW(
M:UM9LE2%_*FI?%FMCC>YAKFBGKB'%G.$:NLRYOT7_<RJPG@&"]Y!&A*TUX.>
MT!$D-Q25EEV&VH)Q]GA%YM 3;6RR.K0,5DE<?0:C;AA\*Z4@0TBST"Z^MBK.
M"AK\VSJ<O1%:7HA""+I%Q(-;IU^B"I8L@9F'PXS>'\"J;^!1ZJ1\<N7D(#^Z
M](]5 R('BI9)ICZMYN3!@V-Z$=/)2V91*P7B/?PU0:H;,=M_X"D2H#%[O%^U
MX\7-OCON4+ZJ@K5(BQG6T\.GO6L4L:H)G=5=-X_@M<DHS,M,P-=$HCH\^4E&
M1F#FKA_S*6L@=JVJ!=(?'X<</H_0[#FKT.W@WG!]IMZW@\F_O:MPD)2)?D:/
M!A#I.AHQ-+U!R1=5?S'/]\IH?QDPYEI3/)!FW\DBQ(P'<$[J/$[XA31Q7P>K
MU)K0%8;4'PG$Z243V+.MQQ_ST/:ZVX],.;C(>[9)JS^=]<EN.A^<:&]SGRMF
M.?'U#P2!)^EE(>B#_8Y.>,DH8R\8X?8N&/?B92Q?TI&;'CS/#&Y:!DZM34G+
ME_CF;N8RKA\W0PR4/MA;(38-NU HA88/(5 A.O'D/NWR K\9+A44-(-7 $OJ
M W@=Y[I[[(67S%]'ZTLO,5-='B#1Q<][X!#$,.ILTO3]A_0OM%0_>";^L<5G
MO\\K1]O*8VU[! ^T-MWDNF<H -]<IKLE$S#TB-_QBN[J&G;^H%7_!Y 8F*J+
M@:>E%*\RN[C/MN^)*Z3&/SB.O!N^UFWFYDU,RPO]E5.\,+;:?VYIM.E+K^58
MBF*/$]&SM97%VMTJ:]&WPP(Z-V\"40E@\M:*TI@:<V9WF0M?-P1ZG$GH$]Z'
MPJ$'J[5\<)/J'?0>1OFM'YC[1%:I(]>(;[QS,MS2&&M](2Z=.<F_K5=_<0^^
M)\31[YY[-Z >@%?+4 -P ]V0S1*SX6<3U#N[!CG;HX]N>#@]QJFT*R9Q=B=@
M,U2+^,9DWBJ][7BDO^-Q URMOOC6IHO!M2T;X@D1SE:WF$]M#1@E*QLJY.+3
MY=J\<I!H6D$X.57BLY6D$]^@3'2T,6)I[KK!\1;W<+K@WKT?W"_ =9>.F6A>
MK+**V-YS9NS>MWR?++FAI; +2SO;C,FZUZJ?R]0^UI8>-33G=V <!'4+(M "
M7X88N[K>D-%<O[%-)CL"/C/;'FL+(%G'2;*'#)(@+SJ?M])DXD#0!;[&!D2M
M6GN>#SXY3@H-NK]XG/T5YH\D$_&]!"!#@)K_C[8W'=L*B*]"_1*8)BKT6$>P
M,\YHZYG+^R=&DZI@6 "@VPN.V(T*Z@>;36?&&+*V+7H.")%"!)'@7L9DL(Y0
MP9AVQ/F@W^#S..<(#=0_#DD0& I'+NSY4LA67?/3@L.Y)^J>RP1U'&W_<$_3
M>8\V($'H(!-<T>,70-? 0JT53H^+9UI)*C8\9+:Y-/W7<S!61G7(FB]N>&PX
MF'1 /#,,8;2FM0_>QID,(3#KJF/?R#O/;+Z=WNL'6UT:K^XIAD]$Y$&9W709
MU88%=>>W-LWM.'0UR7@XF7O<IB5W*RU$#VV65X*W1TK@\LZ)^^3%'FIWJ@@3
M'KH[_L71W01?-S<4.];>@QS\;/<J@YX@S*S]?9^/JGU([SX[=\:]"18W/$3A
M_=[8CA:]RI.82<CQIDQD!%V*RA(7%='U0C;CW%9=[_K$-Z"=,]E&1"_,(7J-
M?<T)&.R"+ ?::6#2_?]^$=3_A#)9N52RZ>*!)O)JLN*%.4!O<O/T43=.,D:Z
MP.#+O"][OFI(1!XB1.>';?;VGEERHZ"],MLE4Z/\MCN)'$T*"D@5"?%Y?D94
M,E$_-#_%G"SX&+2FZH9^0S1@/ /T\6 3!Y'GRC7'U=>.6#2X*5N.?'!;&5^\
MQQTC@#GU^GRFQOQJCO\N01W$ )F'N>8Z&N]]-YYKT'.@6.A:/D#5>&ME9<Y?
MBXA$%ZW&GU#\%;V=+0/ZFS3Y21X/@C=D-*#B_@< ]VS_RCOB26Q^PIZH48HS
MJI[F*I*8P<=<+% JT3=!6?&J]_RHNIHF,]GI\P$SXQ5&P#2(+ 'VZ_:[7DT;
MA_PGQ:9]BI^\4;5T[0^"5XO\:^T1@1:Y+8/R[[0R/'3[)0V5>9.A7IX).M%$
MM<"GD!IY0>(IO E"];;.F$L.=?/<%1/6I!!OQJIDA!;RH,X'+2/:\>:.$"?Z
M+! [#6M=\7(N\658"_(^ME!O?(N8*H D4<J@[][M[0A[(>D.X[:DX[!&U')?
M\!\ OSRB"W;Q6U'QZ1X;\]@VOEP0, NH.V-AKB3?+-0S3.;KYUY1::)4>G1@
M2WM-QP[Y)#BH%QHV K@]@MSBYY1N'.OH5Y6UV.[ ,WVL941QU5;#'CW%NQ(<
M&1+O0&LWU)8]4WV7>QF[:L36WL"&D!X[CD0Z;6F:, 29DM'\NDUJ42[CO<0E
MD+J=[D&<A,UA)KG?8JQDBM758&BOHWX2;5<6,5/,28@62CG&<1^+D M#HJ4<
MR&61?Y?Q!V"VHLI33UE?V%X+S$O%5:TB*1(C3F$(W\_01W,V#:JO5"RNBF;9
M;W++#$IQZ18\2>QMJJX<F&^:-+$-7XX:VACEWEV]T$1SOXLW>ZOQYI5GEP42
M V+K XA25B+' N1*UVJ_T):Y8@4U $,]O8N-BLHSHDD5=L\3UB P]0J"J.E(
MZ31<+KZMI'YJA=&!9C12)\"5VU#KEI]F5D[X_OJ3LB.W=)X-E %2N'D?\P-9
M7I3"UW6VS. XJTC 59\7Q,O9MCHAXFATUD#@9+F&BB*XXIY0*,K76*6[VC#,
M^L-Q<?OUX#)<-FKIP5[S%W.1&1N7Z5EA]E6]_(A="^+"+'K+M=>?U."(]_QA
M-R=:P)DOX?V!RK-,WJ5OQJ?W"#S?AQLMDV,)"0X)5:R$\2XU09%U(H06UE<$
M5B::*:G,AB=/+R?Q%ATG"_ESD9I29]<3<^62O7!1%UQ07YU_C,MM3Y"09 FK
M=>7E3]AR:/L#>*N'6$!+.=%!WW-M<[YE0S3IMQL#:F!(GMU8=TI[Z^ELMS>0
MTQV^Y[_FUG5KN+ZVML'(!F0#+O[(6'P7SERBL^<Z+.*^D;^0=6YP,C++G[RX
MH,'3K ;=-!L\<*!ZJ"&R@5T.D$2$-_UX2B2KZ=SB/,TT4R= ]XD$UDY-)'Q#
MV.1S,V*SCE6++Z8R]D)(?8#_+<:CY_DKMQASCS]7?P*1O>EJ<A\.TA0ZCI:$
M$^P>7RIXHN,Q(7=^_%NW] K>D3VJ3,9Q$C_,LN(S^2#J;H*M%R9*=0K+$*VA
M$<L4\'+\'.)HDE0-,$P6OS#,_1HNZU5B9'2<COBN5E\)3_%!>>"N'A=N>'7>
M3>I$RRI4D+U1J4=L6^FM1IDS'<N!(WN@T3?:5S"/NY(@\#&4JRKX;6N;!J0B
M)%G"4Z_9^<.&)$+.&.QF)]X7</>C76RA_\R+X*@@B^T/P.9Y&_>UW-TZ=#4.
M"^8Z('S11VF?60W,6@1]@STLFFL2:R*60[?VN;%4#5_;#>:4F6PJHW,;]%>@
MCPA<)BMQPGG6(E"[S^]N?%XG-C5X;,=H;]8URY[(TE.B#NS!>RITPE( O+)(
M@1%Z86)2%Y9WO?VF[L( H")#O7/<O?Z=]O:GG3;_.V<:7 ,:!AAT']A[IXV=
MA+H5L286+N]ZV%=XHK:RJ8*[K 2LHDZ6>OPT(,/%\$5(J%O4(I3M."19X7RW
M-<6#C1A"X 9/[13D*>BVEIA=JC[<PX>)D06%\>$'$[^R9I))1O;BD#/)Q]?C
MI5/R,;\>N6;'-?5\7M!&I#K\-"A!D;JN09I9&LK%F0I'V]@AH.Q(RRY'K BK
M!>PBA@-#70>9QQB39V=_;USM/^7C)(G^M%+^)A0?J,,V?)AP,@<Q[F/MR1?U
M+&!B3\N01_2#LA7B<)D-[LZ3!<&TQJH$#8\)FHW!ZEA>@RBX7H;/V'QLPW\
M4GEGA.**9^9S\E=X)H:PK9#-RYT*VTL0F;NX$U)[EZE2)O$:.P (I8M0I:*0
M;W+!W]B2H8B8D?&/]AZ]5] 4_HS,K;<J2GGWW.8W[^L5V=7#F:0$H+2]?FIA
M>RJB;%\.%B#SG1<N*0RP*7\'M1BG%TSH[3)#N/^8ENA[+HH5*3Z8>+::B4\?
M7O6.:PA!L=B$FYCL,[H*^E;8/*ZOJ^H&P<<Z[P^'ZXC-GY8_IM'&R42H,QC6
M LD\M_P.H*M]@^LTJW1%#O4^<6RG_0IC-?E$F+ K%9"$8D!$H8_8+^!O>0A'
M+HXZJM75&@>P%H7VF\5&W2W+6,:F;@B[M7;:)1J6/!27SWKU*,E6YQLO^XJW
MF<-948R0(R0R?1^$GY4_RK]E2;4_*3DE=8K-)S:8Z.59M&:'4]_!W;OO^..3
M.%>#T_#@S'R3FZ]K?/AC[$VUT\:%.L_+FU  ;'V-,<F0RPMAO-MJ!8! N2&&
MA-9<=L/:'+GGO1]^ 1=I.88>5?-^7(@N(=#!LYOBH2(%'.A!$A?H*?Z-*^>K
M^Q[&R=]/^6(=#313E,#;!$/.:7BN24KUW(5OH$E.$ES=DZIDOZ:<*S8V^ASQ
M< UDW4Y8%.:ZM^ _8K:C(5)FV"0CB]P6C.N_^?9=V:H"Y,O^FB5B#?+6XAI-
M"/D=_R(M0\ZGQX7L'(XS0@W50\<-4\%5F(^3P5*7ZYG>HF_X]KQ>7 T(S#<=
M:Y>\9_UZ66Z2?\]C2&B">^=$W:"]6#+/FN0CTP%I!-:G!Q^U=M>PO NLTAC6
M<Q+"507(ERR31CB'N8#"T:O?SCS6FYUY[9O_N$8'7\IT,O =[%3)8W*RZ_V;
MDTV)R$[[1<ST-'=G<-E4D%LZX2MB=7H1>7?*]'MO8D1(+MIP43:QSTWG[Z"+
MVH-U>==[7\?E(>-'X<<%^FEVXOW! G5^E9K3J KJM&9<70%!VCB+Q,D*F<]K
MQ0UN#!=TWA\_'_!8>,SN\-&* >ZVL)CGEY;<;']%^="^82U9(39#<IL(1TEV
MD>$7OGMB.@[_!-Z@>$3LE>(%!!1.76TU7R4%7E@#UEQ/M-@]8K_I;RS.^?7/
MR))=I2JWR ,M.%HH5 *UI\B%%SSFJY4[@[G'ZF9T)P>E7R7$@! 35#A;4:HO
MC_2A2^G]Y=%L-#$H"E9Z8X20F C'2H,XA&[J^H2"W#)>OFJS1]FB::?5 UKZ
M4QMBHC*&VC?@('-<1U)\ <>;(>?>NG2M>6.BS*+:L/%F^X)96GR%04[Q'R-"
MB+E<%^KQ^I>'T%L*8 QO<_S96K+2UW')/=.GDQ&44JGWUB+9>XK7B@F$IP><
M>(F=+8=BORS(*W"7>O\ +)IMMZ&S_,@2;+MUFH)RF-=);GM;\&XH_IK:).MK
MP^DHIR<(ZZC^)6NSXJ?\6TK^GUALB$3AO?&!=>NJVX^RT>NE73#N ^NX4VMN
M"Y<1DR2+A-33Z0:K'"]I1S#^JTL:'Z=PJ\@)0!/GL0" R'3K>OZF0AOJKK<.
MBM2),#>:7'O=H_YW;7C=T-632W[;O,.KV%?L-E!G:L>5_6K_NG+=KB,]GC26
MJU#!PVI9DZ9%#FMOJF1&W!W;&8@4YN#!QB8+3GPY:L^Q:XJ,2L^GL_>2CHK/
M[)C]BF465KA2!]QX 4-F:_SG6V2O8%C@.WU2O>,KX]B/Z(_-0'6BIUX5J13,
MQJB10UOQF^5"ZX7[%4,C$*]SF__XA@;[!NWJO1<%]KN$HAODIH2YT6*:KLPL
M/\92'_*.WH2!.DT*9-?NQT)RX5![TV/;DK1:QZ7)J131^H"-]OO+I:8_@-F"
M.5Z)T]6/Z6?BUM_N+*PE(OBF3'[9_'K4?E>_]@=@?K2$S3:>[_$'P!>G(\V/
M!9_'==7GEO#L>R-4E;F3==Y+E^58W_(JJ6C"R:C)K3B=;8DA<7@W18T>.NKS
M0=")Y$BY0]Y79M^_IRGM<?DH;([<[Z[$^.BB_/N)H]<^:S]MDP56=@\*$FC?
M3=BF-/ VD^)QN#).)SW9Y,$U^6VX11S30\X\>:DG%MRDGRF\;+R%YCRK50R&
M;B%4&T1OS9POS43F/\LN: 8=.;KWV=9;LUP4YM&=<*0!.17P02P5JC[:K0Y+
M,*+L#\XL>=H1=XC/V2N5\8W+6W:9GX=QP]543SRV&+L'HX@WZAJ]6TE?>3L;
MW35/1;!C6-*']>1(]B;7Z\/]@%;$CKI=%$<UN5-^8S+X57\J-RB"V?UJSS4D
MF&N0Z9@-<W!VWX %M>I<G:$. $PDV'=.^CQZCI)_6Y8BI;O-Q=9#5<0"50GR
MW*__>?BC,OM,Y6!)@5.6;EDK5^M1<? J)YH>'@JX7F6H$3M1GA>OK#<P-!8I
M]$DG]KK:5?YZ_-05GHA"M":<,OU&;=K\^SF?@7/:.!<Q7;))*FLXK(V>!_99
M:$IU*G8E(?/NSOW0QZ^J*.S\\"+M\(MCI]AQ4['G/0&GH?Z$*SS;///Q=,.[
M!PBRN"G6VIMI]Y.X,&V]ZOPE*60O;J.HM(%N+L3EY%SC<R)3V-G]E!V?;\3'
M]-]$2F.?V?W'K"'+">QLVE9J6O* O,XK>&P5!:K9KY$8=C,;SR6LLE0>$RW<
MS*?+->(NA+ M1N+;BOL?HG>0WNL\T>?Y!,]FW!J4N&I=K)_$1QOI*IDE,Y\@
M138IHWTBKPA,.54I=M+6(RVM#7Y:*]D>Z%[0Q-7+?8=(:E -=Y\S?246!)RM
MZK V>#8E@?BFLOK?4:(UT\N_<AT9Y(H92O@#T# @LFS51.=MAB@:MA.C+E\+
MH$L=UC*D3-C:"KQ1]O&N&Z,-?\S/2)+P8]S] 0B$S^[\6"D/WG:UP6#E7AFB
M<;BRC)E0>RJE&@E+9\C?#P@67?A^DRZLM9 S,)5QST;+^YEBG. &,3=/WZ=E
ML[J'S-TI<3C=K<+2Z548Y)@[2-BZ,>B#%7F#ITLT0TOZF&'PMU[H=R.XH^?M
MGS?%GD/Y:#/G8QAA 82K_MM,0?5Y'*3H%M:G-T*3YUUKFBO6R;_L2]C?EK$5
MAH0DOE)\$S$9M")J<5G^2W;][*"0-:7#G,?^C0_3-9*Y"9#37(0B=^UR,F"Q
MW8_61"I<@61E>PO*Q]P]*/W#R_)6HK<C@5NHU/J&(/Q^NIJ_)N'AC1?L8P;/
M8RNI*Z7?!<),6U"]OHZG]*%2UH")^0B&-"GQ*B3N<0&V[1;  FEN;6NT;21>
MD4VP/6A18]]+]SUCA8L/U@3@S(EN>155#]4V>Q5U#GQ+8W_KTA*G2IQ(=\>_
MWS,UMH02-E2J;Z#,=/:EXZ 5&YWX%9>/-U-G,[^!Z/5<2+#?HK]^SGZ1.FLB
MQA B9*6MZ2!+9P6#4VB7F(%(" "+T5R\D$^NNI-//@8FTTFZ8MW!><&>^I+=
MX _!>*<#^4Y&%%Z=N'3?E9PESI Y6#B^.FU0BF(]\^3^W*E?ZDO^MF)<L_R!
MKQ^-@"K:W/P8A,O#0]:D A*]_*D516\?R_+ AW& 4S4<)U;([82.YVB(VPT=
M[A:: BR(Y+MCUB3XM5=\4+*/S0B!76@4>Z(X/'U#20*1;1T2EU23$#J+"CI5
MGID;1$%U-0]T/M:C,-#-I*6EU4\9^FG/,P'M&_<VD.&3Q1U,/PCM'3*(?J@<
M7VMJM:7+Z7^OK_ .XRJ<:FB*+&7DL-EIKQ[4:,:W/M!Q3Z&>/A+OQ)!L]M%!
M""X[5&7[)T*BGI\=CUW,@ 75_*W"N?-> G;=X';JQ]>AL_ ZTUNO4GZY(#%$
M;)M+1SQ7[L%2FP4<TE_E8U/GA,%!VL&FDD_:L4B3N3%]H=:M/VYX-M='\%2B
M0!\AM/YKF&,C:_R)J?!^'\H8&EN-@ ?'.R)1BR"SZ/-OO&!8:+_EL*9%!)U/
MC]CW&L/OWRM%8K-3YPM:$L D##59;\.<D.6A4K3M;H$YD1KV1SJ.5NGMA Y6
M(71P=,D7GN[7CNB*E%:COS7=PB>38_JLKANUH),'1T7:UPS<BKV,<\XXJ4<M
M>V06+L>JD@8%5?.TPYE]AB 2I<. <J6/$/<1N)HW+_U/EM RP((T<<R"TK\2
MM^A904:S+>!_P:O6O@4O;E@FR"#VB+")WS31!G\"21L>IKJY.9-M:!F:,821
MY)8B%1$28KQ&*^X8]K]+&:>U&=\JW_K-\/G@B_&) (BNGZ#BS;N42@71NOY$
M5J&MNL2)5(OY'R8L^"^-94<:=;5$;.P3K)MQKH*8\>BR)\R+F-9#XBQ=[!9*
M/G\0+R5S<GR*SOWP5LV__VK5F4%0Z&3:HE3,=M_,W2YFI)60:^,Y02A#W@>*
MI0N-I QR"I BNA%?TY11B?YP*R5VUX.=W; Q+K?5UW1JL5K\HE\;<T1M 'M>
M:>:GQ/'4-KG@76)K=&P@PE*)_+RV9Y[?9R.[IH+MPBC4$MS^3^0#>I(2+#7O
MAW<9R'[]H"ON/922-?V?_FJB!(+DR=8ER[-..,6-#P%S"H%9)#6&[;)N_$L"
M_+,R99.3M5-D2^CBR\#L):1@KB1\ *(;SS>OBNGC=$A&&.F':/J$A0+'"=I6
M-=T(MD%N%51@"&QN'R,'"7]RA&W\%V;6X/G<IFJGN\A;3]Q9"]]034>BW2,M
MC5]^C"[&<O9@AK1" 4R:;4U&5:Y6L]:>$3+3RP&R?/?*@AJ)1CZD#F&?Y(EJ
MI;+K?@?:=Q5<2%Z6->@B<1%31.7-)/NW@YFBT"O]_IFAT#W*C7H>YHR'74%$
M&Z%)L>\OIOY<4",J*WIWJ2>/>)4?__2 WHI4^ X>[9R[CT_G4>/LEC0ZWZ)-
M2^%LQW$\/]":K>8UV@J"):3/0M0T1D '(T<9?[*GVGC*ZBZIZ3M$/Z# ,%0)
MU\"6R.%5^-3[Q,"&D_CW&DUZ'8-UF(XD(.93AU8W5Y*G-0JN=EC*;((VH3 Z
M2UZD85O6@R-4T(MGY/6#ZB8((/8+4>C7_*^<+,/C._6')5L3OV&:=BBGN@XY
M?O#C>,>CNM.VNW5,MW#\J>>>M!EUB2U;:H7"'C55/6Z?A,<M[9)8.<X7DXG2
MV"B-93TVJ U6482U.8X<:7PWQ2$Q^5]T%1?4;L]7[R]V3;Z#7XY%'>Q5"B=+
M2\)%P^S1@#L9&>*MCJMA>UX/7U^MY)PXF& M3OIJ&A.HWHP"!"!SC4QBJ;7.
MSA@N#.5A)5;)V <(*EFQ)C=$@%#.P_!?]>=V[!T"+A-0F\OTJR:+K4B4O<B^
M/ [9GEO*XI3P7$6LCC +>S#,QB)-E+.0ZD0-X_*XNBTYD1D,.+*\Y<DEKO%E
M' 3MK@+1'2J ),65.^<@&47JO#>X GC;;TT\7FW7WT>VB/Y%.@OS_9GZYA%=
M=<)B1E$TR9D>-G0O941PF(CXUV&<!G2A:^'S&-A+5/PMVVN>]6&+:UVG-2ES
M@)H.T:UXJBZ[AZ8.^YBHJ[SUS!HTP6$"3SBE?A@=EW]X7Y5H1$U^5R/(8>P/
M /6;8(N (]8V57C35B[I^.#X;F[#@_0A2-;-P1GQJ(19N;.8;OI8 _\Q$Z#<
M['WN&C9\0]_L,6*LS,WDWSNR#Q"=@Z[Q)$^L>1PBE/A-[YJV!L;T3VO;8J=X
MO$L9P1T[9-M+*0J;1]X6$B.,"V!6-F<J;6U6*&+/)\]=$6EJAD12<J?MUP[W
M4+OUT:<UUA@N%;1*5:QWT[6$:K=$K:X6J8\7>GMY&HU[(3$(37)BDR64[%>7
M?EY3<L8H;N!HTLYVBV"P8.S&H$97V5U(0"T=[3UXQH<4VA&F.Q"<=ON/V5:_
M&95N][)A=E-Q#9FB5*PO4KCZ5J]P>G8XSCW$ "\'"-3,JC'LE+6VU[G75E^5
MMT%-]HOV;QS&C&-R"I^FR-N@3%3\4F2TL6''/2(R2,M?*Y"<QZE-=R6#3%M[
M=#9%!IW==G>*82SZ?]U:Z_])DTM468>*R41F/ 16F$2KR>T1I\C4H$%O)S&I
M(VGXT5@%)[,0BW@ZW>Q1K7>.DIJOQ5#6=X^.U$TZXZO: \I?STQN<;,BR]!:
M/):CB6*K+$ *=(V_D5JP58;0O/ED-+.OM:_1P81Q[^8B; 'PP"\NT^7/#[*M
M\ZEP?.V#(<LCM_H3G;N((KR\LIK&0,&!@=M8QOHSL,\AD:XV09XBO@69]D0E
M47$N_V,??GCY6_=474VF8:K+1&GY7;WT+)Y1IW<*IS.KJ&?&>K'\.[JUKT#4
MK0"N/<W78&S@*#*,]=38TJ9IK?4!O\L:76&,R_CCCX[;P@/D]0Y^?FX,>UVJ
MD!RETQC.5@0$46P79E3>9V9;I_BJJC:T^SZ> 52-(2 G ]EU5G[!D;*-^Z&R
M*:1M-804,W)LK)VH9U). .XH9+%"/%QLHHUMH,4&I[]<Z54ASWG:D)@\D9B;
M8*DSIS"8.L96G]A"C\:L$3(H1?&1HA'/D\#51]RH"&T/GGJ5B,+8]^QFJM%]
MUE:CIE7=@CB29PR_E:5F6+K %68:K'O8[CL?)I\U^EVLLQ"$"GU]7-V:2H-+
MMA>7LV>9&V@<D9;NTMKB<4+0)J!LX^2$A9;1W_Z3B&Q73/"S>2BI!PUC8;0*
M-XXD&0!%U11EVW#.UDN ORX[6PN<R_F:$,5BA!I,1*DUNO4'4#^ \N[K)B]$
MSZ%#G<N^"0+*<S&-$9J<27+Y-C@3=_NB26M)^HIXIB.I%$D?WM%AB+/#VA=*
M$21C%-J4&,)'[$<Y \OFID?9[OZ/!I?T<F>5/WN [@VP7=C[#_CM,:1^&$K$
M>PU7=Z,_1,U"XP!A?NS<$K$U1R/#$2(L^9]9[6TU5L]8W.C66K1P')>#W6&)
M[RR^VO'"+V475!@:57I.T+4^\M;)8QV@(-Q;(#"4$1'??-8(X%<B[,!XW2PI
MD!X+-F']@0Y)TDR (]-"NSGY&/%LUC3N_ $OFLRA7)]/H6?%C3\O=3=)3I V
M#(1?2(KF:%T;Q*^9F:_]X1J'^RN+ MI#=,^4&#*()I:*-ZV2+]L:1*6W@WDM
MZPZ'2+$L3TR9)L7:QMIT;BP"+JQ-E6^0^3J:$L<<C#TQ3&3L/J0?J5C?DJ#G
MY$S=D@RR(L7LB>HP4XL?LAD5AEP=AO+,SPL(:PZP]ZNU#=T-'RALN\1]KRU(
M*J4%;^U"YLJV9F>W]%)T9DT_&O.Z.8P)01SVZ(C\*PTPT@1W862:(V5'7]P6
M8\1]LK$SB&BY#,_8XMMKO\$6;"LO@(V-H5JITD[O$I*'R1>YH%K6(VM>2.?>
M%RJ>'2V+\&O@>TK+\&L,%OG:!/%'_\>6$8#%9DH<@:1!+IOXR,03]$=1>;[H
M0B0WSC1C]\@I "_+'+RA-%%J,( [/!0X[-_$BH6U'>Q^6[[4M.DT<X99R0VT
MG1FEBO_H7(/=AN52BC+O<2R\$,_F1-VL>YC@@B'"D$WE&>_>6^\$S%5UGZLB
M!_A-F#5]<*40W8]1LSBA7HV[G-(Z?&(FSE-LRU@VE,)+9(G@4G)RF8CH$2+Z
M'IDG*58>]XLWV6C-\"Q[7&!&,=B04SIV?R]UO>'&J5 T@)F%C?F.S5AH@^PM
MO35;J^\;B:^/]@_/X&4O3.5#>WNN ^XBOV7:T2\:*@MD :[J,D5'3=>96W-G
M-*E[Q+CXVD(GP_A8)<WOQYR=\2M$Y73WP&%E:(U]KZ6$]K"X<@.8[G,]\XN,
MANSTB3,MHXD34$T5#VE%71>+T! )"%SD+9M^R+[J+^B%!%<J ./@$H+GD_7T
ME5W)^YMJ.BZ#*B"%2"G??6,.3GGE0LZ P@[MM.V;^Q-W_H.B=0)(<4@(GL*6
M,.OB)=[5U4YSM*U&&QPB?2&=L=Z==RUTD]M#RL$VK:+H%?8MAHM*Y-R_E^Q7
MI=Q1L^3@;<, CPFG\&+N[SI30(UM(=5L,^<TA@/[*YG&=+>DFFD43^CI2C'V
MWA3$9I;BE@FD5*$D<K3Y4^\HATYBSNY.E*4O"^KL(6ZC,\- +<W>D,8KJ4$I
M483%=#6Z^(9EQZ(FM?37PXB3N289E4!SJ6XB*M@? ,_[U2,H03"&/:FMI./N
M6+3.00_QUH<>VLO*9=8O%)<EWF$'^V1)DDBXHE^(+ZAYP?J:4!U7E6DD5W"T
MI38Q5-MQ'%LL:K=Y8H"2DY<$4^)]@@Q=!R%:1^$#!!DQGY8LP<7]UQQMHG+N
MC1RTEO=.DKEY^6<L;4$3I^ 08)'GNQ<A@4/]*LO8'@W] 25+.S3MURTQ(L57
M#GSCB[YZ(41]+KWBS#T%1++:($C>..)KPI81LBUWE;&6Z@^QSNC<=7TD:>NA
M>*\L]W[;5&EF&?$YTG4D"ZZPC9-_-(CE]Z0 C#"0!ISPB[$MWL3&BYUO<$=@
MC%B90+3D 8>>2@@P ):/6)D!4^6-(S<J[Y"X831=/^>#XK*:BH]IZ0&Z[VS=
MN4B6MHZV6T"!?9" NT*)IJV1(1D2L08"7+#0@#[G:@&\>;06FHMG,!YL[_&#
MD/A!7=;L^?&52&G35=AH>*&U8;D<4?4I+K?AW111F8<]VIDS>W6>*A</DY"U
M*K<< Q"W%$O8M.:5Q!O9) +</X"WT$&/JVD#)&WOC85481AS4G&@BPN@6RR<
M)0?IIMT,2)!G#G[K,@ $P%$#'5'E,6%[%K2P^W)I-KDK)G8GWJ/92V,F>)Z!
M>KL69S94]REC V+![YQ(B:>/T1[=^M_8QC98']$T+&2X6XF/IBVW;LF/OM-L
MM\^EJQ$4:ZI83OJG-(^O/C\YKC<WN<>P._.>V(<@'B,,'Y]%*3$Z!%>.(^/M
MO<*55[7[M*B3MVJM[LCPY(^&^-O\P=AX&I4)=G$LX#BEFDVF23_JU6J0S<AN
M 9JE#QO+D"<#P"5])W(B.D7 +M70PSKH;'R.71<K;EVE8O^&PUWQ.M"Q*K[2
MS:=']+8,<A-UJZ=.%<X!'!UA;*;U&53,Y IUG>2!:6%@"A\OK#"QG5M%:\AF
M@+@[O #/TU$&Z %NA%V@D_?'VLTZ]TJX^B,$XQ];N<,H9HLH4X361XA7NW^S
M*Q1;N= EJL^L"$#P):.H*;^/HQ%3HV.VFL%"FL6\*SQG]8ST?6H&JUZ[/;Z3
M57!9!GXFQLSUM>'[F!7XJ<F19'4]:OXM,,8@S3.IPG^0MN7C;NG:67"GO;QR
MT[Q9O-SWLZUKXH[,PFNZ%54OG<'SCIQU'^#T+"+?!W+\9"O^TU"\L2(H-W5_
M_+(BO!?G=V&(CEGHX-G K^52V/'[<>A:4;BOZ3E<[6TYMRZ(/L=MB;].E7=)
M')P@U-&T4G7E:"I/+9U;F+M3=13K^@J#;$8%#VIY;8DU4RV'G^T*O/(9.5HJ
MQAY&.ZAM:-&%VNL"7R?]7^U<:S@3"A_?!:U)17.I*!J1LLSMW6C8.ELN!YM+
M"]M)K6)I)E8NO4XHBMAA(:FLS67FGLL(92K;D+DF[+A$N@C=<)(X9^=YWF_O
M\[P?WL_GP__K[_G__K_+QS]MBQ[CF@)C%JIN]U#7@@Z\&ZR5*WF5WS)M>S+U
M3EIY4QS'T]3=X4*N:8ZQ)D 1RY#;7_+E0^+3(!F0UA>OCG1(4(O3J9Q40!4F
M_5Z_/26@S>JA:H[+4S4X#_TA-0.K):N!9-A7M@<5&,4!%R?/>Y.<M9UJZC[6
MKU7-Z;32QYKE7\B_QD71T,*@.E']5\<>)LR1IGO9 K3 ]&$7%_-O) 1X.':>
M2C*I;6#%7]&J<_LI^GT#VPGJRE*@GW6=9\#>6Z<8F#AW'@, VW;%^Y6:-<**
M^FTZBOV+!BJ,LYVA'T$Y %:;]"R'X=@Y9<L.=8C1I,BTI[S!VSC#\"I3;FPM
MWJ'::-6D873]Y7+TXX&&X'O53,7[_,9B!/=4IH?6B*(\DG,:NQ6$B\W1>_NY
MS,:[4=.BOBE0_4*B20)!!0L@8I#]O/7.@<<OEUNK ]8$%S\Z=%!7EL;2WE3T
MX<6A$D[EB"8U8N<F*ZO-V!\0-?ZJ0=5H]\0(;]656LP\P)06+S0*W]V'"CQJ
M+^G-%8N453UH+C57TV=-IOEVJ;A$9.[A\*Q@6[*"P>^LHO\0FO$G<0R+5!6[
MSS (#4H,,I)V*:\Z[\D>U_//,Z/A)J)+$_)=WWXV7M];R(\W[Q#XRQ!>(WSR
M0]Q-EQ(P2H)&O?TL#+-@+$Q:4MI@O7?/H(E6=UF3@W6D<"/WP.@9?^]QDTPB
MP8 (VLJB?+_D>]A]8,C?1,>.[QKYQC(I8N7#37;D^-_,3C[5(O25AVBFF.#2
MM#R]=JW8!FB8>HC\=2:\ZJZ[V#6RM:E/>R<CR<J%L<L.I(MAZ]U;1MWFOXHT
MOBV.O82U#QS0VA@4N/-T*NTV3=.,[%A(XTHJ2'AQQ=Y[-(N2>HY\;+Y-EL+W
MOKTD0?Z\X^C=:BET..!ZP67D5ERS7VN+&LIQ*2(U*LA&DHS/X-\B^MJA =-P
MI_@?I?LL##G +3EE>N?WO@!L2A[C/C\CX&=L[:(SPHVW!;8;9N)0K T1;&?T
M+-KI'GF'799H/JR)D9LP;$TPI!:RKZ;1;&.5P$>Y7C5-N%LZ%[\( =H<DR!G
M^0:XR-.Q?O<R(7</^^#<!R^$W7C*:X3V(V?IAO'*/ORP!I*7><JL:%!;@^V,
MDO5,.IFGCLN'>F6,"MZUYXR>F?M4Z>"T4/BN4-5KKL)A_G+HJFK5:%38UY;L
M"2YU6!Y"14A0HRC&B:1?\-E724F_=V)5)B-E92R?9F#5#K<D8SP+XY>,Y9U,
M=\_&J\HI"7^PD3<_B,&?!"07R.-N9CU9=N,L+TWC"M#+[WLX:KG$J<9FPA"[
MQJ6_3MX,_T(..=$[K=?SB**,%,@_@'_./<3/LB D#9B$!G\Z])M;&;, JU:&
M*'B4'V/] DX)'O/=)I8^]PCI\YRTD:3-SL":WH9JRGHHI!G![3?GJ-\4S?K3
M S:S^X @?T51ZDAN]OP0<I>4B*705%B%["?R@Z9==0F'XG]RH(&[>JB/;R^7
MP4CA^PWLVRO3!_P5=ZXDGD$BUM4VH'H\S5WF[Z=LAR?;$%YE$P'18*X8N*AM
M :- P^GVC!J9Z'M<(0Y;_RR\=&'7-7!>UDC S@(6@[>*I28?/\#<KXRJ\)W@
MHFIHNKUD5N]58VU#GMGZE*M635484-^'(Q]"#=F(DDA$26D) !I;B<&4QNZC
M0+DCL3&U.MR@^E5+AZN.;G,]E;^?S%^VBW#7KPD0]Q,LV7V)OA?$F-)V& 52
M)$H,?Q)"R[#*<NC5%\ZBY^=_SGLBG]EN6I?H=V9SV_0F=6!\C$$X,N\!'H 3
MY71M3V=,0<0@GAK$0 TC-*ZMSYMR2&'P8J;^!)#W&Q[@'A[T722JN#- J N)
MMN''DB% U2:N]-$A23+6"#\.) Z_!@\&?]J=;:\L58ND>\_4588R7*&B5SLE
MT"L?KDSD18PHS,\%1N-^M*CHK<0<[VHH\L#K@B#E#,.'G#?[C\'SO5K-">!_
M#2[9PNP][S#1^1J._?L\L9E&?K3\E@2RF2#<,+6S7]TG5*,<J<C IL"!$$RT
M?J3W"OW-1CO$I^;#M R,]7NQTE90K9"F4T_7]CP9C=B>NYU'AD?JH&1+>P6!
MZC8/=??307+=H"P"6/5]VC1**:]/,PC)A):[54MT#BX%F3TYS\:@C+U7D(S,
M?Q<^NWIKYY%N"7IIBHLW-+]\FCYQ:M5TV.+7[N:HFZ\KGW^?EU@?O8CHOD-X
M3@M#28N4U(5KMP1QO\U=5DJ$B(KYCT1%[%$S 9V$>Y!.$^L!R:C=WSX+2_B3
M1V]X/DB@GJAM2*<^K7;)4@N*V"A^_?9N_]BQT>-[BF;*=:$"\UJ"/GC6^JBR
MCLB7U-$;#]+!VW9SH@B;?59;%U99@L-T1MCU#$7[#GZV\W4 ,<:0=O]OY"/Z
M6Y]AV<8XF.'H_1-'L(N[LDF+5.1HL(Y.QX'.SB^%YOH+>H>F'Y]=4_JD\K]:
MM=^DHB6B7,C4DI7 -Y< (?:(.$SIV?__)]D_\S\'_.?(7U!+ 0(4 Q0    (
M /1#3U:MK=S8L><$ +$A.P 1              "  0    !A;'9R+3(P,C(Q
M,C,Q+FAT;5!+ 0(4 Q0    ( /1#3U:>7?P%)1<  "<( 0 1
M  "  >#G! !A;'9R+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( /1#3U:7UE(T
M@A$  , * 0 5              "  33_! !A;'9R+3(P,C(Q,C,Q7V-A;"YX
M;6Q02P$"% ,4    " #T0T]6I[RW\O0K  !\&P, %0              @ 'I
M$ 4 86QV<BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ ]$-/5A"-=&QF
MP@  ?LH( !4              ( !$#T% &%L=G(M,C R,C$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( /1#3U8Y;?EC;4\  ,D6!@ 5              "  :G_
M!0!A;'9R+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #T0T]6?<EGTX4"
M  !Q"   #P              @ %)3P8 86QV<BUE>#(S7S$N:'1M4$L! A0#
M%     @ ]$-/5O61Y3\V"0  JU4   \              ( !^U$& &%L=G(M
M97@S,5\Q+FAT;5!+ 0(4 Q0    ( /1#3U;%6U_00@D  ,Q5   /
M      "  5Y;!@!A;'9R+65X,S%?,BYH=&U02P$"% ,4    " #T0T]6R+_!
MMG\%  "W,P  #P              @ '-9 8 86QV<BUE>#,R7S$N:'1M4$L!
M A0#%     @ ]$-/5A6RT)R+!0  W#,   \              ( !>6H& &%L
M=G(M97@S,E\R+FAT;5!+ 0(4 Q0    ( /1#3U:)?,$?-C8! %B1 0 2
M          "  3%P!@!I;6<Q,#$U,S8P,S5?,"YJ<&=02P$"% ,4    " #T
M0T]6,HH="D*= 0 ?[0$ $@              @ &7I@< :6UG,3 Q-3,V,#,U
M7S$N:G!G4$L! A0#%     @ ]$-/5J!WYD5M( $ ]UT! !,
M ( !"40) &EM9S$P,34S-C S-5\Q,"YJ<&=02P$"% ,4    " #T0T]6014C
M#VX[ 0"]?0$ $P              @ &G9 H :6UG,3 Q-3,V,#,U7S$Q+FIP
M9U!+ 0(4 Q0    ( /1#3U;&:UURO88  *F^   3              "  4:@
M"P!I;6<Q,#$U,S8P,S5?,3(N:G!G4$L! A0#%     @ ]$-/5IQ#UXH@Z@
M=2P! !,              ( !-"<, &EM9S$P,34S-C S-5\Q,RYJ<&=02P$"
M% ,4    " #T0T]6:NCHHET. 0"%3P$ $P              @ &%$0T :6UG
M,3 Q-3,V,#,U7S$T+FIP9U!+ 0(4 Q0    ( /1#3U: G6/,$NX  *PJ 0 3
M              "  1,@#@!I;6<Q,#$U,S8P,S5?,34N:G!G4$L! A0#%
M  @ ]$-/5OVID"?EZ0  7R\! !,              ( !5@X/ &EM9S$P,34S
M-C S-5\Q-BYJ<&=02P$"% ,4    " #T0T]6V\]+@]4Y 0#OB $ $P
M        @ %L^ \ :6UG,3 Q-3,V,#,U7S$W+FIP9U!+ 0(4 Q0    ( /1#
M3U868L^UW@4! &$Q 0 3              "  7(R$0!I;6<Q,#$U,S8P,S5?
M,3@N:G!G4$L! A0#%     @ ]$-/5J#=S[B-]0  W',! !,
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M,#$U,S8P,S5?,RYJ<&=02P$"% ,4    " #T0T]6K4XKL]I_ 0!4PP$ $@
M            @ $AUQ< :6UG,3 Q-3,V,#,U7S0N:G!G4$L! A0#%     @
M]$-/5D?ED7[,=P$ V,0! !(              ( !*U<9 &EM9S$P,34S-C S
M-5\U+FIP9U!+ 0(4 Q0    ( /1#3U9/K42\280! ,.V 0 2
M  "  2?/&@!I;6<Q,#$U,S8P,S5?-BYJ<&=02P$"% ,4    " #T0T]6M5%G
M-2AC 0#0M@$ $@              @ &@4QP :6UG,3 Q-3,V,#,U7S<N:G!G
M4$L! A0#%     @ ]$-/5HE\P1\V-@$ 6)$! !(              ( !^+8=
M &EM9S$P,34S-C S-5\X+FIP9U!+ 0(4 Q0    ( /1#3U9P+\LK_PX!  U
M 0 2              "  5[M'@!I;6<Q,#$U,S8P,S5?.2YJ<&=02P4&
/ "$ (0!'"   C?P?

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
